Term	Term_Type	Gene_count	Gene_list
ACT_SITE:1	SEQ_UP	2	
ACT_SITE:2	SEQ_UP	2	
ACT_SITE:4-aspartylphosphate intermediate	SEQ_UP	39	
ACT_SITE:5-glutamyl coenzyme A thioester intermediate	SEQ_UP	3	
ACT_SITE:Acyl-ester intermediate	SEQ_UP	21	
ACT_SITE:Acyl-thioester intermediate	SEQ_UP	17	
ACT_SITE:Amidino-cysteine intermediate	SEQ_UP	1	
ACT_SITE:AMP-threonine intermediate	SEQ_UP	2	
ACT_SITE:Charge relay system	SEQ_UP	232	
ACT_SITE:Charge relay system; for autoendoproteolytic cleavage activity	SEQ_UP	1	
ACT_SITE:Cysteine persulfide intermediate	SEQ_UP	7	
ACT_SITE:Cysteine persulfide intermediate; for sulfurtransferase activity	SEQ_UP	1	
ACT_SITE:Cysteine radical intermediate	SEQ_UP	1	
ACT_SITE:Cysteine sulfenic acid (-SOH) intermediate	SEQ_UP	11	
ACT_SITE:Cysteine sulfenic acid (-SOH) intermediate; for peroxidase activity	SEQ_UP	1	
ACT_SITE:Electrophile	SEQ_UP	1	
ACT_SITE:For beta-hydroxyacyl dehydratase activity	SEQ_UP	1	
ACT_SITE:For beta-ketoacyl synthase activity	SEQ_UP	1	
ACT_SITE:For cyclodeaminase activity	SEQ_UP	1	
ACT_SITE:For cyclooxygenase activity	SEQ_UP	2	
ACT_SITE:For deubiquitinase activity	SEQ_UP	1	
ACT_SITE:For formimidoyltransferase activity	SEQ_UP	1	
ACT_SITE:For GATase activity	SEQ_UP	8	
ACT_SITE:For glutaminase activity	SEQ_UP	1	
ACT_SITE:For hydroxyacyl-coenzyme A dehydrogenase activity	SEQ_UP	1	
ACT_SITE:For malonyltransferase activity	SEQ_UP	1	
ACT_SITE:For molybdenum cofactor biosynthesis protein C activity	SEQ_UP	1	
ACT_SITE:For OMPdecase activity	SEQ_UP	1	
ACT_SITE:For phospholipase activity	SEQ_UP	1	
ACT_SITE:For poly [ADP-ribose] polymerase activity	SEQ_UP	2	
ACT_SITE:For ring-opening step	SEQ_UP	2	
ACT_SITE:For sulfotransferase activity	SEQ_UP	4	
ACT_SITE:For thioesterase activity	SEQ_UP	1	
ACT_SITE:Glycyl thioester intermediate	SEQ_UP	75	
ACT_SITE:Glycyl thioester intermediate; for adenylyltransferase activity	SEQ_UP	1	
ACT_SITE:GMP-histidine intermediate	SEQ_UP	1	
ACT_SITE:N6-AMP-lysine intermediate	SEQ_UP	3	
ACT_SITE:N6-GMP-lysine intermediate	SEQ_UP	1	
ACT_SITE:Nucleophile	SEQ_UP	344	
ACT_SITE:Nucleophile; for deubiquitinase activity	SEQ_UP	1	
ACT_SITE:Nucleophile; for E3 ubiquitin-lipopolysaccharide ligase activity	SEQ_UP	1	
ACT_SITE:Nucleophile; for GATase activity	SEQ_UP	1	
ACT_SITE:Nucleophile; for glutaminase activity	SEQ_UP	1	
ACT_SITE:Nucleophile; for N-glycosylase activity	SEQ_UP	1	
ACT_SITE:Nucleophile; for NAALADase activity	SEQ_UP	2	
ACT_SITE:Nucleophile; methyl group acceptor	SEQ_UP	1	
ACT_SITE:O-(3'-phospho-DNA)-tyrosine intermediate	SEQ_UP	2	
ACT_SITE:O-(5'-phospho-DNA)-tyrosine intermediate	SEQ_UP	4	
ACT_SITE:Phosphocysteine intermediate	SEQ_UP	85	
ACT_SITE:Phosphoserine intermediate	SEQ_UP	7	
ACT_SITE:Pros-phosphohistidine intermediate	SEQ_UP	7	
ACT_SITE:Proton acceptor	SEQ_UP	848	
ACT_SITE:Proton acceptor; for AICAR formyltransferase activity	SEQ_UP	1	
ACT_SITE:Proton acceptor; for azaheterocycle hydroxylase activity	SEQ_UP	4	
ACT_SITE:Proton acceptor; for enolization step	SEQ_UP	2	
ACT_SITE:Proton acceptor; for glutaminase activity	SEQ_UP	1	
ACT_SITE:Proton acceptor; for processing activity	SEQ_UP	2	
ACT_SITE:Proton acceptor; for protein kinase activity	SEQ_UP	1	
ACT_SITE:Proton acceptor; for ring-opening step	SEQ_UP	2	
ACT_SITE:Proton acceptor; via imino nitrogen	SEQ_UP	1	
ACT_SITE:Proton donor	SEQ_UP	236	
ACT_SITE:Proton donor; for beta-elimination activity	SEQ_UP	2	
ACT_SITE:Proton donor; for catalytic activity	SEQ_UP	2	
ACT_SITE:Proton donor; for delta-elimination activity	SEQ_UP	1	
ACT_SITE:Proton donor; shared with dimeric partner	SEQ_UP	1	
ACT_SITE:Proton donor/acceptor	SEQ_UP	100	
ACT_SITE:Proton donor/acceptor; for FAICAR cyclization activity	SEQ_UP	1	
ACT_SITE:Proton donors	SEQ_UP	6	
ACT_SITE:Redox-active	SEQ_UP	1	
ACT_SITE:S-palmitoyl cysteine intermediate	SEQ_UP	23	
ACT_SITE:S-selanylcysteine intermediate	SEQ_UP	1	
ACT_SITE:Schiff-base intermediate with acetaldehyde	SEQ_UP	1	
ACT_SITE:Schiff-base intermediate with dihydroxyacetone-P	SEQ_UP	3	
ACT_SITE:Schiff-base intermediate with DNA	SEQ_UP	5	
ACT_SITE:Schiff-base intermediate with DNA; for 5'-deoxyribose-5-phosphate lyase activity	SEQ_UP	1	
ACT_SITE:Schiff-base intermediate with DNA; via amino nitrogen	SEQ_UP	1	
ACT_SITE:Schiff-base intermediate with substrate	SEQ_UP	4	
ACT_SITE:Schiff-base intermediate with substrate; via pyruvic acid	SEQ_UP	2	
ACT_SITE:Schiff-base intermediate with substrate; via pyruvic acid; for decarboxylase activity	SEQ_UP	1	
ACT_SITE:Schiff-base intermediate with substrate; via topaquinone	SEQ_UP	4	
ACT_SITE:Tele-AMP-histidine intermediate	SEQ_UP	6	
ACT_SITE:Tele-GMP-histidine intermediate	SEQ_UP	1	
ACT_SITE:Tele-hemiaminal-histidine intermediate	SEQ_UP	1	
ACT_SITE:Tele-phosphohistidine intermediate	SEQ_UP	10	
ACT_SITE:Tele-UMP-histidine intermediate	SEQ_UP	1	
ACT_SITE:Thioimidate intermediate	SEQ_UP	4	
BINDING:(+)-alpha-tocopherol	SEQ_UP	1	
BINDING:(1,3-beta-D-glucosyl)n	SEQ_UP	1	
BINDING:(3R)-3-hydroxydecanoyl-CoA	SEQ_UP	1	
BINDING:(3R)-3-hydroxydecanoyl-CoA; via amide nitrogen	SEQ_UP	1	
BINDING:(3R)-3-hydroxydecanoyl-CoA; via carbonyl oxygen	SEQ_UP	1	
BINDING:(6S)-10-formyltetrahydrofolate	SEQ_UP	3	
BINDING:(R)-5-diphosphomevalonate	SEQ_UP	1	
BINDING:(S)-2-amino-6-oxohexanoate	SEQ_UP	1	
BINDING:1-eicosanoylglycerol	SEQ_UP	1	
BINDING:10-formyltetrahydrofolate	SEQ_UP	1	
BINDING:10-formyltetrahydrofolate; via amide nitrogen	SEQ_UP	1	
BINDING:11-cis-retinal	SEQ_UP	1	
BINDING:11-deoxycorticosterone	SEQ_UP	1	
BINDING:11-deoxycorticosterone; via carbonyl oxygen	SEQ_UP	1	
BINDING:17beta-hydroxy-5alpha-androstan-3-one	SEQ_UP	1	
BINDING:1D-myo-inositol 1,3,4-trisphosphate	SEQ_UP	1	
BINDING:1D-myo-inositol 1,4-bisphosphate	SEQ_UP	1	
BINDING:1D-myo-inositol 1,4-bisphosphate; via amide nitrogen	SEQ_UP	1	
BINDING:1D-myo-inositol 1,4-bisphosphate; via carbonyl oxygen	SEQ_UP	1	
BINDING:2-(N(omega)-L-arginino)succinate; shared with tetrameric partners; in chain A	SEQ_UP	1	
BINDING:2-(N(omega)-L-arginino)succinate; shared with tetrameric partners; in chain B	SEQ_UP	1	
BINDING:2-(N(omega)-L-arginino)succinate; shared with tetrameric partners; in chain C	SEQ_UP	1	
BINDING:2-oxo-dATP	SEQ_UP	1	
BINDING:2-oxo-dATP; via carbonyl oxygen	SEQ_UP	1	
BINDING:2-oxocarboxylate	SEQ_UP	1	
BINDING:2-oxoglutarate	SEQ_UP	29	
BINDING:2',3'-cGAMP	SEQ_UP	2	
BINDING:2',3'-cGAMP; via carbonyl oxygen	SEQ_UP	1	
BINDING:20-hydroxycholesterol	SEQ_UP	1	
BINDING:25-hydroxycholesterol	SEQ_UP	1	
BINDING:3-deoxy-_-D-manno-oct-2-ulosonate 1; via carbonyl oxygen	SEQ_UP	3	
BINDING:3-deoxy-_-D-manno-oct-2-ulosonate 2	SEQ_UP	3	
BINDING:3-deoxy-_-D-manno-oct-2-ulosonate 2; via carbonyl oxygen	SEQ_UP	1	
BINDING:3-hydroxy-L-kynurenine; binds multimeric 3-hydroxykynurenine chromophore; covalent	SEQ_UP	1	
BINDING:3-iodo-L-tyrosine	SEQ_UP	1	
BINDING:3-iodo-L-tyrosine; via amide nitrogen	SEQ_UP	1	
BINDING:3,3',5-triiodo-L-thyronine	SEQ_UP	2	
BINDING:3,3',5-triiodo-L-thyronine 1	SEQ_UP	1	
BINDING:3,3',5-triiodo-L-thyronine; via amide nitrogen	SEQ_UP	2	
BINDING:3,5-diiodo-L-tyrosine	SEQ_UP	1	
BINDING:3,5-diiodo-L-tyrosine; via amide nitrogen	SEQ_UP	1	
BINDING:3',3'-cGAMP	SEQ_UP	1	
BINDING:3',5'-cAMP	SEQ_UP	5	
BINDING:3',5'-cAMP 1	SEQ_UP	4	
BINDING:3',5'-cAMP 2	SEQ_UP	4	
BINDING:3',5'-cGMP	SEQ_UP	8	
BINDING:3',5'-cGMP 2	SEQ_UP	2	
BINDING:3',5'-cyclic GMP; allosteric activator	SEQ_UP	1	
BINDING:4-imidazolone-5-propanoate	SEQ_UP	1	
BINDING:5-(2-oxoethylideneamino)-6-D-ribitylaminouracil; covalent; pathogen-derived metabolite antigen	SEQ_UP	1	
BINDING:5-(2-oxoethylideneamino)-6-D-ribitylaminouracil; pathogen-derived metabolite antigen	SEQ_UP	1	
BINDING:5-(2-oxopropylideneamino)-6-D-ribitylaminouracil	SEQ_UP	1	
BINDING:5-(2-oxopropylideneamino)-6-D-ribitylaminouracil; covalent; pathogen-derived metabolite antigen	SEQ_UP	1	
BINDING:5-(2-oxopropylideneamino)-6-D-ribitylaminouracil; pathogen-derived metabolite antigen	SEQ_UP	1	
BINDING:5-aminolevulinate 1	SEQ_UP	1	
BINDING:5-aminolevulinate 2	SEQ_UP	1	
BINDING:5-methylcytosine residue in DNA	SEQ_UP	1	
BINDING:5-methyltetrahydrofolate 1; shared with tetrameric partners	SEQ_UP	1	
BINDING:5-methyltetrahydrofolate 2; shared with tetrameric partners	SEQ_UP	1	
BINDING:5-O-(ADP-D-ribosyl)-L-glutamate residue 1	SEQ_UP	1	
BINDING:5-O-(ADP-D-ribosyl)-L-glutamate residue 1; via amide nitrogen	SEQ_UP	1	
BINDING:5-O-(ADP-D-ribosyl)-L-glutamate residue 2	SEQ_UP	1	
BINDING:5-O-(ADP-D-ribosyl)-L-glutamate residue 3	SEQ_UP	1	
BINDING:5-O-(ADP-D-ribosyl)-L-glutamate residue 3; via amide nitrogen	SEQ_UP	1	
BINDING:5-phospho-alpha-D-ribose 1-diphosphate	SEQ_UP	1	
BINDING:5,10-methylenetetrahydrofolate	SEQ_UP	1	
BINDING:5,10-methylenetetrahydrofolate; via carbonyl oxygen	SEQ_UP	1	
BINDING:5,6,7,8-tetrahydrofolate	SEQ_UP	1	
BINDING:6-hydroxy-FAD	SEQ_UP	1	
BINDING:6-hydroxy-FAD; via amide nitrogen and carbonyl oxygen	SEQ_UP	1	
BINDING:7alpha,25-dihydroxycholesterol; agonist	SEQ_UP	1	
BINDING:7beta-hydroxycholesterol	SEQ_UP	1	
BINDING:8-oxo-dGTP	SEQ_UP	1	
BINDING:8-oxo-dGTP; via carbonyl oxygen	SEQ_UP	1	
BINDING:8-oxoguanine	SEQ_UP	1	
BINDING:8-oxoguanine; via carbonyl oxygen	SEQ_UP	1	
BINDING:9-cis retinoic acid	SEQ_UP	1	
BINDING:9-cis retinoic acid; via amide nitrogen	SEQ_UP	1	
BINDING:a 1-acyl-sn-glycero-3-phospho-(1D-myo-inositol); shared with dimeric partner	SEQ_UP	1	
BINDING:a 1-acyl-sn-glycero-3-phospho-(1D-myo-inositol); via amide nitrogen and carbonyl oxygen	SEQ_UP	1	
BINDING:a 1-acyl-sn-glycero-3-phospho-L-serine; shared with dimeric partner	SEQ_UP	1	
BINDING:a 1-acyl-sn-glycero-3-phospho-L-serine; via carbonyl oxygen	SEQ_UP	1	
BINDING:A mannooligosaccharide derivative	SEQ_UP	1	
BINDING:acetyl-CoA	SEQ_UP	1	
BINDING:Acetyl-CoA	SEQ_UP	16	
BINDING:Acetyl-CoA; via carbonyl oxygen	SEQ_UP	2	
BINDING:Acyl-CoA	SEQ_UP	11	
BINDING:Adenosine	SEQ_UP	1	
BINDING:Adenosine 3',5'-bisphosphate	SEQ_UP	1	
BINDING:Adenosine 3',5'-bisphosphate; inhibitor	SEQ_UP	1	
BINDING:Adenylyl sulfate	SEQ_UP	2	
BINDING:ADP	SEQ_UP	7	
BINDING:ADP 1; via amide nitrogen and carbonyl oxygen	SEQ_UP	3	
BINDING:ADP 2	SEQ_UP	3	
BINDING:ADP 2; via amide nitrogen and carbonyl oxygen	SEQ_UP	2	
BINDING:ADP-D-glycero-beta-D-manno-heptose	SEQ_UP	1	
BINDING:ADP; allosteric activator	SEQ_UP	2	
BINDING:ADP; via carbonyl oxygen	SEQ_UP	1	
BINDING:AICAR	SEQ_UP	1	
BINDING:AICAR; shared with dimeric partner	SEQ_UP	1	
BINDING:AICAR; via carbonyl oxygen	SEQ_UP	1	
BINDING:AICAR; via carbonyl oxygen; shared with dimeric partner	SEQ_UP	1	
BINDING:Aldosterone	SEQ_UP	1	
BINDING:all-trans retinoate	SEQ_UP	1	
BINDING:all-trans retinoate; via amide nitrogen	SEQ_UP	1	
BINDING:All-trans retinol	SEQ_UP	2	
BINDING:Alpha-D-glucose 1,6-bisphosphate	SEQ_UP	3	
BINDING:Alpha-D-mannopyranose	SEQ_UP	1	
BINDING:Alpha-D-mannose	SEQ_UP	1	
BINDING:Alpha-D-mannose 1-phosphate	SEQ_UP	2	
BINDING:Alpha-D-mannose 1-phosphate; via amide nitrogen	SEQ_UP	1	
BINDING:alpha-D-xylose-(1->3)-beta-D-glucose-L-seryl residue in glycoprotein substrate	SEQ_UP	1	
BINDING:Alpha-ketoglutarate	SEQ_UP	9	
BINDING:alpha-L-rhamnose	SEQ_UP	1	
BINDING:AMP	SEQ_UP	22	
BINDING:AMP 1	SEQ_UP	2	
BINDING:AMP 1; via amide nitrogen and carbonyl oxygen	SEQ_UP	3	
BINDING:AMP 2	SEQ_UP	5	
BINDING:AMP 2; via amide nitrogen and carbonyl oxygen	SEQ_UP	2	
BINDING:AMP 3	SEQ_UP	3	
BINDING:AMP 3; via amide nitrogen and carbonyl oxygen	SEQ_UP	3	
BINDING:AMP; shared with dimeric partner	SEQ_UP	1	
BINDING:AMP; via amide nitrogen and carbonyl oxygen	SEQ_UP	3	
BINDING:AMP; via carbonyl oxygen	SEQ_UP	3	
BINDING:AMP; via pi-pi stacking	SEQ_UP	1	
BINDING:An alpha-D-glucoside	SEQ_UP	3	
BINDING:an alpha-L-fucosyl-(1->2)-beta-D-galactosyl derivative	SEQ_UP	1	
BINDING:Arginine residue in protein substrate	SEQ_UP	1	
BINDING:Arginine; via carbonyl oxygen	SEQ_UP	1	
BINDING:Ascorbate	SEQ_UP	3	
BINDING:Aspartate	SEQ_UP	8	
BINDING:Aspartate; via amide nitrogen	SEQ_UP	1	
BINDING:ATP	SEQ_UP	715	
BINDING:ATP 1	SEQ_UP	11	
BINDING:ATP 1; via amide nitrogen and carbonyl oxygen	SEQ_UP	3	
BINDING:ATP 1; via carbonyl oxygen	SEQ_UP	2	
BINDING:ATP 2	SEQ_UP	11	
BINDING:ATP 2; via amide nitrogen	SEQ_UP	1	
BINDING:ATP 2; via amide nitrogen and carbonyl oxygen	SEQ_UP	4	
BINDING:ATP 2; via carbonyl oxygen	SEQ_UP	1	
BINDING:ATP; allosteric activator	SEQ_UP	2	
BINDING:ATP; non-catalytic site	SEQ_UP	2	
BINDING:ATP; shared with dimeric partner	SEQ_UP	1	
BINDING:ATP; shared with neighboring subunit	SEQ_UP	3	
BINDING:ATP; via amide nitrogen	SEQ_UP	27	
BINDING:ATP; via amide nitrogen and carbonyl oxygen	SEQ_UP	15	
BINDING:ATP; via amide nitrogen; shared with neighboring subunit	SEQ_UP	2	
BINDING:ATP; via carbonyl oxygen	SEQ_UP	32	
BINDING:Beta-D-fructose	SEQ_UP	1	
BINDING:Beta-D-fructose 1-phosphate	SEQ_UP	1	
BINDING:Beta-D-fructose; via amide nitrogen	SEQ_UP	1	
BINDING:Beta-D-galactose	SEQ_UP	1	
BINDING:Beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl residue	SEQ_UP	1	
BINDING:Beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-N-oleoylsphingosine	SEQ_UP	1	
BINDING:Beta-galactoside	SEQ_UP	1	
BINDING:Beta-galactoside 1	SEQ_UP	1	
BINDING:Beta-galactoside 2	SEQ_UP	1	
BINDING:Bicarbonate	SEQ_UP	1	
BINDING:Bicarbonate; via amide nitrogen	SEQ_UP	1	
BINDING:Bicarbonate; via amide nitrogen and carbonyl oxygen	SEQ_UP	1	
BINDING:Bilirubin	SEQ_UP	1	
BINDING:Biotin; via carbonyl oxygen	SEQ_UP	1	
BINDING:Bortezomib; via amide nitrogen	SEQ_UP	1	
BINDING:c-di-GMP	SEQ_UP	1	
BINDING:c-di-GMP; via carbonyl oxagen	SEQ_UP	1	
BINDING:Caffeine	SEQ_UP	1	
BINDING:Carbamoyl phosphate	SEQ_UP	1	
BINDING:Carbohydrate	SEQ_UP	14	
BINDING:Carbohydrate; via carbonyl oxygen	SEQ_UP	1	
BINDING:Carbonate 1	SEQ_UP	3	
BINDING:Carbonate 1; via amide nitrogen	SEQ_UP	3	
BINDING:Carbonate 2	SEQ_UP	2	
BINDING:Carbonate 2; via amide nitrogen	SEQ_UP	2	
BINDING:Carboxymycobactin	SEQ_UP	1	
BINDING:Carnitine	SEQ_UP	6	
BINDING:Carnitine; via carbonyl oxygen	SEQ_UP	1	
BINDING:CDP-L-ribitol	SEQ_UP	1	
BINDING:CDP-L-ribitol; via amide nitrogen	SEQ_UP	1	
BINDING:Ceramide	SEQ_UP	1	
BINDING:Chenodeoxycholic acid; agonist	SEQ_UP	1	
BINDING:Chitooligosaccharide	SEQ_UP	5	
BINDING:Chloride	SEQ_UP	14	
BINDING:Chloride 1	SEQ_UP	4	
BINDING:Chloride 1; via amide nitrogen	SEQ_UP	3	
BINDING:Chloride 2	SEQ_UP	4	
BINDING:Chloride 2; via amide nitrogen	SEQ_UP	3	
BINDING:Chloride 3	SEQ_UP	1	
BINDING:Chloride; via amide nitrogen	SEQ_UP	11	
BINDING:Cholesterol	SEQ_UP	5	
BINDING:Cinnamaldehyde; agonist; covalent	SEQ_UP	1	
BINDING:Cinnamaldehyde; agonist; covalent; Cys highly reactive	SEQ_UP	1	
BINDING:Citrate	SEQ_UP	1	
BINDING:Citrate; allosteric activator	SEQ_UP	2	
BINDING:Citrate; via amide nitrogen	SEQ_UP	1	
BINDING:Citrulline	SEQ_UP	1	
BINDING:CMP	SEQ_UP	5	
BINDING:CMP-N-acetylneuraminate	SEQ_UP	1	
BINDING:CMP-sialic acid	SEQ_UP	1	
BINDING:cNMP	SEQ_UP	19	
BINDING:CO2	SEQ_UP	1	
BINDING:Cob(II)alamin	SEQ_UP	2	
BINDING:Coenzyme A	SEQ_UP	23	
BINDING:Coenzyme A; via amide nitrogen	SEQ_UP	2	
BINDING:Coenzyme A; via backbone amide and carbonyl oxygen	SEQ_UP	1	
BINDING:Coenzyme A; via carbonyl oxygen	SEQ_UP	6	
BINDING:Cortisol	SEQ_UP	1	
BINDING:CpG-DNA	SEQ_UP	1	
BINDING:creatine	SEQ_UP	1	
BINDING:creatine; via amide nitrogen	SEQ_UP	1	
BINDING:CTP	SEQ_UP	3	
BINDING:Cyclosporin A	SEQ_UP	1	
BINDING:D-2-hydroxyglutarate	SEQ_UP	1	
BINDING:D-fructose	SEQ_UP	1	
BINDING:D-fructose 1,6-bisphosphate; part of allosteric site	SEQ_UP	1	
BINDING:D-glucose	SEQ_UP	7	
BINDING:D-glucose 1	SEQ_UP	4	
BINDING:D-glucose 2	SEQ_UP	4	
BINDING:D-hexose	SEQ_UP	1	
BINDING:D-lactate	SEQ_UP	1	
BINDING:D-malate	SEQ_UP	1	
BINDING:D-threo-isocitrate	SEQ_UP	1	
BINDING:dCTP	SEQ_UP	2	
BINDING:deoxycholic acid	SEQ_UP	1	
BINDING:deoxycholic acid; via carbonyl oxygen	SEQ_UP	1	
BINDING:Dihydroxyacetone	SEQ_UP	1	
BINDING:Dimethylallyl diphosphate	SEQ_UP	2	
BINDING:Dioxygen	SEQ_UP	1	
BINDING:Diphosphate	SEQ_UP	1	
BINDING:DNA	SEQ_UP	8	
BINDING:DNA substrate	SEQ_UP	1	
BINDING:DNA; via amide nitrogen	SEQ_UP	1	
BINDING:dNTP	SEQ_UP	3	
BINDING:dNTP; shared with neighboring subunit	SEQ_UP	1	
BINDING:dNTP; via amide nitrogen; shared with neighboring subunit	SEQ_UP	1	
BINDING:Dolichol phosphate	SEQ_UP	1	
BINDING:Dolichyl diphosphooligosaccharide	SEQ_UP	2	
BINDING:dsDNA	SEQ_UP	1	
BINDING:dTTP; allosteric effector that controls substrate specificity	SEQ_UP	1	
BINDING:dUMP	SEQ_UP	1	
BINDING:dUTP	SEQ_UP	1	
BINDING:dUTP; via amide nitrogen and carbonyl oxygen	SEQ_UP	1	
BINDING:Enterobactin	SEQ_UP	1	
BINDING:Ergosterol	SEQ_UP	1	
BINDING:FAD	SEQ_UP	63	
BINDING:FAD; shared with dimeric partner	SEQ_UP	4	
BINDING:FAD; via amide nitrogen	SEQ_UP	16	
BINDING:FAD; via amide nitrogen and carbonyl oxygen	SEQ_UP	24	
BINDING:FAD; via amide nitrongen and carbonyl oxygen	SEQ_UP	1	
BINDING:FAD; via carbonyl oxygen	SEQ_UP	5	
BINDING:Fatty acid	SEQ_UP	1	
BINDING:FMN	SEQ_UP	14	
BINDING:FMN; via amide nitrogen	SEQ_UP	4	
BINDING:FMN; via amide nitrogen and carbonyl oxygen	SEQ_UP	1	
BINDING:FMN; via carbonyl oxygen	SEQ_UP	1	
BINDING:Folate	SEQ_UP	2	
BINDING:Fructose 2,6-bisphosphate	SEQ_UP	3	
BINDING:Fructose 2,6-bisphosphate; allosteric activator	SEQ_UP	3	
BINDING:Fructose 2,6-bisphosphate; allosteric activator; shared with dimeric partner	SEQ_UP	3	
BINDING:Fructose 2,6-bisphosphate; via amide nitrogen	SEQ_UP	3	
BINDING:Fructose 6-phosphate	SEQ_UP	3	
BINDING:Fructose-1,6-bisphosphate; allosteric activator	SEQ_UP	1	
BINDING:Fucose	SEQ_UP	4	
BINDING:Fucose; via carbonyl oxygen	SEQ_UP	1	
BINDING:Fumarate; allosteric activator	SEQ_UP	1	
BINDING:Galactosylceramide	SEQ_UP	2	
BINDING:Gamma-aminobutyric acid	SEQ_UP	1	
BINDING:Gamma-aminobutyric acid (GABA); agonist	SEQ_UP	1	
BINDING:Ganglioside GT1b	SEQ_UP	1	
BINDING:GDP	SEQ_UP	2	
BINDING:GDP-beta-L-fucose	SEQ_UP	1	
BINDING:GDP; shared with dimeric partner	SEQ_UP	1	
BINDING:GDP; via carbonyl oxygen	SEQ_UP	1	
BINDING:Geranylgeranyl diphosphate	SEQ_UP	1	
BINDING:Glucose	SEQ_UP	1	
BINDING:Glucose-6-phosphate	SEQ_UP	1	
BINDING:Glucose-6-phosphate 1	SEQ_UP	4	
BINDING:Glucose-6-phosphate 2	SEQ_UP	4	
BINDING:Glutamate	SEQ_UP	22	
BINDING:Glutamate; via amide nitrogen	SEQ_UP	1	
BINDING:Glutamine	SEQ_UP	1	
BINDING:Glutathione	SEQ_UP	22	
BINDING:Glutathione; via amide nitrogen	SEQ_UP	1	
BINDING:Glutathione; via amide nitrogen and carbonyl oxygen	SEQ_UP	7	
BINDING:Glyceraldehyde 3-phosphate	SEQ_UP	4	
BINDING:Glycine	SEQ_UP	2	
BINDING:Glyoxylate	SEQ_UP	1	
BINDING:GMP	SEQ_UP	3	
BINDING:GMP; via carbonyl oxygen	SEQ_UP	2	
BINDING:GTP	SEQ_UP	42	
BINDING:GTP binding; via carbonyl oxygen	SEQ_UP	1	
BINDING:GTP; shared with neighboring subunit	SEQ_UP	1	
BINDING:GTP; via amide nitrogen	SEQ_UP	43	
BINDING:GTP; via amide nitrogen and carbonyl oxygen	SEQ_UP	13	
BINDING:GTP; via carbonyl oxygen	SEQ_UP	2	
BINDING:Guanidinoacetate	SEQ_UP	1	
BINDING:H(+); protonated following cystine-binding	SEQ_UP	1	
BINDING:H(+); reversibly protonated during proton transport	SEQ_UP	1	
BINDING:Heme	SEQ_UP	4	
BINDING:Heme b	SEQ_UP	4	
BINDING:Heme b 1	SEQ_UP	3	
BINDING:Heme b 2	SEQ_UP	3	
BINDING:Heme b; covalent, via 2 links	SEQ_UP	3	
BINDING:Heme b; covalent, via 3 links	SEQ_UP	1	
BINDING:Heme c; covalent	SEQ_UP	3	
BINDING:Heme; covalent, via 1 link	SEQ_UP	7	
BINDING:Heme; covalent, via 3 links	SEQ_UP	1	
BINDING:Heparan sulfate	SEQ_UP	1	
BINDING:Heparan sulfate; via amide nitrogen	SEQ_UP	1	
BINDING:Heparin	SEQ_UP	5	
BINDING:Hyaluronan	SEQ_UP	1	
BINDING:Hyperforin; agonist	SEQ_UP	1	
BINDING:IMP	SEQ_UP	5	
BINDING:IMP; shared with dimeric partner	SEQ_UP	2	
BINDING:Inositol hexakisphosphate	SEQ_UP	3	
BINDING:Inositol-(1,3,4,5)-tetrakisphosphate	SEQ_UP	2	
BINDING:Inositol-(1,3,4,5)-tetrakisphosphate; via carbonyl oxygen	SEQ_UP	1	
BINDING:Isopentenyl diphosphate	SEQ_UP	4	
BINDING:Isopentenyl diphosphate; via amide nitrogen	SEQ_UP	1	
BINDING:ITP	SEQ_UP	1	
BINDING:L-alanine	SEQ_UP	2	
BINDING:L-arginine	SEQ_UP	2	
BINDING:L-arginine residue; Arg of R-G-D sequence recognized in fibronectin and fibrinogen	SEQ_UP	1	
BINDING:L-glutamate	SEQ_UP	11	
BINDING:L-glutamate residue; L-glutamate acceptor residue in protein target	SEQ_UP	11	
BINDING:L-glutamine	SEQ_UP	1	
BINDING:L-histidine	SEQ_UP	2	
BINDING:L-kynurenine	SEQ_UP	1	
BINDING:L-lysine	SEQ_UP	1	
BINDING:L-phenylalanine	SEQ_UP	1	
BINDING:L-proline	SEQ_UP	1	
BINDING:L-saccharopine	SEQ_UP	1	
BINDING:L-serine	SEQ_UP	3	
BINDING:L-thyroxine	SEQ_UP	2	
BINDING:L-thyroxine; via amide nitrogen	SEQ_UP	1	
BINDING:L-tryptophan	SEQ_UP	2	
BINDING:L-tryptophan; via carbonyl oxygen	SEQ_UP	1	
BINDING:Leucine	SEQ_UP	3	
BINDING:Leucine; via carbonyl oxygen	SEQ_UP	3	
BINDING:Lysophosphatidic acid	SEQ_UP	1	
BINDING:malonyl-CoA	SEQ_UP	1	
BINDING:Malonyl-CoA	SEQ_UP	1	
BINDING:Mannose	SEQ_UP	1	
BINDING:Matrix attachment region (MAR) of DNA	SEQ_UP	1	
BINDING:Methionine	SEQ_UP	2	
BINDING:Methionine; shared with neighboring subunit	SEQ_UP	2	
BINDING:Methylcob(III)alamin	SEQ_UP	1	
BINDING:Methylcob(III)alamin; via amide nitrogen	SEQ_UP	1	
BINDING:Molybdopterin	SEQ_UP	5	
BINDING:Molybdopterin; via amide nitrogen	SEQ_UP	2	
BINDING:Molybdopterin; via carbonyl oxygen	SEQ_UP	3	
BINDING:mRNA cap	SEQ_UP	1	
BINDING:Murein	SEQ_UP	2	
BINDING:N-acetyl-D-glucosamine	SEQ_UP	7	
BINDING:N-acetyl-L-glutamate; allosteric activator	SEQ_UP	1	
BINDING:N-acyl-1,2-diacyl-sn-glycero-3-phosphoethanolamine	SEQ_UP	1	
BINDING:N-carbamoyl-L-aspartate	SEQ_UP	1	
BINDING:N-carbamoyl-L-aspartate; via amide nitrogen and carbonyl oxygen	SEQ_UP	1	
BINDING:N-eicosanoyl ethanolamine	SEQ_UP	1	
BINDING:N-formimidoyl-L-glutamate	SEQ_UP	1	
BINDING:N-formimidoyl-L-glutamate; via amide nitrogen	SEQ_UP	1	
BINDING:N(6)-methyl-AMP	SEQ_UP	1	
BINDING:N(6)-methyl-AMP; via carbonyl oxygen	SEQ_UP	1	
BINDING:N(6)-methyl-AMP; via tele nitrogen	SEQ_UP	1	
BINDING:N(7)-methyl-GMP	SEQ_UP	2	
BINDING:N(omega)-methyl-L-arginine residue	SEQ_UP	1	
BINDING:N(omega)-methyl-L-arginine residue; via carbonyl oxygen	SEQ_UP	1	
BINDING:N6-methyladenosine residue in RNA	SEQ_UP	5	
BINDING:N7-methylguanosine 5'-triphosphate group; binds m7GTP residue in mRNA cap	SEQ_UP	1	
BINDING:NAD	SEQ_UP	72	
BINDING:NAD 1	SEQ_UP	1	
BINDING:NAD 1; inhibitor	SEQ_UP	1	
BINDING:NAD 1; via amide nitrogen	SEQ_UP	1	
BINDING:NAD 1; via carbonyl oxygen	SEQ_UP	1	
BINDING:NAD 2	SEQ_UP	1	
BINDING:NAD 2; substrate	SEQ_UP	1	
BINDING:NAD; may stabilize a reaction intermediate	SEQ_UP	1	
BINDING:NAD; via amide nitrogen	SEQ_UP	25	
BINDING:NAD; via amide nitrogen and carbonyl oxygen	SEQ_UP	1	
BINDING:NAD; via carbonyl oxygen	SEQ_UP	15	
BINDING:NADP	SEQ_UP	58	
BINDING:NADP 1	SEQ_UP	2	
BINDING:NADP 1; via carbonyl oxygen	SEQ_UP	2	
BINDING:NADP 2	SEQ_UP	2	
BINDING:NADP; shared with dimeric partner	SEQ_UP	1	
BINDING:NADP; via amide nitrogen	SEQ_UP	11	
BINDING:NADP; via amide nitrogen and carbonyl oxygen	SEQ_UP	5	
BINDING:NADP; via carbonyl oxygen	SEQ_UP	11	
BINDING:NADPHX	SEQ_UP	2	
BINDING:NADPHX; via amide nitrogen	SEQ_UP	1	
BINDING:Nicotinamide	SEQ_UP	1	
BINDING:Nicotinamide ribonucleotide	SEQ_UP	1	
BINDING:Nicotinamide ribonucleotide; via amide nitrogen	SEQ_UP	1	
BINDING:Nicotinate	SEQ_UP	1	
BINDING:Nilotinib	SEQ_UP	1	
BINDING:NMP	SEQ_UP	1	
BINDING:NTP	SEQ_UP	3	
BINDING:NTP; via carbonyl oxygen	SEQ_UP	1	
BINDING:O-phospho-L-serine	SEQ_UP	1	
BINDING:Octopamine	SEQ_UP	1	
BINDING:Oleate	SEQ_UP	1	
BINDING:Ornithine	SEQ_UP	1	
BINDING:Orotidine 5'-phosphate	SEQ_UP	1	
BINDING:Oxygen	SEQ_UP	1	
BINDING:Palmitate	SEQ_UP	3	
BINDING:PAPS	SEQ_UP	27	
BINDING:PAPS; via carbonyl oxygen	SEQ_UP	1	
BINDING:Peptide substrate	SEQ_UP	2	
BINDING:Phosphate	SEQ_UP	7	
BINDING:Phosphate; via amide nitrogen	SEQ_UP	6	
BINDING:Phosphatidylcholine	SEQ_UP	2	
BINDING:Phosphatidylcholine; via amide nitrogen	SEQ_UP	1	
BINDING:Phosphatidylglycerol phosphate	SEQ_UP	2	
BINDING:Phosphatidylinositol	SEQ_UP	6	
BINDING:Phosphatidylinositol 3-phosphate	SEQ_UP	18	
BINDING:Phosphatidylinositol 3-phosphate; via amide nitrogen and carbonyl oxygen	SEQ_UP	12	
BINDING:Phosphatidylinositol 3,4-bisphosphate	SEQ_UP	2	
BINDING:Phosphatidylinositol 3,4,5-trisphosphate	SEQ_UP	7	
BINDING:Phosphatidylinositol 4-phosphate	SEQ_UP	3	
BINDING:Phosphatidylinositol 4,5-bisphosphate	SEQ_UP	10	
BINDING:Phosphatidylinositol 4,5-bisphosphate (PIP2)	SEQ_UP	3	
BINDING:Phosphatidylinositol lipid headgroup	SEQ_UP	1	
BINDING:Phosphatidylinositol-4,5-bisphosphate	SEQ_UP	1	
BINDING:Phosphatidylserine	SEQ_UP	6	
BINDING:Phosphatidylserine; via amide nitrogen	SEQ_UP	1	
BINDING:Phosphoceramide	SEQ_UP	1	
BINDING:Phosphoribosylpyrophosphate	SEQ_UP	1	
BINDING:Phosphotyrosine	SEQ_UP	3	
BINDING:Poly-ADP-D-ribose group	SEQ_UP	2	
BINDING:Polyprenyl diphosphate	SEQ_UP	1	
BINDING:Progesterone	SEQ_UP	1	
BINDING:PtdIns4P	SEQ_UP	2	
BINDING:Purine nucleoside	SEQ_UP	2	
BINDING:Putrescine	SEQ_UP	1	
BINDING:Pyridoxal	SEQ_UP	1	
BINDING:Pyridoxal 5'-phosphate	SEQ_UP	3	
BINDING:Pyridoxal phosphate	SEQ_UP	10	
BINDING:Pyridoxal phosphate; shared with dimeric partner	SEQ_UP	3	
BINDING:Pyridoxal phosphate; via amide nitrogen	SEQ_UP	2	
BINDING:Pyridoxal phosphate; via amino nitrogen	SEQ_UP	1	
BINDING:Pyridoxal phosphate; via carbonyl oxygen	SEQ_UP	1	
BINDING:Pyridoxal phosphate; via the backbone amide	SEQ_UP	1	
BINDING:Quinolinate	SEQ_UP	1	
BINDING:Quinolinate; via amide nitrogen	SEQ_UP	1	
BINDING:Resiniferatoxin; agonist	SEQ_UP	1	
BINDING:S-adenosyl-L-homocysteine	SEQ_UP	2	
BINDING:S-adenosyl-L-homocysteine; via amide nitrogen and carbonyl oxygen	SEQ_UP	1	
BINDING:S-adenosyl-L-methionine	SEQ_UP	106	
BINDING:S-adenosyl-L-methionine 1	SEQ_UP	1	
BINDING:S-adenosyl-L-methionine 1; via amide nitrogen and carbonyl oxygen	SEQ_UP	1	
BINDING:S-adenosyl-L-methionine 2	SEQ_UP	1	
BINDING:S-adenosyl-L-methionine; via amide nitrogen	SEQ_UP	30	
BINDING:S-adenosyl-L-methionine; via amide nitrogen and carbonyl oxygen	SEQ_UP	7	
BINDING:S-adenosyl-L-methionine; via backbone amide	SEQ_UP	3	
BINDING:S-adenosyl-L-methionine; via carbonyl oxygen	SEQ_UP	46	
BINDING:S-adenosyl-L-methionine; via the backbone amide	SEQ_UP	1	
BINDING:S-adenosyl-L-methionine; via the carbonyl oxygen	SEQ_UP	1	
BINDING:S-adenosylmethioninamine	SEQ_UP	2	
BINDING:S-adenosylmethionine	SEQ_UP	1	
BINDING:Serine	SEQ_UP	1	
BINDING:Sialic acid	SEQ_UP	6	
BINDING:Spermidine	SEQ_UP	2	
BINDING:ssDNA	SEQ_UP	1	
BINDING:Staurosporine	SEQ_UP	1	
BINDING:Substrate	SEQ_UP	547	
BINDING:Substrate 1	SEQ_UP	1	
BINDING:Substrate 2	SEQ_UP	1	
BINDING:Substrate 2'-3'-cGAMP	SEQ_UP	1	
BINDING:Substrate; shared with catalytic subunit	SEQ_UP	1	
BINDING:Substrate; shared with dimeric partner	SEQ_UP	6	
BINDING:Substrate; shared with homodimeric partner	SEQ_UP	1	
BINDING:Substrate; shared with neighboring subunit	SEQ_UP	2	
BINDING:Substrate; shared with subunit alpha	SEQ_UP	2	
BINDING:Substrate; shared with subunit beta	SEQ_UP	1	
BINDING:Substrate; via amide nitrogen	SEQ_UP	48	
BINDING:Substrate; via amide nitrogen and carbonyl oxygen	SEQ_UP	5	
BINDING:Substrate; via carbonyl oxygen	SEQ_UP	40	
BINDING:Substrate; via carboxylate	SEQ_UP	1	
BINDING:Substrate; via tele nitrogen	SEQ_UP	3	
BINDING:Symmetrical N(omega),N'(omega)-dimethyl-L-arginine residue	SEQ_UP	1	
BINDING:Symmetrical N(omega),N'(omega)-dimethyl-L-arginine residue; via carbonyl oxygen	SEQ_UP	1	
BINDING:Testosterone	SEQ_UP	1	
BINDING:Tetradecanoate	SEQ_UP	4	
BINDING:Tetradecanoyl-CoA	SEQ_UP	2	
BINDING:Tetrahydrofolate	SEQ_UP	1	
BINDING:Thalidomide	SEQ_UP	1	
BINDING:Thiamine pyrophosphate	SEQ_UP	6	
BINDING:Thiamine pyrophosphate; via amide nitrogen	SEQ_UP	2	
BINDING:Thyroxine	SEQ_UP	1	
BINDING:TMP	SEQ_UP	1	
BINDING:tRNA acceptor arm	SEQ_UP	1	
BINDING:tRNA discriminator base	SEQ_UP	1	
BINDING:tRNA variable arm	SEQ_UP	1	
BINDING:tRNA; binds tRNA acceptor arm	SEQ_UP	1	
BINDING:tRNA; binds tRNA discriminator base	SEQ_UP	1	
BINDING:tRNA; binds tRNA variable arm	SEQ_UP	1	
BINDING:Tryptophan	SEQ_UP	1	
BINDING:Tryptophan; via carbonyl oxygen	SEQ_UP	1	
BINDING:Tyrosine	SEQ_UP	2	
BINDING:Ubiquinone	SEQ_UP	1	
BINDING:Ubiquinone; shared with DHSD	SEQ_UP	1	
BINDING:Ubiquinone; shared with IP/SDHB	SEQ_UP	1	
BINDING:Ubiquinone; via amide nitrogen	SEQ_UP	1	
BINDING:Ubiquinone; via carbonyl oxygen	SEQ_UP	1	
BINDING:UDP	SEQ_UP	1	
BINDING:UDP-alpha-D-galactose	SEQ_UP	7	
BINDING:UDP-alpha-D-glucose	SEQ_UP	1	
BINDING:UDP-alpha-D-glucose; shared with dimeric partner	SEQ_UP	1	
BINDING:UDP-alpha-D-glucose; via amide nitrogen	SEQ_UP	1	
BINDING:UDP-alpha-D-xylose	SEQ_UP	1	
BINDING:UDP-alpha-D-xylose; via amide nitrogen	SEQ_UP	1	
BINDING:UDP-alpha-D-xylose; via carbonyl oxygen	SEQ_UP	1	
BINDING:UDP-GlcNAc	SEQ_UP	2	
BINDING:UDP-glucose	SEQ_UP	3	
BINDING:UDP-glucuronate	SEQ_UP	3	
BINDING:UDP-N-acetyl-alpha-D-glucosamine	SEQ_UP	1	
BINDING:UDP-N-acetyl-galactosamine	SEQ_UP	1	
BINDING:UDP-N-acetylglucosamine	SEQ_UP	1	
BINDING:UDP-xylose	SEQ_UP	2	
BINDING:UDP-xylose; via carbonyl oxygen	SEQ_UP	2	
BINDING:UMP	SEQ_UP	2	
BINDING:UMP; via pi-pi stacking	SEQ_UP	1	
BINDING:UTP	SEQ_UP	6	
BINDING:UTP; via amide nitrogen	SEQ_UP	3	
BINDING:UTP; via tele nitrogen	SEQ_UP	1	
BINDING:UTP;via amide nitrogen	SEQ_UP	1	
BINDING:Val-boroPro; inhibitor; covalent	SEQ_UP	1	
BINDING:Vitamin D3	SEQ_UP	1	
BINDING:Xanthine monophosphate	SEQ_UP	1	
CA_BIND:1; low affinity	SEQ_UP	1	
CA_BIND:2; high affinity	SEQ_UP	1	
CARBOHYD:(Microbial infection) N-beta-linked (GlcNAc) arginine	SEQ_UP	3	
CARBOHYD:C-linked (Man) tryptophan	SEQ_UP	9	
CARBOHYD:N-linked (Glc) (glycation) arginine	SEQ_UP	1	
CARBOHYD:N-linked (Glc) (glycation) lysine	SEQ_UP	1	
CARBOHYD:N-linked (GlcNAc...) (complex) asparagine	SEQ_UP	9	
CARBOHYD:N-linked (GlcNAc...) (high mannose) asparagine	SEQ_UP	20	
CARBOHYD:N-linked (GlcNAc...) (high mannose) asparagine; alternate	SEQ_UP	1	
CARBOHYD:N-linked (GlcNAc...) (hybrid) asparagine; alternate	SEQ_UP	1	
CARBOHYD:N-linked (GlcNAc...) (keratan sulfate) asparagine	SEQ_UP	3	
CARBOHYD:N-linked (GlcNAc...) asparagine	SEQ_UP	3690	
CARBOHYD:N-linked (GlcNAc...) asparagine; alternate	SEQ_UP	2	
CARBOHYD:N-linked (GlcNAc...) asparagine; atypical	SEQ_UP	4	
CARBOHYD:N-linked (GlcNAc...) asparagine; atypical; partial	SEQ_UP	1	
CARBOHYD:N-linked (GlcNAc...) asparagine; partial	SEQ_UP	3	
CARBOHYD:N-linked (GlcNAc...) asparagine; when associated with variant T-60	SEQ_UP	1	
CARBOHYD:N-linked (GlcNAc) asparagine	SEQ_UP	1	
CARBOHYD:O-linked (Fuc...) serine	SEQ_UP	5	
CARBOHYD:O-linked (Fuc...) threonine	SEQ_UP	5	
CARBOHYD:O-linked (Fuc...) threonine; alternate	SEQ_UP	1	
CARBOHYD:O-linked (Fuc) serine	SEQ_UP	1	
CARBOHYD:O-linked (Fuc) threonine	SEQ_UP	1	
CARBOHYD:O-linked (Gal...) hydroxylysine	SEQ_UP	5	
CARBOHYD:O-linked (Gal...) hydroxylysine; alternate	SEQ_UP	5	
CARBOHYD:O-linked (GalNAc...) serine	SEQ_UP	22	
CARBOHYD:O-linked (GalNAc...) serine; alternate	SEQ_UP	1	
CARBOHYD:O-linked (GalNAc...) serine; in soluble form	SEQ_UP	1	
CARBOHYD:O-linked (GalNAc...) serine; partial	SEQ_UP	1	
CARBOHYD:O-linked (GalNAc...) threonine	SEQ_UP	51	
CARBOHYD:O-linked (GalNAc...) threonine; alternate	SEQ_UP	2	
CARBOHYD:O-linked (GalNAc...) threonine; partial	SEQ_UP	3	
CARBOHYD:O-linked (GalNAc) serine; by GALNT13	SEQ_UP	1	
CARBOHYD:O-linked (GalNAc) threonine	SEQ_UP	1	
CARBOHYD:O-linked (GalNAc) threonine; by GALNT13	SEQ_UP	1	
CARBOHYD:O-linked (Glc...) serine	SEQ_UP	3	
CARBOHYD:O-linked (Glc...) serine; alternate	SEQ_UP	2	
CARBOHYD:O-linked (Glc...) tyrosine	SEQ_UP	1	
CARBOHYD:O-linked (Glc) serine	SEQ_UP	3	
CARBOHYD:O-linked (Glc) threonine	SEQ_UP	1	
CARBOHYD:O-linked (GlcNAc...) serine; alternate	SEQ_UP	1	
CARBOHYD:O-linked (GlcNAc...) threonine	SEQ_UP	2	
CARBOHYD:O-linked (GlcNAc) serine	SEQ_UP	53	
CARBOHYD:O-linked (GlcNAc) serine; alternate	SEQ_UP	14	
CARBOHYD:O-linked (GlcNAc) threonine	SEQ_UP	24	
CARBOHYD:O-linked (GlcNAc) threonine; alternate	SEQ_UP	2	
CARBOHYD:O-linked (Man...) serine	SEQ_UP	8	
CARBOHYD:O-linked (Man...) threonine	SEQ_UP	1	
CARBOHYD:O-linked (Man) serine	SEQ_UP	4	
CARBOHYD:O-linked (Man) threonine	SEQ_UP	4	
CARBOHYD:O-linked (Man6P...) threonine	SEQ_UP	1	
CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine	SEQ_UP	7	
CARBOHYD:O-linked (Xyl...) (chondroitin sulfate) serine; alternate	SEQ_UP	1	
CARBOHYD:O-linked (Xyl...) (dermatan sulfate) serine	SEQ_UP	1	
CARBOHYD:O-linked (Xyl...) (glycosaminoglycan) serine	SEQ_UP	12	
CARBOHYD:O-linked (Xyl...) (heparan sulfate) serine	SEQ_UP	7	
CARBOHYD:O-linked (Xyl...) (heparan sulfate) serine; alternate	SEQ_UP	1	
CARBOHYD:O-linked (Xyl...) (keratan sulfate) threonine	SEQ_UP	1	
CARBOHYD:O-linked (Xyl...) serine; alternate	SEQ_UP	2	
CARBOHYD:S-linked (Hex...) cysteine	SEQ_UP	1	
COMPBIAS:Acidic residues	SEQ_UP	957	
COMPBIAS:Basic and acidic residues	SEQ_UP	5353	
COMPBIAS:Basic residues	SEQ_UP	639	
COMPBIAS:Polar residues	SEQ_UP	6698	
COMPBIAS:Pro residues	SEQ_UP	1625	
CROSSLNK:1'-histidyl-3'-tyrosine (His-Tyr)	SEQ_UP	1	
CROSSLNK:3'-(S-cysteinyl)-tyrosine (Cys-Tyr)	SEQ_UP	1	
CROSSLNK:5-imidazolinone (Ala-Gly)	SEQ_UP	1	
CROSSLNK:Cysteinyl-selenocysteine (Cys-Sec)	SEQ_UP	5	
CROSSLNK:Cysteinyl-selenocysteine (Cys-Sec); redox-active	SEQ_UP	2	
CROSSLNK:Glycyl cysteine thioester (Cys-Gly) (interchain with G-Cter in ubiquitin)	SEQ_UP	2	
CROSSLNK:Glycyl cysteine thioester (Cys-Gly) (interchain with G-Cter in ubiquitin); alternate	SEQ_UP	2	
CROSSLNK:Glycyl lysine isopeptide (Gly-Lys) (interchain with K-? in acceptor protein)	SEQ_UP	1	
CROSSLNK:Glycyl lysine isopeptide (Gly-Lys) (interchain with K-? in acceptor proteins)	SEQ_UP	10	
CROSSLNK:Glycyl lysine isopeptide (Gly-Lys) (interchain with K-? in acceptor proteins); alternate	SEQ_UP	1	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ATG12)	SEQ_UP	2	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ISG15)	SEQ_UP	9	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ISG15); alternate	SEQ_UP	1	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in NEDD8)	SEQ_UP	7	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO; alternate)	SEQ_UP	1	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO)	SEQ_UP	98	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate	SEQ_UP	65	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1 and SUMO2)	SEQ_UP	1	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1, SUMO2 and SUMO3)	SEQ_UP	1	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1, SUMO2 and SUMO3); alternate	SEQ_UP	1	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1)	SEQ_UP	66	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate	SEQ_UP	159	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2 and SUMO3)	SEQ_UP	3	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2 and SUMO3); alternate	SEQ_UP	2	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)	SEQ_UP	1044	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate	SEQ_UP	319	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO3)	SEQ_UP	3	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO3); alternate	SEQ_UP	1	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin; alternate)	SEQ_UP	1	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)	SEQ_UP	231	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate	SEQ_UP	96	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); by autocatalysis	SEQ_UP	1	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in UFM1)	SEQ_UP	3	
CROSSLNK:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in UFM1); alternate	SEQ_UP	13	
CROSSLNK:Glycyl serine ester (Ser-Gly) (interchain with G-Cter in ubiquitin)	SEQ_UP	1	
CROSSLNK:Glycyl serine ester (Ser-Gly) (interchain with G-Cter in ubiquitin); alternate	SEQ_UP	1	
CROSSLNK:Isoglutamyl cysteine thioester (Cys-Gln)	SEQ_UP	7	
CROSSLNK:Isoglutamyl lysine isopeptide (Gln-Lys) (interchain with K-?)	SEQ_UP	3	
CROSSLNK:Isoglutamyl lysine isopeptide (Gln-Lys) (interchain with K-431)	SEQ_UP	1	
CROSSLNK:Isoglutamyl lysine isopeptide (Lys-Gln) (interchain with Q-?)	SEQ_UP	1	
CROSSLNK:Isoglutamyl lysine isopeptide (Lys-Gln) (interchain with Q-423)	SEQ_UP	1	
CROSSLNK:Lysine tyrosylquinone (Lys-Tyr)	SEQ_UP	5	
CROSSLNK:N5-[4-(S-L-cysteinyl)-5-methyl-1H-imidazol-2-yl]-L-ornithine (Arg-Cys) (interchain with C-151 in KEAP1)	SEQ_UP	1	
CROSSLNK:N5-[4-(S-L-cysteinyl)-5-methyl-1H-imidazol-2-yl]-L-ornithine (Cys-Arg) (interchain with R-135 in KEAP1)	SEQ_UP	1	
CROSSLNK:Peptide (Met-Gly) (interchain with G-Cter in ubiquitin)	SEQ_UP	5	
CROSSLNK:S-Lysyl-methionine sulfilimine (Lys-Met) (interchain with M-1532)	SEQ_UP	1	
CROSSLNK:S-Lysyl-methionine sulfilimine (Lys-Met) (interchain with M-1533)	SEQ_UP	1	
CROSSLNK:S-Lysyl-methionine sulfilimine (Met-Lys) (interchain with K-1650)	SEQ_UP	1	
CROSSLNK:S-Lysyl-methionine sulfilimine (Met-Lys) (interchain with K-1651)	SEQ_UP	1	
DISULFID:Alternate	SEQ_UP	11	
DISULFID:Alternate; present in the absence of reducing agents	SEQ_UP	1	
DISULFID:Alternate; transient; in hyperoxia; unknown whether inter- or intrachain	SEQ_UP	1	
DISULFID:Associated with receptor activation	SEQ_UP	7	
DISULFID:Essential for enzymatic activity	SEQ_UP	4	
DISULFID:In disulfide HMGB1; alternate	SEQ_UP	1	
DISULFID:In disulfide HMGB2; alternate	SEQ_UP	1	
DISULFID:In disulfide HMGB3; alternate	SEQ_UP	1	
DISULFID:In inhibited form	SEQ_UP	1	
DISULFID:In isoform 1	SEQ_UP	1	
DISULFID:In oxidase form	SEQ_UP	1	
DISULFID:In soluble form	SEQ_UP	1	
DISULFID:Interchain	SEQ_UP	163	
DISULFID:Interchain (between A and B chains)	SEQ_UP	4	
DISULFID:Interchain (between alpha and beta chains)	SEQ_UP	5	
DISULFID:Interchain (between alpha and beta subunits)	SEQ_UP	1	
DISULFID:Interchain (between alpha-2-1 and delta-1 chains)	SEQ_UP	1	
DISULFID:Interchain (between alpha-2-2 and delta-2 chains)	SEQ_UP	1	
DISULFID:Interchain (between alpha-2-3 and delta-3 chains)	SEQ_UP	1	
DISULFID:Interchain (between alpha-2-4 and delta-4 chains)	SEQ_UP	1	
DISULFID:Interchain (between B and A chains)	SEQ_UP	6	
DISULFID:Interchain (between beta and alpha chains)	SEQ_UP	2	
DISULFID:Interchain (between heavy and light chains)	SEQ_UP	18	
DISULFID:Interchain (between light and heavy chains)	SEQ_UP	7	
DISULFID:Interchain (between N-terminal propeptide and activated protease fragment chains)	SEQ_UP	1	
DISULFID:Interchain (between non-catalytic and catalytic chains)	SEQ_UP	4	
DISULFID:Interchain (between short and long chains)	SEQ_UP	1	
DISULFID:Interchain (between small and large subunit)	SEQ_UP	1	
DISULFID:Interchain (between SU and TM chains, or C-47 with C-505); in linked form	SEQ_UP	1	
DISULFID:Interchain (between SU and TM chains, or C-47 with C-507); in linked form	SEQ_UP	1	
DISULFID:Interchain (C-577 in SUN2); alternate	SEQ_UP	1	
DISULFID:Interchain (with a heavy chain)	SEQ_UP	6	
DISULFID:Interchain (with a light chain)	SEQ_UP	4	
DISULFID:Interchain (with alpha chain)	SEQ_UP	2	
DISULFID:Interchain (with beta chain)	SEQ_UP	2	
DISULFID:Interchain (with beta-1 chain)	SEQ_UP	1	
DISULFID:Interchain (with beta-3 chain)	SEQ_UP	1	
DISULFID:Interchain (with C-? in TGFB1); in linked form	SEQ_UP	1	
DISULFID:Interchain (with C-100)	SEQ_UP	1	
DISULFID:Interchain (with C-104)	SEQ_UP	1	
DISULFID:Interchain (with C-109); in linked form	SEQ_UP	1	
DISULFID:Interchain (with C-113 in alpha chain)	SEQ_UP	1	
DISULFID:Interchain (with C-116 in KLRC1/NGK2A)	SEQ_UP	1	
DISULFID:Interchain (with C-118 in TAPBP); in linked form	SEQ_UP	1	
DISULFID:Interchain (with C-1254)	SEQ_UP	1	
DISULFID:Interchain (with C-1266)	SEQ_UP	1	
DISULFID:Interchain (with C-1268)	SEQ_UP	1	
DISULFID:Interchain (with C-127); in linked form	SEQ_UP	1	
DISULFID:Interchain (with C-1271)	SEQ_UP	1	
DISULFID:Interchain (with C-1283)	SEQ_UP	1	
DISULFID:Interchain (with C-1285)	SEQ_UP	1	
DISULFID:Interchain (with C-1289)	SEQ_UP	1	
DISULFID:Interchain (with C-1306)	SEQ_UP	1	
DISULFID:Interchain (with C-1312); in homotrimer	SEQ_UP	1	
DISULFID:Interchain (with C-135 in beta chain)	SEQ_UP	1	
DISULFID:Interchain (with C-135)	SEQ_UP	1	
DISULFID:Interchain (with C-1359 or C-1384 in LTBP1); in inactive form	SEQ_UP	1	
DISULFID:Interchain (with C-147 in GP1BB)	SEQ_UP	1	
DISULFID:Interchain (with C-147)	SEQ_UP	1	
DISULFID:Interchain (with C-164 in SLC7A5)	SEQ_UP	1	
DISULFID:Interchain (with C-170 in PRG2 proform)	SEQ_UP	1	
DISULFID:Interchain (with C-172 in FOSB)	SEQ_UP	1	
DISULFID:Interchain (with C-172); in linked form	SEQ_UP	1	
DISULFID:Interchain (with C-173); in linked form	SEQ_UP	1	
DISULFID:Interchain (with C-18)	SEQ_UP	2	
DISULFID:Interchain (with C-186 in PIGT)	SEQ_UP	1	
DISULFID:Interchain (with C-193)	SEQ_UP	1	
DISULFID:Interchain (with C-194 in C8-alpha chain)	SEQ_UP	1	
DISULFID:Interchain (with C-197 in IL12B)	SEQ_UP	1	
DISULFID:Interchain (with C-197)	SEQ_UP	1	
DISULFID:Interchain (with C-210 in SLC3A2)	SEQ_UP	1	
DISULFID:Interchain (with C-213 in beta chain)	SEQ_UP	1	
DISULFID:Interchain (with C-219 in Q65ZC0)	SEQ_UP	1	
DISULFID:Interchain (with C-22)	SEQ_UP	1	
DISULFID:Interchain (with C-223)	SEQ_UP	2	
DISULFID:Interchain (with C-225)	SEQ_UP	1	
DISULFID:Interchain (with C-230); in linked form	SEQ_UP	1	
DISULFID:Interchain (with C-24)	SEQ_UP	1	
DISULFID:Interchain (with C-2458)	SEQ_UP	1	
DISULFID:Interchain (with C-2462)	SEQ_UP	1	
DISULFID:Interchain (with C-248); in linked form	SEQ_UP	1	
DISULFID:Interchain (with C-258)	SEQ_UP	1	
DISULFID:Interchain (with C-26 in chain A)	SEQ_UP	1	
DISULFID:Interchain (with C-264); redox-active	SEQ_UP	1	
DISULFID:Interchain (with C-273)	SEQ_UP	1	
DISULFID:Interchain (with C-274)	SEQ_UP	1	
DISULFID:Interchain (with C-277)	SEQ_UP	1	
DISULFID:Interchain (with C-279 in JUND)	SEQ_UP	1	
DISULFID:Interchain (with C-284)	SEQ_UP	1	
DISULFID:Interchain (with C-286)	SEQ_UP	1	
DISULFID:Interchain (with C-29 in B chain)	SEQ_UP	1	
DISULFID:Interchain (with C-292)	SEQ_UP	1	
DISULFID:Interchain (with C-327)	SEQ_UP	1	
DISULFID:Interchain (with C-33 in TGFB1); in linked form	SEQ_UP	4	
DISULFID:Interchain (with C-347 in XK)	SEQ_UP	1	
DISULFID:Interchain (with C-361)	SEQ_UP	1	
DISULFID:Interchain (with C-37)	SEQ_UP	1	
DISULFID:Interchain (with C-39)	SEQ_UP	2	
DISULFID:Interchain (with C-410 in MICU2)	SEQ_UP	1	
DISULFID:Interchain (with C-412)	SEQ_UP	1	
DISULFID:Interchain (with C-43 or C-50); in multimeric form	SEQ_UP	1	
DISULFID:Interchain (with C-430)	SEQ_UP	1	
DISULFID:Interchain (with C-437)	SEQ_UP	1	
DISULFID:Interchain (with C-45)	SEQ_UP	1	
DISULFID:Interchain (with C-465 in MICU1)	SEQ_UP	1	
DISULFID:Interchain (with C-49 in PRG2 proform)	SEQ_UP	1	
DISULFID:Interchain (with C-51); in linked form	SEQ_UP	1	
DISULFID:Interchain (with C-52; in linked form)	SEQ_UP	1	
DISULFID:Interchain (with C-529)	SEQ_UP	1	
DISULFID:Interchain (with C-53 in Kell)	SEQ_UP	1	
DISULFID:Interchain (with C-568 in DUXA2)	SEQ_UP	1	
DISULFID:Interchain (with C-57 in PDIA3)	SEQ_UP	1	
DISULFID:Interchain (with C-577 in SUN2); alternate	SEQ_UP	3	
DISULFID:Interchain (with C-582 in DUXA2)	SEQ_UP	1	
DISULFID:Interchain (with C-59)	SEQ_UP	1	
DISULFID:Interchain (with C-6)	SEQ_UP	1	
DISULFID:Interchain (with C-60 in C8-gamma chain)	SEQ_UP	1	
DISULFID:Interchain (with C-608 or C-609 in GP1BA)	SEQ_UP	1	
DISULFID:Interchain (with C-62)	SEQ_UP	1	
DISULFID:Interchain (with C-68)	SEQ_UP	1	
DISULFID:Interchain (with C-6851 in SYNE2)	SEQ_UP	1	
DISULFID:Interchain (with C-71)	SEQ_UP	1	
DISULFID:Interchain (with C-733); in homotrimer	SEQ_UP	1	
DISULFID:Interchain (with C-759 in SUN1)	SEQ_UP	2	
DISULFID:Interchain (with C-759 in SUN1); alternate	SEQ_UP	2	
DISULFID:Interchain (with C-80)	SEQ_UP	1	
DISULFID:Interchain (with C-82)	SEQ_UP	1	
DISULFID:Interchain (with C-88)	SEQ_UP	1	
DISULFID:Interchain (with C-90)	SEQ_UP	1	
DISULFID:Interchain (with C-91)	SEQ_UP	1	
DISULFID:Interchain (with C-92 in IL12A and C-74 in IL23A)	SEQ_UP	1	
DISULFID:Interchain (with C-92 in PIGK/GPI8)	SEQ_UP	1	
DISULFID:Interchain (with C-93)	SEQ_UP	1	
DISULFID:Interchain (with C-96)	SEQ_UP	1	
DISULFID:Interchain (with gamma chain)	SEQ_UP	3	
DISULFID:Interchain (with heavy chain)	SEQ_UP	4	
DISULFID:Interchain (with KASH domain-containing nesprins)	SEQ_UP	1	
DISULFID:Interchain (with light chain)	SEQ_UP	1	
DISULFID:Interchain (with NUP155)	SEQ_UP	1	
DISULFID:Interchain (with ROM1)	SEQ_UP	1	
DISULFID:Interchain (with T subunit)	SEQ_UP	1	
DISULFID:Interchain (with TCRB)	SEQ_UP	1	
DISULFID:Interchain, redox-active	SEQ_UP	1	
DISULFID:Interchain; alternate	SEQ_UP	1	
DISULFID:Interchain; redox-active	SEQ_UP	1	
DISULFID:Interchain; with alpha subunit	SEQ_UP	2	
DISULFID:Interchain; with SCN2B or SCN4B	SEQ_UP	6	
DISULFID:Interchain; with the conotoxin GVIIJ (when the channel is not linked to SCN2B or SCN4B; the bond to SCN2B or SCN4B protects the channel from the inhibition by toxin)	SEQ_UP	6	
DISULFID:Or C-106 with C-132	SEQ_UP	1	
DISULFID:Or C-1459 with C-1547	SEQ_UP	1	
DISULFID:Or C-1460 with C-1548	SEQ_UP	1	
DISULFID:Or C-1472 with C-1558	SEQ_UP	1	
DISULFID:Or C-1492 with C-1550	SEQ_UP	1	
DISULFID:Or C-1493 with C-1551	SEQ_UP	1	
DISULFID:Or C-1505 with C-1561	SEQ_UP	1	
DISULFID:Or C-1569 with C-1661	SEQ_UP	1	
DISULFID:Or C-1570 with C-1662	SEQ_UP	1	
DISULFID:Or C-1580 with C-1675	SEQ_UP	1	
DISULFID:Or C-1603 with C-1664	SEQ_UP	1	
DISULFID:Or C-1604 with C-1665	SEQ_UP	1	
DISULFID:Or C-1614 with C-1678	SEQ_UP	1	
DISULFID:Or C-1899 with C-1942	SEQ_UP	1	
DISULFID:Or C-51 with C-4 or C-9	SEQ_UP	1	
DISULFID:Or C-580 with C-609	SEQ_UP	1	
DISULFID:Or C-584 with C-597	SEQ_UP	1	
DISULFID:Or C-90 with C-133	SEQ_UP	1	
DISULFID:Redox-active	SEQ_UP	52	
DISULFID:Redox-active; alternate	SEQ_UP	4	
DNA_BIND:A.T hook	SEQ_UP	12	
DNA_BIND:A.T hook 1	SEQ_UP	11	
DNA_BIND:A.T hook 2	SEQ_UP	11	
DNA_BIND:A.T hook 3	SEQ_UP	9	
DNA_BIND:A.T hook 4	SEQ_UP	1	
DNA_BIND:CG-1	SEQ_UP	2	
DNA_BIND:CTF/NF-I	SEQ_UP	4	
DNA_BIND:CUT	SEQ_UP	3	
DNA_BIND:CUT 1	SEQ_UP	4	
DNA_BIND:CUT 2	SEQ_UP	4	
DNA_BIND:CUT 3	SEQ_UP	2	
DNA_BIND:DM	SEQ_UP	7	
DNA_BIND:ETS	SEQ_UP	26	
DNA_BIND:Fork-head	SEQ_UP	46	
DNA_BIND:GCM	SEQ_UP	2	
DNA_BIND:H-T-H motif	SEQ_UP	20	
DNA_BIND:HMG box	SEQ_UP	52	
DNA_BIND:HMG box 1	SEQ_UP	7	
DNA_BIND:HMG box 2	SEQ_UP	7	
DNA_BIND:HMG box 3	SEQ_UP	1	
DNA_BIND:HMG box 4	SEQ_UP	1	
DNA_BIND:HMG box 5	SEQ_UP	1	
DNA_BIND:HMG box 6	SEQ_UP	1	
DNA_BIND:Homeobox	SEQ_UP	257	
DNA_BIND:Homeobox 1	SEQ_UP	8	
DNA_BIND:Homeobox 2	SEQ_UP	8	
DNA_BIND:Homeobox 3	SEQ_UP	7	
DNA_BIND:Homeobox 4	SEQ_UP	5	
DNA_BIND:Homeobox 5	SEQ_UP	2	
DNA_BIND:Homeobox; atypical	SEQ_UP	6	
DNA_BIND:Homeobox; HNF1-type	SEQ_UP	2	
DNA_BIND:Homeobox; TALE-type	SEQ_UP	17	
DNA_BIND:Integrase-type	SEQ_UP	3	
DNA_BIND:IRF tryptophan pentad repeat	SEQ_UP	9	
DNA_BIND:Mef2-type	SEQ_UP	5	
DNA_BIND:NBD	SEQ_UP	1	
DNA_BIND:NDT80	SEQ_UP	2	
DNA_BIND:NFYA/HAP2-type	SEQ_UP	1	
DNA_BIND:Nuclear receptor	SEQ_UP	46	
DNA_BIND:OB	SEQ_UP	9	
DNA_BIND:Paired	SEQ_UP	9	
DNA_BIND:RFX-type winged-helix	SEQ_UP	8	
DNA_BIND:T-box	SEQ_UP	16	
DNA_BIND:T-box; first part	SEQ_UP	1	
DNA_BIND:T-box; second part	SEQ_UP	1	
DNA_BIND:TEA	SEQ_UP	4	
DNA_BIND:TFIIE beta	SEQ_UP	1	
DOMAIN:1-cysPrx_C	SEQ_UP	1	
DOMAIN:14_3_3	SEQ_UP	7	
DOMAIN:2-Hacid_dh	SEQ_UP	4	
DOMAIN:2-Hacid_dh_C	SEQ_UP	4	
DOMAIN:2-oxoacid_dh	SEQ_UP	1	
DOMAIN:2-oxogl_dehyd_N	SEQ_UP	1	
DOMAIN:2Fe-2S ferredoxin-type	SEQ_UP	10	
DOMAIN:2OG-FeII_Oxy_2	SEQ_UP	1	
DOMAIN:3-PAP	SEQ_UP	1	
DOMAIN:3'-5' exonuclease	SEQ_UP	4	
DOMAIN:3Beta_HSD	SEQ_UP	10	
DOMAIN:3HCDH	SEQ_UP	2	
DOMAIN:3HCDH_N	SEQ_UP	2	
DOMAIN:4_1_CTD	SEQ_UP	4	
DOMAIN:4.1m	SEQ_UP	8	
DOMAIN:40S_SA_C	SEQ_UP	1	
DOMAIN:4F5	SEQ_UP	3	
DOMAIN:4Fe-4S ferredoxin-type	SEQ_UP	6	
DOMAIN:4Fe-4S ferredoxin-type 1	SEQ_UP	3	
DOMAIN:4Fe-4S ferredoxin-type 2	SEQ_UP	3	
DOMAIN:4Fe-4S ferredoxin-type 3	SEQ_UP	1	
DOMAIN:4Fe-4S His(Cys)3-ligated-type	SEQ_UP	1	
DOMAIN:4Fe-4S Mo/W bis-MGD-type	SEQ_UP	1	
DOMAIN:4HBT	SEQ_UP	3	
DOMAIN:5_nucleotid_C	SEQ_UP	2	
DOMAIN:53-BP1_Tudor	SEQ_UP	1	
DOMAIN:5HT_transport_N	SEQ_UP	1	
DOMAIN:6PF2K	SEQ_UP	5	
DOMAIN:6PGD	SEQ_UP	1	
DOMAIN:A to I editase	SEQ_UP	6	
DOMAIN:A_deaminase	SEQ_UP	2	
DOMAIN:A20-type	SEQ_UP	5	
DOMAIN:A2M	SEQ_UP	5	
DOMAIN:A2M_N_2	SEQ_UP	4	
DOMAIN:A2M_recep	SEQ_UP	4	
DOMAIN:AA_kinase	SEQ_UP	1	
DOMAIN:AA_permease	SEQ_UP	10	
DOMAIN:AA_permease_C	SEQ_UP	6	
DOMAIN:AA_permease_N	SEQ_UP	3	
DOMAIN:Aa_trans	SEQ_UP	12	
DOMAIN:AA_TRNA_LIGASE_II	SEQ_UP	13	
DOMAIN:AA_TRNA_LIGASE_II_ALA	SEQ_UP	2	
DOMAIN:AAA	SEQ_UP	47	
DOMAIN:AAA_11	SEQ_UP	9	
DOMAIN:AAA_12	SEQ_UP	8	
DOMAIN:AAA_16	SEQ_UP	2	
DOMAIN:AAA_23	SEQ_UP	1	
DOMAIN:AAA_34	SEQ_UP	2	
DOMAIN:AAA_5	SEQ_UP	2	
DOMAIN:AAA_6	SEQ_UP	9	
DOMAIN:AAA_8	SEQ_UP	6	
DOMAIN:AAA_9	SEQ_UP	8	
DOMAIN:AAA_lid_1	SEQ_UP	2	
DOMAIN:AAA_lid_11	SEQ_UP	8	
DOMAIN:AAA_lid_3	SEQ_UP	5	
DOMAIN:AAA_lid_7	SEQ_UP	1	
DOMAIN:Aamy	SEQ_UP	5	
DOMAIN:Aamy_C	SEQ_UP	1	
DOMAIN:AATF-Che1	SEQ_UP	1	
DOMAIN:AB hydrolase-1	SEQ_UP	28	
DOMAIN:ABC transmembrane type-1	SEQ_UP	25	
DOMAIN:ABC transmembrane type-1 1	SEQ_UP	15	
DOMAIN:ABC transmembrane type-1 2	SEQ_UP	15	
DOMAIN:ABC transmembrane type-2	SEQ_UP	5	
DOMAIN:ABC transporter	SEQ_UP	47	
DOMAIN:ABC transporter 1	SEQ_UP	32	
DOMAIN:ABC transporter 2	SEQ_UP	32	
DOMAIN:ABC_tran_Xtn	SEQ_UP	1	
DOMAIN:ABC_transp_aux	SEQ_UP	1	
DOMAIN:ABC1	SEQ_UP	4	
DOMAIN:ABC2_membrane	SEQ_UP	4	
DOMAIN:ABC2_membrane_7	SEQ_UP	1	
DOMAIN:Abhydro_lipase	SEQ_UP	5	
DOMAIN:Abhydrolase_2	SEQ_UP	2	
DOMAIN:Abhydrolase_3	SEQ_UP	14	
DOMAIN:Abi_HHR	SEQ_UP	1	
DOMAIN:AbLIM_anchor	SEQ_UP	2	
DOMAIN:ABM	SEQ_UP	3	
DOMAIN:AC_N	SEQ_UP	1	
DOMAIN:ACAS_N	SEQ_UP	2	
DOMAIN:ACB	SEQ_UP	9	
DOMAIN:ACC_central	SEQ_UP	1	
DOMAIN:Acetyltransf_13	SEQ_UP	1	
DOMAIN:AChE_tetra	SEQ_UP	2	
DOMAIN:acidPPc	SEQ_UP	8	
DOMAIN:Aconitase	SEQ_UP	3	
DOMAIN:Aconitase_C	SEQ_UP	2	
DOMAIN:ACOX	SEQ_UP	3	
DOMAIN:ACPS	SEQ_UP	1	
DOMAIN:ACR	SEQ_UP	1	
DOMAIN:ACT	SEQ_UP	3	
DOMAIN:ACT 1	SEQ_UP	2	
DOMAIN:ACT 2	SEQ_UP	2	
DOMAIN:Activin_recp	SEQ_UP	3	
DOMAIN:Acyl-CoA_dh_1	SEQ_UP	11	
DOMAIN:Acyl-CoA_dh_M	SEQ_UP	12	
DOMAIN:Acyl-CoA_dh_N	SEQ_UP	10	
DOMAIN:Acyl-CoA_ox_N	SEQ_UP	2	
DOMAIN:Acylphosphatase-like	SEQ_UP	2	
DOMAIN:AD	SEQ_UP	1	
DOMAIN:ADAM_CR_3	SEQ_UP	3	
DOMAIN:ADAM_spacer1	SEQ_UP	4	
DOMAIN:Adaptin_N	SEQ_UP	10	
DOMAIN:ADD	SEQ_UP	5	
DOMAIN:ADD_ATRX	SEQ_UP	1	
DOMAIN:AdenylateSensor	SEQ_UP	1	
DOMAIN:ADF-H	SEQ_UP	10	
DOMAIN:ADF-H 1	SEQ_UP	2	
DOMAIN:ADF-H 2	SEQ_UP	2	
DOMAIN:ADH_N	SEQ_UP	6	
DOMAIN:ADH_N_2	SEQ_UP	1	
DOMAIN:ADH_zinc_N	SEQ_UP	7	
DOMAIN:Adhes-Ig_like	SEQ_UP	1	
DOMAIN:ADK_lid	SEQ_UP	2	
DOMAIN:AdoHcyase_NAD	SEQ_UP	3	
DOMAIN:AdoMet activation	SEQ_UP	1	
DOMAIN:ADPK	SEQ_UP	1	
DOMAIN:Adrift-type SAM-dependent 2'-O-MTase	SEQ_UP	1	
DOMAIN:ADSL_C	SEQ_UP	1	
DOMAIN:AF-4_C	SEQ_UP	4	
DOMAIN:AFP-like	SEQ_UP	1	
DOMAIN:AGC-kinase C-terminal	SEQ_UP	53	
DOMAIN:Agenet	SEQ_UP	1	
DOMAIN:Agenet-like	SEQ_UP	3	
DOMAIN:Agenet-like 1	SEQ_UP	3	
DOMAIN:Agenet-like 2	SEQ_UP	3	
DOMAIN:Ago_hook	SEQ_UP	2	
DOMAIN:Agouti	SEQ_UP	2	
DOMAIN:AGRB_N	SEQ_UP	1	
DOMAIN:AH	SEQ_UP	6	
DOMAIN:Aha1_N	SEQ_UP	2	
DOMAIN:AHD	SEQ_UP	2	
DOMAIN:AhpC-TSA	SEQ_UP	1	
DOMAIN:Aida_N	SEQ_UP	1	
DOMAIN:AIF_C	SEQ_UP	1	
DOMAIN:AIF-MLS	SEQ_UP	2	
DOMAIN:AIG1-type G	SEQ_UP	9	
DOMAIN:AIG1-type G 1	SEQ_UP	1	
DOMAIN:AIG1-type G 2	SEQ_UP	1	
DOMAIN:AIG1-type G 3	SEQ_UP	1	
DOMAIN:AIP3	SEQ_UP	2	
DOMAIN:AIRS	SEQ_UP	2	
DOMAIN:AIRS_C	SEQ_UP	2	
DOMAIN:AJAP1_PANP_C	SEQ_UP	1	
DOMAIN:AKAP_110	SEQ_UP	3	
DOMAIN:AKAP_CAM_BD	SEQ_UP	2	
DOMAIN:AKAP2_C	SEQ_UP	2	
DOMAIN:AKAP7_NLS	SEQ_UP	1	
DOMAIN:AKAP7_RIRII_bdg	SEQ_UP	1	
DOMAIN:AKNA	SEQ_UP	1	
DOMAIN:Ala_racemase_N	SEQ_UP	1	
DOMAIN:AlaDh_PNT_C	SEQ_UP	2	
DOMAIN:AlaDh_PNT_N	SEQ_UP	2	
DOMAIN:AlbA_2	SEQ_UP	7	
DOMAIN:Albumin	SEQ_UP	4	
DOMAIN:Albumin 1	SEQ_UP	4	
DOMAIN:Albumin 2	SEQ_UP	4	
DOMAIN:Albumin 3	SEQ_UP	4	
DOMAIN:Ald_Xan_dh_C	SEQ_UP	1	
DOMAIN:Ald_Xan_dh_C2	SEQ_UP	1	
DOMAIN:Aldedh	SEQ_UP	16	
DOMAIN:Aldo_ket_red	SEQ_UP	17	
DOMAIN:Aldolase_II	SEQ_UP	3	
DOMAIN:ALG11_N	SEQ_UP	1	
DOMAIN:Allantoicase	SEQ_UP	1	
DOMAIN:ALMS_motif	SEQ_UP	2	
DOMAIN:Alpha_adaptinC2	SEQ_UP	4	
DOMAIN:Alpha-2-MRAP_C	SEQ_UP	1	
DOMAIN:Alpha-2-MRAP_N	SEQ_UP	1	
DOMAIN:Alpha-carbonic anhydrase	SEQ_UP	18	
DOMAIN:Alpha-mann_mid	SEQ_UP	4	
DOMAIN:Alpha-type protein kinase	SEQ_UP	6	
DOMAIN:Amidase	SEQ_UP	1	
DOMAIN:Amidohydro-rel	SEQ_UP	9	
DOMAIN:Amino_oxidase	SEQ_UP	14	
DOMAIN:Aminotran_1_2	SEQ_UP	13	
DOMAIN:Aminotran_5	SEQ_UP	5	
DOMAIN:AMMECR1	SEQ_UP	2	
DOMAIN:Ammonium_transp	SEQ_UP	5	
DOMAIN:AMOP	SEQ_UP	4	
DOMAIN:AMP_N	SEQ_UP	1	
DOMAIN:AMP-binding	SEQ_UP	22	
DOMAIN:AMP-binding_C	SEQ_UP	14	
DOMAIN:AMPK1_CBM	SEQ_UP	2	
DOMAIN:AMPKBI	SEQ_UP	2	
DOMAIN:AN1-type	SEQ_UP	6	
DOMAIN:ANAPC4	SEQ_UP	1	
DOMAIN:ANAPC4_WD40	SEQ_UP	15	
DOMAIN:ANAPC5	SEQ_UP	2	
DOMAIN:ANAPC8	SEQ_UP	1	
DOMAIN:Anaphylatoxin-like	SEQ_UP	7	
DOMAIN:Anaphylatoxin-like 1	SEQ_UP	2	
DOMAIN:Anaphylatoxin-like 2	SEQ_UP	2	
DOMAIN:Anaphylatoxin-like 3	SEQ_UP	2	
DOMAIN:ANF_receptor	SEQ_UP	68	
DOMAIN:Angiomotin_C	SEQ_UP	3	
DOMAIN:Anillin	SEQ_UP	1	
DOMAIN:Anillin_N	SEQ_UP	1	
DOMAIN:Anoct_dimer	SEQ_UP	5	
DOMAIN:Ant_C	SEQ_UP	1	
DOMAIN:ANTH	SEQ_UP	3	
DOMAIN:Anth_Ig	SEQ_UP	1	
DOMAIN:Anti_prolifrtn	SEQ_UP	8	
DOMAIN:Anticodon_1	SEQ_UP	5	
DOMAIN:Anticodon_3	SEQ_UP	1	
DOMAIN:Antigen_C	SEQ_UP	1	
DOMAIN:Antistasin-like	SEQ_UP	1	
DOMAIN:Antistasin-like 1	SEQ_UP	1	
DOMAIN:Antistasin-like 2	SEQ_UP	1	
DOMAIN:Antistasin-like 3	SEQ_UP	1	
DOMAIN:Antistasin-like 4	SEQ_UP	1	
DOMAIN:AP_endonuc_2	SEQ_UP	1	
DOMAIN:AP3B1_C	SEQ_UP	2	
DOMAIN:ApaG	SEQ_UP	2	
DOMAIN:APC_basic	SEQ_UP	2	
DOMAIN:APC_N_CC	SEQ_UP	2	
DOMAIN:APC1_C	SEQ_UP	1	
DOMAIN:APEH_N	SEQ_UP	1	
DOMAIN:APG6	SEQ_UP	2	
DOMAIN:APG6_N	SEQ_UP	2	
DOMAIN:APH	SEQ_UP	4	
DOMAIN:APP_amyloid	SEQ_UP	2	
DOMAIN:Apple	SEQ_UP	3	
DOMAIN:Apple 1	SEQ_UP	2	
DOMAIN:Apple 2	SEQ_UP	2	
DOMAIN:Apple 3	SEQ_UP	2	
DOMAIN:Apple 4	SEQ_UP	2	
DOMAIN:Aquarius_N	SEQ_UP	1	
DOMAIN:ARA70	SEQ_UP	1	
DOMAIN:Archease	SEQ_UP	1	
DOMAIN:Arf-GAP	SEQ_UP	23	
DOMAIN:Arg_tRNA_synt_N	SEQ_UP	1	
DOMAIN:ArgoN	SEQ_UP	1	
DOMAIN:Ariadne	SEQ_UP	1	
DOMAIN:ARID	SEQ_UP	15	
DOMAIN:ARL2_Bind_BART	SEQ_UP	2	
DOMAIN:Arm_2	SEQ_UP	5	
DOMAIN:ARMET_C	SEQ_UP	1	
DOMAIN:ARMET_N	SEQ_UP	1	
DOMAIN:ARMT1-like_dom	SEQ_UP	1	
DOMAIN:Arrestin_C	SEQ_UP	9	
DOMAIN:Arrestin_N	SEQ_UP	5	
DOMAIN:ARS2	SEQ_UP	1	
DOMAIN:ArsA_ATPase	SEQ_UP	1	
DOMAIN:ASCH	SEQ_UP	2	
DOMAIN:ASD1	SEQ_UP	3	
DOMAIN:ASD2	SEQ_UP	4	
DOMAIN:ASH	SEQ_UP	2	
DOMAIN:ASL_C2	SEQ_UP	1	
DOMAIN:ASMase_C	SEQ_UP	1	
DOMAIN:Asp_Arg_Hydrox	SEQ_UP	1	
DOMAIN:Asp_protease	SEQ_UP	2	
DOMAIN:Asp-B-Hydro_N	SEQ_UP	2	
DOMAIN:Asparaginase	SEQ_UP	1	
DOMAIN:Asparaginase/glutaminase	SEQ_UP	1	
DOMAIN:Asparagine synthetase	SEQ_UP	2	
DOMAIN:ASTN_1_2_N	SEQ_UP	1	
DOMAIN:ASTN1_2_EGF_Fn	SEQ_UP	1	
DOMAIN:ATE_C	SEQ_UP	1	
DOMAIN:ATE_N	SEQ_UP	1	
DOMAIN:ATF7IP_BD	SEQ_UP	2	
DOMAIN:ATG_C	SEQ_UP	4	
DOMAIN:ATG11	SEQ_UP	1	
DOMAIN:ATG16	SEQ_UP	2	
DOMAIN:ATG17_like	SEQ_UP	1	
DOMAIN:ATG7_N	SEQ_UP	1	
DOMAIN:ATP_Ca_trans_C	SEQ_UP	2	
DOMAIN:ATP-cone	SEQ_UP	1	
DOMAIN:ATP-grasp	SEQ_UP	16	
DOMAIN:ATP-grasp 1	SEQ_UP	2	
DOMAIN:ATP-grasp 2	SEQ_UP	2	
DOMAIN:ATP-grasp_2	SEQ_UP	1	
DOMAIN:ATP-sulfurylase	SEQ_UP	2	
DOMAIN:ATP-synt_ab	SEQ_UP	3	
DOMAIN:ATP-synt_ab_C	SEQ_UP	1	
DOMAIN:ATP-synt_ab_N	SEQ_UP	4	
DOMAIN:ATP-synt_ab_Xtn	SEQ_UP	1	
DOMAIN:ATP-synt_C	SEQ_UP	3	
DOMAIN:ATP-synt_DE_N	SEQ_UP	1	
DOMAIN:ATPase_AAA_core	SEQ_UP	7	
DOMAIN:Atx10homo_assoc	SEQ_UP	1	
DOMAIN:ATXN-1_C	SEQ_UP	1	
DOMAIN:Aurora-A_bind	SEQ_UP	1	
DOMAIN:AWS	SEQ_UP	5	
DOMAIN:AXH	SEQ_UP	3	
DOMAIN:AXIN1_TNKS_BD	SEQ_UP	1	
DOMAIN:AZUL	SEQ_UP	1	
DOMAIN:B box-type	SEQ_UP	60	
DOMAIN:B-block_TFIIIC	SEQ_UP	1	
DOMAIN:B12-binding	SEQ_UP	2	
DOMAIN:B12-binding N-terminal	SEQ_UP	1	
DOMAIN:B2-adapt-app_C	SEQ_UP	4	
DOMAIN:B3_4	SEQ_UP	2	
DOMAIN:B30.2/SPRY	SEQ_UP	83	
DOMAIN:B30.2/SPRY 1	SEQ_UP	3	
DOMAIN:B30.2/SPRY 2	SEQ_UP	3	
DOMAIN:B30.2/SPRY 3	SEQ_UP	3	
DOMAIN:B41	SEQ_UP	2	
DOMAIN:B5	SEQ_UP	1	
DOMAIN:BAAT_C	SEQ_UP	7	
DOMAIN:BACK	SEQ_UP	42	
DOMAIN:BAF250_C	SEQ_UP	2	
DOMAIN:BaffR-Tall_bind	SEQ_UP	1	
DOMAIN:BAG	SEQ_UP	5	
DOMAIN:BAG 1	SEQ_UP	1	
DOMAIN:BAG 2	SEQ_UP	1	
DOMAIN:BAG 3	SEQ_UP	1	
DOMAIN:BAG 4	SEQ_UP	1	
DOMAIN:BAG 5	SEQ_UP	1	
DOMAIN:BAH	SEQ_UP	11	
DOMAIN:BAH 1	SEQ_UP	2	
DOMAIN:BAH 2	SEQ_UP	2	
DOMAIN:BAMBI	SEQ_UP	1	
DOMAIN:BAMBI_C	SEQ_UP	1	
DOMAIN:Band_3_cyto	SEQ_UP	8	
DOMAIN:Bap31	SEQ_UP	2	
DOMAIN:Bap31_Bap29_C	SEQ_UP	2	
DOMAIN:BAR	SEQ_UP	31	
DOMAIN:BAT2_N	SEQ_UP	3	
DOMAIN:BBC	SEQ_UP	1	
DOMAIN:BBS1	SEQ_UP	1	
DOMAIN:BBS2_C	SEQ_UP	1	
DOMAIN:BCAS3	SEQ_UP	1	
DOMAIN:BCDHK_Adom3	SEQ_UP	3	
DOMAIN:BCL	SEQ_UP	8	
DOMAIN:Bclx_interact	SEQ_UP	1	
DOMAIN:BCNT-C	SEQ_UP	1	
DOMAIN:BcrAD_BadFG	SEQ_UP	1	
DOMAIN:BEACH	SEQ_UP	9	
DOMAIN:BEACH-type PH	SEQ_UP	8	
DOMAIN:BED-type	SEQ_UP	1	
DOMAIN:BEN	SEQ_UP	8	
DOMAIN:BEN 1	SEQ_UP	1	
DOMAIN:BEN 2	SEQ_UP	1	
DOMAIN:BEN 3	SEQ_UP	1	
DOMAIN:BEN 4	SEQ_UP	1	
DOMAIN:Beta_elim_lyase	SEQ_UP	2	
DOMAIN:Beta_helix	SEQ_UP	1	
DOMAIN:Beta-APP	SEQ_UP	1	
DOMAIN:Beta-Casp	SEQ_UP	4	
DOMAIN:Beta-lactamase	SEQ_UP	2	
DOMAIN:Beta-TrCP_D	SEQ_UP	1	
DOMAIN:Beta/gamma crystallin 'Greek key'	SEQ_UP	13	
DOMAIN:Beta/gamma crystallin 'Greek key' 1	SEQ_UP	15	
DOMAIN:Beta/gamma crystallin 'Greek key' 2	SEQ_UP	15	
DOMAIN:Beta/gamma crystallin 'Greek key' 3	SEQ_UP	15	
DOMAIN:Beta/gamma crystallin 'Greek key' 4	SEQ_UP	15	
DOMAIN:Beta/gamma crystallin 'Greek key' 5	SEQ_UP	1	
DOMAIN:Beta/gamma crystallin 'Greek key' 6	SEQ_UP	1	
DOMAIN:Beta/gamma crystallin 'Greek key' 7	SEQ_UP	1	
DOMAIN:Beta/gamma crystallin 'Greek key' 8	SEQ_UP	1	
DOMAIN:Beta/gamma crystallin 'Greek key' 9	SEQ_UP	1	
DOMAIN:BetaGal_dom4_5	SEQ_UP	1	
DOMAIN:BH3	SEQ_UP	1	
DOMAIN:BH4_2	SEQ_UP	4	
DOMAIN:BH4_AAA_HYDROXYL_2	SEQ_UP	3	
DOMAIN:BHD_1	SEQ_UP	1	
DOMAIN:BHD_2	SEQ_UP	1	
DOMAIN:BHD_3	SEQ_UP	1	
DOMAIN:bHLH	SEQ_UP	107	
DOMAIN:BHLH	SEQ_UP	84	
DOMAIN:BIG2	SEQ_UP	2	
DOMAIN:Bile_Hydr_Trans	SEQ_UP	8	
DOMAIN:Bim_N	SEQ_UP	1	
DOMAIN:Bin3-type SAM	SEQ_UP	2	
DOMAIN:BING4CT	SEQ_UP	1	
DOMAIN:Biotin carboxylation	SEQ_UP	5	
DOMAIN:Biotin_carb_N	SEQ_UP	1	
DOMAIN:Biotinyl-binding	SEQ_UP	5	
DOMAIN:BK_channel_a	SEQ_UP	4	
DOMAIN:BLVR	SEQ_UP	1	
DOMAIN:bMERB	SEQ_UP	7	
DOMAIN:BMERB	SEQ_UP	6	
DOMAIN:BMP2K_C	SEQ_UP	2	
DOMAIN:Bms1-type G	SEQ_UP	2	
DOMAIN:BOP1NT	SEQ_UP	1	
DOMAIN:BP28CT	SEQ_UP	1	
DOMAIN:BPI1	SEQ_UP	10	
DOMAIN:BPI2	SEQ_UP	6	
DOMAIN:BPL/LPL catalytic	SEQ_UP	3	
DOMAIN:BPS	SEQ_UP	1	
DOMAIN:BPTI/Kunitz inhibitor	SEQ_UP	19	
DOMAIN:BPTI/Kunitz inhibitor 1	SEQ_UP	7	
DOMAIN:BPTI/Kunitz inhibitor 2	SEQ_UP	7	
DOMAIN:BPTI/Kunitz inhibitor 3	SEQ_UP	2	
DOMAIN:BRAP2	SEQ_UP	1	
DOMAIN:Bravo_FIGEY	SEQ_UP	2	
DOMAIN:BRCT	SEQ_UP	23	
DOMAIN:BRCT 1	SEQ_UP	12	
DOMAIN:BRCT 2	SEQ_UP	12	
DOMAIN:BRCT 3	SEQ_UP	3	
DOMAIN:BRCT 4	SEQ_UP	2	
DOMAIN:BRCT 5	SEQ_UP	2	
DOMAIN:BRCT 6	SEQ_UP	2	
DOMAIN:BRCT 7	SEQ_UP	1	
DOMAIN:BRCT_assoc	SEQ_UP	1	
DOMAIN:BRD4_CDT	SEQ_UP	2	
DOMAIN:BRF1	SEQ_UP	1	
DOMAIN:BRICHOS	SEQ_UP	10	
DOMAIN:Brix	SEQ_UP	5	
DOMAIN:BRK	SEQ_UP	3	
DOMAIN:BRO1	SEQ_UP	5	
DOMAIN:Bromo	SEQ_UP	38	
DOMAIN:Bromo 1	SEQ_UP	9	
DOMAIN:Bromo 2	SEQ_UP	9	
DOMAIN:Bromo 3	SEQ_UP	1	
DOMAIN:Bromo 4	SEQ_UP	1	
DOMAIN:Bromo 5	SEQ_UP	1	
DOMAIN:Bromo 6	SEQ_UP	1	
DOMAIN:Bromo; divergent	SEQ_UP	1	
DOMAIN:BSD	SEQ_UP	3	
DOMAIN:BSD 1	SEQ_UP	1	
DOMAIN:BSD 2	SEQ_UP	1	
DOMAIN:BTB	SEQ_UP	208	
DOMAIN:BTB 1	SEQ_UP	10	
DOMAIN:BTB 2	SEQ_UP	10	
DOMAIN:BTB_2	SEQ_UP	9	
DOMAIN:BTB_3	SEQ_UP	2	
DOMAIN:BTD	SEQ_UP	2	
DOMAIN:BTHB	SEQ_UP	1	
DOMAIN:BTP	SEQ_UP	2	
DOMAIN:Btz	SEQ_UP	1	
DOMAIN:BUB1 N-terminal	SEQ_UP	2	
DOMAIN:bZIP	SEQ_UP	54	
DOMAIN:BZIP	SEQ_UP	43	
DOMAIN:C-CAP/cofactor C-like	SEQ_UP	5	
DOMAIN:c-SKI_SMAD_bind	SEQ_UP	3	
DOMAIN:C-type lectin	SEQ_UP	126	
DOMAIN:C-type lectin 1	SEQ_UP	4	
DOMAIN:C-type lectin 2	SEQ_UP	4	
DOMAIN:C-type lectin 3	SEQ_UP	4	
DOMAIN:C-type lectin 4	SEQ_UP	4	
DOMAIN:C-type lectin 5	SEQ_UP	4	
DOMAIN:C-type lectin 6	SEQ_UP	4	
DOMAIN:C-type lectin 7	SEQ_UP	4	
DOMAIN:C-type lectin 8	SEQ_UP	4	
DOMAIN:C-type lectin 9	SEQ_UP	1	
DOMAIN:C-type lysozyme	SEQ_UP	8	
DOMAIN:C1q	SEQ_UP	33	
DOMAIN:C1q 1	SEQ_UP	1	
DOMAIN:C1q 2	SEQ_UP	1	
DOMAIN:C2	SEQ_UP	131	
DOMAIN:C2 1	SEQ_UP	61	
DOMAIN:C2 2	SEQ_UP	61	
DOMAIN:C2 3	SEQ_UP	13	
DOMAIN:C2 4	SEQ_UP	7	
DOMAIN:C2 5	SEQ_UP	7	
DOMAIN:C2 6	SEQ_UP	6	
DOMAIN:C2 7	SEQ_UP	5	
DOMAIN:C2 Aida-type	SEQ_UP	1	
DOMAIN:C2 B9-type	SEQ_UP	3	
DOMAIN:C2 DOCK-type	SEQ_UP	11	
DOMAIN:C2 NT-type	SEQ_UP	4	
DOMAIN:C2 PI3K-type	SEQ_UP	8	
DOMAIN:C2 tensin-type	SEQ_UP	7	
DOMAIN:C2-C2_1	SEQ_UP	1	
DOMAIN:C2-set	SEQ_UP	2	
DOMAIN:C2H2 AKAP95-type	SEQ_UP	3	
DOMAIN:C2H2-type	SEQ_UP	647	
DOMAIN:C2HC RNF-type	SEQ_UP	5	
DOMAIN:C3H1-type	SEQ_UP	48	
DOMAIN:C3HC-type	SEQ_UP	1	
DOMAIN:C5-epim_C	SEQ_UP	1	
DOMAIN:C6_DPF	SEQ_UP	1	
DOMAIN:C8	SEQ_UP	2	
DOMAIN:Ca_chan_IQ	SEQ_UP	6	
DOMAIN:CABIT	SEQ_UP	1	
DOMAIN:CAC1F_C	SEQ_UP	1	
DOMAIN:Cache	SEQ_UP	4	
DOMAIN:Cache 1	SEQ_UP	1	
DOMAIN:Cache 2	SEQ_UP	1	
DOMAIN:Cactin_mid	SEQ_UP	2	
DOMAIN:CactinC_cactus	SEQ_UP	1	
DOMAIN:CADG	SEQ_UP	1	
DOMAIN:Cadherin	SEQ_UP	109	
DOMAIN:Cadherin 1	SEQ_UP	59	
DOMAIN:Cadherin 10	SEQ_UP	6	
DOMAIN:Cadherin 11	SEQ_UP	6	
DOMAIN:Cadherin 12	SEQ_UP	5	
DOMAIN:Cadherin 13	SEQ_UP	5	
DOMAIN:Cadherin 14	SEQ_UP	5	
DOMAIN:Cadherin 15	SEQ_UP	5	
DOMAIN:Cadherin 16	SEQ_UP	5	
DOMAIN:Cadherin 17	SEQ_UP	5	
DOMAIN:Cadherin 18	SEQ_UP	5	
DOMAIN:Cadherin 19	SEQ_UP	5	
DOMAIN:Cadherin 2	SEQ_UP	59	
DOMAIN:Cadherin 20	SEQ_UP	5	
DOMAIN:Cadherin 21	SEQ_UP	5	
DOMAIN:Cadherin 22	SEQ_UP	5	
DOMAIN:Cadherin 23	SEQ_UP	5	
DOMAIN:Cadherin 24	SEQ_UP	5	
DOMAIN:Cadherin 25	SEQ_UP	5	
DOMAIN:Cadherin 26	SEQ_UP	5	
DOMAIN:Cadherin 27	SEQ_UP	5	
DOMAIN:Cadherin 28	SEQ_UP	3	
DOMAIN:Cadherin 29	SEQ_UP	3	
DOMAIN:Cadherin 3	SEQ_UP	56	
DOMAIN:Cadherin 30	SEQ_UP	3	
DOMAIN:Cadherin 31	SEQ_UP	3	
DOMAIN:Cadherin 32	SEQ_UP	3	
DOMAIN:Cadherin 33	SEQ_UP	3	
DOMAIN:Cadherin 34	SEQ_UP	1	
DOMAIN:Cadherin 4	SEQ_UP	55	
DOMAIN:Cadherin 5	SEQ_UP	48	
DOMAIN:Cadherin 6	SEQ_UP	28	
DOMAIN:Cadherin 7	SEQ_UP	11	
DOMAIN:Cadherin 8	SEQ_UP	10	
DOMAIN:Cadherin 9	SEQ_UP	10	
DOMAIN:Cadherin_2	SEQ_UP	2	
DOMAIN:Cadherin_C	SEQ_UP	2	
DOMAIN:Cadherin_C_2	SEQ_UP	4	
DOMAIN:Cadherin_pro	SEQ_UP	3	
DOMAIN:Cadherin_tail	SEQ_UP	12	
DOMAIN:CAF1-p150_N	SEQ_UP	1	
DOMAIN:CAF1C_H4-bd	SEQ_UP	3	
DOMAIN:CALCITONIN	SEQ_UP	2	
DOMAIN:CALCOCO1	SEQ_UP	1	
DOMAIN:Calpain catalytic	SEQ_UP	14	
DOMAIN:calpain_III	SEQ_UP	1	
DOMAIN:Calponin-homology (CH)	SEQ_UP	77	
DOMAIN:Calponin-homology (CH) 1	SEQ_UP	23	
DOMAIN:Calponin-homology (CH) 2	SEQ_UP	23	
DOMAIN:Calponin-homology (CH) 3	SEQ_UP	3	
DOMAIN:Calponin-homology (CH) 4	SEQ_UP	3	
DOMAIN:Calx-beta	SEQ_UP	6	
DOMAIN:Calx-beta 1	SEQ_UP	7	
DOMAIN:Calx-beta 10	SEQ_UP	1	
DOMAIN:Calx-beta 11	SEQ_UP	1	
DOMAIN:Calx-beta 12	SEQ_UP	1	
DOMAIN:Calx-beta 13	SEQ_UP	1	
DOMAIN:Calx-beta 14	SEQ_UP	1	
DOMAIN:Calx-beta 15	SEQ_UP	1	
DOMAIN:Calx-beta 16	SEQ_UP	1	
DOMAIN:Calx-beta 17	SEQ_UP	1	
DOMAIN:Calx-beta 18	SEQ_UP	1	
DOMAIN:Calx-beta 19	SEQ_UP	1	
DOMAIN:Calx-beta 2	SEQ_UP	7	
DOMAIN:Calx-beta 20	SEQ_UP	1	
DOMAIN:Calx-beta 21	SEQ_UP	1	
DOMAIN:Calx-beta 22	SEQ_UP	1	
DOMAIN:Calx-beta 23	SEQ_UP	1	
DOMAIN:Calx-beta 24	SEQ_UP	1	
DOMAIN:Calx-beta 25	SEQ_UP	1	
DOMAIN:Calx-beta 26	SEQ_UP	1	
DOMAIN:Calx-beta 27	SEQ_UP	1	
DOMAIN:Calx-beta 28	SEQ_UP	1	
DOMAIN:Calx-beta 29	SEQ_UP	1	
DOMAIN:Calx-beta 3	SEQ_UP	4	
DOMAIN:Calx-beta 30	SEQ_UP	1	
DOMAIN:Calx-beta 31	SEQ_UP	1	
DOMAIN:Calx-beta 32	SEQ_UP	1	
DOMAIN:Calx-beta 33	SEQ_UP	1	
DOMAIN:Calx-beta 34	SEQ_UP	1	
DOMAIN:Calx-beta 35	SEQ_UP	1	
DOMAIN:Calx-beta 4	SEQ_UP	3	
DOMAIN:Calx-beta 5	SEQ_UP	3	
DOMAIN:Calx-beta 6	SEQ_UP	1	
DOMAIN:Calx-beta 7	SEQ_UP	1	
DOMAIN:Calx-beta 8	SEQ_UP	1	
DOMAIN:Calx-beta 9	SEQ_UP	1	
DOMAIN:CaMBD	SEQ_UP	4	
DOMAIN:CaMKII_AD	SEQ_UP	3	
DOMAIN:CANIN	SEQ_UP	2	
DOMAIN:CAP_N	SEQ_UP	1	
DOMAIN:CAP-Gly	SEQ_UP	8	
DOMAIN:CAP-Gly 1	SEQ_UP	5	
DOMAIN:CAP-Gly 2	SEQ_UP	5	
DOMAIN:CAP-Gly 3	SEQ_UP	2	
DOMAIN:CAP-ZIP_m	SEQ_UP	1	
DOMAIN:CAP10	SEQ_UP	2	
DOMAIN:CAP18_C	SEQ_UP	1	
DOMAIN:Caprin-1_C	SEQ_UP	2	
DOMAIN:Caprin-1_dimer	SEQ_UP	2	
DOMAIN:CARD	SEQ_UP	27	
DOMAIN:CARD 1	SEQ_UP	3	
DOMAIN:CARD 2	SEQ_UP	3	
DOMAIN:CARD_2	SEQ_UP	1	
DOMAIN:Carm_PH	SEQ_UP	3	
DOMAIN:CARM1	SEQ_UP	1	
DOMAIN:CARMIL_C	SEQ_UP	2	
DOMAIN:Carn_acyltransf	SEQ_UP	7	
DOMAIN:Carrier	SEQ_UP	5	
DOMAIN:CAS_C	SEQ_UP	1	
DOMAIN:CAS_CSE1	SEQ_UP	2	
DOMAIN:Cas1_AcylT	SEQ_UP	1	
DOMAIN:Casc1_N	SEQ_UP	1	
DOMAIN:CASH	SEQ_UP	2	
DOMAIN:CASP_C	SEQ_UP	1	
DOMAIN:CASPASE_P10	SEQ_UP	7	
DOMAIN:CASPASE_P20	SEQ_UP	12	
DOMAIN:Catalase	SEQ_UP	2	
DOMAIN:CathepsinC_exc	SEQ_UP	1	
DOMAIN:Cation_ATPase_C	SEQ_UP	8	
DOMAIN:Cation_ATPase_N	SEQ_UP	14	
DOMAIN:Cauli_VI	SEQ_UP	1	
DOMAIN:CBAH	SEQ_UP	2	
DOMAIN:CBF	SEQ_UP	2	
DOMAIN:CBFD_NFYB_HMF	SEQ_UP	8	
DOMAIN:CBFNT	SEQ_UP	1	
DOMAIN:Cbl-PTB	SEQ_UP	3	
DOMAIN:CBM20	SEQ_UP	3	
DOMAIN:CBM21	SEQ_UP	7	
DOMAIN:CBP/p300-type HAT	SEQ_UP	2	
DOMAIN:CBS	SEQ_UP	16	
DOMAIN:CBS 1	SEQ_UP	18	
DOMAIN:CBS 2	SEQ_UP	18	
DOMAIN:CBS 3	SEQ_UP	3	
DOMAIN:CBS 4	SEQ_UP	3	
DOMAIN:CC2-LZ	SEQ_UP	2	
DOMAIN:CCDC144C	SEQ_UP	1	
DOMAIN:CCDC168_N	SEQ_UP	1	
DOMAIN:CCDC50_N	SEQ_UP	1	
DOMAIN:CCDC74_C	SEQ_UP	1	
DOMAIN:CCDC92	SEQ_UP	3	
DOMAIN:CCDC93_CC	SEQ_UP	1	
DOMAIN:CCHC FOG-type	SEQ_UP	1	
DOMAIN:CCHC HIVEP-type	SEQ_UP	1	
DOMAIN:CCHC NOA-type	SEQ_UP	2	
DOMAIN:CCHC-type	SEQ_UP	24	
DOMAIN:CCM2_C	SEQ_UP	2	
DOMAIN:CD47	SEQ_UP	1	
DOMAIN:CDC37_M	SEQ_UP	2	
DOMAIN:CDC37_N	SEQ_UP	1	
DOMAIN:CDC48_2	SEQ_UP	2	
DOMAIN:CDC48_N	SEQ_UP	2	
DOMAIN:Cdc6_C	SEQ_UP	1	
DOMAIN:cDENN	SEQ_UP	20	
DOMAIN:cDENN C9ORF72-type	SEQ_UP	1	
DOMAIN:cDENN FLCN/SMCR8-type	SEQ_UP	2	
DOMAIN:cDENN FNIP1/2-type	SEQ_UP	2	
DOMAIN:CDH1_2_SANT_HL1	SEQ_UP	2	
DOMAIN:CDI	SEQ_UP	3	
DOMAIN:CDKN3	SEQ_UP	1	
DOMAIN:CENP_C_N	SEQ_UP	1	
DOMAIN:CENP-B_dimeris	SEQ_UP	1	
DOMAIN:CENP-C_mid	SEQ_UP	1	
DOMAIN:CENP-F_C_Rb_bdg	SEQ_UP	1	
DOMAIN:CENP-F_leu_zip	SEQ_UP	1	
DOMAIN:CENP-F_N	SEQ_UP	1	
DOMAIN:CENP-T_N	SEQ_UP	1	
DOMAIN:CENP-V/GFA	SEQ_UP	1	
DOMAIN:Centro_C10orf90	SEQ_UP	1	
DOMAIN:CEP170_C	SEQ_UP	1	
DOMAIN:CEP209_CC5	SEQ_UP	1	
DOMAIN:CEP44	SEQ_UP	1	
DOMAIN:Cep57_CLD	SEQ_UP	2	
DOMAIN:Cep57_MT_bd	SEQ_UP	2	
DOMAIN:CEP63	SEQ_UP	2	
DOMAIN:Ceramidase_alk	SEQ_UP	1	
DOMAIN:Ceramidse_alk_C	SEQ_UP	1	
DOMAIN:CERK_C	SEQ_UP	2	
DOMAIN:CG-1	SEQ_UP	2	
DOMAIN:CHAT	SEQ_UP	1	
DOMAIN:CHCH	SEQ_UP	23	
DOMAIN:CHCH 1	SEQ_UP	2	
DOMAIN:CHCH 2	SEQ_UP	2	
DOMAIN:CHDCT2	SEQ_UP	3	
DOMAIN:CHDNT	SEQ_UP	2	
DOMAIN:CheR	SEQ_UP	1	
DOMAIN:CHHC U11-48K-type	SEQ_UP	4	
DOMAIN:Chitin-binding type-2	SEQ_UP	2	
DOMAIN:CHORD	SEQ_UP	1	
DOMAIN:CHORD 1	SEQ_UP	2	
DOMAIN:CHORD 2	SEQ_UP	2	
DOMAIN:Chorein N-terminal	SEQ_UP	7	
DOMAIN:CHRD	SEQ_UP	1	
DOMAIN:CHRD 1	SEQ_UP	1	
DOMAIN:CHRD 2	SEQ_UP	1	
DOMAIN:CHRD 3	SEQ_UP	1	
DOMAIN:CHRD 4	SEQ_UP	1	
DOMAIN:CHRDL_1_2_C	SEQ_UP	1	
DOMAIN:Chromo	SEQ_UP	24	
DOMAIN:Chromo 1	SEQ_UP	11	
DOMAIN:Chromo 2	SEQ_UP	8	
DOMAIN:Chromo 2; shadow subtype	SEQ_UP	3	
DOMAIN:Chromosome_seg	SEQ_UP	1	
DOMAIN:CHY-type	SEQ_UP	1	
DOMAIN:CIA30	SEQ_UP	1	
DOMAIN:CID	SEQ_UP	8	
DOMAIN:CIDE-N	SEQ_UP	5	
DOMAIN:Cir_N	SEQ_UP	1	
DOMAIN:Citrate_bind	SEQ_UP	1	
DOMAIN:CK1gamma_C	SEQ_UP	2	
DOMAIN:CKK	SEQ_UP	3	
DOMAIN:CLa	SEQ_UP	1	
DOMAIN:Clat_adaptor_s	SEQ_UP	13	
DOMAIN:Clathrin_bdg	SEQ_UP	1	
DOMAIN:Clathrin-link	SEQ_UP	1	
DOMAIN:CLb	SEQ_UP	1	
DOMAIN:CLCA	SEQ_UP	2	
DOMAIN:CLEC16A_C	SEQ_UP	1	
DOMAIN:CLIP1_ZNF	SEQ_UP	1	
DOMAIN:CLLAC	SEQ_UP	2	
DOMAIN:ClpB_D2-small	SEQ_UP	1	
DOMAIN:ClpX-type ZB	SEQ_UP	1	
DOMAIN:CLSTN_C	SEQ_UP	1	
DOMAIN:Clu	SEQ_UP	1	
DOMAIN:CMP/dCMP-type deaminase	SEQ_UP	10	
DOMAIN:CMP/dCMP-type deaminase 1	SEQ_UP	2	
DOMAIN:CMP/dCMP-type deaminase 2	SEQ_UP	2	
DOMAIN:Cmyb_C	SEQ_UP	2	
DOMAIN:CN hydrolase	SEQ_UP	7	
DOMAIN:Cnd1	SEQ_UP	2	
DOMAIN:Cnd1_N	SEQ_UP	1	
DOMAIN:Cnd3	SEQ_UP	1	
DOMAIN:CNDH2_C	SEQ_UP	1	
DOMAIN:CNDH2_M	SEQ_UP	1	
DOMAIN:CNDH2_N	SEQ_UP	1	
DOMAIN:CNH	SEQ_UP	15	
DOMAIN:Cnn_1N	SEQ_UP	2	
DOMAIN:CNNM transmembrane	SEQ_UP	4	
DOMAIN:CNOT1_CAF1_bind	SEQ_UP	1	
DOMAIN:CNOT1_HEAT	SEQ_UP	1	
DOMAIN:CNOT1_TTP_bind	SEQ_UP	1	
DOMAIN:CNX	SEQ_UP	18	
DOMAIN:CO_deh_flav_C	SEQ_UP	1	
DOMAIN:CoA carboxyltransferase C-terminal	SEQ_UP	4	
DOMAIN:CoA carboxyltransferase N-terminal	SEQ_UP	4	
DOMAIN:CoA_binding	SEQ_UP	1	
DOMAIN:Coatomer_g_Cpla	SEQ_UP	1	
DOMAIN:Coatomer_WDAD	SEQ_UP	1	
DOMAIN:Cob_adeno_trans	SEQ_UP	1	
DOMAIN:Cobl	SEQ_UP	2	
DOMAIN:CobW C-terminal	SEQ_UP	1	
DOMAIN:Codanin-1_C	SEQ_UP	1	
DOMAIN:COE1_HLH	SEQ_UP	1	
DOMAIN:COesterase	SEQ_UP	23	
DOMAIN:COG2	SEQ_UP	1	
DOMAIN:Cog4	SEQ_UP	1	
DOMAIN:Coiled-coil_56	SEQ_UP	1	
DOMAIN:Coilin_N	SEQ_UP	1	
DOMAIN:Colipase	SEQ_UP	1	
DOMAIN:Colipase_C	SEQ_UP	1	
DOMAIN:Collagen IV NC1	SEQ_UP	6	
DOMAIN:Collagen_trimer	SEQ_UP	2	
DOMAIN:Collagen-like	SEQ_UP	32	
DOMAIN:Collagen-like 1	SEQ_UP	24	
DOMAIN:Collagen-like 10	SEQ_UP	3	
DOMAIN:Collagen-like 11	SEQ_UP	3	
DOMAIN:Collagen-like 12	SEQ_UP	2	
DOMAIN:Collagen-like 13	SEQ_UP	2	
DOMAIN:Collagen-like 14	SEQ_UP	2	
DOMAIN:Collagen-like 15	SEQ_UP	2	
DOMAIN:Collagen-like 2	SEQ_UP	24	
DOMAIN:Collagen-like 3	SEQ_UP	18	
DOMAIN:Collagen-like 4	SEQ_UP	15	
DOMAIN:Collagen-like 5	SEQ_UP	13	
DOMAIN:Collagen-like 6	SEQ_UP	10	
DOMAIN:Collagen-like 7	SEQ_UP	8	
DOMAIN:Collagen-like 8	SEQ_UP	7	
DOMAIN:Collagen-like 9	SEQ_UP	6	
DOMAIN:Collectrin	SEQ_UP	2	
DOMAIN:COMM	SEQ_UP	11	
DOMAIN:COMMD1_N	SEQ_UP	1	
DOMAIN:COMP	SEQ_UP	1	
DOMAIN:Complex1_49kDa	SEQ_UP	1	
DOMAIN:Complex1_51K	SEQ_UP	1	
DOMAIN:Complex1_LYR_dom	SEQ_UP	3	
DOMAIN:Connexin_CCC	SEQ_UP	17	
DOMAIN:Connexin43	SEQ_UP	1	
DOMAIN:COP-gamma_platf	SEQ_UP	1	
DOMAIN:COPI_C	SEQ_UP	1	
DOMAIN:COPIIcoated_ERV	SEQ_UP	3	
DOMAIN:Copine	SEQ_UP	2	
DOMAIN:COQ9	SEQ_UP	1	
DOMAIN:Cor1	SEQ_UP	86	
DOMAIN:CortBP2	SEQ_UP	4	
DOMAIN:COS	SEQ_UP	12	
DOMAIN:Costars	SEQ_UP	1	
DOMAIN:COX1	SEQ_UP	1	
DOMAIN:COX2_CUA	SEQ_UP	1	
DOMAIN:COX2_TM	SEQ_UP	1	
DOMAIN:COX3	SEQ_UP	1	
DOMAIN:CP-type G	SEQ_UP	7	
DOMAIN:CP2	SEQ_UP	4	
DOMAIN:CPSF_A	SEQ_UP	3	
DOMAIN:CPSF73-100_C	SEQ_UP	1	
DOMAIN:CPT_N	SEQ_UP	2	
DOMAIN:CR-type	SEQ_UP	4	
DOMAIN:CRAL_TRIO_N	SEQ_UP	3	
DOMAIN:CRAL-TRIO	SEQ_UP	25	
DOMAIN:CRC	SEQ_UP	2	
DOMAIN:Creatinase_N	SEQ_UP	2	
DOMAIN:CRF	SEQ_UP	1	
DOMAIN:CRIB	SEQ_UP	20	
DOMAIN:CRIC	SEQ_UP	3	
DOMAIN:CRIM	SEQ_UP	1	
DOMAIN:CRIM1_C	SEQ_UP	1	
DOMAIN:CRM1_C	SEQ_UP	2	
DOMAIN:Cryptic POLO box 1 (CPB1)	SEQ_UP	1	
DOMAIN:Cryptic POLO box 2 (CPB2)	SEQ_UP	1	
DOMAIN:CS	SEQ_UP	19	
DOMAIN:CS 1	SEQ_UP	1	
DOMAIN:CS 2	SEQ_UP	1	
DOMAIN:CSD	SEQ_UP	10	
DOMAIN:CSD 1	SEQ_UP	1	
DOMAIN:CSD 2; truncated	SEQ_UP	1	
DOMAIN:CSD 3	SEQ_UP	1	
DOMAIN:CSD 4; truncated	SEQ_UP	1	
DOMAIN:CSD 5	SEQ_UP	1	
DOMAIN:CSD 6	SEQ_UP	1	
DOMAIN:CSD 7	SEQ_UP	1	
DOMAIN:CSD 8	SEQ_UP	1	
DOMAIN:CSD 9	SEQ_UP	1	
DOMAIN:CSN8_PSD8_EIF3K	SEQ_UP	1	
DOMAIN:CSRNP_N	SEQ_UP	2	
DOMAIN:CSTF1_dimer	SEQ_UP	1	
DOMAIN:CSTF2_hinge	SEQ_UP	1	
DOMAIN:CTCHY-type	SEQ_UP	1	
DOMAIN:CTCK	SEQ_UP	26	
DOMAIN:CTD	SEQ_UP	1	
DOMAIN:CTF/NF-I	SEQ_UP	4	
DOMAIN:CtIP_N	SEQ_UP	2	
DOMAIN:CTLH	SEQ_UP	10	
DOMAIN:CTNNB1_binding	SEQ_UP	3	
DOMAIN:CTP_synth_N	SEQ_UP	1	
DOMAIN:CTP_transf_like	SEQ_UP	5	
DOMAIN:Cu_amine_oxid	SEQ_UP	6	
DOMAIN:Cu_amine_oxidN2	SEQ_UP	6	
DOMAIN:Cu_amine_oxidN3	SEQ_UP	6	
DOMAIN:Cu2_monoox_C	SEQ_UP	1	
DOMAIN:Cu2_monooxygen	SEQ_UP	1	
DOMAIN:CUB	SEQ_UP	43	
DOMAIN:CUB 1	SEQ_UP	35	
DOMAIN:CUB 10	SEQ_UP	3	
DOMAIN:CUB 11	SEQ_UP	3	
DOMAIN:CUB 12	SEQ_UP	3	
DOMAIN:CUB 13	SEQ_UP	3	
DOMAIN:CUB 14	SEQ_UP	3	
DOMAIN:CUB 15	SEQ_UP	1	
DOMAIN:CUB 16	SEQ_UP	1	
DOMAIN:CUB 17	SEQ_UP	1	
DOMAIN:CUB 18	SEQ_UP	1	
DOMAIN:CUB 19	SEQ_UP	1	
DOMAIN:CUB 2	SEQ_UP	35	
DOMAIN:CUB 20	SEQ_UP	1	
DOMAIN:CUB 21	SEQ_UP	1	
DOMAIN:CUB 22	SEQ_UP	1	
DOMAIN:CUB 23	SEQ_UP	1	
DOMAIN:CUB 24	SEQ_UP	1	
DOMAIN:CUB 25	SEQ_UP	1	
DOMAIN:CUB 26	SEQ_UP	1	
DOMAIN:CUB 27	SEQ_UP	1	
DOMAIN:CUB 3	SEQ_UP	12	
DOMAIN:CUB 4	SEQ_UP	7	
DOMAIN:CUB 5	SEQ_UP	7	
DOMAIN:CUB 6	SEQ_UP	3	
DOMAIN:CUB 7	SEQ_UP	3	
DOMAIN:CUB 8	SEQ_UP	3	
DOMAIN:CUB 9	SEQ_UP	3	
DOMAIN:CUE	SEQ_UP	8	
DOMAIN:CUE 1	SEQ_UP	1	
DOMAIN:CUE 2	SEQ_UP	1	
DOMAIN:Cul7	SEQ_UP	1	
DOMAIN:Cullin	SEQ_UP	7	
DOMAIN:CULLIN_2	SEQ_UP	9	
DOMAIN:Cullin_Nedd8	SEQ_UP	2	
DOMAIN:CULT	SEQ_UP	1	
DOMAIN:CUPID	SEQ_UP	3	
DOMAIN:Cupin_8	SEQ_UP	1	
DOMAIN:CUT	SEQ_UP	5	
DOMAIN:CUTL	SEQ_UP	2	
DOMAIN:CVC	SEQ_UP	2	
DOMAIN:CW-type	SEQ_UP	6	
DOMAIN:cwf21	SEQ_UP	2	
DOMAIN:CX9C	SEQ_UP	1	
DOMAIN:CXC	SEQ_UP	3	
DOMAIN:CxC4	SEQ_UP	1	
DOMAIN:CXXC-type	SEQ_UP	10	
DOMAIN:Cyclic nucleotide-binding	SEQ_UP	26	
DOMAIN:CYCLIN	SEQ_UP	17	
DOMAIN:Cyclin N-terminal	SEQ_UP	20	
DOMAIN:Cyclin_C	SEQ_UP	4	
DOMAIN:Cyclin_C_2	SEQ_UP	1	
DOMAIN:Cyclin_N2	SEQ_UP	2	
DOMAIN:Cylicin_N	SEQ_UP	2	
DOMAIN:Cys_knot	SEQ_UP	5	
DOMAIN:Cystatin	SEQ_UP	16	
DOMAIN:Cystatin 1	SEQ_UP	1	
DOMAIN:Cystatin 2	SEQ_UP	1	
DOMAIN:Cystatin fetuin-A-type	SEQ_UP	1	
DOMAIN:Cystatin fetuin-A-type 1	SEQ_UP	1	
DOMAIN:Cystatin fetuin-A-type 2	SEQ_UP	1	
DOMAIN:Cystatin fetuin-B-type	SEQ_UP	1	
DOMAIN:Cystatin fetuin-B-type 1	SEQ_UP	1	
DOMAIN:Cystatin fetuin-B-type 2	SEQ_UP	1	
DOMAIN:Cystatin kininogen-type	SEQ_UP	3	
DOMAIN:Cystatin kininogen-type 1	SEQ_UP	1	
DOMAIN:Cystatin kininogen-type 2	SEQ_UP	1	
DOMAIN:Cystatin kininogen-type 3	SEQ_UP	1	
DOMAIN:CYTB_CTER	SEQ_UP	1	
DOMAIN:CYTB_NTER	SEQ_UP	1	
DOMAIN:CYTH	SEQ_UP	1	
DOMAIN:Cytochrome b5 heme-binding	SEQ_UP	15	
DOMAIN:Cytochrome b561	SEQ_UP	6	
DOMAIN:Cytochrome c	SEQ_UP	3	
DOMAIN:CYTOSOL_AP	SEQ_UP	1	
DOMAIN:DAD	SEQ_UP	10	
DOMAIN:DAG_kinase_N	SEQ_UP	2	
DOMAIN:DAGKa	SEQ_UP	4	
DOMAIN:DAGKc	SEQ_UP	15	
DOMAIN:DALR_1	SEQ_UP	2	
DOMAIN:DAO	SEQ_UP	8	
DOMAIN:Daxx	SEQ_UP	1	
DOMAIN:DAZ	SEQ_UP	2	
DOMAIN:DBB	SEQ_UP	2	
DOMAIN:DBF4-type	SEQ_UP	2	
DOMAIN:DBINO	SEQ_UP	1	
DOMAIN:DBR1	SEQ_UP	1	
DOMAIN:DC_STAMP	SEQ_UP	2	
DOMAIN:DCB	SEQ_UP	3	
DOMAIN:DCP2	SEQ_UP	1	
DOMAIN:DCR	SEQ_UP	2	
DOMAIN:DCUN1	SEQ_UP	6	
DOMAIN:DDA1	SEQ_UP	1	
DOMAIN:DDE Tnp4	SEQ_UP	1	
DOMAIN:DDE_Tnp_1_7	SEQ_UP	2	
DOMAIN:DDE-1	SEQ_UP	8	
DOMAIN:dDENN	SEQ_UP	20	
DOMAIN:dDENN C9ORF72-type	SEQ_UP	1	
DOMAIN:dDENN FLCN/SMCR8-type	SEQ_UP	2	
DOMAIN:dDENN FNIP1/2-type	SEQ_UP	2	
DOMAIN:DDHD	SEQ_UP	6	
DOMAIN:DDT	SEQ_UP	5	
DOMAIN:Deacetylase sirtuin-type	SEQ_UP	7	
DOMAIN:DEAD	SEQ_UP	4	
DOMAIN:Death	SEQ_UP	39	
DOMAIN:Death 1	SEQ_UP	2	
DOMAIN:Death 2	SEQ_UP	2	
DOMAIN:DED	SEQ_UP	7	
DOMAIN:DED 1	SEQ_UP	2	
DOMAIN:DED 2	SEQ_UP	2	
DOMAIN:DEFENSIN	SEQ_UP	10	
DOMAIN:Defensin_beta_2	SEQ_UP	9	
DOMAIN:Defensin_propep	SEQ_UP	9	
DOMAIN:DEFSN	SEQ_UP	3	
DOMAIN:DEK C-terminal	SEQ_UP	4	
DOMAIN:DEP	SEQ_UP	20	
DOMAIN:DEP 1	SEQ_UP	3	
DOMAIN:DEP 2	SEQ_UP	3	
DOMAIN:DEUBAD	SEQ_UP	6	
DOMAIN:DFDF	SEQ_UP	3	
DOMAIN:DH	SEQ_UP	68	
DOMAIN:DH 1	SEQ_UP	2	
DOMAIN:DH 2	SEQ_UP	2	
DOMAIN:DhaK	SEQ_UP	1	
DOMAIN:DhaL	SEQ_UP	1	
DOMAIN:DHC_N1	SEQ_UP	5	
DOMAIN:DHC_N2	SEQ_UP	5	
DOMAIN:DHFR	SEQ_UP	1	
DOMAIN:DHHA2	SEQ_UP	1	
DOMAIN:DHHC	SEQ_UP	26	
DOMAIN:DHO_dh	SEQ_UP	1	
DOMAIN:Dicer dsRNA-binding fold	SEQ_UP	1	
DOMAIN:Dilute	SEQ_UP	6	
DOMAIN:Dimer_Tnp_hAT	SEQ_UP	2	
DOMAIN:Dimerisation2	SEQ_UP	1	
DOMAIN:DIRP	SEQ_UP	1	
DOMAIN:Dishevelled	SEQ_UP	1	
DOMAIN:Disintegrin	SEQ_UP	51	
DOMAIN:DIX	SEQ_UP	6	
DOMAIN:DJ-1_PfpI	SEQ_UP	1	
DOMAIN:DKCLD	SEQ_UP	1	
DOMAIN:DLH	SEQ_UP	1	
DOMAIN:DLL_N	SEQ_UP	1	
DOMAIN:DM	SEQ_UP	1	
DOMAIN:DM10	SEQ_UP	3	
DOMAIN:DM10 1	SEQ_UP	2	
DOMAIN:DM10 2	SEQ_UP	2	
DOMAIN:DM10 3	SEQ_UP	2	
DOMAIN:DMA	SEQ_UP	3	
DOMAIN:DMAP1-binding	SEQ_UP	6	
DOMAIN:DMPK_coil	SEQ_UP	1	
DOMAIN:DMRT-like	SEQ_UP	4	
DOMAIN:DNA_binding_1	SEQ_UP	1	
DOMAIN:DNA_gyraseB	SEQ_UP	1	
DOMAIN:DNA_LIGASE_A3	SEQ_UP	3	
DOMAIN:DNA_mis_repair	SEQ_UP	3	
DOMAIN:DNA_MISMATCH_REPAIR_2	SEQ_UP	5	
DOMAIN:DNA_pol_alpha_N	SEQ_UP	1	
DOMAIN:DNA_pol_B	SEQ_UP	3	
DOMAIN:DNA_pol_B_exo1	SEQ_UP	4	
DOMAIN:DNA_pol_D_N	SEQ_UP	1	
DOMAIN:DNA_pol_E_B	SEQ_UP	3	
DOMAIN:Dna2	SEQ_UP	1	
DOMAIN:DnaJ_C	SEQ_UP	3	
DOMAIN:DNApol_Exo	SEQ_UP	1	
DOMAIN:dNK	SEQ_UP	4	
DOMAIN:DNTTIP1_dimer	SEQ_UP	1	
DOMAIN:DOC	SEQ_UP	7	
DOMAIN:DOCKER	SEQ_UP	11	
DOMAIN:DOMON	SEQ_UP	5	
DOMAIN:Dopey_N	SEQ_UP	2	
DOMAIN:DOT1	SEQ_UP	1	
DOMAIN:Doublecortin	SEQ_UP	9	
DOMAIN:Doublecortin 1	SEQ_UP	7	
DOMAIN:Doublecortin 2	SEQ_UP	7	
DOMAIN:DP	SEQ_UP	2	
DOMAIN:DPCK	SEQ_UP	2	
DOMAIN:DPH-type MB	SEQ_UP	2	
DOMAIN:Dpoe2NT	SEQ_UP	1	
DOMAIN:Dpp_8_9_N	SEQ_UP	1	
DOMAIN:Dppa2_A	SEQ_UP	1	
DOMAIN:DPPIV_N	SEQ_UP	5	
DOMAIN:DPPIV_rep	SEQ_UP	1	
DOMAIN:DRBM	SEQ_UP	19	
DOMAIN:DRBM 1	SEQ_UP	12	
DOMAIN:DRBM 2	SEQ_UP	12	
DOMAIN:DRBM 3	SEQ_UP	4	
DOMAIN:DRBM 4	SEQ_UP	1	
DOMAIN:Drf_FH3	SEQ_UP	1	
DOMAIN:Drf_GBD	SEQ_UP	1	
DOMAIN:DRIM	SEQ_UP	1	
DOMAIN:DRMBL	SEQ_UP	1	
DOMAIN:DRY_EERY	SEQ_UP	2	
DOMAIN:DSBA	SEQ_UP	1	
DOMAIN:DSL	SEQ_UP	5	
DOMAIN:DSPc	SEQ_UP	2	
DOMAIN:DTC	SEQ_UP	1	
DOMAIN:DTHCT	SEQ_UP	1	
DOMAIN:DTW	SEQ_UP	1	
DOMAIN:DUF108	SEQ_UP	1	
DOMAIN:DUF1086	SEQ_UP	2	
DOMAIN:DUF1087	SEQ_UP	1	
DOMAIN:DUF1115	SEQ_UP	1	
DOMAIN:DUF1170	SEQ_UP	2	
DOMAIN:DUF1279	SEQ_UP	2	
DOMAIN:DUF1394	SEQ_UP	4	
DOMAIN:DUF1518	SEQ_UP	2	
DOMAIN:DUF155	SEQ_UP	1	
DOMAIN:DUF1604	SEQ_UP	1	
DOMAIN:DUF1619	SEQ_UP	2	
DOMAIN:DUF1681	SEQ_UP	2	
DOMAIN:DUF1713	SEQ_UP	1	
DOMAIN:DUF1716	SEQ_UP	1	
DOMAIN:DUF1725	SEQ_UP	2	
DOMAIN:DUF1726	SEQ_UP	1	
DOMAIN:DUF1736	SEQ_UP	2	
DOMAIN:DUF1744	SEQ_UP	1	
DOMAIN:DUF1767	SEQ_UP	1	
DOMAIN:DUF1785	SEQ_UP	1	
DOMAIN:DUF1891	SEQ_UP	1	
DOMAIN:DUF1897	SEQ_UP	3	
DOMAIN:DUF1899	SEQ_UP	7	
DOMAIN:DUF1907	SEQ_UP	1	
DOMAIN:DUF1908	SEQ_UP	3	
DOMAIN:DUF1968	SEQ_UP	1	
DOMAIN:DUF1981	SEQ_UP	1	
DOMAIN:DUF2012	SEQ_UP	1	
DOMAIN:DUF2040	SEQ_UP	1	
DOMAIN:DUF2052	SEQ_UP	1	
DOMAIN:DUF2075	SEQ_UP	1	
DOMAIN:DUF2431	SEQ_UP	1	
DOMAIN:DUF2439	SEQ_UP	1	
DOMAIN:DUF2448	SEQ_UP	1	
DOMAIN:DUF2451	SEQ_UP	1	
DOMAIN:DUF3342	SEQ_UP	1	
DOMAIN:DUF3361	SEQ_UP	1	
DOMAIN:DUF3371	SEQ_UP	1	
DOMAIN:DUF3377	SEQ_UP	2	
DOMAIN:DUF3384	SEQ_UP	1	
DOMAIN:DUF3385	SEQ_UP	1	
DOMAIN:DUF3398	SEQ_UP	1	
DOMAIN:DUF3402	SEQ_UP	2	
DOMAIN:DUF3446	SEQ_UP	1	
DOMAIN:DUF3452	SEQ_UP	3	
DOMAIN:DUF3454	SEQ_UP	2	
DOMAIN:DUF3456	SEQ_UP	4	
DOMAIN:DUF3480	SEQ_UP	2	
DOMAIN:DUF3496	SEQ_UP	5	
DOMAIN:DUF3498	SEQ_UP	1	
DOMAIN:DUF3504	SEQ_UP	3	
DOMAIN:DUF3510	SEQ_UP	1	
DOMAIN:DUF3517	SEQ_UP	1	
DOMAIN:DUF3523	SEQ_UP	1	
DOMAIN:DUF3524	SEQ_UP	1	
DOMAIN:DUF3543	SEQ_UP	1	
DOMAIN:DUF3669	SEQ_UP	2	
DOMAIN:DUF3677	SEQ_UP	1	
DOMAIN:DUF3694	SEQ_UP	1	
DOMAIN:DUF3699	SEQ_UP	7	
DOMAIN:DUF3715	SEQ_UP	2	
DOMAIN:DUF3719	SEQ_UP	2	
DOMAIN:DUF3730	SEQ_UP	1	
DOMAIN:DUF3740	SEQ_UP	2	
DOMAIN:DUF3752	SEQ_UP	1	
DOMAIN:DUF3819	SEQ_UP	1	
DOMAIN:DUF4062	SEQ_UP	2	
DOMAIN:DUF4147	SEQ_UP	1	
DOMAIN:DUF4149	SEQ_UP	1	
DOMAIN:DUF4171	SEQ_UP	1	
DOMAIN:DUF4195	SEQ_UP	1	
DOMAIN:DUF4196	SEQ_UP	1	
DOMAIN:DUF4200	SEQ_UP	2	
DOMAIN:DUF4201	SEQ_UP	1	
DOMAIN:DUF4203	SEQ_UP	3	
DOMAIN:DUF4205	SEQ_UP	3	
DOMAIN:DUF4206	SEQ_UP	2	
DOMAIN:DUF4207	SEQ_UP	1	
DOMAIN:DUF4208	SEQ_UP	1	
DOMAIN:DUF4209	SEQ_UP	3	
DOMAIN:DUF4210	SEQ_UP	1	
DOMAIN:DUF4211	SEQ_UP	2	
DOMAIN:DUF4371	SEQ_UP	2	
DOMAIN:DUF4392	SEQ_UP	1	
DOMAIN:DUF4455	SEQ_UP	1	
DOMAIN:DUF4456	SEQ_UP	1	
DOMAIN:DUF4457	SEQ_UP	1	
DOMAIN:DUF4460	SEQ_UP	1	
DOMAIN:DUF4461	SEQ_UP	1	
DOMAIN:DUF4476	SEQ_UP	1	
DOMAIN:DUF4477	SEQ_UP	1	
DOMAIN:DUF4482	SEQ_UP	3	
DOMAIN:DUF4485	SEQ_UP	1	
DOMAIN:DUF4502	SEQ_UP	1	
DOMAIN:DUF4503	SEQ_UP	1	
DOMAIN:DUF4515	SEQ_UP	7	
DOMAIN:DUF4524	SEQ_UP	1	
DOMAIN:DUF4537	SEQ_UP	2	
DOMAIN:DUF4549	SEQ_UP	1	
DOMAIN:DUF4550	SEQ_UP	1	
DOMAIN:DUF4585	SEQ_UP	1	
DOMAIN:DUF4587	SEQ_UP	2	
DOMAIN:DUF4592	SEQ_UP	2	
DOMAIN:DUF4596	SEQ_UP	2	
DOMAIN:DUF4599	SEQ_UP	5	
DOMAIN:DUF4604	SEQ_UP	1	
DOMAIN:DUF4605	SEQ_UP	1	
DOMAIN:DUF4614	SEQ_UP	1	
DOMAIN:DUF4629	SEQ_UP	4	
DOMAIN:DUF4632	SEQ_UP	1	
DOMAIN:DUF4637	SEQ_UP	1	
DOMAIN:DUF4682	SEQ_UP	1	
DOMAIN:DUF4683	SEQ_UP	2	
DOMAIN:DUF4685	SEQ_UP	2	
DOMAIN:DUF4704	SEQ_UP	2	
DOMAIN:DUF4708	SEQ_UP	1	
DOMAIN:DUF4709	SEQ_UP	1	
DOMAIN:DUF4716	SEQ_UP	1	
DOMAIN:DUF4724	SEQ_UP	1	
DOMAIN:DUF4745	SEQ_UP	1	
DOMAIN:DUF4757	SEQ_UP	2	
DOMAIN:DUF4764	SEQ_UP	1	
DOMAIN:DUF4772	SEQ_UP	1	
DOMAIN:DUF4821	SEQ_UP	1	
DOMAIN:DUF4939	SEQ_UP	5	
DOMAIN:DUF4962	SEQ_UP	1	
DOMAIN:DUF4976	SEQ_UP	1	
DOMAIN:DUF5523	SEQ_UP	1	
DOMAIN:DUF5577	SEQ_UP	1	
DOMAIN:DUF5595	SEQ_UP	1	
DOMAIN:DUF5614	SEQ_UP	1	
DOMAIN:DUF5745	SEQ_UP	1	
DOMAIN:DUF5861	SEQ_UP	1	
DOMAIN:DUF5917	SEQ_UP	1	
DOMAIN:DUF5920	SEQ_UP	1	
DOMAIN:DUF5921	SEQ_UP	1	
DOMAIN:DUF5922	SEQ_UP	1	
DOMAIN:DUF663	SEQ_UP	1	
DOMAIN:DUF667	SEQ_UP	3	
DOMAIN:DUF676	SEQ_UP	2	
DOMAIN:DUF727	SEQ_UP	1	
DOMAIN:DUF775	SEQ_UP	1	
DOMAIN:DUF908	SEQ_UP	1	
DOMAIN:DUF913	SEQ_UP	1	
DOMAIN:Dus	SEQ_UP	3	
DOMAIN:DUSP	SEQ_UP	7	
DOMAIN:DUSP 1	SEQ_UP	3	
DOMAIN:DUSP 2	SEQ_UP	3	
DOMAIN:DUSP 3	SEQ_UP	1	
DOMAIN:DWNN	SEQ_UP	1	
DOMAIN:Dynactin	SEQ_UP	1	
DOMAIN:Dynamin_M	SEQ_UP	1	
DOMAIN:Dynamin_N	SEQ_UP	3	
DOMAIN:Dynamin-type G	SEQ_UP	14	
DOMAIN:Dynein_AAA_lid	SEQ_UP	3	
DOMAIN:Dynein_attach_N	SEQ_UP	1	
DOMAIN:Dynein_C	SEQ_UP	10	
DOMAIN:Dynein_heavy	SEQ_UP	8	
DOMAIN:DZANK-type	SEQ_UP	1	
DOMAIN:DZF	SEQ_UP	5	
DOMAIN:Dzip-like_N	SEQ_UP	1	
DOMAIN:E_Pc_C	SEQ_UP	2	
DOMAIN:E1	SEQ_UP	3	
DOMAIN:E1_4HB	SEQ_UP	1	
DOMAIN:E1_dh	SEQ_UP	3	
DOMAIN:E1_FCCH	SEQ_UP	1	
DOMAIN:E2	SEQ_UP	3	
DOMAIN:E2_bind	SEQ_UP	1	
DOMAIN:E2F_CC-MB	SEQ_UP	1	
DOMAIN:E2F_TDP	SEQ_UP	8	
DOMAIN:E3_UbLigase_EDD	SEQ_UP	1	
DOMAIN:E3_UbLigase_R4	SEQ_UP	1	
DOMAIN:E3_UbLigase_RBR	SEQ_UP	1	
DOMAIN:EAF	SEQ_UP	1	
DOMAIN:EamA	SEQ_UP	5	
DOMAIN:EamA 1	SEQ_UP	3	
DOMAIN:EamA 2	SEQ_UP	3	
DOMAIN:EB1 C-terminal	SEQ_UP	3	
DOMAIN:EB1_binding	SEQ_UP	1	
DOMAIN:ECH_2	SEQ_UP	1	
DOMAIN:ECR1_N	SEQ_UP	2	
DOMAIN:ECSIT_Cterm	SEQ_UP	1	
DOMAIN:EF_TS	SEQ_UP	1	
DOMAIN:EF-1_beta_acid	SEQ_UP	2	
DOMAIN:EF-1-gamma C-terminal	SEQ_UP	1	
DOMAIN:EF-hand	SEQ_UP	193	
DOMAIN:EF-hand 1	SEQ_UP	162	
DOMAIN:EF-hand 1; atypical	SEQ_UP	1	
DOMAIN:EF-hand 1; degenerate	SEQ_UP	5	
DOMAIN:EF-hand 10	SEQ_UP	1	
DOMAIN:EF-hand 11	SEQ_UP	1	
DOMAIN:EF-hand 12	SEQ_UP	1	
DOMAIN:EF-hand 13	SEQ_UP	1	
DOMAIN:EF-hand 14	SEQ_UP	1	
DOMAIN:EF-hand 15	SEQ_UP	1	
DOMAIN:EF-hand 2	SEQ_UP	166	
DOMAIN:EF-hand 2; degenerate	SEQ_UP	2	
DOMAIN:EF-hand 3	SEQ_UP	90	
DOMAIN:EF-hand 4	SEQ_UP	60	
DOMAIN:EF-hand 5	SEQ_UP	14	
DOMAIN:EF-hand 6	SEQ_UP	8	
DOMAIN:EF-hand 7	SEQ_UP	1	
DOMAIN:EF-hand 8	SEQ_UP	1	
DOMAIN:EF-hand 9	SEQ_UP	1	
DOMAIN:EF-hand_13	SEQ_UP	1	
DOMAIN:EF-hand_14	SEQ_UP	2	
DOMAIN:EF-hand_2	SEQ_UP	3	
DOMAIN:EF-hand_3	SEQ_UP	2	
DOMAIN:EF-hand_like	SEQ_UP	1	
DOMAIN:EF1_GNE	SEQ_UP	2	
DOMAIN:EFG_C	SEQ_UP	1	
DOMAIN:EFG_IV	SEQ_UP	2	
DOMAIN:EGF_2	SEQ_UP	1	
DOMAIN:EGF_CA	SEQ_UP	4	
DOMAIN:EGF-like	SEQ_UP	204	
DOMAIN:EGF-like 1	SEQ_UP	111	
DOMAIN:EGF-like 1; atypical	SEQ_UP	5	
DOMAIN:EGF-like 1; calcium-binding	SEQ_UP	21	
DOMAIN:EGF-like 1; incomplete	SEQ_UP	2	
DOMAIN:EGF-like 10	SEQ_UP	15	
DOMAIN:EGF-like 10; atypical	SEQ_UP	1	
DOMAIN:EGF-like 10; calcium-binding	SEQ_UP	10	
DOMAIN:EGF-like 11	SEQ_UP	10	
DOMAIN:EGF-like 11; calcium-binding	SEQ_UP	14	
DOMAIN:EGF-like 12	SEQ_UP	8	
DOMAIN:EGF-like 12; calcium-binding	SEQ_UP	15	
DOMAIN:EGF-like 13	SEQ_UP	13	
DOMAIN:EGF-like 13; calcium-binding	SEQ_UP	9	
DOMAIN:EGF-like 14	SEQ_UP	13	
DOMAIN:EGF-like 14; calcium-binding	SEQ_UP	9	
DOMAIN:EGF-like 15	SEQ_UP	12	
DOMAIN:EGF-like 15; calcium-binding	SEQ_UP	10	
DOMAIN:EGF-like 16	SEQ_UP	7	
DOMAIN:EGF-like 16; calcium-binding	SEQ_UP	10	
DOMAIN:EGF-like 17	SEQ_UP	7	
DOMAIN:EGF-like 17; calcium-binding	SEQ_UP	6	
DOMAIN:EGF-like 18	SEQ_UP	6	
DOMAIN:EGF-like 18; calcium-binding	SEQ_UP	6	
DOMAIN:EGF-like 19	SEQ_UP	6	
DOMAIN:EGF-like 19; calcium-binding	SEQ_UP	5	
DOMAIN:EGF-like 2	SEQ_UP	83	
DOMAIN:EGF-like 2; atypical	SEQ_UP	2	
DOMAIN:EGF-like 2; calcium-binding	SEQ_UP	54	
DOMAIN:EGF-like 20	SEQ_UP	5	
DOMAIN:EGF-like 20; calcium-binding	SEQ_UP	5	
DOMAIN:EGF-like 21	SEQ_UP	4	
DOMAIN:EGF-like 21; calcium-binding	SEQ_UP	5	
DOMAIN:EGF-like 22	SEQ_UP	5	
DOMAIN:EGF-like 22; calcium-binding	SEQ_UP	3	
DOMAIN:EGF-like 23	SEQ_UP	1	
DOMAIN:EGF-like 23; calcium-binding	SEQ_UP	5	
DOMAIN:EGF-like 24	SEQ_UP	3	
DOMAIN:EGF-like 24; calcium-binding	SEQ_UP	3	
DOMAIN:EGF-like 25	SEQ_UP	2	
DOMAIN:EGF-like 25; calcium-binding	SEQ_UP	4	
DOMAIN:EGF-like 26	SEQ_UP	3	
DOMAIN:EGF-like 26; calcium-binding	SEQ_UP	3	
DOMAIN:EGF-like 27	SEQ_UP	2	
DOMAIN:EGF-like 27; calcium-binding	SEQ_UP	4	
DOMAIN:EGF-like 28	SEQ_UP	4	
DOMAIN:EGF-like 28; calcium-binding	SEQ_UP	2	
DOMAIN:EGF-like 29	SEQ_UP	3	
DOMAIN:EGF-like 29; calcium-binding	SEQ_UP	3	
DOMAIN:EGF-like 3	SEQ_UP	67	
DOMAIN:EGF-like 3; calcium-binding	SEQ_UP	37	
DOMAIN:EGF-like 30; calcium-binding	SEQ_UP	5	
DOMAIN:EGF-like 31	SEQ_UP	1	
DOMAIN:EGF-like 31; calcium-binding	SEQ_UP	4	
DOMAIN:EGF-like 32	SEQ_UP	1	
DOMAIN:EGF-like 32; calcium-binding	SEQ_UP	4	
DOMAIN:EGF-like 33	SEQ_UP	3	
DOMAIN:EGF-like 33; calcium-binding	SEQ_UP	2	
DOMAIN:EGF-like 34	SEQ_UP	3	
DOMAIN:EGF-like 34; calcium-binding	SEQ_UP	2	
DOMAIN:EGF-like 35	SEQ_UP	2	
DOMAIN:EGF-like 35; calcium-binding	SEQ_UP	2	
DOMAIN:EGF-like 36	SEQ_UP	1	
DOMAIN:EGF-like 36; calcium-binding	SEQ_UP	2	
DOMAIN:EGF-like 37; calcium-binding	SEQ_UP	2	
DOMAIN:EGF-like 38; calcium-binding	SEQ_UP	2	
DOMAIN:EGF-like 39; calcium-binding	SEQ_UP	2	
DOMAIN:EGF-like 4	SEQ_UP	49	
DOMAIN:EGF-like 4; calcium-binding	SEQ_UP	35	
DOMAIN:EGF-like 40; calcium-binding	SEQ_UP	2	
DOMAIN:EGF-like 41; calcium-binding	SEQ_UP	2	
DOMAIN:EGF-like 42; calcium-binding	SEQ_UP	2	
DOMAIN:EGF-like 43; calcium-binding	SEQ_UP	2	
DOMAIN:EGF-like 44; calcium-binding	SEQ_UP	2	
DOMAIN:EGF-like 45; calcium-binding	SEQ_UP	2	
DOMAIN:EGF-like 46; calcium-binding	SEQ_UP	2	
DOMAIN:EGF-like 47; calcium-binding	SEQ_UP	2	
DOMAIN:EGF-like 5	SEQ_UP	39	
DOMAIN:EGF-like 5; calcium-binding	SEQ_UP	33	
DOMAIN:EGF-like 6	SEQ_UP	39	
DOMAIN:EGF-like 6; calcium-binding	SEQ_UP	22	
DOMAIN:EGF-like 6; incomplete	SEQ_UP	1	
DOMAIN:EGF-like 7	SEQ_UP	24	
DOMAIN:EGF-like 7; calcium-binding	SEQ_UP	26	
DOMAIN:EGF-like 8	SEQ_UP	24	
DOMAIN:EGF-like 8; calcium-binding	SEQ_UP	21	
DOMAIN:EGF-like 9	SEQ_UP	22	
DOMAIN:EGF-like 9; calcium-binding	SEQ_UP	14	
DOMAIN:EGF-like; calcium-binding	SEQ_UP	10	
DOMAIN:EH	SEQ_UP	11	
DOMAIN:EH 1	SEQ_UP	6	
DOMAIN:EH 2	SEQ_UP	6	
DOMAIN:EH 3	SEQ_UP	2	
DOMAIN:EHN	SEQ_UP	1	
DOMAIN:eIF-3c_N	SEQ_UP	1	
DOMAIN:eIF-5a	SEQ_UP	1	
DOMAIN:eIF2_C	SEQ_UP	1	
DOMAIN:eIF2A	SEQ_UP	3	
DOMAIN:eIF2B_5	SEQ_UP	2	
DOMAIN:eIF3_N	SEQ_UP	1	
DOMAIN:eIF3m_C_helix	SEQ_UP	1	
DOMAIN:Elf-1_N	SEQ_UP	2	
DOMAIN:ELFV_dehydrog	SEQ_UP	1	
DOMAIN:ELL	SEQ_UP	2	
DOMAIN:ELM2	SEQ_UP	13	
DOMAIN:ELMO	SEQ_UP	6	
DOMAIN:EMC1_C	SEQ_UP	1	
DOMAIN:EMI	SEQ_UP	18	
DOMAIN:END	SEQ_UP	2	
DOMAIN:Endo/exonuclease/phosphatase	SEQ_UP	14	
DOMAIN:ENDO3c	SEQ_UP	2	
DOMAIN:Endonuclease_NS	SEQ_UP	4	
DOMAIN:Endostatin	SEQ_UP	1	
DOMAIN:EndoU	SEQ_UP	1	
DOMAIN:EngB-type G	SEQ_UP	1	
DOMAIN:Enkurin	SEQ_UP	2	
DOMAIN:Enolase_C	SEQ_UP	5	
DOMAIN:Enolase_N	SEQ_UP	5	
DOMAIN:ENT	SEQ_UP	1	
DOMAIN:ENTH	SEQ_UP	10	
DOMAIN:EP400_N	SEQ_UP	1	
DOMAIN:EpCAM_N	SEQ_UP	1	
DOMAIN:Eph LBD	SEQ_UP	14	
DOMAIN:Ephrin RBD	SEQ_UP	8	
DOMAIN:Epiglycanin_C	SEQ_UP	1	
DOMAIN:Epimerase	SEQ_UP	3	
DOMAIN:Epimerase_2	SEQ_UP	1	
DOMAIN:EPL1	SEQ_UP	1	
DOMAIN:EpoR_lig-bind	SEQ_UP	4	
DOMAIN:Era-type G	SEQ_UP	1	
DOMAIN:ERAP1_C	SEQ_UP	7	
DOMAIN:ERCC4	SEQ_UP	4	
DOMAIN:eRF1_1	SEQ_UP	2	
DOMAIN:eRF1_2	SEQ_UP	1	
DOMAIN:eRF1_3	SEQ_UP	1	
DOMAIN:Erf4	SEQ_UP	1	
DOMAIN:ERGIC_N	SEQ_UP	2	
DOMAIN:ERp29_N	SEQ_UP	1	
DOMAIN:ERV/ALR sulfhydryl oxidase	SEQ_UP	3	
DOMAIN:EST1	SEQ_UP	3	
DOMAIN:EST1_DNA_bind	SEQ_UP	3	
DOMAIN:ETF	SEQ_UP	2	
DOMAIN:ETS	SEQ_UP	27	
DOMAIN:ETS_PEA3_N	SEQ_UP	3	
DOMAIN:EVE	SEQ_UP	1	
DOMAIN:Exo70	SEQ_UP	1	
DOMAIN:Exonuclease	SEQ_UP	12	
DOMAIN:Exostosin	SEQ_UP	4	
DOMAIN:EXPERA	SEQ_UP	5	
DOMAIN:EXPERA 1	SEQ_UP	2	
DOMAIN:EXPERA 2	SEQ_UP	2	
DOMAIN:Exportin-5	SEQ_UP	1	
DOMAIN:Exportin-T	SEQ_UP	1	
DOMAIN:EXS	SEQ_UP	1	
DOMAIN:F-BAR	SEQ_UP	24	
DOMAIN:F-box	SEQ_UP	85	
DOMAIN:F-box-like	SEQ_UP	2	
DOMAIN:F420_oxidored	SEQ_UP	5	
DOMAIN:F5/8 type A 1	SEQ_UP	3	
DOMAIN:F5/8 type A 2	SEQ_UP	3	
DOMAIN:F5/8 type A 3	SEQ_UP	3	
DOMAIN:F5/8 type C	SEQ_UP	22	
DOMAIN:F5/8 type C 1	SEQ_UP	6	
DOMAIN:F5/8 type C 2	SEQ_UP	6	
DOMAIN:FA	SEQ_UP	1	
DOMAIN:FA_desaturase	SEQ_UP	5	
DOMAIN:FA_FANCE	SEQ_UP	1	
DOMAIN:FAA_hydrolase	SEQ_UP	2	
DOMAIN:FAA_hydrolase_N	SEQ_UP	1	
DOMAIN:FABP	SEQ_UP	12	
DOMAIN:FACT-Spt16_Nlob	SEQ_UP	1	
DOMAIN:FAD_binding_2	SEQ_UP	1	
DOMAIN:FAD_binding_3	SEQ_UP	3	
DOMAIN:FAD_binding_6	SEQ_UP	1	
DOMAIN:FAD_binding_7	SEQ_UP	1	
DOMAIN:FAD-binding FR-type	SEQ_UP	19	
DOMAIN:FAD-binding PCMH-type	SEQ_UP	10	
DOMAIN:FAD-oxidase_C	SEQ_UP	1	
DOMAIN:FAM110_C	SEQ_UP	1	
DOMAIN:FAM110_N	SEQ_UP	2	
DOMAIN:FAM124	SEQ_UP	2	
DOMAIN:FAM176	SEQ_UP	2	
DOMAIN:FAM184	SEQ_UP	1	
DOMAIN:FAM192A_Fyv6_N	SEQ_UP	1	
DOMAIN:FAM193_C	SEQ_UP	2	
DOMAIN:FAM194	SEQ_UP	1	
DOMAIN:FAM212	SEQ_UP	1	
DOMAIN:FAM220	SEQ_UP	1	
DOMAIN:FAM35_C	SEQ_UP	1	
DOMAIN:FAM75	SEQ_UP	15	
DOMAIN:FAM83	SEQ_UP	4	
DOMAIN:FAM86	SEQ_UP	1	
DOMAIN:FAM91_C	SEQ_UP	1	
DOMAIN:FAM91_N	SEQ_UP	1	
DOMAIN:FANCI_HD1	SEQ_UP	1	
DOMAIN:FANCI_HD2	SEQ_UP	1	
DOMAIN:FANCI_S1	SEQ_UP	1	
DOMAIN:FANCI_S1-cap	SEQ_UP	1	
DOMAIN:FANCI_S2	SEQ_UP	1	
DOMAIN:FANCI_S3	SEQ_UP	1	
DOMAIN:FANCL_C	SEQ_UP	1	
DOMAIN:FANCL_d1	SEQ_UP	1	
DOMAIN:FANCL_d3	SEQ_UP	1	
DOMAIN:Fanconi_A_N	SEQ_UP	1	
DOMAIN:FAO_M	SEQ_UP	3	
DOMAIN:FAS1	SEQ_UP	4	
DOMAIN:FAS1 1	SEQ_UP	4	
DOMAIN:FAS1 2	SEQ_UP	4	
DOMAIN:FAS1 3	SEQ_UP	4	
DOMAIN:FAS1 4	SEQ_UP	4	
DOMAIN:FAS1 5	SEQ_UP	2	
DOMAIN:FAS1 6	SEQ_UP	2	
DOMAIN:FAS1 7	SEQ_UP	2	
DOMAIN:Fascin	SEQ_UP	1	
DOMAIN:FAST_1	SEQ_UP	2	
DOMAIN:FAST_2	SEQ_UP	1	
DOMAIN:FAT	SEQ_UP	6	
DOMAIN:FATC	SEQ_UP	6	
DOMAIN:Fatty acid hydroxylase	SEQ_UP	6	
DOMAIN:FAXC_N	SEQ_UP	1	
DOMAIN:FBA	SEQ_UP	6	
DOMAIN:FBPase	SEQ_UP	2	
DOMAIN:FBPase_C	SEQ_UP	2	
DOMAIN:FBXL18_C	SEQ_UP	1	
DOMAIN:FCH	SEQ_UP	1	
DOMAIN:FCP1 homology	SEQ_UP	8	
DOMAIN:FCP1_C	SEQ_UP	1	
DOMAIN:FCS-type	SEQ_UP	5	
DOMAIN:FDX-ACB	SEQ_UP	2	
DOMAIN:Fe_hyd_lg_C	SEQ_UP	1	
DOMAIN:Fe-ADH	SEQ_UP	1	
DOMAIN:Fe-S_biosyn	SEQ_UP	2	
DOMAIN:Fe2OG dioxygenase	SEQ_UP	23	
DOMAIN:Fer4_20	SEQ_UP	1	
DOMAIN:FerB	SEQ_UP	1	
DOMAIN:Ferlin_C	SEQ_UP	2	
DOMAIN:FERM	SEQ_UP	50	
DOMAIN:FERM 1	SEQ_UP	2	
DOMAIN:FERM 2	SEQ_UP	2	
DOMAIN:FERM_F1	SEQ_UP	1	
DOMAIN:FERM_M	SEQ_UP	2	
DOMAIN:Ferric oxidoreductase	SEQ_UP	9	
DOMAIN:Ferritin-like diiron	SEQ_UP	12	
DOMAIN:FeS_assembly_P	SEQ_UP	1	
DOMAIN:Fes1	SEQ_UP	2	
DOMAIN:FF	SEQ_UP	5	
DOMAIN:FF 1	SEQ_UP	6	
DOMAIN:FF 2	SEQ_UP	6	
DOMAIN:FF 3	SEQ_UP	5	
DOMAIN:FF 4	SEQ_UP	5	
DOMAIN:FF 5	SEQ_UP	3	
DOMAIN:FF 6	SEQ_UP	3	
DOMAIN:FFD	SEQ_UP	2	
DOMAIN:FGAR-AT_linker	SEQ_UP	1	
DOMAIN:FGAR-AT_N	SEQ_UP	1	
DOMAIN:FGE-sulfatase	SEQ_UP	2	
DOMAIN:FGGY_C	SEQ_UP	5	
DOMAIN:FGGY_N	SEQ_UP	6	
DOMAIN:FH1	SEQ_UP	11	
DOMAIN:FH2	SEQ_UP	16	
DOMAIN:FHA	SEQ_UP	34	
DOMAIN:FHA_2	SEQ_UP	3	
DOMAIN:FHA-like	SEQ_UP	2	
DOMAIN:FHA; atypical	SEQ_UP	2	
DOMAIN:Fibrillar collagen NC1	SEQ_UP	11	
DOMAIN:Fibrinogen C-terminal	SEQ_UP	32	
DOMAIN:Fibronectin type-I	SEQ_UP	4	
DOMAIN:Fibronectin type-I 1	SEQ_UP	1	
DOMAIN:Fibronectin type-I 10	SEQ_UP	1	
DOMAIN:Fibronectin type-I 11	SEQ_UP	1	
DOMAIN:Fibronectin type-I 12	SEQ_UP	1	
DOMAIN:Fibronectin type-I 2	SEQ_UP	1	
DOMAIN:Fibronectin type-I 3	SEQ_UP	1	
DOMAIN:Fibronectin type-I 4	SEQ_UP	1	
DOMAIN:Fibronectin type-I 5	SEQ_UP	1	
DOMAIN:Fibronectin type-I 6	SEQ_UP	1	
DOMAIN:Fibronectin type-I 7	SEQ_UP	1	
DOMAIN:Fibronectin type-I 8	SEQ_UP	1	
DOMAIN:Fibronectin type-I 9	SEQ_UP	1	
DOMAIN:Fibronectin type-II	SEQ_UP	12	
DOMAIN:Fibronectin type-II 1	SEQ_UP	5	
DOMAIN:Fibronectin type-II 2	SEQ_UP	5	
DOMAIN:Fibronectin type-II 3	SEQ_UP	2	
DOMAIN:Fibronectin type-III	SEQ_UP	190	
DOMAIN:Fibronectin type-III 1	SEQ_UP	131	
DOMAIN:Fibronectin type-III 10	SEQ_UP	11	
DOMAIN:Fibronectin type-III 100	SEQ_UP	1	
DOMAIN:Fibronectin type-III 101	SEQ_UP	1	
DOMAIN:Fibronectin type-III 102	SEQ_UP	1	
DOMAIN:Fibronectin type-III 103	SEQ_UP	1	
DOMAIN:Fibronectin type-III 104	SEQ_UP	1	
DOMAIN:Fibronectin type-III 105	SEQ_UP	1	
DOMAIN:Fibronectin type-III 106	SEQ_UP	1	
DOMAIN:Fibronectin type-III 107	SEQ_UP	1	
DOMAIN:Fibronectin type-III 108	SEQ_UP	1	
DOMAIN:Fibronectin type-III 109	SEQ_UP	1	
DOMAIN:Fibronectin type-III 11	SEQ_UP	10	
DOMAIN:Fibronectin type-III 110	SEQ_UP	1	
DOMAIN:Fibronectin type-III 111	SEQ_UP	1	
DOMAIN:Fibronectin type-III 112	SEQ_UP	1	
DOMAIN:Fibronectin type-III 113	SEQ_UP	1	
DOMAIN:Fibronectin type-III 114	SEQ_UP	1	
DOMAIN:Fibronectin type-III 115	SEQ_UP	1	
DOMAIN:Fibronectin type-III 116	SEQ_UP	1	
DOMAIN:Fibronectin type-III 117	SEQ_UP	1	
DOMAIN:Fibronectin type-III 118	SEQ_UP	1	
DOMAIN:Fibronectin type-III 119	SEQ_UP	1	
DOMAIN:Fibronectin type-III 12	SEQ_UP	10	
DOMAIN:Fibronectin type-III 120	SEQ_UP	1	
DOMAIN:Fibronectin type-III 121	SEQ_UP	1	
DOMAIN:Fibronectin type-III 122	SEQ_UP	1	
DOMAIN:Fibronectin type-III 123	SEQ_UP	1	
DOMAIN:Fibronectin type-III 124	SEQ_UP	1	
DOMAIN:Fibronectin type-III 125	SEQ_UP	1	
DOMAIN:Fibronectin type-III 126	SEQ_UP	1	
DOMAIN:Fibronectin type-III 127	SEQ_UP	1	
DOMAIN:Fibronectin type-III 128	SEQ_UP	1	
DOMAIN:Fibronectin type-III 129	SEQ_UP	1	
DOMAIN:Fibronectin type-III 13	SEQ_UP	8	
DOMAIN:Fibronectin type-III 13; extra domain A	SEQ_UP	1	
DOMAIN:Fibronectin type-III 130	SEQ_UP	1	
DOMAIN:Fibronectin type-III 131	SEQ_UP	1	
DOMAIN:Fibronectin type-III 132	SEQ_UP	1	
DOMAIN:Fibronectin type-III 14	SEQ_UP	7	
DOMAIN:Fibronectin type-III 15	SEQ_UP	6	
DOMAIN:Fibronectin type-III 16	SEQ_UP	6	
DOMAIN:Fibronectin type-III 17	SEQ_UP	6	
DOMAIN:Fibronectin type-III 18	SEQ_UP	3	
DOMAIN:Fibronectin type-III 19	SEQ_UP	1	
DOMAIN:Fibronectin type-III 2	SEQ_UP	131	
DOMAIN:Fibronectin type-III 20	SEQ_UP	2	
DOMAIN:Fibronectin type-III 21	SEQ_UP	2	
DOMAIN:Fibronectin type-III 22	SEQ_UP	2	
DOMAIN:Fibronectin type-III 23	SEQ_UP	2	
DOMAIN:Fibronectin type-III 24	SEQ_UP	2	
DOMAIN:Fibronectin type-III 25	SEQ_UP	2	
DOMAIN:Fibronectin type-III 26	SEQ_UP	2	
DOMAIN:Fibronectin type-III 27	SEQ_UP	2	
DOMAIN:Fibronectin type-III 28	SEQ_UP	2	
DOMAIN:Fibronectin type-III 29	SEQ_UP	2	
DOMAIN:Fibronectin type-III 3	SEQ_UP	81	
DOMAIN:Fibronectin type-III 30	SEQ_UP	2	
DOMAIN:Fibronectin type-III 31	SEQ_UP	2	
DOMAIN:Fibronectin type-III 32	SEQ_UP	2	
DOMAIN:Fibronectin type-III 33	SEQ_UP	2	
DOMAIN:Fibronectin type-III 34	SEQ_UP	2	
DOMAIN:Fibronectin type-III 35	SEQ_UP	2	
DOMAIN:Fibronectin type-III 36	SEQ_UP	2	
DOMAIN:Fibronectin type-III 37	SEQ_UP	1	
DOMAIN:Fibronectin type-III 38	SEQ_UP	1	
DOMAIN:Fibronectin type-III 39	SEQ_UP	1	
DOMAIN:Fibronectin type-III 4	SEQ_UP	62	
DOMAIN:Fibronectin type-III 40	SEQ_UP	1	
DOMAIN:Fibronectin type-III 41	SEQ_UP	1	
DOMAIN:Fibronectin type-III 42	SEQ_UP	1	
DOMAIN:Fibronectin type-III 43	SEQ_UP	1	
DOMAIN:Fibronectin type-III 44	SEQ_UP	1	
DOMAIN:Fibronectin type-III 45	SEQ_UP	1	
DOMAIN:Fibronectin type-III 46	SEQ_UP	1	
DOMAIN:Fibronectin type-III 47	SEQ_UP	1	
DOMAIN:Fibronectin type-III 48	SEQ_UP	1	
DOMAIN:Fibronectin type-III 49	SEQ_UP	1	
DOMAIN:Fibronectin type-III 5	SEQ_UP	42	
DOMAIN:Fibronectin type-III 50	SEQ_UP	1	
DOMAIN:Fibronectin type-III 51	SEQ_UP	1	
DOMAIN:Fibronectin type-III 52	SEQ_UP	1	
DOMAIN:Fibronectin type-III 53	SEQ_UP	1	
DOMAIN:Fibronectin type-III 54	SEQ_UP	1	
DOMAIN:Fibronectin type-III 55	SEQ_UP	1	
DOMAIN:Fibronectin type-III 56	SEQ_UP	1	
DOMAIN:Fibronectin type-III 57	SEQ_UP	1	
DOMAIN:Fibronectin type-III 58	SEQ_UP	1	
DOMAIN:Fibronectin type-III 59	SEQ_UP	1	
DOMAIN:Fibronectin type-III 6	SEQ_UP	32	
DOMAIN:Fibronectin type-III 60	SEQ_UP	1	
DOMAIN:Fibronectin type-III 61	SEQ_UP	1	
DOMAIN:Fibronectin type-III 62	SEQ_UP	1	
DOMAIN:Fibronectin type-III 63	SEQ_UP	1	
DOMAIN:Fibronectin type-III 64	SEQ_UP	1	
DOMAIN:Fibronectin type-III 65	SEQ_UP	1	
DOMAIN:Fibronectin type-III 66	SEQ_UP	1	
DOMAIN:Fibronectin type-III 67	SEQ_UP	1	
DOMAIN:Fibronectin type-III 68	SEQ_UP	1	
DOMAIN:Fibronectin type-III 69	SEQ_UP	1	
DOMAIN:Fibronectin type-III 7	SEQ_UP	23	
DOMAIN:Fibronectin type-III 70	SEQ_UP	1	
DOMAIN:Fibronectin type-III 71	SEQ_UP	1	
DOMAIN:Fibronectin type-III 72	SEQ_UP	1	
DOMAIN:Fibronectin type-III 73	SEQ_UP	1	
DOMAIN:Fibronectin type-III 74	SEQ_UP	1	
DOMAIN:Fibronectin type-III 75	SEQ_UP	1	
DOMAIN:Fibronectin type-III 76	SEQ_UP	1	
DOMAIN:Fibronectin type-III 77	SEQ_UP	1	
DOMAIN:Fibronectin type-III 78	SEQ_UP	1	
DOMAIN:Fibronectin type-III 79	SEQ_UP	1	
DOMAIN:Fibronectin type-III 8	SEQ_UP	22	
DOMAIN:Fibronectin type-III 8; extra domain B	SEQ_UP	1	
DOMAIN:Fibronectin type-III 80	SEQ_UP	1	
DOMAIN:Fibronectin type-III 81	SEQ_UP	1	
DOMAIN:Fibronectin type-III 82	SEQ_UP	1	
DOMAIN:Fibronectin type-III 83	SEQ_UP	1	
DOMAIN:Fibronectin type-III 84	SEQ_UP	1	
DOMAIN:Fibronectin type-III 85	SEQ_UP	1	
DOMAIN:Fibronectin type-III 86	SEQ_UP	1	
DOMAIN:Fibronectin type-III 87	SEQ_UP	1	
DOMAIN:Fibronectin type-III 88	SEQ_UP	1	
DOMAIN:Fibronectin type-III 89	SEQ_UP	1	
DOMAIN:Fibronectin type-III 9	SEQ_UP	16	
DOMAIN:Fibronectin type-III 90	SEQ_UP	1	
DOMAIN:Fibronectin type-III 91	SEQ_UP	1	
DOMAIN:Fibronectin type-III 92	SEQ_UP	1	
DOMAIN:Fibronectin type-III 93	SEQ_UP	1	
DOMAIN:Fibronectin type-III 94	SEQ_UP	1	
DOMAIN:Fibronectin type-III 95	SEQ_UP	1	
DOMAIN:Fibronectin type-III 96	SEQ_UP	1	
DOMAIN:Fibronectin type-III 97	SEQ_UP	1	
DOMAIN:Fibronectin type-III 98	SEQ_UP	1	
DOMAIN:Fibronectin type-III 99	SEQ_UP	1	
DOMAIN:Fido	SEQ_UP	1	
DOMAIN:FIIND	SEQ_UP	2	
DOMAIN:FIIND (incomplete)	SEQ_UP	1	
DOMAIN:FIP-RBD	SEQ_UP	6	
DOMAIN:Fip1	SEQ_UP	1	
DOMAIN:FIST_C	SEQ_UP	1	
DOMAIN:FKTN_N	SEQ_UP	1	
DOMAIN:Flavodoxin_2	SEQ_UP	2	
DOMAIN:Flavodoxin-like	SEQ_UP	8	
DOMAIN:Flavoprotein	SEQ_UP	1	
DOMAIN:FLYWCH_N	SEQ_UP	2	
DOMAIN:FLYWCH-type	SEQ_UP	1	
DOMAIN:FMN hydroxy acid dehydrogenase	SEQ_UP	2	
DOMAIN:Fmp27	SEQ_UP	1	
DOMAIN:Fmp27_GFWDK	SEQ_UP	1	
DOMAIN:Folate_rec	SEQ_UP	4	
DOMAIN:Follistatin-like	SEQ_UP	3	
DOMAIN:Follistatin-like 1	SEQ_UP	2	
DOMAIN:Follistatin-like 2	SEQ_UP	2	
DOMAIN:Follistatin-like 3	SEQ_UP	1	
DOMAIN:FoP_duplication	SEQ_UP	1	
DOMAIN:Fork-head	SEQ_UP	32	
DOMAIN:Formyl_trans_C	SEQ_UP	1	
DOMAIN:Formyl_trans_N	SEQ_UP	3	
DOMAIN:Fox-1_C	SEQ_UP	1	
DOMAIN:FOXO_KIX_bdg	SEQ_UP	1	
DOMAIN:FOXO-TAD	SEQ_UP	1	
DOMAIN:FOXP-CC	SEQ_UP	2	
DOMAIN:FPG_CAT	SEQ_UP	2	
DOMAIN:FPL	SEQ_UP	1	
DOMAIN:Frizzled	SEQ_UP	2	
DOMAIN:Fry_C	SEQ_UP	2	
DOMAIN:FSA_C	SEQ_UP	1	
DOMAIN:FTO_NTD	SEQ_UP	1	
DOMAIN:FtsH_ext	SEQ_UP	2	
DOMAIN:FtsJ	SEQ_UP	1	
DOMAIN:Fucokinase	SEQ_UP	1	
DOMAIN:Fucosidase_C	SEQ_UP	2	
DOMAIN:FumaraseC_C	SEQ_UP	1	
DOMAIN:Furin-like	SEQ_UP	5	
DOMAIN:Furin-like_2	SEQ_UP	3	
DOMAIN:Fuz_longin_1	SEQ_UP	3	
DOMAIN:Fuz_longin_2	SEQ_UP	3	
DOMAIN:Fuz_longin_3	SEQ_UP	3	
DOMAIN:FXMRP1_C_core	SEQ_UP	1	
DOMAIN:FXR_C1	SEQ_UP	1	
DOMAIN:FYR C-terminal	SEQ_UP	5	
DOMAIN:FYR N-terminal	SEQ_UP	5	
DOMAIN:FYVE_2	SEQ_UP	2	
DOMAIN:FYVE-type	SEQ_UP	27	
DOMAIN:FZ	SEQ_UP	23	
DOMAIN:FZ 1	SEQ_UP	1	
DOMAIN:FZ 2	SEQ_UP	1	
DOMAIN:Fzo_mitofusin	SEQ_UP	1	
DOMAIN:G	SEQ_UP	2	
DOMAIN:G protein gamma	SEQ_UP	13	
DOMAIN:G_PROTEIN_RECEP_F1_2	SEQ_UP	1744	
DOMAIN:G_PROTEIN_RECEP_F2_3	SEQ_UP	23	
DOMAIN:G_PROTEIN_RECEP_F2_4	SEQ_UP	49	
DOMAIN:G_PROTEIN_RECEP_F3_4	SEQ_UP	144	
DOMAIN:G-alpha	SEQ_UP	16	
DOMAIN:G-patch	SEQ_UP	25	
DOMAIN:G6PD_C	SEQ_UP	3	
DOMAIN:G6PD_N	SEQ_UP	3	
DOMAIN:G8	SEQ_UP	4	
DOMAIN:G8 1	SEQ_UP	2	
DOMAIN:G8 2	SEQ_UP	2	
DOMAIN:GABP-alpha	SEQ_UP	1	
DOMAIN:GAE	SEQ_UP	5	
DOMAIN:GAF	SEQ_UP	2	
DOMAIN:GAF 1	SEQ_UP	6	
DOMAIN:GAF 2	SEQ_UP	6	
DOMAIN:Gag_p10	SEQ_UP	4	
DOMAIN:Gag_p24	SEQ_UP	1	
DOMAIN:Gag_p30	SEQ_UP	1	
DOMAIN:GAIN	SEQ_UP	1	
DOMAIN:GAIN_A	SEQ_UP	1	
DOMAIN:Gal_mutarotas_2	SEQ_UP	2	
DOMAIN:GALANIN	SEQ_UP	2	
DOMAIN:Galectin	SEQ_UP	15	
DOMAIN:Galectin 1	SEQ_UP	5	
DOMAIN:Galectin 2	SEQ_UP	5	
DOMAIN:GalKase_gal_bdg	SEQ_UP	2	
DOMAIN:GalP_UDP_tr_C	SEQ_UP	1	
DOMAIN:GalP_UDP_transf	SEQ_UP	1	
DOMAIN:Gamma-glutamyl hydrolase	SEQ_UP	1	
DOMAIN:GAR	SEQ_UP	7	
DOMAIN:GARS_N	SEQ_UP	1	
DOMAIN:GAS	SEQ_UP	1	
DOMAIN:Gasdermin	SEQ_UP	8	
DOMAIN:Gasdermin_C	SEQ_UP	6	
DOMAIN:Gastrin	SEQ_UP	2	
DOMAIN:GAT	SEQ_UP	6	
DOMAIN:GATA-type	SEQ_UP	7	
DOMAIN:GATase	SEQ_UP	1	
DOMAIN:GatB_N	SEQ_UP	1	
DOMAIN:GatB_Yqey	SEQ_UP	1	
DOMAIN:Gate	SEQ_UP	2	
DOMAIN:GB1/RHD3-type G	SEQ_UP	16	
DOMAIN:Gb3_synth	SEQ_UP	1	
DOMAIN:GBBH-like_N	SEQ_UP	1	
DOMAIN:GBD/FH3	SEQ_UP	11	
DOMAIN:GBP_C	SEQ_UP	1	
DOMAIN:GbpC	SEQ_UP	1	
DOMAIN:GCFC	SEQ_UP	2	
DOMAIN:GCM	SEQ_UP	2	
DOMAIN:GCP_C_terminal	SEQ_UP	5	
DOMAIN:GCP_N_terminal	SEQ_UP	5	
DOMAIN:GCP6_N	SEQ_UP	1	
DOMAIN:GCV_T	SEQ_UP	4	
DOMAIN:GCV_T_C	SEQ_UP	3	
DOMAIN:GDE_C	SEQ_UP	1	
DOMAIN:GDNF	SEQ_UP	5	
DOMAIN:Ge1_WD40	SEQ_UP	1	
DOMAIN:GED	SEQ_UP	7	
DOMAIN:Gelsolin-like	SEQ_UP	14	
DOMAIN:GF_recep_IV	SEQ_UP	3	
DOMAIN:GFO_IDH_MocA	SEQ_UP	4	
DOMAIN:GFO_IDH_MocA_C	SEQ_UP	2	
DOMAIN:GGACT	SEQ_UP	1	
DOMAIN:GH18	SEQ_UP	10	
DOMAIN:GHMP_kinases_C	SEQ_UP	3	
DOMAIN:GHMP_kinases_N	SEQ_UP	4	
DOMAIN:GIDA	SEQ_UP	1	
DOMAIN:GIDA_C	SEQ_UP	1	
DOMAIN:GIT	SEQ_UP	1	
DOMAIN:GIT_CC	SEQ_UP	1	
DOMAIN:GIT1_C	SEQ_UP	2	
DOMAIN:GIY-YIG	SEQ_UP	2	
DOMAIN:Gla	SEQ_UP	16	
DOMAIN:Gln_synt_b-grasp	SEQ_UP	1	
DOMAIN:GLOBIN	SEQ_UP	15	
DOMAIN:GLTP	SEQ_UP	3	
DOMAIN:GLTSCR1	SEQ_UP	2	
DOMAIN:GLUCAGON	SEQ_UP	6	
DOMAIN:Glucosamine_iso	SEQ_UP	4	
DOMAIN:GLUE C-terminal	SEQ_UP	1	
DOMAIN:GLUE N-terminal	SEQ_UP	1	
DOMAIN:GluR_Homer-bdg	SEQ_UP	1	
DOMAIN:Glutamine amidotransferase type-1	SEQ_UP	6	
DOMAIN:Glutamine amidotransferase type-2	SEQ_UP	5	
DOMAIN:Glutaredoxin	SEQ_UP	7	
DOMAIN:Glutaredoxin 1	SEQ_UP	1	
DOMAIN:Glutaredoxin 2	SEQ_UP	1	
DOMAIN:Gly_acyl_tr_C	SEQ_UP	1	
DOMAIN:Gly_acyl_tr_N	SEQ_UP	2	
DOMAIN:Glyco_hydr_116N	SEQ_UP	1	
DOMAIN:Glyco_hydro_15	SEQ_UP	3	
DOMAIN:Glyco_hydro_2	SEQ_UP	1	
DOMAIN:Glyco_hydro_2_C	SEQ_UP	2	
DOMAIN:Glyco_hydro_2_N	SEQ_UP	2	
DOMAIN:Glyco_hydro_20	SEQ_UP	3	
DOMAIN:Glyco_hydro_30	SEQ_UP	1	
DOMAIN:Glyco_hydro_35	SEQ_UP	5	
DOMAIN:Glyco_hydro_38C	SEQ_UP	4	
DOMAIN:Glyco_hydro_38N	SEQ_UP	3	
DOMAIN:Glyco_hydro_59M	SEQ_UP	1	
DOMAIN:Glyco_hydro_63	SEQ_UP	1	
DOMAIN:Glyco_hydro_63N	SEQ_UP	1	
DOMAIN:Glyco_hydro38C2	SEQ_UP	1	
DOMAIN:Glyco_tran_10_N	SEQ_UP	4	
DOMAIN:Glyco_tran_28_C	SEQ_UP	2	
DOMAIN:Glyco_trans_2-like	SEQ_UP	7	
DOMAIN:Glyco_transf_24	SEQ_UP	2	
DOMAIN:Glyco_transf_64	SEQ_UP	5	
DOMAIN:Glyco_transf_7C	SEQ_UP	7	
DOMAIN:Glyco_transf_7N	SEQ_UP	7	
DOMAIN:Glycohydro_20b2	SEQ_UP	2	
DOMAIN:Glycos_transf_1	SEQ_UP	4	
DOMAIN:GLYCOSYL_HYDROL_F22_1	SEQ_UP	8	
DOMAIN:Glyoxalase	SEQ_UP	2	
DOMAIN:GMC_OxRdtase_N	SEQ_UP	1	
DOMAIN:GMC_oxred_C	SEQ_UP	1	
DOMAIN:GMP_PDE_delta	SEQ_UP	2	
DOMAIN:GMPS ATP-PPase	SEQ_UP	1	
DOMAIN:GN3L_Grn1	SEQ_UP	1	
DOMAIN:GOLD	SEQ_UP	19	
DOMAIN:GOLGA2L5	SEQ_UP	1	
DOMAIN:GoLoco	SEQ_UP	3	
DOMAIN:GoLoco 1	SEQ_UP	4	
DOMAIN:GoLoco 2	SEQ_UP	4	
DOMAIN:GoLoco 3	SEQ_UP	3	
DOMAIN:GoLoco 4	SEQ_UP	2	
DOMAIN:GON	SEQ_UP	2	
DOMAIN:Gp_dh_C	SEQ_UP	3	
DOMAIN:Gp_dh_N	SEQ_UP	6	
DOMAIN:GP-PDE	SEQ_UP	7	
DOMAIN:GPAT_C	SEQ_UP	1	
DOMAIN:GpcrRhopsn4	SEQ_UP	2	
DOMAIN:GPHH	SEQ_UP	4	
DOMAIN:GPS	SEQ_UP	33	
DOMAIN:GPS2_interact	SEQ_UP	1	
DOMAIN:GRAM	SEQ_UP	17	
DOMAIN:GRAM 1	SEQ_UP	4	
DOMAIN:GRAM 2	SEQ_UP	4	
DOMAIN:GRANULINS	SEQ_UP	2	
DOMAIN:GRF-type	SEQ_UP	4	
DOMAIN:Grh/CP2 DB	SEQ_UP	6	
DOMAIN:GRIN_C	SEQ_UP	2	
DOMAIN:GRIP	SEQ_UP	5	
DOMAIN:GS	SEQ_UP	7	
DOMAIN:GS beta-grasp	SEQ_UP	2	
DOMAIN:GS catalytic	SEQ_UP	2	
DOMAIN:GSAP-16	SEQ_UP	1	
DOMAIN:GSH_synthase	SEQ_UP	1	
DOMAIN:GST C-terminal	SEQ_UP	40	
DOMAIN:GST N-terminal	SEQ_UP	30	
DOMAIN:GST_C	SEQ_UP	2	
DOMAIN:GST_C_6	SEQ_UP	4	
DOMAIN:GT23	SEQ_UP	1	
DOMAIN:GTP_cyclohydroI	SEQ_UP	1	
DOMAIN:GTP_EFTU_D2	SEQ_UP	3	
DOMAIN:GTP_EFTU_D3	SEQ_UP	3	
DOMAIN:GTP_EFTU_D4	SEQ_UP	1	
DOMAIN:GTP-bdg_M	SEQ_UP	1	
DOMAIN:GTP-bdg_N	SEQ_UP	1	
DOMAIN:GTPase_binding	SEQ_UP	2	
DOMAIN:GTSE1_N	SEQ_UP	2	
DOMAIN:Guanylate cyclase	SEQ_UP	20	
DOMAIN:Guanylate cyclase 1	SEQ_UP	2	
DOMAIN:Guanylate cyclase 2	SEQ_UP	2	
DOMAIN:Guanylate kinase-like	SEQ_UP	23	
DOMAIN:GUCT	SEQ_UP	1	
DOMAIN:GuKc	SEQ_UP	4	
DOMAIN:GYF	SEQ_UP	3	
DOMAIN:GYF_2	SEQ_UP	1	
DOMAIN:H15	SEQ_UP	14	
DOMAIN:H15 1	SEQ_UP	1	
DOMAIN:H15 2	SEQ_UP	1	
DOMAIN:H15 3	SEQ_UP	1	
DOMAIN:H2TH	SEQ_UP	2	
DOMAIN:HA2	SEQ_UP	5	
DOMAIN:HABP4_PAI-RBP1	SEQ_UP	2	
DOMAIN:HAP1 N-terminal	SEQ_UP	3	
DOMAIN:HARP	SEQ_UP	1	
DOMAIN:HARP 1	SEQ_UP	1	
DOMAIN:HARP 2	SEQ_UP	1	
DOMAIN:Hat1_N	SEQ_UP	1	
DOMAIN:HATPase_c	SEQ_UP	7	
DOMAIN:HAUS-augmin3	SEQ_UP	1	
DOMAIN:HAUS6_N	SEQ_UP	1	
DOMAIN:HBS1_N	SEQ_UP	1	
DOMAIN:HCO3_cotransp	SEQ_UP	8	
DOMAIN:Hcy-binding	SEQ_UP	3	
DOMAIN:HD	SEQ_UP	3	
DOMAIN:HDAC_interact	SEQ_UP	1	
DOMAIN:HDAC4_Gln	SEQ_UP	3	
DOMAIN:HDAg	SEQ_UP	1	
DOMAIN:HDc	SEQ_UP	1	
DOMAIN:hDGE_amylase	SEQ_UP	1	
DOMAIN:HDNR	SEQ_UP	2	
DOMAIN:Headcase	SEQ_UP	1	
DOMAIN:HECT	SEQ_UP	27	
DOMAIN:HECW_N	SEQ_UP	2	
DOMAIN:Helicase ATP-binding	SEQ_UP	117	
DOMAIN:Helicase ATP-binding 1	SEQ_UP	2	
DOMAIN:Helicase ATP-binding 2	SEQ_UP	2	
DOMAIN:Helicase ATP-binding; first part	SEQ_UP	1	
DOMAIN:Helicase ATP-binding; second part	SEQ_UP	1	
DOMAIN:Helicase C-terminal	SEQ_UP	110	
DOMAIN:Helicase C-terminal 1	SEQ_UP	2	
DOMAIN:Helicase C-terminal 2	SEQ_UP	2	
DOMAIN:Helicase_C_4	SEQ_UP	2	
DOMAIN:HELICc2	SEQ_UP	2	
DOMAIN:HELP	SEQ_UP	5	
DOMAIN:HEM4	SEQ_UP	1	
DOMAIN:Hemerythrin	SEQ_UP	1	
DOMAIN:HEPN	SEQ_UP	1	
DOMAIN:Hepsin-SRCR	SEQ_UP	1	
DOMAIN:Hexokinase	SEQ_UP	1	
DOMAIN:Hexokinase 1	SEQ_UP	4	
DOMAIN:Hexokinase 2	SEQ_UP	4	
DOMAIN:Hexokinase_1	SEQ_UP	4	
DOMAIN:Hexokinase_2	SEQ_UP	4	
DOMAIN:Hflx-type G	SEQ_UP	1	
DOMAIN:hGDE_central	SEQ_UP	1	
DOMAIN:hGDE_N	SEQ_UP	1	
DOMAIN:HGTP_anticodon	SEQ_UP	2	
DOMAIN:HH_signal	SEQ_UP	2	
DOMAIN:HhH	SEQ_UP	4	
DOMAIN:HHH_8	SEQ_UP	1	
DOMAIN:HhH1	SEQ_UP	1	
DOMAIN:HIG1	SEQ_UP	5	
DOMAIN:HIN-200	SEQ_UP	9	
DOMAIN:HIN-200 1	SEQ_UP	2	
DOMAIN:HIN-200 2	SEQ_UP	2	
DOMAIN:Hint	SEQ_UP	1	
DOMAIN:HintC	SEQ_UP	3	
DOMAIN:HintN	SEQ_UP	3	
DOMAIN:HipN	SEQ_UP	1	
DOMAIN:HIRAN	SEQ_UP	1	
DOMAIN:Hist_deacetyl	SEQ_UP	10	
DOMAIN:Histidine kinase	SEQ_UP	6	
DOMAIN:Histone	SEQ_UP	46	
DOMAIN:Histone H2A	SEQ_UP	2	
DOMAIN:Histone_H2A_C	SEQ_UP	21	
DOMAIN:Histone-fold	SEQ_UP	6	
DOMAIN:HIT	SEQ_UP	5	
DOMAIN:HIT-type	SEQ_UP	3	
DOMAIN:HJURP_C	SEQ_UP	1	
DOMAIN:HJURP_mid	SEQ_UP	1	
DOMAIN:HMA	SEQ_UP	4	
DOMAIN:HMA 1	SEQ_UP	2	
DOMAIN:HMA 2	SEQ_UP	2	
DOMAIN:HMA 3	SEQ_UP	2	
DOMAIN:HMA 4	SEQ_UP	2	
DOMAIN:HMA 5	SEQ_UP	2	
DOMAIN:HMA 6	SEQ_UP	2	
DOMAIN:HMA 7	SEQ_UP	1	
DOMAIN:HMG box	SEQ_UP	43	
DOMAIN:HMG_CoA_synt_C	SEQ_UP	2	
DOMAIN:HMG_CoA_synt_N	SEQ_UP	2	
DOMAIN:HMMR_C	SEQ_UP	2	
DOMAIN:HNF-p1	SEQ_UP	3	
DOMAIN:HNH	SEQ_UP	1	
DOMAIN:HNOB	SEQ_UP	1	
DOMAIN:HNOBA	SEQ_UP	2	
DOMAIN:hnRNP_Q_AcD	SEQ_UP	2	
DOMAIN:Homeobox	SEQ_UP	192	
DOMAIN:Homeobox_KN	SEQ_UP	4	
DOMAIN:Homez	SEQ_UP	1	
DOMAIN:HOOK	SEQ_UP	1	
DOMAIN:HOOK_N	SEQ_UP	1	
DOMAIN:HORMA	SEQ_UP	4	
DOMAIN:HotDog ACOT-type	SEQ_UP	3	
DOMAIN:HotDog ACOT-type 1	SEQ_UP	5	
DOMAIN:HotDog ACOT-type 2	SEQ_UP	5	
DOMAIN:Hox9_act	SEQ_UP	1	
DOMAIN:HP	SEQ_UP	8	
DOMAIN:HPHLAWLY	SEQ_UP	1	
DOMAIN:HPS3_C	SEQ_UP	1	
DOMAIN:HPS3_Mid	SEQ_UP	1	
DOMAIN:HPS3_N	SEQ_UP	1	
DOMAIN:HRDC	SEQ_UP	3	
DOMAIN:Hrs_helical	SEQ_UP	1	
DOMAIN:HSA	SEQ_UP	5	
DOMAIN:hSac2	SEQ_UP	3	
DOMAIN:HSac2	SEQ_UP	2	
DOMAIN:HscB_4_cys	SEQ_UP	1	
DOMAIN:HSCB_C	SEQ_UP	1	
DOMAIN:HSF_DOMAIN	SEQ_UP	5	
DOMAIN:HSL_N	SEQ_UP	1	
DOMAIN:HSNSD	SEQ_UP	4	
DOMAIN:HSR	SEQ_UP	9	
DOMAIN:HTH CENPB-type	SEQ_UP	9	
DOMAIN:HTH cro/C1-type	SEQ_UP	1	
DOMAIN:HTH HARE-type	SEQ_UP	3	
DOMAIN:HTH La-type RNA-binding	SEQ_UP	7	
DOMAIN:HTH myb-type	SEQ_UP	18	
DOMAIN:HTH myb-type 1	SEQ_UP	5	
DOMAIN:HTH myb-type 2	SEQ_UP	5	
DOMAIN:HTH myb-type 3	SEQ_UP	4	
DOMAIN:HTH OST-type	SEQ_UP	2	
DOMAIN:HTH OST-type 1	SEQ_UP	3	
DOMAIN:HTH OST-type 2	SEQ_UP	3	
DOMAIN:HTH OST-type 3	SEQ_UP	3	
DOMAIN:HTH OST-type 4	SEQ_UP	1	
DOMAIN:HTH OST-type 5	SEQ_UP	1	
DOMAIN:HTH OST-type 6	SEQ_UP	1	
DOMAIN:HTH OST-type 7	SEQ_UP	1	
DOMAIN:HTH OST-type 8	SEQ_UP	1	
DOMAIN:HTH psq-type	SEQ_UP	9	
DOMAIN:HTH TFE/IIEalpha-type	SEQ_UP	2	
DOMAIN:HTH_53	SEQ_UP	1	
DOMAIN:HTH_9	SEQ_UP	1	
DOMAIN:HTH_SUN2	SEQ_UP	1	
DOMAIN:HTTM	SEQ_UP	1	
DOMAIN:HU-CCDC81_euk_1	SEQ_UP	1	
DOMAIN:HU-CCDC81_euk_2	SEQ_UP	1	
DOMAIN:HUN	SEQ_UP	1	
DOMAIN:Hydant_A_N	SEQ_UP	1	
DOMAIN:Hydantoinase_A	SEQ_UP	1	
DOMAIN:Hydantoinase_B	SEQ_UP	1	
DOMAIN:Hydrolase_4	SEQ_UP	5	
DOMAIN:HYLS1_C	SEQ_UP	1	
DOMAIN:HYR	SEQ_UP	2	
DOMAIN:HYR 1	SEQ_UP	1	
DOMAIN:HYR 2	SEQ_UP	1	
DOMAIN:I-set	SEQ_UP	2	
DOMAIN:I/LWEQ	SEQ_UP	4	
DOMAIN:IBB	SEQ_UP	8	
DOMAIN:ICAM_N	SEQ_UP	5	
DOMAIN:IF rod	SEQ_UP	76	
DOMAIN:IF-2	SEQ_UP	2	
DOMAIN:IF3_C	SEQ_UP	1	
DOMAIN:IF3_N	SEQ_UP	1	
DOMAIN:IFNGR1	SEQ_UP	1	
DOMAIN:IFP_35_N	SEQ_UP	2	
DOMAIN:IFRD	SEQ_UP	2	
DOMAIN:IFRD_C	SEQ_UP	2	
DOMAIN:IFT81_CH	SEQ_UP	1	
DOMAIN:ig	SEQ_UP	1	
DOMAIN:IG	SEQ_UP	25	
DOMAIN:Ig_4	SEQ_UP	1	
DOMAIN:Ig_6	SEQ_UP	1	
DOMAIN:Ig_C19orf38	SEQ_UP	1	
DOMAIN:Ig_mannosidase	SEQ_UP	1	
DOMAIN:Ig-like	SEQ_UP	785	
DOMAIN:Ig-like 1	SEQ_UP	30	
DOMAIN:Ig-like 10	SEQ_UP	3	
DOMAIN:Ig-like 100	SEQ_UP	1	
DOMAIN:Ig-like 101	SEQ_UP	1	
DOMAIN:Ig-like 102	SEQ_UP	1	
DOMAIN:Ig-like 103	SEQ_UP	1	
DOMAIN:Ig-like 104	SEQ_UP	1	
DOMAIN:Ig-like 105	SEQ_UP	1	
DOMAIN:Ig-like 106	SEQ_UP	1	
DOMAIN:Ig-like 107	SEQ_UP	1	
DOMAIN:Ig-like 108	SEQ_UP	1	
DOMAIN:Ig-like 109	SEQ_UP	1	
DOMAIN:Ig-like 11	SEQ_UP	3	
DOMAIN:Ig-like 110	SEQ_UP	1	
DOMAIN:Ig-like 111	SEQ_UP	1	
DOMAIN:Ig-like 112	SEQ_UP	1	
DOMAIN:Ig-like 113	SEQ_UP	1	
DOMAIN:Ig-like 114	SEQ_UP	1	
DOMAIN:Ig-like 115	SEQ_UP	1	
DOMAIN:Ig-like 116	SEQ_UP	1	
DOMAIN:Ig-like 117	SEQ_UP	1	
DOMAIN:Ig-like 118	SEQ_UP	1	
DOMAIN:Ig-like 119	SEQ_UP	1	
DOMAIN:Ig-like 12	SEQ_UP	3	
DOMAIN:Ig-like 120	SEQ_UP	1	
DOMAIN:Ig-like 121	SEQ_UP	1	
DOMAIN:Ig-like 122	SEQ_UP	1	
DOMAIN:Ig-like 123	SEQ_UP	1	
DOMAIN:Ig-like 124	SEQ_UP	1	
DOMAIN:Ig-like 125	SEQ_UP	1	
DOMAIN:Ig-like 126	SEQ_UP	1	
DOMAIN:Ig-like 127	SEQ_UP	1	
DOMAIN:Ig-like 128	SEQ_UP	1	
DOMAIN:Ig-like 129	SEQ_UP	1	
DOMAIN:Ig-like 13	SEQ_UP	3	
DOMAIN:Ig-like 130	SEQ_UP	1	
DOMAIN:Ig-like 131	SEQ_UP	1	
DOMAIN:Ig-like 132	SEQ_UP	1	
DOMAIN:Ig-like 133	SEQ_UP	1	
DOMAIN:Ig-like 134	SEQ_UP	1	
DOMAIN:Ig-like 135	SEQ_UP	1	
DOMAIN:Ig-like 136	SEQ_UP	1	
DOMAIN:Ig-like 137	SEQ_UP	1	
DOMAIN:Ig-like 138	SEQ_UP	1	
DOMAIN:Ig-like 139	SEQ_UP	1	
DOMAIN:Ig-like 14	SEQ_UP	3	
DOMAIN:Ig-like 140	SEQ_UP	1	
DOMAIN:Ig-like 141	SEQ_UP	1	
DOMAIN:Ig-like 142	SEQ_UP	1	
DOMAIN:Ig-like 143	SEQ_UP	1	
DOMAIN:Ig-like 144	SEQ_UP	1	
DOMAIN:Ig-like 15	SEQ_UP	2	
DOMAIN:Ig-like 16	SEQ_UP	2	
DOMAIN:Ig-like 17	SEQ_UP	2	
DOMAIN:Ig-like 18	SEQ_UP	2	
DOMAIN:Ig-like 19	SEQ_UP	2	
DOMAIN:Ig-like 2	SEQ_UP	30	
DOMAIN:Ig-like 20	SEQ_UP	2	
DOMAIN:Ig-like 21	SEQ_UP	2	
DOMAIN:Ig-like 22	SEQ_UP	2	
DOMAIN:Ig-like 23	SEQ_UP	2	
DOMAIN:Ig-like 24	SEQ_UP	2	
DOMAIN:Ig-like 25	SEQ_UP	2	
DOMAIN:Ig-like 26	SEQ_UP	2	
DOMAIN:Ig-like 27	SEQ_UP	2	
DOMAIN:Ig-like 28	SEQ_UP	2	
DOMAIN:Ig-like 29	SEQ_UP	2	
DOMAIN:Ig-like 3	SEQ_UP	21	
DOMAIN:Ig-like 30	SEQ_UP	2	
DOMAIN:Ig-like 31	SEQ_UP	2	
DOMAIN:Ig-like 32	SEQ_UP	2	
DOMAIN:Ig-like 33	SEQ_UP	2	
DOMAIN:Ig-like 34	SEQ_UP	2	
DOMAIN:Ig-like 35	SEQ_UP	2	
DOMAIN:Ig-like 36	SEQ_UP	2	
DOMAIN:Ig-like 37	SEQ_UP	2	
DOMAIN:Ig-like 38	SEQ_UP	2	
DOMAIN:Ig-like 39	SEQ_UP	2	
DOMAIN:Ig-like 4	SEQ_UP	13	
DOMAIN:Ig-like 40	SEQ_UP	2	
DOMAIN:Ig-like 41	SEQ_UP	2	
DOMAIN:Ig-like 42	SEQ_UP	2	
DOMAIN:Ig-like 43	SEQ_UP	2	
DOMAIN:Ig-like 44	SEQ_UP	2	
DOMAIN:Ig-like 45	SEQ_UP	2	
DOMAIN:Ig-like 46	SEQ_UP	2	
DOMAIN:Ig-like 47	SEQ_UP	2	
DOMAIN:Ig-like 48	SEQ_UP	2	
DOMAIN:Ig-like 49	SEQ_UP	2	
DOMAIN:Ig-like 5	SEQ_UP	11	
DOMAIN:Ig-like 50	SEQ_UP	2	
DOMAIN:Ig-like 51	SEQ_UP	2	
DOMAIN:Ig-like 52	SEQ_UP	2	
DOMAIN:Ig-like 53	SEQ_UP	2	
DOMAIN:Ig-like 54	SEQ_UP	2	
DOMAIN:Ig-like 55	SEQ_UP	2	
DOMAIN:Ig-like 56	SEQ_UP	1	
DOMAIN:Ig-like 57	SEQ_UP	1	
DOMAIN:Ig-like 58	SEQ_UP	1	
DOMAIN:Ig-like 59	SEQ_UP	1	
DOMAIN:Ig-like 6	SEQ_UP	6	
DOMAIN:Ig-like 60	SEQ_UP	1	
DOMAIN:Ig-like 61	SEQ_UP	1	
DOMAIN:Ig-like 62	SEQ_UP	1	
DOMAIN:Ig-like 63	SEQ_UP	1	
DOMAIN:Ig-like 64	SEQ_UP	1	
DOMAIN:Ig-like 65	SEQ_UP	1	
DOMAIN:Ig-like 66	SEQ_UP	1	
DOMAIN:Ig-like 67	SEQ_UP	1	
DOMAIN:Ig-like 68	SEQ_UP	1	
DOMAIN:Ig-like 69	SEQ_UP	1	
DOMAIN:Ig-like 7	SEQ_UP	4	
DOMAIN:Ig-like 70	SEQ_UP	1	
DOMAIN:Ig-like 71	SEQ_UP	1	
DOMAIN:Ig-like 72	SEQ_UP	1	
DOMAIN:Ig-like 73	SEQ_UP	1	
DOMAIN:Ig-like 74	SEQ_UP	1	
DOMAIN:Ig-like 75	SEQ_UP	1	
DOMAIN:Ig-like 76	SEQ_UP	1	
DOMAIN:Ig-like 77	SEQ_UP	1	
DOMAIN:Ig-like 78	SEQ_UP	1	
DOMAIN:Ig-like 79	SEQ_UP	1	
DOMAIN:Ig-like 8	SEQ_UP	4	
DOMAIN:Ig-like 80	SEQ_UP	1	
DOMAIN:Ig-like 81	SEQ_UP	1	
DOMAIN:Ig-like 82	SEQ_UP	1	
DOMAIN:Ig-like 83	SEQ_UP	1	
DOMAIN:Ig-like 84	SEQ_UP	1	
DOMAIN:Ig-like 85	SEQ_UP	1	
DOMAIN:Ig-like 86	SEQ_UP	1	
DOMAIN:Ig-like 87	SEQ_UP	1	
DOMAIN:Ig-like 88	SEQ_UP	1	
DOMAIN:Ig-like 89	SEQ_UP	1	
DOMAIN:Ig-like 9	SEQ_UP	4	
DOMAIN:Ig-like 90	SEQ_UP	1	
DOMAIN:Ig-like 91	SEQ_UP	1	
DOMAIN:Ig-like 92	SEQ_UP	1	
DOMAIN:Ig-like 93	SEQ_UP	1	
DOMAIN:Ig-like 94	SEQ_UP	1	
DOMAIN:Ig-like 95	SEQ_UP	1	
DOMAIN:Ig-like 96	SEQ_UP	1	
DOMAIN:Ig-like 97	SEQ_UP	1	
DOMAIN:Ig-like 98	SEQ_UP	1	
DOMAIN:Ig-like 99	SEQ_UP	1	
DOMAIN:Ig-like C1-type	SEQ_UP	32	
DOMAIN:Ig-like C1-type 1	SEQ_UP	1	
DOMAIN:Ig-like C1-type 2	SEQ_UP	1	
DOMAIN:Ig-like C2-type	SEQ_UP	107	
DOMAIN:Ig-like C2-type 1	SEQ_UP	146	
DOMAIN:Ig-like C2-type 10	SEQ_UP	8	
DOMAIN:Ig-like C2-type 11	SEQ_UP	6	
DOMAIN:Ig-like C2-type 12	SEQ_UP	6	
DOMAIN:Ig-like C2-type 13	SEQ_UP	4	
DOMAIN:Ig-like C2-type 14	SEQ_UP	4	
DOMAIN:Ig-like C2-type 15	SEQ_UP	4	
DOMAIN:Ig-like C2-type 16	SEQ_UP	3	
DOMAIN:Ig-like C2-type 17	SEQ_UP	2	
DOMAIN:Ig-like C2-type 18	SEQ_UP	2	
DOMAIN:Ig-like C2-type 19	SEQ_UP	2	
DOMAIN:Ig-like C2-type 2	SEQ_UP	145	
DOMAIN:Ig-like C2-type 20	SEQ_UP	2	
DOMAIN:Ig-like C2-type 21	SEQ_UP	2	
DOMAIN:Ig-like C2-type 22	SEQ_UP	2	
DOMAIN:Ig-like C2-type 23	SEQ_UP	2	
DOMAIN:Ig-like C2-type 24	SEQ_UP	2	
DOMAIN:Ig-like C2-type 25	SEQ_UP	2	
DOMAIN:Ig-like C2-type 26	SEQ_UP	2	
DOMAIN:Ig-like C2-type 27	SEQ_UP	2	
DOMAIN:Ig-like C2-type 28	SEQ_UP	2	
DOMAIN:Ig-like C2-type 29	SEQ_UP	2	
DOMAIN:Ig-like C2-type 3	SEQ_UP	97	
DOMAIN:Ig-like C2-type 30	SEQ_UP	2	
DOMAIN:Ig-like C2-type 31	SEQ_UP	2	
DOMAIN:Ig-like C2-type 32	SEQ_UP	2	
DOMAIN:Ig-like C2-type 33	SEQ_UP	2	
DOMAIN:Ig-like C2-type 34	SEQ_UP	2	
DOMAIN:Ig-like C2-type 35	SEQ_UP	2	
DOMAIN:Ig-like C2-type 36	SEQ_UP	2	
DOMAIN:Ig-like C2-type 37	SEQ_UP	2	
DOMAIN:Ig-like C2-type 38	SEQ_UP	2	
DOMAIN:Ig-like C2-type 39	SEQ_UP	2	
DOMAIN:Ig-like C2-type 4	SEQ_UP	64	
DOMAIN:Ig-like C2-type 40	SEQ_UP	2	
DOMAIN:Ig-like C2-type 41	SEQ_UP	2	
DOMAIN:Ig-like C2-type 42	SEQ_UP	2	
DOMAIN:Ig-like C2-type 43	SEQ_UP	2	
DOMAIN:Ig-like C2-type 44	SEQ_UP	1	
DOMAIN:Ig-like C2-type 5	SEQ_UP	53	
DOMAIN:Ig-like C2-type 6	SEQ_UP	36	
DOMAIN:Ig-like C2-type 7	SEQ_UP	20	
DOMAIN:Ig-like C2-type 8	SEQ_UP	12	
DOMAIN:Ig-like C2-type 9	SEQ_UP	10	
DOMAIN:Ig-like V-type	SEQ_UP	117	
DOMAIN:Ig-like V-type 1	SEQ_UP	20	
DOMAIN:Ig-like V-type 1; required for binding to polymeric IgA and IgM	SEQ_UP	1	
DOMAIN:Ig-like V-type 2	SEQ_UP	21	
DOMAIN:Ig-like V-type 3	SEQ_UP	5	
DOMAIN:Ig-like V-type 4	SEQ_UP	4	
DOMAIN:Ig-like V-type 5	SEQ_UP	3	
DOMAIN:Ig-like V-type 6	SEQ_UP	1	
DOMAIN:Ig-like V-type 7	SEQ_UP	1	
DOMAIN:IGc1	SEQ_UP	4	
DOMAIN:IGc2	SEQ_UP	2	
DOMAIN:IGF2_C	SEQ_UP	1	
DOMAIN:IGFBP N-terminal	SEQ_UP	20	
DOMAIN:IGv	SEQ_UP	29	
DOMAIN:IHABP4_N	SEQ_UP	1	
DOMAIN:IKKbetaNEMObind	SEQ_UP	2	
DOMAIN:IL1_propep	SEQ_UP	2	
DOMAIN:Il13Ra_Ig	SEQ_UP	1	
DOMAIN:IL17_R_N	SEQ_UP	1	
DOMAIN:IL17R_D_N	SEQ_UP	1	
DOMAIN:IL17R_fnIII_D1	SEQ_UP	1	
DOMAIN:IL3Ra_N	SEQ_UP	2	
DOMAIN:IL4Ra_N	SEQ_UP	1	
DOMAIN:IL6Ra-bind	SEQ_UP	5	
DOMAIN:ILEI	SEQ_UP	4	
DOMAIN:IlGF	SEQ_UP	7	
DOMAIN:Ima1_N	SEQ_UP	1	
DOMAIN:IMD	SEQ_UP	5	
DOMAIN:IMPDH	SEQ_UP	4	
DOMAIN:Importin N-terminal	SEQ_UP	17	
DOMAIN:INB	SEQ_UP	5	
DOMAIN:INCENP_N	SEQ_UP	1	
DOMAIN:ING	SEQ_UP	3	
DOMAIN:Inhibitor_I29	SEQ_UP	18	
DOMAIN:Inhibitor_Mig-6	SEQ_UP	2	
DOMAIN:INPP5B_PH	SEQ_UP	1	
DOMAIN:Ins134_P3_kin	SEQ_UP	1	
DOMAIN:Ins134_P3_kin_N	SEQ_UP	1	
DOMAIN:Ins145_P3_rec	SEQ_UP	2	
DOMAIN:Insc_C	SEQ_UP	1	
DOMAIN:INSC_LBD	SEQ_UP	1	
DOMAIN:INT_SG_DDX_CT_C	SEQ_UP	2	
DOMAIN:Integrase catalytic	SEQ_UP	8	
DOMAIN:Integrase_H2C2	SEQ_UP	1	
DOMAIN:Integrase-type	SEQ_UP	3	
DOMAIN:Integrin_alpha2	SEQ_UP	11	
DOMAIN:Integrin_b_cyt	SEQ_UP	4	
DOMAIN:Integrin_B_tail	SEQ_UP	5	
DOMAIN:Interfer-bind	SEQ_UP	5	
DOMAIN:IntS14	SEQ_UP	1	
DOMAIN:Ints3_N	SEQ_UP	1	
DOMAIN:Intu_longin_1	SEQ_UP	2	
DOMAIN:Intu_longin_3	SEQ_UP	1	
DOMAIN:Involucrin_N	SEQ_UP	1	
DOMAIN:Involucrin2	SEQ_UP	1	
DOMAIN:Ion_trans	SEQ_UP	63	
DOMAIN:Ion_trans_2	SEQ_UP	16	
DOMAIN:Ipi1_N	SEQ_UP	1	
DOMAIN:IPPc	SEQ_UP	7	
DOMAIN:IPT/TIG	SEQ_UP	15	
DOMAIN:IPT/TIG 1	SEQ_UP	11	
DOMAIN:IPT/TIG 1; atypical	SEQ_UP	1	
DOMAIN:IPT/TIG 10	SEQ_UP	2	
DOMAIN:IPT/TIG 11	SEQ_UP	2	
DOMAIN:IPT/TIG 12	SEQ_UP	1	
DOMAIN:IPT/TIG 12; atypical	SEQ_UP	1	
DOMAIN:IPT/TIG 13	SEQ_UP	1	
DOMAIN:IPT/TIG 14	SEQ_UP	1	
DOMAIN:IPT/TIG 2	SEQ_UP	12	
DOMAIN:IPT/TIG 3	SEQ_UP	12	
DOMAIN:IPT/TIG 4	SEQ_UP	7	
DOMAIN:IPT/TIG 5	SEQ_UP	2	
DOMAIN:IPT/TIG 6	SEQ_UP	1	
DOMAIN:IPT/TIG 6; atypical	SEQ_UP	1	
DOMAIN:IPT/TIG 7	SEQ_UP	2	
DOMAIN:IPT/TIG 8	SEQ_UP	1	
DOMAIN:IPT/TIG 8; atypical	SEQ_UP	1	
DOMAIN:IPT/TIG 9	SEQ_UP	2	
DOMAIN:IQ	SEQ_UP	61	
DOMAIN:IQ 1	SEQ_UP	28	
DOMAIN:IQ 10	SEQ_UP	1	
DOMAIN:IQ 11	SEQ_UP	1	
DOMAIN:IQ 12	SEQ_UP	1	
DOMAIN:IQ 13	SEQ_UP	1	
DOMAIN:IQ 14	SEQ_UP	1	
DOMAIN:IQ 15	SEQ_UP	1	
DOMAIN:IQ 16	SEQ_UP	1	
DOMAIN:IQ 17	SEQ_UP	1	
DOMAIN:IQ 18	SEQ_UP	1	
DOMAIN:IQ 19	SEQ_UP	1	
DOMAIN:IQ 2	SEQ_UP	28	
DOMAIN:IQ 20	SEQ_UP	1	
DOMAIN:IQ 21	SEQ_UP	1	
DOMAIN:IQ 22	SEQ_UP	1	
DOMAIN:IQ 23	SEQ_UP	1	
DOMAIN:IQ 24	SEQ_UP	1	
DOMAIN:IQ 25	SEQ_UP	1	
DOMAIN:IQ 26	SEQ_UP	1	
DOMAIN:IQ 27	SEQ_UP	1	
DOMAIN:IQ 28	SEQ_UP	1	
DOMAIN:IQ 29	SEQ_UP	1	
DOMAIN:IQ 3	SEQ_UP	16	
DOMAIN:IQ 30	SEQ_UP	1	
DOMAIN:IQ 31	SEQ_UP	1	
DOMAIN:IQ 32	SEQ_UP	1	
DOMAIN:IQ 4	SEQ_UP	10	
DOMAIN:IQ 5	SEQ_UP	7	
DOMAIN:IQ 6	SEQ_UP	4	
DOMAIN:IQ 7	SEQ_UP	1	
DOMAIN:IQ 8	SEQ_UP	1	
DOMAIN:IQ 9	SEQ_UP	1	
DOMAIN:IRF tryptophan pentad repeat	SEQ_UP	9	
DOMAIN:IRF-3	SEQ_UP	3	
DOMAIN:IRG-type G	SEQ_UP	19	
DOMAIN:IRK	SEQ_UP	15	
DOMAIN:IRK_C	SEQ_UP	14	
DOMAIN:IRK_N	SEQ_UP	2	
DOMAIN:IRS-type PTB	SEQ_UP	13	
DOMAIN:Iso_dh	SEQ_UP	5	
DOMAIN:Isochorismatase	SEQ_UP	2	
DOMAIN:ISPD_C	SEQ_UP	1	
DOMAIN:ITAM	SEQ_UP	10	
DOMAIN:ITAM 1	SEQ_UP	1	
DOMAIN:ITAM 2	SEQ_UP	1	
DOMAIN:ITAM 3	SEQ_UP	1	
DOMAIN:ITI_HC_C	SEQ_UP	1	
DOMAIN:Izumo-Ig	SEQ_UP	1	
DOMAIN:J	SEQ_UP	52	
DOMAIN:Jacalin-type lectin	SEQ_UP	6	
DOMAIN:JAKMIP_CC3	SEQ_UP	3	
DOMAIN:JHD	SEQ_UP	1	
DOMAIN:JIP_LZII	SEQ_UP	1	
DOMAIN:JmjC	SEQ_UP	33	
DOMAIN:JmjN	SEQ_UP	9	
DOMAIN:JMY	SEQ_UP	2	
DOMAIN:Josephin	SEQ_UP	3	
DOMAIN:Jun	SEQ_UP	1	
DOMAIN:KA1	SEQ_UP	5	
DOMAIN:KAP NTPase	SEQ_UP	2	
DOMAIN:KASH	SEQ_UP	4	
DOMAIN:Katanin_con80	SEQ_UP	1	
DOMAIN:Kazal-like	SEQ_UP	58	
DOMAIN:Kazal-like 1	SEQ_UP	7	
DOMAIN:Kazal-like 2	SEQ_UP	7	
DOMAIN:Kazal-like 2; degenerate	SEQ_UP	1	
DOMAIN:Kazal-like 3	SEQ_UP	3	
DOMAIN:Kazal-like 4	SEQ_UP	1	
DOMAIN:Kazal-like 5	SEQ_UP	1	
DOMAIN:Kazal-like 6	SEQ_UP	1	
DOMAIN:Kazal-like 7	SEQ_UP	1	
DOMAIN:Kazal-like 8	SEQ_UP	1	
DOMAIN:Kazal-like 9	SEQ_UP	1	
DOMAIN:KBD	SEQ_UP	3	
DOMAIN:KcnmB2_inactiv	SEQ_UP	1	
DOMAIN:KCNQ_channel	SEQ_UP	4	
DOMAIN:KCTD18_C	SEQ_UP	1	
DOMAIN:KEN	SEQ_UP	3	
DOMAIN:Keratin_2_head	SEQ_UP	1	
DOMAIN:KH	SEQ_UP	26	
DOMAIN:KH 1	SEQ_UP	22	
DOMAIN:KH 10	SEQ_UP	1	
DOMAIN:KH 11	SEQ_UP	1	
DOMAIN:KH 12	SEQ_UP	1	
DOMAIN:KH 13	SEQ_UP	1	
DOMAIN:KH 14	SEQ_UP	1	
DOMAIN:KH 2	SEQ_UP	22	
DOMAIN:KH 3	SEQ_UP	13	
DOMAIN:KH 4	SEQ_UP	6	
DOMAIN:KH 5	SEQ_UP	1	
DOMAIN:KH 6	SEQ_UP	1	
DOMAIN:KH 7	SEQ_UP	1	
DOMAIN:KH 8	SEQ_UP	1	
DOMAIN:KH 9	SEQ_UP	1	
DOMAIN:KH type-2	SEQ_UP	2	
DOMAIN:KH_dom_type_1	SEQ_UP	7	
DOMAIN:KH-like	SEQ_UP	1	
DOMAIN:KH; atypical	SEQ_UP	7	
DOMAIN:KHA	SEQ_UP	1	
DOMAIN:KID	SEQ_UP	3	
DOMAIN:KIF1B	SEQ_UP	2	
DOMAIN:KIND	SEQ_UP	5	
DOMAIN:KIND 1	SEQ_UP	1	
DOMAIN:KIND 2	SEQ_UP	1	
DOMAIN:Kindlin_2_N	SEQ_UP	2	
DOMAIN:Kinesin motor	SEQ_UP	46	
DOMAIN:KIX	SEQ_UP	2	
DOMAIN:Knl1_RWD_C	SEQ_UP	1	
DOMAIN:KOW	SEQ_UP	4	
DOMAIN:KOW 1	SEQ_UP	2	
DOMAIN:KOW 2	SEQ_UP	2	
DOMAIN:KOW 3	SEQ_UP	1	
DOMAIN:KOW 4	SEQ_UP	1	
DOMAIN:KOW 5	SEQ_UP	1	
DOMAIN:KPBB_C	SEQ_UP	3	
DOMAIN:KR	SEQ_UP	2	
DOMAIN:KRAB	SEQ_UP	383	
DOMAIN:KRAB 1	SEQ_UP	3	
DOMAIN:KRAB 2	SEQ_UP	3	
DOMAIN:KRAB-related	SEQ_UP	22	
DOMAIN:KRAP_IP3R_bind	SEQ_UP	1	
DOMAIN:Kri1_C	SEQ_UP	1	
DOMAIN:Kringle	SEQ_UP	14	
DOMAIN:Kringle 1	SEQ_UP	5	
DOMAIN:Kringle 2	SEQ_UP	5	
DOMAIN:Kringle 3	SEQ_UP	3	
DOMAIN:Kringle 4	SEQ_UP	3	
DOMAIN:Kringle 5	SEQ_UP	1	
DOMAIN:Ku	SEQ_UP	2	
DOMAIN:Ku_N	SEQ_UP	2	
DOMAIN:KxDL	SEQ_UP	1	
DOMAIN:L-type lectin-like	SEQ_UP	4	
DOMAIN:L27	SEQ_UP	13	
DOMAIN:L27 1	SEQ_UP	7	
DOMAIN:L27 2	SEQ_UP	7	
DOMAIN:L27_1	SEQ_UP	1	
DOMAIN:L51_S25_CI-B8	SEQ_UP	2	
DOMAIN:Lactamase_B	SEQ_UP	8	
DOMAIN:Lactamase_B_4	SEQ_UP	1	
DOMAIN:LAG1_DNAbind	SEQ_UP	2	
DOMAIN:LAM_G_DOMAIN	SEQ_UP	40	
DOMAIN:LamGL	SEQ_UP	3	
DOMAIN:Laminin EGF-like	SEQ_UP	22	
DOMAIN:Laminin EGF-like 1	SEQ_UP	25	
DOMAIN:Laminin EGF-like 1; first part	SEQ_UP	1	
DOMAIN:Laminin EGF-like 1; second part	SEQ_UP	1	
DOMAIN:Laminin EGF-like 10	SEQ_UP	10	
DOMAIN:Laminin EGF-like 11	SEQ_UP	8	
DOMAIN:Laminin EGF-like 11; truncated	SEQ_UP	1	
DOMAIN:Laminin EGF-like 12	SEQ_UP	5	
DOMAIN:Laminin EGF-like 12; first part	SEQ_UP	1	
DOMAIN:Laminin EGF-like 12; second part	SEQ_UP	1	
DOMAIN:Laminin EGF-like 13	SEQ_UP	6	
DOMAIN:Laminin EGF-like 14	SEQ_UP	2	
DOMAIN:Laminin EGF-like 14; first part	SEQ_UP	2	
DOMAIN:Laminin EGF-like 14; second part	SEQ_UP	2	
DOMAIN:Laminin EGF-like 15	SEQ_UP	3	
DOMAIN:Laminin EGF-like 15; truncated	SEQ_UP	1	
DOMAIN:Laminin EGF-like 16	SEQ_UP	2	
DOMAIN:Laminin EGF-like 16; first part	SEQ_UP	1	
DOMAIN:Laminin EGF-like 16; second part	SEQ_UP	1	
DOMAIN:Laminin EGF-like 17	SEQ_UP	3	
DOMAIN:Laminin EGF-like 18	SEQ_UP	1	
DOMAIN:Laminin EGF-like 19	SEQ_UP	1	
DOMAIN:Laminin EGF-like 2	SEQ_UP	26	
DOMAIN:Laminin EGF-like 20	SEQ_UP	1	
DOMAIN:Laminin EGF-like 21	SEQ_UP	1	
DOMAIN:Laminin EGF-like 22	SEQ_UP	1	
DOMAIN:Laminin EGF-like 3	SEQ_UP	20	
DOMAIN:Laminin EGF-like 4	SEQ_UP	12	
DOMAIN:Laminin EGF-like 4; first part	SEQ_UP	1	
DOMAIN:Laminin EGF-like 4; second part	SEQ_UP	1	
DOMAIN:Laminin EGF-like 4; truncated	SEQ_UP	2	
DOMAIN:Laminin EGF-like 5	SEQ_UP	6	
DOMAIN:Laminin EGF-like 5; first part	SEQ_UP	5	
DOMAIN:Laminin EGF-like 5; second part	SEQ_UP	5	
DOMAIN:Laminin EGF-like 5; truncated	SEQ_UP	2	
DOMAIN:Laminin EGF-like 6	SEQ_UP	12	
DOMAIN:Laminin EGF-like 7	SEQ_UP	11	
DOMAIN:Laminin EGF-like 8	SEQ_UP	9	
DOMAIN:Laminin EGF-like 8; nidogen-binding	SEQ_UP	1	
DOMAIN:Laminin EGF-like 8; truncated	SEQ_UP	1	
DOMAIN:Laminin EGF-like 9	SEQ_UP	9	
DOMAIN:Laminin EGF-like 9; first part	SEQ_UP	1	
DOMAIN:Laminin EGF-like 9; second part	SEQ_UP	1	
DOMAIN:Laminin G-like	SEQ_UP	27	
DOMAIN:Laminin G-like 1	SEQ_UP	28	
DOMAIN:Laminin G-like 2	SEQ_UP	28	
DOMAIN:Laminin G-like 3	SEQ_UP	19	
DOMAIN:Laminin G-like 4	SEQ_UP	14	
DOMAIN:Laminin G-like 5	SEQ_UP	8	
DOMAIN:Laminin G-like 6	SEQ_UP	3	
DOMAIN:Laminin IV type A	SEQ_UP	7	
DOMAIN:Laminin IV type A 1	SEQ_UP	3	
DOMAIN:Laminin IV type A 2	SEQ_UP	3	
DOMAIN:Laminin IV type A 3	SEQ_UP	1	
DOMAIN:Laminin IV type B	SEQ_UP	2	
DOMAIN:Laminin N-terminal	SEQ_UP	15	
DOMAIN:LAP2alpha	SEQ_UP	1	
DOMAIN:Latrophilin	SEQ_UP	2	
DOMAIN:LBH	SEQ_UP	4	
DOMAIN:LBR_tudor	SEQ_UP	1	
DOMAIN:LCCL	SEQ_UP	4	
DOMAIN:LCCL 1	SEQ_UP	2	
DOMAIN:LCCL 2	SEQ_UP	2	
DOMAIN:Ldh_1_C	SEQ_UP	6	
DOMAIN:Ldh_1_N	SEQ_UP	6	
DOMAIN:LDL-receptor class A	SEQ_UP	17	
DOMAIN:LDL-receptor class A 1	SEQ_UP	25	
DOMAIN:LDL-receptor class A 1; truncated	SEQ_UP	1	
DOMAIN:LDL-receptor class A 10	SEQ_UP	6	
DOMAIN:LDL-receptor class A 11	SEQ_UP	4	
DOMAIN:LDL-receptor class A 12	SEQ_UP	3	
DOMAIN:LDL-receptor class A 13	SEQ_UP	3	
DOMAIN:LDL-receptor class A 14	SEQ_UP	3	
DOMAIN:LDL-receptor class A 15	SEQ_UP	3	
DOMAIN:LDL-receptor class A 16	SEQ_UP	3	
DOMAIN:LDL-receptor class A 17	SEQ_UP	3	
DOMAIN:LDL-receptor class A 18	SEQ_UP	3	
DOMAIN:LDL-receptor class A 19	SEQ_UP	3	
DOMAIN:LDL-receptor class A 2	SEQ_UP	26	
DOMAIN:LDL-receptor class A 20	SEQ_UP	3	
DOMAIN:LDL-receptor class A 21	SEQ_UP	3	
DOMAIN:LDL-receptor class A 22	SEQ_UP	3	
DOMAIN:LDL-receptor class A 23	SEQ_UP	3	
DOMAIN:LDL-receptor class A 24	SEQ_UP	3	
DOMAIN:LDL-receptor class A 25	SEQ_UP	3	
DOMAIN:LDL-receptor class A 26	SEQ_UP	3	
DOMAIN:LDL-receptor class A 27	SEQ_UP	3	
DOMAIN:LDL-receptor class A 28	SEQ_UP	3	
DOMAIN:LDL-receptor class A 29	SEQ_UP	3	
DOMAIN:LDL-receptor class A 3	SEQ_UP	21	
DOMAIN:LDL-receptor class A 30	SEQ_UP	3	
DOMAIN:LDL-receptor class A 31	SEQ_UP	3	
DOMAIN:LDL-receptor class A 32	SEQ_UP	2	
DOMAIN:LDL-receptor class A 33	SEQ_UP	1	
DOMAIN:LDL-receptor class A 34	SEQ_UP	1	
DOMAIN:LDL-receptor class A 35	SEQ_UP	1	
DOMAIN:LDL-receptor class A 36	SEQ_UP	1	
DOMAIN:LDL-receptor class A 4	SEQ_UP	15	
DOMAIN:LDL-receptor class A 5	SEQ_UP	12	
DOMAIN:LDL-receptor class A 6	SEQ_UP	11	
DOMAIN:LDL-receptor class A 7	SEQ_UP	11	
DOMAIN:LDL-receptor class A 8	SEQ_UP	9	
DOMAIN:LDL-receptor class A 9	SEQ_UP	6	
DOMAIN:LDL-receptor class A; atypical	SEQ_UP	1	
DOMAIN:Lebercilin	SEQ_UP	2	
DOMAIN:LEM	SEQ_UP	7	
DOMAIN:LEM-like	SEQ_UP	1	
DOMAIN:Lep_receptor_Ig	SEQ_UP	1	
DOMAIN:LETM1	SEQ_UP	1	
DOMAIN:Letm1 RBD	SEQ_UP	3	
DOMAIN:LETM2_N	SEQ_UP	1	
DOMAIN:Leuk-A4-hydro_C	SEQ_UP	3	
DOMAIN:Lgl_C	SEQ_UP	1	
DOMAIN:LIAS_N	SEQ_UP	1	
DOMAIN:LIFR_N	SEQ_UP	1	
DOMAIN:Lig_chan-Glu_bd	SEQ_UP	13	
DOMAIN:LIG3_BRCT	SEQ_UP	1	
DOMAIN:Ligase_CoA	SEQ_UP	2	
DOMAIN:LIM interaction domain (LID)	SEQ_UP	2	
DOMAIN:LIM zinc-binding	SEQ_UP	66	
DOMAIN:LIM zinc-binding 1	SEQ_UP	50	
DOMAIN:LIM zinc-binding 2	SEQ_UP	50	
DOMAIN:LIM zinc-binding 3	SEQ_UP	26	
DOMAIN:LIM zinc-binding 4	SEQ_UP	11	
DOMAIN:LIM zinc-binding 5	SEQ_UP	2	
DOMAIN:Limkain-b1	SEQ_UP	1	
DOMAIN:LINES_N	SEQ_UP	1	
DOMAIN:Link	SEQ_UP	10	
DOMAIN:Link 1	SEQ_UP	8	
DOMAIN:Link 2	SEQ_UP	8	
DOMAIN:Link 3	SEQ_UP	1	
DOMAIN:Link 4	SEQ_UP	1	
DOMAIN:Lipase	SEQ_UP	7	
DOMAIN:Lipase_3	SEQ_UP	1	
DOMAIN:Lipid_DES	SEQ_UP	1	
DOMAIN:Lipin_mid	SEQ_UP	1	
DOMAIN:Lipin_N	SEQ_UP	2	
DOMAIN:Lipocln_cytosolic_FA-bd_dom	SEQ_UP	39	
DOMAIN:Lipoxygenase	SEQ_UP	7	
DOMAIN:Lipoyl-binding	SEQ_UP	7	
DOMAIN:Lipoyl-binding 1	SEQ_UP	1	
DOMAIN:Lipoyl-binding 2	SEQ_UP	1	
DOMAIN:LisH	SEQ_UP	28	
DOMAIN:LITAF	SEQ_UP	3	
DOMAIN:LLGL	SEQ_UP	3	
DOMAIN:LMWPc	SEQ_UP	1	
DOMAIN:LNR	SEQ_UP	4	
DOMAIN:LNS2	SEQ_UP	5	
DOMAIN:Lon N-terminal	SEQ_UP	6	
DOMAIN:Lon proteolytic	SEQ_UP	2	
DOMAIN:Longin	SEQ_UP	6	
DOMAIN:LRAT	SEQ_UP	6	
DOMAIN:LRRC37	SEQ_UP	2	
DOMAIN:LRRC37AB_C	SEQ_UP	2	
DOMAIN:LRRcap	SEQ_UP	5	
DOMAIN:LRRCT	SEQ_UP	119	
DOMAIN:LRRCT 1	SEQ_UP	11	
DOMAIN:LRRCT 2	SEQ_UP	11	
DOMAIN:LRRCT 3	SEQ_UP	3	
DOMAIN:LRRCT 4	SEQ_UP	3	
DOMAIN:LRRNT	SEQ_UP	97	
DOMAIN:LRRNT 1	SEQ_UP	3	
DOMAIN:LRRNT 2	SEQ_UP	5	
DOMAIN:LRRNT 23	SEQ_UP	1	
DOMAIN:LRRNT 3	SEQ_UP	3	
DOMAIN:LRRNT 4	SEQ_UP	3	
DOMAIN:LSDAT_euk	SEQ_UP	5	
DOMAIN:LSM14	SEQ_UP	2	
DOMAIN:LsmAD	SEQ_UP	2	
DOMAIN:LTD	SEQ_UP	5	
DOMAIN:Ly49	SEQ_UP	5	
DOMAIN:Lyase_1	SEQ_UP	2	
DOMAIN:LysM	SEQ_UP	6	
DOMAIN:LZ3wCH	SEQ_UP	1	
DOMAIN:M20_dimer	SEQ_UP	3	
DOMAIN:Mab-21	SEQ_UP	4	
DOMAIN:MABP	SEQ_UP	5	
DOMAIN:MACPF	SEQ_UP	13	
DOMAIN:Macro	SEQ_UP	10	
DOMAIN:Macro 1	SEQ_UP	2	
DOMAIN:Macro 2	SEQ_UP	2	
DOMAIN:Macro 3	SEQ_UP	1	
DOMAIN:MADS-box	SEQ_UP	6	
DOMAIN:Maelstrom	SEQ_UP	1	
DOMAIN:MAGE	SEQ_UP	31	
DOMAIN:MAGE 1	SEQ_UP	1	
DOMAIN:MAGE 2	SEQ_UP	1	
DOMAIN:MAGUK_N_PEST	SEQ_UP	2	
DOMAIN:malic	SEQ_UP	3	
DOMAIN:Malic_M	SEQ_UP	3	
DOMAIN:MAM	SEQ_UP	16	
DOMAIN:MAM 1	SEQ_UP	5	
DOMAIN:MAM 2	SEQ_UP	5	
DOMAIN:MAM 3	SEQ_UP	4	
DOMAIN:MAM 4	SEQ_UP	3	
DOMAIN:MAM 5	SEQ_UP	2	
DOMAIN:MAM 6	SEQ_UP	2	
DOMAIN:MAM 7	SEQ_UP	1	
DOMAIN:MAM 8	SEQ_UP	1	
DOMAIN:MAM 9	SEQ_UP	1	
DOMAIN:MamL-1	SEQ_UP	2	
DOMAIN:Mannosidase_ig	SEQ_UP	1	
DOMAIN:MANSC	SEQ_UP	6	
DOMAIN:MaoC-like	SEQ_UP	2	
DOMAIN:MAP2_projctn	SEQ_UP	1	
DOMAIN:MAP3K_TRAF_bd	SEQ_UP	1	
DOMAIN:MARVEL	SEQ_UP	29	
DOMAIN:MARVEL 1	SEQ_UP	2	
DOMAIN:MARVEL 2	SEQ_UP	2	
DOMAIN:MATH	SEQ_UP	24	
DOMAIN:Matrin-type	SEQ_UP	7	
DOMAIN:MazG	SEQ_UP	1	
DOMAIN:MBD	SEQ_UP	12	
DOMAIN:MBD_C	SEQ_UP	3	
DOMAIN:MBDa	SEQ_UP	4	
DOMAIN:MCC-bdg_PDZ	SEQ_UP	1	
DOMAIN:MCD	SEQ_UP	1	
DOMAIN:Mcl1_mid	SEQ_UP	1	
DOMAIN:MCM	SEQ_UP	9	
DOMAIN:MCM_lid	SEQ_UP	2	
DOMAIN:MCM_N	SEQ_UP	2	
DOMAIN:MCM_OB	SEQ_UP	2	
DOMAIN:MCM3AP_GANP	SEQ_UP	1	
DOMAIN:MCRS_N	SEQ_UP	1	
DOMAIN:MCU	SEQ_UP	1	
DOMAIN:MDD_C	SEQ_UP	1	
DOMAIN:MDFI	SEQ_UP	1	
DOMAIN:Med1	SEQ_UP	2	
DOMAIN:Med12	SEQ_UP	2	
DOMAIN:Med12-PQL	SEQ_UP	2	
DOMAIN:Med13_C	SEQ_UP	1	
DOMAIN:Med13_N	SEQ_UP	1	
DOMAIN:Med25	SEQ_UP	2	
DOMAIN:Med25_NR-box	SEQ_UP	1	
DOMAIN:Med25_SD1	SEQ_UP	1	
DOMAIN:Med25_VWA	SEQ_UP	1	
DOMAIN:MEF2_binding	SEQ_UP	1	
DOMAIN:Meis_PKNOX_N	SEQ_UP	3	
DOMAIN:MEKK4_N	SEQ_UP	1	
DOMAIN:Melibiase_2_C	SEQ_UP	2	
DOMAIN:MENTAL	SEQ_UP	2	
DOMAIN:Metallophos	SEQ_UP	10	
DOMAIN:Metallophos_2	SEQ_UP	1	
DOMAIN:Metallophos_C	SEQ_UP	1	
DOMAIN:Methyltranfer_dom	SEQ_UP	5	
DOMAIN:Methyltransf_11	SEQ_UP	7	
DOMAIN:Methyltransf_12	SEQ_UP	1	
DOMAIN:Methyltransf_1N	SEQ_UP	1	
DOMAIN:Methyltransf_2	SEQ_UP	1	
DOMAIN:Methyltransf_25	SEQ_UP	8	
DOMAIN:MFS	SEQ_UP	64	
DOMAIN:MFS_1_like	SEQ_UP	1	
DOMAIN:MG2	SEQ_UP	1	
DOMAIN:MGS-like	SEQ_UP	4	
DOMAIN:MgtE	SEQ_UP	2	
DOMAIN:MH1	SEQ_UP	8	
DOMAIN:MH2	SEQ_UP	8	
DOMAIN:MHC_I_2	SEQ_UP	1	
DOMAIN:MHC_I_C	SEQ_UP	5	
DOMAIN:MHC_I-like_Ag-recog	SEQ_UP	21	
DOMAIN:MHC_II_alpha	SEQ_UP	1	
DOMAIN:MHC_II_beta	SEQ_UP	2	
DOMAIN:MHC2-interact	SEQ_UP	1	
DOMAIN:MHCassoc_trimer	SEQ_UP	1	
DOMAIN:MHD	SEQ_UP	13	
DOMAIN:MHD1	SEQ_UP	7	
DOMAIN:MHD2	SEQ_UP	5	
DOMAIN:MI	SEQ_UP	8	
DOMAIN:MI 1	SEQ_UP	1	
DOMAIN:MI 2	SEQ_UP	1	
DOMAIN:MIB/HERC2	SEQ_UP	4	
DOMAIN:MIB/HERC2 1	SEQ_UP	2	
DOMAIN:MIB/HERC2 2	SEQ_UP	2	
DOMAIN:Mic1	SEQ_UP	1	
DOMAIN:MID_MedPIWI	SEQ_UP	1	
DOMAIN:MIEAP	SEQ_UP	1	
DOMAIN:MIF4G	SEQ_UP	10	
DOMAIN:MIF4G 1	SEQ_UP	1	
DOMAIN:MIF4G 2	SEQ_UP	1	
DOMAIN:MIF4G 3	SEQ_UP	1	
DOMAIN:Miff	SEQ_UP	1	
DOMAIN:Milton	SEQ_UP	2	
DOMAIN:MINAR1_C	SEQ_UP	2	
DOMAIN:MINDY_DUB	SEQ_UP	2	
DOMAIN:MIP-T3	SEQ_UP	1	
DOMAIN:MIP-T3_C	SEQ_UP	1	
DOMAIN:MIR	SEQ_UP	7	
DOMAIN:MIR 1	SEQ_UP	10	
DOMAIN:MIR 2	SEQ_UP	10	
DOMAIN:MIR 3	SEQ_UP	10	
DOMAIN:MIR 4	SEQ_UP	6	
DOMAIN:MIR 5	SEQ_UP	6	
DOMAIN:Miro	SEQ_UP	3	
DOMAIN:Miro 1	SEQ_UP	2	
DOMAIN:Miro 2	SEQ_UP	2	
DOMAIN:Mis18	SEQ_UP	2	
DOMAIN:Misat_Tub_SegII	SEQ_UP	1	
DOMAIN:MIT	SEQ_UP	9	
DOMAIN:MIT 1	SEQ_UP	1	
DOMAIN:MIT 2	SEQ_UP	1	
DOMAIN:MITF_TFEB_C_3_N	SEQ_UP	3	
DOMAIN:MitMem_reg	SEQ_UP	2	
DOMAIN:MitoNEET_N	SEQ_UP	1	
DOMAIN:ML	SEQ_UP	3	
DOMAIN:Mlh1_C	SEQ_UP	1	
DOMAIN:MLVIN_C	SEQ_UP	3	
DOMAIN:MmgE_PrpD	SEQ_UP	1	
DOMAIN:MmgE_PrpD_C	SEQ_UP	1	
DOMAIN:MMS1_N	SEQ_UP	3	
DOMAIN:MMS19_C	SEQ_UP	2	
DOMAIN:MMS19_N	SEQ_UP	2	
DOMAIN:MMS22L_C	SEQ_UP	1	
DOMAIN:MMS22L_N	SEQ_UP	1	
DOMAIN:MnmE_helical	SEQ_UP	1	
DOMAIN:MNNL	SEQ_UP	2	
DOMAIN:MoCF_biosynth	SEQ_UP	2	
DOMAIN:MoeA_C	SEQ_UP	1	
DOMAIN:MOEP19	SEQ_UP	4	
DOMAIN:MOFRL	SEQ_UP	1	
DOMAIN:Molybdopterin	SEQ_UP	1	
DOMAIN:Mon2_C	SEQ_UP	1	
DOMAIN:MOR2-PAG1_C	SEQ_UP	2	
DOMAIN:MOR2-PAG1_mid	SEQ_UP	2	
DOMAIN:MOR2-PAG1_N	SEQ_UP	2	
DOMAIN:MOSC	SEQ_UP	3	
DOMAIN:Motilin_assoc	SEQ_UP	1	
DOMAIN:Motilin_ghrelin	SEQ_UP	1	
DOMAIN:MPN	SEQ_UP	18	
DOMAIN:Mre11_DNA_bind	SEQ_UP	1	
DOMAIN:MRG	SEQ_UP	4	
DOMAIN:MRH	SEQ_UP	8	
DOMAIN:MRH 1	SEQ_UP	2	
DOMAIN:MRH 10	SEQ_UP	1	
DOMAIN:MRH 11	SEQ_UP	1	
DOMAIN:MRH 12	SEQ_UP	1	
DOMAIN:MRH 13	SEQ_UP	1	
DOMAIN:MRH 14	SEQ_UP	1	
DOMAIN:MRH 15	SEQ_UP	1	
DOMAIN:MRH 2	SEQ_UP	2	
DOMAIN:MRH 3	SEQ_UP	1	
DOMAIN:MRH 4	SEQ_UP	1	
DOMAIN:MRH 5	SEQ_UP	1	
DOMAIN:MRH 6	SEQ_UP	1	
DOMAIN:MRH 7	SEQ_UP	1	
DOMAIN:MRH 8	SEQ_UP	1	
DOMAIN:MRH 9	SEQ_UP	1	
DOMAIN:mRNA cap 0 methyltransferase	SEQ_UP	1	
DOMAIN:MRNA cap 0 methyltransferase	SEQ_UP	1	
DOMAIN:mRNA_decap_C	SEQ_UP	1	
DOMAIN:MRP	SEQ_UP	1	
DOMAIN:MRP-S23	SEQ_UP	1	
DOMAIN:MRP-S28	SEQ_UP	1	
DOMAIN:MSP	SEQ_UP	7	
DOMAIN:MsrB	SEQ_UP	3	
DOMAIN:MSS4	SEQ_UP	1	
DOMAIN:MT	SEQ_UP	5	
DOMAIN:MtN3/slv 1	SEQ_UP	1	
DOMAIN:MtN3/slv 2	SEQ_UP	1	
DOMAIN:MTP_lip_bd	SEQ_UP	1	
DOMAIN:MTS	SEQ_UP	2	
DOMAIN:MTTase N-terminal	SEQ_UP	2	
DOMAIN:Mucin2_WxxW	SEQ_UP	1	
DOMAIN:MutL_C	SEQ_UP	3	
DOMAIN:MutS_I	SEQ_UP	2	
DOMAIN:MutS_II	SEQ_UP	1	
DOMAIN:MutS_IV	SEQ_UP	2	
DOMAIN:MUTSd	SEQ_UP	1	
DOMAIN:MVP_shoulder	SEQ_UP	1	
DOMAIN:Myb_DNA-bind_2	SEQ_UP	1	
DOMAIN:Myb_DNA-bind_4	SEQ_UP	6	
DOMAIN:Myb-like	SEQ_UP	35	
DOMAIN:Myb-like 1	SEQ_UP	3	
DOMAIN:Myb-like 2	SEQ_UP	3	
DOMAIN:Myc_N	SEQ_UP	3	
DOMAIN:MYM-type	SEQ_UP	1	
DOMAIN:MYND-type	SEQ_UP	12	
DOMAIN:Myosin motor	SEQ_UP	39	
DOMAIN:Myosin N-terminal SH3-like	SEQ_UP	19	
DOMAIN:Myosin_tail_1	SEQ_UP	11	
DOMAIN:Myotubularin phosphatase	SEQ_UP	14	
DOMAIN:MYST-type HAT	SEQ_UP	5	
DOMAIN:MYT1	SEQ_UP	3	
DOMAIN:MyTH4	SEQ_UP	8	
DOMAIN:MyTH4 1	SEQ_UP	3	
DOMAIN:MyTH4 2	SEQ_UP	3	
DOMAIN:MyTH4 3	SEQ_UP	1	
DOMAIN:N_BRCA1_IG	SEQ_UP	1	
DOMAIN:N-acetylmuramoyl-L-alanine amidase	SEQ_UP	3	
DOMAIN:N-acetylmuramoyl-L-alanine amidase 1	SEQ_UP	2	
DOMAIN:N-acetylmuramoyl-L-alanine amidase 2	SEQ_UP	2	
DOMAIN:N-acetyltransferase	SEQ_UP	35	
DOMAIN:N-terminal Ras-GEF	SEQ_UP	38	
DOMAIN:N1221	SEQ_UP	2	
DOMAIN:Na_Ca_ex	SEQ_UP	5	
DOMAIN:Na_H_Exchanger	SEQ_UP	11	
DOMAIN:Na_trans_assoc	SEQ_UP	10	
DOMAIN:Na_trans_cytopl	SEQ_UP	5	
DOMAIN:NAAA-beta	SEQ_UP	2	
DOMAIN:Nab1	SEQ_UP	1	
DOMAIN:NAC-A/B	SEQ_UP	4	
DOMAIN:NACHT	SEQ_UP	35	
DOMAIN:NAD_binding_1	SEQ_UP	4	
DOMAIN:NAD_binding_11	SEQ_UP	1	
DOMAIN:NAD_binding_2	SEQ_UP	1	
DOMAIN:NAD_binding_3	SEQ_UP	1	
DOMAIN:NAD_binding_4	SEQ_UP	1	
DOMAIN:NAD_binding_6	SEQ_UP	1	
DOMAIN:NAD_Gly3P_dh_C	SEQ_UP	2	
DOMAIN:NAD_Gly3P_dh_N	SEQ_UP	2	
DOMAIN:NAD(P)-bd_dom	SEQ_UP	5	
DOMAIN:NADH_4Fe-4S	SEQ_UP	1	
DOMAIN:NADH_dehy_S2_C	SEQ_UP	1	
DOMAIN:NADH_dhqG_C	SEQ_UP	1	
DOMAIN:NADH5_C	SEQ_UP	2	
DOMAIN:NAGLU	SEQ_UP	1	
DOMAIN:NAGLU_C	SEQ_UP	1	
DOMAIN:NAGLU_N	SEQ_UP	1	
DOMAIN:NAMPT_N	SEQ_UP	1	
DOMAIN:Nanos-type	SEQ_UP	2	
DOMAIN:NAPRTase	SEQ_UP	1	
DOMAIN:NAPRTase_N	SEQ_UP	1	
DOMAIN:Nas2_N	SEQ_UP	1	
DOMAIN:NB-ARC	SEQ_UP	1	
DOMAIN:Nbas_N	SEQ_UP	1	
DOMAIN:NBD	SEQ_UP	1	
DOMAIN:Nbl1_Borealin_N	SEQ_UP	1	
DOMAIN:NCD1	SEQ_UP	2	
DOMAIN:NCD2	SEQ_UP	2	
DOMAIN:NCD3G	SEQ_UP	29	
DOMAIN:NCKAP5	SEQ_UP	2	
DOMAIN:Ncstrn_small	SEQ_UP	1	
DOMAIN:NDK	SEQ_UP	8	
DOMAIN:NEMO	SEQ_UP	1	
DOMAIN:NET	SEQ_UP	4	
DOMAIN:NeuB	SEQ_UP	1	
DOMAIN:Neur_chan_LBD	SEQ_UP	36	
DOMAIN:Neur_chan_memb	SEQ_UP	35	
DOMAIN:NEXCaM_BD	SEQ_UP	2	
DOMAIN:Nexin_C	SEQ_UP	1	
DOMAIN:NF-X1-type	SEQ_UP	2	
DOMAIN:NFACT-R_1	SEQ_UP	1	
DOMAIN:Nfu_N	SEQ_UP	1	
DOMAIN:NGF	SEQ_UP	3	
DOMAIN:NGN	SEQ_UP	1	
DOMAIN:NGP1NT	SEQ_UP	1	
DOMAIN:NHR	SEQ_UP	5	
DOMAIN:NHR 1	SEQ_UP	3	
DOMAIN:NHR 2	SEQ_UP	3	
DOMAIN:NHR 3	SEQ_UP	1	
DOMAIN:NHR 4	SEQ_UP	1	
DOMAIN:NHR 5	SEQ_UP	1	
DOMAIN:NHR 6	SEQ_UP	1	
DOMAIN:NID	SEQ_UP	1	
DOMAIN:NID 1	SEQ_UP	2	
DOMAIN:NID 2	SEQ_UP	2	
DOMAIN:NIDO	SEQ_UP	5	
DOMAIN:Nidogen G2 beta-barrel	SEQ_UP	4	
DOMAIN:NifU_N	SEQ_UP	1	
DOMAIN:Nipped-B_C	SEQ_UP	1	
DOMAIN:NIPSNAP	SEQ_UP	4	
DOMAIN:NLE	SEQ_UP	2	
DOMAIN:NlpC/P60	SEQ_UP	1	
DOMAIN:NLRC4_HD2	SEQ_UP	3	
DOMAIN:NMD3	SEQ_UP	1	
DOMAIN:NmrA	SEQ_UP	2	
DOMAIN:NMT	SEQ_UP	2	
DOMAIN:NMT_C	SEQ_UP	2	
DOMAIN:NMU	SEQ_UP	1	
DOMAIN:NOD2_WH	SEQ_UP	2	
DOMAIN:NODP	SEQ_UP	1	
DOMAIN:Noelin-1	SEQ_UP	1	
DOMAIN:NOGCT	SEQ_UP	1	
DOMAIN:Nop	SEQ_UP	3	
DOMAIN:NOP5NT	SEQ_UP	2	
DOMAIN:NopRA1	SEQ_UP	1	
DOMAIN:NOPS	SEQ_UP	2	
DOMAIN:NOSIC	SEQ_UP	2	
DOMAIN:Not1	SEQ_UP	1	
DOMAIN:NOT2_3_5	SEQ_UP	2	
DOMAIN:Not3	SEQ_UP	1	
DOMAIN:Npa1	SEQ_UP	1	
DOMAIN:NPC1_N	SEQ_UP	1	
DOMAIN:NPM1-C	SEQ_UP	1	
DOMAIN:NPP	SEQ_UP	1	
DOMAIN:NR LBD	SEQ_UP	49	
DOMAIN:Nrap	SEQ_UP	1	
DOMAIN:Nrap_D2	SEQ_UP	1	
DOMAIN:Nrap_D3	SEQ_UP	1	
DOMAIN:Nrap_D4	SEQ_UP	1	
DOMAIN:Nrap_D5	SEQ_UP	1	
DOMAIN:Nrap_D6	SEQ_UP	1	
DOMAIN:NRBF2_MIT	SEQ_UP	1	
DOMAIN:NRF	SEQ_UP	1	
DOMAIN:Nrf1_activ_bdg	SEQ_UP	1	
DOMAIN:Nrf1_DNA-bind	SEQ_UP	1	
DOMAIN:Nse4_C	SEQ_UP	1	
DOMAIN:Nse4-Nse3_bdg	SEQ_UP	1	
DOMAIN:Nsp1_C	SEQ_UP	2	
DOMAIN:Nt_Gln_amidase	SEQ_UP	1	
DOMAIN:NtA	SEQ_UP	1	
DOMAIN:NTF2	SEQ_UP	9	
DOMAIN:NTP_transf_2	SEQ_UP	9	
DOMAIN:NTP_transferase	SEQ_UP	2	
DOMAIN:NTR	SEQ_UP	23	
DOMAIN:NUC	SEQ_UP	4	
DOMAIN:NUC129	SEQ_UP	1	
DOMAIN:NUC130_3NT	SEQ_UP	1	
DOMAIN:NUC153	SEQ_UP	2	
DOMAIN:NUC173	SEQ_UP	1	
DOMAIN:NUC202	SEQ_UP	1	
DOMAIN:Nuclear receptor	SEQ_UP	43	
DOMAIN:Nucleic_acid_bd	SEQ_UP	1	
DOMAIN:Nucleolin_bd	SEQ_UP	1	
DOMAIN:Nucleoplasmin	SEQ_UP	3	
DOMAIN:Nucleoporin_C	SEQ_UP	2	
DOMAIN:Nucleoporin_N	SEQ_UP	1	
DOMAIN:Nucleos_tra2_C	SEQ_UP	2	
DOMAIN:Nucleos_tra2_N	SEQ_UP	2	
DOMAIN:NUDE_C	SEQ_UP	1	
DOMAIN:Nudix hydrolase	SEQ_UP	28	
DOMAIN:NUDIX_5	SEQ_UP	1	
DOMAIN:Nudix_hydro	SEQ_UP	1	
DOMAIN:NUDIX-like	SEQ_UP	1	
DOMAIN:Nuf2	SEQ_UP	1	
DOMAIN:Nup153	SEQ_UP	1	
DOMAIN:Nup188	SEQ_UP	2	
DOMAIN:Nup214_FG	SEQ_UP	1	
DOMAIN:NupH_GANP	SEQ_UP	1	
DOMAIN:NYAP_C	SEQ_UP	2	
DOMAIN:NYAP_N	SEQ_UP	2	
DOMAIN:NYD-SP28	SEQ_UP	1	
DOMAIN:NYN	SEQ_UP	1	
DOMAIN:OAR	SEQ_UP	8	
DOMAIN:OAS1_C	SEQ_UP	10	
DOMAIN:OB	SEQ_UP	5	
DOMAIN:OB_NTP_bind	SEQ_UP	2	
DOMAIN:Obg	SEQ_UP	2	
DOMAIN:OBG-type G	SEQ_UP	6	
DOMAIN:Occludin_ELL	SEQ_UP	4	
DOMAIN:OCEL	SEQ_UP	6	
DOMAIN:OCIA	SEQ_UP	2	
DOMAIN:OCRE	SEQ_UP	1	
DOMAIN:OGFr_N	SEQ_UP	2	
DOMAIN:OGG_N	SEQ_UP	1	
DOMAIN:OHCU_decarbox	SEQ_UP	1	
DOMAIN:Olduvai	SEQ_UP	1	
DOMAIN:Olfactomedin-like	SEQ_UP	14	
DOMAIN:OMPdecase	SEQ_UP	1	
DOMAIN:Orange	SEQ_UP	12	
DOMAIN:ORC_WH_C	SEQ_UP	1	
DOMAIN:ORC3_ins	SEQ_UP	1	
DOMAIN:ORC3_N	SEQ_UP	1	
DOMAIN:Orn_Arg_deC_N	SEQ_UP	4	
DOMAIN:Orn_DAP_Arg_deC	SEQ_UP	3	
DOMAIN:OSR1_C	SEQ_UP	2	
DOMAIN:OTCace	SEQ_UP	3	
DOMAIN:OTCace_N	SEQ_UP	3	
DOMAIN:OTU	SEQ_UP	17	
DOMAIN:Oxidored_q5_N	SEQ_UP	1	
DOMAIN:Oxidoreductase-like	SEQ_UP	2	
DOMAIN:OxoGdeHyase_C	SEQ_UP	1	
DOMAIN:P-type	SEQ_UP	10	
DOMAIN:P-type 1	SEQ_UP	1	
DOMAIN:P-type 2	SEQ_UP	1	
DOMAIN:P/Homo B	SEQ_UP	7	
DOMAIN:P4Ha_N	SEQ_UP	1	
DOMAIN:P4Hc	SEQ_UP	1	
DOMAIN:P53	SEQ_UP	3	
DOMAIN:P53_TAD	SEQ_UP	1	
DOMAIN:P53_tetramer	SEQ_UP	3	
DOMAIN:P5CR_dimer	SEQ_UP	2	
DOMAIN:P66_CC	SEQ_UP	1	
DOMAIN:PA	SEQ_UP	16	
DOMAIN:PA14	SEQ_UP	4	
DOMAIN:PA28_alpha	SEQ_UP	4	
DOMAIN:PA28_beta	SEQ_UP	4	
DOMAIN:PA2c	SEQ_UP	9	
DOMAIN:PABC	SEQ_UP	6	
DOMAIN:PABS	SEQ_UP	2	
DOMAIN:PAC	SEQ_UP	25	
DOMAIN:Pacifastin	SEQ_UP	1	
DOMAIN:PACT_coil_coil	SEQ_UP	2	
DOMAIN:PAD	SEQ_UP	3	
DOMAIN:PAD_M	SEQ_UP	4	
DOMAIN:PAD_N	SEQ_UP	3	
DOMAIN:PAH 1	SEQ_UP	3	
DOMAIN:PAH 2	SEQ_UP	3	
DOMAIN:PAH 3	SEQ_UP	2	
DOMAIN:Paired	SEQ_UP	9	
DOMAIN:PALB2_WD40	SEQ_UP	1	
DOMAIN:PALP	SEQ_UP	4	
DOMAIN:PAM2	SEQ_UP	8	
DOMAIN:PAN	SEQ_UP	3	
DOMAIN:Pan3_PK	SEQ_UP	1	
DOMAIN:Pannexin_like	SEQ_UP	4	
DOMAIN:PAP_central	SEQ_UP	3	
DOMAIN:PAP_RNA-bind	SEQ_UP	3	
DOMAIN:PAP-associated	SEQ_UP	5	
DOMAIN:PAP-associated 1	SEQ_UP	2	
DOMAIN:PAP-associated 2	SEQ_UP	2	
DOMAIN:PAPA-1	SEQ_UP	1	
DOMAIN:Par3_HAL_N_term	SEQ_UP	2	
DOMAIN:ParB	SEQ_UP	1	
DOMAIN:PARP alpha-helical	SEQ_UP	5	
DOMAIN:PARP catalytic	SEQ_UP	16	
DOMAIN:PARP-type	SEQ_UP	3	
DOMAIN:PAS	SEQ_UP	32	
DOMAIN:PAS 1	SEQ_UP	19	
DOMAIN:PAS 2	SEQ_UP	19	
DOMAIN:PAS_3	SEQ_UP	1	
DOMAIN:PAW	SEQ_UP	2	
DOMAIN:Pax2_C	SEQ_UP	1	
DOMAIN:Pax7	SEQ_UP	1	
DOMAIN:PAZ	SEQ_UP	9	
DOMAIN:PB1	SEQ_UP	14	
DOMAIN:PBC	SEQ_UP	4	
DOMAIN:PBPe	SEQ_UP	13	
DOMAIN:PCAF_N	SEQ_UP	1	
DOMAIN:PCC_BT	SEQ_UP	1	
DOMAIN:PCI	SEQ_UP	24	
DOMAIN:PCIF1_WW	SEQ_UP	1	
DOMAIN:PCM1_C	SEQ_UP	1	
DOMAIN:PCNA_C	SEQ_UP	1	
DOMAIN:PCNA_N	SEQ_UP	1	
DOMAIN:Pdase_M17_N2	SEQ_UP	1	
DOMAIN:PDE4_UCR	SEQ_UP	4	
DOMAIN:PDEase	SEQ_UP	22	
DOMAIN:PDGF_2	SEQ_UP	4	
DOMAIN:PDZ	SEQ_UP	150	
DOMAIN:PDZ 1	SEQ_UP	36	
DOMAIN:PDZ 10	SEQ_UP	2	
DOMAIN:PDZ 11	SEQ_UP	1	
DOMAIN:PDZ 12	SEQ_UP	1	
DOMAIN:PDZ 13	SEQ_UP	1	
DOMAIN:PDZ 2	SEQ_UP	36	
DOMAIN:PDZ 3	SEQ_UP	26	
DOMAIN:PDZ 4	SEQ_UP	14	
DOMAIN:PDZ 5	SEQ_UP	7	
DOMAIN:PDZ 6	SEQ_UP	6	
DOMAIN:PDZ 7	SEQ_UP	3	
DOMAIN:PDZ 8	SEQ_UP	2	
DOMAIN:PDZ 9	SEQ_UP	2	
DOMAIN:PDZ GRASP-type	SEQ_UP	2	
DOMAIN:PDZ GRASP-type 1	SEQ_UP	2	
DOMAIN:PDZ GRASP-type 2	SEQ_UP	2	
DOMAIN:PDZ_6	SEQ_UP	1	
DOMAIN:Pecanex_C	SEQ_UP	3	
DOMAIN:PEHE	SEQ_UP	3	
DOMAIN:Pentapeptide repeat 1	SEQ_UP	1	
DOMAIN:Pentapeptide repeat 2	SEQ_UP	1	
DOMAIN:Pentapeptide repeat 3	SEQ_UP	1	
DOMAIN:Pentraxin (PTX)	SEQ_UP	12	
DOMAIN:Pep_M12B_propep	SEQ_UP	14	
DOMAIN:Pep3_Vps18	SEQ_UP	1	
DOMAIN:PEPCK_GTP	SEQ_UP	2	
DOMAIN:PEPCK_N	SEQ_UP	2	
DOMAIN:Pepdidase_M14_N	SEQ_UP	5	
DOMAIN:Pept_C1	SEQ_UP	20	
DOMAIN:Peptidase A1	SEQ_UP	11	
DOMAIN:Peptidase A2	SEQ_UP	5	
DOMAIN:Peptidase C50	SEQ_UP	1	
DOMAIN:Peptidase M12A	SEQ_UP	6	
DOMAIN:Peptidase M12B	SEQ_UP	56	
DOMAIN:Peptidase M13	SEQ_UP	7	
DOMAIN:Peptidase M60	SEQ_UP	3	
DOMAIN:Peptidase S1	SEQ_UP	161	
DOMAIN:Peptidase S1 1	SEQ_UP	3	
DOMAIN:Peptidase S1 2	SEQ_UP	3	
DOMAIN:Peptidase S1 3	SEQ_UP	2	
DOMAIN:Peptidase S53	SEQ_UP	1	
DOMAIN:Peptidase S59	SEQ_UP	1	
DOMAIN:Peptidase S72	SEQ_UP	1	
DOMAIN:Peptidase S74	SEQ_UP	2	
DOMAIN:Peptidase S8	SEQ_UP	9	
DOMAIN:Peptidase_C98	SEQ_UP	1	
DOMAIN:Peptidase_M1	SEQ_UP	7	
DOMAIN:Peptidase_M1_N	SEQ_UP	8	
DOMAIN:Peptidase_M10	SEQ_UP	5	
DOMAIN:Peptidase_M13	SEQ_UP	7	
DOMAIN:Peptidase_M13_N	SEQ_UP	8	
DOMAIN:Peptidase_M14	SEQ_UP	9	
DOMAIN:Peptidase_M16	SEQ_UP	6	
DOMAIN:Peptidase_M16_C	SEQ_UP	5	
DOMAIN:Peptidase_M16_M	SEQ_UP	2	
DOMAIN:Peptidase_M24	SEQ_UP	6	
DOMAIN:Peptidase_M24_C	SEQ_UP	2	
DOMAIN:Peptidase_M28	SEQ_UP	7	
DOMAIN:Peptidase_M3	SEQ_UP	3	
DOMAIN:Peptidase_M41	SEQ_UP	3	
DOMAIN:Peptidase_M48	SEQ_UP	1	
DOMAIN:Peptidase_M48_N	SEQ_UP	1	
DOMAIN:Peptidase_M50	SEQ_UP	1	
DOMAIN:Peptidase_S24	SEQ_UP	2	
DOMAIN:Peptidase_S8	SEQ_UP	6	
DOMAIN:Peptidase_S9	SEQ_UP	8	
DOMAIN:Peptidase_S9_N	SEQ_UP	2	
DOMAIN:Period_C	SEQ_UP	1	
DOMAIN:Peripheral subunit-binding (PSBD)	SEQ_UP	3	
DOMAIN:Peroxin/Ferlin	SEQ_UP	1	
DOMAIN:PET	SEQ_UP	8	
DOMAIN:PEX-2N	SEQ_UP	1	
DOMAIN:Pex14_N	SEQ_UP	1	
DOMAIN:Pex2_Pex12	SEQ_UP	1	
DOMAIN:PFK	SEQ_UP	3	
DOMAIN:PfkB	SEQ_UP	2	
DOMAIN:PFU	SEQ_UP	1	
DOMAIN:PG_binding_1	SEQ_UP	3	
DOMAIN:pG1 pseudoGTPase	SEQ_UP	2	
DOMAIN:PG1 pseudoGTPase	SEQ_UP	2	
DOMAIN:pG2 pseudoGTPase	SEQ_UP	2	
DOMAIN:PG2 pseudoGTPase	SEQ_UP	2	
DOMAIN:PGM_PMM_I	SEQ_UP	5	
DOMAIN:PGM_PMM_II	SEQ_UP	3	
DOMAIN:PGM_PMM_III	SEQ_UP	2	
DOMAIN:PGM_PMM_IV	SEQ_UP	2	
DOMAIN:PGRP	SEQ_UP	3	
DOMAIN:PH	SEQ_UP	265	
DOMAIN:PH 1	SEQ_UP	36	
DOMAIN:PH 2	SEQ_UP	35	
DOMAIN:PH 2; first part	SEQ_UP	1	
DOMAIN:PH 2; second part	SEQ_UP	1	
DOMAIN:PH 3	SEQ_UP	3	
DOMAIN:PH 4	SEQ_UP	3	
DOMAIN:PH 5	SEQ_UP	2	
DOMAIN:PH_14	SEQ_UP	4	
DOMAIN:PH_RBD	SEQ_UP	3	
DOMAIN:PH_TFIIH	SEQ_UP	1	
DOMAIN:PH; first part	SEQ_UP	1	
DOMAIN:PH; second part	SEQ_UP	1	
DOMAIN:PHB	SEQ_UP	12	
DOMAIN:PHD	SEQ_UP	5	
DOMAIN:PHD_3	SEQ_UP	1	
DOMAIN:PHD-type	SEQ_UP	76	
DOMAIN:Phe_ZIP	SEQ_UP	3	
DOMAIN:PheRS_DBD1	SEQ_UP	1	
DOMAIN:PheRS_DBD2	SEQ_UP	1	
DOMAIN:PheRS_DBD3	SEQ_UP	1	
DOMAIN:PhetRS_B1	SEQ_UP	1	
DOMAIN:PHM7_cyt	SEQ_UP	1	
DOMAIN:PhoLip_ATPase_C	SEQ_UP	11	
DOMAIN:PhoLip_ATPase_N	SEQ_UP	13	
DOMAIN:Phorbol-ester/DAG-type	SEQ_UP	53	
DOMAIN:Phosducin	SEQ_UP	3	
DOMAIN:Phosphagen kinase C-terminal	SEQ_UP	4	
DOMAIN:Phosphagen kinase N-terminal	SEQ_UP	4	
DOMAIN:Phosphatase tensin-type	SEQ_UP	8	
DOMAIN:Phostensin	SEQ_UP	1	
DOMAIN:Phostensin_N	SEQ_UP	1	
DOMAIN:Photolyase/cryptochrome alpha/beta	SEQ_UP	2	
DOMAIN:PHR	SEQ_UP	1	
DOMAIN:PHTB1_C	SEQ_UP	1	
DOMAIN:PHTB1_N	SEQ_UP	1	
DOMAIN:PHTF	SEQ_UP	2	
DOMAIN:Phtf-FEM1B_bdg	SEQ_UP	2	
DOMAIN:PI-PLC X-box	SEQ_UP	17	
DOMAIN:PI-PLC Y-box	SEQ_UP	15	
DOMAIN:PI31_Prot_C	SEQ_UP	1	
DOMAIN:PI31_Prot_N	SEQ_UP	1	
DOMAIN:PI3K-ABD	SEQ_UP	4	
DOMAIN:PI3K-RBD	SEQ_UP	7	
DOMAIN:PI3K/PI4K catalytic	SEQ_UP	18	
DOMAIN:PI4K_N	SEQ_UP	1	
DOMAIN:PID	SEQ_UP	36	
DOMAIN:PID 1	SEQ_UP	4	
DOMAIN:PID 2	SEQ_UP	4	
DOMAIN:PIEZO	SEQ_UP	2	
DOMAIN:Piezo_RRas_bdg	SEQ_UP	2	
DOMAIN:PIG-H	SEQ_UP	1	
DOMAIN:PIG-P	SEQ_UP	1	
DOMAIN:PIGA	SEQ_UP	1	
DOMAIN:PigN	SEQ_UP	1	
DOMAIN:PIGO_PIGG	SEQ_UP	2	
DOMAIN:PIH1	SEQ_UP	2	
DOMAIN:PIH1_CS	SEQ_UP	1	
DOMAIN:PIK helical	SEQ_UP	10	
DOMAIN:PIN_6	SEQ_UP	1	
DOMAIN:PINc	SEQ_UP	6	
DOMAIN:Pinin_SDK_memA	SEQ_UP	1	
DOMAIN:Pinin_SDK_N	SEQ_UP	1	
DOMAIN:PINIT	SEQ_UP	4	
DOMAIN:PIP49_C	SEQ_UP	2	
DOMAIN:PIP49_N	SEQ_UP	1	
DOMAIN:PIPK	SEQ_UP	8	
DOMAIN:Pirin	SEQ_UP	1	
DOMAIN:Pirin_C	SEQ_UP	1	
DOMAIN:PISA	SEQ_UP	2	
DOMAIN:PITH	SEQ_UP	2	
DOMAIN:Piwi	SEQ_UP	8	
DOMAIN:PK	SEQ_UP	2	
DOMAIN:PK_C	SEQ_UP	1	
DOMAIN:PK_Tyr_Ser-Thr	SEQ_UP	6	
DOMAIN:PKD	SEQ_UP	12	
DOMAIN:PKD 1	SEQ_UP	4	
DOMAIN:PKD 10	SEQ_UP	1	
DOMAIN:PKD 11	SEQ_UP	1	
DOMAIN:PKD 12	SEQ_UP	1	
DOMAIN:PKD 13	SEQ_UP	1	
DOMAIN:PKD 14	SEQ_UP	1	
DOMAIN:PKD 15	SEQ_UP	1	
DOMAIN:PKD 16	SEQ_UP	1	
DOMAIN:PKD 2	SEQ_UP	4	
DOMAIN:PKD 3	SEQ_UP	3	
DOMAIN:PKD 4	SEQ_UP	3	
DOMAIN:PKD 5	SEQ_UP	3	
DOMAIN:PKD 6	SEQ_UP	1	
DOMAIN:PKD 7	SEQ_UP	1	
DOMAIN:PKD 8	SEQ_UP	1	
DOMAIN:PKD 9	SEQ_UP	1	
DOMAIN:PKD_channel	SEQ_UP	7	
DOMAIN:Pkinase_C	SEQ_UP	3	
DOMAIN:PKS_AT	SEQ_UP	1	
DOMAIN:PKS_ER	SEQ_UP	11	
DOMAIN:PKS_KS	SEQ_UP	1	
DOMAIN:PL48	SEQ_UP	1	
DOMAIN:PLA2_inh	SEQ_UP	1	
DOMAIN:PLA2c	SEQ_UP	7	
DOMAIN:PLAC	SEQ_UP	19	
DOMAIN:Plastocyanin-like	SEQ_UP	3	
DOMAIN:Plastocyanin-like 1	SEQ_UP	5	
DOMAIN:Plastocyanin-like 2	SEQ_UP	5	
DOMAIN:Plastocyanin-like 3	SEQ_UP	5	
DOMAIN:Plastocyanin-like 4	SEQ_UP	5	
DOMAIN:Plastocyanin-like 5	SEQ_UP	5	
DOMAIN:Plastocyanin-like 6	SEQ_UP	5	
DOMAIN:PLAT	SEQ_UP	22	
DOMAIN:PLAT 1	SEQ_UP	1	
DOMAIN:PLAT 10	SEQ_UP	1	
DOMAIN:PLAT 11	SEQ_UP	1	
DOMAIN:PLAT 12	SEQ_UP	1	
DOMAIN:PLAT 13	SEQ_UP	1	
DOMAIN:PLAT 14	SEQ_UP	1	
DOMAIN:PLAT 15	SEQ_UP	1	
DOMAIN:PLAT 2	SEQ_UP	1	
DOMAIN:PLAT 3	SEQ_UP	1	
DOMAIN:PLAT 4	SEQ_UP	1	
DOMAIN:PLAT 5	SEQ_UP	1	
DOMAIN:PLAT 6	SEQ_UP	1	
DOMAIN:PLAT 7	SEQ_UP	1	
DOMAIN:PLAT 8	SEQ_UP	1	
DOMAIN:PLAT 9	SEQ_UP	1	
DOMAIN:PLC-beta_C	SEQ_UP	1	
DOMAIN:PLCXc	SEQ_UP	6	
DOMAIN:PLD phosphodiesterase	SEQ_UP	5	
DOMAIN:PLD phosphodiesterase 1	SEQ_UP	6	
DOMAIN:PLD phosphodiesterase 2	SEQ_UP	6	
DOMAIN:Plexin_cytopl	SEQ_UP	5	
DOMAIN:PLL	SEQ_UP	1	
DOMAIN:PlsC	SEQ_UP	11	
DOMAIN:Plug_translocon	SEQ_UP	2	
DOMAIN:Plus3	SEQ_UP	1	
DOMAIN:PMSR	SEQ_UP	1	
DOMAIN:PMT	SEQ_UP	1	
DOMAIN:PNP_UDP_1	SEQ_UP	5	
DOMAIN:PNPLA	SEQ_UP	8	
DOMAIN:PNT	SEQ_UP	10	
DOMAIN:Pol_alpha_B_N	SEQ_UP	1	
DOMAIN:POLAc	SEQ_UP	2	
DOMAIN:POLO box	SEQ_UP	5	
DOMAIN:POLO box 1	SEQ_UP	3	
DOMAIN:POLO box 2	SEQ_UP	3	
DOMAIN:PolyA_pol	SEQ_UP	1	
DOMAIN:Polyketide_cyc	SEQ_UP	2	
DOMAIN:POP1	SEQ_UP	1	
DOMAIN:POPLD	SEQ_UP	1	
DOMAIN:Porphobil_deam	SEQ_UP	1	
DOMAIN:Porphobil_deamC	SEQ_UP	1	
DOMAIN:Post-SET	SEQ_UP	18	
DOMAIN:POTRA	SEQ_UP	1	
DOMAIN:POU-specific	SEQ_UP	16	
DOMAIN:POU-specific atypical	SEQ_UP	3	
DOMAIN:POU2F1_C	SEQ_UP	1	
DOMAIN:PP1-binding	SEQ_UP	2	
DOMAIN:PP1c_bdg	SEQ_UP	1	
DOMAIN:PP28	SEQ_UP	1	
DOMAIN:PPARgamma_N	SEQ_UP	1	
DOMAIN:PPIase cyclophilin-type	SEQ_UP	17	
DOMAIN:PPIase FKBP-type	SEQ_UP	15	
DOMAIN:PPIase FKBP-type 1	SEQ_UP	4	
DOMAIN:PPIase FKBP-type 2	SEQ_UP	4	
DOMAIN:PPIase FKBP-type 3	SEQ_UP	2	
DOMAIN:PPIase FKBP-type 4	SEQ_UP	2	
DOMAIN:PpiC	SEQ_UP	3	
DOMAIN:PPIP5K2_N	SEQ_UP	2	
DOMAIN:PPM-type phosphatase	SEQ_UP	20	
DOMAIN:PPP1R35_C	SEQ_UP	1	
DOMAIN:PPPDE	SEQ_UP	2	
DOMAIN:PQ-loop 1	SEQ_UP	4	
DOMAIN:PQ-loop 2	SEQ_UP	4	
DOMAIN:PQQ_3	SEQ_UP	1	
DOMAIN:Pr_beta_C	SEQ_UP	2	
DOMAIN:PRAD	SEQ_UP	1	
DOMAIN:PRC2_HTH_1	SEQ_UP	1	
DOMAIN:Pre-SET	SEQ_UP	8	
DOMAIN:PRELI/MSF1	SEQ_UP	6	
DOMAIN:Prenylcys_lyase	SEQ_UP	1	
DOMAIN:Preseq_ALAS	SEQ_UP	2	
DOMAIN:Pribosyltran	SEQ_UP	1	
DOMAIN:Pribosyltran_N	SEQ_UP	5	
DOMAIN:Prion/Doppel_prot_b-ribbon_dom	SEQ_UP	3	
DOMAIN:PRK	SEQ_UP	3	
DOMAIN:PRKCSH	SEQ_UP	1	
DOMAIN:PRKCSH-like	SEQ_UP	1	
DOMAIN:PRKG1_interact	SEQ_UP	3	
DOMAIN:PRMT5	SEQ_UP	1	
DOMAIN:PRMT5_C	SEQ_UP	1	
DOMAIN:PRMT5_TIM	SEQ_UP	1	
DOMAIN:Pro_dh	SEQ_UP	2	
DOMAIN:PRO8NT	SEQ_UP	1	
DOMAIN:PROCN	SEQ_UP	1	
DOMAIN:Prokineticin	SEQ_UP	1	
DOMAIN:PRORP	SEQ_UP	1	
DOMAIN:Prospero	SEQ_UP	2	
DOMAIN:Prospero-type homeo	SEQ_UP	2	
DOMAIN:Prot_ATP_ID_OB	SEQ_UP	1	
DOMAIN:PROTEASOME_ALPHA_1	SEQ_UP	8	
DOMAIN:Protein kinase	SEQ_UP	519	
DOMAIN:Protein kinase 1	SEQ_UP	15	
DOMAIN:Protein kinase 2	SEQ_UP	15	
DOMAIN:Protein kinase; inactive	SEQ_UP	1	
DOMAIN:Protocadherin	SEQ_UP	4	
DOMAIN:Proton_antipo_M	SEQ_UP	4	
DOMAIN:Proton_antipo_N	SEQ_UP	1	
DOMAIN:PRP1_N	SEQ_UP	1	
DOMAIN:Prp18	SEQ_UP	1	
DOMAIN:PRP38_assoc	SEQ_UP	1	
DOMAIN:PRT6_C	SEQ_UP	1	
DOMAIN:Pru	SEQ_UP	2	
DOMAIN:PRY	SEQ_UP	1	
DOMAIN:Pseudo-CRIB	SEQ_UP	3	
DOMAIN:PseudoU_synth_1	SEQ_UP	2	
DOMAIN:PseudoU_synth_2	SEQ_UP	2	
DOMAIN:PSI	SEQ_UP	20	
DOMAIN:PSI 1	SEQ_UP	5	
DOMAIN:PSI 2	SEQ_UP	5	
DOMAIN:PSI 3	SEQ_UP	5	
DOMAIN:PSI 4	SEQ_UP	3	
DOMAIN:PSI 5	SEQ_UP	2	
DOMAIN:PSI 6	SEQ_UP	1	
DOMAIN:PSI 7	SEQ_UP	1	
DOMAIN:PSI_integrin	SEQ_UP	3	
DOMAIN:PSP	SEQ_UP	1	
DOMAIN:PTB	SEQ_UP	3	
DOMAIN:Pterin-binding	SEQ_UP	1	
DOMAIN:PTN_MK_C	SEQ_UP	2	
DOMAIN:PTN_MK_N	SEQ_UP	2	
DOMAIN:PTP_N	SEQ_UP	1	
DOMAIN:PTPc_motif	SEQ_UP	1	
DOMAIN:PUA	SEQ_UP	6	
DOMAIN:PUA_2	SEQ_UP	2	
DOMAIN:PUB	SEQ_UP	4	
DOMAIN:PUFD	SEQ_UP	1	
DOMAIN:PUL	SEQ_UP	1	
DOMAIN:PUM-HD	SEQ_UP	3	
DOMAIN:Pur_ac_phosph_N	SEQ_UP	1	
DOMAIN:PWI	SEQ_UP	3	
DOMAIN:PWWP	SEQ_UP	24	
DOMAIN:PWWP 1	SEQ_UP	2	
DOMAIN:PWWP 2	SEQ_UP	2	
DOMAIN:PX	SEQ_UP	47	
DOMAIN:PX; atypical	SEQ_UP	2	
DOMAIN:PXA	SEQ_UP	4	
DOMAIN:Pyr_redox_2	SEQ_UP	9	
DOMAIN:Pyr_redox_dim	SEQ_UP	6	
DOMAIN:Pyrin	SEQ_UP	28	
DOMAIN:Pyruvate carboxyltransferase	SEQ_UP	3	
DOMAIN:Q_MOTIF	SEQ_UP	29	
DOMAIN:QLQ	SEQ_UP	2	
DOMAIN:Qua1	SEQ_UP	2	
DOMAIN:R3H	SEQ_UP	11	
DOMAIN:R3H-assoc	SEQ_UP	1	
DOMAIN:Rab_eff_C	SEQ_UP	1	
DOMAIN:Rab-GAP TBC	SEQ_UP	40	
DOMAIN:Rab3-GAP_cat_C	SEQ_UP	1	
DOMAIN:Rab3-GTPase_cat	SEQ_UP	1	
DOMAIN:RAB3GAP2_C	SEQ_UP	1	
DOMAIN:RAB3GAP2_N	SEQ_UP	1	
DOMAIN:Rab5-bind	SEQ_UP	2	
DOMAIN:Rabaptin	SEQ_UP	2	
DOMAIN:RabBD	SEQ_UP	12	
DOMAIN:RabGGT_insert	SEQ_UP	1	
DOMAIN:Rad21_Rec8	SEQ_UP	2	
DOMAIN:Rad21_Rec8_N	SEQ_UP	2	
DOMAIN:RAD51_interact	SEQ_UP	2	
DOMAIN:Rad60-SLD	SEQ_UP	4	
DOMAIN:rADc	SEQ_UP	2	
DOMAIN:Radical SAM core	SEQ_UP	8	
DOMAIN:RAG1_imp_bd	SEQ_UP	1	
DOMAIN:RAG1-type	SEQ_UP	1	
DOMAIN:RAG2_PHD	SEQ_UP	1	
DOMAIN:RAI1	SEQ_UP	1	
DOMAIN:RAMA	SEQ_UP	2	
DOMAIN:RanBD1	SEQ_UP	6	
DOMAIN:RanBD1 1	SEQ_UP	1	
DOMAIN:RanBD1 2	SEQ_UP	1	
DOMAIN:RanBD1 3	SEQ_UP	1	
DOMAIN:RanBD1 4	SEQ_UP	1	
DOMAIN:RanBP2-type	SEQ_UP	18	
DOMAIN:RanGAP1_C	SEQ_UP	1	
DOMAIN:RAP	SEQ_UP	6	
DOMAIN:Rap-GAP	SEQ_UP	11	
DOMAIN:RAP80_UIM	SEQ_UP	1	
DOMAIN:Raptor_N	SEQ_UP	1	
DOMAIN:Ras-associating	SEQ_UP	41	
DOMAIN:Ras-associating 1	SEQ_UP	2	
DOMAIN:Ras-associating 2	SEQ_UP	2	
DOMAIN:Ras-GAP	SEQ_UP	14	
DOMAIN:Ras-GEF	SEQ_UP	28	
DOMAIN:RasGAP_C	SEQ_UP	2	
DOMAIN:Rav1p_C	SEQ_UP	2	
DOMAIN:RAWUL	SEQ_UP	3	
DOMAIN:RB_A	SEQ_UP	3	
DOMAIN:Rb_C	SEQ_UP	3	
DOMAIN:RBD	SEQ_UP	7	
DOMAIN:RBD 1	SEQ_UP	2	
DOMAIN:RBD 2	SEQ_UP	2	
DOMAIN:RBM1CTR	SEQ_UP	1	
DOMAIN:RBM39linker	SEQ_UP	1	
DOMAIN:RBR	SEQ_UP	3	
DOMAIN:RCK N-terminal	SEQ_UP	3	
DOMAIN:RDD	SEQ_UP	1	
DOMAIN:RECA_2	SEQ_UP	5	
DOMAIN:RECA_3	SEQ_UP	2	
DOMAIN:Recep_L_domain	SEQ_UP	6	
DOMAIN:Receptor_2B4	SEQ_UP	1	
DOMAIN:Receptor_IA-2	SEQ_UP	1	
DOMAIN:RecQ_Zn_bind	SEQ_UP	1	
DOMAIN:RecQ5	SEQ_UP	1	
DOMAIN:RED_C	SEQ_UP	1	
DOMAIN:RED_N	SEQ_UP	1	
DOMAIN:Redoxin	SEQ_UP	1	
DOMAIN:Reelin	SEQ_UP	3	
DOMAIN:REJ	SEQ_UP	4	
DOMAIN:REKLES	SEQ_UP	3	
DOMAIN:RelB_leu_zip	SEQ_UP	1	
DOMAIN:REM-1	SEQ_UP	13	
DOMAIN:REM-1 1	SEQ_UP	3	
DOMAIN:REM-1 2	SEQ_UP	3	
DOMAIN:REM-1 3	SEQ_UP	3	
DOMAIN:Rep_fac_C	SEQ_UP	1	
DOMAIN:Rep_fac-A_C	SEQ_UP	2	
DOMAIN:Rep-A_N	SEQ_UP	1	
DOMAIN:REPA_OB_2	SEQ_UP	1	
DOMAIN:RESP18	SEQ_UP	2	
DOMAIN:Reticulon	SEQ_UP	4	
DOMAIN:Reverse transcriptase	SEQ_UP	5	
DOMAIN:RF_PROK_I	SEQ_UP	1	
DOMAIN:RFC1	SEQ_UP	1	
DOMAIN:RFX-type winged-helix	SEQ_UP	6	
DOMAIN:RFX1_trans_act	SEQ_UP	1	
DOMAIN:RFX5_N	SEQ_UP	1	
DOMAIN:RFXA_RFXANK_bdg	SEQ_UP	1	
DOMAIN:RGM_C	SEQ_UP	2	
DOMAIN:RGM_N	SEQ_UP	2	
DOMAIN:RGS	SEQ_UP	35	
DOMAIN:RGS 1	SEQ_UP	2	
DOMAIN:RGS 2	SEQ_UP	2	
DOMAIN:RGS-like	SEQ_UP	1	
DOMAIN:RGSL	SEQ_UP	2	
DOMAIN:RH1	SEQ_UP	5	
DOMAIN:RH2	SEQ_UP	5	
DOMAIN:RHD	SEQ_UP	10	
DOMAIN:RHD_dimer	SEQ_UP	1	
DOMAIN:RHIM	SEQ_UP	1	
DOMAIN:Rho-GAP	SEQ_UP	67	
DOMAIN:RhoBD	SEQ_UP	2	
DOMAIN:Rhodanese	SEQ_UP	24	
DOMAIN:Rhodanese 1	SEQ_UP	2	
DOMAIN:Rhodanese 2	SEQ_UP	2	
DOMAIN:Rhomboid	SEQ_UP	4	
DOMAIN:Rib_recp_KP_reg	SEQ_UP	2	
DOMAIN:Ribo_biogen_C	SEQ_UP	1	
DOMAIN:RIBORED_LARGE	SEQ_UP	1	
DOMAIN:Ribos_L4_asso_C	SEQ_UP	1	
DOMAIN:Ribosomal_L11	SEQ_UP	2	
DOMAIN:Ribosomal_L11_N	SEQ_UP	2	
DOMAIN:Ribosomal_L14e	SEQ_UP	2	
DOMAIN:Ribosomal_L16	SEQ_UP	2	
DOMAIN:Ribosomal_L18_c	SEQ_UP	1	
DOMAIN:Ribosomal_L18A	SEQ_UP	1	
DOMAIN:Ribosomal_L18e/L15P	SEQ_UP	2	
DOMAIN:Ribosomal_L19e	SEQ_UP	1	
DOMAIN:Ribosomal_L2	SEQ_UP	1	
DOMAIN:Ribosomal_L2_C	SEQ_UP	2	
DOMAIN:Ribosomal_L23eN	SEQ_UP	1	
DOMAIN:Ribosomal_L28e	SEQ_UP	1	
DOMAIN:Ribosomal_L30	SEQ_UP	4	
DOMAIN:Ribosomal_L30_N	SEQ_UP	2	
DOMAIN:Ribosomal_L5	SEQ_UP	1	
DOMAIN:Ribosomal_L5_C	SEQ_UP	1	
DOMAIN:Ribosomal_L6	SEQ_UP	2	
DOMAIN:Ribosomal_L6e_N	SEQ_UP	1	
DOMAIN:Ribosomal_L7Ae	SEQ_UP	10	
DOMAIN:RIBOSOMAL_L9	SEQ_UP	1	
DOMAIN:Ribosomal_S10	SEQ_UP	3	
DOMAIN:Ribosomal_S13_N	SEQ_UP	1	
DOMAIN:Ribosomal_S17_N	SEQ_UP	1	
DOMAIN:Ribosomal_S27	SEQ_UP	1	
DOMAIN:Ribosomal_S3_C	SEQ_UP	1	
DOMAIN:Ribosomal_S4	SEQ_UP	1	
DOMAIN:Ribosomal_S5_C	SEQ_UP	1	
DOMAIN:Ribosomal_S7	SEQ_UP	1	
DOMAIN:RIC1	SEQ_UP	1	
DOMAIN:RIC3	SEQ_UP	1	
DOMAIN:Ricin B-type lectin	SEQ_UP	26	
DOMAIN:RICTOR_M	SEQ_UP	1	
DOMAIN:RICTOR_N	SEQ_UP	1	
DOMAIN:RICTOR_V	SEQ_UP	1	
DOMAIN:RID	SEQ_UP	1	
DOMAIN:Rieske	SEQ_UP	3	
DOMAIN:Rieske 1	SEQ_UP	1	
DOMAIN:Rieske 2	SEQ_UP	1	
DOMAIN:Rif1_N	SEQ_UP	2	
DOMAIN:RIH_assoc	SEQ_UP	1	
DOMAIN:RII_binding_1	SEQ_UP	2	
DOMAIN:RIIa	SEQ_UP	7	
DOMAIN:RING-CH-type	SEQ_UP	8	
DOMAIN:RING-Gid-type	SEQ_UP	2	
DOMAIN:RING-type	SEQ_UP	212	
DOMAIN:RINT1/TIP20	SEQ_UP	1	
DOMAIN:RIO	SEQ_UP	3	
DOMAIN:RIX1	SEQ_UP	1	
DOMAIN:RL	SEQ_UP	1	
DOMAIN:RL10P_insert	SEQ_UP	2	
DOMAIN:RLR CTR	SEQ_UP	3	
DOMAIN:RME-8_N	SEQ_UP	1	
DOMAIN:RmlD_sub_bind	SEQ_UP	1	
DOMAIN:RMT2	SEQ_UP	1	
DOMAIN:RNA_GG_bind	SEQ_UP	1	
DOMAIN:RNA_pol_L_2	SEQ_UP	2	
DOMAIN:RNA_pol_Rbc25	SEQ_UP	1	
DOMAIN:RNA_pol_Rpa2_4	SEQ_UP	1	
DOMAIN:RNA_pol_Rpb1_1	SEQ_UP	2	
DOMAIN:RNA_pol_Rpb1_5	SEQ_UP	1	
DOMAIN:RNA_pol_Rpb2_1	SEQ_UP	2	
DOMAIN:RNA_pol_Rpb2_2	SEQ_UP	2	
DOMAIN:RNA_pol_Rpb2_3	SEQ_UP	1	
DOMAIN:RNA_pol_Rpb2_6	SEQ_UP	1	
DOMAIN:RNA_pol_Rpb2_7	SEQ_UP	2	
DOMAIN:RNA_pol_Rpb5_C	SEQ_UP	1	
DOMAIN:RNA_pol_Rpb5_N	SEQ_UP	1	
DOMAIN:RNA_pol_Rpc82	SEQ_UP	1	
DOMAIN:RNase H type-1	SEQ_UP	6	
DOMAIN:RNase H type-2	SEQ_UP	1	
DOMAIN:RNase III	SEQ_UP	3	
DOMAIN:RNase III 1	SEQ_UP	2	
DOMAIN:RNase III 2	SEQ_UP	2	
DOMAIN:RNase NYN	SEQ_UP	7	
DOMAIN:RNase_HII	SEQ_UP	1	
DOMAIN:RNAse_Pc	SEQ_UP	24	
DOMAIN:RNase_PH	SEQ_UP	5	
DOMAIN:RNase_PH_C	SEQ_UP	5	
DOMAIN:RNB	SEQ_UP	3	
DOMAIN:RNF111_N	SEQ_UP	1	
DOMAIN:RNF220	SEQ_UP	1	
DOMAIN:Robl_LC7	SEQ_UP	1	
DOMAIN:Roc	SEQ_UP	4	
DOMAIN:Rod_C	SEQ_UP	1	
DOMAIN:ROKNT	SEQ_UP	1	
DOMAIN:RPA_C	SEQ_UP	1	
DOMAIN:RPA_interact_C	SEQ_UP	1	
DOMAIN:RPA_interact_M	SEQ_UP	1	
DOMAIN:RPA_interact_N	SEQ_UP	1	
DOMAIN:RPAP1_C	SEQ_UP	1	
DOMAIN:RPAP1_N	SEQ_UP	1	
DOMAIN:RPC5_C	SEQ_UP	1	
DOMAIN:RPGR1_C	SEQ_UP	1	
DOMAIN:RPN1_C	SEQ_UP	1	
DOMAIN:RPN1_RPN2_N	SEQ_UP	1	
DOMAIN:RPN2_C	SEQ_UP	2	
DOMAIN:RPN6_N	SEQ_UP	1	
DOMAIN:RPN7	SEQ_UP	1	
DOMAIN:RPOL_N	SEQ_UP	1	
DOMAIN:RPOL4c	SEQ_UP	2	
DOMAIN:RPOL9	SEQ_UP	1	
DOMAIN:RPOLA_N	SEQ_UP	3	
DOMAIN:RPOLD	SEQ_UP	2	
DOMAIN:RQC	SEQ_UP	1	
DOMAIN:RRM	SEQ_UP	235	
DOMAIN:RRM 1	SEQ_UP	90	
DOMAIN:RRM 2	SEQ_UP	90	
DOMAIN:RRM 3	SEQ_UP	43	
DOMAIN:RRM 3; atypical	SEQ_UP	1	
DOMAIN:RRM 4	SEQ_UP	11	
DOMAIN:RRM 5	SEQ_UP	1	
DOMAIN:RRM 6	SEQ_UP	1	
DOMAIN:RRM Nup35-type	SEQ_UP	1	
DOMAIN:RRM_4	SEQ_UP	1	
DOMAIN:RRM_8	SEQ_UP	1	
DOMAIN:RRM_Rrp7	SEQ_UP	1	
DOMAIN:RrmJ-type SAM-dependent 2'-O-MTase	SEQ_UP	1	
DOMAIN:RRN7-type	SEQ_UP	1	
DOMAIN:rRNA_proc-arch	SEQ_UP	1	
DOMAIN:Rrp44_CSD1	SEQ_UP	1	
DOMAIN:RRP7	SEQ_UP	1	
DOMAIN:Rsm1	SEQ_UP	1	
DOMAIN:RSN1_TM	SEQ_UP	3	
DOMAIN:RT_RNaseH_2	SEQ_UP	1	
DOMAIN:RTC	SEQ_UP	2	
DOMAIN:RTC_insert	SEQ_UP	2	
DOMAIN:RTP1_C1	SEQ_UP	1	
DOMAIN:RTR1-type	SEQ_UP	1	
DOMAIN:Rtt106	SEQ_UP	1	
DOMAIN:RUN	SEQ_UP	19	
DOMAIN:RUN 1	SEQ_UP	2	
DOMAIN:RUN 2	SEQ_UP	2	
DOMAIN:Runt	SEQ_UP	3	
DOMAIN:RunxI	SEQ_UP	1	
DOMAIN:RVP	SEQ_UP	1	
DOMAIN:RWD	SEQ_UP	11	
DOMAIN:RYDR_ITPR	SEQ_UP	2	
DOMAIN:S_100	SEQ_UP	6	
DOMAIN:S-AdoMet_synt_C	SEQ_UP	1	
DOMAIN:S-AdoMet_synt_M	SEQ_UP	2	
DOMAIN:S-AdoMet_synt_N	SEQ_UP	2	
DOMAIN:S1 motif	SEQ_UP	10	
DOMAIN:S1 motif 1	SEQ_UP	1	
DOMAIN:S1 motif 10	SEQ_UP	1	
DOMAIN:S1 motif 11	SEQ_UP	1	
DOMAIN:S1 motif 12	SEQ_UP	1	
DOMAIN:S1 motif 13	SEQ_UP	1	
DOMAIN:S1 motif 2	SEQ_UP	1	
DOMAIN:S1 motif 3	SEQ_UP	1	
DOMAIN:S1 motif 4	SEQ_UP	1	
DOMAIN:S1 motif 5	SEQ_UP	1	
DOMAIN:S1 motif 6	SEQ_UP	1	
DOMAIN:S1 motif 7	SEQ_UP	1	
DOMAIN:S1 motif 8	SEQ_UP	1	
DOMAIN:S1 motif 9	SEQ_UP	1	
DOMAIN:S1-like	SEQ_UP	20	
DOMAIN:S10_plectin	SEQ_UP	1	
DOMAIN:S4	SEQ_UP	2	
DOMAIN:S4 RNA-binding	SEQ_UP	4	
DOMAIN:S5 DRBM	SEQ_UP	3	
DOMAIN:S5A_REDUCTASE	SEQ_UP	4	
DOMAIN:S8_pro-domain	SEQ_UP	3	
DOMAIN:SAB	SEQ_UP	3	
DOMAIN:SAC	SEQ_UP	5	
DOMAIN:SAC3_GANP	SEQ_UP	1	
DOMAIN:Sacchrp_dh_C	SEQ_UP	1	
DOMAIN:Sacchrp_dh_NADP	SEQ_UP	2	
DOMAIN:SAE2	SEQ_UP	1	
DOMAIN:SAICAR_synt	SEQ_UP	1	
DOMAIN:SAM	SEQ_UP	93	
DOMAIN:SAM 1	SEQ_UP	11	
DOMAIN:SAM 2	SEQ_UP	11	
DOMAIN:SAM 3	SEQ_UP	5	
DOMAIN:SAM_3	SEQ_UP	2	
DOMAIN:SAM_MT_RSMB_NOP	SEQ_UP	4	
DOMAIN:SAM-dependent MTase C5-type	SEQ_UP	5	
DOMAIN:SAM-dependent MTase PRMT-type	SEQ_UP	7	
DOMAIN:SAM-dependent MTase PRMT-type 1	SEQ_UP	2	
DOMAIN:SAM-dependent MTase PRMT-type 2	SEQ_UP	2	
DOMAIN:SAM-dependent MTase TRM10-type	SEQ_UP	3	
DOMAIN:Sam68-YY	SEQ_UP	1	
DOMAIN:SAND	SEQ_UP	8	
DOMAIN:SANT	SEQ_UP	30	
DOMAIN:SANT 1	SEQ_UP	8	
DOMAIN:SANT 2	SEQ_UP	8	
DOMAIN:SANTA	SEQ_UP	1	
DOMAIN:SAP	SEQ_UP	24	
DOMAIN:SAP 1	SEQ_UP	2	
DOMAIN:SAP 2	SEQ_UP	2	
DOMAIN:SAP130_C	SEQ_UP	1	
DOMAIN:Saposin A-type	SEQ_UP	3	
DOMAIN:Saposin A-type 1	SEQ_UP	2	
DOMAIN:Saposin A-type 2	SEQ_UP	2	
DOMAIN:Saposin B-type	SEQ_UP	7	
DOMAIN:Saposin B-type 1	SEQ_UP	3	
DOMAIN:Saposin B-type 2	SEQ_UP	3	
DOMAIN:Saposin B-type 3	SEQ_UP	3	
DOMAIN:Saposin B-type 4	SEQ_UP	2	
DOMAIN:SARA	SEQ_UP	1	
DOMAIN:SARAH	SEQ_UP	9	
DOMAIN:SAS-6_N	SEQ_UP	1	
DOMAIN:Sas6_CC	SEQ_UP	1	
DOMAIN:SB	SEQ_UP	1	
DOMAIN:SBDS	SEQ_UP	1	
DOMAIN:SBDS_C	SEQ_UP	1	
DOMAIN:SBF2	SEQ_UP	1	
DOMAIN:SCA7	SEQ_UP	4	
DOMAIN:SCAN box	SEQ_UP	46	
DOMAIN:SCAPER_N	SEQ_UP	1	
DOMAIN:SCD	SEQ_UP	3	
DOMAIN:SCHIP-1	SEQ_UP	1	
DOMAIN:SCP	SEQ_UP	14	
DOMAIN:SCP2	SEQ_UP	5	
DOMAIN:SCY	SEQ_UP	29	
DOMAIN:SDA1	SEQ_UP	1	
DOMAIN:SE	SEQ_UP	1	
DOMAIN:SEA	SEQ_UP	22	
DOMAIN:SEA 1	SEQ_UP	3	
DOMAIN:SEA 2	SEQ_UP	3	
DOMAIN:Sec15	SEQ_UP	2	
DOMAIN:Sec16	SEQ_UP	2	
DOMAIN:Sec16_C	SEQ_UP	3	
DOMAIN:Sec23_BS	SEQ_UP	6	
DOMAIN:Sec23_helical	SEQ_UP	6	
DOMAIN:Sec23_trunk	SEQ_UP	6	
DOMAIN:Sec2p	SEQ_UP	2	
DOMAIN:Sec3_C	SEQ_UP	1	
DOMAIN:Sec3-PIP2_bind	SEQ_UP	2	
DOMAIN:Sec39	SEQ_UP	1	
DOMAIN:Sec5	SEQ_UP	1	
DOMAIN:SEC63	SEQ_UP	4	
DOMAIN:SEC63 1	SEQ_UP	3	
DOMAIN:SEC63 2	SEQ_UP	3	
DOMAIN:SEC7	SEQ_UP	17	
DOMAIN:Sec7_N	SEQ_UP	2	
DOMAIN:Sec8_exocyst	SEQ_UP	1	
DOMAIN:SEEEED	SEQ_UP	1	
DOMAIN:SEFIR	SEQ_UP	6	
DOMAIN:SelP_N	SEQ_UP	1	
DOMAIN:Sema	SEQ_UP	31	
DOMAIN:Semialdhyde_dh	SEQ_UP	1	
DOMAIN:Sen15	SEQ_UP	1	
DOMAIN:Senescence	SEQ_UP	1	
DOMAIN:SEP	SEQ_UP	4	
DOMAIN:Sep15_SelM	SEQ_UP	1	
DOMAIN:Septin-type G	SEQ_UP	14	
DOMAIN:SER_THR_PHOSPHATASE	SEQ_UP	10	
DOMAIN:SERPIN	SEQ_UP	60	
DOMAIN:SERRATE_Ars2_N	SEQ_UP	1	
DOMAIN:SERTA	SEQ_UP	5	
DOMAIN:Seryl_tRNA_N	SEQ_UP	1	
DOMAIN:SET	SEQ_UP	51	
DOMAIN:SF3b1	SEQ_UP	1	
DOMAIN:SF4 helicase	SEQ_UP	1	
DOMAIN:SFM	SEQ_UP	2	
DOMAIN:SGF29 C-terminal	SEQ_UP	1	
DOMAIN:SGNH_hydro	SEQ_UP	3	
DOMAIN:SGS	SEQ_UP	2	
DOMAIN:SGTA_dimer	SEQ_UP	2	
DOMAIN:SH2	SEQ_UP	106	
DOMAIN:SH2 1	SEQ_UP	9	
DOMAIN:SH2 2	SEQ_UP	9	
DOMAIN:SH2; atypical	SEQ_UP	3	
DOMAIN:SH3	SEQ_UP	212	
DOMAIN:SH3 1	SEQ_UP	41	
DOMAIN:SH3 1; truncated	SEQ_UP	1	
DOMAIN:SH3 2	SEQ_UP	42	
DOMAIN:SH3 3	SEQ_UP	19	
DOMAIN:SH3 4	SEQ_UP	8	
DOMAIN:SH3 5	SEQ_UP	5	
DOMAIN:SH3 6	SEQ_UP	1	
DOMAIN:SH3_12	SEQ_UP	1	
DOMAIN:SH3b	SEQ_UP	1	
DOMAIN:Sharpin_PH	SEQ_UP	1	
DOMAIN:SHD	SEQ_UP	2	
DOMAIN:ShKT	SEQ_UP	6	
DOMAIN:SHMT	SEQ_UP	1	
DOMAIN:SHNi-TPR	SEQ_UP	1	
DOMAIN:SHR-BD	SEQ_UP	4	
DOMAIN:SHS2_Rpb7-N	SEQ_UP	1	
DOMAIN:sHSP	SEQ_UP	9	
DOMAIN:SHSP	SEQ_UP	7	
DOMAIN:SIAH-type	SEQ_UP	4	
DOMAIN:Sialidase	SEQ_UP	4	
DOMAIN:SIN1	SEQ_UP	1	
DOMAIN:SIN1_PH	SEQ_UP	1	
DOMAIN:Sin3a_C	SEQ_UP	1	
DOMAIN:Sina	SEQ_UP	1	
DOMAIN:Single-minded C-terminal	SEQ_UP	2	
DOMAIN:SIR2_2	SEQ_UP	1	
DOMAIN:SIS	SEQ_UP	2	
DOMAIN:SIS 1	SEQ_UP	3	
DOMAIN:SIS 2	SEQ_UP	3	
DOMAIN:Ski_Sno	SEQ_UP	3	
DOMAIN:SKICH	SEQ_UP	4	
DOMAIN:SKIP_SNW	SEQ_UP	1	
DOMAIN:Skp1	SEQ_UP	1	
DOMAIN:Skp1_POZ	SEQ_UP	2	
DOMAIN:SLBP_RNA_bind	SEQ_UP	1	
DOMAIN:SLC12	SEQ_UP	8	
DOMAIN:SLC3A2_N	SEQ_UP	1	
DOMAIN:SLD	SEQ_UP	5	
DOMAIN:Sld5	SEQ_UP	1	
DOMAIN:SLED	SEQ_UP	4	
DOMAIN:Slu7	SEQ_UP	1	
DOMAIN:Sm	SEQ_UP	16	
DOMAIN:SM-ATX	SEQ_UP	1	
DOMAIN:SMAP	SEQ_UP	3	
DOMAIN:SMB	SEQ_UP	10	
DOMAIN:SMB 1	SEQ_UP	5	
DOMAIN:SMB 2	SEQ_UP	5	
DOMAIN:SMC hinge	SEQ_UP	6	
DOMAIN:SMC_N	SEQ_UP	5	
DOMAIN:SMG1_N	SEQ_UP	1	
DOMAIN:Smg4_UPF3	SEQ_UP	2	
DOMAIN:SMI1_KNR4	SEQ_UP	1	
DOMAIN:SMK-1	SEQ_UP	4	
DOMAIN:SMN	SEQ_UP	2	
DOMAIN:Smoothelin	SEQ_UP	1	
DOMAIN:SMP_C2CD2L	SEQ_UP	1	
DOMAIN:SMP_LBD	SEQ_UP	1	
DOMAIN:SMP-LBD	SEQ_UP	2	
DOMAIN:SMP-LTD	SEQ_UP	5	
DOMAIN:Smr	SEQ_UP	1	
DOMAIN:SMYLE_N	SEQ_UP	1	
DOMAIN:SnAC	SEQ_UP	1	
DOMAIN:SNCAIP_SNCA_bd	SEQ_UP	1	
DOMAIN:SNF2-rel_dom	SEQ_UP	5	
DOMAIN:SNN_cytoplasm	SEQ_UP	1	
DOMAIN:SNN_linker	SEQ_UP	1	
DOMAIN:SNN_transmemb	SEQ_UP	1	
DOMAIN:SOAR	SEQ_UP	2	
DOMAIN:SOCS	SEQ_UP	2	
DOMAIN:SOCS box	SEQ_UP	36	
DOMAIN:Sod_Cu	SEQ_UP	2	
DOMAIN:Sod_Fe_C	SEQ_UP	1	
DOMAIN:Sod_Fe_N	SEQ_UP	1	
DOMAIN:SoHo	SEQ_UP	3	
DOMAIN:Somatostatin	SEQ_UP	1	
DOMAIN:Sortilin_C	SEQ_UP	1	
DOMAIN:Sortilin-Vps10	SEQ_UP	1	
DOMAIN:Sorting_nexin	SEQ_UP	1	
DOMAIN:Sox C-terminal	SEQ_UP	3	
DOMAIN:SP-RING-type	SEQ_UP	5	
DOMAIN:SPAR_C	SEQ_UP	2	
DOMAIN:SPATA1_C	SEQ_UP	1	
DOMAIN:SPATA6	SEQ_UP	2	
DOMAIN:SPAZ	SEQ_UP	1	
DOMAIN:SPAZ 1	SEQ_UP	1	
DOMAIN:SPAZ 2	SEQ_UP	1	
DOMAIN:Spem1	SEQ_UP	1	
DOMAIN:Speriolin_C	SEQ_UP	1	
DOMAIN:Speriolin_N	SEQ_UP	3	
DOMAIN:Spindle_Spc25	SEQ_UP	1	
DOMAIN:SpmSyn_N	SEQ_UP	1	
DOMAIN:SPOC	SEQ_UP	5	
DOMAIN:Spondin	SEQ_UP	2	
DOMAIN:SpoU_methylase	SEQ_UP	1	
DOMAIN:SPR	SEQ_UP	7	
DOMAIN:SprT-like	SEQ_UP	1	
DOMAIN:SPRY	SEQ_UP	1	
DOMAIN:SPT16	SEQ_UP	1	
DOMAIN:Spt4	SEQ_UP	1	
DOMAIN:SPT6_acidic	SEQ_UP	1	
DOMAIN:SPX	SEQ_UP	1	
DOMAIN:SRA1	SEQ_UP	1	
DOMAIN:SRCR	SEQ_UP	26	
DOMAIN:SRCR 1	SEQ_UP	12	
DOMAIN:SRCR 2	SEQ_UP	12	
DOMAIN:SRCR 3	SEQ_UP	12	
DOMAIN:SRCR 4	SEQ_UP	7	
DOMAIN:SRCR 5	SEQ_UP	3	
DOMAIN:SRCR 6	SEQ_UP	2	
DOMAIN:SRCR 7	SEQ_UP	2	
DOMAIN:SRCR 8	SEQ_UP	2	
DOMAIN:SRCR 9	SEQ_UP	1	
DOMAIN:SRP-alpha_N	SEQ_UP	1	
DOMAIN:SRP54	SEQ_UP	2	
DOMAIN:SRP54_N	SEQ_UP	2	
DOMAIN:SRP72	SEQ_UP	1	
DOMAIN:SRP9-21	SEQ_UP	1	
DOMAIN:SRR1	SEQ_UP	1	
DOMAIN:SRRM_C	SEQ_UP	1	
DOMAIN:SSB	SEQ_UP	1	
DOMAIN:SSD	SEQ_UP	12	
DOMAIN:Ssl1	SEQ_UP	1	
DOMAIN:SSXT	SEQ_UP	2	
DOMAIN:STAG	SEQ_UP	1	
DOMAIN:START	SEQ_UP	15	
DOMAIN:STAS	SEQ_UP	11	
DOMAIN:STAT_alpha	SEQ_UP	1	
DOMAIN:STAT_bind	SEQ_UP	1	
DOMAIN:STAT_int	SEQ_UP	4	
DOMAIN:STAT2_C	SEQ_UP	1	
DOMAIN:STAT6_C	SEQ_UP	1	
DOMAIN:Stealth_CR1	SEQ_UP	1	
DOMAIN:STI1	SEQ_UP	6	
DOMAIN:STI1 1	SEQ_UP	4	
DOMAIN:STI1 2	SEQ_UP	4	
DOMAIN:STI1 3	SEQ_UP	3	
DOMAIN:STI1 4	SEQ_UP	3	
DOMAIN:Stn1	SEQ_UP	1	
DOMAIN:STN1_2	SEQ_UP	1	
DOMAIN:Stonin2_N	SEQ_UP	1	
DOMAIN:Striatin	SEQ_UP	3	
DOMAIN:SU	SEQ_UP	3	
DOMAIN:SUEL-type lectin	SEQ_UP	5	
DOMAIN:SUEL-type lectin 1	SEQ_UP	1	
DOMAIN:SUEL-type lectin 2	SEQ_UP	1	
DOMAIN:Suf	SEQ_UP	1	
DOMAIN:SUFU	SEQ_UP	1	
DOMAIN:SUFU_C	SEQ_UP	1	
DOMAIN:SUI1	SEQ_UP	4	
DOMAIN:Sulfatase	SEQ_UP	10	
DOMAIN:Sulfate_transp	SEQ_UP	8	
DOMAIN:Sulfotransfer_1	SEQ_UP	31	
DOMAIN:SUN	SEQ_UP	6	
DOMAIN:SURF6	SEQ_UP	1	
DOMAIN:SURP motif	SEQ_UP	3	
DOMAIN:Sushi	SEQ_UP	53	
DOMAIN:Sushi 1	SEQ_UP	34	
DOMAIN:Sushi 10	SEQ_UP	6	
DOMAIN:Sushi 11	SEQ_UP	5	
DOMAIN:Sushi 12	SEQ_UP	5	
DOMAIN:Sushi 13	SEQ_UP	5	
DOMAIN:Sushi 14	SEQ_UP	5	
DOMAIN:Sushi 15	SEQ_UP	5	
DOMAIN:Sushi 16	SEQ_UP	4	
DOMAIN:Sushi 17	SEQ_UP	4	
DOMAIN:Sushi 18	SEQ_UP	4	
DOMAIN:Sushi 19	SEQ_UP	4	
DOMAIN:Sushi 2	SEQ_UP	34	
DOMAIN:Sushi 20	SEQ_UP	4	
DOMAIN:Sushi 21	SEQ_UP	3	
DOMAIN:Sushi 22	SEQ_UP	3	
DOMAIN:Sushi 23	SEQ_UP	3	
DOMAIN:Sushi 24	SEQ_UP	3	
DOMAIN:Sushi 25	SEQ_UP	3	
DOMAIN:Sushi 26	SEQ_UP	3	
DOMAIN:Sushi 27	SEQ_UP	3	
DOMAIN:Sushi 28	SEQ_UP	3	
DOMAIN:Sushi 29	SEQ_UP	1	
DOMAIN:Sushi 3	SEQ_UP	24	
DOMAIN:Sushi 30	SEQ_UP	1	
DOMAIN:Sushi 31	SEQ_UP	1	
DOMAIN:Sushi 32	SEQ_UP	1	
DOMAIN:Sushi 33	SEQ_UP	1	
DOMAIN:Sushi 34	SEQ_UP	1	
DOMAIN:Sushi 4	SEQ_UP	20	
DOMAIN:Sushi 5	SEQ_UP	15	
DOMAIN:Sushi 6	SEQ_UP	10	
DOMAIN:Sushi 7	SEQ_UP	8	
DOMAIN:Sushi 8	SEQ_UP	7	
DOMAIN:Sushi 9	SEQ_UP	6	
DOMAIN:Suv3_N	SEQ_UP	1	
DOMAIN:SUZ	SEQ_UP	4	
DOMAIN:SUZ-C	SEQ_UP	4	
DOMAIN:Swi3	SEQ_UP	1	
DOMAIN:SWIB/MDM2	SEQ_UP	6	
DOMAIN:SWIM-type	SEQ_UP	7	
DOMAIN:SWIRM	SEQ_UP	6	
DOMAIN:SWIRM-assoc_2	SEQ_UP	1	
DOMAIN:SYCP2_ARLD	SEQ_UP	1	
DOMAIN:SYMPK_PTA1_N	SEQ_UP	1	
DOMAIN:Symplekin_C	SEQ_UP	1	
DOMAIN:Synapsin	SEQ_UP	2	
DOMAIN:Synapsin_C	SEQ_UP	3	
DOMAIN:SynN	SEQ_UP	2	
DOMAIN:Syntaxin-5_N	SEQ_UP	1	
DOMAIN:T-box	SEQ_UP	16	
DOMAIN:t-SNARE coiled-coil homology	SEQ_UP	20	
DOMAIN:T-SNARE coiled-coil homology	SEQ_UP	21	
DOMAIN:t-SNARE coiled-coil homology 1	SEQ_UP	3	
DOMAIN:t-SNARE coiled-coil homology 2	SEQ_UP	3	
DOMAIN:TACC_C	SEQ_UP	3	
DOMAIN:TACI-CRD2	SEQ_UP	1	
DOMAIN:TAF	SEQ_UP	15	
DOMAIN:TAF4	SEQ_UP	1	
DOMAIN:TAFH	SEQ_UP	5	
DOMAIN:TAFII55_N	SEQ_UP	3	
DOMAIN:Takusan	SEQ_UP	202	
DOMAIN:Talin_middle	SEQ_UP	1	
DOMAIN:TAN	SEQ_UP	1	
DOMAIN:Tankyrase_bdg_C	SEQ_UP	2	
DOMAIN:Tantalus	SEQ_UP	3	
DOMAIN:TAP-C	SEQ_UP	4	
DOMAIN:Tap-RNA_bind	SEQ_UP	2	
DOMAIN:TAT_ubiq	SEQ_UP	1	
DOMAIN:Tau95	SEQ_UP	1	
DOMAIN:Tau95_N	SEQ_UP	1	
DOMAIN:TAZ-type	SEQ_UP	2	
DOMAIN:TB	SEQ_UP	8	
DOMAIN:TB 1	SEQ_UP	6	
DOMAIN:TB 2	SEQ_UP	6	
DOMAIN:TB 3	SEQ_UP	6	
DOMAIN:TB 4	SEQ_UP	6	
DOMAIN:TB 5	SEQ_UP	2	
DOMAIN:TB 6	SEQ_UP	2	
DOMAIN:TB 7	SEQ_UP	2	
DOMAIN:TB 8	SEQ_UP	2	
DOMAIN:TB 9	SEQ_UP	2	
DOMAIN:TBD	SEQ_UP	2	
DOMAIN:TBPIP	SEQ_UP	1	
DOMAIN:TC1	SEQ_UP	1	
DOMAIN:Tcp10_C	SEQ_UP	5	
DOMAIN:TCTP	SEQ_UP	1	
DOMAIN:TDP43_N	SEQ_UP	1	
DOMAIN:TEA	SEQ_UP	4	
DOMAIN:TED_complement	SEQ_UP	1	
DOMAIN:TEDC1	SEQ_UP	1	
DOMAIN:Telo_bind	SEQ_UP	2	
DOMAIN:Telomerase_RBD	SEQ_UP	1	
DOMAIN:Teneurin N-terminal	SEQ_UP	4	
DOMAIN:TERF2_RBM	SEQ_UP	1	
DOMAIN:Tet_JBP	SEQ_UP	3	
DOMAIN:TF_AP-2	SEQ_UP	3	
DOMAIN:Tfb2_C	SEQ_UP	1	
DOMAIN:TFCD_C	SEQ_UP	1	
DOMAIN:TFG	SEQ_UP	2	
DOMAIN:TFIIA_gamma_C	SEQ_UP	1	
DOMAIN:TFIIA_gamma_N	SEQ_UP	1	
DOMAIN:TFIIB-type	SEQ_UP	3	
DOMAIN:TFIID_20kDa	SEQ_UP	1	
DOMAIN:TFIID_NTD2	SEQ_UP	1	
DOMAIN:TFIIE beta	SEQ_UP	1	
DOMAIN:TFIIF_beta	SEQ_UP	1	
DOMAIN:TFIIF_beta_N	SEQ_UP	1	
DOMAIN:TFIIIC_delta	SEQ_UP	1	
DOMAIN:TFIIIC_sub6	SEQ_UP	1	
DOMAIN:TFIIS central	SEQ_UP	8	
DOMAIN:TFIIS N-terminal	SEQ_UP	9	
DOMAIN:TFIIS-type	SEQ_UP	6	
DOMAIN:TFR_dimer	SEQ_UP	3	
DOMAIN:TGc	SEQ_UP	8	
DOMAIN:TGF_BETA_2	SEQ_UP	23	
DOMAIN:TGFb_propeptide	SEQ_UP	3	
DOMAIN:TGS	SEQ_UP	8	
DOMAIN:TGT	SEQ_UP	2	
DOMAIN:TH1	SEQ_UP	8	
DOMAIN:THAP-type	SEQ_UP	4	
DOMAIN:THAP4_heme-bd	SEQ_UP	1	
DOMAIN:THF_DHG_CYH	SEQ_UP	2	
DOMAIN:THF_DHG_CYH_C	SEQ_UP	2	
DOMAIN:Thg1	SEQ_UP	1	
DOMAIN:Thg1C	SEQ_UP	1	
DOMAIN:ThiF	SEQ_UP	5	
DOMAIN:Thiolase_C	SEQ_UP	6	
DOMAIN:Thiolase_N	SEQ_UP	9	
DOMAIN:Thioredoxin	SEQ_UP	45	
DOMAIN:Thioredoxin 1	SEQ_UP	9	
DOMAIN:Thioredoxin 2	SEQ_UP	9	
DOMAIN:Thioredoxin 3	SEQ_UP	4	
DOMAIN:Thioredoxin 4	SEQ_UP	1	
DOMAIN:Thioredoxin_12	SEQ_UP	2	
DOMAIN:Thioredoxin_13	SEQ_UP	2	
DOMAIN:Thioredoxin_14	SEQ_UP	2	
DOMAIN:Thioredoxin_15	SEQ_UP	2	
DOMAIN:Thioredoxin_16	SEQ_UP	1	
DOMAIN:Thioredoxin-like_fold	SEQ_UP	1	
DOMAIN:Tho2	SEQ_UP	2	
DOMAIN:Thoc2	SEQ_UP	2	
DOMAIN:THOC2_N	SEQ_UP	2	
DOMAIN:Thr_synth_N	SEQ_UP	1	
DOMAIN:THUMP	SEQ_UP	3	
DOMAIN:Thymidylat_synt	SEQ_UP	1	
DOMAIN:Thymidylate_kin	SEQ_UP	1	
DOMAIN:Thyroglobulin type-1	SEQ_UP	16	
DOMAIN:Thyroglobulin type-1 1	SEQ_UP	4	
DOMAIN:Thyroglobulin type-1 10	SEQ_UP	1	
DOMAIN:Thyroglobulin type-1 11	SEQ_UP	1	
DOMAIN:Thyroglobulin type-1 2	SEQ_UP	4	
DOMAIN:Thyroglobulin type-1 3	SEQ_UP	1	
DOMAIN:Thyroglobulin type-1 4	SEQ_UP	1	
DOMAIN:Thyroglobulin type-1 5	SEQ_UP	1	
DOMAIN:Thyroglobulin type-1 6	SEQ_UP	1	
DOMAIN:Thyroglobulin type-1 7	SEQ_UP	1	
DOMAIN:Thyroglobulin type-1 8	SEQ_UP	1	
DOMAIN:Thyroglobulin type-1 9	SEQ_UP	1	
DOMAIN:TIL	SEQ_UP	7	
DOMAIN:TIL 1	SEQ_UP	6	
DOMAIN:TIL 10	SEQ_UP	2	
DOMAIN:TIL 11	SEQ_UP	2	
DOMAIN:TIL 12	SEQ_UP	2	
DOMAIN:TIL 13	SEQ_UP	2	
DOMAIN:TIL 14	SEQ_UP	1	
DOMAIN:TIL 15	SEQ_UP	1	
DOMAIN:TIL 16	SEQ_UP	1	
DOMAIN:TIL 17	SEQ_UP	1	
DOMAIN:TIL 18	SEQ_UP	1	
DOMAIN:TIL 19	SEQ_UP	1	
DOMAIN:TIL 2	SEQ_UP	6	
DOMAIN:TIL 20	SEQ_UP	1	
DOMAIN:TIL 21	SEQ_UP	1	
DOMAIN:TIL 22	SEQ_UP	1	
DOMAIN:TIL 23	SEQ_UP	1	
DOMAIN:TIL 24	SEQ_UP	1	
DOMAIN:TIL 25	SEQ_UP	1	
DOMAIN:TIL 3	SEQ_UP	4	
DOMAIN:TIL 4	SEQ_UP	3	
DOMAIN:TIL 5	SEQ_UP	2	
DOMAIN:TIL 6	SEQ_UP	2	
DOMAIN:TIL 7	SEQ_UP	2	
DOMAIN:TIL 8	SEQ_UP	2	
DOMAIN:TIL 9	SEQ_UP	2	
DOMAIN:Tim44	SEQ_UP	2	
DOMAIN:TIMELESS	SEQ_UP	1	
DOMAIN:TIMELESS_C	SEQ_UP	1	
DOMAIN:TINF2_N	SEQ_UP	1	
DOMAIN:TIP_N	SEQ_UP	1	
DOMAIN:TIP120	SEQ_UP	1	
DOMAIN:TIP49	SEQ_UP	2	
DOMAIN:TIP49_C	SEQ_UP	2	
DOMAIN:TIR	SEQ_UP	28	
DOMAIN:Tis11B_N	SEQ_UP	1	
DOMAIN:TK	SEQ_UP	1	
DOMAIN:TLC	SEQ_UP	17	
DOMAIN:TLDc	SEQ_UP	7	
DOMAIN:TLE_N	SEQ_UP	5	
DOMAIN:TM2	SEQ_UP	2	
DOMAIN:TMC	SEQ_UP	5	
DOMAIN:TMEM131_like	SEQ_UP	2	
DOMAIN:TMEM131_like_N	SEQ_UP	2	
DOMAIN:TMEM132	SEQ_UP	5	
DOMAIN:TMEM132D_C	SEQ_UP	4	
DOMAIN:TMEM132D_N	SEQ_UP	5	
DOMAIN:TMEM135_C_rich	SEQ_UP	1	
DOMAIN:TMEM219	SEQ_UP	2	
DOMAIN:TNase-like	SEQ_UP	1	
DOMAIN:TNase-like 1	SEQ_UP	1	
DOMAIN:TNase-like 2	SEQ_UP	1	
DOMAIN:TNase-like 3	SEQ_UP	1	
DOMAIN:TNase-like 4	SEQ_UP	1	
DOMAIN:TNF_2	SEQ_UP	18	
DOMAIN:TNFR_16_TM	SEQ_UP	1	
DOMAIN:TNFR-Cys	SEQ_UP	21	
DOMAIN:Tnp_22_dsRBD	SEQ_UP	1	
DOMAIN:TNRC6-PABC_bdg	SEQ_UP	2	
DOMAIN:TOG	SEQ_UP	8	
DOMAIN:Tom37	SEQ_UP	3	
DOMAIN:TOP1Ac	SEQ_UP	1	
DOMAIN:TOP4c	SEQ_UP	2	
DOMAIN:TOPEUc	SEQ_UP	2	
DOMAIN:Topoisom_I_N	SEQ_UP	1	
DOMAIN:Toprim	SEQ_UP	4	
DOMAIN:TORC_C	SEQ_UP	1	
DOMAIN:TORC_M	SEQ_UP	1	
DOMAIN:Tower	SEQ_UP	1	
DOMAIN:Tox-GHH	SEQ_UP	1	
DOMAIN:TP_methylase	SEQ_UP	1	
DOMAIN:TPH	SEQ_UP	5	
DOMAIN:TPP_enzyme_C	SEQ_UP	2	
DOMAIN:TPP_enzyme_M	SEQ_UP	2	
DOMAIN:TPP_enzyme_N	SEQ_UP	3	
DOMAIN:TPP1	SEQ_UP	1	
DOMAIN:TPPII	SEQ_UP	1	
DOMAIN:TPR_MLP1_2	SEQ_UP	1	
DOMAIN:TPT	SEQ_UP	7	
DOMAIN:TPX2	SEQ_UP	1	
DOMAIN:TPX2_importin	SEQ_UP	1	
DOMAIN:TR_THY	SEQ_UP	2	
DOMAIN:tr-type G	SEQ_UP	19	
DOMAIN:Tr-type G	SEQ_UP	14	
DOMAIN:TRAF_BIRC3_bd	SEQ_UP	1	
DOMAIN:TRAF-type	SEQ_UP	8	
DOMAIN:TRAM	SEQ_UP	2	
DOMAIN:Transferrin-like	SEQ_UP	4	
DOMAIN:Transferrin-like 1	SEQ_UP	4	
DOMAIN:Transferrin-like 2	SEQ_UP	4	
DOMAIN:Transglut_C	SEQ_UP	1	
DOMAIN:Transglut_N	SEQ_UP	5	
DOMAIN:Transket_pyr	SEQ_UP	4	
DOMAIN:Transketolase_C	SEQ_UP	1	
DOMAIN:Transposase_22	SEQ_UP	2	
DOMAIN:TRASH	SEQ_UP	7	
DOMAIN:TRAUB	SEQ_UP	1	
DOMAIN:TRC8_N	SEQ_UP	1	
DOMAIN:Treacle	SEQ_UP	1	
DOMAIN:Treslin_N	SEQ_UP	1	
DOMAIN:TRF	SEQ_UP	1	
DOMAIN:Trm1 methyltransferase	SEQ_UP	2	
DOMAIN:TRM112	SEQ_UP	2	
DOMAIN:TRM13	SEQ_UP	1	
DOMAIN:TrmE_N	SEQ_UP	1	
DOMAIN:TrmE-type G	SEQ_UP	1	
DOMAIN:tRNA_int_endo	SEQ_UP	1	
DOMAIN:tRNA_SAD	SEQ_UP	1	
DOMAIN:tRNA_synt_1c_R1	SEQ_UP	1	
DOMAIN:tRNA_synt_1c_R2	SEQ_UP	1	
DOMAIN:tRNA-binding	SEQ_UP	2	
DOMAIN:TRNA-binding	SEQ_UP	2	
DOMAIN:tRNA-synt_1	SEQ_UP	6	
DOMAIN:tRNA-synt_1c	SEQ_UP	3	
DOMAIN:tRNA-synt_1c_C	SEQ_UP	1	
DOMAIN:tRNA-synt_1e	SEQ_UP	2	
DOMAIN:tRNA-synt_1g	SEQ_UP	3	
DOMAIN:tRNA-synt_2	SEQ_UP	1	
DOMAIN:tRNA-synt_2d	SEQ_UP	2	
DOMAIN:tRNA-synt_His	SEQ_UP	1	
DOMAIN:TROVE	SEQ_UP	2	
DOMAIN:TRP_2	SEQ_UP	7	
DOMAIN:TRPM_tetra	SEQ_UP	3	
DOMAIN:TruB_N	SEQ_UP	2	
DOMAIN:TRUD	SEQ_UP	2	
DOMAIN:TsaA-like	SEQ_UP	1	
DOMAIN:TsaD	SEQ_UP	2	
DOMAIN:TSNAXIP1_N	SEQ_UP	3	
DOMAIN:TSP C-terminal	SEQ_UP	5	
DOMAIN:TSP type-1	SEQ_UP	18	
DOMAIN:TSP type-1 0	SEQ_UP	1	
DOMAIN:TSP type-1 1	SEQ_UP	37	
DOMAIN:TSP type-1 10	SEQ_UP	4	
DOMAIN:TSP type-1 11	SEQ_UP	4	
DOMAIN:TSP type-1 12	SEQ_UP	4	
DOMAIN:TSP type-1 13	SEQ_UP	4	
DOMAIN:TSP type-1 14	SEQ_UP	4	
DOMAIN:TSP type-1 15	SEQ_UP	4	
DOMAIN:TSP type-1 16	SEQ_UP	3	
DOMAIN:TSP type-1 17	SEQ_UP	3	
DOMAIN:TSP type-1 18	SEQ_UP	3	
DOMAIN:TSP type-1 19	SEQ_UP	2	
DOMAIN:TSP type-1 2	SEQ_UP	37	
DOMAIN:TSP type-1 20	SEQ_UP	1	
DOMAIN:TSP type-1 21	SEQ_UP	1	
DOMAIN:TSP type-1 22	SEQ_UP	1	
DOMAIN:TSP type-1 23	SEQ_UP	1	
DOMAIN:TSP type-1 24	SEQ_UP	1	
DOMAIN:TSP type-1 25	SEQ_UP	1	
DOMAIN:TSP type-1 3	SEQ_UP	29	
DOMAIN:TSP type-1 4	SEQ_UP	25	
DOMAIN:TSP type-1 5	SEQ_UP	22	
DOMAIN:TSP type-1 6	SEQ_UP	17	
DOMAIN:TSP type-1 7	SEQ_UP	11	
DOMAIN:TSP type-1 8	SEQ_UP	8	
DOMAIN:TSP type-1 9	SEQ_UP	5	
DOMAIN:TSP1_spondin	SEQ_UP	4	
DOMAIN:TSPc	SEQ_UP	1	
DOMAIN:TTC5_OB	SEQ_UP	1	
DOMAIN:TTC7_N	SEQ_UP	2	
DOMAIN:TTD	SEQ_UP	1	
DOMAIN:TTL	SEQ_UP	14	
DOMAIN:Tub	SEQ_UP	4	
DOMAIN:Tub_N	SEQ_UP	3	
DOMAIN:Tuberin	SEQ_UP	1	
DOMAIN:Tubulin	SEQ_UP	15	
DOMAIN:Tubulin_3	SEQ_UP	1	
DOMAIN:Tubulin_C	SEQ_UP	14	
DOMAIN:Tudor	SEQ_UP	20	
DOMAIN:Tudor 1	SEQ_UP	11	
DOMAIN:Tudor 2	SEQ_UP	11	
DOMAIN:Tudor 3	SEQ_UP	3	
DOMAIN:Tudor 4	SEQ_UP	3	
DOMAIN:Tudor 5	SEQ_UP	1	
DOMAIN:Tudor 6	SEQ_UP	1	
DOMAIN:Tudor_2	SEQ_UP	2	
DOMAIN:Tudor_FRX1	SEQ_UP	1	
DOMAIN:Tudor-knot	SEQ_UP	6	
DOMAIN:Tudor; atypical	SEQ_UP	1	
DOMAIN:TUG-UBL1	SEQ_UP	1	
DOMAIN:TUTase	SEQ_UP	3	
DOMAIN:TYR_PHOSPHATASE_2	SEQ_UP	69	
DOMAIN:Tyrosinase_Cu-bd	SEQ_UP	3	
DOMAIN:Tyrosine-protein phosphatase	SEQ_UP	77	
DOMAIN:Tyrosine-protein phosphatase 1	SEQ_UP	13	
DOMAIN:Tyrosine-protein phosphatase 2	SEQ_UP	13	
DOMAIN:TYW3	SEQ_UP	1	
DOMAIN:U-box	SEQ_UP	7	
DOMAIN:U1-type	SEQ_UP	8	
DOMAIN:U1snRNP70_N	SEQ_UP	1	
DOMAIN:U3snoRNP10	SEQ_UP	1	
DOMAIN:UAS	SEQ_UP	1	
DOMAIN:UBA	SEQ_UP	64	
DOMAIN:UBA 1	SEQ_UP	7	
DOMAIN:UBA 2	SEQ_UP	7	
DOMAIN:UBA 3	SEQ_UP	1	
DOMAIN:UBA_6	SEQ_UP	1	
DOMAIN:UBA_e1_C	SEQ_UP	3	
DOMAIN:UBA-like	SEQ_UP	4	
DOMAIN:UBA2_C	SEQ_UP	1	
DOMAIN:UBC core	SEQ_UP	45	
DOMAIN:Ubiquitin_3	SEQ_UP	1	
DOMAIN:Ubiquitin_4	SEQ_UP	1	
DOMAIN:Ubiquitin-like	SEQ_UP	67	
DOMAIN:Ubiquitin-like 1	SEQ_UP	6	
DOMAIN:Ubiquitin-like 2	SEQ_UP	6	
DOMAIN:Ubiquitin-like 3	SEQ_UP	2	
DOMAIN:Ubiquitin-like 4	SEQ_UP	2	
DOMAIN:Ubiquitin-like 5	SEQ_UP	1	
DOMAIN:Ubiquitin-like 6	SEQ_UP	1	
DOMAIN:Ubiquitin-like 7	SEQ_UP	1	
DOMAIN:Ubiquitin-like 8	SEQ_UP	1	
DOMAIN:Ubiquitin-like 9	SEQ_UP	1	
DOMAIN:UBN_AB	SEQ_UP	2	
DOMAIN:UBP-type	SEQ_UP	10	
DOMAIN:UBR-type	SEQ_UP	7	
DOMAIN:UBX	SEQ_UP	13	
DOMAIN:UBZ1-type	SEQ_UP	3	
DOMAIN:UBZ2-type	SEQ_UP	1	
DOMAIN:UBZ3-type	SEQ_UP	1	
DOMAIN:UBZ4-type	SEQ_UP	4	
DOMAIN:UCH	SEQ_UP	2	
DOMAIN:UCH_1	SEQ_UP	5	
DOMAIN:UCH_C	SEQ_UP	1	
DOMAIN:UCH_N	SEQ_UP	2	
DOMAIN:UCR_hinge	SEQ_UP	1	
DOMAIN:uDENN	SEQ_UP	20	
DOMAIN:UDENN	SEQ_UP	18	
DOMAIN:uDENN C9ORF72-type	SEQ_UP	1	
DOMAIN:uDENN FLCN/SMCR8-type	SEQ_UP	2	
DOMAIN:uDENN FNIP1/2-type	SEQ_UP	2	
DOMAIN:UDENN FNIP1/2-type	SEQ_UP	2	
DOMAIN:UDG	SEQ_UP	2	
DOMAIN:UDPG_MGDP_dh_C	SEQ_UP	1	
DOMAIN:UDPG_MGDP_dh_N	SEQ_UP	1	
DOMAIN:UDPGT	SEQ_UP	14	
DOMAIN:UEV	SEQ_UP	2	
DOMAIN:Ufd2P_core	SEQ_UP	2	
DOMAIN:UIM	SEQ_UP	13	
DOMAIN:UIM 1	SEQ_UP	15	
DOMAIN:UIM 2	SEQ_UP	15	
DOMAIN:UIM 3	SEQ_UP	6	
DOMAIN:UIM 4	SEQ_UP	2	
DOMAIN:ULD	SEQ_UP	2	
DOMAIN:ULP_PROTEASE	SEQ_UP	10	
DOMAIN:UMA	SEQ_UP	5	
DOMAIN:UmuC	SEQ_UP	4	
DOMAIN:UNC45-central	SEQ_UP	1	
DOMAIN:UNC80	SEQ_UP	1	
DOMAIN:UNC80_N	SEQ_UP	1	
DOMAIN:UPA	SEQ_UP	1	
DOMAIN:UPA_2	SEQ_UP	2	
DOMAIN:UPAR/Ly6	SEQ_UP	50	
DOMAIN:UPAR/Ly6 1	SEQ_UP	3	
DOMAIN:UPAR/Ly6 2	SEQ_UP	3	
DOMAIN:UPAR/Ly6 3	SEQ_UP	2	
DOMAIN:UPAR/Ly6 4	SEQ_UP	1	
DOMAIN:UPF0020	SEQ_UP	1	
DOMAIN:UPF0113_N	SEQ_UP	1	
DOMAIN:Urb2	SEQ_UP	1	
DOMAIN:Urocanase	SEQ_UP	1	
DOMAIN:Urocanase_C	SEQ_UP	1	
DOMAIN:Urocanase_N	SEQ_UP	1	
DOMAIN:Uroporphyrinogen_deCOase	SEQ_UP	1	
DOMAIN:USP	SEQ_UP	59	
DOMAIN:USP8_dimer	SEQ_UP	1	
DOMAIN:Utp12	SEQ_UP	2	
DOMAIN:Utp13	SEQ_UP	1	
DOMAIN:UTP15_C	SEQ_UP	1	
DOMAIN:Utp21	SEQ_UP	1	
DOMAIN:UVR	SEQ_UP	1	
DOMAIN:UvrD_C_2	SEQ_UP	1	
DOMAIN:UvrD-like helicase ATP-binding	SEQ_UP	1	
DOMAIN:UXS1_N	SEQ_UP	1	
DOMAIN:V-ATPase_H_C	SEQ_UP	1	
DOMAIN:V-set_CD47	SEQ_UP	1	
DOMAIN:V-SNARE	SEQ_UP	2	
DOMAIN:v-SNARE coiled-coil homology	SEQ_UP	12	
DOMAIN:V-SNARE coiled-coil homology	SEQ_UP	9	
DOMAIN:Vac14_Fig4_bd	SEQ_UP	1	
DOMAIN:VASP_tetra	SEQ_UP	1	
DOMAIN:VASt	SEQ_UP	3	
DOMAIN:Vault	SEQ_UP	1	
DOMAIN:Vault_2	SEQ_UP	1	
DOMAIN:Vault_3	SEQ_UP	1	
DOMAIN:Vault_4	SEQ_UP	1	
DOMAIN:VEFS-Box	SEQ_UP	1	
DOMAIN:VEGF_C	SEQ_UP	1	
DOMAIN:Vert_HS_TF	SEQ_UP	1	
DOMAIN:Vert_IL3-reg_TF	SEQ_UP	1	
DOMAIN:Vezatin	SEQ_UP	1	
DOMAIN:VGCC_alpha2	SEQ_UP	2	
DOMAIN:VHL	SEQ_UP	1	
DOMAIN:VHL_C	SEQ_UP	1	
DOMAIN:VHS	SEQ_UP	9	
DOMAIN:VIR_N	SEQ_UP	1	
DOMAIN:VIT	SEQ_UP	10	
DOMAIN:Vitellogenin	SEQ_UP	2	
DOMAIN:VKc	SEQ_UP	3	
DOMAIN:VLIG-type G	SEQ_UP	3	
DOMAIN:VOC	SEQ_UP	5	
DOMAIN:VOC 1	SEQ_UP	3	
DOMAIN:VOC 2	SEQ_UP	3	
DOMAIN:VPS10	SEQ_UP	2	
DOMAIN:VPS13	SEQ_UP	2	
DOMAIN:VPS13_C	SEQ_UP	3	
DOMAIN:VPS13_mid_rpt	SEQ_UP	2	
DOMAIN:Vps16_C	SEQ_UP	2	
DOMAIN:Vps16_N	SEQ_UP	1	
DOMAIN:VPS28 C-terminal	SEQ_UP	1	
DOMAIN:VPS28 N-terminal	SEQ_UP	1	
DOMAIN:VPS37 C-terminal	SEQ_UP	4	
DOMAIN:Vps39_1	SEQ_UP	1	
DOMAIN:Vps4_C	SEQ_UP	2	
DOMAIN:Vps5	SEQ_UP	2	
DOMAIN:Vps53_N	SEQ_UP	1	
DOMAIN:Vps54	SEQ_UP	1	
DOMAIN:Vps54_N	SEQ_UP	2	
DOMAIN:VPS9	SEQ_UP	10	
DOMAIN:VRR-NUC	SEQ_UP	1	
DOMAIN:Vta1	SEQ_UP	1	
DOMAIN:VWFA	SEQ_UP	89	
DOMAIN:VWFA 1	SEQ_UP	16	
DOMAIN:VWFA 1; binding site for platelet glycoprotein Ib	SEQ_UP	1	
DOMAIN:VWFA 10	SEQ_UP	1	
DOMAIN:VWFA 2	SEQ_UP	17	
DOMAIN:VWFA 3	SEQ_UP	7	
DOMAIN:VWFA 3; principal binding site for collagens type I and III	SEQ_UP	1	
DOMAIN:VWFA 4	SEQ_UP	4	
DOMAIN:VWFA 5	SEQ_UP	3	
DOMAIN:VWFA 6	SEQ_UP	3	
DOMAIN:VWFA 7	SEQ_UP	3	
DOMAIN:VWFA 8	SEQ_UP	3	
DOMAIN:VWFA 9	SEQ_UP	2	
DOMAIN:VWFC	SEQ_UP	32	
DOMAIN:VWFC 1	SEQ_UP	17	
DOMAIN:VWFC 10	SEQ_UP	2	
DOMAIN:VWFC 11	SEQ_UP	2	
DOMAIN:VWFC 12	SEQ_UP	2	
DOMAIN:VWFC 13	SEQ_UP	2	
DOMAIN:VWFC 14	SEQ_UP	2	
DOMAIN:VWFC 15	SEQ_UP	2	
DOMAIN:VWFC 16	SEQ_UP	2	
DOMAIN:VWFC 17	SEQ_UP	2	
DOMAIN:VWFC 18	SEQ_UP	2	
DOMAIN:VWFC 19	SEQ_UP	1	
DOMAIN:VWFC 2	SEQ_UP	17	
DOMAIN:VWFC 20	SEQ_UP	1	
DOMAIN:VWFC 21	SEQ_UP	1	
DOMAIN:VWFC 22	SEQ_UP	1	
DOMAIN:VWFC 23	SEQ_UP	1	
DOMAIN:VWFC 24	SEQ_UP	1	
DOMAIN:VWFC 25	SEQ_UP	1	
DOMAIN:VWFC 3	SEQ_UP	12	
DOMAIN:VWFC 4	SEQ_UP	7	
DOMAIN:VWFC 5	SEQ_UP	6	
DOMAIN:VWFC 6	SEQ_UP	5	
DOMAIN:VWFC 7	SEQ_UP	2	
DOMAIN:VWFC 8	SEQ_UP	2	
DOMAIN:VWFC 9	SEQ_UP	2	
DOMAIN:VWFD	SEQ_UP	17	
DOMAIN:VWFD 1	SEQ_UP	9	
DOMAIN:VWFD 2	SEQ_UP	9	
DOMAIN:VWFD 3	SEQ_UP	9	
DOMAIN:VWFD 4	SEQ_UP	6	
DOMAIN:W2	SEQ_UP	7	
DOMAIN:WAC	SEQ_UP	2	
DOMAIN:WAP	SEQ_UP	21	
DOMAIN:WAP 1	SEQ_UP	4	
DOMAIN:WAP 1; atypical	SEQ_UP	1	
DOMAIN:WAP 2	SEQ_UP	5	
DOMAIN:WAP 3	SEQ_UP	1	
DOMAIN:WAP; atypical	SEQ_UP	1	
DOMAIN:WAPL	SEQ_UP	1	
DOMAIN:WASH_WAHD	SEQ_UP	1	
DOMAIN:WASH-7_N	SEQ_UP	1	
DOMAIN:WBS_methylT	SEQ_UP	1	
DOMAIN:WC-rich	SEQ_UP	1	
DOMAIN:WCOB	SEQ_UP	1	
DOMAIN:WD40_alt	SEQ_UP	1	
DOMAIN:WEF-hand	SEQ_UP	1	
DOMAIN:WGR	SEQ_UP	3	
DOMAIN:WH1	SEQ_UP	13	
DOMAIN:WH2	SEQ_UP	22	
DOMAIN:WH2 1	SEQ_UP	5	
DOMAIN:WH2 2	SEQ_UP	5	
DOMAIN:WH2 3	SEQ_UP	2	
DOMAIN:WHAMM-JMY_N	SEQ_UP	2	
DOMAIN:Wheel	SEQ_UP	1	
DOMAIN:WHEP-TRS	SEQ_UP	6	
DOMAIN:WHEP-TRS 1	SEQ_UP	1	
DOMAIN:WHEP-TRS 2	SEQ_UP	1	
DOMAIN:WHEP-TRS 3	SEQ_UP	1	
DOMAIN:WHIM1	SEQ_UP	1	
DOMAIN:WIF	SEQ_UP	2	
DOMAIN:Winged helix Storkhead-box1	SEQ_UP	2	
DOMAIN:WRNPLPNID	SEQ_UP	3	
DOMAIN:WSC	SEQ_UP	3	
DOMAIN:WSC 1	SEQ_UP	2	
DOMAIN:WSC 2	SEQ_UP	2	
DOMAIN:WW	SEQ_UP	46	
DOMAIN:WW 1	SEQ_UP	28	
DOMAIN:WW 2	SEQ_UP	28	
DOMAIN:WW 3	SEQ_UP	8	
DOMAIN:WW 4	SEQ_UP	4	
DOMAIN:WWE	SEQ_UP	11	
DOMAIN:WWE 1	SEQ_UP	4	
DOMAIN:WWE 2	SEQ_UP	4	
DOMAIN:XAF1_C	SEQ_UP	1	
DOMAIN:XLF	SEQ_UP	1	
DOMAIN:XPA_C	SEQ_UP	1	
DOMAIN:XPG_I_2	SEQ_UP	1	
DOMAIN:XPGI	SEQ_UP	4	
DOMAIN:XPGN	SEQ_UP	4	
DOMAIN:Xpo1	SEQ_UP	3	
DOMAIN:XRCC1_N	SEQ_UP	4	
DOMAIN:XRN_M	SEQ_UP	1	
DOMAIN:XRN_N	SEQ_UP	1	
DOMAIN:XRN1_D1	SEQ_UP	1	
DOMAIN:XRN1_D2_D3	SEQ_UP	1	
DOMAIN:XRN2-binding (XTBD)	SEQ_UP	3	
DOMAIN:xRRM	SEQ_UP	2	
DOMAIN:XRRM	SEQ_UP	2	
DOMAIN:Xylo_C	SEQ_UP	2	
DOMAIN:Yae1_N	SEQ_UP	2	
DOMAIN:YBD	SEQ_UP	2	
DOMAIN:YccV-like	SEQ_UP	1	
DOMAIN:YDG	SEQ_UP	2	
DOMAIN:YEATS	SEQ_UP	3	
DOMAIN:Yip1	SEQ_UP	3	
DOMAIN:Yippee	SEQ_UP	5	
DOMAIN:YjeF C-terminal	SEQ_UP	1	
DOMAIN:YjeF N-terminal	SEQ_UP	3	
DOMAIN:YL1_C	SEQ_UP	1	
DOMAIN:YrdC-like	SEQ_UP	1	
DOMAIN:YTH	SEQ_UP	5	
DOMAIN:Z-binding	SEQ_UP	2	
DOMAIN:Z-binding 1	SEQ_UP	2	
DOMAIN:Z-binding 2	SEQ_UP	2	
DOMAIN:ZAD	SEQ_UP	1	
DOMAIN:ZBR-type	SEQ_UP	1	
DOMAIN:zf_PR_Knuckle	SEQ_UP	1	
DOMAIN:Zf_RING	SEQ_UP	1	
DOMAIN:zf_ZIC	SEQ_UP	1	
DOMAIN:zf-3CxxC	SEQ_UP	5	
DOMAIN:zf-ACC	SEQ_UP	1	
DOMAIN:zf-ANAPC11	SEQ_UP	1	
DOMAIN:zf-C2H2_12	SEQ_UP	3	
DOMAIN:zf-C2H2_2	SEQ_UP	1	
DOMAIN:zf-C2H2_3	SEQ_UP	1	
DOMAIN:zf-C2H2_7	SEQ_UP	1	
DOMAIN:zf-C2HC5	SEQ_UP	1	
DOMAIN:zf-C3H1	SEQ_UP	1	
DOMAIN:zf-C3Hc3H	SEQ_UP	2	
DOMAIN:zf-C4pol	SEQ_UP	2	
DOMAIN:zf-C6H2	SEQ_UP	1	
DOMAIN:zf-CCCH_3	SEQ_UP	2	
DOMAIN:zf-CCHC_6	SEQ_UP	2	
DOMAIN:zf-CHCC	SEQ_UP	1	
DOMAIN:zf-DNA_Pol	SEQ_UP	1	
DOMAIN:zf-LYAR	SEQ_UP	1	
DOMAIN:zf-NADH-PPase	SEQ_UP	1	
DOMAIN:zf-NOSIP	SEQ_UP	1	
DOMAIN:zf-primase	SEQ_UP	1	
DOMAIN:zf-rbx1	SEQ_UP	1	
DOMAIN:zf-RING_12	SEQ_UP	1	
DOMAIN:zf-RING_UBOX	SEQ_UP	3	
DOMAIN:zf-SCNM1	SEQ_UP	1	
DOMAIN:zf-Sec23_Sec24	SEQ_UP	6	
DOMAIN:zf-tcix	SEQ_UP	1	
DOMAIN:zf-TFIIIC	SEQ_UP	1	
DOMAIN:zf-Tim10_DDP	SEQ_UP	4	
DOMAIN:zf-TRM13_CCCH	SEQ_UP	1	
DOMAIN:zf-U1	SEQ_UP	1	
DOMAIN:Zfx_Zfy_act	SEQ_UP	2	
DOMAIN:zinc_ribbon_10	SEQ_UP	1	
DOMAIN:zinc_ribbon_16	SEQ_UP	1	
DOMAIN:zinc_ribbon_2	SEQ_UP	1	
DOMAIN:zinc_ribbon_9	SEQ_UP	1	
DOMAIN:Zinc-hook	SEQ_UP	1	
DOMAIN:ZIP4_domain	SEQ_UP	1	
DOMAIN:Zn_dep_PLPC	SEQ_UP	1	
DOMAIN:ZnF_CDGSH	SEQ_UP	1	
DOMAIN:ZnMc	SEQ_UP	14	
DOMAIN:ZNRF_3_ecto	SEQ_UP	1	
DOMAIN:ZP	SEQ_UP	17	
DOMAIN:Zpr1	SEQ_UP	1	
DOMAIN:ZU5	SEQ_UP	12	
DOMAIN:ZU5 1	SEQ_UP	4	
DOMAIN:ZU5 2	SEQ_UP	4	
DOMAIN:ZZ-type	SEQ_UP	15	
INTRAMEM:Discontinuously helical	SEQ_UP	18	
INTRAMEM:Helical	SEQ_UP	41	
INTRAMEM:Helical; Name=Helix B	SEQ_UP	1	
INTRAMEM:Helical; Name=Helix E	SEQ_UP	1	
INTRAMEM:Helical; Name=HP1	SEQ_UP	1	
INTRAMEM:Helical; Name=HP2	SEQ_UP	1	
INTRAMEM:Helical; Name=Pore helix	SEQ_UP	14	
INTRAMEM:Helical; Name=Pore helix 1	SEQ_UP	2	
INTRAMEM:Helical; Name=Pore helix 2	SEQ_UP	2	
INTRAMEM:Helical; Pore-forming	SEQ_UP	10	
INTRAMEM:Helical; Pore-forming; Name=H5	SEQ_UP	15	
INTRAMEM:Name=A/M1	SEQ_UP	2	
INTRAMEM:Name=B/M2	SEQ_UP	2	
INTRAMEM:Name=H10	SEQ_UP	1	
INTRAMEM:Name=L	SEQ_UP	2	
INTRAMEM:Note=Loop between two helices	SEQ_UP	6	
INTRAMEM:Note=Mediates targeting to membranes	SEQ_UP	2	
INTRAMEM:Note=Mitochondrial inner membrane	SEQ_UP	1	
INTRAMEM:Pore-forming	SEQ_UP	47	
INTRAMEM:Pore-forming; Name=P region	SEQ_UP	2	
INTRAMEM:Pore-forming; Name=Pore-forming 1	SEQ_UP	6	
INTRAMEM:Pore-forming; Name=Pore-forming 2	SEQ_UP	6	
INTRAMEM:Pore-forming; Name=Segment H5	SEQ_UP	23	
LIPID:Cholesterol glycine ester	SEQ_UP	3	
LIPID:GPI-anchor amidated alanine	SEQ_UP	11	
LIPID:GPI-anchor amidated asparagine	SEQ_UP	18	
LIPID:GPI-anchor amidated asparagine; alternate	SEQ_UP	2	
LIPID:GPI-anchor amidated aspartate	SEQ_UP	6	
LIPID:GPI-anchor amidated cysteine	SEQ_UP	3	
LIPID:GPI-anchor amidated cysteine; alternate	SEQ_UP	1	
LIPID:GPI-anchor amidated glycine	SEQ_UP	25	
LIPID:GPI-anchor amidated serine	SEQ_UP	68	
LIPID:GPI-anchor amidated threonine	SEQ_UP	1	
LIPID:N-myristoyl glycine	SEQ_UP	176	
LIPID:N-myristoyl glycine; alternate	SEQ_UP	1	
LIPID:N-palmitoyl cysteine	SEQ_UP	3	
LIPID:N-palmitoyl glycine	SEQ_UP	2	
LIPID:N6-myristoyl lysine	SEQ_UP	2	
LIPID:N6-palmitoyl lysine	SEQ_UP	2	
LIPID:O-decanoyl serine; alternate	SEQ_UP	1	
LIPID:O-hexanoyl serine; alternate	SEQ_UP	1	
LIPID:O-octanoyl serine; alternate	SEQ_UP	1	
LIPID:O-palmitoleoyl serine	SEQ_UP	2	
LIPID:O-palmitoleoyl serine; by PORCN	SEQ_UP	17	
LIPID:O-palmitoyl serine	SEQ_UP	1	
LIPID:Omega-hydroxyceramide glutamate ester	SEQ_UP	1	
LIPID:Phosphatidylethanolamine amidated glycine	SEQ_UP	2	
LIPID:Phosphatidylethanolamine amidated glycine; alternate	SEQ_UP	5	
LIPID:Phosphatidylserine amidated glycine; alternate	SEQ_UP	5	
LIPID:S-(15-deoxy-Delta12,14-prostaglandin J2-9-yl)cysteine	SEQ_UP	1	
LIPID:S-(15-deoxy-Delta12,14-prostaglandin J2-9-yl)cysteine; alternate	SEQ_UP	2	
LIPID:S-farnesyl cysteine	SEQ_UP	55	
LIPID:S-farnesyl cysteine; in plasma membrane form	SEQ_UP	1	
LIPID:S-geranylgeranyl cysteine	SEQ_UP	104	
LIPID:S-geranylgeranyl cysteine; in endosomal form	SEQ_UP	1	
LIPID:S-geranylgeranyl cysteine; partial	SEQ_UP	1	
LIPID:S-palmitoyl cysteine	SEQ_UP	271	
LIPID:S-palmitoyl cysteine; alternate	SEQ_UP	4	
LIPID:S-palmitoyl cysteine; by DHHC3	SEQ_UP	1	
LIPID:S-palmitoyl cysteine; by DHHC8	SEQ_UP	1	
LIPID:S-palmitoyl cysteine; by ZDHHC2	SEQ_UP	1	
LIPID:S-palmitoyl cysteine; by ZDHHC2, ZDHHC3 and ZDHHC7	SEQ_UP	2	
LIPID:S-palmitoyl cysteine; by ZDHHC5	SEQ_UP	2	
LIPID:S-palmitoyl cysteine; in membrane form	SEQ_UP	2	
LIPID:S-stearoyl cysteine; alternate	SEQ_UP	1	
METAL:Calcium	SEQ_UP	191	
METAL:Calcium 1	SEQ_UP	246	
METAL:Calcium 1; catalytic	SEQ_UP	4	
METAL:Calcium 1; low affinity	SEQ_UP	11	
METAL:Calcium 1; possibly ancestral	SEQ_UP	2	
METAL:Calcium 1; shared with neighboring subunits	SEQ_UP	1	
METAL:Calcium 1; via 4-carboxyglutamate	SEQ_UP	1	
METAL:Calcium 1; via amide nitrogen	SEQ_UP	2	
METAL:Calcium 1; via carbonyl oxygen	SEQ_UP	83	
METAL:Calcium 1; via carbonyl oxygen; low affinity	SEQ_UP	2	
METAL:Calcium 1; via carbonyl oxygen; structural	SEQ_UP	1	
METAL:Calcium 10	SEQ_UP	7	
METAL:Calcium 10; via carbonyl oxygen	SEQ_UP	3	
METAL:Calcium 11	SEQ_UP	6	
METAL:Calcium 11; via carbonyl oxygen	SEQ_UP	5	
METAL:Calcium 12	SEQ_UP	5	
METAL:Calcium 12; via carbonyl oxygen	SEQ_UP	4	
METAL:Calcium 13	SEQ_UP	4	
METAL:Calcium 13; via carbonyl oxygen	SEQ_UP	3	
METAL:Calcium 14	SEQ_UP	3	
METAL:Calcium 14; via carbonyl oxygen	SEQ_UP	2	
METAL:Calcium 15	SEQ_UP	1	
METAL:Calcium 15; via carbonyl oxygen	SEQ_UP	1	
METAL:Calcium 2	SEQ_UP	252	
METAL:Calcium 2; catalytic	SEQ_UP	2	
METAL:Calcium 2; high affinity	SEQ_UP	10	
METAL:Calcium 2; low affinity	SEQ_UP	1	
METAL:Calcium 2; possibly ancestral	SEQ_UP	2	
METAL:Calcium 2; shared with neighboring subunits	SEQ_UP	2	
METAL:Calcium 2; structural	SEQ_UP	1	
METAL:Calcium 2; via 4-carboxyglutamate	SEQ_UP	1	
METAL:Calcium 2; via carbonyl oxygen	SEQ_UP	78	
METAL:Calcium 2; via carbonyl oxygen; high affinity	SEQ_UP	1	
METAL:Calcium 2; via carbonyl oxygen; low affinity	SEQ_UP	1	
METAL:Calcium 2; via carbonyl oxygen; structural	SEQ_UP	1	
METAL:Calcium 3	SEQ_UP	130	
METAL:Calcium 3; catalytic	SEQ_UP	2	
METAL:Calcium 3; via 4-carboxyglutamate	SEQ_UP	1	
METAL:Calcium 3; via carbonyl oxygen	SEQ_UP	56	
METAL:Calcium 4	SEQ_UP	68	
METAL:Calcium 4; via 4-carboxyglutamate	SEQ_UP	1	
METAL:Calcium 4; via carbonyl oxygen	SEQ_UP	22	
METAL:Calcium 5	SEQ_UP	35	
METAL:Calcium 5; via 4-carboxyglutamate	SEQ_UP	1	
METAL:Calcium 5; via carbonyl oxygen	SEQ_UP	15	
METAL:Calcium 6	SEQ_UP	24	
METAL:Calcium 6; via 4-carboxyglutamate	SEQ_UP	1	
METAL:Calcium 6; via carbonyl oxygen	SEQ_UP	9	
METAL:Calcium 7	SEQ_UP	10	
METAL:Calcium 7; via carbonyl oxygen	SEQ_UP	7	
METAL:Calcium 8	SEQ_UP	9	
METAL:Calcium 8; via carbonyl oxygen	SEQ_UP	7	
METAL:Calcium 9	SEQ_UP	7	
METAL:Calcium 9; via carbonyl oxygen	SEQ_UP	4	
METAL:Calcium; high affinity	SEQ_UP	2	
METAL:Calcium; low affinity	SEQ_UP	1	
METAL:Calcium; shared with neighboring subunit	SEQ_UP	1	
METAL:Calcium; shared with neighboring subunit in homooligomer	SEQ_UP	1	
METAL:Calcium; shared with neighboring subunits	SEQ_UP	4	
METAL:Calcium; structural	SEQ_UP	1	
METAL:Calcium; via 3-oxoalanine	SEQ_UP	12	
METAL:Calcium; via carbonyl oxygen	SEQ_UP	92	
METAL:Calcium; via carbonyl oxygen; structural	SEQ_UP	1	
METAL:Calcium; via carboxylate	SEQ_UP	1	
METAL:Cobalt	SEQ_UP	2	
METAL:Cobalt (adenosylcob(III)alamin axial ligand)	SEQ_UP	1	
METAL:Cobalt (Cob(II)alamin axial ligand)	SEQ_UP	1	
METAL:Cobalt (methylcob(III)alamin axial ligand)	SEQ_UP	1	
METAL:Cobalt; catalytic	SEQ_UP	1	
METAL:Cobalt; via tele nitrogen	SEQ_UP	1	
METAL:Copper	SEQ_UP	16	
METAL:Copper 1	SEQ_UP	1	
METAL:Copper 1; type 2	SEQ_UP	3	
METAL:Copper 1; via pros nitrogen; catalytic	SEQ_UP	1	
METAL:Copper 2	SEQ_UP	2	
METAL:Copper 2; type 3	SEQ_UP	3	
METAL:Copper 2; via tele nitrogen; catalytic	SEQ_UP	1	
METAL:Copper 3; type 3	SEQ_UP	3	
METAL:Copper 4; type 1	SEQ_UP	3	
METAL:Copper 5; type 1	SEQ_UP	3	
METAL:Copper 6; type 1	SEQ_UP	3	
METAL:Copper A	SEQ_UP	4	
METAL:Copper A1	SEQ_UP	1	
METAL:Copper A2	SEQ_UP	1	
METAL:Copper A2; via carbonyl oxygen	SEQ_UP	1	
METAL:Copper B	SEQ_UP	4	
METAL:Copper B; via pros nitrogen	SEQ_UP	1	
METAL:Copper B; via tele nitrogen	SEQ_UP	1	
METAL:Copper; catalytic	SEQ_UP	2	
METAL:Copper; via amino nitrogen	SEQ_UP	1	
METAL:Copper; via pros nitrogen	SEQ_UP	3	
METAL:Copper; via tele nitrogen	SEQ_UP	3	
METAL:Copper(2+); catalytic	SEQ_UP	1	
METAL:Cu(+) 1	SEQ_UP	2	
METAL:Cu(+) 2	SEQ_UP	2	
METAL:Cu(+) 3	SEQ_UP	2	
METAL:Cu(+) 4	SEQ_UP	2	
METAL:Cu(+) 5	SEQ_UP	2	
METAL:Cu(+) 6	SEQ_UP	2	
METAL:Cu(2+) 1	SEQ_UP	2	
METAL:Cu(2+) 1; via amide nitrogen	SEQ_UP	1	
METAL:Cu(2+) 1; via amide nitrogen and carbonyl oxygen	SEQ_UP	1	
METAL:Cu(2+) 2	SEQ_UP	2	
METAL:Cu(2+) 2; via amide nitrogen	SEQ_UP	1	
METAL:Cu(2+) 2; via amide nitrogen and carbonyl oxygen	SEQ_UP	1	
METAL:Cu(2+) 3	SEQ_UP	1	
METAL:Cu(2+) 3; via amide nitrogen	SEQ_UP	1	
METAL:Cu(2+) 3; via amide nitrogen and carbonyl oxygen	SEQ_UP	1	
METAL:Cu(2+) 4	SEQ_UP	1	
METAL:Cu(2+) 4; via amide nitrogen	SEQ_UP	1	
METAL:Cu(2+) 4; via amide nitrogen and carbonyl oxygen	SEQ_UP	1	
METAL:Divalent metal cation	SEQ_UP	43	
METAL:Divalent metal cation 1	SEQ_UP	30	
METAL:Divalent metal cation 1; catalytic	SEQ_UP	3	
METAL:Divalent metal cation 1; in cluster B	SEQ_UP	4	
METAL:Divalent metal cation 1; via tele nitrogen	SEQ_UP	4	
METAL:Divalent metal cation 2	SEQ_UP	27	
METAL:Divalent metal cation 2; catalytic	SEQ_UP	6	
METAL:Divalent metal cation 2; catalytic; via tele nitrogen	SEQ_UP	3	
METAL:Divalent metal cation 2; in cluster B	SEQ_UP	4	
METAL:Divalent metal cation 2; via carbonyl oxygen	SEQ_UP	1	
METAL:Divalent metal cation 2; via pros nitrogen	SEQ_UP	1	
METAL:Divalent metal cation 2; via tele nitrogen	SEQ_UP	1	
METAL:Divalent metal cation 3; in cluster B	SEQ_UP	4	
METAL:Divalent metal cation 4; in cluster A	SEQ_UP	4	
METAL:Divalent metal cation 5; in cluster A	SEQ_UP	4	
METAL:Divalent metal cation 6; in cluster A	SEQ_UP	4	
METAL:Divalent metal cation 7; in cluster A	SEQ_UP	4	
METAL:Divalent metal cation; catalytic	SEQ_UP	5	
METAL:Divalent metal cation; via carbamate group	SEQ_UP	1	
METAL:Divalent metal cation; via pros nitrogen	SEQ_UP	1	
METAL:Divalent metal cation; via tele nitrogen	SEQ_UP	2	
METAL:Fe(2+); for iron-dependent acireductone dioxygenase activity	SEQ_UP	1	
METAL:Fe(3+)	SEQ_UP	1	
METAL:Fe(3+) 1	SEQ_UP	3	
METAL:Fe(3+) 2	SEQ_UP	3	
METAL:Fe(3+); substrate; via tele nitrogen	SEQ_UP	1	
METAL:Iron	SEQ_UP	42	
METAL:Iron (heme 1 axial ligand)	SEQ_UP	1	
METAL:Iron (heme 2 axial ligand)	SEQ_UP	1	
METAL:Iron (heme axial ligand)	SEQ_UP	92	
METAL:Iron (heme axial ligand); shared with second transmembrane subunit	SEQ_UP	1	
METAL:Iron (heme b axial ligand)	SEQ_UP	8	
METAL:Iron (heme B axial ligand)	SEQ_UP	1	
METAL:Iron (heme b axial ligand); shared with SDHC	SEQ_UP	1	
METAL:Iron (heme b axial ligand); shared with SDHD	SEQ_UP	1	
METAL:Iron (heme b distal ligand)	SEQ_UP	10	
METAL:Iron (heme b proximal ligand)	SEQ_UP	10	
METAL:Iron (heme c axial ligand)	SEQ_UP	3	
METAL:Iron (heme c axial ligand); via tele nitrogen	SEQ_UP	1	
METAL:Iron (heme distal ligand)	SEQ_UP	14	
METAL:Iron (heme proximal ligand)	SEQ_UP	17	
METAL:Iron 1	SEQ_UP	14	
METAL:Iron 1 (heme b 1 axial ligand); via tele nitrogen	SEQ_UP	6	
METAL:Iron 1 (heme b562 axial ligand)	SEQ_UP	1	
METAL:Iron 1 (low-spin heme A axial ligand); via tele nitrogen	SEQ_UP	1	
METAL:Iron 2	SEQ_UP	14	
METAL:Iron 2 (heme b 2 axial ligand); via tele nitrogen	SEQ_UP	6	
METAL:Iron 2 (heme b566 axial ligand)	SEQ_UP	1	
METAL:Iron 2 (high-spin heme A3 axial ligand); via tele nitrogen	SEQ_UP	1	
METAL:Iron-sulfur (2Fe-2S)	SEQ_UP	13	
METAL:Iron-sulfur (2Fe-2S) 1	SEQ_UP	6	
METAL:Iron-sulfur (2Fe-2S) 1; via pros nitrogen	SEQ_UP	1	
METAL:Iron-sulfur (2Fe-2S) 2	SEQ_UP	6	
METAL:Iron-sulfur (2Fe-2S) 2; via pros nitrogen	SEQ_UP	1	
METAL:Iron-sulfur (2Fe-2S); shared with dimeric partner	SEQ_UP	3	
METAL:Iron-sulfur (2Fe-2S); shared with dimeric partner; in inactive form	SEQ_UP	1	
METAL:Iron-sulfur (2Fe-2S); via persulfide group; shared with ISCU	SEQ_UP	1	
METAL:Iron-sulfur (2Fe-2S); via pros nitrogen	SEQ_UP	6	
METAL:Iron-sulfur (3Fe-4S)	SEQ_UP	1	
METAL:Iron-sulfur (4Fe-4S-S-AdoMet)	SEQ_UP	4	
METAL:Iron-sulfur (4Fe-4S)	SEQ_UP	22	
METAL:Iron-sulfur (4Fe-4S) 1	SEQ_UP	8	
METAL:Iron-sulfur (4Fe-4S) 1; 4Fe-4S-S-AdoMet	SEQ_UP	1	
METAL:Iron-sulfur (4Fe-4S) 1; via tele nitrogen	SEQ_UP	1	
METAL:Iron-sulfur (4Fe-4S) 2	SEQ_UP	4	
METAL:Iron-sulfur (4Fe-4S) 2; 4Fe-4S-S-AdoMet	SEQ_UP	3	
METAL:Iron-sulfur (4Fe-4S) 2; 4Fe-4S-substrate	SEQ_UP	1	
METAL:Iron-sulfur (4Fe-4S) 2; shared with heterodimeric partner	SEQ_UP	1	
METAL:Iron-sulfur (4Fe-4S) 3	SEQ_UP	1	
METAL:Iron-sulfur (4Fe-4S) 4	SEQ_UP	1	
METAL:Iron-sulfur (4Fe-4S); shared with dimeric partner	SEQ_UP	2	
METAL:Iron; catalytic	SEQ_UP	51	
METAL:Iron; via carbonyl oxygen; catalytic	SEQ_UP	1	
METAL:Iron; via carboxylate; catalytic	SEQ_UP	6	
METAL:Iron; via tele nitrogen	SEQ_UP	7	
METAL:Iron; via tele nitrogen; catalytic	SEQ_UP	4	
METAL:Li(+); inhibitor	SEQ_UP	1	
METAL:Magnesium	SEQ_UP	198	
METAL:Magnesium 1	SEQ_UP	75	
METAL:Magnesium 1; catalytic	SEQ_UP	19	
METAL:Magnesium 1; via 4-carboxyglutamate	SEQ_UP	1	
METAL:Magnesium 1; via carbonyl oxygen	SEQ_UP	16	
METAL:Magnesium 1; via carbonyl oxygen; catalytic	SEQ_UP	2	
METAL:Magnesium 2	SEQ_UP	76	
METAL:Magnesium 2; catalytic	SEQ_UP	15	
METAL:Magnesium 2; shared with RPB2	SEQ_UP	1	
METAL:Magnesium 2; via 4-carboxyglutamate	SEQ_UP	1	
METAL:Magnesium 2; via carbonyl oxygen	SEQ_UP	5	
METAL:Magnesium 2; via carbonyl oxygen; catalytic	SEQ_UP	9	
METAL:Magnesium 2; via pros nitrogen	SEQ_UP	1	
METAL:Magnesium 3	SEQ_UP	9	
METAL:Magnesium 3; via 4-carboxyglutamate	SEQ_UP	1	
METAL:Magnesium 4	SEQ_UP	1	
METAL:Magnesium or manganese	SEQ_UP	2	
METAL:Magnesium; catalytic	SEQ_UP	22	
METAL:Magnesium; shared with MT-CO1	SEQ_UP	1	
METAL:Magnesium; shared with MT-CO2	SEQ_UP	1	
METAL:Magnesium; shared with RPB1	SEQ_UP	1	
METAL:Magnesium; via carbonyl oxygen	SEQ_UP	39	
METAL:Magnesium; via phosphate group	SEQ_UP	4	
METAL:Magnesium; via pros nitrogen	SEQ_UP	1	
METAL:Magnesium; via tele nitrogen	SEQ_UP	1	
METAL:Manganese	SEQ_UP	61	
METAL:Manganese 1	SEQ_UP	48	
METAL:Manganese 1; via carbonyl oxygen	SEQ_UP	16	
METAL:Manganese 1; via pros nitrogen	SEQ_UP	1	
METAL:Manganese 1; via tele nitrogen	SEQ_UP	3	
METAL:Manganese 2	SEQ_UP	48	
METAL:Manganese 2; via pros nitrogen	SEQ_UP	1	
METAL:Manganese 2; via tele nitrogen	SEQ_UP	4	
METAL:Manganese 3	SEQ_UP	1	
METAL:Manganese 4	SEQ_UP	1	
METAL:Manganese; catalytic	SEQ_UP	7	
METAL:Manganese; catalytic; for phosphatase activity	SEQ_UP	1	
METAL:Manganese; shared with catalytic subunit	SEQ_UP	2	
METAL:Manganese; shared with neighboring subunit	SEQ_UP	1	
METAL:Manganese; via carbamate group	SEQ_UP	1	
METAL:Manganese; via tele nitrogen	SEQ_UP	9	
METAL:Molybdenum (Mo-molybdopterin metal ligand)	SEQ_UP	6	
METAL:Molybdenum (Mo-molybdopterin metal ligand); via amide nitrogen	SEQ_UP	4	
METAL:Molybdenum (Mo-molybdopterin metal ligand); via carbonyl oxygen	SEQ_UP	4	
METAL:Ni(2+); for nickel-dependent acireductone dioxygenase activity	SEQ_UP	1	
METAL:Potassium	SEQ_UP	11	
METAL:Potassium; via carbonyl oxygen	SEQ_UP	9	
METAL:Potassium; via carbonyl oxygen; shared with tetrameric partner	SEQ_UP	2	
METAL:Sodium	SEQ_UP	3	
METAL:Sodium 1	SEQ_UP	10	
METAL:Sodium 1; via carbonyl oxygen	SEQ_UP	10	
METAL:Sodium 2	SEQ_UP	5	
METAL:Sodium 2; via carbonyl oxygen	SEQ_UP	10	
METAL:Sodium; via carbonyl oxygen	SEQ_UP	4	
METAL:Zinc	SEQ_UP	358	
METAL:Zinc 1	SEQ_UP	277	
METAL:Zinc 1; binds zinc A in the binuclear zinc-binding site	SEQ_UP	2	
METAL:Zinc 1; catalytic	SEQ_UP	26	
METAL:Zinc 1; in inhibited form	SEQ_UP	3	
METAL:Zinc 1; shared with dimeric partner	SEQ_UP	1	
METAL:Zinc 1; structural	SEQ_UP	3	
METAL:Zinc 1; via amide nitrogen and carbonyl oxygen	SEQ_UP	1	
METAL:Zinc 1; via carbamate group	SEQ_UP	2	
METAL:Zinc 1; via pros nitrogen	SEQ_UP	23	
METAL:Zinc 1; via pros nitrogen; catalytic	SEQ_UP	2	
METAL:Zinc 1; via tele nitrogen	SEQ_UP	16	
METAL:Zinc 1; via tele nitrogen; catalytic	SEQ_UP	7	
METAL:Zinc 1; via tele nitrogen; structural	SEQ_UP	1	
METAL:Zinc 2	SEQ_UP	279	
METAL:Zinc 2; binds zinc B in the binuclear zinc-binding site	SEQ_UP	2	
METAL:Zinc 2; catalytic	SEQ_UP	26	
METAL:Zinc 2; in inhibited form	SEQ_UP	9	
METAL:Zinc 2; shared with dimeric partner	SEQ_UP	1	
METAL:Zinc 2; structural	SEQ_UP	1	
METAL:Zinc 2; via carbamate group	SEQ_UP	1	
METAL:Zinc 2; via carbonyl oxygen; catalytic	SEQ_UP	1	
METAL:Zinc 2; via pros nitrogen	SEQ_UP	20	
METAL:Zinc 2; via tele nitrogen	SEQ_UP	24	
METAL:Zinc 2; via tele nitrogen; catalytic	SEQ_UP	6	
METAL:Zinc 2; via tele nitrogen; structural	SEQ_UP	1	
METAL:Zinc 3	SEQ_UP	78	
METAL:Zinc 3; structural	SEQ_UP	1	
METAL:Zinc 3; via carbamate group	SEQ_UP	1	
METAL:Zinc 3; via carbonyl oxygen; structural	SEQ_UP	1	
METAL:Zinc 3; via pros nitrogen	SEQ_UP	6	
METAL:Zinc 3; via tele nitrogen	SEQ_UP	8	
METAL:Zinc 3; via tele nitrogen; structural	SEQ_UP	1	
METAL:Zinc 4	SEQ_UP	50	
METAL:Zinc 4; structural	SEQ_UP	1	
METAL:Zinc 4; via tele nitrogen	SEQ_UP	9	
METAL:Zinc 4; via tele nitrogen; structural	SEQ_UP	1	
METAL:Zinc 5	SEQ_UP	27	
METAL:Zinc 5; structural	SEQ_UP	1	
METAL:Zinc 5; via tele nitrogen	SEQ_UP	7	
METAL:Zinc 5; via tele nitrogen; structural	SEQ_UP	1	
METAL:Zinc 6	SEQ_UP	16	
METAL:Zinc 6; via tele nitrogen	SEQ_UP	7	
METAL:Zinc 7	SEQ_UP	2	
METAL:Zinc; alternate	SEQ_UP	1	
METAL:Zinc; catalytic	SEQ_UP	128	
METAL:Zinc; in inhibited form	SEQ_UP	27	
METAL:Zinc; shared with dimeric partner	SEQ_UP	3	
METAL:Zinc; shared with SHH	SEQ_UP	1	
METAL:Zinc; shared with trimeric partners	SEQ_UP	1	
METAL:Zinc; structural	SEQ_UP	2	
METAL:Zinc; via amino nitrogen and carbonyl oxygen; shared with metalloproteinase partner	SEQ_UP	4	
METAL:Zinc; via pros nitrogen	SEQ_UP	11	
METAL:Zinc; via tele nitrogen	SEQ_UP	24	
METAL:Zinc; via tele nitrogen; catalytic	SEQ_UP	13	
METAL:Zn(2+)	SEQ_UP	2	
MOTIF:'HIGH' region	SEQ_UP	17	
MOTIF:'Ionic lock' involved in activated form stabilization	SEQ_UP	1	
MOTIF:'KMSKS' region	SEQ_UP	15	
MOTIF:(Q/R)XXRW	SEQ_UP	1	
MOTIF:(S/T)X(I/L)P motif 1	SEQ_UP	1	
MOTIF:(S/T)X(I/L)P motif 2	SEQ_UP	1	
MOTIF:(S/T)X(I/L)P motif 3; required for interaction with MAPRE1	SEQ_UP	1	
MOTIF:[DE]-X(1,2)-F-X-X-[FL]-X-X-X-R motif	SEQ_UP	3	
MOTIF:[DE]RFG motif; may stabilize a conformation that preferentially activates signaling via beta-arrestin family members	SEQ_UP	1	
MOTIF:[IL]-x-C-x-x-[DE] motif	SEQ_UP	5	
MOTIF:[KR]-[STA]-K motif	SEQ_UP	3	
MOTIF:[NKR]KIAxRE	SEQ_UP	4	
MOTIF:[ST]-Q motif	SEQ_UP	1	
MOTIF:[ST]-Q motif 1	SEQ_UP	1	
MOTIF:[ST]-Q motif 2	SEQ_UP	1	
MOTIF:4S motif; modulates transactivation activity and protein stability	SEQ_UP	1	
MOTIF:9aaTAD	SEQ_UP	35	
MOTIF:9aaTAD 1	SEQ_UP	1	
MOTIF:9aaTAD 2	SEQ_UP	1	
MOTIF:9aaTAD 3	SEQ_UP	1	
MOTIF:9aaTAD; inactive	SEQ_UP	8	
MOTIF:AAAS motif	SEQ_UP	2	
MOTIF:ADDV motif	SEQ_UP	1	
MOTIF:AF-2	SEQ_UP	3	
MOTIF:AF-2 motif	SEQ_UP	1	
MOTIF:AIM1	SEQ_UP	1	
MOTIF:AIM2	SEQ_UP	1	
MOTIF:AKAP CaM-binding	SEQ_UP	2	
MOTIF:AKAP CaM-binding 1	SEQ_UP	1	
MOTIF:AKAP CaM-binding 2	SEQ_UP	1	
MOTIF:AKAP CaM-binding 3	SEQ_UP	1	
MOTIF:ALG-2-binding site motif-2 (ABS-2),	SEQ_UP	1	
MOTIF:AMPK pseudosubstrate	SEQ_UP	3	
MOTIF:Antp-type hexapeptide	SEQ_UP	24	
MOTIF:APIM motif	SEQ_UP	2	
MOTIF:Arginine finger	SEQ_UP	6	
MOTIF:ATG16L1-binding motif	SEQ_UP	3	
MOTIF:ATR-activation domain (AAD)	SEQ_UP	1	
MOTIF:Autoinhibitory	SEQ_UP	2	
MOTIF:AxLyCxL	SEQ_UP	1	
MOTIF:B30.2/SPRY domain-binding motif	SEQ_UP	1	
MOTIF:Basic, involved in binding of the RNA primer	SEQ_UP	1	
MOTIF:Basolateral sorting signal	SEQ_UP	3	
MOTIF:BC1 motif	SEQ_UP	1	
MOTIF:BC2 motif	SEQ_UP	1	
MOTIF:BC3 motif	SEQ_UP	1	
MOTIF:BetaTrCP degron motif	SEQ_UP	1	
MOTIF:BH1	SEQ_UP	10	
MOTIF:BH2	SEQ_UP	11	
MOTIF:BH3	SEQ_UP	18	
MOTIF:BH3 1	SEQ_UP	1	
MOTIF:BH3 2	SEQ_UP	1	
MOTIF:BH4	SEQ_UP	6	
MOTIF:Bipartite nuclear localization signal	SEQ_UP	46	
MOTIF:Bipartite nuclear localization signal (NLS1)	SEQ_UP	1	
MOTIF:Bipartite nuclear localization signal 1	SEQ_UP	3	
MOTIF:Bipartite nuclear localization signal 2	SEQ_UP	3	
MOTIF:Bipartite nuclear localization signal; in isoform 2	SEQ_UP	1	
MOTIF:Box 1 motif	SEQ_UP	25	
MOTIF:C motif	SEQ_UP	1	
MOTIF:C2HC 1	SEQ_UP	3	
MOTIF:C2HC 2	SEQ_UP	3	
MOTIF:CAAX motif	SEQ_UP	5	
MOTIF:Calcium bowl	SEQ_UP	1	
MOTIF:Cardin-Weintraub	SEQ_UP	1	
MOTIF:Caspase cleavage	SEQ_UP	1	
MOTIF:Caspase cleavage related site	SEQ_UP	2	
MOTIF:CAV1-binding	SEQ_UP	1	
MOTIF:Cell attachment site	SEQ_UP	77	
MOTIF:Cell attachment site; atypical	SEQ_UP	2	
MOTIF:CFDEFNR motif	SEQ_UP	2	
MOTIF:CHIC motif (Cys-rich)	SEQ_UP	1	
MOTIF:Cholesterol-binding sequence motif	SEQ_UP	1	
MOTIF:Ciliary targeting motif	SEQ_UP	1	
MOTIF:Clathrin box	SEQ_UP	4	
MOTIF:Clathrin box 1	SEQ_UP	1	
MOTIF:Clathrin box 2	SEQ_UP	1	
MOTIF:Clathrin-binding	SEQ_UP	1	
MOTIF:CLIR	SEQ_UP	1	
MOTIF:CLTCL1/Clathrin-binding	SEQ_UP	1	
MOTIF:Confers specificity for glucose/mannose-type carbohydrates	SEQ_UP	1	
MOTIF:COP1-binding	SEQ_UP	1	
MOTIF:COPI vesicle coat-binding	SEQ_UP	8	
MOTIF:COPII vesicle coat-binding	SEQ_UP	8	
MOTIF:CORNR box 1	SEQ_UP	1	
MOTIF:CORNR box 2	SEQ_UP	1	
MOTIF:CORNR box 3	SEQ_UP	1	
MOTIF:CORNR box of ID1	SEQ_UP	1	
MOTIF:CORNR box of ID2	SEQ_UP	1	
MOTIF:CPLCP	SEQ_UP	1	
MOTIF:CR1	SEQ_UP	1	
MOTIF:CR2	SEQ_UP	1	
MOTIF:Critical for rDNA-binding	SEQ_UP	1	
MOTIF:CTBP-binding	SEQ_UP	1	
MOTIF:CTBP-binding motif	SEQ_UP	3	
MOTIF:CTBP-binding motif 1	SEQ_UP	1	
MOTIF:CTBP-binding motif 2	SEQ_UP	1	
MOTIF:CTBP-binding motif PEDLG	SEQ_UP	1	
MOTIF:CTBP-binding; principal site	SEQ_UP	1	
MOTIF:Cx10C motif	SEQ_UP	4	
MOTIF:Cx2C motif 1	SEQ_UP	1	
MOTIF:Cx2C motif 2	SEQ_UP	1	
MOTIF:CX5R motif	SEQ_UP	2	
MOTIF:CX6CC	SEQ_UP	2	
MOTIF:Cx9C motif	SEQ_UP	4	
MOTIF:Cx9C motif 1	SEQ_UP	18	
MOTIF:Cx9C motif 2	SEQ_UP	18	
MOTIF:Cx9C motif 3	SEQ_UP	2	
MOTIF:Cx9C motif 4	SEQ_UP	2	
MOTIF:CXXC	SEQ_UP	5	
MOTIF:Cy	SEQ_UP	2	
MOTIF:Cyclin-binding motif	SEQ_UP	1	
MOTIF:Cys degron	SEQ_UP	1	
MOTIF:CysB motif	SEQ_UP	4	
MOTIF:Cysteine switch	SEQ_UP	39	
MOTIF:D box 1	SEQ_UP	1	
MOTIF:D box 2	SEQ_UP	1	
MOTIF:D box 3	SEQ_UP	1	
MOTIF:D box 4	SEQ_UP	1	
MOTIF:D-box	SEQ_UP	13	
MOTIF:D-box 1	SEQ_UP	5	
MOTIF:D-box 2	SEQ_UP	5	
MOTIF:D-box 3	SEQ_UP	1	
MOTIF:D-box that targets the protein for proteasomal degradation in anaphase	SEQ_UP	1	
MOTIF:D1	SEQ_UP	1	
MOTIF:D2	SEQ_UP	1	
MOTIF:D3	SEQ_UP	1	
MOTIF:DDB1-binding motif	SEQ_UP	2	
MOTIF:DDX6 binding motif	SEQ_UP	1	
MOTIF:DEAA box	SEQ_UP	2	
MOTIF:DEAD	SEQ_UP	1	
MOTIF:DEAD box	SEQ_UP	32	
MOTIF:DEAD box-like	SEQ_UP	1	
MOTIF:DEAG box	SEQ_UP	2	
MOTIF:DEAH box	SEQ_UP	44	
MOTIF:DEAQ box	SEQ_UP	2	
MOTIF:DECD box	SEQ_UP	2	
MOTIF:DECH box	SEQ_UP	3	
MOTIF:DEF box	SEQ_UP	8	
MOTIF:DEGH box	SEQ_UP	7	
MOTIF:Degron	SEQ_UP	1	
MOTIF:DEIH box	SEQ_UP	2	
MOTIF:DESH box	SEQ_UP	1	
MOTIF:Destruction motif	SEQ_UP	3	
MOTIF:DEVD box	SEQ_UP	1	
MOTIF:DEVH box	SEQ_UP	4	
MOTIF:DFXDF motif 1	SEQ_UP	1	
MOTIF:DFXDF motif 2	SEQ_UP	1	
MOTIF:DFXDF motif 3	SEQ_UP	1	
MOTIF:DGA/G	SEQ_UP	8	
MOTIF:DGEA	SEQ_UP	1	
MOTIF:DHH motif	SEQ_UP	2	
MOTIF:Di-leucine internalization motif; mediates targeting to late endosome and lysosome membranes	SEQ_UP	1	
MOTIF:Di-leucine motif	SEQ_UP	6	
MOTIF:Di-lysine motif	SEQ_UP	15	
MOTIF:Dileucine internalization motif	SEQ_UP	7	
MOTIF:Dileucine internalization motif; mediates AP2 complex-dependent internalization	SEQ_UP	1	
MOTIF:Dileucine motif; mediates targeting to lysosomes	SEQ_UP	1	
MOTIF:DINNN-motif; mediates interaction with SPSB1, SPSB2 and SPSB4	SEQ_UP	1	
MOTIF:Dityrosine basolateral targeting motif	SEQ_UP	1	
MOTIF:DK motif	SEQ_UP	2	
MOTIF:DKFBH motif	SEQ_UP	3	
MOTIF:DLG motif	SEQ_UP	1	
MOTIF:DLG4 binding (PDZ)	SEQ_UP	1	
MOTIF:DPF 1	SEQ_UP	1	
MOTIF:DPF 2	SEQ_UP	1	
MOTIF:DRY motif; important for ligand-induced conformation changes	SEQ_UP	6	
MOTIF:DRY motif; important for ligand-induced conformation changes and signaling	SEQ_UP	1	
MOTIF:DWD box	SEQ_UP	1	
MOTIF:DWD box 1	SEQ_UP	1	
MOTIF:DWD box 2	SEQ_UP	1	
MOTIF:DXD motif	SEQ_UP	3	
MOTIF:DXD motif 1	SEQ_UP	2	
MOTIF:DXD motif 2	SEQ_UP	2	
MOTIF:DXDXT motif	SEQ_UP	3	
MOTIF:DXTW	SEQ_UP	2	
MOTIF:DXXE	SEQ_UP	1	
MOTIF:DXXLL	SEQ_UP	1	
MOTIF:DXXLL motif involved in the interaction with GGA1	SEQ_UP	2	
MOTIF:EEXXXDDL motif	SEQ_UP	1	
MOTIF:EEXXXDL motif	SEQ_UP	2	
MOTIF:Effector region	SEQ_UP	92	
MOTIF:EGTC motif	SEQ_UP	1	
MOTIF:EGTR motif	SEQ_UP	2	
MOTIF:Endocytic sorting signal	SEQ_UP	1	
MOTIF:Endocytosis signal	SEQ_UP	14	
MOTIF:Endoplasmic reticulum retention signal	SEQ_UP	5	
MOTIF:Endoplasmic reticulum targeting	SEQ_UP	1	
MOTIF:Engrailed homology 1 repressor	SEQ_UP	3	
MOTIF:EPN	SEQ_UP	2	
MOTIF:ER export motif	SEQ_UP	1	
MOTIF:ER export signal	SEQ_UP	1	
MOTIF:ER-retrieval signal	SEQ_UP	1	
MOTIF:Essential for CALM1 interaction	SEQ_UP	1	
MOTIF:Essential for nuclear import	SEQ_UP	1	
MOTIF:ETGE motif	SEQ_UP	1	
MOTIF:EWI motif	SEQ_UP	3	
MOTIF:EXKPK motif	SEQ_UP	1	
MOTIF:F&H	SEQ_UP	3	
MOTIF:FAP motif	SEQ_UP	1	
MOTIF:Fast/FoxH1 motif 1 (FM1)	SEQ_UP	1	
MOTIF:Fast/FoxH1 motif 2 (FM2)	SEQ_UP	1	
MOTIF:FFAT	SEQ_UP	8	
MOTIF:FFAT 1	SEQ_UP	1	
MOTIF:FFAT 2	SEQ_UP	1	
MOTIF:FFD box	SEQ_UP	2	
MOTIF:FGF motif	SEQ_UP	1	
MOTIF:FGF motif 1	SEQ_UP	1	
MOTIF:FGF motif 2	SEQ_UP	1	
MOTIF:FGF motif 3	SEQ_UP	1	
MOTIF:FIG[AQ]Y	SEQ_UP	1	
MOTIF:FKBP1A-binding	SEQ_UP	1	
MOTIF:Flavin-containing monooxygenase motif	SEQ_UP	1	
MOTIF:FRIEDE motif	SEQ_UP	2	
MOTIF:FRIP motif	SEQ_UP	4	
MOTIF:FTZ-F1 box	SEQ_UP	1	
MOTIF:FXDXF motif	SEQ_UP	3	
MOTIF:FYXDWWN motif	SEQ_UP	3	
MOTIF:GAR	SEQ_UP	2	
MOTIF:GAR motif; involved in 5hmC binding	SEQ_UP	1	
MOTIF:GBA	SEQ_UP	5	
MOTIF:GFFKR motif	SEQ_UP	14	
MOTIF:GGQ	SEQ_UP	1	
MOTIF:GILK motif	SEQ_UP	1	
MOTIF:Glucan phosphatase signature motif CXAGXGR	SEQ_UP	1	
MOTIF:Gly-cisPro motif, important for rejection of L-amino acids	SEQ_UP	1	
MOTIF:Gly-Pro-Asn (GPN)-loop; involved in dimer interface	SEQ_UP	3	
MOTIF:Gly-transPro motif, allows the protein to recognize chirality of D-amino acids	SEQ_UP	1	
MOTIF:GPAGTGKT motif	SEQ_UP	2	
MOTIF:GPALPP motif 1	SEQ_UP	1	
MOTIF:GPALPP motif 2	SEQ_UP	1	
MOTIF:GPALPP motif 3	SEQ_UP	1	
MOTIF:GPALPP motif 4	SEQ_UP	1	
MOTIF:GPPX3Y	SEQ_UP	1	
MOTIF:GSGFP motif	SEQ_UP	2	
MOTIF:GXGXG motif (S-adenosyl-L-methionine-binding)	SEQ_UP	1	
MOTIF:GXGXXG	SEQ_UP	7	
MOTIF:GXSXG	SEQ_UP	8	
MOTIF:GXXXG motif	SEQ_UP	1	
MOTIF:GXXXX[G/A/S]	SEQ_UP	1	
MOTIF:HBM-like motif	SEQ_UP	1	
MOTIF:HCFC1-binding motif (HBM)	SEQ_UP	9	
MOTIF:HCFC1-binding-motif (HBM)	SEQ_UP	3	
MOTIF:HD1	SEQ_UP	2	
MOTIF:Heparin- and hyaluronan-binding	SEQ_UP	1	
MOTIF:HGGXW	SEQ_UP	1	
MOTIF:HHHGHXHX-motif	SEQ_UP	1	
MOTIF:Histidine box-1	SEQ_UP	16	
MOTIF:Histidine box-2	SEQ_UP	16	
MOTIF:Histidine box-3	SEQ_UP	15	
MOTIF:Histidine triad motif	SEQ_UP	6	
MOTIF:HMX family specific domain 1	SEQ_UP	1	
MOTIF:HMX family specific domain 2	SEQ_UP	1	
MOTIF:Homodimer stabilization; interchain	SEQ_UP	1	
MOTIF:HXHXDH motif	SEQ_UP	1	
MOTIF:HXXXXD motif	SEQ_UP	18	
MOTIF:HXXXXX[HY]NH	SEQ_UP	1	
MOTIF:IAP-binding	SEQ_UP	1	
MOTIF:IAP-binding motif	SEQ_UP	1	
MOTIF:Important for ABL1-mediated Tyr-718 phosphorylation	SEQ_UP	1	
MOTIF:Important for formation of cell junction	SEQ_UP	1	
MOTIF:Important for interaction with 14-3-3 proteins	SEQ_UP	1	
MOTIF:Important for interaction with G proteins	SEQ_UP	1	
MOTIF:Important for signaling	SEQ_UP	2	
MOTIF:Important role in both nutrient sensing and binding/regulation of IMPDH2	SEQ_UP	1	
MOTIF:Inhibitory (S/T)XXXE(G/N) motif	SEQ_UP	1	
MOTIF:Initiation motif	SEQ_UP	1	
MOTIF:INSIG-binding motif	SEQ_UP	1	
MOTIF:Integrase domain-binding motif (IBM)	SEQ_UP	3	
MOTIF:Integrase domain-binding motif 1 (IBM1)	SEQ_UP	3	
MOTIF:Integrase domain-binding motif 2 (IBM2)	SEQ_UP	3	
MOTIF:Integrin interaction	SEQ_UP	1	
MOTIF:Integrin-binding motif	SEQ_UP	1	
MOTIF:Interaction with actin	SEQ_UP	2	
MOTIF:Interaction with clathrin heavy chains	SEQ_UP	1	
MOTIF:Interaction with FBXW7	SEQ_UP	1	
MOTIF:Interaction with GRB2	SEQ_UP	1	
MOTIF:Interaction with nuclear receptors	SEQ_UP	1	
MOTIF:Interaction with phosphatidylinositides	SEQ_UP	1	
MOTIF:Interaction with SRC and ESR1	SEQ_UP	1	
MOTIF:Internalization signal	SEQ_UP	4	
MOTIF:Involved in DLG4-binding	SEQ_UP	1	
MOTIF:Involved in ITCH interaction	SEQ_UP	1	
MOTIF:Involved in the recycling of CRTH2	SEQ_UP	1	
MOTIF:Involved in the stabilization of the negatively charged intermediate by the formation of the oxyanion hole	SEQ_UP	5	
MOTIF:IP motif; mediates targeting to recycling endosomes	SEQ_UP	1	
MOTIF:IQ motif	SEQ_UP	1	
MOTIF:IQ-type	SEQ_UP	1	
MOTIF:IRS1- and SHC1-binding	SEQ_UP	1	
MOTIF:ITAM-like	SEQ_UP	2	
MOTIF:ITIM	SEQ_UP	1	
MOTIF:ITIM motif	SEQ_UP	14	
MOTIF:ITIM motif 1	SEQ_UP	10	
MOTIF:ITIM motif 2	SEQ_UP	10	
MOTIF:ITIM motif 3	SEQ_UP	3	
MOTIF:ITIM motif 4	SEQ_UP	1	
MOTIF:ITIM motif 5	SEQ_UP	1	
MOTIF:ITSM	SEQ_UP	1	
MOTIF:ITSM 1	SEQ_UP	4	
MOTIF:ITSM 1 (atypical)	SEQ_UP	1	
MOTIF:ITSM 2	SEQ_UP	5	
MOTIF:ITSM 3	SEQ_UP	1	
MOTIF:ITSM 4	SEQ_UP	1	
MOTIF:ITSM motif	SEQ_UP	1	
MOTIF:IxM motif; signal for cargo packaging into COPII-coated vesicles	SEQ_UP	2	
MOTIF:JAMM motif	SEQ_UP	8	
MOTIF:KBM	SEQ_UP	2	
MOTIF:KBM 1	SEQ_UP	1	
MOTIF:KBM 2	SEQ_UP	1	
MOTIF:KEN box	SEQ_UP	10	
MOTIF:KEN box 1	SEQ_UP	2	
MOTIF:KEN box 2	SEQ_UP	2	
MOTIF:KEN box 3	SEQ_UP	1	
MOTIF:KIEELE motif	SEQ_UP	1	
MOTIF:Kinase activation loop	SEQ_UP	2	
MOTIF:Kinase interacting site	SEQ_UP	3	
MOTIF:KKRRAP 1	SEQ_UP	2	
MOTIF:KKRRAP 2	SEQ_UP	2	
MOTIF:KLHL15-binding	SEQ_UP	1	
MOTIF:KLKR	SEQ_UP	3	
MOTIF:KTS motif	SEQ_UP	1	
MOTIF:KVKF motif	SEQ_UP	1	
MOTIF:KxGQ motif	SEQ_UP	2	
MOTIF:KxHxx	SEQ_UP	2	
MOTIF:L/FRRG motif	SEQ_UP	4	
MOTIF:LAPYISMD	SEQ_UP	1	
MOTIF:Last loop motif	SEQ_UP	3	
MOTIF:LCK-binding motif	SEQ_UP	4	
MOTIF:LD motif 1	SEQ_UP	3	
MOTIF:LD motif 2	SEQ_UP	3	
MOTIF:LD motif 3	SEQ_UP	3	
MOTIF:LD motif 4	SEQ_UP	2	
MOTIF:LD motif 5	SEQ_UP	1	
MOTIF:Leucine-based sorting signal	SEQ_UP	1	
MOTIF:LFa 1	SEQ_UP	1	
MOTIF:LFa 10	SEQ_UP	1	
MOTIF:LFa 11	SEQ_UP	1	
MOTIF:LFa 12	SEQ_UP	1	
MOTIF:LFa 13	SEQ_UP	1	
MOTIF:LFa 14	SEQ_UP	1	
MOTIF:LFa 15	SEQ_UP	1	
MOTIF:LFa 16	SEQ_UP	1	
MOTIF:LFa 17	SEQ_UP	1	
MOTIF:LFa 2	SEQ_UP	1	
MOTIF:LFa 3	SEQ_UP	1	
MOTIF:LFa 4	SEQ_UP	1	
MOTIF:LFa 5	SEQ_UP	1	
MOTIF:LFa 6	SEQ_UP	1	
MOTIF:LFa 7	SEQ_UP	1	
MOTIF:LFa 8	SEQ_UP	1	
MOTIF:LFa 9	SEQ_UP	1	
MOTIF:LIR	SEQ_UP	14	
MOTIF:LIR 1	SEQ_UP	2	
MOTIF:LIR 10	SEQ_UP	1	
MOTIF:LIR 11	SEQ_UP	1	
MOTIF:LIR 12	SEQ_UP	1	
MOTIF:LIR 13	SEQ_UP	1	
MOTIF:LIR 2	SEQ_UP	2	
MOTIF:LIR 3	SEQ_UP	1	
MOTIF:LIR 4	SEQ_UP	1	
MOTIF:LIR 5	SEQ_UP	1	
MOTIF:LIR 6	SEQ_UP	1	
MOTIF:LIR 7	SEQ_UP	1	
MOTIF:LIR 8	SEQ_UP	1	
MOTIF:LIR 9	SEQ_UP	1	
MOTIF:LIR motif	SEQ_UP	4	
MOTIF:LIR-like	SEQ_UP	1	
MOTIF:LLXXLXXXL motif	SEQ_UP	1	
MOTIF:LPXY motif; mediates binding to WW domain-containing proteins	SEQ_UP	2	
MOTIF:LQQQIQ motif	SEQ_UP	1	
MOTIF:LR motif	SEQ_UP	3	
MOTIF:LR motif 1	SEQ_UP	1	
MOTIF:LR motif 2	SEQ_UP	1	
MOTIF:LRLRGG	SEQ_UP	1	
MOTIF:LRRLL	SEQ_UP	1	
MOTIF:LXCXE motif	SEQ_UP	2	
MOTIF:LXXIL motif	SEQ_UP	4	
MOTIF:LXXL motif 1	SEQ_UP	1	
MOTIF:LXXLL	SEQ_UP	6	
MOTIF:LXXLL motif	SEQ_UP	17	
MOTIF:LXXLL motif 1	SEQ_UP	23	
MOTIF:LXXLL motif 10	SEQ_UP	1	
MOTIF:LXXLL motif 11	SEQ_UP	1	
MOTIF:LXXLL motif 2	SEQ_UP	23	
MOTIF:LXXLL motif 3	SEQ_UP	12	
MOTIF:LXXLL motif 4	SEQ_UP	9	
MOTIF:LXXLL motif 5	SEQ_UP	7	
MOTIF:LXXLL motif 6	SEQ_UP	5	
MOTIF:LXXLL motif 7	SEQ_UP	3	
MOTIF:LXXLL motif 8	SEQ_UP	2	
MOTIF:LXXLL motif 9	SEQ_UP	2	
MOTIF:LYPX(n)L motif 1	SEQ_UP	1	
MOTIF:LYPX(n)L motif 2	SEQ_UP	1	
MOTIF:LYPX(n)L motif 3	SEQ_UP	1	
MOTIF:LYR motif 1; required for interaction with HSC20	SEQ_UP	1	
MOTIF:LYR motif 2; not required for interaction with HSC20	SEQ_UP	1	
MOTIF:LYR motif; required for interaction with HSC20	SEQ_UP	1	
MOTIF:Lys-Thr-X-X-X-Trp motif, mediates interaction with the PDZ domain of Dvl family members	SEQ_UP	9	
MOTIF:Lysosomal targeting motif	SEQ_UP	4	
MOTIF:Lysosomal targeting motif. Required for AP1G1, AP2A2 and AP3D1 interaction	SEQ_UP	1	
MOTIF:lysosomal/melanosomal membrane localization signal	SEQ_UP	1	
MOTIF:MAP kinase binding	SEQ_UP	1	
MOTIF:MAP kinase docking motif; essential for its phosphorylation	SEQ_UP	1	
MOTIF:May mediate ER retention	SEQ_UP	2	
MOTIF:Mediates cell adhesion	SEQ_UP	1	
MOTIF:Mediates endoplasmic reticulum retention	SEQ_UP	1	
MOTIF:Mediates head to head self-assembly of N-terminal ends	SEQ_UP	1	
MOTIF:Mediates lysosomal localization	SEQ_UP	1	
MOTIF:Mediates retrograde transport to the ER	SEQ_UP	1	
MOTIF:MEF2-binding	SEQ_UP	1	
MOTIF:MEF2C-binding	SEQ_UP	1	
MOTIF:Membrane-association motif	SEQ_UP	1	
MOTIF:Menin-binding motif (MBM)	SEQ_UP	3	
MOTIF:Microbody targeting signal	SEQ_UP	44	
MOTIF:Microtubule tip localization signal	SEQ_UP	4	
MOTIF:MIDAS-like motif	SEQ_UP	5	
MOTIF:MIM1-A	SEQ_UP	1	
MOTIF:MIM1-B	SEQ_UP	1	
MOTIF:MIT-interacting motif	SEQ_UP	6	
MOTIF:Mitochondrial localization signal	SEQ_UP	1	
MOTIF:Mitochondrial targeting signal	SEQ_UP	1	
MOTIF:MIU motif	SEQ_UP	1	
MOTIF:MIU motif 1	SEQ_UP	1	
MOTIF:MIU motif 2	SEQ_UP	1	
MOTIF:MREC motif	SEQ_UP	7	
MOTIF:MREI motif	SEQ_UP	8	
MOTIF:Necessary for association with microtubule and interaction with GAPDH	SEQ_UP	1	
MOTIF:NIKS motif; plays an important role in translational termination	SEQ_UP	1	
MOTIF:Non-canonical dileucine endocytic signal	SEQ_UP	1	
MOTIF:Non-canonical ER retention motif	SEQ_UP	1	
MOTIF:NPA	SEQ_UP	1	
MOTIF:NPA 1	SEQ_UP	11	
MOTIF:NPA 2	SEQ_UP	11	
MOTIF:NPC	SEQ_UP	1	
MOTIF:NPF	SEQ_UP	1	
MOTIF:NPF 1	SEQ_UP	2	
MOTIF:NPF 2	SEQ_UP	2	
MOTIF:NPF internalization motif	SEQ_UP	1	
MOTIF:NPF1	SEQ_UP	2	
MOTIF:NPF2	SEQ_UP	2	
MOTIF:NPF3	SEQ_UP	1	
MOTIF:NPxxY motif; important for ligand-induced conformation changes and signaling	SEQ_UP	7	
MOTIF:NPxxY; plays a role in stabilizing the activated conformation of the receptor	SEQ_UP	1	
MOTIF:NPXY motif	SEQ_UP	7	
MOTIF:NPXY motif 1	SEQ_UP	1	
MOTIF:NPXY motif 2	SEQ_UP	1	
MOTIF:NPXY motif; contains endocytosis signal	SEQ_UP	1	
MOTIF:NPxY-like endocytic signal	SEQ_UP	1	
MOTIF:Nuclear and nucleolar localization signal	SEQ_UP	1	
MOTIF:nuclear export sequence (NES)	SEQ_UP	1	
MOTIF:nuclear export sequence (NES1)	SEQ_UP	1	
MOTIF:nuclear export sequence (NES2)	SEQ_UP	1	
MOTIF:Nuclear export signal	SEQ_UP	75	
MOTIF:Nuclear export signal (NES)	SEQ_UP	9	
MOTIF:Nuclear export signal 1	SEQ_UP	10	
MOTIF:Nuclear export signal 2	SEQ_UP	10	
MOTIF:Nuclear export signal 3	SEQ_UP	4	
MOTIF:Nuclear export signal; masked by interaction with SEM1	SEQ_UP	1	
MOTIF:Nuclear export signal; masked by the interaction with BRCA2	SEQ_UP	1	
MOTIF:Nuclear import signal	SEQ_UP	1	
MOTIF:Nuclear localization signal	SEQ_UP	392	
MOTIF:nuclear localization signal (NLS)	SEQ_UP	1	
MOTIF:Nuclear localization signal (NLS)	SEQ_UP	11	
MOTIF:Nuclear localization signal (NLS) 1	SEQ_UP	2	
MOTIF:Nuclear localization signal (NLS) 2	SEQ_UP	2	
MOTIF:Nuclear localization signal (NLS) 3	SEQ_UP	1	
MOTIF:Nuclear localization signal (NLS1)	SEQ_UP	2	
MOTIF:Nuclear localization signal (NLS2)	SEQ_UP	1	
MOTIF:Nuclear localization signal 1	SEQ_UP	10	
MOTIF:Nuclear localization signal 1 (NLS 1)	SEQ_UP	1	
MOTIF:Nuclear localization signal 1 (NLS1)	SEQ_UP	2	
MOTIF:Nuclear localization signal 2	SEQ_UP	10	
MOTIF:Nuclear localization signal 2 (NLS 2)	SEQ_UP	1	
MOTIF:Nuclear localization signal 2 (NLS2)	SEQ_UP	1	
MOTIF:Nuclear localization signal 3	SEQ_UP	2	
MOTIF:Nuclear localization signal 4	SEQ_UP	1	
MOTIF:Nuclear localization signal 5	SEQ_UP	1	
MOTIF:Nuclear localization signal NLS1	SEQ_UP	1	
MOTIF:Nuclear localization signal NLS2	SEQ_UP	1	
MOTIF:Nuclear localization signal; in isoform 6	SEQ_UP	1	
MOTIF:Nuclear localization site	SEQ_UP	1	
MOTIF:Nuclear matrix targeting sequence (NMTS)	SEQ_UP	1	
MOTIF:Nuclear receptor interaction	SEQ_UP	1	
MOTIF:Nuclear receptor interaction motif	SEQ_UP	1	
MOTIF:Nuclear speckle targeting signal	SEQ_UP	1	
MOTIF:Nucleolar localization signal	SEQ_UP	11	
MOTIF:Nucleolar localization signal (NLS)	SEQ_UP	1	
MOTIF:Nucleolar localization signal 1	SEQ_UP	1	
MOTIF:Nucleolar localization signal 2	SEQ_UP	1	
MOTIF:Nucleotide carrier signature motif	SEQ_UP	3	
MOTIF:Nudix box	SEQ_UP	23	
MOTIF:OAR	SEQ_UP	15	
MOTIF:Octapeptide motif	SEQ_UP	2	
MOTIF:OX-2	SEQ_UP	1	
MOTIF:PABPC-interacting motif-2 (PAM-2)	SEQ_UP	1	
MOTIF:PAL	SEQ_UP	7	
MOTIF:PCNA-binding	SEQ_UP	2	
MOTIF:PCNA-interaction protein motif (PIP box)	SEQ_UP	1	
MOTIF:PDZ-binding	SEQ_UP	95	
MOTIF:PDZ-Binding	SEQ_UP	1	
MOTIF:PDZ-binding motif	SEQ_UP	1	
MOTIF:PDZ-binding; involved in localization to the apical cell membrane	SEQ_UP	1	
MOTIF:PDZ-binding; mediates interaction with USH1C	SEQ_UP	1	
MOTIF:Peroxisomal targeting signal	SEQ_UP	1	
MOTIF:Peroxisome localization signal	SEQ_UP	1	
MOTIF:Peroxisome targeting signal	SEQ_UP	1	
MOTIF:PGR	SEQ_UP	1	
MOTIF:Phosphodegron	SEQ_UP	3	
MOTIF:PIM motif	SEQ_UP	3	
MOTIF:PIP-box	SEQ_UP	11	
MOTIF:PIP-box (PCNA interacting peptide)	SEQ_UP	1	
MOTIF:PIP-box K+4 motif	SEQ_UP	2	
MOTIF:PLRP	SEQ_UP	1	
MOTIF:pLxIS motif	SEQ_UP	4	
MOTIF:POLO box domain (PBD)-binding	SEQ_UP	1	
MOTIF:Polybasic region; required for nuclear import	SEQ_UP	1	
MOTIF:Potential nuclear localization signal for the C-terminal fragment generated by PSEN1	SEQ_UP	1	
MOTIF:POU-IV box	SEQ_UP	3	
MOTIF:PP1-binding motif	SEQ_UP	7	
MOTIF:PPPSP motif A	SEQ_UP	2	
MOTIF:PPPSP motif B	SEQ_UP	2	
MOTIF:PPPSP motif C	SEQ_UP	2	
MOTIF:PPPSP motif D	SEQ_UP	2	
MOTIF:PPPSP motif E	SEQ_UP	2	
MOTIF:PPPSP motif; required for interaction with AXIN1	SEQ_UP	1	
MOTIF:PPPY motif	SEQ_UP	1	
MOTIF:PPxY motif	SEQ_UP	12	
MOTIF:PPXY motif	SEQ_UP	1	
MOTIF:PPxy motif 1	SEQ_UP	1	
MOTIF:PPxY motif 1	SEQ_UP	11	
MOTIF:PPxY motif 2	SEQ_UP	12	
MOTIF:PPxY motif 3	SEQ_UP	3	
MOTIF:PPxY motif 4	SEQ_UP	1	
MOTIF:PPxY motif 5	SEQ_UP	1	
MOTIF:PPxY motif 6	SEQ_UP	1	
MOTIF:PPXY motif; mediates binding to WW domain-containing proteins	SEQ_UP	2	
MOTIF:PQIIIT	SEQ_UP	1	
MOTIF:Prevents secretion from ER	SEQ_UP	65	
MOTIF:Profilin-binding motif	SEQ_UP	1	
MOTIF:Protein interaction	SEQ_UP	1	
MOTIF:Pseudophosphorylation motif	SEQ_UP	2	
MOTIF:Pseudosubstrate	SEQ_UP	1	
MOTIF:pSXXF motif	SEQ_UP	1	
MOTIF:PTAP motif 1	SEQ_UP	1	
MOTIF:PTAP motif 2	SEQ_UP	1	
MOTIF:PTAP/PSAP motif	SEQ_UP	1	
MOTIF:PTB	SEQ_UP	1	
MOTIF:PWI	SEQ_UP	1	
MOTIF:PXDLS	SEQ_UP	1	
MOTIF:PXDLS motif	SEQ_UP	1	
MOTIF:PXLE motif	SEQ_UP	1	
MOTIF:PxLPxI/L motif 1; mediates interaction with ANKRA2	SEQ_UP	1	
MOTIF:PxLPxI/L motif 2; mediates interaction with ANKRA2	SEQ_UP	1	
MOTIF:PxLPxI/L motif; mediates interaction with ANKRA2	SEQ_UP	1	
MOTIF:PxLPxI/L motif; mediates interaction with ANKRA2 and 14-3-3 proteins	SEQ_UP	1	
MOTIF:PxLPxI/L motif; mediates interaction with RFXANK	SEQ_UP	1	
MOTIF:PXLXP	SEQ_UP	1	
MOTIF:PxP motif 1	SEQ_UP	1	
MOTIF:PxP motif 2	SEQ_UP	1	
MOTIF:PxVxL motif	SEQ_UP	9	
MOTIF:PXVXL/I motif	SEQ_UP	1	
MOTIF:PXXP	SEQ_UP	2	
MOTIF:PXXP motif; required for interaction with CTTN	SEQ_UP	1	
MOTIF:PXXXPR	SEQ_UP	1	
MOTIF:PXY motif 1	SEQ_UP	1	
MOTIF:PXY motif 2	SEQ_UP	1	
MOTIF:PY-motif	SEQ_UP	2	
MOTIF:Q motif	SEQ_UP	40	
MOTIF:RBM1 motif	SEQ_UP	1	
MOTIF:RBM2 motif	SEQ_UP	1	
MOTIF:Receptor activation motif	SEQ_UP	1	
MOTIF:Recognition site for proteolytical processing	SEQ_UP	1	
MOTIF:Required for efficient binding to PPP1CA and for targeting PPP1CA to the nucleolus	SEQ_UP	1	
MOTIF:Required for interaction with AP1S2	SEQ_UP	1	
MOTIF:Required for interaction with FLNA	SEQ_UP	1	
MOTIF:Required for interaction with HIRA	SEQ_UP	1	
MOTIF:Required for interaction with NPC1L1	SEQ_UP	1	
MOTIF:Required for interaction with SIRT1	SEQ_UP	1	
MOTIF:Required for interaction with SORBS1 (Ten-1 ICD form)	SEQ_UP	1	
MOTIF:Required for interaction with the PEBOW complex	SEQ_UP	1	
MOTIF:Required for methyltransferase activity	SEQ_UP	1	
MOTIF:Required for optimal activity	SEQ_UP	1	
MOTIF:Required for SUMO paralog-specific binding	SEQ_UP	1	
MOTIF:Required for TSG101-binding	SEQ_UP	1	
MOTIF:RFDP motif	SEQ_UP	1	
MOTIF:RFRV motif; mediates interaction with STK39	SEQ_UP	1	
MOTIF:RGD	SEQ_UP	1	
MOTIF:RGD 1	SEQ_UP	1	
MOTIF:RGD 2	SEQ_UP	1	
MOTIF:RIP homotypic interaction motif (RHIM)	SEQ_UP	2	
MOTIF:RIP homotypic interaction motif (RHIM) 1	SEQ_UP	1	
MOTIF:RIP homotypic interaction motif (RHIM) 2	SEQ_UP	1	
MOTIF:RLRK	SEQ_UP	1	
MOTIF:RNA-binding	SEQ_UP	1	
MOTIF:RNMT-activating domain	SEQ_UP	1	
MOTIF:RPA1-binding motif 1	SEQ_UP	1	
MOTIF:RPA1-binding motif 2	SEQ_UP	1	
MOTIF:RRK motif; mediates NuRD recruitment to telomeres	SEQ_UP	1	
MOTIF:RSXSXX motif 1	SEQ_UP	1	
MOTIF:RSXSXX motif 2	SEQ_UP	1	
MOTIF:RSXSXX motif 3	SEQ_UP	1	
MOTIF:RSXSXX motif 4	SEQ_UP	1	
MOTIF:RSXSXX motif 5	SEQ_UP	1	
MOTIF:RVIALD	SEQ_UP	1	
MOTIF:RVxF	SEQ_UP	1	
MOTIF:RXG motif; crucial for prenyltransferase activity	SEQ_UP	1	
MOTIF:RxxxFSD motif 1	SEQ_UP	1	
MOTIF:RxxxFSD motif 2	SEQ_UP	1	
MOTIF:S1P recognition	SEQ_UP	2	
MOTIF:S2P recognition	SEQ_UP	1	
MOTIF:SAPNY motif	SEQ_UP	3	
MOTIF:Secondary area of contact	SEQ_UP	8	
MOTIF:SEG motif	SEQ_UP	2	
MOTIF:Selectivity filter	SEQ_UP	63	
MOTIF:Selectivity filter of repeat I	SEQ_UP	2	
MOTIF:Selectivity filter of repeat II	SEQ_UP	2	
MOTIF:Selectivity filter of repeat III	SEQ_UP	2	
MOTIF:Selectivity filter of repeat IV	SEQ_UP	2	
MOTIF:Selectivity filter part_1	SEQ_UP	7	
MOTIF:Selectivity filter part_2	SEQ_UP	7	
MOTIF:Selectivity filter part_3	SEQ_UP	7	
MOTIF:Selectivity for potassium	SEQ_UP	2	
MOTIF:SG1	SEQ_UP	1	
MOTIF:SH2-binding	SEQ_UP	9	
MOTIF:SH2-binding 1	SEQ_UP	1	
MOTIF:SH2-binding 2	SEQ_UP	1	
MOTIF:SH2-binding; to FYN	SEQ_UP	1	
MOTIF:SH2-binding; to LCP2	SEQ_UP	2	
MOTIF:SH3-binding	SEQ_UP	49	
MOTIF:SH3-binding 1	SEQ_UP	6	
MOTIF:SH3-binding 2	SEQ_UP	6	
MOTIF:SH3-binding 3	SEQ_UP	4	
MOTIF:SH3-binding; class I	SEQ_UP	1	
MOTIF:SH3-binding; class II	SEQ_UP	1	
MOTIF:SH3-binding; interaction with CRK	SEQ_UP	1	
MOTIF:SHP-box	SEQ_UP	2	
MOTIF:SIM motif	SEQ_UP	1	
MOTIF:SLAM-like motif	SEQ_UP	2	
MOTIF:SlyX motif	SEQ_UP	1	
MOTIF:SMAD interaction motif (SIM)	SEQ_UP	3	
MOTIF:ST]-E-Y-X(3)-F motif 1; required for efficient microtubule binding and stabilization	SEQ_UP	1	
MOTIF:ST]-E-Y-X(3)-F motif 2; required for efficient microtubule binding and stabilization	SEQ_UP	1	
MOTIF:ST]-E-Y-X(3)-F motif 3; required for efficient microtubule binding	SEQ_UP	1	
MOTIF:ST]-E-Y-X(3)-F motif 4; required for efficient microtubule binding and stabilization	SEQ_UP	1	
MOTIF:ST]-E-Y-X(3)-Y motif 1; required for efficient microtubule binding and stabilization	SEQ_UP	1	
MOTIF:ST]-E-Y-X(3)-Y motif 2; required for efficient microtubule binding and stabilization	SEQ_UP	1	
MOTIF:Stachel	SEQ_UP	1	
MOTIF:STACHEL	SEQ_UP	1	
MOTIF:Stop-transfer sequence	SEQ_UP	2	
MOTIF:Subfamily II EGMGR motif	SEQ_UP	1	
MOTIF:Subfamily III RTxK motif	SEQ_UP	1	
MOTIF:Substrate binding	SEQ_UP	2	
MOTIF:Substrate recognition	SEQ_UP	1	
MOTIF:Subunit association domain (SAD)	SEQ_UP	1	
MOTIF:Sufficient for inhibition of PCSK1	SEQ_UP	1	
MOTIF:SUMO conjugation	SEQ_UP	1	
MOTIF:SUMO interaction motif 1 (SIM)	SEQ_UP	2	
MOTIF:SUMO interaction motif 1 (SIM); crucial for efficient sumoylation	SEQ_UP	1	
MOTIF:SUMO interaction motif 1 (SIM); mediates the binding to polysumoylated substrates	SEQ_UP	3	
MOTIF:SUMO interaction motif 1; mediates the binding to polysumoylated substrates	SEQ_UP	1	
MOTIF:SUMO interaction motif 2 (SIM)	SEQ_UP	1	
MOTIF:SUMO interaction motif 2 (SIM); mediates the binding to polysumoylated substrates	SEQ_UP	2	
MOTIF:SUMO interaction motif 2; mediates the binding to polysumoylated substrates	SEQ_UP	1	
MOTIF:SUMO interaction motif 3 (SIM)	SEQ_UP	1	
MOTIF:SUMO interaction motif 3; mediates the binding to polysumoylated substrates	SEQ_UP	1	
MOTIF:SUMO interaction motif 4; mediates the binding to polysumoylated substrates	SEQ_UP	1	
MOTIF:SVSE motif	SEQ_UP	2	
MOTIF:SXIP motif 1; mediates interaction with MAPRE1 and targeting to microtubule plus ends	SEQ_UP	1	
MOTIF:SXIP motif 2; mediates interaction with MAPRE1 and targeting to microtubule plus ends	SEQ_UP	1	
MOTIF:SYVS motif	SEQ_UP	2	
MOTIF:Tankyrase-binding domain	SEQ_UP	1	
MOTIF:Tankyrase-binding motif	SEQ_UP	3	
MOTIF:TBM	SEQ_UP	3	
MOTIF:TEK-box 1	SEQ_UP	1	
MOTIF:TEK-box 2	SEQ_UP	1	
MOTIF:TFG box	SEQ_UP	2	
MOTIF:TFLY; involved in RNA binding	SEQ_UP	1	
MOTIF:TOS motif	SEQ_UP	4	
MOTIF:TPR repeat-binding	SEQ_UP	2	
MOTIF:TQE	SEQ_UP	1	
MOTIF:TQT motif 1	SEQ_UP	1	
MOTIF:TQT motif 2	SEQ_UP	1	
MOTIF:TRAF6-binding	SEQ_UP	2	
MOTIF:Trans Golgi network signal	SEQ_UP	1	
MOTIF:Twin CX3C motif	SEQ_UP	7	
MOTIF:TXY	SEQ_UP	11	
MOTIF:Type-2 MIT-interacting motif	SEQ_UP	1	
MOTIF:Tyrosine-based internalization motif	SEQ_UP	2	
MOTIF:Tyrosine-based sorting signal	SEQ_UP	2	
MOTIF:Tyrosine-type lysosomal sorting signal	SEQ_UP	1	
MOTIF:UAP56-binding motif	SEQ_UP	1	
MOTIF:UBAN	SEQ_UP	1	
MOTIF:UbE motif	SEQ_UP	1	
MOTIF:Ubiquitin-binding	SEQ_UP	1	
MOTIF:Ubiquitin-binding 1 (UBM1)	SEQ_UP	1	
MOTIF:Ubiquitin-binding 2 (UBM2)	SEQ_UP	1	
MOTIF:Ubiquitin-interacting	SEQ_UP	1	
MOTIF:UDR	SEQ_UP	1	
MOTIF:UFM1-interacting sequence (UIS)	SEQ_UP	1	
MOTIF:UMI motif	SEQ_UP	2	
MOTIF:WASP-binding motif	SEQ_UP	1	
MOTIF:WDR5 interaction motif (WIN)	SEQ_UP	6	
MOTIF:WKS motif	SEQ_UP	1	
MOTIF:WLDD motif; essential for 7-methylguanosine-containing mRNA cap binding	SEQ_UP	1	
MOTIF:WRPW motif	SEQ_UP	9	
MOTIF:WSXWS motif	SEQ_UP	31	
MOTIF:WTKF motif; mediates interaction with adapter protein complex 2 and is essential for its function in clathrin-mediated endocytosis of INSR	SEQ_UP	1	
MOTIF:WVPP motif	SEQ_UP	1	
MOTIF:WWDYG motif	SEQ_UP	2	
MOTIF:WXXF motif 1	SEQ_UP	3	
MOTIF:WXXF motif 2	SEQ_UP	3	
MOTIF:WXXF motif 3	SEQ_UP	1	
MOTIF:XEXPHE-motif	SEQ_UP	4	
MOTIF:XLM	SEQ_UP	4	
MOTIF:YENPXY motif; contains endocytosis signal	SEQ_UP	1	
MOTIF:YERL motif; mediates interaction with adapter protein complex 2 and is essential for its function in clathrin-mediated endocytosis of INSR	SEQ_UP	1	
MOTIF:YLYF motif	SEQ_UP	1	
MOTIF:YQPW motif	SEQ_UP	1	
MOTIF:YRPW motif	SEQ_UP	1	
MOTIF:YxKxHxxxRP	SEQ_UP	1	
MOTIF:YXXL	SEQ_UP	1	
MOTIF:YXXL motif	SEQ_UP	1	
MOTIF:YXXM motif 1	SEQ_UP	3	
MOTIF:YXXM motif 2	SEQ_UP	3	
MOTIF:YXXM motif 3	SEQ_UP	3	
MOTIF:YXXM motif 4	SEQ_UP	3	
MOTIF:YXXM motif 5	SEQ_UP	3	
MOTIF:YXXM motif 6	SEQ_UP	3	
MOTIF:YXXM motif 7	SEQ_UP	3	
MOTIF:YXXM motif 8	SEQ_UP	1	
MOTIF:YXXM motif 9	SEQ_UP	1	
MOTIF:YXXo lysosomal targeting motif	SEQ_UP	1	
MOTIF:YXXXXLphi motif	SEQ_UP	4	
MOTIF:YXXZ motif	SEQ_UP	1	
MOTIF:ZIM	SEQ_UP	2	
MOTIF:Zinc knuckle motif	SEQ_UP	2	
MUTAGEN:A->AEA: In Re-den mutant; gain-of-function mutation; causes an alopecia phenotype. Attenuates intramolecular interaction between the N- and C-terminal domains, hence may relieve autoinhibition; constitutively active in triggering pyroptosis.	SEQ_UP	1	
MUTAGEN:A->C,D,G,H,K,N,Q,R,S,T: No change in EPO binding.	SEQ_UP	1	
MUTAGEN:A->D: Abolished ability to regulate mitophagy.	SEQ_UP	1	
MUTAGEN:A->D: Abolishes interaction with GBA. No effect on normal location in lysosomes.	SEQ_UP	1	
MUTAGEN:A->D: Compromises SIM1:ARNT2 heterodimer stability. Does not compromises NPAS4:ARNT2 heterodimer stability.	SEQ_UP	1	
MUTAGEN:A->D: Decreases HRE DNA binding.	SEQ_UP	1	
MUTAGEN:A->D: Disrupts intramolecular interactions and autoinhibition, leading to spontaneous pyroptosis-inducing activity.	SEQ_UP	1	
MUTAGEN:A->D: Highly disrupts the dimerization ability of AHR. Reduces transcription activity. Impairs interaction with ARNT.	SEQ_UP	1	
MUTAGEN:A->D: In caracul; causes a wavy hair phenotype.	SEQ_UP	1	
MUTAGEN:A->D: No effect on constitutive activity; No effect on protein level; Does not affect homooligomerization.	SEQ_UP	1	
MUTAGEN:A->D: No effect on dephosphorylating activity; increased the dephosphorylating efficiency; when associated with 911-A.	SEQ_UP	1	
MUTAGEN:A->D: No effect on interaction with TACC3.	SEQ_UP	1	
MUTAGEN:A->D: Nuclear colocalization.	SEQ_UP	1	
MUTAGEN:A->D: Reduces transcription activity. Markedly reduces interaction with AHR. Impairs heterodimer formation with EPAS1. Markedly decreases heterodimer formation with HIF1A. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Compromise NPAS4:ARNT heterodimer stability. Compromise AHR:ARNT heterodimer stability.	SEQ_UP	1	
MUTAGEN:A->D: Spontaneous pyroptosis-inducing activity.	SEQ_UP	1	
MUTAGEN:A->D: Strong decrease of IL1B release, but no effect on autocatalytic cleavage within the FIIND region.	SEQ_UP	1	
MUTAGEN:A->D: Strongly reduces interaction with EPS15 and SYNRG.	SEQ_UP	1	
MUTAGEN:A->D: Unable to interact with RPB14.	SEQ_UP	1	
MUTAGEN:A->E: Abolished ability to promote phosphatidylserine exposure. Promotes localization to the cytoplasm.	SEQ_UP	1	
MUTAGEN:A->E: Abolishes interaction with SEMA6A.	SEQ_UP	1	
MUTAGEN:A->E: Enhanced secretion and increased EPO binding.	SEQ_UP	1	
MUTAGEN:A->E: In Repro9; male sterility due to defects in spermatogenesis. Impaired piRNA biogenesis.	SEQ_UP	1	
MUTAGEN:A->E: In tlt (tilted phenotype); affected mice have defects in the formation of otoconia in the inner ear, but do not suffer from deafness or other inner ear defects. They cannot perceive gravity and have problems with spatial orientation and with keeping their equilibrium. They show typical head-tilting behavior and are unable to swim. Impaired subcellular localization to the plasma membrane. Effects may be due to dysregulation of pH.	SEQ_UP	1	
MUTAGEN:A->E: No effect on interaction with MSL3. Reduces interaction; when associated with E-589. Strongly reduces interaction with MSL3; when associated with E-556 and E-589.	SEQ_UP	1	
MUTAGEN:A->E: Reduced MAIT cell activation.	SEQ_UP	1	
MUTAGEN:A->E: Reduces DNA-binding,, attenuates transcriptional activity, does not effect estrogen-dependent NF-kappa B transcriptional repression.	SEQ_UP	1	
MUTAGEN:A->E: Strongly reduced affinity for USH1G.	SEQ_UP	1	
MUTAGEN:A->F,I,M,W,Y: Little EPO binding.	SEQ_UP	1	
MUTAGEN:A->F: Abolishes LPC transport.	SEQ_UP	1	
MUTAGEN:A->F: Loss of ATP binding and reduces MAPK1 and MAPK3 phosphorylation levels. Loss of kinase activity towards MAP2K1 in vitro. Abnormal constitutive interaction with CRAF. No effect on the interaction with BRAF and MAP2K1.	SEQ_UP	1	
MUTAGEN:A->F: No effect on PDCD1 binding.	SEQ_UP	1	
MUTAGEN:A->G: Decreases (5S)-lipoxygenase activity. Forms 9-hydroperoxyicosatetraenoic acid (9-HPETE) as the major arachidonic acid oxygenation product. Loss of arachidonate (5S)-lipoxygenase activity; when associated with W-360; I-425 and M-426. Forms 11(R)-hydroperoxyicosatetraenoic acid (11(R)-HPETE) as the major arachidonic acid oxygenation product; when associated with W-360; I-425 and M-426.	SEQ_UP	1	
MUTAGEN:A->G: In Rco12; causes a wavy pelage and curly vibrissae.	SEQ_UP	1	
MUTAGEN:A->G: Loss of interaction with XIAP.	SEQ_UP	1	
MUTAGEN:A->G: No effect on basolateral sorting in epithelial cells.	SEQ_UP	1	
MUTAGEN:A->G: No effect on interaction with PARD6B.	SEQ_UP	1	
MUTAGEN:A->I,W: Reduced enzymatic activity and altered stereoselectivity of the oxygenation reaction.	SEQ_UP	1	
MUTAGEN:A->I: Decreases arachidonate (5S)-lipoxygenase activity.	SEQ_UP	1	
MUTAGEN:A->I: Decreases arachidonate (5S)-lipoxygenase activity. Decreases arachidonate 5 lipoxygenase activity; when associated with A-604. Exhibits a (8S)-lipoxygenase activity; when associated with W-360. Exhibits a (15S)-lipoxygenase activity; when associated with W-360 and M-426. Loss of arachidonate (5S)-lipoxygenase activity; when associated with W-360; G-411 and M-426. Forms 11(R)-hydroperoxyicosatetraenoic acid (11(R)-HPETE) as the major arachidonic acid oxygenation product; when associated with W-360; G-411 and M-426. Does not oxygenate arachidonic acid into 5-HETE; when associated with I-425 and M-426. Catalyzes oxygenation of arachidonic acid into a major product (15S)-HETE followed by 12-HETE and 8-HETE; when associated with I-425 and M-426. Catalyzes oxygenation of linoleic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid; when associated with I-425 and M-426. Catalyzes oxygenation of anandamide to 15-OH-ANA. Knockin mice are viable, fertile, and develop normally; when associated with I-425 and M-426. Mice convert arachidonic to 15-HETE, 12-HETE, and 8-HETE; when associated with I-425 and M-426. Mice cannot synthesize pro-inflammatory leukotrienes but show significantly attenuated plasma levels of lipolytic endocannabinoids; when associated with I-425 and M-426. When aging, animals gain significantly more body weight probably due to higher levels of 13-HODE in the adipose tissue; when associated with I-425 and M-426.	SEQ_UP	1	
MUTAGEN:A->I: Slightly increases phosphatase activity with p-nitrophenylphosphate; when associated with N-41 and R-44.	SEQ_UP	1	
MUTAGEN:A->I: Stronger interaction with XIAP third BIR domain.	SEQ_UP	1	
MUTAGEN:A->K: Affects ion selectivity.	SEQ_UP	1	
MUTAGEN:A->K: Inhibits interaction with RHOA, reduces localization at junctions and prevents apical junction formation; when associated with K-155.	SEQ_UP	1	
MUTAGEN:A->K: Inhibits interaction with RHOA, reduces localization at junctions and prevents apical junction formation; when associated with K-60.	SEQ_UP	1	
MUTAGEN:A->L,P,V: Reduced EPO binding.	SEQ_UP	1	
MUTAGEN:A->L: Loss of pericentromeric heterochromatin location. Disrupted DNA binding.	SEQ_UP	1	
MUTAGEN:A->L: No effect on pericentromeric heterochromatin location. Disrupted DNA binding.	SEQ_UP	1	
MUTAGEN:A->L: No effect on UBE2I binding nor on sumoylation.	SEQ_UP	1	
MUTAGEN:A->L: Reduced potassium ion transmembrane transport.	SEQ_UP	1	
MUTAGEN:A->M: Loss of calcium-dependent cell-cell adhesion.	SEQ_UP	1	
MUTAGEN:A->N: Does not affect formation of a heterodimer with TCF3 and ability to bind DNA.	SEQ_UP	1	
MUTAGEN:A->P: Abolishes interaction with HSP70 and TNFRSF1A.	SEQ_UP	1	
MUTAGEN:A->P: Loss of interaction with DLC2.	SEQ_UP	1	
MUTAGEN:A->P: Reduces protease activity.	SEQ_UP	1	
MUTAGEN:A->P: Shows a defect in ciliary localization with no apparent effect on ciliation, mitosis or centriole number.	SEQ_UP	1	
MUTAGEN:A->Q: Decreased 'Lys-48'-linked polyubiquitin binding; when associated with A-230.	SEQ_UP	1	
MUTAGEN:A->Q: Decreased 'Lys-48'-linked polyubiquitin binding. Loss of 'Lys-48'-linked polyubiquitin binding, loss of interaction with BAG6 and loss of association with the proteasome complex; when associated with Q-229 and Q-231.	SEQ_UP	1	
MUTAGEN:A->Q: Decreased 'Lys-48'-linked polyubiquitin binding. Loss of interaction with ubiquitin polymers and ubiquitinated proteins, loss of interaction with BAG6 and no effect on association with the proteasome complex; when associated with Q-201 and Q-229. Loss of 'Lys-48'-linked polyubiquitin binding, loss of interaction with BAG6 and loss of association with the proteasome complex; when associated with Q-205 and Q-229.	SEQ_UP	1	
MUTAGEN:A->Q: Decreased 'Lys-48'-linked polyubiquitin binding. Loss of interaction with ubiquitin polymers and ubiquitinated proteins, loss of interaction with BAG6 and no effect on association with the proteasome complex; when associated with Q-201 and Q-231. Loss of 'Lys-48'-linked polyubiquitin binding, loss of interaction with BAG6 and loss of association with the proteasome complex; when associated with Q-205 and Q-231.	SEQ_UP	1	
MUTAGEN:A->Q: Decreases misincorporation of Cys instead of Ala.	SEQ_UP	1	
MUTAGEN:A->Q: Loss of interaction with ubiquitin polymers and ubiquitinated proteins, loss of interaction with BAG6 and no effect on association with the proteasome complex; when associated with Q-229 and Q-231.	SEQ_UP	1	
MUTAGEN:A->Q: No effect on MHC class I peptide tetramer binding; when associated with T-170.	SEQ_UP	1	
MUTAGEN:A->R: Abolishes interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:A->R: Blocks calcium/calmodulin binding.	SEQ_UP	1	
MUTAGEN:A->R: Does not affect phosphorylarion at Ser-41; when associated with A-195.	SEQ_UP	1	
MUTAGEN:A->R: Reduces PRDM14 and OCT14 occupancy on target sites, no effect on interaction with PRDM14, predicted to impair homooligomerization; when associated with R-330; R-342; E-346; E-360; R-363 and R-374.	SEQ_UP	1	
MUTAGEN:A->R: Temperature-sensitive defect in the interaction with RPB14.	SEQ_UP	1	
MUTAGEN:A->S: Decreased transverse tubule regularity and aberrant calcium handling in septal cardiomyocytes.	SEQ_UP	1	
MUTAGEN:A->S: Does not inhibit interaction with OAZ1.	SEQ_UP	1	
MUTAGEN:A->S: No effect on binding to RII.	SEQ_UP	1	
MUTAGEN:A->S: Reduced activity.	SEQ_UP	1	
MUTAGEN:A->S: Strongly reduces interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:A->T: Decreased transporter activity. Does not affect localization to plasma membrane.	SEQ_UP	1	
MUTAGEN:A->T: Does not affect kinase activity and decreases sensitivity towards small molecule kinase inhibitors.	SEQ_UP	1	
MUTAGEN:A->T: Homozygous knockin male mice are infertile. The spermatogenesis process is normal. However spermatozoa dysplay acrosomal ultrastructural defects. Complete absence of the ACTL7A protein in both testes and sperms. Abnormal distribution of PLCZ1 in sperms.	SEQ_UP	1	
MUTAGEN:A->T: In Rim3 mutant; gain-of-function mutation; causes an alopecia phenotype. Attenuates intramolecular interaction between the N- and C-terminal domains, hence may relieve autoinhibition; constitutively active in triggering pyroptosis.	SEQ_UP	1	
MUTAGEN:A->T: Induces centriole elongation. Impaired CEP164 and IFT88 recruitment. Impaired ciliogenesis.	SEQ_UP	1	
MUTAGEN:A->T: Loss of interaction with RNF4; when associated with S-1702; R-1736 and V-1737.	SEQ_UP	1	
MUTAGEN:A->T: No effect on activity.	SEQ_UP	1	
MUTAGEN:A->T: No effect.	SEQ_UP	1	
MUTAGEN:A->T: Significantly reduces activity.	SEQ_UP	1	
MUTAGEN:A->V: Abrogates tetramerization, reduces dimerization, does not affect binding to microtubules and to phosphorylated light-activated rhodopsin; when associated with A-86 and A-198.	SEQ_UP	1	
MUTAGEN:A->V: Activated.	SEQ_UP	1	
MUTAGEN:A->V: Destabilization of TERC, impaired telomerase function, and reduced rRNA pseudouridylation and pre-rRNA processing.	SEQ_UP	1	
MUTAGEN:A->V: Greatly reduced binding to MAD; when associated with D-308 and A-311.	SEQ_UP	1	
MUTAGEN:A->V: In knockin mouse model, decreases protein levels. Mice exhibit a short sleep phenotype. Changes the electrophysiological properties of dorsal pons neurons.	SEQ_UP	1	
MUTAGEN:A->V: Moderate decrease in cilia motility.	SEQ_UP	1	
MUTAGEN:A->V: No change to global protein fold or protein stability. Alters local protein folding.	SEQ_UP	1	
MUTAGEN:A->V: No effect on ATP binding and MAPK1 and MAPK3 phosphorylation levels. No effect on the interaction with MAP2K1.	SEQ_UP	1	
MUTAGEN:A->V: No effect on kinetic constants with smaller substrates like benzaldehyde or phthalazine. Decreases substrate affinity and slightly increases catalytic efficiency for bulkier substrates like phenanthridine.	SEQ_UP	1	
MUTAGEN:A->V: Reduced potassium ion transmembrane transport.	SEQ_UP	1	
MUTAGEN:A->W: Abolishes interaction with CD4 endocytosis signal motif.	SEQ_UP	1	
MUTAGEN:A->W: Decreases interaction with TLR3.	SEQ_UP	1	
MUTAGEN:A->W: Loss of N-methyltransferase activity.	SEQ_UP	1	
MUTAGEN:A->W: Reduced lipid binding and transactivation. Abolishes ligand binding and reduces transactivation; when associated with F-345.	SEQ_UP	1	
MUTAGEN:A->W: Strongly reduced transactivation.	SEQ_UP	1	
MUTAGEN:A->Y: Reduces enzyme activity and affinity for substrate. Alters the stereospecificity, so that androstenedione is converted to testosterone.	SEQ_UP	1	
MUTAGEN:AA->KK: Abolishes homodimerization. Strongly decreases affinity for pyridoxal phosphate.	SEQ_UP	1	
MUTAGEN:AF->SS: Abolishes interaction with TERF2IP/RAP1 but does not affect protection of telomeres against non-homologous end-joining (NHEJ)-mediated repair.	SEQ_UP	1	
MUTAGEN:AG->DD: Abolishes N-terminal proteolytic processing.	SEQ_UP	1	
MUTAGEN:AKLKE->SKLKQ: Wild-type binding to BoNT/B.	SEQ_UP	1	
MUTAGEN:AKPQVLSS->QQQQQQQQ: No effect on 'Lys-48'-linked polyubiquitin binding.	SEQ_UP	1	
MUTAGEN:AVG->GVV: Confers SIAH1-mediated degradation and strong SIAH1 binding.	SEQ_UP	1	
MUTAGEN:C->A,F,V: No receptor activity in response to MTMT binding, even in the presence of copper.	SEQ_UP	1	
MUTAGEN:C->A,S: Abolished inhibition by nitrofuran derivatives C-178 and C-176; abolished palmitoylation.	SEQ_UP	1	
MUTAGEN:C->A,S: Abolishes deubiquitinase activity without affecting interaction with RNF31. Lethality at midgestation in knockin mice caused by inactivation of the LUBAC complex, leading to cell death mediated by TNFR1 and RIPK1.	SEQ_UP	1	
MUTAGEN:C->A,S: Abolishes enzyme activity.	SEQ_UP	1	
MUTAGEN:C->A,S: Loss of enzyme activity.	SEQ_UP	1	
MUTAGEN:C->A,S: No effect on enzyme activity.	SEQ_UP	1	
MUTAGEN:C->A,V: No receptor activity in response to MTMT binding, even in the presence of copper.	SEQ_UP	1	
MUTAGEN:C->A: 40% decrease in alanine uptake.	SEQ_UP	1	
MUTAGEN:C->A: Abolished deubiquitinase activity.	SEQ_UP	1	
MUTAGEN:C->A: Abolished E3 ubiquitin-protein activity and ability to inhibit type I interferon IFN-beta production.	SEQ_UP	1	
MUTAGEN:C->A: Abolished tyrosine carboxypeptidase activity.	SEQ_UP	2	
MUTAGEN:C->A: Abolishes 'Lys-48'- and 'Lys-63'-specific deubiquitinase activity. Impairs 'Lys-63'-specific deubiquitination of TRAF6 substrate.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes ability to deubiquitinate histone H2A and ability to regulate transcription.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes ability to suppress tumorigenicity when expressed in NCI-H226 cells.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes catalytic activity. Abolishes ability to ubiquitinate ARC.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes cell surface expression.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes deubiquitinating activity.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes disulfide bond formation.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes disulfide reductase activity; when associated with A-158; A-161; A-480; A-483; A-588; A-591 and A-700.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes disulfide reductase activity; when associated with A-158; A-161; A-480; A-483; A-588; A-591 and A-703.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes disulfide reductase activity; when associated with A-158; A-161; A-480; A-483; A-588; A-700 and A-703.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes disulfide reductase activity; when associated with A-158; A-161; A-480; A-483; A-591; A-700 and A-703.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes disulfide reductase activity; when associated with A-158; A-161; A-480; A-588; A-591; A-700 and A-703.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes disulfide reductase activity; when associated with A-158; A-161; A-483; A-588; A-591; A-700 and A-703.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes disulfide reductase activity; when associated with A-158; A-480; A-483; A-588; A-591; A-700 and A-703.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes disulfide reductase activity; when associated with A-161; A-480; A-483; A-588; A-591; A-700 and A-703.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes disulfide-dependent homodimerization; when associated with A-10. Does not affect disulfide-dependent homodimerization; when associated with A-33.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes disulfide-dependent homodimerization. Abolishes disulfide-dependent homodimerization; when associated with A-21.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes E2-like activity.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes E3 ubiquitin ligase activity. Impairs ubiquitination of SCAP and functional regulation of cholesterol biosynthesis. Impairs sterol-induced ubiquitination and degradation of HMGCR.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes E3 ubiquitin-protein ligase activity; when associated with L-12.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes enzyme activity.	SEQ_UP	3	
MUTAGEN:C->A: Abolishes extracellular secretion. Inhibits axonal growth of callosal projections when overexpressed.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes formation of disulfide bonds and ability to interact with TGFB1; when associated with A-219.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes formation of disulfide bonds and ability to interact with TGFB1; when associated with A-363.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes homohexamer formation from homotrimers; when associated with A-34.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes homohexamer formation from homotrimers; when associated with A-38.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes inhibition of NFKB2 processing; when associated with A-52.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes inhibition of NFKB2 processing; when associated with A-55.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes interaction with CTNNB1. No effect on nuclear localization.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes interaction with GATA1.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes interaction with MICU2.	SEQ_UP	2	
MUTAGEN:C->A: Abolishes ion channel activity. No effect on cell surface expression. Reduced glycosylation.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes localization with replicating mitochondria.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes multimeric complex formation.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes palmitoylation and plasma membrane association; when associated with A-3.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes palmitoylation and plasma membrane association; when associated with A-6.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes palmitoylation; when associated with 183-A--A-185.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes palmitoylation.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes palmitoylation. No effect on function and subcellular location.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes protease activity.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes repression of NFE2L2/NRF2-dependent gene expression. Knockin mice die approximately three weeks after birth because of impaired ability of the BCR(KEAP1) complex to ubiquitinate NFE2L2/NRF2; when associated with A-288.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes repression of NFE2L2/NRF2-dependent gene expression. Slows down degradation of NFE2L2/NRF2. Knockin mice die approximately three weeks after birth because of impaired ability of the BCR(KEAP1) complex to ubiquitinate NFE2L2/NRF2; when associated with A-273.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes S-nitrosylation; when associated with Ala-346.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes S-nitrosylation; when associated with Ala-40.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes the ability to mediate myoblast fusion; does not affect interaction with MYMK; does not affect localization to the cell membrane.	SEQ_UP	1	
MUTAGEN:C->A: Abolishes transport activity.	SEQ_UP	1	
MUTAGEN:C->A: Accumulation of uncleaved form with the N-terminal methionine.	SEQ_UP	1	
MUTAGEN:C->A: Almost completely blocks the ability to traffic to the cilia; when associated with 3872-A-A-3873. Affects palmitoylation; when associated with 3872-A-A-3873. Disrupts interaction with RAB8A; when associated with 3872-A-A-3873. Disrupts interaction with ARF4; when associated with 3872-A-A-3873.	SEQ_UP	1	
MUTAGEN:C->A: Cleaved by subtilisin-like proprotein convertase.	SEQ_UP	1	
MUTAGEN:C->A: Complete loss of auto-ubiquitination.	SEQ_UP	1	
MUTAGEN:C->A: Complete loss of disulfide oxidase activity in vitro.	SEQ_UP	1	
MUTAGEN:C->A: Complete loss of palmitoylation, mislocalization from mitochondrial membrane and reduced apoptotic function; when associated with A-159, A-161, A-163 and A-166.	SEQ_UP	1	
MUTAGEN:C->A: Complete loss of palmitoylation, mislocalization from mitochondrial membrane to nucleus and reduced apoptotic function; when associated with A-159, A-161, A-163 and A-164.	SEQ_UP	1	
MUTAGEN:C->A: Complete loss of palmitoylation, mislocalization from mitochondrial membrane to nucleus and reduced apoptotic function; when associated with A-159, A-161, A-164 and A-166.	SEQ_UP	1	
MUTAGEN:C->A: Complete loss of palmitoylation, mislocalization from mitochondrial membrane to nucleus and reduced apoptotic function; when associated with A-159, A-163, A-164 and A-166. Partial loss of palmitoylation; when associated with A-159.	SEQ_UP	1	
MUTAGEN:C->A: Complete loss of palmitoylation, mislocalization from mitochondrial membrane to nucleus and reduced apoptotic function; when associated with A-161, A-163, A-164 and A-166. Partial loss of palmitoylation; when associated with A-161.	SEQ_UP	1	
MUTAGEN:C->A: Completely abolishes S-palmitoylation; when associated with A-478; A-482 and A-485. Doesn't affect trans-Golgi network and endosome localization; when associated with A-478; A-482 and A-485. Reduces membrane raft association; when associated with A-478; A-482 and A-485. Doesn't affect APP processing; when associated with A-478; A-482 and A-485.	SEQ_UP	1	
MUTAGEN:C->A: Decrease in death-inducing activity.	SEQ_UP	1	
MUTAGEN:C->A: Decrease in the level of cell surface expression and transport function. 80% decrease in the level of transport activity; when associated with A-49; A-122 and A-183. Complete loss of transport function; when associated with A-49; A-78; A-99; A-122; A-172; A-183; A-200; A-362; A-335; A-379; A-402 and A-427.	SEQ_UP	1	
MUTAGEN:C->A: Decrease in the level of cell surface expression and transport function. Complete loss of transport function; when associated with A-49; A-78; A-99; A-122; A-172; A-200; A-362; A-335; A-379; A-402; A-427 and A-434.	SEQ_UP	1	
MUTAGEN:C->A: Decrease in the level of cell surface expression and transport function. Complete loss of transport function; when associated with A-49; A-78; A-99; A-172; A-183; A-200; A-362; A-335; A-379; A-402; A-427 and A-434.	SEQ_UP	1	
MUTAGEN:C->A: Decrease in the level of cell surface expression and transport function. Complete loss of transport function; when associated with A-78; A-99; A-122; A-172; A-183; A-200; A-362; A-335; A-379; A-402; A-427 and A-434.	SEQ_UP	1	
MUTAGEN:C->A: Decreased sensitivity to activation by noradrenaline in thermogenic respiration.	SEQ_UP	1	
MUTAGEN:C->A: Decreased UCP1 activity in thermogenic respiration.	SEQ_UP	1	
MUTAGEN:C->A: Decreases endogenous retroviruses silencing and cell growth.	SEQ_UP	1	
MUTAGEN:C->A: Delays neurite degeneration and inhibits DPYSL2/CRMP2 phosphorylation.	SEQ_UP	1	
MUTAGEN:C->A: Does not abolish the localization of ACHE.	SEQ_UP	1	
MUTAGEN:C->A: Does not act as a substrate-trapping mutant.	SEQ_UP	1	
MUTAGEN:C->A: Does not affect ABCB10 glutathionylation.	SEQ_UP	1	
MUTAGEN:C->A: Does not affect ability to promote ZBP1-mediated pyroptosis, apoptosis, and necroptosis (PANoptosis).	SEQ_UP	1	
MUTAGEN:C->A: Does not affect disulfide-dependent homodimerization; when associated with A-21.	SEQ_UP	1	
MUTAGEN:C->A: Does not affect endoplasmic reticulum localization. Does not affect plama membrane localization. Reduces oligomerization. Impairs water permeability.	SEQ_UP	1	
MUTAGEN:C->A: Does not affect glycerophosphocholine cholinephosphodiesterase activity; when associated with S-412. Does not affect choline metabolism; when associated with S-412.	SEQ_UP	1	
MUTAGEN:C->A: Does not affect heterooligomerization with C1QL4; when associated with A-28.	SEQ_UP	2	
MUTAGEN:C->A: Does not affect heterooligomerization with C1QL4; when associated with A-32.	SEQ_UP	2	
MUTAGEN:C->A: Does not affect homo-, nor heterooligomerization with C1QL1, C1QL2 and C1QL3; when associated with A-28. Increased secretion; when associated with A-28. Does not impair inhibition of adipocyte differentiation; when associated with A-28.	SEQ_UP	1	
MUTAGEN:C->A: Does not affect homo-, nor heterooligomerization with C1QL1, C1QL2 and C1QL3; when associated with A-32. Increased secretion; when associated with A-32. Does not impair inhibition of adipocyte differentiation; when associated with A-32.	SEQ_UP	1	
MUTAGEN:C->A: Does not affect homooligomerization.	SEQ_UP	1	
MUTAGEN:C->A: Does not affect nuclear localization. Does not prevent phosphorylation at S-431.	SEQ_UP	1	
MUTAGEN:C->A: Does not affect palmitoylation.	SEQ_UP	1	
MUTAGEN:C->A: Does not affect protein cleveage.	SEQ_UP	1	
MUTAGEN:C->A: Does not affect S-nitrosylation.	SEQ_UP	1	
MUTAGEN:C->A: Does not inhibit calcium-dependent translocation to the cell membrane; when associated with G-286 and G-288.	SEQ_UP	1	
MUTAGEN:C->A: Does not strongly affect N-terminal glutamine amidohydrolase activity.	SEQ_UP	1	
MUTAGEN:C->A: Dominant negative mutant; can prevent Wallerian degeneration when overexpressed.	SEQ_UP	1	
MUTAGEN:C->A: Dominant-negative mutant that abolishes homooligomerization and function in membrane repair.	SEQ_UP	1	
MUTAGEN:C->A: Fails to assemble into disulfide-bonded multimers, while still exhibiting non-covalently associated high molecular weight oligomeric states in solution; retains binding to LRP8 and VLDR receptors but fails to show signaling activity.	SEQ_UP	1	
MUTAGEN:C->A: Fails to autoubiquitinate.	SEQ_UP	1	
MUTAGEN:C->A: Fails to homodimerize.	SEQ_UP	1	
MUTAGEN:C->A: Forms oxidized oligomers regardless of TIKI2. Does not affect palmitoleoylation.	SEQ_UP	1	
MUTAGEN:C->A: Highly decreases glycerophosphocholine cholinephosphodiesterase activity. Loss of choline metabolism.	SEQ_UP	1	
MUTAGEN:C->A: Homozygous embryos die at midgestation. Defects are caused by a dramatic increase in production of Ser-mischarged tRNA(Ala).	SEQ_UP	1	
MUTAGEN:C->A: Impaired ability to mediate deubiquitination of CGAS.	SEQ_UP	1	
MUTAGEN:C->A: Impairs aminoacylation activity.	SEQ_UP	1	
MUTAGEN:C->A: Impairs deubiquitination of EPS15, RNF128 and RNF41.	SEQ_UP	1	
MUTAGEN:C->A: Impairs DNA-binding.	SEQ_UP	1	
MUTAGEN:C->A: Impairs interaction with EHMT1 and EHMT2.	SEQ_UP	1	
MUTAGEN:C->A: Impairs S-nitrosylation. Abolishes S-nitrosylation; when associated with A-262.	SEQ_UP	1	
MUTAGEN:C->A: Impairs S-nitrosylation. Abolishes S-nitrosylation; when associated with A-274.	SEQ_UP	1	
MUTAGEN:C->A: In GM4; defective in methyltransferase activity without affecting DNA methylation.	SEQ_UP	1	
MUTAGEN:C->A: In LM4; does not prevent methyltransferase activity.	SEQ_UP	1	
MUTAGEN:C->A: Induces little effect.	SEQ_UP	1	
MUTAGEN:C->A: Loss of activity. Does not affect the interaction with SBF2/MTMR13.	SEQ_UP	1	
MUTAGEN:C->A: Loss of adipogenesis inhibition, when associated with A-31.	SEQ_UP	1	
MUTAGEN:C->A: Loss of adipogenesis inhibition, when associated with A-48.	SEQ_UP	1	
MUTAGEN:C->A: Loss of association with membranes.	SEQ_UP	3	
MUTAGEN:C->A: Loss of catalytic activity and of autocatalytic processing. Loss of LPS-induced pyroptosis. No effect on the interaction with LPS.	SEQ_UP	1	
MUTAGEN:C->A: Loss of catalytic activity. No effect on BCL2L11-binding, BCL2L11 stabilization, nor on apoptosis.	SEQ_UP	1	
MUTAGEN:C->A: Loss of deubiquitinating activity, does not disassemble TRAF6:UBE2N ubiquitin ligase complex, abolioshes TAX1BP1 interaction with UBE2N.	SEQ_UP	1	
MUTAGEN:C->A: Loss of deubiquitinating activity.	SEQ_UP	1	
MUTAGEN:C->A: Loss of E3 ligase activity.	SEQ_UP	2	
MUTAGEN:C->A: Loss of E3 ubiquitin protein ligase activity.	SEQ_UP	1	
MUTAGEN:C->A: Loss of enzyme activity. No effect on ligand binding.	SEQ_UP	1	
MUTAGEN:C->A: Loss of function.	SEQ_UP	1	
MUTAGEN:C->A: Loss of homodimerization and deoxyribonuclease activity. Shows a 1.3-fold higher rate for the cleavage of the 5hmC-modified DNA junction over unmodified junction, as compared to the 1.8-fold difference seen in the wild type enzyme.	SEQ_UP	1	
MUTAGEN:C->A: Loss of interaction with CNOT7.	SEQ_UP	1	
MUTAGEN:C->A: Loss of interaction with EGFR and FLT3. No effect on E3 ubiquitin protein ligase activity but alters specificity for 'Lys-48'-linked chains; when associated with A-13.	SEQ_UP	1	
MUTAGEN:C->A: Loss of interaction with EGFR and FLT3. No effect on E3 ubiquitin protein ligase activity but alters specificity for 'Lys-48'-linked chains; when associated with A-16.	SEQ_UP	1	
MUTAGEN:C->A: Loss of interaction with EGFR and FLT3. No effect on E3 ubiquitin protein ligase activity; when associated with A-22.	SEQ_UP	1	
MUTAGEN:C->A: Loss of interaction with EGFR and FLT3. No effect on E3 ubiquitin protein ligase activity; when associated with A-25.	SEQ_UP	1	
MUTAGEN:C->A: Loss of kinase activity; when associated with A-1813.	SEQ_UP	1	
MUTAGEN:C->A: Loss of kinase activity; when associated with A-1820.	SEQ_UP	1	
MUTAGEN:C->A: Loss of kinase ativity. Knockin mice show embryonic lethality caused by endothelial cell necroptosis leading to cardiovascular defects. Mlkl deficiency rescues the cardiovascular phenotype of knockin mice, but causes perinatal lethality caused by induction of pyroptosis.	SEQ_UP	1	
MUTAGEN:C->A: Loss of localization to focal adhesion; when associated with A-369.	SEQ_UP	1	
MUTAGEN:C->A: Loss of localization to focal adhesion; when associated with A-372.	SEQ_UP	1	
MUTAGEN:C->A: Loss of methyltransferase activity.	SEQ_UP	1	
MUTAGEN:C->A: Loss of N-terminal glutamine amidohydrolase activity.	SEQ_UP	1	
MUTAGEN:C->A: Loss of oligomerization of Gasdermin-D, N-terminal.	SEQ_UP	1	
MUTAGEN:C->A: Loss of promotion of EKLF sumoylation; when associated with G-346 and G-351.	SEQ_UP	1	
MUTAGEN:C->A: Loss of protease activity.	SEQ_UP	1	
MUTAGEN:C->A: Loss of protein deubiquitination and suppression of inhibition on JNK and NF-kappa-B signaling pathway activation. Loss of the ability to inhibit stress granule (SG) formation. No loss of RNase activity. No effect on ICOS surface expression.	SEQ_UP	1	
MUTAGEN:C->A: Loss of RNA methyltransferase activity.	SEQ_UP	1	
MUTAGEN:C->A: Loss of SLC40A1 degradation; when associated with A-236.	SEQ_UP	1	
MUTAGEN:C->A: Loss of SLC40A1 degradation; when associated with A-239.	SEQ_UP	1	
MUTAGEN:C->A: Loss of SLC40A1 degradation.	SEQ_UP	1	
MUTAGEN:C->A: Loss of transcription activation.	SEQ_UP	1	
MUTAGEN:C->A: Loss of ubiquitin binding. Normal dimer formation.	SEQ_UP	1	
MUTAGEN:C->A: Loss of ubiquitin ligase activity.	SEQ_UP	1	
MUTAGEN:C->A: Loss of ubiquitin protein ligase activity.	SEQ_UP	1	
MUTAGEN:C->A: Loss of ubiquitination activity. Loss of protection against DNA damage. No effect on PAR-binding.	SEQ_UP	1	
MUTAGEN:C->A: Loss of ZDHHC7 and ZDHHC21 binding. Loss of palmitoylation.	SEQ_UP	1	
MUTAGEN:C->A: No change in receptor activity in response to MTMT binding in the presence of copper. Decreased receptor activity in the absence of copper.	SEQ_UP	1	
MUTAGEN:C->A: No change in the interaction with ADIPOQ.	SEQ_UP	1	
MUTAGEN:C->A: No change in the interaction with CTRP9.	SEQ_UP	1	
MUTAGEN:C->A: No effect of cysteine-modifying agent MTSET on ion permeability in contrast to wild-type where MTSET blocks current.	SEQ_UP	1	
MUTAGEN:C->A: No effect on ability to acylate ghrelin.	SEQ_UP	1	
MUTAGEN:C->A: No effect on basal uridylation activity, but loss of LIN28A-enhanced uridylation; when associated with A-326.	SEQ_UP	1	
MUTAGEN:C->A: No effect on basal uridylation activity, but loss of LIN28A-enhanced uridylation; when associated with A-329.	SEQ_UP	1	
MUTAGEN:C->A: No effect on E3 ubiquitin-protein ligase activity.	SEQ_UP	1	
MUTAGEN:C->A: No effect on homotrimer formation, but loss of higher-order oligomeric complexes; when associated with A-29. Does not affect heterooligomerization with C1QL4; when associated with A-29.	SEQ_UP	1	
MUTAGEN:C->A: No effect on homotrimer formation, but loss of higher-order oligomeric complexes; when associated with A-33. Does not affect heterooligomerization with C1QL4; when associated with A-33.	SEQ_UP	1	
MUTAGEN:C->A: No effect on interaction with DNAJC5 and SNAP25.	SEQ_UP	1	
MUTAGEN:C->A: No effect on interaction with PARD6B.	SEQ_UP	1	
MUTAGEN:C->A: No effect on localization to stress granules.	SEQ_UP	1	
MUTAGEN:C->A: No effect on location at the cell membrane. Abolishes palmitoylation; when associated with A-52 and A-53.	SEQ_UP	1	
MUTAGEN:C->A: No effect on MAGED1 binding. Decrease in ubiquitination of MAGED1. No inhibition of DLX5-dependent transcriptional activity.	SEQ_UP	1	
MUTAGEN:C->A: No effect on oligomerization.	SEQ_UP	1	
MUTAGEN:C->A: No effect on pericentromeric heterochromatin location. No change in DNA binding.	SEQ_UP	1	
MUTAGEN:C->A: No effect on S-nitrosylation.	SEQ_UP	1	
MUTAGEN:C->A: No effect on SARS-CoV-2 infection; when associated with 71-A-A-72.	SEQ_UP	1	
MUTAGEN:C->A: No effect on secretion.	SEQ_UP	1	
MUTAGEN:C->A: No effect on subcellular localization.	SEQ_UP	1	
MUTAGEN:C->A: No effect on subcellular location.	SEQ_UP	1	
MUTAGEN:C->A: No effect on TGF-beta and BMP signaling.	SEQ_UP	1	
MUTAGEN:C->A: No effect on the interaction with GYG1. Loss of interaction with GYG1; when associated with A-8.	SEQ_UP	1	
MUTAGEN:C->A: No effect on UCP1 activity in thermogenic respiration.	SEQ_UP	1	
MUTAGEN:C->A: No effect.	SEQ_UP	2	
MUTAGEN:C->A: No methyltransferase activity.	SEQ_UP	1	
MUTAGEN:C->A: No significant effect on alanine uptake.	SEQ_UP	1	
MUTAGEN:C->A: No sulfinic acid detected following treatment with hydrogen peroxide.	SEQ_UP	1	
MUTAGEN:C->A: Not cleaved by subtilisin-like proprotein convertase 4. Not cleaved by subtilisin-like proprotein convertase; when associated with A-795.	SEQ_UP	1	
MUTAGEN:C->A: Not cleaved by subtilisin-like proprotein convertase. Not cleaved by subtilisin-like proprotein convertase; when associated with A-1053.	SEQ_UP	1	
MUTAGEN:C->A: Prevents ABCB10 glutathionylation.	SEQ_UP	1	
MUTAGEN:C->A: Prevents Matn3 protein aggregation; in association with A-72 and D-189.	SEQ_UP	1	
MUTAGEN:C->A: Prevents Matn3 protein aggregation; in association with D-189 and A-258.	SEQ_UP	1	
MUTAGEN:C->A: Reduced electrophoretic mobility; when associated with A-170.	SEQ_UP	1	
MUTAGEN:C->A: Reduced electrophoretic mobility; when associated with A-177.	SEQ_UP	1	
MUTAGEN:C->A: Reduced electrophoretic mobility; when associated with A-49.	SEQ_UP	1	
MUTAGEN:C->A: Reduced electrophoretic mobility; when associated with A-52.	SEQ_UP	1	
MUTAGEN:C->A: Reduced interaction with GORASP2; when associated with A-393.	SEQ_UP	1	
MUTAGEN:C->A: Reduced interaction with GORASP2; when associated with A-396.	SEQ_UP	1	
MUTAGEN:C->A: Reduced interaction with HRAS.	SEQ_UP	1	
MUTAGEN:C->A: Reduced number of monomers.	SEQ_UP	1	
MUTAGEN:C->A: Reduces activity about 5-fold. Reduces DNA-binding capacity. Abolished cysteine-methylation.	SEQ_UP	1	
MUTAGEN:C->A: Reduces DNA binding and strongly decreases transcriptional activation; when associated with A-119.	SEQ_UP	1	
MUTAGEN:C->A: Reduces DNA binding and strongly decreases transcriptional activation; when associated with A-122.	SEQ_UP	1	
MUTAGEN:C->A: Reduces extracellular secretion. No significant effect on axonal growth of callosal projections when overexpressed.	SEQ_UP	1	
MUTAGEN:C->A: Reduces the inhibitory effect of the atypical PHD domain.	SEQ_UP	1	
MUTAGEN:C->A: Reduces transcriptional activation; when associated with A-53.	SEQ_UP	1	
MUTAGEN:C->A: Reduces transcriptional activation; when associated with A-56.	SEQ_UP	1	
MUTAGEN:C->A: Significant reduction in LPC transport.	SEQ_UP	1	
MUTAGEN:C->A: Significantly reduces polynucleotide adenylyltransferase activity.	SEQ_UP	1	
MUTAGEN:C->A: Significantly reduces S-palmitoylation; when associated with A-478 and A-482. Completely abolishes S-palmitoylation; when associated with A-474; A-478 and A-482. Doesn't affect trans-Golgi network and endosome localization; when associated with A-474; A-478 and A-482. Reduces membrane raft association; when associated with A-474; A-478 and A-482. Doesn't affect APP processing; when associated with A-474; A-478 and A-482.	SEQ_UP	1	
MUTAGEN:C->A: Significantly reduces S-palmitoylation; when associated with A-478 and A-485. Completely abolishes S-palmitoylation; when associated with A-474; A-478 and A-485. Doesn't affect trans-Golgi network and endosome localization; when associated with A-474; A-478 and A-485. Reduces membrane raft association; when associated with A-474; A-478 and A-485. Doesn't affect APP processing; when associated with A-474; A-478 and A-485.	SEQ_UP	1	
MUTAGEN:C->A: Significantly reduces S-palmitoylation; when associated with A-482 and A-485. Completely abolishes S-palmitoylation; when associated with A-474; A-482 and A-485. Doesn't affect trans-Golgi network and endosome localization; when associated with A-474; A-482 and A-485. Reduces membrane raft association; when associated with A-474; A-482 and A-485. Doesn't affect APP processing; when associated with A-474; A-482 and A-485.	SEQ_UP	1	
MUTAGEN:C->A: Small loss of electrophoretic mobility.	SEQ_UP	1	
MUTAGEN:C->A: Strong increase in alpha-tubulin initiation step of polyglutamylase activity; when associated with R-180 and I-362. Strong increase in alpha-tubulin initiation step of polyglutamylase activity; when associated with R-180, I-182, I-362 and H-367.	SEQ_UP	1	
MUTAGEN:C->A: Strongly reduced palmitoylation; when associated with A-56 and A-2215.	SEQ_UP	1	
MUTAGEN:C->A: Strongly reduced palmitoylation; when associated with A-56 and A-849.	SEQ_UP	1	
MUTAGEN:C->A: Strongly reduced palmitoylation; when associated with A-849 and A-2215.	SEQ_UP	1	
MUTAGEN:C->A: Strongly reduces 'Lys-63'-linked ubiquitination; when associated with A-69. Abolishes inhibition of NFKB2 processing; when associated with A-69.	SEQ_UP	1	
MUTAGEN:C->A: Strongly reduces expression at the cell membrane. Reduces palmitoylation; when associated with A-52. Abolishes palmitoylation; when associated with A-52 and A-86.	SEQ_UP	1	
MUTAGEN:C->A: Strongly reduces expression at the cell membrane. Reduces palmitoylation; when associated with A-53. Abolishes palmitoylation; when associated with A-53 and A-86.	SEQ_UP	1	
MUTAGEN:C->A: Substrate-trapping mutant.	SEQ_UP	2	
MUTAGEN:C->A: Sulfinic acid detected following treatment with hydrogen peroxide.	SEQ_UP	1	
MUTAGEN:C->D: Impairs enzyme activity.	SEQ_UP	1	
MUTAGEN:C->D: Strongly reduced interaction with HRAS.	SEQ_UP	1	
MUTAGEN:C->E,N,R: Retains ability to degrade NFE2L2/NRF2; when associated with W-273. Abolishes ability to be activated by 15-deoxy-delta(12,14)-prostaglandin J2.	SEQ_UP	1	
MUTAGEN:C->F: Abolishes interaction with elongin BC complex; when associated with P-175.	SEQ_UP	1	
MUTAGEN:C->F: Abolishes mast cell activation and homodimerization.	SEQ_UP	1	
MUTAGEN:C->F: In icb; loss of function.	SEQ_UP	1	
MUTAGEN:C->F: Loss of thiol-dependency of NADase activity.	SEQ_UP	1	
MUTAGEN:C->F: No association with Elongin BC complex; when associated with P-46.	SEQ_UP	1	
MUTAGEN:C->F: No effect on palmitoylation. No change in subcellular location; when associated with V-113 and G-118.	SEQ_UP	1	
MUTAGEN:C->G,R,W: Disrupts interaction with ZFPM1.	SEQ_UP	1	
MUTAGEN:C->G,R: No effect on activity.	SEQ_UP	1	
MUTAGEN:C->G,V: Does not affect interaction with UBR2.	SEQ_UP	1	
MUTAGEN:C->G: Abolishes p53/TP53 polyubiquitination. No effect on interaction with p53/TP53.	SEQ_UP	1	
MUTAGEN:C->G: Disrupts LDB1-binding; when associated with G-28.	SEQ_UP	1	
MUTAGEN:C->G: Disrupts LDB1-binding; when associated with G-88.	SEQ_UP	1	
MUTAGEN:C->G: High transactivation activity.	SEQ_UP	1	
MUTAGEN:C->G: Impaired secretion.	SEQ_UP	1	
MUTAGEN:C->G: Loss of activity. No effect on binding to HSP90AA1.	SEQ_UP	1	
MUTAGEN:C->G: Loss of association with the recycling endosome membranes and loss of TNIK activation; when associated with C-176.	SEQ_UP	2	
MUTAGEN:C->G: Loss of association with the recycling endosome membranes and loss of TNIK activation; when associated with C-177.	SEQ_UP	2	
MUTAGEN:C->G: Loss of E3 ligase activity and affects the joining step of V(D)J recombination.	SEQ_UP	1	
MUTAGEN:C->G: Loss of function.	SEQ_UP	1	
MUTAGEN:C->G: Loss of interaction with PTPN12; when associated with G-366.	SEQ_UP	1	
MUTAGEN:C->G: Loss of promotion of EKLF sumoylation; when associated with G-346 and A-356.	SEQ_UP	1	
MUTAGEN:C->G: Loss of promotion of EKLF sumoylation; when associated with G-351 and A-356.	SEQ_UP	1	
MUTAGEN:C->G: Loss of ubiquitination activity.	SEQ_UP	1	
MUTAGEN:C->G: No cell death.	SEQ_UP	1	
MUTAGEN:C->G: No effect on binding to SIVA1; when associated with R-201.	SEQ_UP	1	
MUTAGEN:C->G: No effect on cell surface expression.	SEQ_UP	1	
MUTAGEN:C->G: No effect on p53/TP53 polyubiquitination.	SEQ_UP	1	
MUTAGEN:C->G: No effect on palmitoylation. No change in subcellular location; when associated with V-113 and F-121.	SEQ_UP	1	
MUTAGEN:C->G: No reduction of association with the recycling endosome membranes and does activate TNIK; when associated with G-176.	SEQ_UP	1	
MUTAGEN:C->G: No reduction of association with the recycling endosome membranes and does activate TNIK; when associated with G-177.	SEQ_UP	1	
MUTAGEN:C->G: Reduces pericentromeric localization. Abolishes pericentromeric localization; when associated with E-580.	SEQ_UP	1	
MUTAGEN:C->G: Significant reduction of copper binding; when associated with G-23 and G-24.	SEQ_UP	1	
MUTAGEN:C->G: Significant reduction of copper binding; when associated with G-23 and G-26.	SEQ_UP	1	
MUTAGEN:C->G: Significant reduction of copper binding; when associated with G-24 and G-26.	SEQ_UP	1	
MUTAGEN:C->H: Transforms the C2HC-type zinc finger into a C2H2-type, leading to abolition of interaction with GATA1.	SEQ_UP	1	
MUTAGEN:C->K: Reduced palmitoylation level.	SEQ_UP	1	
MUTAGEN:C->L: Abolishes E3 ubiquitin-protein ligase activity; when associated with A-15.	SEQ_UP	1	
MUTAGEN:C->M: Decreased receptor activity in response to MTMT binding, even in the presence of copper. Shows low constitutive activity in the presence of copper. MTMT binding in the absence of copper results in an inverse agonist effect.	SEQ_UP	1	
MUTAGEN:C->M: Increases activity with octanoyl-CoA.	SEQ_UP	1	
MUTAGEN:C->N: Increase in nuclear localization.	SEQ_UP	1	
MUTAGEN:C->P: Abolishes DNA-binding.	SEQ_UP	1	
MUTAGEN:C->P: Abolishes histone-lysine N-methyltransferase activity over enzyme concentration of 0-80 nM. Weakened histone-lysine N-methyltransferase activity over enzyme concentration > 5 uM. Abolishes binding with S-adenosyl-L-methionine. Abolishes protein-lysine N-methyltransferas.	SEQ_UP	1	
MUTAGEN:C->P: Important loss of PRKAR2A-binding.	SEQ_UP	1	
MUTAGEN:C->P: Stability of binding to DNA reduced.	SEQ_UP	1	
MUTAGEN:C->Q: Reduces the interaction with RB1.	SEQ_UP	1	
MUTAGEN:C->R,S,Y: Disrupts interaction with ZFPM1.	SEQ_UP	1	
MUTAGEN:C->R,S: Disrupts interaction with ZFPM1.	SEQ_UP	1	
MUTAGEN:C->R: Complete loss of function.	SEQ_UP	1	
MUTAGEN:C->R: Disrupts interaction with ZFPM1 and binding to DNA.	SEQ_UP	1	
MUTAGEN:C->R: Impairs interactions with RNPS1, ACIN1 and PNN; reduces ASAP and PSAP complex assemblies.	SEQ_UP	1	
MUTAGEN:C->R: Increases stimulation of GTase activity by POLR2A binding.	SEQ_UP	1	
MUTAGEN:C->R: Loss of interaction with GYG1. Loss of function. Loss of interaction with GYG1; when associated with A-8.	SEQ_UP	1	
MUTAGEN:C->R: Loss of protein deubiquitination and suppression of inhibition on JNK and NF-kappa-B signaling pathway activations. No loss of RNase activity.	SEQ_UP	1	
MUTAGEN:C->R: No change in enzymatic activity.	SEQ_UP	1	
MUTAGEN:C->R: No effect on localization to stress granules, reduces RNA-binding.	SEQ_UP	1	
MUTAGEN:C->R: No effect on RNA-binding.	SEQ_UP	1	
MUTAGEN:C->S,A,G: No effect on enzymatic activity.	SEQ_UP	1	
MUTAGEN:C->S,A: Loss of enzymatic activity, interaction with IPO11, nuclear import, and effect on cell growth.	SEQ_UP	1	
MUTAGEN:C->S: 20-fold reduction to fibulin-2 binding.	SEQ_UP	1	
MUTAGEN:C->S: 58% reduction in palmitoylation level. 28% membrane association. Very little palmitoylation and less than 8% membrane association; when associated with S-92 or A-92.	SEQ_UP	1	
MUTAGEN:C->S: 65% reduction in palmitoylation level. 29% membrane association. No palmitoylation and less than 8% membrane association; when associated with S-90 or A-90.	SEQ_UP	1	
MUTAGEN:C->S: 79% reduction in palmitoylation level. 18% membrane association. No palmitoylation and less than 8% membrane association; when associated with S-85 or A-85.	SEQ_UP	1	
MUTAGEN:C->S: 91% reduction in palmitoylation level. 14% membrane association. No palmitoylation and less than 8% membrane association; when associated with S-88 or A-88.	SEQ_UP	1	
MUTAGEN:C->S: Abolished ability to catalyze the first step in ufmylation.	SEQ_UP	1	
MUTAGEN:C->S: Abolished ability to promote ubiquitination of reduced FNIP1.	SEQ_UP	1	
MUTAGEN:C->S: Abolished creatine kinase activity.	SEQ_UP	1	
MUTAGEN:C->S: Abolished E3 ubiquitin-protein activity and ability to ubiquitinate TICAM1. Abolished E3 SUMO-protein activity and ability to sumoylate CGAS.	SEQ_UP	1	
MUTAGEN:C->S: Abolished interaction with MAP1LC3B and subsequent pexophagy.	SEQ_UP	1	
MUTAGEN:C->S: Abolished protease activity and ability to desumoylate CGAS.	SEQ_UP	1	
MUTAGEN:C->S: Abolished recognition by the CRL2(FEM1B) complex and subsequent ubiquitination.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes ability to deubiquitinate histone H2A; when associated with R-615.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes activity.	SEQ_UP	2	
MUTAGEN:C->S: Abolishes conductivity.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes deubiquitinating activity.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes enzymatic activity, but does not affect ubiquitin binding.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes formation of a disulfide-linked heterodimer with KCNK1.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes formation of a disulfide-linked heterodimer with KCNK2.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes homodimerization; when associated with S-157 and S-245. Does not affect homodimerization; when associated with S-157.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes homodimerization; when associated with S-84 S-245.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes homodimerization. Abolishes homodimerization; when associated with S-84 and S-157.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes interaction with PEX6 and ubiquitin. Impairs interaction with PEX5.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes isoprenylation.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes palmitoylation and lipid raft localization; when associated with S-28.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes palmitoylation and lipid raft localization; when associated with S-31.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes palmitoylation and plasma membrane association; when associated with S-3.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes palmitoylation and plasma membrane association; when associated with S-6. Abolishes plasma membrane association.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes palmitoylation and transformation activity.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes palmitoylation.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes plasma membrane association; when associated with S-21.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes plasma membrane association; when associated with S-41. Reduced palmitoylation level.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes proteolytic cleavage and cell surface localization.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes S-nitrosylation.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes S-palmitoylation.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes sensitivity to sulfhydryl modification.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes sulfhydration and impairs interaction with RPS3.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes sulfhydration and induces impaired enzyme activity.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes transforming activity.	SEQ_UP	1	
MUTAGEN:C->S: Abolishes ubiquitin ligase activity.	SEQ_UP	1	
MUTAGEN:C->S: Abrogates phosphatase activity.	SEQ_UP	3	
MUTAGEN:C->S: Abrogates sumoylation of LEF1 and increases LEF1-mediated transcriptional activity; when associated with S-330; A-337 and S-340.	SEQ_UP	1	
MUTAGEN:C->S: Abrogates sumoylation of LEF1 and increases LEF1-mediated transcriptional activity; when associated with S-330; S-335 and A-337.	SEQ_UP	1	
MUTAGEN:C->S: Abrogates sumoylation of LEF1 and increases LEF1-mediated transcriptional activity; when associated with S-335; A-337 and S-340.	SEQ_UP	1	
MUTAGEN:C->S: Abrogates ubiquitination activity and the ability to promote DR4- and Fas-induced apoptosis.	SEQ_UP	1	
MUTAGEN:C->S: Abrogates ubiquitination activity.	SEQ_UP	1	
MUTAGEN:C->S: Absence of Ca(2+) mobilization and no LCK association.	SEQ_UP	1	
MUTAGEN:C->S: Accumulation in proteinaceous aggregates devoid of membranes and no interaction with PI3P.	SEQ_UP	1	
MUTAGEN:C->S: Affects the intracellular trafficking, resulting in endoplasmic reticulum retention. Mice carrying homozygous and heterozygous C509S exhibit a progressive decline in locomotor function and a reduction in the number of tyrosine hydroxylase-positive neurons.	SEQ_UP	1	
MUTAGEN:C->S: Almost abolishes enzyme activity.	SEQ_UP	1	
MUTAGEN:C->S: Almost complete loss in cinnamaldehyde or cold-evoked response.	SEQ_UP	1	
MUTAGEN:C->S: Associated with a progressive hearing loss; outer hair cells degenerate rapidly after the first postnatal week.	SEQ_UP	1	
MUTAGEN:C->S: Catalytically inactive and substrate trapping with higher affinity for substrate.	SEQ_UP	1	
MUTAGEN:C->S: Catalytically inactive. Unable to restore phosphatase activity toward PDGFRB.	SEQ_UP	1	
MUTAGEN:C->S: Complete loss of channel activity. Significant decrease of interaction with ERP44.	SEQ_UP	1	
MUTAGEN:C->S: Complete loss of interaction with CD4 or CD8.	SEQ_UP	1	
MUTAGEN:C->S: Decrease in autoubiquitination; when associated with S-13.	SEQ_UP	1	
MUTAGEN:C->S: Decrease in autoubiquitination; when associated with S-16.	SEQ_UP	1	
MUTAGEN:C->S: Decreased enzyme activity to retain 63% of wild type activity.	SEQ_UP	1	
MUTAGEN:C->S: Decreased inhibition by cadmium ions.	SEQ_UP	1	
MUTAGEN:C->S: Decreased receptor activity in response to MTMT binding, even in the presence of copper. Complete loss of receptor activity in the absence of copper.	SEQ_UP	1	
MUTAGEN:C->S: Decreased ZDHHC3 palmitoylation. Changed protein structure. Decreased protein-cysteine S-palmitoyltransferase activity.	SEQ_UP	1	
MUTAGEN:C->S: Decreases sulfotransferase activity (at pH 7.5).	SEQ_UP	1	
MUTAGEN:C->S: Disrupts redox reaction.	SEQ_UP	1	
MUTAGEN:C->S: Does not affect AMPK activity.	SEQ_UP	1	
MUTAGEN:C->S: Does not affect binding to diterpenoid derivative 15-oxospiramilactone (S3) inhibitor.	SEQ_UP	1	
MUTAGEN:C->S: Does not affect Glycerophosphocholine cholinephosphodiesterase activity; when associated withA-393. Does not affect choline metabolism; when associated with A-393.	SEQ_UP	1	
MUTAGEN:C->S: Does not affect guanylate cyclase activity; when associated with S-458.	SEQ_UP	1	
MUTAGEN:C->S: Does not affect guanylate cyclase activity; when associated with S-465.	SEQ_UP	1	
MUTAGEN:C->S: Does not affect heterooligomerization with C1QL2; when associated with S-28.	SEQ_UP	1	
MUTAGEN:C->S: Does not affect heterooligomerization with C1QL2; when associated with S-32.	SEQ_UP	1	
MUTAGEN:C->S: Does not affect homodimerization.	SEQ_UP	1	
MUTAGEN:C->S: Does not affect interaction with MAP1LC3B.	SEQ_UP	1	
MUTAGEN:C->S: Does not affect interaction with MECP2.	SEQ_UP	1	
MUTAGEN:C->S: Does not affect palmitoylation.	SEQ_UP	1	
MUTAGEN:C->S: Does not affect S-nitrosylation.	SEQ_UP	1	
MUTAGEN:C->S: Fails to dephosphorylate PGP in vitro. Does not affect level of Akt phosphorylation.	SEQ_UP	1	
MUTAGEN:C->S: Fails to enhance DLG4 palmitoylation.	SEQ_UP	1	
MUTAGEN:C->S: Fails to homodimerize.	SEQ_UP	1	
MUTAGEN:C->S: Fails to rescue cerebellar LTD in PICK1 knockouts.	SEQ_UP	1	
MUTAGEN:C->S: Gains susceptibility to mouse-specific RU.521; when associated with N-467.	SEQ_UP	1	
MUTAGEN:C->S: Homozygous sudden juvenile death syndrome (sjds) mice die before 20 day of age and exhibit severe proximal tubule injury and formation of giant vacuoles in the renal cortex. Interfers with maintenance of AQP11 oligomeric structure. Aqp11 mutant mice developed proximal tubule (PT)-specific mitochondrial injury. Heterozygous sudden juvenile death syndrome (sjds) mice exhibit higher AQP11 levels but are not further increased in response to glucose. Upon glucose treatment, heterozygous Aqp11 mice show increased blood urea nitrogen levels that are prevented by the antioxidant sulforaphane or by phlorizin.	SEQ_UP	1	
MUTAGEN:C->S: Impairs dimerization and oligomerization.	SEQ_UP	1	
MUTAGEN:C->S: Impairs dimerization.	SEQ_UP	1	
MUTAGEN:C->S: Impairs Golgi localization; when associated with S-10.	SEQ_UP	1	
MUTAGEN:C->S: Impairs Golgi localization; when associated with S-6.	SEQ_UP	1	
MUTAGEN:C->S: Impairs interaction with PEX6.	SEQ_UP	1	
MUTAGEN:C->S: Impairs phosphatase activity.	SEQ_UP	1	
MUTAGEN:C->S: Impairs protection against hydrogen peroxide-induced toxicity.	SEQ_UP	1	
MUTAGEN:C->S: Impairs S-nitrosylation. Abolishes S-nitrosylation; when associated with S-387.	SEQ_UP	1	
MUTAGEN:C->S: Impairs S-nitrosylation. Abolishes S-nitrosylation; when associated with S-390.	SEQ_UP	1	
MUTAGEN:C->S: Important decrease in cinnamaldehyde or cold-evoked response.	SEQ_UP	1	
MUTAGEN:C->S: In after-hour (afh) mutant; lengthening in circadian periodicity.	SEQ_UP	1	
MUTAGEN:C->S: Increase in nuclear localization.	SEQ_UP	1	
MUTAGEN:C->S: Increases methyltransferase activity towards H3 and H4. Increases methyltransferase activity; when associated with E-1950.	SEQ_UP	1	
MUTAGEN:C->S: Inhibits RNA-binding.	SEQ_UP	1	
MUTAGEN:C->S: Instead of the formation of an intermediate complex with a thiol ester bond between ATG10 (E2-like enzyme) and ATG12 (substrate), a stable complex with an O-ester bond is formed. Does not affect ATG12 conjugation to ATG3.	SEQ_UP	1	
MUTAGEN:C->S: Instead of the formation of an intermediate complex with a thiol ester bond between ATG7 (E1-like enzyme) and GABARAPL1 (MAP1LC3, GABARAP or GABARAPL; substrates), a stable complex with an O-ester bond is formed.	SEQ_UP	1	
MUTAGEN:C->S: Loss of activity.	SEQ_UP	3	
MUTAGEN:C->S: Loss of association to membranes.	SEQ_UP	1	
MUTAGEN:C->S: Loss of autoubiquitination.	SEQ_UP	1	
MUTAGEN:C->S: Loss of catalytic activity. No effect on RNF11-binding. No effect on KLF2 ubiquitination. Abolishes ubiquitination of KLF5.	SEQ_UP	1	
MUTAGEN:C->S: Loss of catalytic activity. Slows down degradation of misfolded proteins from the ER.	SEQ_UP	1	
MUTAGEN:C->S: Loss of desumoylase activity.	SEQ_UP	1	
MUTAGEN:C->S: Loss of deubiquitinase activity and binding to diterpenoid derivative 15-oxospiramilactone (S3) inhibitor.	SEQ_UP	1	
MUTAGEN:C->S: Loss of deubiquitinating activity; when associated with R-358.	SEQ_UP	1	
MUTAGEN:C->S: Loss of deubiquitinating activity.	SEQ_UP	2	
MUTAGEN:C->S: Loss of E3 ligase activity.	SEQ_UP	1	
MUTAGEN:C->S: Loss of E3 ubiquitin protein ligase activity.	SEQ_UP	1	
MUTAGEN:C->S: Loss of enzymatic activity; reduced migration-promoting activity.	SEQ_UP	1	
MUTAGEN:C->S: Loss of enzyme activity.	SEQ_UP	2	
MUTAGEN:C->S: Loss of function and interaction with DVL1; when associated with S-205.	SEQ_UP	1	
MUTAGEN:C->S: Loss of function and interaction with DVL1; when associated with S-208.	SEQ_UP	1	
MUTAGEN:C->S: Loss of function in histone modification.	SEQ_UP	1	
MUTAGEN:C->S: Loss of function.	SEQ_UP	1	
MUTAGEN:C->S: Loss of in vitro ubiquitin-conjugating activity.	SEQ_UP	1	
MUTAGEN:C->S: Loss of interchain disulfide bond. No effect on guidance of SLC7A5 to the plasma membrane.	SEQ_UP	1	
MUTAGEN:C->S: Loss of Klrb1b-mediated inhibition of natural killer cell cytotoxicity. Reduced LCK binding, loss of PTPN6 binding and loss of inhibition of Ca(2+) influx upon activation of natural killer cells.	SEQ_UP	1	
MUTAGEN:C->S: Loss of localization to the endoplasmic reticulum membrane. Loss of interaction with BAG6. No effect on association with the proteasome complex.	SEQ_UP	1	
MUTAGEN:C->S: Loss of location at the melanosome membrane; when associated with 11-SSSS-14 and S-16.	SEQ_UP	1	
MUTAGEN:C->S: Loss of location at the melanosome membrane; when associated with 11-SSSS-14 and S-18.	SEQ_UP	1	
MUTAGEN:C->S: Loss of p53/TP53-deubiquitinating activity.	SEQ_UP	1	
MUTAGEN:C->S: Loss of palmitoylation; when associated with S-3.	SEQ_UP	1	
MUTAGEN:C->S: Loss of palmitoylation; when associated with S-4.	SEQ_UP	1	
MUTAGEN:C->S: Loss of palmitoyltransferase activity.	SEQ_UP	1	
MUTAGEN:C->S: Loss of phosphatase activity with glycogen and synthetic substrates.	SEQ_UP	1	
MUTAGEN:C->S: Loss of phosphatase activity.	SEQ_UP	2	
MUTAGEN:C->S: Loss of phosphatase activity. Does not affect interaction with MAPK1.	SEQ_UP	1	
MUTAGEN:C->S: Loss of phospholipase activity and loss of organelle membrane rupture.	SEQ_UP	1	
MUTAGEN:C->S: Loss of promotion of IRF1 sumoylation, as well as of autosumoylation; partial loss of suppression of IRF1 transcriptional activity.	SEQ_UP	1	
MUTAGEN:C->S: Loss of protein-cysteine S-acyltransferase activity. Loss of ZDHHC3 palmitoylation.	SEQ_UP	1	
MUTAGEN:C->S: Loss of protein-cysteine S-palmitoyltransferase activity.	SEQ_UP	3	
MUTAGEN:C->S: Loss of protein-cysteine S-palmitoyltransferase activity. Decreased localization to the cis-Golgi network. Relocalized to the endoplasmic reticulum.	SEQ_UP	1	
MUTAGEN:C->S: Loss of protein-cysteine S-palmitoyltransferase activity. Loss of autopalmitoylation.	SEQ_UP	1	
MUTAGEN:C->S: Loss of redox potential. Abolishes bound persulfide and hydrogen sulfide production.	SEQ_UP	1	
MUTAGEN:C->S: Loss of reduction of influx rate of NLS cargo upon oxidative stress; when associated with S-478.	SEQ_UP	1	
MUTAGEN:C->S: Loss of reduction of influx rate of NLS cargo upon oxidative stress; when associated with S-509.	SEQ_UP	1	
MUTAGEN:C->S: Loss of thiol-dependency of NADase activity.	SEQ_UP	1	
MUTAGEN:C->S: Loss of TPase activity.	SEQ_UP	1	
MUTAGEN:C->S: Loss of ubiquitin-ligase activity. No effect on VEGFR-2/KDFR degradation.	SEQ_UP	1	
MUTAGEN:C->S: Mice display a low bone mass density and show a striking joint disease and calcification of blood vessels. Probably affects protein stability.	SEQ_UP	1	
MUTAGEN:C->S: Mutant mice are deaf, show fusion of stereocilia and degeneration of hair cells, and have low sperm counts.	SEQ_UP	1	
MUTAGEN:C->S: Mutant mice show an hypopigmentation of the coat and have the retinal pigmented epithelium significantly less pigmented than wild-type retinas.	SEQ_UP	1	
MUTAGEN:C->S: No change in receptor activity in response to MTMT binding in the presence of copper. Complete loss of receptor activity in the absence of copper.	SEQ_UP	1	
MUTAGEN:C->S: No change in substrate affinity but 60% reduction in O-GlcNAcase activity.	SEQ_UP	1	
MUTAGEN:C->S: No E2 binding. Loss of ubiquitination activity.	SEQ_UP	1	
MUTAGEN:C->S: No effect on ACHE tetramer recruitment to membrane rafts.	SEQ_UP	1	
MUTAGEN:C->S: No effect on channel activity. Significant decrease of interaction with ERP44. Complete loss of channel inhibition by ERP44.	SEQ_UP	1	
MUTAGEN:C->S: No effect on desumoylase activity.	SEQ_UP	1	
MUTAGEN:C->S: No effect on dimerization. No effect on inhibition of BMP signaling.	SEQ_UP	1	
MUTAGEN:C->S: No effect on inhibition by cadmium ions.	SEQ_UP	1	
MUTAGEN:C->S: No effect on interaction with GPX1.	SEQ_UP	1	
MUTAGEN:C->S: No effect on interaction with ITPR1.	SEQ_UP	1	
MUTAGEN:C->S: No effect on lipase activity toward 1-palmitoyl-2-arachidonoyl-phosphatidylethanolamine (2-AA-PE).	SEQ_UP	1	
MUTAGEN:C->S: No effect on MAPK1 binding. Impairs nuclear envelope breakdown activity in oocytes.	SEQ_UP	1	
MUTAGEN:C->S: No effect on O-GlcNAcase activity.	SEQ_UP	1	
MUTAGEN:C->S: No effect on subcellular location; when associated with 44-C--F-47. Normal terminal myogenic differentiation; when associated with 44-C--F-47.	SEQ_UP	1	
MUTAGEN:C->S: No effect on ZDHHC3 palmitoylation. Changed protein structure. Decreased protein-cysteine S-palmitoyltransferase activity.	SEQ_UP	1	
MUTAGEN:C->S: No effect on ZDHHC3 palmitoylation. No effect on protein-cysteine S-palmitoyltransferase activity.	SEQ_UP	1	
MUTAGEN:C->S: No effect.	SEQ_UP	2	
MUTAGEN:C->S: No formation of homomultimers. No formation of homodimers; when associated with S-369.	SEQ_UP	1	
MUTAGEN:C->S: No formation of homomultimers. No formation of homodimers; when associated with S-393.	SEQ_UP	1	
MUTAGEN:C->S: No increase in phosphorylation of AKT1, FOXO1 and INSR. No increased expression of SLC2A1, FABP4 nor ADIPOQ. Impaired formation of large lipid droplets.	SEQ_UP	1	
MUTAGEN:C->S: No loss of activity.	SEQ_UP	1	
MUTAGEN:C->S: No loss of phospholipase or lysophosphatidylcholine acyltransferase activity.	SEQ_UP	1	
MUTAGEN:C->S: No neuron activity in the VNO.	SEQ_UP	1	
MUTAGEN:C->S: No receptor activity in response to MTMT binding, even in the presence of copper.	SEQ_UP	1	
MUTAGEN:C->S: No receptor activity in response to MTMT binding, even in the presence of copper. Little to no expression detected on plasma membrane.	SEQ_UP	1	
MUTAGEN:C->S: Produces an activated, ligand-independent molecule; when associated with S-1675.	SEQ_UP	1	
MUTAGEN:C->S: Produces an activated, ligand-independent molecule; when associated with S-1682.	SEQ_UP	1	
MUTAGEN:C->S: Protects from inactivation caused by air oxidation or thiol-reactive agents. Reduces the affinity for UDP-GlcNAc; when associated with A-378. Abolishes binding to UDP-GlcNAc; when associated with A-401. Loss of catalytic activity; when associated with A-378 and A-401.	SEQ_UP	1	
MUTAGEN:C->S: Reduced ATPase and helicase activities.	SEQ_UP	1	
MUTAGEN:C->S: Reduced cell surface localization.	SEQ_UP	1	
MUTAGEN:C->S: Reduced cone and rod photoreceptor function as a result of outer segment malformation, including disorganization, short outer segments, and elongated disks which affect both rod and cone photoreceptors. Reduced Prph2 and Rom1 protein abundance in the retina in addition to disruption of the formation of large disulfide-linked protein complexes.	SEQ_UP	1	
MUTAGEN:C->S: Reduced interaction with NR2C2 and enhanced interaction with TAB2 and TAB3. Does not decrease TAB2 or TAB3 expression. No effect on inhibition of ROS or negative regulation of NLRP3 inflammasome activation.	SEQ_UP	1	
MUTAGEN:C->S: Reduces lipid droplet localization.	SEQ_UP	1	
MUTAGEN:C->S: Reduces palmitoylation.	SEQ_UP	1	
MUTAGEN:C->S: Retains kinase activity.	SEQ_UP	1	
MUTAGEN:C->S: Severely impairs glutamate uptake activity.	SEQ_UP	1	
MUTAGEN:C->S: Shows a 2.1-fold higher rate for the cleavage of the 5hmC-modified DNA junction over unmodified junction, as compared to the 1.8-fold difference seen in the wild type enzyme.	SEQ_UP	1	
MUTAGEN:C->S: Strongly reduces effects of in vivo overexpression; impairs multimer formation; does not affect subcellular location to lipid rafts. Homozygous mice are characterized by a smaller size and holoprosencephaly at 10.5 dpc, and shortening of limbs at 13.5 dpc. They die soon after birth.	SEQ_UP	1	
MUTAGEN:C->S: Strongly reduces palmitoylation and its ability to regulate GPCR signaling. Abolishes palmitoylation and its ability to regulate GPCR signaling; when associated with S-252.	SEQ_UP	1	
MUTAGEN:C->S: Strongly reduces palmitoylation and its ability to regulate GPCR signaling. Abolishes palmitoylation and its ability to regulate GPCR signaling; when associated with S-253.	SEQ_UP	1	
MUTAGEN:C->S: Substitution with a small side chain that prevents covalent modification by an electrophile; promotes constitutive ubiquitination of NFE2L2/NRF2 and subsequent repression of phase 2 detoxifying enzymes. Knockin mice are healthy and viable in normal conditions but do not activate NFE2L2/NRF2 in response to oxidative stress.	SEQ_UP	1	
MUTAGEN:C->S: Very important decrease in cinnamaldehyde or cold-evoked response.	SEQ_UP	1	
MUTAGEN:C->T: Abolishes methyltransferase activity.	SEQ_UP	1	
MUTAGEN:C->T: Decreases the NADH oxidoreductase activity. Has not effect on mitochondria to nucleus translocation.	SEQ_UP	1	
MUTAGEN:C->V,S: Decreased receptor activity in response to MTMT binding, even in the presence of copper. Complete loss of receptor activity in the absence of copper.	SEQ_UP	1	
MUTAGEN:C->V: Decreased alpha-tubulin alpha-elongation step of polyglutamylase activity.	SEQ_UP	1	
MUTAGEN:C->V: Decreased receptor activity in response to MTMT binding, even in the presence of copper.	SEQ_UP	1	
MUTAGEN:C->V: Decreased receptor activity in response to MTMT binding, even in the presence of copper. Complete loss of receptor activity in the absence of copper.	SEQ_UP	1	
MUTAGEN:C->V: No effect on palmitoylation. No change in subcellular location; when associated with G-118 and F-121.	SEQ_UP	1	
MUTAGEN:C->V: No receptor activity in response to MTMT binding, even in the presence of copper.	SEQ_UP	1	
MUTAGEN:C->W,M: Retains ability to degrade NFE2L2/NRF2; when associated with E-288.	SEQ_UP	1	
MUTAGEN:C->W: Abolishes interaction with histone H3.	SEQ_UP	1	
MUTAGEN:C->W: Loss of activity.	SEQ_UP	1	
MUTAGEN:C->W: Loss of deacetylase activity. No effect on sulfotransferase activity.	SEQ_UP	1	
MUTAGEN:C->W: Loss of the ability to negatively regulate cell proliferation.	SEQ_UP	1	
MUTAGEN:C->W: Mutant mice show an hypopigmentation of the coat and have the retinal pigmented epithelium significantly less pigmented than wild-type retinas.	SEQ_UP	1	
MUTAGEN:C->Y: Abolishes interaction with histone H3.	SEQ_UP	1	
MUTAGEN:C->Y: Abrogates homodimerization and intermolecular autophosphorylation, with consequent loss of kinase activity. Loss of nuclear localization.	SEQ_UP	1	
MUTAGEN:C->Y: Associates almost exclusively with the membrane. Loss of MAP2K2 and MAP2K2 binding and recruitment to the membrane. Loss of MAP kinase-mediated inhibition of ELK1 phosphorylation. No effect on the interaction with YWHAE.	SEQ_UP	1	
MUTAGEN:C->Y: Loss of inhibition by GNF-2.	SEQ_UP	1	
MUTAGEN:C->Y: Loss of N-terminal lipidation. Fails to localize to the photoreceptor outer segment.	SEQ_UP	1	
MUTAGEN:C->Y: No effect on PDCD1 binding.	SEQ_UP	1	
MUTAGEN:C->Y: Reduced secretion to the medium.	SEQ_UP	1	
MUTAGEN:CAHLQS->GADLQG: Nuclear and cytoplasmic location.	SEQ_UP	1	
MUTAGEN:CC->AA: Abolishes membrane targeting.	SEQ_UP	1	
MUTAGEN:CC->AA: Abolishes palmitoylation.	SEQ_UP	1	
MUTAGEN:CC->AA: Almost completely blocks the ability to traffic to the cilia; when associated with A-3869. Affetcs palmitoylation; when associated with A-3869. Disrupts interaction with RAB8A; when associated with A-3869. Disrupts interaction with ARF4; when associated with A-3869.	SEQ_UP	1	
MUTAGEN:CC->AA: Loss of association with membranes and redistribution to the cytosol.	SEQ_UP	1	
MUTAGEN:CC->AA: No effect on SARS-CoV-2 infection; when associated with A-105.	SEQ_UP	1	
MUTAGEN:CC->SS: Abolished localization to the Golgi apparatus.	SEQ_UP	1	
MUTAGEN:CC->SS: Abolished palmitoylation and membrane association in neurons.	SEQ_UP	1	
MUTAGEN:CC->SS: Abolishes palmitoylation and localization to the cilium membrane.	SEQ_UP	1	
MUTAGEN:CC->SS: Abolishes palmitoylation.	SEQ_UP	1	
MUTAGEN:CC->SS: Does not affect palmitoylation.	SEQ_UP	1	
MUTAGEN:CCC->AAA: Abolishes palmitoylation; when associated with A-102.	SEQ_UP	1	
MUTAGEN:CCC->SLA: Reduces palmitoylation and leads to nuclear localization.	SEQ_UP	1	
MUTAGEN:CCCC->SSSS: Loss of location at the melanosome membrane; when associated with S-16 and S-18.	SEQ_UP	1	
MUTAGEN:CCLFCCPPC->SSLFSSPPS: Loss of palmitoylation and plasma membrane localization. Loss of LG4/PSD95 depalmitoylation.	SEQ_UP	1	
MUTAGEN:CCTC->AATA,SSTS: Abolished localization to the Golgi apparatus.	SEQ_UP	1	
MUTAGEN:CG->RV: Loss of interaction with RNF4; when associated with T-1629 and S-1702.	SEQ_UP	1	
MUTAGEN:CGLCHWC->SGLSHWS: Abolishes palmitoylation. Impaired phagocytosis and localization to lysosomes.	SEQ_UP	1	
MUTAGEN:CH->WN: In chatwo; hypomorphic mutation with reduced protein stability and impaired transcriptional corepression activity. Embryonic development arrests prior to stage E9, with pronounced convergent extention defects and defective morphogenesis of extra-embryonic tissues. The anterior-posterior axis is shortened and embryos fail to undergo gut closure. No effect on interaction with ZFP568.	SEQ_UP	1	
MUTAGEN:CHFC->AHFA: Disrupts 5'-GGAG-3' motif interaction. Binds miRNA but not TUT4.	SEQ_UP	1	
MUTAGEN:CK->RR: In Ld KCST-less, strongly impairs ubiquitination; when associated with R-332; I-337; R-340 and 350-A--A-356. In Ld tail 1S, restores ubiquitination; when associated R-332; I-337; R-340; 350-A--A-352; A-356 and 360-R-R-361.	SEQ_UP	1	
MUTAGEN:CLCRC->SLSRS: Abolished palmitoylation, leading to impaired ability mediate synaptic long-term depression (LTD).	SEQ_UP	1	
MUTAGEN:CLG->AAA: Decreases interaction with NPC1L1.	SEQ_UP	1	
MUTAGEN:CLGC->SLGS: Abolished palmitoylation.	SEQ_UP	1	
MUTAGEN:CNC->ANA: Cleaved by subtilisin-like proprotein convertase.	SEQ_UP	1	
MUTAGEN:CNIC->GNIG: In macrophages, inhibits competition with STAT5 for DNA-binding and abolishes transcriptional repression of genes encoding inflammatory molecules.	SEQ_UP	1	
MUTAGEN:CQVC->AQVA: Results in unstable hexamers. Increased MCM complex DNA helicase activity.	SEQ_UP	1	
MUTAGEN:CR->AA: Reduced interaction with flagellin.	SEQ_UP	1	
MUTAGEN:CRCC->SRSS: Inhibits axonal and dendritic filopodia formation and reduces axonal and dendritic branching.	SEQ_UP	1	
MUTAGEN:CRWKK->VALAL: Fails to bind to RE2 sequence motifs.	SEQ_UP	1	
MUTAGEN:CSDGWDR->ASDGWDA: Probable loss of catalytic activity. Loss of macropinocytosis.	SEQ_UP	1	
MUTAGEN:CTA->LTV: No effect on N-terminal cleavage.	SEQ_UP	1	
MUTAGEN:CTC->STS: Abolished localization to the Golgi apparatus.	SEQ_UP	1	
MUTAGEN:CTVC->ATVA: Unable to restore differentiation of embryonic stem cells (ESCs).	SEQ_UP	1	
MUTAGEN:CVC->SVK: Complete loss of interaction with CD4 or CD8.	SEQ_UP	1	
MUTAGEN:CVHC->AVHA: Results in unstable hexamers. Increased MCM complex DNA helicase activity.	SEQ_UP	1	
MUTAGEN:CVVC->AVVA: Loss of ubiquitin-protein ligase activity. Increase in TSG101-binding.	SEQ_UP	1	
MUTAGEN:CYNC->AYNA: Disrupts 5'-GGAG-3' motif interaction. Disrupts oligoU-addition to pre-miRNA pre-let-7 by TUT4.	SEQ_UP	1	
MUTAGEN:D->A,E: Abolishes phosphatidate phosphatase activity. No effect on interaction or coactivation with PPARA.	SEQ_UP	1	
MUTAGEN:D->A,K,N: Loss of interaction with CXADR.	SEQ_UP	1	
MUTAGEN:D->A,N: Abolishes the enzymatic activity.	SEQ_UP	1	
MUTAGEN:D->A,N: Little or no effect.	SEQ_UP	1	
MUTAGEN:D->A,N: Loss of CASP1-induced cleavage, pyroptosis and IL1B release. Does not impair interaction with CASP1. Abolished ability to induce pyroptosis following inactivation of MAP3K7/TAK1 by Yersinia toxin YopJ.	SEQ_UP	1	
MUTAGEN:D->A,R: No effect on LIF signal transduction suppression.	SEQ_UP	1	
MUTAGEN:D->A: 10-fold decrease in MCM3AP-binding affinity, loss of relocalization to the nucleus in the presence of MCM3AP, decreased deamination activity to about 33% of the wild-type protein.	SEQ_UP	1	
MUTAGEN:D->A: 13-fold less potently activated by the Scolopendra mutilans RhTx toxin.	SEQ_UP	1	
MUTAGEN:D->A: 3-fold increase in substrate affinity and 90% reduction in O-GlcNAcase activity. Regains appreciable level of catalytic efficiency in the acidic pH range. 70% recovery of activity in the presence of sodium azide.	SEQ_UP	1	
MUTAGEN:D->A: 400-fold decrease in rates of factor Xa inhibition.	SEQ_UP	1	
MUTAGEN:D->A: 5-fold decrease in rates of factor Xa inhibition.	SEQ_UP	1	
MUTAGEN:D->A: Abolished oligomerization without affecting interaction with KEAP1; when associated with A-7.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes ability to promote type-I interferon production.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes activity.	SEQ_UP	2	
MUTAGEN:D->A: Abolishes binding of Mg(2+) and increases pore diameter. Impairs intestinal Ca(2+) uptake.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes binding to glycogen synthase and glycogen phosphorylase but has no effect on binding to PP1 or glycogen; when associated with A-250.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes both enzyme activity and ability to inhibit PKB activity.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes calcium-binding. Does not alter subcellular localization and does not prevent inhibition of calcineurin activity.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes dimerization.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes enzyme activity.	SEQ_UP	2	
MUTAGEN:D->A: Abolishes enzyme activity. Abolishes autocatalytic processing.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes exonuclease activity without affecting the telomere localization, leading to impaired 3'-overhang at the leading end telomeres.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes hydroxylation of 5-methylcarboxymethyl uridine.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes interaction with CDK2.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes interaction with EPHA2 SAM domain.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes interaction with histone H3.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes interaction with MECP2.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes interaction with PTPRD. Abolishes synapse assembly.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes interaction with RAB27A.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes lipid kinase activity. Does not affect targeting of TLN1 to plasma membrane. Affects assembly of TLN1 into focal adhesions. Affects uropodium formation and retraction of the cell rear.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes localization to microtubules.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes LPC transport. Abolishes LPC transport; when associated with A-92.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes lysophospholipase activity.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes magnesium and calcium-binding to the EF-hand 5 domain (EF5).	SEQ_UP	1	
MUTAGEN:D->A: Abolishes metal-binding and ability to regulate calcium current.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes phosphatase activity and abolishes coactivation of the SIX1-DACH1 complex.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes phosphatase activity, prevents MAP3K7/TAK1 phosphorylation in vitro, does not abolish interaction with MAP3K7/TAK1, found in a complex with MAP3K7/TAK1, MAP2K4 or MAP2K6 and enhances the association between MAP3K7/TAK1, MAP2K4 or MAP2K6.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes phosphatidylserine translocase activity, abolishes effect on neurite outgrowth.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes production of active form of enzyme.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes proteolytic processing.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes serine/threonine-protein kinase activity and ability to initiate ciliogenesis.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes the decapping activity on both incomplete m7G cap and NAD-cap RNAs.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes ubiquitin phosphorylation; when associated with A-218 and A-361.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes ubiquitin phosphorylation; when associated with A-218 and A-383.	SEQ_UP	1	
MUTAGEN:D->A: Abolishes zinc binding.	SEQ_UP	1	
MUTAGEN:D->A: Acts as a dominant negative mutant that reduces the mitochondrial Ca(2+) peaks; when associated with A-233; A-244 and A-434.	SEQ_UP	1	
MUTAGEN:D->A: Acts as a dominant negative mutant that reduces the mitochondrial Ca(2+) peaks; when associated with A-244; A-423 and A-434.	SEQ_UP	1	
MUTAGEN:D->A: Affects recruitment to heterochromatin by MECP2. Does not interact with MECP2. Is efficiently incorporated in N-Cor repressor complex.	SEQ_UP	1	
MUTAGEN:D->A: Almost abolishes cAMP-binding.	SEQ_UP	1	
MUTAGEN:D->A: Almost abolishes cAMP-binding. Interaction with KCNK2 is not inhibited by cAMP.	SEQ_UP	1	
MUTAGEN:D->A: Almost complete loss of exonuclease activity in TDT-L; when associated with A-170 and A-473. Decreased transferase activity in TDT-S; when associated with A-170 and A-473.	SEQ_UP	1	
MUTAGEN:D->A: Almost complete loss of exonuclease activity in TDT-L; when associated with A-29 and A-170. Decreased transferase activity in TDT-S; when associated with A-29 and A-170.	SEQ_UP	1	
MUTAGEN:D->A: Almost complete loss of exonuclease activity in TDT-L; when associated with A-29 and A-473. Decreased transferase activity in TDT-S; when associated with A-29 and A-473.	SEQ_UP	1	
MUTAGEN:D->A: Almost completely abolishes KLC1-binding.	SEQ_UP	1	
MUTAGEN:D->A: Blocks proteolytic cleavage; increases muscle mass when injected into adult mice.	SEQ_UP	1	
MUTAGEN:D->A: Complete loss of kinase activity.	SEQ_UP	1	
MUTAGEN:D->A: Confers dephosphorylating activity; increased the dephosphorylating efficiency; when associated with 877-D.	SEQ_UP	1	
MUTAGEN:D->A: Decrease of >90% of TPase activity.	SEQ_UP	1	
MUTAGEN:D->A: Decreased beta-carotene 15,15'-monooxygenase activity. Decreased catalytic efficiency. Loss of beta-carotene 15,15'-monooxygenase activity; when associated with A-140.	SEQ_UP	1	
MUTAGEN:D->A: Decreased cholesterol binding. Nearly abolishes cholesterol transport activity.	SEQ_UP	1	
MUTAGEN:D->A: Decreased cholesterol binding. Strongly decreased cholesterol transport activity.	SEQ_UP	1	
MUTAGEN:D->A: Decreased microtubule severing activity.	SEQ_UP	1	
MUTAGEN:D->A: Decreased phosphodiesterase activity.	SEQ_UP	1	
MUTAGEN:D->A: Decreased sphingosine-1-phosphate transport.	SEQ_UP	1	
MUTAGEN:D->A: Decreases affinity for PTPRD. Significantly decreases synaptogenesis.	SEQ_UP	1	
MUTAGEN:D->A: Decreases interaction with SNX27.	SEQ_UP	1	
MUTAGEN:D->A: Decreases transcriptional repression.	SEQ_UP	1	
MUTAGEN:D->A: Deficient in binding to RAN-GTP and in GTP release activity.	SEQ_UP	1	
MUTAGEN:D->A: Disrupts homodimerization. Positively regulates intrinsic apoptotic signaling pathway.	SEQ_UP	1	
MUTAGEN:D->A: Disrupts interaction with SNX27.	SEQ_UP	1	
MUTAGEN:D->A: Disrupts internal salt bridge and abrogates ligand recognition.	SEQ_UP	1	
MUTAGEN:D->A: Disrupts the dot-like nuclear pattern.	SEQ_UP	1	
MUTAGEN:D->A: Disrupts the dot-like nuclear pattern. Abolishes deacetylase activity, but not the interaction with HDAC2 and HDAC3.	SEQ_UP	1	
MUTAGEN:D->A: Does not affect affinity for PTPRD.	SEQ_UP	1	
MUTAGEN:D->A: Does not affect interaction with ADGRA2.	SEQ_UP	1	
MUTAGEN:D->A: Does not affect interaction with ATP2A1.	SEQ_UP	1	
MUTAGEN:D->A: Does not affect mono-ADP-ribosylation by SIRT6.	SEQ_UP	1	
MUTAGEN:D->A: Does not affect phosphorylarion at Ser-41; when associated with R-219.	SEQ_UP	1	
MUTAGEN:D->A: Does not affect sensitivity to Ca(2+).	SEQ_UP	1	
MUTAGEN:D->A: Does not affect the interaction with GATA1.	SEQ_UP	1	
MUTAGEN:D->A: Does not affect the nuclear localization.	SEQ_UP	1	
MUTAGEN:D->A: Does not affect trypsin-binding.	SEQ_UP	1	
MUTAGEN:D->A: Does not inhibit NFAT-induced transcription activation.	SEQ_UP	1	
MUTAGEN:D->A: Dramatic reduction in catalytic activity.	SEQ_UP	1	
MUTAGEN:D->A: EIF4E-binding reduced by 20%; when associated with A-726.	SEQ_UP	1	
MUTAGEN:D->A: Eliminates potentiation of glycine-mediated currents by Zn(2+) and causes neuromotor defects similar to human startle disease.	SEQ_UP	1	
MUTAGEN:D->A: Fails to dephosphorylate PGP in vitro.	SEQ_UP	1	
MUTAGEN:D->A: Failure to rescue cytoskeletal defects when introduced into TYROBP-deficient cells.	SEQ_UP	1	
MUTAGEN:D->A: Greatly reduces Ca(2+) permeation and channel rectification; when associated with A-672.	SEQ_UP	1	
MUTAGEN:D->A: Greatly reduces Ca(2+) permeation and channel rectification; when associated with A-682.	SEQ_UP	1	
MUTAGEN:D->A: Has a diffuse cytosolic localization.	SEQ_UP	1	
MUTAGEN:D->A: Impaired H3.3K36me3 binding.	SEQ_UP	1	
MUTAGEN:D->A: Impairs ability to promote H3K27me3 methylation without affecting ability to associate with the PRC2 complex; when associated with A-72.	SEQ_UP	1	
MUTAGEN:D->A: Impairs C-terminus cleavage.	SEQ_UP	1	
MUTAGEN:D->A: Impairs PARD3 binding.	SEQ_UP	1	
MUTAGEN:D->A: Impairs phosphatase activity.	SEQ_UP	1	
MUTAGEN:D->A: In 1DA mutant; abolished cleavage by caspase, preventing phospholipid scramblase activity.	SEQ_UP	1	
MUTAGEN:D->A: In DAH mutant; causes male infertility due to derepression of LINE1 retrotransposons transcripts.	SEQ_UP	1	
MUTAGEN:D->A: In DAH mutant; does not lead to arrest in meiotic prophase and failure of transposon piRNA amplification.	SEQ_UP	1	
MUTAGEN:D->A: In DAH mutant; leads to arrest in meiotic prophase due to a failure of transposon piRNA amplification, resulting in the marked reduction of piRNA-bound within PIWIL4.	SEQ_UP	1	
MUTAGEN:D->A: Increased permeability to chloride ions.	SEQ_UP	1	
MUTAGEN:D->A: Increased protein level, probably due to defects in ubiquitination. No effect on inhibition of SLC12A3.	SEQ_UP	1	
MUTAGEN:D->A: Increases enzyme activity.	SEQ_UP	1	
MUTAGEN:D->A: Increases GTP release from RAN.	SEQ_UP	1	
MUTAGEN:D->A: Increases IL3-induced production of IL4 by basophils.	SEQ_UP	1	
MUTAGEN:D->A: Increases the TLR7 response and decreases the TLR9 response. Enhances interaction with TLR7, TLR8 and TLR13 and TLR7 transport to endolysosomes in presence of single-stranded RNA. Decreases affinity for TLR9 and its transport to endolysosomes in presence of DNA.	SEQ_UP	1	
MUTAGEN:D->A: Induces a slight reduction in V(D)J recombination without affecting interaction with histones.	SEQ_UP	1	
MUTAGEN:D->A: Induces cell cycle arrest and neurite differentiation.	SEQ_UP	1	
MUTAGEN:D->A: Induces localization to the endoplasmic reticulum when expressed in absence of PKD1.	SEQ_UP	1	
MUTAGEN:D->A: Inhibits dendrite formation.	SEQ_UP	1	
MUTAGEN:D->A: Inhibits lipid kinase activity. Mice are viable and fertile but display defective adaptive and innate immune responses Signaling defects in B-cells, T-cells, mast cells and natural killer cells. Reduced B and T-cell receptor signaling. Affects development and differentiation of B -ells. Reduced memory T-cell number. Affects B- and T-cell proliferation. Attenuates immune responses in vivo. Induces inflammatory bowel disease development. Lost TCR-induced migration and localization to antigenic tissue. Affects natural killer cell maturation and cytokine production.	SEQ_UP	1	
MUTAGEN:D->A: Inhibits processing of prodomain.	SEQ_UP	1	
MUTAGEN:D->A: Interferes with DNA-binding.	SEQ_UP	1	
MUTAGEN:D->A: Kinase defective mutant, abolishes activity.	SEQ_UP	2	
MUTAGEN:D->A: Loss of activity.	SEQ_UP	5	
MUTAGEN:D->A: Loss of alpha-tubulin alpha-elongation step of polyglutamylase activity.	SEQ_UP	1	
MUTAGEN:D->A: Loss of autocatalytic cleavage; when associated with A-212; A-218 and A-225.	SEQ_UP	1	
MUTAGEN:D->A: Loss of autocatalytic cleavage; when associated with A-212; A-218 and A-387.	SEQ_UP	1	
MUTAGEN:D->A: Loss of autocatalytic cleavage; when associated with A-212; A-225 and A-387.	SEQ_UP	1	
MUTAGEN:D->A: Loss of autocatalytic cleavage; when associated with A-218; A-225 and A-387.	SEQ_UP	1	
MUTAGEN:D->A: Loss of CASP8-mediated cleavage; when associated with A-371.	SEQ_UP	1	
MUTAGEN:D->A: Loss of CASP8-mediated cleavage; when associated with A-377.	SEQ_UP	1	
MUTAGEN:D->A: Loss of CASP8-mediated cleavage. Promotes both FADD-dependent apoptosis and RIPK3-dependent necroptosis, thus leading to embryonic lethality at midgestation stages in knockin mice. Heterozygous knockin mice are viable and grossly normal, but are hyperresponsive to inflammatory stimuli.	SEQ_UP	1	
MUTAGEN:D->A: Loss of catalytic activity.	SEQ_UP	1	
MUTAGEN:D->A: Loss of catalytic activity. No effect on its localization. Trapping-mutant that stabilizes interaction with LG4/PSD95.	SEQ_UP	1	
MUTAGEN:D->A: Loss of cleavage and strand transfer activities without affecting allelic exclusion.	SEQ_UP	1	
MUTAGEN:D->A: Loss of cleavage and strand transfer activities.	SEQ_UP	1	
MUTAGEN:D->A: Loss of deubiquitinating activity.	SEQ_UP	1	
MUTAGEN:D->A: Loss of DNA-binding.	SEQ_UP	1	
MUTAGEN:D->A: Loss of enzymatic activity; reduced migration-promoting activity.	SEQ_UP	1	
MUTAGEN:D->A: Loss of enzyme activity; when associated with Y-1085.	SEQ_UP	1	
MUTAGEN:D->A: Loss of enzyme activity; when associated with Y-1295.	SEQ_UP	1	
MUTAGEN:D->A: Loss of enzyme activity; when associated with Y-1620.	SEQ_UP	1	
MUTAGEN:D->A: Loss of enzyme activity.	SEQ_UP	2	
MUTAGEN:D->A: Loss of function; when associated with 571-A-A-572.	SEQ_UP	1	
MUTAGEN:D->A: Loss of function; when associated with A-268; A-320; A-322; A-400 and A-454.	SEQ_UP	1	
MUTAGEN:D->A: Loss of function; when associated with A-268; A-320; A-322; A-400 and A-456.	SEQ_UP	1	
MUTAGEN:D->A: Loss of function; when associated with A-268; A-320; A-322; A-454 and A-456.	SEQ_UP	1	
MUTAGEN:D->A: Loss of function; when associated with A-268; A-320; A-400; A-454 and A-456.	SEQ_UP	1	
MUTAGEN:D->A: Loss of function; when associated with A-268; A-322; A-400; A-454 and A-456.	SEQ_UP	1	
MUTAGEN:D->A: Loss of function; when associated with A-320; A-322; A-400; A-454 and A-456.	SEQ_UP	1	
MUTAGEN:D->A: Loss of function.	SEQ_UP	1	
MUTAGEN:D->A: Loss of inhibition on JNK and NF-kappa-B signaling pathway activation; when associated with A-278.	SEQ_UP	1	
MUTAGEN:D->A: Loss of inhibition on JNK and NF-kappa-B signaling pathway activation; when associated with A-279.	SEQ_UP	1	
MUTAGEN:D->A: Loss of interaction with CNOT7.	SEQ_UP	1	
MUTAGEN:D->A: Loss of interaction with DLC2.	SEQ_UP	1	
MUTAGEN:D->A: Loss of interaction with histone H3 unmethylated at 'Lys-4'. Loss of the ability to negatively regulate cell proliferation.	SEQ_UP	1	
MUTAGEN:D->A: Loss of interaction with histone H3 unmethylated at 'Lys-4'. Loss of the ability to repress target genes expression. Loss of the ability to negatively regulate cell proliferation.	SEQ_UP	1	
MUTAGEN:D->A: Loss of interaction with SQSTM1.	SEQ_UP	1	
MUTAGEN:D->A: Loss of kinase activity and descreased phosphorylation.	SEQ_UP	1	
MUTAGEN:D->A: Loss of kinase activity; displays early embryonic lethality at 10-11 dpc and severe defects in angiogenic sprouting and vascular remodeling. Heterozygous mice yield adult mice with markedly impaired insulin signaling and reduced activation of effector pathways such as Akt/PKB.	SEQ_UP	1	
MUTAGEN:D->A: Loss of kinase activity.	SEQ_UP	2	
MUTAGEN:D->A: Loss of LPA acyltransferase and LPI acyltransferase activities.	SEQ_UP	1	
MUTAGEN:D->A: Loss of lysophosphatidylcholine acyltransferase activity, but no effect on phosholipase activity.	SEQ_UP	1	
MUTAGEN:D->A: Loss of lysyl hydroxylase activity. No effect on glycosyltransferase activity. Mutant mice are born at the expected Mendelian rate and have no visible phenotype, excepting decreased hydroxylysine modifications in type IV collagens in the skin.	SEQ_UP	1	
MUTAGEN:D->A: Loss of MAP3K2/MAP3K3 binding; when associated with A-65.	SEQ_UP	1	
MUTAGEN:D->A: Loss of MAP3K2/MAP3K3 binding; when associated with A-67.	SEQ_UP	1	
MUTAGEN:D->A: Loss of microtubule depolymerization activity.	SEQ_UP	1	
MUTAGEN:D->A: Loss of N-fatty-acyl-amino acid synthase/hydrolase activity.	SEQ_UP	1	
MUTAGEN:D->A: Loss of NLGN1-binding. No effect on CBLN1-binding.	SEQ_UP	1	
MUTAGEN:D->A: Loss of nucleotidyltransferase activity and oocytes are unable to support early embryonic development; when associated with A-1026.	SEQ_UP	1	
MUTAGEN:D->A: Loss of nucleotidyltransferase activity and oocytes are unable to support early embryonic development; when associated with A-1028.	SEQ_UP	1	
MUTAGEN:D->A: Loss of phosphatase activity.	SEQ_UP	1	
MUTAGEN:D->A: Loss of phospholipase activity, but no effect on lysophosphatidylcholine acyltransferase activity.	SEQ_UP	1	
MUTAGEN:D->A: Loss of polynucleotide adenylyltransferase activity.	SEQ_UP	1	
MUTAGEN:D->A: Loss of proteolytical cleavage leading to the production of p11 BID.	SEQ_UP	1	
MUTAGEN:D->A: Loss of RNase activity and no loss of protein deubiquitination; when associated with A-226.	SEQ_UP	1	
MUTAGEN:D->A: Loss of RNase activity, no loss of protein deubiquitination and ability to inhibit stress granule (SG) formation under stress; when associated with A-226.	SEQ_UP	1	
MUTAGEN:D->A: Marked reduction in KLC1-binding.	SEQ_UP	1	
MUTAGEN:D->A: Mutant mice show systolic arrhythmogenic abnormalities. Spontaneous Ca(2+) release from the sarcoplasmic reticulum in the heart is diminished.	SEQ_UP	1	
MUTAGEN:D->A: Nearly abolishes enzyme activity.	SEQ_UP	2	
MUTAGEN:D->A: No change in rates of factor Xa inhibition.	SEQ_UP	1	
MUTAGEN:D->A: No effect on adipogenesis.	SEQ_UP	1	
MUTAGEN:D->A: No effect on calcium channel activity. Abolishes ryanodine binding.	SEQ_UP	1	
MUTAGEN:D->A: No effect on cholesterol binding. Strongly decreased cholesterol transport activity.	SEQ_UP	1	
MUTAGEN:D->A: No effect on IL1B release under basal conditions, nor in response to LT or metabolic inhibitors; when associated with A-701 and A-702.	SEQ_UP	1	
MUTAGEN:D->A: No effect on inhibition of KCNJ1.	SEQ_UP	1	
MUTAGEN:D->A: No effect on inhibition of SLC4A4.	SEQ_UP	1	
MUTAGEN:D->A: No effect on interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:D->A: No effect on interaction with histone H3 unmethylated at 'Lys-4'. No significant effect on the ability to repress target genes expression. No effect on regulation of cell proliferation.	SEQ_UP	1	
MUTAGEN:D->A: No effect on interaction with TACC3.	SEQ_UP	1	
MUTAGEN:D->A: No effect on lipid kinase activity observed when the protein is purified from mammalian cell extracts; when associated with R-155.	SEQ_UP	1	
MUTAGEN:D->A: No effect on pericentromeric heterochromatin location. Disrupted DNA binding.	SEQ_UP	1	
MUTAGEN:D->A: No effect on transmembrane ascorbate ferrireductase activity.	SEQ_UP	1	
MUTAGEN:D->A: No effect on UBE2I binding nor on sumoylation.	SEQ_UP	1	
MUTAGEN:D->A: No effect on zinc binding. Abolishes zinc binding; when associated with A-1593.	SEQ_UP	1	
MUTAGEN:D->A: No effect; when associated with N-965. Restores autocatalytic cleavage and IL1B release in response to anthrax lethal toxin; when associated with V-927 and N-965.	SEQ_UP	1	
MUTAGEN:D->A: No effect.	SEQ_UP	2	
MUTAGEN:D->A: No significant effect on biliary cholesterol secretion.	SEQ_UP	1	
MUTAGEN:D->A: No significant effect on Km for CoA.	SEQ_UP	2	
MUTAGEN:D->A: Not detectable on the plasma membrane. Abolishes hyaluronan synthase activity.	SEQ_UP	1	
MUTAGEN:D->A: Prevents apical junction formation.	SEQ_UP	1	
MUTAGEN:D->A: Prevents cleavage by CASP8 and subsequent inactivation.	SEQ_UP	1	
MUTAGEN:D->A: Prevents interaction with PARD6B.	SEQ_UP	1	
MUTAGEN:D->A: Prevents nuclear translocation of CTNNB1.	SEQ_UP	1	
MUTAGEN:D->A: Probable loss of catalytic activity. Severe reduction in the number of hematopoietic stem and progenitor cells in fetal liver. Slight reduction in translation during erythrocyte development in fetal liver.	SEQ_UP	1	
MUTAGEN:D->A: Reduced 1-phosphatidylinositol-4-phosphate 5-kinase activity by 98%. Loss of actin-remodeling activity.	SEQ_UP	1	
MUTAGEN:D->A: Reduced binding to CHO cells expressing ITAG9-ITGB1.	SEQ_UP	1	
MUTAGEN:D->A: Reduced enzyme activity.	SEQ_UP	1	
MUTAGEN:D->A: Reduced interaction with histones.	SEQ_UP	1	
MUTAGEN:D->A: Reduced interaction with HRAS.	SEQ_UP	1	
MUTAGEN:D->A: Reduced sensitivity to Ca(2+).	SEQ_UP	1	
MUTAGEN:D->A: Reduced trypsin-binding; when associated with A-573.	SEQ_UP	1	
MUTAGEN:D->A: Reduces affinity for adenosine 70-fold. Reduces enzyme activity 110000-fold.	SEQ_UP	1	
MUTAGEN:D->A: Reduces Arf-GAP mediated stimulation of GTP hydrolysis 1000-fold.	SEQ_UP	1	
MUTAGEN:D->A: Reduces interaction with the SH3 domain of STAM2.	SEQ_UP	1	
MUTAGEN:D->A: Reduces oligomerization. Reduces activation of Wnt signaling.	SEQ_UP	1	
MUTAGEN:D->A: Reduces the interaction with RP2; when associated with A-164.	SEQ_UP	1	
MUTAGEN:D->A: Severely impaired the binding of calcium to all three sites.	SEQ_UP	1	
MUTAGEN:D->A: Significant loss of interaction with SPSB2.	SEQ_UP	1	
MUTAGEN:D->A: Significant reduction in LPC transport. Abolishes LPC transport; when associated with A-96.	SEQ_UP	1	
MUTAGEN:D->A: Slight reduction in transactivation activity.	SEQ_UP	1	
MUTAGEN:D->A: Slightly affects binding to NUMB protein.	SEQ_UP	1	
MUTAGEN:D->A: Slightly reduced LPC transport.	SEQ_UP	1	
MUTAGEN:D->A: Slightly reduces activity.	SEQ_UP	1	
MUTAGEN:D->A: Spontaneous IL1B release under basal conditions, loss of response to metabolic inhibitors and to LT; when associated with A-634.	SEQ_UP	1	
MUTAGEN:D->A: Spontaneous IL1B release under basal conditions, loss of response to metabolic inhibitors and to LT.	SEQ_UP	1	
MUTAGEN:D->A: Strong reduction of mitochondrial Ca(2+) peaks.	SEQ_UP	1	
MUTAGEN:D->A: Strongly decreased interaction with KEAP1.	SEQ_UP	1	
MUTAGEN:D->A: Strongly diminishes CTNNB1 binding and transactivation. Prevents nuclear translocation of CTNNB1.	SEQ_UP	1	
MUTAGEN:D->A: Strongly reduced binding affinity for EPHA5 SAM domain.	SEQ_UP	1	
MUTAGEN:D->A: Strongly reduced interaction with EIF4A1.	SEQ_UP	1	
MUTAGEN:D->A: Strongly reduces FLRT3 binding.	SEQ_UP	1	
MUTAGEN:D->A: Strongly reduces substrate binding. No effect on activity.	SEQ_UP	1	
MUTAGEN:D->A: Substrate trapping with much higher affinity for substrate.	SEQ_UP	1	
MUTAGEN:D->C: Abolishes channel activity.	SEQ_UP	1	
MUTAGEN:D->E,N: Loss of enzyme activity.	SEQ_UP	1	
MUTAGEN:D->E: Decrease in sensitivity to the scorpion toxin BMK M1.	SEQ_UP	1	
MUTAGEN:D->E: Impairs cell adhesion ability in vitro.	SEQ_UP	1	
MUTAGEN:D->E: In Gum(D366E) mutant; defects in embryonic angiogenesis. Weaker mutant compared to Gum(W96R) mutant.	SEQ_UP	1	
MUTAGEN:D->E: Increases transcriptional repression. No effect on interaction with THRIM28.	SEQ_UP	1	
MUTAGEN:D->E: Leads to enhanced neuronal differentiation of stem cells; when associated with N-98.	SEQ_UP	1	
MUTAGEN:D->E: Little or no effect on calcium channel activity.	SEQ_UP	1	
MUTAGEN:D->E: Loss of adhesive activity.	SEQ_UP	1	
MUTAGEN:D->E: Loss of both activities.	SEQ_UP	1	
MUTAGEN:D->E: No effect on affinity for adenosine. Reduces enzyme activity 2750-fold.	SEQ_UP	1	
MUTAGEN:D->E: No effect on inhibition of SLC4A4.	SEQ_UP	1	
MUTAGEN:D->E: No effect on interaction with PARD6B.	SEQ_UP	1	
MUTAGEN:D->E: No effect on potentiation of WNT7A signaling.	SEQ_UP	1	
MUTAGEN:D->E: No significant effect on integrin ITGAV:ITGB3 binding.	SEQ_UP	1	
MUTAGEN:D->E: Prevents cleavage by activated CASP3.	SEQ_UP	1	
MUTAGEN:D->E: Reduced cell spreading- and survival-promoting activities.	SEQ_UP	1	
MUTAGEN:D->E: Reduced integrin ITGAV:ITGB3 binding.	SEQ_UP	1	
MUTAGEN:D->E: Substantially reduces interaction with MECP2.	SEQ_UP	1	
MUTAGEN:D->G,V: No effect on interaction with ZFPM1.	SEQ_UP	1	
MUTAGEN:D->G: Abrogates kinase activity without affecting subcellular location.	SEQ_UP	1	
MUTAGEN:D->G: Abrogates kinase activity.	SEQ_UP	1	
MUTAGEN:D->G: Decreased inhibition of NF-kappa-B.	SEQ_UP	1	
MUTAGEN:D->G: Does not affect ability to promote piRNA biosynthesis.	SEQ_UP	1	
MUTAGEN:D->G: Fails to bind sperm. No effect on trypsin inhibitor activity.	SEQ_UP	1	
MUTAGEN:D->G: In Mot; male sterility characterized by reduced sperm output, and sperm with aberrant motility and short tails.	SEQ_UP	1	
MUTAGEN:D->G: In Npc1-nmf164; strongly decreased protein levels. Causes abnormal lipid storage in the spleen and liver, loss of cerebellar Purkinje cells and age-dependent ataxia.	SEQ_UP	1	
MUTAGEN:D->G: In rks; mice exhibit gross left-right abnormalities. Embryos do not show defects in kidney development. The nodes appear normal.	SEQ_UP	1	
MUTAGEN:D->G: Increased speed of phospholipid scrambling.	SEQ_UP	1	
MUTAGEN:D->G: Increases polynucleotide adenylyltransferase activity.	SEQ_UP	1	
MUTAGEN:D->G: Increases pore diameter.	SEQ_UP	1	
MUTAGEN:D->G: Knockin mice exhibit mild age-dependent degeneration of retinal structure and function; Knockin mice exhibit adequate isomerization activity with an accumulation of retinyl esters and a delay in rhodopsin regeneration kinetics and diminished electroretinography responses. Retinae of knockin mice are more sensitive to light exposition and exhibit signs of degenerative features when sujected to light stress. May cause abnormal splicing mRNAs thereby decreasing protein levels.	SEQ_UP	1	
MUTAGEN:D->G: Loss of function.	SEQ_UP	1	
MUTAGEN:D->G: No effect on binding to 5.8S rRNA; when associated with G-132.	SEQ_UP	1	
MUTAGEN:D->G: Reduced channel activity and sensitivity to Ca(2+).	SEQ_UP	1	
MUTAGEN:D->G: Reduced tRNA dimethylallyltransferase activity.	SEQ_UP	1	
MUTAGEN:D->G: Reduces transcriptional regulatory activity.	SEQ_UP	1	
MUTAGEN:D->G: Significantly reduces activity.	SEQ_UP	1	
MUTAGEN:D->G: Strongly reduces the interaction with MLPH.	SEQ_UP	1	
MUTAGEN:D->H: Abrogates interaction with NDEL1, PAFAH1B3 and RSN. Also impairs localization to centrosomes and microtubule plus ends. Reduces protein stability.	SEQ_UP	1	
MUTAGEN:D->H: Embryonic lethality in knockin mice; mice fail to form embryonic bodies and retain pluripotent gene expression, leading to impaired embryonic stem cell differentiation. Defects are caused by a failure to deacetylate histone H3 at 'Lys-9' (H3K9).	SEQ_UP	1	
MUTAGEN:D->H: Impairs calcium-dependent oligomerization and promotes ventricular tachycardia.	SEQ_UP	1	
MUTAGEN:D->H: Induces a decrease in activity.	SEQ_UP	1	
MUTAGEN:D->I: Accumulates in punctate structures in both cytoplasmic and nuclear compartments. Disrupts the integrity of the nuclear envelope.	SEQ_UP	1	
MUTAGEN:D->I: Reduces activity in Wnt signaling; when associated with I-449.	SEQ_UP	1	
MUTAGEN:D->I: Reduces activity in Wnt signaling; when associated with I-452.	SEQ_UP	1	
MUTAGEN:D->K,V: Loss of cytotoxicity.	SEQ_UP	1	
MUTAGEN:D->K: Abolished ability to promote phosphatidylserine exposure. Promotes localization to the cytoplasm.	SEQ_UP	1	
MUTAGEN:D->K: Abolishes assembly of dimers into functional tetramers. Loss of enzyme activity. Forms oligomers with full, phosphate-independent activity; when associated with A-325. Forms dimers with full, phosphate-independent activity; when associated with Q-316 and A-325.	SEQ_UP	1	
MUTAGEN:D->K: Abolishes enzymatic activity and ubiquitin binding.	SEQ_UP	1	
MUTAGEN:D->K: Abolishes interaction with SEMA6A.	SEQ_UP	1	
MUTAGEN:D->K: Decreases plasma membrane aminophospholipid translocation in neuronal cells.	SEQ_UP	1	
MUTAGEN:D->K: EIF4E-binding reduced by 60%; when associated with E-725, E-726 and K-730.	SEQ_UP	1	
MUTAGEN:D->K: Mildly reduced ability to promote lysosome clustering at the center of the cell; when associated with K-177 and K-180.	SEQ_UP	1	
MUTAGEN:D->K: Mildly reduced ability to promote lysosome clustering at the center of the cell; when associated with K-180 and K-181.	SEQ_UP	1	
MUTAGEN:D->K: No effect on protein abundance. Strong decreases of cell surface localization. Decreases alanine uptake.	SEQ_UP	1	
MUTAGEN:D->K: Slight increase in affinity for membranes. Increases membrane tubulation activity.	SEQ_UP	1	
MUTAGEN:D->K: Slightly increased GBA binding. No effect on normal location in lysosomes.	SEQ_UP	1	
MUTAGEN:D->L: No effect on homophilic interaction. Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself; when associated with Q-138.	SEQ_UP	1	
MUTAGEN:D->N,A,E: Loss of enzyme activity.	SEQ_UP	1	
MUTAGEN:D->N,E: Abolishes enzymatic activity.	SEQ_UP	1	
MUTAGEN:D->N,R: Abolished binding to and nuclear export of hypusinated EIF5A.	SEQ_UP	1	
MUTAGEN:D->N,R: Abolishes activity.	SEQ_UP	1	
MUTAGEN:D->N: 2-fold decrease in substrate affinity and 96% reduction in O-GlcNAcase activity. Regains appreciable level of catalytic efficiency in the acidic pH range. 40% recovery of activity in the presence of sodium azide.	SEQ_UP	1	
MUTAGEN:D->N: 2-fold increase in substrate affinity and 77% reduction in O-GlcNAcase activity. Regains appreciable level of catalytic efficiency in the acidic pH range. No recovery of activity in the presence of sodium azide.	SEQ_UP	1	
MUTAGEN:D->N: 92% loss of enzymatic activity.	SEQ_UP	1	
MUTAGEN:D->N: Abolished protein kinase activity and ability to activate necroptosis. Knockin mice die during embryogenesis due to constitutive Ripk1- and Casp8-dependent apoptosis. Perinatal lethality observed in Ripk1 knockout mice is rescued in knockin mice carrying this mutation.	SEQ_UP	1	
MUTAGEN:D->N: Abolished protein kinase activity and ability to regulate apoptosis and necroptosis. Knockin mice are viable.	SEQ_UP	1	
MUTAGEN:D->N: Abolishes ability to deneddylate cullins, but keeps ability to stabilize HIF1A protein.	SEQ_UP	1	
MUTAGEN:D->N: Abolishes ability to deubiquitinate histone H2A and ability to regulate transcription.	SEQ_UP	1	
MUTAGEN:D->N: Abolishes all phosphodiesterase activity. 10% activity can be restored by addition of Zn(2+) ions. Abolishes formation of nucleotidylated intermediate.	SEQ_UP	1	
MUTAGEN:D->N: Abolishes caspase-3 cleavage and increases cell survival. Does not affect kinase activity.	SEQ_UP	1	
MUTAGEN:D->N: Abolishes deubiquitinating activity.	SEQ_UP	1	
MUTAGEN:D->N: Abolishes enzymatic activity.	SEQ_UP	1	
MUTAGEN:D->N: Abolishes estrogen-dependent NF-kappa B transcriptional repression, impairs transcriptional activity, impairs estrogen-induced interaction with NCOA1; when associated with N-542 and Q-546.	SEQ_UP	1	
MUTAGEN:D->N: Abolishes estrogen-dependent NF-kappa B transcriptional repression, impairs transcriptional activity, impairs estrogen-induced interaction with NCOA1; when associated with Q-546 and N-548.	SEQ_UP	1	
MUTAGEN:D->N: Abolishes homooligomerization and FLRT3-mediated cell-cell adhesion; when associated with N-181.	SEQ_UP	1	
MUTAGEN:D->N: Abolishes interaction with MECP2.	SEQ_UP	1	
MUTAGEN:D->N: Abolishes interaction with polyubiquitinated IRAK1.	SEQ_UP	1	
MUTAGEN:D->N: Abolishes kinase activity and ability to mediate necroptosis. No autophosphorylation.	SEQ_UP	1	
MUTAGEN:D->N: Abolishes phosphatase activity.	SEQ_UP	2	
MUTAGEN:D->N: Abolishes surface expression and channel activity.	SEQ_UP	1	
MUTAGEN:D->N: Affects recruitment to heterochromatin by MECP2.	SEQ_UP	1	
MUTAGEN:D->N: Complete loss of apoptotic activity.	SEQ_UP	1	
MUTAGEN:D->N: Decreased ceramide synthase activity.	SEQ_UP	1	
MUTAGEN:D->N: Decreased monoglycylation activity; when associated with N-328.	SEQ_UP	1	
MUTAGEN:D->N: Decreased monoglycylation activity; when associated with N-330.	SEQ_UP	1	
MUTAGEN:D->N: Decreases phosphodiesterase activity by 95%. Abolishes formation of nucleotidylated intermediate.	SEQ_UP	1	
MUTAGEN:D->N: Decreases protein abundance. Strong decreases of cell surface localization. Strong decreases on alanine uptake activity.	SEQ_UP	1	
MUTAGEN:D->N: Diminishes phosphatase activity by 70%.	SEQ_UP	1	
MUTAGEN:D->N: Does not affect caspase-3 cleavage.	SEQ_UP	1	
MUTAGEN:D->N: Does not affect mitochondrial localization and ability to mediate calcium efflux from mitochondrion.	SEQ_UP	1	
MUTAGEN:D->N: Does not affect the endonuclease activity of the RAG complex.	SEQ_UP	1	
MUTAGEN:D->N: Does not inhibit calcium-dependent translocation to the cell membrane; when associated with N-33; N-35 and N-93.	SEQ_UP	1	
MUTAGEN:D->N: Does not inhibit calcium-dependent translocation to the cell membrane; when associated with N-33; N-35 and N-96.	SEQ_UP	1	
MUTAGEN:D->N: Does not inhibit calcium-dependent translocation to the cell membrane; when associated with N-33; N-93 and N-96.	SEQ_UP	1	
MUTAGEN:D->N: Does not inhibit calcium-dependent translocation to the cell membrane; when associated with N-35; N-93 and N-96.	SEQ_UP	1	
MUTAGEN:D->N: Does not inhibit calcium-dependent translocation to the cell membrane; when associated with N-37; N-39 and N-97.	SEQ_UP	1	
MUTAGEN:D->N: Does not inhibit calcium-dependent translocation to the cell membrane; when associated with N-37; N-39 and N-99.	SEQ_UP	1	
MUTAGEN:D->N: Does not inhibit calcium-dependent translocation to the cell membrane; when associated with N-37; N-97 and N-99.	SEQ_UP	1	
MUTAGEN:D->N: Does not inhibit calcium-dependent translocation to the cell membrane; when associated with N-39; N-97 and N-99.	SEQ_UP	1	
MUTAGEN:D->N: Does not inhibit calcium-dependent translocation to the cell membrane. Inhibits strongly calcium-dependent translocation to the cell membrane; when associated with N-229. Leads to the constitutive (calcium-independent) attachment to the cell membrane; when associated with N-167; N-173 and N-229.	SEQ_UP	1	
MUTAGEN:D->N: Does not inhibit calcium-dependent translocation to the cell membrane. Leads to the constitutive (calcium-independent) attachment to the cell membrane; when associated with N-170; N-232 and N-234.	SEQ_UP	1	
MUTAGEN:D->N: Does not strongly affect N-terminal glutamine amidohydrolase activity.	SEQ_UP	1	
MUTAGEN:D->N: Dominant negative, severely disrupts circadian rhythmicity of transcription.	SEQ_UP	1	
MUTAGEN:D->N: Fails to bind to LGI1.	SEQ_UP	1	
MUTAGEN:D->N: Greatly reduces inhibition of calcineurin phosphatase activity.	SEQ_UP	1	
MUTAGEN:D->N: Higher level of processed SREBF1 and SREBF2 when expressed in liver.	SEQ_UP	1	
MUTAGEN:D->N: Impaired calcium channel activity.	SEQ_UP	1	
MUTAGEN:D->N: Impaired cleavage.	SEQ_UP	1	
MUTAGEN:D->N: Impaired N-terminal glutamine amidohydrolase activity.	SEQ_UP	1	
MUTAGEN:D->N: Impaired NLRP6 inflammasome-dependent activation and release of IL1B and IL18.	SEQ_UP	1	
MUTAGEN:D->N: Impairs catalytic activity and abolishes interaction with DAXX.	SEQ_UP	1	
MUTAGEN:D->N: In C47 mutant; does not affect ability to mediate inflammatory response; when associated with 313-N-N-314.	SEQ_UP	1	
MUTAGEN:D->N: In C71 mutant; abolished cleavage and ability to generate caspase-1 subunits; abolished ability to process inflammatory cytokine interleukin-1 beta (IL1B) and ability to induce programmed cell death; when associated with N-103 and 296-N--N-314.	SEQ_UP	1	
MUTAGEN:D->N: In C71 mutant; abolished cleavage and ability to generate caspase-1 subunits; abolished ability to process inflammatory cytokine interleukin-1 beta (IL1B) and ability to induce programmed cell death; when associated with N-122 and 296-N--N-314.	SEQ_UP	1	
MUTAGEN:D->N: Increased autophosphorylation in the absence of PDGFB binding. Increased autophosphorylation in response to PDGFB binding. Constitutive interaction with PIK3R1, and constitutive AKT1 activation.	SEQ_UP	1	
MUTAGEN:D->N: Inhibits strongly calcium-dependent translocation to the cell membrane; when associated with N-231. Leads to the constitutive (calcium-independent) attachment to the cell membrane; when associated with N-167; N-173 and N-231.	SEQ_UP	1	
MUTAGEN:D->N: Inhibits strongly calcium-dependent translocation to the cell membrane. Inhibits strongly calcium-dependent translocation to the cell membrane; when associated with N-167. Leads to the constitutive (calcium-independent) attachment to the cell membrane; when associated with N-167; N-229 and N-231.	SEQ_UP	1	
MUTAGEN:D->N: Inhibits strongly calcium-dependent translocation to the cell membrane. Inhibits strongly calcium-dependent translocation to the cell membrane; when associated with N-173. Leads to the constitutive (calcium-independent) attachment to the cell membrane; when associated with N-173; N-229 and N-231.	SEQ_UP	1	
MUTAGEN:D->N: Leads to a reduction in the amount of calcium-dependent translocation to the cell membrane. Leads to the constitutive (calcium-independent) attachment to the cell membrane; when associated with N-170; N-176 and N-232.	SEQ_UP	1	
MUTAGEN:D->N: Leads to a reduction in the amount of calcium-dependent translocation to the cell membrane. Leads to the constitutive (calcium-independent) attachment to the cell membrane; when associated with N-170; N-176 and N-234.	SEQ_UP	1	
MUTAGEN:D->N: Leads to a reduction in the amount of calcium-dependent translocation to the cell membrane. Leads to the constitutive (calcium-independent) attachment to the cell membrane; when associated with N-176; N-232 and N-234.	SEQ_UP	1	
MUTAGEN:D->N: Leads to enhanced neuronal differentiation of stem cells; when associated with E-96.	SEQ_UP	1	
MUTAGEN:D->N: Little or no effect on calcium channel activity.	SEQ_UP	2	
MUTAGEN:D->N: Loss of activity; when associated with Q-140.	SEQ_UP	1	
MUTAGEN:D->N: Loss of activity.	SEQ_UP	2	
MUTAGEN:D->N: Loss of ATPase activity.	SEQ_UP	1	
MUTAGEN:D->N: Loss of cleavage (both nicking and hairpin formation).	SEQ_UP	1	
MUTAGEN:D->N: Loss of enzyme activity.	SEQ_UP	3	
MUTAGEN:D->N: Loss of exoribonuclease activity.	SEQ_UP	1	
MUTAGEN:D->N: Loss of function; when associated with 571-N-N-572.	SEQ_UP	1	
MUTAGEN:D->N: Loss of inositol 4-phosphatase activity. No effect on subcellular localization. No effect on interaction with OCRL, INPP5B and IPP4A.	SEQ_UP	1	
MUTAGEN:D->N: Loss of interaction with STX4 and insulin-dependent translocation to the cell membrane; when associated with N-157, N-163 and N-297.	SEQ_UP	1	
MUTAGEN:D->N: Loss of interaction with STX4 and insulin-dependent translocation to the cell membrane; when associated with N-157, N-163 and N-303.	SEQ_UP	1	
MUTAGEN:D->N: Loss of interaction with STX4 and insulin-dependent translocation to the cell membrane; when associated with N-157, N-297 and N-303.	SEQ_UP	1	
MUTAGEN:D->N: Loss of interaction with STX4 and insulin-dependent translocation to the cell membrane; when associated with N-163, N-297 and N-303.	SEQ_UP	1	
MUTAGEN:D->N: Loss of kinase activity and binding to VAV3.	SEQ_UP	1	
MUTAGEN:D->N: Loss of kinase activity.	SEQ_UP	1	
MUTAGEN:D->N: Loss of magnesium binding.	SEQ_UP	1	
MUTAGEN:D->N: Loss of RNase activity. Loss of mRNAs and miRNAs degradation. Loss of protein deubiquitination and suppression of inhibition on JNK and NF-kappa-B signaling pathway activation. Inhibits induction of angiogenesis and macrophage M2 polarization. Mislocalized in stress granule (SG). Loss of the ability to inhibit SG formation under stress. Does not inhibit binding to IL6 mRNA. Increases ICOS surface expression.	SEQ_UP	1	
MUTAGEN:D->N: Lower affinity for RAP. Abolishes binding to Reelin.	SEQ_UP	1	
MUTAGEN:D->N: Mislocalization of the protein from Golgi apparatus to endoplasmic reticulum.	SEQ_UP	1	
MUTAGEN:D->N: No change in caspase-3-induced cleavage product.	SEQ_UP	1	
MUTAGEN:D->N: No effect on enzyme activity.	SEQ_UP	1	
MUTAGEN:D->N: No effect on interaction with UNC5D; when associated with T-250.	SEQ_UP	1	
MUTAGEN:D->N: No effect on MHC class I peptide tetramer binding; when associated with D-250.	SEQ_UP	1	
MUTAGEN:D->N: No effect on protein abundance. Increases localization to the cell membrane. Increases alanine uptake activity.	SEQ_UP	1	
MUTAGEN:D->N: No effect on protein abundance. Strong decreases of cell surface localization. Decreases alanine uptake activity.	SEQ_UP	1	
MUTAGEN:D->N: No effect; specificity not affected.	SEQ_UP	1	
MUTAGEN:D->N: No effect.	SEQ_UP	1	
MUTAGEN:D->N: No significant effect on enzyme activity.	SEQ_UP	1	
MUTAGEN:D->N: Prevents interaction with LIN7C.	SEQ_UP	1	
MUTAGEN:D->N: Reduced activity.	SEQ_UP	1	
MUTAGEN:D->N: Reduced interaction with CATSPERZ due to defects in Ca(2+)-binding; when associated with Q-160.	SEQ_UP	1	
MUTAGEN:D->N: Reduces activity. Loss of endogenous retroelement metabolization.	SEQ_UP	1	
MUTAGEN:D->N: Reduces affinity for adenosine 10-fold. Reduces enzyme activity 100-fold.	SEQ_UP	1	
MUTAGEN:D->N: Reduces surface expression and abolishes channel activity.	SEQ_UP	1	
MUTAGEN:D->N: Results in loss of primer extension catalytic activity but retains ability to bind to the primase complex.	SEQ_UP	1	
MUTAGEN:D->Q: Decreases phosphodiesterase activity by 90%. Accumulates nucleotidylated intermediate.	SEQ_UP	1	
MUTAGEN:D->Q: Loss of enzyme activity.	SEQ_UP	1	
MUTAGEN:D->R: Abolishes kinase activity.	SEQ_UP	1	
MUTAGEN:D->R: Decreases the rate of channel opening. No effect; when associated with D-57.	SEQ_UP	1	
MUTAGEN:D->R: Defective in Ca(2+) oscillation activity and shows slower nuclear translocation.	SEQ_UP	1	
MUTAGEN:D->R: Expected to disrupt calcium binding. Loss of scramblase activity.	SEQ_UP	1	
MUTAGEN:D->R: Inhibits interaction with ITPR1.	SEQ_UP	1	
MUTAGEN:D->R: Loss of JAK signal transduction suppression. Reduced binding to JH1.	SEQ_UP	1	
MUTAGEN:D->R: Reduced neuron activity in the VNO.	SEQ_UP	1	
MUTAGEN:D->R: Strongly reduces PER1 binding.	SEQ_UP	1	
MUTAGEN:D->S: Abolishes the binding to PDCD1. Costimulates proliferation and IFNG production of T-cells.	SEQ_UP	1	
MUTAGEN:D->S: No effect on PDCD1 binding.	SEQ_UP	2	
MUTAGEN:D->S: Strongly decreased cytotoxicity.	SEQ_UP	1	
MUTAGEN:D->T: Abolishes homooligomerization and FLRT2-mediated cell-cell adhesion; when associated with N-186.	SEQ_UP	1	
MUTAGEN:D->V,H: Loss of CASP8-mediated cleavage. Embryonic lethality in knockin mice. Promotes activation of the protein kinase activity, leading to increased cell death.	SEQ_UP	1	
MUTAGEN:D->V: Abolishes location at nodal cilia and cannot complement the laterality defect of null mutants.	SEQ_UP	1	
MUTAGEN:D->V: Decrease in MEK binding.	SEQ_UP	1	
MUTAGEN:D->V: Enhances kinase activity and causes low seizure threshold, sporadic tonic-clonic seizures, brain enlargement and ectopic neurons in the dentate hilus and molecular layer of the hippocampus.	SEQ_UP	1	
MUTAGEN:D->V: Impairs inhibition of the Wnt signaling pathway; when associated with V-144.	SEQ_UP	1	
MUTAGEN:D->V: Impairs inhibition of the Wnt signaling pathway; when associated with V-146.	SEQ_UP	1	
MUTAGEN:D->V: Loss of desumoylase activity.	SEQ_UP	1	
MUTAGEN:D->V: Moderately reduces Ptch1 binding in vitro and signaling potency in chicken embryo neural plate explant assays compared with wild-type sequence.	SEQ_UP	1	
MUTAGEN:D->V: Restores autocatalytic cleavage, as observed in allele 1, but not response to anthrax lethal toxin (LT), nor to metabolic inhibitors. Restores autocatalytic cleavage and IL1B release in response to LT; when associated with A-935 and N-965.	SEQ_UP	1	
MUTAGEN:D->V: Significant decrease in autophosphorylation.	SEQ_UP	2	
MUTAGEN:D->Y: Increased interaction with TRAPPC3.	SEQ_UP	1	
MUTAGEN:D->Y: Mice carrying this mutation show atrophic ovaries without oocytes, but no other visible phenotype.	SEQ_UP	1	
MUTAGEN:D->Y: Partial loss of repressor activity.	SEQ_UP	1	
MUTAGEN:DD->AA: Abolishes BMP1-mediated cleavage of ectodomain release of olfactomedin-like domain.	SEQ_UP	1	
MUTAGEN:DD->AA: Abolishes repression of germ cell-related genes and L1 retrotransposons.	SEQ_UP	1	
MUTAGEN:DD->AA: Increases ICOS surface expression.	SEQ_UP	1	
MUTAGEN:DD->AA: Loss of function; when associated with A-1049.	SEQ_UP	1	
MUTAGEN:DD->AA: Loss of long-range transport of PI3P-positive organelles in embryonic fibroblasts. Expression of mutant protein in ANK2 null mutant fibroblasts partially rescues ITGB1 recycling to about 50% of the wild-type levels.	SEQ_UP	1	
MUTAGEN:DD->AA: Major reduction in ANK3-binding.	SEQ_UP	1	
MUTAGEN:DD->KK: Abolishes channel activity.	SEQ_UP	1	
MUTAGEN:DD->NN: In C47 mutant; does not affect ability to mediate inflammatory response and cell death; when associated with N-296.	SEQ_UP	1	
MUTAGEN:DD->NN: Loss of function; when associated with N-1049.	SEQ_UP	1	
MUTAGEN:DDD->AAA: Greatly decreases interaction with MAP1LC3B.	SEQ_UP	1	
MUTAGEN:DDDPD->AAAAA: Alters calcium binding.	SEQ_UP	1	
MUTAGEN:DDE->KKK: Does not inhibit interaction with ITPR1.	SEQ_UP	1	
MUTAGEN:DE->AA: Abolishes ATPase activity.	SEQ_UP	1	
MUTAGEN:DE->AA: Abolishes DNA polymerase activity and ability to confer resistance to DNA damage.	SEQ_UP	1	
MUTAGEN:DE->AA: Complete loss of ANK3-binding.	SEQ_UP	1	
MUTAGEN:DE->AA: Decreased MCM complex DNA helicase activity. Reduced ssDNA binding. No effect on MCM complex formation. No effect on MCM complex ATP binding and ATPase activity.	SEQ_UP	1	
MUTAGEN:DE->AA: Loss of MCM complex DNA helicase activity. Loss of ATP-binding. No effect on MCM complex formation. No effect on MCM complex ATPase activity and ssDNA binding.	SEQ_UP	1	
MUTAGEN:DE->AA: Strongly decreases MCM complex ATPase and DNA helicase activities. No effect on MCM complex formation. No effect on ATP and ssDNA binding.	SEQ_UP	1	
MUTAGEN:DEAGQ->GGAAG: Isoform 2: Abolishes the suppressor of cell proliferation activity.	SEQ_UP	1	
MUTAGEN:DEFSPMLLPS->AAAAAAAAAA: Loss of interaction with ZBTB7A.	SEQ_UP	1	
MUTAGEN:DETD->AETA: In 2DA mutant; abolished cleavage by caspase, preventing phospholipid scramblase activity.	SEQ_UP	1	
MUTAGEN:DF->NA: Abolishes ubiquitin binding; loss of inhibitory activity on TNF-induced NF-kappa-B activation; no effect on interaction with TNFAIP3.	SEQ_UP	1	
MUTAGEN:DFY->AAA: Strongly decreased affinity for NPC2.	SEQ_UP	1	
MUTAGEN:DGEA->AGEV: Inhibition of migration potentiation.	SEQ_UP	1	
MUTAGEN:DH->AA: Fails to enhance DLG4 palmitoylation.	SEQ_UP	2	
MUTAGEN:DH->AA: No loss of interaction with NOS2.	SEQ_UP	1	
MUTAGEN:DH->KA: Abolishes cleavage of the 5' autoinhibitory fragment of the long primary miRNA transcript, pri-miR-17-92.	SEQ_UP	1	
MUTAGEN:DKD->NKN: Loss of Ca(2+)-binding in the second C2 domain. Impaired delivery of lysosomal membrane to nascent phagosomes; when associated with 225-N--N-227. Impaired synaptic vesicle replenishment; when associated with 225-N--N-227.	SEQ_UP	1	
MUTAGEN:DL->AS: Abolishes binding to CTBP1 and impairs function in transcription repression.	SEQ_UP	1	
MUTAGEN:DL->AS: Abolishes interaction with CTBP2; it however does not abolish the corepressor activity in erythropoiesis.	SEQ_UP	1	
MUTAGEN:DL->AS: Loss of interaction with CTBP1 and CTBP2 and loss of repression of WAT-specific genes.	SEQ_UP	1	
MUTAGEN:DLG->AGE: Abolished ubiquitination and degradation by the BCR(KEAP1) complex in the cytoplasm.	SEQ_UP	1	
MUTAGEN:DLGCG->NAVAV: Abolishes methyltransferase activity.	SEQ_UP	1	
MUTAGEN:DLIDIL->ALIDIA: Does not affect ubiquitination and degradation by the BCR(KEAP1) complex in the cytoplasm.	SEQ_UP	1	
MUTAGEN:DLL->AAA: Impaired interaction with the AP-2 complex and impaired TCR down-modulation and recycling in TH2 cells; when associated with A-482.	SEQ_UP	1	
MUTAGEN:DLL->AAA: Loss of interaction with clathrin heavy chains; when associated with 187-AAAAA-191.	SEQ_UP	1	
MUTAGEN:DLLEPGSSPSDLTD->ALLAPGSSPSALTA: In AP1; promotes ability to release of interleukin-1 (IL1B and IL18) precursors.	SEQ_UP	1	
MUTAGEN:DLVD->ALVA: In 2DA mutant; abolished cleavage by CASP3 and ability to promote phosphatidylserine exposure.	SEQ_UP	1	
MUTAGEN:DN->GG: Abrogates kinase activity.	SEQ_UP	1	
MUTAGEN:DPPW->APPA: Loss of activity.	SEQ_UP	1	
MUTAGEN:DPSTGE->AAAAAA: Abolishes interaction with KEAP1.	SEQ_UP	1	
MUTAGEN:DR->NN: In DR/NN; abolished activity without affecting avility to bind CX3CL1.	SEQ_UP	1	
MUTAGEN:DR->RD: Decreases expression; No reduction of cAMP upon induction.	SEQ_UP	1	
MUTAGEN:DRL->PGH: Activation of ANF promoter abolished, no effect on SM22 promoter.	SEQ_UP	1	
MUTAGEN:DSDLL->NSDAA: Does not affect binding to connexins but results in their intracellular accumulation.	SEQ_UP	1	
MUTAGEN:DSE->ASA: No effect on protein folding and histone binding.	SEQ_UP	1	
MUTAGEN:DSSEDSSEDED->NSSQNSSQQQN: Strongly reduced pyrophosphorylation.	SEQ_UP	1	
MUTAGEN:DSVRDSEEDFLTDAIFEDD->NSVRDSEEDFLTNAIFENN: In C71 mutant; abolished cleavage and ability to generate caspase-1 subunits; abolished ability to process inflammatory cytokine interleukin-1 beta (IL1B) and ability to induce programmed cell death; when associated with N-103 and N-122.	SEQ_UP	1	
MUTAGEN:DSVRDSEEDFLTDAIFEDD->NSVRNSEENFLTNAIFENN: In C60 mutant; impaired cleavage and ability to generate caspase-1 subunits p10 and p20; abolished ability to process inflammatory cytokine interleukin-1 beta (IL1B) without affecting ability to induce programmed cell death.	SEQ_UP	1	
MUTAGEN:DV->AA: No effect on transcriptional repression. No effect on interaction with THRIM28.	SEQ_UP	1	
MUTAGEN:DV->AA: Strongly decreases transcriptional repression. No effect on interaction with THRIM28. No effect on interaction with THRIM28.	SEQ_UP	1	
MUTAGEN:DVD->NNN: Does not alter dystroglycan processing in vitro.	SEQ_UP	1	
MUTAGEN:DVQVQGLVE->AVQVQGLVA: In AP2; promotes ability to release of interleukin-1 (IL1B and IL18) precursors.	SEQ_UP	1	
MUTAGEN:DY->VH: Reduced interaction with RUNX1, decrease in its ability to regulate the expression of IL2, TNFRSF18, IL2RA and CTLA4 in a RUNX1-dependent manner. Loss of interaction with RUNX1 but no effect on interaction with NFATC2 and loss of its ability to regulate the expression of IL2, TNFRSF18, IL2RA and CTLA4 in a RUNX1-dependent manner; when associated with L-332.	SEQ_UP	1	
MUTAGEN:DYD->NYN: Loss of Ca(2+)-binding in the first C2 domain. Impaired delivery of lysosomal membrane to nascent phagosomes; when associated with 357-N--N-359. Impaired synaptic vesicle replenishment; when associated with 357-N--N-359.	SEQ_UP	1	
MUTAGEN:DYDRFSRND->AYARFSRNA: In C2A*; loss of function due to abolished Ca(2+)-binding to the first C2 domain. Impaired ability to mediate synaptic facilitation.	SEQ_UP	1	
MUTAGEN:E->A,Q,R: No effect on interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:E->A,Q: Loss of cleavage (both nicking and hairpin formation).	SEQ_UP	1	
MUTAGEN:E->A,Q: Strongly decreases the enzymatic activity.	SEQ_UP	1	
MUTAGEN:E->A,R: Abrogates L-rhamnose binding.	SEQ_UP	1	
MUTAGEN:E->A,R: Strongly shifts the voltage-dependent channel activation to much more depolarized membrane potentials.	SEQ_UP	1	
MUTAGEN:E->A: 3-fold increase in Km for CoA.	SEQ_UP	1	
MUTAGEN:E->A: Abolished homodimerization and subsequent activation. Does not affect nuclear localization and tethering to chromatin.	SEQ_UP	1	
MUTAGEN:E->A: Abolishes ability to promote type-I interferon production.	SEQ_UP	1	
MUTAGEN:E->A: Abolishes ability to rescue Purkinje cell degeneration in pcd mice when expressed in a transgene.	SEQ_UP	1	
MUTAGEN:E->A: Abolishes ATPase activity.	SEQ_UP	1	
MUTAGEN:E->A: Abolishes binding to glycogen synthase and glycogen phosphorylase but has no effect on binding to PP1 or glycogen; when associated with A-247.	SEQ_UP	1	
MUTAGEN:E->A: Abolishes catalytic activity.	SEQ_UP	1	
MUTAGEN:E->A: Abolishes deglutamylase activity.	SEQ_UP	2	
MUTAGEN:E->A: Abolishes enzyme activity.	SEQ_UP	2	
MUTAGEN:E->A: Abolishes in vitro enzyme activity.	SEQ_UP	1	
MUTAGEN:E->A: Abolishes interaction with PTPRD. Significantly reduces synapse assembly.	SEQ_UP	1	
MUTAGEN:E->A: Abolishes interaction with RAB27A.	SEQ_UP	1	
MUTAGEN:E->A: Abolishes interaction with TAX1BP3.	SEQ_UP	1	
MUTAGEN:E->A: Abolishes linear polyubiquitin-binding; when associated with A-313 and A-317.	SEQ_UP	1	
MUTAGEN:E->A: Abolishes linear polyubiquitin-binding; when associated with A-313 and A-320.	SEQ_UP	1	
MUTAGEN:E->A: Abolishes outwardly-rectifying currents.	SEQ_UP	1	
MUTAGEN:E->A: Abolishes prodomain removal.	SEQ_UP	1	
MUTAGEN:E->A: Abolishes sensitivity to Mg(2+), but not sensitivity to Ca(2+).	SEQ_UP	1	
MUTAGEN:E->A: Abolishes sumoylation.	SEQ_UP	1	
MUTAGEN:E->A: Abolishes the decapping activity on both incomplete m7G cap and NAD-cap RNAs. Abolishes the 5'-3' exoribonuclease activity.	SEQ_UP	1	
MUTAGEN:E->A: Absence of sumoylation. Enhanced protein degradation. Reduced self-renewal ability in ES cells. 55% lower expression of YES1.	SEQ_UP	1	
MUTAGEN:E->A: Acts as a dominant negative mutant that reduces the mitochondrial Ca(2+) peaks; when associated with A-233; A-244 and A-423.	SEQ_UP	1	
MUTAGEN:E->A: Acts as a dominant negative mutant that reduces the mitochondrial Ca(2+) peaks; when associated with A-233; A-423 and A-434.	SEQ_UP	1	
MUTAGEN:E->A: Affects recruitment to heterochromatin by MECP2.	SEQ_UP	1	
MUTAGEN:E->A: Almost abolishes interaction with BIRC2; when associated with A-292.	SEQ_UP	1	
MUTAGEN:E->A: Almost abolishes interaction with BIRC2; when associated with A-294.	SEQ_UP	1	
MUTAGEN:E->A: Complete loss of kinase activity and of nuclear localization.	SEQ_UP	1	
MUTAGEN:E->A: Complete loss of kinase activity.	SEQ_UP	1	
MUTAGEN:E->A: Decrease in binding to DNA.	SEQ_UP	1	
MUTAGEN:E->A: Decrease in cytidine deaminase and antiviral activity; when associated with A-301.	SEQ_UP	1	
MUTAGEN:E->A: Decrease in cytidine deaminase and antiviral activity; when associated with A-84.	SEQ_UP	1	
MUTAGEN:E->A: Decrease in cytidine deaminase and antiviral activity.	SEQ_UP	1	
MUTAGEN:E->A: Decreased beta-carotene 15,15'-monooxygenase activity.	SEQ_UP	1	
MUTAGEN:E->A: Decreased beta-carotene 15,15'-monooxygenase activity. Decreased catalytic efficiency. Loss of beta-carotene 15,15'-monooxygenase activity; when associated with A-52.	SEQ_UP	1	
MUTAGEN:E->A: Decreased interaction with CARD11.	SEQ_UP	1	
MUTAGEN:E->A: Decreased transmembrane ascorbate ferrireductase activity. Approximately 75% reduction in enzyme activity.	SEQ_UP	1	
MUTAGEN:E->A: Decreases affinity for IL1RAP.	SEQ_UP	1	
MUTAGEN:E->A: Decreases cAMP-binding.	SEQ_UP	1	
MUTAGEN:E->A: Decreases interaction with SCN8A in the absence of calcium.	SEQ_UP	1	
MUTAGEN:E->A: Decreases the enzymatic activity.	SEQ_UP	1	
MUTAGEN:E->A: Deficient in binding to RAN-GTP and in GTP release activity.	SEQ_UP	1	
MUTAGEN:E->A: Does not affect mono-ADP-ribosylation by SIRT6.	SEQ_UP	1	
MUTAGEN:E->A: Fails to dephosphorylate PGP in vitro.	SEQ_UP	1	
MUTAGEN:E->A: Highly decreases glycerophosphocholine cholinephosphodiesterase activity. Loss of choline metabolism.	SEQ_UP	1	
MUTAGEN:E->A: Impaired cleavage (defective in hairpin formation).	SEQ_UP	1	
MUTAGEN:E->A: Impaired cleavage.	SEQ_UP	1	
MUTAGEN:E->A: Impaired H3.3K36me3 binding.	SEQ_UP	1	
MUTAGEN:E->A: Impairs interaction with DISC1.	SEQ_UP	1	
MUTAGEN:E->A: Impairs interaction with HIF1AN.	SEQ_UP	1	
MUTAGEN:E->A: Impairs linear polyubiquitin-binding. Abolishes linear polyubiquitin-binding, no effect on 'Lys-63'-linked polyubiquitin-binding and impairs NF-kappa-B activation; when associated with A-309 and A-312. Abolishes linear polyubiquitin-binding; when associated with A-317 and A-320.	SEQ_UP	1	
MUTAGEN:E->A: Increased DNA-binding activity.	SEQ_UP	1	
MUTAGEN:E->A: Increased IL1B release under basal conditions. No effect on IL1B release in response to LT or metabolic inhibitors.	SEQ_UP	1	
MUTAGEN:E->A: Increased nucleotidyltransferase activity.	SEQ_UP	1	
MUTAGEN:E->A: Increases catalytic efficiency 30-fold. Increases affinity for NADH 20-fold.	SEQ_UP	1	
MUTAGEN:E->A: Loss of activity.	SEQ_UP	2	
MUTAGEN:E->A: Loss of angiogenic activity. Increased ribonuclease activity.	SEQ_UP	1	
MUTAGEN:E->A: Loss of beta-carotene 15,15'-monooxygenase activity.	SEQ_UP	1	
MUTAGEN:E->A: Loss of catalytic activity, as measured by the saturation of retinol to 13,14-dihydroretinol. Loss of adipocyte differentiation in a 3T3-L1 cell culture model.	SEQ_UP	1	
MUTAGEN:E->A: Loss of catalytic activity.	SEQ_UP	2	
MUTAGEN:E->A: Loss of CNPY3-binding.	SEQ_UP	1	
MUTAGEN:E->A: Loss of enzyme activity.	SEQ_UP	1	
MUTAGEN:E->A: Loss of fatty acyl-coenzyme A diphosphatase activity.	SEQ_UP	2	
MUTAGEN:E->A: Loss of function. Does not prevent proteolytic processing.	SEQ_UP	1	
MUTAGEN:E->A: Loss of interaction with CNOT7.	SEQ_UP	1	
MUTAGEN:E->A: Loss of interaction with SQSTM1.	SEQ_UP	1	
MUTAGEN:E->A: Loss of interaction with UBQLN1; when associated with A-863 and A-864.	SEQ_UP	1	
MUTAGEN:E->A: Loss of interaction with UBQLN1; when associated with A-864 and A-865.	SEQ_UP	1	
MUTAGEN:E->A: Loss of LPA acyltransferase and LPI acyltransferase activities.	SEQ_UP	1	
MUTAGEN:E->A: Loss of MAP3K2/MAP3K3 binding; when associated with A-64.	SEQ_UP	1	
MUTAGEN:E->A: Loss of nucleoside-diphosphatase activity.	SEQ_UP	1	
MUTAGEN:E->A: Loss of polyglutamylation, reduced cell reprogramming and pluripotency maintenance. Forms heterodimer with KLF5. No change in promoter-binding of target genes. Embryo lethality in mutant homozygous mice.	SEQ_UP	1	
MUTAGEN:E->A: Loss of polynucleotide adenylyltransferase activity.	SEQ_UP	1	
MUTAGEN:E->A: Loss of threonyl dipeptidase activity.	SEQ_UP	1	
MUTAGEN:E->A: Lowers dephosphorylation.	SEQ_UP	1	
MUTAGEN:E->A: Marked reduction in KLC1-binding.	SEQ_UP	1	
MUTAGEN:E->A: Markedly decreases enzyme stability, both apo and ligand-bound forms. Markedly decreases sulfotransferase activity (at pH 7.5).	SEQ_UP	1	
MUTAGEN:E->A: No change in DNA binding. No loss of self-renewal ability in iPS cells. No change in nuclear location.	SEQ_UP	1	
MUTAGEN:E->A: No change in JAK2/STAT5 activation nor mitogenic response.	SEQ_UP	1	
MUTAGEN:E->A: No change in KLF4 polyglutamylation.	SEQ_UP	1	
MUTAGEN:E->A: No effect on CDE RNA-binding.	SEQ_UP	1	
MUTAGEN:E->A: No effect on cytidine deaminase and antiviral activity.	SEQ_UP	1	
MUTAGEN:E->A: No effect on DNA-binding, no effect on repression of E2F1:TFDP1-mediated transcription and no effect on adipogenesis and granulopoiesis; when associated with A-288.	SEQ_UP	1	
MUTAGEN:E->A: No effect on enzyme activity against dopamine.	SEQ_UP	1	
MUTAGEN:E->A: No effect on IL1B release under basal conditions, nor in response to LT or metabolic inhibitors.	SEQ_UP	1	
MUTAGEN:E->A: No effect on interaction with CNOT7.	SEQ_UP	1	
MUTAGEN:E->A: No effect on interaction with PARD6B.	SEQ_UP	1	
MUTAGEN:E->A: No effect on interaction with TACC3.	SEQ_UP	1	
MUTAGEN:E->A: No effect on interaction with TBK1 and IKBKE.	SEQ_UP	1	
MUTAGEN:E->A: No effect on kinase activity.	SEQ_UP	1	
MUTAGEN:E->A: No effect on STAT3 phosphorylation.	SEQ_UP	1	
MUTAGEN:E->A: No effect on TRAF6-induced NF-kappa-B activation.	SEQ_UP	1	
MUTAGEN:E->A: No effect on transmembrane ascorbate ferrireductase activity.	SEQ_UP	1	
MUTAGEN:E->A: No effect.	SEQ_UP	2	
MUTAGEN:E->A: No impact on substrate affinity of SLC6A19-mediated amino acid transport.	SEQ_UP	1	
MUTAGEN:E->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-276.	SEQ_UP	1	
MUTAGEN:E->A: No loss of its ability to regulate TBX21-dependent gene expression or its ability to interact with SMARCA4; when associated with A-1388 and A-1468.	SEQ_UP	1	
MUTAGEN:E->A: No significant effect on beta-carotene 15,15'-monooxygenase activity.	SEQ_UP	1	
MUTAGEN:E->A: No significant effect on Km for CoA.	SEQ_UP	1	
MUTAGEN:E->A: No UBE2I binding nor sumoylation.	SEQ_UP	1	
MUTAGEN:E->A: Not sumoylated and not ubiquitinated.	SEQ_UP	1	
MUTAGEN:E->A: Partial loss of selectivity for calcium over monocovalent cations.	SEQ_UP	1	
MUTAGEN:E->A: Prevents nuclear translocation of CTNNB1.	SEQ_UP	1	
MUTAGEN:E->A: Reduced affinity for Asprosin.	SEQ_UP	1	
MUTAGEN:E->A: Reduced binding to CHO cells expressing ITAG9-ITGB1.	SEQ_UP	1	
MUTAGEN:E->A: Reduced interaction with histones.	SEQ_UP	1	
MUTAGEN:E->A: Reduced interaction with REC114.	SEQ_UP	1	
MUTAGEN:E->A: Reduced lysophospholipase activity.	SEQ_UP	1	
MUTAGEN:E->A: Reduced recovery of intracellular sodium-dependent pH.	SEQ_UP	1	
MUTAGEN:E->A: Reduced trypsin-binding; when associated with A-550.	SEQ_UP	1	
MUTAGEN:E->A: Reduces activity about 10-fold.	SEQ_UP	1	
MUTAGEN:E->A: Reduces activity about 15-fold. Loss of substrate binding.	SEQ_UP	1	
MUTAGEN:E->A: Reduces DNA binding.	SEQ_UP	1	
MUTAGEN:E->A: Reduces interaction with BIRC2.	SEQ_UP	1	
MUTAGEN:E->A: Reduces substrate affinity of SLC6A19-mediated amino acid transport.	SEQ_UP	1	
MUTAGEN:E->A: Reduces the interaction with RP2; when associated with A-168.	SEQ_UP	1	
MUTAGEN:E->A: Reduces transcription activity. Decreases interaction with ARNT.	SEQ_UP	1	
MUTAGEN:E->A: Significant reduction in LPC transport.	SEQ_UP	1	
MUTAGEN:E->A: Significantly decreases interaction with MECP2.	SEQ_UP	1	
MUTAGEN:E->A: Significantly weaker interaction with RABGAP1L.	SEQ_UP	1	
MUTAGEN:E->A: Slight reduction of transcriptional repression. Great reduction of transcriptional repression; when associated with A-199.	SEQ_UP	1	
MUTAGEN:E->A: Slightly affects interaction with MLKL; when associated with A-230. Affects interaction with MLKL; when associated with A-230 and A-232.	SEQ_UP	1	
MUTAGEN:E->A: Slightly affects the interaction with GATA1.	SEQ_UP	1	
MUTAGEN:E->A: Slightly reduced LPC transport.	SEQ_UP	1	
MUTAGEN:E->A: Spontaneous IL1B release under basal conditions, no effect on the response to metabolic inhibitors, partial loss of response to LT; when associated with A-686.	SEQ_UP	1	
MUTAGEN:E->A: Strongly decreased affinity for NPC2; when associated with 503-A-A-504.	SEQ_UP	1	
MUTAGEN:E->A: Strongly decreased cholesterol export.	SEQ_UP	1	
MUTAGEN:E->A: Strongly decreased interaction with KEAP1.	SEQ_UP	1	
MUTAGEN:E->A: Strongly increased threshold for activation by calcium.	SEQ_UP	1	
MUTAGEN:E->A: Strongly reduces AMPH, SNAP91 and BIN1 binding. Slightly reduces EPS15 and auxilin binding.	SEQ_UP	1	
MUTAGEN:E->A: Strongly reduces interaction with OAZ1 and unable to abrogate both the inhibitory effect of OAZ1 on ornithine decarboxylase (ODC) activity and polyamine uptake; when associated with A-140 and A-142.	SEQ_UP	1	
MUTAGEN:E->A: Weakly decreases interaction with MECP2.	SEQ_UP	1	
MUTAGEN:E->A: Wild-type binding to BoNT/B.	SEQ_UP	1	
MUTAGEN:E->D,A: Remains sensitive to Mg(2+).	SEQ_UP	1	
MUTAGEN:E->D,K,R: High transactivation activity.	SEQ_UP	1	
MUTAGEN:E->D,Q: 100-fold decreased affinity for L-rhamnose.	SEQ_UP	1	
MUTAGEN:E->D: Abolishes peptidase activity but no effect on GPIase activity.	SEQ_UP	1	
MUTAGEN:E->D: Decreases expression of both ABCG5 and ABCG8. Disrupts sterol transport activity.	SEQ_UP	1	
MUTAGEN:E->D: Decreases transcriptional repression.	SEQ_UP	1	
MUTAGEN:E->D: Does not affect interaction with MECP2.	SEQ_UP	1	
MUTAGEN:E->D: No change in activity.	SEQ_UP	1	
MUTAGEN:E->D: No effect on sterol transport.	SEQ_UP	1	
MUTAGEN:E->D: Reduced polyglycylation.	SEQ_UP	1	
MUTAGEN:E->D: Reduces catalytic activity 700-fold. No effect on affinity for adenosine.	SEQ_UP	1	
MUTAGEN:E->G,K: Decreased sumoylation; aberrant localization with decreased nuclear rim staining and formation of intranuclear foci; associated with increased cell death.	SEQ_UP	1	
MUTAGEN:E->G,K: Rescues the inhibitory effects of ASPN on BMP2-induced cytodifferentiation.	SEQ_UP	1	
MUTAGEN:E->G: Decrease in activity.	SEQ_UP	1	
MUTAGEN:E->G: Gain of SCFA-independent constitutive G protein-coupled receptor activity.	SEQ_UP	1	
MUTAGEN:E->G: In lrm4; mice exhibit gross left-right abnormalities. Embryos do not show defects in kidney development. The nodes appear normal. Abolishes location at nodal cilia, but does not affect interaction with Pkd1l1.	SEQ_UP	1	
MUTAGEN:E->G: In qk-Kt4; induces embryonic lethality possibly due to its inability to homodimerize.	SEQ_UP	1	
MUTAGEN:E->G: In rahu mutant; male sterility due to defects in spermatogenesis, probably caused by transposon derepression due to impaired DNA demethylation.	SEQ_UP	1	
MUTAGEN:E->G: Increases stability and improves binding to MHC I class ligand; when associated with G-121; G-175 and K-227.	SEQ_UP	1	
MUTAGEN:E->G: Loss of tubulin monoglycylation activity.	SEQ_UP	1	
MUTAGEN:E->G: No effect on binding to 5.8S rRNA; when associated with G-130.	SEQ_UP	1	
MUTAGEN:E->G: Reduces catalytic activity 3200-fold. No effect on affinity for adenosine.	SEQ_UP	1	
MUTAGEN:E->K: Abolishes localization to meiotic nuage; when associated with N-1019.	SEQ_UP	1	
MUTAGEN:E->K: Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself; when associated with N-185.	SEQ_UP	1	
MUTAGEN:E->K: Constitutive activation.	SEQ_UP	1	
MUTAGEN:E->K: Disrupts interaction with Rab8; accumulation in the retinal outer plexiform layer; loss of retinal ganglion cells and connecting synapses, degeneration of entire retina without elevation of intraocular pressure.	SEQ_UP	1	
MUTAGEN:E->K: Does not affect interaction with IRF4 and ability to mediate differentiation of Th17 cells. Retains 50% of activity; when associated with D63 and 69-Q-T-70. Loss of function; when associated with Q-55; A-56 and D-63.	SEQ_UP	1	
MUTAGEN:E->K: Does not modify the functional properties of the protein.	SEQ_UP	1	
MUTAGEN:E->K: EIF4E-binding reduced by 60%; when associated with K-724, E-725 and E-726.	SEQ_UP	1	
MUTAGEN:E->K: Exhibits siderocytosis with increased zinc protoporphyrin.	SEQ_UP	1	
MUTAGEN:E->K: Gives susceptibility to xenotropic murine leukemia retroviruses infection.	SEQ_UP	1	
MUTAGEN:E->K: Homozygous mutant mice exhibit retinal degeneration.	SEQ_UP	1	
MUTAGEN:E->K: Impaired ability to associate with CGAS-DNA droplets.	SEQ_UP	1	
MUTAGEN:E->K: Impaired interaction and cleavage by CASP1.	SEQ_UP	1	
MUTAGEN:E->K: Impairs epithelium polarity.	SEQ_UP	1	
MUTAGEN:E->K: Impairs epithelium polarization.	SEQ_UP	1	
MUTAGEN:E->K: In Yoda; protein degradation is impaired. Homozygotes are embryonic lethal. Heterozygotes have reduced body size, craniofacial abnormalities, and reduced bone mineral density.	SEQ_UP	1	
MUTAGEN:E->K: Knockin mutant mice are viable and survive into adulthood. Mice display abnormalities in multiple organ systems, including loose skin, bent forelimb, aortic aneurysm, tortuous artery, and pulmonary emphysema. In addition to elastic fiber abnormalities in the skin and large arteries, collagen fibrils are irregularly shaped, with many large fibrils in the dermis. Mice have large artery stiffness and systolic hypertension. Reduces protein secretion.	SEQ_UP	1	
MUTAGEN:E->K: Loss of inhibition by GNF-2.	SEQ_UP	1	
MUTAGEN:E->K: Loss of interaction with RABGAP1L. Localizes on motile vesicles, but does not cotransport with RABGAP1L. Loss of polarized transport of PI3P-positive organelles to the leading edge of the migrating fibroblasts. Expression of mutant protein does not rescue ITGB1 recycling deficit of ANK2 null mutant fibroblasts nor the impaired haptotactic response of the fibroblasts.	SEQ_UP	1	
MUTAGEN:E->K: Loss of interaction with SYNCRIP.	SEQ_UP	1	
MUTAGEN:E->K: Loss of transcriptional repression.	SEQ_UP	1	
MUTAGEN:E->K: Mildly reduced ability to promote lysosome clustering at the center of the cell; when associated with K-177 and K-181.	SEQ_UP	1	
MUTAGEN:E->K: No effect on inhibition of SLC12A3.	SEQ_UP	1	
MUTAGEN:E->K: No spontaneous pyroptosis-inducing activity; when associated with D-184.	SEQ_UP	1	
MUTAGEN:E->K: Reduced JAK2/STAT5 activation and mitogenic response.	SEQ_UP	1	
MUTAGEN:E->K: Reduced potassium ion transmembrane transport.	SEQ_UP	1	
MUTAGEN:E->K: Reduces binding to EDAR.	SEQ_UP	1	
MUTAGEN:E->K: Significantly impaired guanine nucleotide exchange factor activity on ARF6 in PC12 cells.	SEQ_UP	1	
MUTAGEN:E->L: Increases degradation via the proteasomal pathway. No effect on endoplasmic reticulum location. Impairs vitamin A uptake. No effect on retinol acyltransferase activity.	SEQ_UP	1	
MUTAGEN:E->L: Reduces enzyme activity against dopamine.	SEQ_UP	1	
MUTAGEN:E->M: No effect on LPS-binding, LPS-induced oligomerization, and LPS-induced pyroptosis; when associated with E-38.	SEQ_UP	1	
MUTAGEN:E->M: Retains ATP-binding ability.	SEQ_UP	1	
MUTAGEN:E->N: Abolishes sensitivity to Mg(2+), but not sensitivity to Ca(2+).	SEQ_UP	1	
MUTAGEN:E->P: 50-fold reduction in bioactivity.	SEQ_UP	1	
MUTAGEN:E->P: Adheres to and takes up L.monocytogenes InlA coated beads.	SEQ_UP	1	
MUTAGEN:E->P: Alters PSMC3/MND1 formation.	SEQ_UP	1	
MUTAGEN:E->P: Reduction in bioactivity.	SEQ_UP	1	
MUTAGEN:E->Q,A: Abolishes the enzymatic activity.	SEQ_UP	1	
MUTAGEN:E->Q,R: Abolished binding to and nuclear export of hypusinated EIF5A.	SEQ_UP	1	
MUTAGEN:E->Q: Abolished protease activity and ability to cleave OPA1. Abolished autocatalytic processing.	SEQ_UP	1	
MUTAGEN:E->Q: Abolishes calcium-binding.	SEQ_UP	1	
MUTAGEN:E->Q: Abolishes catalytic activity.	SEQ_UP	1	
MUTAGEN:E->Q: Abolishes deglutamylase activity; when associated with S-230.	SEQ_UP	1	
MUTAGEN:E->Q: Abolishes deglutamylase activity; when associated with S-252.	SEQ_UP	1	
MUTAGEN:E->Q: Abolishes deglutamylase activity; when associated with S-803.	SEQ_UP	1	
MUTAGEN:E->Q: Abolishes deglutamylase activity; when associated with S-912.	SEQ_UP	1	
MUTAGEN:E->Q: Abolishes estrogen-dependent NF-kappa B transcriptional repression, impairs transcriptional activity, impairs estrogen-induced interaction with NCOA1; when associated with N-542 and N-548.	SEQ_UP	1	
MUTAGEN:E->Q: Abolishes histone methyltransferase activity and reduces coactivator activity.	SEQ_UP	1	
MUTAGEN:E->Q: Abolishes phosphatase activity.	SEQ_UP	1	
MUTAGEN:E->Q: Abolishes the binding to CDK5RAP1, CDK5RAP2, CDKRAP3, but not to CDK5.	SEQ_UP	1	
MUTAGEN:E->Q: Abrogates Malassezia recognition; when associated with D-171.	SEQ_UP	1	
MUTAGEN:E->Q: Absence of proteolytic activity. Loss of its processing into the mature form.	SEQ_UP	2	
MUTAGEN:E->Q: Absence of proteolytic activity. No loss of its processing into the mature form.	SEQ_UP	1	
MUTAGEN:E->Q: Affects ATP hydrolysis but not binding.	SEQ_UP	1	
MUTAGEN:E->Q: Complete loss of LTA4 hydrolase and peptidase enzyme activities.	SEQ_UP	1	
MUTAGEN:E->Q: Confers sodium-dependent sugar transport activity not found in the wild type protein.	SEQ_UP	1	
MUTAGEN:E->Q: Defective in ATP-hydrolysis. Causes membrane-association. Induces vacuolation of endosomal compartments and impairs cholesterol and protein sorting. Increased perinuclear localization.	SEQ_UP	1	
MUTAGEN:E->Q: Disrupts channel closure.	SEQ_UP	1	
MUTAGEN:E->Q: Disrupts targeting to membrane; when associated with A-67; N-68; Q-70; P-73 and A-74.	SEQ_UP	1	
MUTAGEN:E->Q: Does not affect mitochondrial localization but abolishes ability to mediate calcium efflux from mitochondrion.	SEQ_UP	1	
MUTAGEN:E->Q: Does not affect signaling activity in any of Shh signaling assays and causes no apparent defects in cholesterol-mediated autoprocessing reactions.	SEQ_UP	1	
MUTAGEN:E->Q: Does not affect the endonuclease activity of the RAG complex.	SEQ_UP	1	
MUTAGEN:E->Q: Does not strongly affect N-terminal glutamine amidohydrolase activity.	SEQ_UP	1	
MUTAGEN:E->Q: Expected to disrupt calcium binding. Loss of scramblase and ion channel activity.	SEQ_UP	1	
MUTAGEN:E->Q: Fails to interacts with AGO2. Decreases nuclear localization.	SEQ_UP	1	
MUTAGEN:E->Q: Impaired cleavage.	SEQ_UP	1	
MUTAGEN:E->Q: Impairs ATPase activity.	SEQ_UP	1	
MUTAGEN:E->Q: In Mvh(KI); heterozygous and homozygous knockin male mice are infertile due to derepression of transposable elements. Defects in piRNA biogenesis. Pre-piRNAs fail to mature into piRNAs.	SEQ_UP	1	
MUTAGEN:E->Q: In Tdrd9(KI); heterozygous and homozygous knockin male mice are infertile due to derepression of transposable elements. PiRNA biogenesis in not affected but piRNAs fail to accumulate in the nucleus.	SEQ_UP	1	
MUTAGEN:E->Q: Little or no effect on calcium channel activity.	SEQ_UP	1	
MUTAGEN:E->Q: Localizes in the nuclear envelope.	SEQ_UP	1	
MUTAGEN:E->Q: Loss of activity with different N-heterocyclic compounds as substrates. 60% reduction of activity with benzaldehyde.	SEQ_UP	1	
MUTAGEN:E->Q: Loss of activity; when associated with N-136.	SEQ_UP	1	
MUTAGEN:E->Q: Loss of activity.	SEQ_UP	2	
MUTAGEN:E->Q: Loss of alpha-tubulin alpha-elongation step of polyglutamylase activity.	SEQ_UP	1	
MUTAGEN:E->Q: Loss of binding to AKT2.	SEQ_UP	1	
MUTAGEN:E->Q: Loss of calcium binding; when associated with Q-149 and Q-226.	SEQ_UP	1	
MUTAGEN:E->Q: Loss of calcium binding; when associated with Q-149 and Q-263.	SEQ_UP	1	
MUTAGEN:E->Q: Loss of calcium binding; when associated with Q-226 and Q-263.	SEQ_UP	1	
MUTAGEN:E->Q: Loss of catalytic activity against glutathione.	SEQ_UP	1	
MUTAGEN:E->Q: Loss of diphosphoinositol polyphosphate phosphohydrolase activity, but retains ability to regulate the ERK1/2 pathway.	SEQ_UP	1	
MUTAGEN:E->Q: Loss of DNA-binding.	SEQ_UP	1	
MUTAGEN:E->Q: Loss of enzyme activity.	SEQ_UP	2	
MUTAGEN:E->Q: Loss of ERAD activity.	SEQ_UP	1	
MUTAGEN:E->Q: Loss of the cytidine deaminase activity; when associated with R-56.	SEQ_UP	1	
MUTAGEN:E->Q: Loss of transactivation function.	SEQ_UP	1	
MUTAGEN:E->Q: Mildly decreases cholesterol transport. No effect on plant sterol transport.	SEQ_UP	1	
MUTAGEN:E->Q: No effect on interaction with LIN7C.	SEQ_UP	1	
MUTAGEN:E->Q: No effect.	SEQ_UP	2	
MUTAGEN:E->Q: Partially restored current Na(+) leak current when expressed in UNC80 knockout neurons.	SEQ_UP	1	
MUTAGEN:E->Q: Perinuclear localization.	SEQ_UP	1	
MUTAGEN:E->Q: Reduced activity.	SEQ_UP	1	
MUTAGEN:E->Q: Reduced interaction with CATSPERZ due to defects in Ca(2+)-binding; when associated with N-72.	SEQ_UP	1	
MUTAGEN:E->Q: Reduces catalytic activity 4800-fold, and slightly increases affinity for substrate.	SEQ_UP	1	
MUTAGEN:E->Q: Reduces sensitivity to block by extracellular acidification. Sensitivity to block by low extracellular pH is nearly abolished; when associated with N-935.	SEQ_UP	1	
MUTAGEN:E->Q: Requires much higher calcium levels for the activation of scramblase and ion channel activity.	SEQ_UP	1	
MUTAGEN:E->Q: Same affinity for RAP. Lower affinity for Reelin.	SEQ_UP	1	
MUTAGEN:E->Q: Same affinity for RAP. Same affinity for Reelin.	SEQ_UP	1	
MUTAGEN:E->Q: Significantly decreases interaction with MECP2.	SEQ_UP	1	
MUTAGEN:E->Q: Strongly decreases expression of both ABCG5 and ABCG8. Disrupts sterol transport activity.	SEQ_UP	1	
MUTAGEN:E->R,Q: No neuron activity in the VNO and marked reduction in the accessory olfactory bulb.	SEQ_UP	1	
MUTAGEN:E->R: Abolished ability to promote phosphatidylserine exposure.	SEQ_UP	1	
MUTAGEN:E->R: Abolished binding to hypusinated EIF5A.	SEQ_UP	1	
MUTAGEN:E->R: Abolishes interaction with KAT8.	SEQ_UP	1	
MUTAGEN:E->R: Alters the voltage-dependent gating; when associated with R-287.	SEQ_UP	1	
MUTAGEN:E->R: Decreased binding to JAM2.	SEQ_UP	1	
MUTAGEN:E->R: Disrupts intramolecular interactions and autoinhibition, leading to spontaneous pyroptosis-inducing activity.	SEQ_UP	1	
MUTAGEN:E->R: Does not affect recognition by the CRL2(FEM1B) complex and subsequent ubiquitination.	SEQ_UP	1	
MUTAGEN:E->R: Does not affect trypsin-binding.	SEQ_UP	1	
MUTAGEN:E->R: Impairs interaction with DNM1.	SEQ_UP	1	
MUTAGEN:E->R: Knockin mice show impaired spermatogenesis, loss of histone H3K4me3 binding, severe disruption of chromosomal synapsis and DNA double-strand breaks repair in spermatocytes; when associated with I-247 and P-294.	SEQ_UP	1	
MUTAGEN:E->R: Loss of trimerization; when associated with 439-E--L-441 DEL.	SEQ_UP	1	
MUTAGEN:E->R: No effect on binding to SIVA1; when associated with G-204.	SEQ_UP	1	
MUTAGEN:E->R: No effect on LIF-induced signal transduction suppression.	SEQ_UP	1	
MUTAGEN:E->R: Strongly decreased cytotoxicity.	SEQ_UP	1	
MUTAGEN:E->S: Loss of activity.	SEQ_UP	1	
MUTAGEN:E->S: No effect on its ability to hydrolyze NAD.	SEQ_UP	1	
MUTAGEN:E->S: No effect on PDCD1 binding.	SEQ_UP	2	
MUTAGEN:E->S: Significantly reduces the binding to PDCD1.	SEQ_UP	2	
MUTAGEN:E->V: Decreased protein abundance. Decreased autophosphorylation. Changed subcellular localization. Homozygous mice for that mutation are hyperactive and display repetitive behaviors. They also display social deficits and decreased exploratory behavior.	SEQ_UP	1	
MUTAGEN:E->V: Decreases activity three-fold.	SEQ_UP	1	
MUTAGEN:E->V: Disrupts interaction with ZFPM1. Binds normally to DNA.	SEQ_UP	1	
MUTAGEN:E->V: Impairs its ability to form a complex with triglycerides and MTTP, as well as its ability to facilitate MTTP-mediated lipid transfer and MTTP-mediated apoB lipoprotein assembly and secretion.	SEQ_UP	1	
MUTAGEN:E->V: Knockin new born mice are healthy and survive into adulthood without overt signs of respiratory distress. Knockin mice show a severe lung phenotype that begins with alveolar inflammatory cell infiltration at the early stage of the mouse life followed by aberrant lung remodeling with characteristics of diffuse parenchymal lung disease (DPLD)- and emphysema-like alveolar disruption in older mice.	SEQ_UP	1	
MUTAGEN:E->V: Loss of activity.	SEQ_UP	1	
MUTAGEN:E->V: Loss of interaction with 'Lys-63'-linked ubiquitin.	SEQ_UP	1	
MUTAGEN:E->V: Loss of NAP1 polyglycylase activity.	SEQ_UP	1	
MUTAGEN:E->V: No change in JAK2/STAT5 activation nor mitogenic response.	SEQ_UP	1	
MUTAGEN:E->V: Reduced interaction with SYT9.	SEQ_UP	1	
MUTAGEN:E->V: Strongly reduces calcium channel activity; when associated with W-251.	SEQ_UP	1	
MUTAGEN:E->Y: Abolishes interaction with CD4 endocytosis signal motif.	SEQ_UP	1	
MUTAGEN:ED->AA: Does not inhibit transport activity. Does not inhibit colocalization with SLC51A at the plasma membrane. Does not decrease glycosylation of SLC51A.	SEQ_UP	1	
MUTAGEN:ED->AG: Abolishes most of transactivation activity.	SEQ_UP	1	
MUTAGEN:ED->QN: Reduces CIDE-N/CIDE-N interaction between the 2 homodimer subunits and inhibits lipid droplet enlargement.	SEQ_UP	1	
MUTAGEN:EDGDADPEPENYNYDDDDDEEEEEE->AAGAAAPAPANYNYAAAAAAAAAAA : Nearly abolishes LPL transport to the lumenal surface of endothelial cells.	SEQ_UP	1	
MUTAGEN:EDL->AAA: Dominant-negative mutant, leading to enhanced ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A.	SEQ_UP	1	
MUTAGEN:EDSKGGHPSSSETKEEQNKED->AASKGGHPSSSATKAAQNKAA: Prevents autoprocessing.	SEQ_UP	1	
MUTAGEN:EE->AA: Abolishes interaction and stabilization of BUB3.	SEQ_UP	1	
MUTAGEN:EE->AA: Decreases endocytosis.	SEQ_UP	1	
MUTAGEN:EE->AA: Does not affect mitochondrial localization and ability to mediate calcium efflux from mitochondrion.	SEQ_UP	1	
MUTAGEN:EE->AA: Impairs localization to secretory granules, promotes location at the TGN, decreases interaction with alpha- and gamma-type adaptin subunits.	SEQ_UP	1	
MUTAGEN:EE->QQ: Abolished deNADding activity.	SEQ_UP	1	
MUTAGEN:EE->QQ: Binds phospholipids only in the absence of divalent cations.	SEQ_UP	1	
MUTAGEN:EE->RR: Decreases transcriptional repression of target genes. Decreases FBXL3 binding. Increases PER2 binding.	SEQ_UP	1	
MUTAGEN:EED->AAA: No effect on CDK2-binding.	SEQ_UP	1	
MUTAGEN:EED->QQN: Abolishes CIDE-N/CIDE-N interaction between the 2 homodimer subunits and inhibits lipid droplet enlargement. No effect on homodimerization.	SEQ_UP	1	
MUTAGEN:EEDLLV->AAAAA: Decreased localization to the Golgi apparatus; when associated with 8-A--A-11.	SEQ_UP	1	
MUTAGEN:EEE->AAA: Abolishes CTNNB1 binding.	SEQ_UP	1	
MUTAGEN:EEE->RVV: Does not bind to SIVA1.	SEQ_UP	1	
MUTAGEN:EFD->AFA: Abolished nucleotidyltransferase activity. Does not affect nuclear localization and tethering to chromatin.	SEQ_UP	1	
MUTAGEN:EIKLQIK->AAAAAAA: Loss of homomerization, of autocatalytic cleavage within the FIIND region and of IL1B release. No effect on CASP1-binding.	SEQ_UP	1	
MUTAGEN:EKE->AKA: Partial loss of interaction with APC.	SEQ_UP	1	
MUTAGEN:EKERD->KKERK: Loss of interaction with APC and DCTN1.	SEQ_UP	1	
MUTAGEN:EKFF->QKFM: Wild-type binding to BoNT/B. Wild-type in binding to BoNT/G.	SEQ_UP	1	
MUTAGEN:ELEII->ALEIA: Loss of binding to RAB27A, remaining cytoplasmic.	SEQ_UP	1	
MUTAGEN:ELR->PSF: Activation of ANF promoter abolished, no effect on SM22 promoter.	SEQ_UP	1	
MUTAGEN:EN->AA: Inhibits GAP activity. Does not inhibit interaction with GNAI1 in the centrosomes. Reduces the down-regulation of G(i)-dependent signaling. Does not affect subcellular location and does not promote gene transcription activation. Inhibits strongly the down-regulation of G(i)-dependent signaling; when associated with F-519. Inhibits the interaction with GNAI1 in the centrosomes; when associated with A-518.	SEQ_UP	1	
MUTAGEN:EP->DL: Loss of transactivation function.	SEQ_UP	1	
MUTAGEN:EQN->AAA: Partially inhibits U RNA-binding.	SEQ_UP	1	
MUTAGEN:EQQ->AAA: Changes the structure of the leucine zipper and thereby confers the ability to form heterodimers with MAX.	SEQ_UP	1	
MUTAGEN:ER->AA: Abolishes ubiquitin binding; loss of inhibitory activity on NF-kappa-B activation.	SEQ_UP	1	
MUTAGEN:ER->AQ: Inhibits neurons differentiation.	SEQ_UP	1	
MUTAGEN:ERY->RDR: Reduced basal glucose uptake and glucose-dependent mitochondrial respiration.	SEQ_UP	1	
MUTAGEN:ESR->AAA: Abolishes interaction with TAX1BP3.	SEQ_UP	1	
MUTAGEN:ETAE->AAAA: Does not inhibit U RNA-binding.	SEQ_UP	1	
MUTAGEN:ETSV->AAAA: Does not affect interaction with RNF31.	SEQ_UP	1	
MUTAGEN:EVMCR->DVMTQ: Increased histone deacetylase activity, ability to promote double-strand break (DSB) repair, leading to increased life span; when associated with K-235 and H-249.	SEQ_UP	1	
MUTAGEN:EVN->ATA: Abolishes interaction with HIF1AN. Fails to induce expansion of the hematovascular lineage in embryonic stem cells.	SEQ_UP	1	
MUTAGEN:EVR->QVH: Restores zinc-binding and activity.	SEQ_UP	1	
MUTAGEN:EYFPR->AAFPA: Impairs interaction with DNM1L.	SEQ_UP	1	
MUTAGEN:F->A,D: Induces a nuclear accumulation in unstimulated cells.	SEQ_UP	1	
MUTAGEN:F->A,E: Loss of binding to DNMT3A.	SEQ_UP	1	
MUTAGEN:F->A,E: Loss of JAK signal transduction suppression. Reduced binding to JH1.	SEQ_UP	1	
MUTAGEN:F->A,F,Y: Loss of binding to AP-2.	SEQ_UP	1	
MUTAGEN:F->A,G,P: Low transactivation activity.	SEQ_UP	1	
MUTAGEN:F->A,I,L,N,Q,S,T: Very low transporter activity.	SEQ_UP	1	
MUTAGEN:F->A,L,Q: Mildly impairs protein maturation.	SEQ_UP	1	
MUTAGEN:F->A,L: Abolishes interaction with EPHA2 SAM domain.	SEQ_UP	1	
MUTAGEN:F->A,N: Abolishes interaction with ADGRL3.	SEQ_UP	1	
MUTAGEN:F->A,R: Abolishes interaction with SEMA6A.	SEQ_UP	1	
MUTAGEN:F->A,S,D: Loss of JAK signal transduction suppression.	SEQ_UP	1	
MUTAGEN:F->A,W: Capable of nicking but defective for hairpinning.	SEQ_UP	1	
MUTAGEN:F->A,W: Loss of interaction with CXADR.	SEQ_UP	1	
MUTAGEN:F->A,W: No effect on interaction with TLR3.	SEQ_UP	1	
MUTAGEN:F->A,Y: Impairs binding to MAPKAPK5.	SEQ_UP	1	
MUTAGEN:F->A,Y: No effect on interaction with nuclear receptors.	SEQ_UP	1	
MUTAGEN:F->A: 3- to 4-fold increase in Km for CoA. Reduced affinity for CoA.	SEQ_UP	1	
MUTAGEN:F->A: 4-fold reduction of sperm-egg fusion.	SEQ_UP	1	
MUTAGEN:F->A: Abolished H3.3K36me3 binding.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes binding of glycoprotein targets.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes binding to GRB10.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes binding to histone H3K9me3 and ability to repress transcription of target genes.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes binding to PP1 but has no effect on binding to glycogen synthase, glycogen phosphorylase or glycogen; when associated with A-85.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes binding to trimethylated histone H3.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes cytoplasmic retention and mRNA-binding affinity; when associated with A-109.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes dimerization of the TLR4 complex and stimulation of TNF production in response to bacterial lipopolysaccharide.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes endoribonuclease activity.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes estrogen-dependent NF-kappa B transcriptional repression, impairs transcriptional activity, abolishes estrogen-induced interaction with NCOA1.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes interaction with AP2B1.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes interaction with ATP2A1/SERCA1.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes interaction with CDK2.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes interaction with DCLRE1B/Apollo, leading to activate the ATM signaling pathway.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes interaction with PCNA.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes interaction with PPP1CA.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes interaction with RHOQ, but not the interaction with CDC42; when associated with A-136.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes ligand-induced translocation to the nucleus.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes linear polyubiquitin-binding, impairs 'Lys-63'-linked polyubiquitin-binding and impairs of NF-kappa-B activation.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes localization at the plasma membrane; reduces increase of intrinsic ATPase activity upon interaction with membranes.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes RNA-binding activity but not AR-mediated transcription coactivation; when associated with A-118; A-120 and A-197.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes RNA-binding activity but not AR-mediated transcription coactivation; when associated with A-118; A-197 and A-199.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes RNA-binding activity but not AR-mediated transcription coactivation; when associated with A-120; A-197 and A-199.	SEQ_UP	1	
MUTAGEN:F->A: Abolishes the binding to PDCD1. Costimulates proliferation and IFNG production of T-cells.	SEQ_UP	1	
MUTAGEN:F->A: Abrogates PP1-binding.	SEQ_UP	1	
MUTAGEN:F->A: Abrogates tetramerization, reduces dimerization, does not affect binding to microtubules and to phosphorylated light-activated rhodopsin; when associated with A-198, or with A-198 and V-349.	SEQ_UP	1	
MUTAGEN:F->A: Abrogates tetramerization, reduces dimerization, does not affect binding to microtubules and to phosphorylated light-activated rhodopsin; when associated with A-86, or with A-86 and V-349.	SEQ_UP	1	
MUTAGEN:F->A: Almost abolishes response to semaphorin.	SEQ_UP	1	
MUTAGEN:F->A: Alters chloride anion transport behavior.	SEQ_UP	1	
MUTAGEN:F->A: Alters interaction with MAPK8IP1.	SEQ_UP	1	
MUTAGEN:F->A: Constitutively active form; when associated with 289-A--A-292.	SEQ_UP	1	
MUTAGEN:F->A: Decreased protein expression and stability. Decreased embryonic stem cell self-renewal.	SEQ_UP	1	
MUTAGEN:F->A: Decreased threshold for activation by calcium.	SEQ_UP	1	
MUTAGEN:F->A: Decreased transmembrane ascorbate ferrireductase activity. Approximately 45% reduction in enzyme activity.	SEQ_UP	1	
MUTAGEN:F->A: Decreases affinity for FBXL3. Slightly increases affinity for PER2.	SEQ_UP	1	
MUTAGEN:F->A: Decreases interaction with TLR3.	SEQ_UP	1	
MUTAGEN:F->A: Decreases phosphodiesterase activity by 50%. Decreased formation of nucleotidylated intermediate.	SEQ_UP	1	
MUTAGEN:F->A: Diminished binding of coactivator NCOA2 in the presence of TCPOBOP.	SEQ_UP	1	
MUTAGEN:F->A: Disrupts interaction with EIF4A and fails to stimulate translation.	SEQ_UP	1	
MUTAGEN:F->A: Disrupts interaction with KATNA1:KATNB1; when associated with A-302.	SEQ_UP	1	
MUTAGEN:F->A: Disrupts interaction with KATNA1:KATNB1; when associated with A-377.	SEQ_UP	1	
MUTAGEN:F->A: Disrupts interaction with KATNA1:KATNB1.	SEQ_UP	1	
MUTAGEN:F->A: Disrupts pericentromeric heterochromatin location. Partial cytoplasmic location. Abolishes DNA binding.	SEQ_UP	1	
MUTAGEN:F->A: Highly disrupts the dimerization ability of AHR.	SEQ_UP	1	
MUTAGEN:F->A: Impaired interaction with DWORF and PLN; when associated with A-796 and A-802.	SEQ_UP	1	
MUTAGEN:F->A: Impaired interaction with RPTOR.	SEQ_UP	1	
MUTAGEN:F->A: Impairs ability to promote H3K27me3 methylation without affecting ability to associate with the PRC2 complex; when associated with A-74.	SEQ_UP	1	
MUTAGEN:F->A: Impairs binding to 2'-O-methylated 3'-end of piRNAs.	SEQ_UP	1	
MUTAGEN:F->A: Impairs both actin capping and bundling activities.	SEQ_UP	1	
MUTAGEN:F->A: Impairs DNA-binding.	SEQ_UP	1	
MUTAGEN:F->A: Impairs interaction with GATA1.	SEQ_UP	1	
MUTAGEN:F->A: Impairs interaction with PP1; when associated with A-219.	SEQ_UP	1	
MUTAGEN:F->A: Impairs interaction with PP1; when associated with A-308.	SEQ_UP	1	
MUTAGEN:F->A: Impairs single-stranded DNA binding; when associated with A-96.	SEQ_UP	1	
MUTAGEN:F->A: Increased permeability to chloride ions.	SEQ_UP	1	
MUTAGEN:F->A: Increased speed of phospholipid scrambling. Constitutive scramblase activity at basal cytosolic calcium levels; when associated with A-563 and A-612.	SEQ_UP	1	
MUTAGEN:F->A: Increases activity towards short-chain fatty acids.	SEQ_UP	1	
MUTAGEN:F->A: Loss of activity due to the incapacity to bind the regulatory subunit DNMT3L.	SEQ_UP	1	
MUTAGEN:F->A: Loss of AP-1 and NF-kappa-B transcription factor activity. Reduced ability to activate MAP2K1, MAP2K4, MAP2K7, CHUK and IKBKB.	SEQ_UP	1	
MUTAGEN:F->A: Loss of cholesterol binding. Abolishes cholesterol transport activity.	SEQ_UP	1	
MUTAGEN:F->A: Loss of interaction with 'Lys-63'-linked ubiquitin.	SEQ_UP	1	
MUTAGEN:F->A: Loss of interaction with p300 KIX domain; eliminated the autonomous transactivation function.	SEQ_UP	1	
MUTAGEN:F->A: Loss of LIF/EPO-induced signal transduction suppression. Abolishes binding to JAK2 and to EPOR.	SEQ_UP	1	
MUTAGEN:F->A: Loss of lyso-PAFAT activity. LPCAT activity is partially reduced.	SEQ_UP	1	
MUTAGEN:F->A: Loss of self-renewal in embryonic stem cells in absence of LIF; when associated with A-424. Does not interact with NCOA3; when associated with A-424.	SEQ_UP	1	
MUTAGEN:F->A: Loss of transcriptional activation; when associated with A-449.	SEQ_UP	1	
MUTAGEN:F->A: No binding to BoNT/B. No binding to BoNT/G.	SEQ_UP	1	
MUTAGEN:F->A: No binding to BoNT/B. Wild-type binding to BoNT/G.	SEQ_UP	1	
MUTAGEN:F->A: No binding to C.botulinum neurotoxin type B (BoNT/B, botB). Requires gangliosides to bind BoNT/B, wild-type binding to BoNT/G.	SEQ_UP	1	
MUTAGEN:F->A: No effect on autophosphorylation. Fails to induce activation of the AP-1 transcription factor, MAPK7 or MAPK8.	SEQ_UP	1	
MUTAGEN:F->A: No effect on carbonate dehydratase activity. Enhanced proton transfer; when associated with H-94 or C-161.	SEQ_UP	1	
MUTAGEN:F->A: No effect on subcellular location.	SEQ_UP	1	
MUTAGEN:F->A: No fibulin-1C binding. No change to fibulin-2 binding.	SEQ_UP	1	
MUTAGEN:F->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-294.	SEQ_UP	1	
MUTAGEN:F->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-295.	SEQ_UP	1	
MUTAGEN:F->A: No UBE2I binding nor sumoylation. Not targeted to nuclear pore complexes; when associated with R-526.	SEQ_UP	1	
MUTAGEN:F->A: Reduced binding to CHO cells expressing ITAG9-ITGB1.	SEQ_UP	1	
MUTAGEN:F->A: Reduced binding to U6 snRNA without affecting binding to 7SK RNA. Reduced 2'-O-methylation of U6 snRNAs.	SEQ_UP	1	
MUTAGEN:F->A: Reduced catalytic activity and impaired inhibition by the R-subunit.	SEQ_UP	1	
MUTAGEN:F->A: Reduced enzymatic activity and altered stereoselectivity of the oxygenation reaction.	SEQ_UP	1	
MUTAGEN:F->A: Reduced interaction with HRAS.	SEQ_UP	1	
MUTAGEN:F->A: Reduced lysophospholipase activity.	SEQ_UP	1	
MUTAGEN:F->A: Reduced phosphorylation by ERK. Reduced AP1 activity by 65%.	SEQ_UP	1	
MUTAGEN:F->A: Reduces activity about 20-fold. Loss of substrate binding.	SEQ_UP	1	
MUTAGEN:F->A: Reduces affinity for BMP2 and BMP4. Reduces inhibition of BMP2 signaling.	SEQ_UP	1	
MUTAGEN:F->A: Reduces affinity for BMP2 and BMP4. Strongly reduces inhibition of BMP2 signaling.	SEQ_UP	1	
MUTAGEN:F->A: Reduces binding affinity for misfolded proteins by 40%.	SEQ_UP	1	
MUTAGEN:F->A: Reduces oligomerization. Reduces activation of Wnt signaling.	SEQ_UP	1	
MUTAGEN:F->A: Reduces SNAP91, AMPH and BIN1 binding. Abolishes AMPH and SNAP91 binding; when associated with A-916. Abolishes EPN1 and EPS15 binding; when associated with A-905.	SEQ_UP	1	
MUTAGEN:F->A: Reduction in class switch recombination of the immunoglobulin heavy chain in B cells.	SEQ_UP	1	
MUTAGEN:F->A: Severe loss of interaction with GYS2.	SEQ_UP	1	
MUTAGEN:F->A: Significant reduction in LPC transport.	SEQ_UP	1	
MUTAGEN:F->A: Significantly decreased NF-kappa-B activation.	SEQ_UP	1	
MUTAGEN:F->A: Slightly increased LPC transport.	SEQ_UP	1	
MUTAGEN:F->A: Slightly reduced LPC transport.	SEQ_UP	1	
MUTAGEN:F->A: Strongly diminishes CTNNB1 binding and transactivation. Prevents nuclear translocation of CTNNB1.	SEQ_UP	1	
MUTAGEN:F->A: Strongly reduced interaction with ANKRD31; when associated with A-104.	SEQ_UP	1	
MUTAGEN:F->A: Strongly reduced interaction with ANKRD31; when associated with A-81.	SEQ_UP	1	
MUTAGEN:F->A: Strongly reduces affinity for BMP2 and BMP4. Strongly reduces inhibition of BMP2 signaling.	SEQ_UP	1	
MUTAGEN:F->C,M: No effect on protein maturation.	SEQ_UP	1	
MUTAGEN:F->C: Changes thiol-independent NADase activity to thiol-dependent; when associated with C-80.	SEQ_UP	1	
MUTAGEN:F->C: In LCH mutant; abolishes formation of the tetramer and deoxynucleoside triphosphate (dNTPase) activity; when associated with L-109 and H-143.	SEQ_UP	1	
MUTAGEN:F->C: No effect on palmitoylation. No change in subcellular location; when associated with H-135.	SEQ_UP	1	
MUTAGEN:F->C: Reduced sensitivity to cocaine.	SEQ_UP	1	
MUTAGEN:F->C: Strongly reduces production of IL1B in response to bacterial flagellin.	SEQ_UP	1	
MUTAGEN:F->D: Abolishes binding of FBXL3 and SKP1. Strongly decreases CRY2 degradation.	SEQ_UP	1	
MUTAGEN:F->D: Abolishes binding to CD200R.	SEQ_UP	1	
MUTAGEN:F->D: Abolishes dimerization. Weakly interacts with C1q domain of CBLN1.	SEQ_UP	1	
MUTAGEN:F->D: Abolishes interaction with GBA. No effect on normal location in lysosomes.	SEQ_UP	1	
MUTAGEN:F->D: Abolishes RNA-binding but not homodimerization; when associated with D-43; D-82 and D-84.	SEQ_UP	1	
MUTAGEN:F->D: Abolishes RNA-binding but not homodimerization; when associated with D-43; D-82 and D-87.	SEQ_UP	1	
MUTAGEN:F->D: Abolishes RNA-binding but not homodimerization; when associated with D-82; D-84 and D-87.	SEQ_UP	1	
MUTAGEN:F->D: Abrogates interaction with EED.	SEQ_UP	1	
MUTAGEN:F->D: Decreases heterodimer formation with ARNT.	SEQ_UP	1	
MUTAGEN:F->D: Destabilizes heterodimerization with ARNT. Compromises the transcriptional repression activity of heterodimer ARNT:NPAS1.	SEQ_UP	1	
MUTAGEN:F->D: Highly disrupts the dimerization ability of AHR. Reduces the AHR transcription factor activity induction by 50%.	SEQ_UP	1	
MUTAGEN:F->D: Increased KLC1-binding.	SEQ_UP	1	
MUTAGEN:F->D: Loss of efficient trimer formation.	SEQ_UP	1	
MUTAGEN:F->D: Loss of JAK signal transduction suppression. Destabilization of SOCS1.	SEQ_UP	1	
MUTAGEN:F->D: Reduced homoolimerization, leading to reduced ability to induce pyroptosis.	SEQ_UP	1	
MUTAGEN:F->D: Reduces the AHR induction activity by ?50%. Translocate to thee nucleus at a high level.	SEQ_UP	1	
MUTAGEN:F->D: Reduces transcription activity. Impairs interaction with ARNT.	SEQ_UP	1	
MUTAGEN:F->E,D,G,H,I,K,P,R,Y: Abolishes normal maturation.	SEQ_UP	1	
MUTAGEN:F->E,K,Q: Constitutive lipid scramblase activity at basal cytosolic calcium levels.	SEQ_UP	1	
MUTAGEN:F->E,S: Reduced binding to JH1.	SEQ_UP	1	
MUTAGEN:F->E: Abolishes association with microtubules and the ability to promote microtubule polymerization.	SEQ_UP	1	
MUTAGEN:F->E: Abolishes dimerization.	SEQ_UP	1	
MUTAGEN:F->E: Abolishes interaction with INSC.	SEQ_UP	1	
MUTAGEN:F->E: Loss of function mutant which is unable to promote clathrin coated-pits formation. Cytosolic mutant; when associated with E-73.	SEQ_UP	1	
MUTAGEN:F->E: Loss of interaction with TLE5 and TLE4.	SEQ_UP	1	
MUTAGEN:F->E: No effect on interaction with MSL3. Reduces interaction; when associated with E-589. Strongly reduces interaction with MSL3; when associated with E-556 and E-589.	SEQ_UP	1	
MUTAGEN:F->E: Reduces homodimerization. Abolishes homodimerization; when associated with E-267.	SEQ_UP	1	
MUTAGEN:F->E: Strongly reduces interaction with MSL3; when associated with E-556 and E-576 or E-556 and E-577.	SEQ_UP	1	
MUTAGEN:F->E: Strongly reduces interaction with MSL3; when associated with E-576 and E-589 or E-577 and E-589.	SEQ_UP	1	
MUTAGEN:F->EF: Disrupts amphipathicity and abolishes Golgi localization; when associated with Glu-367.	SEQ_UP	1	
MUTAGEN:F->H: Induces a slight decrease in activity.	SEQ_UP	1	
MUTAGEN:F->H: Reduces oligomerization. Strongly reduced activation of Wnt signaling.	SEQ_UP	1	
MUTAGEN:F->I: No effect.	SEQ_UP	1	
MUTAGEN:F->L: 7-fold reduction in binding to CD200.	SEQ_UP	1	
MUTAGEN:F->L: Abolishes phosphatase activity.	SEQ_UP	1	
MUTAGEN:F->L: Abolishes RNA binding; when associated with L-63 and L-65.	SEQ_UP	1	
MUTAGEN:F->L: Abolishes RNA binding; when associated with L-63 and L-68.	SEQ_UP	1	
MUTAGEN:F->L: Abolishes RNA binding; when associated with L-65 and L-68.	SEQ_UP	1	
MUTAGEN:F->L: Decreased lipid scramblase activity.	SEQ_UP	1	
MUTAGEN:F->L: Decreases autophosphorylation, binding to tRNA and Sindbis virus genomic RNA and eIF-2-alpha phosphorylation in amino acid-starved cells; when associated with I-1143.	SEQ_UP	1	
MUTAGEN:F->L: In LCH mutant; abolishes formation of the tetramer and deoxynucleoside triphosphate (dNTPase) activity; when associated with C-112 and H-143.	SEQ_UP	1	
MUTAGEN:F->L: Loss of localization to the cell membrane.	SEQ_UP	1	
MUTAGEN:F->L: No effect on JAK signal transduction inhibition nor on binding to JH1.	SEQ_UP	1	
MUTAGEN:F->L: No effect on JAK signal transduction suppression nor on binding to JH1.	SEQ_UP	1	
MUTAGEN:F->L: Severely decreased cytidine deaminase activity. Loss of mutagenic activity.	SEQ_UP	1	
MUTAGEN:F->L: Strongly reduced inhibition by GNF-2.	SEQ_UP	1	
MUTAGEN:F->M: Functional transporter with 4-fold decrease in cocaine sensitivity.	SEQ_UP	1	
MUTAGEN:F->M: Requires gangliosides to bind BoNT/B, no binding to BoNT/G with or without gangliosides.	SEQ_UP	1	
MUTAGEN:F->N,S,V: Nearly abolishes normal maturation.	SEQ_UP	1	
MUTAGEN:F->N: Introduces an N-glycosylation site and disrupts interaction with NGF and BDNF.	SEQ_UP	1	
MUTAGEN:F->N: Prevents dimerization of death domains and activation of JNK and NF-kappa-B.	SEQ_UP	1	
MUTAGEN:F->P: Abrogates transcriptional repression of MYOD1.	SEQ_UP	1	
MUTAGEN:F->P: Impaired formation of a heterodimer with TCF3 and decreased ability to bind DNA.	SEQ_UP	1	
MUTAGEN:F->P: Loss of interaction with MYO5A.	SEQ_UP	1	
MUTAGEN:F->Q: Reduced affinity for USH1G.	SEQ_UP	1	
MUTAGEN:F->R: Abolishes interaction with HOMER1.	SEQ_UP	1	
MUTAGEN:F->R: Abolishes interaction with KAT8.	SEQ_UP	1	
MUTAGEN:F->R: Retains 10% of wild-type activity.	SEQ_UP	1	
MUTAGEN:F->S: Aberrant protein folding and increased proteasomal degradation.	SEQ_UP	1	
MUTAGEN:F->S: Abolishes interaction with PCNA. No effect on activity.	SEQ_UP	1	
MUTAGEN:F->S: Abrogates interaction with NDLE1, NUDC, PAFAH1B3 and RSN. Also impairs localization to centrosomes and microtubule plus ends. Reduces protein stability.	SEQ_UP	1	
MUTAGEN:F->S: Decreases affinity for CALM about 30-fold.	SEQ_UP	1	
MUTAGEN:F->S: Decreases expression of isoform 1.	SEQ_UP	1	
MUTAGEN:F->S: Impairs tetramerization and promotes formation of homodimers. Impairs activation by phosphate.	SEQ_UP	1	
MUTAGEN:F->S: In lln mutant; loss of function.	SEQ_UP	1	
MUTAGEN:F->S: Inhibits interaction with GLI2. Decreased nuclear colocalization with GLI2. No effect on DNA-binding. Decreased Ihh-induced transcriptional activity and transcription coactivator activity with GLI2.	SEQ_UP	1	
MUTAGEN:F->S: Mice display white fur, hearing loss, anemia and mast cell deficiency, plus sterility in both males and females.	SEQ_UP	1	
MUTAGEN:F->S: Shows no significant DNA binding to a Prop1 response element in gel shift assays; transcriptional activation of a luciferase reporter gene is reduced to approximately 34% compared with that of wild-type Prop1 in transiently transfected human embryonic kidney cells.	SEQ_UP	1	
MUTAGEN:F->T: Decreased affinity for 700-bp RNA.	SEQ_UP	1	
MUTAGEN:F->T: Decreased gymnosis and decreased affinity for 700-bp RNA. No effect on subcellular location.	SEQ_UP	1	
MUTAGEN:F->V: Abolishes interaction with APLP1.	SEQ_UP	1	
MUTAGEN:F->V: Abolishes interaction with EPS15 and impairs interaction with ITSN1, fails to internalize integrin beta-1; when associated with V-589 and V-736. Abolishes interaction with ITSN1; when associated with V-255, V-398, V-589 and V-736.	SEQ_UP	1	
MUTAGEN:F->V: Abolishes interaction with EPS15 and impairs interaction with ITSN1, fails to internalize integrin beta-1; when associated with V-589 and V-765. Abolishes interaction with ITSN1; when associated with V-255, V-398, V-589, and V-765.	SEQ_UP	1	
MUTAGEN:F->V: Abolishes interaction with EPS15 and impairs interaction with ITSN1, fails to internalize integrin beta-1; when associated with V-736 and V-765. Abolishes interaction with ITSN1; when associated with V-255, V-398, V-736 and V-765.	SEQ_UP	1	
MUTAGEN:F->V: Abolishes interaction with ITSN1, fails to internalize integrin beta-1; when associated with V-255, V-589, V-736 and V-765.	SEQ_UP	1	
MUTAGEN:F->V: Abolishes interaction with ITSN1, fails to internalize integrin beta-1; when associated with V-398, V-589, V-736 and V-765.	SEQ_UP	1	
MUTAGEN:F->W,Y: Retention of transporter activity and high sensitivity to cocaine.	SEQ_UP	1	
MUTAGEN:F->W: Diminished binding of coactivator NCOA2 in the presence of TCPOBOP.	SEQ_UP	1	
MUTAGEN:F->W: Increases formation of (8S)-hydroperoxyicosatetraenoic acid ((8S)-HPETE). Exhibits a (8S)-lipoxygenase activity; when associated with I-425. Exhibits a (15S)-lipoxygenase activity; when associated with I-425 and M-426. Loss of arachidonate (5S)-lipoxygenase activity; when associated with G-411; I-425 and M-426. Forms 11(R)-hydroperoxyicosatetraenoic acid (11(R)-HPETE) as the major arachidonic acid oxygenation product; when associated with G-411; I-425 and M-426. Does not oxygenate arachidonic acid into 5-HETE; when associated with I-425 and M-426. Catalyzes oxygenation of arachidonic acid into a major product (15S)-HETE followed by 12-HETE and 8-HETE;when associated with I-425 and M-426. Catalyzes oxygenation of linoleic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid; when associated with I-425 and M-426. Catalyzes oxygenation of anandamide to 15-OH-ANA. Knockin mice are viable, fertile, and develop normally; when associated with I-425 and M-426. Mice convert arachidonic to 15-HETE, 12-HETE, and 8-HETE; when associated with I-425 and M-426. Mice cannot synthesize pro-inflammatory leukotrienes but show significantly attenuated plasma levels of lipolytic endocannabinoids; when associated with I-425 and M-426. When aging, animals gain significantly more body weight probably due to higher levels of 13-HODE in the adipose tissue; when associated with I-425 and M-426.	SEQ_UP	1	
MUTAGEN:F->W: Increases interaction with TLR3.	SEQ_UP	1	
MUTAGEN:F->W: Loss of enzymatic activity.	SEQ_UP	1	
MUTAGEN:F->W: No effect on binding to AP-2.	SEQ_UP	1	
MUTAGEN:F->W: No effect on interaction with TLR3.	SEQ_UP	1	
MUTAGEN:F->W: No effect on nuclear import; when associated with A-77 and A-78.	SEQ_UP	1	
MUTAGEN:F->W: Slightly increased lipid scramblase activity.	SEQ_UP	1	
MUTAGEN:F->Y: Does not induce any change in single channel conductance or variance in open current levels.	SEQ_UP	1	
MUTAGEN:F->Y: Impair expression of folded protein.	SEQ_UP	1	
MUTAGEN:F->Y: Loss of interaction with MAVS.	SEQ_UP	1	
MUTAGEN:F->Y: Loss of methyltransferase activity for H4K20me1 peptide.	SEQ_UP	1	
MUTAGEN:FF->AA: Abolishes formation of tight-junction strand-like structures.	SEQ_UP	1	
MUTAGEN:FL->AA: Abolishes interaction with ASXL1 and NCOA1.	SEQ_UP	1	
MUTAGEN:FL->AA: Mildly reduced interaction with flagellin.	SEQ_UP	1	
MUTAGEN:FQEPENDPR->GSGSGSGSG: Abolishes nuclear pore localization; when associated with S-284.	SEQ_UP	1	
MUTAGEN:FRLH->ARLA: No effect on interaction with PTPRD. No effect on synapse assembly.	SEQ_UP	1	
MUTAGEN:FVFR->AAAA: Inhibits interaction with EFCAB7.	SEQ_UP	1	
MUTAGEN:FVGDL->DVPDD: Impairs nuclear localization.	SEQ_UP	1	
MUTAGEN:FW->GG: Abolished ability to form a pore, leading to educed ability to induce pyroptosis.	SEQ_UP	1	
MUTAGEN:FY->AA: Decreased affinity for NPC2. Loss of function in cholesterol transport. No effect on subcellular location. Strongly decreased affinity for NPC2; when associated with A-421.	SEQ_UP	1	
MUTAGEN:G->A,P: No effect on threshold for activation by calcium.	SEQ_UP	1	
MUTAGEN:G->A,R: Increases interaction with NEK7.	SEQ_UP	1	
MUTAGEN:G->A: Abolished ADP-ribosyltransferase activity in vitro without affecting the NAD-dependent protein deacetylase activity.	SEQ_UP	1	
MUTAGEN:G->A: Abolishes binding to DVL1.	SEQ_UP	1	
MUTAGEN:G->A: Abolishes binding to EPOR. No effect on binding to JAK2.	SEQ_UP	1	
MUTAGEN:G->A: Abolishes conductivity; when associated with A-349 and A-350.	SEQ_UP	1	
MUTAGEN:G->A: Abolishes conductivity; when associated with A-350 and A-351.	SEQ_UP	1	
MUTAGEN:G->A: Abolishes cytosolic localization.	SEQ_UP	1	
MUTAGEN:G->A: Abolishes enzyme activity; when associated with M-287.	SEQ_UP	1	
MUTAGEN:G->A: Abolishes histone-lysine N-methyltransferase activity.	SEQ_UP	1	
MUTAGEN:G->A: Abolishes localization to membranes.	SEQ_UP	1	
MUTAGEN:G->A: Abolishes localization to microtubules.	SEQ_UP	1	
MUTAGEN:G->A: Abolishes myristoylation and localization to endosomes.	SEQ_UP	1	
MUTAGEN:G->A: Abolishes myristoylation and membrane association.	SEQ_UP	1	
MUTAGEN:G->A: Abolishes myristoylation and palmitoylation.	SEQ_UP	2	
MUTAGEN:G->A: Abolishes phosphatase activity.	SEQ_UP	1	
MUTAGEN:G->A: Abolishes stimulation of interferon production; when associated with A-199.	SEQ_UP	1	
MUTAGEN:G->A: Decreased levels in mitochondrion and reduced activity of mitochondrial respiratory complex I.	SEQ_UP	1	
MUTAGEN:G->A: Decreased lipid phosphatase activity.	SEQ_UP	1	
MUTAGEN:G->A: Decreased threshold for activation by calcium.	SEQ_UP	1	
MUTAGEN:G->A: Decreases ATP binding about 50%.	SEQ_UP	1	
MUTAGEN:G->A: Decreases binding to GRB10.	SEQ_UP	1	
MUTAGEN:G->A: Does not affect interaction with CEP55.	SEQ_UP	1	
MUTAGEN:G->A: Does not affect ion selectivity.	SEQ_UP	1	
MUTAGEN:G->A: Does not affect subcellular localization.	SEQ_UP	1	
MUTAGEN:G->A: Does not affect the NAD-dependent protein defatty-acylase activity. Abolished NAD-dependent protein deacetylase and mono-ADP-ribosyltransferase activities.	SEQ_UP	1	
MUTAGEN:G->A: Impairs GTPase activity and increases stimulation of the protein kinase activity of mTORC1.	SEQ_UP	1	
MUTAGEN:G->A: Impairs interaction with EZH2.	SEQ_UP	1	
MUTAGEN:G->A: Induces a slight decrease in activity.	SEQ_UP	1	
MUTAGEN:G->A: Loss of AP-1 and NF-kappa-B transcription factor activity.	SEQ_UP	1	
MUTAGEN:G->A: Loss of MAP3K2/MAP3K3 binding; when associated with A-68.	SEQ_UP	1	
MUTAGEN:G->A: Loss of pericentromeric heterochromatin location. Disrupted DNA binding.	SEQ_UP	1	
MUTAGEN:G->A: Loss of polynucleotide adenylyltransferase activity.	SEQ_UP	1	
MUTAGEN:G->A: Loss of SAMM50-binding. Reduced affinity toward OPA1. No effect on IMMT-binding.	SEQ_UP	1	
MUTAGEN:G->A: Loss of the ability to negatively regulate cell proliferation.	SEQ_UP	1	
MUTAGEN:G->A: No effect on calcium channel activity. Abolishes ryanodine binding.	SEQ_UP	1	
MUTAGEN:G->A: No effect on LIF signal transduction suppression.	SEQ_UP	1	
MUTAGEN:G->A: No effect on location at the melanosome membrane.	SEQ_UP	1	
MUTAGEN:G->A: No effect on nuclear speckled pattern localization; when associated with A-166 and R-170.	SEQ_UP	1	
MUTAGEN:G->A: No effect on nuclear speckled pattern localization; when associated with A-168 and R-170.	SEQ_UP	1	
MUTAGEN:G->A: No effect on pericentromeric heterochromatin location. No change in DNA binding.	SEQ_UP	1	
MUTAGEN:G->A: No effect.	SEQ_UP	1	
MUTAGEN:G->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-263.	SEQ_UP	1	
MUTAGEN:G->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-266.	SEQ_UP	1	
MUTAGEN:G->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-291.	SEQ_UP	1	
MUTAGEN:G->A: Partial loss of activity.	SEQ_UP	1	
MUTAGEN:G->A: Protein is detected exclusively in the aqueous phase.	SEQ_UP	1	
MUTAGEN:G->A: Reduced activity.	SEQ_UP	1	
MUTAGEN:G->A: Reduced calcium channel activity. Reduces single channel conductance by 97%. No effect on ryaodine binding.	SEQ_UP	1	
MUTAGEN:G->A: Reduced enzymatic activity and changed stereoselectivity of the oxygenation reaction.	SEQ_UP	1	
MUTAGEN:G->A: Reduces histone acetyltransferase activity; when associated with A-670 and A-672.	SEQ_UP	1	
MUTAGEN:G->A: Requires lower calcium levels for activation of scramblase and ion channel activity.	SEQ_UP	1	
MUTAGEN:G->A: Results in relocalization from membrane to cytosol; impairs ability to promote LPS-induced IL6 and CCL5 production.	SEQ_UP	1	
MUTAGEN:G->A: Slightly affects binding to NUMB protein.	SEQ_UP	1	
MUTAGEN:G->A: Slightly affects the interaction with GATA1.	SEQ_UP	1	
MUTAGEN:G->A: Slightly increased activity.	SEQ_UP	1	
MUTAGEN:G->A: Strongly decreased interaction with KEAP1.	SEQ_UP	1	
MUTAGEN:G->A: Strongly reduced calcium channel activity. Abolishes ryanodine binding.	SEQ_UP	1	
MUTAGEN:G->C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y: Loss of activity.	SEQ_UP	1	
MUTAGEN:G->C: Confers phosphatase activity.	SEQ_UP	1	
MUTAGEN:G->D: Abolishes cholesterol transport activity, and nearly abolishes plant sterol transport.	SEQ_UP	1	
MUTAGEN:G->D: Abolishes guanine nucleotide exchange factor (GEF) activity and impaired TCR down-modulation and recycling in TH2 cells.	SEQ_UP	1	
MUTAGEN:G->D: Abolishes transcriptional repression of target genes. Abolishes interaction with PER2.	SEQ_UP	1	
MUTAGEN:G->D: Affects ATP hydrolysis but not binding.	SEQ_UP	1	
MUTAGEN:G->D: Change of cotransport Na(+):Pi stoichiometry to 3:1; when associated with 189-AGA-191.	SEQ_UP	1	
MUTAGEN:G->D: Impaired ability to homooligomerize at 30 degrees Celsius.	SEQ_UP	1	
MUTAGEN:G->D: In a mouse model for harlequin ichthyosis (HI), homozygous mice are embryonic lethal but occasionally pups are found in the first few hours after birth but die and are severely dehydrated and fail to suckle normally. Homozygous pups show hallmarks of HI desease including hyperkeratosis, abnormal extracellular lipid lamellae and defects in cornified envelope processing. At 14.5 dpc and 15.5 dpc homozygous embryos appear normal; however from 16.5 dpc onwards they are characterized by an absence of normal skin folds around the trunk and limbs. As development progressed, embryos develop a taut, thick epidermis and multiple contractures affecting the limbs. Late stage embryos are smaller.	SEQ_UP	1	
MUTAGEN:G->D: Loss of ability to inhibit CLOCK-ARNTL-mediated transcriptional activity. No loss of ability to inhibit NR1I2 transcriptional activity.	SEQ_UP	1	
MUTAGEN:G->D: Loss of chymotryptic specificity and acquisition of trypsin-like cleavage specificity.	SEQ_UP	1	
MUTAGEN:G->D: Loss of oligomerization. Abolishes activation of Wnt signaling.	SEQ_UP	1	
MUTAGEN:G->D: No effect on cholesterol and sitosterol transport activity. Mildly reduced expression of ABCG5 and ABCG8.	SEQ_UP	1	
MUTAGEN:G->D: No effect on recruitment to endocytic membrane. No effect on membrane fusion produced by sphingosine.	SEQ_UP	1	
MUTAGEN:G->D: Reduced interaction with BLZF1.	SEQ_UP	1	
MUTAGEN:G->D: Severe reduction of kinase activity.	SEQ_UP	1	
MUTAGEN:G->E,R: Abrogates kinase activity.	SEQ_UP	1	
MUTAGEN:G->E,V: Disrupts interaction with ZFPM1 and binding to DNA.	SEQ_UP	1	
MUTAGEN:G->E: Abolishes interaction with ZAP70, but does not affect interaction with SLA.	SEQ_UP	1	
MUTAGEN:G->E: Abolishes potassium channel activity.	SEQ_UP	1	
MUTAGEN:G->E: Abolishes sphingosine kinase activity. Decreases apoptosis induction. Abolishes sphingosine kinase activity. No effect on endoplasmic reticulum location increase upon serum starvation. Abolishes sphingosine kinase activity and decreases apoptosis induction; when associated with A-219.	SEQ_UP	1	
MUTAGEN:G->E: Decrease in MEK binding.	SEQ_UP	1	
MUTAGEN:G->E: Decreased protein abundance. Not delivered to the plasma membrane.	SEQ_UP	1	
MUTAGEN:G->E: In Past-time (Psttm) mutant; causes period shortening due to Cry1 and Cry2 destabilization.	SEQ_UP	1	
MUTAGEN:G->E: No effect.	SEQ_UP	1	
MUTAGEN:G->E: Partial decrease in MAP2K1 and MAP2K2 binding. No effect on the interaction with YWHAE.	SEQ_UP	1	
MUTAGEN:G->E: Reduced rRNA pseudouridylation and pre-rRNA processing.	SEQ_UP	1	
MUTAGEN:G->E: Results in retention of the protein in the Golgi apparatus.	SEQ_UP	1	
MUTAGEN:G->E: Retention in the endoplasmic reticulum/cis-Golgi; when associated with H-112.	SEQ_UP	1	
MUTAGEN:G->E: Severely impaired interaction with membranes and strongly reduced catalytic activity.	SEQ_UP	1	
MUTAGEN:G->E: Strongly reduced interaction with DNA.	SEQ_UP	1	
MUTAGEN:G->E: Strongly reduces production of IL1B in response to bacterial flagellin.	SEQ_UP	1	
MUTAGEN:G->F,H,N,S,W: Greatly impairs interaction with DAB2.	SEQ_UP	1	
MUTAGEN:G->F: Does not affect ion selectivity.	SEQ_UP	1	
MUTAGEN:G->I: Reduced interaction with NDUFS1, ROS production and apoptosis.	SEQ_UP	1	
MUTAGEN:G->K: Increases affinity for actin.	SEQ_UP	1	
MUTAGEN:G->K: Nearly abolishes interaction with flagellin.	SEQ_UP	1	
MUTAGEN:G->L: Loss of channel activity.	SEQ_UP	1	
MUTAGEN:G->L: Loss of cis-Golgi localization.	SEQ_UP	1	
MUTAGEN:G->L: No effect on cis-Golgi localization.	SEQ_UP	1	
MUTAGEN:G->M: Loss of activity with octanoyl-CoA and myristoyl-CoA.	SEQ_UP	1	
MUTAGEN:G->N: No effect on protein abundance. No effect on cell surface localization. No effect on alanine uptake activity.	SEQ_UP	1	
MUTAGEN:G->P: Loss of enzyme activity.	SEQ_UP	1	
MUTAGEN:G->P: Low constitutive channel activity. Decreased threshold for activation by calcium.	SEQ_UP	1	
MUTAGEN:G->P: No effect.	SEQ_UP	1	
MUTAGEN:G->R: Abolished ability to promote phosphatidylserine exposure. Promotes localization to the cytoplasm.	SEQ_UP	1	
MUTAGEN:G->R: Abolishes estrogen binding; impairs repression of NF-kappa activity.	SEQ_UP	1	
MUTAGEN:G->R: Abolishes interaction with PACSIN2.	SEQ_UP	1	
MUTAGEN:G->R: Abolishes kinase activity.	SEQ_UP	1	
MUTAGEN:G->R: Abrogates kinase activity.	SEQ_UP	1	
MUTAGEN:G->R: Corresponds to R-114 variant associated with SPGF16 in human. Impairs nuclear inner membrane location, expressed in the cytosol with some protein aggregation near the nuclear envelope.	SEQ_UP	1	
MUTAGEN:G->R: Defects in otoconia biogenesis.	SEQ_UP	1	
MUTAGEN:G->R: Does not affect localization to the plasma membrane.	SEQ_UP	1	
MUTAGEN:G->R: Does not affect subcellular location. Impaired DNA-binding.	SEQ_UP	1	
MUTAGEN:G->R: Erroneous subcellular location; when associated with S-124. No positive effect on terminal myogenic differentiation; when associated with S-124.	SEQ_UP	1	
MUTAGEN:G->R: Failure to correctly traffic to the cell membrane and complete loss of Mg(2+) transport.	SEQ_UP	1	
MUTAGEN:G->R: Impairs secretion.	SEQ_UP	1	
MUTAGEN:G->R: Impairs the interaction with PIDD.	SEQ_UP	1	
MUTAGEN:G->R: In ALY; no binding to IKKA.	SEQ_UP	1	
MUTAGEN:G->R: Inhibits myoblast fusion.	SEQ_UP	1	
MUTAGEN:G->R: Introduces a cleavage site for a furin-like protease resulting in abnormal protein processing; cleavage at this site removes 11 amino acids from the N-terminal domain and reduces affinity of Shh for Ptch1 and signaling potency in assays using chicken embryo neural plate explants and mouse C3H10T1/2 stem cells.	SEQ_UP	1	
MUTAGEN:G->R: Loss of interaction with GYG1. Loss of function. Loss of interaction with GYG1; when associated with A-8.	SEQ_UP	1	
MUTAGEN:G->R: Loss of MAIT cell activation.	SEQ_UP	1	
MUTAGEN:G->R: No effect on nuclear speckled pattern localization; when associated with A-166 and A-168.	SEQ_UP	1	
MUTAGEN:G->R: No effect on protein abundance. Changed DNA-binding transcription factor activity. Changed sequence-specific DNA binding. Binds novel and non-specific DNA motifs and acts as a dominant negative through its homodimerization and heterodimerization activities. Profound B cell development defects observed in homozygous or heterozygous animals. Impairs the differentiation of cells in adaptive immunity.	SEQ_UP	1	
MUTAGEN:G->R: No effect on protein abundance. Strong decreases of cell surface localization. Decreases alanine uptake activity.	SEQ_UP	1	
MUTAGEN:G->R: No effect on voltage-dependent channel opening or current amplitude, but decreased rate of inactivation during prolonged depolarization.	SEQ_UP	1	
MUTAGEN:G->R: Reduced interaction with BBS1.	SEQ_UP	1	
MUTAGEN:G->R: Results in increased cell proliferation. Results in STAT3 phosphorylation and signaling activation.	SEQ_UP	1	
MUTAGEN:G->R: Unable to inhibit TNF-induced necrosis; when associated with F-31. Unable to induce TNF nuclear translocation; when associated with F-31.	SEQ_UP	1	
MUTAGEN:G->S: Abrogates interaction with PAFAH1B3 and RSN. Also impairs localization to centrosomes and microtubule plus ends. Reduces protein stability.	SEQ_UP	1	
MUTAGEN:G->S: Erroneous subcellular location. No positive effect on terminal myogenic differentiation.	SEQ_UP	1	
MUTAGEN:G->S: Increases kinase activity. Causes loss of dopaminergic neurons in the substantia nigra of 20-month old mice due to increased phosphorylation of APP. Reduces primary ciliogenesis.	SEQ_UP	1	
MUTAGEN:G->S: Increases polynucleotide adenylyltransferase activity.	SEQ_UP	1	
MUTAGEN:G->S: Induces centriole elongation. Reduced ciliogenesis.	SEQ_UP	1	
MUTAGEN:G->S: Knockin mice hearts exhibit a severe combined COX and copper deficiency and a mislocalization of copper transporter protein CTR1 to the cytoplasm.	SEQ_UP	1	
MUTAGEN:G->S: Loss of catalytic activity.	SEQ_UP	1	
MUTAGEN:G->S: Loss of tubulin monoglycylation activity.	SEQ_UP	1	
MUTAGEN:G->S: No effect on protein abundance. No effect on cell surface expression. Decreases alanine uptake activity.	SEQ_UP	1	
MUTAGEN:G->S: No effect on sterol transport; when associated with I-214.	SEQ_UP	1	
MUTAGEN:G->S: Significantly reduces activity.	SEQ_UP	1	
MUTAGEN:G->S: Strongly reduced in vitro enzyme activity.	SEQ_UP	1	
MUTAGEN:G->S: Strongly reduces enzyme activity.	SEQ_UP	1	
MUTAGEN:G->T: Abolishes interaction with FLRT2; when associated with N-324.	SEQ_UP	1	
MUTAGEN:G->T: Does not affect ability to promote phosphatidylserine exposure.	SEQ_UP	1	
MUTAGEN:G->V: Affects ATP hydrolysis but not binding.	SEQ_UP	1	
MUTAGEN:G->V: Constitutively active. Interacts with PARD6 proteins.	SEQ_UP	1	
MUTAGEN:G->V: Does not affect oligomerization formation.	SEQ_UP	1	
MUTAGEN:G->V: Induces a slight decrease in activity.	SEQ_UP	1	
MUTAGEN:G->V: Loss of enzymatic activity.	SEQ_UP	1	
MUTAGEN:G->V: Loss of GTP-binding activity.	SEQ_UP	1	
MUTAGEN:G->V: Loss of interaction with SYNCRIP.	SEQ_UP	1	
MUTAGEN:G->V: Loss of protein abundance. Increased abundance of ubiquitinated synaptic proteins. Decreased ubiquitin-mediated trafficking of membrane proteins through the endolysosomal pathway. Decreased synaptic vesicle recycling. Decreased cerebellar Purkinje cell migration and dendrite extension.	SEQ_UP	1	
MUTAGEN:G->V: Markly decreased expression, hearing loss associated with degeneration of cochlear hair cells and spiral ganglion cells.	SEQ_UP	1	
MUTAGEN:G->V: Mislocalized to the nucleoplasm. No effect on MDM2-binding.	SEQ_UP	1	
MUTAGEN:G->V: Mislocalized to the nucleoplasm. No effect on the reduction of MDM2 ubiquitination.	SEQ_UP	1	
MUTAGEN:G->V: No effect on filopodia formation.	SEQ_UP	1	
MUTAGEN:G->W: Impairs inhibition of the Wnt signaling pathway.	SEQ_UP	1	
MUTAGEN:G->W: Loss of activity, but function in microtubule stability not affected; when associated with W-134 and P-139.	SEQ_UP	1	
MUTAGEN:G->W: Loss of catalytic activity, but function in microtubule stability not affected; when associated with W-136 and P-139.	SEQ_UP	1	
MUTAGEN:G->W: Partially able to rescue mitochondrial respiratory chain defects observed in knockout mice.	SEQ_UP	1	
MUTAGEN:G->W: Strongly reduces affinity for DNA; when associated with A-166; A-227 and A-229.	SEQ_UP	1	
MUTAGEN:G->W: Strongly reduces affinity for DNA; when associated with A-48 and A-53.	SEQ_UP	1	
MUTAGEN:G->Y: Impairs interaction with DAB2.	SEQ_UP	1	
MUTAGEN:GAL->QQQ: Gain of function mutation. Mutant mice display enhanced persistent sodium current, have seizures and behavioral abnormalities. Half of the mice die before four months of age, and only 10% survive to nine months. Epilepsy severity in this model is strain-dependent. Mutation in a C57BL/6J background exhibit a mild disorder, whereas animals intercrossed with SJL7/j mice show a severe phenotype.	SEQ_UP	1	
MUTAGEN:GCT->LCL: No effect on N-terminal cleavage.	SEQ_UP	1	
MUTAGEN:GCTA->LLLV: Impairs N-terminal cleavage.	SEQ_UP	1	
MUTAGEN:GF->AA: Abolishes interaction with VCP.	SEQ_UP	1	
MUTAGEN:GG->AA: Strongly inhibits U RNA-binding.	SEQ_UP	1	
MUTAGEN:GG->KK: Abolishes homodimerization.	SEQ_UP	1	
MUTAGEN:GGKAAL->KKAAKT: Strong decreases on constitutive activity; No effect on protein level; Does not affect homooligomerization.	SEQ_UP	1	
MUTAGEN:GK->ED: Abolished interaction with TIMM4, thereby abolishing ability to regulate mitophagy.	SEQ_UP	1	
MUTAGEN:GK->SA: Loss of function.	SEQ_UP	1	
MUTAGEN:GKFGG->AKFAA: Abolishes homodimerization.	SEQ_UP	1	
MUTAGEN:GKS->AAA: Constitutive IL1B release.	SEQ_UP	1	
MUTAGEN:GNS->STR: Strongly reduces production of IL1B in response to bacterial flagellin.	SEQ_UP	1	
MUTAGEN:GP->AA: Strongly reduced interaction with MET. Loss of interaction with PARW.	SEQ_UP	1	
MUTAGEN:GRKN->AAAA: In mut4; does not affect localization to primary cilia.	SEQ_UP	1	
MUTAGEN:GS->AA: Partially inhibits U RNA-binding.	SEQ_UP	1	
MUTAGEN:GSGTG->ASATA: Abolished S-adenosyl-L-methionine-binding and ability to stabilize the small subunits of mitochondrial ribosome.	SEQ_UP	1	
MUTAGEN:GVAV->AAAA: Decreases repression of NFE2L2/NRF2-dependent gene expression.	SEQ_UP	1	
MUTAGEN:GYGFV->PDGDE: Impairs nuclear localization.	SEQ_UP	1	
MUTAGEN:GYSFVRF->PDSDERD: Abolishes nuclear export.	SEQ_UP	1	
MUTAGEN:H->A,D,E,N,Q,R: Little change in DNA-binding ability.	SEQ_UP	1	
MUTAGEN:H->A,D: Loss of enzyme activity.	SEQ_UP	1	
MUTAGEN:H->A,D: No effect on JAK signal transduction suppression.	SEQ_UP	1	
MUTAGEN:H->A,K,N,V: No receptor activity in response to MTMT binding, even in the presence of copper.	SEQ_UP	1	
MUTAGEN:H->A,K,R: No receptor activity in response to MTMT binding, even in the presence of copper.	SEQ_UP	1	
MUTAGEN:H->A,K: No receptor activity in response to MTMT binding, even in the presence of copper.	SEQ_UP	1	
MUTAGEN:H->A,L,R: No receptor activity in response to MTMT binding, even in the presence of copper.	SEQ_UP	1	
MUTAGEN:H->A,L,V,K,R: Little or no effect.	SEQ_UP	1	
MUTAGEN:H->A,Q: Abolishes enzyme activity.	SEQ_UP	2	
MUTAGEN:H->A: 54% Loss of activity.	SEQ_UP	1	
MUTAGEN:H->A: Abolished ability to acylate ghrelin. Does not affect proteic cleveage. loss of serine O-acyltransferase activity.	SEQ_UP	1	
MUTAGEN:H->A: Abolished acyltransferase activity. Impaired ability to interact with WNT3A.	SEQ_UP	1	
MUTAGEN:H->A: Abolished recognition by the CRL2(FEM1B) complex and subsequent ubiquitination.	SEQ_UP	1	
MUTAGEN:H->A: Abolishes ability to deubiquitinate histone H2A and ability to regulate transcription.	SEQ_UP	1	
MUTAGEN:H->A: Abolishes ability to rescue Purkinje cell degeneration in pcd mice when expressed in a transgene.	SEQ_UP	1	
MUTAGEN:H->A: Abolishes activity.	SEQ_UP	1	
MUTAGEN:H->A: Abolishes adhesion to oocytes.	SEQ_UP	1	
MUTAGEN:H->A: Abolishes ADP binding.	SEQ_UP	1	
MUTAGEN:H->A: Abolishes amino-acid binding without affecting interaction with the translating ribosome.	SEQ_UP	1	
MUTAGEN:H->A: Abolishes deacetylase activity, but not the interaction with HDAC2 and HDAC3.	SEQ_UP	1	
MUTAGEN:H->A: Abolishes deacetylase activity.	SEQ_UP	1	
MUTAGEN:H->A: Abolishes deacetylation of FOXO3. Does not inhibit interaction with FOXO3.	SEQ_UP	1	
MUTAGEN:H->A: Abolishes endoribonuclease activity.	SEQ_UP	1	
MUTAGEN:H->A: Abolishes enzymatic activity.	SEQ_UP	3	
MUTAGEN:H->A: Abolishes enzyme activity.	SEQ_UP	3	
MUTAGEN:H->A: Abolishes exonuclease activity, leading to activate the ATM signaling pathway; when associated with 31-A--N-35.	SEQ_UP	1	
MUTAGEN:H->A: Abolishes hydroxylation of 5-methylcarboxymethyl uridine.	SEQ_UP	1	
MUTAGEN:H->A: Abolishes interaction with NCOR2; mice have impaired GC formation and immunoglobulin affinity maturation with lower proliferation and survival of GC B-cells but normal differentiation of helper T-cell subsets and inflammatory response; in macrophages, no effect on transcriptional repression of genes encoding inflammatory molecules; when associated with K-21. In macrophages, no effect on competition with STAT5 for DNA-binding and transcriptional repression of genes encoding inflammatory molecules; when associated with K-21 and 377-Q--Q-380.	SEQ_UP	1	
MUTAGEN:H->A: Abolishes LPC transport.	SEQ_UP	1	
MUTAGEN:H->A: Abolishes lysophospholipase activity.	SEQ_UP	1	
MUTAGEN:H->A: Abolishes phosphatidylinositol 3,4,5-trisphosphate binding.	SEQ_UP	2	
MUTAGEN:H->A: Abolishes phosphoinositide-binding of C-terminus; when associated with A-152, A-158 and A-160.	SEQ_UP	1	
MUTAGEN:H->A: Abrogates RNA-binding by DRBM 3 and interaction with XPO5 and nuclear export; when associated with A-237.	SEQ_UP	1	
MUTAGEN:H->A: Abrogates sumoylation of LEF1 and increases LEF1-mediated transcriptional activity; when associated with S-330; S-335 and S-340.	SEQ_UP	1	
MUTAGEN:H->A: Allows robust hairpin activity.	SEQ_UP	1	
MUTAGEN:H->A: Catalytically inactive.	SEQ_UP	1	
MUTAGEN:H->A: Causes local perturbations of protein folding; when associated with T-122.	SEQ_UP	1	
MUTAGEN:H->A: Complete loss of activity.	SEQ_UP	1	
MUTAGEN:H->A: Complete loss of activity. Abolishes autocatalytic processing.	SEQ_UP	1	
MUTAGEN:H->A: Decrease of 55-60% of TPase activity.	SEQ_UP	1	
MUTAGEN:H->A: Decreased alpha-tubulin alpha-elongation step of polyglutamylase activity.	SEQ_UP	1	
MUTAGEN:H->A: Decreased protein abundance.	SEQ_UP	1	
MUTAGEN:H->A: Decreased transmembrane ascorbate ferrireductase activity.	SEQ_UP	1	
MUTAGEN:H->A: Decreases heterodimer formation with ARNT.	SEQ_UP	1	
MUTAGEN:H->A: Decreases heterodimer formation with EPAS1. Decreases heterodimer formation with HIF1A. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Does not compromise NPAS4:ARNT heterodimer stability. Does not compromise AHR:ARNT heterodimer stability.	SEQ_UP	1	
MUTAGEN:H->A: Destabilizes heterodimerization with ARNT. Compromises the transcriptional repression activity of heterodimer ARNT:NPAS1.	SEQ_UP	1	
MUTAGEN:H->A: Displays lower E3 ligase activity and affects the joining step of V(D)J recombination.	SEQ_UP	1	
MUTAGEN:H->A: Does not affect ability to promote sperm-egg interaction.	SEQ_UP	1	
MUTAGEN:H->A: Does not affect binding to diterpenoid derivative 15-oxospiramilactone (S3) inhibitor.	SEQ_UP	1	
MUTAGEN:H->A: Dramatically decreased Th2 cell differentiation.	SEQ_UP	1	
MUTAGEN:H->A: Enhanced interaction with TMC1.	SEQ_UP	1	
MUTAGEN:H->A: Has no effect on Treg effector functions.	SEQ_UP	1	
MUTAGEN:H->A: Impairs DNA-binding; when associated with A-443.	SEQ_UP	1	
MUTAGEN:H->A: Impairs interaction with EHMT1 and EHMT2.	SEQ_UP	1	
MUTAGEN:H->A: Impairs post-transfer editing activity but no effect on aminoacylation activity; when associated with A-154.	SEQ_UP	1	
MUTAGEN:H->A: Impairs post-transfer editing activity but no effect on aminoacylation activity; when associated with A-158.	SEQ_UP	1	
MUTAGEN:H->A: Impairs post-transfer editing activity but no effect on aminoacylation activity; when associated with A-222.	SEQ_UP	1	
MUTAGEN:H->A: Impairs post-transfer editing activity but no effect on aminoacylation activity; when associated with A-226.	SEQ_UP	1	
MUTAGEN:H->A: Impairs the ability to synthesize triacylglycerols, as well as retinyl and wax esters, in an in vitro acyltransferase assay.	SEQ_UP	1	
MUTAGEN:H->A: Increased permeability to chloride ions.	SEQ_UP	1	
MUTAGEN:H->A: Increases affinity for adenosine 20-fold. Reduces enzyme activity 500-fold.	SEQ_UP	1	
MUTAGEN:H->A: Inhibition of activity.	SEQ_UP	1	
MUTAGEN:H->A: Leads to a strong reduction in PtdIns(4,5)P2-binding.	SEQ_UP	1	
MUTAGEN:H->A: Loss of activity.	SEQ_UP	2	
MUTAGEN:H->A: Loss of activity. Loss of endogenous retroelement metabolization.	SEQ_UP	1	
MUTAGEN:H->A: Loss of catalytic activity.	SEQ_UP	1	
MUTAGEN:H->A: Loss of demethylase activity.	SEQ_UP	1	
MUTAGEN:H->A: Loss of E3 ubiquitin protein ligase activity.	SEQ_UP	1	
MUTAGEN:H->A: Loss of enzyme activity and iron incorporation.	SEQ_UP	1	
MUTAGEN:H->A: Loss of enzyme activity.	SEQ_UP	2	
MUTAGEN:H->A: Loss of function.	SEQ_UP	1	
MUTAGEN:H->A: Loss of glucan binding. Abolishes activation of NF-kappa-B.	SEQ_UP	1	
MUTAGEN:H->A: Loss of heme binding.	SEQ_UP	1	
MUTAGEN:H->A: Loss of interaction with CNOT7.	SEQ_UP	1	
MUTAGEN:H->A: Loss of LPA acyltransferase and LPI acyltransferase activities.	SEQ_UP	1	
MUTAGEN:H->A: Loss of N-fatty-acyl-amino acid synthase/hydrolase activity.	SEQ_UP	1	
MUTAGEN:H->A: Loss of N-terminal glutamine amidohydrolase activity.	SEQ_UP	1	
MUTAGEN:H->A: Loss of NF-kappa-B activation.	SEQ_UP	1	
MUTAGEN:H->A: Loss of O-acyltransferase activity.	SEQ_UP	1	
MUTAGEN:H->A: Loss of phosphatase activity.	SEQ_UP	1	
MUTAGEN:H->A: Loss of phosphatidylinositol 4,5-bisphosphate hydrolyzing activity. In neurons, generates supernumerary protrusions.	SEQ_UP	1	
MUTAGEN:H->A: Loss of phospholipase activity, but no effect on lysophosphatidylcholine acyltransferase activity.	SEQ_UP	1	
MUTAGEN:H->A: Loss of plasmanylethanolamine desaturase activity. Does not affect endoplasmic reticulum membrane localization.	SEQ_UP	1	
MUTAGEN:H->A: Loss of polynucleotide adenylyltransferase activity.	SEQ_UP	1	
MUTAGEN:H->A: Loss of ribonuclease activity. Loss of angiogenic activity.	SEQ_UP	1	
MUTAGEN:H->A: Loss of transcription activation.	SEQ_UP	1	
MUTAGEN:H->A: Loss of transmembrane ascorbate ferrireductase activity.	SEQ_UP	1	
MUTAGEN:H->A: Loss of ubiquitination activity.	SEQ_UP	1	
MUTAGEN:H->A: Near loss of channel sensitivity to inhibition by ATP.	SEQ_UP	1	
MUTAGEN:H->A: Nearly abolishes enzyme activity.	SEQ_UP	1	
MUTAGEN:H->A: No activity with sphingomyelin as substrate; retains 70% of wild-type activity with bis(p-nitrophenyl) phosphate as substrate.	SEQ_UP	1	
MUTAGEN:H->A: No change in binding to DNA.	SEQ_UP	1	
MUTAGEN:H->A: No effect on enzyme activity.	SEQ_UP	1	
MUTAGEN:H->A: No effect on interaction with PARD6B.	SEQ_UP	1	
MUTAGEN:H->A: No effect on PDCD1 binding.	SEQ_UP	1	
MUTAGEN:H->A: No effect on protein abundance.	SEQ_UP	1	
MUTAGEN:H->A: No effect on protein abundance. Decreased reduction by ascorbate; when associated with A-159.	SEQ_UP	1	
MUTAGEN:H->A: No effect on protein abundance. Decreased reduction by ascorbate; when associated with A-86.	SEQ_UP	1	
MUTAGEN:H->A: No effect on protein abundance. Loss of beta-carotene 15,15'-monooxygenase activity. Decreased iron binding.	SEQ_UP	1	
MUTAGEN:H->A: No effect on protein abundance. Loss of beta-carotene 15,15'-monooxygenase activity. Loss of iron binding.	SEQ_UP	1	
MUTAGEN:H->A: No effect on transmembrane ascorbate ferrireductase activity.	SEQ_UP	1	
MUTAGEN:H->A: No effect on UBE2I binding nor on sumoylation.	SEQ_UP	1	
MUTAGEN:H->A: No effect on zinc binding.	SEQ_UP	1	
MUTAGEN:H->A: No effect.	SEQ_UP	1	
MUTAGEN:H->A: No loss of dsRNA binding capacity. Binding capacity was reduced 40-60%; when associated with A-203. Binding capacity was reduced to 5-10%; when associated with A-152 and A-203. Loss of binding capacity; when associated with A-152; A-203 and A-257.	SEQ_UP	1	
MUTAGEN:H->A: No loss of dsRNA binding capacity. Binding capacity was reduced 40-60%; when associated with A-91. Binding capacity was reduced to 5-10%; when associated with A-91 and A-152. Loss of binding capacity; when associated with A-91; A-152 and A-257.	SEQ_UP	1	
MUTAGEN:H->A: No loss of dsRNA binding capacity. Loss of 40-60% dsRNA binding; when associated with A-203. Binding capacity was reduced to 5-10%; when associated with A-91 and A-203. Loss of binding capacity; when associated with A-91; A-203 and A-257.	SEQ_UP	1	
MUTAGEN:H->A: No loss of dsRNA binding capacity. Loss of 5-10 % dsRNA binding capacity; when associated with A-152 and A-203. Loss of binding capacity; when associated with A-91; A-152 and A-203.	SEQ_UP	1	
MUTAGEN:H->A: No loss of its ability to regulate TBX21-dependent gene expression or its ability to interact with SMARCA4; when associated with A-1388 and A-1390.	SEQ_UP	1	
MUTAGEN:H->A: No loss of its ability to regulate TBX21-dependent gene expression or its ability to interact with SMARCA4; when associated with A-1390 and A-1468.	SEQ_UP	1	
MUTAGEN:H->A: No significant effect on beta-carotene 15,15'-monooxygenase activity.	SEQ_UP	1	
MUTAGEN:H->A: No significant effect on beta-carotene 15,15'-monooxygenase activity. Decreased catalytic efficiency.	SEQ_UP	1	
MUTAGEN:H->A: No significant effect on beta-carotene 15,15'-monooxygenase activity. Decreased stability.	SEQ_UP	1	
MUTAGEN:H->A: Phosphopantetheine adenylyltransferase activity abolished.	SEQ_UP	1	
MUTAGEN:H->A: Reduced activity.	SEQ_UP	1	
MUTAGEN:H->A: Reduced enzyme activity.	SEQ_UP	1	
MUTAGEN:H->A: Reduced histidine methylation by METTL9.	SEQ_UP	1	
MUTAGEN:H->A: Reduced phosphodiesterase activity. Decreases inhibition of innate immune responses.	SEQ_UP	1	
MUTAGEN:H->A: Reduces activity.	SEQ_UP	2	
MUTAGEN:H->A: Reduces affinity for substrate and catalytic activity by about 50%.	SEQ_UP	1	
MUTAGEN:H->A: Reduces autoproteolysis. No effect on inhibition of adenylate cyclase activity.	SEQ_UP	1	
MUTAGEN:H->A: Reduces DNA binding.	SEQ_UP	1	
MUTAGEN:H->A: Reduces enzyme activity.	SEQ_UP	2	
MUTAGEN:H->A: Reduces zinc binding by 60%. Abolishes zinc binding; when associated with A-1595.	SEQ_UP	1	
MUTAGEN:H->A: Significant decrease in DNA binding affinity resulting in a loss of the transcriptional activity.	SEQ_UP	1	
MUTAGEN:H->A: Significantly decreased NF-kappa-B activation.	SEQ_UP	1	
MUTAGEN:H->A: Slightly impaired interaction with KIF23. Abolishes interaction with GGA1, SPAG9 and RAB11FIP4.	SEQ_UP	1	
MUTAGEN:H->A: Slightly reduces activity.	SEQ_UP	1	
MUTAGEN:H->A: Strongly decreased cholesterol export.	SEQ_UP	1	
MUTAGEN:H->A: Strongly reduced interaction with DNA.	SEQ_UP	1	
MUTAGEN:H->A: Strongly reduced riboflavin transport; when associated with 391-A--A-394.	SEQ_UP	1	
MUTAGEN:H->A: Strongly reduced tyrosine carboxypeptidase activity.	SEQ_UP	1	
MUTAGEN:H->A: Strongly reduces 'Lys-63'-linked ubiquitination; when associated with A-69. Abolishes inhibition of NFKB2 processing; when associated with A-67.	SEQ_UP	1	
MUTAGEN:H->A: Strongly reduces activity.	SEQ_UP	1	
MUTAGEN:H->A: Strongly reduces plasmanylethanolamine desaturase activity. Does not affect endoplasmic reticulum membrane localization.	SEQ_UP	1	
MUTAGEN:H->C: No E2 binding. Loss of ubiquitination activity.	SEQ_UP	1	
MUTAGEN:H->D: Abolishes transforming activity.	SEQ_UP	1	
MUTAGEN:H->D: Affects ion selectivity.	SEQ_UP	1	
MUTAGEN:H->D: Decreased ceramide synthase activity.	SEQ_UP	1	
MUTAGEN:H->D: Loss of CDC42-binding and impairment of autophosphorylation.	SEQ_UP	1	
MUTAGEN:H->D: Loss of interaction with TNFRSF14.	SEQ_UP	1	
MUTAGEN:H->D: Strongly reduced transactivation; when associated with D-440.	SEQ_UP	1	
MUTAGEN:H->D: Strongly reduced transactivation; when associated with D-442.	SEQ_UP	1	
MUTAGEN:H->E,N: Abolishes interaction with UNC5D.	SEQ_UP	1	
MUTAGEN:H->E: 43% reduced binding to LRP6.	SEQ_UP	1	
MUTAGEN:H->E: 50% reduced binding to LRP6.	SEQ_UP	1	
MUTAGEN:H->E: Decreased monoglycylation activity.	SEQ_UP	1	
MUTAGEN:H->E: Nearly abolishes enzyme activity.	SEQ_UP	1	
MUTAGEN:H->E: No effect on JAK signal transduction suppression.	SEQ_UP	1	
MUTAGEN:H->E: Reduces affinity for FBXL3.	SEQ_UP	1	
MUTAGEN:H->E: Shifts voltage dependence of activation to more positive values and abolishes pH-sensitivity.	SEQ_UP	1	
MUTAGEN:H->F,A: Abolishes the enzymatic activity.	SEQ_UP	1	
MUTAGEN:H->F,Y: No change in receptor activity in response to MTMT binding. No change in the copper-induced enhancement of receptor activity.	SEQ_UP	1	
MUTAGEN:H->F: Catalytically inactive; defective in promoting NOS3/eNOS-uncoupling in endothelial cells.	SEQ_UP	1	
MUTAGEN:H->F: Decreases the enzymatic activity.	SEQ_UP	1	
MUTAGEN:H->F: Disrupts the dot-like nuclear pattern.	SEQ_UP	1	
MUTAGEN:H->F: Loss of interaction with 53BP1; when associated with F-283.	SEQ_UP	1	
MUTAGEN:H->F: Loss of interaction with 53BP1; when associated with F-84.	SEQ_UP	1	
MUTAGEN:H->F: No effect.	SEQ_UP	1	
MUTAGEN:H->G: Does not affect ability to promote piRNA biosynthesis.	SEQ_UP	1	
MUTAGEN:H->G: Has little effect on sulfotransferase activity (at pH 7.5).	SEQ_UP	1	
MUTAGEN:H->G: Loss of interaction with PTPN12; when associated with G-369.	SEQ_UP	1	
MUTAGEN:H->G: No methyltransferase activity.	SEQ_UP	1	
MUTAGEN:H->G: Reduces sensitivity to Mg(2+), but not sensitivity to Ca(2+).	SEQ_UP	1	
MUTAGEN:H->I: Small increase in alpha-tubulin initiation step of polyglutamylase activity. Increased alpha-tubulin initiation step of polyglutamylase activity; when associated with R-180. Strong increase in alpha-tubulin initiation step of polyglutamylase activity; when associated with A-179 and R-180. Strong increase in alpha-tubulin initiation step of polyglutamylase activity; when associated with A-179, R-180, I-362 and H-367.	SEQ_UP	1	
MUTAGEN:H->K,A: 50% decrease in enzymatic activity.	SEQ_UP	1	
MUTAGEN:H->K,L,S,R: Loss of estrogen sulfotransferase activity.	SEQ_UP	1	
MUTAGEN:H->K,N: Induces a slight decrease in activity.	SEQ_UP	1	
MUTAGEN:H->K: Abolishes peptidase activity but no effect on GPIase activity; when associated with K-993.	SEQ_UP	1	
MUTAGEN:H->K: Abolishes peptidase activity but no effect on GPIase activity; when associated with K-997.	SEQ_UP	1	
MUTAGEN:H->K: Decreased receptor activity in response to MTMT binding, even in the presence of copper.	SEQ_UP	1	
MUTAGEN:H->K: Decreased receptor activity in response to MTMT binding, even in the presence of copper. Complete loss of receptor activity in the absence of copper.	SEQ_UP	1	
MUTAGEN:H->L: Abolishes GTPase activity.	SEQ_UP	1	
MUTAGEN:H->L: Abolishes phosphatase activity.	SEQ_UP	1	
MUTAGEN:H->L: Constitutively active.	SEQ_UP	1	
MUTAGEN:H->L: Decrease in receptor activation.	SEQ_UP	1	
MUTAGEN:H->L: Decreased tubulin deglutamylation.	SEQ_UP	1	
MUTAGEN:H->L: Does not reduce interaction with RAP2A. Strongly reduces interaction with RAP2A; when associated with L-336.	SEQ_UP	1	
MUTAGEN:H->L: Improved binding of dioxygen and carbon monoxide to the iron atom.	SEQ_UP	1	
MUTAGEN:H->L: Loss of enzymatic activity.	SEQ_UP	1	
MUTAGEN:H->L: Loss of function.	SEQ_UP	1	
MUTAGEN:H->L: Loss of lipid phosphatase activity.	SEQ_UP	1	
MUTAGEN:H->L: Mutant mice develop early onset ataxia, exhibit reduced body weight and usually die around 10 weeks after birth. Increases SPT affininity toward C18-CoA substrate by twofold and elevates C20 long chain base production in the brain and eye. Produces neurodegenerative effects such as aberrant membrane strucutres, accumulation of ubiquitinated protein on membranes and axon degeneration.	SEQ_UP	1	
MUTAGEN:H->L: Reduced recovery of intracellular sodium-dependent pH.	SEQ_UP	1	
MUTAGEN:H->L: Reduces the inhibitory effect of the atypical PHD domain.	SEQ_UP	1	
MUTAGEN:H->L: Strongly decreased phosphodiesterase activity.	SEQ_UP	1	
MUTAGEN:H->L: When expressed in hippocampal neurons, strongly decreases the number of dendritic spines; when associated with L-78 and R-312.	SEQ_UP	1	
MUTAGEN:H->L: When expressed in hippocampal neurons, strongly decreases the number of dendritic spines; when associated with L-81 and R-312.	SEQ_UP	1	
MUTAGEN:H->L: When expressed in hippocampal neurons, strongly decreases the number of dendritic spines; when associated with L-83 and R-299.	SEQ_UP	1	
MUTAGEN:H->L: When expressed in hippocampal neurons, strongly decreases the number of dendritic spines; when associated with L-86 and R-299.	SEQ_UP	1	
MUTAGEN:H->N: Abolishes interaction with UNC5B.	SEQ_UP	1	
MUTAGEN:H->N: Decreases sulfotransferase activity (at pH 6.27). Does not affect sulfotransferase activity (at pH 7.5).	SEQ_UP	1	
MUTAGEN:H->N: Does not affect protein cleveage.	SEQ_UP	1	
MUTAGEN:H->N: Gains susceptibility to mouse-specific RU.521; when associated with S-419.	SEQ_UP	1	
MUTAGEN:H->N: Insensitive to extracellular protons.	SEQ_UP	1	
MUTAGEN:H->N: Loss of DNA binding and transactivation activity. No change in interaction with SIN3A nor with HDAC1. No effect on repressive activity.	SEQ_UP	1	
MUTAGEN:H->N: Loss of endosomal localization.	SEQ_UP	1	
MUTAGEN:H->N: Loss of inhibition of SPI1-mediated transcriptional activation.	SEQ_UP	1	
MUTAGEN:H->N: Loss of nuclease activity.	SEQ_UP	1	
MUTAGEN:H->N: No effect on interaction with LIN7C.	SEQ_UP	1	
MUTAGEN:H->N: Partially prevents interaction with LIN7C.	SEQ_UP	1	
MUTAGEN:H->N: Reduced enzyme activity.	SEQ_UP	1	
MUTAGEN:H->N: Reduced interaction with SUMO2.	SEQ_UP	1	
MUTAGEN:H->N: Reduces sensitivity to block by extracellular acidification. Sensitivity to block by low extracellular pH is nearly abolished; when associated with Q-831.	SEQ_UP	1	
MUTAGEN:H->N: Shows normal sensitivity to acid block and significant recovery from acid-enhanced inactivation.	SEQ_UP	1	
MUTAGEN:H->N: Significantly decreases calcium-dependent binding to phospholipids; when associated with N-44.	SEQ_UP	1	
MUTAGEN:H->N: Significantly decreases calcium-dependent binding to phospholipids; when associated with N-82.	SEQ_UP	1	
MUTAGEN:H->N: Strongly reduced activity at low pH, with minor effect on activity at neutral pH.	SEQ_UP	1	
MUTAGEN:H->N: Strongly reduced affinity for PLXNA2.	SEQ_UP	1	
MUTAGEN:H->N: Strongly reduced enzyme activity.	SEQ_UP	1	
MUTAGEN:H->P,R: Misfolded, leading to the interaction with TOR1A, ubiquitination and a decrease of the half-life. Impairs intracellular transport. No effect on glycosylation.	SEQ_UP	1	
MUTAGEN:H->P: Does not affect protein expression. Decreases intracellular cholesterol accumulation in the vesicle.	SEQ_UP	1	
MUTAGEN:H->P: Loss of interaction with CEBPA.	SEQ_UP	1	
MUTAGEN:H->Q: Abolishes ability to stimulate ATPase activity of HSPA5/BiP.	SEQ_UP	1	
MUTAGEN:H->Q: Abolishes activity.	SEQ_UP	1	
MUTAGEN:H->Q: Abolishes all phosphodiesterase activity. 15% activity can be restored by addition of Zn(2+) ions. Abolishes formation of nucleotidylated intermediate.	SEQ_UP	1	
MUTAGEN:H->Q: Abolishes all phosphodiesterase activity. 60% activity can be restored by addition of Zn(2+) ions. Abolishes formation of nucleotidylated intermediate.	SEQ_UP	1	
MUTAGEN:H->Q: Abolishes deubiquitinating activity.	SEQ_UP	1	
MUTAGEN:H->Q: Abolishes pH-sensitivity.	SEQ_UP	1	
MUTAGEN:H->Q: Accumulation of uncleaved form with the N-terminal methionine.	SEQ_UP	1	
MUTAGEN:H->Q: Decreases phosphodiesterase activity by 95%. 65% activity can be restored by addition of Zn(2+) ions. Accumulates nucleotidylated intermediate.	SEQ_UP	1	
MUTAGEN:H->Q: Impaired acrosome reaction.	SEQ_UP	1	
MUTAGEN:H->Q: Impairs cysteinyl leukotrienes synthesis and phagocytosis of IgG immune complexes by synovial fluid monocyte/macrophage cells.	SEQ_UP	1	
MUTAGEN:H->Q: Impairs interaction with IRF4 and the recruitment of IRF4 to AICE motifs, leading to defects in mediate differentiation of Th17 cells. Loss of function; when associated with A-56; D-63 and K-77.	SEQ_UP	1	
MUTAGEN:H->Q: Increases GTPase activity.	SEQ_UP	1	
MUTAGEN:H->Q: Induces a strong decrease in activity.	SEQ_UP	1	
MUTAGEN:H->Q: Inhibits cell growth. No effect on interaction with PHB2.	SEQ_UP	1	
MUTAGEN:H->Q: Loss of fatty acid elongase activity.	SEQ_UP	1	
MUTAGEN:H->Q: Loss of function in regulation of glutamatergic synaptic transmission.	SEQ_UP	1	
MUTAGEN:H->Q: Loss of interaction with 'Lys-63'-linked ubiquitin.	SEQ_UP	1	
MUTAGEN:H->Q: Loss of palmitoyltransferase activity toward DNAJC5 and SNAP25.	SEQ_UP	1	
MUTAGEN:H->Q: Loss of transcriptional repression; when associated with R-33.	SEQ_UP	1	
MUTAGEN:H->Q: Nearly abolishes enzyme activity.	SEQ_UP	1	
MUTAGEN:H->R,Q: Loss of enzyme activity.	SEQ_UP	1	
MUTAGEN:H->R: Abolishes ability to deubiquitinate histone H2A; when associated with S-329.	SEQ_UP	1	
MUTAGEN:H->R: Abolishes interaction with KAT8.	SEQ_UP	1	
MUTAGEN:H->R: Abolishes pH-sensitivity.	SEQ_UP	1	
MUTAGEN:H->R: Abrogates self-association and interaction with DAB1, dynein, NDEL1, PAFAH1B3 and RSN. Also impairs localization to centrosomes and microtubule plus ends. Reduces protein stability.	SEQ_UP	1	
MUTAGEN:H->R: Disrupts interaction with ZFPM1. Binds normally to DNA.	SEQ_UP	1	
MUTAGEN:H->R: Greatly impairs interaction with APLP1.	SEQ_UP	1	
MUTAGEN:H->R: Impairs the NADH oxidoreductase activity. Impairs mitochondria to nucleus translocation. Confers protection to doxorubicin-induced cytotoxicity.	SEQ_UP	1	
MUTAGEN:H->R: In ketu; homozygotes mice are both male- and female-sterile. In the testis, mutant germ cells carry out an abortive attempt at meiosis: They express hallmark meiotic proteins and initiate recombination, but fail to fully extinguish the spermatogonial mitotic division program, proceed prematurely to an aberrant metaphase-like state, and undergo apoptosis. The mutation probably causes misfolding or protein aggregation. Slightly reduced helicase activity.	SEQ_UP	1	
MUTAGEN:H->R: Loss of deubiquitinating activity; when associated with S-194.	SEQ_UP	1	
MUTAGEN:H->R: Loss of function in TLR signaling. Impaired in its own transport from endoplasmic reticulum to endosome, lysosome and phagosome. Loss of the interaction with TLR3, TLR7, TLR9 and TLR13 and of the ability to transport them to endolysosome.	SEQ_UP	1	
MUTAGEN:H->R: Loss of the cytidine deaminase activity; when associated with Q-58.	SEQ_UP	1	
MUTAGEN:H->R: No receptor activity in response to MTMT binding, even in the presence of copper. Little to no expression detected on plasma membrane.	SEQ_UP	1	
MUTAGEN:H->R: Reduced interaction with SUMO2.	SEQ_UP	1	
MUTAGEN:H->R: Reduces enzyme activity 1500-fold. No effect on affinity for adenosine.	SEQ_UP	1	
MUTAGEN:H->S: Abolishes deglutamylase activity; when associated with Q-233.	SEQ_UP	1	
MUTAGEN:H->S: Abolishes deglutamylase activity; when associated with Q-255.	SEQ_UP	1	
MUTAGEN:H->S: Abolishes deglutamylase activity; when associated with Q-806.	SEQ_UP	1	
MUTAGEN:H->S: Abolishes deglutamylase activity; when associated with Q-915.	SEQ_UP	1	
MUTAGEN:H->S: Loss of E3 ligase activity.	SEQ_UP	1	
MUTAGEN:H->S: Loss of ubiquitination activity.	SEQ_UP	1	
MUTAGEN:H->S: No effect on MHC class I peptide tetramer binding; when associated with S-174.	SEQ_UP	1	
MUTAGEN:H->T: Impairs sulfotransferase activity.	SEQ_UP	1	
MUTAGEN:H->V: Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself;when associated with D-69 and R-368.	SEQ_UP	1	
MUTAGEN:H->V: Changes the stereoselectivity of the oxygenation reaction to produce (15S)-HPETE instead of (8S)-HPETE. Completely changes the stereoselectivity; when associated with D-603.	SEQ_UP	1	
MUTAGEN:H->V: Reduces number of fusion-competent vesicles in neurons.	SEQ_UP	1	
MUTAGEN:H->Y: Abolished NAD-dependent protein deacetylase, deacylase and mono-ADP-ribosyltransferase activities.	SEQ_UP	1	
MUTAGEN:H->Y: Abolishes deacylase and deacetylase activities. Reduced interaction with SIRT1, without abolishing it.	SEQ_UP	1	
MUTAGEN:H->Y: Complete loss of LTA4 hydrolase and peptidase enzyme activities.	SEQ_UP	1	
MUTAGEN:H->Y: Decreased protein abundance. Not associated with changes in subcellular location.	SEQ_UP	1	
MUTAGEN:H->Y: Impairs peroxidase and cyclooxygenase activities toward 2-arachidonoyl glycerol.	SEQ_UP	1	
MUTAGEN:H->Y: Loss of deacetylation activity. Loss of inhibition of E2F1 and loss of coactivation of FOXO1-mediated transcription.	SEQ_UP	1	
MUTAGEN:H->Y: Loss of enzyme activity; when associated with A-1087.	SEQ_UP	1	
MUTAGEN:H->Y: Loss of enzyme activity; when associated with A-1297.	SEQ_UP	1	
MUTAGEN:H->Y: Loss of enzyme activity; when associated with A-1622.	SEQ_UP	1	
MUTAGEN:H->Y: Loss of enzyme activity.	SEQ_UP	1	
MUTAGEN:H->Y: Loss of ubiquitin ligase activity.	SEQ_UP	1	
MUTAGEN:H->Y: No effect on protein abundance. No effect on cell surface localization. Increases alanine uptake activity.	SEQ_UP	1	
MUTAGEN:H->Y: Shows a defect in ciliary localization with no apparent effect on ciliation, mitosis or centriole number.	SEQ_UP	1	
MUTAGEN:HCR->ACA: No effect on nuclear import.	SEQ_UP	1	
MUTAGEN:HDFE->AAFA,ERFR: Does not affect trypsin-binding.	SEQ_UP	1	
MUTAGEN:HGP->LSK: Strongly decreased channel activity due to decreased expression at the cell membrane, leading to hypertrophy of the right heart ventricle, heart failure and perinatal death; when associated with 1797-P--L-2139 DEL.	SEQ_UP	1	
MUTAGEN:HH->AA: Abolished guanosine exchange factor (GEF) activity for Ran.	SEQ_UP	1	
MUTAGEN:HH->EE: Loss of function.	SEQ_UP	1	
MUTAGEN:HH->GL,GP: Almost complete loss of binding to G(o) alpha subunit. No inhibition of GTPase activity.	SEQ_UP	1	
MUTAGEN:HHA->QAS: Deacetylase-dead mutant. No effect on its interaction with ARNTL/BMAL1, CRY1 and FBXL3 or its ability to regulate the circadian clock.	SEQ_UP	1	
MUTAGEN:HL->AA: Abolishes response to semaphorin.	SEQ_UP	1	
MUTAGEN:HL->AA: Severely reduced transcriptional repression activity.	SEQ_UP	1	
MUTAGEN:HLR->ALA: Strongly reduces affinity for DNA.	SEQ_UP	1	
MUTAGEN:HMHCD->AMACN: Abolishes exonuclease activity, leading to activate the ATM signaling pathway; when associated with A-230.	SEQ_UP	1	
MUTAGEN:HRLL->AAAA: Abolishes the interactions with estrogen and retinoid-acids receptors.	SEQ_UP	1	
MUTAGEN:HS->R: Abrogates transcriptional repression but does not affect DNA-binding.	SEQ_UP	1	
MUTAGEN:I->A,G,T: Strongly decreases affinity for the synthetic compound 5,6-dimethylxanthenone 4-acetic acid (DMXAA).	SEQ_UP	1	
MUTAGEN:I->A,S,L: Abolishes interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:I->A,S,V: Abolishes interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:I->A,W: No effect on interaction with TLR3.	SEQ_UP	1	
MUTAGEN:I->A: Abolishes inhibition of FOXO1 transcriptional activity.	SEQ_UP	1	
MUTAGEN:I->A: Abolishes interaction with PCNA.	SEQ_UP	1	
MUTAGEN:I->A: Abolishes interaction with RAB27A.	SEQ_UP	1	
MUTAGEN:I->A: Abolishes interaction with TAX1BP3.	SEQ_UP	1	
MUTAGEN:I->A: Abolishes localization to microtubules.	SEQ_UP	1	
MUTAGEN:I->A: Abolishes the binding to PDCD1.	SEQ_UP	2	
MUTAGEN:I->A: Abolishes the binding to PDCD1. Costimulates proliferation and IFNG production of T-cells.	SEQ_UP	1	
MUTAGEN:I->A: Abolishes the interaction with many chromatin regulators but not that with KMT5B and KMT5C; when associated with A-750 and A-754.	SEQ_UP	1	
MUTAGEN:I->A: Affects basolateral membrane sorting in vitro but not in vivo; when associated with 76-A-A-77 and A-222.	SEQ_UP	1	
MUTAGEN:I->A: Decrease in MARK3 binding; when associated with A-401.	SEQ_UP	1	
MUTAGEN:I->A: Decreased DNA binding and transcriptional activity.	SEQ_UP	1	
MUTAGEN:I->A: Decreased threshold for activation by calcium.	SEQ_UP	1	
MUTAGEN:I->A: Greatly reduced activity.	SEQ_UP	1	
MUTAGEN:I->A: Impairs interaction with BRAF and association with membrane ruffles; when associated with A-78.	SEQ_UP	1	
MUTAGEN:I->A: Impairs interaction with F-actin; when assocoated with A-128.	SEQ_UP	1	
MUTAGEN:I->A: Impairs interaction with F-actin; when assocoated with A-131.	SEQ_UP	1	
MUTAGEN:I->A: Impairs interaction with GATA1.	SEQ_UP	1	
MUTAGEN:I->A: Increased speed of phospholipid scrambling. Constitutive scramblase activity at basal cytosolic calcium levels; when associated with A-518 and A-563.	SEQ_UP	1	
MUTAGEN:I->A: Localizes mainly in cytoplasm and not in nucleus; when associated with D-483 and A-610.	SEQ_UP	1	
MUTAGEN:I->A: Loss of autophosphorylation. Fails to induce activation of the AP-1 transcription factor, MAPK7 or MAPK8.	SEQ_UP	1	
MUTAGEN:I->A: Loss of interaction with calcineurin and activation by elevated intracellular calcium; when associated with A-214.	SEQ_UP	1	
MUTAGEN:I->A: Loss of MAPK7 binding; when associated with A-20.	SEQ_UP	1	
MUTAGEN:I->A: Loss of NF-kappa-B transcription factor activity and reduced ability to activate MAP2K1, MAP2K4, MAP2K7. No effect on AP-1 activity or activation of CHUK and IKBKB. Loss of binding to IKBKB.	SEQ_UP	1	
MUTAGEN:I->A: Low constitutive channel activity. Decreased threshold for activation by calcium.	SEQ_UP	1	
MUTAGEN:I->A: No effect on acetylated histone binding.	SEQ_UP	1	
MUTAGEN:I->A: No effect on activity for acetyl-CoA. Reduced activity for palmitoyl-CoA.	SEQ_UP	1	
MUTAGEN:I->A: No effect on DNA-binding, represses E2F1:TFDP1-mediated transcription and causes adipose hypoplasia and myeloid dysplasia; when associated with A-298.	SEQ_UP	1	
MUTAGEN:I->A: No effect on subcellular location.	SEQ_UP	1	
MUTAGEN:I->A: No effect on transcriptional activity and estrogen-induced interaction with NCOA1. Abolishes estrogen-induced interaction with NCOA1; when associated with A-376 and A-380.	SEQ_UP	1	
MUTAGEN:I->A: No effect on UBE2I binding nor on sumoylation.	SEQ_UP	1	
MUTAGEN:I->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-264.	SEQ_UP	1	
MUTAGEN:I->A: Reduces affinity for actin.	SEQ_UP	1	
MUTAGEN:I->A: Reduces Arf-GAP mediated stimulation of GTP hydrolysis 100-fold and abolishes Arf-GAP mediated stimulation of GTP hydrolysis; when associated with A-306.	SEQ_UP	1	
MUTAGEN:I->A: Reduces binding to RII.	SEQ_UP	1	
MUTAGEN:I->A: Reduces enzyme activity by about 60%.	SEQ_UP	1	
MUTAGEN:I->A: Reduces oligomerization. Abolishes interaction with DIXDC1. Reduces activation of Wnt signaling.	SEQ_UP	1	
MUTAGEN:I->A: Severe loss of interaction with GYS2.	SEQ_UP	1	
MUTAGEN:I->A: Slightly reduced activity.	SEQ_UP	1	
MUTAGEN:I->A: Spontaneous IL1B release under basal conditions, loss of response to metabolic inhibitors and to LT; when associated with A-746.	SEQ_UP	1	
MUTAGEN:I->A: Strongly reduced activation by elevated intracellular calcium. Loss of interaction with calcineurin and activation by elevated intracellular calcium; when associated with A-212.	SEQ_UP	1	
MUTAGEN:I->A: Strongly reduced interaction with CDH23.	SEQ_UP	1	
MUTAGEN:I->D,R,K,G: Loss of activity.	SEQ_UP	1	
MUTAGEN:I->D: Abolishes binding of FBXL3 and SKP1. Strongly decreases CRY2 degradation.	SEQ_UP	1	
MUTAGEN:I->D: Abolishes interaction with GBA. No effect on normal location in lysosomes.	SEQ_UP	1	
MUTAGEN:I->D: Abolishes transcriptional activity and estrogen-induced interaction with NCOA1.	SEQ_UP	1	
MUTAGEN:I->D: Completely abolished the AHR induction activity, the ligand-induced nuclear translocation of AHR, and drastically reduced DRE-binding in vitro.	SEQ_UP	1	
MUTAGEN:I->D: Compromises SIM1:ARNT2 heterodimer stability. Does not compromises NPAS4:ARNT2 heterodimer stability.	SEQ_UP	1	
MUTAGEN:I->D: Greatly reduced binding to MAD; when associated with V-307 and A-311.	SEQ_UP	1	
MUTAGEN:I->D: Highly reduces transcription activity. Impairs interaction with AHR. Impairs heterodimer formation with EPAS1. Impairs heterodimer formation with HIF1A. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Compromise NPAS4:ARNT heterodimer stability. Compromise AHR:ARNT heterodimer stability.	SEQ_UP	1	
MUTAGEN:I->D: Impairs heterodimer formation with EPAS1. Markedly decreases heterodimer formation with HIF1A. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Does not compromise NPAS4:ARNT heterodimer stability. Does not compromise AHR:ARNT heterodimer stability.	SEQ_UP	1	
MUTAGEN:I->D: No effect on cholesterol binding. Strongly decreased cholesterol transport activity.	SEQ_UP	1	
MUTAGEN:I->D: Reduced CLOCK binding. Slightly reduced transcriptional activation by the CLOCK-ARNTL/BMAL1 heterodimer. Impairs regulation of circadian clock. Loss of ability to inhibit the expression of CD274 in macrophages.	SEQ_UP	1	
MUTAGEN:I->D: Reduced homoolimerization, leading to reduced ability to induce pyroptosis.	SEQ_UP	1	
MUTAGEN:I->D: Reduces calcium-sensitive phospholipid binding.	SEQ_UP	1	
MUTAGEN:I->D: Reduces transcription activity. Decreases interaction with ARNT.	SEQ_UP	1	
MUTAGEN:I->D: Slightly reduced degradation, probably caused by reduced ubiquitination by the SCF(FBXL17) complex.	SEQ_UP	1	
MUTAGEN:I->E,K: Constitutive lipid scramblase activity at basal cytosolic calcium levels.	SEQ_UP	1	
MUTAGEN:I->E: Abolishes binding to CD200R.	SEQ_UP	1	
MUTAGEN:I->E: Abolishes dimerization.	SEQ_UP	1	
MUTAGEN:I->E: Abolishes homodimer formation.	SEQ_UP	1	
MUTAGEN:I->E: Abolishes homodimerization.	SEQ_UP	3	
MUTAGEN:I->E: Abrogates interaction with EED.	SEQ_UP	1	
MUTAGEN:I->E: Disrupts one GNAI3 binding site.	SEQ_UP	1	
MUTAGEN:I->E: Loss of binding to JH1/Y-1007 of JAK2 and loss of signal transduction suppression.	SEQ_UP	1	
MUTAGEN:I->E: Loss of binding to rabkinesin-6.	SEQ_UP	1	
MUTAGEN:I->E: Strongly reduces affinity for MLPH and SYTL4.	SEQ_UP	1	
MUTAGEN:I->F: Alters protein structure and causes an increase in whole body metabolism, leading to a lean phenotype in adult males, but not in females.	SEQ_UP	1	
MUTAGEN:I->F: Diminishes significantly the interaction and coactivation OF PPARA; when associated with F-727.	SEQ_UP	1	
MUTAGEN:I->F: In Rco13; causes a wavy pelage and curly vibrissae.	SEQ_UP	1	
MUTAGEN:I->F: Induces resistance to 5,10-dideazatetrahydrofolate; when associated with G-105.	SEQ_UP	1	
MUTAGEN:I->F: Loss of channel activity.	SEQ_UP	1	
MUTAGEN:I->F: Mice display a low bone mass density and are associated with osteopenia and elevated inflammatory cytokines.	SEQ_UP	1	
MUTAGEN:I->F: Strongly reduces production of IL1B in response to bacterial flagellin; then associated with I-11.	SEQ_UP	1	
MUTAGEN:I->G: No effect.	SEQ_UP	1	
MUTAGEN:I->K: Abolishes binding to MAPKAPK5.	SEQ_UP	2	
MUTAGEN:I->K: Loss of kinase activity. No effect on cell membrane location.	SEQ_UP	1	
MUTAGEN:I->K: Normal response to light but reduced retinal electrical activity in response to light in dark adapted retinas. Gross morphology is normal.	SEQ_UP	1	
MUTAGEN:I->L: No effect on interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:I->M: Increases 1-acylglycerol-3-phosphate O-acyltransferase activity 2-fold; promotes hepatic lipid synthesis.	SEQ_UP	1	
MUTAGEN:I->N: Abrogates kinase activity.	SEQ_UP	1	
MUTAGEN:I->N: Decreased protein abundance.	SEQ_UP	1	
MUTAGEN:I->N: Does not glycosylated.	SEQ_UP	1	
MUTAGEN:I->N: Does not rescue cortical neuron migration defects in PHACTR1 knocked-down mice.	SEQ_UP	1	
MUTAGEN:I->N: Hypomorphic allele. Abrogates interaction with EZH2 and impairs transcriptional repression.	SEQ_UP	1	
MUTAGEN:I->N: Knockin mice develop peripheral neuropathy that mimic the phenotype of intermediate forms of Charcot-Marie-Tooth disease. Knockin mice shown impairments in motor and neuromuscular functions, and aberrant myelination and axonal phenotypes.	SEQ_UP	1	
MUTAGEN:I->N: Loss of function mutant which is unable to promote clathrin coated-pits formation. Binds to membrane but is unable to induce membrane tubulation. Induces the formation of large and static clathrin-coated pits.	SEQ_UP	1	
MUTAGEN:I->N: Mediates autoprocessing but are unable to mediate cleavage of Gasdermin-D (GSDMD).	SEQ_UP	1	
MUTAGEN:I->N: Mice display postpartum failure of lactation and strongly reduced milk protein synthesis. Otherwise, mice develop normally and mammary glands are normal. The mutation causes an activation of the OAS2 pathway, characterized by a strong increase of Ribonuclease L (RNASEL) activity.	SEQ_UP	1	
MUTAGEN:I->N: Reduced ability to induce pyroptosis. No effect on protein expression. No effect on cleavage by CASP4.	SEQ_UP	1	
MUTAGEN:I->P: Greatly reduces MHC class I peptide tetramer binding; when associated with S-196.	SEQ_UP	1	
MUTAGEN:I->P: Increased PRKAR2A-binding; when associated with P-245.	SEQ_UP	1	
MUTAGEN:I->P: Loss of interaction with PPP1R12C and PPP1R12A.	SEQ_UP	1	
MUTAGEN:I->P: Loss of PRKAR2A-binding; when associated with P-197.	SEQ_UP	1	
MUTAGEN:I->Q: Increases intrinsic ATPase activity.	SEQ_UP	1	
MUTAGEN:I->Q: No effect on MHC class I peptide tetramer binding.	SEQ_UP	1	
MUTAGEN:I->R: Abolishes response to semaphorin.	SEQ_UP	1	
MUTAGEN:I->R: Decreased interaction with MAP4. No effect on interaction with IFT20.	SEQ_UP	1	
MUTAGEN:I->R: Impairs self-association and reduces protein stability.	SEQ_UP	1	
MUTAGEN:I->R: Strongly decreases adhesion to oocytes.	SEQ_UP	1	
MUTAGEN:I->S,N: Little activity (8-15%).	SEQ_UP	1	
MUTAGEN:I->S: Displays constitutive phospholipid scramblase activity.	SEQ_UP	1	
MUTAGEN:I->S: Disrupts interaction with VPS35.	SEQ_UP	1	
MUTAGEN:I->S: Impairs interaction with CDC42 and RHOQ and reduces insulin-stimulated translocation to the plasma membrane.	SEQ_UP	1	
MUTAGEN:I->S: In l11Jus1; embryos survive through implantation but fail prior to gastrulation. Cdkna1 expression is up-regulated while expression of several Wnt pathway members is down-regulated.	SEQ_UP	1	
MUTAGEN:I->S: Increases sulfotransferase activity.	SEQ_UP	1	
MUTAGEN:I->S: Loss of promotion of EKLF sumoylation.	SEQ_UP	1	
MUTAGEN:I->S: Partially impairs lipid-binding activity and hence PtdIns(4,5)P2 clustering.	SEQ_UP	1	
MUTAGEN:I->T: Causes myotonia.	SEQ_UP	1	
MUTAGEN:I->T: Causes paralysis and perinatal death in homozygous mice, apparently due to asphyxia. Mutant mice have greatly reduced and amorphous skeletal muscle.	SEQ_UP	1	
MUTAGEN:I->T: Does not affect ability to promote phosphatidylserine exposure.	SEQ_UP	1	
MUTAGEN:I->T: Embryos have congenital heart defects with transposition of the great artery, 61% exhibiting situs inversus or heterotaxy and 39% exhibiting situs solitus. This mutation corresponds to the pathological variant 'T-226' identified in humans.	SEQ_UP	1	
MUTAGEN:I->T: Gain-of-function mutation; causes an alopecia phenotype.	SEQ_UP	1	
MUTAGEN:I->T: Greatly reduces MHC class I peptide tetramer binding; when associated with N-225.	SEQ_UP	1	
MUTAGEN:I->T: In overtime (ovtm) mutant; loss of function, lengthening of the circadian periodiocity and Cry1 stabilization of protein levels.	SEQ_UP	1	
MUTAGEN:I->T: In Pgu; chronic motor incoordination; decreases the number of functional channels at the cell surface.	SEQ_UP	1	
MUTAGEN:I->T: No effect on protein abundance. No effect on cell surface localization. No effect on alanine uptake activity.	SEQ_UP	1	
MUTAGEN:I->T: No significant effect on lipid phosphatase activity.	SEQ_UP	1	
MUTAGEN:I->T: Reduced ATPase and helicase activities.	SEQ_UP	1	
MUTAGEN:I->T: Reduced potassium channel activity in knockin mice.	SEQ_UP	1	
MUTAGEN:I->V: Nearly full activity.	SEQ_UP	1	
MUTAGEN:I->V: No effect on cholesterol and sitosterol transport activity; when associated with G-196.	SEQ_UP	1	
MUTAGEN:I->V: No loss of repressor activity.	SEQ_UP	1	
MUTAGEN:I->V: Promotes the formation of differentiated late retinal amacrine cells.	SEQ_UP	1	
MUTAGEN:I->V: Significant reduction of apoptotic activity.	SEQ_UP	1	
MUTAGEN:I->V: Stimulates induction of neurite outgrowth and expression of synaptic genes. Abolishes the inhibitory effect on basal transcription and on gene activation by POU4F1.	SEQ_UP	1	
MUTAGEN:I->V: Strongly reduces interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:I->W: Decreased lipid scramblase activity.	SEQ_UP	1	
MUTAGEN:IE->AL: Changes substrate specificity so that stearate becomes a good substrate.	SEQ_UP	1	
MUTAGEN:IHES->DEDD: Constitutively active form; when associated with A-301.	SEQ_UP	1	
MUTAGEN:IHRL->AHRA: Accumulates in the nucleus. Exlcusively nuclear; when associated with 113-A--A-116 and 985-A--A-990.	SEQ_UP	1	
MUTAGEN:II->AA: Strongly reduced interaction with flagellin.	SEQ_UP	1	
MUTAGEN:IIF->AAA: Complete loss of ANK3-binding.	SEQ_UP	1	
MUTAGEN:IKP->AAA: Reduces the ability to traffic to the cilia. Reduces interaction with RAB8A. Does not affect interaction with ARF4.	SEQ_UP	1	
MUTAGEN:IL->AA: Abolishes CREBBP binding.	SEQ_UP	1	
MUTAGEN:IL->AA: Abolishes homodimerization; when associated with A-519.	SEQ_UP	1	
MUTAGEN:IL->AA: Impairs localization to secretory granules, promotes location at the plasma membrane, defective ind gamma endocytosis, highly decreases interaction with alpha- and gamma-type adaptin subunits.	SEQ_UP	1	
MUTAGEN:ILHRLL->AAHRAA: Abolishes interaction with RORC; when associated with 644-A-A-645 and 744-A--A-749.	SEQ_UP	1	
MUTAGEN:ILIVVPEIFL->AAAAAPEAAA: No interaction with SHH and no secretion of SHH.	SEQ_UP	1	
MUTAGEN:ILLV->ALLA: Reduced homoolimerization, leading to reduced ability to induce pyroptosis.	SEQ_UP	1	
MUTAGEN:IM->AA: Increases channel expression at the cell membrane, resulting in higher channel activity.	SEQ_UP	1	
MUTAGEN:IM->DN: Disrupts interaction with VPS35:VPS29 dimer; no endosomal localization.	SEQ_UP	2	
MUTAGEN:IM->FF: Increases membrane tubulation.	SEQ_UP	1	
MUTAGEN:IM->QQ: Abolishes membrane tubulation. No effect on phospholipid binding.	SEQ_UP	1	
MUTAGEN:IN->LH: Only binds to BoNT/B in presence of gangliosides.	SEQ_UP	1	
MUTAGEN:INI->NIN: Slows channel activation.	SEQ_UP	1	
MUTAGEN:INI->SDS: Nuclear and cytoplasmic location.	SEQ_UP	1	
MUTAGEN:IPRGNP->SGSGSG: Slightly decreased tethering to chromatin, leading to mild constitutive activation in the absence of DNA.	SEQ_UP	1	
MUTAGEN:IQ->AA: Loss of interaction with calmodulin.	SEQ_UP	1	
MUTAGEN:IQF->AQA: Inhibits SLC4A4 dephosphorylation by PP1 phosphatase and activity.	SEQ_UP	1	
MUTAGEN:IQIG->AAAA: In mRHIMA; abolished interaction with RIPK3 and subsequent necroptosis. In ZBP1(Mr1) knockin mice are viable and do not develop skin inflammation in response to lethal dose of influenza A virus (IAV).	SEQ_UP	1	
MUTAGEN:IRK->AAA: Abolishes interaction with PALS1.	SEQ_UP	1	
MUTAGEN:IS->AA: Does not abolish interaction with CDC42 and RHOQ.	SEQ_UP	1	
MUTAGEN:IS->AA: No binding with CDC42.	SEQ_UP	1	
MUTAGEN:ISL->SSV: Increased protein-cysteine S-stearoyltransferase activity.	SEQ_UP	1	
MUTAGEN:ISMLTGLFGATAGTIFVYGKDIKTDLNTVRKNMGVCMQHDVLFSYLTTKEHL LLYGSIKVPHWTKTQLHEEVKR->M: In a mouse model for harlequin ichthyosis (HI), smooth skin (smsk) mutant mice show a pronounced perinatal lethal skin phenotype in 25% of the offspring and newborn mutant pups die within a few hours after birth, and appear severely dehydrated with dry cracking skin. Smsk homozygous mutants embryos show a normal appearance at 14.5 dpc, but at 16.5 dpc develop a partial absence of normal skin folds around the trunk and limbs, and by 18.5 dpc develop a taut, thick skin and limb contractures.	SEQ_UP	1	
MUTAGEN:IVF->AAA: Decreases the affinity for CALM.	SEQ_UP	1	
MUTAGEN:IWY->AWA: Abolishes interaction with PTPRD; when associates with 82-A--A-85. Significantly reduces synaptogenesis; when associates with 82-A--A-85.	SEQ_UP	1	
MUTAGEN:K->A,D: Does not induce a nuclear accumulation in unstimulated cells.	SEQ_UP	1	
MUTAGEN:K->A,E: Strongly reduced interaction with SPIRE1.	SEQ_UP	1	
MUTAGEN:K->A,G: No effect on 'Lys-48'-linked polyubiquitin binding.	SEQ_UP	1	
MUTAGEN:K->A,G: Strongly reduced 2'-5'-oligoadenylate synthase activity.	SEQ_UP	1	
MUTAGEN:K->A,H: Abolishes enzyme activity.	SEQ_UP	1	
MUTAGEN:K->A,L,M: Loss of DNA binding.	SEQ_UP	1	
MUTAGEN:K->A,M: Loss of protection against viral infection.	SEQ_UP	1	
MUTAGEN:K->A,Q: Decreased permeability to chloride ions.	SEQ_UP	1	
MUTAGEN:K->A,Q: Greatly reduced interaction with RXRA and NCOR1 and transcriptional activation.	SEQ_UP	1	
MUTAGEN:K->A,Q: No effect on interaction with EP300.	SEQ_UP	1	
MUTAGEN:K->A,R,S,T: Loss of activity.	SEQ_UP	1	
MUTAGEN:K->A,R: Abrogates L-rhamnose binding.	SEQ_UP	1	
MUTAGEN:K->A,R: Loss of kinase activity.	SEQ_UP	1	
MUTAGEN:K->A,R: No effect on DNA binding. No change in transactivation activity. No loss of superactivation by CBP or EP300.	SEQ_UP	1	
MUTAGEN:K->A,R: No effect on DNA binding. Transactivation activity reduced by 50%. Loss of superactivation by CBP of EP300.	SEQ_UP	1	
MUTAGEN:K->A,R: Strongly reduced catalytic activity.	SEQ_UP	1	
MUTAGEN:K->A: 3-fold increase in Km for CoA.	SEQ_UP	1	
MUTAGEN:K->A: Abolished ability to inhibit T-cell activation.	SEQ_UP	1	
MUTAGEN:K->A: Abolished ceramide synthase activity.	SEQ_UP	1	
MUTAGEN:K->A: Abolished mono-ADP-ribosylation by SIRT6 and recruitment to the enhancer region of the Heme oxygenase-1 (HO-1) locus.	SEQ_UP	1	
MUTAGEN:K->A: Abolished mono-ADP-ribosylation by SIRT6.	SEQ_UP	1	
MUTAGEN:K->A: Abolished oligomerization without affecting interaction with KEAP1; when associated with A-69.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes ApoER2-binding.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes ATP-binding.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes binding to HRAS and KRAS; does not affect kinase activity; displays defective development of the lymphatic vasculature, resulting in perinatal appearance of chylous ascites and is highly resistant to endogenous Ras oncogene-induced tumorigenesis; when associated with D-208.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes binding to PtdIns(4,5)P2.	SEQ_UP	2	
MUTAGEN:K->A: Abolishes DNA-binding.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes endoribonuclease activity.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes enzymatic activity.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes glucocorticoid-mediated degradation and enhances transcription trans-activation.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes IFNB1 production upon infection with various viruses.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes inhibition of retrotransposition.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes interaction with HSP90.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes interaction with phosphatidylinositol 4,5-bisphosphate and reduces secretion by 40%; when associated with A-332.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes interaction with RAB9A.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes interaction with the SH3 domain of STAM2.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes interaction with TYROBP or FcR gamma.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes ligand-induced translocation to the nucleus; when associated with A-22 and A-31.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes ligand-induced translocation to the nucleus; when associated with A-31 and A-32.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes linear polyubiquitin-binding, impairs 'Lys-63'-linked polyubiquitin-binding and impairs NF-kappa-B activation; when associated with A-293 and A-301.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes lipid droplet enlargement activity, but not localization to lipid droplets, nor enrichement at contact sites; when associated with A-182 and A-190.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes lipid droplet enlargement activity, but not localization to lipid droplets, nor enrichement at contact sites; when associated with A-186 and A-190.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes localization to microtubules.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes localization to phagocytic cups; when associated with A-893.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes LPC transport.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes most of the nuclear localization and reduces transcriptional repressor activity; when associated with A-10.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes most of the nuclear localization and reduces transcriptional repressor activity; when associated with A-11.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes nuclear localization.	SEQ_UP	2	
MUTAGEN:K->A: Abolishes phosphatidylinositol 3,4,5-trisphosphate binding.	SEQ_UP	2	
MUTAGEN:K->A: Abolishes phosphoinositide-binding of C-terminus; when associated with A-152, A-160 and A-161.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes phosphoinositide-binding of C-terminus; when associated with A-158, A-160 and A-161.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes RNA-binding activity but not AR-mediated transcription coactivation; when associated with A-118; A-120 and A-199.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes sumoylation. Strongly associated with PML nuclear bodies. No effect on activation of OCT4 but activation not suppressed by additional SUMO1. Increased binding to KAT2B and reduced binding to NRIP1. Abolishes PML association; when associated with A-210.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes the binding to PDCD1.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes the enzymatic activity.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes the nuclear localization but does not affect the enzyme activity; when associated with A-201.	SEQ_UP	1	
MUTAGEN:K->A: Abolishes ubiquitin phosphorylation; when associated with A-361 and A-383.	SEQ_UP	1	
MUTAGEN:K->A: Abrogates nuclear localization.	SEQ_UP	1	
MUTAGEN:K->A: Abrogates RNA-binding by DRBM 3 and interaction with XPO5 and nuclear export; when associated with A-235.	SEQ_UP	1	
MUTAGEN:K->A: Almost complete loss of 1-phosphatidylinositol-4-phosphate 5-kinase activity.	SEQ_UP	1	
MUTAGEN:K->A: Almost complete loss of RNA-binding and loss of GTase activity.	SEQ_UP	1	
MUTAGEN:K->A: Apoptotic cell corpse-containing phagosomes fail to mature into acidic phagosomes. Loss of PIK3C3 and RAB5A recruitment to phagosomes.	SEQ_UP	1	
MUTAGEN:K->A: Binds PtdIns(4,5)P2 at wild-type level.	SEQ_UP	1	
MUTAGEN:K->A: Blocks internalization from cell surface; when associated with A-27.	SEQ_UP	1	
MUTAGEN:K->A: Capable of nicking but defective for hairpinning.	SEQ_UP	1	
MUTAGEN:K->A: Catalytically inactive mutant. Homozygous knockin male mice are sterile and display meiotic arrest at the zygotene-like stage of prophase I. LINE1 retrotransposons are derepressed and piRNA biogenesis is abolished.	SEQ_UP	1	
MUTAGEN:K->A: Complete loss of homooligomerization, lipid-binding, relocalization of Gasdermin-D, N-terminal to the plasma membrane and pyroptosis, as well as loss of bactericidal activity; when associated with A-138 or with S-138; A-152 and A-154. Partial loss of homooligomerization and pyroptosis; when associated with A-138, with A-152 or with A-152 and A-154.	SEQ_UP	1	
MUTAGEN:K->A: Complete loss of induced necrosis.	SEQ_UP	1	
MUTAGEN:K->A: Constitutive enzyme activity that is fully active also in the absence phosphate. Forms oligomers with full, phosphate-independent activity; when associated with K-391. Forms dimers with full, phosphate-independent activity; when associated with Q-316 and K-391.	SEQ_UP	1	
MUTAGEN:K->A: Constitutively active. Binds GTP but fails to hydrolyze it. Does not localize to the parasitophorous vacuole membrane following T.gondii infection.	SEQ_UP	1	
MUTAGEN:K->A: Decreased ability to bind heterodimeric capping protein (CP) and to inhibit the actin-capping activity of CP.	SEQ_UP	1	
MUTAGEN:K->A: Decreased cholesterol binding. Nearly abolishes cholesterol transport activity.	SEQ_UP	1	
MUTAGEN:K->A: Decreased cholesterol binding. Strongly decreased cholesterol transport activity.	SEQ_UP	1	
MUTAGEN:K->A: Decreased DNA-binding and abolished homodimerization. Does not affect nuclear localization and tethering to chromatin.	SEQ_UP	1	
MUTAGEN:K->A: Decreased interaction with BCL10.	SEQ_UP	1	
MUTAGEN:K->A: Decreased permeability to chloride ions.	SEQ_UP	1	
MUTAGEN:K->A: Decreased protein expression and stability.	SEQ_UP	1	
MUTAGEN:K->A: Decreased protein expression and stability. Decreased embryonic stem cell self-renewal.	SEQ_UP	1	
MUTAGEN:K->A: Decreased protein stability.	SEQ_UP	1	
MUTAGEN:K->A: Decreased receptor activity in response to MTMT binding, even in the presence of copper.	SEQ_UP	1	
MUTAGEN:K->A: Decreased sphingosine-1-phosphate transport.	SEQ_UP	1	
MUTAGEN:K->A: Decreased sumoylation followed by increased ubiquitination; when associated with A-858.	SEQ_UP	1	
MUTAGEN:K->A: Decreased sumoylation followed by increased ubiquitination; when associated with A-861.	SEQ_UP	1	
MUTAGEN:K->A: Decreases adhesion to oocytes.	SEQ_UP	1	
MUTAGEN:K->A: Decreases DNA-binding. No effect on transcriptional repression.	SEQ_UP	1	
MUTAGEN:K->A: Decreases PER1 phosphorylation.	SEQ_UP	1	
MUTAGEN:K->A: Decreases phosphodiesterase activity by 40%. Decreased formation of nucleotidylated intermediate.	SEQ_UP	1	
MUTAGEN:K->A: Decreases the enzymatic activity.	SEQ_UP	1	
MUTAGEN:K->A: Disrupts binding to plasminogen.	SEQ_UP	1	
MUTAGEN:K->A: Disrupts pericentromeric heterochromatin location. Partial cytoplasmic location.	SEQ_UP	1	
MUTAGEN:K->A: Does not abolish the interaction with PKCA.	SEQ_UP	1	
MUTAGEN:K->A: Does not affect histone-lysine N-methyltransferase activity. Does not affect protein-lysine N-methyltransferas activity.	SEQ_UP	1	
MUTAGEN:K->A: Does not affect histone-lysine N-methyltransferase activity. Does not affect protein-lysine N-methyltransferase activity.	SEQ_UP	1	
MUTAGEN:K->A: Does not affect interaction with ATP2A1.	SEQ_UP	1	
MUTAGEN:K->A: Does not affect interaction with the SH3 domain of STAM2.	SEQ_UP	1	
MUTAGEN:K->A: Does not affect mono-ADP-ribosylation by SIRT6.	SEQ_UP	1	
MUTAGEN:K->A: Does not affect phosphatase activity. Loss of phosphatase activity; when associated with A-294 and A-295. Does not affect interaction with MAPK1.	SEQ_UP	1	
MUTAGEN:K->A: Does not affect recognition by the CRL2(FEM1B) complex and subsequent ubiquitination.	SEQ_UP	1	
MUTAGEN:K->A: Does not affect the interaction with GATA1.	SEQ_UP	1	
MUTAGEN:K->A: Does not inhibit calcium-dependent translocation to the cell membrane; when associated with A-272 and A-273.	SEQ_UP	1	
MUTAGEN:K->A: Does not inhibit calcium-dependent translocation to the cell membrane; when associated with A-272 and A-274.	SEQ_UP	1	
MUTAGEN:K->A: Does not inhibit calcium-dependent translocation to the cell membrane; when associated with A-273 and A-274.	SEQ_UP	1	
MUTAGEN:K->A: Does not inhibit interaction with OAZ1. Reduces interaction with OAZ1; when associated with A-116. Strongly reduces interaction with OAZ1 and unable to abrogate the inhibitory effect of OAZ1 on ornithine decarboxylase (ODC) activity and polyamine uptake; when associated with A-139 and A-140.	SEQ_UP	1	
MUTAGEN:K->A: Does not inhibit interaction with OAZ1. Reduces interaction with OAZ1; when associated with A-142.	SEQ_UP	1	
MUTAGEN:K->A: Dominant negative.	SEQ_UP	1	
MUTAGEN:K->A: Greatly reduces transcriptional activity and estrogen-induced interaction with NCOA1.	SEQ_UP	1	
MUTAGEN:K->A: Impaired ability to homooligomerize at 30 degrees Celsius.	SEQ_UP	1	
MUTAGEN:K->A: Impaired interaction with the AP-2 complex and impaired TCR down-modulation and recycling in TH2 cells; when associated with 547-A--A-549.	SEQ_UP	1	
MUTAGEN:K->A: Impaired membrane association in neurons; when associated with A-151; A-162; A-167 and A-172.	SEQ_UP	1	
MUTAGEN:K->A: Impaired membrane association in neurons; when associated with A-155; A-162; A-167 and A-172.	SEQ_UP	1	
MUTAGEN:K->A: Impaired tail-anchored protein insertion and a shift from GET1-CAMLG heterotetramerization to formation of heterodimers but does not affect recruitment of GET3 to the endoplasmic reticulum; when associated with A-202.	SEQ_UP	1	
MUTAGEN:K->A: Impairs ATP-binding inducing a 80% decrease in enzyme activity.	SEQ_UP	1	
MUTAGEN:K->A: Impairs autoinhibition; when associated with A-385. Impairs translocation to the cell membrane.	SEQ_UP	1	
MUTAGEN:K->A: Impairs autoinhibition; when associated with A-388.	SEQ_UP	1	
MUTAGEN:K->A: Impairs binding to and processing of 5.8S rRNA; when associated with A-107.	SEQ_UP	1	
MUTAGEN:K->A: Impairs binding to and processing of 5.8S rRNA; when associated with A-108.	SEQ_UP	1	
MUTAGEN:K->A: Impairs binding to PtdIns(4,5)P2.	SEQ_UP	1	
MUTAGEN:K->A: Impairs interaction of the first PDZ domain with SCARB1.	SEQ_UP	1	
MUTAGEN:K->A: Impairs lipid-binding activity and hence PtdIns(4,5)P2 clustering; when associated with A-109.	SEQ_UP	1	
MUTAGEN:K->A: Impairs lipid-binding activity and hence PtdIns(4,5)P2 clustering; when associated with A-116.	SEQ_UP	1	
MUTAGEN:K->A: Impairs lipid-binding activity and hence PtdIns(4,5)P2 clustering; when associated with A-127.	SEQ_UP	1	
MUTAGEN:K->A: Impairs lipid-binding activity and hence PtdIns(4,5)P2 clustering; when associated with A-145 and A-147.	SEQ_UP	1	
MUTAGEN:K->A: Impairs RNA binding and mitochondrial translation; when associated with A-88.	SEQ_UP	1	
MUTAGEN:K->A: Impairs RNA binding and mitochondrial translation; when associated with A-92.	SEQ_UP	1	
MUTAGEN:K->A: Impairs the ability to rescue growth in cdc25ts mutant yeasts.	SEQ_UP	1	
MUTAGEN:K->A: Impairs the ability to resucue growth in cdc25ts mutant yeasts.	SEQ_UP	1	
MUTAGEN:K->A: In kinase dead mutant; lacks kinase activity. Overexpression inhibits insulin-stimulated translocation of SLC2A4/GLUT4 in a dominant negative manner.	SEQ_UP	1	
MUTAGEN:K->A: Increased radiosensitivity. No effect on phosphorylation after DNA damage. No effect on Ser-140 phosphorylation, nor on TP53BP1 recruitment to DNA double-strand breaks.	SEQ_UP	1	
MUTAGEN:K->A: Increased stability due to impaired ubiquitination; when associated with A-254 and A-300.	SEQ_UP	1	
MUTAGEN:K->A: Increased stability due to impaired ubiquitination; when associated with A-254 and A-327.	SEQ_UP	1	
MUTAGEN:K->A: Increased stability due to impaired ubiquitination; when associated with A-300 and A-327.	SEQ_UP	1	
MUTAGEN:K->A: Increased stability.	SEQ_UP	1	
MUTAGEN:K->A: Increases catalytic efficiency.	SEQ_UP	1	
MUTAGEN:K->A: Increases localization at the cell surface when expressed in absence of PKD1.	SEQ_UP	1	
MUTAGEN:K->A: Inhibits binding to PIP2 and disrupts membrane binding.	SEQ_UP	1	
MUTAGEN:K->A: Inhibits interaction with PLIN1; when associated with A-75.	SEQ_UP	1	
MUTAGEN:K->A: Inhibits interaction with PLIN1; when associated with A-77.	SEQ_UP	1	
MUTAGEN:K->A: Inhibits prenylation activity. In myoblasts, impaired insulin-induced RAC1 activation, possibly due to impaired insulin-induced geranyl-geranyltransferase activation. No effect on MUSK-binding.	SEQ_UP	1	
MUTAGEN:K->A: Inhibits Schwann cell peripheral myelination; when associated with A-831; A-848 and A-1327.	SEQ_UP	1	
MUTAGEN:K->A: Inhibits Schwann cell peripheral myelination; when associated with A-831; A-848 and A-881.	SEQ_UP	1	
MUTAGEN:K->A: Inhibits Schwann cell peripheral myelination; when associated with A-831; A-881 and A-1327.	SEQ_UP	1	
MUTAGEN:K->A: Inhibits Schwann cell peripheral myelination; when associated with A-848; A-881 and A-1327.	SEQ_UP	1	
MUTAGEN:K->A: Loss of actin-binding.	SEQ_UP	1	
MUTAGEN:K->A: Loss of activity and autophosphorylation.	SEQ_UP	1	
MUTAGEN:K->A: Loss of activity.	SEQ_UP	2	
MUTAGEN:K->A: Loss of alpha-tubulin alpha-elongation step of polyglutamylase activity.	SEQ_UP	1	
MUTAGEN:K->A: Loss of ATP hydrolysis.	SEQ_UP	1	
MUTAGEN:K->A: Loss of autophosphorylation.	SEQ_UP	1	
MUTAGEN:K->A: Loss of binding activity.	SEQ_UP	2	
MUTAGEN:K->A: Loss of catalytic activity; when associated with S-217 and A-378. Abolishes binding to UDP-GlcNAc; when associated with S-217.	SEQ_UP	1	
MUTAGEN:K->A: Loss of catalytic activity.	SEQ_UP	1	
MUTAGEN:K->A: Loss of exonuclease activity.	SEQ_UP	1	
MUTAGEN:K->A: Loss of GTase activity.	SEQ_UP	1	
MUTAGEN:K->A: Loss of interaction with DLC2.	SEQ_UP	1	
MUTAGEN:K->A: Loss of kinase activity; no effect on FIZ1-binding.	SEQ_UP	1	
MUTAGEN:K->A: Loss of kinase activity.	SEQ_UP	8	
MUTAGEN:K->A: Loss of kinase activity. No effect on colocalization with microtubules.	SEQ_UP	1	
MUTAGEN:K->A: Loss of kinase activity. Protects cells from TNF-induced cell death.	SEQ_UP	1	
MUTAGEN:K->A: Loss of microtubule depolymerization activity.	SEQ_UP	1	
MUTAGEN:K->A: Loss of oligomerization. Strongly reduced activation of Wnt signaling.	SEQ_UP	1	
MUTAGEN:K->A: Loss of phosphorylation.	SEQ_UP	1	
MUTAGEN:K->A: Loss of self-renewal in embryonic stem cells in absence of LIF. Does not interact with NCOA3.	SEQ_UP	1	
MUTAGEN:K->A: Loss of sulfotransferase activity (at pH 7.5).	SEQ_UP	1	
MUTAGEN:K->A: Loss of tocopherol secretion (in vivo). No effect on tocopherol binding and intermembrane transfer (in vitro).	SEQ_UP	1	
MUTAGEN:K->A: Loss of ubiquitination. No loss of interaction with DDB1-CUL4A complex.	SEQ_UP	1	
MUTAGEN:K->A: Mildly reduces affinity for ADP.	SEQ_UP	1	
MUTAGEN:K->A: Moderately decreased Th2 cell differentiation.	SEQ_UP	1	
MUTAGEN:K->A: Moderately defective with 56% of activity.	SEQ_UP	1	
MUTAGEN:K->A: Nearly abolishes enzyme activity.	SEQ_UP	1	
MUTAGEN:K->A: No activity.	SEQ_UP	1	
MUTAGEN:K->A: No ATPase activity.	SEQ_UP	1	
MUTAGEN:K->A: No change in rates of factor Xa inhibition.	SEQ_UP	1	
MUTAGEN:K->A: No effect on affinity for androstenedione. Slight increase of catalytic activity.	SEQ_UP	1	
MUTAGEN:K->A: No effect on binding to MAD.	SEQ_UP	1	
MUTAGEN:K->A: No effect on carbohydrate binding.	SEQ_UP	1	
MUTAGEN:K->A: No effect on CDE RNA-binding.	SEQ_UP	1	
MUTAGEN:K->A: No effect on cellular location.	SEQ_UP	1	
MUTAGEN:K->A: No effect on channel pore properties.	SEQ_UP	1	
MUTAGEN:K->A: No effect on cholesterol binding. Strongly decreased cholesterol transport activity.	SEQ_UP	1	
MUTAGEN:K->A: No effect on deacetylase activity. Loss of sulfotransferase activity.	SEQ_UP	1	
MUTAGEN:K->A: No effect on DENND1A-,DENND1B- nor DENND1C-binding.	SEQ_UP	1	
MUTAGEN:K->A: No effect on IL1B release under basal conditions, nor in response to LT or metabolic inhibitors; when associated with A-734.	SEQ_UP	1	
MUTAGEN:K->A: No effect on interaction with PER2.	SEQ_UP	1	
MUTAGEN:K->A: No effect on interaction with SQSTM1; when associated with A-118.	SEQ_UP	1	
MUTAGEN:K->A: No effect on interaction with TACC3.	SEQ_UP	1	
MUTAGEN:K->A: No effect on lipid scramblase activity.	SEQ_UP	1	
MUTAGEN:K->A: No effect on lipid-binding; when associated with A-149 and A-152.	SEQ_UP	1	
MUTAGEN:K->A: No effect on lipid-binding; when associated with A-152 and A-155.	SEQ_UP	1	
MUTAGEN:K->A: No effect on pericentromeric heterochromatin location. No change in DNA binding.	SEQ_UP	1	
MUTAGEN:K->A: No effect on phospholipid-binding.	SEQ_UP	1	
MUTAGEN:K->A: No effect on protein abundance.	SEQ_UP	1	
MUTAGEN:K->A: No effect on protein stability; when associated with A-226. Drastically increased protein stability and decreased ubiquitination; when associated with A-224 and A-236.	SEQ_UP	1	
MUTAGEN:K->A: No effect on protein stability; when associated with A-226. Drastically increased protein stability and decreased ubiquitination; when associated with A-226 and A-236.	SEQ_UP	1	
MUTAGEN:K->A: No effect on protein stability. Drastically increased protein stability and decreased ubiquitination; when associated with A-224 and A-226.	SEQ_UP	1	
MUTAGEN:K->A: No effect on pyroptosis; when associated with A-237; A-239 and A-248.	SEQ_UP	1	
MUTAGEN:K->A: No effect on pyroptosis; when associated with A-239 or with A-239; A-248 and A-249.	SEQ_UP	1	
MUTAGEN:K->A: No effect on radiosensitivity; when associated with A-10, A-14 and A-16.	SEQ_UP	1	
MUTAGEN:K->A: No effect on radiosensitivity; when associated with A-6, A-10 and A-14.	SEQ_UP	1	
MUTAGEN:K->A: No effect on radiosensitivity; when associated with A-6, A-10 and A-16.	SEQ_UP	1	
MUTAGEN:K->A: No effect on radiosensitivity; when associated with A-6, A-14 and A-16.	SEQ_UP	1	
MUTAGEN:K->A: No effect on sumoylation.	SEQ_UP	1	
MUTAGEN:K->A: No effect.	SEQ_UP	1	
MUTAGEN:K->A: No fibulin-1C binding. No change to fibulin-2 binding.	SEQ_UP	1	
MUTAGEN:K->A: No loss of interaction with GYS2.	SEQ_UP	1	
MUTAGEN:K->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-274.	SEQ_UP	1	
MUTAGEN:K->A: No UBE2I binding nor sumoylation.	SEQ_UP	1	
MUTAGEN:K->A: Partial loss of autocatalytic kinase activity. Complete loss of kinase activity and of nuclear localization; when associated with A-271 and A-272.	SEQ_UP	1	
MUTAGEN:K->A: Partial loss of cleavage by LT and of LT-induced IL1B processing. Loss of cleavage by LT and of LT-induced IL1B processing; when associated with Q-43 and Q-45. No effect on IL1B release in response to metabolic inhibitors; when associated with Q-43 and Q-45.	SEQ_UP	1	
MUTAGEN:K->A: Partial loss of kinase activity. Complete loss of kinase activity and of nuclear localization; when associated with A-270 and A-272.	SEQ_UP	1	
MUTAGEN:K->A: Progressive loss of motor neurons, axonal motor neuropathy, and muscle paralysis leading to death within hours of birth. Mice exhibit microcephaly due to reduced numbers of cortical neurons. Embryos have normal numbers and proliferation of neuronal progenitors, but neuronal progenitor cells undergo enhanced cell death, resulting in reduced numbers of cortical neurons.	SEQ_UP	1	
MUTAGEN:K->A: Reduced ATPase and helicase activities.	SEQ_UP	1	
MUTAGEN:K->A: Reduced autocatalytic cleavage. Strongly reduced autocatalytic cleavage; when associated with A-196. Strongly reduced autocatalytic cleavage; when associated with A-196 and 190-A-A-191.	SEQ_UP	1	
MUTAGEN:K->A: Reduced hairpin activity.	SEQ_UP	1	
MUTAGEN:K->A: Reduced interaction with HRAS.	SEQ_UP	1	
MUTAGEN:K->A: Reduced interaction with SPSB2.	SEQ_UP	1	
MUTAGEN:K->A: Reduced sumoylation levels. No effect on DNA-binding and slight reduction of transcriptional repression. Abolishes sumoylation. No effect on DNA-binding but great reduction in transcriptional repression; when associated with A-197.	SEQ_UP	1	
MUTAGEN:K->A: Reduced sumoylation levels. No effect on DNA-binding and slight reduction of transcriptional repression. Abolishes sumoylation. No effect on DNA-binding but great reduction of transcriptional repression; when associated with A-10.	SEQ_UP	1	
MUTAGEN:K->A: Reduces activity about 3-fold.	SEQ_UP	1	
MUTAGEN:K->A: Reduces affinity for PTPRD.	SEQ_UP	1	
MUTAGEN:K->A: Reduces calcium flux by about 50%.	SEQ_UP	1	
MUTAGEN:K->A: Reduces DNA binding.	SEQ_UP	1	
MUTAGEN:K->A: Reduces interaction with NUP88.	SEQ_UP	1	
MUTAGEN:K->A: Reduces interaction with PER2 by 60%.	SEQ_UP	1	
MUTAGEN:K->A: Reduces oligomerization. Reduces activation of Wnt signaling.	SEQ_UP	1	
MUTAGEN:K->A: Reduces phosphatidylinositol 3,4,5-trisphosphate binding.	SEQ_UP	1	
MUTAGEN:K->A: Severe decrease of interaction with BTG4.	SEQ_UP	1	
MUTAGEN:K->A: Slightly affects interaction with MLKL; when associated with A-236. Affects interaction with MLKL; when associated with A-232 and A-236.	SEQ_UP	1	
MUTAGEN:K->A: Slightly decreased interaction with BCL10.	SEQ_UP	1	
MUTAGEN:K->A: Slightly inhibits interaction with PLIN1; when associated with A-112 or A-117.	SEQ_UP	1	
MUTAGEN:K->A: Slightly inhibits interaction with PLIN1; when associated with A-115.	SEQ_UP	1	
MUTAGEN:K->A: Slightly inhibits interaction with PLIN1.	SEQ_UP	1	
MUTAGEN:K->A: Spontaneous IL1B release under basal conditions, loss of response to metabolic inhibitors and to LT; when associated with A-659.	SEQ_UP	1	
MUTAGEN:K->A: Spontaneous IL1B release under basal conditions, loss of response to metabolic inhibitors, no effect on the response to LT; when associated with A-663.	SEQ_UP	1	
MUTAGEN:K->A: Strongly decrease the enzymatic activity.	SEQ_UP	1	
MUTAGEN:K->A: Strongly decreases CDE and ADE RNA-binding. Increases target-mRNA expression. Increases ICOS surface expression; when associated with A-239 and A-260.	SEQ_UP	1	
MUTAGEN:K->A: Strongly decresases CDE and ADE RNA-binding.	SEQ_UP	1	
MUTAGEN:K->A: Strongly decresases CDE and ADE RNA-binding. Increases target-mRNA expression. Abolishes CDE RNA-binding and highly increases target-mRNA expression; when associated with A-260. Increases target-mRNA expression. Increases ICOS surface expression; when associated with A-220 and A-260.	SEQ_UP	1	
MUTAGEN:K->A: Strongly reduced binding affinity for INPPL1 SAM domain.	SEQ_UP	1	
MUTAGEN:K->A: Strongly reduced binding affinity for SAMD5 SAM domain.	SEQ_UP	1	
MUTAGEN:K->A: Strongly reduced estrogen sulfotransferase activity. Strongly reduced affinity for estradiol.	SEQ_UP	1	
MUTAGEN:K->A: Strongly reduced interaction with HRAS.	SEQ_UP	1	
MUTAGEN:K->A: Strongly reduced RNA binding.	SEQ_UP	1	
MUTAGEN:K->A: Strongly reduces affinity for DNA; when associated with A-166; W-226 and A-227.	SEQ_UP	1	
MUTAGEN:K->A: Strongly reduces affinity for DNA; when associated with A-187 and A-189.	SEQ_UP	1	
MUTAGEN:K->A: Strongly reduces affinity for DNA; when associated with A-187 and A-198.	SEQ_UP	1	
MUTAGEN:K->A: Strongly reduces affinity for DNA; when associated with A-48 and W-54.	SEQ_UP	1	
MUTAGEN:K->A: Strongly reduces affinity for DNA; when associated with A-53 and W-54.	SEQ_UP	1	
MUTAGEN:K->A: Strongly reduces affinity for DNA; when associated with A-76 and A-236.	SEQ_UP	1	
MUTAGEN:K->A: Strongly reduces affinity for DNA; when associated with A-79 and A-236.	SEQ_UP	1	
MUTAGEN:K->A: Strongly reduces phosphatidylinositol 3,4,5-trisphosphate binding.	SEQ_UP	1	
MUTAGEN:K->A: Sustantial reduction in nuclear localization and loss of XDH induction; when associated with A-23.	SEQ_UP	1	
MUTAGEN:K->A: Sustantial reduction in nuclear localization and loss of XDH induction; when associated with A-24.	SEQ_UP	1	
MUTAGEN:K->A: Unable to inhibit TORC1 signaling; when associated with A-419 and A-422.	SEQ_UP	1	
MUTAGEN:K->A: Unable to inhibit TORC1 signaling; when associated with A-419 and A-426.	SEQ_UP	1	
MUTAGEN:K->A: Very strong reduction of the interaction with HRAS.	SEQ_UP	1	
MUTAGEN:K->C: No effect on carbonate dehydratase activity.	SEQ_UP	1	
MUTAGEN:K->D,E: Strongly reduces FBXL3 binding. Reduces PER2 binding.	SEQ_UP	1	
MUTAGEN:K->D: Abolished interaction with SLC25A4/ANT1.	SEQ_UP	1	
MUTAGEN:K->D: Abolishes interaction with GBA. No effect on normal location in lysosomes.	SEQ_UP	1	
MUTAGEN:K->D: Abolishes localization at the plasma membrane; abolishes increase of intrinsic ATPase activity upon interaction with membranes.	SEQ_UP	1	
MUTAGEN:K->D: Abolishes localization at the plasma membrane; reduces increase of intrinsic ATPase activity upon interaction with membranes.	SEQ_UP	1	
MUTAGEN:K->D: Abolishes localization at the plasma membrane.	SEQ_UP	1	
MUTAGEN:K->D: Abolishes transcriptional activity and estrogen-induced interaction with NCOA1.	SEQ_UP	1	
MUTAGEN:K->D: Catalytically inactive form.	SEQ_UP	1	
MUTAGEN:K->D: Decreases HRE DNA binding; when associated with D-184.	SEQ_UP	1	
MUTAGEN:K->D: Loss of antimicrobial activity; when associated with A-96.	SEQ_UP	1	
MUTAGEN:K->D: Loss of localization to membranes, reduced binding to phosphatidic acid.	SEQ_UP	1	
MUTAGEN:K->D: Reduced specificity for HRAS and diminished discrimination between HRAS and RAP1A.	SEQ_UP	1	
MUTAGEN:K->D: Retains 50% of activity; when associated with 69-Q-T-70 and K-77. Loss of function; when associated with Q-55; A-56 and K-77.	SEQ_UP	1	
MUTAGEN:K->D: Significantly reduces binding affinities of the AHR?ARNT heterodimer to DRE.	SEQ_UP	1	
MUTAGEN:K->DT: Confers virus infectibility.	SEQ_UP	1	
MUTAGEN:K->E: 50% reduced binding to LRP6.	SEQ_UP	1	
MUTAGEN:K->E: Abolished ADP:ATP antiporter activity without affecting ability to regulate mitophagy; when associated with E-244.	SEQ_UP	1	
MUTAGEN:K->E: Abolished protein serine/threonine kinase activity.	SEQ_UP	1	
MUTAGEN:K->E: Abolishes binding to TELO2-phosphopeptide.	SEQ_UP	1	
MUTAGEN:K->E: Abolishes enzymatic activity.	SEQ_UP	1	
MUTAGEN:K->E: Abolishes interaction with NCOR2.	SEQ_UP	1	
MUTAGEN:K->E: Abolishes kinase activity. Reduces tyrosine phosphorylation by 90%; when associated with F-471.	SEQ_UP	1	
MUTAGEN:K->E: Abolishes membrane tubulation; when associated with E-127.	SEQ_UP	1	
MUTAGEN:K->E: Abolishes membrane tubulation; when associated with E-130.	SEQ_UP	1	
MUTAGEN:K->E: Abolishes nuclear localization; when associated with E-41.	SEQ_UP	1	
MUTAGEN:K->E: Abolishes nuclear localization; when associated with E-43.	SEQ_UP	1	
MUTAGEN:K->E: Abolishes nuclear translocation.	SEQ_UP	1	
MUTAGEN:K->E: Abolishes nuclear translocation. Prolongs Ca(2+) oscillations allowing them to occur during interphase.	SEQ_UP	1	
MUTAGEN:K->E: Abolishes the interaction with RAP6A and localization to Golgi membrane.	SEQ_UP	1	
MUTAGEN:K->E: Abrogates DNA-binding.	SEQ_UP	1	
MUTAGEN:K->E: Complete loss of LPS-binding, LPS-induced oligomerization, and LPS-induced pyroptosis; when associated with E-54 and A-55.	SEQ_UP	1	
MUTAGEN:K->E: Constitutively activated kinase.	SEQ_UP	1	
MUTAGEN:K->E: Decreased DNA-binding and subsequent activation. Does not affect nuclear localization and tethering to chromatin.	SEQ_UP	1	
MUTAGEN:K->E: Decreased monoglycylation activity; when associated with E-106.	SEQ_UP	1	
MUTAGEN:K->E: Decreased monoglycylation activity; when associated with E-96.	SEQ_UP	1	
MUTAGEN:K->E: Decreased monoglycylation activity.	SEQ_UP	1	
MUTAGEN:K->E: Decreased sumoylation; when associated with E-361; E-573; E-664; E-935 and E-1013.	SEQ_UP	1	
MUTAGEN:K->E: Decreased sumoylation; when associated with E-361; E-573; E-664; E-935 and E-961.	SEQ_UP	1	
MUTAGEN:K->E: Decreased sumoylation; when associated with E-361; E-573; E-664; E-961 and E-1013.	SEQ_UP	1	
MUTAGEN:K->E: Decreased sumoylation; when associated with E-361; E-573; E-935; E-961 and E-1013.	SEQ_UP	1	
MUTAGEN:K->E: Decreased sumoylation; when associated with E-361; E-664; E-935; E-961 and E-1013.	SEQ_UP	1	
MUTAGEN:K->E: Decreased sumoylation; when associated with E-573; E-664; E-935; E-961 and E-1013.	SEQ_UP	1	
MUTAGEN:K->E: Decreases affinity for membranes.	SEQ_UP	1	
MUTAGEN:K->E: Defective in Ca(2+) oscillation activity and loss of nuclear translocation.	SEQ_UP	1	
MUTAGEN:K->E: Defects in otoconia biogenesis.	SEQ_UP	1	
MUTAGEN:K->E: Disrupts interaction with PRDM14.	SEQ_UP	1	
MUTAGEN:K->E: Does not affect interaction with nucleosomes.	SEQ_UP	1	
MUTAGEN:K->E: Does not affect ion selectivity.	SEQ_UP	1	
MUTAGEN:K->E: EIF4E-binding reduced by 70%. EIF4E-binding reduced by 60%; when associated with K-724, E-726 and K-730.	SEQ_UP	1	
MUTAGEN:K->E: Has very little effect on anion transport.	SEQ_UP	1	
MUTAGEN:K->E: Impaired tethering to chromatin, leading to constitutive activation in the absence of DNA.	SEQ_UP	1	
MUTAGEN:K->E: Impairs outward anion transport properties.	SEQ_UP	1	
MUTAGEN:K->E: Increased stimulation of enzyme activity by phosphate.	SEQ_UP	1	
MUTAGEN:K->E: Increases affinity for DNA and protein stability; when associated with R-147.	SEQ_UP	1	
MUTAGEN:K->E: Kinase inactivation.	SEQ_UP	1	
MUTAGEN:K->E: Loss of function mutant which is unable to promote clathrin coated-pits formation. Cytosolic mutant which is unable to bind and induce membrane tubulation; when associated with E-146.	SEQ_UP	1	
MUTAGEN:K->E: Loss of function mutant which is unable to promote clathrin coated-pits formation. Cytosolic mutant which is unable to bind and induce membrane tubulation; when associated with E-165.	SEQ_UP	1	
MUTAGEN:K->E: Loss of interaction with calmodulin; when associated with E-526.	SEQ_UP	1	
MUTAGEN:K->E: Loss of interaction with EPS15 and ITSN1.	SEQ_UP	1	
MUTAGEN:K->E: Loss of kinase activity and ability to activate JNK family. Inhibits the ability of CLNK to up-regulate CD3-triggered activation of the IL2 promoter.	SEQ_UP	1	
MUTAGEN:K->E: Loss of kinase activity but no loss of interaction with RELT.	SEQ_UP	1	
MUTAGEN:K->E: Loss of kinase activity. Decreases RABEPK location to membranes. Abolishes EGFR translocation to the nucleus.	SEQ_UP	1	
MUTAGEN:K->E: No effect on binding to DBNL.	SEQ_UP	1	
MUTAGEN:K->E: No effect on binding to TELO2-phosphopeptide.	SEQ_UP	1	
MUTAGEN:K->E: No effect on homophilic interaction. Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself; when associated with R-323.	SEQ_UP	1	
MUTAGEN:K->E: No effect on interaction with ZFPM1.	SEQ_UP	1	
MUTAGEN:K->E: No effect on LPS-binding, LPS-induced oligomerization, and LPS-induced pyroptosis; when associated with M-40.	SEQ_UP	1	
MUTAGEN:K->E: No effect on transcriptional repression.	SEQ_UP	1	
MUTAGEN:K->E: No effect on tyrosine carboxypeptidase activity.	SEQ_UP	1	
MUTAGEN:K->E: No p38-alpha/MAPK14-, p38-beta/MAPK11-, ERK3/MAPK6-, ERK4/MAPK4-induced activation.	SEQ_UP	1	
MUTAGEN:K->E: Reduced affinity for DNA.	SEQ_UP	1	
MUTAGEN:K->E: Reduced anion permeability and increased cation permeability.	SEQ_UP	1	
MUTAGEN:K->E: Reduced neuron activity in the VNO.	SEQ_UP	1	
MUTAGEN:K->E: Reduced tyrosine carboxypeptidase activity.	SEQ_UP	1	
MUTAGEN:K->E: Reduces the binding affinity of AHR?ARNT to the DRE by more than 10-fold.	SEQ_UP	1	
MUTAGEN:K->E: Results in exclusive localization to early endosomes and no effect on ability to promote LPS-induced IL6 and CCL5 production; when associated with E-15 and E-17.	SEQ_UP	1	
MUTAGEN:K->E: Results in exclusive localization to early endosomes and no effect on ability to promote LPS-induced IL6 and CCL5 production; when associated with E-7 and E-15.	SEQ_UP	1	
MUTAGEN:K->E: Severely attenuated LPS-binding, LPS-induced oligomerization and activation, and LPS-induced pyroptosis; when associated with E-62 and E-63.	SEQ_UP	1	
MUTAGEN:K->E: Severely attenuated LPS-binding, LPS-induced oligomerization and activation, and LPS-induced pyroptosis; when associated with E-62 and E-64.	SEQ_UP	1	
MUTAGEN:K->E: Severely attenuated LPS-binding, LPS-induced oligomerization and activation, and LPS-induced pyroptosis; when associated with E-63 and E-64.	SEQ_UP	1	
MUTAGEN:K->E: Severely attenuated LPS-binding, LPS-induced oligomerization and activation, and LPS-induced pyroptosis.	SEQ_UP	1	
MUTAGEN:K->E: Slightly decreased interaction with nucleosomes.	SEQ_UP	1	
MUTAGEN:K->E: Strongly reduced affinity for PLXNA2.	SEQ_UP	1	
MUTAGEN:K->E: Strongly reduced transactivation.	SEQ_UP	1	
MUTAGEN:K->E: Strongly reduced tyrosine carboxypeptidase activity.	SEQ_UP	1	
MUTAGEN:K->E: Strongly reduces affinity for MLPH and SYTL4.	SEQ_UP	1	
MUTAGEN:K->E: Strongly reduces phosphatidylinositol binding.	SEQ_UP	1	
MUTAGEN:K->F: Reduced methylation levels. Little effect on interaction with RXRA or NCOR1. Small loss in transcriptional activation.	SEQ_UP	1	
MUTAGEN:K->H,R,M: Prevents autocatalytic cleavage and generation of Myelin regulatory factor, N-terminal part.	SEQ_UP	1	
MUTAGEN:K->H: No effect on palmitoylation. No change in subcellular location; when associated with C-129.	SEQ_UP	1	
MUTAGEN:K->H: No effect on substrate affinity but decreases catalytic efficiency for smaller substrates like benzaldehyde or phthalazine. Increases substrate affinity and activity for bulkier substrates like phenanthridine.	SEQ_UP	1	
MUTAGEN:K->H: No receptor activity in response to MTMT binding, even in the presence of copper.	SEQ_UP	1	
MUTAGEN:K->I: Inhibits DNA-binding activity and transcriptional activation of NEUROD1 expression.	SEQ_UP	1	
MUTAGEN:K->I: Loss of kinase activity.	SEQ_UP	1	
MUTAGEN:K->I: No effect on receptor activation.	SEQ_UP	1	
MUTAGEN:K->L: Decreased sumoylation; aberrant localization with decreased nuclear rim staining and formation of intranuclear foci; associated with increased cell death.	SEQ_UP	1	
MUTAGEN:K->L: Does not affect ceramide synthase activity.	SEQ_UP	1	
MUTAGEN:K->L: Loss of interaction with RUNX1 but no effect on interaction with NFATC2 and loss of its ability to regulate the expression of IL2, TNFRSF18, IL2RA and CTLA4 in a RUNX1-dependent manner; when associated with 329-VH-330.	SEQ_UP	1	
MUTAGEN:K->L: Loss of TLR7 signaling.	SEQ_UP	1	
MUTAGEN:K->L: Near loss of the ability to trigger histamine release from mast cells. No effect on interaction with NTRK1.	SEQ_UP	1	
MUTAGEN:K->L: Reduces transcriptional activity and estrogen-induced interaction with NCOA1.	SEQ_UP	1	
MUTAGEN:K->M,R: Kinase-dead. Loss of autophosphorylation but has no effect on regulation of cell adhesion.	SEQ_UP	1	
MUTAGEN:K->M: Abolishes activity.	SEQ_UP	1	
MUTAGEN:K->M: Abolishes ATP-binding and induces necroptosis in absence of exogeous stimuli and independently of RIPK3.	SEQ_UP	1	
MUTAGEN:K->M: Abolishes ATP-binding in the helicase domain without affecting the ability to confer resistance to DNA damage.	SEQ_UP	1	
MUTAGEN:K->M: Abolishes autoubiquitination.	SEQ_UP	1	
MUTAGEN:K->M: Abolishes enzyme activity; when associated with A-281.	SEQ_UP	1	
MUTAGEN:K->M: Abolishes pyruvate kinase activity without affecting interaction with the ribosome.	SEQ_UP	1	
MUTAGEN:K->M: Abolishes Rab6-binding.	SEQ_UP	1	
MUTAGEN:K->M: Abrogates kinase activity and autophosphorylation. Retains ability to homodimerize. Abrogates ability to induce ubiquitination and degradation of LEF1 and repress canonical Wnt/beta-catenin signaling. Abrogates ability to induce MYB degradation, and reduces ability to repress MYBL1 and MYBL2.	SEQ_UP	1	
MUTAGEN:K->M: Complete loss of kinase activity. Phosphorylation is restored by co-transfection with wild-type protein.	SEQ_UP	1	
MUTAGEN:K->M: Disrupts sterol transport activity. Decreases expression of both ABCG5 and ABCG8.	SEQ_UP	1	
MUTAGEN:K->M: Does not affect intracellular vesicle localization. Affects cholesterol internalization.	SEQ_UP	1	
MUTAGEN:K->M: Does not affect intracellular vesicle localization.Affects cholesterol internalization.	SEQ_UP	1	
MUTAGEN:K->M: Impairs kinase activity.	SEQ_UP	1	
MUTAGEN:K->M: In DN mutant; Loss of kinase activity; leading to disrupted Ras and Rap protein signaling, altered spine morphology and aberrant memory formation in mice.	SEQ_UP	1	
MUTAGEN:K->M: In Rad50S; hypomorphic allele that induces growth defects and cancer predisposition. Homozygous individuals die with complete bone marrow depletion as a result of progressive hematopoietic stem cell failure.	SEQ_UP	1	
MUTAGEN:K->M: Inactivation.	SEQ_UP	1	
MUTAGEN:K->M: Interferes with DNA-binding.	SEQ_UP	1	
MUTAGEN:K->M: Loss of autophosphorylation and kinase activity.	SEQ_UP	1	
MUTAGEN:K->M: Loss of estrogen sulfotransferase activity.	SEQ_UP	1	
MUTAGEN:K->M: Loss of function.	SEQ_UP	1	
MUTAGEN:K->M: Loss of kinase activity and no phosphorylation of ODF2. No effect on interaction with ODF2.	SEQ_UP	1	
MUTAGEN:K->M: Loss of kinase activity.	SEQ_UP	7	
MUTAGEN:K->M: Loss of kinase activity. Abolishes binding to THOC5.	SEQ_UP	1	
MUTAGEN:K->M: Loss of kinase activity. Pronounced reduction in thymocytes and hematopoietic stem cells and progenitor cells.	SEQ_UP	1	
MUTAGEN:K->M: No effect on cilium length.	SEQ_UP	1	
MUTAGEN:K->M: No effect on interaction with NLRP3.	SEQ_UP	1	
MUTAGEN:K->M: Prevents apical junction formation.	SEQ_UP	1	
MUTAGEN:K->M: Results in enlarged multinucleated cells.	SEQ_UP	1	
MUTAGEN:K->M: Strongly reduces activity in Wnt signaling. Abolishes location at the cell membrane.	SEQ_UP	1	
MUTAGEN:K->N,R: Loss of stimulation of rRNA synthesis. Loss of protein synthesis promotion. No effect on interaction with DDX3X, EIF3G, EIF3H and RPL27.	SEQ_UP	1	
MUTAGEN:K->N: Disrupts targeting to membrane; when associated with A-67; Q-70; P-73; A-74 and Q-75.	SEQ_UP	1	
MUTAGEN:K->N: Greatly reduces MHC class I peptide tetramer binding; when associated with T-226.	SEQ_UP	1	
MUTAGEN:K->N: Impairs calcium-dependent binding to phospholipids; when associated with N-24 and N-49.	SEQ_UP	1	
MUTAGEN:K->N: Impairs calcium-dependent binding to phospholipids; when associated with N-49 and N-52.	SEQ_UP	1	
MUTAGEN:K->N: Increases affinity to CDCA and transcriptional activity in response to CDCA; when associated with I-388.	SEQ_UP	1	
MUTAGEN:K->N: Loss of angiogenic activity. No effect on ribonuclease activity.	SEQ_UP	1	
MUTAGEN:K->N: No effect on activation of phospholipid synthesis.	SEQ_UP	1	
MUTAGEN:K->N: No effect on phosphopeptide recognition.	SEQ_UP	1	
MUTAGEN:K->N: Reduced activity.	SEQ_UP	1	
MUTAGEN:K->N: Significantly decreases calcium-dependent binding to phospholipids.	SEQ_UP	1	
MUTAGEN:K->P: Impaired inhibition by the R-subunit.	SEQ_UP	1	
MUTAGEN:K->Q,A: Mimics acetylation. Cytoplasmic location in absence or presence of insulin. Decreased DNA-binding by about half. Enhanced phosphorylation by PKB/AKT1, no effect on interaction with CEBPA; when associated with either A-245 or Q-245 and either A-262 or Q-262. either A-262 or Q-262. Cytoplasmic location in absence or presence of insulin, no change on the inhibitory effect of oxidative stress on insulin-induced phosphorylations, but no inhibition of these phosphorylations by resveratrol; when associated with Q-219; Q-245; Q-259; Q-262; Q-271 and Q-291. Increased insulin-induced phosphorylation at Ser-253 and binding of 14-3-3 proteins; when associated with A-24; Q-219; Q-245; Q-259; Q-262; Q-271 and Q-291.	SEQ_UP	1	
MUTAGEN:K->Q,A: Mimics acetylation. Decreased DNA-binding by about half and enhanced phosphorylation by PKB/AKT1, no effect on interaction with CEBPA; when associated with either A-242 or Q-242 and either A-245 or Q-245. Cytoplasmic location in absence or presence of insulin, no change on the inhibitory effect of oxidative stress on insulin-induced phosphorylations, but no inhibition of these phosphorylations by resveratrol; when associated with Q-219; Q-242; Q-245; Q-259; Q-271 and Q-291. Increased insulin-induced phosphorylation at Ser-253 and binding of 14-3-3 proteins; when associated with A-24; Q-219; Q-242; Q-245; Q-259; Q-271 and Q-291.	SEQ_UP	1	
MUTAGEN:K->Q,A: Mimics acetylation. Decreased DNA-binding by about half. Enhanced phosphorylation by PKB/AKT1, no effect on interaction with CEBPA; when associated with either A-242 or Q-242 and either A-262 or Q-262. Cytoplasmic location in absence or presence of insulin, no change on the inhibitory effect of oxidative stress on insulin-induced phosphorylations, but no inhibition of these phosphorylations by resveratrol; when associated with Q-219; Q-242; Q-259; Q-262; Q-271 and Q-291. Increased insulin-induced phosphorylation at Ser-253 and binding of 14-3-3 proteins; when associated with A-24; Q-219; Q-242; Q-259; Q-262; Q-271 and Q-291.	SEQ_UP	1	
MUTAGEN:K->Q,R: Decreases phosphorylation at S-232 and S-300 but does not affect activity or substrate metabolism.	SEQ_UP	1	
MUTAGEN:K->Q,R: Reduced pyruvate carboxylase activity.	SEQ_UP	1	
MUTAGEN:K->Q: 7-fold increase in DNA binding.	SEQ_UP	1	
MUTAGEN:K->Q: Abolishes interaction with RILP and localization to the peri-Golgi region.	SEQ_UP	1	
MUTAGEN:K->Q: Abolishes LDLR endocytosis.	SEQ_UP	1	
MUTAGEN:K->Q: Abolishes phosphatase activity.	SEQ_UP	1	
MUTAGEN:K->Q: Almost abolishes N-terminal methylation at A-2.	SEQ_UP	1	
MUTAGEN:K->Q: Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself; when associated with L-284.	SEQ_UP	1	
MUTAGEN:K->Q: Decreases current amplitude.	SEQ_UP	1	
MUTAGEN:K->Q: Defective in ATP-binding. Causes membrane association. Induces vacuolation of endosomal compartments and impairs cholesterol sorting.	SEQ_UP	1	
MUTAGEN:K->Q: Does not affect binding with PTPRZ1. Does not affect binding with PTPRZ1; when associated with Q-105. Does not affect positive regulation of neuron migration.	SEQ_UP	1	
MUTAGEN:K->Q: Does not affect binding with PTPRZ1. Does not affect binding with PTPRZ1; when associated with Q-106. Does not affect positive regulation of neuron migration.	SEQ_UP	1	
MUTAGEN:K->Q: Does not reduce the interaction with RP2.	SEQ_UP	1	
MUTAGEN:K->Q: Enhances interaction with CEBPB.	SEQ_UP	1	
MUTAGEN:K->Q: Forms dimers with full, phosphate-independent activity; when associated with A-325 and K-391.	SEQ_UP	1	
MUTAGEN:K->Q: Loss of membrane localization; when associated with Q-698; Q-699; Q-700 and Q-705.	SEQ_UP	1	
MUTAGEN:K->Q: Loss of membrane localization; when associated with Q-698; Q-699; Q-700 and Q-706.	SEQ_UP	1	
MUTAGEN:K->Q: Loss of membrane localization; when associated with Q-698; Q-699; Q-705 and Q-706.	SEQ_UP	1	
MUTAGEN:K->Q: Loss of membrane localization; when associated with Q-698; Q-700; Q-705 and Q-706.	SEQ_UP	1	
MUTAGEN:K->Q: Loss of membrane localization; when associated with Q-699; Q-700; Q-705 and Q-706.	SEQ_UP	1	
MUTAGEN:K->Q: Mimicks constitutive acetylation, leading to increased malonyl-CoA decarboxylase activity.	SEQ_UP	1	
MUTAGEN:K->Q: Mimicks residue acetylation; impaired interaction with FBXL17, leading to decreased ubiquitination by the SCF(FBXL17) complex.	SEQ_UP	1	
MUTAGEN:K->Q: Mimicks residue acetylation; increased interaction with FBXL17, leading to increased ubiquitination by the SCF(FBXL17) complex.	SEQ_UP	1	
MUTAGEN:K->Q: Mimics acetylation. Cytoplasmic location in absence or presence of insulin, no change on the inhibitory effect of oxidative stress on insulin-induced phosphorylations, but no inhibition of these phosphorylations by resveratrol; when associated with Q-219; Q-242; Q-245; Q-259; Q-262 and Q-271. Increased insulin-induced phosphorylation at Ser-253 and binding of 14-3-3 proteins; when associated with A-24: Q-219; Q-242; Q-245; Q-259; Q-262 and Q-271.	SEQ_UP	1	
MUTAGEN:K->Q: Mimics acetylation. Cytoplasmic location in absence or presence of insulin, no change on the inhibitory effect of oxidative stress on insulin-induced phosphorylations, but no inhibition of these phosphorylations by resveratrol; when associated with Q-219; Q-242; Q-245; Q-259; Q-262 and Q-291. Increased insulin-induced phosphorylation at Ser-253 and binding of 14-3-3 proteins; when associated with A-24; Q-219; Q-242; Q-245; Q-259; Q-262 and Q-291.	SEQ_UP	1	
MUTAGEN:K->Q: Mimics acetylation. Cytoplasmic location in absence or presence of insulin, no change on the inhibitory effect of oxidative stress on insulin-induced phosphorylations, but no inhibition of these phosphorylations by resveratrol; when associated with Q-219; Q-242; Q-245; Q-262; Q-271 and Q-291. Increased insulin-induced phosphorylation at Ser-253 and binding of 14-3-3 proteins; when associated with A-24; Q-219; Q-242; Q-245; Q-262; Q-271 and Q-291.	SEQ_UP	1	
MUTAGEN:K->Q: Mimics acetylation. Cytoplasmic location in absence or presence of insulin, no change on the inhibitory effect of oxidative stress on insulin-induced phosphorylations, but no inhibition of these phosphorylations by resveratrol; when associated with Q-242; Q-245; Q-259; Q-262; Q-271 and Q-291. Increased insulin-induced phosphorylation at Ser-253 and binding of 14-3-3 proteins; when associated with A-24; Q-242; Q-245; Q-259; Q-262; Q-271 and Q-291.	SEQ_UP	1	
MUTAGEN:K->Q: No effect on calcium-dependent neurotransmitter release.	SEQ_UP	1	
MUTAGEN:K->Q: Reduced pyruvate carboxylase activity.	SEQ_UP	1	
MUTAGEN:K->Q: Reduces binding to phosphoinositide; when associated with GLN-33; GLN-34 AND GLN-38.	SEQ_UP	1	
MUTAGEN:K->Q: Reduces binding to phosphoinositide; when associated with GLN-33; GLN-34 AND GLN-42.	SEQ_UP	1	
MUTAGEN:K->Q: Reduces binding to phosphoinositide; when associated with GLN-33; GLN-38 AND GLN-42.	SEQ_UP	1	
MUTAGEN:K->Q: Reduces binding to phosphoinositide; when associated with GLN-34; GLN-38 AND GLN-42.	SEQ_UP	1	
MUTAGEN:K->Q: Reduces phosphatidylinositol binding.	SEQ_UP	1	
MUTAGEN:K->Q: Same as wild-type.	SEQ_UP	1	
MUTAGEN:K->Q: Shifts voltage dependence of activation to more negative values.	SEQ_UP	1	
MUTAGEN:K->Q: Strongly reduces phosphatidylinositol binding. Abolishes phosphatidylinositol binding; when associated with Q-55 and Q-56.	SEQ_UP	1	
MUTAGEN:K->Q: Strongly reduces phosphatidylinositol binding. Abolishes phosphatidylinositol binding; when associated with Q-55 and Q-57.	SEQ_UP	1	
MUTAGEN:K->Q: Strongly reduces phosphatidylinositol binding. Abolishes phosphatidylinositol binding; when associated with Q-56 and Q-57.	SEQ_UP	1	
MUTAGEN:K->R,M: Kinase defective mutant, abolishes activity.	SEQ_UP	1	
MUTAGEN:K->R,S: Strongly reduced estrogen sulfotransferase activity. Strongly reduced affinity for estradiol.	SEQ_UP	1	
MUTAGEN:K->R: 40% decrease in IL1-induced NF-kappa-B activation.	SEQ_UP	1	
MUTAGEN:K->R: Abolished cystine transport. Abolished interaction with components of the v-ATPase and Ragulator complexes. Does not affect ability to lysosomal localization of LAMP2A.	SEQ_UP	1	
MUTAGEN:K->R: Abolished sumoylation by TRIM38, leading to decreased stability.	SEQ_UP	1	
MUTAGEN:K->R: Abolished ubiquitination by RNF2.	SEQ_UP	1	
MUTAGEN:K->R: Abolished ubiquitination by TRIM38.	SEQ_UP	1	
MUTAGEN:K->R: Abolished ubiquitination by TRIM56, leading to impaired homodimerization and activation. Does not affect sumoylation. Strongly reduced sumoylation; when associated with R-372 and R-382.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes acetylation by KAT8/MOF, leading to increase interaction with TTF1 and association with pRNA.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes acetylation.	SEQ_UP	2	
MUTAGEN:K->R: Abolishes ATG12 conjugation, leading to an expansion in mitochondrial mass and fragmented mitochondrial morphology. Does not affect PE-conjugation to ATG8-like proteins.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes CDC20 binding; when associated with Q-314.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes enzymatic activity.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes G4-DNA unwinding activity.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes interaction with NCOR2.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes kinase activity and ability to regulate centrosome duplication.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes kinase activity.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes kinase activity. Impaired hemoglobin synthesis and proliferation of differentiating erythroid cells in knockin mice.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes monomethylation by SETD6 and interaction with EHMT1.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes polyubiquitination; when associated with R-121.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes sumoylation.	SEQ_UP	2	
MUTAGEN:K->R: Abolishes sumoylation. Abolishes sumoylation; when associated with R-868 and R-872.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes sumoylation. No change in nuclear localization but no colocalization with SUMO1. Reduces inhibition of megakaryocytic differentiation. No decrease in bone marrow precursors to form megakaryocytic colonies. No effect on erythroid differentiation.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes sumoylation. No change in PIAS4 binding nor on transcriptional activity.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes sumoylation. No effect on activation of OCT4 but activation not suppressed by additional SUMO1. Enhanced interaction with KAT2B; when associated with A-210 or E-210.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes sumoylation. No effect on nuclear body location.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes ubiquitination by TRAF6, binding to SQSTM1/p62, translocation to the nucleus and NGFR/p75(NTR)-mediated apoptosis.	SEQ_UP	1	
MUTAGEN:K->R: Abolishes ubiquitination. Abolishes ubiquitination and induction of phosphorylation; when associated with R-209.	SEQ_UP	1	
MUTAGEN:K->R: Absence of sumoylation. Enhanced protein degradation. Reduced self-renewal ability in ES cells. 70% lower expression of YES1. Reduced DNA binding. No change in nuclear location. No change in nuclear localization. Absence of sumoylation; when associated with R-215 and R-244.	SEQ_UP	1	
MUTAGEN:K->R: Absence of sumoylation. Increased FGF4 activation. No effect on nuclear localization.	SEQ_UP	1	
MUTAGEN:K->R: Absence of sumoylation. Not targeted to the nuclear envelope rim nor to nuclear pore complexes. Disrupted sumoylation. No interaction with SUMO1; when associated with A-564 and with or without SUMO1 A-97.	SEQ_UP	1	
MUTAGEN:K->R: Accumulates at the plasma membrane, increased half-life and increased CASP9-mediated cell death.	SEQ_UP	1	
MUTAGEN:K->R: At least 60% of RNA-binding activity and loss of GTase activity.	SEQ_UP	1	
MUTAGEN:K->R: Blocks homodimerization, activation of its kinase activity, formation of complex IIa, necroptosis and apoptosis.	SEQ_UP	1	
MUTAGEN:K->R: Complete loss of acetylation.	SEQ_UP	1	
MUTAGEN:K->R: Decrease in sumoylation and its transcriptional activity. Abolishes sumoylation and interaction with ESR1 and decrease in its transcriptional activity; when associated with R-67.	SEQ_UP	1	
MUTAGEN:K->R: Decrease in sumoylation and its transcriptional activity. Abolishes sumoylation and interaction with ESR1 and decrease in its transcriptional activity; when associated with R-851.	SEQ_UP	1	
MUTAGEN:K->R: Decreased acetylation, leading to decreased transcription elongation during the activation phase of the circadian cycle.	SEQ_UP	1	
MUTAGEN:K->R: Decreased acetylation, leading to increased protein deacetylase activity.	SEQ_UP	1	
MUTAGEN:K->R: Decreased acetylation, leading to reduced malonyl-CoA decarboxylase activity.	SEQ_UP	1	
MUTAGEN:K->R: Decreased acetylation; when associated with R-340 and Lys-369.	SEQ_UP	1	
MUTAGEN:K->R: Decreased acetylation; when associated with R-69 and Lys-340.	SEQ_UP	1	
MUTAGEN:K->R: Decreased acetylation; when associated with R-69 and Lys-369.	SEQ_UP	1	
MUTAGEN:K->R: Decreased localization of SQSTM1/p62 to damaged mitochondria; when associated with R-25; R-33 and 122-R-R-123.	SEQ_UP	1	
MUTAGEN:K->R: Decreased localization of SQSTM1/p62 to damaged mitochondria; when associated with R-25; R-66 and 122-R-R-123.	SEQ_UP	1	
MUTAGEN:K->R: Decreased localization of SQSTM1/p62 to damaged mitochondria; when associated with R-33; R-66 and 122-R-R-123.	SEQ_UP	1	
MUTAGEN:K->R: Decreased propionylation, leading to increased transcription activator activity.	SEQ_UP	1	
MUTAGEN:K->R: Decreased stability of the protein, probably due inability to interact with TBL1X; when associated with R-45. Abolishes sumoylation; when associated with R-45.	SEQ_UP	1	
MUTAGEN:K->R: Decreased stability of the protein, probably due inability to interact with TBL1X; when associated with R-71. Abolishes sumoylation; when associated with R-71.	SEQ_UP	1	
MUTAGEN:K->R: Decreases acetylation levels and interaction with CEBPB.	SEQ_UP	1	
MUTAGEN:K->R: Decreases ATP binding about 50%.	SEQ_UP	1	
MUTAGEN:K->R: Decreases levels of mono-ADP-ribosylation without loss of enzyme activity.	SEQ_UP	1	
MUTAGEN:K->R: Decreases Notch signaling pathway.	SEQ_UP	1	
MUTAGEN:K->R: Does not affect ATG12 conjugation.	SEQ_UP	1	
MUTAGEN:K->R: Does not affect ceramide synthase activity.	SEQ_UP	1	
MUTAGEN:K->R: Does not affect deubiquitination by USP29. Reduced sumoylation.	SEQ_UP	1	
MUTAGEN:K->R: Does not affect protein cleveage.	SEQ_UP	1	
MUTAGEN:K->R: Does not affect protein deacetylase activity.	SEQ_UP	1	
MUTAGEN:K->R: Does not affect ubiquitination by RNF2.	SEQ_UP	1	
MUTAGEN:K->R: Does not affect ubiquitination by TRIM38.	SEQ_UP	1	
MUTAGEN:K->R: Does not affect ubiquitination by TRIM56.	SEQ_UP	1	
MUTAGEN:K->R: Dominant negative. Loss of transactivation activity. No effect on interaction with EP300.	SEQ_UP	1	
MUTAGEN:K->R: Enhanced transcriptional activity. No sumoylation, loss of recruitment of HDAC2 to DAAX and greatly enhanced transcriptional activity; when associated with R-1034 and R-1057.	SEQ_UP	1	
MUTAGEN:K->R: Enhanced transcriptional activity. No sumoylation, loss of recruitment of HDAC2 to DAAX and greatly enhanced transcriptional activity; when associated with R-999 and R-1034.	SEQ_UP	1	
MUTAGEN:K->R: Enhanced transcriptional activity. No sumoylation, loss of recruitment of HDAC2 to DAAX and greatly enhanced transcriptional activity; when associated with R-999 and R-1057.	SEQ_UP	1	
MUTAGEN:K->R: Enhances insulin secretion after glucose stimulation.	SEQ_UP	1	
MUTAGEN:K->R: Enhances stability and accumulates in the cytoplasm; when associated with R-231 (isoform 1).	SEQ_UP	1	
MUTAGEN:K->R: Enhances stability and accumulates in the cytoplasm; when associated with R-252 (isoform 1).	SEQ_UP	1	
MUTAGEN:K->R: Greatly decreases 'K-48'-linked ubiquitination.	SEQ_UP	1	
MUTAGEN:K->R: Greatly impairs polyubiquitination. Abolishes polyubiquitination; when associated with R-146.	SEQ_UP	1	
MUTAGEN:K->R: Greatly reduced levels of PIAS3-mediated sumoylation. Completely abolishes sumoylation; when associated with R-315 and R-322.	SEQ_UP	1	
MUTAGEN:K->R: Highly decreases Notch signaling pathway. Multi-ubiquitination pattern is reduced, although it does appear to be mono-ubiquitinated. Interacts with MIB1. Loss of cis and trans interaction with NOTCH1. Increases its association with lipid raft microdomains.	SEQ_UP	1	
MUTAGEN:K->R: Impaired deubiquitination by USP29. Does not affect sumoylation.	SEQ_UP	1	
MUTAGEN:K->R: Impaired formation of HMW multimers; when associated with R-68; R-71 and R-104.	SEQ_UP	1	
MUTAGEN:K->R: Impaired formation of HMW multimers; when associated with R-68; R-71 and R-80.	SEQ_UP	1	
MUTAGEN:K->R: Impaired formation of HMW multimers; when associated with R-68; R-80 and R-104.	SEQ_UP	1	
MUTAGEN:K->R: Impaired formation of HMW multimers; when associated with R-71; R-80 and R-104.	SEQ_UP	1	
MUTAGEN:K->R: Impaired interaction with ATXN3; when associated with R-2 and R-4.	SEQ_UP	1	
MUTAGEN:K->R: Impaired interaction with ATXN3; when associated with R-2 and R-7.	SEQ_UP	1	
MUTAGEN:K->R: Impaired interaction with ATXN3; when associated with R-4 and R-7.	SEQ_UP	1	
MUTAGEN:K->R: Impaired interaction with FBXL17, leading to decreased ubiquitination by the SCF(FBXL17) complex.	SEQ_UP	1	
MUTAGEN:K->R: In ANKRD16(3XR); abolished ability to enhance hydrolysis of Ser-mischarged tRNA(Ala); when associated with R-102 and R-135.	SEQ_UP	1	
MUTAGEN:K->R: In ANKRD16(3XR); abolished ability to enhance hydrolysis of Ser-mischarged tRNA(Ala); when associated with R-102 and R-165.	SEQ_UP	1	
MUTAGEN:K->R: In ANKRD16(3XR); abolished ability to enhance hydrolysis of Ser-mischarged tRNA(Ala); when associated with R-135 and R-165.	SEQ_UP	1	
MUTAGEN:K->R: In K-less, no effect on ubiquitination; when associated with R-55, R-155, R-170, R-197, R-210, R-220, R-267 and R-277.	SEQ_UP	1	
MUTAGEN:K->R: In K-less, no effect on ubiquitination; when associated with R-55, R-92, R-155, R-170, R-197, R-210, R-220 and R-267.	SEQ_UP	1	
MUTAGEN:K->R: In K-less, no effect on ubiquitination; when associated with R-55, R-92, R-155, R-170, R-197, R-210, R-220 and R-277.	SEQ_UP	1	
MUTAGEN:K->R: In K-less, no effect on ubiquitination; when associated with R-55, R-92, R-155, R-170, R-197, R-210, R-267 and R-277.	SEQ_UP	1	
MUTAGEN:K->R: In K-less, no effect on ubiquitination; when associated with R-55, R-92, R-155, R-170, R-197, R-220, R-267 and R-277.	SEQ_UP	1	
MUTAGEN:K->R: In K-less, no effect on ubiquitination; when associated with R-55, R-92, R-155, R-170, R-210, R-220, R-267 and R-277.	SEQ_UP	1	
MUTAGEN:K->R: In K-less, no effect on ubiquitination; when associated with R-55, R-92, R-155, R-197, R-210, R-220, R-267 and R-277.	SEQ_UP	1	
MUTAGEN:K->R: In K-less, no effect on ubiquitination; when associated with R-55, R-92, R-170, R-197, R-210, R-220, R-267 and R-277.	SEQ_UP	1	
MUTAGEN:K->R: In K-less, no effect on ubiquitination; when associated with R-92, R-155, R-170, R-197, R-210, R-220, R-267 and R-277.	SEQ_UP	1	
MUTAGEN:K->R: In K2R; abolished acetylation by KAT5/TIP60 and decreased kinase activity; when associated with R-162.	SEQ_UP	1	
MUTAGEN:K->R: In K2R; abolished acetylation by KAT5/TIP60 and decreased kinase activity; when associated with R-606.	SEQ_UP	1	
MUTAGEN:K->R: In Ld KCST-less, strongly impairs ubiquitination; when associated with I-337; R-340; 350-A--A-356 and 360-R-R-361. In Ld tail 1S, restores ubiquitination; when associated I-337; R-340; 350-A--A-352; A-356 and 360-R-R-361.	SEQ_UP	1	
MUTAGEN:K->R: In Ld KCST-less, strongly impairs ubiquitination; when associated with R-332; I-337; 350-A--A-356 and 360-R-R-361. In Ld tail 1S, restores ubiquitination; when associated R-332; I-337; 350-A--A-352; A-356 and 360-R-R-361.	SEQ_UP	1	
MUTAGEN:K->R: Increased cell reprogramming and pluripotency. No change in promoter-binding of target genes.	SEQ_UP	1	
MUTAGEN:K->R: Increased interaction with FBXL17, leading to increased ubiquitination by the SCF(FBXL17) complex.	SEQ_UP	1	
MUTAGEN:K->R: Increased nuclear localization.	SEQ_UP	1	
MUTAGEN:K->R: Increased stability of the protein caused by impaired ubiquitination by the SCF(FBXL17) complex.	SEQ_UP	1	
MUTAGEN:K->R: Increased stability of the protein.	SEQ_UP	1	
MUTAGEN:K->R: Increases PER1 nuclear import.	SEQ_UP	1	
MUTAGEN:K->R: Increases protein expression and stability; when associated with R-25, R-160 and R-177. Increases apoptosis; when associated with R-25, R-160 and R-177.	SEQ_UP	1	
MUTAGEN:K->R: Increases protein expression and stability; when associated with R-25, R-32 and R-160. Increases apoptosis; when associated with R-25, R-32 and R-160.	SEQ_UP	1	
MUTAGEN:K->R: Increases protein expression and stability; when associated with R-25, R-32 and R-177. Increases apoptosis; when associated with R-25, R-32 and R-177.	SEQ_UP	1	
MUTAGEN:K->R: Increases protein expression and stability; when associated with R-32, R-160 and R-177. Increases apoptosis; when associated with R-32, R-160 and R-177.	SEQ_UP	1	
MUTAGEN:K->R: Inhibits autophosphorylation, eIF-2-alpha phosphorylation and antiviral activity against Sindbis virus.	SEQ_UP	1	
MUTAGEN:K->R: Inhibits interaction with AXIN1 and ZBED3.	SEQ_UP	1	
MUTAGEN:K->R: Inhibits interaction with PER2. Does not suppress its nuclear localization. Inhibits its repression activity on CLOCK|NPAS2-ARNTL-driven transcription.	SEQ_UP	1	
MUTAGEN:K->R: Inhibits localization to nuclear speckles.	SEQ_UP	1	
MUTAGEN:K->R: Leads to constitutive protein kinase activity.	SEQ_UP	1	
MUTAGEN:K->R: Little change in sumoylation. Completely abolishes sumoylation; when associated with R-178 and R-315.	SEQ_UP	1	
MUTAGEN:K->R: Little change in sumoylation. Completely abolishes sumoylation; when associated with R-178 and R-322.	SEQ_UP	1	
MUTAGEN:K->R: Loss of ability to regulate activity of mitochondrial respiratory chain complexes.	SEQ_UP	1	
MUTAGEN:K->R: Loss of acetylation and loss of regulation of growth-factor-induced gene expression; when associated with R-1838; R-1859; R-1866; R-1873; R-1887; R-1908 and R-1922.	SEQ_UP	1	
MUTAGEN:K->R: Loss of acetylation and loss of regulation of growth-factor-induced gene expression; when associated with R-1859; R-1866; R-1873; R-1887; R-1908; R-1922 and R-1936.	SEQ_UP	1	
MUTAGEN:K->R: Loss of acetylation. Decreased binding affinity to EP300. Loss of EP300-mediated transcriptional coactivation.	SEQ_UP	1	
MUTAGEN:K->R: Loss of activity and no phosphorylation.	SEQ_UP	1	
MUTAGEN:K->R: Loss of activity.	SEQ_UP	2	
MUTAGEN:K->R: Loss of ATP-binding.	SEQ_UP	1	
MUTAGEN:K->R: Loss of conjugation.	SEQ_UP	1	
MUTAGEN:K->R: Loss of enzyme activity. Abolishes ubiquitination in response to VEGFA binding.	SEQ_UP	1	
MUTAGEN:K->R: Loss of function.	SEQ_UP	1	
MUTAGEN:K->R: Loss of immunosuppressive activity. No effect on fusogenic activity.	SEQ_UP	1	
MUTAGEN:K->R: Loss of kinase activity and autophosphorylation.	SEQ_UP	1	
MUTAGEN:K->R: Loss of kinase activity and impaired activation of SF1.	SEQ_UP	1	
MUTAGEN:K->R: Loss of kinase activity; no effect on nuclear subcellular location.	SEQ_UP	1	
MUTAGEN:K->R: Loss of kinase activity.	SEQ_UP	2	
MUTAGEN:K->R: Loss of lipid phosphatase activity.	SEQ_UP	1	
MUTAGEN:K->R: Loss of repressor activity.	SEQ_UP	1	
MUTAGEN:K->R: Loss of SUMO modification, increases transactivation activity, increases macrophage differentiation and inhibits myeloid progenitor growth; when associated with R-297.	SEQ_UP	1	
MUTAGEN:K->R: Loss of SUMO modification, increases transactivation activity, increases macrophage differentiation and inhibits myeloid progenitor growth; when associated with R-32.	SEQ_UP	1	
MUTAGEN:K->R: Loss of sumoylation; when associated with R-724.	SEQ_UP	1	
MUTAGEN:K->R: Loss of sumoylation; when associated with R-742.	SEQ_UP	1	
MUTAGEN:K->R: Loss of ubiquitination, no effect on interaction with WWP2; when associated with R-1859; R-1866; R-1873; R-1887 and R-1908. Loss of acetylation and loss of regulation of growth-factor-induced gene expression; when associated with R-1838; R-1859; R-1866; R-1873; R-1887; R-1908 and R-1936.	SEQ_UP	1	
MUTAGEN:K->R: Loss of ubiquitination, no effect on interaction with WWP2; when associated with R-1859; R-1866; R-1873; R-1887 and R-1922. Loss of acetylation and loss of regulation of growth-factor-induced gene expression; when associated with R.1838; R-1859; R-1866; R-1873; R-1887; R-1922 and R-1936.	SEQ_UP	1	
MUTAGEN:K->R: Loss of ubiquitination, no effect on interaction with WWP2; when associated with R-1859; R-1866; R-1873; R-1908 and R-1922. Loss of acetylation and loss of regulation of growth-factor-induced gene expression; when associated with R-1838; R-1859; R-1866; R-1873; R-1908; R-1922 and R-1936.	SEQ_UP	1	
MUTAGEN:K->R: Loss of ubiquitination, no effect on interaction with WWP2; when associated with R-1859; R-1866; R-1887; R-1908 and R-1922. Loss of acetylation and loss of regulation of growth-factor-induced gene expression; when associated with R-1838; R-1859; R-1866; R-1887; R-1908; R-1922 and R-1936.	SEQ_UP	1	
MUTAGEN:K->R: Loss of ubiquitination, no effect on interaction with WWP2; when associated with R-1859; R-1873; R-1887; R-1908 and R-1922. Loss of acetylation and loss of regulation of growth-factor-induced gene expression; when associated with R-1859; R-1859; R-1873; R-1887; R-1908; R-1922 and R-1936.	SEQ_UP	1	
MUTAGEN:K->R: Loss of ubiquitination, no effect on interaction with WWP2; when associated with R-1866; R-1873; R-1887; R-1908 and R-1922. Loss of acetylation and loss of regulation of growth-factor-induced gene expression; when associated with R-1838; R-1866; R-1873; R-1887; R-1908; R-1922 and R-1936.	SEQ_UP	1	
MUTAGEN:K->R: Loss of ubiquitination; when associated with R-454.	SEQ_UP	1	
MUTAGEN:K->R: Loss of ubiquitination; when associated with R-466.	SEQ_UP	1	
MUTAGEN:K->R: Loss of ubiquitination. Decreases TNF-alpha-mediated NF-kappaB activation. Increases interaction with CFLAR, CASP8, FADD AND RIPK3. Decreases interaction with MAP3K7. Enhances kinase activity and promotes apoptosis and necroptosis. Knockin mice display early embryonic lethality resulting from excessive cell death and severe inflammation.	SEQ_UP	1	
MUTAGEN:K->R: Markedly reduced sumoylation; when associated with R-43.	SEQ_UP	1	
MUTAGEN:K->R: Markedly reduced sumoylation; when associated with R-459.	SEQ_UP	1	
MUTAGEN:K->R: Mildly reduces phosphatase activity; when associated with R-71 and A-73. Strongly reduces phosphatase activity; when associated with S-67; R-71 and A-73. Abolishes phosphatase activity; when associated with S-67 and A-73.	SEQ_UP	1	
MUTAGEN:K->R: No change in sumoylation; when associated with R-244. Loss of sumoylation. No change in nuclear localization; when associated with R-118 and R-244.	SEQ_UP	1	
MUTAGEN:K->R: No change in sumoylation.	SEQ_UP	1	
MUTAGEN:K->R: No change in sumoylation. Abolishes sumoylation; when associated with R-868 and R-882.	SEQ_UP	1	
MUTAGEN:K->R: No change in sumoylation. Abolishes sumoylation; when associated with R-872 and R-882.	SEQ_UP	1	
MUTAGEN:K->R: No change in sumoylation. No change in sumoylation; when associated with R-215. Loss of sumoylation; when associated with R-118 and R-215. No change in nuclear localization; when associated with R-118 and R-215.	SEQ_UP	1	
MUTAGEN:K->R: No effect on acetylation levels. Slightly decreases acetylation levels; when associated with R-210. Slightly decreases acetylation levels; when associated with R-216.	SEQ_UP	1	
MUTAGEN:K->R: No effect on acetylation levels. Slightly decreases acetylation levels; when associated with R-339. Decreases acetylation levels; when associated with R-210 and R-216.	SEQ_UP	1	
MUTAGEN:K->R: No effect on autocatalytic cleavage within the FIIND region.	SEQ_UP	1	
MUTAGEN:K->R: No effect on COP1-mediated degradation of TORC1 under forksolin stimulation.	SEQ_UP	1	
MUTAGEN:K->R: No effect on DNA-binding or its nuclear localization.	SEQ_UP	1	
MUTAGEN:K->R: No effect on lipid kinase activity when the protein is purified from mammalian cell extracts. No effect on lipid kinase activity when the protein is purified from mammalian cell extracts; when associated with A-281.	SEQ_UP	1	
MUTAGEN:K->R: No effect on localization of SQSTM1/p62 to damaged mitochondria.	SEQ_UP	1	
MUTAGEN:K->R: No effect on MHC class I peptide tetramer binding.	SEQ_UP	1	
MUTAGEN:K->R: No effect on phosphorylation after DNA damage, but increased radiosensitivity. Further increase in radiosensitivity; when associated with A-140.	SEQ_UP	1	
MUTAGEN:K->R: No effect on protein stability, inhibited sumoylation, increased transcriptional activity; when associated with R-229.	SEQ_UP	1	
MUTAGEN:K->R: No effect on protein stability, inhibited sumoylation, increased transcriptional activity; when associated with R-258.	SEQ_UP	1	
MUTAGEN:K->R: No effect on sumoylation.	SEQ_UP	4	
MUTAGEN:K->R: No effect on transactivation activity.	SEQ_UP	1	
MUTAGEN:K->R: No effect on transactivation activity. Not acetylated after glucocorticoid-stimulation and no increase of transactivation activity; when associated with R-101 and R-102.	SEQ_UP	1	
MUTAGEN:K->R: No effect on ubiquitination. No effect on induction of phosphorylation; when associated with R-34.	SEQ_UP	1	
MUTAGEN:K->R: No effect on ubiquitination. No effect on induction of phosphorylation; when associated with R-562.	SEQ_UP	1	
MUTAGEN:K->R: No enzymatic activity, but still interacts with TP53 and NLK. Blocks the ability to induce cell growth arrest. Decreases corepressor activity.	SEQ_UP	1	
MUTAGEN:K->R: No loss of repressor activity, somite segmentation disrupted at later stages.	SEQ_UP	1	
MUTAGEN:K->R: No loss of repressor activity.	SEQ_UP	1	
MUTAGEN:K->R: No loss of ubiquitination; when associated with R-118, R-119 and R-493.	SEQ_UP	1	
MUTAGEN:K->R: No loss of ubiquitination; when associated with R-118, R-119 and R-494.	SEQ_UP	1	
MUTAGEN:K->R: No loss of ubiquitination; when associated with R-118, R-493 and R-494.	SEQ_UP	1	
MUTAGEN:K->R: No loss of ubiquitination; when associated with R-119, R-493 and R-494.	SEQ_UP	1	
MUTAGEN:K->R: No sumoylation.	SEQ_UP	1	
MUTAGEN:K->R: Not acetylated after glucocorticoid-stimulation and no increase of transactivation activity; when associated with R-98 and R-102.	SEQ_UP	1	
MUTAGEN:K->R: Not acetylated and no increase of transactivation activity after glucocorticoid-stimulation; when associated with R-98 and R-101.	SEQ_UP	1	
MUTAGEN:K->R: Not sumoylated. Decreases ubiquitination and increases stability. Loss of proliferation inhibition in T cells. No effect on transactivation activity.	SEQ_UP	1	
MUTAGEN:K->R: Promotes location to the nucleus. Reduces proteasomal degradation, but does not prevent ubiquitination.	SEQ_UP	1	
MUTAGEN:K->R: Reduced acetylation and transcriptional activity increased by about 1.5 fold. Completely abolishes acetylation, increases interaction with CEBPA and transcriptional activity increased by about 3-fold; when associated with R-245 and R-262. Transcriptional activity not inhibited by FCOR; when associated with R-245; R-259; R-262; R-271 and R-291. Predominantly nuclear and translocates to the cytoplasm on insulin-stimulation. No change on the inhibitory effect of oxidative stress on insulin-induced phosphorylations, but no inhibition of these phosphorylations by resveratrol; when associated with R-219; R-245; R-259; R-262; R-271 and R-291. Increased binding of 14-3-3 proteins even with decreased insulin-induced phosphorylation at Ser-253; when associated with A-24; R-219; R-245; R-259; R-262; R-271 and R-291.	SEQ_UP	1	
MUTAGEN:K->R: Reduced acetylation and transcriptional activity increased by about 1.5-fold. Completely abolishes acetylation, increases interaction with CEBPA and transcriptional activity increased by about 3-fold; when associated with R-242 and R-262. Transcriptional activity not inhibited by FCOR; when associated with R-242; R-259; R-262; R-271 and R-291. Predominantly nuclear and translocates to the cytoplasm on insulin-stimulation. No change on the inhibitory effect of oxidative stress on insulin-induced phosphorylations, but no inhibition of these phosphorylations by resveratrol; when associated with R-219; R-242; R-259; R-262; R-271 and R-291. Increased binding of 14-3-3 proteins even with decreased insulin-induced phosphorylation at Ser-253; when associated with A-24; R-219; R-242; R-259; R-262; R-271 and R-291.	SEQ_UP	1	
MUTAGEN:K->R: Reduced acetylation by 30%. Some loss of DNA binding and transactivation activity.	SEQ_UP	1	
MUTAGEN:K->R: Reduced estrogen sulfotransferase activity.	SEQ_UP	1	
MUTAGEN:K->R: Reduced MAIT cell activation.	SEQ_UP	1	
MUTAGEN:K->R: Reduced sumoylation.	SEQ_UP	1	
MUTAGEN:K->R: Reduces 'Lys-48'-linked polyubiquitination; when associated with R-106.	SEQ_UP	1	
MUTAGEN:K->R: Reduces 'Lys-48'-linked polyubiquitination; when associated with R-155.	SEQ_UP	1	
MUTAGEN:K->R: Reduces activity by 23%; reduces activity by 80% when associated with R-318.	SEQ_UP	1	
MUTAGEN:K->R: Reduces activity by 37%; reduces activity by 80% when associated with R-322.	SEQ_UP	1	
MUTAGEN:K->R: Reduces activity by 90% when associated with R-318 and R-322.	SEQ_UP	1	
MUTAGEN:K->R: Reduces sumoylation. Abolishes sumoylation and nuclear localization; when associated with R-599.	SEQ_UP	1	
MUTAGEN:K->R: Reduces sumoylation. Abolishes sumoylation and nuclear localization; when associated with R-629.	SEQ_UP	1	
MUTAGEN:K->R: Reduces TRIM25-mediated ubiquitination in response to DNA damage. Reduces recruitment of BLM to replication forks and impairs the restart of stalled replication forks.	SEQ_UP	1	
MUTAGEN:K->R: Resistant to KLHL3-dependent protein degradation.	SEQ_UP	1	
MUTAGEN:K->R: Reverses IR-Induced increases in superoxide and genomic Instability in SIRT3-deficient mice.	SEQ_UP	1	
MUTAGEN:K->R: Sensitive to FBXL3-ediated degradation but noz affected by expression of FBXL21.	SEQ_UP	1	
MUTAGEN:K->R: Significant decrease in; transcriptional activity, localization in PML body, ubiquitination and proteasome-mediated proteolysis.	SEQ_UP	1	
MUTAGEN:K->R: Significant loss of ubiquitination. Loss of phosphorylation at T-302 causing loss of its ability to interact with NFATC2. Loss its ability to activate IFN-gamma transcription due to loss of DNA-binding activity. Loss of its ability to suppress IL-2 and Th2 cytokine production. Increased protein stability. Localization seen in both the nucleus and cytoplasm. No loss of interaction with GATA3 and RELA.	SEQ_UP	1	
MUTAGEN:K->R: Significant reduction in acetylation and transcriptional activity increased by about 2.0 fold. Completely abolishes acetylation, increases interaction with CEBPA and transcriptional activity increased by about 3-fold; when associated with R-242 and R-245. Transcriptional activity not inhibited by FCOR; when associated with R-242; R-245; R-259; R-271 and R-291. Predominantly nuclear and translocates to the cytoplasm on insulin-stimulation. No change on the inhibitory effect of oxidative stress on insulin-induced phosphorylations, but no inhibition of these phosphorylations by resveratrol; when associated with R-219; R-242; R-245; R-259; R-271 and R-291. Increased binding of 14-3-3 proteins even with decreased insulin-induced phosphorylation at Ser-253; when associated with A-24; R-219; R-242; R-245; R-259; R-271 and R-291.	SEQ_UP	1	
MUTAGEN:K->R: Slight decrease in TRAF6-induced polyubiquitination.	SEQ_UP	1	
MUTAGEN:K->R: Slight decrease in TRAF6-induced polyubiquitination. Decrease in TRAF6-induced polyubiquitination; when associated with R-318. Important decrease in TRAF6-induced polyubiquitination; when associated with R-314 and R-318.	SEQ_UP	1	
MUTAGEN:K->R: Slight decrease in TRAF6-induced polyubiquitination. Decrease in TRAF6-induced polyubiquitination; when associated with R-319. Important decrease in TRAF6-induced polyubiquitination; when associated with R-314 and R-319.	SEQ_UP	1	
MUTAGEN:K->R: Slight decrease in TRAF6-induced polyubiquitination. Important decrease in TRAF6-induced polyubiquitination; when associated with R-318 and R-319.	SEQ_UP	1	
MUTAGEN:K->R: Slightly decreases acetylation levels. No effect on protein stability. Slightly decreases acetylation levels; when associated with R-207. Slightly decreases acetylation levels and increases protein stability; when associated with R-210. Increases protein stability; when associated with R-339. Decreases acetylation levels; when associated with R-210 and R-343. Abolishes acetylation levels and ubiquitination and highly increases protein stability; when associated with R-210 and R-339.	SEQ_UP	1	
MUTAGEN:K->R: Slightly decreases acetylation levels. No effect on protein stability. Slightly decreases acetylation levels; when associated with R-207. Slightly decreases acetylation levels and increases protein stability; when associated with R-216. Increases protein stability; when associated with R-339. Decreases acetylation levels; when associated with R-216 and R-343. Abolishes acetylation levels and ubiquitination and highly increases protein stability; when associated with R-216 and R-339.	SEQ_UP	1	
MUTAGEN:K->R: Slightly decreases acetylation levels. Slightly increases protein stability. Slightly decreases acetylation levels; when associated with R-343. Increases protein stability; when associated with R-210 or R-216. Abolishes acetylation levels and ubiquitination and highly increases protein stability; when associated with R-210 and R-216.	SEQ_UP	1	
MUTAGEN:K->R: Some loss of sumoylation. Complete loss of sumoylation, increased repressor activity but no change in pericentromeric heterochromatin location; when associated with R-240 and R-459.	SEQ_UP	1	
MUTAGEN:K->R: Some loss of sumoylation. Complete loss of sumoylation, increased repressor activity but no change in pericentromeric heterochromatin location.; when associated with R-58 and R-459.	SEQ_UP	1	
MUTAGEN:K->R: Strong reduction in tubulin acetylation, no effect on tubulin-binding; when associated with R-146; R-233 and R-244.	SEQ_UP	1	
MUTAGEN:K->R: Strong reduction in tubulin acetylation, no effect on tubulin-binding; when associated with R-56; R-146 and R-233.	SEQ_UP	1	
MUTAGEN:K->R: Strong reduction in tubulin acetylation, no effect on tubulin-binding; when associated with R-56; R-146 and R-244.	SEQ_UP	1	
MUTAGEN:K->R: Strong reduction in tubulin acetylation, no effect on tubulin-binding; when associated with R-56; R-233 and R-244.	SEQ_UP	1	
MUTAGEN:K->R: Strongly decreased sumoylation.	SEQ_UP	1	
MUTAGEN:K->R: Strongly decreases ubiquitination. Abolishes ubiquitination and induction of phosphorylation; when associated with R-158.	SEQ_UP	1	
MUTAGEN:K->R: Strongly reduced sumoylation; when associated with R-335 and R-372.	SEQ_UP	1	
MUTAGEN:K->R: Strongly reduced sumoylation; when associated with R-335 and R-382.	SEQ_UP	1	
MUTAGEN:K->R: Strongly reduces cholesterol transport activity, but has little effect on biliary secretion of campesterol and sitosterol. No effect on ATP-binding and on expression of ABCG5 and ABCG8.	SEQ_UP	1	
MUTAGEN:K->R: Sumoylated.	SEQ_UP	1	
MUTAGEN:K->R: Transcriptional activity not inhibited by FCOR; when associated with R-242; R-245; R-259; R-262 and R-271. Predominantly nuclear and translocates to the cytoplasm on insulin-stimulation. No inhibitory effect of oxidative stress on insulin-induced phosphorylations, but no inhibition of these phosphorylations by resveratrol; when associated with R-219; R-242; R-245; R-259; R-262 and R-271. Increased binding of 14-3-3 proteins even with decreased insulin-induced phosphorylation at Ser-253; when associated with A-24; R-219; R-242; R-245; R-259; R-262 and R-271.	SEQ_UP	1	
MUTAGEN:K->R: Transcriptional activity not inhibited by FCOR; when associated with R-242; R-245; R-259; R-262 and R-291. Predominantly nuclear and translocates to the cytoplasm on insulin-stimulation. No inhibitory effect of oxidative stress on insulin-induced phosphorylations, but no inhibition of these phosphorylations by resveratrol; when associated with R-219; R-242; R-245; R-259; R-262 and R-291. Increased binding of 14-3-3 proteins even with decreased insulin-induced phosphorylation at Ser-253; when associated with A-24; R-219; R-242; R-245; R-259; R-262 and R-291.	SEQ_UP	1	
MUTAGEN:K->R: Transcriptional activity not inhibited by FCOR; when associated with R-242; R-245; R-262; R-271 and R-291. Predominantly nuclear and translocates to the cytoplasm on insulin-stimulation. No change on the inhibitory effect of oxidative stress on insulin-induced phosphorylations, but no inhibition of these phosphorylations by resveratrol; when associated with R-219; R-242; R-245; R-262; R-271 and R-291. Increased binding of 14-3-3 proteins even with decreased insulin-induced phosphorylation at Ser-253; when associated with A-24; R-219; R-242; R-245; R-262; R-271 and R-291.	SEQ_UP	1	
MUTAGEN:K->R: Translocates to the cytoplasm after insulin-stimulation. No change on the inhibitory effect of oxidative stress on insulin-induced phosphorylations, but no inhibition of these phosphorylations by resveratrol; when associated with R-242; R-245; R-259; R-262; R-271 and R-291. Increased binding of 14-3-3 proteins even with decreased insulin-induced phosphorylation at Ser-253; when associated with A-24; R-242; R-245; R-259; R-262; R-271 and R-291.	SEQ_UP	1	
MUTAGEN:K->R: Translocates to the nucleus and no COP1-mediated degradation.	SEQ_UP	1	
MUTAGEN:K->R: When expressed in hippocampal neurons, decreases the number of dendritic spines. Strong decrease in the number of dendritic spines; when associated with L-78 and L-81.	SEQ_UP	1	
MUTAGEN:K->R: When expressed in hippocampal neurons, decreases the number of dendritic spines. Strong decrease in the number of dendritic spines; when associated with L-83 and L-86.	SEQ_UP	1	
MUTAGEN:K->S: Abolishes the binding to PDCD1.	SEQ_UP	1	
MUTAGEN:K->S: Abolishes the binding to PDCD1. Costimulates proliferation and IFNG production of T-cells.	SEQ_UP	1	
MUTAGEN:K->S: Impairs catalytic activity.	SEQ_UP	1	
MUTAGEN:K->S: Loss of activity.	SEQ_UP	1	
MUTAGEN:K->S: Loss of methylation and dimethylation but no effect on phosphorylation; when associated with S-1838; S-1859; S-1866; S-1873; S-1887; S-1908 and S-1922. Highly decreases methylation and dimethylation; when associated with S-1859; S-1866; S-1873; S-1887; S-1908 and S-1922. Decreases methylation but no effect on dimethylation; when associated with S-1859; S-1866 and S-1887.	SEQ_UP	1	
MUTAGEN:K->S: Loss of methylation and dimethylation but no effect on phosphorylation; when associated with S-1838; S-1859; S-1866; S-1873; S-1887; S-1908 and S-1936. Highly decreases methylation and dimethylation; when associated with S-1859; S-1866; S-1873; S-1887; S-1908 and S-1936.	SEQ_UP	1	
MUTAGEN:K->S: Loss of methylation and dimethylation but no effect on phosphorylation; when associated with S-1838; S-1859; S-1866; S-1873; S-1887; S-1922 and S-1936. Highly decreases methylation and dimethylation; when associated with S-1859; S-1866; S-1873; S-1887; S-1922 and S-1936. Decreases methylation but no effect on dimethylation; when associated with S-1859; S-1866; S-1887 and S-1936.	SEQ_UP	1	
MUTAGEN:K->S: Loss of methylation and dimethylation but no effect on phosphorylation; when associated with S-1838; S-1859; S-1866; S-1873; S-1908; S-1922 and S-1936. Highly decreases methylation and dimethylation; when associated with S-1859; S-1866; S-1873; S-1908; S-1922 and S-1936. Decreases methylation but no effect on dimethylation; when associated with S-1859; S-1866; S-1908 and S-1936.	SEQ_UP	1	
MUTAGEN:K->S: Loss of methylation and dimethylation but no effect on phosphorylation; when associated with S-1838; S-1859; S-1866; S-1887; S-1908; S-1922 and S-1936. Highly decreases methylation and dimethylation; when associated with S-1859; S-1866; S-1887; S-1908 and S-1936.	SEQ_UP	1	
MUTAGEN:K->S: Loss of methylation and dimethylation but no effect on phosphorylation; when associated with S-1838; S-1859; S-1873; S-1887; S-1908; S-1922 and S-1936. Highly decreases methylation and dimethylation; when associated with S-1859; S-1873; S-1887; S-1908; S-1922 and S-1936. Decreases methylation but no effect on dimethylation; when associated with S-1859; S-1887; S-1908 and S-1936.	SEQ_UP	1	
MUTAGEN:K->S: Loss of methylation and dimethylation but no effect on phosphorylation; when associated with S-1838; S-1866; S-1873; S-1887; S-1908; S-1922 and S-1936. Highly decreases methylation and dimethylation; when associated with S-1866; S-1873; S-1887; S-1908; S-1922 and S-1936. Decreases methylation but no effect on dimethylation; when associated with S-1866; S-1887; S-1908 and S-1936.	SEQ_UP	1	
MUTAGEN:K->S: Loss of methylation and dimethylation but no effect on phosphorylation; when associated with S-1859; S-1866; S-1873; S-1887; S-1908; S-1922 and S-1936.	SEQ_UP	1	
MUTAGEN:K->S: No effect on PDCD1 binding.	SEQ_UP	2	
MUTAGEN:K->S: No effect on trypsin inhibitor activity or sperm binding.	SEQ_UP	1	
MUTAGEN:K->T: Abolishes ability to form paracellular chloride channel.	SEQ_UP	1	
MUTAGEN:K->T: Abolishes nuclear localization.	SEQ_UP	1	
MUTAGEN:K->T: Abolishes nuclear localization. Inhibits development of ataxia.	SEQ_UP	1	
MUTAGEN:K->T: Acquires binding to CD200; when associated with K-87 and F-138.	SEQ_UP	1	
MUTAGEN:K->T: Decreased kinase activity.	SEQ_UP	1	
MUTAGEN:K->T: No effect on protein abundance. No effect on cell surface localization. No effect on alanine uptake activity.	SEQ_UP	1	
MUTAGEN:K->T: Strongly reduces FLRT2 binding; when associated with N-267.	SEQ_UP	1	
MUTAGEN:K->V: Reduced activity.	SEQ_UP	1	
MUTAGEN:K->Y: Does not abolish interaction with RILP and localization to the peri-Golgi region.	SEQ_UP	1	
MUTAGEN:KAKR->AAKA: Abolishes nuclear accumulation.	SEQ_UP	1	
MUTAGEN:KD->AA: Abolishes interaction with other proteins, but not with itself. Partial loss of the ASIC1/ASIC3 channel regulation by PKC.	SEQ_UP	1	
MUTAGEN:KDD->FSY: Shortened centrioles. Reduced ciliogenesis.	SEQ_UP	1	
MUTAGEN:KDKKK->ADAAA: Impaired formation of liquid-liquid phase separation (LLPS), leading to reduced formation of the NLRP6 inflammasome and GSDMD-dependent release of IL18.	SEQ_UP	1	
MUTAGEN:KECLK->MECLM: Decreased DNA-binding and subsequent activation. Does not affect nuclear localization and tethering to chromatin.	SEQ_UP	1	
MUTAGEN:KEN->AAA: Drastically enhances protein stability.	SEQ_UP	1	
MUTAGEN:KESPDMTK->RESPDMTR: No effect on nuclear localization.	SEQ_UP	1	
MUTAGEN:KGEKSKYP->AAAAAAAA: Abolishes interaction with MYD88 and IL-1-dependent activation of NF-kappa-B.	SEQ_UP	1	
MUTAGEN:KGGTKK->RGGTRR: Decreased propionylation.	SEQ_UP	1	
MUTAGEN:KGKKK->AGAAA: No effect on DNA binding. Reduces acetylation. Reduces binding to CREBBP. Reduces ability to induce erythroid differentiation. Abrogates acetylation; when associated with 245-A-A-246. Abrogates ability to induce erythroid differentiation; when associated with 245-A-A-246. Reduces binding to CREBBP; when associated with 245-A-A-246. Disrupts stable association with chromatin; when associated with 245-A-A-246.	SEQ_UP	1	
MUTAGEN:KGKKK->RGRRR: No effect on DNA binding.	SEQ_UP	1	
MUTAGEN:KH->AA: Abolishes targeting to the nucleus.	SEQ_UP	1	
MUTAGEN:KH->AA: No effect on STAT3 phosphorylation.	SEQ_UP	1	
MUTAGEN:KHR->AAA: No effect on cleavage by LT, nor on IL1B processing. No effect on cleavage by LT, nor on IL1B processing; when associated with 38-A-A-39.	SEQ_UP	1	
MUTAGEN:KIK->AIA: Localizes mainly in cytoplasm and not in nucleus.	SEQ_UP	1	
MUTAGEN:KK->AA: Abolishes nuclear localization.	SEQ_UP	1	
MUTAGEN:KK->AA: ATP-binding site mutant; unable to activate MAPKAPK5.	SEQ_UP	1	
MUTAGEN:KK->AA: Complete loss of ubiquitination and increased radiosensitivity.	SEQ_UP	1	
MUTAGEN:KK->AA: Decreased interaction with COPB1.	SEQ_UP	1	
MUTAGEN:KK->AA: Does not affect localization to the nucleus.	SEQ_UP	1	
MUTAGEN:KK->AA: No effect on DNA binding. Reduces acetylation. Reduces ability to induce erythroid differentiation. Abrogates acetylation; when associated with 312-A--A-316. Abrogates ability to induce erythroid differentiation; when associated with 312-A--A-316. Reduces binding to CREBBP; when associated with 312-A--A-316. Disrupts stable association with chromatin; when associated with 312-A--A-316.	SEQ_UP	1	
MUTAGEN:KK->AA: Prevents nuclear localization of mutants lacking DRBM 3 function; when associated with 289-AAA-291.	SEQ_UP	1	
MUTAGEN:KK->AA: Reduces the increase of channel activity in response to ethanol and improves tolerance of intoxicating levels of alcohol.	SEQ_UP	1	
MUTAGEN:KK->AV: Reduced nuclear location.	SEQ_UP	1	
MUTAGEN:KK->DD: Loss of antimicrobial activity.	SEQ_UP	1	
MUTAGEN:KK->EE: Decreased actin-binding. Loss of actin binding; when associated with D-28 and 418-E-E-419.	SEQ_UP	1	
MUTAGEN:KK->EE: Decreased actin-binding. Loss of actin binding; when associated with D-28 and 427-E-E-428.	SEQ_UP	1	
MUTAGEN:KK->EE: Loss of interaction with ANK2. Loss of colocalization and cotransportation on motile vesicles with ANK2.	SEQ_UP	1	
MUTAGEN:KK->MM: No effect on interaction with NLRP3.	SEQ_UP	1	
MUTAGEN:KK->NS: Reduces nuclear localization.	SEQ_UP	1	
MUTAGEN:KK->RA: Abolishes LPS-stimulated IL12B synthesis.	SEQ_UP	1	
MUTAGEN:KK->RR: Decreased localization of SQSTM1/p62 to damaged mitochondria; when associated with R-25; R-33 and R-66.	SEQ_UP	1	
MUTAGEN:KK->RR: No effect on DNA binding.	SEQ_UP	1	
MUTAGEN:KK->RR: Some loss of sumoylation; Largely localized to the cytoplasm.	SEQ_UP	1	
MUTAGEN:KK->RR: Some loss of sumoylation. No change in nuclear localization.	SEQ_UP	1	
MUTAGEN:KKAEL->AKARA: Does not affect binding to ROCK1.	SEQ_UP	1	
MUTAGEN:KKAKKETSSSDSSEDSSEDEDK->AAAAAETSSSDSSEDSSEDEDA: Strongly reduced pyrophosphorylation.	SEQ_UP	1	
MUTAGEN:KKCRK->VALAL: Fails to bind to RE2 sequence motifs.	SEQ_UP	1	
MUTAGEN:KKCRLRRRMDSGRKNR->AACALAAAMDSGAANA: Loss of nuclear localization.	SEQ_UP	1	
MUTAGEN:KKEKEMKK->SSSSSSSS: No effect on RNA-binding.	SEQ_UP	1	
MUTAGEN:KKGKK->AAGAA: Abolishes binding to chondroitin sulfate proteoglycans. Abolishes receptor oligomerization via binding to large heparan sulfate proteoglycan structures.	SEQ_UP	1	
MUTAGEN:KKK->AAA: Abolishes nuclear import.	SEQ_UP	1	
MUTAGEN:KKK->AAA: Abolishes nuclear localization.	SEQ_UP	1	
MUTAGEN:KKK->NNN: Localizes to cytoplasm; when associated with 22-QQQ-24.	SEQ_UP	1	
MUTAGEN:KKK->QIN: Loss of interaction with EZR, MSN and RDX and co-localization to microvilli with EZR, MSN and RDX.	SEQ_UP	1	
MUTAGEN:KKK->QQQ: Abolishes phosphoinositide-binding and ability to activate TRPV1 without affecting the interaction with TRPV1.	SEQ_UP	1	
MUTAGEN:KKKQKQRQK->AAAQAQAQA: Abolishes phosphoinositide-binding but does not affect the interaction with TRPV1.	SEQ_UP	1	
MUTAGEN:KKKR->A: Abolishes processing of the protein.	SEQ_UP	1	
MUTAGEN:KKKR->AS: Abolishes processing of the protein.	SEQ_UP	1	
MUTAGEN:KKLR->NKLQ: Loss of exclusive nuclear localization, no effect on the interaction with SV40 large T antigen, adenovirus E1a, nor E2F1. Decreased growth inhibition activity, when transfected in Saos-2 cells. Complete loss of nuclear localization, loss of growth inhibition, when transfected in Saos-2 cells and loss of interaction with SV40 large T antigen, adenovirus E1a and E2F1; when associated with 733-K--P-769.	SEQ_UP	1	
MUTAGEN:KKMK->EEME: Abolishes membrane tubulation.	SEQ_UP	1	
MUTAGEN:KKR->AAA: Abolishes nuclear localization.	SEQ_UP	1	
MUTAGEN:KKR->AAA: Prevents nuclear localization of mutants lacking DRBM 3 function; when associated with 257-AA-258.	SEQ_UP	1	
MUTAGEN:KKR->QQQ: No binding to IP4, reduced binding to phospholipids.	SEQ_UP	1	
MUTAGEN:KKR->STS: Not detected in nucleus. Redistributed in cytoplasm.	SEQ_UP	1	
MUTAGEN:KKRK->AAAA: Abolishes nuclear localization; when associated with A-37 and A-38.	SEQ_UP	1	
MUTAGEN:KKS->AAA: Reduces the ability to traffic to the cilia.	SEQ_UP	1	
MUTAGEN:KKSR->AASA: Nearly abolishes protein processing.	SEQ_UP	1	
MUTAGEN:KKYK->QQYQ: In macrophages, no effect on transcriptional repression of genes encoding inflammatory molecules. In macrophages, no effect on competition with STAT5 for DNA-binding and transcriptional repression of genes encoding inflammatory molecules; when associated with K-21 and A-116.	SEQ_UP	1	
MUTAGEN:KL->AA: No effect on cleavage by LT, nor on IL1B processing.	SEQ_UP	1	
MUTAGEN:KL->RP: Abolishes homooligomerization.	SEQ_UP	1	
MUTAGEN:KLKNLKK->ALANLAA: Abolishes nuclear localization.	SEQ_UP	1	
MUTAGEN:KLR->ALA: Loss of interaction with APC and DCTN1.	SEQ_UP	1	
MUTAGEN:KN->MA: Reduced phosphodiesterase activity. Decreases inhibition of innate immune responses.	SEQ_UP	1	
MUTAGEN:KNTNKK->RNTNRR: Highly decreases Notch signaling pathway. Multi-ubiquitination pattern is reduced, although it does appear to be mono-ubiquitinated. Interacts with MIB1. Loss of cis interaction with NOTCH1.	SEQ_UP	1	
MUTAGEN:KPK->RKR: Loss of localization to the endoplasmic reticulum. Loss of fatty acid elongase activity.	SEQ_UP	1	
MUTAGEN:KPLG->AAAA: Strongly reduces interaction with PARD3. Does not abolish interaction with CDC42 and RHOQ.	SEQ_UP	1	
MUTAGEN:KQE->DTGD: Confers virus infectibility.	SEQ_UP	1	
MUTAGEN:KQEASTKA->DTGDVSSKV: Confers virus infectibility.	SEQ_UP	1	
MUTAGEN:KQKQR->NQNQS: Does not affect the subcellular localization.	SEQ_UP	1	
MUTAGEN:KR->AA: Abolished accumulation in the nucleus.	SEQ_UP	1	
MUTAGEN:KR->AA: Abolishes production of the mature chain and promotes apoptosis of superior cervical ganglion neurons; when associated with 49-A-A-50 and 120-A-A-121.	SEQ_UP	1	
MUTAGEN:KR->AA: Abolishes production of the mature chain and promotes apoptosis of superior cervical ganglion neurons; when associated with 49-A-A-50 and 79-A-A-80.	SEQ_UP	1	
MUTAGEN:KR->AA: Disrupts interaction with FYN SH3 domain.	SEQ_UP	1	
MUTAGEN:KR->AA: Loss of nuclear localization.	SEQ_UP	1	
MUTAGEN:KR->AA: Partially reduces its import in the nucleus.	SEQ_UP	1	
MUTAGEN:KR->EE: Abolishes translocation to PML nuclear bodies upon oxidative stress.	SEQ_UP	1	
MUTAGEN:KR->NA: Abolishes proteolytic cleavage of the propeptide.	SEQ_UP	1	
MUTAGEN:KR->NG: Abolishes formation the soluble form.	SEQ_UP	1	
MUTAGEN:KR->SS: Abolishes inhibition of PCSK1.	SEQ_UP	1	
MUTAGEN:KR->TG: Abolishes nuclear localization.	SEQ_UP	1	
MUTAGEN:KRFK->TSFT: Abolishes nuclear localization.	SEQ_UP	1	
MUTAGEN:KRK->AAA: Loss of interaction with FARP2.	SEQ_UP	1	
MUTAGEN:KRK->DRD: Abolishes binding to GMNN.	SEQ_UP	1	
MUTAGEN:KRK->QQQ: Binds phospholipids only in the absence of divalent cations.	SEQ_UP	1	
MUTAGEN:KRK->RRR: Impaired nuclear localization.	SEQ_UP	1	
MUTAGEN:KRKR->AAAA: Abrogates nuclear localization activity.	SEQ_UP	1	
MUTAGEN:KRKR->ARAA: Strongly reduces its import in the nucleus. Abolishes its import in the nucleus, does not change its export to the cytoplasm and the export of U snRNA complex; when associated with 190-AA-191.	SEQ_UP	1	
MUTAGEN:KRKR->QGTG: Abolishes the TNF-induced nuclear translocation.	SEQ_UP	1	
MUTAGEN:KRPR->AAAA: Induces relocalization to the cytosol.	SEQ_UP	1	
MUTAGEN:KRR->NGG: Loss of phosphorylation, interaction with EZR and localization to the uropodium.	SEQ_UP	1	
MUTAGEN:KRR->QQQ: Abolishes interaction with TRPA1. Increases interaction with TRPV1. Enhances interaction between TRPA1 and TRPV1.	SEQ_UP	1	
MUTAGEN:KS->AA: Almost abolishes MCM complex DNA helicase activity. Strongly decreases MCM complex ATPase activity. No effect on MCM complex formation. No effect on ATP and ssDNA binding.	SEQ_UP	1	
MUTAGEN:KS->AA: Decreased MCM complex DNA helicase activity. Loss of ATP-binding. Decreased MCM complex ATPase activity. No effect on MCM complex formation.	SEQ_UP	1	
MUTAGEN:KSTFKK->ASTFAA: Abolishes ubiquitination by the APC/C.	SEQ_UP	1	
MUTAGEN:KTFR->ATFA: Fails to bind to NIH-3T3 fibroblast cells; when associated with A-291.	SEQ_UP	1	
MUTAGEN:KTRK->AAAA: Almost completely blocks the ability to traffic to cilia. Disrupts interaction with RAB8A. Disrupts interaction with ARF4.	SEQ_UP	1	
MUTAGEN:KTRKIKP->AAAAAAA: Prevents ciliary localizytion.	SEQ_UP	1	
MUTAGEN:KTTLPGVVD->SG: Increased phosphodiesterase activity (in vitro).	SEQ_UP	1	
MUTAGEN:KVEEK->AVEEA: No effect on binding to NIH-3T3 fibroblast cells.	SEQ_UP	1	
MUTAGEN:KVVKNVIK->AVVANVIA: Reduced ability to induct pyroptosis.	SEQ_UP	1	
MUTAGEN:KWFKQ->AAASM: In H3; does not affect the interaction with SRF and keeps its ability to prevent transcription of cardiac-specific genes.	SEQ_UP	1	
MUTAGEN:KYKK->QYQQ: Abolishes ubiquitination and antibacterial activity and results in diffuse perinuclear distribution.	SEQ_UP	1	
MUTAGEN:L->A,D: Does not induce a nuclear accumulation in unstimulated cells.	SEQ_UP	1	
MUTAGEN:L->A,D: Induces a nuclear accumulation in unstimulated cells.	SEQ_UP	1	
MUTAGEN:L->A,D: Strongly reduced interaction with HRAS.	SEQ_UP	1	
MUTAGEN:L->A,F,P,T: Slightly reduced activity.	SEQ_UP	1	
MUTAGEN:L->A: 3- to 4-fold increase in Km for CoA. Reduced affinity for CoA.	SEQ_UP	1	
MUTAGEN:L->A: 60% of ENPP1 redirected to apical surface in epithelial cells. 75% of ENPP1 redirected to apical surface in epithelial cells; abrogation of increased NPP activity in oestoblastic matrix vesicles; when associated with A-32.	SEQ_UP	1	
MUTAGEN:L->A: 70% of ENPP1 redirected to apical surface in epithelial cells; abrogation of increased NPP activity in oestoblastic matrix vesicles. 75% of ENPP1 redirected to apical surface in epithelial cells; abrogation of increased NPP activity in oestoblastic matrix vesicles; when associated with A-31.	SEQ_UP	1	
MUTAGEN:L->A: Abolished ability to promote ubiquitination of reduced FNIP1.	SEQ_UP	1	
MUTAGEN:L->A: Abolished acyltransferase activity.	SEQ_UP	1	
MUTAGEN:L->A: Abolished ubiquitination and degradation by the BCR(KEAP1) complex in the cytoplasm; when associated with 19-A--A-23.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes binding to CD200R.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes binding to NUMB protein.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes cytosolic localization.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes estrogen-induced interaction with NCOA1.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes export from nucleus; when associated with A-67 and A-87.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes export from nucleus; when associated with A-67 and A-92.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes export from nucleus; when associated with A-87 and A-92.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes homodimerization.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes inhibition of FOXO1 transcriptional activity.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes interaction with ATP2A1/SERCA1.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes interaction with MAP2.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes interaction with RAB9A.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes interaction with SLC9A3R1 and effect on synapse formation.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes interaction with TBK1 and IKBKE.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes interaction with the elongin BC complex.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes localization to the nucleus and ability to prevent DNA demethylation; when associated with A-44.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes localization to the nucleus and ability to prevent DNA demethylation; when associated with A-46.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes nuclear export and interactions with itself and p75NTR/NGFR; when associated with A-94 and A-97.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes nuclear export and interactions with itself and p75NTR/NGFR; when associated with A-97 and A-99.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes receptor recycling; when associated with A-387.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes receptor recycling; when associated with A-390.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes the cytoplasmic localization; when associated with A-311; A-316 and A-320.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes the cytoplasmic localization; when associated with A-311; A-316 and A-322.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes the cytoplasmic localization; when associated with A-311; A-320 and A-322.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes the cytoplasmic localization; when associated with A-316; A-320 and A-322.	SEQ_UP	1	
MUTAGEN:L->A: Abolishes the interaction with RAP6A and localization to Golgi membrane; when associated with Ser-932.	SEQ_UP	1	
MUTAGEN:L->A: Abrogates completely INPP5D recruitment.	SEQ_UP	1	
MUTAGEN:L->A: Accumulation in the nucleus.	SEQ_UP	1	
MUTAGEN:L->A: Accumulation within the nucleus; when associated with A-289.	SEQ_UP	1	
MUTAGEN:L->A: Accumulation within the nucleus; when associated with A-291.	SEQ_UP	1	
MUTAGEN:L->A: Affects basolateral membrane sorting in vitro but not in vivo; when associated with 76-A-A-77 and A-219.	SEQ_UP	1	
MUTAGEN:L->A: Alters interaction with YWHAH.	SEQ_UP	1	
MUTAGEN:L->A: Constitutive active mutant. In a knockin model, mouse display increased amounts of head dips and open arm time on the maze, compared to littermate controls. In addition, they also explore further into the open arm on the elevated plus maze and are less active in the closed arm compared to littermate controls. Male knockin mice display no differences in anxiety, but their locomotor activity increases compared to non-transgenic littermates.	SEQ_UP	1	
MUTAGEN:L->A: Decrease in the interaction with BCL2 and BCL2L2.	SEQ_UP	1	
MUTAGEN:L->A: Decreased 'Lys-48'-linked polyubiquitin binding.	SEQ_UP	1	
MUTAGEN:L->A: Decreased 'Lys-48'-linked polyubiquitin binding. Loss of interaction with BAG6. Decreased association with the proteasome complex.	SEQ_UP	1	
MUTAGEN:L->A: Decreased activity; when associated with A-422 and A-429.	SEQ_UP	1	
MUTAGEN:L->A: Decreased transcriptional activity by about 2-fold in the absence of serum; when associated with A-463. Nuclear location but transcriptional activity decreased by about 50%. Abolishes the SIRT1 deacetylase binding and increases acetylation; when associated with A-24; A-253; A-316 and A-462.	SEQ_UP	1	
MUTAGEN:L->A: Decreased transcriptional activity by about 2-fold in the absence of serum; when associated with A-463. Nuclear location but transcriptional activity decreased by about 50%. Abolishes the SIRT1 deacetylase binding and increases acetylation; when associated with A-24; A-253; A-316 and A-463.	SEQ_UP	1	
MUTAGEN:L->A: Decreases adhesion to oocytes.	SEQ_UP	1	
MUTAGEN:L->A: Decreases interaction with SNX27.	SEQ_UP	1	
MUTAGEN:L->A: Disrupted binding to UBE2I, and no sumoylation.	SEQ_UP	1	
MUTAGEN:L->A: Disrupts homotrimerization; disrupts interaction with SYNE2; when associated with A-432.	SEQ_UP	1	
MUTAGEN:L->A: Disrupts homotrimerization; disrupts interaction with SYNE2; when associated with A-435.	SEQ_UP	1	
MUTAGEN:L->A: Disrupts interaction with SNX27.	SEQ_UP	1	
MUTAGEN:L->A: Disrupts KATNA1:KATNB1 interaction with ASPM.	SEQ_UP	1	
MUTAGEN:L->A: Does not affect ability to promote sperm-egg interaction.	SEQ_UP	1	
MUTAGEN:L->A: Does not affect the interaction with GATA1.	SEQ_UP	1	
MUTAGEN:L->A: Drastic decrease of CBX5, CBX1 and CBX3 binding; When associated with A-889.	SEQ_UP	1	
MUTAGEN:L->A: Enhances FOXO1 nuclear translocation but does not abolish inhibition of FOXO1 transcriptional activity in the absence of forskolin.	SEQ_UP	1	
MUTAGEN:L->A: Greatly decreases interaction with MAP1LC3B.	SEQ_UP	1	
MUTAGEN:L->A: Greatly reduced activity.	SEQ_UP	1	
MUTAGEN:L->A: Greatly reduced binding to MAD; when associated with A-329.	SEQ_UP	1	
MUTAGEN:L->A: Greatly reduced binding to MAD; when associated with A-332.	SEQ_UP	1	
MUTAGEN:L->A: Greatly reduced interaction with STAT3.	SEQ_UP	1	
MUTAGEN:L->A: Impaired interaction and cleavage by CASP1.	SEQ_UP	1	
MUTAGEN:L->A: Impaired interaction with DWORF and PLN; when associated with A-795 and A-809.	SEQ_UP	1	
MUTAGEN:L->A: Impairs autoinhibition; when associated with A-389. Impairs translocation to the cell membrane.	SEQ_UP	1	
MUTAGEN:L->A: Impairs autoinhibition; when associated with A-392.	SEQ_UP	1	
MUTAGEN:L->A: Impairs IL11RA binding and mildly reduces stimulation of cell proliferation.	SEQ_UP	1	
MUTAGEN:L->A: Impairs interaction with BRAF and association with membrane ruffles; when associated with A-78.	SEQ_UP	1	
MUTAGEN:L->A: Impairs interaction with CSF2RB. Impairs IL3-induced production of IL4 by basophils.	SEQ_UP	1	
MUTAGEN:L->A: Impairs interaction with DISC1.	SEQ_UP	1	
MUTAGEN:L->A: Impairs RHOA activation; when associated with 566-A-A-567.	SEQ_UP	1	
MUTAGEN:L->A: Impairs ubiquitin binding and post-translation modification via ubiquitination; when associated with A-509. Abolishes ubiquitin binding and localization to nuclear foci after UV-induced DNA damage but does not affect catalytic activity; when associated with A-508, A-693 and A-694.	SEQ_UP	1	
MUTAGEN:L->A: Impairs ubiquitin binding and post-translation modification via ubiquitination; when associated with A-694. Abolishes ubiquitin binding and localization to nuclear foci after UV-induced DNA damage but does not affect catalytic activity; when associated with A-508, A-509 and A-694.	SEQ_UP	1	
MUTAGEN:L->A: Increase in nuclear localization.	SEQ_UP	1	
MUTAGEN:L->A: Increased protein expression and stability.	SEQ_UP	1	
MUTAGEN:L->A: Increased threshold for activation by calcium.	SEQ_UP	1	
MUTAGEN:L->A: Increases the TLR7 response and decreases the TLR9 response.	SEQ_UP	1	
MUTAGEN:L->A: Induces a nuclear accumulation in unstimulated cells.	SEQ_UP	1	
MUTAGEN:L->A: Inhibits interaction with ubiquitin and ubiquitinated proteins; when associated with A-274. Reduces the cleavage of PTCRA; when associated with A-274.	SEQ_UP	1	
MUTAGEN:L->A: Inhibits interaction with ubiquitin and ubiquitinated proteins; when associated with A-278. Reduces the cleavage of PTCRA; when associated with A-278.	SEQ_UP	1	
MUTAGEN:L->A: Less than 10% of the wild-type maximal activity.	SEQ_UP	1	
MUTAGEN:L->A: Localizes mainly in cytoplasm and not in nucleus; when associated with D-483 and A-607.	SEQ_UP	1	
MUTAGEN:L->A: Loss of AP-1 transcription factor activity and reduced ability to activate CHUK and IKBKB. No effect on NF-kappa-B activity or activation of MAP2K1, MAP2K4, MAP2K7. Loss of binding to MAP2K4.	SEQ_UP	1	
MUTAGEN:L->A: Loss of binding to PP2A B-alpha regulatory subunit.	SEQ_UP	2	
MUTAGEN:L->A: Loss of E3 ubiquitin-protein ligase complex association and loss of activity of the complex. Does not affect localization of isoform 1 to the Z line or its interaction with DES.	SEQ_UP	1	
MUTAGEN:L->A: Loss of function; when associated with Q-55; D-63 and K-77.	SEQ_UP	1	
MUTAGEN:L->A: Loss of interaction with MAP1LC3B and significant decrease in its autophagy-mediated degradation; when associated with A-494.	SEQ_UP	1	
MUTAGEN:L->A: Loss of interaction with SMYD1.	SEQ_UP	1	
MUTAGEN:L->A: Loss of interaction with UBQLN1; when associated with A-177.	SEQ_UP	1	
MUTAGEN:L->A: Loss of nuclear export.	SEQ_UP	1	
MUTAGEN:L->A: Loss of pericentromeric heterochromatin location. Abolishes DNA binding.	SEQ_UP	1	
MUTAGEN:L->A: Loss of pro-apoptotic activity and of targeting to mitochondria; when associated with A-27.	SEQ_UP	1	
MUTAGEN:L->A: Loss of pro-apoptotic activity and of targeting to mitochondria; when associated with A-78.	SEQ_UP	1	
MUTAGEN:L->A: Loss of protein phosphorylation at Y-329 and Y-334; when associated with A-270.	SEQ_UP	1	
MUTAGEN:L->A: Loss of self-renewal in embryonic stem cells in absence of LIF; when associated with A-425. Does not interact with NCOA3; when associated with A-425.	SEQ_UP	1	
MUTAGEN:L->A: Loss of transcriptional activation; when associated with A-450.	SEQ_UP	1	
MUTAGEN:L->A: Loss of transcriptional activation; when associated with A-453.	SEQ_UP	1	
MUTAGEN:L->A: Loss of ubiquitination and interaction with UBQLN1; when associated with A-883.	SEQ_UP	1	
MUTAGEN:L->A: Loss of ubiquitination and interaction with UBQLN1; when associated with A-885.	SEQ_UP	1	
MUTAGEN:L->A: Nearly abolishes enzyme activity.	SEQ_UP	1	
MUTAGEN:L->A: No change in DNA binding. Loss of self-renewal ability in iPS cells. No change in nuclear location. No loss of ability to bind SOX2. Reduced levels of CHD4 and SMARCA4 in a POU5F1 pulldown assay.	SEQ_UP	1	
MUTAGEN:L->A: No change in increased NPP activity in oestoblastic matrix vesicles.	SEQ_UP	1	
MUTAGEN:L->A: No effect on 'Lys-48'-linked polyubiquitin binding.	SEQ_UP	1	
MUTAGEN:L->A: No effect on affinity for CALM; when associated with A-737.	SEQ_UP	1	
MUTAGEN:L->A: No effect on autophosphorylation and AP-1 transcription factor, MAPK7 or MAPK8 activity. Fails to induce activation and loss of autophosphorylation; when associated with A-582.	SEQ_UP	1	
MUTAGEN:L->A: No effect on interaction with MAP2.	SEQ_UP	1	
MUTAGEN:L->A: No effect on interaction with TACC3.	SEQ_UP	1	
MUTAGEN:L->A: No effect on interaction with TLR3.	SEQ_UP	1	
MUTAGEN:L->A: No effect on its interaction with MAP1LC3B and moderate decrease in its autophagy-mediated degradation; when associated with A-287.	SEQ_UP	1	
MUTAGEN:L->A: No effect on its interaction with MAP1LC3B and moderate decrease in its autophagy-mediated degradation; when associated with A-488.	SEQ_UP	1	
MUTAGEN:L->A: No effect on LIF-induced signal transduction suppression.	SEQ_UP	1	
MUTAGEN:L->A: No effect on nuclear import; when associated with A-77 and W-174.	SEQ_UP	1	
MUTAGEN:L->A: No effect on PDCD1 binding.	SEQ_UP	1	
MUTAGEN:L->A: No effect on pericentromeric heterochromatin location. Disrupted DNA binding.	SEQ_UP	1	
MUTAGEN:L->A: No effect on pericentromeric heterochromatin location. No change in DNA binding.	SEQ_UP	1	
MUTAGEN:L->A: No effect on subcellular location.	SEQ_UP	1	
MUTAGEN:L->A: No effect on UBE2I binding nor on sumoylation.	SEQ_UP	1	
MUTAGEN:L->A: No effect.	SEQ_UP	1	
MUTAGEN:L->A: No loss of interaction with GYS2.	SEQ_UP	1	
MUTAGEN:L->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-286.	SEQ_UP	1	
MUTAGEN:L->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-288.	SEQ_UP	1	
MUTAGEN:L->A: No sumoylation.	SEQ_UP	1	
MUTAGEN:L->A: Not exported to the cytoplasm; when associated with A-234.	SEQ_UP	1	
MUTAGEN:L->A: Not exported to the cytoplasm; when associated with A-236.	SEQ_UP	1	
MUTAGEN:L->A: Nuclear localization. Causes nuclear relocalization of MAPK10.	SEQ_UP	1	
MUTAGEN:L->A: PDCD1 binding.	SEQ_UP	1	
MUTAGEN:L->A: Prevents receptor internalization.	SEQ_UP	1	
MUTAGEN:L->A: Reduced binding to CHO cells expressing ITAG9-ITGB1.	SEQ_UP	1	
MUTAGEN:L->A: Reduced homoolimerization, leading to reduced ability to induce pyroptosis.	SEQ_UP	1	
MUTAGEN:L->A: Reduced lysophospholipase activity.	SEQ_UP	1	
MUTAGEN:L->A: Reduced nuclear export; when associated with A-251.	SEQ_UP	1	
MUTAGEN:L->A: Reduced nuclear export; when associated with A-272.	SEQ_UP	1	
MUTAGEN:L->A: Reduced nuclear export; when associated with A-274.	SEQ_UP	1	
MUTAGEN:L->A: Reduced phosphorylation.	SEQ_UP	1	
MUTAGEN:L->A: Reduces Arf-GAP mediated stimulation of GTP hydrolysis 100-fold and abolishes Arf-GAP mediated stimulation of GTP hydrolysis; when associated with A-285.	SEQ_UP	1	
MUTAGEN:L->A: Reduces calcium flux by about 50%.	SEQ_UP	1	
MUTAGEN:L->A: Reduces DNA-binding, attenuates transcriptional activity, does not effect estrogen-dependent NF-kappa B transcriptional repression; when associated with E-508 and E-512.	SEQ_UP	1	
MUTAGEN:L->A: Reduces DNA-binding, attenuates transcriptional activity, does not effect estrogen-dependent NF-kappa B transcriptional repression; when associated with E-508 and E-515.	SEQ_UP	1	
MUTAGEN:L->A: Reduces DNA-binding, attenuates transcriptional activity, does not effect estrogen-dependent NF-kappa B transcriptional repression; when associated with E-512 and E-515.	SEQ_UP	1	
MUTAGEN:L->A: Reduces transcriptional activity, no effect on estrogen-induced interaction with NCOA1. Abolishes estrogen-induced interaction with NCOA1; when associated with A-362 and A-380.	SEQ_UP	1	
MUTAGEN:L->A: Reduction in homodimerization.	SEQ_UP	1	
MUTAGEN:L->A: Reduction in homodimerization. Abolishes homodimerization; when associated with P-281.	SEQ_UP	1	
MUTAGEN:L->A: Severe loss of interaction with GYS2.	SEQ_UP	1	
MUTAGEN:L->A: Severely reduced transcriptional repression activity.	SEQ_UP	1	
MUTAGEN:L->A: Significant decrease in interaction with ARL6IP1 and no influence on SLC1A1/EAAC1-mediated glutamate transport; when associated with A-110.	SEQ_UP	1	
MUTAGEN:L->A: Significant reduction in interaction with RDX.	SEQ_UP	1	
MUTAGEN:L->A: Significant reduction in nucleocytoplasmic shuttling; when associated with A-154.	SEQ_UP	1	
MUTAGEN:L->A: Significant reduction in nucleocytoplasmic shuttling; when associated with A-157.	SEQ_UP	1	
MUTAGEN:L->A: Significant reduction in nucleocytoplasmic shuttling; when associated with A-370.	SEQ_UP	1	
MUTAGEN:L->A: Significant reduction in nucleocytoplasmic shuttling; when associated with A-374.	SEQ_UP	1	
MUTAGEN:L->A: Slightly affects the interaction with GATA1.	SEQ_UP	1	
MUTAGEN:L->A: Slightly reduces affinity for BMP2 and BMP4. No effect on inhibition of BMP2 signaling.	SEQ_UP	1	
MUTAGEN:L->A: Strongly decreased transcriptional activation in response to viral infection.	SEQ_UP	1	
MUTAGEN:L->A: Strongly decreases sphingosine kinase activity. Decreases apoptosis induction. No effect on endoplasmic reticulum location increase upon serum starvation. Abolishes sphingosine kinase activity and decreases apoptosis induction; when associated with E-213.	SEQ_UP	1	
MUTAGEN:L->A: Strongly inhibits depolymerization; when associated with A-1009 and A-1010.	SEQ_UP	1	
MUTAGEN:L->A: Strongly inhibits depolymerization; when associated with A-1009 and A-1019.	SEQ_UP	1	
MUTAGEN:L->A: Strongly inhibits depolymerization; when associated with A-1010 and A-1019.	SEQ_UP	1	
MUTAGEN:L->A: Strongly reduced interaction with ANKRD31; when associated with A-28.	SEQ_UP	1	
MUTAGEN:L->A: Strongly reduced interaction with ANKRD31; when associated with A-74.	SEQ_UP	1	
MUTAGEN:L->A: Strongly reduces interaction with OAZ1 and unable to abrogate both the inhibitory effect of OAZ1 on ornithine decarboxylase (ODC) activity and polyamine uptake; when associated with A-139 and A-142.	SEQ_UP	1	
MUTAGEN:L->A: Strongly reduces interaction with STX1A.	SEQ_UP	1	
MUTAGEN:L->A: Wild-type in binding to C.botulinum neurotoxin type G (BoNT/G, botG).	SEQ_UP	1	
MUTAGEN:L->C: Abolishes channel activity.	SEQ_UP	1	
MUTAGEN:L->D,K: Strongly reduced binding of target proteins. Strongly reduced degradation of target proteins.	SEQ_UP	1	
MUTAGEN:L->D: Abolishes barbed-end actin-binding without affecting actin bundling activity.	SEQ_UP	1	
MUTAGEN:L->D: Abolishes binding to JAK2. No effect on binding to EPOR.	SEQ_UP	1	
MUTAGEN:L->D: Abolishes interaction with GBA. No effect on normal location in lysosomes.	SEQ_UP	1	
MUTAGEN:L->D: Abolishes interaction with HIF1AN.	SEQ_UP	1	
MUTAGEN:L->D: Decreases FBXL3 binding. Strongly decreases CRY2 degradation.	SEQ_UP	1	
MUTAGEN:L->D: Disrupts intramolecular interactions and autoinhibition, leading to spontaneous pyroptosis-inducing activity.	SEQ_UP	1	
MUTAGEN:L->D: Does not abolish interaction with ASIC3, but abolishes regulation of ASIC3 channel activity; when associated with D-97 and D-109.	SEQ_UP	1	
MUTAGEN:L->D: Does not abolish interaction with ASIC3, but abolishes regulation of ASIC3 channel activity; when associated with D-97 and D-145.	SEQ_UP	1	
MUTAGEN:L->D: Does not affect transcription factor activity.	SEQ_UP	1	
MUTAGEN:L->D: Induces a nuclear decrease in unstimulated cells.	SEQ_UP	1	
MUTAGEN:L->D: Interfers with transcription factor activity.	SEQ_UP	1	
MUTAGEN:L->D: Markedly decreased induction of pyroptosis and defects in liposome-binding. No spontaneous pyroptosis-inducing activity; when associated with K-14.	SEQ_UP	1	
MUTAGEN:L->D: No effect on transcriptional activation in response to viral infection.	SEQ_UP	1	
MUTAGEN:L->D: Reduced homoolimerization, leading to reduced ability to induce pyroptosis.	SEQ_UP	1	
MUTAGEN:L->D: Reduces binding affinity for misfolded proteins by 40%.	SEQ_UP	1	
MUTAGEN:L->D: Reduces transcriptional activity and estrogen-induced interaction with NCOA1.	SEQ_UP	1	
MUTAGEN:L->D: Significantly reduces binding affinities of the AHR?ARNT heterodimer to DRE.	SEQ_UP	1	
MUTAGEN:L->D: Spontaneous pyroptosis-inducing activity.	SEQ_UP	1	
MUTAGEN:L->D: Strongly reduces Sin3A binding.	SEQ_UP	1	
MUTAGEN:L->E: Abolished ability to promote phosphatidylserine exposure. Promotes localization to the cytoplasm.	SEQ_UP	1	
MUTAGEN:L->E: Abolishes DNA-binding, abolishes transcriptional activity and estrogen-dependent NF-kappa B transcriptional repression; when associated with E-508 and E-512.	SEQ_UP	1	
MUTAGEN:L->E: Abolishes DNA-binding, abolishes transcriptional activity and estrogen-dependent NF-kappa B transcriptional repression; when associated with E-508 and E-515.	SEQ_UP	1	
MUTAGEN:L->E: Abolishes DNA-binding, abolishes transcriptional activity and estrogen-dependent NF-kappa B transcriptional repression; when associated with E-512 and E-515.	SEQ_UP	1	
MUTAGEN:L->E: Abolishes interaction with GPSM2.	SEQ_UP	1	
MUTAGEN:L->E: Abolishes Rac1 activation; when associated with A-1427.	SEQ_UP	1	
MUTAGEN:L->E: Abrogates interaction with EED.	SEQ_UP	1	
MUTAGEN:L->E: Abrogates interaction with EZH2.	SEQ_UP	1	
MUTAGEN:L->E: Compromises SIM1:ARNT2 heterodimer stability. Compromises NPAS4:ARNT2 heterodimer stability.	SEQ_UP	1	
MUTAGEN:L->E: Compromises SIM1:ARNT2 heterodimer stability. Does not compromises NPAS4:ARNT2 heterodimer stability.	SEQ_UP	1	
MUTAGEN:L->E: Decreased ceramide synthase activity.	SEQ_UP	1	
MUTAGEN:L->E: Disrupts interaction with ANKRD27.	SEQ_UP	1	
MUTAGEN:L->E: Disrupts one GNAI3 binding site.	SEQ_UP	1	
MUTAGEN:L->E: Embryonic lethal.	SEQ_UP	2	
MUTAGEN:L->E: Highly disrupts the dimerization ability of AHR. Reduces transcription activity. Decreases interaction with ARNT.	SEQ_UP	1	
MUTAGEN:L->E: Highly disrupts the dimerization ability of AHR. Reduces transcription activity. Impairs interaction with ARNT.	SEQ_UP	1	
MUTAGEN:L->E: Highly reduces transcription activity. Impairs interaction with AHR. Impairs heterodimer formation with EPAS1. Impairs heterodimer formation with HIF1A. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Compromise NPAS4:ARNT heterodimer stability. Compromise AHR:ARNT heterodimer stability.	SEQ_UP	1	
MUTAGEN:L->E: Impaired pore-formation.	SEQ_UP	1	
MUTAGEN:L->E: Impairs heterodimer formation with EPAS1. Impairs heterodimer formation with HIF1A. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Compromise NPAS4:ARNT heterodimer stability. Compromise AHR:ARNT heterodimer stability.	SEQ_UP	1	
MUTAGEN:L->E: Impairs interaction with EZH2.	SEQ_UP	1	
MUTAGEN:L->E: Inhibits transformation by N-terminal truncated form.	SEQ_UP	1	
MUTAGEN:L->E: Loss of binding to JH1/Y-1007 of JAK2 and loss of signal transduction suppression.	SEQ_UP	1	
MUTAGEN:L->E: Loss of function mutant which is unable to promote clathrin coated-pits formation. Binds to membrane but is unable to induce membrane tubulation. Induces the formation of large and static clathrin-coated pits.	SEQ_UP	1	
MUTAGEN:L->E: No effect on chiting-binding. No restoration of chitinase activity.	SEQ_UP	1	
MUTAGEN:L->E: Reduced ARNTL/BMAL1 binding. Abolishes transcriptional activation by the CLOCK-ARNTL/BMAL1 heterodimer.	SEQ_UP	1	
MUTAGEN:L->E: Reduced ARNTL/BMAL1 binding. Abolishes transcriptional activation by the CLOCK-ARNTL/BMAL1 heterodimer. Abolishes regulation of circadian clock.	SEQ_UP	1	
MUTAGEN:L->E: Reduced CLOCK binding. Abolishes transcriptional activation by the CLOCK-ARNTL/BMAL1 heterodimer.	SEQ_UP	1	
MUTAGEN:L->E: Reduces PRDM14 and OCT14 occupancy on target sites, no effect on interaction with PRDM14, predicted to impair homooligomerization; when associated with R-330; R-342; R-345; R-363 and R-374.	SEQ_UP	1	
MUTAGEN:L->E: Reduces PRDM14 and OCT14 occupancy on target sites, no effect on interaction with PRDM14, predicted to impair homooligomerization; when associated with R-342; R-345; E-346; E-360; R-363 and R-374.	SEQ_UP	1	
MUTAGEN:L->E: Reduces the AHR induction transcription activity by 50%. Increases ligand-induced nuclear translocation of AHR.	SEQ_UP	1	
MUTAGEN:L->E: Significantly reduces binding affinities of the AHR?ARNT heterodimer to DRE.	SEQ_UP	1	
MUTAGEN:L->E: Strongly reduces interaction with EPS15 and SYNRG.	SEQ_UP	1	
MUTAGEN:L->F: Abolishes ligand binding and reduces transactivation; when associated with W-270.	SEQ_UP	1	
MUTAGEN:L->F: Acquires binding to CD200; when associated with K-87 and T-90.	SEQ_UP	1	
MUTAGEN:L->F: Binds to DNA with reduced affinity.	SEQ_UP	1	
MUTAGEN:L->F: Diminished binding of coactivator NCOA2 in the presence of TCPOBOP.	SEQ_UP	1	
MUTAGEN:L->F: Diminishes significantly the interaction and coactivation OF PPARA; when associated with F-726.	SEQ_UP	1	
MUTAGEN:L->F: Displays constitutive phospholipid scramblase activity.	SEQ_UP	1	
MUTAGEN:L->F: Dramatic increase in binding NCOA2. Little effect on binding of coactivator NCOA2 in the presence of TCPOBOP.	SEQ_UP	1	
MUTAGEN:L->F: No effect on homophilic interaction. Changed homophilic interaction; when associated with P-143.	SEQ_UP	1	
MUTAGEN:L->F: No effect on protein-cysteine S-palmitoyltransferase activity. No effect on localization to the cis-Golgi network.	SEQ_UP	1	
MUTAGEN:L->F: Shows a defect in ciliary localization with no apparent effect on ciliation, mitosis or centriole number.	SEQ_UP	1	
MUTAGEN:L->F: Stability of binding to DNA reduced.	SEQ_UP	1	
MUTAGEN:L->F: Unable to inhibit TNF-induced necrosis; when associated with R-69. Unable to induce TNF nuclear translocation; when associated with R-69.	SEQ_UP	1	
MUTAGEN:L->G: 17-fold less potently activated by the Scolopendra mutilans RhTx toxin.	SEQ_UP	1	
MUTAGEN:L->G: Accumulation in the nucleus due to defects in nuclear export.	SEQ_UP	1	
MUTAGEN:L->G: Almost abolishes response to semaphorin.	SEQ_UP	1	
MUTAGEN:L->G: Does not interacts with ITPR1. Triggers apoptosis.	SEQ_UP	1	
MUTAGEN:L->G: Impairs IL17A-mediated signaling.	SEQ_UP	1	
MUTAGEN:L->G: Inhibits partially calcium-dependent translocation to the cell membrane. Inhibits calcium-dependent translocation to the cell membrane; when associated with G-282 and G-283.	SEQ_UP	1	
MUTAGEN:L->G: Low transactivation activity.	SEQ_UP	1	
MUTAGEN:L->G: No effect on PARD6B interaction. Prevents interaction with PATJ; when associated with G-154.	SEQ_UP	1	
MUTAGEN:L->G: Partially prevents interaction with LIN7C.	SEQ_UP	1	
MUTAGEN:L->G: Prevents interaction with LIN7C.	SEQ_UP	1	
MUTAGEN:L->G: Reduced homoolimerization, leading to reduced ability to induce pyroptosis.	SEQ_UP	1	
MUTAGEN:L->G: Results in inhibition of JNK binding.	SEQ_UP	1	
MUTAGEN:L->G: Strongly reduced interaction with PCDH15.	SEQ_UP	1	
MUTAGEN:L->H: Decreases sulfotransferase activity (at pH 6.27).	SEQ_UP	1	
MUTAGEN:L->H: Loss of interaction with TNFRSF14.	SEQ_UP	1	
MUTAGEN:L->H: Strongly increases activity with pyridoxal phosphate.	SEQ_UP	1	
MUTAGEN:L->I: 75% decrease of both activities.	SEQ_UP	1	
MUTAGEN:L->I: Complete loss RAN-GEF activity. Partial loss of RAN-binding.	SEQ_UP	1	
MUTAGEN:L->I: Reduced secretion to the medium; localizes mainly to the Golgi apparatus. Mild dystrophy with reduced alpha-dystroglycan glycosylation and no apparent brain defects.	SEQ_UP	1	
MUTAGEN:L->K: Abolishes binding to CD200R.	SEQ_UP	1	
MUTAGEN:L->K: Loss of MAIT cell activation.	SEQ_UP	1	
MUTAGEN:L->K: Minor effect on binding and degradation of target proteins.	SEQ_UP	1	
MUTAGEN:L->M: Reduced activity.	SEQ_UP	1	
MUTAGEN:L->N: Does not glycosylated.	SEQ_UP	1	
MUTAGEN:L->N: Strongly decreases RNA-binding.	SEQ_UP	1	
MUTAGEN:L->P,R: No effect on activity.	SEQ_UP	1	
MUTAGEN:L->P: 25-fold reduction in bioactivity.	SEQ_UP	1	
MUTAGEN:L->P: 450-fold reduction in bioactivity.	SEQ_UP	1	
MUTAGEN:L->P: 5500-fold reduction in bioactivity.	SEQ_UP	1	
MUTAGEN:L->P: Abolishes CDC20 binding.	SEQ_UP	1	
MUTAGEN:L->P: Abolishes DNA-binding and transactivator/repressor activity; when associated with I-407.	SEQ_UP	1	
MUTAGEN:L->P: Abolishes interaction with elongin BC complex; when associated with F-179.	SEQ_UP	1	
MUTAGEN:L->P: Abolishes interaction with HSP70 and TNFRSF1A.	SEQ_UP	1	
MUTAGEN:L->P: Abolishes interaction with MXI1.	SEQ_UP	1	
MUTAGEN:L->P: Abolishes interaction with USF2.	SEQ_UP	1	
MUTAGEN:L->P: Abolishes interaction with XRCC6.	SEQ_UP	1	
MUTAGEN:L->P: Abolishes PKA-RI-alpha binding; when associated with P-265.	SEQ_UP	1	
MUTAGEN:L->P: Abolishes PKA-RI-alpha binding; when associated with P-269.	SEQ_UP	1	
MUTAGEN:L->P: Complete loss of PRKAR2A-binding.	SEQ_UP	1	
MUTAGEN:L->P: Decreased protein abundance. Not delivered to the plasma membrane.	SEQ_UP	1	
MUTAGEN:L->P: Decreases protein expression. Decreases mitochondrial ribosomal subunits and translationally competent mitoribosomes. Mutant mice show heart hypertrophy and liver steatosis.	SEQ_UP	1	
MUTAGEN:L->P: Defects in depolarization of photoreceptors in the inner retina, and defects in cone photoreceptor light response. Gross morphology is normal.	SEQ_UP	1	
MUTAGEN:L->P: Defects in photoreceptor light response and loss of photoreceptors by one year of age.	SEQ_UP	1	
MUTAGEN:L->P: Disrupts interaction with ZFPM1 and binding to DNA.	SEQ_UP	1	
MUTAGEN:L->P: Disrupts targeting to membrane; when associated with A-67; N-68; Q-70; A-74 and Q-75.	SEQ_UP	1	
MUTAGEN:L->P: Does not rescue cortical neuron migration defects in PHACTR1 knocked-down mice.	SEQ_UP	1	
MUTAGEN:L->P: Failure to restore localization of PALS1 and PATJ to cell-cell contacts and to restore tight junction and adherens junction formation in cells where PALS1 has been knocked down.	SEQ_UP	1	
MUTAGEN:L->P: Highly susceptible to mouse cytomegalovirus infection. Shows low level of cytokine induction and natural killer activation on viral infection.	SEQ_UP	1	
MUTAGEN:L->P: Homozygous mice have their visual function which is severely reduced, consistent with significant loss of retinal ganglion cells and degeneration of axons in the optic nerve. They also display a severe multi-systemic disease characterized by reduced lifespan (<4 months), decreased weight, dilated cardiomyopathy, extrapyramidal dysfunction and gross neuro-muscular defects.	SEQ_UP	1	
MUTAGEN:L->P: Impaired ability to induce necroptosis.	SEQ_UP	1	
MUTAGEN:L->P: Impairs interaction with KAT7.	SEQ_UP	1	
MUTAGEN:L->P: In chato; probable null mutation. Almost abolishes transcriptional repression. No effect on interaction with THRIM28. Embryonic development arrests at stage 9 dpc. Widespread morphogenetic defects are found in all germ layers, associated with defective convergent extension movements. The anterior-posterior axis is abnormally shortened, somites are mediolaterally expanded, and the neural tube fails to close normally. Morphogenesis of most mesodermal tissues is also defective. The definitive endoderm fails to narrow and elongate leading to an open gut tube. Extraembryonic tissues are also abnormal with bubble-like protrusions in the yolk sac, aberrant migration of extraembryonic mesoderm, and incomplete placental development. Abolishes interaction with TRIM28; when associated with P-154.	SEQ_UP	1	
MUTAGEN:L->P: In maki; expanded motor neuron domain in the 10.5 dpc neural tube.	SEQ_UP	1	
MUTAGEN:L->P: In MommeD6; severe developmental delay leading to lethality before gastrulation. Mutants exhibit impaired primitive streak elongation, delayed epithelial-to-mesenchymal transition during gastrulation and an increase in p53/TP53-driven apoptosis. Epiblasts show an increased expression of p53 pathway genes as well as several pluripotency-associated long non-coding RNAs.	SEQ_UP	1	
MUTAGEN:L->P: In Rco2 mutant; gain-of-function mutation; causes an alopecia phenotype. Attenuates intramolecular interaction between the N- and C-terminal domains, hence may relieve autoinhibition; constitutively active in triggering pyroptosis.	SEQ_UP	1	
MUTAGEN:L->P: In Rex mutant Re; mice exhibit curly hair and vibrissae. The diameter of the hair shaft is irregular due to morphological abnormalities in all three layers of the irs.	SEQ_UP	1	
MUTAGEN:L->P: In wim; embryos arrest at 10.5-11.5 dpc and display an open neural tube in the head that lack the normal groove on the ventral midline. They lack ventral neural cell types and display other phenotypes characteristic of defects in Sonic hedgehog signaling.	SEQ_UP	1	
MUTAGEN:L->P: Increased PRKAR2A-binding; when associated with P-245.	SEQ_UP	1	
MUTAGEN:L->P: Loss of activity, but function in microtubule stability not affected; when associated with W-134 and W-136.	SEQ_UP	1	
MUTAGEN:L->P: Loss of interaction with PPP1R12C and PPP1R12A.	SEQ_UP	1	
MUTAGEN:L->P: Lowers translocation to the nucleus.	SEQ_UP	1	
MUTAGEN:L->P: Mice bearing this mutation exhibit several retinal pigment epithelium (RPE) anomalies, including pigmentary abnormalities, focal thickening, elevated lesions, and decreased light-activated responses. Mutant animals show dysmorphology in the form of RPE cell shedding and accumulation of large multinucleated RPE cells.	SEQ_UP	1	
MUTAGEN:L->P: Mutant male mice exhibit meiotic arrest, azoospermia and infertility. Females exhibit infertility or low reproductive capacity.	SEQ_UP	1	
MUTAGEN:L->P: No association with Elongin BC complex; when associated with F-50.	SEQ_UP	1	
MUTAGEN:L->P: No effect on protein abundance. No effect on cell surface localization. No effect on alanine uptake activity.	SEQ_UP	1	
MUTAGEN:L->P: No effect on transcriptional repression. Abolishes interaction with TRIM28; when associated with P-64.	SEQ_UP	1	
MUTAGEN:L->P: No effect.	SEQ_UP	1	
MUTAGEN:L->P: Not able to rescue mitochondrial respiratory chain defects observed in knockout mice.	SEQ_UP	1	
MUTAGEN:L->P: Null allele. Abrogates interaction with EZH2 and impairs transcriptional repression.	SEQ_UP	1	
MUTAGEN:L->P: Progressive ataxia associated with Purkinje cell death. Retinal thinning due to photoreceptor cell death.	SEQ_UP	1	
MUTAGEN:L->P: Reduction in homodimerization.	SEQ_UP	1	
MUTAGEN:L->P: Reduction in homodimerization. Abolishes homodimerization; when associated with A-281.	SEQ_UP	1	
MUTAGEN:L->P: Results in retention of the protein in the Golgi apparatus.	SEQ_UP	1	
MUTAGEN:L->P: Significant loss of transactivation activity.	SEQ_UP	1	
MUTAGEN:L->Q: 50% reduced activity.	SEQ_UP	1	
MUTAGEN:L->Q: Abolished interaction with ATF4.	SEQ_UP	1	
MUTAGEN:L->Q: Does not inhibit interaction with TTI1 or TTI2. Inhibits weakly interaction with TTI1 or TTI2; when associated with E-407 or R-424. Inhibits interaction with TTI1 or TTI2; when associated with E-407 and R-424.	SEQ_UP	1	
MUTAGEN:L->Q: Impair expression of folded protein.	SEQ_UP	1	
MUTAGEN:L->Q: In ENU mutant Arhgap35-D34; mutant animals show hypodysplastic kidneys and neural tube closure defects; the number of ciliated cells and cilia average length are drastically reduced in the proximal tubules. Results in loss of activation of GTP hydrolysis.	SEQ_UP	1	
MUTAGEN:L->Q: In mlh (mergulhador phenotype); affected mice have defects in the formation of otoconia in the inner ear, but do not suffer from deafness or other inner ear defects. They cannot perceive gravity and have problems with spatial orientation and with keeping their equilibrium. They show typical head-tilting behavior and are unable to swim. Impaired subcellular localization to the plasma membrane.	SEQ_UP	1	
MUTAGEN:L->Q: In wobbly mutant; destabilization of the elongator complex and reduced tRNA wobble base modification leading to protein misfolding and aggregation in Purkinje neurons (PN), PN degeneration, microgliosis triggered by the NLPR3 inflammasome and an ataxia-like phenotype.	SEQ_UP	1	
MUTAGEN:L->Q: Increases guanyl-nucleotide exchange factor activity with RAC1; when associated with R-730.	SEQ_UP	1	
MUTAGEN:L->Q: Loss of cleavage by LT and of LT-induced IL1B processing and suppression of LT-induced pyroptosis in macrophages, no effect on IL1B release in response to metabolic inhibitors; when associated with A-44 and Q-45.	SEQ_UP	1	
MUTAGEN:L->Q: Loss of cleavage by LT and of LT-induced IL1B processing. Loss of cleavage by LT and of LT-induced IL1B processing; when associated with Q-43 and A-44. No effect on IL1B release in response to metabolic inhibitors; when associated with Q-43 and A-44.	SEQ_UP	1	
MUTAGEN:L->Q: Loss of function and oligomerization.	SEQ_UP	1	
MUTAGEN:L->Q: Loss of trimeric subunit ABC assembly.	SEQ_UP	1	
MUTAGEN:L->Q: No change in apoptosis induction; when associated with Q-71 and Q-74.	SEQ_UP	1	
MUTAGEN:L->Q: No change in apoptosis induction; when associated with Q-71 and Q-78.	SEQ_UP	1	
MUTAGEN:L->Q: No change in apoptosis induction; when associated with Q-74 and Q-78.	SEQ_UP	1	
MUTAGEN:L->Q: Significanly reduced interaction with SUMO2.	SEQ_UP	1	
MUTAGEN:L->R: Abolishes interaction with XRCC6.	SEQ_UP	1	
MUTAGEN:L->R: Does not inhibit interaction with TTI1 or TTI2. Inhibits weakly interaction with TTI1 or TTI2; when associated with Q-395 or E-407. Inhibits interaction with TTI1 or TTI2; when associated with Q-395 and E-407.	SEQ_UP	1	
MUTAGEN:L->R: Impaired acyltransferase activity.	SEQ_UP	1	
MUTAGEN:L->R: Impairs self-association, reduces protein stability and promotes localization to actin fibers.	SEQ_UP	1	
MUTAGEN:L->R: Increases guanyl-nucleotide exchange factor activity with RAC1; when associated with Q-733.	SEQ_UP	1	
MUTAGEN:L->R: Loss of activity.	SEQ_UP	1	
MUTAGEN:L->R: Misfolded, leading to the interaction with TOR1A, ubiquitination and a decrease of the half-life. Impairs intracellular transport. No effect on glycosylation.	SEQ_UP	1	
MUTAGEN:L->R: Mislocalization of the protein from Golgi apparatus to endoplasmic reticulum.	SEQ_UP	1	
MUTAGEN:L->R: No effect on channel activity of the complex with LRRC8A.	SEQ_UP	1	
MUTAGEN:L->R: Reduced interaction with GORASP2.	SEQ_UP	1	
MUTAGEN:L->R: Reduced JAK2/STAT5 activation.	SEQ_UP	1	
MUTAGEN:L->R: Reduces PRDM14 and OCT14 occupancy on target sites, no effect on interaction with PRDM14, predicted to impair homooligomerization; when associated with R-330; R-342; R-345; E-346; E-360 and R-363.	SEQ_UP	1	
MUTAGEN:L->R: Reduces PRDM14 and OCT14 occupancy on target sites, no effect on interaction with PRDM14, predicted to impair homooligomerization; when associated with R-330; R-342; R-345; E-346; E-360 and R-374.	SEQ_UP	1	
MUTAGEN:L->R: Reduces PRDM14 and OCT14 occupancy on target sites, no effect on interaction with PRDM14, predicted to impair homooligomerization; when associated with R-330; R-345; E-346; E-360; R-363 and R-374.	SEQ_UP	1	
MUTAGEN:L->R: Retains 20% of wild-type activity with sphingomyelin as substrate; retains 50% of wild-type activity with bis(p-nitrophenyl) phosphate as substrate.	SEQ_UP	1	
MUTAGEN:L->R: Strongly reduced affinity for PLXNA2.	SEQ_UP	1	
MUTAGEN:L->R: Strongly reduced interaction with XRCC6.	SEQ_UP	1	
MUTAGEN:L->R: Strongly reduced response to semaphorin.	SEQ_UP	1	
MUTAGEN:L->R: Strongly reduces production of IL1B in response to bacterial flagellin.	SEQ_UP	1	
MUTAGEN:L->R: When overexpressed ubiquitously in conditional knockin mice, perinatally lethal; when overexpressed in osteoblasts in conditional knockin mice, produces a severe skeletal phenotype marked by a drastic increase in cortical thickness due to an enhanced endosteal bone formation; when overexpressed in osteoclasts in conditional knockin mice, no effect on bone hemostasis.	SEQ_UP	1	
MUTAGEN:L->S: Abolishes interaction with CD4 endocytosis signal motif.	SEQ_UP	1	
MUTAGEN:L->S: Decreased lipid phosphatase activity.	SEQ_UP	1	
MUTAGEN:L->S: Decreases affinity for CALM 230-fold; when associated with S-737.	SEQ_UP	1	
MUTAGEN:L->S: Fails to repress CD8 expression. Abolishes interaction with HDAC4 and HDAC5. No effect on homodimerization and DNA binding.	SEQ_UP	1	
MUTAGEN:L->S: Inhibits calcium-dependent translocation to the cell membrane; when associated with S-282 and S-283.	SEQ_UP	1	
MUTAGEN:L->S: Loss of inhibition of Ca(2+) influx upon activation of natural killer cells.	SEQ_UP	1	
MUTAGEN:L->S: Loss of interaction with ARHGEF28.	SEQ_UP	1	
MUTAGEN:L->S: No effect on lipid-binding.	SEQ_UP	1	
MUTAGEN:L->S: No endosomal localization; no effect on interaction with VPS35:VPS29 dimer; when associated with E-199.	SEQ_UP	1	
MUTAGEN:L->S: Partial loss of down-regulation of CD86 cell surface expression. Almost complete loss of down-regulation of CD86 cell surface expression; when associated with F-232.	SEQ_UP	1	
MUTAGEN:L->S: Significant hearing impairment, associated with loss or degeneration of cochlear outer hair cells.	SEQ_UP	1	
MUTAGEN:L->S: Slightly reduces interaction with CD4 endocytosis signal motif.	SEQ_UP	1	
MUTAGEN:L->T,V: Decreases sulfotransferase activity (at pH 7.5).	SEQ_UP	1	
MUTAGEN:L->T: Loss of interaction with 'Lys-63'-linked ubiquitin.	SEQ_UP	1	
MUTAGEN:L->T: Significantly reduces activity.	SEQ_UP	1	
MUTAGEN:L->V: Abolishes interaction with AP-2 complex.	SEQ_UP	1	
MUTAGEN:L->V: Loss of HA activity.	SEQ_UP	1	
MUTAGEN:L->V: Loss of proteolytic cleavage; when associated with L-392 and A-423.	SEQ_UP	1	
MUTAGEN:L->V: Loss of S1P cleavage; when associated with A-427.	SEQ_UP	1	
MUTAGEN:L->V: Loss of S1P cleavage.	SEQ_UP	1	
MUTAGEN:L->V: Males are infertile and show a significant reduction in the number of spermatids in testis, due to premature exfoliation of spermatids from the seminiferous epithelium. Sertoli cells contain reduced numbers of stable microtubules. The protein localizes exclusively to the basal compartment of Sertoli cells.	SEQ_UP	1	
MUTAGEN:L->W: Increases interaction with TLR3.	SEQ_UP	1	
MUTAGEN:L->W: No effect on protein abundance. No effect on cell surface localization. Decreases alanine uptake activity.	SEQ_UP	1	
MUTAGEN:L->W: Reduces binding to phosphoinositide.	SEQ_UP	1	
MUTAGEN:L->W: Strongly reduced transactivation.	SEQ_UP	1	
MUTAGEN:LC->KL: Abolishes histone acetyltransferase activity.	SEQ_UP	1	
MUTAGEN:LCCLL->ACCAA: Abolishes interaction with PPARA and NR1D1. No effect on interaction with CRY1. Abolishes interaction with PPARA and NR1D1 as well as reduces the amplitude of ARNTL expression; when associated with 1052-E--A-1055.	SEQ_UP	1	
MUTAGEN:LCCTCV->ACCACA: Does not affect subcellular localization.	SEQ_UP	1	
MUTAGEN:LDSGELVPEL->ADSGELAPEA: In 5A mutant; abolished interaction with CASP1; when associated with 306-L--L310.	SEQ_UP	1	
MUTAGEN:LEEKR->AAAAA: Retains the ability to interact with microtubules but abolishes the apical localization in epithelial cells.	SEQ_UP	1	
MUTAGEN:LEHLEMVRVPFL->AEHAEMVRVPFA: Decreased cytoplasmic localization.	SEQ_UP	1	
MUTAGEN:LEL->AEA: Abolishes nuclear export.	SEQ_UP	1	
MUTAGEN:LEMEL->AEMEA: In 5A mutant; abolished interaction with CASP1; when associated with 361-L--L370.	SEQ_UP	1	
MUTAGEN:LF->AA: Abrogates STAT3 phosphorylation.	SEQ_UP	1	
MUTAGEN:LFHEFL->AAHEAA: Loss of interaction with CACNB3 and loss of the ability to negatively regulate voltage-dependent L-type calcium channel; when associated with 426-A-A-427.	SEQ_UP	1	
MUTAGEN:LFL->AFA: Abolishes binding of PP1CC, decreases DNA binding, abolishes pericentromeric location, and results in IKAROS degradation.	SEQ_UP	1	
MUTAGEN:LFW->EEE: Abolished ability to form a pore.	SEQ_UP	1	
MUTAGEN:LG->EF: Loss of DNA-binding.	SEQ_UP	1	
MUTAGEN:LGILGM->AGIAGA: Reduces U snRNA export. Strongly abolishes the U snRNA export complex formation. Does not abolish the pre-complex formation.	SEQ_UP	1	
MUTAGEN:LGREY->AAAAA: Does not interacts with ITPR1.	SEQ_UP	1	
MUTAGEN:LHL->AHA: Decreased cytoplasmic localization.	SEQ_UP	1	
MUTAGEN:LIAAE->AAASM: In H2; induces a strong reduction in interaction with SRF and subsequent ability to prevent transcription of cardiac-specific genes.	SEQ_UP	1	
MUTAGEN:LIDIL->AIDIA: Abolished ubiquitination and degradation by the BCR(KEAP1) complex in the cytoplasm; when associated with A-30.	SEQ_UP	1	
MUTAGEN:LKEL->AKEA: Accumulates in the nucleus. Exlcusively nuclear; when associated with 464-A--A-467 and 985-A--A-990.	SEQ_UP	1	
MUTAGEN:LKENLDRR->AAENLDDA: Loss of binding to ROCK1 and ability to trigger apical constriction in cells.	SEQ_UP	1	
MUTAGEN:LKKLL->AKKAA: Strongly reduces coactivation of RORA activity.	SEQ_UP	1	
MUTAGEN:LKT->AAA,RRR,SSS: No catalytic activity.	SEQ_UP	1	
MUTAGEN:LL->AA,VV: Impaired endocytosis associated with retention at the plasma membrane.	SEQ_UP	1	
MUTAGEN:LL->AA,VV: Impaired trafficking from endosome to TGN.	SEQ_UP	1	
MUTAGEN:LL->AA: Abolishes estrogen-dependent NF-kappa B transcriptional repression, abolishes estrogen-induced interaction with NCOA1.	SEQ_UP	1	
MUTAGEN:LL->AA: Abolishes interaction with AP2B1.	SEQ_UP	1	
MUTAGEN:LL->AA: Abolishes interaction with RORC; when associated with 689-A--A-694 and 744-A--A-749.	SEQ_UP	1	
MUTAGEN:LL->AA: Impaired trafficking from endosome to TGN.	SEQ_UP	1	
MUTAGEN:LL->AA: Increased localization to the plasma membrane.	SEQ_UP	1	
MUTAGEN:LL->AA: Inhibits endocytosis. Abolishes interaction with AP2A1.	SEQ_UP	1	
MUTAGEN:LL->AA: Mislocalization to the plasma membrane. Localizes to lysosomes when expressed with wild-type Glmp.	SEQ_UP	1	
MUTAGEN:LL->AA: Strongly decreases interaction with liganded nuclear receptors. No effect on interaction with non-liganded nuclear receptors.	SEQ_UP	1	
MUTAGEN:LL->AA: Strongly expressed in the nucleus, mainly associated with PML nuclear bodies but not with centrosomes. Promotes gene transcription activation.	SEQ_UP	1	
MUTAGEN:LL->DE: Not secreted; nuclear localization.	SEQ_UP	1	
MUTAGEN:LL->RQ: Abolishes interaction with XRCC6.	SEQ_UP	1	
MUTAGEN:LL->VV: Has no effect on trafficking from endosome to TGN.	SEQ_UP	1	
MUTAGEN:LLG->AAA: Loss of interaction with MET and PARW. Loss of interaction with NOS2.	SEQ_UP	1	
MUTAGEN:LLGLD->AAAAA: Loss of interaction with clathrin heavy chains; when associated with 212-AAA-214.	SEQ_UP	1	
MUTAGEN:LLGLD->AAAAA: Loss of interaction with clathrin heavy chains.	SEQ_UP	1	
MUTAGEN:LLIEQRKL->ALIEQAKA: Loss of dimerization, binding to ROCK1 and ability to trigger apical constriction in cells.	SEQ_UP	1	
MUTAGEN:LLLRL->RSLRF: Abolishes interaction with ZFPM2.	SEQ_UP	1	
MUTAGEN:LLLTDGLL->AAATGAA: Abolishes nuclear export; when associated with A-425; A-427; A-428; A-429; A-430 and A-431.	SEQ_UP	1	
MUTAGEN:LLRYLL->AARAA: Abolishes interaction with RORC; when associated with 644-A-A-645 and 689-A--A-694.	SEQ_UP	1	
MUTAGEN:LLSL->AASA: Loss of dimerization, binding to ROCK1 and ability to trigger apical constriction in cells.	SEQ_UP	1	
MUTAGEN:LM->AA: Affects basolateral membrane sorting in vitro but not in vivo; when associated with A-219 and A-222.	SEQ_UP	1	
MUTAGEN:LM->AA: Decreases phosphatidylserine binding.	SEQ_UP	1	
MUTAGEN:LNLLQL->ANAAQA: Slightly accumulates in the nucleus. Exlcusively nuclear; when associated with 464-A--A-467 and 985-A--A-990.	SEQ_UP	1	
MUTAGEN:LP->AA: Does not abolish interaction with RXRIP110.	SEQ_UP	1	
MUTAGEN:LQAETDQLEDEKSALQTEIANLLKEKEKL->AQAETDQAEDEKSAAQTEIAN AAKEKEKA: Disrupts interaction with SMARCB1, SMARCD1, ARID1A and JUN.	SEQ_UP	1	
MUTAGEN:LQQVNHKLRQENMVL->AQQVNHKARQENMVA: In L1.2.3A mutant; reduced affinity for importin-beta.	SEQ_UP	1	
MUTAGEN:LQVLL->AQVAA: Nuclear and cytoplasmic location.	SEQ_UP	1	
MUTAGEN:LR->EE: Abolishes the activity of STOML3.	SEQ_UP	1	
MUTAGEN:LR->EF: Loss of DNA-binding.	SEQ_UP	1	
MUTAGEN:LR->GS: No effect on the interaction with MAP2K1, MAP2K2 and YWHAE. Abolishes interaction with BRAF. Abolishes location at membrane ruffles.	SEQ_UP	1	
MUTAGEN:LRL->ARA: Inhibits nuclear export.	SEQ_UP	1	
MUTAGEN:LRLERL->ARAERA: Inhibits nuclear export.	SEQ_UP	1	
MUTAGEN:LTLHELL->IIIRDII: Partial loss of function. No effect on oligomerization.	SEQ_UP	1	
MUTAGEN:LTY->ATA: Increases the affinity for CALM.	SEQ_UP	1	
MUTAGEN:LV->AA: Little affects the ability to traffic to the cilia. Does not affect interaction with RAB8A. Does not affect interaction with ARF4.	SEQ_UP	1	
MUTAGEN:LVF->AAA: Strongly increases affinity for RHO.	SEQ_UP	1	
MUTAGEN:LVNL->AVNA: Abolishes interaction with nuclear receptors.	SEQ_UP	1	
MUTAGEN:LW->AA: Loss of interaction with CACNB3 and loss of the ability to negatively regulate voltage-dependent L-type calcium channel; when associated with 545-A--A-550.	SEQ_UP	1	
MUTAGEN:LW->AA: Strongly reduced interaction with flagellin.	SEQ_UP	1	
MUTAGEN:M->A,E: Abolishes formation of tight-junction strand-like structures.	SEQ_UP	1	
MUTAGEN:M->A,W: No effect on interaction with TLR3.	SEQ_UP	1	
MUTAGEN:M->A: 2-fold decrease in rates of factor Xa inhibition.	SEQ_UP	1	
MUTAGEN:M->A: Abolishes binding to H3K4me3 without affecting phosphoinositide-binding.	SEQ_UP	1	
MUTAGEN:M->A: Abolishes interaction with CDK2.	SEQ_UP	1	
MUTAGEN:M->A: Abolishes interaction with RAB9A.	SEQ_UP	1	
MUTAGEN:M->A: Abolishes lowering of temperature threshold for activation in response to reactive oxygen species.	SEQ_UP	1	
MUTAGEN:M->A: Abolishes the interaction with many chromatin regulators but not that with KMT5B and KMT5C; when associated with A-746 and A-750.	SEQ_UP	1	
MUTAGEN:M->A: Almost completely abolishes KLC1-binding.	SEQ_UP	1	
MUTAGEN:M->A: Blocks internalization from cell surface; when associated with A-24.	SEQ_UP	1	
MUTAGEN:M->A: Decreased L-threonine 3-dehydrogenase activity.	SEQ_UP	1	
MUTAGEN:M->A: Decreased receptor activity in response to MTMT binding, even in the presence of copper.	SEQ_UP	2	
MUTAGEN:M->A: Decreased receptor activity in response to MTMT binding, even in the presence of copper. Complete loss of receptor activity in the absence of copper.	SEQ_UP	1	
MUTAGEN:M->A: Impaired ability to release autoinhibition, leading to defects in actin nucleation and elongation factor activity in the nucleus.	SEQ_UP	1	
MUTAGEN:M->A: Impairs binding to 2'-O-methylated 3'-end of piRNAs.	SEQ_UP	1	
MUTAGEN:M->A: Impairs Ca(2+) permeation.	SEQ_UP	1	
MUTAGEN:M->A: Increased protein expression. No effect on protein stability.	SEQ_UP	1	
MUTAGEN:M->A: Loss of 44,4 kDa fragment.	SEQ_UP	1	
MUTAGEN:M->A: Loss of AP-1 and NF-kappa-B transcription factor activity. Reduced ability to activate MAP2K1, MAP2K4, MAP2K7, CHUK and IKBKB.	SEQ_UP	1	
MUTAGEN:M->A: Loss of transcriptional activation; when associated with A-454.	SEQ_UP	1	
MUTAGEN:M->A: Lowers activity towards short-chain fatty acids.	SEQ_UP	1	
MUTAGEN:M->A: No effect on IL1B release under basal conditions, nor in response to LT or metabolic inhibitors; when associated with A-698 and A-701.	SEQ_UP	1	
MUTAGEN:M->A: No effect on protein stability.	SEQ_UP	1	
MUTAGEN:M->A: No effect on transmembrane ascorbate ferrireductase activity.	SEQ_UP	1	
MUTAGEN:M->A: No effect on UBE2I binding nor on sumoylation.	SEQ_UP	1	
MUTAGEN:M->A: No loss of interaction with PTPN13 (via PDZ domains).	SEQ_UP	1	
MUTAGEN:M->A: Reduced lysophospholipase activity.	SEQ_UP	1	
MUTAGEN:M->A: Slightly decreases activity with octanoyl-CoA.	SEQ_UP	1	
MUTAGEN:M->A: Strongly decreases activity with octanoyl-CoA.	SEQ_UP	1	
MUTAGEN:M->C: Formation of disulfide-linked homodimer.	SEQ_UP	1	
MUTAGEN:M->C: No effect on protein abundance. No effect on cell surface localization. No effect on alanine uptake activity.	SEQ_UP	1	
MUTAGEN:M->D: Abolishes interaction with GBA. No effect on normal location in lysosomes.	SEQ_UP	1	
MUTAGEN:M->D: Interfers with transcription factor activity.	SEQ_UP	1	
MUTAGEN:M->D: Strongly reduces Sin3A binding.	SEQ_UP	1	
MUTAGEN:M->E: Abolishes interaction with GPSM2.	SEQ_UP	1	
MUTAGEN:M->E: Decreased L-threonine 3-dehydrogenase activity. Decreased affinity for L-threonine.	SEQ_UP	1	
MUTAGEN:M->E: Does not inhibit interaction with TTI1 or TTI2. Inhibits weakly interaction with TTI1 or TTI2; when associated with Q-395 or R-424. Inhibits interaction with TTI1 or TTI2; when associated with Q-395 and R-424.	SEQ_UP	1	
MUTAGEN:M->E: Reduces PRDM14 and OCT14 occupancy on target sites, no effect on interaction with PRDM14, predicted to impair homooligomerization; when associated with R-330; R-342; R-345; E-346; E-360; R-363 and R-374.	SEQ_UP	1	
MUTAGEN:M->G: Lowers activity towards short-chain fatty acids. Strong increase in activity towards medium chain fatty acids.	SEQ_UP	1	
MUTAGEN:M->I,L: No effect on formation of tight-junction strand-like structures.	SEQ_UP	1	
MUTAGEN:M->I: Erroneous subcellular location; when associated with Q-85. No positive effect on terminal myogenic differentiation; when associated with Q-85.	SEQ_UP	1	
MUTAGEN:M->I: In Jll; dominant allele that increases enzyme activity, and decreases fasting insulin levels, fasting leptin levels, weight gain and fat accumulation when mice are kept on a high fat diet.	SEQ_UP	1	
MUTAGEN:M->I: Loss of 44,4 kDa form.	SEQ_UP	1	
MUTAGEN:M->I: Loss of tubulin monoglycylation activity.	SEQ_UP	1	
MUTAGEN:M->I: Reduces binding to RAR, RXR and RAR/RXR.	SEQ_UP	1	
MUTAGEN:M->K: Abolishes binding to RAR, RXR and RAR/RXR.	SEQ_UP	1	
MUTAGEN:M->K: Corresponds to variant K-162 associated with SPGF16 in human. Increases interaction with DNAJB13. Impairs nuclear inner membrane location, expressed in the cytosol with some protein aggregation near the nuclear envelope.	SEQ_UP	1	
MUTAGEN:M->K: In Aotea; randomization of laterality. Mutants exhibit a range of cardiovascular anomalies, including right aortic arch, perimembranous and muscular ventricular septal defects, ventricular non-compaction and anomalous venous return. Respiratory cilia are either immotile or have slow dyskinetic motion compared to wild-type animals. Tracheal airway cilia show a marked reduction in outer dynein arms. In the brain, fluid flow is generated by ependymal cilia, but is slower than in wild-type animals. Aotea mutants develop hydrocephalus at 3 to 4 weeks of age and die.	SEQ_UP	1	
MUTAGEN:M->K: Loss of HSP90B1-binding. Impairs association with TLR2 and TLR4; does not impair association with TLR9; partially affects responses of TLR2 and TLR4; affects responses of TLR9; does not affect cell-surface expression of TLR2; affects cell-surface expression of TLR4 and TLR9.	SEQ_UP	1	
MUTAGEN:M->K: No effect.	SEQ_UP	1	
MUTAGEN:M->K: Strongly reduced binding of target proteins. Strongly reduced degradation of target proteins.	SEQ_UP	1	
MUTAGEN:M->L: No effect on NICD processing.	SEQ_UP	2	
MUTAGEN:M->L: Reduces binding to RAR, RXR and RAR/RXR.	SEQ_UP	1	
MUTAGEN:M->P: Loss of interaction with VCL.	SEQ_UP	1	
MUTAGEN:M->R: Abolishes catalytic activity on phthalazine and acetaldehyde. Decreases catalytic efficiency on benzaldehyde and retinal. Abolishes catalytic activity; when associated with E-806.	SEQ_UP	1	
MUTAGEN:M->R: Abolishes ionotropic glutamate receptor activity, no effect on cold receptor activity.	SEQ_UP	1	
MUTAGEN:M->R: Homozygous mice display tortuous vessels aneurysm, loss of oxidase activity and die perinatally of aortic aneurysm and dissection. Heterozygous mice display thicker arterial wall with discontinuous elastic lamellae.	SEQ_UP	1	
MUTAGEN:M->R: In sanroque; partial loss of ICOS regulation, no effect on localization to stress granules, no effect on RNA-binding.	SEQ_UP	1	
MUTAGEN:M->R: Increases affinity for DNA; when associated with E-137.	SEQ_UP	1	
MUTAGEN:M->R: Knockin mice exhibit olfaction deficits, male infertility, ventriculomegaly, retinopathy and obesity.	SEQ_UP	1	
MUTAGEN:M->S: Does not affect affinity for S-adenosyl-L-methionine.	SEQ_UP	1	
MUTAGEN:M->S: No effect on protein abundance. No effect on cell surface localization. No effect on alanine uptake activity.	SEQ_UP	1	
MUTAGEN:M->T: Abolishes expression of A-type isoforms.	SEQ_UP	1	
MUTAGEN:M->T: Abolishes expression of B-type isoforms. 1-B.	SEQ_UP	1	
MUTAGEN:M->T: Decreased localization to the nucleus. No effect on homodimerization. Decreased transcription cis-regulatory region binding. Loss of DNA-binding transcription factor activity. Acts as a dominant negative.	SEQ_UP	1	
MUTAGEN:M->T: Mild muscular dystrophy phenotype of variable penetrance due to defects in axon guidance. Mislocalization to the endoplasmic reticulum.	SEQ_UP	1	
MUTAGEN:M->V: A very low percentage of homozygous mice are present at 30 days after birth, suggesting high perinatal lethality. In anesthesized heterozygous mice, electromyographs from hind-limb muscle show high background activity, indicative of myotonia. Isolated extensor digitorum longus muscle from heterozygous mice displays reduced twitch force, with a normal speed of muscle contraction, but an increased muscle relaxation half-time. Isolated skeletal muscle from heterozygous mice has strongly decreased force when the K(+) levels are increased to 10 mM. Homozygous mice display prominent hind-limb weakness and muscle atrophy.	SEQ_UP	1	
MUTAGEN:M->V: Abolishes isoform 2.	SEQ_UP	1	
MUTAGEN:M->V: Decreased NICD processing.	SEQ_UP	1	
MUTAGEN:M->V: Increased inhibition of NF-kappa-B.	SEQ_UP	1	
MUTAGEN:M->W: Prevents interaction with PALS1.	SEQ_UP	1	
MUTAGEN:Missing: Abolished ability to activate pyroptosis, necroptosis and apoptosis (PANoptosis) in response to influenza A virus (IAV) infection in knockin mice.	SEQ_UP	1	
MUTAGEN:Missing: Abolished binding to neuron-restrictive silencer element.	SEQ_UP	1	
MUTAGEN:Missing: Abolished ceramide synthase activity.	SEQ_UP	1	
MUTAGEN:Missing: Abolished interaction with KEAP1.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes accumulation in the nucleus.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes activity.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes arachidonate 15-lipoxygenase activity. Abolishes arachidonate 12-lipoxygenase activity. Abolishes linoleate 13-lipoxygenase activity.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes binding of PIAS1 and PIAS2. Dramatically reduces sumoylation and abolishes AXIN1-mediated JNK activation. No effect on homodimerization nor on Wnt-signaling.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes calcium uptake into mitochondria. Abolishes interaction with MCU.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes cleavage by calpain at the C-terminus.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes cleavage by calpain at the N-terminus.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes enzymatic activity.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes expression at the apical cell membrane. Strongly decreases cholesterol secretion into bile.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes histone methyltransferase activity and subsequent repression. In GM3; does not form heterodimer with EHMT1 and is defective in mediating both H3K9me and DNA methylation.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes homophilic interactions.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes interaction with APBA1. Abolishes transport of vesicles containing N-methyl-D-aspartate (NMDA) receptor subunit NR2B along microtubules.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes interaction with DYNLL2.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes interaction with FBXW7.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes interaction with NR1D1.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes interaction with PPP1CC.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes interaction with PTPN6/SHP-1.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes interaction with RPTOR.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes interaction with SUN1. Fails to localize at telomere.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes interaction with TERF2 and localization to telomeres, leading to activate the ATM signaling pathway.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes localization at the cell membrane.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes localization to synapses and induces diffuse expression in photoreceptor cells.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes location at nodal cilia and cannot complement the laterality defect of null mutants; when associated with G-6.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes nuclear localization and palmitoylation.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes nuclear localization of the Junctophilin-2 N-terminal fragment chain.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes nuclear localization.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes oxidase activity and secretion but does not affect binding to the CDH1 promoter, repression of CDH1 transcription, interaction with SNAI1, binding to the CDH1 promoter, repression of CDH1 transcription or ability to induce EMT.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes production of IL1B in response to bacterial flagellin.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes protein processing.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes proteolytic processing. Gain of function mutant.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes retention in the endoplasmic reticulum so that the protein is secreted.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes the colocalization with GPHN.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes thioredoxin reductase, glutaredoxin and gluthioine reductase activities.	SEQ_UP	1	
MUTAGEN:Missing: Abolishes ubiquitin binding and localization to nuclear foci after UV-induced DNA damage.	SEQ_UP	1	
MUTAGEN:Missing: Abrogates interaction with GATA4 and repression of GATA4-mediated transcription.	SEQ_UP	1	
MUTAGEN:Missing: Absence of auditory brain stem response (ABR) to click stimuli demonstrates that the mice are profoundly deaf. Distortion product otoacoustic emissions (DPOAEs) are absent at 4 weeks of age at all frequencies tested. Normal hair bundle morphology as at postnatal day (P) 5 the sensory epithelia are patterned into three rows of outer hair cells (OHCs) and one row of inner hair cells (IHCs). The bundles of OHCs appear similar in size to those of wild-type mice and form a normal staircase pattern.	SEQ_UP	1	
MUTAGEN:Missing: Complete inhibition of secretion.	SEQ_UP	1	
MUTAGEN:Missing: Constitutive IL1B processing.	SEQ_UP	1	
MUTAGEN:Missing: Decreased binding to neuron-restrictive silencer element.	SEQ_UP	1	
MUTAGEN:Missing: Decreased promotion of neurite outgrowth. No effect on homomeric interactions.	SEQ_UP	1	
MUTAGEN:Missing: Decreased protein abundance.	SEQ_UP	1	
MUTAGEN:Missing: Does not affect mitochondrion localization.	SEQ_UP	1	
MUTAGEN:Missing: Does not bind heme.	SEQ_UP	1	
MUTAGEN:Missing: Drastic decrease in basal cAMP production.	SEQ_UP	1	
MUTAGEN:Missing: Enamel of mutant mice has a rough surface and is hypomineralized.	SEQ_UP	1	
MUTAGEN:Missing: Erroneous subcellular location. No positive effect on terminal myogenic differentiation.	SEQ_UP	1	
MUTAGEN:Missing: Failed to reduce poly(A) tailed ICOS mRNA. Failed to regulate the production of inflammatory cytokines.	SEQ_UP	1	
MUTAGEN:Missing: Fails to induce myogenic differentiation in C2C12 cells.	SEQ_UP	1	
MUTAGEN:Missing: Fails to interact with AGO2.	SEQ_UP	1	
MUTAGEN:Missing: Fails to interact with DLG1. No effect on cell surface localization.	SEQ_UP	1	
MUTAGEN:Missing: Has no effect on enzymatic activity.	SEQ_UP	1	
MUTAGEN:Missing: Heterozygous mice are viable and healthy. Results in early lethality at homozygosity.	SEQ_UP	1	
MUTAGEN:Missing: Homozygous mice show severe morphological and skeletal abnormalities including short stature along with limb, rib, pelvis, and skull deformities with minimal trabecular bone and reduced cortical bone thickness in long bones.	SEQ_UP	1	
MUTAGEN:Missing: Impaired conjugation of target proteins.	SEQ_UP	1	
MUTAGEN:Missing: Impaired interaction with DLG4.	SEQ_UP	1	
MUTAGEN:Missing: Impaired interaction with HOXA1. Loss of glycosylation of HOXA1.	SEQ_UP	1	
MUTAGEN:Missing: Impaired non-canonical autophagy, leading to susceptibility to influenza A virus (IAV) infection in mice.	SEQ_UP	1	
MUTAGEN:Missing: Impaired recycling affecting its internalization, leading to decreased activity on the plasma surface.	SEQ_UP	1	
MUTAGEN:Missing: Impairs IgE-induced mast cell activation in the presence of antigen; Impairs IgE-induced mast cell survival in the absence of antigen.	SEQ_UP	1	
MUTAGEN:Missing: Impairs induction of SELP in activated platelets.	SEQ_UP	1	
MUTAGEN:Missing: Impairs inhibition of the Wnt signaling pathway.	SEQ_UP	1	
MUTAGEN:Missing: Impairs protein folding, due to small local changes that probably disrupt crucial interactions with the transmembrane domain. Abolishes normal maturation. Impairs trafficking to the apical cell membrane.	SEQ_UP	1	
MUTAGEN:Missing: In caracul Rinshoken; causes a wavy hair phenotype.	SEQ_UP	1	
MUTAGEN:Missing: In CS; shows negligible immobility in the tail suspension test (TST) and forced swimming test (FST). Both male and female CS mice show virtually no immobile posture immobility in the TST and FST.	SEQ_UP	1	
MUTAGEN:Missing: In depilated (dep) mutant mice. Loss of protein-cysteine S-palmitoyltransferase activity. Relocalized to the endoplasmic reticulum.	SEQ_UP	1	
MUTAGEN:Missing: In Dfl mutant; gain-of-function mutation; causes an alopecia phenotype.	SEQ_UP	1	
MUTAGEN:Missing: In explorer; no obvious external deformities but mutants are 40% smaller than wild-type litter mates and show reduced frequency of CD3+ T cells, CD4+ T cells and CD8+ T cells which all display elevated CD44 expression.	SEQ_UP	1	
MUTAGEN:Missing: In LM3; does not form heterodimer with EHMT2 and is defective in mediating both H3K9me and DNA methylation.	SEQ_UP	1	
MUTAGEN:Missing: In mei4; Sterility in both sexes due to meiotic defects.	SEQ_UP	1	
MUTAGEN:Missing: In response to TCR stimulation, increases CD4+ T-cell proliferation and impairs IFNG and IL22 production.	SEQ_UP	1	
MUTAGEN:Missing: In Rex wavy coat; mice exhibit curly hair and vibrissae. The diameter of the hair shaft is irregular due to morphological abnormalities in all three layers of the irs.	SEQ_UP	1	
MUTAGEN:Missing: In st (strawberry phenotype); affected mice exhibit severe lymphopenia, failure of lymphocyte development, reduced natural killer (NK) cell function and impaired B-cell development.	SEQ_UP	1	
MUTAGEN:Missing: In wpy; widespread embryonic dysmorphologies, including highly penetrant polydactyly of all four limbs as well as craniofacial defects. Mice develop cystic kidney disease.	SEQ_UP	1	
MUTAGEN:Missing: In xiamen; reduced Rabl3 expression, reduced interaction with Gpr89, reduced thermal stability, reduced frequency of CD3+ T cells, increased CD4+-to-CD8+ T cell ratio, higher CD44 expression in CD8+ T cells and increased B cell-to-T cell ratio.	SEQ_UP	1	
MUTAGEN:Missing: Increased binding to neuron-restrictive silencer element.	SEQ_UP	1	
MUTAGEN:Missing: Increased nuclear localization in non-stress conditions. No change in protein accumulation and stability in response to DNA damage. No change in subcellular localization in non-stress conditions; when associated with 13-L--Y-24. No change in protein accumulation and stability in response to DNA damage; when associated with 13-L--Y-24.	SEQ_UP	1	
MUTAGEN:Missing: Increases basal catalytic activity. Does not affect interaction with PPP3R1/calreticulin B and calmodulin.	SEQ_UP	1	
MUTAGEN:Missing: Increases catalytic activity independently of calmodulin. Does not affect interaction with PPP3R1/calreticulin B and calmodulin.	SEQ_UP	1	
MUTAGEN:Missing: Increases catalytic activity independently of calmodulin. Loss of interaction with calmodulin. Does not affect interaction with PPP3R1/calreticulin B.	SEQ_UP	1	
MUTAGEN:Missing: Increases natural killer cell activation and interferon-gamma production. Loss of FGR binding.	SEQ_UP	1	
MUTAGEN:Missing: Induces an age-dependent neurodegenerative phenotype.	SEQ_UP	1	
MUTAGEN:Missing: Inhibits interaction with ITPR1.	SEQ_UP	1	
MUTAGEN:Missing: Inhibits repression of ZBTB7B expression.	SEQ_UP	2	
MUTAGEN:Missing: Interaction with TRIP6.	SEQ_UP	1	
MUTAGEN:Missing: Interacts with HOXA1. Interaction is localized to the nucleus.	SEQ_UP	1	
MUTAGEN:Missing: Interacts with OGT.	SEQ_UP	1	
MUTAGEN:Missing: Interacts with PDLIM4. Loss of interaction with PTPN13.	SEQ_UP	1	
MUTAGEN:Missing: Kinky tail mutant mice show kinky tail and white spot at the belly; additionally, homozygous mutants show microphthalmia and anterior segment dysgenesis including corneal opacity, severe iris bombe (forward-bowing iris) and very shallow or absent anterior chamber.	SEQ_UP	1	
MUTAGEN:Missing: Knockin mutant mice show retinal morphological anomalies and altered electroretinographic responses to light stimuli.	SEQ_UP	1	
MUTAGEN:Missing: Leads to neonatal lethality in homozygote mices. Abolishes association of UNC79 with the NALCN complex. Affects subcellular location, retained in soma and absence in axons and dendrites.	SEQ_UP	1	
MUTAGEN:Missing: Localizes to the nucleus instead of the cytoplasm.	SEQ_UP	1	
MUTAGEN:Missing: Locates in the nucleus.	SEQ_UP	1	
MUTAGEN:Missing: Loss of activity.	SEQ_UP	1	
MUTAGEN:Missing: Loss of association with polysomes and loss of translation stimulation.	SEQ_UP	1	
MUTAGEN:Missing: Loss of beta-catenin-binding.	SEQ_UP	1	
MUTAGEN:Missing: Loss of catalytic activity, as measured by the saturation of retinol to 13,14-dihydroretinol. Loss of adipocyte differentiation in a 3T3-L1 cell culture model.	SEQ_UP	1	
MUTAGEN:Missing: Loss of catalytic activity. Loss of interaction with PPP3R1/calreticulin B and calmodulin.	SEQ_UP	1	
MUTAGEN:Missing: Loss of cell membrane recruitment following EGF stimulation.	SEQ_UP	1	
MUTAGEN:Missing: Loss of dimerization. Almost complete loss of DNA-binding. Reduced transcriptional repression activity.	SEQ_UP	3	
MUTAGEN:Missing: Loss of DLG4-binding.	SEQ_UP	1	
MUTAGEN:Missing: Loss of exclusive nuclear localization and loss of growth inhibition, when transfected in Saos-2 cells. No effect on the interaction with SV40 large T antigen.	SEQ_UP	1	
MUTAGEN:Missing: Loss of exclusive nuclear localization. Complete loss of nuclear localization, loss of growth inhibition, when transfected in Saos-2 cells and loss of interaction with SV40 large T antigen, adenovirus E1a and E2F1; when associated with 866-N--Q-869.	SEQ_UP	1	
MUTAGEN:Missing: Loss of exclusive nuclear localization. Decreased growth inhibition activity, when transfected in Saos-2 cells. No effect on the interaction with SV40 large T antigen, adenovirus E1a, nor E2F1.	SEQ_UP	1	
MUTAGEN:Missing: Loss of heme binding.	SEQ_UP	1	
MUTAGEN:Missing: Loss of homodimerization, decrease in transcriptional repressor activity, elimination of its Treg suppressor activity, defects in Th1 and Th2 cytokine secretion and down-regulation of cell surface markers on regulatory T-cells.	SEQ_UP	1	
MUTAGEN:Missing: Loss of in vitro ATPase activity.	SEQ_UP	1	
MUTAGEN:Missing: Loss of interaction with CDC42, RHOA and RAC1.	SEQ_UP	1	
MUTAGEN:Missing: Loss of interaction with DLG4.	SEQ_UP	1	
MUTAGEN:Missing: Loss of interaction with HOXA1. Loss of glycosylation of HOXA1.	SEQ_UP	1	
MUTAGEN:Missing: Loss of interaction with MAPK1.	SEQ_UP	1	
MUTAGEN:Missing: Loss of interaction with OGT.	SEQ_UP	1	
MUTAGEN:Missing: Loss of interaction with PDZ-domain of DLG4.	SEQ_UP	2	
MUTAGEN:Missing: Loss of interaction with SBF2/MTMR13 which results in a decrease in SBF2/MTMR13 localization to membranes.	SEQ_UP	1	
MUTAGEN:Missing: Loss of localization to the endoplasmic reticulum.	SEQ_UP	1	
MUTAGEN:Missing: Loss of MAPK9 binding. Absence of Ser-347 phosphorylation.	SEQ_UP	1	
MUTAGEN:Missing: Loss of MCL1-binding, strong decrease in BCL2L1-binding, no effect on USP27X-binding; when associated with I-153 del.	SEQ_UP	1	
MUTAGEN:Missing: Loss of MCL1-binding, strong decrease in BCL2L1-binding, no effect on USP27X-binding; when associated with L-150 del.	SEQ_UP	1	
MUTAGEN:Missing: Loss of mitochondrial localization. Loss of cannabinoid-induced reduction of respiration, mitochondrial mobility, synaptic transmission and memory formation. No effect on MAPK/ERK signaling, nor on G protein activation.	SEQ_UP	1	
MUTAGEN:Missing: Loss of mitochondrion localization.	SEQ_UP	1	
MUTAGEN:Missing: Loss of phosphatase activity.	SEQ_UP	1	
MUTAGEN:Missing: Loss of SLC9A3R2 binding and reduced nuclear localization. Partial recovery of nuclear accumulation; when associated with A-89.	SEQ_UP	1	
MUTAGEN:Missing: Loss of trimerization; when associated with R-469.	SEQ_UP	1	
MUTAGEN:Missing: Low spontaneous IL1B release and loss of activation by LT. Increased IL1B release in response to metabolic inhibitors.	SEQ_UP	1	
MUTAGEN:Missing: Low spontaneous IL1B release and loss of activation by LT. No effect on activation by metabolic inhibitors.	SEQ_UP	1	
MUTAGEN:Missing: Marked decrease in secretion.	SEQ_UP	1	
MUTAGEN:Missing: Mice develop hair and nail defects resembling pachyonychia congenita.	SEQ_UP	1	
MUTAGEN:Missing: Mutant heterozygous mice have a thicker corpus callosum, hypoplastic cortex and cerebellum, increased neuronal apoptosis, and decreased protein levels.	SEQ_UP	1	
MUTAGEN:Missing: Nearly abolishes activity with nucleotide phosphates. Confers very low activity with lysophospholipids.	SEQ_UP	1	
MUTAGEN:Missing: No effect on 'Lys-48'-linked polyubiquitin binding.	SEQ_UP	1	
MUTAGEN:Missing: No effect on accumulation in the nucleus.	SEQ_UP	1	
MUTAGEN:Missing: No effect on activity.	SEQ_UP	1	
MUTAGEN:Missing: No effect on IL1B release.	SEQ_UP	1	
MUTAGEN:Missing: No effect on interaction with NR1D1.	SEQ_UP	1	
MUTAGEN:Missing: No effect on response to LT, attenuated response to metabolic inhibitors.	SEQ_UP	1	
MUTAGEN:Missing: No effect on secretion nor lysophospholipase activity.	SEQ_UP	1	
MUTAGEN:Missing: No effect on secretion; greatly inhibits lysoPLD activity. Inhibits secretion. Almost complete loss of lysoPLD activity; when associated with N-53 del.	SEQ_UP	1	
MUTAGEN:Missing: No effect on secretion; slightly decreases lysophospholipase activity. Almost complete loss of lysophospholipase activity; when associated with N-410 del.	SEQ_UP	1	
MUTAGEN:Missing: No effect on secretion.	SEQ_UP	1	
MUTAGEN:Missing: No effect on subcellular location; when associated with S-142. Normal terminal myogenic differentiation; when associated with S-142.	SEQ_UP	1	
MUTAGEN:Missing: No effect on transport activity.	SEQ_UP	1	
MUTAGEN:Missing: Nuclear envelope abnormalities specific to neurons.	SEQ_UP	1	
MUTAGEN:Missing: Partial retention in the endoplasmic reticulum; still forms homodimers.	SEQ_UP	1	
MUTAGEN:Missing: Premature lethality from 3 months of age, with no survival beyond 6 months. Progressive defects in motor coordination and balance from age 3 months, accompanied by a twitching phenotype. Marked degeneration of astrocytes in the cerebrum. Significant loss of peptidase activity, leading to accumulation of the TPP1 substrate ATP5MC1 in lysosomes.	SEQ_UP	1	
MUTAGEN:Missing: Prevents degradation during metaphase.	SEQ_UP	1	
MUTAGEN:Missing: Reduced 14-3-3 interaction. Reduced inactivation following cAMP signaling.	SEQ_UP	1	
MUTAGEN:Missing: Reduced association with polysomes and reduced stimulation of translation.	SEQ_UP	1	
MUTAGEN:Missing: Reduced enzyme activity.	SEQ_UP	1	
MUTAGEN:Missing: Reduced potassium ion transmembrane transport.	SEQ_UP	1	
MUTAGEN:Missing: Reduces Tyr phosphorylation by at least 50% and almost completely abrogates interaction with PTPN11 and PTPN6.	SEQ_UP	1	
MUTAGEN:Missing: Results in cytosolic distribution.	SEQ_UP	1	
MUTAGEN:Missing: Significantly more secreted than wild-type.	SEQ_UP	1	
MUTAGEN:Missing: Slightly increases natural killer cell activation and interferon-gamma production.	SEQ_UP	1	
MUTAGEN:Missing: Slightly reduces interaction with PER2.	SEQ_UP	1	
MUTAGEN:Missing: Strongly decreased channel activity due to decreased expression at the cell membrane, leading to hypertrophy of the right heart ventricle, heart failure and perinatal death; when associated with 1794-L--K-1796.	SEQ_UP	1	
MUTAGEN:Missing: Strongly decreases binding with phosphatidic acid and phosphatidylserine. Abolishes binding with phosphatidic acid and phosphatidylserine; when associated with A-33. Strongly decreases sphingomyelin phosphodiesterase activity; when associated with A-33. Abolishes sphingomyelin phosphodiesterase activity and locates at endoplasmic reticulum; when associated with A-33 and 92-A-A-93.	SEQ_UP	1	
MUTAGEN:Missing: Strongly decreases ISGF3 binding to the ISRE of IKBKE-dependent genes but noo effect on ISGF3 binding to the ISRE of IKBKE-independent genes.	SEQ_UP	1	
MUTAGEN:Missing: Strongly increased location in the nucleus.	SEQ_UP	1	
MUTAGEN:Missing: Suppression of SIX3-binding to rhodopsin promoter. Impairs the ability of Six3 to stimulate RHO transcription.	SEQ_UP	1	
MUTAGEN:ML->AA: Abolishes interaction with ASXL1 and NCOA1.	SEQ_UP	1	
MUTAGEN:ML->AA: Affects basolateral membrane sorting in vitro but not in vivo; when associated with A-222 and A-225.	SEQ_UP	1	
MUTAGEN:ML->AA: No effect on estrogen-dependent NF-kappa B transcriptional repression, greatly impairs transcriptional activity, abolishes estrogen-induced interaction with NCOA1.	SEQ_UP	1	
MUTAGEN:ML->RP: Abolishes homooligomerization.	SEQ_UP	1	
MUTAGEN:MM->TT: Nearly abolishes membrane tubulation activity.	SEQ_UP	1	
MUTAGEN:MNNLSFSELCCLFCCPPCPG->MGSNKSKPKDASQRRRSLEP: Loss of palmitoylation activity towards LG4/PSD95 and appears more diffused at the plasma membrane.	SEQ_UP	1	
MUTAGEN:MP->GG: Nearly abolishes inhibition of ATP2A1-mediated calcium uptake.	SEQ_UP	1	
MUTAGEN:MPL->AAA: Does not inhibit interaction with ZNF473. Reduces weakly histone 3' end processing.	SEQ_UP	1	
MUTAGEN:MPQ->GGG: No effect on inhibition of ATP2A1-mediated calcium uptake.	SEQ_UP	1	
MUTAGEN:MWY->AWA: Decreases affinity for PTPRD; when associated with 88-A--A-91. Significantly decreases synaptogenesis; when associated with 88-A--A-91.	SEQ_UP	1	
MUTAGEN:N->A,D,L,T: Decreased enzyme activity with N(1)-acetylspermine.	SEQ_UP	1	
MUTAGEN:N->A,D,Q,K: Abolishes interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:N->A,D: Decreases the enzymatic activity.	SEQ_UP	1	
MUTAGEN:N->A,Q: Abolishes enzyme activity.	SEQ_UP	1	
MUTAGEN:N->A,Q: Abolishes N-glycosylation.	SEQ_UP	1	
MUTAGEN:N->A,Q: Impaired N-glycosylation and reduced homooligomerization.	SEQ_UP	1	
MUTAGEN:N->A,Q: Loss of interaction with SPSB2.	SEQ_UP	1	
MUTAGEN:N->A,Q: Significant loss of interaction with SPSB2.	SEQ_UP	1	
MUTAGEN:N->A,S: No effect on interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:N->A: 40% increased enzyme activity.	SEQ_UP	1	
MUTAGEN:N->A: Abolished ability to acylate ghrelin.	SEQ_UP	1	
MUTAGEN:N->A: Abolishes binding to CD200R.	SEQ_UP	1	
MUTAGEN:N->A: Abolishes binding to NUMB protein.	SEQ_UP	1	
MUTAGEN:N->A: Abolishes endoribonuclease activity.	SEQ_UP	1	
MUTAGEN:N->A: Abolishes enzyme activity.	SEQ_UP	1	
MUTAGEN:N->A: Abolishes formation of 55 kDa cleavage product.	SEQ_UP	1	
MUTAGEN:N->A: Abolishes interaction with APC2.	SEQ_UP	1	
MUTAGEN:N->A: Abolishes interaction with HIF1AN.	SEQ_UP	1	
MUTAGEN:N->A: Abolishes interaction with RAB9A.	SEQ_UP	1	
MUTAGEN:N->A: Abolishes interaction with TACC3.	SEQ_UP	1	
MUTAGEN:N->A: Abolishes the interaction with many chromatin regulators but not that with KMT5B and KMT5C; when associated with A-746 and A-754.	SEQ_UP	1	
MUTAGEN:N->A: Abrogates interaction with EED.	SEQ_UP	1	
MUTAGEN:N->A: Almost complete loss of RNA-binding and loss of GTase activity.	SEQ_UP	1	
MUTAGEN:N->A: Alters interaction with MAPK8IP1.	SEQ_UP	1	
MUTAGEN:N->A: Alters interaction with YWHAH.	SEQ_UP	1	
MUTAGEN:N->A: Complete loss of selectivity for calcium over monocovalent cations.	SEQ_UP	1	
MUTAGEN:N->A: Compromises SIM1:ARNT2 heterodimer stability. Does not compromises NPAS4:ARNT2 heterodimer stability.	SEQ_UP	1	
MUTAGEN:N->A: Confers transcriptional activity at normoxia; when associated with A-530.	SEQ_UP	1	
MUTAGEN:N->A: Decreased cholesterol binding. Strongly decreased cholesterol transport activity.	SEQ_UP	1	
MUTAGEN:N->A: Decreased DNA binding and transcriptional activity.	SEQ_UP	1	
MUTAGEN:N->A: Decreased N-glycosylation.	SEQ_UP	1	
MUTAGEN:N->A: Decreased specific binding to triglyceride. Decreased lipid droplet size. No change in protein expression levels and subcellular localization to the ER.	SEQ_UP	1	
MUTAGEN:N->A: Decreases heterodimer formation with EPAS1. Decreases heterodimer formation with HIF1A. Impairs heterodimer formation with EPAS1; when associated with A-366. Impairs heterodimer formation with HIF1A; when associated with A-366. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Does not compromise NPAS4:ARNT heterodimer stability. Does not compromise AHR:ARNT heterodimer stability.	SEQ_UP	1	
MUTAGEN:N->A: Does not affect acyltransferase activity.	SEQ_UP	1	
MUTAGEN:N->A: Does not affect enzyme activity.	SEQ_UP	1	
MUTAGEN:N->A: Does not affect interaction with APC2.	SEQ_UP	1	
MUTAGEN:N->A: Does not affect polynucleotide adenylyltransferase activity. Increases cell apoptosis.	SEQ_UP	1	
MUTAGEN:N->A: Does not affect recognition by the CRL2(FEM1B) complex and subsequent ubiquitination.	SEQ_UP	1	
MUTAGEN:N->A: Does not affect the interaction with VCP.	SEQ_UP	1	
MUTAGEN:N->A: Does not affect trypsin-binding.	SEQ_UP	1	
MUTAGEN:N->A: Dramatic reduction in catalytic activity.	SEQ_UP	1	
MUTAGEN:N->A: Impaired H3.3K36me3 binding.	SEQ_UP	1	
MUTAGEN:N->A: Impaired interaction with SQSTM1/p62.	SEQ_UP	1	
MUTAGEN:N->A: Impairs DNA-binding; when associated with A-445.	SEQ_UP	1	
MUTAGEN:N->A: Impairs interaction with GATA1.	SEQ_UP	1	
MUTAGEN:N->A: Impairs TMEM35A/NACHO-mediated proper subunit assembly and trafficking to cell membrane.	SEQ_UP	1	
MUTAGEN:N->A: Increased localization to the plasma membrane.	SEQ_UP	1	
MUTAGEN:N->A: Increased permeability to chloride ions.	SEQ_UP	1	
MUTAGEN:N->A: Interferes with heterodimerization.	SEQ_UP	2	
MUTAGEN:N->A: Little or no effect. Induces a slight decrease in activity; when associated with A-466.	SEQ_UP	1	
MUTAGEN:N->A: Loss of alpha-tubulin alpha-elongation step of polyglutamylase activity.	SEQ_UP	1	
MUTAGEN:N->A: Loss of DNA glycosylase activity.	SEQ_UP	1	
MUTAGEN:N->A: Loss of glycosylation site.	SEQ_UP	1	
MUTAGEN:N->A: Loss of N-glycosylation; 90% decrease of plasma membrane expression.	SEQ_UP	1	
MUTAGEN:N->A: Loss of N-glycosylation; when associated with N-594.	SEQ_UP	1	
MUTAGEN:N->A: Loss of N-glycosylation; when associated with N-601.	SEQ_UP	1	
MUTAGEN:N->A: Loss of NLGN1-binding. No effect on CBLN1-binding.	SEQ_UP	1	
MUTAGEN:N->A: Loss of pericentromeric heterochromatin location. Abolishes DNA binding.	SEQ_UP	1	
MUTAGEN:N->A: Mildly impaired interaction with RAB9A.	SEQ_UP	1	
MUTAGEN:N->A: Nearly abolishes enzyme activity.	SEQ_UP	1	
MUTAGEN:N->A: No change in DNA binding. No change in nuclear location.	SEQ_UP	1	
MUTAGEN:N->A: No change in DNA binding. Reduced self-renewal ability in iPS cells. No change in nuclear location.	SEQ_UP	1	
MUTAGEN:N->A: No change in molecular weight, indicating lack of N-glycosylation.	SEQ_UP	1	
MUTAGEN:N->A: No effect on DNA binding.	SEQ_UP	1	
MUTAGEN:N->A: No effect on early endosome localization and reduced JNK1 activation; when associated with A-287.	SEQ_UP	1	
MUTAGEN:N->A: No effect on glycosylation.	SEQ_UP	1	
MUTAGEN:N->A: No effect on IL1B release under basal conditions, nor in response to LT or metabolic inhibitors.	SEQ_UP	1	
MUTAGEN:N->A: No effect on N-glycosylation.	SEQ_UP	1	
MUTAGEN:N->A: No effect on P-selectin binding; when associated with T-66.	SEQ_UP	1	
MUTAGEN:N->A: No effect on pericentromeric heterochromatin location. No change in DNA binding.	SEQ_UP	1	
MUTAGEN:N->A: No effect on protein stability. Decreased embryonic stem cell self-renewal.	SEQ_UP	1	
MUTAGEN:N->A: No effect on subcellular location. Abolishes Golgi and lysosomal localization; when associated with A-364.	SEQ_UP	1	
MUTAGEN:N->A: No effect on transmembrane ascorbate ferrireductase activity.	SEQ_UP	1	
MUTAGEN:N->A: No effect on UBE2I binding nor on sumoylation.	SEQ_UP	1	
MUTAGEN:N->A: No effect.	SEQ_UP	1	
MUTAGEN:N->A: No loss of interaction with PTPN13 (via PDZ domains).	SEQ_UP	1	
MUTAGEN:N->A: No MAPK8IP1 nor APBA1 nor Dab1 binding. No effect on APBB1 binding.	SEQ_UP	1	
MUTAGEN:N->A: Prevents from leaving the ER.	SEQ_UP	1	
MUTAGEN:N->A: Reduced ability to promote HIF1AN-dependent 2-oxoglutarate decarboxylation and greatly reduced transactivation capacity. Abolished ability to promote HIF1AN-dependent 2-oxoglutarate decarboxylation; when associated with G-2012. Almost abolished transactivation capacity; when associated with A-2012.	SEQ_UP	1	
MUTAGEN:N->A: Reduced activity.	SEQ_UP	1	
MUTAGEN:N->A: Reduced glycosylation.	SEQ_UP	1	
MUTAGEN:N->A: Reduced interaction with DNA.	SEQ_UP	1	
MUTAGEN:N->A: Reduced interaction with histones.	SEQ_UP	1	
MUTAGEN:N->A: Reduced lysophospholipase activity.	SEQ_UP	1	
MUTAGEN:N->A: Reduces ability to activate insulin and glucagon gene expression.	SEQ_UP	1	
MUTAGEN:N->A: Reduces activity about 10-fold.	SEQ_UP	1	
MUTAGEN:N->A: Reduces histone acetyltransferase activity; when associated with A-656 and A-658.	SEQ_UP	1	
MUTAGEN:N->A: Reduces the binding affinity of AHR?ARNT to the DRE by more than 10-fold.	SEQ_UP	1	
MUTAGEN:N->A: Significant reduction in LPC transport.	SEQ_UP	1	
MUTAGEN:N->A: Significantly decreased NF-kappa-B activation.	SEQ_UP	1	
MUTAGEN:N->A: Significantly reduced binding to NFIL3 promoter.	SEQ_UP	1	
MUTAGEN:N->A: Significantly reduced binding to symmetric dimethylarginines.	SEQ_UP	1	
MUTAGEN:N->A: Slightly reduced ability to promote HIF1AN-dependent 2-oxoglutarate decarboxylation. Abolished ability to promote HIF1AN-dependent 2-oxoglutarate decarboxylation and almost abolished transactivation capacity; when associated with A-1945.	SEQ_UP	1	
MUTAGEN:N->A: Slightly reduces phosphatidylinositol 3,4,5-trisphosphate binding.	SEQ_UP	1	
MUTAGEN:N->A: Strong decrease in cGAMP-binding.	SEQ_UP	1	
MUTAGEN:N->A: Strong decrease of DNA binding.	SEQ_UP	1	
MUTAGEN:N->A: Strongly increased threshold for activation by calcium.	SEQ_UP	1	
MUTAGEN:N->A: Strongly reduces affinity for DNA; when associated with A-166; W-226 and A-229.	SEQ_UP	1	
MUTAGEN:N->A: Strongly reduces affinity for DNA; when associated with A-76 and A-79.	SEQ_UP	1	
MUTAGEN:N->C: Reduces interaction with EHD2.	SEQ_UP	1	
MUTAGEN:N->D: 50% decrease in enzymatic activity.	SEQ_UP	1	
MUTAGEN:N->D: Abrogates Malassezia recognition; when associated with Q-169.	SEQ_UP	1	
MUTAGEN:N->D: Decreased threshold for activation by calcium.	SEQ_UP	1	
MUTAGEN:N->D: Decreases HRE DNA binding; when associated with D-186.	SEQ_UP	1	
MUTAGEN:N->D: Decreases interaction with VPS35.	SEQ_UP	1	
MUTAGEN:N->D: Does not affect ability to promote sperm-egg interaction.	SEQ_UP	1	
MUTAGEN:N->D: Greatly reduces MHC class I peptide tetramer binding; when associated with L-162.	SEQ_UP	1	
MUTAGEN:N->D: In mutant N-D: Abolished N-glycosylation; when associated with D-22; D-30; D-53; D-72; D-105; D-115; D-128; D-154; D-169; D-179; D-200 and D-210.	SEQ_UP	1	
MUTAGEN:N->D: In mutant N-D: Abolished N-glycosylation; when associated with D-22; D-30; D-53; D-72; D-76; D-105; D-115; D-128; D-154; D-169; D-179 and D-200.	SEQ_UP	1	
MUTAGEN:N->D: In mutant N-D: Abolished N-glycosylation; when associated with D-22; D-30; D-53; D-72; D-76; D-105; D-115; D-128; D-154; D-169; D-179 and D-210.	SEQ_UP	1	
MUTAGEN:N->D: In mutant N-D: Abolished N-glycosylation; when associated with D-22; D-30; D-53; D-72; D-76; D-105; D-115; D-128; D-154; D-169; D-200 and D-210.	SEQ_UP	1	
MUTAGEN:N->D: In mutant N-D: Abolished N-glycosylation; when associated with D-22; D-30; D-53; D-72; D-76; D-105; D-115; D-128; D-154; D-179; D-200 and D-210.	SEQ_UP	1	
MUTAGEN:N->D: In mutant N-D: Abolished N-glycosylation; when associated with D-22; D-30; D-53; D-72; D-76; D-105; D-115; D-128; D-169; D-179; D-200 and D-210.	SEQ_UP	1	
MUTAGEN:N->D: In mutant N-D: Abolished N-glycosylation; when associated with D-22; D-30; D-53; D-72; D-76; D-105; D-115; D-154; D-169; D-179; D-200 and D-210.	SEQ_UP	1	
MUTAGEN:N->D: In mutant N-D: Abolished N-glycosylation; when associated with D-22; D-30; D-53; D-72; D-76; D-105; D-128; D-154; D-169; D-179; D-200 and D-210.	SEQ_UP	1	
MUTAGEN:N->D: In mutant N-D: Abolished N-glycosylation; when associated with D-22; D-30; D-53; D-72; D-76; D-115; D-128; D-154; D-169; D-179; D-200 and D-210.	SEQ_UP	1	
MUTAGEN:N->D: In mutant N-D: Abolished N-glycosylation; when associated with D-22; D-30; D-53; D-76; D-105; D-115; D-128; D-154; D-169; D-179; D-200 and D-210.	SEQ_UP	1	
MUTAGEN:N->D: In mutant N-D: Abolished N-glycosylation; when associated with D-22; D-30; D-72; D-76; D-105; D-115; D-128; D-154; D-169; D-179; D-200 and D-210.	SEQ_UP	1	
MUTAGEN:N->D: In mutant N-D: Abolished N-glycosylation; when associated with D-22; D-53; D-72; D-76; D-105; D-115; D-128; D-154; D-169; D-179; D-200 and D-210.	SEQ_UP	1	
MUTAGEN:N->D: In mutant N-D: Abolished N-glycosylation; when associated with D-30; D-53; D-72; D-76; D-105; D-115; D-128; D-154; D-169; D-179; D-200 and D-210.	SEQ_UP	1	
MUTAGEN:N->D: Loss of DNA binding.	SEQ_UP	1	
MUTAGEN:N->D: Loss of SCFA-independent constitutive G protein-coupled receptor activity.	SEQ_UP	1	
MUTAGEN:N->D: No effect on binding to MAD.	SEQ_UP	1	
MUTAGEN:N->D: No effect on MHC class I peptide tetramer binding; when associated with N-248.	SEQ_UP	1	
MUTAGEN:N->D: No effect on protein abundance. Strong decreases of cell surface localization. Decreases alanine uptake.	SEQ_UP	1	
MUTAGEN:N->D: Reduced stability of the protein.	SEQ_UP	1	
MUTAGEN:N->D: Reduces oligomerization.	SEQ_UP	1	
MUTAGEN:N->D: Slighty reduced ion channel sensitivity to cold stimuli. No significant effect on ion channel sensitivity to menthol plus cold stimuli.	SEQ_UP	1	
MUTAGEN:N->E: Abolishes interaction with INSC.	SEQ_UP	1	
MUTAGEN:N->E: Strongly reduced affinity for DNA.	SEQ_UP	1	
MUTAGEN:N->F: Diminished binding of coactivator NCOA2 in the presence of TCPOBOP.	SEQ_UP	1	
MUTAGEN:N->F: Nearly abolishes interaction with NUMA1.	SEQ_UP	1	
MUTAGEN:N->G,L,M,P: Greatly impairs interaction with DAB2.	SEQ_UP	1	
MUTAGEN:N->G: Impairs interaction with MAP2K2/MEK2.	SEQ_UP	1	
MUTAGEN:N->G: Increased targeting to the endosomal/lysosomal compartment and reduced myotube formation.	SEQ_UP	1	
MUTAGEN:N->G: Reduced ability to promote HIF1AN-dependent 2-oxoglutarate decarboxylation. Abolished ability to promote HIF1AN-dependent 2-oxoglutarate decarboxylation; when associated with A-1945.	SEQ_UP	1	
MUTAGEN:N->G: Reduces apparent molecular weight of the protein, in agreement with the loss of one glycosylation site. Abolishes secretion of the extracellular domain; when associated with Q-73.	SEQ_UP	1	
MUTAGEN:N->G: Reduces binding to RAR, RXR and RAR/RXR.	SEQ_UP	1	
MUTAGEN:N->G: Strongly inhibits interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:N->H: Does not affect protein cleveage.	SEQ_UP	1	
MUTAGEN:N->H: No effect.	SEQ_UP	1	
MUTAGEN:N->H: Significantly increases polynucleotide adenylyltransferase activity.	SEQ_UP	1	
MUTAGEN:N->I: Corresponds to I-348 variant associated with SPGF16 in human. Impairs nuclear inner membrane location and increases interaction with DNAJB13.	SEQ_UP	1	
MUTAGEN:N->I: Does not rescue cortical neuron migration defects in PHACTR1 knocked-down mice.	SEQ_UP	1	
MUTAGEN:N->I: No effect on TERF1-binding. Loss of ability to stabilize TERF1 protein.	SEQ_UP	1	
MUTAGEN:N->I: Reduced potassium ion transmembrane transport.	SEQ_UP	1	
MUTAGEN:N->I: Strongly reduced affinity for PCDH15.	SEQ_UP	1	
MUTAGEN:N->K: Abolishes binding to CD200R.	SEQ_UP	1	
MUTAGEN:N->K: Abolishes interaction with NCOR2; mice have impaired GC formation and immunoglobulin affinity maturation with lower proliferation and survival of GC B-cells but normal differentiation of helper T-cell subsets and inflammatory response; in macrophages, no effect on transcriptional repression of genes encoding inflammatory molecules; when associated with A-116. In macrophages, no effect on competition with STAT5 for DNA-binding and transcriptional repression of genes encoding inflammatory molecules; when associated with A-116 and 377-Q--Q-380.	SEQ_UP	1	
MUTAGEN:N->K: Acquires binding to CD200; when associated with T-90 and F-138.	SEQ_UP	1	
MUTAGEN:N->K: Complete loss of glycosylation; when associated with K-54.	SEQ_UP	1	
MUTAGEN:N->K: Complete loss of glycosylation; when associated with K-88.	SEQ_UP	1	
MUTAGEN:N->K: Down-regulation of VPS16 expression in mice; mice exhibited obvious abnormality in the behavior and significantly impaired motor function.	SEQ_UP	1	
MUTAGEN:N->K: Induces alteration of the DNA-binding surface and leads to decreased synthesis of cyclic GMP-AMP (cGAMP); when associated with L-180.	SEQ_UP	1	
MUTAGEN:N->K: No effect.	SEQ_UP	1	
MUTAGEN:N->K: Reduced ion channel sensitivity to cold stimuli or menthol plus cold stimuli.	SEQ_UP	1	
MUTAGEN:N->K: Shows no change in activities at different temperatures.	SEQ_UP	1	
MUTAGEN:N->L: No effect on channel activation kinetics.	SEQ_UP	1	
MUTAGEN:N->L: Stabilizes the protein, 17-fold lower Vmax.	SEQ_UP	1	
MUTAGEN:N->M: Increases formation of (8S)-hydroperoxyicosatetraenoic acid ((8S)-HPETE) and (12S)-hydroperoxyicosatetraenoic acid ((12S)-HPETE). Exhibits a (15S)-lipoxygenase activity; when associated with W-360 and I-425. Loss of arachidonate (5S)-lipoxygenase activity; when associated with W-360; G-411 and I-425. Forms 11(R)-hydroperoxyicosatetraenoic acid (11(R)-HPETE) as the major arachidonic acid oxygenation product; when associated with W-360; G-411 and I-425.	SEQ_UP	1	
MUTAGEN:N->P: Abolishes interaction with VCP.	SEQ_UP	1	
MUTAGEN:N->Q: Abolishes DNA-binding.	SEQ_UP	1	
MUTAGEN:N->Q: Abolishes glycosylation and impairs secretion.	SEQ_UP	1	
MUTAGEN:N->Q: Abolishes glycosylation; when associated with Q-114, Q-120 and Q-312.	SEQ_UP	1	
MUTAGEN:N->Q: Abolishes glycosylation; when associated with Q-114, Q-120 and Q-326.	SEQ_UP	1	
MUTAGEN:N->Q: Abolishes glycosylation; when associated with Q-114, Q-312 and Q-326.	SEQ_UP	1	
MUTAGEN:N->Q: Abolishes glycosylation; when associated with Q-120, Q-312 and Q-326.	SEQ_UP	1	
MUTAGEN:N->Q: Abolishes glycosylation.	SEQ_UP	1	
MUTAGEN:N->Q: Abolishes glycosylation. Shifts threshold of temperature activation from 26.5 to 24 degrees Celsius. Reduced cell surface expression, association with lipid rafts and response to cold.	SEQ_UP	1	
MUTAGEN:N->Q: Abolishes localization to the Golgi apparatus; when associated with Q-115.	SEQ_UP	1	
MUTAGEN:N->Q: Abolishes localization to the Golgi apparatus; when associated with Q-88.	SEQ_UP	1	
MUTAGEN:N->Q: Abolishes N-glycosylation.	SEQ_UP	1	
MUTAGEN:N->Q: Almost no change in fusion-facilitating activity.	SEQ_UP	1	
MUTAGEN:N->Q: At least 60% of RNA binding activity and loss of GTase activity.	SEQ_UP	1	
MUTAGEN:N->Q: Complete loss of PAH transport activity.	SEQ_UP	1	
MUTAGEN:N->Q: Decreased glycosylation.	SEQ_UP	1	
MUTAGEN:N->Q: Decreased N-glycosylation.	SEQ_UP	1	
MUTAGEN:N->Q: Does not affect glycosylation.	SEQ_UP	1	
MUTAGEN:N->Q: Fails to form disulfide bonds and to induce filopodia-like protrusions.	SEQ_UP	1	
MUTAGEN:N->Q: Faster electrophoretic migration typical of a size reduction probably due to glycosylation loss.	SEQ_UP	1	
MUTAGEN:N->Q: Faster electrophoretic migration typical of a size reduction probably due to glycosylation loss. Abolishes proteolytic cleavage.	SEQ_UP	1	
MUTAGEN:N->Q: Impairs cell surface expression.	SEQ_UP	1	
MUTAGEN:N->Q: Impairs glycosylation.	SEQ_UP	2	
MUTAGEN:N->Q: Increased susceptibility to heat-inactivation. Forms homodimers and oligomers; when associated with Q-139 or Q-257. Inactive, impaired ability to form homodimers or oligomers; when associated with Q-139 and Q-257.	SEQ_UP	1	
MUTAGEN:N->Q: Increased susceptibility to heat-inactivation. Forms homodimers and oligomers; when associated with Q-221. Inactive, impaired ability to form homodimers or oligomers; when associated with Q-139 or Q-139 and Q-221.	SEQ_UP	1	
MUTAGEN:N->Q: Increased susceptibility to heat-inactivation. Forms homodimers and oligomers; when associated with Q-221. Inactive, impaired ability to form homodimers or oligomers; when associated with Q-257 or Q-221 and Q-257.	SEQ_UP	1	
MUTAGEN:N->Q: Increases homodimerization.	SEQ_UP	1	
MUTAGEN:N->Q: Loss of a probable N-glycosylation site. Increased expression at the cell membrane, leading to increased ion currents.	SEQ_UP	1	
MUTAGEN:N->Q: Loss of activation by low pH.	SEQ_UP	1	
MUTAGEN:N->Q: Loss of glycosylation site. Causes retention in the endoplasmic reticulum and abolishes normal location in lysosomes.	SEQ_UP	1	
MUTAGEN:N->Q: Loss of glycosylation site. No effect on normal location in lysosomes.	SEQ_UP	1	
MUTAGEN:N->Q: Loss of N-glycosylation.	SEQ_UP	1	
MUTAGEN:N->Q: Loss of N-glycosylation. No significant effect on lipid phosphatase activity.	SEQ_UP	1	
MUTAGEN:N->Q: Loss of one N-glycosylation site. Abolishes N-glycosylation; when associated with Q-585.	SEQ_UP	1	
MUTAGEN:N->Q: Loss of one N-glycosylation site. Abolishes N-glycosylation; when associated with Q-592.	SEQ_UP	1	
MUTAGEN:N->Q: N-glycosylated.	SEQ_UP	1	
MUTAGEN:N->Q: No effect on activation by low pH.	SEQ_UP	1	
MUTAGEN:N->Q: No effect on extracellular secretion.	SEQ_UP	1	
MUTAGEN:N->Q: No effect on glycosylation or ability to form functional channels.	SEQ_UP	1	
MUTAGEN:N->Q: No effect on glycosylation; when associated with Q-120.	SEQ_UP	1	
MUTAGEN:N->Q: No effect on glycosylation; when associated with Q-355.	SEQ_UP	1	
MUTAGEN:N->Q: No effect on its ability to form homohexameric or heteromeric complexes with other CBLN family members. Increased interaction with GRID2, NRXN1 and NRXN3. Loss of N-glycosylation; when associated with Q-23.	SEQ_UP	1	
MUTAGEN:N->Q: No effect on its ability to form homohexameric or heteromeric complexes with other CBLN family members. Increased interaction with GRID2, NRXN1 and NRXN3. Loss of N-glycosylation; when associated with Q-79.	SEQ_UP	1	
MUTAGEN:N->Q: No effect on its ability to form homohexameric or heteromeric complexes with other CBLN family members. Increased interaction with NRXN1 and NRXN3. Total loss of N-glycosylation; when associated with Q-110.	SEQ_UP	1	
MUTAGEN:N->Q: No effect on its ability to form homohexameric or heteromeric complexes with other CBLN family members. Increased interaction with NRXN1, NRXN3 and DCC. Shows interaction with NEO1, GRID1 and GRID2. Total loss of N-glycosylation; when associated with Q-26.	SEQ_UP	1	
MUTAGEN:N->Q: No effect on its ability to form homohexameric or heteromeric complexes with other CBLN family members. Increased interaction with NRXN1, NRXN3 and DCC. Shows interaction with NEO1, GRID1 and GRID2. Total loss of N-glycosylation; when associated with Q-85.	SEQ_UP	1	
MUTAGEN:N->Q: No effect on its ability to form homohexameric or heteromeric complexes with other CBLN family members. Increased interaction with NRXN1. Total loss of N-glycosylation; when associated with Q-53.	SEQ_UP	1	
MUTAGEN:N->Q: No effect on lipid phosphatase activity.	SEQ_UP	1	
MUTAGEN:N->Q: Not glycosylated.	SEQ_UP	1	
MUTAGEN:N->Q: Reduced glycosylation and increased protein stability; when associated with Q-314 and Q-373.	SEQ_UP	1	
MUTAGEN:N->Q: Reduced glycosylation and increased protein stability; when associated with Q-373 and Q-373.	SEQ_UP	1	
MUTAGEN:N->Q: Reduced glycosylation and increased protein stability; when associated with Q-73 and Q-314.	SEQ_UP	1	
MUTAGEN:N->Q: Reduced glycosylation.	SEQ_UP	1	
MUTAGEN:N->Q: Reduces activity about 3-fold.	SEQ_UP	1	
MUTAGEN:N->Q: Reduces apparent molecular weight of the protein, in agreement with the loss of one glycosylation site. Abolishes secretion of the extracellular domain; when associated with G-185.	SEQ_UP	1	
MUTAGEN:N->Q: Slight decrease of DNA binding.	SEQ_UP	1	
MUTAGEN:N->Q: Strongly reduced current amplitude and localization to cell membrane.	SEQ_UP	1	
MUTAGEN:N->S,L: Strongly inhibits interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:N->S: Decrease of IL1B release, but no effect on autocatalytic cleavage within the FIIND region.	SEQ_UP	1	
MUTAGEN:N->S: Decreases bisecting N-acetylglucosamine levels. Almost abolishes bisecting N-acetylglucosamine levels but has no effect on surface expression; when associated with S-153.	SEQ_UP	1	
MUTAGEN:N->S: Decreases bisecting N-acetylglucosamine levels. Almost abolishes bisecting N-acetylglucosamine levels but has no effect on surface expression; when associated with S-223.	SEQ_UP	1	
MUTAGEN:N->S: Does not affect ability to promote H3K27me3 methylation; when associated with S-78.	SEQ_UP	1	
MUTAGEN:N->S: Has a dominant negative effect on the proximal promoter region of HESX1 gene; represses reporter expression.	SEQ_UP	1	
MUTAGEN:N->S: Loss of binding to other proteins.	SEQ_UP	1	
MUTAGEN:N->S: Loss of one glycosylation site.	SEQ_UP	1	
MUTAGEN:N->S: Loss of transcriptional activity.	SEQ_UP	1	
MUTAGEN:N->S: No effect on interaction with IZUMO1.	SEQ_UP	1	
MUTAGEN:N->S: Slightly decreases bisecting N-acetylglucosamine levels.	SEQ_UP	1	
MUTAGEN:N->T: No effect on MHC class I peptide tetramer binding; when associated with Q-169.	SEQ_UP	1	
MUTAGEN:N->T: No effect on P-selectin binding; when associated with A-261.	SEQ_UP	1	
MUTAGEN:N->V: 70% reduction of GAP activity; when associated with A-56.	SEQ_UP	1	
MUTAGEN:N->W: Abolishes interaction with CD4 endocytosis signal motif.	SEQ_UP	1	
MUTAGEN:N->W: Increases sulfotransferase activity (at pH 7.5).	SEQ_UP	1	
MUTAGEN:N->Y: Strongly enhanced binding to symmetric dimethylarginines.	SEQ_UP	1	
MUTAGEN:ND->AA: Decreases phosphatidylserine binding, abolishes phagocytic activity.	SEQ_UP	1	
MUTAGEN:NDKS->ADAA: Strongly reduces affinity for DNA.	SEQ_UP	1	
MUTAGEN:NH->LE: In GM6; does not form heterodimer with EHMT1 and is defective in mediating H3K9me.	SEQ_UP	1	
MUTAGEN:NHL->WQK: Abolishes peroxisome localization.	SEQ_UP	1	
MUTAGEN:NKKS->AAAA: Abolished ability to induce plasma membrane rupture in response to death stimuli.	SEQ_UP	1	
MUTAGEN:NLLL->EAAA: No effect on interaction with PPARA. Abolishes interaction with PPARA and NR1D1 as well as reduces the amplitude of ARNTL expression; when associated with 306-A--A-310.	SEQ_UP	1	
MUTAGEN:NNENL->AAAAA: Loss of self-renewal ability in iPS cells.	SEQ_UP	1	
MUTAGEN:NNENLQEICKSETLVQA->SSSGSPTNLDKIAAQGR: Reduced DNA binding. Loss of self-renewal ability in iPS cells. No change in nuclear location.	SEQ_UP	1	
MUTAGEN:NNLN->ANLA: Abolishes deamidation and impaired interaction with RPTOR.	SEQ_UP	1	
MUTAGEN:NNLN->DNLD: Increased interaction with RPTOR.	SEQ_UP	1	
MUTAGEN:NPAF->I: Abolishes binding to NUMB protein.	SEQ_UP	1	
MUTAGEN:NPF->SPL: Reduces interaction with EHD2.	SEQ_UP	1	
MUTAGEN:NPLLY->DPLLA: In ZBP1(Zalpha2); abolished ability to sense influenza A virus (IAV) Z-RNAs. In ZBP1(Zalpha2); knockin mice are viable and develop mild skin lesions in response to influenza A virus (IAV). ZBP1(Zalpha2) knockin mice are protected from the activation of RIPK3 and MLKL as well as the cell death. In ZBP1(Zalpha1-Zalpha2); knockin mice are viable and develop mild skin lesions in response to influenza A virus (IAV); mice are protected from the activation of RIPK3 and MLKL as well as the cell death; when associated with 46-D--A-50.	SEQ_UP	1	
MUTAGEN:NPPF->APPA: Abolished rRNA N6-adenosine-methyltransferase activity.	SEQ_UP	1	
MUTAGEN:NQ->QN: Induces a decrease in activity.	SEQ_UP	1	
MUTAGEN:NQVLY->DQVLA: In ZBP1(Zalpha1); no effect. In ZBP1(Zalpha1-Zalpha2); knockin mice are viable and develop mild skin lesions in response to influenza A virus (IAV); mice are protected from the activation of RIPK3 and MLKL as well as the cell death; when associated with 122-D--A-126.	SEQ_UP	1	
MUTAGEN:NR->AA: Abolishes ability to rescue Purkinje cell degeneration in pcd mice when expressed in a transgene.	SEQ_UP	1	
MUTAGEN:NSLFIW->SRPHTR: Increases surface expression in transfected pro-B cells and enhances interaction with FCER1G. Slightly increases surface expression and enhances interaction with FCER1G; when associated with 189-Y--L-198.	SEQ_UP	1	
MUTAGEN:NSTGIPFFYMTAKDPAVADLVKN->QSTGIPFFYMTAKDPAVADLVKQ: Abolishes N-glycosylation.	SEQ_UP	1	
MUTAGEN:P->A,G: Abolishes interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:P->A,G: Moderately increased threshold for activation by calcium.	SEQ_UP	1	
MUTAGEN:P->A,G: No effect on 'Lys-48'-linked polyubiquitin binding.	SEQ_UP	1	
MUTAGEN:P->A,K: Fails to induce Th2 cytokine production.	SEQ_UP	1	
MUTAGEN:P->A,L: Strongly reduces transactivation and transforming capability.	SEQ_UP	1	
MUTAGEN:P->A: Abolishes binding to DBNL.	SEQ_UP	1	
MUTAGEN:P->A: Abolishes binding to RAR, RXR and RAR/RXR.	SEQ_UP	1	
MUTAGEN:P->A: Abolishes calcium uptake into mitochondria. Abolishes interaction with MCU.	SEQ_UP	1	
MUTAGEN:P->A: Abolishes interaction with CEP55.	SEQ_UP	1	
MUTAGEN:P->A: Abolishes interaction with RHOQ, but not the interaction with CDC42; when associated with A-139.	SEQ_UP	1	
MUTAGEN:P->A: Abolishes interaction with the SH3 domain of STAM2.	SEQ_UP	1	
MUTAGEN:P->A: Abolishes ligand binding; when associated with F-280.	SEQ_UP	1	
MUTAGEN:P->A: Abolishes nuclear localization.	SEQ_UP	1	
MUTAGEN:P->A: Abolishes phosphorylation at Ser-391. Abolishes interaction with PPP2CA and PPP2R1A.	SEQ_UP	1	
MUTAGEN:P->A: Abrogates interaction with NCOR1 and KDM1A. Greatly diminished interaction with HDAC2. Loss of ability to promote erythrocyte and granulocyte differentiation.	SEQ_UP	1	
MUTAGEN:P->A: Abrogates transcriptional repression. No change in nuclear location.	SEQ_UP	1	
MUTAGEN:P->A: Almost complete loss of CTTN-binding and loss of regulation of spine density; when associated with A-540.	SEQ_UP	1	
MUTAGEN:P->A: Almost complete loss of CTTN-binding and loss of regulation of spine density; when associated with A-543.	SEQ_UP	1	
MUTAGEN:P->A: Confers transcriptional activity at normoxia; when associated with A-851.	SEQ_UP	1	
MUTAGEN:P->A: Decreased interaction with ADGRA2.	SEQ_UP	1	
MUTAGEN:P->A: Disrupts targeting to membrane; when associated with N-68; Q-70; P-73; A-74 and Q-75.	SEQ_UP	1	
MUTAGEN:P->A: Does not affect neither the nuclear localization nor the enzyme activity.	SEQ_UP	1	
MUTAGEN:P->A: Does not affect recognition by the CRL2(FEM1B) complex and subsequent ubiquitination.	SEQ_UP	1	
MUTAGEN:P->A: Does not affect the interaction with GATA1.	SEQ_UP	1	
MUTAGEN:P->A: Does not affect the nuclear localization.	SEQ_UP	1	
MUTAGEN:P->A: Does not bind to SIVA1.	SEQ_UP	1	
MUTAGEN:P->A: Does not impair nuclear localization.	SEQ_UP	1	
MUTAGEN:P->A: Drastic decrease in GRB2-binding, but no effect on VAV-binding; when associated with A-552. Partial loss of enhancement of LPS-induced TNF production; when associated with A-552.	SEQ_UP	1	
MUTAGEN:P->A: Drastic decrease in GRB2-binding, but no effect on VAV-binding; when associated with A-555. Partial loss of enhancement of LPS-induced TNF production; when associated with A-555.	SEQ_UP	1	
MUTAGEN:P->A: Impairs DNA-binding.	SEQ_UP	1	
MUTAGEN:P->A: Impairs ubiquitin binding and post-translation modification via ubiquitination; when associated with A-508. Abolishes ubiquitin binding and localization to nuclear foci after UV-induced DNA damage but does not affect catalytic activity; when associated with A-509, A-693 and A-694.	SEQ_UP	1	
MUTAGEN:P->A: Impairs ubiquitin binding and post-translation modification via ubiquitination; when associated with A-693. Abolishes ubiquitin binding and localization to nuclear foci after UV-induced DNA damage but does not affect catalytic activity; when associated with A-508, A-509 and A-693.	SEQ_UP	1	
MUTAGEN:P->A: Increased localization to the plasma membrane.	SEQ_UP	1	
MUTAGEN:P->A: Inhibits interaction with ZDHHC13 and ZDHHC17.	SEQ_UP	1	
MUTAGEN:P->A: Loss of autophosphorylation and fails to induce activation of the AP-1 transcription factor, MAPK7 or MAPK8; when associated with A-575 and A-576.	SEQ_UP	1	
MUTAGEN:P->A: Loss of autophosphorylation.	SEQ_UP	1	
MUTAGEN:P->A: Loss of E3 ubiquitin protein ligase activity.	SEQ_UP	2	
MUTAGEN:P->A: Loss of E3 ubiquitin-protein ligase activity.	SEQ_UP	1	
MUTAGEN:P->A: Loss of interaction with FCHO2; when associated with A-294.	SEQ_UP	1	
MUTAGEN:P->A: Loss of interaction with FCHO2; when associated with A-299.	SEQ_UP	1	
MUTAGEN:P->A: Loss of interaction with TNFRSF14.	SEQ_UP	1	
MUTAGEN:P->A: Loss of proline isomerization; no phenotype when introduced in mice, animals are viable and fertile with no microcephaly or defective cortical lamination; no splicing defect.	SEQ_UP	1	
MUTAGEN:P->A: No effect on autophosphorylation and AP-1 transcription factor, MAPK7 or MAPK8 activity. Fails to induce activation and loss of autophosphorylation; when associated with A-581.	SEQ_UP	1	
MUTAGEN:P->A: No effect on binding to NUMB protein.	SEQ_UP	1	
MUTAGEN:P->A: No effect on cAMP-binding.	SEQ_UP	1	
MUTAGEN:P->A: No effect on interaction with CNOT7.	SEQ_UP	1	
MUTAGEN:P->A: No effect on interaction with FYN SH3 domain.	SEQ_UP	1	
MUTAGEN:P->A: No effect on interaction with PARD6B.	SEQ_UP	1	
MUTAGEN:P->A: No effect on LIF signal transduction suppression.	SEQ_UP	1	
MUTAGEN:P->A: No effect on STAT3 phosphorylation.	SEQ_UP	1	
MUTAGEN:P->A: No effect on transmembrane ascorbate ferrireductase activity.	SEQ_UP	1	
MUTAGEN:P->A: No impact on interaction with EIF4A.	SEQ_UP	1	
MUTAGEN:P->A: No interaction with COP1. Inhibition of degradation under exposure to FSK/INS.	SEQ_UP	1	
MUTAGEN:P->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-277.	SEQ_UP	1	
MUTAGEN:P->A: Reduced activity.	SEQ_UP	1	
MUTAGEN:P->A: Reduced binding to CHO cells expressing ITAG9-ITGB1.	SEQ_UP	1	
MUTAGEN:P->A: Reduced CTTN-binding; when associated with A-599.	SEQ_UP	1	
MUTAGEN:P->A: Reduced CTTN-binding; when associated with A-602.	SEQ_UP	1	
MUTAGEN:P->A: Reduces histone acetyltransferase activity; when associated with A-658 and A-659.	SEQ_UP	1	
MUTAGEN:P->A: Significant reduction in binding to SRC and CRK and decrease in phosphorylation; when associated with A-910. Loss of binding and phosphorylation; when associated with A-811 and A-910.	SEQ_UP	1	
MUTAGEN:P->A: Significant reduction in binding to SRC and CRK and decrease in phosphorylation; when associated with A-913. Loss of binding and phosphorylation; when associated with A-811 and A-913.	SEQ_UP	1	
MUTAGEN:P->A: Slightly affects binding to NUMB protein.	SEQ_UP	1	
MUTAGEN:P->A: Stimulates interaction with SH3KBP1.	SEQ_UP	1	
MUTAGEN:P->A: Strongly decreased interaction with KEAP1.	SEQ_UP	1	
MUTAGEN:P->A: Strongly inhibits interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:P->C: Abolishes interaction with HOMER1. Does not affect enzymatic activity. Fails to associate with the plasma membrane.	SEQ_UP	1	
MUTAGEN:P->D: Abolishes interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:P->D: Abrogates interaction with EED.	SEQ_UP	1	
MUTAGEN:P->E,F,I,K,L,Q,R,V,W,Y: Greatly impairs interaction with DAB2.	SEQ_UP	1	
MUTAGEN:P->E: Retains 10% of wild-type activity.	SEQ_UP	1	
MUTAGEN:P->F: Abolishes interaction with AP-2 complex.	SEQ_UP	1	
MUTAGEN:P->F: Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself.	SEQ_UP	1	
MUTAGEN:P->G: Loss of tautomerase activity, reduced activation of intracellular signaling pathways, and reduced interaction with CXCR2 and COPS5.	SEQ_UP	1	
MUTAGEN:P->G: No effect.	SEQ_UP	1	
MUTAGEN:P->G: Reduces inhibition of ATP2A1-mediated calcium uptake.	SEQ_UP	1	
MUTAGEN:P->G: Results in inhibition of JNK binding.	SEQ_UP	1	
MUTAGEN:P->H: Abolishes MYD88-binding and response to microbial cell wall components.	SEQ_UP	1	
MUTAGEN:P->H: Dominant negative mutant, blocks response to Gram-positive pathogens.	SEQ_UP	1	
MUTAGEN:P->H: Fails to activate NF-kappa-B.	SEQ_UP	1	
MUTAGEN:P->H: Significant reduction in LPC transport.	SEQ_UP	1	
MUTAGEN:P->H: Strongly increases enzyme activity, serves as proton acceptor.	SEQ_UP	1	
MUTAGEN:P->I: Abolishes DNA-binding and transactivator/repressor activity; when associated with P-383.	SEQ_UP	1	
MUTAGEN:P->I: Loss of lipid phosphatase activity.	SEQ_UP	1	
MUTAGEN:P->K: No effect on interaction with FYN SH3 domain.	SEQ_UP	1	
MUTAGEN:P->L: Abolishes cold receptor activity, no effect on ionotropic glutamate receptor activity.	SEQ_UP	1	
MUTAGEN:P->L: Abolishes interaction with DNM1, MAPT, SYNJ1 and WASL.	SEQ_UP	1	
MUTAGEN:P->L: Abolishes LPC transport.	SEQ_UP	1	
MUTAGEN:P->L: Abolishes phosphatase activity.	SEQ_UP	1	
MUTAGEN:P->L: Decreased affinity for 700-bp RNA.	SEQ_UP	1	
MUTAGEN:P->L: Decreased protein abundance. Not delivered to the plasma membrane. Heterozygotes mice with this mutation display abnormal social behavior.	SEQ_UP	1	
MUTAGEN:P->L: Decreases interaction with NOD2.	SEQ_UP	1	
MUTAGEN:P->L: Does not affect its inhibitory function.	SEQ_UP	1	
MUTAGEN:P->L: Dominant-negative mutant that induces defects in membrane repair.	SEQ_UP	1	
MUTAGEN:P->L: Lethality immediately after birth in knockin mice; caused by creation of a dileucine internalization motif that promotes mislocalization of the protein.	SEQ_UP	1	
MUTAGEN:P->L: Loss of DNM1-, SYNJ1- and WASL-binding.	SEQ_UP	1	
MUTAGEN:P->L: Loss of DNM1-, SYNJ1- and WASL-binding. Loss of effect on transferrin endocytosis.	SEQ_UP	1	
MUTAGEN:P->L: Loss of proteolytic cleavage; when associated with V-423 and V-426.	SEQ_UP	1	
MUTAGEN:P->L: No effect on interaction with GRB2.	SEQ_UP	1	
MUTAGEN:P->L: Not properly targeted to the Golgi apparatus; strongly reduced secretion to the medium; localizes mainly to the ER compartment. Strongly impaired glycosylation of alpha-dystroglycan in muscles and brain.	SEQ_UP	1	
MUTAGEN:P->L: Reduces interaction with histone H3.	SEQ_UP	1	
MUTAGEN:P->L: Slightly affects inhibitory function. Abolishes inhibitory function; when associated with E-111.	SEQ_UP	1	
MUTAGEN:P->L: Strongly reduced 2'-5'-oligoadenylate synthase activity.	SEQ_UP	1	
MUTAGEN:P->N: Reduces interaction with EPS15 and SYNRG.	SEQ_UP	1	
MUTAGEN:P->N: Strongly reduces FLRT2 binding; when associated with T-246.	SEQ_UP	1	
MUTAGEN:P->Q: Mice carrying this mutant show narrowed dental pulp cavities, increased dentin thickness, and abnormal tooth attrition, as well as anomalies in the number and organization of dentinal tubules, indicating dysplasia of the mineralized dentin; the width of the predentin zone is reduced in heterozygous animals or null in homozygotes, with significantly increased numbers of odontoblasts in the pulp cavity compared to wild-type mice.	SEQ_UP	1	
MUTAGEN:P->R: Abolishes interaction with NCOR2.	SEQ_UP	1	
MUTAGEN:P->R: Does not interact with MECP2. Affects recruitment to heterochromatin by MECP2. Is efficiently incorporated in N-Cor repressor complex.	SEQ_UP	1	
MUTAGEN:P->R: Mildly affects interaction with MECP2.	SEQ_UP	1	
MUTAGEN:P->S: Disrupts interaction with VPS35:VPS29 dimer; no endosomal localization; when associated with S-247.	SEQ_UP	1	
MUTAGEN:P->S: Does not affect interaction with NALCN. Does not affect interaction with UNC79. Affects NALCN channel activation.	SEQ_UP	1	
MUTAGEN:P->S: Erroneous subcellular location; when associated with R-119. No positive effect on terminal myogenic differentiation; when associated with R-119.	SEQ_UP	1	
MUTAGEN:P->S: Greatly reduces MHC class I peptide tetramer binding; when associated with P-195.	SEQ_UP	1	
MUTAGEN:P->S: Impairs enzyme activity.	SEQ_UP	1	
MUTAGEN:P->S: Loss of inhibition by GNF-2.	SEQ_UP	1	
MUTAGEN:P->S: Loss of interaction with RNF4; when associated with T-1629; R-1736 and V-1737.	SEQ_UP	1	
MUTAGEN:P->S: Mis-localization predominantly to the cytoplasmic compartment.	SEQ_UP	1	
MUTAGEN:P->S: No effect on activity.	SEQ_UP	1	
MUTAGEN:P->S: No effect on interaction with NPHS2.	SEQ_UP	1	
MUTAGEN:P->S: Strongly reduced inhibition by GNF-2.	SEQ_UP	1	
MUTAGEN:P->T: Causes local perturbations of protein folding; when associated with T-122.	SEQ_UP	1	
MUTAGEN:P->T: Does not modify the functional properties of the protein.	SEQ_UP	1	
MUTAGEN:P->T: No effect on interaction with UNC5D; when associated with N-248.	SEQ_UP	1	
MUTAGEN:P->T: Significant reduction in LPC transport.	SEQ_UP	1	
MUTAGEN:PC->GT: No effect on localization.	SEQ_UP	1	
MUTAGEN:PC->VD: No effect on localization.	SEQ_UP	1	
MUTAGEN:PER->AAA: Does not inhibit interaction with ZNF473. Reduces weakly histone 3' end processing.	SEQ_UP	1	
MUTAGEN:PF->AA: Abolishes interaction with histone H4 acetylated N-terminus; when associated with A-298.	SEQ_UP	1	
MUTAGEN:PF->AA: Abolishes interaction with histone H4 acetylated N-terminus; when associated with A-55.	SEQ_UP	1	
MUTAGEN:PF->AA: Loss of function giving rise to cholesterol accumulation in kidney, liver, lung and spleen. No effect on lysosomal location. Mice display age-dependent weight loss, neurodegeneration with loss of Purkinje cells, ataxia and premature death at a median age of 84 days.	SEQ_UP	1	
MUTAGEN:PIAF->AIAA: Decreases affinity for PTPRD; when associated with 75-A--A-77. Significantly decreases synaptogenesis; when associated with 88-A--A-91.	SEQ_UP	1	
MUTAGEN:PIDL->AIAA: Abolishes interaction with CTBP2.	SEQ_UP	1	
MUTAGEN:PINF->AINA: Abolishes interaction with PTPRD; when associates with 69-A--A-71 Significantly reduces synaptogenesis; when associates with 82-A--A-85.	SEQ_UP	1	
MUTAGEN:PKL->QAQ: No effect on cleavage by LT.	SEQ_UP	1	
MUTAGEN:PKRP->AKRA: Significantly reduced interaction with CTTN; when associated with 259-ANQA-262.	SEQ_UP	1	
MUTAGEN:PLL->AAA: Does not inhibit interaction with ZNF473. Reduces strongly histone 3' end processing.	SEQ_UP	1	
MUTAGEN:PLNLV->AANAA: No significant effect on transcriptional repression activity.	SEQ_UP	2	
MUTAGEN:PMKF->LMKC: Abolished interaction with HOMER1.	SEQ_UP	1	
MUTAGEN:PNQP->ANQA: Significantly reduced interaction with CTTN; when associated with 235-AKRA-238.	SEQ_UP	1	
MUTAGEN:PP->AL: Strongly reduced interaction with PACSIN3.	SEQ_UP	1	
MUTAGEN:PP->LH: Reduces degradation (isoform 1); when associated with 177-L-H-178.	SEQ_UP	1	
MUTAGEN:PP->LH: Reduces degradation (isoform 1); when associated with 238-L-H-239.	SEQ_UP	1	
MUTAGEN:PP->RR: Abolished methyltransferase activity.	SEQ_UP	1	
MUTAGEN:PPGP->AAGA: Strongly impairs phosphorylation.	SEQ_UP	1	
MUTAGEN:PPP->AAA: Abolishes interaction with SUN1. Fails to localize at telomere.	SEQ_UP	1	
MUTAGEN:PPP->AAA: No effect on DNA-binding or interaction with CDK2 and CDK4. No effect on cell cycle inhibition.	SEQ_UP	1	
MUTAGEN:PPP->SSS: Abolished interaction with GIGYF2 and impaired TTP-mediated mRNA repression; when associated with 191-S--S-193.	SEQ_UP	1	
MUTAGEN:PPP->SSS: Abolished interaction with GIGYF2 and impaired TTP-mediated mRNA repression; when associated with 64-S--S-66.	SEQ_UP	1	
MUTAGEN:PPP->SSS: Does not affect interaction with GIGYF2.	SEQ_UP	1	
MUTAGEN:PPPPPPP->APPPAPA: No effect on DNA-binding or interaction with CDK2 and CDK4. No effect on cell cycle inhibition.	SEQ_UP	1	
MUTAGEN:PSAP->ASAA: Loss of TSG101-binding.	SEQ_UP	1	
MUTAGEN:PTY->AAA: Loss of transactivation activity. No induction of histone H3 'K-4' acetylation.	SEQ_UP	1	
MUTAGEN:PV->AA: Loss of promotion of EKLF sumoylation.	SEQ_UP	1	
MUTAGEN:PVWPSSP->AVWASSA: Loss of interaction with PI3 kinase.	SEQ_UP	1	
MUTAGEN:Q->A,C,D,E,G,F,H,I,L,M,P,W,Y: Drastic reduction in basal cAMP production.	SEQ_UP	1	
MUTAGEN:Q->A,D: Induces a nuclear accumulation in unstimulated cells.	SEQ_UP	1	
MUTAGEN:Q->A,E: Alters chloride anion transport behavior.	SEQ_UP	1	
MUTAGEN:Q->A,M,N,S,T: No effect on binding to AP-2.	SEQ_UP	1	
MUTAGEN:Q->A: 99% decrease in cross-linking efficiency; when associated with A-35 and A-36.	SEQ_UP	1	
MUTAGEN:Q->A: 99% decrease in cross-linking efficiency; when associated with A-35 and A-48.	SEQ_UP	1	
MUTAGEN:Q->A: 99% decrease in cross-linking efficiency; when associated with A-36 and A-48.	SEQ_UP	1	
MUTAGEN:Q->A: Abolished serotonylation by TGM2. Reduced neurite length.	SEQ_UP	2	
MUTAGEN:Q->A: Abolishes enzyme activity.	SEQ_UP	2	
MUTAGEN:Q->A: Abolishes interaction with DYNLL2.	SEQ_UP	1	
MUTAGEN:Q->A: Abolishes interaction with PCNA.	SEQ_UP	1	
MUTAGEN:Q->A: Abolishes interaction with TBK1 and IKBKE.	SEQ_UP	1	
MUTAGEN:Q->A: Abolishes Rac1 activation; when associated with E-1435.	SEQ_UP	1	
MUTAGEN:Q->A: Abolishes response to semaphorin.	SEQ_UP	1	
MUTAGEN:Q->A: Decreased 'Lys-48'-linked polyubiquitin binding; when associated with Q-227.	SEQ_UP	1	
MUTAGEN:Q->A: Decreased alpha-tubulin alpha-elongation step of polyglutamylase activity.	SEQ_UP	1	
MUTAGEN:Q->A: Decreased protein expression. No effect on protein stability.	SEQ_UP	1	
MUTAGEN:Q->A: Decreased transmembrane ascorbate ferrireductase activity. Approximately 55% reduction in enzyme activity.	SEQ_UP	1	
MUTAGEN:Q->A: Decreases interaction with CALM1 in the absence of calcium.	SEQ_UP	1	
MUTAGEN:Q->A: Disrupts interaction with RAB32 and RAB38; inhibits peripheral distribution of TYRP1 in melanocytes; no effect on dendrite formation in melanocytes.	SEQ_UP	1	
MUTAGEN:Q->A: Does not affect interaction with ADGRA2.	SEQ_UP	1	
MUTAGEN:Q->A: Does not affect interaction with the SH3 domain of STAM2.	SEQ_UP	1	
MUTAGEN:Q->A: Does not affect proteolysis activity.	SEQ_UP	1	
MUTAGEN:Q->A: Does not affect the interaction with GATA1.	SEQ_UP	1	
MUTAGEN:Q->A: Does not affect the nuclear localization but affects the enzyme activity.	SEQ_UP	1	
MUTAGEN:Q->A: Does not inhibit calcium-dependent translocation to the cell membrane; when associated with G-287 and G-288.	SEQ_UP	1	
MUTAGEN:Q->A: Impaired ability to homooligomerize at 30 degrees Celsius.	SEQ_UP	1	
MUTAGEN:Q->A: Impaired enzyme activity and polyuridylated RNA-binding.	SEQ_UP	1	
MUTAGEN:Q->A: Impaired interaction with SQSTM1/p62.	SEQ_UP	1	
MUTAGEN:Q->A: Impairs ability to activate integrins.	SEQ_UP	1	
MUTAGEN:Q->A: In mut3; does not affect localization to primary cilia; when associated with 243-A-A-244.	SEQ_UP	1	
MUTAGEN:Q->A: Increased permeability to chloride ions.	SEQ_UP	1	
MUTAGEN:Q->A: Increased protein expression. No effect on protein stability.	SEQ_UP	1	
MUTAGEN:Q->A: Inhibits GDI activity. Does not inhibit interaction with GNAI1 in the centrosomes, does not affect subcellular location and does not promote gene transcription activation. Inhibits interaction with GNAI1 in the centrosomes; when associated with A-92-93-A.	SEQ_UP	1	
MUTAGEN:Q->A: Little or no effect. Induces a slight decrease in activity; when associated with A-465.	SEQ_UP	1	
MUTAGEN:Q->A: Loss of autophosphorylation and fails to induce activation of the AP-1 transcription factor, MAPK7 or MAPK8; when associated with A-574 and A-576.	SEQ_UP	1	
MUTAGEN:Q->A: Loss of enzyme activity and polyuridylated RNA-binding; when associated with A-74.	SEQ_UP	1	
MUTAGEN:Q->A: Loss of pericentromeric heterochromatin location. Disrupted DNA binding.	SEQ_UP	1	
MUTAGEN:Q->A: Low spontaneous IL1B release, no effect on the response to metabolic inhibitors, nor to LT.	SEQ_UP	1	
MUTAGEN:Q->A: No change in DNA binding. No loss of self-renewal ability in iPS cells. No change in nuclear location.	SEQ_UP	1	
MUTAGEN:Q->A: No effect on IL1B release under basal conditions, nor in response to LT or metabolic inhibitors.	SEQ_UP	1	
MUTAGEN:Q->A: No effect on interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:Q->A: No effect on interaction with SQSTM1.	SEQ_UP	1	
MUTAGEN:Q->A: No effect on phagocytic activity.	SEQ_UP	1	
MUTAGEN:Q->A: No loss of binding to AP2A1 and AP2A2.	SEQ_UP	1	
MUTAGEN:Q->A: Reduced interaction with HRAS.	SEQ_UP	1	
MUTAGEN:Q->A: Reduces DENND1A- and DENND1C-binding.	SEQ_UP	1	
MUTAGEN:Q->A: Reduces enzyme activity.	SEQ_UP	1	
MUTAGEN:Q->A: Slightly reduced LPC transport.	SEQ_UP	1	
MUTAGEN:Q->A: Strongly decreased cholesterol export.	SEQ_UP	1	
MUTAGEN:Q->A: Strongly decreases the enzymatic activity.	SEQ_UP	1	
MUTAGEN:Q->C: Reduces sensitivity to Mg(2+), but not sensitivity to Ca(2+).	SEQ_UP	1	
MUTAGEN:Q->D,N: Strongly decreased selectivity for monovalent cations and increased permeability for Ca(2+).	SEQ_UP	1	
MUTAGEN:Q->D: No effect on protein abundance. Almost complete loss of cell surface localization. Decreases alanine uptake activity.	SEQ_UP	1	
MUTAGEN:Q->E: 50% of wild-type activity.	SEQ_UP	1	
MUTAGEN:Q->E: Abolishes DNA-binding. Does not affect ability to activate expression of CDKN2A.	SEQ_UP	1	
MUTAGEN:Q->E: Abolishes interaction with PCNA. No effect on activity.	SEQ_UP	1	
MUTAGEN:Q->E: Decreased selectivity for monovalent cations and increased permeability for Ca(2+).	SEQ_UP	1	
MUTAGEN:Q->E: Displays constitutive phospholipid scramblase activity.	SEQ_UP	1	
MUTAGEN:Q->E: Impaired 1-alpha hydroxylase activity toward 25-hydroxyvitamin D3. Impaired heme binding.	SEQ_UP	1	
MUTAGEN:Q->E: Increased affinity for L.monocytogenes InlA. Greatly increased affinity; when associated with P-172.	SEQ_UP	1	
MUTAGEN:Q->E: Increased protein level, probably due to defects in ubiquitination. Prevents inhibition of SLC12A3.	SEQ_UP	1	
MUTAGEN:Q->E: No effect.	SEQ_UP	1	
MUTAGEN:Q->E: Sensitive to inhibition by some components of the venom of Centruroides sculpturatus.	SEQ_UP	1	
MUTAGEN:Q->F: No effect on lipid scramblase activity.	SEQ_UP	1	
MUTAGEN:Q->G: No effect on interaction with GRIP1 and GRIP2.	SEQ_UP	1	
MUTAGEN:Q->G: Same as wild-type.	SEQ_UP	1	
MUTAGEN:Q->G: Strongly reduces inhibition of ATP2A1-mediated calcium uptake.	SEQ_UP	1	
MUTAGEN:Q->H: Abolishes LPC transport.	SEQ_UP	1	
MUTAGEN:Q->H: Acatalasemia.	SEQ_UP	1	
MUTAGEN:Q->H: Decreases transcriptional repression.	SEQ_UP	1	
MUTAGEN:Q->H: Does not affect signaling activity in any of Shh signaling assays and causes no apparent defects in cholesterol-mediated autoprocessing reactions.	SEQ_UP	1	
MUTAGEN:Q->H: Increased histone deacetylase activity, ability to promote double-strand break (DSB) repair, leading to increased life span; when associated with K-235 and 260-D--Q-264.	SEQ_UP	1	
MUTAGEN:Q->I,M: Confers ability to bind monoubiquitin and polyubiquitin, irrespective of the type of linkage.	SEQ_UP	1	
MUTAGEN:Q->K,N,R,S: No effect on basal cAMP production.	SEQ_UP	1	
MUTAGEN:Q->K: Abolishes DNA-binding.	SEQ_UP	1	
MUTAGEN:Q->K: Changes the specificity for binding motifs in promoters. Recognizes the PITX1 consensus DNA-binding sites and triggers the expression of a gene pattern similar to PITX1.	SEQ_UP	1	
MUTAGEN:Q->K: Decreases sedoheptulose kinase activity.	SEQ_UP	1	
MUTAGEN:Q->K: Enhances binding to CD200R.	SEQ_UP	1	
MUTAGEN:Q->K: Loss of early endosome localization; when associated with T-455.	SEQ_UP	1	
MUTAGEN:Q->K: Moderately decreased sensitivity to activation by calcium.	SEQ_UP	1	
MUTAGEN:Q->K: No effect on binding to CD200R.	SEQ_UP	1	
MUTAGEN:Q->K: No effect on enzyme activity.	SEQ_UP	1	
MUTAGEN:Q->K: Shows less organization of the circumferential actin-filament network compared to controls.	SEQ_UP	1	
MUTAGEN:Q->K: Slower channel activation. Increased permeability to chloride ions.	SEQ_UP	1	
MUTAGEN:Q->L: 65% decrease in cross-linking efficiency; when associated with L-35.	SEQ_UP	1	
MUTAGEN:Q->L: 65% decrease in cross-linking efficiency; when associated with L-36.	SEQ_UP	1	
MUTAGEN:Q->L: Abolishes phosphatase activity.	SEQ_UP	1	
MUTAGEN:Q->L: Constitutively activated. Enhances interaction with DOCK11.	SEQ_UP	1	
MUTAGEN:Q->L: Constitutively active mutant locked in the active GTP-bound form; alters endocytic recycling.	SEQ_UP	1	
MUTAGEN:Q->L: Constitutively active. Disrupts general recycling of receptors in embryonic fibroblasts.	SEQ_UP	1	
MUTAGEN:Q->L: Constitutively active. Dramatic reduction of the rate of GTP hydrolysis.	SEQ_UP	1	
MUTAGEN:Q->L: Constitutively active. Interacts with GARIN1B.	SEQ_UP	2	
MUTAGEN:Q->L: Defects in GTP hydrolysis. Increase in integrin-binding.	SEQ_UP	1	
MUTAGEN:Q->L: Does not affect interaction with ATG16L1. Induces lipidation of LC3.	SEQ_UP	1	
MUTAGEN:Q->L: Does not inhibit interaction with PDE6D.	SEQ_UP	1	
MUTAGEN:Q->L: Does not reduce affinity fo GTP and GDP. Enhances interaction with PDE6D.	SEQ_UP	1	
MUTAGEN:Q->L: Does not reduce the interaction with RP2.	SEQ_UP	1	
MUTAGEN:Q->L: Greatly reduced JAK2/STAT5 activation and some loss of mitogenic response.	SEQ_UP	1	
MUTAGEN:Q->L: In Jeff mutant; heterozygotes are deaf with chronic proliferative otitis media, have a shortened snout and occipital region, and are smaller than wild-type littermates. Homozygotes demonstrate perinatal lethality due to respiratory problems, are born with upper eyelids open and show clefting of the hard or soft palate as well as facial clefting.	SEQ_UP	1	
MUTAGEN:Q->L: Induces the formation of larger endosomes. No effect on interaction with INPP5F. Prevents interaction with DYN2 without affecting the interaction with PIK3C3.	SEQ_UP	1	
MUTAGEN:Q->L: Inhibits RP2-dependent GTP-hydrolysis rate.	SEQ_UP	1	
MUTAGEN:Q->L: Inhibits the proper trafficking of melanogenic enzymes TYR, TYRP1 and DCT/TYRP2 to melanosomes in melanocytes.	SEQ_UP	2	
MUTAGEN:Q->L: Loss of binding to rabkinesin-6; when associated with N-28.	SEQ_UP	1	
MUTAGEN:Q->L: Loss of GTP-binding activity.	SEQ_UP	1	
MUTAGEN:Q->L: Loss of GTPase activity.	SEQ_UP	2	
MUTAGEN:Q->L: Loss of GTPase activity. Increased fast recycling.	SEQ_UP	1	
MUTAGEN:Q->L: No effect on autocatalytic cleavage within the FIIND region.	SEQ_UP	1	
MUTAGEN:Q->L: No effect on neurite transport. Reduced axonal transport in a Madd RNAi-mediated knockdown or a Kif1b knockout background.	SEQ_UP	1	
MUTAGEN:Q->L: No effect on the interaction with MTMR6.	SEQ_UP	1	
MUTAGEN:Q->L: No effect on transcriptional repression.	SEQ_UP	1	
MUTAGEN:Q->L: Probable constitutively active mutant that prevents EHD1 localization to endosome membranes. No effect on interaction with TJAP1.	SEQ_UP	1	
MUTAGEN:Q->L: Probable constitutively active mutant unable to hydrolyze GTP; increases degradation of the transferrin receptor.	SEQ_UP	1	
MUTAGEN:Q->L: Probable constitutively active mutant unable to hydrolyze GTP; increases dendrite number and length.	SEQ_UP	1	
MUTAGEN:Q->L: Probable constitutively active mutant unable to hydrolyze GTP; stimulates translocation of SLC2A4 to the plasma membrane.	SEQ_UP	1	
MUTAGEN:Q->L: Stabilizes homotrimerization; no effect on interaction with SYNE2.	SEQ_UP	1	
MUTAGEN:Q->L: Strongly decreases interaction with RANGRF. Partial decrease in RANBP10-binding. No effect on interaction with NEMP1 and KPNB1.	SEQ_UP	1	
MUTAGEN:Q->M: Retains ATP-binding ability and induces necroptosis in absence of exogeous stimuli and independently of RIPK3.	SEQ_UP	1	
MUTAGEN:Q->N: 85%-90% decrease of both activities.	SEQ_UP	1	
MUTAGEN:Q->N: Decreases affinity for NADP. Changes enzyme activity, leading to the production of testosterone and concomitantly reducing the production of epi-testosterone.	SEQ_UP	1	
MUTAGEN:Q->N: Does not glycosylated.	SEQ_UP	1	
MUTAGEN:Q->P: Changed homophilic interaction; when associated with F-326.	SEQ_UP	1	
MUTAGEN:Q->P: Constitutively active in IL1B release. In conventional housing conditions, mice bearing this mutation develop a systemic inflammatory phenotype associated with elevated IL1B and IL18 levels at 3-5 months of age. In a germ-free environment, they exhibit neutrophilia and myocarditis.	SEQ_UP	1	
MUTAGEN:Q->P: Gain-of-function mutant; increased potassium channel activity in knockin mice.	SEQ_UP	1	
MUTAGEN:Q->P: Loss of interaction with LPL.	SEQ_UP	1	
MUTAGEN:Q->P: No effect on activity.	SEQ_UP	1	
MUTAGEN:Q->P: Reduced ATPase and helicase activities.	SEQ_UP	1	
MUTAGEN:Q->QFQ: In lzme; causes arrest of embryonic development during gastrulation due to chondroitin sulfate and heparan sulfate deficiency, impaired FGF signaling and impaired migration of mesoderm and endoderm.	SEQ_UP	1	
MUTAGEN:Q->R: Abolishes ionotropic glutamate receptor activity, no effect on cold receptor activity.	SEQ_UP	1	
MUTAGEN:Q->R: Activated.	SEQ_UP	1	
MUTAGEN:Q->R: Alters the voltage-dependent gating; when associated with K-284.	SEQ_UP	1	
MUTAGEN:Q->R: Changes the function in transcription regulation.	SEQ_UP	1	
MUTAGEN:Q->R: Found in chemically induced liver tumors.	SEQ_UP	1	
MUTAGEN:Q->R: Increased alpha-tubulin initiation step of polyglutamylase activity. Increased alpha-tubulin initiation step of polyglutamylase activity; when associated with I-362. Strong increase in alpha-tubulin initiation step of polyglutamylase activity; when associated with A-179 and I-362. Strong increase in alpha-tubulin initiation step of polyglutamylase activity; when associated with A-179, I-182, I-362 and H-367.	SEQ_UP	1	
MUTAGEN:Q->R: Increases affinity for DNA and protein stability; when associated with E-112.	SEQ_UP	1	
MUTAGEN:Q->R: Loss of transcriptional repression; when associated with Q-64.	SEQ_UP	1	
MUTAGEN:Q->R: No change in DNA binding. Loss of self-renewal ability in iPS cells. No change in nuclear location.	SEQ_UP	1	
MUTAGEN:Q->R: No effect on protein abundance. No effect on cell surface localization. No effect on alanine uptake activity.	SEQ_UP	1	
MUTAGEN:Q->R: Reduced MAPK3/ERK1 and MAPK1/ERK2-binding.	SEQ_UP	1	
MUTAGEN:Q->S: No effect on PDCD1 binding.	SEQ_UP	1	
MUTAGEN:Q->T,V: Small reduction in basal cAMP production.	SEQ_UP	1	
MUTAGEN:Q->T: Does not affect ability to promote phosphatidylserine exposure.	SEQ_UP	1	
MUTAGEN:Q->V: Loss of binding to rabkinesin-6.	SEQ_UP	1	
MUTAGEN:Q->V: No effect on protein abundance. Strong decrease of cell surface localization. Decreases alanine uptake.	SEQ_UP	1	
MUTAGEN:Q->W: Does not modify the functional properties of the protein.	SEQ_UP	1	
MUTAGEN:QE->AA: Decreased relocalization to autophagosomes and subsequent degradation.	SEQ_UP	1	
MUTAGEN:QF->AA: Strongly reduced interaction with flagellin.	SEQ_UP	1	
MUTAGEN:QG->PP: Mice display deficits in anxiety as well as in repetitive and social behaviors. Decreases levels of serotonin synapses in midbrain, SLC6A4 activity and location at integrin adhesion complexes in synapses.	SEQ_UP	1	
MUTAGEN:QIG->AAA: In RIPK1(mRHIM); perinatal lethality in knockin mice caused by Ripk3- and Zbp1-dependent necroptosis. Lethality is prevented by Ripk3, Mlkl or Zbp1 deficiency. Knockin mice do not show defects caused by Casp8-dependent apoptosis observed in knockout mice.	SEQ_UP	1	
MUTAGEN:QL->AA: No loss of interaction with NOS2.	SEQ_UP	1	
MUTAGEN:QNPEG->AAAAA: Abolishes interaction with PIWIL1.	SEQ_UP	1	
MUTAGEN:QQ->EE: Loss of inhibitory activity on TNF-induced NF-kappa-B activation; no effect on interaction with TNFAIP3.	SEQ_UP	1	
MUTAGEN:QR->AA: Impairs RHOA activation; when associated with A-562.	SEQ_UP	1	
MUTAGEN:QR->AL: Fails to repress CD8 expression. Abolishes interaction with HDAC4 and HDAC5. No effect on homodimerization and DNA binding.	SEQ_UP	1	
MUTAGEN:QRRG->ERRE: Abolished acetyltransferase activity.	SEQ_UP	1	
MUTAGEN:QS->AA: No effect on RHOA activation; when associated with 554-A-A-555.	SEQ_UP	1	
MUTAGEN:QT->AA: Mildly reduced interaction with flagellin.	SEQ_UP	1	
MUTAGEN:QW->AA: Abolishes interaction with integrins ITGB1 and ITGB3.	SEQ_UP	1	
MUTAGEN:QY->AA: Loss of interaction with MET and PARW.	SEQ_UP	1	
MUTAGEN:R->A,C: Impaired cleavage (both nicking and hairpin formation).	SEQ_UP	1	
MUTAGEN:R->A,E: Abolishes the enzymatic activity.	SEQ_UP	1	
MUTAGEN:R->A,E: No effect on JAK signal transduction suppression.	SEQ_UP	1	
MUTAGEN:R->A,G: Reduces affinity for GDP-bound GNAI3 50-fold. Reduces affinity for GDP-bound GNAI3 500-fold; when associated with A-647.	SEQ_UP	1	
MUTAGEN:R->A,G: Reduces phosphatidylinositol 3,4,5-trisphosphate binding.	SEQ_UP	1	
MUTAGEN:R->A,K: High transactivation activity.	SEQ_UP	1	
MUTAGEN:R->A,Q: Strongly reduced RNA binding. Prevents cellular senescence and promotes continued cell division.	SEQ_UP	1	
MUTAGEN:R->A,S: Complete loss of homooligomerization, lipid-binding, relocalization of Gasdermin-D, N-terminal to the plasma membrane and pyroptosis, as well as loss of bactericidal activity; when associated with A-146; A-152 and A-154. Partial loss of homooligomerization and pyroptosis; when associated with A-146.	SEQ_UP	1	
MUTAGEN:R->A: 10-fold increase in Km for CoA.	SEQ_UP	1	
MUTAGEN:R->A: 100-fold loss of affinity for PIP3 and accumulation in the cytosol.	SEQ_UP	1	
MUTAGEN:R->A: 4-fold increase in Km for CoA. Reduced affinity for CoA.	SEQ_UP	1	
MUTAGEN:R->A: 70% reduction of GAP activity; when associated with V-169.	SEQ_UP	1	
MUTAGEN:R->A: Abolished ability to cleave Gasdermin-D (GSDMD).	SEQ_UP	1	
MUTAGEN:R->A: Abolished methylation; when associated with A-323.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes activity.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes adhesion to oocytes.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes AMPH and BIN1 binding. Reduces EPS15, SNAP91 and auxilin binding.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes Arf-GAP mediated stimulation of GTP hydrolysis.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes binding to STAT3 3'UTR stem loop structure. Abolishes binding to TNFRSF4/OX40 mRNA.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes both the nuclear localization and the enzyme activity.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes calmodulin binding, unable to potentiate synaptic transmission.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes cleavage by SP1.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes coupling to G(i)-proteins. Abolishes inhibition of adenylate cyclase activity. No effect on interaction with PDZD7.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes DNA-binding.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes DNA-binding. No effect on transcriptional repression.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes furin-mediated cleavage and shedding of ectodomain.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes ganglioside binding.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes IL22-binding.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes interaction with MUSK and function; when associated with A-158 and A-159.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes interaction with NUMA1; when associated with A-228. Abolishes interaction with FRMPD1; when associated with A-228.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes interaction with NUMA1; when associated with A-243. Abolishes interaction with FRMPD1; when associated with A-243.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes interaction with phosphatidylinositol 4,5-bisphosphate and reduces secretion by 40%; when associated with A-330.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes interaction with TACC3.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes interaction with the SH3 domain of STAM2.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes ligand-induced translocation to the nucleus; when associated with A-22 and A-32.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes linear polyubiquitin-binding, no effect on 'Lys-63'-linked polyubiquitin-binding and impairs NF-kappa-B activation; when associated with A-309 and A-313.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes linear polyubiquitin-binding, no effect on 'Lys-63'-linked polyubiquitin-binding and impairs NF-kappa-B activation; when associated with A-312 and A-313.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes lipid droplet enlargement activity, but not localization to lipid droplets, nor enrichement at contact sites; when associated with A-182 and A-186.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes localization to microtubules minus ends; decreases ASPM localization to microtubules minus ends; no enhancement of ASPM activity in blocking microtubule minus-end growth.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes localization to phagocytic cups; when associated with A-883.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes location on endosome membranes.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes LPC transport.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes maturation and cleavage by CORIN.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes methylation, no effect on subcellular location.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes nuclear localization; when associated with A-324.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes nuclear localization; when associated with A-330.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes nuclear localization.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes phagocytic activity.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes phosphatase activity.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes phosphatidylinositol 3,4,5-trisphosphate binding.	SEQ_UP	2	
MUTAGEN:R->A: Abolishes phosphoinositide-binding of C-terminus; when associated with A-152, A-160 and A-161.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes proteolytical cleavage.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes the enzymatic activity.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes the nuclear localization but does not affect the enzyme activity; when associated with A-198.	SEQ_UP	1	
MUTAGEN:R->A: Abolishes transactivation activity.	SEQ_UP	1	
MUTAGEN:R->A: Abrogates interaction with PAFAH1B2.	SEQ_UP	1	
MUTAGEN:R->A: Abrogates phosphopeptide recognition.	SEQ_UP	1	
MUTAGEN:R->A: Allows robust hairpin activity.	SEQ_UP	1	
MUTAGEN:R->A: Almost complete loss of RNA-binding and loss of GTase activity.	SEQ_UP	1	
MUTAGEN:R->A: Capable of nicking but defective for hairpinning.	SEQ_UP	1	
MUTAGEN:R->A: Complete loss of homooligomerization, lipid-binding, relocalization of Gasdermin-D, N-terminal to the plasma membrane and pyroptosis, as well as loss of bactericidal activity; when associated with A-138 or with S-138; A-146 and A-152. Partial loss of homooligomerization and pyroptosis; when associated with A-152 or with A-146 and A-152.	SEQ_UP	1	
MUTAGEN:R->A: Complete loss of homooligomerization, lipid-binding, relocalization of Gasdermin-D, N-terminal to the plasma membrane and pyroptosis, as well as loss of bactericidal activity; when associated with A-138 or with S-138; A-146 and A-154. Partial loss of homooligomerization and pyroptosis; when associated with A-146 or with A-154, or with A-146 and A-154.	SEQ_UP	1	
MUTAGEN:R->A: Complete loss of kinase activity and of nuclear localization. Complete loss of kinase activity and of nuclear localization; when associated with A-270 and A-272.	SEQ_UP	1	
MUTAGEN:R->A: Complete loss of lipolytic function.	SEQ_UP	1	
MUTAGEN:R->A: Compromises SIM1:ARNT2 heterodimer stability. Does not compromises NPAS4:ARNT2 heterodimer stability.	SEQ_UP	1	
MUTAGEN:R->A: Constitutively nuclear; when associated with A-431 and A-469. Strongly reduced affinity for actin.	SEQ_UP	1	
MUTAGEN:R->A: Constitutively nuclear; when associated with A-431 and A-507. Strongly reduced affinity for actin.	SEQ_UP	1	
MUTAGEN:R->A: Constitutively nuclear; when associated with A-469 and A-507. Strongly reduced affinity for actin.	SEQ_UP	1	
MUTAGEN:R->A: Decrease in binding to DNA.	SEQ_UP	1	
MUTAGEN:R->A: Decreased interaction with ADGRA2.	SEQ_UP	1	
MUTAGEN:R->A: Decreased interaction with BCL10.	SEQ_UP	1	
MUTAGEN:R->A: Decreased lipid scramblase and ion channel activity. Requires lower calcium levels for activation of ion channel activity.	SEQ_UP	1	
MUTAGEN:R->A: Decreased permeability to chloride ions.	SEQ_UP	1	
MUTAGEN:R->A: Decreased protein stability. Decreased embryonic stem cell self-renewal.	SEQ_UP	1	
MUTAGEN:R->A: Decreased transmembrane ascorbate ferrireductase activity. Approximately 75% reduction in enzyme activity.	SEQ_UP	1	
MUTAGEN:R->A: Decreases affinity for interaction with IL1RAPL1.	SEQ_UP	1	
MUTAGEN:R->A: Decreases heterodimer formation with ARNT. Impairs heterodimer formation with ARNT; when associated with D-191.	SEQ_UP	1	
MUTAGEN:R->A: Decreases HRE DNA binding.	SEQ_UP	1	
MUTAGEN:R->A: Decreases interaction with CALM1 in the absence of calcium.	SEQ_UP	1	
MUTAGEN:R->A: Decreases interaction with CALM1 in the presence and absence of calcium and reduces rate of channel inactivation.	SEQ_UP	1	
MUTAGEN:R->A: Defects in converting nicked products to hairpins.	SEQ_UP	1	
MUTAGEN:R->A: Destabilizes heterodimerization with ARNT. Compromises the transcriptional repression activity of heterodimer ARNT:NPAS1.	SEQ_UP	1	
MUTAGEN:R->A: Diminishes binding to phosphoinositides.	SEQ_UP	1	
MUTAGEN:R->A: Disruption of its microtubule-binding and microtubule bundling activities. Failure to rescue ciliary central apparatus formation in SPEF1-depleted ependymal cilia.	SEQ_UP	1	
MUTAGEN:R->A: Disrupts pericentromeric heterochromatin location. Partial cytoplasmic location. Abolishes DNA binding.	SEQ_UP	1	
MUTAGEN:R->A: Does not affect interaction with MAPK1.	SEQ_UP	1	
MUTAGEN:R->A: Does not affect interaction with MAPK1. Loss of interaction with MAPK1; when associated with A-62.	SEQ_UP	1	
MUTAGEN:R->A: Does not affect interaction with SQSTM1/p62. Abolished interaction with SQSTM1/p62; when associated with A-380 and A-415.	SEQ_UP	1	
MUTAGEN:R->A: Does not affect maturation and cleavage by CORIN.	SEQ_UP	1	
MUTAGEN:R->A: Does not affect recognition by the CRL2(FEM1B) complex and subsequent ubiquitination.	SEQ_UP	1	
MUTAGEN:R->A: Does not affect shedding activity; when associated with A-203.	SEQ_UP	1	
MUTAGEN:R->A: Does not affect shedding activity; when associated with A-205.	SEQ_UP	1	
MUTAGEN:R->A: Does not affect the ability to inhibit PKB activity.	SEQ_UP	1	
MUTAGEN:R->A: Does not affect the interaction with GATA1.	SEQ_UP	1	
MUTAGEN:R->A: Does not affect the mono-ADP-ribosyltransferase activity. Abolished NAD-dependent protein deacetylase and defatty-acylase activities.	SEQ_UP	1	
MUTAGEN:R->A: Does not increase glutathione transferase activity and reduces cellular protection.	SEQ_UP	1	
MUTAGEN:R->A: Does not strongly affect the nuclear localization but strongly affects the enzyme activity.	SEQ_UP	1	
MUTAGEN:R->A: EIF4E-binding reduced by 20%; when associated with A-724.	SEQ_UP	1	
MUTAGEN:R->A: Enhanced surface expression and a lower localization to endosomal vesicles.	SEQ_UP	1	
MUTAGEN:R->A: Enhances protein processing.	SEQ_UP	1	
MUTAGEN:R->A: Fails to bind to heparan sulfate or to NIH-3T3 fibroblast cells; when associated with A-238 and A-244.	SEQ_UP	1	
MUTAGEN:R->A: Fails to bind to heparan sulfate or to NIH-3T3 fibroblast cells; when associated with A-238 and A-295.	SEQ_UP	1	
MUTAGEN:R->A: Fails to bind to heparan sulfate or to NIH-3T3 fibroblast cells; when associated with A-244 and A-295.	SEQ_UP	1	
MUTAGEN:R->A: Fails to bind to NIH-3T3 fibroblast cells; when associated with 273-A--A-276.	SEQ_UP	1	
MUTAGEN:R->A: Fails to induce Th2 cytokine production.	SEQ_UP	1	
MUTAGEN:R->A: Fails to inhibit LPS-induced cytokine production.	SEQ_UP	1	
MUTAGEN:R->A: Greatly reduced ABL1-binding; reduced tyrosine phosphorylation.	SEQ_UP	1	
MUTAGEN:R->A: Impaired ability to induce pyroptosis; when associated with A-132.	SEQ_UP	1	
MUTAGEN:R->A: Impaired DNA-binding and exonuclease activities.	SEQ_UP	1	
MUTAGEN:R->A: Impaired H3.3K36me3 binding.	SEQ_UP	1	
MUTAGEN:R->A: Impaired interaction with G-actin, leading to cytoplasmic accumulation.	SEQ_UP	1	
MUTAGEN:R->A: Impaired interaction with G-actin, leading to nuclear accumulation in unstimulated cells.	SEQ_UP	1	
MUTAGEN:R->A: Impaired interaction with SQSTM1/p62. Abolished interaction with SQSTM1/p62; when associated with A-380 and A-483.	SEQ_UP	1	
MUTAGEN:R->A: Impaired interaction with SQSTM1/p62. Abolished interaction with SQSTM1/p62; when associated with A-415 and A-483.	SEQ_UP	1	
MUTAGEN:R->A: Impaired membrane association in neurons; when associated with A-151; A-155; A-162 and A-167.	SEQ_UP	1	
MUTAGEN:R->A: Impaired membrane association in neurons; when associated with A-151; A-155; A-162 and A-172.	SEQ_UP	1	
MUTAGEN:R->A: Impaired membrane association in neurons; when associated with A-151; A-155; A-167 and A-172.	SEQ_UP	1	
MUTAGEN:R->A: Impaired tail-anchored protein insertion and a shift from GET1-CAMLG heterotetramerization to formation of heterodimers but does not affect recruitment of GET3 to the endoplasmic reticulum; when associated with A-207.	SEQ_UP	1	
MUTAGEN:R->A: Impairs aminoacylation activity.	SEQ_UP	1	
MUTAGEN:R->A: Impairs both actin capping and bundling activities.	SEQ_UP	1	
MUTAGEN:R->A: Impairs DNA-binding and hairpin formation while maintaining some nicking activity.	SEQ_UP	1	
MUTAGEN:R->A: Impairs DNA-binding and reduces hairpin formation without affecting nicking activity.	SEQ_UP	1	
MUTAGEN:R->A: Impairs lipid-binding activity and hence PtdIns(4,5)P2 clustering; when associated with A-135.	SEQ_UP	1	
MUTAGEN:R->A: Impairs lipid-binding activity and hence PtdIns(4,5)P2 clustering; when associated with A-145 and A-146.	SEQ_UP	1	
MUTAGEN:R->A: Impairs lipid-binding activity and hence PtdIns(4,5)P2 clustering; when associated with A-146 and A-147.	SEQ_UP	1	
MUTAGEN:R->A: Impairs protein folding. Abolishes binding of ARNTL, PER1 and FBXL3. Strongly reduces SKP1 binding.	SEQ_UP	1	
MUTAGEN:R->A: Impairs the ability to rescue growth in cdc25ts mutant yeasts.	SEQ_UP	1	
MUTAGEN:R->A: Impairs the ability to resucue growth in cdc25ts mutant yeasts.	SEQ_UP	1	
MUTAGEN:R->A: In 123-1A: Reduced interaction with G-actin, leading to a constitutively active SRF-MRTFA complex; when associated with A-24 and A-112.	SEQ_UP	1	
MUTAGEN:R->A: In 123-1A: Reduced interaction with G-actin, leading to a constitutively active SRF-MRTFA complex; when associated with A-24 and A-68.	SEQ_UP	1	
MUTAGEN:R->A: In 123-1A: Reduced interaction with G-actin, leading to a constitutively active SRF-MRTFA complex; when associated with A-68 and A-112.	SEQ_UP	1	
MUTAGEN:R->A: Increases GTP release from RAN.	SEQ_UP	1	
MUTAGEN:R->A: Increases the cytoplasmic protein content; when associated with A-98.	SEQ_UP	1	
MUTAGEN:R->A: Increases the cytoplasmic protein content; when associated with A-99.	SEQ_UP	1	
MUTAGEN:R->A: Induces a strong decrease in gabapentin-binding.	SEQ_UP	1	
MUTAGEN:R->A: Induces aberrant nuclear localization of the phosphorylated form.	SEQ_UP	1	
MUTAGEN:R->A: Inhibits binding to PIP2 and disrupts membrane binding.	SEQ_UP	1	
MUTAGEN:R->A: Interferes with DNA-binding.	SEQ_UP	1	
MUTAGEN:R->A: Leads to a strong reduction in PtdIns(4,5)P2-binding.	SEQ_UP	1	
MUTAGEN:R->A: Loss GTPase-activating (GAP) activity.	SEQ_UP	1	
MUTAGEN:R->A: Loss of ability to bind heterodimeric capping protein (CP) and to inhibit the actin-capping activity of CP.	SEQ_UP	1	
MUTAGEN:R->A: Loss of activity and dephosphorylation of CDH5.	SEQ_UP	1	
MUTAGEN:R->A: Loss of activity.	SEQ_UP	1	
MUTAGEN:R->A: Loss of activity. Strongly reduces substrate binding.	SEQ_UP	1	
MUTAGEN:R->A: Loss of alpha-tubulin alpha-elongation polyglutamylase activity.	SEQ_UP	1	
MUTAGEN:R->A: Loss of alpha-tubulin alpha-elongation step of polyglutamylase activity.	SEQ_UP	1	
MUTAGEN:R->A: Loss of angiogenic activity. No effect on ribonuclease activity.	SEQ_UP	1	
MUTAGEN:R->A: Loss of AP-1 transcription factor activity, no effect on NF-kappa-B activity.	SEQ_UP	1	
MUTAGEN:R->A: Loss of binding activity.	SEQ_UP	2	
MUTAGEN:R->A: Loss of binding to phosphatidylinositol 3-phosphate (PI3P) lipids and loss of localization to PI3P-positive organelles. Expression of mutant protein does not rescue ITGB1 recycling deficit of ANK2 null mutant fibroblasts.	SEQ_UP	1	
MUTAGEN:R->A: Loss of catalytic activity; when associated with S-217 and A-401. Reduces the affinity for UDP-GlcNAc; when associated with S-217.	SEQ_UP	1	
MUTAGEN:R->A: Loss of enzyme activity and polyuridylated RNA-binding; when associated with A-612.	SEQ_UP	1	
MUTAGEN:R->A: Loss of enzyme activity.	SEQ_UP	1	
MUTAGEN:R->A: Loss of function.	SEQ_UP	1	
MUTAGEN:R->A: Loss of interaction with CNOT7.	SEQ_UP	1	
MUTAGEN:R->A: Loss of interaction with CXADR.	SEQ_UP	1	
MUTAGEN:R->A: Loss of interaction with FCER1G and TYROBP; when associated with A-194.	SEQ_UP	1	
MUTAGEN:R->A: Loss of interaction with FCER1G and TYROBP; when associated with A-41.	SEQ_UP	1	
MUTAGEN:R->A: Loss of interaction with MAPK1. Loss of interaction with MAPK1; when associated with A-61.	SEQ_UP	1	
MUTAGEN:R->A: Loss of isomerase activity. No phenotype when introduced in mice, animals are viable and fertile with no microcephaly or defective cortical lamination; no splicing defect.	SEQ_UP	1	
MUTAGEN:R->A: Loss of lyso-PAFAT activity. LPCAT activity is partially reduced.	SEQ_UP	1	
MUTAGEN:R->A: Loss of MALT1-dependent cleavage and degradation in T-cells.	SEQ_UP	1	
MUTAGEN:R->A: Loss of MAPK7 binding; when associated with A-21.	SEQ_UP	1	
MUTAGEN:R->A: Loss of nuclear localization. Reduces DNA binding.	SEQ_UP	1	
MUTAGEN:R->A: Loss of PAR-binding and of protection against DNA damage; when associated with A-156.	SEQ_UP	1	
MUTAGEN:R->A: Loss of phosphatase activity. Loss of phosphatase activity; when associated with A-292 and A-294. Does not affect interaction with MAPK1.	SEQ_UP	1	
MUTAGEN:R->A: Loss of phosphatase activity. Loss of phosphatase activity; when associated with A-292 and A-295. Does not affect interaction with MAPK1.	SEQ_UP	1	
MUTAGEN:R->A: Loss of phospholipid-binding.	SEQ_UP	2	
MUTAGEN:R->A: Loss of polynucleotide adenylyltransferase activity.	SEQ_UP	1	
MUTAGEN:R->A: Loss of protein methyltransferase activity.	SEQ_UP	1	
MUTAGEN:R->A: Loss of proteolytic cleavage; when associated with L-392 and V-426.	SEQ_UP	1	
MUTAGEN:R->A: Loss of S1P cleavage; when associated with V-430.	SEQ_UP	1	
MUTAGEN:R->A: Loss of S1P cleavage.	SEQ_UP	1	
MUTAGEN:R->A: Loss of sialic acid binding.	SEQ_UP	1	
MUTAGEN:R->A: Loss of TPase activity.	SEQ_UP	1	
MUTAGEN:R->A: Loss of transmembrane ascorbate ferrireductase activity.	SEQ_UP	1	
MUTAGEN:R->A: Lowers dephosphorylation.	SEQ_UP	1	
MUTAGEN:R->A: Markedly decreases heterodimer formation with ARNT. Impairs heterodimer formation with ARNT; when associated with D-192.	SEQ_UP	1	
MUTAGEN:R->A: Markedly decreases heterodimer formation with EPAS1. Decreases heterodimer formation with HIF1A. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Does not compromise NPAS4:ARNT heterodimer stability. Does not compromise AHR:ARNT heterodimer stability.	SEQ_UP	1	
MUTAGEN:R->A: Markedly decreases heterodimer formation with EPAS1. Markedly decreases heterodimer formation with HIF1A. Impairs heterodimer formation with EPAS1; when associated with N-448. Impairs heterodimer formation with HIF1A; when associated with N-448. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Does not compromise NPAS4:ARNT heterodimer stability. Does not compromise AHR:ARNT heterodimer stability.	SEQ_UP	1	
MUTAGEN:R->A: Mimics the charge change that accompanies citrullination, resulting in impaired nucleosome-binding.	SEQ_UP	1	
MUTAGEN:R->A: Nearly abolishes enzyme activity.	SEQ_UP	1	
MUTAGEN:R->A: No change to herarin-binding.	SEQ_UP	1	
MUTAGEN:R->A: No effect on anion channel activity. Impairs channel selectivity, so that the channel is also permeable to Na(+) ions.	SEQ_UP	1	
MUTAGEN:R->A: No effect on binding to NIH-3T3 fibroblast cells; when associated with A-109.	SEQ_UP	1	
MUTAGEN:R->A: No effect on binding to NIH-3T3 fibroblast cells; when associated with A-216.	SEQ_UP	1	
MUTAGEN:R->A: No effect on binding with phosphatidic acid.	SEQ_UP	1	
MUTAGEN:R->A: No effect on calcium channel activity. Abolishes ryanodine binding.	SEQ_UP	1	
MUTAGEN:R->A: No effect on CDE RNA-binding.	SEQ_UP	1	
MUTAGEN:R->A: No effect on DNA-binding, represses E2F1:TFDP1-mediated transcription and causes adipose hypoplasia and myeloid dysplasia; when associated with A-295.	SEQ_UP	1	
MUTAGEN:R->A: No effect on IL11RA binding. Decreases stimulation of cell proliferation.	SEQ_UP	1	
MUTAGEN:R->A: No effect on IL1B release under basal conditions, nor in response to LT or metabolic inhibitors; when associated with A-698 and A-702.	SEQ_UP	1	
MUTAGEN:R->A: No effect on IL1B release under basal conditions, nor in response to LT or metabolic inhibitors.	SEQ_UP	1	
MUTAGEN:R->A: No effect on interaction with PARD6B.	SEQ_UP	1	
MUTAGEN:R->A: No effect on interaction with PTPRD. No effect on synapse assembly.	SEQ_UP	1	
MUTAGEN:R->A: No effect on interaction with SQSTM1.	SEQ_UP	1	
MUTAGEN:R->A: No effect on LIF signal transduction suppression.	SEQ_UP	1	
MUTAGEN:R->A: No effect on lipid-binding; when associated with A-149 and A-155.	SEQ_UP	1	
MUTAGEN:R->A: No effect on LPC transport.	SEQ_UP	1	
MUTAGEN:R->A: No effect on NK cell development, impairs promotion of NK cell cytotoxicity and IFN-gamma production in response to hematopoietic cells.	SEQ_UP	1	
MUTAGEN:R->A: No effect on pericentromeric heterochromatin location. No change in DNA binding.	SEQ_UP	1	
MUTAGEN:R->A: No effect on protein abundance. Decreased reduction by ascorbate.	SEQ_UP	1	
MUTAGEN:R->A: No effect on proteolytic processing. Abolishes proteolytic processing; when associated with G-178.	SEQ_UP	1	
MUTAGEN:R->A: No effect on pyroptosis; when associated with A-237 or with A-237; A-248 and A-249.	SEQ_UP	1	
MUTAGEN:R->A: No effect on pyroptosis; when associated with A-237; A-239 and A-249.	SEQ_UP	1	
MUTAGEN:R->A: No effect on subcellular location. Abolishes Golgi and lysosomal localization; when associated with A-360 or A-367.	SEQ_UP	1	
MUTAGEN:R->A: No effect on subcellular location. Abolishes Golgi and lysosomal localization; when associated with A-364.	SEQ_UP	1	
MUTAGEN:R->A: No effect on UBE2I binding nor on sumoylation.	SEQ_UP	1	
MUTAGEN:R->A: No impact on interaction with EIF4A.	SEQ_UP	1	
MUTAGEN:R->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-292.	SEQ_UP	1	
MUTAGEN:R->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-301.	SEQ_UP	1	
MUTAGEN:R->A: No loss of interaction with SH3KBP1, loss of translocation of SH3KBP1 to EGFR containing vesicles upon EGF stimulation, slight delay in the degradation of EGFR upon EGF activation and enhancement of EGFR signaling induced serum response element (SRE) transcriptional reporter activity. Loss of interaction with SH3KBP1, no loss of translocation of SH3KBP1 to EGFR containing vesicles upon EGF stimulation, no effect on the degradation of EGFR upon EGF activation and no effect on EGFR signaling induced serum response element (SRE) transcriptional reporter activity; when associated with A-623.	SEQ_UP	1	
MUTAGEN:R->A: No loss of interaction with SH3KBP1, loss of translocation of SH3KBP1 to EGFR containing vesicles upon EGF stimulation, strong delay in the degradation of EGFR upon EGF activation and enhancement of EGFR signaling induced serum response element (SRE) transcriptional reporter activity. Loss of interaction with SH3KBP1, no loss of translocation of SH3KBP1 to EGFR containing vesicles upon EGF stimulation, no effect on the degradation of EGFR upon EGF activation and no effect on EGFR signaling induced serum response element (SRE) transcriptional reporter activity; when associated with A-683.	SEQ_UP	1	
MUTAGEN:R->A: No methyltransferase activity.	SEQ_UP	1	
MUTAGEN:R->A: No significant effect on interaction with BLZF1.	SEQ_UP	1	
MUTAGEN:R->A: No significant effect on Km for CoA.	SEQ_UP	1	
MUTAGEN:R->A: No significant effect on MHC class II-binding.	SEQ_UP	1	
MUTAGEN:R->A: Not cleaved by subtilisin-like proprotein convertase 4.	SEQ_UP	1	
MUTAGEN:R->A: Nuclear localization to the same extent as wild-type; when associated with F-705.	SEQ_UP	1	
MUTAGEN:R->A: Partial loss of transcription repression. No change in nuclear location.	SEQ_UP	1	
MUTAGEN:R->A: Prevents isoform 6 from localizing to the nucleus; when associated with A-1385.	SEQ_UP	1	
MUTAGEN:R->A: Prevents isoform 6 from localizing to the nucleus; when associated with A-1386.	SEQ_UP	1	
MUTAGEN:R->A: Promotes self-association and secretion independent of CBLN1.	SEQ_UP	1	
MUTAGEN:R->A: Promotes ubiquitination and degradation by the proteasome. Abolished methylation; when associated with A-312.	SEQ_UP	1	
MUTAGEN:R->A: Reduced activity.	SEQ_UP	2	
MUTAGEN:R->A: Reduced binding to CHO cells expressing ITAG9-ITGB1.	SEQ_UP	1	
MUTAGEN:R->A: Reduced propeptide cleavage.	SEQ_UP	1	
MUTAGEN:R->A: Reduces activity about 15-fold.	SEQ_UP	1	
MUTAGEN:R->A: Reduces activity about 2-fold. Reduces DNA-binding capacity.	SEQ_UP	1	
MUTAGEN:R->A: Reduces activity about 3-fold. Reduces DNA-binding capacity.	SEQ_UP	1	
MUTAGEN:R->A: Reduces activity about 30-fold. Reduces DNA-binding capacity.	SEQ_UP	1	
MUTAGEN:R->A: Reduces activity about 6-fold. Reduces DNA-binding capacity.	SEQ_UP	1	
MUTAGEN:R->A: Reduces affinity for actin.	SEQ_UP	1	
MUTAGEN:R->A: Reduces affinity for GDP-bound GNAI3 500-fold; when associated with A-642.	SEQ_UP	1	
MUTAGEN:R->A: Reduces affinity with IL1RAPL1. Reduces the synaptogenic activity to ~7%.	SEQ_UP	1	
MUTAGEN:R->A: Reduces ARE-containing RNA-binding. Loss of ARE-containing RNA-binding; when associated with A-153.	SEQ_UP	1	
MUTAGEN:R->A: Reduces ARE-containing RNA-binding. Loss of ARE-containing RNA-binding; when associated with A-157.	SEQ_UP	1	
MUTAGEN:R->A: Reduces DNA-binding capacity. No effect on activity.	SEQ_UP	1	
MUTAGEN:R->A: Reduces GRIA1 recycling. Abolishes the increase of spine density and size, as well as reduces the increase of GRIA1 expression in surface associated with long-term potentiation.	SEQ_UP	1	
MUTAGEN:R->A: Reduces interaction with SHTN1; when associated with F-1047.	SEQ_UP	1	
MUTAGEN:R->A: Reduces MALT1-dependent cleavage and degradation in T-cells.	SEQ_UP	1	
MUTAGEN:R->A: Reduces PARD3 binding; when associated with A-622.	SEQ_UP	1	
MUTAGEN:R->A: Reduces PARD3 binding; when associated with A-645.	SEQ_UP	1	
MUTAGEN:R->A: Reduces the shedding activity; when associated with A-56. Does not prevent pro-domain processing between the pro- and metalloprotease domain; when associated with A-56.	SEQ_UP	1	
MUTAGEN:R->A: Significant reduction in binding to SRC and CRK and loss of phosphorylation. Loss of binding and phosphorylation; when associated with A-910 and A-913.	SEQ_UP	1	
MUTAGEN:R->A: Significant reduction in interaction with RDX.	SEQ_UP	1	
MUTAGEN:R->A: Significantly decreased NF-kappa-B activation.	SEQ_UP	1	
MUTAGEN:R->A: Significantly reduces polynucleotide adenylyltransferase activity.	SEQ_UP	1	
MUTAGEN:R->A: Slightly affects the interaction with GATA1.	SEQ_UP	1	
MUTAGEN:R->A: Slightly reduced binding to NFIL3 promoter.	SEQ_UP	1	
MUTAGEN:R->A: Slightly reduced LPC transport.	SEQ_UP	1	
MUTAGEN:R->A: Srongly reduces IL11RA binding and stimulation of cell proliferation.	SEQ_UP	1	
MUTAGEN:R->A: Still partially active.	SEQ_UP	1	
MUTAGEN:R->A: Strongly decreased interaction with BCL10.	SEQ_UP	1	
MUTAGEN:R->A: Strongly decreased methylation.	SEQ_UP	1	
MUTAGEN:R->A: Strongly decreases binding with phosphatidic acid and phosphatidylserine. Abolishes binding with phosphatidic acid and phosphatidylserine; when associated with 45-DEL-48. Strongly decreases sphingomyelin phosphodiesterase activity; when associated with 45-DEL-48. Abolishes sphingomyelin phosphodiesterase activity and locates at endoplasmic reticulum; when associated with 45-DEL-48 and 92-A-A-93.	SEQ_UP	1	
MUTAGEN:R->A: Strongly decreases binding with phosphatidic acid.	SEQ_UP	1	
MUTAGEN:R->A: Strongly decreases interaction with TLR3.	SEQ_UP	1	
MUTAGEN:R->A: Strongly decresases CDE and ADE RNA-binding. Increases target-mRNA expression. Abolishes CDE RNA-binding and highly increases target-mRNA expression; when associated with A-239. Increases target-mRNA expression. Increases ICOS surface expression; when associated with A-220 and A-239.	SEQ_UP	1	
MUTAGEN:R->A: Strongly reduced autocatalytic cleavage; when associated with A-199. Strongly reduced autocatalytic cleavage; when associated with A-199 and 190-A-A-191. Slightly reduced autocatalytic cleavage; when associated with 190-A-A-191.	SEQ_UP	1	
MUTAGEN:R->A: Strongly reduced exonuclease activity.	SEQ_UP	1	
MUTAGEN:R->A: Strongly reduced interaction with ANKRD31.	SEQ_UP	1	
MUTAGEN:R->A: Strongly reduced interaction with DIXDC1.	SEQ_UP	1	
MUTAGEN:R->A: Strongly reduced interaction with DNA.	SEQ_UP	1	
MUTAGEN:R->A: Strongly reduces AMPH and SNAP91 binding. Abolishes DENND1B-binding; no effect on DENND1A-, nor DENND1C-binding. Abolishes AMPH and SNAP91 binding; when associated with A-837.	SEQ_UP	1	
MUTAGEN:R->A: Strongly reduces AMPH, SNAP91, auxilin and BIN1 binding. Abolishes EPN1 and EPS15 binding; when associated with A-837.	SEQ_UP	1	
MUTAGEN:R->A: Unable to inhibit TORC1 signaling; when associated with A-422 and A-426.	SEQ_UP	1	
MUTAGEN:R->A: Weak or no effect on ability to induce pyroptosis. Impaired ability to induce pyroptosis; when associated with A-145.	SEQ_UP	1	
MUTAGEN:R->A: Weakly decrease the enzymatic activity.	SEQ_UP	1	
MUTAGEN:R->C,K: Abolishes interaction with INPPL1 SAM domain.	SEQ_UP	1	
MUTAGEN:R->C: Abolishes interaction with NCOR2. Mice exhibit a severe neurological Rett syndrome-like phenotype.	SEQ_UP	1	
MUTAGEN:R->C: Abolishes phosphatase activity.	SEQ_UP	1	
MUTAGEN:R->C: Abolishes transcriptional activity. Does not impair ligand binding.	SEQ_UP	1	
MUTAGEN:R->C: Brain from homozygous mice shows defects in the guidance of commissural axons and nerves, without evidence of cortical cells migration defects.	SEQ_UP	1	
MUTAGEN:R->C: Corresponds to C-356 variant associated with SPGF16 in human. Impairs nuclear inner membrane location and decreases interaction with DNAJB13.	SEQ_UP	1	
MUTAGEN:R->C: Decreases interaction of PAK3 with CDC42 but increases interaction with RAC1.	SEQ_UP	1	
MUTAGEN:R->C: Does not affect acyltransferase activity.	SEQ_UP	1	
MUTAGEN:R->C: Does not affect localization to the plasma membrane.	SEQ_UP	1	
MUTAGEN:R->C: Does not affect protein expression. Decreases intracellular cholesterol accumulation in the vesicle.	SEQ_UP	1	
MUTAGEN:R->C: Does not modify the functional properties of the protein.	SEQ_UP	1	
MUTAGEN:R->C: Does not rescue cortical neuron migration defects in PHACTR1 knocked-down mice.	SEQ_UP	1	
MUTAGEN:R->C: Enhanced kinase activity. Over-production of thymocytes and hematopoietic stem cells and progenitor cells.	SEQ_UP	1	
MUTAGEN:R->C: Greatly reduced binding to IP4 and to phospholipids.	SEQ_UP	1	
MUTAGEN:R->C: Homozygous mutant embryos show a small pancreas, exencephaly, eye defects and edema.	SEQ_UP	1	
MUTAGEN:R->C: Impaired ability to recruit SEC61A and SEC31A to endoplasmic reticulum exit sites. Impaired ability to regulate ER to Golgi vesicle-mediated transport.	SEQ_UP	1	
MUTAGEN:R->C: Impairs EGF-induced phosphorylation at S-211 and T-388 and binding to phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol 3,4-bisphosphate.	SEQ_UP	1	
MUTAGEN:R->C: Increased channel activity, leading to permanently increased cytoplasmic Ca(2+) levels. Increased activation by calcium, and increased ryanodine binding.	SEQ_UP	1	
MUTAGEN:R->C: Mice show an atypical limb development, are covered by an abnormal smooth skin and die shortly after birth. The esophageal lumen is obliterated by adhesion of the stratified, squamous epithelium lining this structure. The hindlimbs, tail and body are fused together by a thickened epidermis. Epidermis is hyperproliferative but does not undergo a normal differentiation program.	SEQ_UP	1	
MUTAGEN:R->C: No change in osteoclast formation and bone resorption.	SEQ_UP	1	
MUTAGEN:R->C: No effect on protein abundance. Mice homozygous for that mutation do not display any developmental abnormality.	SEQ_UP	1	
MUTAGEN:R->C: Reduced JAK2/STAT5 activation.	SEQ_UP	1	
MUTAGEN:R->C: Shortens circadian rhythm. Accelerates PER2 degradation.	SEQ_UP	1	
MUTAGEN:R->D: Abolishes inhibition of EGF-mediated p42/44 ERK signaling.	SEQ_UP	1	
MUTAGEN:R->D: Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself;when associated with V-67 and R-368.	SEQ_UP	1	
MUTAGEN:R->D: Decreased actin-binding. Loss of actin binding; when associated with 418-E-E-419 and 427-E-E-428.	SEQ_UP	1	
MUTAGEN:R->D: Decreases the rate of channel opening. No effect; when associated with R-642.	SEQ_UP	1	
MUTAGEN:R->D: Disrupts interaction with PRDM14.	SEQ_UP	1	
MUTAGEN:R->D: Does not abolish interaction with ASIC3, but abolishes regulation of ASIC3 channel activity; when associated with D-109 and D-145.	SEQ_UP	1	
MUTAGEN:R->D: Drastically reduces the AHR transcription activity inductiona. Increases constitutive AHR nuclear translocation in the absence of ligands. Reduces binding affinity for the DRE by more than 30-fold in vitro.	SEQ_UP	1	
MUTAGEN:R->D: Drastically reduces the binding affinity of AHR?ARNT to dioxin response element (DRE). Impairs ligand-induced nuclear translocation of AHR.	SEQ_UP	1	
MUTAGEN:R->D: Loss of antimicrobial activity; when associated with A-92.	SEQ_UP	1	
MUTAGEN:R->D: Loss of interaction with TNFRSF14.	SEQ_UP	1	
MUTAGEN:R->D: Reduced affinity for Asprosin.	SEQ_UP	1	
MUTAGEN:R->D: Slight decrease in affinity for membranes. Nearly abolishes membrane tubulation activity.	SEQ_UP	1	
MUTAGEN:R->E,A: Abolishes the enzymatic activity.	SEQ_UP	1	
MUTAGEN:R->E,L: Strongly decreased cytotoxicity.	SEQ_UP	1	
MUTAGEN:R->E: 50% reduced binding to LRP6.	SEQ_UP	1	
MUTAGEN:R->E: Abolished ADP:ATP antiporter activity without affecting ability to regulate mitophagy; when associated with E-43.	SEQ_UP	1	
MUTAGEN:R->E: Abolished interaction with nucleosomes.	SEQ_UP	1	
MUTAGEN:R->E: Abolished tethering to chromatin, leading to strong constitutive activation in the absence of DNA.	SEQ_UP	1	
MUTAGEN:R->E: Abolishes CIDE-N/CIDE-N interaction between the 2 homodimer subunits.	SEQ_UP	1	
MUTAGEN:R->E: Abolishes interaction with NXF1; when associated with E-29.	SEQ_UP	1	
MUTAGEN:R->E: Abolishes interaction with NXF1; when associated with E-30.	SEQ_UP	1	
MUTAGEN:R->E: Abolishes interaction with SLITRK2.	SEQ_UP	1	
MUTAGEN:R->E: Abolishes interaction with ZAP70, and its inhibitory function.	SEQ_UP	1	
MUTAGEN:R->E: Abolishes localization to endosomes. Strongly affects inhibitory function. Abolishes inhibitory function; when associated with L-73.	SEQ_UP	1	
MUTAGEN:R->E: Abolishes nuclear localization; when associated with E-243.	SEQ_UP	1	
MUTAGEN:R->E: Abolishes nuclear localization; when associated with E-246.	SEQ_UP	1	
MUTAGEN:R->E: Abolishes nuclear translocation.	SEQ_UP	1	
MUTAGEN:R->E: Allows binding to CUL1 and RBX1 and formation of an authentic SCF (SKP1-CUL1-F-box protein) complex.	SEQ_UP	1	
MUTAGEN:R->E: Complete loss of LPS-binding, LPS-induced oligomerization, and LPS-induced pyroptosis; when associated with E-53 and A-55.	SEQ_UP	1	
MUTAGEN:R->E: Decreased binding to MHC class II.	SEQ_UP	1	
MUTAGEN:R->E: Decreased interaction with MYMK without affecting localization to the cell membrane.	SEQ_UP	1	
MUTAGEN:R->E: Decreased monoglycylation activity; when associated with E-104.	SEQ_UP	1	
MUTAGEN:R->E: Decreased monoglycylation activity; when associated with E-93.	SEQ_UP	1	
MUTAGEN:R->E: Decreased monoglycylation activity.	SEQ_UP	1	
MUTAGEN:R->E: Decreases interaction with membrane IgM (with greater effect in B1a than in B2 cells).	SEQ_UP	1	
MUTAGEN:R->E: Disrupts interaction with PRKCSH. Nearly abolishes enzyme activity.	SEQ_UP	1	
MUTAGEN:R->E: EIF4E-binding reduced by 60%; when associated with K-724, E-725 and K-730.	SEQ_UP	1	
MUTAGEN:R->E: Has very little effect on anion transport.	SEQ_UP	1	
MUTAGEN:R->E: Impaired ability to homooligomerize at 30 degrees Celsius.	SEQ_UP	1	
MUTAGEN:R->E: Impaired tethering to chromatin, leading to constitutive activation in the absence of DNA.	SEQ_UP	1	
MUTAGEN:R->E: Impairs interaction with NXF1.	SEQ_UP	1	
MUTAGEN:R->E: Increases intrinsic ATPase activity.	SEQ_UP	1	
MUTAGEN:R->E: Intermediate transactivation activity.	SEQ_UP	1	
MUTAGEN:R->E: Loss of ability to bind heterodimeric capping protein (CP) and to inhibit the actin-capping activity of CP.	SEQ_UP	1	
MUTAGEN:R->E: Loss of dimerization; when associated with A-161.	SEQ_UP	1	
MUTAGEN:R->E: Loss of function and transforming activity.	SEQ_UP	1	
MUTAGEN:R->E: Loss of interaction with calmodulin; when associated with E-525.	SEQ_UP	1	
MUTAGEN:R->E: Loss of interaction with calmodulin.	SEQ_UP	1	
MUTAGEN:R->E: Loss of interaction with Ras. Loss of Ras activation. Loss of ubiquitination.	SEQ_UP	1	
MUTAGEN:R->E: Loss of MAIT cell activation.	SEQ_UP	1	
MUTAGEN:R->E: No effect on LIF signal transduction suppression.	SEQ_UP	1	
MUTAGEN:R->E: No endosomal localization; no effect on interaction with VPS35:VPS29 dimer; when associated with S-197.	SEQ_UP	1	
MUTAGEN:R->E: Partial inhibition of BMP2-induced cytodifferentiation; when associated with E-170.	SEQ_UP	1	
MUTAGEN:R->E: Partial inhibition of BMP2-induced cytodifferentiation; when associated with E-219.	SEQ_UP	1	
MUTAGEN:R->E: Partial loss of interaction with Ras. Partial loss of Ras activation. Partial loss of ubiquitination.	SEQ_UP	1	
MUTAGEN:R->E: Reduced anion permeability and increased cation permeability.	SEQ_UP	1	
MUTAGEN:R->E: Reduced neuron activity in the VNO.	SEQ_UP	1	
MUTAGEN:R->E: Reduces affinity for cAMP and impairs tetramerization.	SEQ_UP	1	
MUTAGEN:R->E: Reduces DNA binding. Decreases transcription factor activity.	SEQ_UP	1	
MUTAGEN:R->E: Reduces interaction with CD4 endocytosis signal motif; when associated with AP2S1 S-15.	SEQ_UP	1	
MUTAGEN:R->E: Slightly decreased tethering to chromatin. Does not affect interaction with nucleosomes.	SEQ_UP	1	
MUTAGEN:R->E: Slightly reduced tyrosine carboxypeptidase activity.	SEQ_UP	1	
MUTAGEN:R->E: Strongly decreased interaction with nucleosomes.	SEQ_UP	1	
MUTAGEN:R->E: Strongly inhibits dimerization.	SEQ_UP	1	
MUTAGEN:R->E: Strongly reduced enzyme activity.	SEQ_UP	1	
MUTAGEN:R->E: Strongly reduced interaction with nucleosomes.	SEQ_UP	1	
MUTAGEN:R->E: Strongly reduced tyrosine carboxypeptidase activity.	SEQ_UP	1	
MUTAGEN:R->E: Virtually inactive.	SEQ_UP	1	
MUTAGEN:R->ER: Disrupts amphipathicity and abolishes Golgi localization; when associated with Glu-362.	SEQ_UP	1	
MUTAGEN:R->F: Homozygous mice are born at the expected Mendelian rate and have no visible phenotype. Hind-limb muscles show decreased excitability and decreased force when K(+) levels are low (in vivo). Isolated soleus muscle from homozygous mice has an increased susceptibility to loss of force generation at 2 mM K(+).	SEQ_UP	1	
MUTAGEN:R->F: Reduces interaction with GNAI1 and GNAI2. Inhibits strongly the down-regulation of G(i)-dependent signaling; when associated with A-92-93-A.	SEQ_UP	1	
MUTAGEN:R->G: Abolished ability to ubiquitinate NFE2L2/NRF2 without affecting homodimerization.	SEQ_UP	1	
MUTAGEN:R->G: Abolishes ability to bind DNA without altering the ability of the SMC hinge domain to mediate homodimerization.	SEQ_UP	1	
MUTAGEN:R->G: Abolishes hydrogen sulfide production. Slightly increased basal levels of bound persulfide.	SEQ_UP	1	
MUTAGEN:R->G: Abolishes interaction with RAB3A.	SEQ_UP	1	
MUTAGEN:R->G: Abolishes phosphatase activity.	SEQ_UP	1	
MUTAGEN:R->G: Abolishes proteolytic processing; when associated with A-177.	SEQ_UP	1	
MUTAGEN:R->G: Abolishes the formation of a preferential cleavage product. Abolishes protein cleavage; when associated with G-579.	SEQ_UP	1	
MUTAGEN:R->G: Abolishes the formation of an alternative cleavage product. Abolishes protein cleavage; when associated with G-510.	SEQ_UP	1	
MUTAGEN:R->G: Abolishes the nuclear localization; when associated with G-101.	SEQ_UP	1	
MUTAGEN:R->G: Abolishes the nuclear localization; when associated with G-109.	SEQ_UP	1	
MUTAGEN:R->G: Does not inhibit transport activity. Does not inhibit colocalization with SLC51A at the plasma membrane.	SEQ_UP	1	
MUTAGEN:R->G: Heterozygous mice are viable and healthy. Results in early lethality at homozygosity.	SEQ_UP	1	
MUTAGEN:R->G: Impaired interaction with CDH23.	SEQ_UP	1	
MUTAGEN:R->G: Important decrease in binding affinity to hyaluronan.	SEQ_UP	1	
MUTAGEN:R->G: Increases kinase activity. Reduces primary ciliogenesis. Causes fragmentation of the trans-Golgi network.	SEQ_UP	1	
MUTAGEN:R->G: Increases stability and improves binding to MHC I class ligand; when associated with G-175; G-197 and K-227.	SEQ_UP	1	
MUTAGEN:R->G: Induces an age-dependent neurodegenerative phenotype.	SEQ_UP	1	
MUTAGEN:R->G: Loss of interaction with NUP50. No cyclin E-mediated degradation of phosphorylated p27KIP1.	SEQ_UP	1	
MUTAGEN:R->G: Low transactivation activity.	SEQ_UP	1	
MUTAGEN:R->G: No effect on cleavage.	SEQ_UP	1	
MUTAGEN:R->G: No effect on location at nodal cilia and can rescue the laterality defect of null mutants. Abolishes location at nodal cilia and cannot complement the laterality defect of null mutants; when associated with DEL 819-966.	SEQ_UP	1	
MUTAGEN:R->G: No effect on MHC class I peptide tetramer binding.	SEQ_UP	1	
MUTAGEN:R->G: No effect on trypsin inhibitor activity or sperm binding.	SEQ_UP	1	
MUTAGEN:R->G: Reduces hydrogen sulfide production by 50%. No change in basal levels of bound persulfide.	SEQ_UP	1	
MUTAGEN:R->G: Results in inhibition of JNK binding.	SEQ_UP	1	
MUTAGEN:R->G: Slightly abolishes phosphatase activity.	SEQ_UP	1	
MUTAGEN:R->H: Abolishes DNA-binding.	SEQ_UP	1	
MUTAGEN:R->H: Accelerated clearance of VWF from blood plasma.	SEQ_UP	1	
MUTAGEN:R->H: Decreased receptor activity in response to MTMT binding, even in the presence of copper.	SEQ_UP	1	
MUTAGEN:R->H: Decreased-binding affinity to hyaluronan.	SEQ_UP	1	
MUTAGEN:R->H: Decreases myeloid cell immune response. Reduces expression levels.	SEQ_UP	1	
MUTAGEN:R->H: Homozygous mice display spontaneous generalized seizures and premature death between P16 and P26. Heterozygous mice show infrequent spontaneous seizures, increased susceptibility to chemically and hyperthermia-induced generalized seizures and sleep abnormalities. Heterozygous mice also show deficits in social behavior, spatial memory, cued fear conditioning, pre-pulse inhibition and risk assessment.	SEQ_UP	1	
MUTAGEN:R->H: In LCH mutant; abolishes formation of the tetramer and deoxynucleoside triphosphate (dNTPase) activity; when associated with L-109 and C-112.	SEQ_UP	1	
MUTAGEN:R->H: Loss of channel activity. Functions as dominant negative mutation that impairs function of wild-type channel subunits. Causes impaired Purkinje cell dendrite growth and premature death of cerebellar Purkinje cells.	SEQ_UP	1	
MUTAGEN:R->H: No change in synaptic density.	SEQ_UP	1	
MUTAGEN:R->H: No effect on LPC transport.	SEQ_UP	1	
MUTAGEN:R->H: Not associated with changes in subcellular location.	SEQ_UP	1	
MUTAGEN:R->H: Reduces activity. Loss of endogenous retroelement metabolization.	SEQ_UP	1	
MUTAGEN:R->H: Severe decrease in MAP2K1 and MAP2K2 binding. No effect on the interaction with YWHAE.	SEQ_UP	1	
MUTAGEN:R->H: Slightly reduces affinity for MLPH.	SEQ_UP	1	
MUTAGEN:R->H: Strongly reduces histone methyltransferase activity.	SEQ_UP	1	
MUTAGEN:R->I: Abolishes the association with FCER1G.	SEQ_UP	1	
MUTAGEN:R->I: Decreases autophosphorylation, binding to tRNA and Sindbis virus genomic RNA and eIF-2-alpha phosphorylation in amino acid-starved cells; when associated with L-1142.	SEQ_UP	1	
MUTAGEN:R->I: Strong increase in alpha-tubulin initiation step of polyglutamylase activity; when associated with A-179, R-180, I-362 and H-367.	SEQ_UP	1	
MUTAGEN:R->I: Strongly reduced affinity for PCDH15.	SEQ_UP	1	
MUTAGEN:R->I: Strongly reduces production of IL1B in response to bacterial flagellin; then associated with F-15.	SEQ_UP	1	
MUTAGEN:R->K,M: No effect on ATP-binding and on expression of both ABCG5 and ABCG8. No effect on sterol transport.	SEQ_UP	1	
MUTAGEN:R->K: 85%-90% decrease of both activities.	SEQ_UP	1	
MUTAGEN:R->K: Abolishes binding to phosphorylated Lilrb4a.	SEQ_UP	1	
MUTAGEN:R->K: Abolishes calcium responses to NAD.	SEQ_UP	1	
MUTAGEN:R->K: Abolishes dimethylation. Impairs transcription coactivator activity and regulation of alternative splicing. No effect on methyltransferase activity.	SEQ_UP	1	
MUTAGEN:R->K: Abolishes interaction with membranes enriched in phosphatidylinositol 3-phosphate. Abolishes location on endosome membranes.	SEQ_UP	1	
MUTAGEN:R->K: Abolishes interaction with TDRD1; when associated with K-39; K-45 and K-74.	SEQ_UP	1	
MUTAGEN:R->K: Abolishes interaction with TDRD1; when associated with K-9; K-39 and K-45.	SEQ_UP	1	
MUTAGEN:R->K: Abolishes interaction with TDRD1; when associated with K-9; K-39 and K-74.	SEQ_UP	1	
MUTAGEN:R->K: Abolishes interaction with TDRD1; when associated with K-9; K-45 and K-74.	SEQ_UP	1	
MUTAGEN:R->K: Associates more strongly with SYK. Increases calcium response upon BCR ligation.	SEQ_UP	1	
MUTAGEN:R->K: At least 60% of RNA-binding activity and loss of GTase activity.	SEQ_UP	1	
MUTAGEN:R->K: Decreased L-threonine 3-dehydrogenase activity. No effect on protein NAD(+)-binding. No gross effect on protein folding. No effect on protein stability.	SEQ_UP	1	
MUTAGEN:R->K: Does not affect RhoA or CDC42 activity.	SEQ_UP	1	
MUTAGEN:R->K: Does not change transactivation activity.	SEQ_UP	1	
MUTAGEN:R->K: Forms homodimers processed at L-112 that seem more stable than the wild-type.	SEQ_UP	1	
MUTAGEN:R->K: Impairs the interaction with CD79A and CD79B.	SEQ_UP	1	
MUTAGEN:R->K: Increased histone deacetylase activity, ability to promote double-strand break (DSB) repair, leading to increased life span; when associated with H-249 and 260-D--Q-264.	SEQ_UP	1	
MUTAGEN:R->K: Increases stability and improves binding to MHC I class ligand; when associated with G-121; G-175 and G-197.	SEQ_UP	1	
MUTAGEN:R->K: Inhibits stress granules localization and translational repression.	SEQ_UP	1	
MUTAGEN:R->K: Inhibits translational repression.	SEQ_UP	1	
MUTAGEN:R->K: Knockin mice grow normally and do not show any visible phenotype. Slightly impaired angiogenesis. Does not affect ATPase or E3 ubiquitin ligase activities.	SEQ_UP	1	
MUTAGEN:R->K: Little change in levels of methylation; when associated with K-147; K-154; K-311 and K-313.	SEQ_UP	1	
MUTAGEN:R->K: Little change in levels of methylation; when associated with K-29; K-147; K-154 and K-311.	SEQ_UP	1	
MUTAGEN:R->K: Little change in levels of methylation; when associated with K-29; K-147; K-154 and K-313.	SEQ_UP	1	
MUTAGEN:R->K: Little change in levels of methylation; when associated with K-29; K-147; K-311 and K-313.	SEQ_UP	1	
MUTAGEN:R->K: Little change in levels of methylation; when associated with K-29; K-154; K-311 and K-313.	SEQ_UP	1	
MUTAGEN:R->K: Little effect on LIF-induced signal transduction suppression. Loss of EPO-induced signal transduction suppression. Abolishes binding to JAK2 and EPOR.	SEQ_UP	1	
MUTAGEN:R->K: Loss of binding to FYB1 and MAP4K1. Reduced tyrosine phosphorylation. No effect on the suppression of natural killer cell activation and suppression of interferon-gamma production.	SEQ_UP	1	
MUTAGEN:R->K: Loss of binding to POLR2A. Retains the ability to support transcription elongation but the resulting transcripts contain splicing defects and accumulate to high levels within the nucleus.	SEQ_UP	1	
MUTAGEN:R->K: Loss of GTase activity.	SEQ_UP	1	
MUTAGEN:R->K: Loss of LIF signal transduction suppression. Loss of binding to KIT. No effect on binding to VAV.	SEQ_UP	1	
MUTAGEN:R->K: Loss of lipid phosphatase activity.	SEQ_UP	1	
MUTAGEN:R->K: Loss of phosphatase activity.	SEQ_UP	1	
MUTAGEN:R->K: No change in methylation levels.	SEQ_UP	1	
MUTAGEN:R->K: No effect on calcium responses to NAD.	SEQ_UP	1	
MUTAGEN:R->K: No effect on fusogenic activity. Confers immunosuppressive activity not found in the wild type protein.	SEQ_UP	1	
MUTAGEN:R->K: No effect on interaction with FYN SH3 domain.	SEQ_UP	1	
MUTAGEN:R->K: No effect.	SEQ_UP	1	
MUTAGEN:R->K: Reduced interaction with NR1I2 and NR1I3. Significant decrease in interaction with NR1I2 and NR1I3; when associated with E-394 and M-396.	SEQ_UP	1	
MUTAGEN:R->K: Reduces Arf-GAP mediated stimulation of GTP hydrolysis more than 10000-fold.	SEQ_UP	1	
MUTAGEN:R->K: Results in hyposensitivity to noxious heat.	SEQ_UP	1	
MUTAGEN:R->K: Retains the positive charge, resulting in slightly decreased nucleosome-binding.	SEQ_UP	1	
MUTAGEN:R->K: Some decrease in levels of methylation. Greatly decreased methylation levels; when associated with K-248.	SEQ_UP	1	
MUTAGEN:R->K: Some decrease in levels of methylation. Greatly decreased methylation levels; when associated with K-250.	SEQ_UP	1	
MUTAGEN:R->L: 10-fold loss in affinity to sialic acid.	SEQ_UP	1	
MUTAGEN:R->L: Abolished RAC1 GTPase activity. Abolished ability to induce neurite branching. No effect on filopodia biogenesis and neurite outgrowth.	SEQ_UP	1	
MUTAGEN:R->L: Abolishes binding to CD79A and SYK.	SEQ_UP	1	
MUTAGEN:R->L: Abolishes cholesterol transport.	SEQ_UP	1	
MUTAGEN:R->L: Abolishes trypsin inhibitor activity. No effect on sperm binding.	SEQ_UP	1	
MUTAGEN:R->L: Decrease in receptor activation.	SEQ_UP	1	
MUTAGEN:R->L: Does not affect association with TLR2, TLR4 and TLR9; does not affect cell-surface expression of TLR2, TLR4 and TLR9; does not affect responses of TLR2, TLR4 and TLR9.	SEQ_UP	1	
MUTAGEN:R->L: Impairs DNA-binding and hairpin formation while maintaining some nicking activity.	SEQ_UP	1	
MUTAGEN:R->L: Impairs the ability to rescue growth in cdc25ts mutant yeasts.	SEQ_UP	1	
MUTAGEN:R->L: In add; reduces methyltransferase activity; causes hyperkinesis, circling, head-tossing, aggression, progressive degeneration of the organ of Corti, hair cell defects and profound deafness. Distortion product otoacoustic emissions (DPOAEs) are absent at 4 weeks of age at all frequencies tested. At postnatal day (P) 5 the sensory epithelia are patterned into three rows of outer hair cells (OHCs) and one row of inner hair cells (IHCs) with no obvious structural abnormalities. The bundles of OHCs appear similar in size to those of wild-type mice and form a normal staircase pattern. The hair bundles of OHCs have a slightly more rounded morphology, especially in basal regions of the cochlea. The morphology of IHCs is not significantly altered. Hair cells are maintained in the presence of gentamicin, an aminoglycoside antibiotic that enters hair cells through their transduction channels and normally causes hair cell death. Mechanotransduction currents are very small in P4 hair cells and completely absent in P7 hair cells. Membrane potential, outward-evoked currents and nonlinear capacitance are normal in OHCs. No difference in the expression or localization of tip link proteins CDH23 and PCDH15 or ATP2B2, MYO7A, ESPN and WHRN proteins at P5-P8 in hair bundles of hair cells. No difference in the number of tip links in IHCs and OHCs at P7-P8. No difference in the levels of catecholamines, including norepinephrine, homovanillic acid (HVA) and norepinephrine, or serotonin levels in the inner ear. Loss of reverse polarity currents.	SEQ_UP	1	
MUTAGEN:R->L: Increased programmed cell death in spermatogenic cells; decreased expression of MAP1LC3B.	SEQ_UP	1	
MUTAGEN:R->L: Induces alteration of the DNA-binding surface and leads to decreased synthesis of cyclic GMP-AMP (cGAMP); when associated with K-182.	SEQ_UP	1	
MUTAGEN:R->L: Loss of Rho GAP activity. Enhances cell spreading.	SEQ_UP	1	
MUTAGEN:R->L: No effect on receptor activation.	SEQ_UP	1	
MUTAGEN:R->L: Reduces interaction with RABGEF1 and RAP2A. Strongly reduces interaction with RAP2A; when associated with L-409.	SEQ_UP	1	
MUTAGEN:R->L: Reduces methyltransferase activity against norepinephrine.	SEQ_UP	1	
MUTAGEN:R->M: 2- to 3-fold increase in Km for CoA.	SEQ_UP	1	
MUTAGEN:R->M: 2-fold increase in Km for CoA. Reduced affinity for CoA.	SEQ_UP	1	
MUTAGEN:R->M: Impaired interaction with NFE2L2/NRF2.	SEQ_UP	1	
MUTAGEN:R->M: Loss of phosphatase activity.	SEQ_UP	1	
MUTAGEN:R->M: No significant effect on Km for CoA.	SEQ_UP	2	
MUTAGEN:R->M: Severe decrease in MAP2K1 and MAP2K2 binding. No effect on the interaction with YWHAE.	SEQ_UP	1	
MUTAGEN:R->M: Strongly reduced transactivation.	SEQ_UP	1	
MUTAGEN:R->N: Abolished activity without affecting avility to bind CX3CL1.	SEQ_UP	1	
MUTAGEN:R->N: Abolishes binding to CREB.	SEQ_UP	1	
MUTAGEN:R->N: Abolishes homooligomerization and FLRT2-mediated cell-cell adhesion; when associated with T-188.	SEQ_UP	1	
MUTAGEN:R->N: Abolishes homooligomerization and FLRT3-mediated cell-cell adhesion; when associated with T-183.	SEQ_UP	1	
MUTAGEN:R->N: Abolishes interaction with FLRT2; when associated with T-294.	SEQ_UP	1	
MUTAGEN:R->N: Abolishes interaction with FLRT2; when associated with T-326.	SEQ_UP	1	
MUTAGEN:R->N: Abolishes interaction with STAT3.	SEQ_UP	1	
MUTAGEN:R->N: Complete loss of activation of phospholipid synthesis. No effect on CDS1-binding.	SEQ_UP	1	
MUTAGEN:R->N: Does not glycosylated.	SEQ_UP	1	
MUTAGEN:R->N: Impairs calcium-dependent binding to phospholipids; when associated with N-24 and N-52.	SEQ_UP	1	
MUTAGEN:R->N: No effect on activation of phospholipid synthesis, nor on CDS1-binding.	SEQ_UP	1	
MUTAGEN:R->N: No effect on homophilic interaction. Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself; when associated with K-317.	SEQ_UP	1	
MUTAGEN:R->N: Slightly increases phosphatase activity with p-nitrophenylphosphate; when associated with R-44 and I-45.	SEQ_UP	1	
MUTAGEN:R->P: Causes twisted hair shafts, broken hair follicles at sebaceous gland level and occasional rupture of the hair bulb or epidermal cyst-like changes.	SEQ_UP	1	
MUTAGEN:R->P: In humdy; failure to close the neural tube and optic fissure, causing exencephaly and retinal coloboma and common birth defects. Specifically disrupts interaction with PPP1CA while it does not affect interaction with actin.	SEQ_UP	1	
MUTAGEN:R->P: Increases protein decay. forms subsarcolemmal aggregates. Changes the subcellular localization and turnover of its direct, extrasarcomeric binding partners. Knockin mice develop age-dependent desmin-positive protein aggregation pathology, skeletal muscle weakness, dilated cardiomyopathy, as well as cardiac arrhythmias and conduction defects. Knockin mice exhibit altered axial myofibrillar lattice arrangement in fast- and slow-twitch muscle fibers, increased axial stiffness and stretch-induced vulnerability in soleus muscle fiber bundles, reduced Ca(2+)-sensitivity in heterozygous fiber bundles and increased Ca(2+)-sensitivity in homozygous fiber bundles.	SEQ_UP	1	
MUTAGEN:R->P: Loss of localization to cytoplasmic vesicle.	SEQ_UP	2	
MUTAGEN:R->Q,W: Reduced cell surface localization.	SEQ_UP	1	
MUTAGEN:R->Q: Abolishes CDC20 binding; when associated with R-302.	SEQ_UP	1	
MUTAGEN:R->Q: Abolishes interaction with membranes enriched in phosphatidylinositol 3-phosphate.	SEQ_UP	1	
MUTAGEN:R->Q: Abolishes interaction with STAT3.	SEQ_UP	1	
MUTAGEN:R->Q: Abolishes location on endosome membranes. Abolishes binding to membranes enriched in phosphatidylinositol 3-phosphate. Mildly decreases binding to membranes enriched in phosphatidylinositol 4,5-bisphosphate.	SEQ_UP	1	
MUTAGEN:R->Q: Abolishes location on endosome membranes. Abolishes binding to membranes enriched in phosphatidylinositol 3-phosphate. No significant effect on binding to membranes enriched in phosphatidylinositol 4,5-bisphosphate.	SEQ_UP	1	
MUTAGEN:R->Q: Abolishes surface expression and channel activity.	SEQ_UP	1	
MUTAGEN:R->Q: Alters the voltage-dependent gating.	SEQ_UP	1	
MUTAGEN:R->Q: Decreased affinity for NPC2.	SEQ_UP	1	
MUTAGEN:R->Q: Decreased-binding affinity to hyaluronan.	SEQ_UP	1	
MUTAGEN:R->Q: Decreases affinity binding to PTPRZ1. Decreases affinity binding to PTPRZ1; when associated with Q-105 and Q-106. Decreases neuron migration. Decreases neuron migration; when associated with Q-105 and Q-106.	SEQ_UP	1	
MUTAGEN:R->Q: Decreases interaction with UNC79.	SEQ_UP	1	
MUTAGEN:R->Q: Disrupts channel closure.	SEQ_UP	1	
MUTAGEN:R->Q: Disrupts targeting to membrane; when associated with A-67; N-68; P-73; A-74 and Q-75.	SEQ_UP	1	
MUTAGEN:R->Q: Does not affect pro-coagulant function. Partially resistant to inactivation by activated protein C.	SEQ_UP	1	
MUTAGEN:R->Q: Erroneous subcellular location; when associated with I-81. No positive effect on terminal myogenic differentiation; when associated with I-81.	SEQ_UP	1	
MUTAGEN:R->Q: Faster channel activation kinetics.	SEQ_UP	1	
MUTAGEN:R->Q: Impaired acyltransferase activity.	SEQ_UP	1	
MUTAGEN:R->Q: In Aey12; dominant negative mutation. Viable and fertile with a small eye phenotype. The lens is absent and only the lens envelope remains. The retina is misfolded and poorly differentiated. Heterozygotes show variable degrees of lens opacity and abnormal primary lens fiber elongation. Defects are apparent from embryonic stage 12.5 dpc onwards.	SEQ_UP	1	
MUTAGEN:R->Q: Inactive. Abolishes GTPase activity in vitro. Greatly diminishes cytoskeletal reorganization.	SEQ_UP	1	
MUTAGEN:R->Q: Inhibits interaction with PER2. Does not suppress its nuclear localization. Inhibits its repression activity on CLOCK|NPAS2-ARNTL-driven transcription.	SEQ_UP	1	
MUTAGEN:R->Q: Loss of catalytic activity. No loss of accumulation of coat proteins on internal membranes upon overexpression of Acap1.	SEQ_UP	1	
MUTAGEN:R->Q: Loss of deoxyribonuclease activity.	SEQ_UP	1	
MUTAGEN:R->Q: Loss of DNA binding activity; mice are microphthalmic but viable with defects in retinal morphology and pigmentation as a result of delayed retinal neurogenesis. Reduction in transcription repression activity.	SEQ_UP	1	
MUTAGEN:R->Q: Loss of DNA-binding activity but no effect on PRDM16-mediated BAT gene transcription activation.	SEQ_UP	1	
MUTAGEN:R->Q: Loss of function in histone modification. Loss of nuclear localization.	SEQ_UP	1	
MUTAGEN:R->Q: Loss of GTPase activation.	SEQ_UP	2	
MUTAGEN:R->Q: Loss of IL-6 signal transduction suppression. No effect on binding to TYK2.	SEQ_UP	1	
MUTAGEN:R->Q: No effect on activity.	SEQ_UP	1	
MUTAGEN:R->Q: No effect on DNA-binding.	SEQ_UP	1	
MUTAGEN:R->Q: No effect on proteolytic cleavage.	SEQ_UP	1	
MUTAGEN:R->Q: No loss of male fertility.	SEQ_UP	1	
MUTAGEN:R->Q: Reduced GTP-hydrolysis.	SEQ_UP	1	
MUTAGEN:R->Q: Reduced potassium ion transmembrane transport.	SEQ_UP	1	
MUTAGEN:R->Q: Reduces affinity for calcium and results in decreased calcium-dependent neurotransmitter release.	SEQ_UP	1	
MUTAGEN:R->Q: Reduces binding to phosphoinositide; when associated with GLN-109.	SEQ_UP	1	
MUTAGEN:R->Q: Reduces binding to phosphoinositide; when associated with GLN-93.	SEQ_UP	1	
MUTAGEN:R->Q: Reduces phosphatidylinositol binding.	SEQ_UP	1	
MUTAGEN:R->Q: Reduces surface expression and abolishes channel activity.	SEQ_UP	1	
MUTAGEN:R->Q: Reduces surface expression and decreases current amplitude.	SEQ_UP	1	
MUTAGEN:R->Q: Reduces surface expression and disrupts channel closure.	SEQ_UP	1	
MUTAGEN:R->Q: Results in aberrent localization of TRIM72 and defects in membrane repair.	SEQ_UP	1	
MUTAGEN:R->Q: Same activation kinetics as wild-type.	SEQ_UP	1	
MUTAGEN:R->Q: Shifts voltage dependence of activation to more negative values.	SEQ_UP	1	
MUTAGEN:R->Q: Strongly decreased affinity for NPC2. No effect on lysosomal location.	SEQ_UP	1	
MUTAGEN:R->S,M: Impairs enzyme activity.	SEQ_UP	1	
MUTAGEN:R->S: 30% of wild-type activity.	SEQ_UP	1	
MUTAGEN:R->S: Abolishes STOML3 modulation of mechanosensitive currents.	SEQ_UP	1	
MUTAGEN:R->S: Disrupts interaction with VPS35:VPS29 dimer; no endosomal localization; when associated with S-245.	SEQ_UP	1	
MUTAGEN:R->S: Induces an age-dependent neurodegenerative phenotype.	SEQ_UP	1	
MUTAGEN:R->S: No effect on PDCD1 binding.	SEQ_UP	1	
MUTAGEN:R->S: No stimulation of CASP9 activity.	SEQ_UP	1	
MUTAGEN:R->S: Reduces enzyme activity.	SEQ_UP	1	
MUTAGEN:R->S: Reduces interaction with CD4 endocytosis signal motif; when associated with AP2A2 E-21.	SEQ_UP	1	
MUTAGEN:R->S: Results in myristoylation of G-2, which restores the transformation activity; when associated with G-2.	SEQ_UP	1	
MUTAGEN:R->S: Significantly reduces the binding to PDCD1.	SEQ_UP	1	
MUTAGEN:R->T: Abolishes interaction with BRCA2 and location to double-strand breaks in chromosomes.	SEQ_UP	1	
MUTAGEN:R->T: Abolishes interaction with FLRT2; when associated with N-292.	SEQ_UP	1	
MUTAGEN:R->T: Increased mobility in differentiating cells. Greatly reduced DNA binding.	SEQ_UP	1	
MUTAGEN:R->T: No effect on localization. Decreased O-glycosylation. Loss of function in LPA internalization into cells. Loss of function in regulation of glutamatergic synaptic transmission.	SEQ_UP	1	
MUTAGEN:R->T: No effect on protein abundance. Strong decreases of cell surface localization. Decreases alanine uptake.	SEQ_UP	1	
MUTAGEN:R->T: No effect on trypsin inhibitor activity or sperm binding.	SEQ_UP	1	
MUTAGEN:R->T: No effect.	SEQ_UP	1	
MUTAGEN:R->T: Strongly reduces FLRT2 binding; when associated with N-244.	SEQ_UP	1	
MUTAGEN:R->V: Does not affect association with Fc receptor gamma chain.	SEQ_UP	1	
MUTAGEN:R->V: Loss of MAIT cell activation.	SEQ_UP	1	
MUTAGEN:R->W,A: No receptor activity in response to MTMT binding, even in the presence of copper.	SEQ_UP	1	
MUTAGEN:R->W,H,A: No receptor activity in response to MTMT binding, even in the presence of copper.	SEQ_UP	1	
MUTAGEN:R->W: Abolishes binding to phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 4,5-bisphosphate.	SEQ_UP	1	
MUTAGEN:R->W: Decreased tubulin deglutamylation.	SEQ_UP	1	
MUTAGEN:R->W: Homozygous mice are not viable. Embryos show early lethality along with fetal growth restriction and lack of visible blood vessels in yolk sacs.	SEQ_UP	1	
MUTAGEN:R->W: Induces abnormal auditory brainstem responses indicative of neuronal dysfunction along the auditory pathway.	SEQ_UP	1	
MUTAGEN:R->W: Loss of repressor activity.	SEQ_UP	1	
MUTAGEN:R->W: Loss of tocopherol secretion (in vivo). No effect on tocopherol binding and intermembrane transfer (in vitro).	SEQ_UP	1	
MUTAGEN:R->W: Mislocalization of the protein from Golgi apparatus to endoplasmic reticulum.	SEQ_UP	1	
MUTAGEN:R->W: No effect on interaction with TLR3.	SEQ_UP	1	
MUTAGEN:R->W: No effect on kinase activity. No effect on cell membrane location.	SEQ_UP	1	
MUTAGEN:R->W: No effect.	SEQ_UP	1	
MUTAGEN:R->W: Reduction in DNA binding activity; mice are microphthalmic but viable with severe defects in retinal morphology and extensive pigmentation as a result of a lack of retinal neurogenesis.	SEQ_UP	1	
MUTAGEN:R->W: Resulty in increased tubulin polymerization in vitro.	SEQ_UP	1	
MUTAGEN:R->W: Strongly reduced catalytic activity.	SEQ_UP	1	
MUTAGEN:R->W: Strongly reduces calcium channel activity; when associated with V-256.	SEQ_UP	1	
MUTAGEN:RALVRELNPR->AALVAELNPAA: Impaired pore-formation.	SEQ_UP	1	
MUTAGEN:RARR->AAAA: Does not affect formation of liquid-liquid phase separation (LLPS).	SEQ_UP	1	
MUTAGEN:RDLR->HDLH: Loss of proteolytic processing.	SEQ_UP	1	
MUTAGEN:RE->AQ: Loss of inhibitory activity on TNF-induced NF-kappa-B activation; no effect on interaction with TNFAIP3.	SEQ_UP	1	
MUTAGEN:REDRED->AAAAAA: Loss of nuclear location. Location is mainly cytoplasmic or diffuse.	SEQ_UP	1	
MUTAGEN:RER->LEG: Loss of DNA-binding.	SEQ_UP	1	
MUTAGEN:RG->AA: Loss of interaction with NOS2.	SEQ_UP	1	
MUTAGEN:RGD->KGE: Abolishes protection against axon degeneration.	SEQ_UP	1	
MUTAGEN:RGE->SAS: No endosomal localization; no effect on interaction with VPS35:VPS29 dimer.	SEQ_UP	1	
MUTAGEN:RK->AA: Abolishes CoA-binding. No effect on transcriptional repressor activity.	SEQ_UP	1	
MUTAGEN:RK->AA: Decreased accumulation in the nucleus.	SEQ_UP	1	
MUTAGEN:RK->AA: Disrupts interaction with FYN SH3 domain.	SEQ_UP	1	
MUTAGEN:RK->AA: Leads to cytoplasmic relocalization.	SEQ_UP	1	
MUTAGEN:RK->AA: Localizes mainly in cytoplasm and not in nucleus.	SEQ_UP	1	
MUTAGEN:RK->AA: Strongly reduces its import in the nucleus. Abolishes its import in the nucleus, does not change its export to the cytoplasm and the export of the U snRNA complex; when associated with 71-ARAA-74.	SEQ_UP	1	
MUTAGEN:RK->GE,EE: Reduced binding to monomeric actin. No VASP-induced actin polymerization.	SEQ_UP	1	
MUTAGEN:RK->QT: Retains 50% of activity; when associated with D-63 and K-77.	SEQ_UP	1	
MUTAGEN:RK->SN: Abolishes nuclear localization.	SEQ_UP	1	
MUTAGEN:RKFSSSRFWKPR->AAFSSSRFWAPA: Reduced ability to induce pyroptosis.	SEQ_UP	1	
MUTAGEN:RKKR->PNNW: Loss of ability to suppress the proliferation of effector T-cells.	SEQ_UP	1	
MUTAGEN:RKKR->QNKS: Loss of proteolytic processing.	SEQ_UP	1	
MUTAGEN:RKKRRGIIEKRRR->LE: Abrogates DNA-binding and transcriptional repression.	SEQ_UP	1	
MUTAGEN:RKR->AAA: Reduced binding to ELMO1 and failure to promote engulfment of apoptotic thymocytes.	SEQ_UP	1	
MUTAGEN:RKRK->AAAA: Locates to the cytoplasm. Has no effect on enzyme activity or axonal protection.	SEQ_UP	1	
MUTAGEN:RKRK->EEEE: Abolished ability to form a pore.	SEQ_UP	1	
MUTAGEN:RKRR->AAAA: Leads to cytoplasmic relocalization; when associated with 12-A--A-16.	SEQ_UP	1	
MUTAGEN:RKWKRK->AAWAAA: Impaired DNA-binding activity.	SEQ_UP	1	
MUTAGEN:RL->AA: Inhibits interaction with RHOC. Reduces homooligomerization activity. Inhibits RHOC-dependent homooligomerization activity. Abolishes ability to rescue the morphological hair bundle defect in hair cell of RIPOR2-deficient mice.	SEQ_UP	1	
MUTAGEN:RL->AA: No effect on RHOA activation; when associated with 547-A-A-548.	SEQ_UP	1	
MUTAGEN:RLDQLK->AAAAAA: 40% decreased enzyme activity.	SEQ_UP	1	
MUTAGEN:RLTR->ELTE: Localized to the perinuclear region but not retained in or targeted to the medial part of the Golgi apparatus.	SEQ_UP	1	
MUTAGEN:RMQELYREELER->QMQELYQEELEQ: Loss of interaction with CALM1.	SEQ_UP	1	
MUTAGEN:RPRK->APAA: Clear and exclusive nuclear accumulation.	SEQ_UP	1	
MUTAGEN:RPRRR->APAAA: Leads to cytoplasmic relocalization; when associated with 67-A--A-70.	SEQ_UP	1	
MUTAGEN:RPSR->KPSE: Slight reduction in binding to phosphorylated Lilrb4a.	SEQ_UP	1	
MUTAGEN:RQ->KK: Does not affect formation of a heterodimer with TCF3 and ability to bind DNA.	SEQ_UP	1	
MUTAGEN:RQR->AQA: Loss of binding to AP2A1 and AP2A2. Decreased localization to the plasma membrane.	SEQ_UP	1	
MUTAGEN:RQRR->AAAA: Processing by furin-like convertase abolished.	SEQ_UP	1	
MUTAGEN:RR->AA,EE: Strongly shifts the voltage-dependent channel activation to more depolarized membrane potentials.	SEQ_UP	1	
MUTAGEN:RR->AA: Abolishes ATP-dependent oligomerization.	SEQ_UP	1	
MUTAGEN:RR->AA: Abolishes binding with phosphatidic acid. No effect on cell membrane location. Strongly decreases sphingomyelin phosphodiesterase activity. Abolishes sphingomyelin phosphodiesterase activity and locates at endoplasmic reticulum; when associated with A-33 and 45-DEL-48.	SEQ_UP	1	
MUTAGEN:RR->AA: Abolishes interaction with MUSK and function; when associated with A-174.	SEQ_UP	1	
MUTAGEN:RR->AA: Abolishes nuclear localization; when associated with A-227; A-228; A-229 and A-230.	SEQ_UP	1	
MUTAGEN:RR->AA: Abolishes production of the mature chain and promotes apoptosis of superior cervical ganglion neurons; when associated with 79-A-A-80 and 120-A-A-121.	SEQ_UP	1	
MUTAGEN:RR->AA: Abolishes response to semaphorin.	SEQ_UP	1	
MUTAGEN:RR->AA: Greatly decreased interaction with MAPK8 and ligase activity.	SEQ_UP	1	
MUTAGEN:RR->AA: Inhibits transport activity. Inhibits localization at the plasma membrane and membrane orientation. Decreases glycosylation of SLC51A.	SEQ_UP	1	
MUTAGEN:RR->AA: Loss of interaction with SMARCA4.	SEQ_UP	1	
MUTAGEN:RR->AA: Loss of nuclear localization.	SEQ_UP	1	
MUTAGEN:RR->AA: Nuclear localization.	SEQ_UP	1	
MUTAGEN:RR->AA: Partially reduces its import in the nucleus.	SEQ_UP	1	
MUTAGEN:RR->AA: Reduces membrane localization.	SEQ_UP	1	
MUTAGEN:RR->AA: Reduces phosphatidylinositol phosphate binding.	SEQ_UP	1	
MUTAGEN:RR->AA: Strongly reduced autocatalytic cleavage; when associated with A-196 and A-199. Slightly reduced autocatalytic cleavage; when associated with A-196.	SEQ_UP	1	
MUTAGEN:RR->AG: Abolishes DNA-binding. No effect neither on interaction with NCOA1 and NCOA2 nor on inhibition of NFATC1 expression.	SEQ_UP	1	
MUTAGEN:RR->EE: Attenuated repression of Adam10 transcription.	SEQ_UP	1	
MUTAGEN:RR->EE: Loss of nuclear location. Loss of DNA synthesis inhibition.	SEQ_UP	1	
MUTAGEN:RR->M: Loss of MAPK1 binding. No effect on nuclear envelope breakdown activity in oocytes.	SEQ_UP	1	
MUTAGEN:RR->VV: Strongly reduced nuclear location.	SEQ_UP	1	
MUTAGEN:RRAR->AAAA,AAAR,ARAR,RAAR: Abolishes interaction with MAPK1.	SEQ_UP	1	
MUTAGEN:RREN->AAEA: Abolishes interaction with DNM1L.	SEQ_UP	1	
MUTAGEN:RRER->SSES: Most important decrease in binding affinity to hyaluronan.	SEQ_UP	1	
MUTAGEN:RRK->QQQ: Abolishes nuclear localization.	SEQ_UP	1	
MUTAGEN:RRK->SRT: Abolishes the nuclear speckle localization but not the nuclear localization.	SEQ_UP	1	
MUTAGEN:RRKRSR->AAAAAA: Abolishes ability to suppress tumorigenicity when expressed in NCI-H226 cells.	SEQ_UP	1	
MUTAGEN:RRLL->ARLA: Does not affect piRNA-binding but abolishes ubiquitination by the APC/C. Causes male sterility.	SEQ_UP	1	
MUTAGEN:RRR->AAA: Abolishes interaction with PALS1.	SEQ_UP	1	
MUTAGEN:RRR->AAA: Abolishes nuclear import.	SEQ_UP	1	
MUTAGEN:RRR->AAA: Almost complete loss of interaction with MAPK8.	SEQ_UP	1	
MUTAGEN:RRR->ARA: Cleaved by subtilisin-like proprotein convertase 4.	SEQ_UP	1	
MUTAGEN:RRR->GGA: Loss of interaction with EZR, MSN and RDX and co-localization to microvilli.	SEQ_UP	1	
MUTAGEN:RRR->QQQ: Localizes to cytoplasm; when associated with 37-NNN-39.	SEQ_UP	1	
MUTAGEN:RRRLWV->AAALWA: Abolishes interaction with MAPK8.	SEQ_UP	1	
MUTAGEN:RRRRFER->ARARFEA: Not cleaved by subtilisin-like proprotein convertase 4.	SEQ_UP	1	
MUTAGEN:RRRRRR->AAAAAA: Localizes in nucleus and cytoplasm. Localizes mainly in cytoplasm; when associated with 70-A--A-73.	SEQ_UP	1	
MUTAGEN:RRTR->AATA: Localizes in nucleus and cytoplasm. Localizes mainly in cytoplasm; when associated with 145-A--A-150.	SEQ_UP	1	
MUTAGEN:RTK->ATA: Localizes mainly in cytoplasm and not in nucleus.	SEQ_UP	1	
MUTAGEN:RVAR->AVAA: Impairs propeptide cleavage.	SEQ_UP	1	
MUTAGEN:RVRTGRSIR->AVATGASIA: Abolishes localization to mitochondria in fat cells.	SEQ_UP	1	
MUTAGEN:RVVK->AVVA,EVVE: Does not affect trypsin-binding.	SEQ_UP	1	
MUTAGEN:RYLL->AAAA: Abolishes the interactions with estrogen and retinoid-acids receptors.	SEQ_UP	1	
MUTAGEN:S->A,C,G: Reduced EPO binding.	SEQ_UP	1	
MUTAGEN:S->A,D: Abolishes interaction with TAX1BP3.	SEQ_UP	1	
MUTAGEN:S->A,D: Impairs interaction with AMPK and subsequent phosphorylation by AMPK.	SEQ_UP	1	
MUTAGEN:S->A,D: Little change in baolateral sorting in epithelial cells.	SEQ_UP	1	
MUTAGEN:S->A,D: Loss of function in LPA import into cell.	SEQ_UP	1	
MUTAGEN:S->A,D: No effect on interaction with EIF4A1.	SEQ_UP	1	
MUTAGEN:S->A,D: Normal MAPK3/ERK1 and MAPK1/ERK2-binding.	SEQ_UP	1	
MUTAGEN:S->A,D: Unable to activate MAPKAPK5 promote MAPKAPK5 localization to the cytoplasm.	SEQ_UP	1	
MUTAGEN:S->A,E,T: Loss of localization to the perinuclear region. Loss of translocation to the nucleus upon PMA stimulation.	SEQ_UP	1	
MUTAGEN:S->A,E: Abolishes DNA-binding and transcriptional activity.	SEQ_UP	1	
MUTAGEN:S->A,E: Abolishes phosphorylation. Abolishes interaction with PPP2CA and PPP2R1A. Slight increase in phosphorylation at Ser-273 and in the interaction with 14-3-3 proteins.	SEQ_UP	1	
MUTAGEN:S->A,E: Loss of phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A,E: Partial loss of phosphorylation and loss of interaction with RAN-GTP; when associated with A/E-366; A/E-376; A/E-380 and A/E-419.	SEQ_UP	1	
MUTAGEN:S->A,E: Partial loss of phosphorylation and loss of interaction with RAN-GTP; when associated with A/E-366; A/E-376; A/E-419 and A/E-420.	SEQ_UP	1	
MUTAGEN:S->A,E: Partial loss of phosphorylation and loss of interaction with RAN-GTP; when associated with A/E-366; A/E-380; A/E-419 and A/E-420.	SEQ_UP	1	
MUTAGEN:S->A,E: Partial loss of phosphorylation and loss of interaction with RAN-GTP; when associated with A/E-376; A/E-380; A/E-419 and A/E-420.	SEQ_UP	1	
MUTAGEN:S->A,E: Partial loss of phosphorylation and loss of interaction with RAN; when associated with A/E-366; A/E-376; A/E-380 and A/E-420.	SEQ_UP	1	
MUTAGEN:S->A,E: Strongly reduces transcriptional activity and interaction with NFKB1/p50 and NFKB2/p52.	SEQ_UP	1	
MUTAGEN:S->A,H,N: Retains catalytic activity indicating it is not required for iron ligand-binding.	SEQ_UP	1	
MUTAGEN:S->A,R,D: Abolished phosphorylation by RPS6KA3/RSK2.	SEQ_UP	1	
MUTAGEN:S->A,R: Abolished binding to and nuclear export of hypusinated EIF5A.	SEQ_UP	1	
MUTAGEN:S->A,V,I: Impaired 1-alpha hydroxylase activity toward 25-hydroxyvitamin D3.	SEQ_UP	1	
MUTAGEN:S->A,W: Strongly decreases interaction with TLR3.	SEQ_UP	1	
MUTAGEN:S->A: 50% decrease of cell growth; when associated with A-167. 50% increase of cell migration; when associated with A-167.	SEQ_UP	1	
MUTAGEN:S->A: 50% decrease of cell growth; when associated with A-171. 50% increase of cell migration; when associated with A-171.	SEQ_UP	1	
MUTAGEN:S->A: 70% reduction in binding to YWHAZ and increased nuclear localization.	SEQ_UP	1	
MUTAGEN:S->A: Abolished ability to activate IRF3.	SEQ_UP	1	
MUTAGEN:S->A: Abolished acyltransferase activity. Impaired ability to interact with WNT3A.	SEQ_UP	1	
MUTAGEN:S->A: Abolished both phosphorylation and pyrophosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: Abolished HIPK2-mediated proteasomal degradation.	SEQ_UP	1	
MUTAGEN:S->A: Abolished homodimerization and subsequent activation.	SEQ_UP	1	
MUTAGEN:S->A: Abolished phosphorylation by CaMK2; knockin mice display normal baseline synaptic transmission and long-term potentiation (LTP) in the hippocampus, but metabotropic receptor-LTD is increased; when associated with A-278.	SEQ_UP	1	
MUTAGEN:S->A: Abolished phosphorylation by CDK5.	SEQ_UP	1	
MUTAGEN:S->A: Abolished phosphorylation by GSK3 and decreased acetyltransferase activity. Impaired ability to activate the cGAS-STING antiviral response in knockin mice. Lean phenotype caused by impaired ability to promote the synthesis of diacylglycerol in knockin mice. Decreased ability to promote homologous recombination (HR)repair in response to DNA double-strand breaks (DSBs).	SEQ_UP	1	
MUTAGEN:S->A: Abolished phosphorylation by MAPK1/MAPK3.	SEQ_UP	1	
MUTAGEN:S->A: Abolished phosphorylation by PKA, leading to deacreased ability to activate transcription of target genes; does not affect subcellular localization; when associated with A-211.	SEQ_UP	1	
MUTAGEN:S->A: Abolished phosphorylation by PKA, leading to deacreased ability to activate transcription of target genes; does not affect subcellular localization; when associated with A-64.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes ability to mediate necroptosis. Affects interaction with MLKL; when associated with A-230 and A-236.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes activity.	SEQ_UP	2	
MUTAGEN:S->A: Abolishes ADP binding.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes ADRB2 internalization.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes AMPK-mediated phosphorylation; when associated with A-177.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes AMPK-mediated phosphorylation; when associated with A-722.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes AMPK-mediated phosphorylation; when associated with A-792.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes AMPK-mediated phosphorylation.	SEQ_UP	2	
MUTAGEN:S->A: Abolishes autocatalytic cleavage.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes autoproteolysis. No effect on inhibition of adenylate cyclase activity.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes catalytic activity.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes CoA-binding. No effect on transcriptional repressor activity.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes enzymatic activity.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes enzyme activity.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes enzyme activity. Unable to mediate serine depalmitoleoylation of WNT proteins.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes in vitro phosphorylation by CaMK2; when associated with A-154; A-649 and A-651.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes in vitro phosphorylation by CaMK2; when associated with A-154; A-649 and A-683.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes in vitro phosphorylation by CaMK2; when associated with A-154; A-651 and A-683.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes in vitro phosphorylation by CaMK2; when associated with A-649; A-651 and A-683.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes in vitro phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes incorporation of beta-alanine.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes inhibitory effect on FAS-mediated apoptosis. Does not change effect on TNFRSF1A-mediated apoptosis.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes insulin-induced phosphorylation when associated with A-463. Nuclear location but transcriptional activity decreased by about 50%. Abolishes the SIRT1 deacetylase binding and increases acetylation; when associated with A-24; A-316; A-462 and A-463.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes insulin-stimulated translation, abrogates tumorigenesis.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes interaction with 14-3-3 proteins.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes interaction with FBXW11. Prevents interalization from the cell membrane and lysosomal degradation.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes interaction with SHANK1 and SHANK2.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes localization to the nucleus and enhances localization to the mitochondrion. Reduces stalled replication fork restart. Abolishes ATR-mediated phosphorylation of S-151. No effect on phosphorylation and activation of ATR. No effect on localization to centrosomes or centrosome integrity.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes lysophospholipase activity.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes metal-binding and ability to regulate calcium current.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes mitotic phosphorylation and decreases mitotic index as well as CDK1 activity; when associated with A-574; A-643; A-656; A-664; A-686 and A-699.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes mitotic phosphorylation and decreases mitotic index as well as CDK1 activity; when associated with A-574; A-643; A-656; A-664; A-686 and A-760.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes mitotic phosphorylation and decreases mitotic index as well as CDK1 activity; when associated with A-574; A-643; A-656; A-686; A-699 and A-760.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes mitotic phosphorylation and decreases mitotic index as well as CDK1 activity; when associated with A-574; A-643; A-664; A-686; A-699 and A-760.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes mitotic phosphorylation and decreases mitotic index as well as CDK1 activity; when associated with A-574; A-656; A-664; A-686; A-699 and A-760.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes one phosphorylation site. Decreases phosphorylation by PKA.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes palmitoleoylation, promoting formation of disulfide bonds and oligomerization.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphoralation.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation and impairs ability to maintain meiotic arrest in oocytes during the germinal vesicle (GV) stage and metaphase II exit during egg activation.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation and prevents activation of caspase-1 and pyroptosis in response to S.typhimurium.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation and prevents phosphorylation of S-77.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation by AKT.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation by CAMK2A. Loss of transcriptional activity.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation by CDK16.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation by CDK5. Impairs normal denrite development.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation by CK2.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation by GSK3B. Reduces phosphorylation by MAPK. Affects polarized cell migration. Increases RhoGAP catalytic activity.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation by GSK3B. Reduces phosphorylation by MAPK. No effect on polarized cell migration.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation by MAPKAPK5 and impairs GTP-binding.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation by PKA and impairs nuclear export following ACTH treatment.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation by PKA.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation by PKA. No change in protein levels. Loss of protein stability on PKA stimulation mediated repression. No change in interaction with HDAC4 in response to PKA; when associated with A-121.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation by PKA. No change in protein levels. Loss of protein stability on PKA stimulation. Loss of PKA-mediated repression. No change in interaction with HDAC4 in response to PKA; when associated with A-190.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation by PKA. No effect on ability to bind DNA nor on transactivation activity.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation by PKC and impairs Golgi targeting; no effect on phospholipid transfer activity.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation by SIK1 and fails to promote beta-catenin expression; when associated with A-250.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation by SIK1 and fails to promote beta-catenin expression; when associated with A-488.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation in response to insulin but has no effect on cellular location.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation, abolishes CD44 splicing regulation; when associated with A-71 and A-84.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation, no effect on DNA binding nor on pericentromeric location. Loss of DNA binding and pericentromeric location; when associated with A-140 and A-167.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation, no effect on DNA binding nor on pericentromeric location. Loss of DNA binding and pericentromeric location; when associated with A-140 and A-195.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation.	SEQ_UP	2	
MUTAGEN:S->A: Abolishes phosphorylation. No change in binding to gamma satellites A and B. No change in pericentromeric location. Increased DNA binding affinity toward TDT.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation. No change in pericentromeric location.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes phosphorylation. No effect on the interaction with GYG1. Does not affect the result of other mutations; when associated with A-135; R-135; R-141; A-239; A-243; or R-243.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes PKA-mediated phosphorylation. No enhanced calcium release. Abolishes PKA-mediated phosphorylation: When associated with A-990; A-1190; A-1351 and A-1581.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes protease activity.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes protease activity. No inhibition of BMP4-mediated signaling.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes regulation of neuronal A-type current in response to activation of metabotropic glutamate receptors.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes secretion.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes stimulation of interferon production; when associated with A-199.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes stimulatory effect of Ras.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes the interaction with YWHAE and leads to accumulation in the nucleus.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes ubiquitination; largely impairs proteasomal degradation; results in overproduction of IL-6 upon overexpression; in association with A-253 and A-433.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes ubiquitination; largely impairs proteasomal degradation; results in overproduction of IL-6 upon overexpression; in association with A-253 and A-458.	SEQ_UP	1	
MUTAGEN:S->A: Abolishes ubiquitination; largely impairs proteasomal degradation; results in overproduction of IL-6 upon overexpression; in association with A-433 and A-458.	SEQ_UP	1	
MUTAGEN:S->A: Absence of phosphorylation. Inhibits interaction with DHX9. Does not affect DNA-binding affinity or subcellular localization. Inhibits strongly transcriptional activation.	SEQ_UP	1	
MUTAGEN:S->A: Absence of phosphorylation. Reduced protein degradation. Reduced self-renewal ability in ES cells. No change in FBXW4 binding. Loss of FBXW8 binding.	SEQ_UP	1	
MUTAGEN:S->A: Affects phosphorylation by PKG.	SEQ_UP	1	
MUTAGEN:S->A: Almost complete loss of transcriptional activation; when associated with A-437.	SEQ_UP	1	
MUTAGEN:S->A: Almost complete loss of transcriptional activation; when associated with A-438.	SEQ_UP	1	
MUTAGEN:S->A: Almost loss of glycerophosphocholine cholinephosphodiesterase activity. Loss of choline metabolism.	SEQ_UP	1	
MUTAGEN:S->A: Almost no effect on transcriptional activation in response to viral infection.	SEQ_UP	1	
MUTAGEN:S->A: Alters chloride anion transport behavior.	SEQ_UP	1	
MUTAGEN:S->A: Attenuates light-induced phase shifts of locomotion and expression of c-Fos and mPer1 in the SCN.	SEQ_UP	1	
MUTAGEN:S->A: Complete loss of MAPK-mediated phosphorylation; when associated with A-148 and A-183. In neurons, induces the generation of large, flat lamellipodial protrusions; when associated with A-148 and A-183.	SEQ_UP	1	
MUTAGEN:S->A: Complete loss of phosphorylation by MAPKAPK2, partial loss of phosphorylation by PKA, no effect on phosphorylation by PKC and CaMK2.	SEQ_UP	1	
MUTAGEN:S->A: Complete loss of phosphorylation. Complete loss of phosphorylation and defective autophagic function; when associated with Ala-94.	SEQ_UP	1	
MUTAGEN:S->A: Constitutive targeting to the plasma membrane; when associated with A-297.	SEQ_UP	1	
MUTAGEN:S->A: Constitutive targeting to the plasma membrane; when associated with A-392.	SEQ_UP	1	
MUTAGEN:S->A: Constitutively active.	SEQ_UP	1	
MUTAGEN:S->A: Deacetylase-dead mutant. No effect on its interaction with ARNTL/BMAL1, CRY1 and FBXL3 or its ability to regulate the circadian clock.	SEQ_UP	1	
MUTAGEN:S->A: Decrease in cGAMP-binding.	SEQ_UP	1	
MUTAGEN:S->A: Decreased ability to promote PGE2-EP4-mediated inhibition of inflammation; when associated with A-108.	SEQ_UP	1	
MUTAGEN:S->A: Decreased ability to promote PGE2-EP4-mediated inhibition of inflammation; when associated with A-608.	SEQ_UP	1	
MUTAGEN:S->A: Decreased cyclic GMP-AMP synthase activity.	SEQ_UP	1	
MUTAGEN:S->A: Decreased gymnosis and RNA and DNA uptake by lysosomes and degradation. Decreased affinity for 700-bp RNA. No effect on lysosomal subcellular location, nor on LAMP2-binding.	SEQ_UP	1	
MUTAGEN:S->A: Decreased L-threonine 3-dehydrogenase activity.	SEQ_UP	1	
MUTAGEN:S->A: Decreased level of phosphorylation. Loss of phosphorylation; when associated with A-94.	SEQ_UP	1	
MUTAGEN:S->A: Decreased levels of global dipeptidyl peptidase activity. Homozygous pups are born at the expected Mendelian rate and display no obvious morphological defects, but none survive to weaning. Homozygous pups display suckling defects and survive only when fed manually. The suckling defects are probably due to increased apoptosis of migratory tongue muscle progenitor cells, leading to defects in the development of intrinsic muscles in the distal tongue and decreased tongue size.	SEQ_UP	1	
MUTAGEN:S->A: Decreased permeability to chloride ions.	SEQ_UP	1	
MUTAGEN:S->A: Decreased phosphorylation levels.	SEQ_UP	1	
MUTAGEN:S->A: Decreased phosphorylation; does not affect the phospholipid scramblase activity.	SEQ_UP	1	
MUTAGEN:S->A: Decreased phosphorylation; when associated with A-48.	SEQ_UP	1	
MUTAGEN:S->A: Decreased phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: Decreased phosphorylation. No change in subcellular localization in non-stress conditions. No change in nuclear accumulation in response to DNA damage. Impaired stability in response to DNA damage.	SEQ_UP	1	
MUTAGEN:S->A: Decreased transcriptional activation.	SEQ_UP	1	
MUTAGEN:S->A: Decreased transmembrane ascorbate ferrireductase activity. Approximately 50% reduction in enzyme activity.	SEQ_UP	1	
MUTAGEN:S->A: Decreases abundance and increases disorganization of zygotic subcortical F-actin, disrupts centralization of the mitotic spindle and leads to asymmetric two-cell embryos.	SEQ_UP	1	
MUTAGEN:S->A: Decreases acetylation by SPHK1.	SEQ_UP	1	
MUTAGEN:S->A: Decreases association with PTPN11.	SEQ_UP	1	
MUTAGEN:S->A: Decreases CDE RNA-binding.	SEQ_UP	1	
MUTAGEN:S->A: Decreases insulin-induced phosphorylation by approximately 30%. Abolishes the SIRT1 deacetylase binding and increases acetylation; when associated with A-24; A-253; A-462 and A-463.	SEQ_UP	1	
MUTAGEN:S->A: Decreases phosphorylation and increases NF-kappa-B activity.	SEQ_UP	1	
MUTAGEN:S->A: Decreases phosphorylation and no effect on interaction with CDK7. Strongly reduces transcriptional activity.	SEQ_UP	1	
MUTAGEN:S->A: Decreases phosphorylation by NLK; when associated with A-284; A-295; A-326; A-380; A-391; A-399 and A-413.	SEQ_UP	1	
MUTAGEN:S->A: Decreases phosphorylation by NLK; when associated with A-284; A-295; A-326; A-380; A-391; A-399 and A-415.	SEQ_UP	1	
MUTAGEN:S->A: Decreases phosphorylation by NLK; when associated with A-284; A-295; A-326; A-380; A-399; A-413 and A-415.	SEQ_UP	1	
MUTAGEN:S->A: Decreases phosphorylation by NLK; when associated with A-284; A-295; A-326; A-391; A-399; A-413 and A-415.	SEQ_UP	1	
MUTAGEN:S->A: Decreases phosphorylation by NLK; when associated with A-284; A-295; A-380; A-391; A-399; A-413 and A-415.	SEQ_UP	1	
MUTAGEN:S->A: Decreases phosphorylation by NLK; when associated with A-284; A-326; A-380; A-391; A-399; A-413 and A-415.	SEQ_UP	1	
MUTAGEN:S->A: Decreases phosphorylation by NLK; when associated with A-295; A-326; A-380; A-391; A-399; A-413 and A-415.	SEQ_UP	1	
MUTAGEN:S->A: Decreases phosphorylation by RPS6KA2.	SEQ_UP	1	
MUTAGEN:S->A: Decreases the interaction with AXIN1, GSK3B-mediated beta-catenin phosphorylation, cytoplasmic beta-catenin accumulation and Wnt-mediated transcription activation.	SEQ_UP	1	
MUTAGEN:S->A: Decreases without abolishing O-GlcNAcylation.	SEQ_UP	1	
MUTAGEN:S->A: Diminishes LCFA import and decreases nucleotide binding. No effect on localization to the cell membrane.	SEQ_UP	1	
MUTAGEN:S->A: Diminishes phosphorylation by HIPK1.	SEQ_UP	1	
MUTAGEN:S->A: Disruption of phosphorylation by MAPK and GSK3B, acquisition of DNA-binding activity and transactivation function; when associated with A-179 and A-188.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect acyltransferase activity.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect AMPK-mediated phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect ceramide synthase activity.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect interaction with 14-3-3 proteins.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect interaction with KEAP1. Decreased phosphorylation by MTOR.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect interaction with TRIM6.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect MN9 antibody detectability.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect palmitoleoylation.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect phosphorylation at Ser-391 or the interaction with PPP2CA and PPP2R1A.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect phosphorylation by AMPK in vitro.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect phosphorylation by CK2.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect phosphorylation by PKC/PRKCD.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect phosphorylation by PKG.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect phosphorylation by RPS6KA2.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect phosphorylation by RPS6KA3/RSK2.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect polynucleotide adenylyltransferase activity. Increases cell apoptosis.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect protein cleveage.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect recognition by the CRL2(FEM1B) complex and subsequent ubiquitination.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect secretion.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect subcellular location; when associated with A-497.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect the interaction with GATA1.	SEQ_UP	1	
MUTAGEN:S->A: Does not affect ubiquitination by ZNRF1.	SEQ_UP	1	
MUTAGEN:S->A: Does not bind to SIVA1.	SEQ_UP	1	
MUTAGEN:S->A: Does not detach from actin following BDNF treatment; when associated with A-628.	SEQ_UP	1	
MUTAGEN:S->A: Does not inhibits subcellular localization. Does not affect phosphorylation in response to forskolin.	SEQ_UP	1	
MUTAGEN:S->A: Does not methylates either an unmodified or monomethylated H4K20 substrate. Methylates a di-methylated H4K20 peptide.	SEQ_UP	1	
MUTAGEN:S->A: Does not phosphorylated by MAPK14/p38-alpha-activated MAPKAPK2/MK2. Does not affect localization. Does not affect interaction with ZCCHC8.	SEQ_UP	1	
MUTAGEN:S->A: Does not prevent S-farnesylation. Defects in neuron polarization.	SEQ_UP	1	
MUTAGEN:S->A: Dominant negative form; when associated with V-315.	SEQ_UP	1	
MUTAGEN:S->A: Eliminates MAPK-mediated phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: Enhanced stimulation of interferon production.	SEQ_UP	1	
MUTAGEN:S->A: Enhanced transcriptional activation; Greatly enhanced transcriptional activation; when associated with A-15.	SEQ_UP	1	
MUTAGEN:S->A: Enhanced transcriptional activation; Greatly enhanced transcriptional activation; when associated with A-68.	SEQ_UP	1	
MUTAGEN:S->A: Enhances association with PTPN11.	SEQ_UP	1	
MUTAGEN:S->A: Enhances basal channel activity and abolishes stimulation by calcineurin.	SEQ_UP	1	
MUTAGEN:S->A: Enhances cell cycle arrest.	SEQ_UP	1	
MUTAGEN:S->A: Enhances pro-apoptotic activity; no phosphorylation; interacts with Bcl-X(L).	SEQ_UP	1	
MUTAGEN:S->A: Enhances pro-apoptotic activity; no phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: Enhances pro-apoptotic activity.	SEQ_UP	1	
MUTAGEN:S->A: Enzyme inactivation. Reduces the cleavage of PTCRA and TRAC. Does not inhibit interaction with PTCRA. Stimulates interaction with ubiquitinated proteins.	SEQ_UP	1	
MUTAGEN:S->A: Expected to abolish a phosphorylation site. Decreased channel activity. No effect on phosphorylation at S-1897. Causes heart hypertrophy and decreased exercise tolerance in adult mice.	SEQ_UP	1	
MUTAGEN:S->A: Formation of unusual long bridge-like intermediate filament structures between two daughter cells during cytokinesis; when associated with A-76. Increased formation of unusual long bridge-like intermediate filament structures between two daughter cells during cytokinesis; when associated with A-32 and A-76.	SEQ_UP	1	
MUTAGEN:S->A: Greatly reduced GSK3B-mediated phosphorylation and large effect on the inhibitory activity in Wnt-signaling; when associated with A-480 and A-492.	SEQ_UP	1	
MUTAGEN:S->A: Greatly reduced GSK3B-mediated phosphorylation; when associated with A-480 and A-485.	SEQ_UP	1	
MUTAGEN:S->A: Greatly reduced PKC-stimulated protein stability and activation of RARB reporter.	SEQ_UP	1	
MUTAGEN:S->A: Greatly reduces interaction with 14-3-3 proteins.	SEQ_UP	1	
MUTAGEN:S->A: High transactivation activity.	SEQ_UP	1	
MUTAGEN:S->A: Highly increases transactivation activity; when associated with A-180.	SEQ_UP	1	
MUTAGEN:S->A: Highly increases transactivation activity; when associated with A-181.	SEQ_UP	1	
MUTAGEN:S->A: Impaired ability to form homodimers or oligomers; when associated with A-259.	SEQ_UP	1	
MUTAGEN:S->A: Impaired exonuclease activity without affecting much the DNA-binding activity.	SEQ_UP	1	
MUTAGEN:S->A: Impaired interaction with SQSTM1/p62.	SEQ_UP	1	
MUTAGEN:S->A: Impaired nuclear accumulation, decreased interaction with CLOCK and disruption of circadian clock function.	SEQ_UP	1	
MUTAGEN:S->A: Impaired phosphorylation and decreased acetyltransferase activity, leading to decreased ability to promote homologous recombination (HR)repair in response to DNA double-strand breaks (DSBs).	SEQ_UP	1	
MUTAGEN:S->A: Impaired phosphorylation by MTOR, leading to constitutive nuclear localization.	SEQ_UP	1	
MUTAGEN:S->A: Impairs calcium-dependent biosynthesis of NAPEs and NAEs. Reduces tubule growth and cargo transport from clathrin-independent endosomes.	SEQ_UP	1	
MUTAGEN:S->A: Impairs interaction with RIPK3.	SEQ_UP	1	
MUTAGEN:S->A: Impairs interaction with YWHAB.	SEQ_UP	1	
MUTAGEN:S->A: Impairs phosphorylation by AMPK and ability to promote autophagy; when associated with A-317.	SEQ_UP	1	
MUTAGEN:S->A: Impairs phosphorylation by AMPK and ability to promote autophagy; when associated with A-777.	SEQ_UP	1	
MUTAGEN:S->A: Impairs phosphorylation by MAPKAPK2, decreases its stability and cytoplasmic localization, increases interaction with PPP2CA, inhibits binding to 14-3-3 proteins, but does not impair binding to ARE-containing transcripts, recruitment of mRNA decay factors and ZFP36-mediated deadenylation and decay of ARE-containing transcripts; when associated with A-178.	SEQ_UP	1	
MUTAGEN:S->A: Impairs shuttling to the cytoplasm.	SEQ_UP	1	
MUTAGEN:S->A: Impairs TP53 activation.	SEQ_UP	1	
MUTAGEN:S->A: In 9A mutant; abolished phosphorylation by PRKDC; does not affect ability to repair double-strand breaks (DSBs), possibly because of redundancy with NHEJ1/XLF phosphorylation sites; when associated with A-193, A-254, A-295, A-307, A-312, A-315, A-319 and A-320.	SEQ_UP	1	
MUTAGEN:S->A: In 9A mutant; abolished phosphorylation by PRKDC; does not affect ability to repair double-strand breaks (DSBs), possibly because of redundancy with NHEJ1/XLF phosphorylation sites; when associated with A-53, A-193, A-254, A-295, A-307, A-312, A-315 and A-319.	SEQ_UP	1	
MUTAGEN:S->A: In 9A mutant; abolished phosphorylation by PRKDC; does not affect ability to repair double-strand breaks (DSBs), possibly because of redundancy with NHEJ1/XLF phosphorylation sites; when associated with A-53, A-193, A-254, A-295, A-307, A-312, A-315 and A-320.	SEQ_UP	1	
MUTAGEN:S->A: In 9A mutant; abolished phosphorylation by PRKDC; does not affect ability to repair double-strand breaks (DSBs), possibly because of redundancy with NHEJ1/XLF phosphorylation sites; when associated with A-53, A-193, A-254, A-295, A-307, A-315, A-319 and A-320.	SEQ_UP	1	
MUTAGEN:S->A: In 9A mutant; abolished phosphorylation by PRKDC; does not affect ability to repair double-strand breaks (DSBs), possibly because of redundancy with NHEJ1/XLF phosphorylation sites; when associated with A-53, A-193, A-254, A-295, A-312, A-315, A-319 and A-320.	SEQ_UP	1	
MUTAGEN:S->A: In 9A mutant; abolished phosphorylation by PRKDC; does not affect ability to repair double-strand breaks (DSBs), possibly because of redundancy with NHEJ1/XLF phosphorylation sites; when associated with A-53, A-193, A-254, A-307, A-312, A-315, A-319 and A-320.	SEQ_UP	1	
MUTAGEN:S->A: In 9A mutant; abolished phosphorylation by PRKDC; does not affect ability to repair double-strand breaks (DSBs), possibly because of redundancy with NHEJ1/XLF phosphorylation sites; when associated with A-53, A-193, A-295, A-307, A-312, A-315, A-319 and A-320.	SEQ_UP	1	
MUTAGEN:S->A: In 9A mutant; abolished phosphorylation by PRKDC; does not affect ability to repair double-strand breaks (DSBs), possibly because of redundancy with NHEJ1/XLF phosphorylation sites; when associated with A-53, A-254, A-295, A-307, A-312, A-315, A-319 and A-320.	SEQ_UP	1	
MUTAGEN:S->A: In Ld tail 1S, restores ubiquitination; when associated R-332; I-337; R-340 and A-356.	SEQ_UP	1	
MUTAGEN:S->A: Increase in protein stability, transcriptional activity and the ability to suppress the proliferation of conventional T-cells in vitro; when associated with A-19; A-114 and A-175.	SEQ_UP	1	
MUTAGEN:S->A: Increased degradation by the proteasome and a decrease in isoform 2/deltaFosB transactivation activity.	SEQ_UP	1	
MUTAGEN:S->A: Increased genomic instability and radiosensitivity; when associated with A-137. Reduced homologous recombination. No effect on Lys-40 acetylation. Further increase in radiosensitivity; when associated with R-37.	SEQ_UP	1	
MUTAGEN:S->A: Increased genomic instability and radiosensitivity; when associated with A-140.	SEQ_UP	1	
MUTAGEN:S->A: Increased localization to the plasma membrane.	SEQ_UP	1	
MUTAGEN:S->A: Increases basal and ligand-induced adipogenic activity. Abolishes repression by PER2 on transactivation activity.	SEQ_UP	1	
MUTAGEN:S->A: Increases interaction with AHCYL1; when associated with A-1588.	SEQ_UP	1	
MUTAGEN:S->A: Increases interaction with AHCYL1; when associated with A-1755.	SEQ_UP	1	
MUTAGEN:S->A: Induces a decrease in phosphorylation by TBK1, leading to reduced ability to activate IRF3.	SEQ_UP	1	
MUTAGEN:S->A: Induces centriole elongation. Impaired IFT88 recruitment. Impaired ciliogenesis.	SEQ_UP	1	
MUTAGEN:S->A: Inhibition of phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: Inhibition on transcriptional activation on CD13 proximal promoter in endothelial cells.	SEQ_UP	1	
MUTAGEN:S->A: Inhibits interaction with SFN.	SEQ_UP	1	
MUTAGEN:S->A: Inhibits its transcriptional activity; when associated with A-217.	SEQ_UP	1	
MUTAGEN:S->A: Inhibits its transcriptional activity; when associated with A-34.	SEQ_UP	1	
MUTAGEN:S->A: Leads to mitochondrial depolarization.	SEQ_UP	1	
MUTAGEN:S->A: Less efficiently phosphorylated in vitro.	SEQ_UP	1	
MUTAGEN:S->A: Little effect on PKC-stimulated protein stability nor on activation of RARB reporter.	SEQ_UP	1	
MUTAGEN:S->A: Localized at the cell surface, inhibits gelatinase and dipeptidyl peptidase activities and stimulates tumor suppression activity.	SEQ_UP	1	
MUTAGEN:S->A: Loss of 14-3-3 protein-binding.	SEQ_UP	1	
MUTAGEN:S->A: Loss of activity and phosphorylation. Unable to rescue aberrant mitochondrial fission in PINK1 null mutant neurons.	SEQ_UP	1	
MUTAGEN:S->A: Loss of activity. No effect on DNA-binding capacity.	SEQ_UP	1	
MUTAGEN:S->A: Loss of autocatalytic cleavage within the FIIND region, abolishing the ability to activate the inflammasome. Abolished interaction with DPP9. No effect on cleavage by LT.	SEQ_UP	1	
MUTAGEN:S->A: Loss of basal kinase activity and phorbol ester-stimulated kinase activity; when associated with A-744.	SEQ_UP	1	
MUTAGEN:S->A: Loss of basal kinase activity and phorbol ester-stimulated kinase activity; when associated with A-748.	SEQ_UP	1	
MUTAGEN:S->A: Loss of calpain/Cdk5-mediated neuron apoptosis.	SEQ_UP	1	
MUTAGEN:S->A: Loss of cardiac myofibril assembly; when associated with A-14 and A-15. Loss of phosphorylation; when associated with A-14 and A-15. Loss of calcium sensitivity of force development; when associated with A-14 and A-15.	SEQ_UP	1	
MUTAGEN:S->A: Loss of cardiac myofibril assembly; when associated with A-14 and A-19. Loss of phosphorylation; when associated with A-14 and A-19. Loss of calcium sensitivity of force development; when associated with A-14 and A-19. Increase of phosphorylation. Phosphorylation at Ser-14 and at Ser-19. Phosphorylation at Ser-19; when associated with A-14. Significant decrease in phosphorylation by MLCK; when associated with A-14. Adult lethality associated with early defects in cardiac twitch relaxation and torsion leading to dilated cardiomyopathy, heart failure and premature death; when associated with A-14. Significant acceleration of twitch relaxation in absence of changes in calcium transients; when associated with A-14. Absence of transmural phosphorylation gradient leading to alteration of torsion; when associated with A-14.	SEQ_UP	1	
MUTAGEN:S->A: Loss of cardiac myofibril assembly; when associated with A-15 and A-19. Loss of phosphorylation; when associated with A-15 and A-19. Loss of calcium sensitivity of force development; when associated with A-15 and A-19. Phosphorylation at Ser-19; when associated with A-15. Significant decrease in phosphorylation by MLCK; when associated with A-15. Adult lethality associated with early defects in cardiac twitch relaxation and torsion leading to dilated cardiomyopathy, heart failure and premature death; when associated with A-15.Significant acceleration of twitch relaxation in absence of changes in calcium transients; when associated with A-15. Absence of transmural phosphorylation gradient leading to alteration of torsion; when associated with A-14.	SEQ_UP	1	
MUTAGEN:S->A: Loss of catalytic activity.	SEQ_UP	2	
MUTAGEN:S->A: Loss of catalytic activity. No effect on the redistribution of AP-1 from the membrane to the cytoplasm.	SEQ_UP	1	
MUTAGEN:S->A: Loss of CDK1-mediated phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: Loss of constituitive phosphorylation. No effect on RXRA transcriptional activity.	SEQ_UP	1	
MUTAGEN:S->A: Loss of enzymatic activity. No effect on BMP4-binding.	SEQ_UP	1	
MUTAGEN:S->A: Loss of enzyme activity.	SEQ_UP	1	
MUTAGEN:S->A: Loss of function in translation inhibition. Loss of interaction with SLC27A1. Mutant mice have no apparent developmental defect but display reduced adiposity associated with decreased insulin levels and adipocytes size. They also display increased lipolysis and fatty acid beta-oxidation and an extended lifespan. Adipocytes display decreased insulin-stimulated long-chain fatty acid uptake.	SEQ_UP	1	
MUTAGEN:S->A: Loss of glycosaminoglycan chains; when associated with A-533.	SEQ_UP	1	
MUTAGEN:S->A: Loss of glycosaminoglycan chains; when associated with A-544.	SEQ_UP	1	
MUTAGEN:S->A: Loss of glycosylation.	SEQ_UP	1	
MUTAGEN:S->A: Loss of glycosylation. No effect on osteoblast mineralization. Loss of glycosylation; when associated with A-43; A-54; A-60 AND A-67.	SEQ_UP	1	
MUTAGEN:S->A: Loss of interaction with CACNB2. QT prolongation and ventricular arrhythmias, caused by the augmentation of L-type Ca(2+) channels in the heart.	SEQ_UP	1	
MUTAGEN:S->A: Loss of interaction with DLG4; when associated with A-832 and A-834.	SEQ_UP	1	
MUTAGEN:S->A: Loss of interaction with FBXW7.	SEQ_UP	1	
MUTAGEN:S->A: Loss of interaction with UBQLN1; when associated with A-176.	SEQ_UP	1	
MUTAGEN:S->A: Loss of interaction with UBQLN1; when associated with A-863 and A-865.	SEQ_UP	1	
MUTAGEN:S->A: Loss of interaction with YWHAB and defects in the completion of cytokinesis.	SEQ_UP	1	
MUTAGEN:S->A: Loss of interaction with YWHAH.	SEQ_UP	1	
MUTAGEN:S->A: Loss of interferon-gamma induced phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: Loss of MAPK8-mediated phosphorylation and no protein degradation.	SEQ_UP	1	
MUTAGEN:S->A: Loss of nucleophilicity of Ser-294.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phospholipase activity, but no effect on lysophosphatidylcholine acyltransferase activity.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phospholipase activity.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation at S-203; decreased nuclear localization in non-stress conditions; loss of nuclear accumulation and stability in response to DNA damage. No change in subcellular localization in non-stress conditions; when associated with 13-L--Y-24. No change in protein accumulation and stability in response to DNA damage; when associated with 13-L--Y-24.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation at Ser-332 and Ser-334; when associated with A-321; A-332 and A-334.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation at Ser-332 and Ser-334; when associated with A-321; A-332 and A-336.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation at Ser-332 and Ser-334; when associated with A-321; A-334 and A-336.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation but no loss of autophagic function; when associated with A-163.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation but no significant effect on channel activity.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation by GSK3-beta. Decreased interaction with GDI2.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation by PDPK1; loss of activation by PDPK1 and EGF.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation by PKA, constitutive MAPK binding.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation by PKA. Reduces long-term potentiation in mossy-fiber synapses in the hippocampus but has no effect on short-term potentiation. Inhibits the effect of forskolin on synaptic transmission and inhibitory post-synaptic currents. No effect on excitatory and inhibitory synaptic transmission in the hippocampus. No effect on brain structure.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation by PKG (in vitro). No effect on location at cell membrane.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation by PLK1. Increased interaction with PCM1.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation by RPS6KA4 and RPS6KA5.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation in G(0) phase. No change in cMYC-induced CDK2-mediated phosphorylation. Rapid dissociation from the cyclin E/CDK2 complex after induction by cMYC. Loss of protein stability in G(0) phase. No change in protein stability at S-phase.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation of the chymotryptic peptide.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation site. Abolishes increased vasoconstriction in response to elevated blood glucose.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation site. Reduces global phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation site. Strongly reduced interaction with YWHAG and YWHAB.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation; No inhibition of activity and constitutively active.	SEQ_UP	2	
MUTAGEN:S->A: Loss of phosphorylation.	SEQ_UP	4	
MUTAGEN:S->A: Loss of phosphorylation. Does not protect cells from TNF-induced cell death.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation. Increase in protein stability, transcriptional activity and the ability to suppress the proliferation of conventional T-cells in vitro; when associated with A-88; A-114 and A-175.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation. Loss of nuclear localization.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation. Promotes activation of its kinase activity, proteolytic cleavage, ubiquitination and interaction with FADD to mediate apoptosis. Loss of phosphorylation at Ser-332 and Ser-334; when associated with A-332; A-334 and A-336.	SEQ_UP	1	
MUTAGEN:S->A: Loss of phosphorylation. Unable to suppress apoptosis.	SEQ_UP	1	
MUTAGEN:S->A: Loss of polynucleotide adenylyltransferase activity.	SEQ_UP	1	
MUTAGEN:S->A: Loss of protease activity.	SEQ_UP	2	
MUTAGEN:S->A: Loss of protein phosphorylation at Y-329 and Y-334; when associated with A-269.	SEQ_UP	1	
MUTAGEN:S->A: Loss of S-adenosyl-L-methionine binding. Loss of protein methyltransferase activity. Localized in the nucleus.	SEQ_UP	1	
MUTAGEN:S->A: Loss of the effect on myogenic differentiation; when associated with A-834. Loss of interaction with DLG4; when associated with A-833 and A-834.	SEQ_UP	1	
MUTAGEN:S->A: Loss of the lipid hydrolase activity.	SEQ_UP	1	
MUTAGEN:S->A: Loss of triacylglycerol hydrolysis activity.	SEQ_UP	1	
MUTAGEN:S->A: Loss of TRIM2-binding; when associated with A-55 and A-65.	SEQ_UP	1	
MUTAGEN:S->A: Loss of TRIM2-binding; when associated with A-55 and A-73.	SEQ_UP	1	
MUTAGEN:S->A: Loss of TRIM2-binding; when associated with A-65 and A-73.	SEQ_UP	1	
MUTAGEN:S->A: Loss of YWHAZ binding with increased nuclear localization. Partial recovery of nuclear accumulation; when associated with deletion of 392-L--L-395.	SEQ_UP	1	
MUTAGEN:S->A: No addition of glycosaminoglycan; no effect on the synthesis of the protein.	SEQ_UP	1	
MUTAGEN:S->A: No change in kinase activity; when associated with A-31; A-336 and A-366.	SEQ_UP	1	
MUTAGEN:S->A: No change in kinase activity; when associated with A-325; A-336 and A-366.	SEQ_UP	1	
MUTAGEN:S->A: No change in pericentromeric location. Greatly reduced phosphorylation; when associated with A-384; A-386; A-388; A392 and A-393. No effect on DNA-binding activity. Increased DNA-binding activity; when associated with A-384; A-386; A-388; A-392 and A-393.	SEQ_UP	1	
MUTAGEN:S->A: No change in phosphorylation levels and no effect on transcriptional activity.	SEQ_UP	1	
MUTAGEN:S->A: No change in subcellular location nor colocalization with vinculin at focal adhesions nor with N-WASP at the leading edge. Loss of cell mobility function; when associated with A-637.	SEQ_UP	1	
MUTAGEN:S->A: No change in subcellular location nor colocalization with vinculin at focal adhesions nor with N-WASP at the leading edge. No loss of cell mobility function. when associated with A-255.	SEQ_UP	1	
MUTAGEN:S->A: No change of phosphorylation by Rho-kinase.	SEQ_UP	1	
MUTAGEN:S->A: No changes in channel activity.	SEQ_UP	1	
MUTAGEN:S->A: No chondroitin sulfate attachment. no effect on transport to the cell surface.	SEQ_UP	1	
MUTAGEN:S->A: No effect on ACHE tetramer recruitment to membrane rafts; when associated with 138-A--A-142.	SEQ_UP	1	
MUTAGEN:S->A: No effect on activity.	SEQ_UP	1	
MUTAGEN:S->A: No effect on association with the proteasome complex; when associated with A-163 and A-173.	SEQ_UP	1	
MUTAGEN:S->A: No effect on association with the proteasome complex; when associated with A-163 and A-187.	SEQ_UP	1	
MUTAGEN:S->A: No effect on association with the proteasome complex; when associated with A-173 and A-187.	SEQ_UP	1	
MUTAGEN:S->A: No effect on basal activity, but abolishes ionizing radiation-induced activation.	SEQ_UP	1	
MUTAGEN:S->A: No effect on binding to YWHAZ.	SEQ_UP	1	
MUTAGEN:S->A: No effect on cell aggregation or E-cadherin/catenin complex assembly. Decreases strength of cell-cell adhesion.	SEQ_UP	1	
MUTAGEN:S->A: No effect on chondroitin sulfate attachment.	SEQ_UP	1	
MUTAGEN:S->A: No effect on circadian period length and protein stability.	SEQ_UP	1	
MUTAGEN:S->A: No effect on constituitive phosphorylation, decreased stress-induced phosphorylation but no effect on RXRA transcriptional activity. Abolishes stress-induced phosphorylation but no effect on RXRA transcriptional activity; when associated with A-61 and A-87.	SEQ_UP	1	
MUTAGEN:S->A: No effect on constituitive phosphorylation, decreased stress-induced phosphorylation but no effect on RXRA transcriptional activity. Abolishes stress-induced phosphorylation but no effect on RXRA transcriptional activity; when associated with A-75 and A-87. No effect on RXRA transcriptional activity.	SEQ_UP	1	
MUTAGEN:S->A: No effect on constituitive phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: No effect on constiuitive phosphorylation but loss of stress-induced phosphorylation. No effect on RXRA transcriptional activity.	SEQ_UP	1	
MUTAGEN:S->A: No effect on DNA-binding. Loss of interaction with CDK2 and CDK4 as well as cell cycle inhibition.	SEQ_UP	1	
MUTAGEN:S->A: No effect on early endosome localization and reduced JNK1 activation; when associated with A-288.	SEQ_UP	1	
MUTAGEN:S->A: No effect on IL1B release under basal conditions, nor in response to LT or metabolic inhibitors.	SEQ_UP	1	
MUTAGEN:S->A: No effect on in vitro phosphorylation by PKC.	SEQ_UP	1	
MUTAGEN:S->A: No effect on interaction with 14-3-3 proteins.	SEQ_UP	1	
MUTAGEN:S->A: No effect on interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:S->A: No effect on interaction with TACC3.	SEQ_UP	1	
MUTAGEN:S->A: No effect on interaction with TLR4.	SEQ_UP	1	
MUTAGEN:S->A: No effect on its interaction with NEK7.	SEQ_UP	1	
MUTAGEN:S->A: No effect on localization to the plasma membrane. No effect on binding and activation by DLL1. Decreased localization to the plasma membrane; when associated with V-311.	SEQ_UP	1	
MUTAGEN:S->A: No effect on LPC transport.	SEQ_UP	1	
MUTAGEN:S->A: No effect on MAPK1/3 (ERK1/2) phosphorylation in response to IL18, with or without IL12. Substantial reduction in MAPK1/3 (ERK1/2) phosphorylation in response to IL18, with or without IL12; when associated with A-53 and A-58.	SEQ_UP	1	
MUTAGEN:S->A: No effect on O-glycosylation by POGLUT1. Loss of O-xylosylation.	SEQ_UP	1	
MUTAGEN:S->A: No effect on overall phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: No effect on overall phosphorylation. Reduces overall phosphorylation by 36%; when associated with A-332.	SEQ_UP	1	
MUTAGEN:S->A: No effect on overall phosphorylation. Reduces overall phosphorylation by 36%; when associated with A-339.	SEQ_UP	1	
MUTAGEN:S->A: No effect on PDGF-stimulated enhancement of transcriptional activity. Completely abolishes PDGF-stimulated enhancement of transcriptional activity; when associated with A-232; A-325 and A-331.	SEQ_UP	1	
MUTAGEN:S->A: No effect on pericentromeric heterochromatin location. No change in DNA binding.	SEQ_UP	1	
MUTAGEN:S->A: No effect on phosphorylation by HIPK1.	SEQ_UP	1	
MUTAGEN:S->A: No effect on phosphorylation by PKC, PKA, MAPKAPK2 and CaMK2.	SEQ_UP	1	
MUTAGEN:S->A: No effect on phosphorylation by PKC; abolishes phospholipid transfer activity.	SEQ_UP	1	
MUTAGEN:S->A: No effect on phosphorylation, no effect on transcriptional activity.	SEQ_UP	1	
MUTAGEN:S->A: No effect on phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: No effect on phosphorylation. Little effect on inhibitory activity on Wnt-signaling.	SEQ_UP	1	
MUTAGEN:S->A: No effect on PKA-mediated phosphorylation. Abolishes PKA-mediated phosphorylation: When associated with A-937; A-1190; A-1351 and A-1581.	SEQ_UP	1	
MUTAGEN:S->A: No effect on PKA-mediated phosphorylation. Abolishes PKA-mediated phosphorylation: When associated with A-937; A-990; A-1190 and A-1351.	SEQ_UP	1	
MUTAGEN:S->A: No effect on PKA-mediated phosphorylation. Abolishes PKA-mediated phosphorylation: When associated with A-937; A-990; A-1190 and A-1581.	SEQ_UP	1	
MUTAGEN:S->A: No effect on PKA-mediated phosphorylation. Abolishes PKA-mediated phosphorylation: When associated with A-937; A-990; A-1351 and A-1581.	SEQ_UP	1	
MUTAGEN:S->A: No effect on PKA-mediated phosphorylation. Enhanced calcium release on PKA activation.	SEQ_UP	1	
MUTAGEN:S->A: No effect on SRF activation; No effect on SRF activation, on interaction with EP300 and on SM-promoter activation; when associated with A-812; A-859 and A-893.	SEQ_UP	1	
MUTAGEN:S->A: No effect on SRF activation; No effect on SRF activation. No effect on SRF activation, on interaction with EP300 and on SM-promoter activation; when associated with A-812, A-866 and A-893.	SEQ_UP	1	
MUTAGEN:S->A: No effect on SRF activation. No effect on SRF activation, on interaction with EP300 and on SM-promoter activation; when associated with A-859; A-866 and A-893.	SEQ_UP	1	
MUTAGEN:S->A: No effect on stability, nuclear localization or inhibitory function in TGFB signaling. Abolishes transcriptional activity.	SEQ_UP	1	
MUTAGEN:S->A: No effect on subcellular localization.	SEQ_UP	1	
MUTAGEN:S->A: No effect on sumoylation and little effect on binding KAT2B. Some reduced DNA-binding. Greatly reduced DNA-binding, binding to KAT2B and activation of the RARB promoter; when associated with A-170.	SEQ_UP	1	
MUTAGEN:S->A: No effect on sumoylation nor on DNA-binding and little effect on binding KAT2B. Greatly reduced DNA-binding, binding to KAT2B and activation of the RARB promoter; when associated with A-185.	SEQ_UP	1	
MUTAGEN:S->A: No effect on sumoylation; when associated with 6-A--A-9; A-237; A-243 and A-320.	SEQ_UP	1	
MUTAGEN:S->A: No effect on sumoylation; when associated with 6-A--A-9; A-237; A-243 and A-521.	SEQ_UP	1	
MUTAGEN:S->A: No effect on sumoylation; when associated with 6-A--A-9; A-237; A-320 and A-521.	SEQ_UP	1	
MUTAGEN:S->A: No effect on sumoylation; when associated with 6-A--A-9; A-243; A-320 and A-521.	SEQ_UP	1	
MUTAGEN:S->A: No effect on sumoylation.	SEQ_UP	1	
MUTAGEN:S->A: No effect on TP53 activation.	SEQ_UP	1	
MUTAGEN:S->A: No effect on transcriptional activation on CD13 proximal promoter. Increases liver specific transactivation on the IL-4 promoter.	SEQ_UP	1	
MUTAGEN:S->A: No effect on transcriptional activation.	SEQ_UP	1	
MUTAGEN:S->A: No effect on transmembrane ascorbate ferrireductase activity.	SEQ_UP	1	
MUTAGEN:S->A: No effect.	SEQ_UP	4	
MUTAGEN:S->A: No IGF1-induced increase in cytoplasmic localization. Increased transactivation activity.	SEQ_UP	1	
MUTAGEN:S->A: No impact on interaction with EIF4A.	SEQ_UP	1	
MUTAGEN:S->A: No loss in its ability to induce IFN-gamma. Significant reduction in its ability to induce IFN-gamma and reduced ability to promote addition of permissive chromatin-remodeling mark H3K4Me2 to the IFNG promoter region; when associated with A-52 and A-76.	SEQ_UP	1	
MUTAGEN:S->A: No loss in its ability to induce IFN-gamma. Significant reduction in its ability to induce IFN-gamma and reduced ability to promote addition of permissive chromatin-remodeling mark H3K4Me2 to the IFNG promoter region; when associated with A-76 and A-224.	SEQ_UP	1	
MUTAGEN:S->A: No loss of glycosylation. Loss of glycosylation; when associated with A-36; A-54; A-60 AND A-67.	SEQ_UP	1	
MUTAGEN:S->A: No loss of interaction with RUNX1. No loss in its ability to induce IFN-gamma.	SEQ_UP	1	
MUTAGEN:S->A: No loss of MAPK8-mediated phosphorylation and no effect on ligase activity. Almost complete inactivation of ligase activity; when associated with A-199. Greatly reduced MAPK8-mediated phosphorylation; when associated with A-199 or A-222. Completely abolishes MAPK8-mediated phosphorylation; when associated with A-199 and A-222.	SEQ_UP	1	
MUTAGEN:S->A: No loss of MAPK8-mediated phosphorylation and no effect on ligase activity. Almost complete inactivation of ligase activity; when associated with A-232. Greatly reduced MAPK8-mediated phosphorylation; when associated with A-222 or A-232. Completely abolishes MAPK8-mediated phosphorylation; when associated with A-222 and A-232.	SEQ_UP	1	
MUTAGEN:S->A: No loss of the stimulatory effect of Ras.	SEQ_UP	1	
MUTAGEN:S->A: No phosphorylation by AMPK, reduced fatty acid oxidation in skeletal muscle, increased lipid deposition in skeletal muscle, and development of insulin resistance.	SEQ_UP	1	
MUTAGEN:S->A: No phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: Normal erythrocyte and platelet numbers; when associated with A-2026 and 2050-A--A-2053.	SEQ_UP	1	
MUTAGEN:S->A: Normal erythrocyte and platelet numbers; when associated with A-2038 and 2050-A--A-2053.	SEQ_UP	1	
MUTAGEN:S->A: Normal MAPK3/ERK1 and MAPK1/ER2K-binding.	SEQ_UP	1	
MUTAGEN:S->A: Not phosphorylated; when associated with V-638 and A-693. Not phosphorylated and doesn't prevent phosphorylation at T-638 and S-693, Reduces NOTCH1 transactivation; when associated with V-638 and A-693. Reduces cell surface levels of proteins; when associated with V-638 and A-693. Increases ectodomain shedding; when associated with V-638 and A-693.	SEQ_UP	1	
MUTAGEN:S->A: Not phosphorylated; when associated with V-638 and A-696. Not phosphorylated and prevents phosphorylation at S-696. Reduces NOTCH1 transactivation; when associated with V-638 and A-696. Reduces cell surface levels of proteins; when associated with V-638 and A-696. Increases ectodomain shedding; when associated with V-638 and A-696.	SEQ_UP	1	
MUTAGEN:S->A: Not secreted and loss of EPO binding.	SEQ_UP	1	
MUTAGEN:S->A: Partial loss of phosphorylation. Complete loss of phosphorylation and defective autophagic function; when associated with Ala-91.	SEQ_UP	1	
MUTAGEN:S->A: Partial loss of transcription repression. No change in nuclear location.	SEQ_UP	1	
MUTAGEN:S->A: Phosphomimetic mutant that leads to stabilization of the protein; when associated with A-280.	SEQ_UP	1	
MUTAGEN:S->A: Phosphomimetic mutant that leads to stabilization of the protein; when associated with A-71.	SEQ_UP	1	
MUTAGEN:S->A: Poorly phosphorylated.	SEQ_UP	1	
MUTAGEN:S->A: Prevents autocatalytic cleavage and generation of Myelin regulatory factor, N-terminal part.	SEQ_UP	1	
MUTAGEN:S->A: Promotes stabilization due to impaired ubiquitination; when associated with A-212; A-223; A-230 and A-234. Does not affect phosphorylation by RPS6KA3/RSK2.	SEQ_UP	1	
MUTAGEN:S->A: Promotes stabilization due to impaired ubiquitination; when associated with A-212; A-223; A-230 and A-247.	SEQ_UP	1	
MUTAGEN:S->A: Promotes stabilization due to impaired ubiquitination; when associated with A-212; A-223; A-234 and A-247.	SEQ_UP	1	
MUTAGEN:S->A: Promotes stabilization due to impaired ubiquitination; when associated with A-212; A-230; A-234 and A-247.	SEQ_UP	1	
MUTAGEN:S->A: Promotes stabilization due to impaired ubiquitination.	SEQ_UP	1	
MUTAGEN:S->A: Protease-dead.	SEQ_UP	1	
MUTAGEN:S->A: Protects against tachycardia and subsequent death due to heart failure.	SEQ_UP	1	
MUTAGEN:S->A: Reduced activity.	SEQ_UP	1	
MUTAGEN:S->A: Reduced CDK5-mediated phosphorylation. Loss of CDK5-mediated phosphorylation; when associated with T-232.	SEQ_UP	1	
MUTAGEN:S->A: Reduced DNA binding activity.	SEQ_UP	1	
MUTAGEN:S->A: Reduced homodimerization and subsequent activation.	SEQ_UP	1	
MUTAGEN:S->A: Reduced in vitro MAPK-catalyzed phosphorylation. No effect on inhibition of CLOCK-ARNTL-mediated transcriptional activity. Very little in vitro MAPK-catalyzed phosphorylation; when associated with A-265. Shorter circadian rhythm; when associated with A-553.	SEQ_UP	1	
MUTAGEN:S->A: Reduced in vitro MAPK-catalyzed phosphorylation. No effect on inhibition of CLOCK-ARNTL-mediated transcriptional activity. Very little in vitro MAPK-catalyzed phosphorylation; when associated with A-557.	SEQ_UP	1	
MUTAGEN:S->A: Reduced interaction with 14-3-3 proteins in response to cAMP signaling and, thus, still able to inhibit TORC activity.	SEQ_UP	1	
MUTAGEN:S->A: Reduced interaction with 14-3-3 proteins in response to cAMP signaling and, thus, still able to inhibit TORC activity. Resistant to inhibition by cAMP signaling and, thus, still able to inhibit TORC activity; when associated with A-358 and A-484.	SEQ_UP	1	
MUTAGEN:S->A: Reduced interaction with 14-3-3 proteins in response to cAMP signaling and, thus, still able to inhibit TORC activity. Resistant to inhibition by cAMP signaling and, thus, still able to inhibit TORC activity; when associated with A-484 and A-587.	SEQ_UP	1	
MUTAGEN:S->A: Reduced MAPK-catalyzed in vitro phosphorylation. No effect on inhibition of CLOCK-ARNTL/BMAL1-mediated transcriptional activity.	SEQ_UP	1	
MUTAGEN:S->A: Reduced phosphorylation and formation of unusual long bridge-like intermediate filament structures between two daughter cells during cytokinesis. Almost complete loss of phosphorylation; when associated with A-7 and A-28. Increased formation of unusual long bridge-like intermediate filament structures between two daughter cells during cytokinesis; when associated with A-60 and A-76.	SEQ_UP	1	
MUTAGEN:S->A: Reduced phosphorylation by HIPK2.	SEQ_UP	1	
MUTAGEN:S->A: Reduced phosphorylation by MAPK1/MAPK3.	SEQ_UP	1	
MUTAGEN:S->A: Reduced phosphorylation by PLK1 and abolishes depletion from kinetochores and subsequent degradation by the APC/C complex.	SEQ_UP	1	
MUTAGEN:S->A: Reduced phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: Reduced phosphorylation. Almost complete loss of phosphorylation; when associated with A-28 and A-32.	SEQ_UP	1	
MUTAGEN:S->A: Reduced phosphorylation. Almost complete loss of phosphorylation; when associated with A-7 and A-32.	SEQ_UP	1	
MUTAGEN:S->A: Reduced phosphorylation. Does not affect nuclear localization.	SEQ_UP	1	
MUTAGEN:S->A: Reduced phosphorylation. No nuclear entry of PER1, CRY1 nor CKSN1E; when associated with A-663.	SEQ_UP	1	
MUTAGEN:S->A: Reduced phosphorylation. No nuclear entry PER1, CRY1 nor CKSN1E; when associated with A-661.	SEQ_UP	1	
MUTAGEN:S->A: Reduced phosphorylation. Significant loss of phosphorylation; when associated with A-343.	SEQ_UP	1	
MUTAGEN:S->A: Reduced phosphorylation. Significant loss of phosphorylation; when associated with A-347.	SEQ_UP	1	
MUTAGEN:S->A: Reduced polyubiquitination when co-expressed with NEDD4; when associated with Ala-1859.	SEQ_UP	1	
MUTAGEN:S->A: Reduced TG hydrolase activity.	SEQ_UP	1	
MUTAGEN:S->A: Reduces binding to SNF.	SEQ_UP	1	
MUTAGEN:S->A: Reduces both interaction with 14-3-3 proteins and YWHAB-induced cytoplasmic localization. Impairs phosphorylation by MAPKAPK2, decreases its stability and cytoplasmic localization, increases interaction with PPP2CA, inhibits binding to 14-3-3 proteins, but does not impair binding to ARE-containing transcripts, recruitment of mRNA decay factors and ZFP36-mediated deadenylation and decay of ARE-containing transcripts; when associated with A-52.	SEQ_UP	1	
MUTAGEN:S->A: Reduces endothelial cell migration and differentiation.	SEQ_UP	1	
MUTAGEN:S->A: Reduces enzyme activity by about half. Reduces enzyme activity tenfold; when associated with A-67 and A-81.	SEQ_UP	1	
MUTAGEN:S->A: Reduces histone acetyltransferase activity; when associated with A-669 and A-672.	SEQ_UP	1	
MUTAGEN:S->A: Reduces interaction with 14-3-3 proteins without affecting the interaction with PPP2R1A; when associated with A-329 and A-370.	SEQ_UP	1	
MUTAGEN:S->A: Reduces interaction with 14-3-3 proteins without affecting the interaction with PPP2R1A; when associated with A-62 and A-329.	SEQ_UP	1	
MUTAGEN:S->A: Reduces interaction with 14-3-3 proteins without affecting the interaction with PPP2R1A; when associated with A-62 and A-370.	SEQ_UP	1	
MUTAGEN:S->A: Reduces interaction with 14-3-3 proteins. Abolishes interaction with 14-3-3 proteins without affecting the interaction with PPP2R1A; when associated with A-162.	SEQ_UP	1	
MUTAGEN:S->A: Reduces its phosphorylation status, does not interact with IKBKB/IKKB and BTRC, inhibits IL6 mRNA instability and IKK-mediated degradation of ZC3H12A; when associated with A-435.	SEQ_UP	1	
MUTAGEN:S->A: Reduces its phosphorylation status, does not interact with IKBKB/IKKB and BTRC, inhibits IL6 mRNA instability and IKK-mediated degradation of ZC3H12A; when associated with A-439.	SEQ_UP	1	
MUTAGEN:S->A: Reduces overall phosphorylation by 25%.	SEQ_UP	1	
MUTAGEN:S->A: Reduces phosphorylation by CDK5 and impairs interaction with YWHAE. Impairs interaction with KATNA1; when associated with A-198 and A-219.	SEQ_UP	1	
MUTAGEN:S->A: Reduces phosphorylation by CDK5 and impairs interaction with YWHAE. Impairs interaction with KATNA1; when associated with A-219 and A-231.	SEQ_UP	1	
MUTAGEN:S->A: Reduces phosphorylation by GSK3B by 50%. No effect on polarized cell migration.	SEQ_UP	1	
MUTAGEN:S->A: Reduces phosphorylation by PIM2 by 60%, and decreases the transcriptional activity of MYC.	SEQ_UP	1	
MUTAGEN:S->A: Reduces phosphorylation by PKA.	SEQ_UP	1	
MUTAGEN:S->A: Reduces phosphorylation in response to calcium.	SEQ_UP	1	
MUTAGEN:S->A: Reduces restart of stalled replication forks and cells show an increase in DNA double strand breaks. Decreases phosphorylation of ATR at 'S-428'. Reduces TRIM25 ubiquitination of BLM and subsequent localization to DNA replication forks. Reduces phosphorylation and activation of ATR. No effect on Filia distribution at replication forks or nascent DNA degradation following DNA damage. Not effect on interaction with OOEP.	SEQ_UP	1	
MUTAGEN:S->A: Reduces strongly phosphorylation. Reduces transactivation on the insulin promoter in glucose-stimulated insulinoma cells; when associated with A-259 and A-266.	SEQ_UP	1	
MUTAGEN:S->A: Reduces the interaction with CRYAB and MTOR.	SEQ_UP	1	
MUTAGEN:S->A: Reduces weakly phosphorylation. Reduces strongly phosphorylation; when associated with A-162 and A-259. Reduces transactivation on the insulin promoter in glucose-stimulated insulinoma cells; when associated with A-259 and A-274.	SEQ_UP	1	
MUTAGEN:S->A: Reduces weakly phosphorylation. Reduces strongly phosphorylation; when associated with A-162 and A-266. Reduces transactivation on the insulin promoter in glucose-stimulated insulinoma cells; when associated with A-266 and A-274.	SEQ_UP	1	
MUTAGEN:S->A: Reduces weakly phosphorylation. Reduces strongly phosphorylation; when associated with A-259 and A-266.	SEQ_UP	1	
MUTAGEN:S->A: Reduction in the ability of MTA1S to repress ER transactivation.	SEQ_UP	1	
MUTAGEN:S->A: Remains exclusively in the nucleolus; when associated with A-107.	SEQ_UP	1	
MUTAGEN:S->A: Remains stable, even in the face of severe hypoxia.	SEQ_UP	1	
MUTAGEN:S->A: Retains genomic stability and cell cycle checkpoint correction and kinase activity towards downstream targets; when associated with A-1987. Retains genomic stability, cell cycle checkpoint correction and kinase activity on downstream targets; when associated with A-1899 and A-1987.	SEQ_UP	1	
MUTAGEN:S->A: Retains genomic stability and cell cycle checkpoint correction and kinase activity towards downstream targets; when associated with A-367. Retains genomic stability, cell cycle checkpoint correction and kinase activity on downstream targets; when associated with A-367 and A-1987.	SEQ_UP	1	
MUTAGEN:S->A: Retains genomic stability, cell cycle checkpoint correction and kinase activity on downstream targets; when associated with A-367 and A-1987.	SEQ_UP	1	
MUTAGEN:S->A: Shorter circadian rhythm; when associated with A-557.	SEQ_UP	1	
MUTAGEN:S->A: Significant loss in AMPK-mediated phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: Significant loss of phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: Significant reduction in LPC transport.	SEQ_UP	1	
MUTAGEN:S->A: Significantly decreased NF-kappa-B activation.	SEQ_UP	1	
MUTAGEN:S->A: Significantly reduced phosphorylation and 2- to 3-fold increase in ability to arrest in G(1); when associated with A-384; A-386; A-388 and A-392. Further reduction in phosphorylation; when associated with A-63; A-384; A-386; A-386 and A-388.	SEQ_UP	1	
MUTAGEN:S->A: Significantly reduced phosphorylation and 2- to 3-fold increase in ability to arrest in G(1); when associated with A-384; A-386; A-392 and A-393. Further reduction in phosphorylation; when associated with A-63; A-384; A-386; A-392 and A-393.	SEQ_UP	1	
MUTAGEN:S->A: Significantly reduced phosphorylation and 2- to 3-fold increase in ability to arrest in G(1); when associated with A-384; A-388; A-392 and A-393. Further reduction in phosphorylation; when associated with A-63; A-384; A-388; A-392 and A-393.	SEQ_UP	1	
MUTAGEN:S->A: Significantly reduced phosphorylation and 2- to 3-fold increase in ability to arrest in G(1); when associated with A-386; A-388; A-392 and A-393. and A-392. Further reduction in phosphorylation; when associated with A-63; A-386; A-388; A-392 and A-393.	SEQ_UP	1	
MUTAGEN:S->A: Slight decrease phosphorylation by Rho-kinase. No change in promoting neurite growth; when associated with A-1662 and A-1668.	SEQ_UP	1	
MUTAGEN:S->A: Slightly decresases CDE and ADE RNA-binding.	SEQ_UP	1	
MUTAGEN:S->A: Slightly reduced enzyme activity. half. Reduces enzyme activity tenfold; when associated with A-45 and A-67.	SEQ_UP	1	
MUTAGEN:S->A: Slightly reduced TG hydrolase activity.	SEQ_UP	1	
MUTAGEN:S->A: Slightly reduces enzyme activity.	SEQ_UP	1	
MUTAGEN:S->A: Spontaneous IL1B release under basal conditions, loss of response to metabolic inhibitors and to LT; when associated with A-632.	SEQ_UP	1	
MUTAGEN:S->A: Spontaneous IL1B release under basal conditions, loss of response to metabolic inhibitors and to LT; when associated with A-744.	SEQ_UP	1	
MUTAGEN:S->A: Still phosphorylated.	SEQ_UP	1	
MUTAGEN:S->A: Strong decrease in catalytic activity; when associated with A-707.	SEQ_UP	1	
MUTAGEN:S->A: Strong decrease in catalytic activity; when associated with A-711.	SEQ_UP	1	
MUTAGEN:S->A: Strong reduction of CaMK1-dependent nuclear export. Reduces interaction with YWHAE.	SEQ_UP	1	
MUTAGEN:S->A: Strongly decreased transcriptional activation in response to viral infection; when associated with A-425.	SEQ_UP	1	
MUTAGEN:S->A: Strongly decreased transcriptional activation in response to viral infection; when associated with A-426.	SEQ_UP	1	
MUTAGEN:S->A: Strongly impairs affects phosphorylation by SIK1.	SEQ_UP	1	
MUTAGEN:S->A: Strongly reduced tyrosine carboxypeptidase activity.	SEQ_UP	1	
MUTAGEN:S->A: Strongly reduces affinity for DNA; when associated with.	SEQ_UP	1	
MUTAGEN:S->A: Strongly reduces internalization and down-regulation of the activated receptor; when associated with A-1188.	SEQ_UP	1	
MUTAGEN:S->A: Strongly reduces internalization and down-regulation of the activated receptor; when associated with A-1191.	SEQ_UP	1	
MUTAGEN:S->A: Strongly reduces phosphorylation by SGK1.	SEQ_UP	1	
MUTAGEN:S->A: Unable to activate MAPKAPK5 promote MAPKAPK5 localization to the cytoplasm.	SEQ_UP	1	
MUTAGEN:S->A: Up-regulates CREB transcription factor activity.	SEQ_UP	1	
MUTAGEN:S->A: Up-regulates CREB transcription factor activity. Reduces interaction with 14-3-3 proteins.	SEQ_UP	2	
MUTAGEN:S->A: Up-regulates CREB transcription factor activity. Reduces interaction with 14-3-3 proteins. Abolishes interaction with 14-3-3 proteins without affecting the interaction with PPP2R1A; when associated with A-273.	SEQ_UP	1	
MUTAGEN:S->A: Up-regulates CREB-mediated gluconeogenic gene expression. No degradation of CRTC2. Loss of SIK2-mediated phosphorylation.	SEQ_UP	1	
MUTAGEN:S->A: Up-regulation of KLH18-mediated degradation; when associated with A-37 and A-39.	SEQ_UP	1	
MUTAGEN:S->A: Up-regulation of KLH18-mediated degradation; when associated with A-37 and A-41.	SEQ_UP	1	
MUTAGEN:S->A: Up-regulation of KLH18-mediated degradation; when associated with A-39 and A-41.	SEQ_UP	1	
MUTAGEN:S->A: Weak effect possibly due to low expression of this mutant.	SEQ_UP	2	
MUTAGEN:S->A: Weakly affects phosphorylation by SIK1.	SEQ_UP	1	
MUTAGEN:S->A: Weakly decrease the enzymatic activity.	SEQ_UP	1	
MUTAGEN:S->A: Weakly reduces phosphorylation by SGK1.	SEQ_UP	1	
MUTAGEN:S->C,D,E,F,H,I,K,L,M,N,P,Q,R,V,W,Y: Loss of EPO binding.	SEQ_UP	1	
MUTAGEN:S->C,T: Loss of S-adenosyl-L-methionine binding. Loss of protein methyltransferase activity.	SEQ_UP	1	
MUTAGEN:S->C: Abolishes active hydrolase probe binding in serine hydrolase assays.	SEQ_UP	1	
MUTAGEN:S->C: Changes thiol-independent NADase activity to thiol-dependent; when associated with C-201.	SEQ_UP	1	
MUTAGEN:S->C: Decreased microtubule severing activity.	SEQ_UP	1	
MUTAGEN:S->C: Does not affect autocatalytic cleavage and generation of Myelin regulatory factor, N-terminal part.	SEQ_UP	1	
MUTAGEN:S->C: No effect on viral infection.	SEQ_UP	1	
MUTAGEN:S->C: Retains 2% of the initial activity; deacylation of the acyl-enzyme intermediate becomes rate-limiting.	SEQ_UP	1	
MUTAGEN:S->D,E,F,H,I,K,L,M,N,P,Q,R,V,W: Loss of EPO binding.	SEQ_UP	1	
MUTAGEN:S->D,E: Mimicks phosphorylation state; inducing early depletion from kinetochores and subsequent degradation by the APC/C complex.	SEQ_UP	1	
MUTAGEN:S->D,E: Mimics phosphorylation, unable to incorporate into microtubules.	SEQ_UP	1	
MUTAGEN:S->D: 3.5-fold increase in SNAP25 binding.	SEQ_UP	1	
MUTAGEN:S->D: Abolishes DNA double-strand break repair and subsequent regulation of apoptosis. Abolishes localization to the mitochondrion. No effect on localization to centrosomes or centrosome integrity.	SEQ_UP	1	
MUTAGEN:S->D: Abolishes interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:S->D: Abolishes phosphatidate phosphatase activity but does not prevent membrane association.	SEQ_UP	1	
MUTAGEN:S->D: Abolishes phosphorylation by CaMK2D. Tendency to tachycardia and subsequent death due to heart failure.	SEQ_UP	1	
MUTAGEN:S->D: Abolishes phosphorylation, no effect on DNA binding nor on pericentromeric location. Loss of DNA binding and pericentromeric location; when associated with E-140 and E-167.	SEQ_UP	1	
MUTAGEN:S->D: Adopts a nucleus-wide distribution; when associated with D-107.	SEQ_UP	1	
MUTAGEN:S->D: Constitutively active in translation inhibition (phosphomimetic). Mutant mice have no apparent developmental defect and do not display overt phenotype related to adiposity or lifespan.	SEQ_UP	1	
MUTAGEN:S->D: Decreased binding to gamma satellite A by 5-fold and to gamma satellite B by 3-fold. Diffuse nuclear location.	SEQ_UP	1	
MUTAGEN:S->D: Decreased binding to gamma satellite A by 5-fold and to gamma satellite B by 3-fold. Diffuse nuclear location. Decreased DNA binding affinity toward TdT by 3-fold.	SEQ_UP	1	
MUTAGEN:S->D: Does not significantly increase cell motility; when associated with D-171. Does not significantly decrease cell growth; when associated with A-171.	SEQ_UP	1	
MUTAGEN:S->D: Dominant active form; when associated with D-315.	SEQ_UP	1	
MUTAGEN:S->D: Enhanced DNA binding activity.	SEQ_UP	1	
MUTAGEN:S->D: Enhanced EGF- and RSK-mediated transformation; when associated with D-362.	SEQ_UP	1	
MUTAGEN:S->D: Enhanced EGF- and RSK-mediated transformation; when associated with D-374.	SEQ_UP	1	
MUTAGEN:S->D: High basal kinase activity, loss of phorbol ester-stimulated kinase activity; when associated with D-744.	SEQ_UP	1	
MUTAGEN:S->D: High basal kinase activity, loss of phorbol ester-stimulated kinase activity; when associated with D-748.	SEQ_UP	1	
MUTAGEN:S->D: Increased protein stability.	SEQ_UP	1	
MUTAGEN:S->D: Increased transcriptional activation; when associated with D-437.	SEQ_UP	1	
MUTAGEN:S->D: Increased transcriptional activation; when associated with D-438.	SEQ_UP	1	
MUTAGEN:S->D: Induction of F-actin-bundling; when associated with D-148 and D-183. In neurons, induces the generation of long and prominent filopodia; when associated with D-148 and D-183.	SEQ_UP	1	
MUTAGEN:S->D: Leads to phosphorylation on other serine residues.	SEQ_UP	1	
MUTAGEN:S->D: Lengthen circadian period. No effect on repressive activity. Increases protein stability.	SEQ_UP	1	
MUTAGEN:S->D: Little change in phosphorylation by CDK1 or CDK2. Completely abolished phosphorylation by CDK1 or CDK2; when associated with D-411.	SEQ_UP	1	
MUTAGEN:S->D: Loss of binding to AP-2 and can bind to AP-1; when associated with G-273.	SEQ_UP	1	
MUTAGEN:S->D: Loss of GTP-binding.	SEQ_UP	1	
MUTAGEN:S->D: Loss of interaction with PCM1.	SEQ_UP	1	
MUTAGEN:S->D: Loss of localization to the plasma membrane.	SEQ_UP	1	
MUTAGEN:S->D: Mimicks phosphorylation state, leading to localization to the cytoplasm.	SEQ_UP	1	
MUTAGEN:S->D: Mimicks phosphorylation state, lesading to enhance kinase activity and promote pronuclear formation.	SEQ_UP	1	
MUTAGEN:S->D: Mimics phosphorylation state and induces necroptosis in absence of exogeous stimuli and independently of RIPK3.e.	SEQ_UP	1	
MUTAGEN:S->D: Mimics phosphorylation status; does not affect the phospholipid scramblase activity.	SEQ_UP	1	
MUTAGEN:S->D: Mimics phosphorylation; causes rapid macrophage pyroptosis without infection.	SEQ_UP	1	
MUTAGEN:S->D: Mimics phosphorylation; constitutively active mutant that shows constitutive protein acetyltransferase activity. Increased ability to promote homologous recombination (HR)repair in response to DNA double-strand breaks (DSBs).	SEQ_UP	1	
MUTAGEN:S->D: Mimics phosphorylation; constitutively active mutant that shows constitutive protein acetyltransferase and acyltransferase activities in knockin mice. Increased ability to promote homologous recombination (HR)repair in response to DNA double-strand breaks (DSBs).	SEQ_UP	1	
MUTAGEN:S->D: More sensitive to in vitro proteolysis.	SEQ_UP	1	
MUTAGEN:S->D: No change in binding to gamma satellites A and B. No change in pericentromeric location.	SEQ_UP	1	
MUTAGEN:S->D: No change in subcellular localization in non-stress conditions. No change in protein accumulation and stability in response to DNA damage.	SEQ_UP	1	
MUTAGEN:S->D: No change in subcellular location nor colocalization with vinculin at focal adhesions nor with N-WASP at the leading edge. No loss of cell mobility function; when associated with D-637.	SEQ_UP	1	
MUTAGEN:S->D: No change in subcellular location nor colocalization with vinculin at focal adhesions nor with N-WASP at the leading edge. No loss of cell mobility function. when associated with D-255.	SEQ_UP	1	
MUTAGEN:S->D: No effect on association with the proteasome complex; when associated with D-163 and D-173.	SEQ_UP	1	
MUTAGEN:S->D: No effect on association with the proteasome complex; when associated with D-163 and D-187.	SEQ_UP	1	
MUTAGEN:S->D: No effect on association with the proteasome complex; when associated with D-173 and D-187.	SEQ_UP	1	
MUTAGEN:S->D: No effect on circadian period length and protein stability.	SEQ_UP	1	
MUTAGEN:S->D: No effect on localization at replication forks, nascent DNA degradation following DNA damage, restart of stalled replication forks or levels of DNA damage.	SEQ_UP	1	
MUTAGEN:S->D: No effect on protein abundance. No effect on cell surface localization. No effect on alanine uptake activity.	SEQ_UP	1	
MUTAGEN:S->D: No effect on repression by PER2 on transactivation activity.	SEQ_UP	1	
MUTAGEN:S->D: No effect on SRF activation. Impairs SRF activation, reduces interaction with EP300 and SM-promoter activation; when associated with D-812; D-859 and D-893.	SEQ_UP	1	
MUTAGEN:S->D: No effect on SRF activation. Impairs SRF activation, reduces interaction with EP300 and SM-promoter activation; when associated with D-812; D-866 and D-893.	SEQ_UP	1	
MUTAGEN:S->D: No effect on SRF activation. Impairs SRF activation, reduces interaction with EP300 and SM-promoter activation; when associated with D-859; D-866 and D-893.	SEQ_UP	1	
MUTAGEN:S->D: No effect on subcellular localization.	SEQ_UP	1	
MUTAGEN:S->D: No effect.	SEQ_UP	1	
MUTAGEN:S->D: No loss of phosphorylation or localization to the uropodium. Loss of interaction with EZR.	SEQ_UP	1	
MUTAGEN:S->D: No pro-apoptotic activity, no interaction with Bcl-X(L).	SEQ_UP	1	
MUTAGEN:S->D: No pro-apoptotic activity; even when associated with A-112.	SEQ_UP	1	
MUTAGEN:S->D: Phophomimetic mutant. Does not protect cells from TNF-induced cell death.	SEQ_UP	1	
MUTAGEN:S->D: Phophomimetic mutant. Significant loss of kinase activity. Protects cells from TNF-induced cell death.	SEQ_UP	1	
MUTAGEN:S->D: Phospho-mimetic mutant; increased cyclic GMP-AMP synthase activity.	SEQ_UP	1	
MUTAGEN:S->D: Phosphomimetic mutant that lead to increased centrosome number.	SEQ_UP	2	
MUTAGEN:S->D: Phosphomimetic mutant that leads to destabilization of the protein and abolishes ability to bind PER2; when associated with D-280.	SEQ_UP	1	
MUTAGEN:S->D: Phosphomimetic mutant that leads to destabilization of the protein and abolishes ability to bind PER2; when associated with D-71.	SEQ_UP	1	
MUTAGEN:S->D: Phosphomimetic mutant which enhances channel function.	SEQ_UP	1	
MUTAGEN:S->D: Phosphomimetic mutant; able to rescue mitochondrial depolarization in a Pink1 mutant background.	SEQ_UP	1	
MUTAGEN:S->D: Phosphomimetic mutant; impaired ability to homooligomerize at 30 degrees Celsius.	SEQ_UP	1	
MUTAGEN:S->D: Phosphorylation mimicking mutant. Increased interaction with GDI2.	SEQ_UP	1	
MUTAGEN:S->D: Prevents aberrant myotube formation in PIEZO1-deficient myoblast; when associated with D-19.	SEQ_UP	1	
MUTAGEN:S->D: Reduced inhibition of CLOCK-ARNTL-mediated transcriptional activity. No effect on nuclear localization nor on protein stability.	SEQ_UP	1	
MUTAGEN:S->D: Reduced inhibition of CLOCK-ARNTL/BMAL1-mediated transcriptional activity.	SEQ_UP	1	
MUTAGEN:S->D: Reduced interaction with SYT9, but no effect on the interaction with HSC70.	SEQ_UP	1	
MUTAGEN:S->D: Reduced MAPK3/ERK1 and MAPK1/ER2K-binding.	SEQ_UP	1	
MUTAGEN:S->D: Reduced membrane-binding affinity.	SEQ_UP	1	
MUTAGEN:S->D: Reduces actin polymerization to a lesser extent than wild-type.	SEQ_UP	1	
MUTAGEN:S->D: Reduces actin polymerization to a lesser extent than wild-type. Greater effect on actin polymerization; when associated with D-235 and E-274.	SEQ_UP	1	
MUTAGEN:S->D: Retains the ability to dimerize with JUNB and localization in the nucleus but abolishes DNA-binding.	SEQ_UP	1	
MUTAGEN:S->D: Significant decrease in transcriptional activation by the CLOCK-ARNTL/BMAL1 heterodimer. Significant decrease in transcriptional activation by the CLOCK-ARNTL/BMAL1 heterodimer, reduced nuclear localization and DNA-binding; when associated with D-38.	SEQ_UP	1	
MUTAGEN:S->D: Significant decrease in transcriptional activation by the CLOCK-ARNTL/BMAL1 heterodimer. Significant decrease in transcriptional activation by the CLOCK-ARNTL/BMAL1 heterodimer, reduced nuclear localization and DNA-binding; when associated with D-42.	SEQ_UP	1	
MUTAGEN:S->D: Strongly decreased transcriptional activation in response to viral infection; when associated with D-425.	SEQ_UP	1	
MUTAGEN:S->D: Strongly decreased transcriptional activation in response to viral infection; when associated with D-426.	SEQ_UP	1	
MUTAGEN:S->E: Abnormal subnuclear localization upon glucose accumulation.	SEQ_UP	1	
MUTAGEN:S->E: Abolishes dimerization.	SEQ_UP	1	
MUTAGEN:S->E: Abolishes homodimerization. Strongly reduced E3 ubiquitin ligase activity.	SEQ_UP	1	
MUTAGEN:S->E: Abolishes interaction with GPSM2.	SEQ_UP	1	
MUTAGEN:S->E: Abolishes phosphorylation, no effect on DNA binding nor on pericentromeric location. Loss of DNA binding and pericentromeric location; when associated with E-140 and D-195.	SEQ_UP	1	
MUTAGEN:S->E: Complete loss of phosphorylation by MAPKAPK2, partial loss of phosphorylation by PKA, no effect on phosphorylation by PKC and CaMK2.	SEQ_UP	1	
MUTAGEN:S->E: Decreases interaction with AHCYL1; when associated with A-1588.	SEQ_UP	1	
MUTAGEN:S->E: Decreases interaction with AHCYL1; when associated with A-1755.	SEQ_UP	1	
MUTAGEN:S->E: Enhanced EGF- and RSK-mediated transformation; when associated with E-362.	SEQ_UP	1	
MUTAGEN:S->E: Increased enhancement of EGF- and RSK-mediated transformation; when associated with E-374.	SEQ_UP	1	
MUTAGEN:S->E: Increases filopodial density.	SEQ_UP	1	
MUTAGEN:S->E: Increases guanine exchange factor activity.	SEQ_UP	1	
MUTAGEN:S->E: Inhibits its proteolytic cleavage and interaction with FADD. Promotes its interaction with RIPK3 to mediate necroptosis; when associated with E-332; E-334 and E-336.	SEQ_UP	1	
MUTAGEN:S->E: Interferes with oligomerization.	SEQ_UP	1	
MUTAGEN:S->E: Loss of interaction with PDPK1 and phosphorylation at S-227.	SEQ_UP	1	
MUTAGEN:S->E: Loss of phosphorylation and activation by PDPK1.	SEQ_UP	1	
MUTAGEN:S->E: Loss of S-adenosyl-L-methionine binding. Loss of protein methyltransferase activity. Localized in the cytosol.	SEQ_UP	1	
MUTAGEN:S->E: May abolish association with nucleosomes; when associated with E-18.	SEQ_UP	1	
MUTAGEN:S->E: May abolish association with nucleosomes; when associated with E-22.	SEQ_UP	1	
MUTAGEN:S->E: Mimicks phosphorylation state and induces constitutive protein kinase activity.	SEQ_UP	1	
MUTAGEN:S->E: Mimicks phosphorylation state; promotes detachment from actin in absence of BDNF treatment; when associated with E-628.	SEQ_UP	1	
MUTAGEN:S->E: Mimics phosphorylation by PKA, prevents MAPK binding.	SEQ_UP	1	
MUTAGEN:S->E: No effect on cell aggregation or E-cadherin/catenin complex assembly. Increases strength of cell-cell adhesion.	SEQ_UP	1	
MUTAGEN:S->E: No effect on JAK signal transduction suppression.	SEQ_UP	1	
MUTAGEN:S->E: No effect on zygotic subcortical F-actin abundance and centralization of the mitotic spindle.	SEQ_UP	1	
MUTAGEN:S->E: No interaction with ubiquitin.	SEQ_UP	1	
MUTAGEN:S->E: Phosphomimetic mutant; promotes interaction with KEAP1 and nuclear accumulation of NFE2L2/NRF2.	SEQ_UP	1	
MUTAGEN:S->E: Promotes its interaction with RIPK3 to mediate necroptosis; when associated with E-321; E-332 and E-334.	SEQ_UP	1	
MUTAGEN:S->E: Promotes its interaction with RIPK3 to mediate necroptosis; when associated with E-321; E-332 and E-336.	SEQ_UP	1	
MUTAGEN:S->E: Promotes its interaction with RIPK3 to mediate necroptosis; when associated with E-321; E-334 and E-336.	SEQ_UP	1	
MUTAGEN:S->E: Promotes mono and/or diubiquitination and nuclear exclusion. Reduces phosphorylation at S-345.	SEQ_UP	1	
MUTAGEN:S->E: Reduced interaction with NR1I2 and NR1I3. Significant decrease in interaction with NR1I2 and NR1I3; when associated with M-396 and K-397.	SEQ_UP	1	
MUTAGEN:S->E: Reduced membrane-binding affinity.	SEQ_UP	1	
MUTAGEN:S->E: Slightly reduces activity.	SEQ_UP	1	
MUTAGEN:S->E: Some repression of transcriptional activation; Repressed transcriptional activity by about 10-fold; when associated with E-19.	SEQ_UP	1	
MUTAGEN:S->E: Some repression of transcriptional activation; Repressed transcriptional activity by about 10-fold; when associated with E-68.	SEQ_UP	1	
MUTAGEN:S->F: Abolishes phosphorylation by PKB/AKT2.	SEQ_UP	1	
MUTAGEN:S->F: Cannot rescue the effect PIP5K1C knockdown on EGF-stimulated cell migration. Decreased tailin assembly into focal adhesions.	SEQ_UP	1	
MUTAGEN:S->F: Impaired acyltransferase activity.	SEQ_UP	1	
MUTAGEN:S->F: No effect.	SEQ_UP	1	
MUTAGEN:S->F: Significant reduction of apoptotic activity.	SEQ_UP	1	
MUTAGEN:S->G: 50-fold less EPO binding.	SEQ_UP	1	
MUTAGEN:S->G: Complete loss of apoptotic activity.	SEQ_UP	1	
MUTAGEN:S->G: Decreased 'Lys-48'-linked polyubiquitin binding.	SEQ_UP	1	
MUTAGEN:S->G: Increases stability. Increases stability and improves binding to MHC I class ligand; when associated with G-121; G-197 and K-227.	SEQ_UP	1	
MUTAGEN:S->G: No effect on cholesterol and sitosterol transport activity; when associated with V-194.	SEQ_UP	1	
MUTAGEN:S->G: Reduces CDK4-mediated phosphorylation.	SEQ_UP	1	
MUTAGEN:S->G: Results in inhibition of JNK binding.	SEQ_UP	1	
MUTAGEN:S->G: Results in myristoylation of G-2, which restores the transformation activity; when associated with S-6.	SEQ_UP	1	
MUTAGEN:S->G: Results in retention of the protein in the Golgi apparatus.	SEQ_UP	1	
MUTAGEN:S->H: Strong increase in alpha-tubulin initiation step of polyglutamylase activity; when associated with A-179, R-180, I-182 and I-262.	SEQ_UP	1	
MUTAGEN:S->I: Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself.	SEQ_UP	1	
MUTAGEN:S->I: Does not affect association with TLR2, TLR4 and TLR9; does not affect cell-surface expression of TLR2, TLR4 and TLR9; does not affect responses of TLR2, TLR4 and TLR9.	SEQ_UP	1	
MUTAGEN:S->I: Little effect on inhibitory activity on Wnt-signaling.	SEQ_UP	1	
MUTAGEN:S->I: Loss of interaction with SYNCRIP.	SEQ_UP	1	
MUTAGEN:S->L,M,F: No effect on interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:S->L: Aberrant protein folding and increased proteasomal degradation.	SEQ_UP	1	
MUTAGEN:S->L: Abolished 2'-5'-oligoadenylate synthase activity.	SEQ_UP	1	
MUTAGEN:S->L: Abolished ability to hydrolyze 2',3'-cGAMP without affecting ability to hydrolyze ATP.	SEQ_UP	1	
MUTAGEN:S->L: Abolished ability to promote phosphatidylserine exposure. Promotes localization to the cytoplasm.	SEQ_UP	1	
MUTAGEN:S->L: Abolishes expression at the cell membrane.	SEQ_UP	1	
MUTAGEN:S->L: Abolishes phosphatidate phosphatase activity but does not prevent membrane association nor coactivator activity.	SEQ_UP	1	
MUTAGEN:S->L: Abolishes phosphatidate phosphatase activity but does not prevent membrane association.	SEQ_UP	1	
MUTAGEN:S->L: Decreased transporter activity. Increased accumulation of protein in ER.	SEQ_UP	1	
MUTAGEN:S->L: Disrupts KATNA1:KATNB1 interaction with ASPM.	SEQ_UP	1	
MUTAGEN:S->L: In Mutt mutant; 13% of heterozygotes show a reduced startle response to a toneburst of 24 kHz and a mild craniofacial abnormality. 17% of homozygotes show perinatal lethality. Surviving homozygotes demonstrate a marked craniofacial abnormality and reduced hearing.	SEQ_UP	1	
MUTAGEN:S->L: Increased localization to the nucleus. Decreased transcription cis-regulatory region binding. No effect on DNA-binding transcription factor activity.	SEQ_UP	1	
MUTAGEN:S->L: Mutant females show reduced fertility with smaller litter sizes. Produces DNA repair defects during meiotic prophase I. Reduces loading of BRME1 and HSF2BP at the recombination nodules. Males show a slight non-significant reduction in fertility. No effect on interaction with BRCA2 and BRME1. No effect on subcellular location. Reduces BRME1 expression.	SEQ_UP	1	
MUTAGEN:S->L: No effect on cis-Golgi localization.	SEQ_UP	1	
MUTAGEN:S->L: Significant reduction in LPC transport.	SEQ_UP	1	
MUTAGEN:S->L: Significant reduction of apoptotic activity.	SEQ_UP	1	
MUTAGEN:S->M: Loss of in vitro phosphorylation by TSSK4.	SEQ_UP	1	
MUTAGEN:S->N: Abolishes GTP binding.	SEQ_UP	1	
MUTAGEN:S->N: Abolishes interaction with PML.	SEQ_UP	1	
MUTAGEN:S->N: Abrogates interaction with HOOK3. Greatly reduces binding affinity for GDP and GTP. Abolishes GTP-dependent oligomer formation.	SEQ_UP	1	
MUTAGEN:S->N: Constitutively inactive. Loss of Golgi apparatus location. Loss of interaction with GARIN1B.	SEQ_UP	1	
MUTAGEN:S->N: Constitutively inactive. Loss of interaction with GARIN1B.	SEQ_UP	1	
MUTAGEN:S->N: Dominant negative mutant locked in the inactive GDP-bound form; partially relocalizes to the Golgi and alters endocytic recycling.	SEQ_UP	1	
MUTAGEN:S->N: Dominant negative. Loss of interaction with AFDN, RLF and RALGDS.	SEQ_UP	1	
MUTAGEN:S->N: Increases the interaction with MTMR6.	SEQ_UP	1	
MUTAGEN:S->N: Inhibits endosome localization. Disrupts interaction of RAB5A and OCRL with INPP5F. Prevents its localization to apoptotic cell corpse-containing early phagosomes. Maturation of apoptotic cell-containing phagosome into acidic phagosomes is decreased. Interacts with PIK3C3.	SEQ_UP	1	
MUTAGEN:S->N: Loss of affinity for GTP and loss of interaction with RUNDC3A.	SEQ_UP	1	
MUTAGEN:S->N: Loss of catalytic activity and localization to cytoplasmic vesicle.	SEQ_UP	2	
MUTAGEN:S->N: Loss of GTP-binding activity.	SEQ_UP	1	
MUTAGEN:S->N: Loss of interaction with MICALL1.	SEQ_UP	1	
MUTAGEN:S->N: Loss of targeting to plasma membrane and phagosomes.	SEQ_UP	1	
MUTAGEN:S->N: No effect.	SEQ_UP	1	
MUTAGEN:S->N: Predominantly in the GTP-bound state. No effect on subcellular location.	SEQ_UP	1	
MUTAGEN:S->N: Reduced activity.	SEQ_UP	1	
MUTAGEN:S->N: Restores autocatalytic cleavage, as observed in allele 1, and produces constitutive IL1B release; when associated with V-927 and A-935.	SEQ_UP	1	
MUTAGEN:S->P: Abrogates interaction with NDEL1, PAFAH1B3 and RSN. Also impairs localization to centrosomes and microtubule plus ends. Reduces protein stability.	SEQ_UP	1	
MUTAGEN:S->P: In an experimental autoimmune encephalomyelitis (EAE) disease model, 50 percent of animals have no EAE symptoms. In the remaining animals, EAE is less severe with a reduction in the demyelination of the spinal cord and in the number of CD4(+) T-cells infiltrating the central nervous system. In addition, CD4(+) T-cell proliferation and apoptosis are increased. Reduced CD4(+) T-cell transmigration towards chemokine CXCL12 and CCL5.	SEQ_UP	1	
MUTAGEN:S->P: In chaos1; mice display higher frequencies of spontaneous and radiation- or mitomycin C-induced micronucleated erythrocytes.	SEQ_UP	1	
MUTAGEN:S->P: In l11Jus4; embryos survive through implantation but fail prior to gastrulation.	SEQ_UP	1	
MUTAGEN:S->P: Intermediate transactivation activity.	SEQ_UP	1	
MUTAGEN:S->P: No effect on activity.	SEQ_UP	1	
MUTAGEN:S->P: Prevents accumulation in pericentric heterochromatin.	SEQ_UP	1	
MUTAGEN:S->P: Shows very weak DNA binding to a Prop1 response element in gel shift assays; transcriptional activation of a luciferase reporter gene is reduced to 43% compared with that of wild-type Prop1 in transiently transfected human embryonic kidney cells.	SEQ_UP	1	
MUTAGEN:S->P: Strongly reduced inhibition by GNF-2.	SEQ_UP	1	
MUTAGEN:S->Q: Decreases current amplitude.	SEQ_UP	1	
MUTAGEN:S->Q: Increase in GTPase activity. No effect neither on prenylation, nor on subcellular location.	SEQ_UP	1	
MUTAGEN:S->R: Able to partially restore the interaction with the G-205 GATA1 mutant, which is usually unable to interact with ZFPM1.	SEQ_UP	1	
MUTAGEN:S->R: Abolished binding to hypusinated EIF5A.	SEQ_UP	1	
MUTAGEN:S->R: Abolishes interaction with the FKBP1A-rapamycin complex.	SEQ_UP	1	
MUTAGEN:S->R: Changed cilium assembly. Adult animals develop myxomatous mitral valves and functional mitral valve prolapse.	SEQ_UP	1	
MUTAGEN:S->R: Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself; when associated with E-141.	SEQ_UP	1	
MUTAGEN:S->R: Disrupts intramolecular interactions and autoinhibition, leading to spontaneous pyroptosis-inducing activity.	SEQ_UP	1	
MUTAGEN:S->R: Induces centriole elongation. Impaired IFT88 recruitment. Reduced ciliogenesis.	SEQ_UP	1	
MUTAGEN:S->R: Mildly reduces phosphatase activity; when associated with R-72 and A-73. Strongly reduces phosphatase activity; when associated with S-67; R-72 and A-73.	SEQ_UP	1	
MUTAGEN:S->R: No effect on homophilic interaction. Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself; when associated with V-67 and D-69.	SEQ_UP	1	
MUTAGEN:S->R: No effect on protein abundance. Strong decreases of cell surface localization. Decreases alanine uptake activity.	SEQ_UP	1	
MUTAGEN:S->R: Shifts channel activation to more negative voltage, slows channel opening and speeds up channel closure. Reduces sensitivity to activation by cAMP.	SEQ_UP	1	
MUTAGEN:S->R: Slightly reduced JAK2/STAT5 activation and mitogenic response.	SEQ_UP	1	
MUTAGEN:S->T: 2-fold less EPO binding.	SEQ_UP	1	
MUTAGEN:S->T: Abolishes interaction with APLP1.	SEQ_UP	1	
MUTAGEN:S->T: Abolishes LDLR endocytosis.	SEQ_UP	1	
MUTAGEN:S->T: Almost loss of glycerophosphocholine cholinephosphodiesterase activity. Loss of choline metabolism.	SEQ_UP	1	
MUTAGEN:S->T: Efficiently phosphorylated in vitro.	SEQ_UP	1	
MUTAGEN:S->T: Loss of lipid phosphatase activity.	SEQ_UP	1	
MUTAGEN:S->T: No loss of EPO binding.	SEQ_UP	1	
MUTAGEN:S->T: Strongly increases activity towards ethanol, increases KM for benzoquinone 10-fold.	SEQ_UP	1	
MUTAGEN:S->V: Abolished ability to promote phosphatidylserine exposure.	SEQ_UP	1	
MUTAGEN:S->W: Abrogates interaction with NDEL1.	SEQ_UP	1	
MUTAGEN:S->W: No effect on interaction with TLR3.	SEQ_UP	1	
MUTAGEN:S->Y,A: Abolished NAD-dependent protein deacetylase, defatty-acylase and mono-ADP-ribosyltransferase activities.	SEQ_UP	1	
MUTAGEN:S->Y: Confers ability to bind ferric iron and carbonate; when associated with R-143.	SEQ_UP	1	
MUTAGEN:S->Y: Constitutively active protein tyrosine kinase activity. Causes an immune dysregulation disorder. Treatment with SYK-specific inhibitor ameliorates the disease phenotype.	SEQ_UP	1	
MUTAGEN:S->Y: Decresases CDE and ADE RNA-binding.	SEQ_UP	1	
MUTAGEN:S->Y: Greatly reduced EPO binding.	SEQ_UP	1	
MUTAGEN:S->Y: Impairs LDLR endocytosis.	SEQ_UP	1	
MUTAGEN:S->Y: No effect on PDCD1 binding.	SEQ_UP	2	
MUTAGEN:S->Y: No effect on production of IL1B in response to bacterial flagellin.	SEQ_UP	1	
MUTAGEN:S->Y: Significantly reduces the binding to PDCD1.	SEQ_UP	1	
MUTAGEN:SAPAS->AAPAA: Decreased phosphorylation by GSK3A and interaction with 14-3-3 proteins.	SEQ_UP	1	
MUTAGEN:SDFETEDFDVRSRTSVQT->ADFETEDFDVRARAAVQA: No effect on cell aggregation or E-cadherin/catenin complex assembly. Decreases strength of cell-cell adhesion.	SEQ_UP	1	
MUTAGEN:SDFETEDFDVRSRTSVQT->EDFETEDFDVREREEVQE: No effect on cell aggregation or E-cadherin/catenin complex assembly. Increases strength of cell-cell adhesion.	SEQ_UP	1	
MUTAGEN:SFLLMVFVVV->YFLLMVFVEL: Reduces surface expression in transfected pro-B cells and enhances interaction with FCER1G. Slightly increases surface expression in transfected pro-B cells and enhances interaction with FCER1G; when associated with 177-S--R-182.	SEQ_UP	1	
MUTAGEN:SFQ->AAA: Sperm-egg fusion abolished.	SEQ_UP	1	
MUTAGEN:SGLS->AGLA: Abolishes ubiquitination and degradation by the SCF(BTRC) complex.	SEQ_UP	1	
MUTAGEN:SGR->AAA: Decreases repression of NFE2L2/NRF2-dependent gene expression.	SEQ_UP	1	
MUTAGEN:SGS->AGA: Change of cotransport Na(+):Pi stoichiometry to 3:1; when associated with D-195.	SEQ_UP	1	
MUTAGEN:SGV->AAA: Abolishes repression of NFE2L2/NRF2-dependent gene expression.	SEQ_UP	1	
MUTAGEN:SISEE->AIAEA: Does not inhibit U RNA-binding.	SEQ_UP	1	
MUTAGEN:SK->AA: Impairs interaction with RIPK3.	SEQ_UP	1	
MUTAGEN:SL->DD: Partially resistant to proteolysis by TIKI1 and TIKI2. Completely resistant to proteolysis by TIKI1 and TIKI2; when associated with 33-D-D-34.	SEQ_UP	1	
MUTAGEN:SLSGRLA->ALEADLE: Reduces binding to ROCK1 and ability to trigger apical constriction in cells.	SEQ_UP	1	
MUTAGEN:SMMS->MM: No effect on ISGF3 binding to ISREs.	SEQ_UP	1	
MUTAGEN:SMS->AMA,EME: Strongly reduces phosphorylation by PRKCZ and abolishes interaction with PKRCI.	SEQ_UP	1	
MUTAGEN:SNS->AAA: Loss of interaction with PAWR. Significant loss of interaction with NOS2.	SEQ_UP	1	
MUTAGEN:SQS->AQG: In Ld tail 1S, restores ubiquitination; when associated R-332; I-337; R-340; A-356 and 360-R-R-361.	SEQ_UP	1	
MUTAGEN:SQSSEMS->AQGAEMA: In Ld KCST-less, strongly impairs ubiquitination; when associated with R-332; I-337 and 360-R-R-361.	SEQ_UP	1	
MUTAGEN:SREGS->AREGA: Decreased phosphorylation by GSK3A and interaction with 14-3-3 proteins.	SEQ_UP	1	
MUTAGEN:SRPHTR->NSLFIW: Decreases surface expression in transfected pro-B cells and impairs interaction with FCER1G.	SEQ_UP	1	
MUTAGEN:SS->AA: Does not affect secretion.	SEQ_UP	1	
MUTAGEN:SS->AA: Does not greatly affect phosphorylation status.	SEQ_UP	1	
MUTAGEN:SS->AA: Enhances nuclear localization.	SEQ_UP	1	
MUTAGEN:SS->AA: No effect on phosphorylation.	SEQ_UP	1	
MUTAGEN:SS->DD: Completely resistant to proteolysis by TIKI1 and TIKI2; when associated with 25-D-D-26.	SEQ_UP	1	
MUTAGEN:SS->DD: Decreased localization to the plasma membrane.	SEQ_UP	1	
MUTAGEN:SS->EE: Abolishes nuclear localization.	SEQ_UP	1	
MUTAGEN:SSS->AAA: Almost no effect on transcriptional activation in response to viral infection.	SEQ_UP	1	
MUTAGEN:SSS->DDD: Strongly increased transcriptional activation in response to viral infection.	SEQ_UP	1	
MUTAGEN:SSSDSS->AAADAA: Abolished pyrophosphorylation.	SEQ_UP	1	
MUTAGEN:SSSQS->AAAQA: No effect on ACHE tetramer recruitment to membrane rafts; when associated with A-131.	SEQ_UP	1	
MUTAGEN:SSSSS->AAAAA: No effect on sumoylation of LEF1, nor on LEF1-binding.	SEQ_UP	1	
MUTAGEN:SSTST->ASAAA: In mut5; does not affect localization to primary cilia.	SEQ_UP	1	
MUTAGEN:ST->AA: Abolishes interaction with nuclear receptors.	SEQ_UP	1	
MUTAGEN:ST->CR: Reduced DNA binding activity.	SEQ_UP	1	
MUTAGEN:ST->DD: Enhanced DNA binding activity.	SEQ_UP	1	
MUTAGEN:SVASGISQCSCSSTS->AVAAGIAQCACAATA: No effect on interaction with BTRC and FBXW11.	SEQ_UP	1	
MUTAGEN:SVSS->AVAA: No effect on sumoylation; when associated with A-237; A-243; A-320 and A-521.	SEQ_UP	1	
MUTAGEN:SY->AA: Does not abolish interaction with RXRIP110.	SEQ_UP	1	
MUTAGEN:SY->GG: Abolishes interaction with RXRIP110.	SEQ_UP	1	
MUTAGEN:SYIS->AYIA: Strongly reduced riboflavin transport; when associated with A-275.	SEQ_UP	1	
MUTAGEN:SYSS->AYAA: Normal erythrocyte and platelet numbers; when associated with A-2026 and A-2038.	SEQ_UP	1	
MUTAGEN:T->A,G: Reduces phosphatidylinositol 3,4,5-trisphosphate binding.	SEQ_UP	1	
MUTAGEN:T->A,I: Accumulates in punctate structures in both cytoplasmic and nuclear compartments.	SEQ_UP	1	
MUTAGEN:T->A,V: Increased ability to restrict LINE-1 retrotransposon activity.	SEQ_UP	1	
MUTAGEN:T->A,V: No effect on interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:T->A,W: Decreases interaction with TLR3.	SEQ_UP	1	
MUTAGEN:T->A: 8-fold less potently activated by the Scolopendra mutilans RhTx toxin.	SEQ_UP	1	
MUTAGEN:T->A: Abolished phosphorylation by CaMK2; knockin mice display normal baseline synaptic transmission and long-term potentiation (LTP) in the hippocampus, but metabotropic receptor-LTD is increased; when associated with A-278.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes ability to mediate necroptosis.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes ability to suppress cell growth. Decreased phosphorylation; when associated with A-366. No change in kinase activity; when associated with A-31; A-325 and A-366.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes activation by STK11/LKB1.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes all phosphodiesterase activity. Abolishes formation of nucleotidylated intermediate.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes AMPK-mediated phosphorylation; when associated with A-538.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes ATP binding.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes autophosphorylation. Loss of FOXO3 activation. Reduces association with DAGLA. Enhances DAGLA enzymatic activity with an increase of 2-AG levels in dorsolateral striatal tissue of knockin mice. Inhibition of 2-AG breakdown using JZL-184 decreased locomotor activity in knockin mice.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes dimerization.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes ganglioside binding.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes GTP hydrolysis.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes in vitro phosphorylation.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes increase of intrinsic ATPase activity upon interaction with membranes.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes inhibition of FOXO1 transcriptional activity.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes inositol 1,4,5-triphosphate binding.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes interaction with S100A10, plasma membrane localization and channel activity.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes interaction with TACC3.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes kinase activity.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes mitotic phosphorylation and decreases mitotic index as well as CDK1 activity; when associated with A-574; A-643; A-656; A-664; A-699 and A-760.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes mitotic phosphorylation and decreases mitotic index as well as CDK1 activity; when associated with A-643; A-656; A-664; A-686; A-699 and A-760.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes phosphatase activity.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes phosphatase activity. Abolishes phosphatase activity; when associated with S-67 and R-72. Strongly reduces phosphatase activity; when associated with S-67; R-71 and R-72. Mildly reduces phosphatase activity; when associated with R-71 and R-72.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes phosphorylation and strongly reduces inhibitory activity.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes phosphorylation by GSK3B. Reduces phosphorylation by MAPK. Affects polarized cell migration. Increases RhoGAP catalytic activity.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes phosphorylation in response to forskolin. Localizes mainly to the cytosol. Weakly enhances FOXO1 acetylation. Weakly abolishes inhibition of FOXO1 transcriptional activity.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes phosphorylation, abolishes CD44 splicing regulation; when associated with A-58 and A-71.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes phosphorylation, abolishes CD44 splicing regulation; when associated with A-58 and A-84.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes phosphorylation, DNA binding and pericentromeric location. Loss of DNA binding and pericentromeric location; when associated with A-167 and A-195.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes phosphorylation.	SEQ_UP	2	
MUTAGEN:T->A: Abolishes phosphorylation. No change in binding to gamma satellites A and B. No change in pericentromeric location.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes plasma membrane localization and channel activity.	SEQ_UP	1	
MUTAGEN:T->A: Abolishes sumoylation. No repression of OCT4 gene expression with or without retinoic acid and enhanced interaction with KAT2B and HDAC3. Abolishes interaction with HDAC3 and PML association; when associated with R-238.	SEQ_UP	1	
MUTAGEN:T->A: Almost complete loss of kinase activity; even upon arsenite treatment.	SEQ_UP	1	
MUTAGEN:T->A: Almost no EGF-mediated phosphorylation, greatly reduced cellular transformation, and reduced AP1 activity by 20%; when associated with A-325. No effect on PDGF-stimulated enhancement of transcriptional activity. Completely abolishes PDGF-stimulated enhancement of transcriptional activity; when associated with A-232; A-325;and A-374.	SEQ_UP	1	
MUTAGEN:T->A: Almost no EGF-mediated phosphorylation, greatly reduced cellular transformation, and reduced AP1 activity by 20%; when associated with A-331. No effect on PDGF-stimulated enhancement of transcriptional activity. Completely abolishes PDGF-stimulated enhancement of transcriptional activity; when associated with A-232; A-331 and A-374.	SEQ_UP	1	
MUTAGEN:T->A: Blocks phosphorylation by MAPK8.	SEQ_UP	1	
MUTAGEN:T->A: Catalytically inactive.	SEQ_UP	1	
MUTAGEN:T->A: Complete loss of MAPK-mediated phosphorylation; when associated with A-120 and A-148. In neurons, induces the generation of large, flat lamellipodial protrusions; when associated with A-120 and A-148.	SEQ_UP	1	
MUTAGEN:T->A: Complete loss of MAPK-mediated phosphorylation; when associated with A-120 and A-183. In neurons, induces the generation of large, flat lamellipodial protrusions; when associated with A-120 and A-183.	SEQ_UP	1	
MUTAGEN:T->A: Constitutively nuclear. Strongly reduced interaction with FBXO4. Strongly reduced ubiquitination.	SEQ_UP	1	
MUTAGEN:T->A: Decrease of 55-60% of TPase activity.	SEQ_UP	1	
MUTAGEN:T->A: Decreased dendritic localization and decreased translation of reporter mRNA, when associated with Ala-149.	SEQ_UP	1	
MUTAGEN:T->A: Decreased dendritic localization and decreased translation of reporter mRNA, when associated with Ala-165.	SEQ_UP	1	
MUTAGEN:T->A: Decreased export of sphingosine-1-phosphate.	SEQ_UP	1	
MUTAGEN:T->A: Decreased L-threonine 3-dehydrogenase activity.	SEQ_UP	1	
MUTAGEN:T->A: Decreased level of phosphorylation. Loss of phosphorylation; when associated with A-96.	SEQ_UP	1	
MUTAGEN:T->A: Decreased phosphorylation; does not affect the phospholipid scramblase activity.	SEQ_UP	1	
MUTAGEN:T->A: Decreased phosphorylation; impairs the phospholipid scramblase activity.	SEQ_UP	1	
MUTAGEN:T->A: Decreased phosphorylation; when associated with A-43.	SEQ_UP	1	
MUTAGEN:T->A: Decreased protein expression and stability. Decreased embryonic stem cell self-renewal.	SEQ_UP	1	
MUTAGEN:T->A: Decreased protein expression. Decreased embryonic stem cell self-renewal.	SEQ_UP	1	
MUTAGEN:T->A: Decreases insulin-induced phosphorylation by approximately 30%. Nuclear location but transcriptional activity decreased by about 50%. Abolishes the SIRT1 deacetylase binding and increases acetylation; when associated with A-253; A-316; A-462 and A-463. Increased insulin-induced phosphorylation at Ser-253 and binding of 14-3-3 proteins; when associated with Q-219; Q-242; Q-245; Q-259; Q-262; Q-271 and Q-291. Increased binding of 14-3-3 proteins even with decreased insulin-induced phosphorylation at Ser-253; when associated with R-219; R-242; R-245; R-259; R-262; R-271 and R-291.	SEQ_UP	1	
MUTAGEN:T->A: Decreases interaction with CREBBP.	SEQ_UP	1	
MUTAGEN:T->A: Decreases phosphorylation by NLK; when associated with A-284; A-295; A-326; A-380; A-391; A-413 and A-415.	SEQ_UP	1	
MUTAGEN:T->A: Decreases phosphorylation by RPS6KA2.	SEQ_UP	1	
MUTAGEN:T->A: Decreases the interaction with AXIN1, GSK3B-mediated beta-catenin phosphorylation, cytoplasmic beta-catenin accumulation and Wnt-mediated transcription activation.	SEQ_UP	1	
MUTAGEN:T->A: Delayed neurite degeneration.	SEQ_UP	1	
MUTAGEN:T->A: Diminished interaction with CDKN1A and impaired ability to repair UV-induced DNA damage by affecting CDKN1A UV-induced degradation. Decreased phosphorylation; when associated with A-336. No change in kinase activity; when associated with A-31; A-325 and A-336.	SEQ_UP	1	
MUTAGEN:T->A: Diminishes LCFA import and decreases nucleotide binding. No effect on localization to the cell membrane.	SEQ_UP	1	
MUTAGEN:T->A: Diminishes phosphatase activity by 24-fold.	SEQ_UP	1	
MUTAGEN:T->A: Diminishes phosphatase activity.	SEQ_UP	1	
MUTAGEN:T->A: Diminishes the number of microvilli-like structures.	SEQ_UP	1	
MUTAGEN:T->A: Disruption of phosphorylation by MAPK and GSK3B, acquisition of DNA-binding activity and transactivation function; when associated with A-179 and A-184.	SEQ_UP	1	
MUTAGEN:T->A: Disruption of phosphorylation by MAPK and GSK3B, acquisition of DNA-binding activity and transactivation function; when associated with A-184 and A-188.	SEQ_UP	1	
MUTAGEN:T->A: Disrupts targeting to membrane; when associated with A-67; N-68; Q-70; P-73 and Q-75.	SEQ_UP	1	
MUTAGEN:T->A: Distorted neuronal morphology with disturbed polarity and deacetylation of microtubules.	SEQ_UP	1	
MUTAGEN:T->A: Does not affect interaction with Kif5A.	SEQ_UP	1	
MUTAGEN:T->A: Does not affect interaction with the SH3 domain of STAM2.	SEQ_UP	1	
MUTAGEN:T->A: Does not affect interaction with TRIM6.	SEQ_UP	1	
MUTAGEN:T->A: Does not affect MN9 antibody detectability.	SEQ_UP	1	
MUTAGEN:T->A: Does not affect palmitoleoylation.	SEQ_UP	1	
MUTAGEN:T->A: Does not affect phosphorylation at Ser-391 or the interaction with PPP2CA and PPP2R1A.	SEQ_UP	1	
MUTAGEN:T->A: Does not affect phosphorylation by AMPK in vitro.	SEQ_UP	1	
MUTAGEN:T->A: Does not affect phosphorylation by CK2.	SEQ_UP	1	
MUTAGEN:T->A: Does not affect phosphorylation by PKA and nuclear export following ACTH treatment.	SEQ_UP	1	
MUTAGEN:T->A: Does not affect phosphorylation by PKG.	SEQ_UP	1	
MUTAGEN:T->A: Does not affect phosphorylation by RPS6KA2.	SEQ_UP	1	
MUTAGEN:T->A: Does not affect protein expression. Affects intracellular vesicles localization. Impairs intracellular cholesterol accumulation in the vesicle.	SEQ_UP	1	
MUTAGEN:T->A: Does not affect pyrophosphorylation.	SEQ_UP	1	
MUTAGEN:T->A: Does not affect recognition by the CRL2(FEM1B) complex and subsequent ubiquitination.	SEQ_UP	1	
MUTAGEN:T->A: Does not affect subcellular location; when associated with A-261.	SEQ_UP	1	
MUTAGEN:T->A: Does not affect ubiquitination by ZNRF1.	SEQ_UP	1	
MUTAGEN:T->A: Does not detach from actin following BDNF treatment; when associated with A-624.	SEQ_UP	1	
MUTAGEN:T->A: Does not greatlay affect hyperphosphorylation.	SEQ_UP	1	
MUTAGEN:T->A: Does not inhibit calcium-dependent translocation to the cell membrane; when associated with G-286 and G-287.	SEQ_UP	1	
MUTAGEN:T->A: Does not inhibit formate transport in PMA-induced cells.	SEQ_UP	1	
MUTAGEN:T->A: Does not potentiate the phosphorylation of the CREB transcription factor; when associated with A-123.	SEQ_UP	1	
MUTAGEN:T->A: Does not potentiate the phosphorylation of the CREB transcription factor; when associated with A-72.	SEQ_UP	1	
MUTAGEN:T->A: Eliminates platelet aggregation activity.	SEQ_UP	1	
MUTAGEN:T->A: Fails to activate MAP2K1, MAP2K4, MAP2K7, CHUK and IKBKB.	SEQ_UP	1	
MUTAGEN:T->A: Fails to interact with INSR.	SEQ_UP	1	
MUTAGEN:T->A: Fails to rescue pronephric kidney tubule atrophy in zebrafish morpholino knockdown.	SEQ_UP	1	
MUTAGEN:T->A: Formation of unusual long bridge-like intermediate filament structures between two daughter cells during cytokinesis; when associated with A-60. Increased formation of unusual long bridge-like intermediate filament structures between two daughter cells during cytokinesis; when associated with A-32 and A-60.	SEQ_UP	1	
MUTAGEN:T->A: Greatly decreased P-selectin binding and tethering and rolling of cells. No further reduction in P-selectin binding when associated with A-55. Binding of P-selectin completely abolished; when associated with Y-54; A-55; and Y-56.	SEQ_UP	1	
MUTAGEN:T->A: Greatly reduced GSK3B-mediated phosphorylation; when associated with A-485 and A-492.	SEQ_UP	1	
MUTAGEN:T->A: Greatly reduced transactivation activity.	SEQ_UP	1	
MUTAGEN:T->A: Impaired ability to form homodimers or oligomers; when associated with A-141.	SEQ_UP	1	
MUTAGEN:T->A: Impaired hyperphosphorylation.	SEQ_UP	1	
MUTAGEN:T->A: Impairs cell surface expression.	SEQ_UP	1	
MUTAGEN:T->A: Impairs DNA-binding and phosphorylation by MAPK1.	SEQ_UP	1	
MUTAGEN:T->A: Impairs interaction with DYNLL2.	SEQ_UP	1	
MUTAGEN:T->A: Impairs interaction with TACC3.	SEQ_UP	1	
MUTAGEN:T->A: Impairs interaction with YWHAB.	SEQ_UP	1	
MUTAGEN:T->A: Impairs kinase activity, when associated with A-171.	SEQ_UP	1	
MUTAGEN:T->A: Impairs kinase activity, when associated with A-175.	SEQ_UP	1	
MUTAGEN:T->A: Impairs protein kinase activity and shuttling to the cytoplasm.	SEQ_UP	1	
MUTAGEN:T->A: Impairs tubulin binding.	SEQ_UP	1	
MUTAGEN:T->A: In 9A mutant; abolished phosphorylation by PRKDC; does not affect ability to repair double-strand breaks (DSBs), possibly because of redundancy with NHEJ1/XLF phosphorylation sites; when associated with A-53, A-193, A-254, A-295, A-307, A-312, A-319 and A-320.	SEQ_UP	1	
MUTAGEN:T->A: Increase in protein stability, transcriptional activity and the ability to suppress the proliferation of conventional T-cells in vitro; when associated with A-19; A-88 and A-114.	SEQ_UP	1	
MUTAGEN:T->A: Increase in protein stability, transcriptional activity and the ability to suppress the proliferation of conventional T-cells in vitro; when associated with A-19; A-88 and A-175.	SEQ_UP	1	
MUTAGEN:T->A: Increases pain sensitivity; reduces threshold for induction of cortical spreading depression; increases arterial dilation during cortical spreading depression and increases spontaneous and evoked calcium signaling in astrocytes.	SEQ_UP	1	
MUTAGEN:T->A: Inhibits CPE-containing cytoplasmic polyadenylation and translation activation.	SEQ_UP	1	
MUTAGEN:T->A: Interferes with heterodimerization.	SEQ_UP	1	
MUTAGEN:T->A: Lethal at 4-week-old; impaired hematopoiesis due to a decrease in hematopoietic stem and progenitor cells which causes a severe reduction in the numbers of erythrocytes, platelets, lymphocytes and neutrophils; reduced protein synthesis in bone marrow and fetal erythrocyte precursors; normal V(D)J recombination in B-cells; when associated with 2614-A--A-2616, A-2634 and A-2643.	SEQ_UP	1	
MUTAGEN:T->A: Lethal at 4-week-old; impaired hematopoiesis due to a decrease in hematopoietic stem and progenitor cells which causes a severe reduction in the numbers of erythrocytes, platelets, lymphocytes and neutrophils; reduced protein synthesis in bone marrow and fetal erythrocyte precursors; normal V(D)J recombination in B-cells; when associated with A-2605, 2614-A--A-2616 and A-2634.	SEQ_UP	1	
MUTAGEN:T->A: Lethal at 4-week-old; impaired hematopoiesis due to a decrease in hematopoietic stem and progenitor cells which causes a severe reduction in the numbers of erythrocytes, platelets, lymphocytes and neutrophils; reduced protein synthesis in bone marrow and fetal erythrocyte precursors; normal V(D)J recombination in B-cells; when associated with A-2605, 2614-A--A-2616 and A-2643.	SEQ_UP	1	
MUTAGEN:T->A: Loss of activity; when associated with F-161.	SEQ_UP	1	
MUTAGEN:T->A: Loss of autophosphorylation and fails to induce activation of the AP-1 transcription factor, MAPK7 or MAPK8; when associated with A-575 and A-576.	SEQ_UP	1	
MUTAGEN:T->A: Loss of hepatocyte proliferation induction by TGFA.	SEQ_UP	1	
MUTAGEN:T->A: Loss of interaction with 'Lys-63'-linked ubiquitin.	SEQ_UP	1	
MUTAGEN:T->A: Loss of interaction with AFDN, RLF and RALGDS; when associated with L-78.	SEQ_UP	1	
MUTAGEN:T->A: Loss of interaction with CALM1. No effect on desumoylase activity.	SEQ_UP	1	
MUTAGEN:T->A: Loss of interaction with FBXW7 and loss of CDK1-mediated phosphorylation.	SEQ_UP	1	
MUTAGEN:T->A: Loss of interaction with MAGI2 and SHANK1 and loss of function.	SEQ_UP	1	
MUTAGEN:T->A: Loss of interaction with NEMP1.	SEQ_UP	1	
MUTAGEN:T->A: Loss of interaction with RUNDC3A.	SEQ_UP	1	
MUTAGEN:T->A: Loss of kinase activity and autophosphorylation. Fails to activate MAP2K1, MAP2K4, MAP2K7, CHUK and IKBKB.	SEQ_UP	1	
MUTAGEN:T->A: Loss of kinase activity and no phosphorylation of ODF2. No effect on interaction with ODF2.	SEQ_UP	1	
MUTAGEN:T->A: Loss of kinase activity; loss of phosphorylation by CDK7; no effect on autophosphorylation.	SEQ_UP	1	
MUTAGEN:T->A: Loss of kinase activity; when associated with T-209.	SEQ_UP	1	
MUTAGEN:T->A: Loss of kinase activity; when associated with T-214.	SEQ_UP	1	
MUTAGEN:T->A: Loss of kinase activity.	SEQ_UP	1	
MUTAGEN:T->A: Loss of N-glycosylation. No effect on fatty acid elongase activity.	SEQ_UP	1	
MUTAGEN:T->A: Loss of phosphorylation and its ability to interact with NFATC2. Loss of its ability to suppress IL-2 and Th2 cytokine production. No loss of DNA-binding and no loss its ability to activate IFN-gamma transcription.	SEQ_UP	1	
MUTAGEN:T->A: Loss of phosphorylation but no loss of autophagic function; when associated with A-165.	SEQ_UP	1	
MUTAGEN:T->A: Loss of phosphorylation by CDK1. Loss of PLK1-binding.	SEQ_UP	1	
MUTAGEN:T->A: MN9 antibody detectability is lost.	SEQ_UP	1	
MUTAGEN:T->A: No change in binding to DNA.	SEQ_UP	1	
MUTAGEN:T->A: No change in DNA-binding activity.	SEQ_UP	1	
MUTAGEN:T->A: No change of phosphorylation by Rho-kinase.	SEQ_UP	1	
MUTAGEN:T->A: No dephosphorylation.	SEQ_UP	1	
MUTAGEN:T->A: No effect on constituitive phosphorylation, decreased stress-induced phosphorylation but no effect on RXRA transcriptional activity. Abolishes stress-induced phosphorylation but no effect on RXRA transcriptional activity; when associated with A-61 and A-75. phosphorylation. No effect on RXRA transcriptional activity.	SEQ_UP	1	
MUTAGEN:T->A: No effect on IL1B release under basal conditions, nor in response to LT or metabolic inhibitors; when associated with A-738.	SEQ_UP	1	
MUTAGEN:T->A: No effect on interaction with TACC3.	SEQ_UP	1	
MUTAGEN:T->A: No effect on its interaction with RDX.	SEQ_UP	1	
MUTAGEN:T->A: No effect on JAK signal transduction suppression.	SEQ_UP	1	
MUTAGEN:T->A: No effect on kinase activity.	SEQ_UP	1	
MUTAGEN:T->A: No effect on LIF signal transduction suppression.	SEQ_UP	1	
MUTAGEN:T->A: No effect on LPC transport.	SEQ_UP	1	
MUTAGEN:T->A: No effect on MAPK1/3 (ERK1/2) phosphorylation in response to IL18, with or without IL12. Substantial reduction in MAPK1/3 (ERK1/2) phosphorylation in response to IL18, with or without IL12; when associated with A-53 and A-71.	SEQ_UP	1	
MUTAGEN:T->A: No effect on overall phosphorylation.	SEQ_UP	1	
MUTAGEN:T->A: No effect on P-selectin binding. Greatly reduced P-selectin binding and tethering and rolling of cells; when associated with A-58. Binding of P-selectin completely abolished; when associated with Y-54; Y-56 and A-58.	SEQ_UP	1	
MUTAGEN:T->A: No effect on PDGF-stimulated enhancement of transcriptional activity. Completely abolishes PDGF-stimulated enhancement of transcriptional activity; when associated with A-325; A-331 and A-374.	SEQ_UP	1	
MUTAGEN:T->A: No effect on pericentromeric heterochromatin location. No change in DNA binding.	SEQ_UP	1	
MUTAGEN:T->A: No effect on phosphorylation.	SEQ_UP	1	
MUTAGEN:T->A: No effect on predominant location in the cytosol.	SEQ_UP	1	
MUTAGEN:T->A: No effect on SRF activation; No effect on SRF activation, on interaction with EP300 and on SM-specific genes transcription; when associated with A-812; A-859 and A-866.	SEQ_UP	1	
MUTAGEN:T->A: No effect on subcellular localization.	SEQ_UP	1	
MUTAGEN:T->A: No effect on sumoylation.	SEQ_UP	1	
MUTAGEN:T->A: No effect on the regulation of neuronal A-type current in response to activation of metabotropic glutamate receptors.	SEQ_UP	1	
MUTAGEN:T->A: No effect on the stability of the protein under normal conditions. Enhances cleavage and degradation mediated by activated CASP3 and CASP7. Results in reduced autophagy and defective clearance of intestinal pathogens. Increases secretion of pro-inflammatory cytokine IL1B and type I IFN.	SEQ_UP	1	
MUTAGEN:T->A: No effect on UBE2I binding nor on sumoylation.	SEQ_UP	1	
MUTAGEN:T->A: No effect.	SEQ_UP	2	
MUTAGEN:T->A: No IGF1-induced increase in cytoplasmic localization.	SEQ_UP	1	
MUTAGEN:T->A: No loss in its ability to induce IFN-gamma.	SEQ_UP	1	
MUTAGEN:T->A: No loss of glycosylation. Loss of glycosylation; when associated with A-36; A-43; A-54 AND A-60.	SEQ_UP	1	
MUTAGEN:T->A: No loss of glycosylation. Loss of glycosylation; when associated with A-36; A-43; A-54 AND A-67.	SEQ_UP	1	
MUTAGEN:T->A: No loss of glycosylation. Loss of glycosylation; when associated with A-36; A-43; A-60 AND A-67.	SEQ_UP	1	
MUTAGEN:T->A: No loss of interaction with PAWR.	SEQ_UP	1	
MUTAGEN:T->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-267.	SEQ_UP	1	
MUTAGEN:T->A: No loss of MAPK8-mediated phosphorylation. Greatly reduced MAPK8-mediated phosphorylation; when associated with A-199 or A-232. Completely abolishes MAPK8-mediated phosphorylation; when associated with A-199 and A-232.	SEQ_UP	1	
MUTAGEN:T->A: No loss of phospshorylation.	SEQ_UP	1	
MUTAGEN:T->A: Phosphorylation blocked.	SEQ_UP	1	
MUTAGEN:T->A: Prevents degradation of isoform 3.	SEQ_UP	1	
MUTAGEN:T->A: Prevents phosphorylation and activation by STK11/LKB1 complex.	SEQ_UP	1	
MUTAGEN:T->A: Prevents the correct removal of the propeptide.	SEQ_UP	1	
MUTAGEN:T->A: Promotes stabilization due to impaired ubiquitination; when associated with A-223; A-230; A-234 and A-247.	SEQ_UP	1	
MUTAGEN:T->A: Reduced CDK5-mediated phosphorylation. Confers neuron resistance to MPP(+)/MPTP (1-methyl-4-phenylpyridinium). Loss of CDK5-mediated phosphorylation; when associated with S-53.	SEQ_UP	1	
MUTAGEN:T->A: Reduced inhibitory activity towards TORCs in presence and absence of cAMP signaling.	SEQ_UP	1	
MUTAGEN:T->A: Reduced interaction with 14-3-3 proteins in response to cAMP signaling and, thus, still able to inhibit TORC activity. Resistant to inhibition by cAMP signaling and, thus, still able to inhibit TORC activity; when associated with A-358 and A-587.	SEQ_UP	1	
MUTAGEN:T->A: Reduced phosphorylation by PKC/PRKCD, leading to impaired interaction with BCL10 and decreased activation of NF-kappa-B and MAP kinase p38 pathways.	SEQ_UP	1	
MUTAGEN:T->A: Reduced polyubiquitination when co-expressed with NEDD4; when associated with Ala-1962.	SEQ_UP	1	
MUTAGEN:T->A: Reduced tRNA dimethylallyltransferase activity.	SEQ_UP	1	
MUTAGEN:T->A: Reduces binding to SNF.	SEQ_UP	1	
MUTAGEN:T->A: Reduces enzyme activity by about half. Reduces enzyme activity tenfold; when associated with A-45 and A-81.	SEQ_UP	1	
MUTAGEN:T->A: Reduces phosphorylation by CDK5 and impairs interaction with YWHAE. Impairs interaction with KATNA1; when associated with A-198 and A-231.	SEQ_UP	1	
MUTAGEN:T->A: Reduces sensitivity to Mg(2+), but not sensitivity to Ca(2+).	SEQ_UP	1	
MUTAGEN:T->A: Reduces stabilization activity on RNF41.	SEQ_UP	1	
MUTAGEN:T->A: Remains exclusively in the nucleolus; when associated with A-109.	SEQ_UP	1	
MUTAGEN:T->A: Results in hyperphosphorylation of the RAF-dependent sites and prolonged ERK phosphorylation.	SEQ_UP	1	
MUTAGEN:T->A: Results in loss of phosphorylation of MAPK8IP3; when associated with A-266 and A-287. Does not effect binding of components of the JNK pathway.	SEQ_UP	1	
MUTAGEN:T->A: Results in loss of phosphorylation of MAPK8IP3; when associated with A-276 and A-287. Does not effect binding of components of the JNK pathway.	SEQ_UP	1	
MUTAGEN:T->A: Significant reduction in LPC transport.	SEQ_UP	1	
MUTAGEN:T->A: Significantly reduced phosphorylation and 2- to 3-fold increase in ability to arrest in G(1); when associated with A-384; A-386; A-388 and A-392. Further reduction in phosphorylation; when associated with A-63; A-384; A-386; A-388 and A-392.	SEQ_UP	1	
MUTAGEN:T->A: Slight decrease phosphorylation by Rho-kinase. No change in promoting neurite growth; when associated with A-1662 and A-1672.	SEQ_UP	1	
MUTAGEN:T->A: Slightly increased LPC transport.	SEQ_UP	1	
MUTAGEN:T->A: Slightly reduced LPC transport.	SEQ_UP	1	
MUTAGEN:T->A: Spontaneous IL1B release under basal conditions, loss of response to metabolic inhibitors and to LT; when associated with A-658.	SEQ_UP	1	
MUTAGEN:T->A: Spontaneous IL1B release under basal conditions, no effect on the response to metabolic inhibitors, partial loss of response to LT; when associated with A-687.	SEQ_UP	1	
MUTAGEN:T->A: Strong decrease in kinase activity; when associated with A-208.	SEQ_UP	1	
MUTAGEN:T->A: Strong decrease in kinase activity; when associated with A-320.	SEQ_UP	1	
MUTAGEN:T->A: Strongly decrease phosphorylation by Rho-kinase. No change in promoting neurite growth; when associated with A-1668 and A-1672.	SEQ_UP	1	
MUTAGEN:T->A: Strongly decreased interaction with KEAP1.	SEQ_UP	1	
MUTAGEN:T->A: Strongly reduces affinity for DNA; when associated with A-189 and A-198.	SEQ_UP	1	
MUTAGEN:T->A: Substantial reduction in MAPK1/3 (ERK1/2) phosphorylation in response to IL18, with or without IL12.	SEQ_UP	1	
MUTAGEN:T->A: Telomere-attachment defects.	SEQ_UP	1	
MUTAGEN:T->C: No change in binding to DNA and confers DNA-binding sensitivity to sulfhydryl modifications.	SEQ_UP	1	
MUTAGEN:T->D,E: Abrogates autophosphorylation.	SEQ_UP	1	
MUTAGEN:T->D,E: Displays a more cytosolic distribution.	SEQ_UP	1	
MUTAGEN:T->D,E: No interaction with DLG1 and DLG4.	SEQ_UP	1	
MUTAGEN:T->D,V: Does not significantly affect kinase activity.	SEQ_UP	1	
MUTAGEN:T->D: Abolishes binding to HRAS and KRAS; does not affect kinase activity; displays defective development of the lymphatic vasculature, resulting in perinatal appearance of chylous ascites and is highly resistant to endogenous Ras oncogene-induced tumorigenesis; when associated with A-227.	SEQ_UP	1	
MUTAGEN:T->D: Activating mutant.	SEQ_UP	1	
MUTAGEN:T->D: Adopts a nucleus-wide distribution; when associated with D-109.	SEQ_UP	1	
MUTAGEN:T->D: Almost complete loss of kinase activity; even upon arsenite treatment.	SEQ_UP	1	
MUTAGEN:T->D: Constitutively active kinase; loss of regulation by heme and arsenite.	SEQ_UP	1	
MUTAGEN:T->D: Decreased binding to gamma satellites A and B by 3-fold. Little change in pericentromeric location.	SEQ_UP	1	
MUTAGEN:T->D: Dominant active form; when associated with D-311.	SEQ_UP	1	
MUTAGEN:T->D: Dramatic decrease in DNA-binding.	SEQ_UP	1	
MUTAGEN:T->D: Greatly reduced phosphorylation by CDK1 or CDK2. Completely abolished phosphorylation by CDK1 or CDK2; when associated with D-444.	SEQ_UP	1	
MUTAGEN:T->D: Impairs DNA-binding.	SEQ_UP	1	
MUTAGEN:T->D: Increased deacetylase activity toward p53/TP53 and increases resistance to genotoxic stress (mimicks residue phosphorylation).	SEQ_UP	1	
MUTAGEN:T->D: Induction of F-actin-bundling; when associated with D-120 and D-148. In neurons, induces the generation of long and prominent filopodia; when associated with D-120 and D-148.	SEQ_UP	1	
MUTAGEN:T->D: Induction of F-actin-bundling; when associated with D-120 and D-183. In neurons, induces the generation of long and prominent filopodia; when associated with D-120 and D-183.	SEQ_UP	1	
MUTAGEN:T->D: Inhibits in vitro interaction between ITCH HECT domain and PRR/WW motifs. More sensitive to in vitro proteolysis.	SEQ_UP	1	
MUTAGEN:T->D: Mimicks phosphorylation state, localizes mainly to the nucleus. Strongly enhances FOXO1 acetylation. Strongly abolishes inhibition of FOXO1 transcriptional activity.	SEQ_UP	1	
MUTAGEN:T->D: Mimics phosphorylation state; impairs interaction with TERF1.	SEQ_UP	1	
MUTAGEN:T->D: Mimics phosphorylation status; activation of the phospholipid scramblase activity.	SEQ_UP	1	
MUTAGEN:T->D: Mimics phosphorylation status; does not affect the phospholipid scramblase activity.	SEQ_UP	1	
MUTAGEN:T->D: No change in transactivation activity.	SEQ_UP	1	
MUTAGEN:T->D: No effect on kinase activity.	SEQ_UP	1	
MUTAGEN:T->D: No effect on microvilli-like structures.	SEQ_UP	1	
MUTAGEN:T->D: No effect on SRF activation. Impairs SRF activation, reduces interaction with EP300 and SM-promoter activation; when associated with D-812; D-859 and D-866.	SEQ_UP	1	
MUTAGEN:T->D: No phosphorylation by PDPK1.	SEQ_UP	1	
MUTAGEN:T->D: Phosphomimetic mutant; does not affect ability to homooligomerize.	SEQ_UP	1	
MUTAGEN:T->D: Phosphomimetic mutant. Enhanced FOXO3 activation.	SEQ_UP	1	
MUTAGEN:T->D: Prevents aberrant myotube formation in PIEZO1-deficient myoblast; when associated with D-20.	SEQ_UP	1	
MUTAGEN:T->D: Reduces interaction with Kif5A.	SEQ_UP	1	
MUTAGEN:T->D: Results in hypophosphorylation of the RAF-dependent sites and faster ERK inactivation.	SEQ_UP	1	
MUTAGEN:T->D: Strongly increased location in the nucleus.	SEQ_UP	1	
MUTAGEN:T->E: Abolishes dimerization.	SEQ_UP	1	
MUTAGEN:T->E: Abolishes phosphorylation, DNA binding and pericentromeric location. Loss of DNA binding and pericentromeric location; when associated with E-167 and D-195.	SEQ_UP	1	
MUTAGEN:T->E: Confers neuron sensitivity to MPP(+)/MPTP (1-methyl-4-phenylpyridinium).	SEQ_UP	1	
MUTAGEN:T->E: Does not affect histone methyltransferase activity. Increases methyltransferase activity; when associated with S-1920.	SEQ_UP	1	
MUTAGEN:T->E: Increases activity four-fold.	SEQ_UP	1	
MUTAGEN:T->E: Induces hepatocyte proliferation.	SEQ_UP	1	
MUTAGEN:T->E: Loss of cMyc-induced CDK2-mediated phosphorylation. Rapid dissociation from the cyclin E/CDK2 complex after induction by c-Myc.	SEQ_UP	1	
MUTAGEN:T->E: Loss of kinase activity and autophosphorylation.	SEQ_UP	1	
MUTAGEN:T->E: Loss of localization to the plasma membrane.	SEQ_UP	1	
MUTAGEN:T->E: Loss of PLK1-binding.	SEQ_UP	1	
MUTAGEN:T->E: Low levels of constitutive activity.	SEQ_UP	2	
MUTAGEN:T->E: Mimicks phosphorylation state and constitutive protein kinase activity; when associated with E-208.	SEQ_UP	1	
MUTAGEN:T->E: Mimicks phosphorylation state and constitutive protein kinase activity; when associated with E-320.	SEQ_UP	1	
MUTAGEN:T->E: Mimicks phosphorylation state, leading to increased activity.	SEQ_UP	1	
MUTAGEN:T->E: Mimicks phosphorylation state, reduced ability to restrict LINE-1 retrotransposon activity.	SEQ_UP	1	
MUTAGEN:T->E: Mimicks phosphorylation state; promotes detachment from actin in absence of BDNF treatment; when associated with E-624.	SEQ_UP	1	
MUTAGEN:T->E: No effect on MAPK8IP1 binding.	SEQ_UP	1	
MUTAGEN:T->E: Reduces actin polymerization to a lesser extent than wild-type.	SEQ_UP	1	
MUTAGEN:T->E: Strongly reduced binding and degradation of target proteins; when associated with D-158.	SEQ_UP	1	
MUTAGEN:T->E: Sumoylated. Repressed OCT4 gene expression. Enhanced interaction with KAT2B; when associated with R-238.	SEQ_UP	1	
MUTAGEN:T->E: When expressed in hippocampal neurons, increases the density of both spines and dendritic protrusions.	SEQ_UP	2	
MUTAGEN:T->F: Does not affect ability to promote phosphatidylserine exposure.	SEQ_UP	1	
MUTAGEN:T->F: Significant reduction in LPC transport.	SEQ_UP	1	
MUTAGEN:T->G: Abolishes interaction with DYNLL2.	SEQ_UP	1	
MUTAGEN:T->G: Reduces affinity for GTP 20-fold.	SEQ_UP	1	
MUTAGEN:T->G: Results in inhibition of JNK binding.	SEQ_UP	1	
MUTAGEN:T->I: Confers constitutive activity.	SEQ_UP	1	
MUTAGEN:T->I: In Ld KCST-less, strongly impairs ubiquitination; when associated with R-332; R-340; 350-A--A-356 and 360-R-R-361. In Ld tail 1S, restores ubiquitination; when associated R-332; R-340; 350-A--A-352; A-356 and 360-R-R-361.	SEQ_UP	1	
MUTAGEN:T->I: Loss of inhibition by imatinib. Loss of inhibition by GNF-2.	SEQ_UP	1	
MUTAGEN:T->I: Loss of interaction with SYNCRIP.	SEQ_UP	1	
MUTAGEN:T->I: Nearly abolishes phosphatase activity.	SEQ_UP	1	
MUTAGEN:T->I: No effect on interaction with FYN SH3 domain.	SEQ_UP	1	
MUTAGEN:T->I: No effect on protein abundance. Not associated with changes in subcellular location.	SEQ_UP	1	
MUTAGEN:T->I: No significant effect on lipid phosphatase activity.	SEQ_UP	1	
MUTAGEN:T->I: Slightly reduced affinity for DNA.	SEQ_UP	1	
MUTAGEN:T->K: Decreases sedoheptulose kinase activity; when associated with M-14.	SEQ_UP	1	
MUTAGEN:T->K: Greatly reduces MHC class I peptide tetramer binding; when associated with D-160.	SEQ_UP	1	
MUTAGEN:T->L: Reduces affinity to GTP and GDP. Inhibits interaction with PDE6D.	SEQ_UP	1	
MUTAGEN:T->M: Abolishes LPC transport.	SEQ_UP	1	
MUTAGEN:T->M: Corresponds to M-275 variant associated with SPGF16 in human. Impairs nuclear inner membrane location and decreases interaction with DNAJB13.	SEQ_UP	1	
MUTAGEN:T->M: Decreased transporter activity. Loss of localization to plasma membrane.	SEQ_UP	1	
MUTAGEN:T->M: Decreased tubulin deglutamylation.	SEQ_UP	1	
MUTAGEN:T->M: Decreases sedoheptulose kinase activity; when associated with K-15.	SEQ_UP	1	
MUTAGEN:T->M: Does not cause loss of water channel activity, but impairs trafficking from cytoplasmic vesicles to the cell membrane.	SEQ_UP	1	
MUTAGEN:T->M: Loss of localization to the nucleus. Distributes diffusely in cells. Interacts normally with NCOR2.	SEQ_UP	1	
MUTAGEN:T->M: Macrophages exhibit increased apoptosis, reduced proliferation, and reduced phagocytosis. Macrophages also exhibit increased inflammatory cytokine secretion. Microglia demonstrate reduced immune activity. Also decreases cerebral blood flow and reduces cerebral glucose metabolism.	SEQ_UP	1	
MUTAGEN:T->M: Significant reduction in LPC transport.	SEQ_UP	1	
MUTAGEN:T->N: Abolishes processive activity.	SEQ_UP	1	
MUTAGEN:T->N: Affects interaction with ATG16L1.	SEQ_UP	1	
MUTAGEN:T->N: Constitutively inactivated. Abolishes interaction with PARD6 and DOCK11. Inhibits filopodia formation.	SEQ_UP	1	
MUTAGEN:T->N: Defects in GTP-binding. Decrease in integrin-binding.	SEQ_UP	1	
MUTAGEN:T->N: Inactive GDP-bound form which does not bind TJAP1.	SEQ_UP	1	
MUTAGEN:T->N: Inhibits interaction with PDE6D.	SEQ_UP	1	
MUTAGEN:T->N: Loss of ability to induce formation of neurite-like membrane protrusions in non-neuronal cells.	SEQ_UP	1	
MUTAGEN:T->N: Loss of activity; delays formation of epithelial polarity.	SEQ_UP	1	
MUTAGEN:T->N: Loss of binding to rabkinesin-6; when associated with L-73.	SEQ_UP	1	
MUTAGEN:T->N: No effect on RANBP10-binding. Loss of interaction with NEMP1.	SEQ_UP	1	
MUTAGEN:T->N: Reduced axon localization and aggregation in neuronal cell bodies.	SEQ_UP	1	
MUTAGEN:T->N: Strongly reduces FLRT2 binding; when associated with T-269.	SEQ_UP	1	
MUTAGEN:T->P: Decreased levels of protein expression in thymocytes. Reduced numbers of CD4 and CD8 single-positive thymocytes as well as reduced numbers of peripheral CD4 and CD8 T-cells.	SEQ_UP	1	
MUTAGEN:T->P: Decreased lipid phosphatase activity.	SEQ_UP	1	
MUTAGEN:T->P: Does not affect the interaction with TECTA nor subcellular localization.	SEQ_UP	1	
MUTAGEN:T->P: In Fgn mutant; gain-of-function mutation; causes an alopecia phenotype. Attenuates intramolecular interaction between the N- and C-terminal domains, hence may relieve autoinhibition; constitutively active in triggering pyroptosis.	SEQ_UP	1	
MUTAGEN:T->Q: Increased kinase activity and autophosphorylation.	SEQ_UP	1	
MUTAGEN:T->R: Converts the coenzyme specificity from NADP to NAD.	SEQ_UP	1	
MUTAGEN:T->R: Failure to correctly traffic to the cell membrane and diminished Mg(2+) transport.	SEQ_UP	1	
MUTAGEN:T->R: Increases polynucleotide adenylyltransferase activity.	SEQ_UP	1	
MUTAGEN:T->R: Slightly increases phosphatase activity with p-nitrophenylphosphate; when associated with N-41 and I-45.	SEQ_UP	1	
MUTAGEN:T->R: The mutant protein is able to coassemble and traffic to the cell membrane.	SEQ_UP	1	
MUTAGEN:T->S: Decreases phosphodiesterase activity by 95%. Accumulates nucleotidylated intermediate.	SEQ_UP	1	
MUTAGEN:T->S: Impairs interaction with DYNLL2.	SEQ_UP	1	
MUTAGEN:T->S: No effect on lipid phosphatase activity.	SEQ_UP	1	
MUTAGEN:T->S: Reduced kinase activity and autophosphorylation.	SEQ_UP	1	
MUTAGEN:T->S: Strongly reduces phosphatase activity; when associated with R-71; R-72 and A-73. Abolishes phosphatase activity; when associated with R-72 and A-73.	SEQ_UP	1	
MUTAGEN:T->TT: Gives susceptibility to xenotropic murine leukemia retroviruses infection.	SEQ_UP	1	
MUTAGEN:T->V,L: No effect on interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:T->V: Abrogates autophosphorylation. Retains ability to homodimerize. Abrogates ability to induce MYB degradation.	SEQ_UP	1	
MUTAGEN:T->V: Decreases activity three-fold.	SEQ_UP	1	
MUTAGEN:T->V: Dominant negative form; when associated with A-311.	SEQ_UP	1	
MUTAGEN:T->V: Loss of cMYC-induced CDK2-mediated phosphorylation Dissociates very slowly from the cyclin E/CDK2 complex after induction by cMYC. Cell cycle arrest.	SEQ_UP	1	
MUTAGEN:T->V: No significant effect on its binding and activation by DLL1 or JAG1. No effect on RFNG-, LFNG- and MFNG-mediated enhancement of its activation by DLL1. Decrease in LFNG- and MFNG-mediated inhibition of its activation by JAG1. Significant decrease in LFNG- and MFNG-mediated inhibition of its activation by JAG1; when associated with V-232.	SEQ_UP	1	
MUTAGEN:T->V: No significant effect on its binding and activation by DLL1 or JAG1. No effect on RFNG-, LFNG- and MFNG-mediated enhancement of its activation by DLL1. No effect on LFNG- and MFNG-mediated inhibition of its activation by JAG1.	SEQ_UP	1	
MUTAGEN:T->V: No significant effect on its binding and activation by DLL1 or JAG1. No significant effect on RFNG-, LFNG- and MFNG-mediated enhancement of its activation by DLL1. Decrease in LFNG- and MFNG-mediated inhibition of its activation by JAG1. Significant decrease in LFNG- and MFNG-mediated inhibition of its activation by JAG1; when associated with V-1402.	SEQ_UP	1	
MUTAGEN:T->V: Not phosphorylated; when associated with A-693 and A-696. Not phosphorylated and doesn't prevent phosphorylation at S-693 and S-696. Reduces NOTCH1 transactivation; when associated with A-693 and A-696. Reduces cell surface levels of proteins; when associated with A-693 and A-696. Increases ectodomain shedding; when associated with A-693 and A-696.	SEQ_UP	1	
MUTAGEN:T->V: Reduced binding and activation by DLL1 but not JAG1. Decrease in RFNG- and LFNG-mediated enhancement of its activation by DLL1. Loss of RFNG-mediated enhancement of its activation by JAG1. Significant loss of binding and activation by DLL1 or JAG1 and complete loss of RFNG- and LFNG-mediated enhancement of its activation by DLL1; when associated with V-311.	SEQ_UP	1	
MUTAGEN:T->V: Reduced binding and activation by DLL1 but not JAG1. No effect on RFNG-, LFNG- and MFNG-mediated enhancement of its activation by DLL1. No effect on LFNG- and MFNG-mediated inhibition of its activation by JAG1.	SEQ_UP	1	
MUTAGEN:T->V: Reduced binding and activation by JAG1 but not DLL1. Decrease in MFNG-mediated enhancement of its activation by DLL1.	SEQ_UP	1	
MUTAGEN:T->V: Reduced binding and activation by JAG1 but not DLL1. No effect on RFNG-, LFNG- and MFNG-mediated enhancement of its activation by DLL1. No effect on LFNG- and MFNG-mediated inhibition of its activation by JAG1.	SEQ_UP	1	
MUTAGEN:T->V: Reduces phosphorylation. Impairs deacetylase activity toward p53/TP53 and decreases resistance to genotoxic stress. Does not change nuclear localization.	SEQ_UP	1	
MUTAGEN:T->V: Significant loss of binding and activation by DLL1 or JAG1. Decrease in RFNG-, LFNG- and MFNG-mediated enhancement of its activation by DLL1. Decrease in LFNG-mediated inhibition of its activation by JAG1. Significant loss of binding and activation by DLL1 or JAG1 and complete loss of RFNG- and LFNG-mediated enhancement of its activation by DLL1; when associated with V-466. Decreased localization to the plasma membrane; when associated with A-435.	SEQ_UP	1	
MUTAGEN:T->W: Does not abolish interaction with ASIC3, but abolishes regulation of ASIC2 and ASIC3 channel activity.	SEQ_UP	1	
MUTAGEN:T->Y: Abolishes interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:T->Y: No effect on PDCD1 binding.	SEQ_UP	1	
MUTAGEN:T->Y: Significantly reduces the binding to PDCD1.	SEQ_UP	1	
MUTAGEN:TCV->AAA: Does not affect subcellular localization.	SEQ_UP	1	
MUTAGEN:TDTSVRRNDLSVISS->ADAAVRRNDLAVIAA: Impairs LCFA-mediated phosphorylation and interaction with ARRB2.	SEQ_UP	1	
MUTAGEN:TDY->ADF: Loss of kinase activity and of autophosphorylation; loss of phosphorylation by CDK7; no effect on nuclear subcellular location.	SEQ_UP	1	
MUTAGEN:TF->AA: Loss of ubiquitin binding.	SEQ_UP	1	
MUTAGEN:TGL->AGA: Almost abolishes interaction with SHANK3.	SEQ_UP	1	
MUTAGEN:TH->AA: Significant loss of interaction with NOS2.	SEQ_UP	1	
MUTAGEN:TLCCTCV->AAAAAAA: Abolished localization to the Golgi apparatus.	SEQ_UP	1	
MUTAGEN:TLCCTCV->AACCACA: Does not affect subcellular localization.	SEQ_UP	1	
MUTAGEN:TP->AA: Partially inhibits U RNA-binding.	SEQ_UP	1	
MUTAGEN:TPPPTPVPS->APPPAPVPA: Decreases phosphorylated form. Deregulation of hepatic glucose metabolism.	SEQ_UP	1	
MUTAGEN:TQT->AQA: Lethal at 4-week-old; impaired hematopoiesis due to a decrease in hematopoietic stem and progenitor cells which causes a severe reduction in the numbers of erythrocytes, platelets, lymphocytes and neutrophils; reduced protein synthesis in bone marrow and fetal erythrocyte precursors; normal V(D)J recombination in B-cells; when associated with A-2605, A-2634 and A-2643.	SEQ_UP	1	
MUTAGEN:TS->AA: No effect on its interaction with NEK7.	SEQ_UP	1	
MUTAGEN:TSGTTG->LEAAA: Abolishes very-long-chain acyl-CoA synthetase activity.	SEQ_UP	1	
MUTAGEN:TSVSPATFPSPLVT->AAVAPAAFPAPLVA: No effect on nuclear import.	SEQ_UP	1	
MUTAGEN:TWT->AWA: Decreased localization to the plasma membrane.	SEQ_UP	1	
MUTAGEN:U->C: Increased sensitivity to hydrogen peroxide-induced toxicity.	SEQ_UP	1	
MUTAGEN:U->C: Mice develop normally and were born at the expected Mendelian ratio. Homozygous mice however lose body weight by P14-P16 and are susceptible to fatal epileptic seizures. Cells are extremely sensitive to peroxide-induced cell death because the enzyme is inactivated: The enzyme undergoes overoxidation and irreversible inactivation in the presence of exceeding concentrations of its substrates. Unlike the wild-type enzyme, which can form a selenylamide in the absence of reducing equivalents, thereby preventing its irreversible overoxidation, the mutant fails to form such an intermediate during its catalytic cycle.	SEQ_UP	1	
MUTAGEN:U->C: Optimum pH 7.5.	SEQ_UP	1	
MUTAGEN:U->C: Thioredoxin reductase activity reduced to 21%. Glutaredoxin activity reduced to 14%. Glutathione reductase activity reduced to 18%.	SEQ_UP	1	
MUTAGEN:U->S: Abolishes thioredoxin reductase, glutaredoxin and gluthioine reductase activities.	SEQ_UP	1	
MUTAGEN:U->S: Early embryonic lethality in homozygous mice. Male subfertility in heterozygous mice due to impaired spermatogenesis.	SEQ_UP	1	
MUTAGEN:U->S: Impairs protection against hydrogen peroxide-induced toxicity.	SEQ_UP	1	
MUTAGEN:V->A,C,I,P: Partial retention in the endoplasmic reticulum.	SEQ_UP	1	
MUTAGEN:V->A,D,E,I: No effect on binding to AP-2.	SEQ_UP	1	
MUTAGEN:V->A,G: Increased enzymatic activity and changed stereoselectivity of the oxygenation reaction to produce (11R)-HPETE preferentially instead of (12R)-HPETE.	SEQ_UP	1	
MUTAGEN:V->A,L: Mildly increases the affinity for CALM.	SEQ_UP	1	
MUTAGEN:V->A: Abolishes binding to DVL1.	SEQ_UP	1	
MUTAGEN:V->A: Abolishes binding to PP1 but has no effect on binding to glycogen synthase, glycogen phosphorylase or glycogen; when associated with A-87.	SEQ_UP	1	
MUTAGEN:V->A: Abolishes homodimerization. Strongly reduced E3 ubiquitin ligase activity.	SEQ_UP	1	
MUTAGEN:V->A: Abolishes interaction with histone H4 acetylated N-terminus; when associated with 293-AA-294.	SEQ_UP	1	
MUTAGEN:V->A: Abolishes interaction with histone H4 acetylated N-terminus; when associated with 50-AA-51.	SEQ_UP	1	
MUTAGEN:V->A: Abolishes interaction with RAB27A.	SEQ_UP	1	
MUTAGEN:V->A: Abolishes interaction with TACC3.	SEQ_UP	1	
MUTAGEN:V->A: Abolishes linear polyubiquitin-binding, impairs 'Lys-63'-linked polyubiquitin-binding and impairs NF-kappa-B activation; when associated with A-301 and A-302.	SEQ_UP	1	
MUTAGEN:V->A: Abolishes localization to cilium.	SEQ_UP	1	
MUTAGEN:V->A: Abolishes localization to microtubules.	SEQ_UP	1	
MUTAGEN:V->A: Decrease in MARK3 binding; when associated with A-397.	SEQ_UP	1	
MUTAGEN:V->A: Decreased activity; when associated with A-422 and A-436.	SEQ_UP	1	
MUTAGEN:V->A: Decreased activity; when associated with A-429 and A-436.	SEQ_UP	1	
MUTAGEN:V->A: Decreased calcium-dependent cell-cell adhesion.	SEQ_UP	1	
MUTAGEN:V->A: Decreased DNA binding and transcriptional activity.	SEQ_UP	1	
MUTAGEN:V->A: Disrupts interaction with ANKRD27; inhibits peripheral distribution of TYRP1 in melanocytes.	SEQ_UP	1	
MUTAGEN:V->A: Disrupts interaction with ANKRD27.	SEQ_UP	1	
MUTAGEN:V->A: Does not affect ability to promote phosphatidylserine exposure.	SEQ_UP	1	
MUTAGEN:V->A: Does not affect the interaction with GATA1.	SEQ_UP	1	
MUTAGEN:V->A: Drastic decrease of CBX5, CBX1 and CBX3 binding; When associated with A-891.	SEQ_UP	1	
MUTAGEN:V->A: Greatly reduced activity.	SEQ_UP	1	
MUTAGEN:V->A: Greatly reduced binding to MAD; when associated with V-307 and D-308.	SEQ_UP	1	
MUTAGEN:V->A: Impaired interaction with DWORF and PLN; when associated with A-802 and A-809.	SEQ_UP	1	
MUTAGEN:V->A: Impairs interaction with PP1; when associated with A-221.	SEQ_UP	1	
MUTAGEN:V->A: Impairs interaction with PP1; when associated with A-310.	SEQ_UP	1	
MUTAGEN:V->A: Impairs interaction with PTPN11 and PTPN6. Doesn't affect phosphorylation.	SEQ_UP	1	
MUTAGEN:V->A: Increased threshold for activation by calcium. Increased permeability to chloride ions.	SEQ_UP	1	
MUTAGEN:V->A: Interferes with heterodimerization.	SEQ_UP	1	
MUTAGEN:V->A: Loss of AP-1 and NF-kappa-B transcription factor activity. Reduced ability to activate MAP2K1, MAP2K4, MAP2K7, CHUK and IKBKB.	SEQ_UP	1	
MUTAGEN:V->A: Loss of interaction with DLG4.	SEQ_UP	1	
MUTAGEN:V->A: Loss of interaction with PARW. No effect on interaction with MET. Loss of interaction with NOS2.	SEQ_UP	1	
MUTAGEN:V->A: Loss of microtubule depolymerization activity.	SEQ_UP	1	
MUTAGEN:V->A: Loss of the effect on myogenic differentiation; when associated with A-832. Loss of interaction with DLG4; when associated with A-832 and A-833.	SEQ_UP	1	
MUTAGEN:V->A: No activity for acetyl-CoA. Activity for palmitoyl-CoA decreased.	SEQ_UP	1	
MUTAGEN:V->A: No effect on acetylated histone binding.	SEQ_UP	1	
MUTAGEN:V->A: No effect on affinity for CALM; when associated with A-740.	SEQ_UP	1	
MUTAGEN:V->A: No effect on affinity for NPC2.	SEQ_UP	1	
MUTAGEN:V->A: No effect on AP-1 transcription factor activity.	SEQ_UP	1	
MUTAGEN:V->A: No effect on cholesterol binding. Strongly decreased cholesterol transport activity.	SEQ_UP	1	
MUTAGEN:V->A: No effect on DNA-binding, no effect on repression of E2F1:TFDP1-mediated transcription and no effect on adipogenesis and granulopoiesis; when associated with A-291.	SEQ_UP	1	
MUTAGEN:V->A: No effect on interaction with SQSTM1; when associated with A-29.	SEQ_UP	1	
MUTAGEN:V->A: No effect on interaction with TACC3.	SEQ_UP	1	
MUTAGEN:V->A: No effect on interaction with TLR4.	SEQ_UP	1	
MUTAGEN:V->A: No effect on nuclear import; when associated with A-78 and W-174.	SEQ_UP	1	
MUTAGEN:V->A: No effect on subcellular location.	SEQ_UP	1	
MUTAGEN:V->A: No effect on transcriptional activity and estrogen-induced interaction with NCOA1. Abolishes estrogen-induced interaction with NCOA1; when associated with A-362 and A-376.	SEQ_UP	1	
MUTAGEN:V->A: No effect.	SEQ_UP	1	
MUTAGEN:V->A: No interaction with COP1. Inhibition of degradation under exposure to FSK/INS.	SEQ_UP	1	
MUTAGEN:V->A: No interaction with DLG1 and DLG4.	SEQ_UP	1	
MUTAGEN:V->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-261.	SEQ_UP	1	
MUTAGEN:V->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-265.	SEQ_UP	1	
MUTAGEN:V->A: Reduced activity.	SEQ_UP	1	
MUTAGEN:V->A: Reduced binding to p300 KIX domain; severe reduction in the autonomous transactivation function.	SEQ_UP	1	
MUTAGEN:V->A: Reduced interaction with MAP1LC3B and significant decrease in its autophagy-mediated degradation; when associated with A-273.	SEQ_UP	1	
MUTAGEN:V->A: Reduced interaction with SPSB2.	SEQ_UP	1	
MUTAGEN:V->A: Reduced nuclear export; when associated with A-249.	SEQ_UP	1	
MUTAGEN:V->A: Reduces histone acetyltransferase activity; when associated with A-669 and A-670.	SEQ_UP	1	
MUTAGEN:V->A: Reduces interaction with GOPC.	SEQ_UP	1	
MUTAGEN:V->A: Reduces interaction with the SH3 domain of STAM2.	SEQ_UP	1	
MUTAGEN:V->A: Spontaneous IL1B release under basal conditions, loss of response to metabolic inhibitors, no effect on the response to LT; when associated with A-664.	SEQ_UP	1	
MUTAGEN:V->D,K: Retention in the endoplasmic reticulum; does not form homodimers.	SEQ_UP	1	
MUTAGEN:V->D: Aberrant protein folding and increased proteasomal degradation.	SEQ_UP	1	
MUTAGEN:V->D: Abolishes barbed-end actin-binding without affecting actin bundling activity.	SEQ_UP	1	
MUTAGEN:V->D: Abolishes interaction with CD4 endocytosis signal motif.	SEQ_UP	1	
MUTAGEN:V->D: Abolishes transcriptional activity and estrogen-induced interaction with NCOA1.	SEQ_UP	1	
MUTAGEN:V->D: Alters RRM 1 stability. Abolishes regulation of alternative splicing.	SEQ_UP	1	
MUTAGEN:V->D: Compromises SIM1:ARNT2 heterodimer stability. Does not compromises NPAS4:ARNT2 heterodimer stability.	SEQ_UP	1	
MUTAGEN:V->D: Decreases heterodimer formation with ARNT. Impairs heterodimer formation with ARNT; when associated with A-170.	SEQ_UP	1	
MUTAGEN:V->D: Decreases interaction with VPS35.	SEQ_UP	1	
MUTAGEN:V->D: Destabilizes heterodimerization with ARNT. Compromises the transcriptional repression activity of heterodimer ARNT:NPAS1.	SEQ_UP	1	
MUTAGEN:V->D: Highly disrupts the dimerization ability of AHR. Reduces transcription activity. Impairs interaction with ARNT.	SEQ_UP	1	
MUTAGEN:V->D: Impairs heterodimer formation with EPAS1. Impairs heterodimer formation with HIF1A. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Compromise NPAS4:ARNT heterodimer stability. Compromise AHR:ARNT heterodimer stability.	SEQ_UP	1	
MUTAGEN:V->D: Increased protein levels of Creld2 and Manf in chondrocytes. Prevents Matn3 protein aggregation; in association with A-72 and A-258.	SEQ_UP	1	
MUTAGEN:V->D: Loss of autocatalytic cleavage within the FIIND region and of IL1B release, decrease in CASP1-binding. No effect on homomerization.	SEQ_UP	1	
MUTAGEN:V->D: Markedly decreases heterodimer formation with ARNT. Impairs heterodimer formation with ARNT; when associated with A-171.	SEQ_UP	1	
MUTAGEN:V->D: Markedly decreases heterodimer formation with EPAS1. Markedly decreases heterodimer formation with HIF1A. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Does not compromise NPAS4:ARNT heterodimer stability. Does not compromise AHR:ARNT heterodimer stability.	SEQ_UP	1	
MUTAGEN:V->D: Reduced homoolimerization, leading to reduced ability to induce pyroptosis.	SEQ_UP	1	
MUTAGEN:V->D: Reduces activity. Loss of endogenous retroelement metabolization.	SEQ_UP	1	
MUTAGEN:V->D: Reduces oligomerization. Reduces activation of Wnt signaling.	SEQ_UP	1	
MUTAGEN:V->D: Significanly reduced interaction with SUMO2. Loss of desumoylase activity.	SEQ_UP	1	
MUTAGEN:V->E: Abolishes homodimerization.	SEQ_UP	1	
MUTAGEN:V->E: Abolishes homodimerization. Strongly reduced E3 ubiquitin ligase activity.	SEQ_UP	1	
MUTAGEN:V->E: Abolishes interaction with PP1.	SEQ_UP	1	
MUTAGEN:V->E: Abrogates interaction with EED.	SEQ_UP	1	
MUTAGEN:V->E: Decreases substrate affinity and activity on benzaldehyde, phthalazine and acetaldehyde, while increases affinity for more hydrophobic aldehydes like retinal. Abolishes catalytic activity; when associated with R-884.	SEQ_UP	1	
MUTAGEN:V->E: Equivalent to human variant V66E involved in CTS2 disease. Reduces secretion in tendon cells and nhibits oligomerization. Mutant mice develop inflammation and fibrosis in Achilles tendons and carpal tunnel. They show compromised regenerative capability of tendons.	SEQ_UP	1	
MUTAGEN:V->E: In qk-k24; induces embryonic lethality possibly due to blood vessel defects; prevents RNA-binding but not homodimerization.	SEQ_UP	1	
MUTAGEN:V->E: Inactive mutant unable to increase cAMP upon induction.	SEQ_UP	1	
MUTAGEN:V->E: Reduces pericentromeric localization. Abolishes pericentromeric localization; when associated with G-239.	SEQ_UP	1	
MUTAGEN:V->E: Retains 20% of wild-type activity with sphingomyelin as substrate; retains 70% of wild-type activity with bis(p-nitrophenyl) phosphate as substrate.	SEQ_UP	1	
MUTAGEN:V->F: Abolishes splicing regulation.	SEQ_UP	2	
MUTAGEN:V->F: Decreases cAMP-binding.	SEQ_UP	1	
MUTAGEN:V->F: In short circuit/sci mutant; shorter circadian period, homozygous lethality during embryonic development and diminished ability to activate the transcription of circadian-related neuropeptides.	SEQ_UP	1	
MUTAGEN:V->F: Loss of cholesterol binding. Abolishes cholesterol transport activity. Abolishes stimulation of biliary cholesterol secretion.	SEQ_UP	1	
MUTAGEN:V->F: Reduces interaction with CD4 endocytosis signal motif.	SEQ_UP	1	
MUTAGEN:V->G: Disrupts interaction with ZFPM1. Binds normally to DNA.	SEQ_UP	1	
MUTAGEN:V->G: Does not inhibit calcium-dependent translocation to the cell membrane. Inhibits calcium-dependent translocation to the cell membrane; when associated with G-282 and G-284.	SEQ_UP	1	
MUTAGEN:V->G: Does not inhibit calcium-dependent translocation to the cell membrane. Inhibits calcium-dependent translocation to the cell membrane; when associated with G-283 and G-284.	SEQ_UP	1	
MUTAGEN:V->G: Increased phosphatidylinositol 3,4,5-trisphosphate binding.	SEQ_UP	1	
MUTAGEN:V->G: Loss of activity.	SEQ_UP	1	
MUTAGEN:V->G: Loss of binding to AP-2 and can bind to AP-1; when associated with D-270.	SEQ_UP	1	
MUTAGEN:V->G: Loss of interaction with GRIP1 and GRIP2.	SEQ_UP	1	
MUTAGEN:V->G: No effect on PARD6B interaction. Prevents interaction with PATJ; when associated with G-150.	SEQ_UP	1	
MUTAGEN:V->G: Prevents interaction with LIN7C.	SEQ_UP	1	
MUTAGEN:V->G: Prevents interaction with PARD6B. Does not affect localization to the tight junctions.	SEQ_UP	1	
MUTAGEN:V->G: Rescued partially pronephric kidney tubule atrophy in zebrafish morpholino knockdown.	SEQ_UP	1	
MUTAGEN:V->I: Abolishes transcriptional activity. Increases transcriptional repression. Disrupts induction of neurite outgrowth and expression of synaptic genes. No effect on transactivation of BCL2 expression.	SEQ_UP	1	
MUTAGEN:V->I: Increases affinity to CDCA and transcriptional activity in response to CDCA; when associated with N-370.	SEQ_UP	1	
MUTAGEN:V->I: No effect on interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:V->I: No effect on interaction with PARD6B.	SEQ_UP	1	
MUTAGEN:V->I: No effect on sterol transport; when associated with S-216.	SEQ_UP	1	
MUTAGEN:V->I: Reduced function.	SEQ_UP	1	
MUTAGEN:V->I: Shows less organization of the circumferential actin-filament network compared to controls.	SEQ_UP	1	
MUTAGEN:V->K,L,R: Increased permeability to chloride ions.	SEQ_UP	1	
MUTAGEN:V->K: No change in DNA binding. No loss of self-renewal ability in iPS cells. No change in nuclear location.	SEQ_UP	1	
MUTAGEN:V->L,N,P,S: Loss of binding to AP-2.	SEQ_UP	1	
MUTAGEN:V->L: Homozygous knockin male mice are infertile. Testis size, sperm concentration, viability and motility are normal. However the acrosome is detached from the nuclear envelope in sperm. Proacrosomal vesicles in the Golgi phase are atypical and separated in testis and they failed to fuse in the cap phase.	SEQ_UP	1	
MUTAGEN:V->L: Localizes mainly to the ER compartment.	SEQ_UP	1	
MUTAGEN:V->L: Loss of co-localization with CACNA1S and strongly decreased co-localization with CACNA1C; when associated with E-133.	SEQ_UP	1	
MUTAGEN:V->L: NICD processing severely reduced.	SEQ_UP	2	
MUTAGEN:V->L: No effect on autocatalytic cleavage within the FIIND region.	SEQ_UP	1	
MUTAGEN:V->L: Reduced activity.	SEQ_UP	1	
MUTAGEN:V->L: Strongly reduced inhibition by GNF-2.	SEQ_UP	1	
MUTAGEN:V->M,N,Y,H,E,Q,T,S,L,W,F,G: Retention in the endoplasmic reticulum.	SEQ_UP	1	
MUTAGEN:V->M: Abolishes CDC20 binding.	SEQ_UP	1	
MUTAGEN:V->M: Abolishes interaction with SUV39H1.	SEQ_UP	1	
MUTAGEN:V->M: Corresponds to M-261 variant associated with SPGF16 in human. Decreases protein solubility, impairs nuclear inner membrane location and decreases interaction with DNAJB13.	SEQ_UP	1	
MUTAGEN:V->M: Disrupts interaction with ZFPM1. Binds normally to DNA.	SEQ_UP	1	
MUTAGEN:V->M: Kinase dead; loss of autophosphorylation and loss of CHN1 phosphorylation. No effect on interaction with NGEF.	SEQ_UP	1	
MUTAGEN:V->M: Loss of activity.	SEQ_UP	1	
MUTAGEN:V->M: No change to global protein fold or protein stability. Alters local protein folding.	SEQ_UP	1	
MUTAGEN:V->M: No effect on interaction with histone H3.	SEQ_UP	1	
MUTAGEN:V->M: No effect.	SEQ_UP	1	
MUTAGEN:V->M: Reduced hippocampal volume, dendritic complexity and context-dependent memory. Decreased density of dendritic mushroom spines and synapses. Impaired fear extinction. Increased anxiety-related behaviors.	SEQ_UP	1	
MUTAGEN:V->M: Reduced interaction with NR1I2 and NR1I3. Significant decrease in interaction with NR1I2 and NR1I3; when associated with E-394 and K-397.	SEQ_UP	1	
MUTAGEN:V->M: Results in impaired glucagon binding and glucagon-mediated signaling. Homozygous mice show hyperglucagonemia with alpha-cell hyperplasia and enlargement of the pancreas.	SEQ_UP	1	
MUTAGEN:V->M: Significantly reduces activity.	SEQ_UP	1	
MUTAGEN:V->N,E: Prevents binding to CBX1 and CBX5.	SEQ_UP	1	
MUTAGEN:V->N: Does not lead to glycosylation, suggesting that the non-cleavable signal sequence remains partly or entirely embedded in the membrane.	SEQ_UP	1	
MUTAGEN:V->P: Abolishes homodimerization and oligomerization. Abolishes regulation of ASIC2 and ASIC3 channel activity.	SEQ_UP	1	
MUTAGEN:V->P: Constitutively active channel that is targeted to the cell membrane.	SEQ_UP	1	
MUTAGEN:V->P: Eliminates the C-terminal degron and promotes stabilization of the protein.	SEQ_UP	1	
MUTAGEN:V->P: Loss of interaction with TRAF6 and TRAF6-induced polyubiquitination.	SEQ_UP	1	
MUTAGEN:V->P: Loss of PRKAR2A-binding; when associated with P-206.	SEQ_UP	1	
MUTAGEN:V->P: Reduced binding to p300 KIX domain; severe reduction in the autonomous transactivation function.	SEQ_UP	1	
MUTAGEN:V->P: Reduced oligomerization. Does not sensitize mechanically gated currents.	SEQ_UP	1	
MUTAGEN:V->P: Strongly reduced binding affinity for SAMD5 SAM domain.	SEQ_UP	1	
MUTAGEN:V->Q: Loss of interaction with MYO5A.	SEQ_UP	1	
MUTAGEN:V->R: Abolishes interaction with SUV39H1.	SEQ_UP	1	
MUTAGEN:V->R: Loss of function in calcium transport.	SEQ_UP	1	
MUTAGEN:V->R: No effect.	SEQ_UP	1	
MUTAGEN:V->R: No reduction of cAMP upon induction.	SEQ_UP	1	
MUTAGEN:V->R: Retains 10% of wild-type activity with sphingomyelin as substrate; retains 70% of wild-type activity with bis(p-nitrophenyl) phosphate as substrate.	SEQ_UP	1	
MUTAGEN:V->S,D: Prevents binding to CBX1 and CBX5.	SEQ_UP	1	
MUTAGEN:V->S: Abolishes interaction with CD4 endocytosis signal motif.	SEQ_UP	1	
MUTAGEN:V->S: Decreases affinity for CALM 230-fold; when associated with S-740.	SEQ_UP	1	
MUTAGEN:V->S: Does not affect ability to promote phosphatidylserine exposure.	SEQ_UP	1	
MUTAGEN:V->S: Inhibits calcium-dependent translocation to the cell membrane; when associated with S-282 and S-284.	SEQ_UP	1	
MUTAGEN:V->S: Inhibits calcium-dependent translocation to the cell membrane; when associated with S-283 and S-284.	SEQ_UP	1	
MUTAGEN:V->T: Impairs interaction with HIF1AN.	SEQ_UP	1	
MUTAGEN:V->T: Loss of phosphorylation-independent activation of channel activity by ethanol. CaMK2-dependent phosphorylation leads to populations of partially phosphorylated tetramers with a range of responses to ethanol from activation to inhibition.	SEQ_UP	1	
MUTAGEN:V->W: Strongly reduced transactivation.	SEQ_UP	1	
MUTAGEN:VCIV->ACIA: Does not affect subcellular location.	SEQ_UP	1	
MUTAGEN:VDLLIVI->ADAAAAA: Abolishes nuclear export; when associated with A-138; A-139; A-140; A-144 and A-145.	SEQ_UP	1	
MUTAGEN:VDW->AAA: Loss of interaction with AXIN1. Loss of function in AXIN1 degradation. Loss of function in Wnt signaling.	SEQ_UP	1	
MUTAGEN:VEIV->AEAA: Abolishes binding to sumoylated proteins and ubiquitination and degradation of PML; when associated with 300-A--A-303 and 382-A--A-385.	SEQ_UP	1	
MUTAGEN:VGAS->LGVT: Induces faster Ca(2+)-dependent channel inactivation.	SEQ_UP	1	
MUTAGEN:VGG->EEE: Impairs interaction with DNM1L.	SEQ_UP	1	
MUTAGEN:VHCG->AAAA: In mut2; weakly affects localization to primary cilia.	SEQ_UP	1	
MUTAGEN:VK->AA: Does not affect subcellular location.	SEQ_UP	1	
MUTAGEN:VKARK->AAAAA: In mut1; abolishes localization to primary cilia.	SEQ_UP	1	
MUTAGEN:VKDKFN->TTTTT: Predominant cytoplasmic localization.	SEQ_UP	1	
MUTAGEN:VKT->GGG: Impairs gating cooperativity.	SEQ_UP	1	
MUTAGEN:VLD->AAA: Abolishes histone methyltransferase activity and coactivator activity.	SEQ_UP	1	
MUTAGEN:VLVIICYKAIKRK->GIAIICLKAISDM: Decrease in ACHE tetramer recruitment to membrane rafts.	SEQ_UP	1	
MUTAGEN:VQIG->AAAA: In RIPK3(RHIM); abolished interaction with ZBP1 and subsequent necroptosis. Perinatal lethality observed in Ripk1 knockout mice is rescued in knockin mice carrying this mutation.	SEQ_UP	1	
MUTAGEN:VQLG->AAAA: In mRHIMB; does not affect ability to induce necroptosis.	SEQ_UP	1	
MUTAGEN:VSSVFQNMRL->ASSVAQNARA: Accumulation in the nucleus due to defects in nuclear export.	SEQ_UP	1	
MUTAGEN:VV->AA: In mut3; does not affect localization to primary cilia; when associated with A-251.	SEQ_UP	1	
MUTAGEN:VVDL->AADA: Abolishes binding to sumoylated proteins and ubiquitination and degradation of PML; when associated with 300-A--A-303 and 326-A--A-329.	SEQ_UP	1	
MUTAGEN:VVVI->AVAA: Abolishes binding to sumoylated proteins and ubiquitination and degradation of PML; when associated with 326-A--A-329 and 382-A--A-385.	SEQ_UP	1	
MUTAGEN:VW->RR: Prevents accumulation in pericentric heterochromatin.	SEQ_UP	1	
MUTAGEN:W->A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,V,Y: Loss of EPO binding.	SEQ_UP	1	
MUTAGEN:W->A,C,D,E,G,H,I,K,L,M,N,P,Q,R,S,T,V: Loss of EPO binding.	SEQ_UP	1	
MUTAGEN:W->A,F,Y: Loss of binding to AP-2.	SEQ_UP	1	
MUTAGEN:W->A,F: Decreases the enzymatic activity.	SEQ_UP	1	
MUTAGEN:W->A,Y: Loss of calcium-dependent cell-cell adhesion.	SEQ_UP	1	
MUTAGEN:W->A: Abolished binding to N6-methyladenosine (m6A)-containing RNAs; when associated with A-378.	SEQ_UP	1	
MUTAGEN:W->A: Abolished binding to N6-methyladenosine (m6A)-containing RNAs; when associated with A-429.	SEQ_UP	1	
MUTAGEN:W->A: Abolished H3.3K36me3 binding.	SEQ_UP	1	
MUTAGEN:W->A: Abolished interaction with REC114.	SEQ_UP	1	
MUTAGEN:W->A: Abolishes adhesion to oocytes.	SEQ_UP	1	
MUTAGEN:W->A: Abolishes AMPH, BIN1, DGKD, EPS15, EPN1, auxilin and SNAP91 binding.	SEQ_UP	1	
MUTAGEN:W->A: Abolishes binding of glycoprotein targets. Strongly reduced ubiquitination of glycoprotein targets.	SEQ_UP	1	
MUTAGEN:W->A: Abolishes cortactin-mediated endocytosis of KCNA2.	SEQ_UP	1	
MUTAGEN:W->A: Abolishes enzyme activity.	SEQ_UP	1	
MUTAGEN:W->A: Abolishes interaction with AP2B1.	SEQ_UP	1	
MUTAGEN:W->A: Abolishes interaction with PACSIN2.	SEQ_UP	1	
MUTAGEN:W->A: Abolishes Interaction with PTPRD. Abolishes synaptogenesis.	SEQ_UP	1	
MUTAGEN:W->A: Abolishes Methyllysine-binding.	SEQ_UP	1	
MUTAGEN:W->A: Binding to CYFIP1 reduced by 70%.	SEQ_UP	1	
MUTAGEN:W->A: Capable of nicking but defective for hairpinning.	SEQ_UP	1	
MUTAGEN:W->A: Complete loss of kinase activity and of nuclear localization.	SEQ_UP	1	
MUTAGEN:W->A: Complete loss of LPS-binding, LPS-induced oligomerization, and LPS-induced pyroptosis; when associated with E-54 and A-55.	SEQ_UP	1	
MUTAGEN:W->A: Decrease in enzyme activity. Has no axonal protective effect.	SEQ_UP	1	
MUTAGEN:W->A: Decreased monoglycylation activity.	SEQ_UP	1	
MUTAGEN:W->A: Decreased transmembrane ascorbate ferrireductase activity. Approximately 80% reduction in enzyme activity.	SEQ_UP	1	
MUTAGEN:W->A: Decreases binding to GRB10.	SEQ_UP	1	
MUTAGEN:W->A: Decreases channel sensitivity to inhibition by ATP.	SEQ_UP	1	
MUTAGEN:W->A: Decreases FBXL3 binding. Strongly decreases CRY2 degradation.	SEQ_UP	1	
MUTAGEN:W->A: Decreases interaction with TLR3.	SEQ_UP	1	
MUTAGEN:W->A: Decreases the activation of Arp2/3 without affecting the intrinsic nucleation activity.	SEQ_UP	1	
MUTAGEN:W->A: Deficient in both nicking and hairpin formation.	SEQ_UP	1	
MUTAGEN:W->A: Does not affect ability to promote sperm-egg interaction.	SEQ_UP	1	
MUTAGEN:W->A: Does not affect acyltransferase activity.	SEQ_UP	1	
MUTAGEN:W->A: Does not affect proteolysis activity.	SEQ_UP	1	
MUTAGEN:W->A: Does not affect the interaction with GATA1.	SEQ_UP	1	
MUTAGEN:W->A: Doesn't affect binding of misfolded proteins.	SEQ_UP	1	
MUTAGEN:W->A: Greatly decreases interaction with MAP1LC3B.	SEQ_UP	1	
MUTAGEN:W->A: Greatly decreases phosphatidylserine binding.	SEQ_UP	1	
MUTAGEN:W->A: Greatly reduced activity.	SEQ_UP	1	
MUTAGEN:W->A: Impaired ability to promote sperm-egg interaction due to reduced interaction with IZUMO1.	SEQ_UP	1	
MUTAGEN:W->A: Impaired acyltransferase activity.	SEQ_UP	1	
MUTAGEN:W->A: Impairs ability to promote H3K27me3 methylation without affecting ability to associate with the PRC2 complex; when associated with A-54.	SEQ_UP	1	
MUTAGEN:W->A: Impairs DNA-binding.	SEQ_UP	1	
MUTAGEN:W->A: Impairs interaction with RAB32 and RAB38.	SEQ_UP	1	
MUTAGEN:W->A: Impairs single-stranded DNA binding; when associated with A-151.	SEQ_UP	1	
MUTAGEN:W->A: Increases redox potential, reacts faster to NADH and forms two-fold longer-lived CTC.	SEQ_UP	1	
MUTAGEN:W->A: Induces cell cycle arrest.	SEQ_UP	1	
MUTAGEN:W->A: Inhibits interaction with TLR4. Inhibits IL12B expression after TLR4 activation by lipopolysaccharide. No effect on interaction with LYN.	SEQ_UP	1	
MUTAGEN:W->A: Leads to constitutive protein kinase activity.	SEQ_UP	1	
MUTAGEN:W->A: Loss of binding to AKT2 and enhanced binding to MAP3K11.	SEQ_UP	1	
MUTAGEN:W->A: Loss of calcium flux.	SEQ_UP	1	
MUTAGEN:W->A: Loss of dimerization; when associated with E-173.	SEQ_UP	1	
MUTAGEN:W->A: Loss of glucan binding. Abolishes activation of NF-kappa-B.	SEQ_UP	1	
MUTAGEN:W->A: Loss of interaction with CNOT7 and CNOT8. No effect on interaction with EIF4E.	SEQ_UP	1	
MUTAGEN:W->A: Loss of interaction with CNOT7.	SEQ_UP	1	
MUTAGEN:W->A: Loss of interaction with PPP1CA but no effect on interaction with TOX4 or WDR82. Cell cycle arrest at mitosis and cell death. Exhibits normal association with chromosomes but shows defects in the process of chromosome decondensation at late telophase.	SEQ_UP	1	
MUTAGEN:W->A: Loss of interaction with SQSTM1.	SEQ_UP	1	
MUTAGEN:W->A: Loss of promotion of NCOA2 sumoylation.	SEQ_UP	1	
MUTAGEN:W->A: Loss of the ability to induce filopodia and to initiate neurite outgrowht. Abolished interaction with GPHN.	SEQ_UP	1	
MUTAGEN:W->A: Loss of ubiquitin ligase activity and loss of down-regulation of CD86 cell surface expression.	SEQ_UP	1	
MUTAGEN:W->A: Marked reduction in KLC1-binding; when associated with A-903. Marked alteration in anterograde axonal transport.	SEQ_UP	1	
MUTAGEN:W->A: Marked reduction in KLC1-binding; when associated with A-972. Marked alteration in anterograde axonal transport.	SEQ_UP	1	
MUTAGEN:W->A: No effect on cooperative binding with PBX1 to CYP17.	SEQ_UP	1	
MUTAGEN:W->A: No effect on IL1B release under basal conditions, nor in response to LT or metabolic inhibitors.	SEQ_UP	1	
MUTAGEN:W->A: No effect on interaction with TBK1 and IKBKE.	SEQ_UP	1	
MUTAGEN:W->A: No effect on interaction with TLR3.	SEQ_UP	1	
MUTAGEN:W->A: No effect on the interaction with GYG1. No effect on the interaction with GYG1; when associated with A-8.	SEQ_UP	1	
MUTAGEN:W->A: No loss of interaction with GYS2.	SEQ_UP	1	
MUTAGEN:W->A: Reduced ARNTL/BMAL1 binding. Slightly reduced transcriptional activation by the CLOCK-ARNTL/BMAL1 heterodimer.	SEQ_UP	1	
MUTAGEN:W->A: Reduces affinity for PTPRD.	SEQ_UP	1	
MUTAGEN:W->A: Reduces lipid droplet localization.	SEQ_UP	1	
MUTAGEN:W->A: Significant loss of interaction with NOS2.	SEQ_UP	1	
MUTAGEN:W->A: Significant reduction in LPC transport.	SEQ_UP	1	
MUTAGEN:W->A: Significantly decreased NF-kappa-B activation.	SEQ_UP	1	
MUTAGEN:W->A: Significantly reduced interaction with adapter protein complex 2 and disruption of its function in clathrin-mediated endocytosis of INSR.	SEQ_UP	1	
MUTAGEN:W->A: Slightly increases IL11RA binding. Abolishes interaction with IL6ST. Abolishes stimulation of cell proliferation.	SEQ_UP	1	
MUTAGEN:W->A: Slightly reduces enzyme activity.	SEQ_UP	1	
MUTAGEN:W->A: Strongly reduced binding to methylated histone H3 (H3K27me3). Causes premature cellular senescence.	SEQ_UP	1	
MUTAGEN:W->A: Strongly reduces affinity for BMP2 and BMP4. Reduces inhibition of BMP2 signaling.	SEQ_UP	1	
MUTAGEN:W->A: Strongly reduces Arf-GAP mediated stimulation of GTP hydrolysis.	SEQ_UP	1	
MUTAGEN:W->A: Unable to bind Cripto receptor.	SEQ_UP	1	
MUTAGEN:W->C: Centrosomal localization retained.	SEQ_UP	1	
MUTAGEN:W->C: Decreased localization to the nucleus. No effect on homodimerization. No effect on transcription cis-regulatory region binding. No effect on DNA-binding transcription factor activity.	SEQ_UP	1	
MUTAGEN:W->C: Decreases phosphatidylserine binding.	SEQ_UP	1	
MUTAGEN:W->D: Decreases sedoheptulose kinase activity.	SEQ_UP	1	
MUTAGEN:W->E: Abolishes association with microtubules.	SEQ_UP	1	
MUTAGEN:W->E: Abolishes dimerization.	SEQ_UP	1	
MUTAGEN:W->E: Abolishes homodimerization.	SEQ_UP	2	
MUTAGEN:W->E: Abolishes interaction with GPSM2.	SEQ_UP	1	
MUTAGEN:W->E: Loss of function mutant which is unable to promote clathrin coated-pits formation. Cytosolic mutant; when associated with E-38.	SEQ_UP	1	
MUTAGEN:W->E: Results in exclusive localization to early endosomes and no effect on ability to promote LPS-induced IL6 and CCL5 production; when associated with E-7 and E-17.	SEQ_UP	1	
MUTAGEN:W->F: 14-fold less EPO binding.	SEQ_UP	1	
MUTAGEN:W->F: Abolishes channel activity. Alters potassium channel kinetics in heart myocytes. Abolishes the fast component of I(to) in heart ventricle.	SEQ_UP	1	
MUTAGEN:W->F: Abolishes ligand binding; when associated with A-283.	SEQ_UP	1	
MUTAGEN:W->F: Capable of nicking and retains some hairpinning.	SEQ_UP	1	
MUTAGEN:W->F: Greatly reduced EPO binding.	SEQ_UP	1	
MUTAGEN:W->G: Causes a failure of Shh processing leading to retention of the immature glycosylated protein within the endoplasmic reticulum of transfected cells; causes a temperature-dependent conformational change that allows Shh to bind Ptch1 at 4 or 32 degrees Celsius but not at 37 degrees Celsius; drastically reduces signaling potency in chicken embryo neural plate explant assays.	SEQ_UP	1	
MUTAGEN:W->G: Induces resistance to 5,10-dideazatetrahydrofolate; when associated with F-48.	SEQ_UP	1	
MUTAGEN:W->G: Loss of glycogen phosphatase activity. Nearly abolishes phosphatase activity.	SEQ_UP	1	
MUTAGEN:W->G: Loss of interaction with CEBPA.	SEQ_UP	1	
MUTAGEN:W->G: Loss of interaction with GRIP1 and GRIP2.	SEQ_UP	1	
MUTAGEN:W->G: No calmodulin binding.	SEQ_UP	1	
MUTAGEN:W->I: Knockin mice show impaired spermatogenesis, loss of histone H3K4me3 binding, severe disruption of chromosomal synapsis and DNA double-strand breaks repair in spermatocytes; when associated with R-292 and P-294.	SEQ_UP	1	
MUTAGEN:W->I: Reduces affinity for substrate and catalytic activity by about 50%.	SEQ_UP	1	
MUTAGEN:W->K: Increase in autophosphorylation activity.	SEQ_UP	1	
MUTAGEN:W->L: Inhibits transformation by N-terminal truncated form.	SEQ_UP	1	
MUTAGEN:W->L: Miri mutant, animals exhibit visceral heterotaxy, with heart defects commonly associated with heterotaxy.	SEQ_UP	1	
MUTAGEN:W->N: Retains 10% of wild-type activity.	SEQ_UP	1	
MUTAGEN:W->P: Knockin mice show impaired spermatogenesis, loss of histone H3K4me3 binding, severe disruption of chromosomal synapsis and DNA double-strand breaks repair in spermatocytes; when associated with I-247 and R-292.	SEQ_UP	1	
MUTAGEN:W->Q: Abolishes C-linked mannosylation.	SEQ_UP	1	
MUTAGEN:W->Q: Loss of sialic acid binding.	SEQ_UP	1	
MUTAGEN:W->R: Abolishes binding to H3K4me3 without affecting phosphoinositide-binding. Impairs enzymatic activity of the RAG complex.	SEQ_UP	1	
MUTAGEN:W->R: Causes a failure of Shh processing leading to retention of the immature glycosylated protein within the endoplasmic reticulum of transfected cells; causes a temperature-dependent conformational change that allows Shh to bind Ptch1 at 4 or 32 degrees Celsius but not at 37 degrees Celsius; drastically reduces signaling potency in chicken embryo neural plate explant assays.	SEQ_UP	1	
MUTAGEN:W->R: Confers ability to bind ferric iron and carbonate; when associated with Y-207.	SEQ_UP	1	
MUTAGEN:W->R: Impairs enzyme activity.	SEQ_UP	1	
MUTAGEN:W->R: In Gum(W96R) mutant; defects in embryonic angiogenesis. Embryos appear normal before 11.5 dpc but die between 12.5 dpc-14 dpc, probably due to defects in organization of branching vascular networks in the head and trunk.	SEQ_UP	1	
MUTAGEN:W->R: In pug; strongly reduced enzyme activity leads to defects in proteoglycan synthesis, abnormal chondrocyte maturation, premature ossification and dwarfism with short limbs and a compressed ribcage, which may be the cause for the increased mortality before weaning.	SEQ_UP	1	
MUTAGEN:W->R: Loss of function.	SEQ_UP	1	
MUTAGEN:W->R: Loss of interaction with GYG1. Loss of interaction with GYG1; when associated with A-8.	SEQ_UP	1	
MUTAGEN:W->R: Loss of localization to the nucleus. Loss of transcription cis-regulatory region binding. Loss of DNA-binding transcription factor activity. Acts as a dominant negative.	SEQ_UP	1	
MUTAGEN:W->R: Mice develop an age- and gene dosage-dependent hypertrophic cardiomyopathy and heart failure phenotype, characterized by almost complete loss of contractile reserve under catecholamine induced stress. They display increased in septum wall thickness, fractional shortening, and wall thickness per diameter (h/r). There is also evidence for skeletal muscle pathology. In addition, homozygous mutants show increased left ventricle (LC) mass per body weight (BW) and significantly reduced body weight. An increased nuclear localization of Csrp3 is also observed. Decreases interaction with TCAP.	SEQ_UP	1	
MUTAGEN:W->R: No JAK2 binding nor JAK2/STAT5 activation. No EPO-induced phosphorylation. Complete loss of mitogenic response.	SEQ_UP	1	
MUTAGEN:W->R: The protein is stably expressed.	SEQ_UP	1	
MUTAGEN:W->S: Abolishes proteolytic cleavage and cell surface localization.	SEQ_UP	1	
MUTAGEN:W->S: Deficient in oligomerization (dimerization maintained). Inefficient formation of planar membrane structures. No effect on lipid-binding.	SEQ_UP	1	
MUTAGEN:W->S: Loss of normal excitation-contraction coupling. Loss of function in enhancing calcium channel activity.	SEQ_UP	1	
MUTAGEN:W->S: Strongly reduces interaction with RAB27A.	SEQ_UP	1	
MUTAGEN:W->T: Loss of early endosome localization; when associated with K-454.	SEQ_UP	1	
MUTAGEN:W->Y: 100-fold less EPO binding.	SEQ_UP	1	
MUTAGEN:W->Y: Loss of both activities.	SEQ_UP	1	
MUTAGEN:WF->AA: Mildly reduced interaction with flagellin.	SEQ_UP	1	
MUTAGEN:WF->AA: Reduces the ability to traffic to the cilia. Reduces interaction with RAB8A.	SEQ_UP	1	
MUTAGEN:WFQN->SVAA: Interacts with OGT.	SEQ_UP	1	
MUTAGEN:WL->GA: Stimulates cleavage of the N-terminal methionine.	SEQ_UP	1	
MUTAGEN:WM->AA: Interacts with OGT.	SEQ_UP	1	
MUTAGEN:WN->AA: Inhibits transport activity. Inhibits weakly colocalization with SLC51A at the plasma membrane. Decreases glycosylation of SLC51A.	SEQ_UP	1	
MUTAGEN:WN->FQ: Does not inhibit transport activity. Does not inhibit colocalization with SLC51A at the plasma membrane. Does not decrease glycosylation of SLC51A.	SEQ_UP	1	
MUTAGEN:WP->ST: Prevents accumulation in pericentric heterochromatin.	SEQ_UP	1	
MUTAGEN:WSQ->VFE: Decreases phosphatidylserine binding.	SEQ_UP	1	
MUTAGEN:WW->AA: Loss of CLNK binding.	SEQ_UP	1	
MUTAGEN:WY->GA: Impairs interaction with pRNA and heterochromatin formation but retains ability to trigger DNA methylation and silence rDNA transcription.	SEQ_UP	1	
MUTAGEN:Y->A,D: Still binds H3K4me3 and H3R2me2 but with reduced affinity.	SEQ_UP	1	
MUTAGEN:Y->A,F,R: Loss of S-adenosyl-L-methionine binding. Loss of protein methyltransferase activity.	SEQ_UP	1	
MUTAGEN:Y->A,F: Abolishes inositol 1,4,5-triphosphate binding.	SEQ_UP	1	
MUTAGEN:Y->A,F: Loss of interaction with CXADR.	SEQ_UP	1	
MUTAGEN:Y->A,L,F: Capable of nicking but defective for hairpinning.	SEQ_UP	1	
MUTAGEN:Y->A,W: Strongly decreases interaction with TLR3.	SEQ_UP	1	
MUTAGEN:Y->A: 10-fold less potently activated by the Scolopendra mutilans RhTx toxin.	SEQ_UP	1	
MUTAGEN:Y->A: 2-fold reduction in maximal activity.	SEQ_UP	1	
MUTAGEN:Y->A: 50-fold decrease in rates of factor Xa inhibition.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes binding of glycoprotein targets.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes binding to H3K4me3 without affecting phosphoinositide-binding.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes binding to NUMB protein.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes conductivity; when associated with A-349 and A-351.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes cytoplasmic retention and mRNA-binding affinity; when associated with A-111.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes cytosolic localization.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes endoribonuclease activity.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes FGF2-induced lens fiber differentiation via inhibition of FGF-mediated ERK1/2 phosphorylation.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes FLRT3 binding.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes ganglioside binding.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes homodimerization; when associated with 515-A-A-516.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes homodimerization. Loss of E3 ubiquitin ligase activity.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes IL22-binding.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes in vitro binding to 'Lys-10' methylated H3, H3K9me3. Prevents enrichment at pericentric heterochromatin.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes in vitro binding to H3K9me3. Prevents enrichment at pericentric heterochromatin.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes interaction with CDK2.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes interaction with CEP55.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes interaction with NEDD4.	SEQ_UP	6	
MUTAGEN:Y->A: Abolishes interaction with RAB9A.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes interaction with TBK1 but not with IKBKE.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes linear polyubiquitin-binding, impairs 'Lys-63'-linked polyubiquitin-binding and impairs NF-kappa-B activation; when associated with A-293 and A-302.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes localization to lysosomes.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes lysosomal localization and results in mislocalization to the cell surface. Localizes to lysosomes when expressed with wild-type MFSD1.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes Methyllysine-binding.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes phosphorylation by EPHB2.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes SLAMF1:SH2D1A-mediated intracellular tyrosine phosphorylation, no effect on interaction with SH2D1A; when associated with A-315.	SEQ_UP	1	
MUTAGEN:Y->A: Abolishes SLAMF1:SH2D1A-mediated intracellular tyrosine phosphorylation, no effect on interaction with SH2D1A; when associated with A-335.	SEQ_UP	1	
MUTAGEN:Y->A: Accumulates at the plasma membrane. No effect on anti-SARS-CoV-2 activity.	SEQ_UP	1	
MUTAGEN:Y->A: Affects basolateral membrane sorting in vitro but not in vivo; when associated with 76-A-A-77 and A-222.	SEQ_UP	1	
MUTAGEN:Y->A: Affects basolateral membrane sorting in vitro but not in vivo; when associated with 76-A-A-77 and A-225.	SEQ_UP	1	
MUTAGEN:Y->A: Almost abolishes response to semaphorin.	SEQ_UP	1	
MUTAGEN:Y->A: Alters interaction with NEDD4.	SEQ_UP	2	
MUTAGEN:Y->A: Cell surface localization.	SEQ_UP	1	
MUTAGEN:Y->A: Decrease in binding to DNA.	SEQ_UP	1	
MUTAGEN:Y->A: Decreased interaction with ADGRA2.	SEQ_UP	1	
MUTAGEN:Y->A: Decreased monoglycylation activity.	SEQ_UP	1	
MUTAGEN:Y->A: Decreased protein expression and stability. Decreased embryonic stem cell self-renewal.	SEQ_UP	1	
MUTAGEN:Y->A: Decreases binding to GRB10.	SEQ_UP	1	
MUTAGEN:Y->A: Decreases CDE RNA-binding. Increases target-mRNA expression.	SEQ_UP	1	
MUTAGEN:Y->A: Decreases ganglioside binding.	SEQ_UP	1	
MUTAGEN:Y->A: Decreases interaction with CALM1 in the presence and absence of calcium and reduces rate of channel inactivation.	SEQ_UP	1	
MUTAGEN:Y->A: Deficient in both nicking and hairpin formation.	SEQ_UP	1	
MUTAGEN:Y->A: Diminished binding of coactivator NCOA2 in the presence of TCPOBOP.	SEQ_UP	1	
MUTAGEN:Y->A: Disrupts channel closure.	SEQ_UP	1	
MUTAGEN:Y->A: Disrupts interaction of the first PDZ domain with SCARB1. Abolishes interaction with SCARB1; when associated with A-253.	SEQ_UP	1	
MUTAGEN:Y->A: Disrupts interaction of the third PDZ domain with SCARB1. Abolishes interaction with SCARB1; when associated with A-20.	SEQ_UP	1	
MUTAGEN:Y->A: Disrupts interaction with RAB32 and RAB38; inhibits peripheral distribution of TYRP1 in melanocytes; no effect on dendrite formation in melanocytes.	SEQ_UP	1	
MUTAGEN:Y->A: Disrupts KATNA1:KATNB1 interaction with ASPM; abolishes localization to microtubules minus ends; decreases ASPM localization to microtubules minus ends; no enhancement of ASPM activity in blocking microtubule minus-end growth.	SEQ_UP	1	
MUTAGEN:Y->A: Does not affect recognition by the CRL2(FEM1B) complex and subsequent ubiquitination.	SEQ_UP	1	
MUTAGEN:Y->A: Does not inhibit lysosomal/late endosomal targeting.	SEQ_UP	1	
MUTAGEN:Y->A: Dramatically decreased Th2 cell differentiation.	SEQ_UP	1	
MUTAGEN:Y->A: Drastically reduced activity.	SEQ_UP	1	
MUTAGEN:Y->A: Fails to be restricted to the somatodendritic compartment.	SEQ_UP	1	
MUTAGEN:Y->A: Greatly reduces SLAMF1:SH2D1A-mediated intracellular tyrosine phosphorylation.	SEQ_UP	1	
MUTAGEN:Y->A: Highly decreases glycerophosphocholine cholinephosphodiesterase activity. Loss of choline metabolism.	SEQ_UP	1	
MUTAGEN:Y->A: Impaired acyltransferase activity.	SEQ_UP	1	
MUTAGEN:Y->A: Impaired acyltransferase activity. Impaired ability to interact with WNT3A.	SEQ_UP	1	
MUTAGEN:Y->A: Impaired interaction with SQSTM1/p62.	SEQ_UP	1	
MUTAGEN:Y->A: Impairs ability to promote H3K27me3 methylation without affecting ability to associate with the PRC2 complex; when associated with A-48.	SEQ_UP	1	
MUTAGEN:Y->A: Impairs binding to NEDD4.	SEQ_UP	1	
MUTAGEN:Y->A: Impairs DNA-binding.	SEQ_UP	1	
MUTAGEN:Y->A: Impairs interaction with GATA1. Strongly impairs interaction with GATA1; when associated with A-277; A-612 and/or A-985.	SEQ_UP	1	
MUTAGEN:Y->A: Impairs interaction with GATA1. Strongly impairs interaction with GATA1; when associated with A-277; A-718 and/or A-985.	SEQ_UP	1	
MUTAGEN:Y->A: Impairs interaction with GATA1. Strongly impairs interaction with GATA1; when associated with A-612; A-718 and/or A-985.	SEQ_UP	1	
MUTAGEN:Y->A: Impairs interaction with RAB32 and RAB38.	SEQ_UP	1	
MUTAGEN:Y->A: In DADm mutant; loss of ability to interact with HDAC3 which causes aberrant regulation of clock genes and results in abnormal circadian behavior. Mice are also leaner and more insulin sensitive due to increased energy expenditure and exhibit dramatic alterations in cyclic expression of several critical genes involved in lipid metabolism in the liver.	SEQ_UP	1	
MUTAGEN:Y->A: Increased permeability to chloride ions.	SEQ_UP	1	
MUTAGEN:Y->A: Increased protein expression. Decreased protein stability.	SEQ_UP	1	
MUTAGEN:Y->A: Increased speed of phospholipid scrambling. Requires lower calcium levels for activation of scramblase and ion channel activity. Constitutive scramblase activity at basal cytosolic calcium levels; when associated with A-518 and A-612.	SEQ_UP	1	
MUTAGEN:Y->A: Inefficient targeting to the endosomal/lysosomal compartment and enhanced myotube formation.	SEQ_UP	1	
MUTAGEN:Y->A: Inhibition of migration potentiation.	SEQ_UP	1	
MUTAGEN:Y->A: Inhibits dendrite formation.	SEQ_UP	1	
MUTAGEN:Y->A: Inhibits interaction with NPHS2.	SEQ_UP	1	
MUTAGEN:Y->A: Inhibits lysosomal/late endosomal targeting.	SEQ_UP	1	
MUTAGEN:Y->A: Interferes with heterodimerization.	SEQ_UP	1	
MUTAGEN:Y->A: Is able to rescue the mechanotransduction defect of L-48.	SEQ_UP	1	
MUTAGEN:Y->A: Loss of cholesterol binding. Abolishes cholesterol transport activity.	SEQ_UP	1	
MUTAGEN:Y->A: Loss of function.	SEQ_UP	2	
MUTAGEN:Y->A: Loss of interaction with CXADR.	SEQ_UP	1	
MUTAGEN:Y->A: Loss of interaction with GYG1. Loss of function. Loss of interaction with GYG1; when associated with A-8.	SEQ_UP	1	
MUTAGEN:Y->A: Loss of interaction with KIF23, GGA1, SPAG9 and RAB11FIP4.	SEQ_UP	1	
MUTAGEN:Y->A: Loss of interaction with MAP1LC3B and significant decrease in its autophagy-mediated degradation; when associated with A-497.	SEQ_UP	1	
MUTAGEN:Y->A: Loss of interaction with NEDD4 and drastic reduction in its ubiquitination.	SEQ_UP	1	
MUTAGEN:Y->A: Loss of interaction with PARW. No effect on interaction with MET. Loss of interaction with NOS2.	SEQ_UP	1	
MUTAGEN:Y->A: Loss of kinase activity.	SEQ_UP	1	
MUTAGEN:Y->A: Loss of PAR-binding and of protection against DNA damage; when associated with A-157.	SEQ_UP	1	
MUTAGEN:Y->A: Loss of pericentromeric heterochromatin location. Abolishes DNA binding.	SEQ_UP	1	
MUTAGEN:Y->A: Loss of phosphorylation and interaction with SRC, and inhibition of bone resorption.	SEQ_UP	1	
MUTAGEN:Y->A: Loss of transmembrane ascorbate ferrireductase activity.	SEQ_UP	1	
MUTAGEN:Y->A: Minimal loss of kinase activity.	SEQ_UP	1	
MUTAGEN:Y->A: Nearly abolishes calcium flux.	SEQ_UP	1	
MUTAGEN:Y->A: No efect on its interaction with MAP1LC3B and moderate decrease in its autophagy-mediated degradation; when associated with A-491.	SEQ_UP	1	
MUTAGEN:Y->A: No effect on acetylated histone binding.	SEQ_UP	1	
MUTAGEN:Y->A: No effect on binding of coactivator NCOA2 in the presence of TCPOBOP.	SEQ_UP	1	
MUTAGEN:Y->A: No effect on C-terminus cleavage.	SEQ_UP	1	
MUTAGEN:Y->A: No effect on carbonate dehydratase activity.	SEQ_UP	1	
MUTAGEN:Y->A: No effect on DNA-binding, represses E2F1:TFDP1-mediated transcription and causes adipose hypoplasia and myeloid dysplasia.	SEQ_UP	1	
MUTAGEN:Y->A: No effect on IL1B release under basal conditions, nor in response to LT or metabolic inhibitors.	SEQ_UP	1	
MUTAGEN:Y->A: No effect on interaction with NEDD4.	SEQ_UP	3	
MUTAGEN:Y->A: No effect on interaction with SLITRK2. Decreases the affinity for IL1RAPL1. Abolishes interaction with IL1RAP.	SEQ_UP	1	
MUTAGEN:Y->A: No effect on its interaction with MAP1LC3B and moderate decrease in its autophagy-mediated degradation; when associated with A-290.	SEQ_UP	1	
MUTAGEN:Y->A: No effect on MAPK8IP1 binding.	SEQ_UP	1	
MUTAGEN:Y->A: No effect on PARD3 binding.	SEQ_UP	1	
MUTAGEN:Y->A: No effect on transmembrane ascorbate ferrireductase activity.	SEQ_UP	1	
MUTAGEN:Y->A: No loss in its ability to induce IFN-gamma.	SEQ_UP	1	
MUTAGEN:Y->A: No loss in its ability to induce IFN-gamma. Significant reduction in its ability to induce IFN-gamma and reduced ability to promote addition of permissive chromatin-remodeling mark H3K4Me2 to the IFNG promoter region; when associated with A-52 and A-224.	SEQ_UP	1	
MUTAGEN:Y->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-272.	SEQ_UP	1	
MUTAGEN:Y->A: No loss of interaction with PTPN13 (via PDZ domains); when associated with A-299.	SEQ_UP	1	
MUTAGEN:Y->A: No MAPK8IP1 nor APBA1 nor Dab1 binding. No effect on APBB1 binding.	SEQ_UP	1	
MUTAGEN:Y->A: No regulation by NEDD4L.	SEQ_UP	1	
MUTAGEN:Y->A: Reduced interaction with histones.	SEQ_UP	1	
MUTAGEN:Y->A: Reduced interaction with MAP1LC3B and significant decrease in its autophagy-mediated degradation; when associated with A-276.	SEQ_UP	1	
MUTAGEN:Y->A: Reduced phosphorylation by ERK.	SEQ_UP	1	
MUTAGEN:Y->A: Reduces binding affinity for misfolded proteins by 40%.	SEQ_UP	1	
MUTAGEN:Y->A: Reduces channel activation by 4-alpha-PDD and heat but not hypo-osmotic cell swelling.	SEQ_UP	1	
MUTAGEN:Y->A: Reduces histone acetyltransferase activity; when associated with A-656 and A-659.	SEQ_UP	1	
MUTAGEN:Y->A: Reduces protein methyltransferase activity.	SEQ_UP	1	
MUTAGEN:Y->A: Reduces tyrosine phosphorylation. Abolishes tyrosine phosphorylation and interaction with GRB2 and FYN; when associated with A-945.	SEQ_UP	1	
MUTAGEN:Y->A: Severe loss of interaction with GYS2.	SEQ_UP	1	
MUTAGEN:Y->A: Significant decrease in interaction with ARL6IP1 and no influence on SLC1A1/EAAC1-mediated glutamate transport; when associated with A-112.	SEQ_UP	1	
MUTAGEN:Y->A: Significant reduction in LPC transport.	SEQ_UP	1	
MUTAGEN:Y->A: Significantly decreased NF-kappa-B activation.	SEQ_UP	1	
MUTAGEN:Y->A: Significantly reduced interaction with adapter protein complex 2 and disruption of its function in clathrin-mediated endocytosis of INSR.	SEQ_UP	1	
MUTAGEN:Y->A: Slightly affects the interaction with GATA1.	SEQ_UP	1	
MUTAGEN:Y->A: Slightly affects the interaction with GATA1. Strongly impairs interaction with GATA1; when associated with A-277; A-612 and/or A-718.	SEQ_UP	1	
MUTAGEN:Y->A: Slightly reduced activity.	SEQ_UP	1	
MUTAGEN:Y->A: Some loss of JAK signal transduction signaling. Reduced binding to JH1.	SEQ_UP	1	
MUTAGEN:Y->A: Strongly decreased phosphodiesterase activity.	SEQ_UP	1	
MUTAGEN:Y->A: Strongly decreases channel sensitivity to inhibition by ATP.	SEQ_UP	1	
MUTAGEN:Y->A: Strongly reduced nuclear localization.	SEQ_UP	1	
MUTAGEN:Y->A: Strongly reduces affinity for BMP2 and BMP4. Strongly reduces inhibition of BMP2 signaling.	SEQ_UP	1	
MUTAGEN:Y->C: Abolishes channel activity.	SEQ_UP	1	
MUTAGEN:Y->C: Binding to HIV-1 Tat similar to human CCNT1.	SEQ_UP	1	
MUTAGEN:Y->C: Decreased protein abundance; decreased 3',5'-cyclic-nucleotide phosphodiesterase activity.	SEQ_UP	1	
MUTAGEN:Y->C: Decreases phosphatidylserine binding.	SEQ_UP	1	
MUTAGEN:Y->C: Does not inhibit cell survival upon DNA damage. Not phosphorylates p53/TP53.	SEQ_UP	1	
MUTAGEN:Y->C: In Bsk mutant; gain-of-function mutation; causes an alopecia phenotype. Attenuates intramolecular interaction between the N- and C-terminal domains, hence may relieve autoinhibition; constitutively active in triggering pyroptosis.	SEQ_UP	1	
MUTAGEN:Y->C: Increased cytoplasmic vacuole size. Knockin mice develop albinism and lysosomal-storage disease.	SEQ_UP	1	
MUTAGEN:Y->C: Loss of interaction with SYNCRIP.	SEQ_UP	1	
MUTAGEN:Y->C: No effect on carbonate dehydratase activity. Enhanced proton transfer; when associated with A-95.	SEQ_UP	1	
MUTAGEN:Y->C: Reduced cell surface localization.	SEQ_UP	1	
MUTAGEN:Y->C: Reduced cone and rod photoreceptor function as a result of outer segment malformation, including disorganization, short outer segments, and elongated disks which affect both rod and cone photoreceptors. Reduced Prph2 protein abundance in the retina.	SEQ_UP	1	
MUTAGEN:Y->C: Reduces protein solubility and causes formation of an abnormal disulfide bond between C-111 and C-139 in approximately half of the molecules.	SEQ_UP	1	
MUTAGEN:Y->C: Strongly reduced inhibition by GNF-2.	SEQ_UP	1	
MUTAGEN:Y->D: Abolishes interaction with GBA. No effect on normal location in lysosomes.	SEQ_UP	1	
MUTAGEN:Y->D: Abolishes RNA-binding but not homodimerization; when associated with D-43; D-84 and D-87.	SEQ_UP	1	
MUTAGEN:Y->D: Abrogates the intramolecular linker-DENN domain interaction and enhances GEF activity towards Rab12.	SEQ_UP	1	
MUTAGEN:Y->D: Changes the stereoselectivity of the oxygenation reaction to produce (15S)-HPETE instead of (8S)-HPETE. Completely changes the stereoselectivity; when associated with V-604.	SEQ_UP	1	
MUTAGEN:Y->D: Decreased threshold for activation by calcium.	SEQ_UP	1	
MUTAGEN:Y->D: Decreased tubulin deglutamylation.	SEQ_UP	1	
MUTAGEN:Y->D: Decreases affinity for NADP. Changes enzyme activity, leading to the production of testosterone and concomitantly reducing the production of epi-testosterone.	SEQ_UP	1	
MUTAGEN:Y->D: Decreases heterodimer formation with EPAS1. Decreases heterodimer formation with HIF1A. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Does not compromise NPAS4:ARNT heterodimer stability. Does not compromise AHR:ARNT heterodimer stability.	SEQ_UP	1	
MUTAGEN:Y->D: Loss of oligomerization.	SEQ_UP	1	
MUTAGEN:Y->D: Loss of oligomerization. Abolishes interaction with DIXDC1. Abolishes activation of Wnt signaling.	SEQ_UP	1	
MUTAGEN:Y->D: Spontaneous pyroptosis-inducing activity.	SEQ_UP	2	
MUTAGEN:Y->D: Strongly reduced inhibition by GNF-2.	SEQ_UP	1	
MUTAGEN:Y->E: Abolishes homodimer formation.	SEQ_UP	1	
MUTAGEN:Y->E: Abolishes interaction with NEDD9. Abolishes interaction with BCAR1. Abolishes phosphorylation of NEDD9. Abolishes promotion of migration and adhesion in T cells.	SEQ_UP	1	
MUTAGEN:Y->E: Disrupts binding to BCAR1 and inhibits EGF-induced tyrosine phosphorylation.	SEQ_UP	1	
MUTAGEN:Y->E: Expected to disrupt microtubule binding. Abolishes the ability to promote microtubule polymerization.	SEQ_UP	1	
MUTAGEN:Y->E: Increases affinity for DNA; when associated with R-126.	SEQ_UP	1	
MUTAGEN:Y->E: Loss of co-localization with CACNA1S and strongly decreased co-localization with CACNA1C; when associated with L-104.	SEQ_UP	1	
MUTAGEN:Y->E: Minimal loss of kinase activity; when associated with E-366.	SEQ_UP	1	
MUTAGEN:Y->E: Minimal loss of kinase activity; when associated with E-368.	SEQ_UP	1	
MUTAGEN:Y->E: No effect on homodimerization. Abolishes homodimerization; when associated with E-444.	SEQ_UP	1	
MUTAGEN:Y->E: No effect on phosphorylation. Protein preferentially localized in cytoplasm.	SEQ_UP	1	
MUTAGEN:Y->E: No significant effect on kinase activity and loss of binding to VAV2 and VAV3. Inhibits EFNA1-induced vascular assembly and RAC1 activation in endothelial cells, no significant effect on kinase activity, significant reduction in phosphorylation and binding to VAV3; when associated with E-589.	SEQ_UP	1	
MUTAGEN:Y->E: No significant effect on kinase activity and loss of binding to VAV2 and VAV3. Inhibits EFNA1-induced vascular assembly and RAC1 activation in endothelial cells, no significant effect on kinase activity, significant reduction in phosphorylation and binding to VAV3; when associated with E-595.	SEQ_UP	1	
MUTAGEN:Y->E: Phosphorylation mimic mutant, leads to dissociation of JAK2 from the erythropoietin receptor complex.	SEQ_UP	1	
MUTAGEN:Y->F,H,Q: Alters leukotriene hydrolase activity, strongly enhancing the formation of a metabolite that is normally produced in trace amounts.	SEQ_UP	1	
MUTAGEN:Y->F: 2-fold increase in basal phospholipase activity.	SEQ_UP	1	
MUTAGEN:Y->F: 2-fold reduction in maximal activity.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes autoinhibition, leading to increased kinase activity and constitutive phosphorylation of LYN substrates.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes autophosphorylation.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes binding to EPHA5 SAM domain.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes binding to GRB2.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes binding to PIK3R2. Slight reduction of phosphorylation in HEK293T cells. Abolishes phosphorylation in HEK293T cells and in neurons; when associated with F-257.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes binding to PIK3R2. Slight reduction of phosphorylation in HEK293T cells. Abolishes phosphorylation in HEK293T cells and in neurons; when associated with F-300.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes binding to PTPN6 and PTPN11.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes downstream phosphorylation of CBL and VAV1; when associated with F-266, F-325 and F-344.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes downstream phosphorylation of CBL and VAV1; when associated with F-266, F-325 and F-369.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes downstream phosphorylation of CBL and VAV1; when associated with F-266, F-344 and F-369.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes downstream phosphorylation of CBL and VAV1; when associated with F-325, F-344 and F-369.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes histone-lysine N-methyltransferase activity.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with DOK proteins.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with FHL2.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with FYN, phosphorylation by FYN, and effects on cell growth.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with GRB2.	SEQ_UP	2	
MUTAGEN:Y->F: Abolishes interaction with IRS1 but not with IRS2.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with NCOA1 and NCOA2.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with PIK3R1.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with PIK3R1. Strongly reduced phosphorylation of PLCG2. No effect on binding to THOC5.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with PTPN11, leading to an increased level of phosphorylation.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with PTPN11/SHP-2.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with PTPN6 and PTPN11. Loss of function; when associated with F-216.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with PTPN6 and PTPN11. Loss of function; when associated with F-241.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with PTPN6/SHP-1 and PTPN11/SHP-2; when associated with F-794.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with PTPN6/SHP-1 and PTPN11/SHP-2; when associated with F-824.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with PTPN6/SHP-1.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with WWP1.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with WWP2; if associated with F-174.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with WWP2; if associated with F-208.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with ZAP70; when associated with F-73.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes interaction with ZAP70; when associated with F-83.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes internalization after cross-linking.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes LCK, PIK3R1 and LYN binding; when associated with F-261.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes methyltransferase activity.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes phosphatidylinositol 3,4,5-trisphosphate binding.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes phosphorylation and ability to regulate cytoskeletal organization; when associated with F-103.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes phosphorylation and ability to regulate cytoskeletal organization; when associated with F-92.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes phosphorylation and RNA-binding; when associated with F-285; F-288; F-290 and F-292.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes phosphorylation and RNA-binding; when associated with F-285; F-288; F-290 and F-303.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes phosphorylation and RNA-binding; when associated with F-285; F-288; F-292 and F-303.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes phosphorylation and RNA-binding; when associated with F-285; F-290; F-292 and F-303.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes phosphorylation and RNA-binding; when associated with F-288; F-290; F-292 and F-303.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes phosphorylation by FYN and interaction with FYN.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes phosphorylation of FRS2 and activation of MAP kinases.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes phosphorylation, disrupts interaction with PIK3R1 and PIK3R2, no LGALS9-mediated disruption of interaction with BAG6; when associated with F-256.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes phosphorylation, disrupts interaction with PIK3R1 and PIK3R2, no LGALS9-mediated disruption of interaction with BAG6; when associated with F-263.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes phosphorylation. Protein preferentially localized in nucleus.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes the formation of KLRG1/PTPN11 and KLRG1/INPP5D.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes the interaction with MLPH.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes the recruitment and activation of the tyrosine kinase Syk.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes tyrosine phosphorylation and interaction with SYK; when associated with F-559.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes tyrosine phosphorylation and interaction with SYK; when associated with F-570.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes tyrosine phosphorylation and interactions with GRB2 and PTPN11; when associated with F-196; F-306; F-349 and F-392.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes tyrosine phosphorylation and interactions with GRB2 and PTPN11; when associated with F-196; F-306; F-349 and F-436.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes tyrosine phosphorylation and interactions with GRB2 and PTPN11; when associated with F-196; F-306; F-392 and F-436.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes tyrosine phosphorylation and interactions with GRB2 and PTPN11; when associated with F-196; F-349; F-392 and F-436.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes tyrosine phosphorylation and interactions with GRB2 and PTPN11; when associated with F-306; F-349; F-392 and F-436.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes tyrosine phosphorylation, no effect on interaction with SLAMF7 and CD244, abolishes SLAMF7-, CD244-, LY9- and CD8 mediated NK cell activation, fails to inhibit natural cytotoxicity and to suppress IFN-gamma secretion in response to ligation with CD244, FCGR3 or KLRB1C; when associated with F-127.	SEQ_UP	1	
MUTAGEN:Y->F: Abolishes tyrosine phosphorylation, no effect on interaction with SLAMF7 and CD244, abolishes SLAMF7-, CD244-, LY9- and CD84-mediated NK cell activation, fails to inhibit natural cytotoxicity and to suppress IFN-gamma secretion in response to ligation with CD244, FCGR3 or KLRB1C; when associated with F-120.	SEQ_UP	1	
MUTAGEN:Y->F: About 60% loss of STAT1 phosphorylation by JAK2.	SEQ_UP	1	
MUTAGEN:Y->F: Abrogates interaction with PTPN6.	SEQ_UP	1	
MUTAGEN:Y->F: Affects the phosphorylation pattern.	SEQ_UP	1	
MUTAGEN:Y->F: Almost complete loss of down-regulation of CD86 cell surface expression; when associated with S-225.	SEQ_UP	1	
MUTAGEN:Y->F: Attenuates activation by MAPK1/ERK1 and MAPK3/ERK2.	SEQ_UP	1	
MUTAGEN:Y->F: Binds to PTPN6 and PTPN11 SH2 domains.	SEQ_UP	1	
MUTAGEN:Y->F: Can hydrolyze nucleotides, with about fourfold higher rates for adenine versus uridine and no strong preference for diphosphates or triphosphates.	SEQ_UP	1	
MUTAGEN:Y->F: Cannot rescue the effect PIP5K1C knockdown on EGF-stimulated cell migration. Does not affect lipid kinase activity. Does not alter binding to tailin. Decreased tailin assembly into focal adhesions. Increased interaction with PLCG1.	SEQ_UP	1	
MUTAGEN:Y->F: Causes a mild reduction of protein solubility.	SEQ_UP	1	
MUTAGEN:Y->F: Causes thymic tumors.	SEQ_UP	1	
MUTAGEN:Y->F: Complete loss of interaction with SOCS1.	SEQ_UP	1	
MUTAGEN:Y->F: Complete loss of protein phosphorylation.	SEQ_UP	1	
MUTAGEN:Y->F: Complete loss of STAT1 and STAT3 activation.	SEQ_UP	1	
MUTAGEN:Y->F: Complete loss of STAT3 activation; in association with F-443.	SEQ_UP	1	
MUTAGEN:Y->F: Complete loss of STAT3 activation; in association with F-493.	SEQ_UP	1	
MUTAGEN:Y->F: Decreased Ca(2+) mobilization.	SEQ_UP	1	
MUTAGEN:Y->F: Decreased lipid phosphatase activity.	SEQ_UP	1	
MUTAGEN:Y->F: Decreased phosphorylation by FGFR1.	SEQ_UP	1	
MUTAGEN:Y->F: Decreased phosphorylation by SRC and increased autopalmitoylation; when associated with F-295.	SEQ_UP	1	
MUTAGEN:Y->F: Decreased phosphorylation by SRC and increased autopalmitoylation; when associated with F-297.	SEQ_UP	1	
MUTAGEN:Y->F: Decreased the ability of JAK2 to autophosphorylate.	SEQ_UP	1	
MUTAGEN:Y->F: Decreases downstream phosphorylation of CBL and VAV1.	SEQ_UP	1	
MUTAGEN:Y->F: Decreases inhibitory signaling in germinal center formation (absence of SH2D1A/SAP); when associated with F-295 and F-319.	SEQ_UP	1	
MUTAGEN:Y->F: Decreases inhibitory signaling in germinal center formation (absence of SH2D1A/SAP); when associated with F-295 and F-349.	SEQ_UP	1	
MUTAGEN:Y->F: Decreases inhibitory signaling in germinal center formation (absence of SH2D1A/SAP); when associated with F-319 and F-349.	SEQ_UP	1	
MUTAGEN:Y->F: Decreases interaction with DDX58; when associated with F-590, F-635 and F-659.	SEQ_UP	1	
MUTAGEN:Y->F: Decreases interaction with DDX58; when associated with F-590, F-659 and F-682.	SEQ_UP	1	
MUTAGEN:Y->F: Decreases interaction with DDX58; when associated with F-590,F-635 and F-682.	SEQ_UP	1	
MUTAGEN:Y->F: Decreases interaction with DDX58; when associated with F-635, F-659 and F-682.	SEQ_UP	1	
MUTAGEN:Y->F: Decreases phosphorylation. Nearly abolishes phosphorylation; when associated with F-572 and F-605.	SEQ_UP	1	
MUTAGEN:Y->F: Decreases phosphorylation. Nearly abolishes phosphorylation; when associated with F-572 and F-643.	SEQ_UP	1	
MUTAGEN:Y->F: Decreases phosphorylation. Nearly abolishes phosphorylation; when associated with F-605 and F-643.	SEQ_UP	1	
MUTAGEN:Y->F: Diminishes the ability to induce SRC-mediated activation of luciferase.	SEQ_UP	1	
MUTAGEN:Y->F: Disrupts interaction with SH2D1B, abolishes NK cell activation in presence of SH2D1B, no effect on NK cell inhibition in absence of SH2D1B.	SEQ_UP	1	
MUTAGEN:Y->F: Does not affect interaction with MECP2.	SEQ_UP	1	
MUTAGEN:Y->F: Does not affect kinase activity nor secretion to the extracellular medium.	SEQ_UP	1	
MUTAGEN:Y->F: Does not affect nuclear localization.	SEQ_UP	1	
MUTAGEN:Y->F: Does not affect recruitment to heterochromatin by MECP2.	SEQ_UP	1	
MUTAGEN:Y->F: Does not affect the ability to inhibit PKB activity.	SEQ_UP	1	
MUTAGEN:Y->F: Does not modifies the structure of cell contacts. No effect on localization at the plasma membrane. No change in shedding activity.	SEQ_UP	1	
MUTAGEN:Y->F: Enhanced reduction of BCR-induced IL2 secretion. No effect on interaction with INPP5D SH2 domain. Abolishes interaction with CSK SH2 domain. No effect on BCR-triggered tyrosine phosphorylation. Abolishes reduction of BCR-induced IL2 secretion, the interaction with INPP5D SH2 domain and BCR-triggered tyrosine phosphorylation; when associated with F-343.	SEQ_UP	1	
MUTAGEN:Y->F: Enhances TCR-mediated signaling.	SEQ_UP	1	
MUTAGEN:Y->F: Fails to bind PIK3R1 in a BCR-signaling dependent manner; when associated with Y-264; Y-420 and Y-445. Loss of regulatory function in Toll-like receptor signaling probably due to loss of interaction with PIK3R1; when associated with Y-264; Y-420 and Y-445. Impairs mature B-cell generation; when associated with Y-264; Y-420 and Y-445.	SEQ_UP	1	
MUTAGEN:Y->F: Fails to bind PIK3R1 in a BCR-signaling dependent manner; when associated with Y-264; Y-420 and Y-460. Loss of regulatory function in Toll-like receptor signaling probably due to loss of interaction with PIK3R1; when associated with Y-264; Y-420 and Y-460. Impairs mature B-cell generation; when associated with Y-264; Y-420 and Y-460.	SEQ_UP	1	
MUTAGEN:Y->F: Fails to bind PIK3R1 in a BCR-signaling dependent manner; when associated with Y-264; Y-445 and Y-460. Loss of regulatory function in Toll-like receptor signaling probably due to loss of interaction with PIK3R1; when associated with Y-264; Y-445 and Y-460. Impairs mature B-cell generation; when associated with Y-264; Y-445 and Y-460.	SEQ_UP	1	
MUTAGEN:Y->F: Fails to bind PIK3R1 in a BCR-signaling dependent manner; when associated with Y-420; Y-445 and Y-460. Loss of regulatory function in Toll-like receptor signaling probably due to loss of interaction with PIK3R1; when associated with Y-420; Y-445 and Y-460. Impairs mature B-cell generation; when associated with Y-420; Y-445 and Y-460.	SEQ_UP	1	
MUTAGEN:Y->F: Fails to induce pre-BCR down-regulation, leading to splenomegaly and leukemia.	SEQ_UP	1	
MUTAGEN:Y->F: Greatly decreased P-selectin binding and tethering and rolling of cells. No further reduction of P-selectin binding; when associated with Y-56. Binding of P-selectin completely abolished; when associated with A-55; Y-56 and A-58.	SEQ_UP	1	
MUTAGEN:Y->F: Greatly promotes interaction with DAB2.	SEQ_UP	1	
MUTAGEN:Y->F: Has little effect on tyrosine phosphorylation. Reduces pre-B-cell differentiation. Abolishes binding to BLNK. Inhibits phosphorylation of BLNK. No effect on cap formation or BCR internalization. Impaired antigen presentation; when associated with F-176.	SEQ_UP	1	
MUTAGEN:Y->F: Impairs binding to chromatin.	SEQ_UP	1	
MUTAGEN:Y->F: In GM7; defective in methyltransferase activity without affecting DNA methylation; when associated with V-1120.	SEQ_UP	1	
MUTAGEN:Y->F: In LM7; does not prevent methyltransferase activity; when associated with V-1153.	SEQ_UP	1	
MUTAGEN:Y->F: Increase in the kinase activation level.	SEQ_UP	1	
MUTAGEN:Y->F: Increased enzyme activity in the absence of phosphate. No effect on stimulation of enzyme activity by phosphate.	SEQ_UP	1	
MUTAGEN:Y->F: Increases protein abundance at plasma membrane. Greatly reduces channel activity.	SEQ_UP	1	
MUTAGEN:Y->F: Increases tyrosine phosphorylation. Inhibits phosphorylation of BLNK. Impaired antigen presentation; when associated with F-204.	SEQ_UP	1	
MUTAGEN:Y->F: Inefficient EGFR internalization.	SEQ_UP	1	
MUTAGEN:Y->F: Inhibits EFNA1-induced vascular assembly and abolishes kinase activity.	SEQ_UP	1	
MUTAGEN:Y->F: Inhibits EFNA1-induced vascular assembly and kinase activity.	SEQ_UP	1	
MUTAGEN:Y->F: Inhibits EFNA1-induced vascular assembly and RAC1 activation in endothelial cells. Inhibits kinase activity. Loss of binding to VAV3 and PI3-kinase p85 subunit.	SEQ_UP	1	
MUTAGEN:Y->F: Inhibits EFNA1-induced vascular assembly and RAC1 activation in endothelial cells. No significant effect on kinase activity. Loss of binding to PI3-kinase p85 subunit.	SEQ_UP	1	
MUTAGEN:Y->F: Inhibits interaction with BLNK. No effect on interactions with TLR4, GRB2 and CSK.	SEQ_UP	1	
MUTAGEN:Y->F: Inhibits interaction with BLNK. Slightly inhibits interaction with GRB2. No effect on interactions with TLR4 and CSK.	SEQ_UP	1	
MUTAGEN:Y->F: Inhibits interaction with TLR4. Decreases IL12B expression after TLR4 activation by lipopolysaccharide. Inhibits interaction with CSK. No effect on interactions with LYN, GRB2, and BLNK.	SEQ_UP	1	
MUTAGEN:Y->F: Inhibits prenylation activity. In myoblasts, impaired insulin-induced RAC1 activation, possibly due to impaired insulin-induced geranyl-geranyltransferase activation. 68% decrease in MUSK-binding.	SEQ_UP	1	
MUTAGEN:Y->F: Leads to constitutive activation of BLK.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of activity; when associated with A-159.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of ephrin-mediated growth cone collapse. No effect on interaction with EPHA4.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of exonuclease activity.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of function.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of GRB2 binding.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of inhibition of B-cell calcium mobilization.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of interaction with DOK7.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of interaction with MAVS.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of interaction with NOS2.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of interaction with PI3 kinase.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of interaction with PLCG1.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of interaction with RUNX1 and loss of its ability to inhibit RUNX1 transcriptional activity and suppress TH17 lineage development. Significant loss of ABL1-mediated phosphorylation and loss of transcriptional activator activity; when associated with F-219 and F-225.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of interaction with SHB.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of interaction with SHC1.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of kinase activity and of autophosphorylation; no effect on phosphorylation by CDK7.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of phosphorylation and loss of interaction with PLCG1, PLCG2 and VAV. No effect on the suppression of natural killer cell activation and suppression of interferon-gamma production; when associated with F-69, F-101, F-153, F-174 and F-188.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of phosphorylation and loss of interaction with PLCG1, PLCG2 and VAV. No effect on the suppression of natural killer cell activation and suppression of interferon-gamma production; when associated with F-69, F-96, F-101, F-153 and F-174.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of phosphorylation and loss of interaction with PLCG1, PLCG2 and VAV. No effect on the suppression of natural killer cell activation and suppression of interferon-gamma production; when associated with F-69, F-96, F-101, F-153 and F-188.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of phosphorylation and loss of interaction with PLCG1, PLCG2 and VAV. No effect on the suppression of natural killer cell activation and suppression of interferon-gamma production; when associated with F-69, F-96, F-101, F-174 and F-188.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of phosphorylation and loss of interaction with PLCG1, PLCG2 and VAV. No effect on the suppression of natural killer cell activation and suppression of interferon-gamma production; when associated with F-69, F-96, F-153, F-174 and F-188.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of phosphorylation and loss of interaction with PLCG1, PLCG2 and VAV. No effect on the suppression of natural killer cell activation and suppression of interferon-gamma production; when associated with F-96, F-101, F-153, F-174 and F-188.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of phosphorylation by CSK. Abolishes interaction with AP-2 complex. Cannot rescue the effect PIP5K1C knockdown on EGF-stimulated cell migration.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of phosphorylation. Loss of LYN-binding. Slight decrease in GRB2-binding. No effect on VAV-binding. Partial loss of enhancement of LPS-induced TNF production.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of PTPN6 binding and inhibition of Ca(2+) influx upon activation of natural killer cells.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of tyrosine phosphorylation at the C-terminus. Reduced tyrosine phosphorylation; when associated with F-869 and F-873. Interferes with accumulation at synapses. Interferes with AMPA-mediated receptor internalization.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of tyrosine phosphorylation by WEE1 and CABLES1.	SEQ_UP	1	
MUTAGEN:Y->F: Loss of tyrosine phosphorylation. Abolishes interaction with FYN and GRB2.	SEQ_UP	2	
MUTAGEN:Y->F: Loss of tyrosine phosphorylations by CABLES1 and ABL1; decreased activity.	SEQ_UP	1	
MUTAGEN:Y->F: Minimal reduction in ability to autophosphorylate.	SEQ_UP	2	
MUTAGEN:Y->F: Minor effect on phosphorylation by FES. Abolishes phosphorylation by FES; when associated with F-388.	SEQ_UP	1	
MUTAGEN:Y->F: Modulates macrophage cytokine secretion.	SEQ_UP	1	
MUTAGEN:Y->F: More stably associated with the erythropoietin receptor complex.	SEQ_UP	1	
MUTAGEN:Y->F: No autophosphorylation.	SEQ_UP	1	
MUTAGEN:Y->F: No change in the phosphorylation level. Loss of protein phosphorylation; when associated with F-329.	SEQ_UP	1	
MUTAGEN:Y->F: No change in the phosphorylation level. Loss of protein phosphorylation; when associated with F-334.	SEQ_UP	1	
MUTAGEN:Y->F: No change of phosphorylation implicated in interaction with PTPN6 and PTPN11. Severe reduction of phosphorylation; when associated with F-245 and/or F-274.	SEQ_UP	1	
MUTAGEN:Y->F: No change of phosphorylation implicated in interaction with PTPN6 and PTPN11. Severe reduction of phosphorylation; when associated with F-245 and/or F-299.	SEQ_UP	1	
MUTAGEN:Y->F: No change of phosphorylation implicated in interaction with PTPN6 and PTPN11. Severe reduction of phosphorylation; when associated with F-274 and/or F-299.	SEQ_UP	1	
MUTAGEN:Y->F: No changes in channel activation by 4-alpha-PDD or heat.	SEQ_UP	1	
MUTAGEN:Y->F: No changes in channel activity.	SEQ_UP	1	
MUTAGEN:Y->F: No detectable phenotype.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on binding to NUMB protein.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on binding to THOC5.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on binding to THOC5. Slightly reduced enhancement of cell proliferation.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on cellular location.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on enzyme activity. Decreases affinity for NADP.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on EPO-induced tyrosine phosphorylation.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on interaction with GRIP1 and GRIP2.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on interaction with KCNA2, but decreases KCNA2 levels at the cell membrane.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on interaction with KCNA2.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on interaction with PI3 kinase.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on interaction with SH2D1, no effect on NK cell activation in presence of SH2D1B, no effect on NK cell inhibition in absence of SH2D1B.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on interaction with SH2D1B, increases NK cell activation in presence of SH2D1B, abolishes NK cell inhibition in absence of SH2D1B.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on macrophage cytokine secretion.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on P-selectin binding. Greatly decreased P-selectin binding and tethering and rolling of cells; when associated with Y-54. Binding of P-selectin completely abolished; when associated with Y-54; A-55 and A-58.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on phosphorylation.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on pre-BCR down-regulation.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on the reduction of BCR-induced IL2 secretion, nor on the interaction with the SH2 domain of INPP5D or CSK nor on BCR-triggered tyrosine phosphorylation; when associated with F-378.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on the reduction of BCR-induced IL2 secretion, nor on the interaction with the SH2 domain of INPP5D or CSK nor on BCR-triggered tyrosine phosphorylation; when associated with F-399.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on tyrosine phosphorylation. Reduced tyrosine phosphorylation; when associated with F-869 and F-876.	SEQ_UP	1	
MUTAGEN:Y->F: No effect on tyrosine phosphorylation. Reduced tyrosine phosphorylation; when associated with F-873 and F-876.	SEQ_UP	1	
MUTAGEN:Y->F: No impact on substrate affinity of SLC6A19-mediated amino acid transport.	SEQ_UP	1	
MUTAGEN:Y->F: No loss of binding to SH2 domain of RASGAP or NCK. Complete loss of binding to SH2 domain of RASGAP; when associated with F-304.	SEQ_UP	1	
MUTAGEN:Y->F: No loss of binding to SH2 domain of RASGAP. Complete loss of binding to SH2 domain of NCK.	SEQ_UP	1	
MUTAGEN:Y->F: No loss of binding to SH2 domain of RASGAP. Complete loss of binding to SH2 domain of RASGAP; when associated with F-276.	SEQ_UP	1	
MUTAGEN:Y->F: No loss of IL12-induced STAT4 activation nor T-cell proliferation. No effect on IFN-gamma production.	SEQ_UP	1	
MUTAGEN:Y->F: No loss of IL12-induced STAT4 activation. Greatly reduced IL12-induced T-cell proliferation and IFN-gamma production.	SEQ_UP	1	
MUTAGEN:Y->F: No loss of interaction with ITK and GATA3.	SEQ_UP	1	
MUTAGEN:Y->F: No loss of interaction with RUNX1.	SEQ_UP	1	
MUTAGEN:Y->F: No loss of interaction with RUNX1. Loss of interaction with ITK and GATA3.	SEQ_UP	1	
MUTAGEN:Y->F: No loss of interaction with SPSB4; when associated with F-596.	SEQ_UP	1	
MUTAGEN:Y->F: No loss of interaction with SPSB4; when associated with F-602.	SEQ_UP	1	
MUTAGEN:Y->F: No loss of PTPN11 binding.	SEQ_UP	1	
MUTAGEN:Y->F: No PTPN11 binding, reduced PTPN11 tyrosine phosphorylation and reduced cell proliferation.	SEQ_UP	1	
MUTAGEN:Y->F: No PTPN6 binding, binds PTPN11.	SEQ_UP	1	
MUTAGEN:Y->F: No reduction in ability to autophosphorylate.	SEQ_UP	1	
MUTAGEN:Y->F: No significant effect on kinase activity. Significant reduction in phosphorylation.	SEQ_UP	1	
MUTAGEN:Y->F: No significant effect on MHC class II-binding.	SEQ_UP	1	
MUTAGEN:Y->F: No significant effect on phosphorylation by FER.	SEQ_UP	1	
MUTAGEN:Y->F: No STAT5 activation.	SEQ_UP	1	
MUTAGEN:Y->F: No stimulation of granule polarization during NK-mediated cytotoxicity.	SEQ_UP	1	
MUTAGEN:Y->F: Nuclear localization to the same extent as wild-type; when associated with A-609.	SEQ_UP	1	
MUTAGEN:Y->F: Partial reduction in ability to autophosphorylate.	SEQ_UP	1	
MUTAGEN:Y->F: Partially suppresses inhibition of mast cell activation. Abolishes inhibition of mast cell activation; when associated with F-300.	SEQ_UP	1	
MUTAGEN:Y->F: Partially suppresses inhibition of mast cell activation. Abolishes inhibition of mast cell activation; when associated with F-322.	SEQ_UP	1	
MUTAGEN:Y->F: Phosphorylated on tyrosine. Abrogates interaction with PTPN11. Abrogates interaction with PTPN11 and phosphorylation; when associated with F-488. Suppresses T cell proliferation; when associated with F-488. Increases cytokine production; when associated with F-488. Activates JNK cascade; when associated with F-488. Abrogates CEACAM1-L phosphorylation in endothelial cells upon VEGF stimulation. Impairs interaction with and inactivation of SYK; when associated with F-488.	SEQ_UP	1	
MUTAGEN:Y->F: Phosphorylated on tyrosine. Abrogates interaction with PTPN11. Abrogates interaction with PTPN11 and phosphorylation; when associated with F-515. Reduces endothelial cell migration and differentiation. Suppresses T cell proliferation; when associated with F-515. Increases cytokine production; when associated with F-515. Activates JNK cascade; when associated with F-515. Abrogates CEACAM1-L phosphorylation in endothelial cells and decreases amounts of released nitric oxide upon VEGF stimulation. Impairs interaction with and inactivation of SYK; when associated with F-515.	SEQ_UP	1	
MUTAGEN:Y->F: Phosphorylation blocked.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced activity in response to growth hormone.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced autophosphorylation.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced binding to PIK3R2. Slight reduction of phosphorylation in HEK293T cells. Abolishes phosphorylation in HEK293T cells and neurons; when associated with F-212.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced binding to PIK3R2. Slight reduction of phosphorylation in HEK293T cells. Abolishes phosphorylation in HEK293T cells and neurons; when associated with F-277.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced endocytosis; when associated with F-783.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced endocytosis; when associated with F-795.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced interaction with CBL. Prolonged signaling, due to reduced internalization and degradation. Reduced interaction with FYN. Promotes cell proliferation. Reduced autophosphorylation at Tyr-807.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced kinase activity. Strongly reduced phosphorylation of PLCG2. Diminishes binding to THOC5.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced levels of autophosphorylation.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced levels of autophosphorylation. Abolishes interaction with GRB2 and GRB7. Abolishes phosphorylation of GRB7 and PIK3R1.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced phosphorylation and reduced association with FYN.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced phosphorylation.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced phosphorylation. Almost complete loss of phosphorylation; when associated with F-25 and F-373.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced phosphorylation. Almost complete loss of phosphorylation; when associated with F-25 and F-508.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced phosphorylation. Almost complete loss of phosphorylation; when associated with F-373 and F-508.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced phosphorylation. Loss of phosphorylation; when associated with F-38.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced phosphorylation. Loss of phosphorylation; when associated with F-60.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced tyrosine kinase activity.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced tyrosine phosphorylation. Abolished ability to mediate recruitment of PTPN11/SHP-2.	SEQ_UP	1	
MUTAGEN:Y->F: Reduced tyrosine phosphorylation. Decreased ability to mediate recruitment of PTPN11/SHP-2.	SEQ_UP	1	
MUTAGEN:Y->F: Reduces binding to PTPN6.	SEQ_UP	1	
MUTAGEN:Y->F: Reduces GRB2 binding.	SEQ_UP	1	
MUTAGEN:Y->F: Reduces interaction with SHTN1; when associated with A-1048.	SEQ_UP	1	
MUTAGEN:Y->F: Reduces phosphatidylinositol 3,4,5-trisphosphate binding.	SEQ_UP	1	
MUTAGEN:Y->F: Reduces phosphorylation by SRC or downstream kinase; when associated with F-185 and F-198. Abolishes phosphorylation by SRC or downstream kinase; when associated with F-185; F-198; F-220 and F-232.	SEQ_UP	1	
MUTAGEN:Y->F: Reduces phosphorylation by SRC or downstream kinase; when associated with F-185 and F-200. Abolishes phosphorylation by SRC or downstream kinase; when associated with F-185; F-200; F-220 and F-232.	SEQ_UP	1	
MUTAGEN:Y->F: Reduces phosphorylation by SRC or downstream kinase; when associated with F-198 and F-200. Abolishes phosphorylation by SRC or downstream kinase; when associated with F-198; F-200; F-220 and F-232.	SEQ_UP	1	
MUTAGEN:Y->F: Reduces phosphorylation by SRC or downstream kinase; when associated with F-220. Abolishes phosphorylation by SRC or downstream kinase; when associated with F-185; F-198; F-200 and F-220. Abolishes interaction with CRKL SH2 domain; when associated with F-220.	SEQ_UP	1	
MUTAGEN:Y->F: Reduces phosphorylation by SRC or downstream kinase; when associated with F-232. Abolishes phosphorylation by SRC or downstream kinase; when associated with F-185; F-198; F-200 and F-232. Abolishes interaction with CRKL SH2 domain; when associated with F-232.	SEQ_UP	1	
MUTAGEN:Y->F: Reduces phosphorylation. Abolishes phosphorylation; when associated with F-350.	SEQ_UP	1	
MUTAGEN:Y->F: Reduces phosphorylation. Impairs podosome rosette formation. Abolishes phosphorylation; when associated with F-340.	SEQ_UP	1	
MUTAGEN:Y->F: Reduces tyrosine phosphorylation by 90%; when associated with E-608.	SEQ_UP	1	
MUTAGEN:Y->F: Reduces tyrosine phosphorylation by FER by about 60%.	SEQ_UP	1	
MUTAGEN:Y->F: Results are conflicting as to whether hypotonicity-dependent channel activity is abolished.	SEQ_UP	1	
MUTAGEN:Y->F: Retains the intramolecular linker-DENN domain interaction and impairs GEF activity towards Rab12.	SEQ_UP	1	
MUTAGEN:Y->F: Significant loss of ABL1-mediated phosphorylation and loss of transcriptional activator activity; when associated with F-219 and F-304.	SEQ_UP	1	
MUTAGEN:Y->F: Significant loss of ABL1-mediated phosphorylation and loss of transcriptional activator activity; when associated with F-225 and F-304.	SEQ_UP	1	
MUTAGEN:Y->F: Significant loss of interaction with TNK2. Loss of membrane localization. Significant reduction in phosphorylation on Ser-473.	SEQ_UP	1	
MUTAGEN:Y->F: Significant loss of phosphorylation and loss of regulation of ribosomal transcriptional activity.	SEQ_UP	1	
MUTAGEN:Y->F: Significant reduction in catalytic efficiency.	SEQ_UP	1	
MUTAGEN:Y->F: Slight reduction of phosphorylation in HEK293T cells. Abolishes phosphorylation in HEK293T cells and in neurons; when associated with F-1416.	SEQ_UP	1	
MUTAGEN:Y->F: Slight reduction of phosphorylation in HEK293T cells. Abolishes phosphorylation in HEK293T cells and neurons; when associated with F-1441.	SEQ_UP	1	
MUTAGEN:Y->F: Slightly decreased estrogen sulfotransferase activity.	SEQ_UP	1	
MUTAGEN:Y->F: Some reduction of BCR-induced IL2 secretion. Some interaction with INPP5D SH2 domain. Some decrease in BCR-triggered tyrosine phosphorylation. Abolishes reduction of BCR-induced IL2 secretion, the interaction with INPP5D SH2 domain and BCR-triggered tyrosine phosphorylation; when associated with F-325.	SEQ_UP	1	
MUTAGEN:Y->F: Specifically abolishes interaction with GRB2; mild decrease in phosphorylation.	SEQ_UP	1	
MUTAGEN:Y->F: Strong inhibitory signaling in germinal center formation (absence of SH2D1A/SAP); when associated with F-295 and F-335.	SEQ_UP	1	
MUTAGEN:Y->F: Strong inhibitory signaling in germinal center formation (absence of SH2D1A/SAP); when associated with F-295 and F-349.	SEQ_UP	1	
MUTAGEN:Y->F: Strong inhibitory signaling in germinal center formation (absence of SH2D1A/SAP); when associated with F-319 and F-335.	SEQ_UP	1	
MUTAGEN:Y->F: Strong inhibitory signaling in germinal center formation (absence of SH2D1A/SAP); when associated with F-319 and F-349.	SEQ_UP	1	
MUTAGEN:Y->F: Strong inhibitory signaling in germinal center formation (absence of SH2D1A/SAP); when associated with F-335 and F-349.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly impairs function, tyrosine phosphorylation, subcellular location and interaction with DOK1; when associated with F-1021.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly impairs function, tyrosine phosphorylation, subcellular location and interaction with DOK1; when associated with F-918.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly reduced autophosphorylation.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly reduced enzyme activity; when associated with 576-F-F-577. Abolishes activation of MAPK1/ERK2 in response to integrin signaling. Abolishes activation of SRC. Abolishes interaction with PIK3R1.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly reduced levels of vascular smooth muscle cells and pericytes in developing blood vessels; when associated with F-578; F-715; F-739; F-750; F-1008 and F-1020.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly reduced levels of vascular smooth muscle cells and pericytes in developing blood vessels; when associated with F-578; F-715; F-739; F-750; F-770 and F-1008.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly reduced levels of vascular smooth muscle cells and pericytes in developing blood vessels; when associated with F-578; F-715; F-739; F-750; F-770 and F-1020.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly reduced levels of vascular smooth muscle cells and pericytes in developing blood vessels; when associated with F-578; F-715; F-739; F-770; F-1008 and F-1020.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly reduced levels of vascular smooth muscle cells and pericytes in developing blood vessels; when associated with F-578; F-715; F-750; F-770; F-1008 and F-1020.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly reduced levels of vascular smooth muscle cells and pericytes in developing blood vessels; when associated with F-578; F-739; F-750; F-770; F-1008 and F-1020.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly reduced levels of vascular smooth muscle cells and pericytes in developing blood vessels; when associated with F-715; F-739; F-750; F-770; F-1008 and F-1020.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly reduced tyrosine phosphorylation. Abolishes interaction with FHL2.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly reduces phosphorylation by CSK; when associated with F-1399.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly reduces phosphorylation by CSK; when associated with F-1404.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly reduces phosphorylation by FES. Abolishes phosphorylation by FES; when associated with F-405.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly reduces PLCG2 binding. Abolishes LCK, PIK3R1 and LYN binding; when associated with F-242.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly reduces tyrosine phosphorylation and pre-B-cell differentiation; when associated with F-182. No effect on constitutive internalization of BCR.	SEQ_UP	1	
MUTAGEN:Y->F: Strongly reduces tyrosine phosphorylation and pre-B-cell differentiation; when associated with F-193. Abolishes constitutive internalization of BCR.	SEQ_UP	1	
MUTAGEN:Y->F: Weakly decreases downstream phosphorylation of CBL and VAV1; when associated with F-325 and F-344.	SEQ_UP	1	
MUTAGEN:Y->F: Weakly decreases downstream phosphorylation of CBL and VAV1; when associated with F-325 and F-369.	SEQ_UP	1	
MUTAGEN:Y->F: Weakly decreases downstream phosphorylation of CBL and VAV1; when associated with F-344 and F-369.	SEQ_UP	1	
MUTAGEN:Y->G,H,V: Greatly impairs interaction with DAB2.	SEQ_UP	1	
MUTAGEN:Y->G: Loss of interaction with GRIP1 and GRIP2.	SEQ_UP	1	
MUTAGEN:Y->G: May alter protein folding or stability. Loss of kinase activity. No effect on interaction with PIK3R1.	SEQ_UP	1	
MUTAGEN:Y->G: No change in increased NPP activity in oestoblastic matrix vesicles.	SEQ_UP	1	
MUTAGEN:Y->G: No MAPK8IP1 nor APBA1 nor APBB1 nor DAB1 binding.	SEQ_UP	1	
MUTAGEN:Y->G: Reduced binding of APBB1.	SEQ_UP	1	
MUTAGEN:Y->G: Slightly impaired signaling.	SEQ_UP	1	
MUTAGEN:Y->H: In AE mutant; gain-of-function mutation; causes an alopecia phenotype; constitutively active in triggering cell death. Mice also display hypoplastic mammary glands, impairing lactation function.	SEQ_UP	1	
MUTAGEN:Y->H: Knockin homozygous mice develop progressive pulmonary fibrosis. The mutant protein is not secreted in bronchoalveolar fluid from mutant mice.	SEQ_UP	1	
MUTAGEN:Y->H: Loss of enzyme activity.	SEQ_UP	1	
MUTAGEN:Y->H: Negatively regulates of T and B cell proliferation upon activation. Significantly increases cell surface expression on T and B cells. Impairs internalization.	SEQ_UP	1	
MUTAGEN:Y->H: No effect on carbonate dehydratase activity.	SEQ_UP	1	
MUTAGEN:Y->H: No effect on carbonate dehydratase activity. Enhanced proton transfer due to removal of the steric hindrance of F-95; when associated with A-95.	SEQ_UP	1	
MUTAGEN:Y->H: No effect on protein abundance. No effect on cell surface localization. No effect on alanine uptake activity.	SEQ_UP	1	
MUTAGEN:Y->H: Reduces binding affinity for misfolded proteins by 40%.	SEQ_UP	1	
MUTAGEN:Y->H: Retention in the endoplasmic reticulum/cis-Golgi; when associated with E-110.	SEQ_UP	1	
MUTAGEN:Y->I,W: Impairs interaction with DAB2.	SEQ_UP	1	
MUTAGEN:Y->I: Impair expression of folded protein.	SEQ_UP	1	
MUTAGEN:Y->I: Loss of the ability to promote lysosome clustering at the center of the cell. No effect on location at lysosome membranes.	SEQ_UP	1	
MUTAGEN:Y->I: Reduces affinity for substrate and catalytic activity by about 50%.	SEQ_UP	1	
MUTAGEN:Y->K,Q: Constitutive lipid scramblase activity at basal cytosolic calcium levels.	SEQ_UP	1	
MUTAGEN:Y->L,V: Strongly reduces protein solubility.	SEQ_UP	1	
MUTAGEN:Y->L: Loss of MAIT cell activation.	SEQ_UP	1	
MUTAGEN:Y->L: No change in EPO-induced JAK2 activation and EPO-induced tyrosine phosphorylation. No phosphorylation; when associated with S-1138. No phosphorylation; when associated with both S-1138 and F-1077. No change in STAT3 activation. No PTPN11 binding. No SOCS3 binding nor inhibition of signaling. Greatly reduced ERK/FOS activation. Mutants are hyperphagic, obese and hyperglycaemic, females show a defect in lactation.	SEQ_UP	1	
MUTAGEN:Y->M: Slightly decreases substrate affinity but no effect on activity with smaller substrates like benzaldehyde or phthalazine. Increases catalytic efficiency with bulkier substrates like phenanthridine or more charged substrates like N1-methylnicotinamide.	SEQ_UP	1	
MUTAGEN:Y->N: Abolishes localization to meiotic nuage; when associated with K-1023.	SEQ_UP	1	
MUTAGEN:Y->N: In plt1; loss of function inducing thrombocytopenia and kidney disease.	SEQ_UP	1	
MUTAGEN:Y->N: In Rex mutant M100573; mice exhibit curly hair and vibrissae. The diameter of the hair shaft is irregular due to morphological abnormalities in all three layers of the irs.	SEQ_UP	1	
MUTAGEN:Y->N: Koli mutant, animals exhibit visceral heterotaxy, with heart defects commonly associated with heterotaxy.	SEQ_UP	1	
MUTAGEN:Y->N: Nearly abolishes phosphatase activity.	SEQ_UP	1	
MUTAGEN:Y->N: Strongly reduced binding to symmetric dimethylarginines.	SEQ_UP	1	
MUTAGEN:Y->P: Impairs IgE-induced mast cell activation in the presence of antigen; Impairs IgE-induced mast cell survival in the absence of antigen; when associated with P-65. Impairs IL3-induced production of IL4 by basophils; when associated with P-65.	SEQ_UP	1	
MUTAGEN:Y->P: Impairs IgE-induced mast cell activation in the presence of antigen; Impairs IgE-induced mast cell survival in the absence of antigen; when associated with P-76. Impairs IL3-induced production of IL4 by basophils; when associated with P-76.	SEQ_UP	1	
MUTAGEN:Y->Q: Loss of trimeric subunit ABC assembly.	SEQ_UP	2	
MUTAGEN:Y->R: Impairs interaction with CBFA2T2.	SEQ_UP	1	
MUTAGEN:Y->R: Loss of MAIT cell activation.	SEQ_UP	1	
MUTAGEN:Y->S,F: Strongly inhibits interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:Y->S,T: Capable of both nicking and hairpinning.	SEQ_UP	1	
MUTAGEN:Y->S: Abolishes cholesterol transport.	SEQ_UP	1	
MUTAGEN:Y->S: Abolishes interaction with CD4 endocytosis signal motif.	SEQ_UP	1	
MUTAGEN:Y->S: Abolishes interaction with Clostridium perfringens CPE.	SEQ_UP	1	
MUTAGEN:Y->S: Abolishes nuclear pore localization; when associated with 272-GSGSGSGSG-280.	SEQ_UP	1	
MUTAGEN:Y->S: Abolishes phospholipid binding.	SEQ_UP	1	
MUTAGEN:Y->S: Abolishes the interaction with RAP6A and localization to Golgi membrane; when associated with Ala-935.	SEQ_UP	1	
MUTAGEN:Y->S: Decreased lysosomal localization. Decreased interaction with AP-1 and AP-2 complexes; when associated with S-410. Almost complete loss of lysosomal localization and decreased interaction with AP-1 and AP-2 complexes; when associated with S-428. Decreased interaction with AP-1 and AP-2 complexes, almost complete loss of lysosomal localization, mislocalization to the Golgi apparatus and almost complete loss of RNA degradation by lysosomes; when associated with S-410 and S-428.	SEQ_UP	1	
MUTAGEN:Y->S: Disrupts channel closure.	SEQ_UP	1	
MUTAGEN:Y->S: Does not affect ability to promote H3K27me3 methylation; when associated with S-75.	SEQ_UP	1	
MUTAGEN:Y->S: Drastically decreased lysosomal localization. Almost complete loss of lysosomal localization and decreased interaction with AP-1 and AP-2 complexes; when associated with S-359. No effect on interaction with AP-1 and AP-2 complexes, nor on RNA uptake by lysosomes; when associated with S-410. Decreased interaction with AP-1 and AP-2 complexes, almost complete loss of lysosomal localization, mislocalization to the Golgi apparatus and almost complete loss of RNA degradation by lysosomes; when associated with S-359 and S-410.	SEQ_UP	1	
MUTAGEN:Y->S: Drastically decreased lysosomal localization. Decreased interaction with AP-1 and AP-2 complexes; when associated with S-359. Decreased interaction with AP-1 and AP-2 complexes, almost complete loss of lysosomal localization, mislocalization to the Golgi apparatus and almost complete loss of RNA degradation by lysosomes; when associated with S-359 and S-428. No effect on interaction with AP-1 and AP-2 complexes, nor on RNA uptake by lysosomes; when associated with S-428.	SEQ_UP	1	
MUTAGEN:Y->S: No change in EPO-induced JAK2 activation and EPO-induced tyrosine phosphorylation. No phosphorylation; when associated with L-985. No phosphorylation; when associated with L-985 and F-1077. No STAT3 activation. No change in SOCS3 binding nor signaling inhibition. No effect on ERK/FOS activation.	SEQ_UP	1	
MUTAGEN:Y->S: No effect on lipid scramblase activity.	SEQ_UP	1	
MUTAGEN:Y->S: No effect on lysosomal localization, nor on RNA uptake by lysosomes.	SEQ_UP	1	
MUTAGEN:Y->S: No effect on MHC class I binding; when associated with S-173.	SEQ_UP	1	
MUTAGEN:Y->S: No effect on PDCD1 binding.	SEQ_UP	1	
MUTAGEN:Y->S: Reduces protein solubility.	SEQ_UP	1	
MUTAGEN:Y->S: Reduces tyrosine phosphorylation. Abolishes tyrosine phosphorylation and interaction with GRB2 and FYN; when associated with A-953.	SEQ_UP	1	
MUTAGEN:Y->S: Strong decrease in cGAMP-binding.	SEQ_UP	1	
MUTAGEN:Y->V: In GM7; defective in methyltransferase activity without affecting DNA methylation; when associated with F-1207.	SEQ_UP	1	
MUTAGEN:Y->V: In LM7; does not prevent methyltransferase activity; when associated with F-1240.	SEQ_UP	1	
MUTAGEN:Y->V: Severely impairs sperm binding. No effect on trypsin inhibitor activity.	SEQ_UP	1	
MUTAGEN:Y->W: Abolishes receptor ligation-induced phosphorylation.	SEQ_UP	1	
MUTAGEN:Y->W: Decreased lipid phosphatase activity.	SEQ_UP	1	
MUTAGEN:Y->W: Greatly impairs interaction with DAB2.	SEQ_UP	1	
MUTAGEN:Y->W: Loss of lipid scramblase activity.	SEQ_UP	1	
MUTAGEN:Y->W: Loss of N-methyltransferase activity.	SEQ_UP	1	
MUTAGEN:Y->W: Mildly increases the affinity for CALM.	SEQ_UP	1	
MUTAGEN:YCGGI->DRPPD: Abolishes nuclear export.	SEQ_UP	1	
MUTAGEN:YE->AA: Strongly reduced interaction with flagellin.	SEQ_UP	1	
MUTAGEN:YES->AAA: Does not inhibit interaction with ZNF473 and histone 3'-end processing.	SEQ_UP	1	
MUTAGEN:YFLLMVFVEL->SFLLMVFVVV: Increases surface expression in transfected pro-B cells and impairs interaction with FCER1G.	SEQ_UP	1	
MUTAGEN:YHQ->AAA: Strongly reduced interaction with MET and PARW.	SEQ_UP	1	
MUTAGEN:YL->AA: Abolished interaction with REC114.	SEQ_UP	1	
MUTAGEN:YL->AA: Decreases interaction with RAB7A.	SEQ_UP	1	
MUTAGEN:YLY->FLF: No binding to PTPN6 SH2 domains. Enhanced JAK2 activation and cell proliferation.	SEQ_UP	1	
MUTAGEN:YLYF->AAAA: Impairs interaction with INSIG1.	SEQ_UP	1	
MUTAGEN:YNL->ANA: Increases the affinity for CALM.	SEQ_UP	1	
MUTAGEN:YP->AA: No loss of interaction with PDCD6IP. Loss of interaction with PDCD6IP; when associated with 4-A--A-5 and 47-A--A-48.	SEQ_UP	1	
MUTAGEN:YP->AA: No loss of interaction with PDCD6IP. Loss of interaction with PDCD6IP; when associated with 4-A--A-5 and 51-A--A-52.	SEQ_UP	1	
MUTAGEN:YP->AA: No loss of interaction with PDCD6IP. Loss of interaction with PDCD6IP; when associated with 46-A--A-47 and 50-A--A-51.	SEQ_UP	1	
MUTAGEN:YQRL->AAAA: Decreased localization to the Golgi apparatus; when associated with 22-A--A-27.	SEQ_UP	1	
MUTAGEN:YRYRFRRRSSSRST->ARARARRRAAARAA: Decreased interaction with AP4M1. Has no effect on interaction with GRIA1. Dominant negative mutant which alters AMPARs localization to the somatodendritic compartment.	SEQ_UP	1	
MUTAGEN:YSFD->ASAA: Abolishes interaction with AURKA.	SEQ_UP	1	
MUTAGEN:YSN->FSA: No effect on enzyme activity and innate immune responses.	SEQ_UP	1	
MUTAGEN:YTKEEL->ATKEEA: Abolished interaction with EIF4E.	SEQ_UP	1	
MUTAGEN:YY->AA: Abolishes piRNA-binding and ubiquitination by the APC/C.	SEQ_UP	1	
MUTAGEN:YY->FF: Does not modifies the structure of cell contacts. No effect on localization at the plasma membrane. No change in shedding activity.	SEQ_UP	1	
MUTAGEN:YY->FF: Enhances stability. Modifies the structure of cell contacts. Localization at the plasma membrane is increased. Does not affect dimerization. No change in shedding activity.	SEQ_UP	1	
MUTAGEN:YY->FF: Specifically abolishes interaction with PIK3R1; mild decrease in phosphorylation.	SEQ_UP	1	
MUTAGEN:YY->FF: Strongly reduced enzyme activity; when associated with F-397.	SEQ_UP	1	
NON_STD:Selenocysteine	SEQ_UP	25	
NP_BIND:3',5'-cAMP	SEQ_UP	7	
NP_BIND:3',5'-cAMP 1	SEQ_UP	4	
NP_BIND:3',5'-cAMP 2	SEQ_UP	4	
NP_BIND:3',5'-cGMP	SEQ_UP	5	
NP_BIND:3',5'-cGMP 1	SEQ_UP	2	
NP_BIND:3',5'-cGMP 2	SEQ_UP	2	
NP_BIND:6-hydroxy-FAD	SEQ_UP	1	
NP_BIND:Adenosine 3',5'-bisphosphate	SEQ_UP	1	
NP_BIND:ADP	SEQ_UP	3	
NP_BIND:ADP 1	SEQ_UP	3	
NP_BIND:ADP 2	SEQ_UP	3	
NP_BIND:AMP	SEQ_UP	20	
NP_BIND:AMP 1	SEQ_UP	5	
NP_BIND:AMP 2	SEQ_UP	5	
NP_BIND:AMP 3	SEQ_UP	3	
NP_BIND:AMP binding	SEQ_UP	1	
NP_BIND:ATP	SEQ_UP	1077	
NP_BIND:ATP 1	SEQ_UP	40	
NP_BIND:ATP 2	SEQ_UP	40	
NP_BIND:ATP binding	SEQ_UP	2	
NP_BIND:ATP; allosteric activator	SEQ_UP	1	
NP_BIND:ATP; shared with dimeric partner	SEQ_UP	2	
NP_BIND:CMP	SEQ_UP	1	
NP_BIND:cNMP	SEQ_UP	28	
NP_BIND:cNMP 1	SEQ_UP	2	
NP_BIND:cNMP 2	SEQ_UP	2	
NP_BIND:cNMP 3	SEQ_UP	2	
NP_BIND:CTP	SEQ_UP	3	
NP_BIND:dCTP binding	SEQ_UP	2	
NP_BIND:dNTP	SEQ_UP	1	
NP_BIND:dTTP; allosteric effector that controls substrate specificity	SEQ_UP	1	
NP_BIND:FAD	SEQ_UP	76	
NP_BIND:FAD; shared with dimeric partner	SEQ_UP	4	
NP_BIND:FMN	SEQ_UP	19	
NP_BIND:GMP	SEQ_UP	3	
NP_BIND:GTP	SEQ_UP	302	
NP_BIND:GTP 1	SEQ_UP	2	
NP_BIND:GTP 2	SEQ_UP	2	
NP_BIND:GTP-binding	SEQ_UP	1	
NP_BIND:IMP	SEQ_UP	1	
NP_BIND:NAD	SEQ_UP	87	
NP_BIND:NAD 1	SEQ_UP	1	
NP_BIND:NAD 1; inhibitor	SEQ_UP	1	
NP_BIND:NAD 2; substrate	SEQ_UP	1	
NP_BIND:NAD binding	SEQ_UP	1	
NP_BIND:NADH	SEQ_UP	1	
NP_BIND:NADP	SEQ_UP	93	
NP_BIND:NADP 1	SEQ_UP	2	
NP_BIND:NADP 2	SEQ_UP	2	
NP_BIND:NADP; for enoyl reductase activity	SEQ_UP	1	
NP_BIND:NADP; for ketoreductase activity	SEQ_UP	1	
NP_BIND:NADP; shared with dimeric partner	SEQ_UP	1	
NP_BIND:NADP; shared with neighboring subunit	SEQ_UP	2	
NP_BIND:NMP	SEQ_UP	1	
NP_BIND:NTP	SEQ_UP	3	
NP_BIND:PAPS	SEQ_UP	34	
NP_BIND:Substrate	SEQ_UP	2	
NP_BIND:Substrate binding	SEQ_UP	1	
NP_BIND:Thiamine pyrophosphate	SEQ_UP	3	
NP_BIND:UDP	SEQ_UP	1	
NP_BIND:UDP-GlcNAc	SEQ_UP	1	
NP_BIND:UDP-glucuronate binding	SEQ_UP	3	
NP_BIND:UDP-N-acetyl-alpha-D-glucosamine	SEQ_UP	1	
NP_BIND:UMP binding	SEQ_UP	1	
PEPTIDE:[des-Ser1]-cerebellin	SEQ_UP	1	
PEPTIDE:Activation peptide	SEQ_UP	2	
PEPTIDE:Activation peptide fragment 1	SEQ_UP	1	
PEPTIDE:Activation peptide fragment 2	SEQ_UP	1	
PEPTIDE:Adrenomedullin	SEQ_UP	1	
PEPTIDE:Adrenomedullin-2	SEQ_UP	1	
PEPTIDE:Alpha-defensin 1	SEQ_UP	1	
PEPTIDE:Alpha-defensin 10	SEQ_UP	1	
PEPTIDE:Alpha-defensin 11	SEQ_UP	1	
PEPTIDE:Alpha-defensin 13	SEQ_UP	1	
PEPTIDE:Alpha-defensin 14	SEQ_UP	1	
PEPTIDE:Alpha-defensin 15	SEQ_UP	1	
PEPTIDE:Alpha-defensin 16	SEQ_UP	1	
PEPTIDE:Alpha-defensin 17	SEQ_UP	1	
PEPTIDE:Alpha-defensin 2	SEQ_UP	1	
PEPTIDE:Alpha-defensin 20	SEQ_UP	1	
PEPTIDE:Alpha-defensin 21	SEQ_UP	1	
PEPTIDE:Alpha-defensin 22	SEQ_UP	1	
PEPTIDE:Alpha-defensin 23	SEQ_UP	1	
PEPTIDE:Alpha-defensin 24	SEQ_UP	1	
PEPTIDE:Alpha-defensin 25	SEQ_UP	1	
PEPTIDE:Alpha-defensin 26	SEQ_UP	1	
PEPTIDE:Alpha-defensin 3	SEQ_UP	1	
PEPTIDE:Alpha-defensin 31	SEQ_UP	1	
PEPTIDE:Alpha-defensin 5	SEQ_UP	1	
PEPTIDE:Alpha-defensin 6/12	SEQ_UP	2	
PEPTIDE:Alpha-defensin 7	SEQ_UP	1	
PEPTIDE:Alpha-defensin 8	SEQ_UP	1	
PEPTIDE:Alpha-defensin 9	SEQ_UP	1	
PEPTIDE:Alpha-defensin-related sequence 10	SEQ_UP	1	
PEPTIDE:Alpha-defensin-related sequence 12	SEQ_UP	1	
PEPTIDE:Alpha-defensin-related sequence 2	SEQ_UP	1	
PEPTIDE:Alpha-neoendorphin	SEQ_UP	1	
PEPTIDE:Angiotensin 1-4	SEQ_UP	1	
PEPTIDE:Angiotensin 1-5	SEQ_UP	1	
PEPTIDE:Angiotensin 1-7	SEQ_UP	1	
PEPTIDE:Angiotensin 1-9	SEQ_UP	1	
PEPTIDE:Angiotensin-1	SEQ_UP	1	
PEPTIDE:Angiotensin-2	SEQ_UP	1	
PEPTIDE:Angiotensin-3	SEQ_UP	1	
PEPTIDE:Angiotensin-4	SEQ_UP	1	
PEPTIDE:Annexin Ac2-26	SEQ_UP	1	
PEPTIDE:Antrin	SEQ_UP	1	
PEPTIDE:Apelin-13	SEQ_UP	1	
PEPTIDE:Apelin-28	SEQ_UP	1	
PEPTIDE:Apelin-31	SEQ_UP	1	
PEPTIDE:Apelin-36	SEQ_UP	1	
PEPTIDE:Arg-vasopressin	SEQ_UP	1	
PEPTIDE:Atrial natriuretic peptide	SEQ_UP	1	
PEPTIDE:Atriopeptin-1	SEQ_UP	1	
PEPTIDE:Atriopeptin-2	SEQ_UP	1	
PEPTIDE:Atriopeptin-3	SEQ_UP	1	
PEPTIDE:Augurin	SEQ_UP	1	
PEPTIDE:Auriculin-A	SEQ_UP	1	
PEPTIDE:Auriculin-B	SEQ_UP	1	
PEPTIDE:Auriculin-C	SEQ_UP	1	
PEPTIDE:Auriculin-D	SEQ_UP	1	
PEPTIDE:Beta-defensin 1	SEQ_UP	1	
PEPTIDE:Beta-defensin 19	SEQ_UP	1	
PEPTIDE:Beta-defensin 2	SEQ_UP	1	
PEPTIDE:Beta-defensin 3	SEQ_UP	1	
PEPTIDE:Beta-defensin 36	SEQ_UP	1	
PEPTIDE:Beta-defensin 4	SEQ_UP	1	
PEPTIDE:Beta-defensin 7	SEQ_UP	1	
PEPTIDE:Beta-defensin 8	SEQ_UP	1	
PEPTIDE:Beta-endorphin	SEQ_UP	1	
PEPTIDE:Beta-granin	SEQ_UP	1	
PEPTIDE:Beta-neoendorphin	SEQ_UP	1	
PEPTIDE:Big dynorphin	SEQ_UP	1	
PEPTIDE:Big endothelin-1	SEQ_UP	1	
PEPTIDE:Big gastrin	SEQ_UP	1	
PEPTIDE:Big LEN	SEQ_UP	1	
PEPTIDE:Big PEN-LEN	SEQ_UP	1	
PEPTIDE:Big SAAS	SEQ_UP	1	
PEPTIDE:Bradykinin	SEQ_UP	1	
PEPTIDE:Brain natriuretic peptide 45	SEQ_UP	1	
PEPTIDE:Bri23 peptide	SEQ_UP	1	
PEPTIDE:C-flanking peptide of NPY	SEQ_UP	1	
PEPTIDE:C-terminal peptide	SEQ_UP	2	
PEPTIDE:C-terminal-flanking peptide	SEQ_UP	1	
PEPTIDE:C30	SEQ_UP	1	
PEPTIDE:Calcitonin	SEQ_UP	1	
PEPTIDE:Calcitonin gene-related peptide 1	SEQ_UP	1	
PEPTIDE:Calcitonin gene-related peptide 2	SEQ_UP	1	
PEPTIDE:CAMPATH-1 antigen	SEQ_UP	1	
PEPTIDE:CART(1-52)	SEQ_UP	1	
PEPTIDE:CART(55-102)	SEQ_UP	1	
PEPTIDE:CART(62-102)	SEQ_UP	1	
PEPTIDE:Catestatin	SEQ_UP	1	
PEPTIDE:Cathelin-related antimicrobial peptide	SEQ_UP	1	
PEPTIDE:CCB peptide	SEQ_UP	1	
PEPTIDE:Cerebellin	SEQ_UP	1	
PEPTIDE:Cholecystokinin-12	SEQ_UP	1	
PEPTIDE:Cholecystokinin-33	SEQ_UP	1	
PEPTIDE:Cholecystokinin-8	SEQ_UP	1	
PEPTIDE:Class-II-associated invariant chain peptide	SEQ_UP	1	
PEPTIDE:CNP-22	SEQ_UP	1	
PEPTIDE:CNP-29	SEQ_UP	1	
PEPTIDE:CNP-53	SEQ_UP	1	
PEPTIDE:Complement C3f fragment	SEQ_UP	1	
PEPTIDE:Copeptin	SEQ_UP	1	
PEPTIDE:Corticoliberin	SEQ_UP	1	
PEPTIDE:Corticotropin	SEQ_UP	1	
PEPTIDE:Corticotropin-like intermediary peptide	SEQ_UP	1	
PEPTIDE:Cortistatin-14	SEQ_UP	1	
PEPTIDE:CT-BRI3	SEQ_UP	1	
PEPTIDE:Defensin alpha 4	SEQ_UP	1	
PEPTIDE:Dynorphin A(1-13)	SEQ_UP	1	
PEPTIDE:Dynorphin A(1-17)	SEQ_UP	1	
PEPTIDE:Dynorphin A(1-8)	SEQ_UP	1	
PEPTIDE:Endothelin-1	SEQ_UP	1	
PEPTIDE:Endothelin-2	SEQ_UP	1	
PEPTIDE:Endothelin-3	SEQ_UP	1	
PEPTIDE:Fibrinopeptide A	SEQ_UP	1	
PEPTIDE:Fibrinopeptide B	SEQ_UP	1	
PEPTIDE:Galanin	SEQ_UP	1	
PEPTIDE:Galanin message-associated peptide	SEQ_UP	1	
PEPTIDE:Gastric inhibitory polypeptide	SEQ_UP	1	
PEPTIDE:Gastrin	SEQ_UP	1	
PEPTIDE:Gastrin-71	SEQ_UP	1	
PEPTIDE:Gastrin-releasing peptide	SEQ_UP	1	
PEPTIDE:GE-25	SEQ_UP	1	
PEPTIDE:Ghrelin	SEQ_UP	1	
PEPTIDE:Glicentin	SEQ_UP	1	
PEPTIDE:Glicentin-related polypeptide	SEQ_UP	1	
PEPTIDE:Glucagon	SEQ_UP	1	
PEPTIDE:Glucagon-like peptide 1	SEQ_UP	1	
PEPTIDE:Glucagon-like peptide 1(7-36)	SEQ_UP	1	
PEPTIDE:Glucagon-like peptide 1(7-37)	SEQ_UP	1	
PEPTIDE:Glucagon-like peptide 2	SEQ_UP	1	
PEPTIDE:Gonadoliberin-1	SEQ_UP	1	
PEPTIDE:GPIPIRRH peptide	SEQ_UP	1	
PEPTIDE:Granulin-1	SEQ_UP	1	
PEPTIDE:Granulin-2	SEQ_UP	1	
PEPTIDE:Granulin-3	SEQ_UP	1	
PEPTIDE:Granulin-4	SEQ_UP	1	
PEPTIDE:Granulin-5	SEQ_UP	1	
PEPTIDE:Granulin-6	SEQ_UP	1	
PEPTIDE:Granulin-7	SEQ_UP	1	
PEPTIDE:Guanylin	SEQ_UP	1	
PEPTIDE:Hematopoietic system regulatory peptide	SEQ_UP	1	
PEPTIDE:Hemokinin	SEQ_UP	1	
PEPTIDE:Hepcidin	SEQ_UP	1	
PEPTIDE:Hepcidin-2	SEQ_UP	1	
PEPTIDE:Hippocampal cholinergic neurostimulating peptide	SEQ_UP	1	
PEPTIDE:Insulin-1 A chain	SEQ_UP	1	
PEPTIDE:Insulin-1 B chain	SEQ_UP	1	
PEPTIDE:Insulin-2 A chain	SEQ_UP	1	
PEPTIDE:Insulin-2 B chain	SEQ_UP	1	
PEPTIDE:Insulin-like 3 A chain	SEQ_UP	1	
PEPTIDE:Insulin-like 3 B chain	SEQ_UP	1	
PEPTIDE:Insulin-like peptide INSL5 A chain	SEQ_UP	1	
PEPTIDE:Insulin-like peptide INSL6 A chain	SEQ_UP	1	
PEPTIDE:Insulin-like peptide INSL6 B chain	SEQ_UP	1	
PEPTIDE:Intermedin-short	SEQ_UP	1	
PEPTIDE:Intestinal peptide PHI-27	SEQ_UP	1	
PEPTIDE:Intestinal peptide PHI-42	SEQ_UP	1	
PEPTIDE:Islet amyloid polypeptide	SEQ_UP	1	
PEPTIDE:Kaliuretic peptide	SEQ_UP	1	
PEPTIDE:KEP	SEQ_UP	1	
PEPTIDE:Kisspeptin-10	SEQ_UP	1	
PEPTIDE:Leu-enkephalin	SEQ_UP	2	
PEPTIDE:Leumorphin	SEQ_UP	1	
PEPTIDE:LHAL tetrapeptide	SEQ_UP	1	
PEPTIDE:Lipotropin beta	SEQ_UP	1	
PEPTIDE:Lipotropin gamma	SEQ_UP	1	
PEPTIDE:Little LEN	SEQ_UP	1	
PEPTIDE:Little SAAS	SEQ_UP	1	
PEPTIDE:Long-acting natriuretic peptide	SEQ_UP	1	
PEPTIDE:Manserin	SEQ_UP	1	
PEPTIDE:Melanin-concentrating hormone	SEQ_UP	1	
PEPTIDE:Melanocyte-stimulating hormone alpha	SEQ_UP	1	
PEPTIDE:Melanocyte-stimulating hormone beta	SEQ_UP	1	
PEPTIDE:Melanotropin gamma	SEQ_UP	1	
PEPTIDE:Met-enkephalin	SEQ_UP	2	
PEPTIDE:Met-enkephalin-Arg-Phe	SEQ_UP	1	
PEPTIDE:Met-enkephalin-Arg-Ser-Leu	SEQ_UP	1	
PEPTIDE:Metastin	SEQ_UP	1	
PEPTIDE:Minor histocompatibility antigen HA-28	SEQ_UP	1	
PEPTIDE:Natriuretic peptides B	SEQ_UP	1	
PEPTIDE:NEUG(55-78)	SEQ_UP	1	
PEPTIDE:Neuroendocrine regulatory peptide-1	SEQ_UP	1	
PEPTIDE:Neuroendocrine regulatory peptide-2	SEQ_UP	1	
PEPTIDE:Neurokinin A	SEQ_UP	1	
PEPTIDE:Neurokinin-B	SEQ_UP	1	
PEPTIDE:Neuromedin N	SEQ_UP	1	
PEPTIDE:Neuromedin precursor-related peptide 33	SEQ_UP	1	
PEPTIDE:Neuromedin precursor-related peptide 36	SEQ_UP	1	
PEPTIDE:Neuromedin-B	SEQ_UP	1	
PEPTIDE:Neuromedin-B-32	SEQ_UP	1	
PEPTIDE:Neuromedin-C	SEQ_UP	1	
PEPTIDE:Neuromedin-S	SEQ_UP	1	
PEPTIDE:Neuromedin-U-23	SEQ_UP	1	
PEPTIDE:Neuronostatin	SEQ_UP	1	
PEPTIDE:Neuropeptide AF-like	SEQ_UP	1	
PEPTIDE:Neuropeptide B-29	SEQ_UP	1	
PEPTIDE:Neuropeptide FF	SEQ_UP	1	
PEPTIDE:Neuropeptide gamma, 1st part	SEQ_UP	1	
PEPTIDE:Neuropeptide gamma, 2nd part	SEQ_UP	1	
PEPTIDE:Neuropeptide K	SEQ_UP	1	
PEPTIDE:Neuropeptide NPSF	SEQ_UP	1	
PEPTIDE:Neuropeptide NPVF	SEQ_UP	1	
PEPTIDE:Neuropeptide RFRP-1	SEQ_UP	1	
PEPTIDE:Neuropeptide S	SEQ_UP	1	
PEPTIDE:Neuropeptide SF	SEQ_UP	1	
PEPTIDE:Neuropeptide Y	SEQ_UP	1	
PEPTIDE:Neuropeptide-glutamic acid-isoleucine	SEQ_UP	1	
PEPTIDE:Neuropeptide-glycine-glutamic acid	SEQ_UP	1	
PEPTIDE:Neurotensin	SEQ_UP	1	
PEPTIDE:Nociceptin	SEQ_UP	1	
PEPTIDE:Nocistatin	SEQ_UP	1	
PEPTIDE:NPP	SEQ_UP	1	
PEPTIDE:Obestatin	SEQ_UP	1	
PEPTIDE:Orexin-A	SEQ_UP	1	
PEPTIDE:Orexin-B	SEQ_UP	1	
PEPTIDE:Orphanin FQ2	SEQ_UP	1	
PEPTIDE:Osteostatin	SEQ_UP	1	
PEPTIDE:Oxyntomodulin	SEQ_UP	1	
PEPTIDE:Oxytocin	SEQ_UP	1	
PEPTIDE:P-beta	SEQ_UP	1	
PEPTIDE:p-Glu serpinin precursor	SEQ_UP	1	
PEPTIDE:P3(40)	SEQ_UP	1	
PEPTIDE:P3(42)	SEQ_UP	1	
PEPTIDE:PACAP-related peptide	SEQ_UP	1	
PEPTIDE:Pancreastatin	SEQ_UP	1	
PEPTIDE:Pancreatic hormone	SEQ_UP	1	
PEPTIDE:Paragranulin	SEQ_UP	1	
PEPTIDE:PE-11	SEQ_UP	1	
PEPTIDE:PEN	SEQ_UP	1	
PEPTIDE:PEN-19	SEQ_UP	1	
PEPTIDE:PEN-20	SEQ_UP	1	
PEPTIDE:PENK(114-133)	SEQ_UP	1	
PEPTIDE:PENK(143-184)	SEQ_UP	1	
PEPTIDE:PENK(238-259)	SEQ_UP	1	
PEPTIDE:Peptide Lv	SEQ_UP	1	
PEPTIDE:Peptide YY	SEQ_UP	1	
PEPTIDE:Peptide YY(3-36)	SEQ_UP	1	
PEPTIDE:Phoenixin-14	SEQ_UP	1	
PEPTIDE:Phoenixin-20	SEQ_UP	1	
PEPTIDE:Pituitary adenylate cyclase-activating polypeptide 27	SEQ_UP	1	
PEPTIDE:Pituitary adenylate cyclase-activating polypeptide 38	SEQ_UP	1	
PEPTIDE:Preptin	SEQ_UP	1	
PEPTIDE:Proadrenomedullin N-20 terminal peptide	SEQ_UP	1	
PEPTIDE:Processed Osteocrin	SEQ_UP	1	
PEPTIDE:Prolactin release-inhibiting factor 1	SEQ_UP	1	
PEPTIDE:Proxenin	SEQ_UP	1	
PEPTIDE:QRF-amide	SEQ_UP	1	
PEPTIDE:Relaxin A chain	SEQ_UP	1	
PEPTIDE:Relaxin B chain	SEQ_UP	1	
PEPTIDE:Relaxin-3 A chain	SEQ_UP	1	
PEPTIDE:Relaxin-3 B chain	SEQ_UP	1	
PEPTIDE:Rimorphin	SEQ_UP	1	
PEPTIDE:Salusin-beta	SEQ_UP	1	
PEPTIDE:Sarcolipin	SEQ_UP	1	
PEPTIDE:Secretin	SEQ_UP	1	
PEPTIDE:Secretoneurin	SEQ_UP	1	
PEPTIDE:Serpinin	SEQ_UP	1	
PEPTIDE:Serpinin-RRG	SEQ_UP	1	
PEPTIDE:Signal transducer CD24	SEQ_UP	1	
PEPTIDE:Somatoliberin	SEQ_UP	1	
PEPTIDE:Somatostatin-14	SEQ_UP	1	
PEPTIDE:Somatostatin-28	SEQ_UP	1	
PEPTIDE:Spexin-1	SEQ_UP	1	
PEPTIDE:Spexin-2	SEQ_UP	1	
PEPTIDE:Substance P	SEQ_UP	1	
PEPTIDE:Synenkephalin	SEQ_UP	1	
PEPTIDE:Tail peptide	SEQ_UP	1	
PEPTIDE:Thymosin alpha	SEQ_UP	1	
PEPTIDE:Thyrotropin-releasing hormone	SEQ_UP	1	
PEPTIDE:Tuberoinfundibular peptide of 39 residues	SEQ_UP	1	
PEPTIDE:Urocortin	SEQ_UP	1	
PEPTIDE:Urodilatin	SEQ_UP	1	
PEPTIDE:Uroguanylin	SEQ_UP	1	
PEPTIDE:Urotensin-2	SEQ_UP	1	
PEPTIDE:Urotensin-2B	SEQ_UP	1	
PEPTIDE:Vasoactive intestinal peptide	SEQ_UP	1	
PEPTIDE:Vessel dilator	SEQ_UP	1	
PEPTIDE:VGF-derived peptide TLQP-21	SEQ_UP	1	
PEPTIDE:VGF-derived peptide TLQP-62	SEQ_UP	1	
PEPTIDE:WE-14	SEQ_UP	1	
PEPTIDE:Xenin	SEQ_UP	1	
PROPEP:Acidic	SEQ_UP	1	
PROPEP:Activation peptide	SEQ_UP	86	
PROPEP:Activation peptide (connecting region)	SEQ_UP	1	
PROPEP:Anchors to the small subunit	SEQ_UP	1	
PROPEP:C peptide	SEQ_UP	2	
PROPEP:C peptide like	SEQ_UP	1	
PROPEP:C-terminal	SEQ_UP	1	
PROPEP:C-terminal propeptide	SEQ_UP	7	
PROPEP:Cleaved by PCSK5	SEQ_UP	1	
PROPEP:Connecting peptide	SEQ_UP	4	
PROPEP:E peptide	SEQ_UP	2	
PROPEP:Enterostatin, activation peptide	SEQ_UP	1	
PROPEP:Inhibin alpha N-terminal region	SEQ_UP	1	
PROPEP:Inhibition peptide	SEQ_UP	1	
PROPEP:Linker peptide	SEQ_UP	1	
PROPEP:N-terminal propeptide	SEQ_UP	6	
PROPEP:N-terminal propeptide (7S domain)	SEQ_UP	2	
PROPEP:Or 135	SEQ_UP	2	
PROPEP:PreproAM C-terminal fragment	SEQ_UP	1	
PROPEP:Pro-rich	SEQ_UP	1	
PROPEP:Removed by BMP1	SEQ_UP	1	
PROPEP:Removed by furin	SEQ_UP	1	
PROPEP:Removed by plasmin	SEQ_UP	1	
PROPEP:Removed for receptor activation	SEQ_UP	4	
PROPEP:Removed in Lamin-A/C form	SEQ_UP	1	
PROPEP:Removed in mature form	SEQ_UP	279	
PROPEP:Removed in Prelamin-A/C form and in Lamin-A/C form	SEQ_UP	1	
PROPEP:Removed in secreted form	SEQ_UP	1	
PROPEP:UBL	SEQ_UP	1	
PROPEP:Ucma-N	SEQ_UP	1	
REGION:(1,3-beta-D-glucosyl)n binding	SEQ_UP	1	
REGION:(3R)-3-hydroxydecanoyl-CoA binding	SEQ_UP	1	
REGION:(3R)-hydroxyacyl-CoA dehydrogenase	SEQ_UP	1	
REGION:(6S)-10-formyltetrahydrofolate binding	SEQ_UP	3	
REGION:(R)-5-diphosphomevalonate binding	SEQ_UP	1	
REGION:1 X 17 AA tandem repeats	SEQ_UP	1	
REGION:1-eicosanoylglycerol binding	SEQ_UP	1	
REGION:10 X 10 AA tandem approximate repeats of P-A-K-P-Q-P-Q-Q-P-X	SEQ_UP	1	
REGION:10 X 10 AA tandem repeats	SEQ_UP	1	
REGION:10 X 2 AA tandem repeats of G-S	SEQ_UP	1	
REGION:10 X 4 AA tandem repeats of S-P-[RGMKC]-[RK]	SEQ_UP	1	
REGION:10 X 5 AA repeat of P-H-X-X-E	SEQ_UP	1	
REGION:10 X 6 AA tandem repeat of A-E-A-P-A-A	SEQ_UP	1	
REGION:10 X 8 AA approximate tandem repeats of P-[TS]-P-S-P-[QA]-[SG]-Y, motif CTR2	SEQ_UP	1	
REGION:10 X approximate tandem repeats	SEQ_UP	2	
REGION:10 X repeats starting with a Trp in each unit	SEQ_UP	1	
REGION:10-formyltetrahydrofolate binding	SEQ_UP	1	
REGION:11 X 12 AA approximate repeats of an acidic serine cluster	SEQ_UP	1	
REGION:11 X 2 AA repeats of G-[YCGS]	SEQ_UP	1	
REGION:11 X 2 AA repeats of P-H	SEQ_UP	1	
REGION:11 X 3 AA approximate repeats	SEQ_UP	1	
REGION:11 X 3 AA approximate repeats of K-K-[DE]	SEQ_UP	1	
REGION:11 X 3 AA tandem repeats P-X-X	SEQ_UP	1	
REGION:11 X 5 AA approximate repeats	SEQ_UP	1	
REGION:11 X 5 AA repeats of C-C-[AEQVR]-[ALPTV]-[AGHST]	SEQ_UP	1	
REGION:11 X 7 AA tandem repeats of [DR]-P-Y-R-[LI][AG][QHP]	SEQ_UP	1	
REGION:12 X 11 AA tandem repeats of [MV]-G-I-P-P-P-P-P-L-P-G	SEQ_UP	1	
REGION:12 X 2 AA repeats of G-[YCGS]	SEQ_UP	1	
REGION:12 X 5 AA tandem repeats of G-[AT]-G-[MI]-Q	SEQ_UP	1	
REGION:12 X 5 AA tandem repeats of M-E-A-R-[AG]	SEQ_UP	1	
REGION:13 X 10 AA tandem repeats of L-A-[ST]-[NSG]-[TS]-MDSQM	SEQ_UP	1	
REGION:13 X 2 AA tandem repeats of E-X	SEQ_UP	1	
REGION:13 X 22 AA approximate tandem repeats	SEQ_UP	1	
REGION:13 X 3 AA repeats of D-P-F	SEQ_UP	1	
REGION:13 X 8 AA approximate tandem repeats	SEQ_UP	1	
REGION:130's region	SEQ_UP	1	
REGION:14 X 2 AA repeats of F-G	SEQ_UP	1	
REGION:14 X 2 AA repeats of G-[YCGS]	SEQ_UP	1	
REGION:14 X 4 AA repeats of C-C-X-P	SEQ_UP	2	
REGION:14 X 5 AA approximate repeats	SEQ_UP	1	
REGION:14 X 6 AA repeats of [ED]-R-S-M-M-S	SEQ_UP	1	
REGION:14 X 8 AA approximate tandem repeats	SEQ_UP	1	
REGION:14 X approximate tandem repeats	SEQ_UP	1	
REGION:15 X 15 AA approximate tandem repeats	SEQ_UP	1	
REGION:15 X 4 AA repeats of C-C-X-P	SEQ_UP	1	
REGION:15 X 5 AA repeats of C-C-X(3)	SEQ_UP	1	
REGION:15 X 5 AA repeats of S/P-P-P-E/P-E/A	SEQ_UP	1	
REGION:15 X 6 AA tandem repeats	SEQ_UP	1	
REGION:15 X 8 AA tandem repeats of [QR]-R-[GVE]-R-[EQ]-[RSAV]-[EGQ]-[RAK]	SEQ_UP	1	
REGION:15 X approximate tandem repeats	SEQ_UP	1	
REGION:16 X 2 AA repeats of P-Q	SEQ_UP	1	
REGION:16 X 20 AA approximate tandem repeats	SEQ_UP	1	
REGION:17 X 2 AA tandem repeats of R-[ED]	SEQ_UP	1	
REGION:17 X 47 AA approximate tandem repeat	SEQ_UP	1	
REGION:18 X 4 AA approximate repeats	SEQ_UP	1	
REGION:2 approximate repeats	SEQ_UP	1	
REGION:2 approximate SP repeats	SEQ_UP	1	
REGION:2 X 104 AA approximate repeats	SEQ_UP	1	
REGION:2 X 11 AA approximate repeats, Asp/Glu-rich (acidic) (hirudin-like)	SEQ_UP	1	
REGION:2 X 12 AA approximate tandem repeats	SEQ_UP	1	
REGION:2 X 13 AA imperfect tandem repeats	SEQ_UP	1	
REGION:2 X 15 AA tandem repeats of L-[EQ]-[KR] [MV]-K-[EQ]-E-[IL]-[IL]-E-[AEV]-[FV]-[KRV]-[KQ]-E	SEQ_UP	1	
REGION:2 X 16 AA Gly-rich approximate repeats	SEQ_UP	2	
REGION:2 X 17 AA approximate tandem repeats	SEQ_UP	1	
REGION:2 X 19 AA perfect repeats	SEQ_UP	2	
REGION:2 X 19 AA repeats of P-S-R-R-R-R-S-R-S-V-V-R-R-R-S-F-S-I-S	SEQ_UP	1	
REGION:2 X 22 AA approximate repeats	SEQ_UP	1	
REGION:2 X 22 AA approximate tandem repeats	SEQ_UP	1	
REGION:2 X 3 AA tandem repeats of C-R-X	SEQ_UP	1	
REGION:2 X 3 AA tandem repeats of E-W-K	SEQ_UP	2	
REGION:2 X 3 AA tandem repeats of K-G-Q	SEQ_UP	1	
REGION:2 X 4 AA repeats of C-C-X-P	SEQ_UP	1	
REGION:2 X 4 AA repeats of N-X-I-Y	SEQ_UP	1	
REGION:2 X 5 AA repeats of [RC]-C-L-C-D	SEQ_UP	1	
REGION:2 X 50 AA approximate repeats	SEQ_UP	1	
REGION:2 X 53-55 AA tandem repeats	SEQ_UP	1	
REGION:2 X 6 AA approximate repeats	SEQ_UP	1	
REGION:2 X 7 AA repeats of G-S-D-[LP]-K-H-A	SEQ_UP	1	
REGION:2 X 8 AA tandem repeats of A-X-A-K-A-P-A-[KQ]	SEQ_UP	1	
REGION:2 X approximate repeats	SEQ_UP	1	
REGION:2 X approximate repeats, basic	SEQ_UP	1	
REGION:2 X approximate tandem repeats	SEQ_UP	3	
REGION:2 X type B repeats	SEQ_UP	1	
REGION:2-5A binding (P-loop) 1	SEQ_UP	1	
REGION:2-5A binding (P-loop) 2	SEQ_UP	1	
REGION:2-oxo-dATP binding	SEQ_UP	1	
REGION:2-oxoglutarate binding	SEQ_UP	5	
REGION:2',3'-cGAMP binding	SEQ_UP	1	
REGION:20 X 12 AA approximate tandem repeats of R-[DE]-[EK]-[EG]-H-[AV]-P-E-[PS]-[IM]-V-[HLR]	SEQ_UP	1	
REGION:20 X 2 AA repeats of F-G	SEQ_UP	1	
REGION:21 X 10 AA approximate tandem repeats of [DA]-[DE]-[ED]-R-[PLIGFSV]-[RPS]-[RW]-[RL]-[GNIHT]-[DGLPTAM]	SEQ_UP	1	
REGION:21 X 15 AA approximate tandem repeat of Q-P-K-X-G-D-I-P-K-S-[PS]-E-[KE]-X-I	SEQ_UP	1	
REGION:21 X 2 AA approximate tandem repeats of P-Q	SEQ_UP	1	
REGION:21 X 2 AA repeats of G-[YCGS]	SEQ_UP	1	
REGION:21 X 7 AA tandem repeats of S-K-[TAI]-[TI]-[TAP]-[GED]-[IVM]	SEQ_UP	1	
REGION:21 X 8 AA approximate tandem repeats	SEQ_UP	1	
REGION:22 X 12 AA approximate tandem repeats of Q-K-G-R-Q-D-Q-S-P-H-Q-G	SEQ_UP	1	
REGION:22 X 6 AA tandem repeats of W-[PQ]-X-P-X-X	SEQ_UP	1	
REGION:23 X 2 AA repeats of G-[YCGS]	SEQ_UP	1	
REGION:24 X 2 AA repeats of G-[YCGS]	SEQ_UP	1	
REGION:25 X 2 AA repeats of G-[YCGS]	SEQ_UP	2	
REGION:27 X 6 AA repeats of [GEVSTPAN]-[ILMV]-[DE]-[RH]-[MLVI]-[GAV]	SEQ_UP	1	
REGION:28 X 8 AA repeats of V-G-Q-A-E-E-A-T	SEQ_UP	1	
REGION:29 X 33 AA approximate tandem repeat	SEQ_UP	1	
REGION:3 X 10 AA tandem repeats of G-[PST]-R-S-R-S-H-T-S-E	SEQ_UP	1	
REGION:3 X 11 AA approximate tandem repeats	SEQ_UP	1	
REGION:3 X 11 AA tandem repats of P-P-L-P-P-E-E-P-P-[TME]-[MTG]	SEQ_UP	1	
REGION:3 X 112 AA tandem repeats	SEQ_UP	1	
REGION:3 X 12 AA approximate repeats	SEQ_UP	1	
REGION:3 X 12 AA tandem repeats of G-P-G-I-G-R-P-[HP]-P-P-P-[PF]	SEQ_UP	1	
REGION:3 X 2 AA tandem repeats of [DE]-R	SEQ_UP	1	
REGION:3 X 3 AA repeats of N-P-F	SEQ_UP	3	
REGION:3 X 3 AA repeats of R-G-G	SEQ_UP	1	
REGION:3 X 3 AA tandem repeats of C-Q-X	SEQ_UP	1	
REGION:3 X 31 AA approximate tandem repeats	SEQ_UP	1	
REGION:3 X 37 AA tandem repeats	SEQ_UP	1	
REGION:3 X 39 AA approximate tandem repeats	SEQ_UP	1	
REGION:3 X 4 AA approximate tandem repeats	SEQ_UP	1	
REGION:3 X 4 AA repeats of D-X-H-P	SEQ_UP	1	
REGION:3 X 4 AA repeats of P-X-X-P	SEQ_UP	1	
REGION:3 X 4 AA repeats of Y-Y-G-Y	SEQ_UP	1	
REGION:3 X 5 AA repeat of P-H-D-D-K	SEQ_UP	1	
REGION:3 X 5 AA repeats	SEQ_UP	1	
REGION:3 X 5 AA repeats of C-C-X(3)	SEQ_UP	2	
REGION:3 X 5 AA repeats of E-S-G-X-V	SEQ_UP	1	
REGION:3 X 5 AA repeats of H-S-D-H-R	SEQ_UP	1	
REGION:3 X 5 AA tandem repeats of G-Y-P-P-X	SEQ_UP	1	
REGION:3 X 50 AA type C repeats	SEQ_UP	1	
REGION:3 X 57 AA approximate repeats	SEQ_UP	1	
REGION:3 X 6 AA tandem repeats of D-A-E-P-G-A	SEQ_UP	1	
REGION:3 X 6 AA tandem repeats of D-R-[EQ]-W-[NQK]-[FY]	SEQ_UP	1	
REGION:3 X 7 AA tandem repeats of [PT]-[AT]-A-[ENT]-[PT]-[PTS]-[AG]	SEQ_UP	1	
REGION:3 X 7 AA tandem repeats of A-[GR]-T-S-T-A-Q	SEQ_UP	1	
REGION:3 X 9 AA approximate tandem repeats	SEQ_UP	5	
REGION:3 X approximate repeats	SEQ_UP	2	
REGION:3 X approximate SP repeats	SEQ_UP	1	
REGION:3 X repeats	SEQ_UP	1	
REGION:3 X SP repeats	SEQ_UP	2	
REGION:3 X tandem repeats of [ST]-P-[VLI]-R-[RL]-[RK]-[RF]-S-R	SEQ_UP	1	
REGION:3-hydroxyacyl-CoA dehydrogenase	SEQ_UP	1	
REGION:3.5 X 9 AA approximate tandem repeats	SEQ_UP	1	
REGION:3' overhang DNA-binding	SEQ_UP	1	
REGION:3',5'-cAMP binding	SEQ_UP	1	
REGION:31 X approximate tandem repeats	SEQ_UP	1	
REGION:32 X 2 AA approximate tandem repeats of R-[DSE]	SEQ_UP	1	
REGION:32 X 9 AA approximate tandem repeats of [TNP]-L-S-P-D-L-S-Q-T	SEQ_UP	1	
REGION:37 X 8 AA repeats of K-X-P-X-P-T-T-X	SEQ_UP	1	
REGION:4 X 11 AA tandem repeats of [EGS]-K-T-K-[EQ]-[GQ]-V-X(4)	SEQ_UP	2	
REGION:4 X 11 AA tandem repeats of [EGSA]-K-T-K-[EQ]-[GQ]-V-X(4)	SEQ_UP	1	
REGION:4 X 11 AA tandem repeats of VQLQP-[AL]-[QT]-[EG]-[VQ]-[ATV]-[ST]	SEQ_UP	1	
REGION:4 X 11 AA tandem repeats, O-glycosylated region	SEQ_UP	1	
REGION:4 X 12 AA imperfect repeats	SEQ_UP	1	
REGION:4 X 15 AA tandem repeats of A-A-A-A-A-P-E-A-A-A-S-[PL]-E-S-S	SEQ_UP	1	
REGION:4 X 16 AA repeats of C-X(10)-C-X-C-X(1,3)-C	SEQ_UP	2	
REGION:4 X 29 AA approximate repeats	SEQ_UP	1	
REGION:4 X 3 AA tandem repeats of C-P-X	SEQ_UP	1	
REGION:4 X 308-326 AA approximate repeats	SEQ_UP	1	
REGION:4 X 4 AA repeats of N-T-S-L	SEQ_UP	1	
REGION:4 X 4 AA repeats of T-P-P-Q	SEQ_UP	1	
REGION:4 X 4 AA tandem repeats of [GS]-S-R-[AR]	SEQ_UP	1	
REGION:4 X 4 AA tandem repeats of G-S-R-X	SEQ_UP	1	
REGION:4 X 4 AA tandem repeats of K-G-S-P	SEQ_UP	1	
REGION:4 X 5 AA repeats of C-C-X(3)	SEQ_UP	1	
REGION:4 X 5 AA tandem repeats of Q-K-A-[APS]-X	SEQ_UP	1	
REGION:4 X 57 AA type A repeats	SEQ_UP	1	
REGION:4 X 6 AA repeats of G-[LPQ]-[PL]-L-P-L	SEQ_UP	1	
REGION:4 X 6 AA repeats of P-A-A-P-E-A	SEQ_UP	1	
REGION:4 X 67 AA tandem repeats	SEQ_UP	1	
REGION:4 X 7 AA tandem repeats of T-S-T-A-Q-A-[GR]	SEQ_UP	1	
REGION:4 X 9 AA approximate tandem repeats	SEQ_UP	1	
REGION:4 X approximate repeats	SEQ_UP	5	
REGION:4 X approximate tandem repeat Mc	SEQ_UP	1	
REGION:4 X approximate tandem repeats	SEQ_UP	1	
REGION:4.1-binding domain	SEQ_UP	1	
REGION:4.5 X 38 AA tandem repeats (Domain A)	SEQ_UP	1	
REGION:4.5 X 38 AA tandem repeats (Domain B)	SEQ_UP	1	
REGION:4.5 X 38 AA tandem repeats (Domain C)	SEQ_UP	1	
REGION:4.5 X approximate repeats	SEQ_UP	1	
REGION:4'-phosphopantetheine phosphatase	SEQ_UP	1	
REGION:45 X 5 AA approximate tandem repeats of [LVMGIED]-[PQSKHARMI]-[EDKLVTR]-[LIVMAP]-[AQKHRPEVSD]; that may have a tripeptide spacer of [LVIDEA]-[PMSVI]-[KEATDQ]	SEQ_UP	1	
REGION:46 X 2 AA repeats of F-G	SEQ_UP	1	
REGION:48 X 12 AA approximate tandem repeats of Q-[KT]-[GD]-[RS]-Q-[DG]-Q-S-[PS]-H-X-G	SEQ_UP	1	
REGION:48 X 2 AA repeats of G-[YCGS]	SEQ_UP	1	
REGION:4H	SEQ_UP	3	
REGION:5 X 11 AA tandem repeats of [TI]-R-N-[DN]-[GS]-Q-[SP]-I-T-[NK]-[IVN]	SEQ_UP	1	
REGION:5 X 12 AA approximate tandem repeats	SEQ_UP	1	
REGION:5 X 2 AA repeats of F-G	SEQ_UP	2	
REGION:5 X 2 AA tandem repeats of [RM]-G	SEQ_UP	1	
REGION:5 X 2 AA tandem repeats of P-G	SEQ_UP	1	
REGION:5 X 20 AA approximate repeat of F-X-V-E-X-T-P-X-C-F-S-R-X-S-S-L-S-S-L-S	SEQ_UP	1	
REGION:5 X 21 AA tandem repeats	SEQ_UP	1	
REGION:5 X 28 AA approximate tandem repeats	SEQ_UP	1	
REGION:5 X 29 AA tandem repeats	SEQ_UP	1	
REGION:5 X 3 AA repeats of [DE]-P-W	SEQ_UP	1	
REGION:5 X 3 AA repeats of R-G-G	SEQ_UP	1	
REGION:5 X 4 AA approximate tandem repeats	SEQ_UP	1	
REGION:5 X 4 AA repeats of G-X-G-G	SEQ_UP	1	
REGION:5 X 4 AA repeats of P-X-X-P	SEQ_UP	3	
REGION:5 X 4 AA tandem repeats of [ST]-P-X-[RK]	SEQ_UP	1	
REGION:5 X 4 AA tandem repeats of Q-X-K-[ST]	SEQ_UP	1	
REGION:5 X 5 AA repeats of C-C-X(3)	SEQ_UP	1	
REGION:5 X 7 AA approximate tandem repeats of D-R-[NS]-H-E-K-S	SEQ_UP	1	
REGION:5 X 7 AA tandem repeats of K-A-S-P-Q-[AT]-[AT]	SEQ_UP	1	
REGION:5 X 8 AA tandem repeats of P-H-G-G-G-W-G-Q	SEQ_UP	1	
REGION:5 X 9 AA approximate tandem repeats	SEQ_UP	5	
REGION:5 X approximate repeats	SEQ_UP	1	
REGION:5 X Knot repeats	SEQ_UP	1	
REGION:5-methylcytosine residue in DNA binding	SEQ_UP	1	
REGION:5-O-(ADP-D-ribosyl)-L-glutamate residue 1 binding	SEQ_UP	1	
REGION:5-O-(ADP-D-ribosyl)-L-glutamate residue 2 binding	SEQ_UP	1	
REGION:5-O-(ADP-D-ribosyl)-L-glutamate residue 3 binding	SEQ_UP	1	
REGION:5-phosphatase	SEQ_UP	2	
REGION:5-phospho-alpha-D-ribose 1-diphosphate binding	SEQ_UP	1	
REGION:5,6,7,8-tetrahydrofolate binding	SEQ_UP	1	
REGION:5'-3' exonuclease domain	SEQ_UP	1	
REGION:51 X 2 AA repeats of G-[YCGS]	SEQ_UP	1	
REGION:52 X 6 AA approximate tandem repeats of K-S-P-[AGISV]-[EATK]-[APVQ]	SEQ_UP	1	
REGION:55 kDa regulatory domain	SEQ_UP	1	
REGION:6 X 12 AA tandem repeats	SEQ_UP	1	
REGION:6 X 2 AA approximate repeats of H-G	SEQ_UP	1	
REGION:6 X 2 AA tandem repeats of [DE]-R	SEQ_UP	1	
REGION:6 X 3 AA repeats of [DE]-P-W	SEQ_UP	1	
REGION:6 X 3 AA tandem repeats of C-P-X	SEQ_UP	2	
REGION:6 X 4 AA repeats of P-X-X-P	SEQ_UP	2	
REGION:6 X 4 AA tandem repeats of G-S-R-[SR]	SEQ_UP	1	
REGION:6 X 6 AA approximate tandem repeats of C-[GSK]-G-[GSPH]-A-[SLP]	SEQ_UP	1	
REGION:6 X 7 AA tandem repeat of Y-G-X-P-P-X-G	SEQ_UP	1	
REGION:6 X 8 AA repeats of R-R-S-R-S-X-S-X	SEQ_UP	1	
REGION:6 X 8 AA tandem repeats	SEQ_UP	1	
REGION:6 X approximate repeats	SEQ_UP	1	
REGION:6 X SEK repeats	SEQ_UP	1	
REGION:6-phosphofructo-2-kinase	SEQ_UP	3	
REGION:6-phosphogluconolactonase	SEQ_UP	1	
REGION:61 X 10 AA tandem repeats of [NSQ]-[NKQVGA]-[GSAQKRT]-[ASGDTK]-[KGTQSAV]-[KGAED]-[EQVGIPTDMA]-[EGVAS]-[AGVPETNS]-[AQNGPTVS]	SEQ_UP	1	
REGION:66 X 2 AA repeats of G-[YCGS]	SEQ_UP	1	
REGION:7 X 13 AA approximate tandem repeats, RPT domain	SEQ_UP	1	
REGION:7 X 2 AA tandem repeats of K-G	SEQ_UP	1	
REGION:7 X 2 AA tandem repeats of P-E	SEQ_UP	1	
REGION:7 X 3 AA tandem repeats of C-P-X	SEQ_UP	2	
REGION:7 X 5 AA tandem repeats of [LM]-E-[QR]-[EQ]-[QR]	SEQ_UP	1	
REGION:7 X 6 AA tandem repeat of E-E-X(4)	SEQ_UP	1	
REGION:7 X 7 AA repeats of P-S-R-R-S-R-[TS]	SEQ_UP	1	
REGION:7 X 8 AA tandem repeats	SEQ_UP	1	
REGION:7 X 9 AA tandem repeats of P-[KQ]-C-[PT]-E-P-C-P-P	SEQ_UP	1	
REGION:7S domain	SEQ_UP	2	
REGION:8 X 2 AA repeats of F-G	SEQ_UP	1	
REGION:8 X 2 AA repeats of G-[YCGS]	SEQ_UP	1	
REGION:8 X 2 AA tandem repeats of R-G	SEQ_UP	1	
REGION:8 X 22 AA approximate tandem repeats	SEQ_UP	1	
REGION:8 X 3 AA repeats of D-P-W	SEQ_UP	1	
REGION:8 X 3 AA repeats of R-G-G	SEQ_UP	1	
REGION:8 X 4 AA repeats of C-C-X-P	SEQ_UP	1	
REGION:8 X 5 AA repeats of A-S-P-A-R	SEQ_UP	1	
REGION:8 X 5 AA tandem repeats of M-E-T-R-[AG]	SEQ_UP	1	
REGION:8 X 6 AA tandem repeats of P-S-[VSG]-S-[VIAG]-[HDRL]	SEQ_UP	1	
REGION:8 X 8 AA tandem repeats of X-T-P-X-K-K-X-X	SEQ_UP	1	
REGION:8 X 9 AA approximate tandem repeat of [AP]-P-G-G-P-Y-G-G-P-P	SEQ_UP	1	
REGION:8 X approximate tandem repeats	SEQ_UP	1	
REGION:8-Cys3 region	SEQ_UP	1	
REGION:8-oxo-dGTP binding	SEQ_UP	1	
REGION:80 X heptapeptide repeats (approximate) (mucin-like domain)	SEQ_UP	1	
REGION:89 kDa domain	SEQ_UP	1	
REGION:9 X 7 AA approximate tandem repeats of G-S-[QR]-T-P-X-[YQ], motif CTR1	SEQ_UP	1	
REGION:9 X 9 AA tandem repeats of Y-P-G-X(3)-P-[GS]-A	SEQ_UP	1	
REGION:A	SEQ_UP	8	
REGION:A domain	SEQ_UP	1	
REGION:A domain; contributes to trimerization	SEQ_UP	1	
REGION:A-domain	SEQ_UP	1	
REGION:A-domain (Tetramerization)	SEQ_UP	1	
REGION:A-domain; part 1	SEQ_UP	1	
REGION:A-domain; part 2	SEQ_UP	1	
REGION:A; required for its colocalization with lamins at the nuclear envelope	SEQ_UP	1	
REGION:A.T hook-like	SEQ_UP	1	
REGION:AAA 1	SEQ_UP	9	
REGION:AAA 2	SEQ_UP	9	
REGION:AAA 3	SEQ_UP	9	
REGION:AAA 4	SEQ_UP	9	
REGION:AAA 5	SEQ_UP	9	
REGION:AAA 6	SEQ_UP	8	
REGION:Abolishes DNA transcriptional activity when missing	SEQ_UP	1	
REGION:Abolishes microtubules binding when missing	SEQ_UP	1	
REGION:ABR (APC-binding region) domain	SEQ_UP	1	
REGION:AC 1	SEQ_UP	1	
REGION:AC 2	SEQ_UP	1	
REGION:Accessory region	SEQ_UP	1	
REGION:Acetyl-CoA and acyl-CoA binding	SEQ_UP	1	
REGION:acetyl-CoA binding	SEQ_UP	1	
REGION:Acetyl-CoA binding	SEQ_UP	22	
REGION:Acetyl-CoA-binding domain	SEQ_UP	1	
REGION:Acetylated histone H3 binding	SEQ_UP	1	
REGION:Acetyltransferase	SEQ_UP	1	
REGION:Acidic	SEQ_UP	3	
REGION:Acidic 1	SEQ_UP	1	
REGION:Acidic 2	SEQ_UP	1	
REGION:Acidic 3	SEQ_UP	1	
REGION:Acidic region required for transactivation activity	SEQ_UP	1	
REGION:Acidic tract A2	SEQ_UP	1	
REGION:Acidic; binds calcium and is required for modulating the calcium-binding kinetics of calmodulin	SEQ_UP	1	
REGION:Actin binding	SEQ_UP	1	
REGION:Actin filament-binding	SEQ_UP	1	
REGION:Actin-actin interfilament contact point	SEQ_UP	1	
REGION:Actin-binding	SEQ_UP	58	
REGION:Actin-binding (calcium/calmodulin-insensitive)	SEQ_UP	1	
REGION:Actin-binding (calcium/calmodulin-sensitive)	SEQ_UP	1	
REGION:Actin-binding 1	SEQ_UP	4	
REGION:Actin-binding 2	SEQ_UP	4	
REGION:Actin-binding region (ABR)	SEQ_UP	1	
REGION:Actin-binding, Ca-sensitive	SEQ_UP	1	
REGION:Actin-severing	SEQ_UP	2	
REGION:Activates transcription; Inhibition of nuclear import due to lack of NLS and KPNA2 interaction	SEQ_UP	1	
REGION:Activating domain	SEQ_UP	1	
REGION:Activation domain	SEQ_UP	1	
REGION:Activation domain; required for transcription activation	SEQ_UP	1	
REGION:Activation function (AF)-1 domain	SEQ_UP	1	
REGION:Activation loop	SEQ_UP	20	
REGION:Activation of NF-kappa-B	SEQ_UP	1	
REGION:Activation peptide homolog	SEQ_UP	1	
REGION:Activation segment	SEQ_UP	3	
REGION:Active repression domain	SEQ_UP	1	
REGION:Acyl and malonyl transferases	SEQ_UP	1	
REGION:Acyl-CoA binding	SEQ_UP	10	
REGION:Acyltransferase	SEQ_UP	1	
REGION:AD	SEQ_UP	1	
REGION:Adenine-nucleotide binding in RNA target	SEQ_UP	2	
REGION:Adenosine 3',5'-bisphosphate; inhibitor	SEQ_UP	1	
REGION:Adenylate kinase	SEQ_UP	1	
REGION:Adenylate kinase 1	SEQ_UP	2	
REGION:Adenylate kinase 2	SEQ_UP	2	
REGION:Adenylyl sulfate binding	SEQ_UP	2	
REGION:Adenylyl-sulfate kinase	SEQ_UP	2	
REGION:ADP-D-glycero-beta-D-manno-heptose binding	SEQ_UP	1	
REGION:AF-2 domain	SEQ_UP	1	
REGION:AF1; mediates transcriptional activation	SEQ_UP	1	
REGION:AF2; mediates transcriptional activation	SEQ_UP	1	
REGION:AF3; mediates transcriptional activation (in isoform B)	SEQ_UP	1	
REGION:Agonist binding	SEQ_UP	11	
REGION:AICAR binding	SEQ_UP	1	
REGION:AICAR formyltransferase	SEQ_UP	1	
REGION:AID/alpha-interaction domain; mediates interaction with the beta subunit	SEQ_UP	1	
REGION:AIR	SEQ_UP	1	
REGION:AIR carboxylase domain	SEQ_UP	1	
REGION:AIRS domain	SEQ_UP	1	
REGION:AIS	SEQ_UP	2	
REGION:Aldehyde dehydrogenase domain	SEQ_UP	2	
REGION:Allosteric effector binding	SEQ_UP	1	
REGION:Allosteric inhibitor binding	SEQ_UP	1	
REGION:Allosteric switch region	SEQ_UP	1	
REGION:Allows a rapid multiple mono-ubiquitination of the APC substrate, but strongly inhibits the slow ubiquitin chain elongation catalyzed by UBCH10	SEQ_UP	1	
REGION:Allylic polyprenyl diphosphate-binding site	SEQ_UP	1	
REGION:ALMS motif	SEQ_UP	3	
REGION:Alpha	SEQ_UP	3	
REGION:Alpha-1	SEQ_UP	17	
REGION:Alpha-2	SEQ_UP	17	
REGION:Alpha-3	SEQ_UP	13	
REGION:Alpha-D-mannopyranose binding	SEQ_UP	1	
REGION:Alpha-D-mannose binding	SEQ_UP	1	
REGION:Alpha-helical domain	SEQ_UP	1	
REGION:Alpha-helical linker	SEQ_UP	1	
REGION:Alpha-helical region with structural similarity to HEAT repeats	SEQ_UP	1	
REGION:Alpha-ketoglutarate binding	SEQ_UP	9	
REGION:alpha-L-rhamnose binding	SEQ_UP	1	
REGION:Alpha/beta-tubulin binding	SEQ_UP	1	
REGION:Amino-acid kinase domain (AAK)	SEQ_UP	1	
REGION:Amino-terminal	SEQ_UP	1	
REGION:Amphipathic	SEQ_UP	1	
REGION:Amphipathic helix	SEQ_UP	1	
REGION:Amphipathic helix (AH)	SEQ_UP	1	
REGION:Amphipathic helix H1	SEQ_UP	1	
REGION:Amphipathic helix H2	SEQ_UP	1	
REGION:Amphipathic helix H3	SEQ_UP	1	
REGION:Ancestral calcium site	SEQ_UP	1	
REGION:Anion binding	SEQ_UP	1	
REGION:ANK2- and ANK-3 binding	SEQ_UP	1	
REGION:Anthranilate phosphoribosyltransferase homolog	SEQ_UP	1	
REGION:Antiparallel alpha-helical coiled coil region	SEQ_UP	1	
REGION:AP-2 complex binding	SEQ_UP	1	
REGION:AP1-binding	SEQ_UP	1	
REGION:APC-binding	SEQ_UP	3	
REGION:Approximate repeats	SEQ_UP	3	
REGION:ARF-binding	SEQ_UP	1	
REGION:ARF-binding domain (ABD)	SEQ_UP	1	
REGION:ARF-like	SEQ_UP	1	
REGION:Arg/Asp/Glu-rich domain	SEQ_UP	1	
REGION:Arg/Ser tandem repeat-rich	SEQ_UP	1	
REGION:Arg/Ser-rich domain	SEQ_UP	2	
REGION:Arginine-binding	SEQ_UP	1	
REGION:Ariadne domain	SEQ_UP	2	
REGION:Arm domain	SEQ_UP	1	
REGION:Arm-like	SEQ_UP	1	
REGION:ARM-like and Heat-like helical repeats	SEQ_UP	1	
REGION:Aromatic cage required for H3.3K36me3-specific binding	SEQ_UP	1	
REGION:ASARM motif; interaction with PHEX	SEQ_UP	1	
REGION:ASH	SEQ_UP	2	
REGION:Asparaginase	SEQ_UP	1	
REGION:Aspartate	SEQ_UP	2	
REGION:Aspartate binding	SEQ_UP	4	
REGION:Assembles INO80 complex module consisting of conserved components ACTR8, ACTL6A and YY1	SEQ_UP	1	
REGION:Assembles INO80 complex module consisting of conserved components INO80B, INO80C, ACTR5, RVBL1, RVBL2	SEQ_UP	1	
REGION:Assembles INO80 complex module with putative regulatory components INO80E, INO80F, UCHL5, NFRKB, MCRS1 and IN80D	SEQ_UP	1	
REGION:Association with alpha- and beta-tubulin	SEQ_UP	1	
REGION:ATCase (Aspartate transcarbamylase)	SEQ_UP	1	
REGION:ATG8 family proteins-binding	SEQ_UP	1	
REGION:ATPase activity domain	SEQ_UP	1	
REGION:ATPase domain	SEQ_UP	1	
REGION:Atypical RING finger domain 1	SEQ_UP	1	
REGION:Atypical RING finger domain 2	SEQ_UP	1	
REGION:Auto-inhibitory	SEQ_UP	1	
REGION:Autoinhibitory	SEQ_UP	1	
REGION:Autoinhibitory acidic region; in absence of 7SK snRNA interacts with the basic region preventing interaction with P-TEFb and modulating subcellular localization	SEQ_UP	1	
REGION:Autoinhibitory domain	SEQ_UP	17	
REGION:Autoinhibitory domain (AID)	SEQ_UP	1	
REGION:Autoinhibitory helix	SEQ_UP	2	
REGION:Autoinhibitory helix linker	SEQ_UP	1	
REGION:Autoinhibitory linker	SEQ_UP	1	
REGION:Autoinhibitory region	SEQ_UP	2	
REGION:Autoinhibitory segment	SEQ_UP	3	
REGION:Automodification domain	SEQ_UP	1	
REGION:Autoregulatory region	SEQ_UP	3	
REGION:Axin-binding	SEQ_UP	1	
REGION:B	SEQ_UP	6	
REGION:B domain	SEQ_UP	2	
REGION:B domain; contributes to trimerization	SEQ_UP	1	
REGION:B-box	SEQ_UP	1	
REGION:B-box coiled-coil; BBC	SEQ_UP	1	
REGION:B-linker	SEQ_UP	1	
REGION:B-reader	SEQ_UP	1	
REGION:B; linker	SEQ_UP	3	
REGION:B; required for interaction with RAN-GTP	SEQ_UP	1	
REGION:BAG-similar domain, required and sufficient for interaction with UBL4A	SEQ_UP	1	
REGION:Bait region	SEQ_UP	4	
REGION:Bait region (approximate)	SEQ_UP	1	
REGION:Ball and chain	SEQ_UP	1	
REGION:Band 3 binding	SEQ_UP	1	
REGION:BAR-like	SEQ_UP	2	
REGION:Basic	SEQ_UP	1	
REGION:Basic (possible receptor binding region)	SEQ_UP	1	
REGION:Basic (repression of DNA-binding)	SEQ_UP	1	
REGION:Basic motif	SEQ_UP	55	
REGION:Basic motif; degenerate	SEQ_UP	2	
REGION:Basic motif; required for the activation of phospholipid synthesis, but not for CDS1-binding	SEQ_UP	1	
REGION:Basic region	SEQ_UP	1	
REGION:Basic region; mediates nuclear localization and interaction with 7SK snRNA and NR3C1	SEQ_UP	1	
REGION:BATS	SEQ_UP	1	
REGION:BC-box	SEQ_UP	2	
REGION:Beta	SEQ_UP	3	
REGION:Beta barrel	SEQ_UP	1	
REGION:Beta domain	SEQ_UP	3	
REGION:Beta-1	SEQ_UP	3	
REGION:Beta-2	SEQ_UP	3	
REGION:Beta-chain polymerization, binding distal domain of another fibrin	SEQ_UP	1	
REGION:Beta-D-fructose 1-phosphate binding	SEQ_UP	1	
REGION:Beta-D-fructose 6-phosphate binding	SEQ_UP	1	
REGION:Beta-D-galactose binding	SEQ_UP	1	
REGION:Beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-N-oleoylsphingosine binding	SEQ_UP	1	
REGION:Beta-galactoside binding	SEQ_UP	6	
REGION:Beta-galactoside binding 1	SEQ_UP	1	
REGION:Beta-galactoside binding 2	SEQ_UP	1	
REGION:Beta-hairpin required for oligomerization	SEQ_UP	2	
REGION:Beta-ketoacyl reductase	SEQ_UP	1	
REGION:Beta-ketoacyl synthase	SEQ_UP	1	
REGION:Beta-propeller 1	SEQ_UP	2	
REGION:Beta-propeller 2	SEQ_UP	2	
REGION:Beta-propeller 3	SEQ_UP	2	
REGION:Beta-propeller 4	SEQ_UP	2	
REGION:Beta(2)beta(3) 'finger-like' loop	SEQ_UP	3	
REGION:BH3-like	SEQ_UP	1	
REGION:BID region	SEQ_UP	1	
REGION:Bind to RHO promoter	SEQ_UP	1	
REGION:Binding activity	SEQ_UP	1	
REGION:Binding of phosphoribosylpyrophosphate	SEQ_UP	2	
REGION:Binding pocket for hydrophobic ligands	SEQ_UP	1	
REGION:Binding site for the uncoating ATPase, involved in lattice disassembly	SEQ_UP	1	
REGION:Binding to ABL SH2-domain	SEQ_UP	1	
REGION:Binding to ACTN2	SEQ_UP	1	
REGION:Binding to ACTN2, PPP3CA and TCAP	SEQ_UP	1	
REGION:Binding to AGER/RAGE	SEQ_UP	1	
REGION:Binding to CDKN1B	SEQ_UP	1	
REGION:Binding to corepressors	SEQ_UP	1	
REGION:Binding to CtBP	SEQ_UP	1	
REGION:Binding to DNA	SEQ_UP	1	
REGION:Binding to EXOSC5	SEQ_UP	1	
REGION:Binding to FLNC	SEQ_UP	1	
REGION:Binding to intermediate filaments	SEQ_UP	1	
REGION:Binding to phosphoinositides	SEQ_UP	1	
REGION:Binding to RAG1	SEQ_UP	1	
REGION:Binding to the beta subunit	SEQ_UP	6	
REGION:Binding to the DYNLT2B-DYNLT1/DYNLT3 dimer	SEQ_UP	1	
REGION:Binding to the PDZ domain of EBP50	SEQ_UP	1	
REGION:Binding to TMEV Leader protein	SEQ_UP	1	
REGION:Binds A/T-rich DNA	SEQ_UP	1	
REGION:Binds actin	SEQ_UP	3	
REGION:Binds and tubulates liposomes	SEQ_UP	1	
REGION:Binds CBX1 and CBX3 chromo shadow domains	SEQ_UP	1	
REGION:Binds F-actin	SEQ_UP	1	
REGION:Binds lamins B	SEQ_UP	1	
REGION:Binds PCNA	SEQ_UP	1	
REGION:Binds POLR2J	SEQ_UP	1	
REGION:Binds predominantly to PtdIns(P5) and weaker to PtdIns(P3) abd PtdIns(P4); involved in neurite outgrowth regulation	SEQ_UP	1	
REGION:Binds RB1	SEQ_UP	1	
REGION:Binds RB1 and SP1	SEQ_UP	1	
REGION:Binds SCN2B	SEQ_UP	1	
REGION:Binds to GNAI2 and GNAI3	SEQ_UP	1	
REGION:Binds to HSPA5/GRP78	SEQ_UP	1	
REGION:Binds to ITPR1, ITPR2 and ITPR3	SEQ_UP	1	
REGION:Binds to necdin	SEQ_UP	1	
REGION:Binds to p60	SEQ_UP	1	
REGION:Binds to SNTB1	SEQ_UP	1	
REGION:Binds to SOS	SEQ_UP	1	
REGION:Binds to UPF3B	SEQ_UP	1	
REGION:Binds to vinculin	SEQ_UP	1	
REGION:Binds urokinase plasminogen activator surface receptor	SEQ_UP	1	
REGION:Binds with microtubules and centrioles	SEQ_UP	1	
REGION:Bowtie tail	SEQ_UP	1	
REGION:Bridging helix	SEQ_UP	2	
REGION:Bromodomain-like (BRDL)	SEQ_UP	1	
REGION:Bundle signaling element (BSE)	SEQ_UP	1	
REGION:C	SEQ_UP	2	
REGION:C domain	SEQ_UP	1	
REGION:C region (By similarity to lambda light-chain)	SEQ_UP	1	
REGION:C segment	SEQ_UP	1	
REGION:c-di-GMP binding	SEQ_UP	1	
REGION:C-domain	SEQ_UP	2	
REGION:C-helix region	SEQ_UP	1	
REGION:C-linker	SEQ_UP	1	
REGION:C-LIP	SEQ_UP	3	
REGION:c-MTBD region	SEQ_UP	6	
REGION:C-tail signal; necessary for mitochondrion outer membrane localization and integration in the TOM complex	SEQ_UP	1	
REGION:C-terminal	SEQ_UP	3	
REGION:C-terminal (CTD)	SEQ_UP	4	
REGION:C-terminal (CTD) region	SEQ_UP	1	
REGION:C-terminal AD (CTNNB1 binding site); interaction with CCAR1	SEQ_UP	1	
REGION:C-terminal arm	SEQ_UP	3	
REGION:C-terminal assembly domain	SEQ_UP	1	
REGION:C-terminal autoinhibitory region	SEQ_UP	4	
REGION:C-terminal barrel	SEQ_UP	1	
REGION:C-terminal basic extension	SEQ_UP	5	
REGION:C-terminal conserved inhibitory domain (CCID)	SEQ_UP	1	
REGION:C-terminal cyclin fold	SEQ_UP	1	
REGION:C-terminal cytoplasmic tail	SEQ_UP	2	
REGION:C-terminal dimerization domain	SEQ_UP	1	
REGION:C-terminal domain	SEQ_UP	7	
REGION:C-terminal domain (CTD)	SEQ_UP	1	
REGION:C-terminal domain (CTD); 52 X 7 AA approximate tandem repeats of Y-[ST]-P-[STQ]-[ST]-P-[SRNTEVKGN]	SEQ_UP	1	
REGION:C-terminal domain; essential for histone methyltransferase activity, nuclear localization and mediates interaction with HSP90AA1	SEQ_UP	1	
REGION:C-terminal domain; mediates interaction with SESN2	SEQ_UP	1	
REGION:C-terminal domain; mediates TORC1 regulation	SEQ_UP	3	
REGION:C-terminal extension of DRBM 3 and constituent of a bi-partite nuclear localization signal	SEQ_UP	1	
REGION:C-terminal globular domain	SEQ_UP	1	
REGION:C-terminal hydrophobic region	SEQ_UP	1	
REGION:C-terminal inhibitory domain; interacts with PCSK1	SEQ_UP	1	
REGION:C-terminal lobe	SEQ_UP	1	
REGION:C-terminal regulatory PFK domain 2	SEQ_UP	3	
REGION:C-terminal short (CTS) helix	SEQ_UP	2	
REGION:C-terminal subdomain A	SEQ_UP	1	
REGION:C-terminal subdomain B	SEQ_UP	1	
REGION:C-terminal tail	SEQ_UP	3	
REGION:C-terminal tail (CTT)	SEQ_UP	1	
REGION:C-terminal tail; required for its localization to cytoplasmic vesicle	SEQ_UP	1	
REGION:C-terminal VHL recognition site	SEQ_UP	1	
REGION:C-X-P repeat region	SEQ_UP	1	
REGION:C; actin-binding and synaptic-vesicle binding	SEQ_UP	3	
REGION:C1	SEQ_UP	1	
REGION:C1q binding	SEQ_UP	1	
REGION:C2	SEQ_UP	1	
REGION:C5-methylcytosine binding	SEQ_UP	1	
REGION:Ca(2+)-dependent actin binding	SEQ_UP	1	
REGION:CA2-binding	SEQ_UP	2	
REGION:CABIT	SEQ_UP	2	
REGION:CABIT 1	SEQ_UP	3	
REGION:CABIT 2	SEQ_UP	3	
REGION:CAD (involved in subunit assembly)	SEQ_UP	2	
REGION:Calcineurin A binding	SEQ_UP	2	
REGION:Calcineurin B binding	SEQ_UP	3	
REGION:Calcineurin-binding	SEQ_UP	5	
REGION:Calcium-dependent carbohydrate binding	SEQ_UP	1	
REGION:Calmodulin-binding	SEQ_UP	54	
REGION:Calmodulin-binding (1-9-14 motif)	SEQ_UP	1	
REGION:Calmodulin-binding (domain-C)	SEQ_UP	2	
REGION:Calmodulin-binding (domain-N)	SEQ_UP	2	
REGION:Calmodulin-binding (IQ motif)	SEQ_UP	1	
REGION:Calmodulin-binding (PSD)	SEQ_UP	1	
REGION:Calmodulin-binding IQ region	SEQ_UP	1	
REGION:Calmodulin-binding subdomain A	SEQ_UP	3	
REGION:Calmodulin-binding subdomain B	SEQ_UP	2	
REGION:CAMK2 inhibitory domain	SEQ_UP	1	
REGION:CAP	SEQ_UP	2	
REGION:Carbamoyl phosphate binding	SEQ_UP	1	
REGION:Carbohydrate binding	SEQ_UP	8	
REGION:Carbohydrate-binding	SEQ_UP	2	
REGION:Carbohydrate-binding stem domain	SEQ_UP	1	
REGION:Carboxyltransferase	SEQ_UP	4	
REGION:Carboxymycobactin binding	SEQ_UP	1	
REGION:Carboxypeptidase-like 1	SEQ_UP	1	
REGION:Carboxypeptidase-like 2	SEQ_UP	1	
REGION:Carboxypeptidase-like 3	SEQ_UP	1	
REGION:CARD-binding motif (CBM)	SEQ_UP	2	
REGION:Cardiolipin-binding	SEQ_UP	3	
REGION:Carnosine-binding	SEQ_UP	1	
REGION:Carrier domain	SEQ_UP	2	
REGION:CASK-binding	SEQ_UP	1	
REGION:CASP8AP2-binding	SEQ_UP	1	
REGION:Caspase	SEQ_UP	1	
REGION:Caspase-like	SEQ_UP	1	
REGION:Catalytic	SEQ_UP	26	
REGION:Catalytic (GEF)	SEQ_UP	1	
REGION:Catalytic domain	SEQ_UP	4	
REGION:Catalytic loop	SEQ_UP	17	
REGION:Catalytic subdomain A	SEQ_UP	17	
REGION:Catalytic subdomain B	SEQ_UP	17	
REGION:CATD	SEQ_UP	1	
REGION:Caveolin-binding	SEQ_UP	3	
REGION:CcN domain	SEQ_UP	4	
REGION:CCN domain	SEQ_UP	1	
REGION:CCP110-binding	SEQ_UP	1	
REGION:CD58 binding region 1	SEQ_UP	1	
REGION:CD58 binding region 2	SEQ_UP	1	
REGION:CDP-L-ribitol	SEQ_UP	1	
REGION:Cell surface signal	SEQ_UP	1	
REGION:Cell-attachment	SEQ_UP	1	
REGION:Central conserved domain (CCD); mediates interaction with RNF183, LRRK2 and SEC13	SEQ_UP	1	
REGION:Central conserved domain (CCD); required for localization to endoplasmic reticulum exit sites	SEQ_UP	1	
REGION:Central fibrous rod domain	SEQ_UP	3	
REGION:Central sheet, part 1	SEQ_UP	1	
REGION:Central sheet, part 2	SEQ_UP	1	
REGION:Central sheet, part 3	SEQ_UP	1	
REGION:Centrosomal localization signal (CLS)	SEQ_UP	1	
REGION:Centrosomal targeting domain	SEQ_UP	1	
REGION:centrosome localization domain (CLD)	SEQ_UP	1	
REGION:CEP97 binding	SEQ_UP	1	
REGION:cGMP-binding, high affinity	SEQ_UP	1	
REGION:cGMP-binding, high affinity; cAMP-binding, low affinity	SEQ_UP	1	
REGION:cGMP-binding, high affinity; cAMP-binding, moderate affinity	SEQ_UP	1	
REGION:cGMP-binding, low affinity	SEQ_UP	1	
REGION:CH (calponin-homology)-like region	SEQ_UP	1	
REGION:CH1	SEQ_UP	7	
REGION:CH2	SEQ_UP	4	
REGION:CH3	SEQ_UP	3	
REGION:CH4	SEQ_UP	2	
REGION:ChAM (Chromatin-association motif); required for chromatin association, mediates nucleosome association	SEQ_UP	1	
REGION:Channel pore-region	SEQ_UP	1	
REGION:Chaperone activity	SEQ_UP	1	
REGION:Chaperone domain	SEQ_UP	1	
REGION:Chaperonin-like domain	SEQ_UP	1	
REGION:Chemokine and involved in interaction with ITGAV:ITGB3 and ITGA4:ITGB1	SEQ_UP	1	
REGION:Chemokine binding	SEQ_UP	1	
REGION:Chemokine binding, important for signaling	SEQ_UP	1	
REGION:Chitooligosaccharide binding	SEQ_UP	6	
REGION:Cholesterol recognition/amino acid consensus (CRAC) region	SEQ_UP	1	
REGION:Cholinesterase-like (ChEL)	SEQ_UP	1	
REGION:Chondroitin sulfate A binding	SEQ_UP	1	
REGION:Chondroitin sulfate binding	SEQ_UP	1	
REGION:Chromodomain	SEQ_UP	1	
REGION:Ciliary targeting sequence (CST)	SEQ_UP	1	
REGION:Cis-determinant of acceptor ubiquitin-binding	SEQ_UP	1	
REGION:Cisternal side	SEQ_UP	1	
REGION:Class A specific domain	SEQ_UP	2	
REGION:Clathrin-binding	SEQ_UP	2	
REGION:Clathrin-binding domain (CBD)	SEQ_UP	1	
REGION:Cleavage sites for elastase	SEQ_UP	1	
REGION:Clustered O-linked oligosaccharides	SEQ_UP	3	
REGION:CMP-sialic acid binding	SEQ_UP	1	
REGION:CoA-binding	SEQ_UP	2	
REGION:Cob(II)alamin binding	SEQ_UP	2	
REGION:CoCUN	SEQ_UP	1	
REGION:Coenzyme A binding	SEQ_UP	19	
REGION:Coil 1A	SEQ_UP	65	
REGION:Coil 1b	SEQ_UP	1	
REGION:Coil 1B	SEQ_UP	64	
REGION:Coil 2	SEQ_UP	59	
REGION:Coil 2A	SEQ_UP	6	
REGION:Coil 2B	SEQ_UP	6	
REGION:Collagen-binding	SEQ_UP	4	
REGION:Collagenase-like 1	SEQ_UP	1	
REGION:Collagenase-like 2	SEQ_UP	1	
REGION:COMP N-terminal	SEQ_UP	1	
REGION:Competitively blocks access of APC substrates to the D-box coreceptor formed by FZR1 and ANAPC10	SEQ_UP	1	
REGION:Complementarity-determining-1	SEQ_UP	16	
REGION:Complementarity-determining-2	SEQ_UP	16	
REGION:Complementarity-determining-3	SEQ_UP	9	
REGION:Confers cellular localization similar to full-length form	SEQ_UP	1	
REGION:Connecting peptide	SEQ_UP	34	
REGION:Contributes to single strand DNA binding activity	SEQ_UP	1	
REGION:Copper-binding	SEQ_UP	1	
REGION:Core	SEQ_UP	2	
REGION:Core aggregation region	SEQ_UP	1	
REGION:Core helicase	SEQ_UP	1	
REGION:Core promoter DNA-binding	SEQ_UP	1	
REGION:Could be involved in the assembly of the multisynthetase complex	SEQ_UP	1	
REGION:CP motif	SEQ_UP	1	
REGION:CPD	SEQ_UP	1	
REGION:CpG-DNA binding	SEQ_UP	1	
REGION:CPSase (Carbamoyl-phosphate synthase)	SEQ_UP	1	
REGION:CPSase A	SEQ_UP	1	
REGION:CPSase B	SEQ_UP	1	
REGION:CR1; interaction with MBD2	SEQ_UP	1	
REGION:CR1; interaction with MBD2 and MBD3	SEQ_UP	1	
REGION:CR2; histone tail-binding	SEQ_UP	2	
REGION:Crambin-like	SEQ_UP	1	
REGION:CRD1; mediates transcriptional repression	SEQ_UP	1	
REGION:CREBBP-binding region	SEQ_UP	1	
REGION:Critical for end-to-end subunit interaction	SEQ_UP	1	
REGION:Critical for homodimerization	SEQ_UP	1	
REGION:Critical for hydrolysis GM2 gangliosides	SEQ_UP	1	
REGION:Critical for lipid-binding	SEQ_UP	1	
REGION:Critical for tubulation activity	SEQ_UP	1	
REGION:CRK-binding	SEQ_UP	1	
REGION:CRM (Cys-rich motif)	SEQ_UP	1	
REGION:Crucial for activation of GJA1	SEQ_UP	1	
REGION:CRY binding domain	SEQ_UP	3	
REGION:Cryptic mitochondrial signal peptide	SEQ_UP	1	
REGION:CS-1	SEQ_UP	1	
REGION:CS-2	SEQ_UP	1	
REGION:CSDE1-binding	SEQ_UP	1	
REGION:CSNK1E binding domain	SEQ_UP	2	
REGION:CTAD	SEQ_UP	2	
REGION:CTBP1-binding	SEQ_UP	2	
REGION:CTD-like region	SEQ_UP	1	
REGION:CTE	SEQ_UP	1	
REGION:CTNNB1-binding	SEQ_UP	4	
REGION:CTP-binding	SEQ_UP	1	
REGION:Cu(2+) binding	SEQ_UP	1	
REGION:CuBD subdomain	SEQ_UP	3	
REGION:CX	SEQ_UP	1	
REGION:CX3CL1-binding	SEQ_UP	2	
REGION:Cyclic dinucleotide-binding domain (CBD)	SEQ_UP	1	
REGION:Cyclic nucleotide-binding domain (CNBD)	SEQ_UP	1	
REGION:Cyclin A:CDK2 binding	SEQ_UP	1	
REGION:Cyclin A/CDK2 binding	SEQ_UP	2	
REGION:Cyclin-like 1	SEQ_UP	2	
REGION:Cyclin-like 2	SEQ_UP	2	
REGION:Cyclodeaminase/cyclohydrolase	SEQ_UP	1	
REGION:Cyclosporin A binding	SEQ_UP	1	
REGION:Cys-loop	SEQ_UP	7	
REGION:Cys-rich	SEQ_UP	1	
REGION:Cystatin-like fold 1	SEQ_UP	1	
REGION:Cystatin-like fold 2	SEQ_UP	1	
REGION:Cysteine motif	SEQ_UP	4	
REGION:Cysteine-containing	SEQ_UP	1	
REGION:Cysteine-rich	SEQ_UP	1	
REGION:Cysteine-rich (CR)	SEQ_UP	1	
REGION:Cysteine-rich tandem repeats	SEQ_UP	9	
REGION:Cytokine-stimulating activity	SEQ_UP	1	
REGION:Cytosolic Ser/Thr-rich junction	SEQ_UP	1	
REGION:D	SEQ_UP	2	
REGION:D domain	SEQ_UP	5	
REGION:D-fructose 1,6-bisphosphate binding; part of allosteric site	SEQ_UP	1	
REGION:D-fructose binding	SEQ_UP	1	
REGION:D-glucose 1 binding	SEQ_UP	4	
REGION:D-glucose 2 binding	SEQ_UP	4	
REGION:D-glucose binding	SEQ_UP	7	
REGION:D-hexose binding	SEQ_UP	1	
REGION:D-threo-isocitrate binding	SEQ_UP	1	
REGION:D; Pro-rich linker	SEQ_UP	1	
REGION:DACHbox-C	SEQ_UP	2	
REGION:DACHbox-N	SEQ_UP	2	
REGION:Damage-recruitment motif	SEQ_UP	1	
REGION:DBHS	SEQ_UP	1	
REGION:DCB; DCB:DCB domain and DCB:HUS domain interaction	SEQ_UP	2	
REGION:DCB1	SEQ_UP	2	
REGION:DCB2	SEQ_UP	2	
REGION:DCTN1-binding	SEQ_UP	3	
REGION:DD1	SEQ_UP	1	
REGION:deca-GX3 motif; required for interaction with YAE1 and the CIA complex	SEQ_UP	1	
REGION:Decreased nuclear import with localization in the nucleus but also in the cytoplasm	SEQ_UP	1	
REGION:Demethylase activity	SEQ_UP	1	
REGION:Dentonin	SEQ_UP	1	
REGION:Deoxynucleoside triphosphate binding	SEQ_UP	1	
REGION:Deubiquitinase activity	SEQ_UP	1	
REGION:DHOase (dihydroorotase)	SEQ_UP	1	
REGION:Diacetylated histone H3 binding	SEQ_UP	1	
REGION:Dihydropyridine binding	SEQ_UP	4	
REGION:Dihydroxyacetone binding	SEQ_UP	1	
REGION:Dimerization	SEQ_UP	16	
REGION:Dimerization (DIM)	SEQ_UP	3	
REGION:Dimerization and phosphorylation	SEQ_UP	4	
REGION:Dimerization arm	SEQ_UP	1	
REGION:Dimerization with NSUN4	SEQ_UP	1	
REGION:Dimethylallyl diphosphate binding	SEQ_UP	1	
REGION:DISC1-interaction domain	SEQ_UP	1	
REGION:Disordered	SEQ_UP	13063	
REGION:Disordered linker	SEQ_UP	2	
REGION:Disordered R region	SEQ_UP	1	
REGION:Distal segment	SEQ_UP	1	
REGION:Divergent helix-loop-helix motif	SEQ_UP	3	
REGION:Divergent targeting domain	SEQ_UP	1	
REGION:DKK-type Cys-1	SEQ_UP	4	
REGION:DKK-type Cys-2	SEQ_UP	4	
REGION:DNA annealing helicase activity	SEQ_UP	1	
REGION:DNA Holliday junction binding	SEQ_UP	1	
REGION:DNA primase	SEQ_UP	1	
REGION:DNA replication foci-targeting sequence	SEQ_UP	1	
REGION:DNA-binding	SEQ_UP	31	
REGION:DNA-binding domain	SEQ_UP	1	
REGION:DNA-binding regulation	SEQ_UP	1	
REGION:DNA-binding; H2TH (helix-2turn-helix) motif which binds double-stranded DNA	SEQ_UP	1	
REGION:DNA-binding; major groove	SEQ_UP	1	
REGION:DNA-binding; may bind double-stranded DNA	SEQ_UP	1	
REGION:DNA-binding; may bind to the undamaged single-strand DNA of the DNA repair bubble	SEQ_UP	1	
REGION:DNA-binding; minor groove	SEQ_UP	1	
REGION:DNA-binding; preference for heteroduplex DNA	SEQ_UP	1	
REGION:DNA-binding; preference for single stranded DNA; required for formation of stable nucleoprotein complex	SEQ_UP	1	
REGION:DNA/RNA binding	SEQ_UP	1	
REGION:Docking to the peroxisome membrane and binding to PEX3	SEQ_UP	1	
REGION:Does not affect nuclear localization pattern	SEQ_UP	1	
REGION:Dolichol phosphate binding	SEQ_UP	1	
REGION:Domain A	SEQ_UP	3	
REGION:Domain A (catalytic)	SEQ_UP	1	
REGION:Domain alpha	SEQ_UP	3	
REGION:Domain B	SEQ_UP	4	
REGION:Domain D	SEQ_UP	1	
REGION:Domain I	SEQ_UP	4	
REGION:Domain II	SEQ_UP	4	
REGION:Domain II and I	SEQ_UP	8	
REGION:Domain III	SEQ_UP	11	
REGION:Domain III 1	SEQ_UP	1	
REGION:Domain III 2	SEQ_UP	1	
REGION:Domain III A	SEQ_UP	1	
REGION:Domain III B	SEQ_UP	1	
REGION:Domain IV	SEQ_UP	7	
REGION:Domain IV 1 (domain IV B)	SEQ_UP	2	
REGION:Domain linker	SEQ_UP	1	
REGION:Domain N	SEQ_UP	1	
REGION:Domain V	SEQ_UP	1	
REGION:Domain; mediates interaction with E4F1	SEQ_UP	1	
REGION:Dominant negative effect on myogenic differentiation	SEQ_UP	1	
REGION:DPY-30	SEQ_UP	1	
REGION:DS-like domain	SEQ_UP	1	
REGION:DSM (DHX36-specific motif)	SEQ_UP	1	
REGION:dUMP binding	SEQ_UP	1	
REGION:dUMP binding; shared with dimeric partner	SEQ_UP	1	
REGION:dUTP binding	SEQ_UP	1	
REGION:DVD domain	SEQ_UP	3	
REGION:DVL1-binding	SEQ_UP	1	
REGION:DYNLL2 binding	SEQ_UP	1	
REGION:DYNLRB1 binding	SEQ_UP	1	
REGION:Dysbindin	SEQ_UP	1	
REGION:E	SEQ_UP	3	
REGION:E domain; essential for proper cell surface glycosylation	SEQ_UP	1	
REGION:E1	SEQ_UP	1	
REGION:E2	SEQ_UP	1	
REGION:EAD (Gln/Pro/Thr-rich)	SEQ_UP	1	
REGION:Ear; mediates interaction with TEPSIN	SEQ_UP	1	
REGION:Earmuff domain	SEQ_UP	1	
REGION:EBD domain	SEQ_UP	1	
REGION:EBM motif; may mediate interaction with the EJC	SEQ_UP	1	
REGION:ECH-like	SEQ_UP	1	
REGION:Ectodomain G	SEQ_UP	1	
REGION:EF-hand-like	SEQ_UP	3	
REGION:Effector domain involved in lipid-binding and calmodulin-binding	SEQ_UP	1	
REGION:Effector region	SEQ_UP	1	
REGION:EGF-like	SEQ_UP	1	
REGION:eIF2A-like	SEQ_UP	1	
REGION:eIF3/EIF4A-binding	SEQ_UP	2	
REGION:EIF4A-binding	SEQ_UP	2	
REGION:EIF4E-binding	SEQ_UP	3	
REGION:EIF4EBP1/2/3 binding	SEQ_UP	3	
REGION:EJC-binding motif 1; mediates interaction with the EJC	SEQ_UP	1	
REGION:EJC-binding motif 2; mediates interaction with the EJC	SEQ_UP	1	
REGION:EJC-binding motif; may mediate interaction with the EJC	SEQ_UP	1	
REGION:Elastase inhibitory domain	SEQ_UP	1	
REGION:EMD-binding	SEQ_UP	1	
REGION:Endonuclease activity	SEQ_UP	2	
REGION:Endoplasmic reticulum location	SEQ_UP	1	
REGION:Endosome targeting	SEQ_UP	1	
REGION:Endothelin-like	SEQ_UP	3	
REGION:Enhances binding of RB protein to E2F	SEQ_UP	1	
REGION:Enoyl reductase	SEQ_UP	1	
REGION:Enoyl-CoA hydratase / isomerase	SEQ_UP	1	
REGION:Enoyl-CoA hydratase 2	SEQ_UP	1	
REGION:EP300/CRSP3-binding region	SEQ_UP	1	
REGION:Epitope recognized by Goodpasture antibodies	SEQ_UP	1	
REGION:Epitope; recognized by IF-specific monoclonal antibody	SEQ_UP	1	
REGION:Epoxide hydrolase	SEQ_UP	1	
REGION:Erythroid-specific transcriptional activation	SEQ_UP	1	
REGION:Escort domain	SEQ_UP	1	
REGION:Essential for activity	SEQ_UP	1	
REGION:Essential for apoptotic activity	SEQ_UP	1	
REGION:Essential for ATP binding and ATPase activity	SEQ_UP	1	
REGION:Essential for binding to SLC9A3R1 PDZ domain	SEQ_UP	1	
REGION:Essential for binding to the MRN complex and for RPA focus formation on DNA damage	SEQ_UP	1	
REGION:Essential for chloroform and halothane sensitivity	SEQ_UP	1	
REGION:Essential for cleavage by ADAM17	SEQ_UP	1	
REGION:Essential for cleavage by HPN	SEQ_UP	1	
REGION:Essential for cleavage by TMPRSS11D and TMPRSS2	SEQ_UP	1	
REGION:Essential for deoxyribonuclease activity	SEQ_UP	1	
REGION:Essential for determining substrate specificity	SEQ_UP	2	
REGION:Essential for DNA binding	SEQ_UP	1	
REGION:Essential for enzyme activity	SEQ_UP	1	
REGION:Essential for ESRRB transcriptional activity and interaction with NCOA3	SEQ_UP	1	
REGION:Essential for GPI attachment	SEQ_UP	1	
REGION:Essential for homodimerization	SEQ_UP	1	
REGION:Essential for homodimerization and microtubule bundling activity	SEQ_UP	1	
REGION:Essential for interaction with ARNTL/BMAL1, E-box binding and repressor activity against the CLOCK-ARNTL/BMAL1 heterodimer	SEQ_UP	1	
REGION:Essential for interaction with BAX	SEQ_UP	1	
REGION:Essential for interaction with CBLN1; modulates interaction affinity with NLGN1, NLGN2 and NLGN3; prevents interaction with DAG1/alpha-dystroglycan; modulates interaction with alpha-latrotoxin	SEQ_UP	1	
REGION:Essential for interaction with GCK	SEQ_UP	1	
REGION:Essential for interaction with GDF2	SEQ_UP	1	
REGION:Essential for interaction with GOLGA2/GM130	SEQ_UP	1	
REGION:Essential for interaction with GORASP2	SEQ_UP	1	
REGION:Essential for interaction with GRID2	SEQ_UP	1	
REGION:Essential for interaction with HIF1AN	SEQ_UP	2	
REGION:Essential for interaction with NRXN1 and linker of two C1q trimers into disulfide-linked hexamers	SEQ_UP	1	
REGION:Essential for interaction with PTPN11 and PTPN6	SEQ_UP	1	
REGION:Essential for interaction with PTPRD	SEQ_UP	1	
REGION:Essential for interaction with SGTA and TTC1	SEQ_UP	1	
REGION:Essential for interaction with SMYD3, TSC1 and STIP1/HOP	SEQ_UP	1	
REGION:Essential for its histone acetyltransferase activity	SEQ_UP	1	
REGION:Essential for its interaction with RNA polymerase II, transcription-coupled nucleotide excision repair activity, association with chromatin after UV irradiation and for mediating the UV-induced translocation of ERRC8 to the nuclear matrix	SEQ_UP	1	
REGION:Essential for its translational repressor activity	SEQ_UP	1	
REGION:Essential for lipid droplet targeting	SEQ_UP	1	
REGION:Essential for loading of BUBR1, MAD1L1 and MAD2L1 to kinetochores	SEQ_UP	1	
REGION:Essential for mediating its function in dendritic development; may contribute to neuronal-specific targeting	SEQ_UP	1	
REGION:Essential for MYOD1 inhibition	SEQ_UP	1	
REGION:Essential for nuclear localization, interaction with RORG, repression of RORG transcriptional activator activity	SEQ_UP	1	
REGION:Essential for palmitoylation of SHH	SEQ_UP	1	
REGION:Essential for phosphatidylinositol-4-phosphate phosphatase activity	SEQ_UP	1	
REGION:Essential for polyglutamine aggregation suppression	SEQ_UP	1	
REGION:Essential for PPP1CA inhibition	SEQ_UP	1	
REGION:Essential for receptor binding and receptor activation	SEQ_UP	1	
REGION:Essential for TMEM35A/NACHO-mediated proper subunit assembly and trafficking to cell membrane	SEQ_UP	1	
REGION:Essential for TNFSF13B/TALL1/BAFF/BLyS binding	SEQ_UP	1	
REGION:Essential for transcriptional repressor activity and for interaction with KAT5 and HDAC7	SEQ_UP	1	
REGION:Essential for transport from endoplasmic reticulum to Golgi apparatus and interaction with SAR1A	SEQ_UP	1	
REGION:Essential to induce neural progenitor proliferation	SEQ_UP	1	
REGION:Essential to the intracellular anchoring function	SEQ_UP	1	
REGION:EVH2	SEQ_UP	3	
REGION:EVH2 block A	SEQ_UP	3	
REGION:EVH2 block B	SEQ_UP	3	
REGION:EVH2 block C	SEQ_UP	3	
REGION:Evolutionary conserved domain (ECD)	SEQ_UP	1	
REGION:Extended PHD1 domain (ePHD1)	SEQ_UP	1	
REGION:Extended PHD2 domain (ePHD2)	SEQ_UP	1	
REGION:Extended SH2 subdomain (ESS)	SEQ_UP	2	
REGION:Extracellular and involved in cell to cell contact	SEQ_UP	1	
REGION:Extracellular domain (ECD)	SEQ_UP	2	
REGION:Extracellular loop 1 (EL1)	SEQ_UP	1	
REGION:Extracellular/lumenal pore loop	SEQ_UP	3	
REGION:F-actin binding	SEQ_UP	1	
REGION:F-actin bundling activity	SEQ_UP	1	
REGION:F-actin-binding	SEQ_UP	2	
REGION:F-box-like	SEQ_UP	2	
REGION:Facilitates phospholipid membrane insertion	SEQ_UP	1	
REGION:FAD synthase	SEQ_UP	1	
REGION:FAD-binding	SEQ_UP	1	
REGION:FAD-dependent oxidoreductase	SEQ_UP	1	
REGION:Farnesyl diphosphate binding	SEQ_UP	1	
REGION:Fatty acid binding	SEQ_UP	3	
REGION:Fe-S binding site A	SEQ_UP	1	
REGION:Fe-S binding site B	SEQ_UP	1	
REGION:Fe2OG dioxygenase domain	SEQ_UP	1	
REGION:FERM-like	SEQ_UP	1	
REGION:FERM-like region F1	SEQ_UP	1	
REGION:FERM-like region F2	SEQ_UP	1	
REGION:FERM-like region F3	SEQ_UP	1	
REGION:FERMT2-binding	SEQ_UP	1	
REGION:FG repeats 1	SEQ_UP	1	
REGION:FG repeats 2	SEQ_UP	1	
REGION:FG-repeats	SEQ_UP	1	
REGION:Fibrillin unique N-terminal (FUN) domain	SEQ_UP	1	
REGION:Fibrin- and heparin-binding 1	SEQ_UP	1	
REGION:Fibrin-binding 2	SEQ_UP	1	
REGION:Filamin-binding	SEQ_UP	1	
REGION:First lumenal domain	SEQ_UP	2	
REGION:Flexible and important for F-actin binding	SEQ_UP	1	
REGION:Flexible hinge	SEQ_UP	2	
REGION:Flexible linker	SEQ_UP	7	
REGION:Flexible linker region involved in nuclear import of HSP70 proteins	SEQ_UP	1	
REGION:Flexible linker; important for secretion and polymerization into filaments	SEQ_UP	1	
REGION:Flexible loop	SEQ_UP	3	
REGION:Flexible stalk domain	SEQ_UP	1	
REGION:Flexible tail	SEQ_UP	1	
REGION:Focal adhesion targeting (FAT)	SEQ_UP	1	
REGION:Focal adhesion-targeting (FAT)	SEQ_UP	1	
REGION:Folate binding	SEQ_UP	3	
REGION:Formiminotransferase C-subdomain	SEQ_UP	1	
REGION:Formiminotransferase N-subdomain	SEQ_UP	1	
REGION:Forms an intramolecular interaction with the C-terminal coiled coil domain keeping the protein in a closed conformation	SEQ_UP	1	
REGION:Forms an intramolecular interaction with the N-terminal Calponin-homology and LIM zinc-binding domains-containing region keeping the protein in a closed conformation	SEQ_UP	1	
REGION:Formyltetrahydrofolate synthetase	SEQ_UP	1	
REGION:Formyltetrahydrofolate synthetase domain	SEQ_UP	1	
REGION:Framework-1	SEQ_UP	16	
REGION:Framework-2	SEQ_UP	16	
REGION:Framework-3	SEQ_UP	16	
REGION:Framework-4	SEQ_UP	6	
REGION:Free ubiquitin binding	SEQ_UP	1	
REGION:Fructose 2,6-bisphosphate binding; allosteric activator	SEQ_UP	3	
REGION:Fructose-1,6-bisphosphate binding; allosteric activator	SEQ_UP	1	
REGION:Fructose-2,6-bisphosphatase	SEQ_UP	3	
REGION:Fucose binding	SEQ_UP	4	
REGION:Fusion peptide	SEQ_UP	2	
REGION:G domain	SEQ_UP	1	
REGION:G-loop	SEQ_UP	18	
REGION:G; Pro-rich linker	SEQ_UP	1	
REGION:G1	SEQ_UP	18	
REGION:G1 motif	SEQ_UP	42	
REGION:G1-A	SEQ_UP	1	
REGION:G1-B	SEQ_UP	1	
REGION:G1-B'	SEQ_UP	1	
REGION:G2	SEQ_UP	18	
REGION:G2 motif	SEQ_UP	30	
REGION:G2-B	SEQ_UP	1	
REGION:G2-B'	SEQ_UP	1	
REGION:G3	SEQ_UP	19	
REGION:G3 motif	SEQ_UP	42	
REGION:G3BP1-binding	SEQ_UP	1	
REGION:G4	SEQ_UP	18	
REGION:G4 motif	SEQ_UP	42	
REGION:G5	SEQ_UP	18	
REGION:G5 motif	SEQ_UP	30	
REGION:GAG-alpha (glucosaminoglycan attachment domain)	SEQ_UP	1	
REGION:GAG-beta	SEQ_UP	1	
REGION:Galactosylceramide binding	SEQ_UP	2	
REGION:Gamma-aminobutyric acid binding	SEQ_UP	1	
REGION:Gamma-glutamyl phosphate reductase	SEQ_UP	1	
REGION:Ganglioside GT1b binding	SEQ_UP	1	
REGION:GART domain	SEQ_UP	1	
REGION:GATase (Glutamine amidotransferase)	SEQ_UP	1	
REGION:Gate loop 1	SEQ_UP	1	
REGION:Gate loop 2	SEQ_UP	1	
REGION:GDP binding	SEQ_UP	1	
REGION:GDP-beta-L-fucose binding	SEQ_UP	1	
REGION:Geranylgeranyl diphosphate binding	SEQ_UP	2	
REGION:GFLD subdomain	SEQ_UP	3	
REGION:GGA1-binding motif	SEQ_UP	1	
REGION:GGQ domain	SEQ_UP	1	
REGION:GIT1-binding	SEQ_UP	1	
REGION:GLEBS	SEQ_UP	1	
REGION:GLEBS; interaction with RAE1	SEQ_UP	1	
REGION:Globin	SEQ_UP	2	
REGION:Globular	SEQ_UP	12	
REGION:Globular 1	SEQ_UP	3	
REGION:Globular 2	SEQ_UP	3	
REGION:Globular A domain	SEQ_UP	1	
REGION:Globular autoinhibitory domain	SEQ_UP	1	
REGION:Globular B domain	SEQ_UP	1	
REGION:Globular head	SEQ_UP	2	
REGION:Globular or compact configuration stabilized by disulfide bonds	SEQ_UP	1	
REGION:Globular terminal domain	SEQ_UP	1	
REGION:Glucose-6-phosphate 1 binding	SEQ_UP	4	
REGION:Glucose-6-phosphate 2 binding	SEQ_UP	4	
REGION:Glucose-6-phosphate binding	SEQ_UP	1	
REGION:Glucosyltransferase	SEQ_UP	1	
REGION:Glucuronyltransferase activity	SEQ_UP	2	
REGION:Glutamate 5-kinase	SEQ_UP	1	
REGION:Glutamate binding	SEQ_UP	21	
REGION:Glutamate--tRNA ligase	SEQ_UP	1	
REGION:Glutamine binding	SEQ_UP	1	
REGION:Glutathione binding	SEQ_UP	29	
REGION:Glyceraldehyde 3-phosphate binding	SEQ_UP	4	
REGION:Glycine binding	SEQ_UP	2	
REGION:Glycogen-binding domain	SEQ_UP	1	
REGION:Glycogen-binding motif	SEQ_UP	1	
REGION:Glycolipid transfer protein homology domain	SEQ_UP	1	
REGION:Glycosaminoglycan-binding site	SEQ_UP	1	
REGION:Glycosyl hydrolase-1 1	SEQ_UP	2	
REGION:Glycosyl hydrolase-1 2	SEQ_UP	2	
REGION:Glycosyltransferase activity	SEQ_UP	1	
REGION:GLYR1-binding	SEQ_UP	1	
REGION:GMP binding	SEQ_UP	2	
REGION:GoLD	SEQ_UP	1	
REGION:Golgi localization	SEQ_UP	1	
REGION:Golgi targeting	SEQ_UP	2	
REGION:Golgi to endosome transport and interactions with GGA1 and GGA2	SEQ_UP	1	
REGION:Golgi-targeting domain	SEQ_UP	1	
REGION:GP domain	SEQ_UP	4	
REGION:GPSM2-binding domain	SEQ_UP	1	
REGION:GQ motif	SEQ_UP	1	
REGION:GRASP	SEQ_UP	2	
REGION:GRB2 binding site	SEQ_UP	1	
REGION:GRB2-binding	SEQ_UP	2	
REGION:GRID	SEQ_UP	1	
REGION:GRR	SEQ_UP	2	
REGION:GTase	SEQ_UP	1	
REGION:GTP binding	SEQ_UP	1	
REGION:GTP-binding	SEQ_UP	1	
REGION:GTPase domain (Globular)	SEQ_UP	6	
REGION:GTPase-binding	SEQ_UP	3	
REGION:Guanidinoacetate binding	SEQ_UP	1	
REGION:Guanine-nucleotide binding in RNA target	SEQ_UP	2	
REGION:Gyf binding	SEQ_UP	1	
REGION:H-S-H (helix-span-helix), dimerization	SEQ_UP	5	
REGION:H; Pro/Ser-rich linker	SEQ_UP	1	
REGION:H3-like	SEQ_UP	1	
REGION:HA-stretch	SEQ_UP	2	
REGION:HA2	SEQ_UP	1	
REGION:HA2; required for interaction with EIF3G and RPL26	SEQ_UP	1	
REGION:HAF-H domain; necessary to form higher-order Hrd1 complexes	SEQ_UP	1	
REGION:Harmonin homology domain	SEQ_UP	1	
REGION:Has GTPase activity, required for proper localization	SEQ_UP	1	
REGION:HATC (Hobo-Ac-Tam3) domain	SEQ_UP	1	
REGION:HDAC5-binding	SEQ_UP	1	
REGION:Head	SEQ_UP	68	
REGION:Head (Globular)	SEQ_UP	1	
REGION:Head domain	SEQ_UP	1	
REGION:Headpiece	SEQ_UP	2	
REGION:Heavy chain arm	SEQ_UP	1	
REGION:Heavy metals binding	SEQ_UP	1	
REGION:HECT-like	SEQ_UP	1	
REGION:Helical region with structural similarity to ARM repeat domains	SEQ_UP	1	
REGION:Helicase activity	SEQ_UP	1	
REGION:Helicase-like	SEQ_UP	1	
REGION:Helix bundle 1	SEQ_UP	1	
REGION:Helix bundle 2	SEQ_UP	1	
REGION:Helix bundle 3	SEQ_UP	1	
REGION:Helix bundle 4	SEQ_UP	1	
REGION:Helix-loop-helix motif	SEQ_UP	4	
REGION:Heme b 1 binding	SEQ_UP	3	
REGION:Heme-binding motif	SEQ_UP	1	
REGION:Hemerythrin-like	SEQ_UP	1	
REGION:Heparan sulfate N-deacetylase 1	SEQ_UP	1	
REGION:Heparan sulfate N-deacetylase 2	SEQ_UP	1	
REGION:Heparan sulfate N-deacetylase 3	SEQ_UP	1	
REGION:Heparan sulfate N-deacetylase 4	SEQ_UP	1	
REGION:Heparan sulfate N-sulfotransferase 1	SEQ_UP	1	
REGION:Heparan sulfate N-sulfotransferase 2	SEQ_UP	1	
REGION:Heparan sulfate N-sulfotransferase 3	SEQ_UP	1	
REGION:Heparan sulfate N-sulfotransferase 4	SEQ_UP	1	
REGION:Heparan sulfate proteoglycan binding	SEQ_UP	1	
REGION:Heparan sulfate-binding	SEQ_UP	1	
REGION:Heparin binding	SEQ_UP	1	
REGION:Heparin-binding	SEQ_UP	25	
REGION:Heparin-binding 2	SEQ_UP	1	
REGION:Heparin-binding region	SEQ_UP	1	
REGION:HEPN-C	SEQ_UP	2	
REGION:HEPN-N	SEQ_UP	2	
REGION:Heterodimerization	SEQ_UP	1	
REGION:Hexokinase large subdomain	SEQ_UP	1	
REGION:Hexokinase large subdomain 1	SEQ_UP	4	
REGION:Hexokinase large subdomain 2	SEQ_UP	4	
REGION:Hexokinase small subdomain	SEQ_UP	1	
REGION:Hexokinase small subdomain 1	SEQ_UP	4	
REGION:Hexokinase small subdomain 2	SEQ_UP	4	
REGION:Hexose-6-phosphate dehydrogenase	SEQ_UP	1	
REGION:HhH2, dimerization with ERCC1	SEQ_UP	1	
REGION:HhH2, dimerization with ERRC4/XPF	SEQ_UP	1	
REGION:HIF1AN-binding	SEQ_UP	2	
REGION:High affinity receptor-binding region which is also known as the TP508 peptide	SEQ_UP	1	
REGION:Highly charged	SEQ_UP	1	
REGION:Highly hydrophilic	SEQ_UP	1	
REGION:Highly mobile activation loop	SEQ_UP	1	
REGION:Hinge	SEQ_UP	19	
REGION:Hinge 1	SEQ_UP	3	
REGION:Hinge 2	SEQ_UP	3	
REGION:His	SEQ_UP	1	
REGION:His-loop	SEQ_UP	7	
REGION:His-rich loop	SEQ_UP	2	
REGION:Histidyl-tRNA synthetase-like	SEQ_UP	1	
REGION:Histone acetyltransferase (HAT)	SEQ_UP	1	
REGION:Histone deacetylase	SEQ_UP	9	
REGION:Histone deacetylase 1	SEQ_UP	1	
REGION:Histone deacetylase 2	SEQ_UP	1	
REGION:Histone H3-binding	SEQ_UP	1	
REGION:Histone H3K27cr binding	SEQ_UP	1	
REGION:Histone H3K36me3 binding	SEQ_UP	1	
REGION:Histone H3K4me3 and H3R8me2a binding	SEQ_UP	3	
REGION:Histone H3K4me3 binding	SEQ_UP	1	
REGION:Histone H3K4me3 N-terminus binding	SEQ_UP	1	
REGION:Histone H3K9me binding	SEQ_UP	2	
REGION:Histone H3K9me3 binding	SEQ_UP	1	
REGION:Histone H3R2me0 binding	SEQ_UP	1	
REGION:Histone H4 binding	SEQ_UP	1	
REGION:Histone H4K5ac H4K8ac and histone H4K5bu H4K8bu binding	SEQ_UP	1	
REGION:Histone-binding	SEQ_UP	2	
REGION:Homeo-Prospero	SEQ_UP	2	
REGION:Homeobox-like	SEQ_UP	5	
REGION:Homeodomain binding	SEQ_UP	1	
REGION:Homeodomain-like HTH domain	SEQ_UP	1	
REGION:Homodimerization	SEQ_UP	13	
REGION:Homodimerization domain D	SEQ_UP	2	
REGION:Homooligomerization	SEQ_UP	1	
REGION:HP1 box	SEQ_UP	1	
REGION:HUS; DCB:HUS domain interaction	SEQ_UP	2	
REGION:Hyaluronan-binding motif involved in chondroitin sulfate A- and C-binding	SEQ_UP	1	
REGION:Hyaluronan-binding motif involved in chondroitin sulfate A- and C-binding motif	SEQ_UP	1	
REGION:Hyaluronan-binding motif involved in chondroitin sulfate A-binding	SEQ_UP	1	
REGION:Hyaluronan-binding motif involved in chondroitin sulfate C-binding	SEQ_UP	1	
REGION:Hyaluronic acid-binding	SEQ_UP	1	
REGION:HYB domain	SEQ_UP	1	
REGION:Hybrid domain 1	SEQ_UP	1	
REGION:Hybrid domain 2	SEQ_UP	1	
REGION:Hydrolase domain	SEQ_UP	2	
REGION:Hydrolytic domain	SEQ_UP	1	
REGION:Hydrophilic	SEQ_UP	5	
REGION:Hydrophobic	SEQ_UP	2	
REGION:Hydrophobic dimerization interface	SEQ_UP	1	
REGION:Hydrophobic repeat HR-A/B	SEQ_UP	3	
REGION:Hydrophobic repeat HR-C	SEQ_UP	3	
REGION:Hydrophobic; mediates interaction with membranes	SEQ_UP	1	
REGION:Hyperforin binding; agonist	SEQ_UP	1	
REGION:Hypervariable region	SEQ_UP	3	
REGION:I-domain	SEQ_UP	3	
REGION:IAB-binding	SEQ_UP	1	
REGION:ID	SEQ_UP	1	
REGION:ID1	SEQ_UP	1	
REGION:ID2	SEQ_UP	1	
REGION:IFT57-binding	SEQ_UP	1	
REGION:Ig-hinge-like	SEQ_UP	1	
REGION:II	SEQ_UP	3	
REGION:III	SEQ_UP	3	
REGION:immunoglobulin-like	SEQ_UP	4	
REGION:Immunosuppression	SEQ_UP	1	
REGION:IMP binding	SEQ_UP	4	
REGION:IMP cyclohydrolase	SEQ_UP	1	
REGION:Impairs access of bound RNA to the active site	SEQ_UP	1	
REGION:Implicated in MHC class I binding	SEQ_UP	1	
REGION:Implicated in the circadian rhythmicity	SEQ_UP	1	
REGION:Import sequence; necessary for mitochondrion outer membrane localization and integration in the TOM complex	SEQ_UP	1	
REGION:Important for accumulation in the nucleus	SEQ_UP	1	
REGION:Important for actin binding	SEQ_UP	2	
REGION:Important for agonist binding	SEQ_UP	1	
REGION:Important for AKT1 activation and IL8 production	SEQ_UP	1	
REGION:Important for allosteric inhibitor binding	SEQ_UP	1	
REGION:Important for amyloid formation	SEQ_UP	1	
REGION:Important for antagonist binding	SEQ_UP	1	
REGION:Important for antimicrobial activity	SEQ_UP	1	
REGION:Important for apoenzyme conformational stability	SEQ_UP	1	
REGION:Important for arginine binding and amino acid transport	SEQ_UP	1	
REGION:Important for association with membranes	SEQ_UP	1	
REGION:Important for autoinhibitory function	SEQ_UP	1	
REGION:Important for binding and subsequent lysosomal degradation of target proteins	SEQ_UP	1	
REGION:Important for binding substrate proteins	SEQ_UP	1	
REGION:Important for binding to annexin A2	SEQ_UP	1	
REGION:Important for binding to glycosaminoglycan chains	SEQ_UP	1	
REGION:Important for binding to Rho GTPases	SEQ_UP	1	
REGION:Important for branch point selection	SEQ_UP	1	
REGION:Important for CDC42-dependent filopodia induction	SEQ_UP	1	
REGION:Important for chemokine binding and signaling	SEQ_UP	1	
REGION:Important for cholesterol binding and cholesterol transfer from NPC1 to liposomes	SEQ_UP	1	
REGION:Important for cleavage of target proteins	SEQ_UP	1	
REGION:Important for coactivator binding	SEQ_UP	1	
REGION:Important for cytoplasmic localization	SEQ_UP	1	
REGION:Important for degradation of atrial natriuretic peptide by IDE	SEQ_UP	1	
REGION:Important for dimerization	SEQ_UP	8	
REGION:Important for dimerization and interaction with PSMF1	SEQ_UP	1	
REGION:Important for dimerization, phosphorylation and activation	SEQ_UP	1	
REGION:Important for DNA and nucleosome binding	SEQ_UP	1	
REGION:Important for DNA and phosphoinositide binding	SEQ_UP	1	
REGION:Important for donor substrate binding	SEQ_UP	1	
REGION:Important for enzyme activity	SEQ_UP	1	
REGION:Important for enzyme activity, localization to cytoplasmic vesicles, and protein stability	SEQ_UP	1	
REGION:Important for flexibility of DNA ends that protrude from nucleosomes	SEQ_UP	1	
REGION:Important for formation of active hexamer structure	SEQ_UP	1	
REGION:Important for function in growth cone organization	SEQ_UP	1	
REGION:Important for GINS complex assembly	SEQ_UP	1	
REGION:Important for heparin binding	SEQ_UP	1	
REGION:Important for hexamer formation	SEQ_UP	1	
REGION:Important for homodimerization	SEQ_UP	3	
REGION:Important for homodimerization and interaction with FBXO7	SEQ_UP	1	
REGION:Important for homodimerization and oligomerization	SEQ_UP	1	
REGION:Important for homomultimer formation	SEQ_UP	1	
REGION:Important for homomultimer formation and localization to presynaptic regions	SEQ_UP	1	
REGION:Important for inositol polyphosphate binding	SEQ_UP	1	
REGION:Important for interaction with ALDOA	SEQ_UP	1	
REGION:Important for interaction with ATG101	SEQ_UP	1	
REGION:Important for interaction with ATG13	SEQ_UP	1	
REGION:Important for interaction with ATG13 and for autophagosome formation	SEQ_UP	1	
REGION:Important for interaction with BBRC36 and other subunits of the BRISC complex	SEQ_UP	1	
REGION:Important for interaction with BIRC2 and BIRC3	SEQ_UP	1	
REGION:Important for interaction with CD80 and CD86	SEQ_UP	1	
REGION:Important for interaction with CDK6	SEQ_UP	1	
REGION:Important for interaction with CEP170	SEQ_UP	1	
REGION:Important for interaction with CTNNBL1	SEQ_UP	1	
REGION:Important for interaction with DNA	SEQ_UP	1	
REGION:Important for interaction with DNM1L	SEQ_UP	1	
REGION:Important for interaction with FLRT2	SEQ_UP	1	
REGION:Important for interaction with GBA	SEQ_UP	1	
REGION:Important for interaction with GCK	SEQ_UP	1	
REGION:Important for interaction with GPSM2	SEQ_UP	2	
REGION:Important for interaction with histones	SEQ_UP	1	
REGION:Important for interaction with HTR2A	SEQ_UP	1	
REGION:Important for interaction with IL11RA and for the stimulation of cell proliferation	SEQ_UP	1	
REGION:Important for interaction with IRS1, SHC1 and STAT5B	SEQ_UP	1	
REGION:Important for interaction with IZUMO1	SEQ_UP	1	
REGION:Important for interaction with IZUMO1R	SEQ_UP	1	
REGION:Important for interaction with lipoprotein particles	SEQ_UP	1	
REGION:Important for interaction with LPL	SEQ_UP	1	
REGION:Important for interaction with MAG	SEQ_UP	1	
REGION:Important for interaction with MAP2K3	SEQ_UP	1	
REGION:Important for interaction with membranes	SEQ_UP	2	
REGION:Important for interaction with membranes containing phosphoinositides	SEQ_UP	2	
REGION:Important for interaction with NOTCH1	SEQ_UP	1	
REGION:Important for interaction with NUMA1; INSC and FRMPD1	SEQ_UP	1	
REGION:Important for interaction with PACS1 and PACS2	SEQ_UP	1	
REGION:Important for interaction with phosphorylated proteins	SEQ_UP	1	
REGION:Important for interaction with phosphotyrosine-binding proteins	SEQ_UP	1	
REGION:Important for interaction with PINK1	SEQ_UP	1	
REGION:Important for interaction with piRNA	SEQ_UP	2	
REGION:Important for interaction with PRKAR2A	SEQ_UP	1	
REGION:Important for interaction with RAB9A and RAB9B	SEQ_UP	1	
REGION:Important for interaction with RBX1	SEQ_UP	1	
REGION:Important for interaction with SHMT2	SEQ_UP	1	
REGION:Important for interaction with SMAD4	SEQ_UP	1	
REGION:Important for interaction with SMURF2	SEQ_UP	1	
REGION:Important for interaction with SPIRE1	SEQ_UP	1	
REGION:Important for interaction with STAC1, STAC2 and STAC3	SEQ_UP	1	
REGION:Important for interaction with STRA6	SEQ_UP	1	
REGION:Important for interaction with SUMO1 and SUMO2	SEQ_UP	1	
REGION:Important for interaction with target DNA	SEQ_UP	1	
REGION:Important for interaction with TXNL4A	SEQ_UP	1	
REGION:Important for interaction with TYK2	SEQ_UP	1	
REGION:Important for interaction with U1 snRNA	SEQ_UP	1	
REGION:Important for intracellular retention in recycling endosomes	SEQ_UP	1	
REGION:Important for ligand binding and specificity	SEQ_UP	1	
REGION:Important for ligand-binding	SEQ_UP	1	
REGION:Important for localization in at the junctional membrane	SEQ_UP	1	
REGION:Important for location in the cytosol	SEQ_UP	1	
REGION:Important for LPL transport to the lumenal surface of endothelial cells	SEQ_UP	1	
REGION:Important for maintaining surface expression and for interaction with FCER1G	SEQ_UP	2	
REGION:Important for membrane binding	SEQ_UP	1	
REGION:Important for membrane trafficking	SEQ_UP	1	
REGION:Important for normal channel activation and inactivation, for interaction with KCNIP2, and probably other family members as well	SEQ_UP	1	
REGION:Important for normal N-type inactivation	SEQ_UP	1	
REGION:Important for normal regulation of the kinase activity and for maintaining the kinase in an inactive state in the absence of ligand binding	SEQ_UP	1	
REGION:Important for nuclear localization	SEQ_UP	3	
REGION:Important for nuclear localization and chromatin binding	SEQ_UP	1	
REGION:Important for nucleosome binding activity of the PRC2 complex	SEQ_UP	1	
REGION:Important for oligomerization	SEQ_UP	2	
REGION:Important for oligomerization and fiber formation	SEQ_UP	1	
REGION:Important for peptide agonist binding	SEQ_UP	1	
REGION:Important for PRC2 dimer stability	SEQ_UP	1	
REGION:Important for protein degradation	SEQ_UP	1	
REGION:Important for protein stability	SEQ_UP	1	
REGION:Important for rapid channel inactivation	SEQ_UP	1	
REGION:Important for receptor binding	SEQ_UP	2	
REGION:Important for recycling of cargo proteins with the sequence motif K-D-E-L from the Golgi to the endoplasmic reticulum	SEQ_UP	3	
REGION:Important for regulation of lamellipodia formation	SEQ_UP	1	
REGION:Important for secretion	SEQ_UP	1	
REGION:Important for selectivity against fructose	SEQ_UP	1	
REGION:Important for substrate binding	SEQ_UP	2	
REGION:Important for surfactant activity and antibacterial properties	SEQ_UP	1	
REGION:Important for the formation of tight-junction strand-like structures	SEQ_UP	1	
REGION:Important for transcriptional activation	SEQ_UP	1	
REGION:Important for transcriptional repression activity	SEQ_UP	1	
REGION:Important for transport activity	SEQ_UP	3	
REGION:Important for tubulin binding	SEQ_UP	1	
REGION:Important for U4 snRNA-binding	SEQ_UP	1	
REGION:Important for ubiquitin binding	SEQ_UP	1	
REGION:IN box	SEQ_UP	1	
REGION:Inactivation gate	SEQ_UP	1	
REGION:Indispensable for interaction with MAGI1	SEQ_UP	1	
REGION:Inhibition of Nodal signaling	SEQ_UP	1	
REGION:Inhibitor binding	SEQ_UP	1	
REGION:Inhibitor-binding	SEQ_UP	1	
REGION:Inhibitory	SEQ_UP	1	
REGION:Inhibitory domain	SEQ_UP	1	
REGION:Inhibitory domain (ID)	SEQ_UP	1	
REGION:Inhibits APC ubiquitin ligase activity	SEQ_UP	1	
REGION:Inhibits capping activity of CP	SEQ_UP	1	
REGION:Inhibits enzyme activity in the absence of bound histone	SEQ_UP	1	
REGION:Inhibits homodimerization	SEQ_UP	1	
REGION:Inhibits receptor signaling in absence of type IV collagen	SEQ_UP	1	
REGION:Inhibits transcriptional repression, interaction with ERCC3 and apoptosis induction	SEQ_UP	1	
REGION:Inka box	SEQ_UP	1	
REGION:Inka box 1	SEQ_UP	1	
REGION:Inka box 2	SEQ_UP	1	
REGION:Inner juxtamembrane helix (IJMH)	SEQ_UP	1	
REGION:Inositol 1,4,5-trisphosphate binding	SEQ_UP	3	
REGION:Inositol-(1,3,4,5)-tetrakisphosphate 1-binding	SEQ_UP	1	
REGION:Inositol-(1,3,4,5)-tetrakisphosphate binding	SEQ_UP	1	
REGION:Inositolphosphate binding	SEQ_UP	1	
REGION:Insulin-binding	SEQ_UP	1	
REGION:Integrase-binding domain (IBD)	SEQ_UP	1	
REGION:Interaction with 14-3-3 epsilon	SEQ_UP	1	
REGION:Interaction with 5-mCpG DNA	SEQ_UP	4	
REGION:Interaction with 5' end of substrate DNA	SEQ_UP	1	
REGION:Interaction with 7-methylguanosine mRNA cap structure	SEQ_UP	1	
REGION:Interaction with ABL1	SEQ_UP	1	
REGION:Interaction with ACBD3	SEQ_UP	1	
REGION:Interaction with actin	SEQ_UP	1	
REGION:Interaction with actin 1	SEQ_UP	1	
REGION:Interaction with actin 2	SEQ_UP	1	
REGION:Interaction with actin 3	SEQ_UP	1	
REGION:Interaction with ACTL6A	SEQ_UP	1	
REGION:Interaction with ACTN1	SEQ_UP	1	
REGION:Interaction with ACTN2	SEQ_UP	1	
REGION:Interaction with ACTN4	SEQ_UP	1	
REGION:Interaction with ADGRB1	SEQ_UP	1	
REGION:Interaction with ADGRG6	SEQ_UP	1	
REGION:Interaction with ADGRL3	SEQ_UP	1	
REGION:Interaction with ADORA2A and GNAS	SEQ_UP	1	
REGION:Interaction with ADRA2A, ADRA2B and ADRA2C	SEQ_UP	1	
REGION:Interaction with ADRB1 and TGFA	SEQ_UP	1	
REGION:Interaction with ADRM1	SEQ_UP	1	
REGION:Interaction with AEBP2 and PHF19	SEQ_UP	1	
REGION:Interaction with AGO2 and APOBEC3G	SEQ_UP	1	
REGION:Interaction with AGTR1	SEQ_UP	1	
REGION:Interaction with AHSA1	SEQ_UP	1	
REGION:Interaction with AIFM1	SEQ_UP	1	
REGION:Interaction with AKAP13	SEQ_UP	2	
REGION:Interaction with AKAP9	SEQ_UP	1	
REGION:Interaction with AKT family members	SEQ_UP	1	
REGION:Interaction with AKT2	SEQ_UP	1	
REGION:Interaction with alpha subunit	SEQ_UP	1	
REGION:Interaction with alpha-actinin	SEQ_UP	2	
REGION:Interaction with alpha-tubulin	SEQ_UP	1	
REGION:Interaction with alpha-tubulin, gamma-tubulin, BIRC5 and FBXO5	SEQ_UP	1	
REGION:Interaction with ALX1	SEQ_UP	1	
REGION:Interaction with ALYREF/THOC4 and LUZP4	SEQ_UP	1	
REGION:Interaction with AMN	SEQ_UP	1	
REGION:Interaction with amyloid-beta peptide	SEQ_UP	1	
REGION:Interaction with ANK1	SEQ_UP	1	
REGION:Interaction with ANK1 isoform Mu7	SEQ_UP	1	
REGION:Interaction with ANK2	SEQ_UP	1	
REGION:Interaction with ANK3	SEQ_UP	1	
REGION:Interaction with ANLN and localization to the midbody	SEQ_UP	1	
REGION:Interaction with AP1G1	SEQ_UP	1	
REGION:Interaction with AP1G1 and somatodendritic targeting	SEQ_UP	1	
REGION:Interaction with AP1G1, AP1G2 and GGA1	SEQ_UP	1	
REGION:Interaction with AP2A1, AP2A2 and AP2M1	SEQ_UP	1	
REGION:Interaction with AP2B1	SEQ_UP	1	
REGION:Interaction with AP4B1	SEQ_UP	1	
REGION:Interaction with AP4E1	SEQ_UP	1	
REGION:Interaction with AP4M1	SEQ_UP	1	
REGION:Interaction with APBB1	SEQ_UP	1	
REGION:Interaction with APOBEC1	SEQ_UP	1	
REGION:Interaction with APPBP1	SEQ_UP	1	
REGION:Interaction with AR	SEQ_UP	7	
REGION:Interaction with ARC	SEQ_UP	2	
REGION:Interaction with AREL1	SEQ_UP	1	
REGION:Interaction with ARF1 and ARF6	SEQ_UP	1	
REGION:Interaction with ARF1 and IL1B	SEQ_UP	1	
REGION:Interaction with ARF3	SEQ_UP	1	
REGION:Interaction with argonaute family proteins	SEQ_UP	1	
REGION:Interaction with argonaute proteins	SEQ_UP	1	
REGION:Interaction with ARHGAP17, DAAM1, DIAPH1 and DIAPH2	SEQ_UP	2	
REGION:Interaction with ARHGAP31	SEQ_UP	1	
REGION:Interaction with ARHGAP33, ANKRA2, CDC42, PRDX3, RAD26L, RBBP6, RPS7 and TRIP4	SEQ_UP	1	
REGION:Interaction with ARHGEF28	SEQ_UP	1	
REGION:Interaction with ARHGEF5	SEQ_UP	1	
REGION:Interaction with ARHGEF7	SEQ_UP	2	
REGION:Interaction with ARID3A	SEQ_UP	1	
REGION:Interaction with ARIH2	SEQ_UP	1	
REGION:Interaction with ARL8B	SEQ_UP	1	
REGION:Interaction with ARMC12	SEQ_UP	1	
REGION:Interaction with ARNTL	SEQ_UP	1	
REGION:Interaction with ASAP1	SEQ_UP	1	
REGION:Interaction with ASF1A	SEQ_UP	2	
REGION:Interaction with ASF1A and ASF1B	SEQ_UP	1	
REGION:Interaction with ASF1A/B	SEQ_UP	1	
REGION:Interaction with ASH2L	SEQ_UP	1	
REGION:Interaction with ASH2L, RBBP5 and WDR5	SEQ_UP	1	
REGION:Interaction with ASS1	SEQ_UP	1	
REGION:Interaction with ATE1	SEQ_UP	1	
REGION:Interaction with ATF2	SEQ_UP	2	
REGION:Interaction with ATF4	SEQ_UP	1	
REGION:Interaction with ATF4 and ATF5	SEQ_UP	1	
REGION:Interaction with ATF5	SEQ_UP	1	
REGION:Interaction with ATG16L1	SEQ_UP	1	
REGION:Interaction with ATG5	SEQ_UP	2	
REGION:Interaction with ATM, CKIP, IFP35 and NMI	SEQ_UP	1	
REGION:Interaction with ATP5F1A	SEQ_UP	1	
REGION:Interaction with ATP6V1A	SEQ_UP	1	
REGION:Interaction with ATRIP	SEQ_UP	2	
REGION:Interaction with ATXN1	SEQ_UP	1	
REGION:Interaction with AURKA	SEQ_UP	2	
REGION:Interaction with AURKA and FBXW7	SEQ_UP	1	
REGION:Interaction with AURKB and INCENP	SEQ_UP	1	
REGION:Interaction with AXIN1	SEQ_UP	3	
REGION:Interaction with AZI2, TANK and TBKBP1	SEQ_UP	1	
REGION:Interaction with BAALC	SEQ_UP	1	
REGION:Interaction with BACE1	SEQ_UP	1	
REGION:Interaction with bacterial lipopeptide	SEQ_UP	1	
REGION:Interaction with BAG1	SEQ_UP	1	
REGION:Interaction with BAG6	SEQ_UP	1	
REGION:Interaction with BBS1, BBS2, BBS4, BBS7, BBS8 and BBS9	SEQ_UP	1	
REGION:Interaction with BBS1, BBS8 and BBS9	SEQ_UP	1	
REGION:Interaction with BBS5 and BBS7	SEQ_UP	1	
REGION:Interaction with BCCIP	SEQ_UP	1	
REGION:Interaction with BCL2 and BCL2L1 isoform Bcl-X(L)	SEQ_UP	1	
REGION:Interaction with BCL2L1 isoform Bcl-x(L) and inhibition of BCL2L1 anti-apoptotic activity	SEQ_UP	1	
REGION:Interaction with BCL2L10	SEQ_UP	1	
REGION:Interaction with BCL6	SEQ_UP	1	
REGION:Interaction with BCL9	SEQ_UP	2	
REGION:Interaction with BCORL1	SEQ_UP	1	
REGION:Interaction with BECN1	SEQ_UP	1	
REGION:Interaction with beta subunit	SEQ_UP	1	
REGION:Interaction with beta-actin	SEQ_UP	1	
REGION:Interaction with beta-catenin	SEQ_UP	2	
REGION:Interaction with beta-gamma G protein dimers	SEQ_UP	1	
REGION:Interaction with beta-tubulin	SEQ_UP	1	
REGION:Interaction with BH3 domain of BCL2	SEQ_UP	1	
REGION:Interaction with BICD2	SEQ_UP	2	
REGION:Interaction with BIN1 and AMPH	SEQ_UP	1	
REGION:Interaction with BIN2	SEQ_UP	1	
REGION:Interaction with BIRC2	SEQ_UP	1	
REGION:Interaction with BIRC2/c-IAP1	SEQ_UP	1	
REGION:Interaction with BLM	SEQ_UP	1	
REGION:Interaction with BMI1	SEQ_UP	2	
REGION:Interaction with BRCA1	SEQ_UP	5	
REGION:Interaction with BRCA2	SEQ_UP	4	
REGION:Interaction with BRME1	SEQ_UP	1	
REGION:Interaction with BRPF1	SEQ_UP	1	
REGION:Interaction with BSS9	SEQ_UP	1	
REGION:Interaction with BST2	SEQ_UP	1	
REGION:Interaction with BTRC	SEQ_UP	1	
REGION:Interaction with C1D	SEQ_UP	3	
REGION:Interaction with C1QBP	SEQ_UP	1	
REGION:Interaction with C9orf72	SEQ_UP	1	
REGION:Interaction with CA4	SEQ_UP	1	
REGION:Interaction with CABLES1	SEQ_UP	1	
REGION:Interaction with CADH1	SEQ_UP	1	
REGION:Interaction with CALB1	SEQ_UP	1	
REGION:Interaction with calcineurin	SEQ_UP	2	
REGION:Interaction with CALCOCO1	SEQ_UP	1	
REGION:Interaction with CALM	SEQ_UP	6	
REGION:Interaction with CALM; calcium-dependent	SEQ_UP	1	
REGION:Interaction with CALM1	SEQ_UP	1	
REGION:Interaction with calmodulin	SEQ_UP	10	
REGION:Interaction with Calmodulin	SEQ_UP	1	
REGION:Interaction with calmodulin and ITPR3	SEQ_UP	1	
REGION:Interaction with CAMK2A	SEQ_UP	1	
REGION:Interaction with capping proteins (CPs)	SEQ_UP	1	
REGION:Interaction with CARD9	SEQ_UP	1	
REGION:Interaction with CASK	SEQ_UP	1	
REGION:Interaction with CASP3	SEQ_UP	1	
REGION:Interaction with CASP8	SEQ_UP	1	
REGION:Interaction with CASP8 propeptide	SEQ_UP	1	
REGION:Interaction with CASP8 subunits p18 and p10	SEQ_UP	1	
REGION:Interaction with caspase-7	SEQ_UP	1	
REGION:Interaction with CASR	SEQ_UP	1	
REGION:Interaction with CAV1	SEQ_UP	2	
REGION:Interaction with CAVIN1	SEQ_UP	2	
REGION:Interaction with CAVIN3	SEQ_UP	1	
REGION:Interaction with CBFA2T2	SEQ_UP	1	
REGION:Interaction with CBFA2T3	SEQ_UP	2	
REGION:Interaction with CBLN1	SEQ_UP	1	
REGION:Interaction with CBLN1 homotrimer	SEQ_UP	1	
REGION:Interaction with CCAR1	SEQ_UP	1	
REGION:Interaction with CCAR2	SEQ_UP	4	
REGION:Interaction with CCNA1	SEQ_UP	1	
REGION:Interaction with CCNA1 and CCNA1/CDK2 complex; essential for CDK2 inhibitory activity	SEQ_UP	1	
REGION:Interaction with CCNC	SEQ_UP	1	
REGION:Interaction with CCND1, CCND2 and CCND3	SEQ_UP	1	
REGION:Interaction with CCND2	SEQ_UP	1	
REGION:Interaction with CCNT1, HEXIM1 and HEXIM2	SEQ_UP	1	
REGION:Interaction with CD163	SEQ_UP	1	
REGION:Interaction with CD274/PDCD1L1	SEQ_UP	1	
REGION:Interaction with CD2AP	SEQ_UP	3	
REGION:Interaction with CD2AP and NPHS1	SEQ_UP	1	
REGION:Interaction with CDC2-CCNB1	SEQ_UP	1	
REGION:Interaction with CDC42	SEQ_UP	3	
REGION:Interaction with CDC5L	SEQ_UP	1	
REGION:Interaction with CDC5L, SF3B1 and MELK	SEQ_UP	1	
REGION:Interaction with CDK17	SEQ_UP	1	
REGION:Interaction with CDK2	SEQ_UP	4	
REGION:Interaction with CDK2AP2	SEQ_UP	1	
REGION:Interaction with CDK3	SEQ_UP	1	
REGION:Interaction with CDK5R1	SEQ_UP	1	
REGION:Interaction with CDK5RAP2	SEQ_UP	1	
REGION:Interaction with CDK5RAP3 and MDM2	SEQ_UP	1	
REGION:Interaction with CDKN1A	SEQ_UP	2	
REGION:Interaction with CDKN2A	SEQ_UP	1	
REGION:Interaction with CDT1	SEQ_UP	1	
REGION:Interaction with CDT1 and CUL4A	SEQ_UP	1	
REGION:Interaction with CDYL	SEQ_UP	1	
REGION:Interaction with CEBPA	SEQ_UP	2	
REGION:Interaction with CENPF	SEQ_UP	4	
REGION:Interaction with CENPJ	SEQ_UP	1	
REGION:Interaction with centrosomes	SEQ_UP	1	
REGION:Interaction with CEP164 and required for UV resistance	SEQ_UP	1	
REGION:Interaction with CEP290, BBS1, BBS2, BBS4, BBS5, BBS7, BBS8 and BBS9	SEQ_UP	1	
REGION:Interaction with CEP55	SEQ_UP	2	
REGION:Interaction with CEP76	SEQ_UP	1	
REGION:Interaction with CEP85	SEQ_UP	1	
REGION:Interaction with CEP97	SEQ_UP	1	
REGION:Interaction with CETN2	SEQ_UP	2	
REGION:Interaction with CFLAR	SEQ_UP	1	
REGION:Interaction with CFP/properdin	SEQ_UP	1	
REGION:Interaction with CFP1	SEQ_UP	1	
REGION:Interaction with CGNL1	SEQ_UP	1	
REGION:Interaction with CH-TOG	SEQ_UP	1	
REGION:Interaction with CHEK1	SEQ_UP	1	
REGION:Interaction with CHEK2	SEQ_UP	1	
REGION:Interaction with CHMP3	SEQ_UP	1	
REGION:Interaction with CHMP4A, CHMP4B and CHMP4C	SEQ_UP	1	
REGION:Interaction with CHMP5	SEQ_UP	1	
REGION:Interaction with CHP2	SEQ_UP	1	
REGION:Interaction with CHRM2	SEQ_UP	1	
REGION:Interaction with CHUK	SEQ_UP	1	
REGION:Interaction with CHUK/IKBKB	SEQ_UP	1	
REGION:Interaction with CIART	SEQ_UP	1	
REGION:Interaction with CINP	SEQ_UP	1	
REGION:Interaction with clathrin heavy chains	SEQ_UP	1	
REGION:Interaction with clathrin; sufficient to induce clathrin assembly	SEQ_UP	1	
REGION:Interaction with CLF2	SEQ_UP	1	
REGION:Interaction with CLINT1	SEQ_UP	1	
REGION:Interaction with CLIP2 and RSN	SEQ_UP	1	
REGION:Interaction with CLNK	SEQ_UP	1	
REGION:Interaction with CLOCK	SEQ_UP	2	
REGION:Interaction with CLSPN	SEQ_UP	1	
REGION:Interaction with CNOT1	SEQ_UP	1	
REGION:Interaction with CNOT6, CNOT6L, CNOT7 and CNOT8	SEQ_UP	1	
REGION:Interaction with coactivator LXXLL motif	SEQ_UP	1	
REGION:Interaction with COL5A1	SEQ_UP	1	
REGION:Interaction with COL6A2	SEQ_UP	1	
REGION:Interaction with collagen	SEQ_UP	1	
REGION:Interaction with collided ribosomes	SEQ_UP	1	
REGION:Interaction with Complement C3 beta chain	SEQ_UP	1	
REGION:Interaction with condensed chromosomes in telophase	SEQ_UP	1	
REGION:Interaction with COPB1	SEQ_UP	1	
REGION:Interaction with COPG1	SEQ_UP	1	
REGION:Interaction with COPS3	SEQ_UP	1	
REGION:Interaction with CREBBP	SEQ_UP	4	
REGION:Interaction with CRIPAK	SEQ_UP	1	
REGION:Interaction with CRISP2	SEQ_UP	1	
REGION:Interaction with CRY1	SEQ_UP	2	
REGION:Interaction with CRYAB	SEQ_UP	1	
REGION:Interaction with CSDE1	SEQ_UP	1	
REGION:Interaction with CSF1R	SEQ_UP	1	
REGION:Interaction with CSK	SEQ_UP	4	
REGION:Interaction with CTBP1	SEQ_UP	3	
REGION:Interaction with CTBP1 and CTBP2 1	SEQ_UP	1	
REGION:Interaction with CTBP1 and CTBP2 2	SEQ_UP	1	
REGION:Interaction with CTBP1, CTBP2 and ZNF516	SEQ_UP	1	
REGION:Interaction with CTBP2	SEQ_UP	2	
REGION:Interaction with CTC1	SEQ_UP	1	
REGION:Interaction with CTNNA1	SEQ_UP	1	
REGION:Interaction with CTNNA2	SEQ_UP	1	
REGION:Interaction with CTNNB1	SEQ_UP	7	
REGION:Interaction with CTNNB1 and GLI3	SEQ_UP	1	
REGION:Interaction with CTNND1	SEQ_UP	3	
REGION:Interaction with CUBN	SEQ_UP	1	
REGION:Interaction with CUL2	SEQ_UP	1	
REGION:Interaction with CUL3	SEQ_UP	1	
REGION:Interaction with CUX1 and HDAC1	SEQ_UP	1	
REGION:Interaction with CYBA	SEQ_UP	1	
REGION:Interaction with cyclic nucleotide-binding pocket	SEQ_UP	1	
REGION:Interaction with CYFIP2	SEQ_UP	1	
REGION:Interaction with CYLD	SEQ_UP	2	
REGION:Interaction with CYTH1	SEQ_UP	1	
REGION:Interaction with cytokine/interferon/growth hormone receptors	SEQ_UP	2	
REGION:Interaction with D(2) dopamine receptor	SEQ_UP	1	
REGION:Interaction with DAAM1, DIAPH1 and DIAPH2	SEQ_UP	1	
REGION:Interaction with DAB1	SEQ_UP	2	
REGION:Interaction with DAB2	SEQ_UP	7	
REGION:Interaction with DAPK1	SEQ_UP	1	
REGION:Interaction with DAPK3	SEQ_UP	1	
REGION:Interaction with DAXX	SEQ_UP	2	
REGION:Interaction with DCC	SEQ_UP	3	
REGION:Interaction with DCTN1	SEQ_UP	1	
REGION:Interaction with DCX	SEQ_UP	1	
REGION:Interaction with DDB1	SEQ_UP	1	
REGION:Interaction with DDIT3/CHOP	SEQ_UP	1	
REGION:Interaction with DDN	SEQ_UP	2	
REGION:Interaction with DDX3X	SEQ_UP	1	
REGION:Interaction with DDX5	SEQ_UP	1	
REGION:Interaction with DDX5; self-association	SEQ_UP	1	
REGION:Interaction with DDX6	SEQ_UP	1	
REGION:Interaction with DEAF1	SEQ_UP	1	
REGION:Interaction with DHX33	SEQ_UP	1	
REGION:Interaction with dimethylated histone H4	SEQ_UP	1	
REGION:Interaction with DISC1	SEQ_UP	1	
REGION:Interaction with DLC2	SEQ_UP	1	
REGION:Interaction with DLG5	SEQ_UP	2	
REGION:Interaction with DLL4	SEQ_UP	1	
REGION:Interaction with DMAP1	SEQ_UP	1	
REGION:Interaction with DMD and UTRN	SEQ_UP	1	
REGION:Interaction with DNA	SEQ_UP	31	
REGION:Interaction with DNA substrate	SEQ_UP	1	
REGION:Interaction with DNAJB6	SEQ_UP	2	
REGION:Interaction with DNJC9	SEQ_UP	1	
REGION:Interaction with DNM1	SEQ_UP	1	
REGION:Interaction with DNM1 and DNM3	SEQ_UP	1	
REGION:Interaction with DNM1 and WASL	SEQ_UP	1	
REGION:Interaction with DNM2	SEQ_UP	1	
REGION:Interaction with DNM2 and WASL	SEQ_UP	3	
REGION:Interaction with DNMT1 and DNMT3A	SEQ_UP	1	
REGION:Interaction with DNMT1 and DNMT3B	SEQ_UP	1	
REGION:Interaction with DNMT1, DNMT3A and DNMT3B	SEQ_UP	1	
REGION:Interaction with DNMT3A	SEQ_UP	2	
REGION:Interaction with DNMT3B	SEQ_UP	1	
REGION:Interaction with DOCK1	SEQ_UP	1	
REGION:Interaction with DPF motifs-containing proteins	SEQ_UP	1	
REGION:Interaction with DPF3/BAF45C isoform 2	SEQ_UP	1	
REGION:Interaction with DPY30	SEQ_UP	1	
REGION:Interaction with DRD2	SEQ_UP	2	
REGION:Interaction with DRG2	SEQ_UP	1	
REGION:Interaction with DROSHA	SEQ_UP	1	
REGION:Interaction with DSC1	SEQ_UP	1	
REGION:Interaction with DSC1 and DSG1	SEQ_UP	1	
REGION:Interaction with dsRNA	SEQ_UP	3	
REGION:Interaction with DST (isoform 1)	SEQ_UP	1	
REGION:Interaction with DTNA	SEQ_UP	1	
REGION:Interaction with DVL1	SEQ_UP	1	
REGION:Interaction with DVL1, DVL2 and DVL3	SEQ_UP	2	
REGION:Interaction with DVL3	SEQ_UP	1	
REGION:Interaction with DYL2	SEQ_UP	1	
REGION:Interaction with DYNC1I2	SEQ_UP	1	
REGION:Interaction with DYNC1LI2	SEQ_UP	1	
REGION:Interaction with dynein	SEQ_UP	1	
REGION:Interaction with dynein and dynactin	SEQ_UP	1	
REGION:Interaction with dynein and NDEL1	SEQ_UP	1	
REGION:Interaction with DYNLL1, DYNC1H1, DYNC1I2, DCTN1 and DCTN2	SEQ_UP	1	
REGION:Interaction with DYNLT1	SEQ_UP	3	
REGION:Interaction with E4F1	SEQ_UP	4	
REGION:Interaction with EED	SEQ_UP	2	
REGION:Interaction with EFNB1	SEQ_UP	1	
REGION:Interaction with EGFR and ERBB2 and regulation of EGFR activation	SEQ_UP	1	
REGION:Interaction with EGLN1/PHD2	SEQ_UP	1	
REGION:Interaction with EIF2AK2	SEQ_UP	1	
REGION:Interaction with EIF2AK2/PKR	SEQ_UP	1	
REGION:Interaction with EIF3B	SEQ_UP	1	
REGION:Interaction with EIF3L	SEQ_UP	1	
REGION:Interaction with EIF4E	SEQ_UP	1	
REGION:Interaction with Elongin BC complex	SEQ_UP	4	
REGION:Interaction with EML4	SEQ_UP	1	
REGION:Interaction with ENG	SEQ_UP	1	
REGION:Interaction with EPB41L1	SEQ_UP	1	
REGION:Interaction with EPB41L2	SEQ_UP	1	
REGION:Interaction with EPB41L5	SEQ_UP	2	
REGION:Interaction with EPHA2	SEQ_UP	1	
REGION:Interaction with EPM2A	SEQ_UP	1	
REGION:Interaction with EPS8	SEQ_UP	1	
REGION:Interaction with Epstein-Barr virus BMLF1	SEQ_UP	1	
REGION:Interaction with ERBB4	SEQ_UP	1	
REGION:Interaction with ERCC1	SEQ_UP	1	
REGION:Interaction with ERCC2 and GTF2H1	SEQ_UP	1	
REGION:Interaction with ERCC6	SEQ_UP	1	
REGION:Interaction with ERCC6/CSB	SEQ_UP	1	
REGION:Interaction with ERLEC1, OS9 and SYVN1	SEQ_UP	1	
REGION:Interaction with ERLIN1	SEQ_UP	1	
REGION:Interaction with ERP44	SEQ_UP	1	
REGION:Interaction with ESCRT-I	SEQ_UP	1	
REGION:Interaction with ESR1	SEQ_UP	4	
REGION:Interaction with ESR1 and ESR2	SEQ_UP	1	
REGION:Interaction with ESR1, NR1H4, NR3C1, PGR and SMARCA4	SEQ_UP	1	
REGION:Interaction with ETV6	SEQ_UP	1	
REGION:Interaction with EVI5	SEQ_UP	1	
REGION:Interaction with EXO1	SEQ_UP	2	
REGION:Interaction with EZH2	SEQ_UP	2	
REGION:Interaction with EZR	SEQ_UP	2	
REGION:Interaction with F-actin	SEQ_UP	5	
REGION:Interaction with F2RL1	SEQ_UP	2	
REGION:Interaction with FAAP24	SEQ_UP	1	
REGION:Interaction with FADD	SEQ_UP	2	
REGION:Interaction with FAM120B	SEQ_UP	1	
REGION:Interaction with FAM124B	SEQ_UP	1	
REGION:Interaction with FANCD2	SEQ_UP	2	
REGION:Interaction with FANCE	SEQ_UP	1	
REGION:Interaction with FAS	SEQ_UP	1	
REGION:Interaction with FASLG	SEQ_UP	1	
REGION:Interaction with FCHSD2	SEQ_UP	1	
REGION:Interaction with FCN2	SEQ_UP	1	
REGION:Interaction with FGF13	SEQ_UP	1	
REGION:Interaction with FGFR	SEQ_UP	1	
REGION:Interaction with FGL1	SEQ_UP	1	
REGION:Interaction with FHL3	SEQ_UP	1	
REGION:Interaction with FHOD1	SEQ_UP	1	
REGION:Interaction with FKBP1A	SEQ_UP	2	
REGION:Interaction with FLCN and FNIP1	SEQ_UP	1	
REGION:Interaction with FLNA	SEQ_UP	1	
REGION:Interaction with FLNC	SEQ_UP	1	
REGION:Interaction with FLOT1	SEQ_UP	1	
REGION:Interaction with FLRT3	SEQ_UP	1	
REGION:Interaction with FMR1	SEQ_UP	1	
REGION:Interaction with FNIP2 and TSC1	SEQ_UP	1	
REGION:Interaction with FOXO1	SEQ_UP	1	
REGION:Interaction with FOXP3	SEQ_UP	2	
REGION:Interaction with FRMD4A	SEQ_UP	1	
REGION:Interaction with furin	SEQ_UP	1	
REGION:Interaction with FXN and ISCU	SEQ_UP	1	
REGION:Interaction with FYB1	SEQ_UP	1	
REGION:Interaction with FYN	SEQ_UP	1	
REGION:Interaction with FYN SH3 domain	SEQ_UP	1	
REGION:Interaction with FYN when phosphorylated at Tyr-282	SEQ_UP	1	
REGION:Interaction with G proteins	SEQ_UP	1	
REGION:Interaction with G(o)-alpha	SEQ_UP	1	
REGION:Interaction with GAB2	SEQ_UP	1	
REGION:Interaction with GABA A beta subunit	SEQ_UP	1	
REGION:Interaction with GABARAP	SEQ_UP	1	
REGION:Interaction with GABARAP and GABARAPL2	SEQ_UP	1	
REGION:Interaction with GABBR1	SEQ_UP	1	
REGION:Interaction with GABP2	SEQ_UP	1	
REGION:Interaction with GABPB1 and FANK1	SEQ_UP	1	
REGION:Interaction with GABRG2	SEQ_UP	1	
REGION:Interaction with GABRR3	SEQ_UP	1	
REGION:Interaction with galactose moiety of substrate glycoprotein	SEQ_UP	3	
REGION:Interaction with gamma-tubulin and localization to the centrosome	SEQ_UP	1	
REGION:Interaction with GAS2L2	SEQ_UP	1	
REGION:Interaction with GAS6	SEQ_UP	1	
REGION:Interaction with GATA1	SEQ_UP	3	
REGION:Interaction with GATA2	SEQ_UP	1	
REGION:Interaction with GET3/TRC40	SEQ_UP	1	
REGION:Interaction with GGN	SEQ_UP	1	
REGION:Interaction with GGNBP1	SEQ_UP	1	
REGION:Interaction with GIPC	SEQ_UP	1	
REGION:Interaction with GLE1	SEQ_UP	1	
REGION:Interaction with GLIS2 1	SEQ_UP	1	
REGION:Interaction with GLIS2 2	SEQ_UP	1	
REGION:Interaction with GLUT4	SEQ_UP	1	
REGION:Interaction with GMNN	SEQ_UP	1	
REGION:Interaction with GNAO1	SEQ_UP	1	
REGION:Interaction with GNAS	SEQ_UP	1	
REGION:Interaction with GNAS and GNAI1	SEQ_UP	1	
REGION:Interaction with GNB1	SEQ_UP	1	
REGION:Interaction with GNB1, GNB2 and GNB3	SEQ_UP	1	
REGION:Interaction with GOPC	SEQ_UP	2	
REGION:Interaction with GORASP1/GRASP65	SEQ_UP	1	
REGION:Interaction with GORASP2	SEQ_UP	1	
REGION:Interaction with GPHN	SEQ_UP	2	
REGION:Interaction with GPIHBP1	SEQ_UP	1	
REGION:Interaction with GRB2	SEQ_UP	3	
REGION:Interaction with GRB2, ERI3 and SYN1	SEQ_UP	1	
REGION:Interaction with GRB2, GRAP2 and PIK3R1	SEQ_UP	1	
REGION:Interaction with GRIN2A	SEQ_UP	1	
REGION:Interaction with GRK1	SEQ_UP	1	
REGION:Interaction with GSK3B	SEQ_UP	4	
REGION:Interaction with GSK3B and acts as GSK3B inhibitor	SEQ_UP	1	
REGION:Interaction with guide RNA	SEQ_UP	3	
REGION:Interaction with GW182 family members	SEQ_UP	1	
REGION:Interaction with GYS1	SEQ_UP	1	
REGION:Interaction with H1-4	SEQ_UP	1	
REGION:Interaction with H3K4me2	SEQ_UP	1	
REGION:Interaction with HAP1	SEQ_UP	1	
REGION:Interaction with HAX1	SEQ_UP	4	
REGION:Interaction with HCFC1	SEQ_UP	3	
REGION:Interaction with HCK	SEQ_UP	1	
REGION:Interaction with HCN3	SEQ_UP	1	
REGION:Interaction with HD	SEQ_UP	1	
REGION:Interaction with HDAC1	SEQ_UP	2	
REGION:Interaction with HDAC1 and MTA1	SEQ_UP	1	
REGION:Interaction with HDGFL2	SEQ_UP	1	
REGION:Interaction with HERC5	SEQ_UP	1	
REGION:Interaction with HGS	SEQ_UP	2	
REGION:Interaction with HHV-8 ORF57 protein and with ICP27 from HHV-1	SEQ_UP	1	
REGION:Interaction with HIF1A	SEQ_UP	2	
REGION:Interaction with HIP2	SEQ_UP	1	
REGION:Interaction with HIPK1	SEQ_UP	1	
REGION:Interaction with HIPK2	SEQ_UP	6	
REGION:Interaction with HIPK2 and NLK	SEQ_UP	1	
REGION:Interaction with HIPK3	SEQ_UP	2	
REGION:Interaction with histone	SEQ_UP	2	
REGION:Interaction with histone H2B	SEQ_UP	1	
REGION:Interaction with histone H2B and H3	SEQ_UP	1	
REGION:Interaction with histone H3	SEQ_UP	4	
REGION:Interaction with histone H3 and CHAF1B	SEQ_UP	1	
REGION:Interaction with histone H3 that is not methylated at 'Lys-4' (H3K4me0)	SEQ_UP	1	
REGION:Interaction with histone H3, CHAF1B, and HIRA	SEQ_UP	1	
REGION:Interaction with histone H3.3	SEQ_UP	1	
REGION:Interaction with histone H3K4me3	SEQ_UP	1	
REGION:Interaction with histone H4	SEQ_UP	1	
REGION:Interaction with histone H4 N-terminus	SEQ_UP	1	
REGION:Interaction with histones	SEQ_UP	1	
REGION:Interaction with HMGA1	SEQ_UP	1	
REGION:Interaction with HNRNPA1	SEQ_UP	1	
REGION:Interaction with HPS6	SEQ_UP	1	
REGION:Interaction with HRAS, MRAS and RIT1	SEQ_UP	1	
REGION:Interaction with HSF1	SEQ_UP	1	
REGION:Interaction with HSF2BP	SEQ_UP	1	
REGION:Interaction with Hsp70	SEQ_UP	1	
REGION:Interaction with HSP70	SEQ_UP	1	
REGION:Interaction with HSP90AA1	SEQ_UP	1	
REGION:Interaction with HSP90AA1 and HSP90AB1	SEQ_UP	1	
REGION:Interaction with HSP90AB1	SEQ_UP	1	
REGION:Interaction with HSP90B1	SEQ_UP	1	
REGION:Interaction with HSPA5 and localization to the endoplasmic reticulum	SEQ_UP	1	
REGION:Interaction with HSPA8	SEQ_UP	1	
REGION:Interaction with HSPB1	SEQ_UP	1	
REGION:Interaction with HYPK	SEQ_UP	1	
REGION:Interaction with ID2	SEQ_UP	1	
REGION:Interaction with IFFO1	SEQ_UP	1	
REGION:Interaction with IFI204	SEQ_UP	4	
REGION:Interaction with IFT20	SEQ_UP	1	
REGION:Interaction with IGF2R cytoplasmic domain	SEQ_UP	1	
REGION:Interaction with IKBKE	SEQ_UP	1	
REGION:Interaction with IKBKG	SEQ_UP	2	
REGION:Interaction with IKBKG/NEMO	SEQ_UP	1	
REGION:Interaction with IKZF4	SEQ_UP	1	
REGION:Interaction with IL1RAPL1	SEQ_UP	1	
REGION:Interaction with inositol phospholipids	SEQ_UP	1	
REGION:Interaction with INPPL1	SEQ_UP	1	
REGION:Interaction with integrins	SEQ_UP	1	
REGION:Interaction with IQCB1	SEQ_UP	1	
REGION:Interaction with IRF3	SEQ_UP	1	
REGION:Interaction with IRS1	SEQ_UP	1	
REGION:Interaction with isopentenylpyrophosphate transferase	SEQ_UP	1	
REGION:Interaction with IST1	SEQ_UP	4	
REGION:Interaction with ITCH	SEQ_UP	1	
REGION:Interaction with ITGA5	SEQ_UP	1	
REGION:Interaction with ITGB1	SEQ_UP	2	
REGION:Interaction with ITGB1BP1	SEQ_UP	2	
REGION:Interaction with ITPR1	SEQ_UP	2	
REGION:Interaction with ITPR2	SEQ_UP	1	
REGION:Interaction with IWS1	SEQ_UP	1	
REGION:Interaction with JAK2 (low-affinity binding; independent of JAK2 phosphorylation)	SEQ_UP	1	
REGION:Interaction with JARID2 and EPOP	SEQ_UP	1	
REGION:Interaction with JUN	SEQ_UP	1	
REGION:Interaction with JUP and CTNNB1	SEQ_UP	1	
REGION:Interaction with KANK1 and KANK2	SEQ_UP	1	
REGION:Interaction with KAT2B	SEQ_UP	1	
REGION:Interaction with KAT6A	SEQ_UP	2	
REGION:Interaction with KAT6A and KAT6B	SEQ_UP	1	
REGION:Interaction with KAT6B	SEQ_UP	2	
REGION:Interaction with KAT7	SEQ_UP	2	
REGION:Interaction with KAT7/HBO1 and histones	SEQ_UP	2	
REGION:Interaction with KAT8	SEQ_UP	2	
REGION:Interaction with KATNA1	SEQ_UP	1	
REGION:Interaction with KATNA1 and NDEL1	SEQ_UP	1	
REGION:Interaction with KATNB1	SEQ_UP	2	
REGION:Interaction with KBP	SEQ_UP	1	
REGION:Interaction with KCND2	SEQ_UP	4	
REGION:Interaction with KCNE1 C-terminus	SEQ_UP	1	
REGION:Interaction with KCNIP1	SEQ_UP	1	
REGION:Interaction with KCNIP1, KCNIP2, and other family members	SEQ_UP	1	
REGION:Interaction with KCNIP2	SEQ_UP	2	
REGION:Interaction with KCTD3	SEQ_UP	1	
REGION:Interaction with KDM1A	SEQ_UP	1	
REGION:Interaction with KDM1B	SEQ_UP	1	
REGION:Interaction with KDM5B	SEQ_UP	2	
REGION:Interaction with KDM6A	SEQ_UP	1	
REGION:Interaction with KDM8	SEQ_UP	1	
REGION:Interaction with KEAP1	SEQ_UP	2	
REGION:Interaction with keratin proteins	SEQ_UP	1	
REGION:Interaction with KIF21B	SEQ_UP	1	
REGION:Interaction with KIF24	SEQ_UP	1	
REGION:Interaction with KIF5A	SEQ_UP	1	
REGION:Interaction with KIF5B	SEQ_UP	1	
REGION:Interaction with KIF9	SEQ_UP	1	
REGION:Interaction with KLC1	SEQ_UP	1	
REGION:Interaction with KLF7	SEQ_UP	1	
REGION:Interaction with KLHL18	SEQ_UP	1	
REGION:Interaction with KMT2A/MLL1	SEQ_UP	1	
REGION:Interaction with KNDC1	SEQ_UP	1	
REGION:Interaction with KNSTRN	SEQ_UP	1	
REGION:Interaction with KPNA2	SEQ_UP	1	
REGION:Interaction with KRIT1	SEQ_UP	2	
REGION:Interaction with KRT14	SEQ_UP	1	
REGION:Interaction with KRT14 and KRT18	SEQ_UP	1	
REGION:Interaction with KRT18	SEQ_UP	1	
REGION:Interaction with KRT5	SEQ_UP	1	
REGION:Interaction with lamin A/C complexes	SEQ_UP	1	
REGION:Interaction with LAMTOR2 and LAMTOR3	SEQ_UP	1	
REGION:Interaction with LAMTOR5, important for protein stability	SEQ_UP	1	
REGION:Interaction with LANCL1	SEQ_UP	1	
REGION:Interaction with LASP1	SEQ_UP	1	
REGION:Interaction with LAYN	SEQ_UP	1	
REGION:Interaction with LCK	SEQ_UP	1	
REGION:Interaction with LCK and PIK3R1	SEQ_UP	1	
REGION:Interaction with LCK, PLCG2 and PIK3R1	SEQ_UP	1	
REGION:Interaction with LGALS8	SEQ_UP	1	
REGION:Interaction with LGB	SEQ_UP	1	
REGION:Interaction with LIG4	SEQ_UP	1	
REGION:Interaction with LIMD1	SEQ_UP	1	
REGION:Interaction with LIMK	SEQ_UP	1	
REGION:Interaction with LIMS1	SEQ_UP	1	
REGION:Interaction with LIN7C	SEQ_UP	1	
REGION:Interaction with LIPE	SEQ_UP	1	
REGION:Interaction with lipopolysaccharide	SEQ_UP	1	
REGION:Interaction with LIRE1	SEQ_UP	1	
REGION:Interaction with LMNA	SEQ_UP	2	
REGION:Interaction with LMO2	SEQ_UP	1	
REGION:Interaction with LMO4	SEQ_UP	1	
REGION:Interaction with LPAR2 and GRIN2B	SEQ_UP	1	
REGION:Interaction with LPXN	SEQ_UP	1	
REGION:Interaction with LRRFIP1 and LRRFIP2	SEQ_UP	1	
REGION:Interaction with LRWD1	SEQ_UP	1	
REGION:Interaction with LSM14A	SEQ_UP	1	
REGION:Interaction with LSM7 and SNRPG	SEQ_UP	1	
REGION:Interaction with LTF	SEQ_UP	1	
REGION:Interaction with LZTL1	SEQ_UP	1	
REGION:Interaction with m3G-cap structure	SEQ_UP	1	
REGION:Interaction with m6A-containing mRNAs	SEQ_UP	1	
REGION:Interaction with MACF1	SEQ_UP	1	
REGION:Interaction with MAD2L1	SEQ_UP	1	
REGION:Interaction with MAFB	SEQ_UP	1	
REGION:Interaction with MAGEB18	SEQ_UP	1	
REGION:Interaction with MAGEC2	SEQ_UP	1	
REGION:Interaction with MAGEE1	SEQ_UP	1	
REGION:Interaction with MAGI1	SEQ_UP	1	
REGION:Interaction with MAGI1 and PTPN13	SEQ_UP	1	
REGION:Interaction with MAGI2	SEQ_UP	1	
REGION:Interaction with MAP kinases	SEQ_UP	2	
REGION:Interaction with MAP1A	SEQ_UP	1	
REGION:Interaction with MAP3K12	SEQ_UP	1	
REGION:Interaction with MAP3K14/NIK	SEQ_UP	1	
REGION:Interaction with MAP3K2	SEQ_UP	1	
REGION:Interaction with MAP3K2/MAP3K3	SEQ_UP	1	
REGION:Interaction with MAP3K7	SEQ_UP	2	
REGION:Interaction with MAPK1	SEQ_UP	3	
REGION:Interaction with MAPK1 and MAPK3	SEQ_UP	1	
REGION:Interaction with MAPK10	SEQ_UP	1	
REGION:Interaction with MAPK7	SEQ_UP	1	
REGION:Interaction with MAPK8IP1	SEQ_UP	1	
REGION:Interaction with MAPK8IP3/JIP3	SEQ_UP	1	
REGION:Interaction with MAPRE1 and MAPRE3	SEQ_UP	1	
REGION:Interaction with MAPT	SEQ_UP	1	
REGION:Interaction with MARCHF6	SEQ_UP	1	
REGION:Interaction with MAVS	SEQ_UP	1	
REGION:Interaction with MBD1	SEQ_UP	1	
REGION:Interaction with MBL1	SEQ_UP	1	
REGION:Interaction with MBL2	SEQ_UP	1	
REGION:Interaction with MC4R	SEQ_UP	1	
REGION:Interaction with MCC	SEQ_UP	1	
REGION:Interaction with MCF2L and SRC	SEQ_UP	1	
REGION:Interaction with MCM2	SEQ_UP	1	
REGION:Interaction with MCM7	SEQ_UP	1	
REGION:Interaction with MDFIC and MDFI	SEQ_UP	1	
REGION:Interaction with MDM2	SEQ_UP	1	
REGION:Interaction with MEAF6 and ING5	SEQ_UP	1	
REGION:Interaction with MECP2	SEQ_UP	1	
REGION:Interaction with MED1 and CCAR1	SEQ_UP	1	
REGION:Interaction with MEF2	SEQ_UP	1	
REGION:Interaction with MEF2A	SEQ_UP	2	
REGION:Interaction with MEF2C	SEQ_UP	1	
REGION:Interaction with melanocortin receptors	SEQ_UP	1	
REGION:Interaction with membrane phospholipid headgroups	SEQ_UP	1	
REGION:Interaction with membranes containing phosphatidylinositol phosphate	SEQ_UP	1	
REGION:Interaction with MET	SEQ_UP	1	
REGION:Interaction with METTL14	SEQ_UP	1	
REGION:Interaction with METTL3	SEQ_UP	1	
REGION:Interaction with MFAP4	SEQ_UP	2	
REGION:Interaction with MIA3	SEQ_UP	1	
REGION:Interaction with microtubules	SEQ_UP	3	
REGION:Interaction with microtubules, MAPRE1 and MAPRE3	SEQ_UP	2	
REGION:Interaction with microtubules; sufficient for microtubule severing activity	SEQ_UP	1	
REGION:Interaction with MID1	SEQ_UP	1	
REGION:Interaction with MIZF	SEQ_UP	1	
REGION:Interaction with MLH1	SEQ_UP	1	
REGION:Interaction with MLIP	SEQ_UP	1	
REGION:Interaction with MLLT10	SEQ_UP	1	
REGION:Interaction with MLST8	SEQ_UP	1	
REGION:Interaction with monomethylated and dimethylated peptides	SEQ_UP	1	
REGION:Interaction with MORN4	SEQ_UP	1	
REGION:Interaction with MPHOSPH9	SEQ_UP	2	
REGION:Interaction with MPL	SEQ_UP	1	
REGION:Interaction with MREG	SEQ_UP	1	
REGION:Interaction with mRNA	SEQ_UP	1	
REGION:Interaction with MSH2	SEQ_UP	1	
REGION:Interaction with MSH3	SEQ_UP	1	
REGION:Interaction with MSL2	SEQ_UP	1	
REGION:Interaction with MSL3 MRG domain	SEQ_UP	1	
REGION:Interaction with MSX2	SEQ_UP	1	
REGION:Interaction with MTBP	SEQ_UP	1	
REGION:Interaction with MTCH1	SEQ_UP	1	
REGION:Interaction with MTM1	SEQ_UP	1	
REGION:Interaction with MTOR	SEQ_UP	1	
REGION:Interaction with MTOR, MAPKAP1 and RICTOR	SEQ_UP	1	
REGION:Interaction with MTUS2/TIP150	SEQ_UP	1	
REGION:Interaction with MUC20	SEQ_UP	1	
REGION:Interaction with murein	SEQ_UP	2	
REGION:Interaction with MUS81	SEQ_UP	1	
REGION:Interaction with MYB	SEQ_UP	1	
REGION:Interaction with MYC	SEQ_UP	2	
REGION:Interaction with MYLK	SEQ_UP	1	
REGION:Interaction with MYO6	SEQ_UP	1	
REGION:Interaction with NAA15	SEQ_UP	2	
REGION:Interaction with NAE1	SEQ_UP	1	
REGION:Interaction with NANOG	SEQ_UP	1	
REGION:Interaction with NBN	SEQ_UP	3	
REGION:Interaction with NCALD	SEQ_UP	1	
REGION:Interaction with NCBP1/CBP80	SEQ_UP	1	
REGION:Interaction with NCK2 (minor)	SEQ_UP	1	
REGION:Interaction with NCK2 and GRIN3A	SEQ_UP	1	
REGION:Interaction with NCK2 second and third SH3 domain (minor)	SEQ_UP	1	
REGION:Interaction with NCK2 third SH3 domain (major)	SEQ_UP	1	
REGION:Interaction with NCKAP5L	SEQ_UP	1	
REGION:Interaction with NCOA1	SEQ_UP	2	
REGION:Interaction with NCOA1, NCOA2, NCOA3 and KAT2B	SEQ_UP	1	
REGION:Interaction with NCOA2	SEQ_UP	1	
REGION:Interaction with NCOA6	SEQ_UP	1	
REGION:Interaction with NCOR1	SEQ_UP	5	
REGION:Interaction with NCOR1 and NCOR2	SEQ_UP	1	
REGION:Interaction with NCOR2	SEQ_UP	1	
REGION:Interaction with NCOR2 and ATXN1	SEQ_UP	1	
REGION:Interaction with NCS1	SEQ_UP	1	
REGION:Interaction with NDC80 and ZW10	SEQ_UP	1	
REGION:Interaction with NDE1	SEQ_UP	1	
REGION:Interaction with NDEL1	SEQ_UP	2	
REGION:Interaction with NDEL1 and PAFAH1B1	SEQ_UP	1	
REGION:Interaction with NEB	SEQ_UP	2	
REGION:Interaction with NEDD4	SEQ_UP	1	
REGION:Interaction with NEDD4, NEDD4L and WWP2	SEQ_UP	1	
REGION:Interaction with NEDD8	SEQ_UP	1	
REGION:Interaction with Nef	SEQ_UP	1	
REGION:Interaction with NEFL	SEQ_UP	1	
REGION:Interaction with NEK2	SEQ_UP	1	
REGION:Interaction with NEK2 and ZWINT	SEQ_UP	1	
REGION:Interaction with NEK6	SEQ_UP	1	
REGION:Interaction with NEK7	SEQ_UP	1	
REGION:Interaction with NF2	SEQ_UP	3	
REGION:Interaction with NFKB1/p50	SEQ_UP	1	
REGION:Interaction with NFS1	SEQ_UP	1	
REGION:Interaction with NGFR	SEQ_UP	1	
REGION:Interaction with NIF3L1	SEQ_UP	1	
REGION:Interaction with NOS1	SEQ_UP	2	
REGION:Interaction with NOSIP	SEQ_UP	2	
REGION:Interaction with Notch1	SEQ_UP	1	
REGION:Interaction with NOTCH1	SEQ_UP	1	
REGION:Interaction with NOV	SEQ_UP	1	
REGION:Interaction with NOXO1	SEQ_UP	1	
REGION:Interaction with NPAT	SEQ_UP	1	
REGION:Interaction with NPM1	SEQ_UP	2	
REGION:Interaction with NR0B2	SEQ_UP	1	
REGION:Interaction with NR1D1	SEQ_UP	4	
REGION:Interaction with NR1D2	SEQ_UP	1	
REGION:Interaction with NR1F2	SEQ_UP	1	
REGION:Interaction with NR2F6	SEQ_UP	1	
REGION:Interaction with NR3C1	SEQ_UP	3	
REGION:Interaction with NR5A2, PPARG and NR1H3	SEQ_UP	1	
REGION:Interaction with NRIP1	SEQ_UP	1	
REGION:Interaction with NSMCE1	SEQ_UP	1	
REGION:Interaction with NSMCE3	SEQ_UP	1	
REGION:Interaction with NTRK1	SEQ_UP	1	
REGION:Interaction with NTRK2	SEQ_UP	1	
REGION:Interaction with nucleosomes via an acidic patch on histone H2A and histone H2B	SEQ_UP	1	
REGION:Interaction with NUP155	SEQ_UP	1	
REGION:Interaction with NUPL2	SEQ_UP	1	
REGION:Interaction with NXF1	SEQ_UP	1	
REGION:Interaction with O-glycosylated substrate glycoprotein	SEQ_UP	1	
REGION:Interaction with OGT	SEQ_UP	3	
REGION:Interaction with OPTN	SEQ_UP	1	
REGION:Interaction with ORAI1	SEQ_UP	1	
REGION:Interaction with OTX2 and is required for repressor activity	SEQ_UP	1	
REGION:Interaction with P-TEFb	SEQ_UP	2	
REGION:Interaction with p115/USO1	SEQ_UP	1	
REGION:Interaction with p300/EP300	SEQ_UP	1	
REGION:Interaction with p53	SEQ_UP	1	
REGION:Interaction with P53	SEQ_UP	1	
REGION:Interaction with p53/TP53	SEQ_UP	4	
REGION:Interaction with p53/TP53 and MDM2	SEQ_UP	1	
REGION:Interaction with p75NTR/NGFR	SEQ_UP	1	
REGION:Interaction with PAAF1	SEQ_UP	1	
REGION:Interaction with PABPC1	SEQ_UP	2	
REGION:Interaction with PABPC1 and PABC4	SEQ_UP	1	
REGION:Interaction with PAFAH1B1	SEQ_UP	3	
REGION:Interaction with PAGE4	SEQ_UP	1	
REGION:Interaction with PAGR1	SEQ_UP	1	
REGION:Interaction with PAK1	SEQ_UP	1	
REGION:Interaction with PAK4	SEQ_UP	1	
REGION:Interaction with PALB2	SEQ_UP	3	
REGION:Interaction with PALS1	SEQ_UP	1	
REGION:Interaction with PAPOLA	SEQ_UP	1	
REGION:Interaction with PARD3 and CDC42	SEQ_UP	2	
REGION:Interaction with PARD6A	SEQ_UP	1	
REGION:Interaction with PARD6B	SEQ_UP	1	
REGION:Interaction with PARK7	SEQ_UP	1	
REGION:Interaction with PARP1	SEQ_UP	2	
REGION:Interaction with PATL1	SEQ_UP	1	
REGION:Interaction with PAWR	SEQ_UP	1	
REGION:Interaction with PAX3	SEQ_UP	1	
REGION:Interaction with PBX1	SEQ_UP	1	
REGION:Interaction with PCLO	SEQ_UP	1	
REGION:Interaction with PCM1	SEQ_UP	1	
REGION:Interaction with PCNA	SEQ_UP	4	
REGION:Interaction with PCNP	SEQ_UP	1	
REGION:Interaction with PCNT	SEQ_UP	2	
REGION:Interaction with PCNT and AKAP9	SEQ_UP	1	
REGION:Interaction with PDCD6	SEQ_UP	1	
REGION:Interaction with PDCD6IP	SEQ_UP	2	
REGION:Interaction with PDE3B	SEQ_UP	1	
REGION:Interaction with PDE6G	SEQ_UP	2	
REGION:Interaction with PDPK1	SEQ_UP	1	
REGION:Interaction with PDZD3	SEQ_UP	1	
REGION:Interaction with PDZK1	SEQ_UP	1	
REGION:Interaction with PEBP1/RKIP	SEQ_UP	1	
REGION:Interaction with peptide substrate	SEQ_UP	2	
REGION:Interaction with PER2	SEQ_UP	2	
REGION:Interaction with PEX19	SEQ_UP	5	
REGION:Interaction with PEX19, PEX11G and FIS1 and peroxisome targeting	SEQ_UP	1	
REGION:Interaction with PEX7	SEQ_UP	1	
REGION:Interaction with PHC2	SEQ_UP	1	
REGION:Interaction with PHF5A	SEQ_UP	1	
REGION:Interaction with PHF5A, SF3B1 and SF3B5	SEQ_UP	1	
REGION:Interaction with PHLDB2	SEQ_UP	1	
REGION:Interaction with phosphatidylinositol 3,5-bisphosphate	SEQ_UP	1	
REGION:Interaction with phosphoinositide-3 kinase	SEQ_UP	3	
REGION:Interaction with phosphoinositides	SEQ_UP	2	
REGION:Interaction with phospholamban 1	SEQ_UP	1	
REGION:Interaction with phospholamban 2	SEQ_UP	1	
REGION:Interaction with phospholipids	SEQ_UP	1	
REGION:Interaction with PIAS1	SEQ_UP	1	
REGION:Interaction with PICALM	SEQ_UP	1	
REGION:Interaction with PIK3C2B	SEQ_UP	1	
REGION:Interaction with PIK3C3	SEQ_UP	1	
REGION:Interaction with PIK3R1	SEQ_UP	2	
REGION:Interaction with PIK3R6	SEQ_UP	1	
REGION:Interaction with PIM1	SEQ_UP	1	
REGION:Interaction with PIMREG	SEQ_UP	1	
REGION:Interaction with PIN1	SEQ_UP	2	
REGION:Interaction with PIP5K1C	SEQ_UP	1	
REGION:Interaction with PIT-1	SEQ_UP	1	
REGION:Interaction with plakophilin 1 and junction plakoglobin	SEQ_UP	1	
REGION:Interaction with PLCG1	SEQ_UP	2	
REGION:Interaction with PLK1 and TERF2-TERF2IP	SEQ_UP	1	
REGION:Interaction with PLK4	SEQ_UP	2	
REGION:Interaction with PLN	SEQ_UP	2	
REGION:Interaction with PLRG1	SEQ_UP	1	
REGION:Interaction with PLSCR1	SEQ_UP	2	
REGION:Interaction with PML	SEQ_UP	1	
REGION:Interaction with PNPLA2 and ABHD5	SEQ_UP	1	
REGION:Interaction with POLG	SEQ_UP	1	
REGION:Interaction with POLR1F	SEQ_UP	1	
REGION:Interaction with POLR2A	SEQ_UP	5	
REGION:Interaction with POLR2A and PAF1	SEQ_UP	1	
REGION:Interaction with POLR2A; SFRS1; SFRS9 and SFRS10	SEQ_UP	1	
REGION:Interaction with polyubiquitin	SEQ_UP	1	
REGION:Interaction with POT1	SEQ_UP	1	
REGION:Interaction with POU4F1	SEQ_UP	1	
REGION:Interaction with POU5F1	SEQ_UP	1	
REGION:Interaction with PP1	SEQ_UP	1	
REGION:Interaction with PPARG	SEQ_UP	3	
REGION:Interaction with PPARGC1A and THRA	SEQ_UP	1	
REGION:Interaction with PPIA/CYPA	SEQ_UP	1	
REGION:Interaction with PPIB	SEQ_UP	3	
REGION:Interaction with PPIF	SEQ_UP	1	
REGION:Interaction with PPIL1	SEQ_UP	1	
REGION:Interaction with PPP1C	SEQ_UP	1	
REGION:Interaction with PPP1CA	SEQ_UP	1	
REGION:Interaction with PPP1CC isoform gamma-2	SEQ_UP	1	
REGION:Interaction with PPP1R12A	SEQ_UP	2	
REGION:Interaction with PPP1R12A, PPP1R12B and PPP1R12C	SEQ_UP	1	
REGION:Interaction with PPP1R15A	SEQ_UP	3	
REGION:Interaction with PPP1R16B	SEQ_UP	1	
REGION:Interaction with PPP1R8	SEQ_UP	2	
REGION:Interaction with PPP1R9B	SEQ_UP	1	
REGION:Interaction with PPP2CA	SEQ_UP	3	
REGION:Interaction with PPP5C	SEQ_UP	1	
REGION:Interaction with PPP6C	SEQ_UP	1	
REGION:Interaction with PRDM14	SEQ_UP	1	
REGION:Interaction with pre-mRNA branch site	SEQ_UP	1	
REGION:Interaction with PRKAA1	SEQ_UP	1	
REGION:Interaction with PRKAR1A, PRKAR2A and PRKAR2B	SEQ_UP	1	
REGION:Interaction with PRKCI and PRKCZ	SEQ_UP	3	
REGION:Interaction with PRKCZ	SEQ_UP	1	
REGION:Interaction with PRKCZ and dimerization	SEQ_UP	1	
REGION:Interaction with PRKG1	SEQ_UP	1	
REGION:Interaction with PRKN	SEQ_UP	1	
REGION:Interaction with PRMT1	SEQ_UP	2	
REGION:Interaction with protein phosphatase 1	SEQ_UP	2	
REGION:Interaction with PSCD3	SEQ_UP	1	
REGION:Interaction with PSEN1	SEQ_UP	2	
REGION:Interaction with PSMC2 and SMC1A	SEQ_UP	1	
REGION:Interaction with PSME3	SEQ_UP	1	
REGION:Interaction with PTBP1	SEQ_UP	1	
REGION:Interaction with PtdIns(4,5)P2-containing membranes	SEQ_UP	1	
REGION:Interaction with PTEN	SEQ_UP	2	
REGION:Interaction with PTK2, PXN and LYN	SEQ_UP	1	
REGION:Interaction with PTK2/FAK1	SEQ_UP	2	
REGION:Interaction with PTK2/FAK1; required for regulation of axonal branching and synapse formation	SEQ_UP	1	
REGION:Interaction with PTK2B/PYK2	SEQ_UP	1	
REGION:Interaction with PTP4A1	SEQ_UP	1	
REGION:Interaction with PTPN11	SEQ_UP	1	
REGION:Interaction with PTPN13/PTPL1	SEQ_UP	1	
REGION:Interaction with PTPN22	SEQ_UP	1	
REGION:Interaction with PTPN23	SEQ_UP	1	
REGION:Interaction with PTPRH	SEQ_UP	1	
REGION:Interaction with PxIxIF motif in substrate	SEQ_UP	1	
REGION:Interaction with PXN	SEQ_UP	1	
REGION:Interaction with PXN and TGFB1I1	SEQ_UP	1	
REGION:Interaction with PYGO1	SEQ_UP	1	
REGION:Interaction with PYHIN1 and necessary for interaction with RFFL and RNF34	SEQ_UP	1	
REGION:Interaction with RAB11A and RAB11B	SEQ_UP	1	
REGION:Interaction with RAB1B	SEQ_UP	1	
REGION:Interaction with RAB27A	SEQ_UP	1	
REGION:Interaction with RAB32	SEQ_UP	1	
REGION:Interaction with RAB38	SEQ_UP	1	
REGION:Interaction with RAB4	SEQ_UP	1	
REGION:Interaction with RAB4A	SEQ_UP	1	
REGION:Interaction with RAB5B	SEQ_UP	2	
REGION:Interaction with RAB6A	SEQ_UP	2	
REGION:Interaction with Rab7	SEQ_UP	1	
REGION:Interaction with RAB7A	SEQ_UP	2	
REGION:Interaction with Rab8	SEQ_UP	1	
REGION:Interaction with Rab9	SEQ_UP	1	
REGION:Interaction with RAC1	SEQ_UP	4	
REGION:Interaction with RACGAP1	SEQ_UP	1	
REGION:Interaction with RAD17	SEQ_UP	1	
REGION:Interaction with RAD23B	SEQ_UP	1	
REGION:Interaction with RAD51	SEQ_UP	5	
REGION:Interaction with RAD51 and BRCA2	SEQ_UP	1	
REGION:Interaction with RAD51, BRCA2 and POLH	SEQ_UP	1	
REGION:Interaction with RAD51B, RAD51D and XRCC3	SEQ_UP	1	
REGION:Interaction with RAD51C	SEQ_UP	2	
REGION:Interaction with RAD52, TIPIN, UNG and XPA	SEQ_UP	1	
REGION:Interaction with RAF1	SEQ_UP	1	
REGION:Interaction with RALBP1	SEQ_UP	2	
REGION:Interaction with RAN	SEQ_UP	1	
REGION:Interaction with RANBP1	SEQ_UP	1	
REGION:Interaction with RANBP2	SEQ_UP	1	
REGION:Interaction with RANBP9	SEQ_UP	5	
REGION:Interaction with RAP1B	SEQ_UP	1	
REGION:Interaction with RAP2A	SEQ_UP	1	
REGION:Interaction with RAPGEF3	SEQ_UP	1	
REGION:Interaction with RARA	SEQ_UP	1	
REGION:Interaction with RASGRF2	SEQ_UP	1	
REGION:Interaction with RASSF9	SEQ_UP	1	
REGION:Interaction with RB1	SEQ_UP	5	
REGION:Interaction with RB1-1	SEQ_UP	1	
REGION:Interaction with RB1-2	SEQ_UP	1	
REGION:Interaction with RBBP4	SEQ_UP	1	
REGION:Interaction with RBBP5	SEQ_UP	1	
REGION:Interaction with RBBP8/CtIP	SEQ_UP	1	
REGION:Interaction with RBCK1	SEQ_UP	1	
REGION:Interaction with RBL1 and RBL2	SEQ_UP	1	
REGION:Interaction with RBM14	SEQ_UP	1	
REGION:Interaction with RBP1	SEQ_UP	1	
REGION:Interaction with RBPJ	SEQ_UP	1	
REGION:Interaction with RBPJ/RBPSUH	SEQ_UP	1	
REGION:Interaction with RBPSUH	SEQ_UP	1	
REGION:Interaction with RCCD1	SEQ_UP	1	
REGION:Interaction with RCOR1	SEQ_UP	1	
REGION:Interaction with RCVRN	SEQ_UP	1	
REGION:Interaction with RELA	SEQ_UP	2	
REGION:Interaction with RELA and NFKB1	SEQ_UP	1	
REGION:Interaction with RELT	SEQ_UP	1	
REGION:Interaction with REST	SEQ_UP	2	
REGION:Interaction with RET	SEQ_UP	1	
REGION:Interaction with RGS2	SEQ_UP	1	
REGION:Interaction with Rho	SEQ_UP	1	
REGION:Interaction with RHO	SEQ_UP	2	
REGION:Interaction with Rho/Rac	SEQ_UP	1	
REGION:Interaction with RHOA	SEQ_UP	2	
REGION:Interaction with RHOD and RAB5A	SEQ_UP	1	
REGION:Interaction with RhoG	SEQ_UP	1	
REGION:Interaction with RHPN1	SEQ_UP	1	
REGION:Interaction with RICTOR	SEQ_UP	1	
REGION:Interaction with RINT1	SEQ_UP	1	
REGION:Interaction with RIPK1	SEQ_UP	1	
REGION:Interaction with RLIM	SEQ_UP	1	
REGION:Interaction with RNA	SEQ_UP	4	
REGION:Interaction with RNA polymerase II	SEQ_UP	1	
REGION:Interaction with RND2	SEQ_UP	1	
REGION:Interaction with RNF111	SEQ_UP	1	
REGION:Interaction with RNF19A	SEQ_UP	1	
REGION:Interaction with RNF31	SEQ_UP	1	
REGION:Interaction with RNMT	SEQ_UP	1	
REGION:Interaction with ROCK1	SEQ_UP	2	
REGION:Interaction with ROCK2	SEQ_UP	1	
REGION:Interaction with RORA	SEQ_UP	1	
REGION:Interaction with RORG	SEQ_UP	1	
REGION:Interaction with RP9	SEQ_UP	1	
REGION:Interaction with RPA1	SEQ_UP	1	
REGION:Interaction with RPA194	SEQ_UP	1	
REGION:Interaction with RPGR	SEQ_UP	1	
REGION:Interaction with RPL5	SEQ_UP	1	
REGION:Interaction with RPLP0	SEQ_UP	1	
REGION:Interaction with RPO2TC1	SEQ_UP	1	
REGION:Interaction with RSN and localization to the Golgi and kinetochores	SEQ_UP	1	
REGION:Interaction with RTN3	SEQ_UP	1	
REGION:Interaction with RTN4R and RTN4RL2	SEQ_UP	1	
REGION:Interaction with RUNX1	SEQ_UP	1	
REGION:Interaction with RUNX1 and RUNX2	SEQ_UP	1	
REGION:Interaction with RUNX1-1	SEQ_UP	1	
REGION:Interaction with RUNX1-2	SEQ_UP	1	
REGION:Interaction with S100A10	SEQ_UP	2	
REGION:Interaction with S100A6	SEQ_UP	1	
REGION:Interaction with S100B	SEQ_UP	1	
REGION:Interaction with SACM1L	SEQ_UP	1	
REGION:Interaction with SAFB1	SEQ_UP	2	
REGION:Interaction with SAFB2	SEQ_UP	1	
REGION:Interaction with SAG	SEQ_UP	1	
REGION:Interaction with SAP18 and ACIN1	SEQ_UP	1	
REGION:Interaction with SAP30	SEQ_UP	1	
REGION:Interaction with SAV1 and STK3/MST2	SEQ_UP	1	
REGION:Interaction with SCFD1	SEQ_UP	1	
REGION:Interaction with SCIMP	SEQ_UP	1	
REGION:Interaction with SCRIB	SEQ_UP	2	
REGION:Interaction with SCYL3	SEQ_UP	1	
REGION:Interaction with SDCBP	SEQ_UP	1	
REGION:Interaction with SDHAF1	SEQ_UP	1	
REGION:Interaction with SDHB	SEQ_UP	1	
REGION:Interaction with SEC13	SEQ_UP	1	
REGION:Interaction with Sec23	SEQ_UP	1	
REGION:Interaction with SEC23A	SEQ_UP	1	
REGION:Interaction with SEL1L	SEQ_UP	1	
REGION:Interaction with SEM1	SEQ_UP	1	
REGION:Interaction with SEMG1	SEQ_UP	1	
REGION:Interaction with SEPTIN12	SEQ_UP	1	
REGION:Interaction with SERF1A	SEQ_UP	1	
REGION:Interaction with SETDB1	SEQ_UP	1	
REGION:Interaction with SF3B1	SEQ_UP	1	
REGION:Interaction with SF3B1 and SF3B3	SEQ_UP	1	
REGION:Interaction with SF3B1 AND SF3B3	SEQ_UP	1	
REGION:Interaction with SF3B1 and SF3B5	SEQ_UP	1	
REGION:Interaction with SF3B3	SEQ_UP	1	
REGION:Interaction with SF3B3 and SF3B5	SEQ_UP	1	
REGION:Interaction with SF3B5	SEQ_UP	1	
REGION:Interaction with SH3 domains	SEQ_UP	1	
REGION:Interaction with SH3GL1 or SH3GL3	SEQ_UP	1	
REGION:Interaction with SH3GL2	SEQ_UP	1	
REGION:Interaction with SH3KBP1	SEQ_UP	1	
REGION:Interaction with SHANK1	SEQ_UP	1	
REGION:Interaction with SHANK2	SEQ_UP	1	
REGION:Interaction with SHH zinc binding site	SEQ_UP	1	
REGION:Interaction with SIAH1	SEQ_UP	2	
REGION:Interaction with SIN3A	SEQ_UP	5	
REGION:Interaction with SIN3A and SIN3B	SEQ_UP	3	
REGION:Interaction with SIN3A/B	SEQ_UP	2	
REGION:Interaction with SIN3B	SEQ_UP	1	
REGION:Interaction with SIRT1	SEQ_UP	2	
REGION:Interaction with SIRT2	SEQ_UP	1	
REGION:Interaction with SIX6 and HDAC3	SEQ_UP	1	
REGION:Interaction with SKI and SMAD1	SEQ_UP	1	
REGION:Interaction with SKIP	SEQ_UP	1	
REGION:Interaction with SKP1	SEQ_UP	1	
REGION:Interaction with SLC11A2	SEQ_UP	1	
REGION:Interaction with SLC26A8	SEQ_UP	1	
REGION:Interaction with SLC9A3R1	SEQ_UP	1	
REGION:Interaction with SLC9A7	SEQ_UP	1	
REGION:Interaction with SLFN12	SEQ_UP	1	
REGION:Interaction with SLX1	SEQ_UP	1	
REGION:Interaction with SMAD1, SMAD2, SMAD3 and SMAD5	SEQ_UP	1	
REGION:Interaction with SMAD7	SEQ_UP	1	
REGION:Interaction with SMARCA5	SEQ_UP	1	
REGION:Interaction with SMARCB1	SEQ_UP	1	
REGION:Interaction with SMARCC1 and SMARCC2	SEQ_UP	1	
REGION:Interaction with SMC1A	SEQ_UP	1	
REGION:Interaction with SMC2 and SMC4	SEQ_UP	1	
REGION:Interaction with SMN	SEQ_UP	1	
REGION:Interaction with SMO	SEQ_UP	2	
REGION:Interaction with SMURF1	SEQ_UP	1	
REGION:Interaction with SNAP25	SEQ_UP	1	
REGION:Interaction with SNAP25 and TRAK2	SEQ_UP	1	
REGION:Interaction with SNAPIN	SEQ_UP	2	
REGION:Interaction with SNX1	SEQ_UP	1	
REGION:Interaction with SNX17	SEQ_UP	1	
REGION:Interaction with SNX3	SEQ_UP	1	
REGION:Interaction with SOCS2	SEQ_UP	1	
REGION:Interaction with SORBS2, SPIN90 and SRC	SEQ_UP	1	
REGION:Interaction with SORBS2, SPIN90, SRC and PFN1	SEQ_UP	1	
REGION:Interaction with SOX13	SEQ_UP	1	
REGION:Interaction with SOX9	SEQ_UP	1	
REGION:Interaction with SP1 and SP3	SEQ_UP	1	
REGION:Interaction with SPAG5	SEQ_UP	1	
REGION:Interaction with SPAST	SEQ_UP	2	
REGION:Interaction with SPOP	SEQ_UP	1	
REGION:Interaction with SPP1	SEQ_UP	1	
REGION:Interaction with SPTBN1	SEQ_UP	1	
REGION:Interaction with SQSTM1	SEQ_UP	4	
REGION:Interaction with SRC	SEQ_UP	1	
REGION:Interaction with SRCAP	SEQ_UP	1	
REGION:Interaction with SREBF1	SEQ_UP	2	
REGION:Interaction with SREBF2	SEQ_UP	1	
REGION:Interaction with SRFBP1	SEQ_UP	1	
REGION:Interaction with ss-DNA	SEQ_UP	1	
REGION:Interaction with ssDNA	SEQ_UP	1	
REGION:Interaction with STAC2	SEQ_UP	1	
REGION:Interaction with STAG1	SEQ_UP	1	
REGION:Interaction with STAM	SEQ_UP	1	
REGION:Interaction with STAM1	SEQ_UP	1	
REGION:Interaction with STAMBP	SEQ_UP	1	
REGION:Interaction with STAT2	SEQ_UP	1	
REGION:Interaction with STAT3	SEQ_UP	2	
REGION:Interaction with STIL	SEQ_UP	1	
REGION:Interaction with STIM1	SEQ_UP	1	
REGION:Interaction with STK11/LKB1	SEQ_UP	1	
REGION:Interaction with STX5	SEQ_UP	1	
REGION:Interaction with substrate RNA	SEQ_UP	1	
REGION:Interaction with substrate tRNA	SEQ_UP	1	
REGION:Interaction with SUDS3 and HDAC1	SEQ_UP	1	
REGION:Interaction with SUFU	SEQ_UP	1	
REGION:Interaction with sulfatases	SEQ_UP	1	
REGION:interaction with SUMO	SEQ_UP	1	
REGION:Interaction with SUMO	SEQ_UP	1	
REGION:Interaction with SUMO1	SEQ_UP	3	
REGION:Interaction with SUMO2 1	SEQ_UP	1	
REGION:Interaction with SUMO2 2	SEQ_UP	1	
REGION:Interaction with sumoylated RANGAP1	SEQ_UP	1	
REGION:Interaction with SUPT4H1 and SUPT4H2	SEQ_UP	1	
REGION:Interaction with SUPT5H	SEQ_UP	2	
REGION:Interaction with SUPT6H	SEQ_UP	2	
REGION:Interaction with SUPT6H and ALYREF	SEQ_UP	1	
REGION:Interaction with SUV39H1 and probably MAPK9 and SMAD3	SEQ_UP	1	
REGION:Interaction with SUZ12	SEQ_UP	3	
REGION:Interaction with SYNE3	SEQ_UP	1	
REGION:Interaction with SYNM	SEQ_UP	2	
REGION:Interaction with SYT1	SEQ_UP	2	
REGION:Interaction with SYVN1	SEQ_UP	1	
REGION:Interaction with TAB2	SEQ_UP	1	
REGION:Interaction with TACC1	SEQ_UP	1	
REGION:Interaction with TACC3	SEQ_UP	2	
REGION:Interaction with TAF4B	SEQ_UP	1	
REGION:Interaction with TANK	SEQ_UP	2	
REGION:Interaction with target base in tRNA	SEQ_UP	1	
REGION:Interaction with target DNA	SEQ_UP	4	
REGION:Interaction with target proteins	SEQ_UP	1	
REGION:Interaction with TAX1BP1	SEQ_UP	1	
REGION:Interaction with TBC1D15	SEQ_UP	1	
REGION:Interaction with TBK1 and IKBKE	SEQ_UP	3	
REGION:Interaction with TBL1XR1	SEQ_UP	1	
REGION:Interaction with TBP	SEQ_UP	1	
REGION:Interaction with TBP and NR5A1	SEQ_UP	1	
REGION:Interaction with TBX21	SEQ_UP	1	
REGION:Interaction with TCAP	SEQ_UP	1	
REGION:Interaction with TCF3	SEQ_UP	1	
REGION:Interaction with TDRD7	SEQ_UP	2	
REGION:Interaction with TEPSIN	SEQ_UP	1	
REGION:Interaction with TERF1	SEQ_UP	1	
REGION:Interaction with TERF2IP	SEQ_UP	1	
REGION:Interaction with TESC	SEQ_UP	1	
REGION:Interaction with TGF-beta ligand	SEQ_UP	1	
REGION:Interaction with TGFA	SEQ_UP	1	
REGION:Interaction with TGFB1	SEQ_UP	1	
REGION:Interaction with TGFB1I1	SEQ_UP	5	
REGION:Interaction with TGFBR1	SEQ_UP	1	
REGION:Interaction with TGN38	SEQ_UP	1	
REGION:Interaction with THBS4	SEQ_UP	1	
REGION:Interaction with the 5'-triphosphate group of PPP-RNA	SEQ_UP	1	
REGION:Interaction with the C-terminus of CDCA1 and the SPBC24-SPBC25 subcomplex	SEQ_UP	1	
REGION:Interaction with the C-terminus of NDC80 and the SPBC24-SPBC25 subcomplex	SEQ_UP	1	
REGION:Interaction with the C-terminus of SPBC24	SEQ_UP	1	
REGION:Interaction with the C-terminus of SPBC25	SEQ_UP	1	
REGION:Interaction with the C2HC RNF-type zinc finger	SEQ_UP	1	
REGION:Interaction with the CCR4-NOT complex	SEQ_UP	1	
REGION:Interaction with the cholesterol-anchor of SHH	SEQ_UP	1	
REGION:Interaction with the consensus sequence C-X-S-X-[PA]-C in peptide substrates	SEQ_UP	1	
REGION:Interaction with the CYBA-CYBB complex	SEQ_UP	1	
REGION:Interaction with the Elongin BC complex	SEQ_UP	1	
REGION:Interaction with the F-box domain of F-box proteins	SEQ_UP	1	
REGION:Interaction with the H2A.Z/H2AZ1	SEQ_UP	1	
REGION:Interaction with the K-D-E-L motif on target proteins	SEQ_UP	3	
REGION:Interaction with the major vault protein	SEQ_UP	1	
REGION:Interaction with the Mediator complex	SEQ_UP	2	
REGION:Interaction with the Mediator complex and THRA	SEQ_UP	1	
REGION:Interaction with the MRN complex	SEQ_UP	1	
REGION:Interaction with the N-terminus of CDCA1	SEQ_UP	1	
REGION:Interaction with the N-terminus of NDC80	SEQ_UP	1	
REGION:Interaction with the N-terminus of SPBC24	SEQ_UP	1	
REGION:Interaction with the N-terminus of SPBC25	SEQ_UP	1	
REGION:Interaction with the NDC80-CDCA1 subcomplex	SEQ_UP	1	
REGION:Interaction with the NDC80-NUF2 subcomplex	SEQ_UP	1	
REGION:Interaction with the poly-A tract of mRNA	SEQ_UP	1	
REGION:Interaction with the PRC2/EED-EZH2 complex	SEQ_UP	3	
REGION:Interaction with the RING-type zinc finger	SEQ_UP	1	
REGION:Interaction with the SMAD1/SMAD4 complex	SEQ_UP	1	
REGION:Interaction with the SNARE complex	SEQ_UP	2	
REGION:Interaction with THOC5	SEQ_UP	1	
REGION:Interaction with THOC7	SEQ_UP	1	
REGION:Interaction with THRA	SEQ_UP	1	
REGION:Interaction with THRAP3	SEQ_UP	1	
REGION:Interaction with TIMELESS	SEQ_UP	2	
REGION:Interaction with TIMP2	SEQ_UP	1	
REGION:Interaction with TJP1/ZO1	SEQ_UP	1	
REGION:Interaction with TLE5	SEQ_UP	1	
REGION:Interaction with TLN1	SEQ_UP	1	
REGION:Interaction with TLN1 and VCL	SEQ_UP	1	
REGION:Interaction with TLR4	SEQ_UP	1	
REGION:Interaction with TMEM182	SEQ_UP	1	
REGION:Interaction with TMEM64 and PDIA3	SEQ_UP	1	
REGION:Interaction with TMSB4X	SEQ_UP	1	
REGION:Interaction with TNC and TNR	SEQ_UP	1	
REGION:Interaction with TNFRSF1A	SEQ_UP	1	
REGION:Interaction with TNFRSF1B	SEQ_UP	1	
REGION:Interaction with TNIP1	SEQ_UP	1	
REGION:Interaction with TNPO3	SEQ_UP	2	
REGION:Interaction with TOP1	SEQ_UP	1	
REGION:Interaction with TOR1A	SEQ_UP	3	
REGION:Interaction with TOX4	SEQ_UP	1	
REGION:Interaction with TP53	SEQ_UP	7	
REGION:Interaction with TP53 and TP73	SEQ_UP	1	
REGION:Interaction with TP53BP1	SEQ_UP	1	
REGION:Interaction with TP73	SEQ_UP	1	
REGION:Interaction with TRADD	SEQ_UP	1	
REGION:Interaction with TRAF1 and TRAF2	SEQ_UP	1	
REGION:Interaction with TRAF2	SEQ_UP	2	
REGION:Interaction with TRAF3IP1	SEQ_UP	1	
REGION:Interaction with TRAF5	SEQ_UP	1	
REGION:Interaction with TRAF6	SEQ_UP	3	
REGION:Interaction with TRAF6 1	SEQ_UP	1	
REGION:Interaction with TRAF6 2	SEQ_UP	1	
REGION:Interaction with TRIB1	SEQ_UP	1	
REGION:Interaction with TRIB3	SEQ_UP	1	
REGION:Interaction with TRIM3	SEQ_UP	1	
REGION:Interaction with TRIM39	SEQ_UP	1	
REGION:Interaction with trimethylated histone H3 (H3K4)	SEQ_UP	1	
REGION:Interaction with TRIP	SEQ_UP	1	
REGION:Interaction with tRNA	SEQ_UP	4	
REGION:Interaction with tropomyosin alpha	SEQ_UP	1	
REGION:Interaction with TRPC proteins	SEQ_UP	1	
REGION:Interaction with TSG101	SEQ_UP	2	
REGION:Interaction with TSG101, VPS37B and VPS28	SEQ_UP	1	
REGION:Interaction with TSGA10	SEQ_UP	1	
REGION:Interaction with TSPYL5	SEQ_UP	1	
REGION:Interaction with TTN	SEQ_UP	3	
REGION:Interaction with TUBA1A	SEQ_UP	1	
REGION:Interaction with tubulin	SEQ_UP	2	
REGION:Interaction with Type I keratins and keratin filaments	SEQ_UP	1	
REGION:Interaction with U4 snRNA	SEQ_UP	1	
REGION:Interaction with U4 snRNA and U4atac snRNA	SEQ_UP	1	
REGION:Interaction with UBA3	SEQ_UP	3	
REGION:Interaction with UBE1C	SEQ_UP	1	
REGION:Interaction with UBE2C	SEQ_UP	1	
REGION:Interaction with UBE2I	SEQ_UP	3	
REGION:Interaction with UBE2I/UBC9	SEQ_UP	1	
REGION:Interaction with UBE2L3	SEQ_UP	1	
REGION:Interaction with UBE2M core domain	SEQ_UP	1	
REGION:Interaction with UBE2M N-terminus	SEQ_UP	1	
REGION:Interaction with ubiquitin	SEQ_UP	4	
REGION:Interaction with ubiquitin. Crossover loop which restricts access of large ubiquitin adducts to the active site	SEQ_UP	1	
REGION:Interaction with ubiquitinated proteins	SEQ_UP	1	
REGION:Interaction with UBL1	SEQ_UP	1	
REGION:Interaction with UBQLN1	SEQ_UP	4	
REGION:Interaction with UBQLN2	SEQ_UP	1	
REGION:Interaction with UBQLN4	SEQ_UP	1	
REGION:Interaction with UBXN4	SEQ_UP	1	
REGION:Interaction with UBXN6	SEQ_UP	1	
REGION:Interaction with UCHL5	SEQ_UP	1	
REGION:Interaction with UNC13D	SEQ_UP	1	
REGION:Interaction with UNC13D and DYNLT1	SEQ_UP	1	
REGION:Interaction with UPF1	SEQ_UP	1	
REGION:Interaction with USP21	SEQ_UP	1	
REGION:Interaction with USP7	SEQ_UP	3	
REGION:Interaction with USP8	SEQ_UP	1	
REGION:Interaction with UVRAG	SEQ_UP	2	
REGION:Interaction with VAPA	SEQ_UP	1	
REGION:Interaction with VAPA and VAPB	SEQ_UP	1	
REGION:Interaction with VASP	SEQ_UP	2	
REGION:Interaction with VAV1	SEQ_UP	1	
REGION:Interaction with VAV2	SEQ_UP	1	
REGION:Interaction with VCL	SEQ_UP	2	
REGION:Interaction with VCL and F-actin	SEQ_UP	1	
REGION:Interaction with VDAC2	SEQ_UP	1	
REGION:Interaction with VDR	SEQ_UP	1	
REGION:Interaction with VHL	SEQ_UP	1	
REGION:Interaction with VP16	SEQ_UP	1	
REGION:Interaction with VPS33A	SEQ_UP	1	
REGION:Interaction with VPS35	SEQ_UP	1	
REGION:Interaction with VPS4A	SEQ_UP	1	
REGION:Interaction with VPS4A, MITD1 and STAMBP	SEQ_UP	2	
REGION:Interaction with VPS4B	SEQ_UP	4	
REGION:Interaction with VRK2	SEQ_UP	1	
REGION:Interaction with VTA1	SEQ_UP	3	
REGION:Interaction with VTI1B	SEQ_UP	1	
REGION:Interaction with WAPL and PDS5B	SEQ_UP	1	
REGION:Interaction with WARS1	SEQ_UP	1	
REGION:Interaction with WAS	SEQ_UP	1	
REGION:Interaction with WDR5	SEQ_UP	1	
REGION:Interaction with WDR74	SEQ_UP	1	
REGION:Interaction with WDR82	SEQ_UP	1	
REGION:Interaction with Wnt proteins	SEQ_UP	1	
REGION:Interaction with WRNIP1	SEQ_UP	1	
REGION:Interaction with WWOX	SEQ_UP	1	
REGION:Interaction with WWP1	SEQ_UP	2	
REGION:Interaction with XRCC2	SEQ_UP	1	
REGION:Interaction with YAP1	SEQ_UP	2	
REGION:Interaction with YEATS4	SEQ_UP	1	
REGION:Interaction with YES1, SRC and FYN	SEQ_UP	1	
REGION:Interaction with YWHAB	SEQ_UP	2	
REGION:Interaction with YWHAE	SEQ_UP	1	
REGION:Interaction with YWHAG	SEQ_UP	1	
REGION:Interaction with YWHAH	SEQ_UP	1	
REGION:Interaction with Z-DNA	SEQ_UP	1	
REGION:Interaction with ZAP70	SEQ_UP	1	
REGION:Interaction with ZBTB16	SEQ_UP	1	
REGION:Interaction with ZBTB17	SEQ_UP	1	
REGION:Interaction with ZBTB33	SEQ_UP	1	
REGION:Interaction with ZBTB33 and HEXIM1	SEQ_UP	1	
REGION:Interaction with ZBTB43	SEQ_UP	1	
REGION:Interaction with ZBTB7A	SEQ_UP	1	
REGION:Interaction with ZC3HAV1	SEQ_UP	1	
REGION:Interaction with ZDHHC17	SEQ_UP	2	
REGION:Interaction with ZFP36	SEQ_UP	1	
REGION:Interaction with ZFP90	SEQ_UP	1	
REGION:Interaction with ZFP91	SEQ_UP	1	
REGION:Interaction with ZFPM2	SEQ_UP	1	
REGION:Interaction with ZHX2	SEQ_UP	1	
REGION:Interaction with ZIC2	SEQ_UP	1	
REGION:Interaction with ZIK1	SEQ_UP	1	
REGION:Interaction with ZMYND11	SEQ_UP	1	
REGION:Interaction with ZNF106	SEQ_UP	1	
REGION:Interaction with ZNF224	SEQ_UP	1	
REGION:Interaction with ZNF289/ARFGAP2	SEQ_UP	1	
REGION:Interaction with ZNF296	SEQ_UP	1	
REGION:Interaction with ZNF318	SEQ_UP	1	
REGION:Interaction with ZNF366	SEQ_UP	1	
REGION:Interaction with ZNF42	SEQ_UP	1	
REGION:Interaction with ZNHIT1	SEQ_UP	1	
REGION:Interaction with ZWINT	SEQ_UP	1	
REGION:Interaction with ZYX	SEQ_UP	1	
REGION:Interactions with ADPRT/PARP1 and NCL	SEQ_UP	1	
REGION:Interactions with CD4 and CD8	SEQ_UP	1	
REGION:Interactions with CSTF3 and SYMPK	SEQ_UP	1	
REGION:Interactions with DUSP26, MAPK1 and MAPK2	SEQ_UP	1	
REGION:Interactions with HDAC1 and ARID4B	SEQ_UP	1	
REGION:Interactions with HOMER1 and NF2	SEQ_UP	1	
REGION:Interactions with ITPR1	SEQ_UP	1	
REGION:Interactions with LRPAP1 and NGFB	SEQ_UP	1	
REGION:Interactions with NFKBIA and NFKBIB	SEQ_UP	1	
REGION:Interactions with RUVBL1 and RUVBL2	SEQ_UP	1	
REGION:Interactions with SIN3A and HDAC1	SEQ_UP	1	
REGION:Interactions with SUDS3 and SAP130	SEQ_UP	1	
REGION:Interactions with TJP1, TJP2 and TJP3	SEQ_UP	7	
REGION:Interactions with TJP1, TJP2, TJP3 and PATJ	SEQ_UP	1	
REGION:Interactions with ZNF403/GGNBP2 and OAZ3	SEQ_UP	1	
REGION:Interacts with BAG6	SEQ_UP	1	
REGION:Interacts with BFSP2 and VIM	SEQ_UP	1	
REGION:Interacts with DUSP and ubiquitin-like 1 domains and is required for USP4 activation	SEQ_UP	1	
REGION:Interacts with DYNLL1 AND DYNLL2	SEQ_UP	1	
REGION:Interacts with hydroxy-aryl-aldehyde inhibitors	SEQ_UP	1	
REGION:Interacts with PRIM1	SEQ_UP	1	
REGION:Interacts with SPRY1, SPRY2, and SPRY4	SEQ_UP	1	
REGION:Interacts with SPRY1, SPRY2, SPRY3 and SPRY4	SEQ_UP	1	
REGION:Interacts with target acceptor peptide in protein substrate	SEQ_UP	2	
REGION:Interacts with WDR41 within the C9orf72-SMCR8 complex	SEQ_UP	1	
REGION:Interdomain A	SEQ_UP	2	
REGION:Interdomain B	SEQ_UP	2	
REGION:Interdomain linker	SEQ_UP	5	
REGION:Interferon-stimulated-response-element binding region	SEQ_UP	1	
REGION:Intermediate	SEQ_UP	1	
REGION:Intermediate domain	SEQ_UP	1	
REGION:Internal hydrophobic patch (IHP)	SEQ_UP	1	
REGION:Internal MTS-like signal	SEQ_UP	1	
REGION:Interphase loop	SEQ_UP	1	
REGION:Interpropeller linker	SEQ_UP	1	
REGION:Interrupted collagenous region	SEQ_UP	2	
REGION:Intersubunit contact	SEQ_UP	1	
REGION:Intervening spacer sequence 1	SEQ_UP	1	
REGION:Intervening spacer sequence 2	SEQ_UP	1	
REGION:Intracellular loop 1 (IL1)	SEQ_UP	1	
REGION:Intracellular loop 2 (IL2)	SEQ_UP	1	
REGION:Intrachain binding of the propeptide and the extracellular domain	SEQ_UP	1	
REGION:Intradomain insert; mediate targeting to Z lines	SEQ_UP	1	
REGION:Intramolecular interaction with C-terminus	SEQ_UP	3	
REGION:Intramolecular interaction with N-terminus	SEQ_UP	3	
REGION:Intramolecular interaction with the ANK repeats	SEQ_UP	1	
REGION:Involved in AKAP5 and PRKAR2A interaction	SEQ_UP	1	
REGION:Involved in ATP2A2 binding	SEQ_UP	1	
REGION:Involved in binding BAIAP2	SEQ_UP	1	
REGION:Involved in binding clathrin heavy chain	SEQ_UP	2	
REGION:Involved in binding clathrin light chain	SEQ_UP	1	
REGION:Involved in binding PPP1CA	SEQ_UP	1	
REGION:Involved in binding TNC	SEQ_UP	3	
REGION:Involved in binding TNC and actin	SEQ_UP	3	
REGION:Involved in binding to RB1	SEQ_UP	1	
REGION:Involved in C5AR1 binding	SEQ_UP	1	
REGION:Involved in Ca(2+)-dependent inactivation	SEQ_UP	1	
REGION:Involved in CALM1 interaction	SEQ_UP	1	
REGION:Involved in CASP9 binding	SEQ_UP	1	
REGION:Involved in CDK5RAP3-binding	SEQ_UP	1	
REGION:Involved in cell filopodia formation	SEQ_UP	1	
REGION:Involved in chromatin-binding	SEQ_UP	1	
REGION:Involved in condensin complex recruitment	SEQ_UP	1	
REGION:Involved in CX3CL1-, NRG1-, FGF1- and IGF1-binding	SEQ_UP	1	
REGION:Involved in CYFIP1- and NCKAP1-binding	SEQ_UP	3	
REGION:Involved in CYTH2-binding	SEQ_UP	1	
REGION:Involved in dimerization	SEQ_UP	3	
REGION:Involved in dimerization; when bound to chemokine	SEQ_UP	1	
REGION:Involved in DNA binding	SEQ_UP	1	
REGION:Involved in DNA-binding	SEQ_UP	1	
REGION:Involved in FAM8A1 interaction	SEQ_UP	1	
REGION:Involved in GNA13 binding	SEQ_UP	1	
REGION:Involved in GSK-3 binding	SEQ_UP	2	
REGION:Involved in HAX-1 binding	SEQ_UP	1	
REGION:Involved in HCLS1 binding	SEQ_UP	1	
REGION:Involved in heparin-binding and antiangiogenic activity	SEQ_UP	1	
REGION:Involved in homodimerization	SEQ_UP	3	
REGION:Involved in homomerization	SEQ_UP	1	
REGION:Involved in interaction with MAGI1	SEQ_UP	1	
REGION:Involved in interaction with PPP1CA	SEQ_UP	1	
REGION:Involved in interaction with pre-mRNA 5' splice site	SEQ_UP	1	
REGION:Involved in localization to nuclear speckles	SEQ_UP	1	
REGION:Involved in localization to secretory granules; interaction with CPE	SEQ_UP	1	
REGION:Involved in masking transactivation domain	SEQ_UP	1	
REGION:Involved in metalloproteinase-binding	SEQ_UP	4	
REGION:Involved in NRG1- and IGF1-binding	SEQ_UP	1	
REGION:Involved in nuclear export	SEQ_UP	1	
REGION:Involved in nuclear foci localization	SEQ_UP	1	
REGION:Involved in nuclear matrix association	SEQ_UP	1	
REGION:Involved in nuclear speckle localization	SEQ_UP	1	
REGION:Involved in oligomerization	SEQ_UP	1	
REGION:Involved in ORAI1, STIM1, PPP2CA and PPP2R1A interaction	SEQ_UP	1	
REGION:Involved in PKC-binding	SEQ_UP	1	
REGION:Involved in PKD2 binding	SEQ_UP	1	
REGION:Involved in PLN binding	SEQ_UP	1	
REGION:Involved in PP-1 binding	SEQ_UP	1	
REGION:Involved in PP-1 inhibition	SEQ_UP	1	
REGION:Involved in primer binding	SEQ_UP	1	
REGION:Involved in proton transfer	SEQ_UP	1	
REGION:Involved in repression of activated transcription	SEQ_UP	1	
REGION:Involved in RNA binding	SEQ_UP	1	
REGION:Involved in RNA-binding	SEQ_UP	1	
REGION:Involved in splicing regulation activity	SEQ_UP	1	
REGION:Involved in ssDNA binding	SEQ_UP	1	
REGION:Involved in stabilization of the HSPB1:HSBP6 heterodimer	SEQ_UP	1	
REGION:Involved in stimulation of ATPase activity by DNA and RNA, nucleic acid binding and unwinding	SEQ_UP	1	
REGION:Involved in subunit assembly	SEQ_UP	3	
REGION:Involved in the binding to lipid droplets	SEQ_UP	1	
REGION:Involved in the ligation of specific target proteins	SEQ_UP	1	
REGION:Involved in the trafficking and surface expression of NMDARs	SEQ_UP	1	
REGION:Ion transport-like	SEQ_UP	1	
REGION:Isomerase	SEQ_UP	1	
REGION:ITP binding	SEQ_UP	1	
REGION:IV (linker domain)	SEQ_UP	3	
REGION:J region (By similarity to lambda light-chain)	SEQ_UP	1	
REGION:J segment	SEQ_UP	1	
REGION:J-like	SEQ_UP	1	
REGION:J; Pro-rich linker	SEQ_UP	1	
REGION:JNK-binding domain (JBD)	SEQ_UP	2	
REGION:JNK-binding domain (JBD); essential for its function in axon elongation	SEQ_UP	1	
REGION:K-box	SEQ_UP	2	
REGION:K-loop	SEQ_UP	1	
REGION:KA1; binds the bulging loops of U6 snRNA but is dispensable for terminal uridylyltransferase activity	SEQ_UP	1	
REGION:Kinase	SEQ_UP	2	
REGION:Kinase domain	SEQ_UP	1	
REGION:Kinase inhibitory region (KIR)	SEQ_UP	2	
REGION:Kinesin-binding domain (KBD); essential for its function in axon elongation	SEQ_UP	1	
REGION:Kinetochore binding domain	SEQ_UP	1	
REGION:KIP-binding	SEQ_UP	1	
REGION:KIS	SEQ_UP	1	
REGION:KLERQ	SEQ_UP	1	
REGION:Knob domain	SEQ_UP	1	
REGION:KS	SEQ_UP	1	
REGION:L-arginine binding	SEQ_UP	2	
REGION:L-glutamate	SEQ_UP	9	
REGION:L-glutamate binding	SEQ_UP	1	
REGION:L-histidine binding	SEQ_UP	2	
REGION:L-phenylalanine binding	SEQ_UP	1	
REGION:L-proline binding	SEQ_UP	1	
REGION:L-saccharopine binding	SEQ_UP	1	
REGION:L-serine binding	SEQ_UP	2	
REGION:L-thyroxine binding	SEQ_UP	1	
REGION:L3 loop	SEQ_UP	1	
REGION:Laminin-binding	SEQ_UP	1	
REGION:LATS2 binding	SEQ_UP	1	
REGION:LCN1-binding	SEQ_UP	1	
REGION:LDD domain	SEQ_UP	1	
REGION:LDL and other lipoprotein receptors binding	SEQ_UP	1	
REGION:LDL receptor binding	SEQ_UP	2	
REGION:Leptin-binding	SEQ_UP	1	
REGION:Leucine zipper alpha helical coiled-coil region	SEQ_UP	1	
REGION:Leucine zipper-like domain (LZ); essential for its function in axon elongation	SEQ_UP	1	
REGION:Leucine-binding	SEQ_UP	3	
REGION:Leucine-rich region; critical for dimer formation and for interaction with RFXAP	SEQ_UP	1	
REGION:Leucine-zipper	SEQ_UP	114	
REGION:Leucine-zipper 1	SEQ_UP	10	
REGION:Leucine-zipper 2	SEQ_UP	10	
REGION:Leucine-zipper 3	SEQ_UP	1	
REGION:LID	SEQ_UP	8	
REGION:LID 1	SEQ_UP	2	
REGION:LID 2	SEQ_UP	2	
REGION:Ligand-binding	SEQ_UP	1	
REGION:Ligand-binding 1 (LB1)	SEQ_UP	1	
REGION:Ligand-binding 2 (LB2)	SEQ_UP	1	
REGION:Ligand-dependent nuclear receptor binding	SEQ_UP	1	
REGION:Ligase	SEQ_UP	1	
REGION:LIM protein-binding	SEQ_UP	1	
REGION:LIM-binding domain (LID)	SEQ_UP	2	
REGION:Linear diubiquitin binding	SEQ_UP	1	
REGION:Linear polyubiquitin-binding, does not bind to 'Lys-63'-linked polyubiquitin	SEQ_UP	1	
REGION:Linker	SEQ_UP	40	
REGION:Linker (Pro-rich)	SEQ_UP	1	
REGION:Linker 1	SEQ_UP	65	
REGION:Linker 12	SEQ_UP	59	
REGION:Linker 2	SEQ_UP	12	
REGION:Linker helix loop	SEQ_UP	1	
REGION:Linker loop domain	SEQ_UP	2	
REGION:Linker region	SEQ_UP	3	
REGION:Linoleate binding	SEQ_UP	1	
REGION:Lipid binding	SEQ_UP	4	
REGION:Lipid-binding	SEQ_UP	5	
REGION:Lipid-binding and lipoprotein association	SEQ_UP	1	
REGION:Lipopolysaccharide binding	SEQ_UP	1	
REGION:Lipoprotein lipase cofactor	SEQ_UP	2	
REGION:LISN domain, inhibits interaction with ITPR1	SEQ_UP	1	
REGION:LMNA binding	SEQ_UP	1	
REGION:LMNA-binding	SEQ_UP	2	
REGION:Localization to kinetochores	SEQ_UP	1	
REGION:Localization to mRNA processing bodies (P-bodies)	SEQ_UP	1	
REGION:Localization to nuclear speckles	SEQ_UP	1	
REGION:Localization to the cleavage furrow	SEQ_UP	1	
REGION:Localization to the growing distal tip of microtubules	SEQ_UP	1	
REGION:Loop 1	SEQ_UP	1	
REGION:Loop 2	SEQ_UP	1	
REGION:Loop 3	SEQ_UP	1	
REGION:Loop L1; predicted to block binding of double-stranded DNA or RNA	SEQ_UP	1	
REGION:Loop-1	SEQ_UP	1	
REGION:Loop-7	SEQ_UP	1	
REGION:Low charge region	SEQ_UP	1	
REGION:LPA/PIP2-binding site 1	SEQ_UP	1	
REGION:LPA/PIP2-binding site 2	SEQ_UP	1	
REGION:LPA/PIP2-binding site 3	SEQ_UP	1	
REGION:LPS binding (delipidated)	SEQ_UP	1	
REGION:LPS binding (Lipid A)	SEQ_UP	1	
REGION:Lung-homing for mammary tumors	SEQ_UP	1	
REGION:LYN-binding	SEQ_UP	1	
REGION:Lysine-ketoglutarate reductase	SEQ_UP	1	
REGION:Lysophosphatidic acid binding	SEQ_UP	1	
REGION:Lysosomal targeting region	SEQ_UP	1	
REGION:Lysyl-oxidase like	SEQ_UP	5	
REGION:M-domain	SEQ_UP	2	
REGION:M6 cassette	SEQ_UP	1	
REGION:Maintains the protein in an inactive state	SEQ_UP	1	
REGION:Major non-specific RNA-binding	SEQ_UP	1	
REGION:Makorin-type Cys-His	SEQ_UP	3	
REGION:malonyl-CoA binding	SEQ_UP	1	
REGION:Malonyl-CoA binding	SEQ_UP	1	
REGION:Mannose binding	SEQ_UP	1	
REGION:MAP kinase docking site	SEQ_UP	1	
REGION:MAP1LC3B-binding	SEQ_UP	1	
REGION:Massively activates transcription	SEQ_UP	1	
REGION:Matrix attachment region (MAR) of DNA binding	SEQ_UP	1	
REGION:May be involved in recognition of long-chain fatty acids in GPI	SEQ_UP	1	
REGION:May contain a degradation domain	SEQ_UP	1	
REGION:May mediate active transcriptional repression	SEQ_UP	1	
REGION:May mediate interaction with PRPF9	SEQ_UP	1	
REGION:May mediate interaction with PSMC5	SEQ_UP	1	
REGION:May mediate the interaction with C17orf75, FAM91A1 and WDR11	SEQ_UP	1	
REGION:May mediate the interaction with FKBP15 and WASHC2; required for endosome to Golgi trafficking	SEQ_UP	1	
REGION:May mediate the interaction with WASHC1	SEQ_UP	1	
REGION:May not be required for kinase activity; required to stimulate MEF2C activity	SEQ_UP	1	
REGION:May play a role in cytoprotective signaling	SEQ_UP	1	
REGION:May play an important role in murine norovirus (MNV) binding	SEQ_UP	1	
REGION:Maybe required for stable oligomeric structure	SEQ_UP	1	
REGION:MBD region	SEQ_UP	1	
REGION:MBOAT fold	SEQ_UP	1	
REGION:Mediate transcriptional repression	SEQ_UP	1	
REGION:Mediates actin nucleation	SEQ_UP	1	
REGION:Mediates association with membranes	SEQ_UP	3	
REGION:Mediates association with membranes and could form transmembrane domains	SEQ_UP	1	
REGION:Mediates association with microtubules	SEQ_UP	1	
REGION:Mediates cell survival and induction of the IAP family of survival proteins	SEQ_UP	1	
REGION:Mediates cytoplasmic retention and interaction with MAPK8IP1	SEQ_UP	1	
REGION:Mediates cytoplasmic retention and interaction with YWHAH	SEQ_UP	1	
REGION:Mediates dendritic targeting	SEQ_UP	2	
REGION:Mediates dimerization	SEQ_UP	1	
REGION:Mediates dimerization and binding to membranes enriched in Pi(4,5)-P2 and induces their tubulation	SEQ_UP	1	
REGION:Mediates dimerization, DNA-binding, transcription repression of CCNA2 and interaction with HMGA2	SEQ_UP	1	
REGION:Mediates direct interaction with MYO6	SEQ_UP	1	
REGION:Mediates direct interaction with RBBP4	SEQ_UP	1	
REGION:Mediates HDAC-dependent transcriptional repression	SEQ_UP	1	
REGION:Mediates heterotypic interactions between MLXIP and MLX and is required for cytoplasmic localization	SEQ_UP	1	
REGION:Mediates homodimerization and heterodimerization	SEQ_UP	1	
REGION:Mediates homooligomerization	SEQ_UP	2	
REGION:Mediates immunoglobulin Fc fragment-binding	SEQ_UP	1	
REGION:Mediates interaction with 28S rRNA of ribosome-coding tubulin	SEQ_UP	1	
REGION:Mediates interaction with AGFG1, CALM, DAB2, EPS15, EPS15R, ITSN1 and clathrin	SEQ_UP	1	
REGION:Mediates interaction with ALDH1A1	SEQ_UP	1	
REGION:Mediates interaction with alpha-catenin	SEQ_UP	1	
REGION:Mediates interaction with ANKS1A and ANKS1B	SEQ_UP	1	
REGION:Mediates interaction with ANKS4B	SEQ_UP	1	
REGION:Mediates interaction with APC2	SEQ_UP	1	
REGION:Mediates interaction with ARHGEF16	SEQ_UP	1	
REGION:Mediates interaction with beta-tubulin and is required for microtubule bundle formation	SEQ_UP	1	
REGION:Mediates interaction with BRPF1, required for histone H3 acetyltransferase activity	SEQ_UP	1	
REGION:Mediates interaction with CACNA1S	SEQ_UP	1	
REGION:Mediates interaction with calmodulin	SEQ_UP	2	
REGION:Mediates interaction with CAMSAP1	SEQ_UP	1	
REGION:Mediates interaction with CBFA2T3	SEQ_UP	1	
REGION:Mediates interaction with CCNT1	SEQ_UP	1	
REGION:Mediates interaction with CDHR2, CDHR5 and USH1C	SEQ_UP	1	
REGION:Mediates interaction with CDK5RAP2 and is required for homodimerization and microtubule bundle formation	SEQ_UP	1	
REGION:Mediates interaction with CDK5RAP3	SEQ_UP	2	
REGION:Mediates interaction with CDKN2A	SEQ_UP	1	
REGION:Mediates interaction with CDKN2A/isoform tumor suppressor ARF	SEQ_UP	1	
REGION:Mediates interaction with CHD6 and is necessary to activate transcription	SEQ_UP	1	
REGION:Mediates interaction with CHUK/IKKA and IKBKB/IKKB	SEQ_UP	1	
REGION:Mediates interaction with CLDN4	SEQ_UP	1	
REGION:Mediates interaction with COPS2	SEQ_UP	1	
REGION:Mediates interaction with CSNK1A1 and is required for FAM83H activity in keratin cytoskeleton organization	SEQ_UP	1	
REGION:Mediates interaction with CTNNB1	SEQ_UP	1	
REGION:Mediates interaction with CTNND1	SEQ_UP	1	
REGION:Mediates interaction with DAB2, EPS15, EPS15R and ITSN1	SEQ_UP	1	
REGION:Mediates interaction with DDRGK1	SEQ_UP	2	
REGION:Mediates interaction with DNTTIP2	SEQ_UP	2	
REGION:Mediates interaction with DOC2B	SEQ_UP	1	
REGION:Mediates interaction with DOCK7	SEQ_UP	1	
REGION:Mediates interaction with DYNLT1	SEQ_UP	1	
REGION:Mediates interaction with DZIP1	SEQ_UP	2	
REGION:Mediates interaction with E4F1	SEQ_UP	1	
REGION:Mediates interaction with EFEMP1	SEQ_UP	1	
REGION:Mediates interaction with ESR1 and STUB1	SEQ_UP	1	
REGION:Mediates interaction with EXOC2, EXOC4 and EXOC5	SEQ_UP	1	
REGION:Mediates interaction with GATA1	SEQ_UP	1	
REGION:Mediates interaction with GDI2 and RAB8A	SEQ_UP	1	
REGION:Mediates interaction with GLI3	SEQ_UP	1	
REGION:Mediates interaction with GLI3 and localization to the cilium basal body	SEQ_UP	1	
REGION:Mediates interaction with GLS	SEQ_UP	1	
REGION:Mediates interaction with GOLPH3 and is necessary and sufficient for localization to the Golgi	SEQ_UP	1	
REGION:Mediates interaction with HSP90	SEQ_UP	1	
REGION:Mediates interaction with human herpesvirus 8 protein ORF16	SEQ_UP	1	
REGION:Mediates interaction with IFNAR2	SEQ_UP	1	
REGION:Mediates interaction with IRS1	SEQ_UP	1	
REGION:Mediates interaction with KHDRBS1	SEQ_UP	1	
REGION:Mediates interaction with KIDINS220	SEQ_UP	1	
REGION:Mediates interaction with laminin-2	SEQ_UP	1	
REGION:Mediates interaction with LAT, GRB2, and FGR; involved in translocation to the glycolipid-enriched microdomain and restoration of BCR-induced calcium response in BLNK-deficient DT40 cells expressing LAT	SEQ_UP	1	
REGION:Mediates interaction with LIMCH1	SEQ_UP	1	
REGION:Mediates interaction with LIMK1	SEQ_UP	1	
REGION:Mediates interaction with LMAN1	SEQ_UP	1	
REGION:Mediates interaction with MAD2L2	SEQ_UP	3	
REGION:Mediates interaction with MAP1B	SEQ_UP	1	
REGION:Mediates interaction with MAPRE1	SEQ_UP	1	
REGION:Mediates interaction with MECOM	SEQ_UP	1	
REGION:Mediates interaction with MIA2	SEQ_UP	1	
REGION:Mediates interaction with MIA3	SEQ_UP	1	
REGION:Mediates interaction with MICALL2	SEQ_UP	1	
REGION:Mediates interaction with microtubules	SEQ_UP	2	
REGION:Mediates interaction with MMS19	SEQ_UP	1	
REGION:Mediates interaction with MYH9	SEQ_UP	1	
REGION:Mediates interaction with MYO7B	SEQ_UP	2	
REGION:Mediates interaction with NEDD4	SEQ_UP	1	
REGION:Mediates interaction with NEK2 and is required for its function in the suppression of centrosome disjunction	SEQ_UP	1	
REGION:Mediates interaction with NIF3L1	SEQ_UP	1	
REGION:Mediates interaction with PCM1	SEQ_UP	1	
REGION:Mediates interaction with PHIP	SEQ_UP	1	
REGION:Mediates interaction with PIK3CG and required for endocytosis	SEQ_UP	1	
REGION:Mediates interaction with PLCG1; essential for BCR signaling; involved in restoration of BCR-induced calcium response and ERK2 and JNK2 activation in BLNK-deficient cells expressing LAT	SEQ_UP	1	
REGION:Mediates interaction with PRKAR2A	SEQ_UP	1	
REGION:Mediates interaction with PRMT3	SEQ_UP	1	
REGION:Mediates interaction with PRPF3	SEQ_UP	1	
REGION:Mediates interaction with RAB13 and is required for transition from the closed to the open conformation	SEQ_UP	1	
REGION:Mediates interaction with RAB3GAP1, RAB3GAP2 and UBXN6	SEQ_UP	1	
REGION:Mediates interaction with RAB6A	SEQ_UP	1	
REGION:Mediates interaction with RAB9A	SEQ_UP	1	
REGION:Mediates interaction with RAC1	SEQ_UP	1	
REGION:Mediates interaction with RALA and RALB	SEQ_UP	1	
REGION:Mediates interaction with RAP2A	SEQ_UP	2	
REGION:Mediates interaction with RASGRP1	SEQ_UP	1	
REGION:Mediates interaction with RASSF1	SEQ_UP	1	
REGION:Mediates interaction with RELA	SEQ_UP	1	
REGION:Mediates interaction with REPS1 and REPS2	SEQ_UP	1	
REGION:Mediates interaction with REV1 and REV3L and homodimerization	SEQ_UP	1	
REGION:Mediates interaction with RNF135	SEQ_UP	1	
REGION:Mediates interaction with RNF34	SEQ_UP	1	
REGION:Mediates interaction with RNF4	SEQ_UP	1	
REGION:Mediates interaction with RPA2	SEQ_UP	2	
REGION:Mediates interaction with SART3	SEQ_UP	2	
REGION:Mediates interaction with SCAI and ACTB	SEQ_UP	1	
REGION:Mediates interaction with SEC14L1	SEQ_UP	2	
REGION:Mediates interaction with SH3BP4	SEQ_UP	1	
REGION:Mediates interaction with SHLD1	SEQ_UP	1	
REGION:Mediates interaction with SKI and regulation of TGF-beta signaling	SEQ_UP	1	
REGION:Mediates interaction with SMAD4	SEQ_UP	1	
REGION:Mediates interaction with sodium channels	SEQ_UP	1	
REGION:Mediates interaction with SORBS3	SEQ_UP	1	
REGION:Mediates interaction with SP100	SEQ_UP	1	
REGION:Mediates interaction with STAT2	SEQ_UP	1	
REGION:Mediates interaction with STAT2 (and required for the recruitment of USP18)	SEQ_UP	1	
REGION:Mediates interaction with STAT2 and necessary for the negative regulation of the type I IFN signaling pathway	SEQ_UP	1	
REGION:Mediates interaction with STING1	SEQ_UP	1	
REGION:Mediates interaction with STX17	SEQ_UP	1	
REGION:Mediates interaction with STXBP3	SEQ_UP	1	
REGION:Mediates interaction with TEFM	SEQ_UP	1	
REGION:Mediates interaction with the adaptor protein complex AP-2	SEQ_UP	1	
REGION:Mediates interaction with the alpha subunit	SEQ_UP	1	
REGION:Mediates interaction with the cohesin complex	SEQ_UP	1	
REGION:Mediates interaction with the GATOR1 complex	SEQ_UP	1	
REGION:Mediates interaction with the P-TEFb complex	SEQ_UP	1	
REGION:Mediates interaction with the PDZ domain of NOS1	SEQ_UP	1	
REGION:Mediates interaction with TIMP3	SEQ_UP	1	
REGION:Mediates interaction with TLN2	SEQ_UP	1	
REGION:Mediates interaction with TLR4	SEQ_UP	1	
REGION:Mediates interaction with TMEM185A	SEQ_UP	1	
REGION:Mediates interaction with TNIK	SEQ_UP	1	
REGION:Mediates interaction with TP53	SEQ_UP	1	
REGION:Mediates interaction with TRIM28	SEQ_UP	1	
REGION:Mediates interaction with TRIP4	SEQ_UP	2	
REGION:Mediates interaction with TRPS1	SEQ_UP	1	
REGION:Mediates interaction with TRPV2	SEQ_UP	1	
REGION:Mediates interaction with TYK2 and GABBR1	SEQ_UP	1	
REGION:Mediates interaction with type IV collagen	SEQ_UP	1	
REGION:Mediates interaction with UFL1	SEQ_UP	2	
REGION:Mediates interaction with USH1C and MYO7B and is required for proper localization to microvilli tips and function in microvilli organization	SEQ_UP	2	
REGION:Mediates interaction with USP17L2	SEQ_UP	1	
REGION:Mediates interaction with USP18	SEQ_UP	1	
REGION:Mediates interaction with WDR45B	SEQ_UP	1	
REGION:Mediates interaction with XRCC5/Ku80 and XRCC6/Ku70 and association with the non-homologous end joining core complex	SEQ_UP	1	
REGION:Mediates interaction with ZBTB7A	SEQ_UP	1	
REGION:Mediates interaction with ZDHHC1 and ZDHHC11	SEQ_UP	1	
REGION:Mediates interaction with ZDHHC11	SEQ_UP	1	
REGION:Mediates lipid-binding	SEQ_UP	1	
REGION:Mediates localization to microvilli	SEQ_UP	1	
REGION:Mediates localization to plasma membrane and recycling endosomes	SEQ_UP	1	
REGION:Mediates localization to the chromosome and the spindle and negatively regulates chromosome alignment	SEQ_UP	1	
REGION:Mediates localization to the Golgi	SEQ_UP	1	
REGION:Mediates localization to the nucleus	SEQ_UP	1	
REGION:Mediates localization to the spindle and the kinetochore and is required for the attachment of spindle microtubules to the kinetochore	SEQ_UP	1	
REGION:Mediates membrane-binding	SEQ_UP	2	
REGION:Mediates microtubule-binding and homooligomerization	SEQ_UP	1	
REGION:Mediates modulation by decavanadate and PIP2-binding	SEQ_UP	1	
REGION:Mediates motor neuron attachment	SEQ_UP	1	
REGION:Mediates nuclear export	SEQ_UP	2	
REGION:Mediates nucleotide-independent binding to F-actin and interaction with GOLPH3	SEQ_UP	1	
REGION:Mediates oxidative antimutator activity	SEQ_UP	1	
REGION:Mediates promoter DNA-binding and activation of transcription	SEQ_UP	1	
REGION:Mediates regulation of adenylate cyclase activity by C5 alpha-induced G- beta and gamma pathway	SEQ_UP	1	
REGION:Mediates regulation of adenylate cyclase activity by sphingosine 1-phosphate-induced G alpha 13 pathway	SEQ_UP	1	
REGION:Mediates retention in the endoplasmic reticulum	SEQ_UP	1	
REGION:Mediates specificity for BMP ligand	SEQ_UP	2	
REGION:Mediates targeting and association with DCVs	SEQ_UP	1	
REGION:Mediates targeting to cell membrane and phagosomes	SEQ_UP	1	
REGION:Mediates targeting to the cell plasma membrane	SEQ_UP	1	
REGION:Mediates targeting to the Golgi	SEQ_UP	1	
REGION:Mediates targeting to the mitochondria	SEQ_UP	1	
REGION:Mediates targeting to the nucleus	SEQ_UP	1	
REGION:Mediates the interaction with AP4M1	SEQ_UP	1	
REGION:Mediates the interaction with BCAR1/p130CAS	SEQ_UP	1	
REGION:Mediates the interaction with RAB13 and RAB35 and intramolecular interaction with the CH domain	SEQ_UP	1	
REGION:Mediates the shuttling between the nucleus and the cytoplasm	SEQ_UP	1	
REGION:Mediates the transcription activity and dimerization of the AHR:ARNT complex	SEQ_UP	1	
REGION:Mediates transactivation of PPARG	SEQ_UP	1	
REGION:Mediates transcriptional activation	SEQ_UP	3	
REGION:Mediates transcriptional activity	SEQ_UP	2	
REGION:Mediates transcriptional repression	SEQ_UP	1	
REGION:Mediates transcriptional transrepression (in isoform A)	SEQ_UP	1	
REGION:Membrane (anion exchange)	SEQ_UP	2	
REGION:Membrane attachment	SEQ_UP	1	
REGION:Membrane targeting	SEQ_UP	1	
REGION:Membrane targeting domain	SEQ_UP	1	
REGION:Membrane-anchoring	SEQ_UP	2	
REGION:Membrane-binding amphipathic helix	SEQ_UP	11	
REGION:Membrane-binding domain 1	SEQ_UP	1	
REGION:Membrane-binding domain 2	SEQ_UP	1	
REGION:Membrane-bound segment which detaches upon phosphorylation	SEQ_UP	1	
REGION:Metalloprotease	SEQ_UP	4	
REGION:Metalloprotease domain	SEQ_UP	4	
REGION:Methionine-rich intra-molecular domain	SEQ_UP	1	
REGION:Methyl-CpG binding and interaction with HDAC1	SEQ_UP	1	
REGION:Methylcob(III)alamin binding	SEQ_UP	1	
REGION:Methylenetetrahydrofolate dehydrogenase and cyclohydrolase	SEQ_UP	1	
REGION:Methylenetetrahydrofolate dehydrogenase and methenyltetrahydrofolate cyclohydrolase (D/C) domain	SEQ_UP	1	
REGION:Methyltransferase (MTase)	SEQ_UP	1	
REGION:Methyltransferase domain	SEQ_UP	1	
REGION:Methyltransferase-like region	SEQ_UP	1	
REGION:MFD domain	SEQ_UP	1	
REGION:Microtubule binding	SEQ_UP	1	
REGION:Microtubule binding domain	SEQ_UP	1	
REGION:Microtubule-binding	SEQ_UP	6	
REGION:Microtubule-binding region	SEQ_UP	1	
REGION:MID region	SEQ_UP	1	
REGION:MID/MTR4-interacting domain	SEQ_UP	1	
REGION:Middle domain	SEQ_UP	2	
REGION:MIF2 homology domain II	SEQ_UP	1	
REGION:MIF2 homology domain III	SEQ_UP	1	
REGION:Might negatively regulate ATPase activity	SEQ_UP	1	
REGION:Mini-exon peptide A9; sufficient for interaction with IL1RAPL1	SEQ_UP	1	
REGION:Mini-exon peptide B; required for interaction with SLITRK2 and in the function in pre-synaptic differentiation; Acts as an adjustable linker to control relative positions and orientations of the PTPRD second and third immunoglobilin domains for their simultaneous interactions with the first immunoglobilin domain of IL1RAPL1 and IL1RAP; Modulates affinity for IL1RAPL1 and IL1RAP	SEQ_UP	1	
REGION:Minimal domain that binds to TCF3/E12	SEQ_UP	1	
REGION:Minimal inhibitory domain (MID)	SEQ_UP	1	
REGION:Minimal region for the interaction with PKD2	SEQ_UP	1	
REGION:Minimal sensor domain involved in damage recognition	SEQ_UP	1	
REGION:Minimal transactivation domain (MTD)	SEQ_UP	1	
REGION:Minor non-specific RNA-binding	SEQ_UP	1	
REGION:Mitochondrial targeting sequence	SEQ_UP	1	
REGION:Mitochondrial targeting sequence (MTS)	SEQ_UP	1	
REGION:Mitochondrial targeting signal	SEQ_UP	1	
REGION:Mitochondrial-binding peptide (MBP)	SEQ_UP	3	
REGION:Mitochondrion outer membrane (MOM)-targeting sequence	SEQ_UP	4	
REGION:MIU	SEQ_UP	1	
REGION:Mn 1	SEQ_UP	1	
REGION:Mn 2	SEQ_UP	1	
REGION:Mn 3	SEQ_UP	1	
REGION:Mo-molybdopterin-binding	SEQ_UP	1	
REGION:MOAP1-binding	SEQ_UP	1	
REGION:Moco domain	SEQ_UP	1	
REGION:Modulates adenylate cyclase activity by modulating the binding of G(s)alpha to the high-affinity G(s)alpha binding site in 7C1a/7C2	SEQ_UP	1	
REGION:Modulating	SEQ_UP	14	
REGION:Modulating (transactivation AF-1); mediates interaction with MACROD1	SEQ_UP	1	
REGION:Modulating domain	SEQ_UP	1	
REGION:Modulating, Pro-Rich	SEQ_UP	1	
REGION:Molybdenum cofactor biosynthesis protein A	SEQ_UP	1	
REGION:Molybdenum cofactor biosynthesis protein C	SEQ_UP	1	
REGION:Molybdenum cofactor biosynthesis protein-like	SEQ_UP	1	
REGION:Molybdopterin binding	SEQ_UP	3	
REGION:Molybdopterin-binding	SEQ_UP	1	
REGION:Monooxygenase domain	SEQ_UP	3	
REGION:MOSC N-terminal region	SEQ_UP	1	
REGION:MPT adenylyltransferase	SEQ_UP	1	
REGION:MPT Mo-transferase	SEQ_UP	1	
REGION:mRNA cap binding	SEQ_UP	2	
REGION:MTAD	SEQ_UP	1	
REGION:MTBD; microtubule-binding domain	SEQ_UP	1	
REGION:MTH138-like domain	SEQ_UP	1	
REGION:MTREX binding	SEQ_UP	1	
REGION:Mucin-like	SEQ_UP	2	
REGION:Mucin-like domain	SEQ_UP	1	
REGION:Mucin-like stalk	SEQ_UP	1	
REGION:Multimerization domain	SEQ_UP	1	
REGION:Myc binding	SEQ_UP	1	
REGION:MYC-binding	SEQ_UP	2	
REGION:MyMOMA region	SEQ_UP	1	
REGION:Myosin-binding	SEQ_UP	1	
REGION:N	SEQ_UP	1	
REGION:N-acetyl-D-glucosamine binding	SEQ_UP	9	
REGION:N-acetylmannosamine kinase	SEQ_UP	1	
REGION:N-domain	SEQ_UP	6	
REGION:N-LIP	SEQ_UP	3	
REGION:N-SMase activation domain (NSD)	SEQ_UP	1	
REGION:N-terminal	SEQ_UP	8	
REGION:N-terminal AD (CTNNB1 binding site)	SEQ_UP	1	
REGION:N-terminal adhesion motif	SEQ_UP	1	
REGION:N-terminal arm	SEQ_UP	7	
REGION:N-terminal auto-inhibitory domain; necessary for interaction with SMARCA4/BRG1	SEQ_UP	1	
REGION:N-terminal barrel	SEQ_UP	1	
REGION:N-terminal bundle and brace (NBB); mediates INSP6 binding	SEQ_UP	1	
REGION:N-terminal catalytic PFK domain 1	SEQ_UP	3	
REGION:N-terminal cyclin fold	SEQ_UP	1	
REGION:N-terminal domain	SEQ_UP	9	
REGION:N-terminal domain similar to Nudix hydrolase domain	SEQ_UP	1	
REGION:N-terminal domain; essential for its chromatin remodeling activity	SEQ_UP	1	
REGION:N-terminal domain; may mediate the alkylhydroperoxide reductase activity	SEQ_UP	2	
REGION:N-terminal domain; mediates the alkylhydroperoxide reductase activity	SEQ_UP	1	
REGION:N-terminal extension of DRBM 3 and constituent of a bi-partite nuclear localization signal	SEQ_UP	1	
REGION:N-terminal globular domain	SEQ_UP	1	
REGION:N-terminal globular head	SEQ_UP	1	
REGION:N-terminal helix	SEQ_UP	1	
REGION:N-terminal inhibitory region	SEQ_UP	1	
REGION:N-terminal lobe	SEQ_UP	1	
REGION:N-terminal MCU domain	SEQ_UP	1	
REGION:N-terminal protein interaction domain	SEQ_UP	1	
REGION:N-terminal region (NRD)	SEQ_UP	1	
REGION:N-terminal SAM-like domain	SEQ_UP	1	
REGION:N-terminal sequence (NTS)	SEQ_UP	1	
REGION:N-terminal stalk following vasculostatin-120 cleavage which is not required for signaling activity	SEQ_UP	1	
REGION:N-terminal VHL recognition site	SEQ_UP	1	
REGION:N'-domain region	SEQ_UP	2	
REGION:N(1)-(5-phospho-beta-D-ribosyl)glycinamide binding	SEQ_UP	1	
REGION:N(6)-methyl-AMP binding	SEQ_UP	1	
REGION:N6-methyladenosine residue in RNA binding	SEQ_UP	5	
REGION:N7-methylguanosine 5'-triphosphate group binding; binds m7GTP residue in mRNA cap	SEQ_UP	4	
REGION:NAALADase	SEQ_UP	2	
REGION:NAD binding	SEQ_UP	2	
REGION:NADPHX	SEQ_UP	2	
REGION:NAKAP95-binding C	SEQ_UP	1	
REGION:NAKAP95-binding N	SEQ_UP	1	
REGION:Narpin; mediates binding with FGFR1 and has antidepressant-like activity	SEQ_UP	1	
REGION:NCD1	SEQ_UP	2	
REGION:NCD2	SEQ_UP	2	
REGION:NCOA1-binding region	SEQ_UP	1	
REGION:NCOA2-binding	SEQ_UP	1	
REGION:NCOA6IP-binding region	SEQ_UP	1	
REGION:NDK	SEQ_UP	1	
REGION:NDK 1	SEQ_UP	1	
REGION:NDK 2	SEQ_UP	1	
REGION:NDK 3	SEQ_UP	1	
REGION:Necessary and sufficient fopr interaction with ARPC2	SEQ_UP	1	
REGION:Necessary and sufficient for CEP20-binding	SEQ_UP	1	
REGION:Necessary and sufficient for homooligomerization and localization to centrosomes and pericentriolar satellites	SEQ_UP	1	
REGION:Necessary and sufficient for inhibition of PRC2/EED-EZH1 and PRC2/EED-EZH2 complex activity	SEQ_UP	1	
REGION:Necessary and sufficient for interaction with actinins	SEQ_UP	1	
REGION:Necessary and sufficient for interaction with ADAM10	SEQ_UP	1	
REGION:Necessary and sufficient for interaction with CCDC85B	SEQ_UP	1	
REGION:Necessary and sufficient for interaction with DNAJC5 and SNAP25	SEQ_UP	1	
REGION:Necessary and sufficient for interaction with GMNN and sufficient for homodimerization	SEQ_UP	1	
REGION:Necessary and sufficient for interaction with IDAS and CDT1	SEQ_UP	1	
REGION:Necessary and sufficient for interaction with MPDZ	SEQ_UP	1	
REGION:Necessary and sufficient for interaction with PAX7	SEQ_UP	1	
REGION:Necessary and sufficient for interaction with PCGF1	SEQ_UP	1	
REGION:Necessary and sufficient for interaction with PCNT and localization at the centrosome	SEQ_UP	1	
REGION:Necessary and sufficient for interaction with PCP4	SEQ_UP	3	
REGION:Necessary and sufficient for interaction with SHTN1	SEQ_UP	1	
REGION:Necessary and sufficient for its degradation during the cell cycle	SEQ_UP	1	
REGION:Necessary and sufficient for localization to autophagosome	SEQ_UP	1	
REGION:Necessary and sufficient for nuclear localization	SEQ_UP	1	
REGION:Necessary and sufficient for ORC complex assembly	SEQ_UP	1	
REGION:Necessary and sufficient for PEX19-mediated localization into peroxisome membrane	SEQ_UP	1	
REGION:Necessary and sufficient for proper nuclear localization	SEQ_UP	1	
REGION:Necessary and sufficient for the association with mRNA decay enzymes and mRNA decay activation	SEQ_UP	2	
REGION:Necessary and sufficient for the interaction with SQSTM1	SEQ_UP	1	
REGION:Necessary and sufficient for U6 snRNA binding	SEQ_UP	1	
REGION:Necessary and sufficient to associate with tubular recycling endosome membranes, mediate phosphatidic acid-binding and membrane tubulation	SEQ_UP	1	
REGION:Necessary and sufficient to elicit dendritic processes and synaptic contacts	SEQ_UP	1	
REGION:Necessary and sufficient to mediate inhibition of NF-kappa-B downstream of activated TLRs; may mediate interaction with MYD88 and TIRAP	SEQ_UP	1	
REGION:Necessary and sufficient to mediate interaction with CANX	SEQ_UP	1	
REGION:Necessary and sufficient to promote mitochondrial fission	SEQ_UP	1	
REGION:Necessary and sufficient to stimulate pre-mRNAs 3'-end cleavage in a CFIm complex-dependent manner	SEQ_UP	1	
REGION:Necessary but not sufficient for MKNK1-binding	SEQ_UP	2	
REGION:Necessary but not sufficient for spindle localization	SEQ_UP	1	
REGION:Necessary for adherens junction and tight junction localization	SEQ_UP	1	
REGION:Necessary for alternative splicing activity	SEQ_UP	1	
REGION:Necessary for association to the NPC	SEQ_UP	1	
REGION:Necessary for association with actin	SEQ_UP	1	
REGION:Necessary for association with microtubules	SEQ_UP	1	
REGION:Necessary for association with the pre-rRNP complexes	SEQ_UP	1	
REGION:Necessary for binding to ITPR1, CEBPA and p53/TP53 mRNAs	SEQ_UP	1	
REGION:Necessary for binding to phosphoinositide-3-P; not sufficient for targeting to endosomes	SEQ_UP	1	
REGION:Necessary for binding to the m3G-cap structure	SEQ_UP	1	
REGION:Necessary for cell membrane association (isoform 2)	SEQ_UP	1	
REGION:Necessary for centriole targeting and microtubule association	SEQ_UP	1	
REGION:Necessary for colocalization and binding with microtubules	SEQ_UP	1	
REGION:Necessary for cytoplasmic localization	SEQ_UP	2	
REGION:Necessary for cytoplasmic retention	SEQ_UP	1	
REGION:Necessary for dimerization	SEQ_UP	1	
REGION:Necessary for dimerization and homooligomerization	SEQ_UP	1	
REGION:Necessary for DNA and RNA-binding	SEQ_UP	1	
REGION:Necessary for E3 ubiquitin-protein ligase activity and repression of SMAD4 signaling and transcriptional repression	SEQ_UP	1	
REGION:Necessary for endoplasmic reticulum localization	SEQ_UP	1	
REGION:Necessary for endothelial cell focal adhesions and anti-angiogenic activities	SEQ_UP	1	
REGION:Necessary for formation of large intracellular vacuoles	SEQ_UP	1	
REGION:Necessary for GR/NR3C1-mediated remodeling and transcription from chromatin; required for GR/NR3C1 interaction with the BRG1/SMARCA4 complex in vivo	SEQ_UP	1	
REGION:Necessary for heme-binding and pri-miRNA processing	SEQ_UP	1	
REGION:Necessary for homodimerization	SEQ_UP	1	
REGION:Necessary for homodimerization and competence for chromatin assembly	SEQ_UP	1	
REGION:Necessary for homooligomerization and targeting to endosomes	SEQ_UP	1	
REGION:Necessary for interaction with ACTA1	SEQ_UP	1	
REGION:Necessary for interaction with ACTN1	SEQ_UP	1	
REGION:Necessary for interaction with ACVRL1	SEQ_UP	1	
REGION:Necessary for interaction with AKT1	SEQ_UP	1	
REGION:Necessary for interaction with AP2A1, RAB11A, subcellular location, endocytosis activity and homooligomerization	SEQ_UP	1	
REGION:Necessary for interaction with AP2M1, self-assembly and formation of the irregular, mosaic-like adhesion pattern	SEQ_UP	1	
REGION:Necessary for interaction with APEX1	SEQ_UP	1	
REGION:Necessary for interaction with APP and inhibitor effects on APP processing	SEQ_UP	1	
REGION:Necessary for interaction with BRD7 and transcriptional activation	SEQ_UP	1	
REGION:Necessary for interaction with BUB3	SEQ_UP	1	
REGION:Necessary for interaction with CBLN3, and homotrimerization	SEQ_UP	2	
REGION:Necessary for interaction with CBP80	SEQ_UP	1	
REGION:Necessary for interaction with CBX2	SEQ_UP	1	
REGION:Necessary for interaction with CCND1	SEQ_UP	1	
REGION:Necessary for interaction with CIR1	SEQ_UP	1	
REGION:Necessary for interaction with CREB1 and NRF1	SEQ_UP	1	
REGION:Necessary for interaction with CREB1 and NRF1 and for transcriptional coactivation	SEQ_UP	1	
REGION:Necessary for interaction with CREBBP and for the recruitment of CREBBP to the nuclear bodies	SEQ_UP	1	
REGION:Necessary for interaction with CTNNB1	SEQ_UP	1	
REGION:Necessary for interaction with CYFIP1, CYFIP2, FXR1 and FXR2	SEQ_UP	1	
REGION:Necessary for interaction with CYTH1	SEQ_UP	1	
REGION:Necessary for interaction with DDX1	SEQ_UP	1	
REGION:Necessary for interaction with DGCR8 and pri-miRNA processing activity	SEQ_UP	1	
REGION:Necessary for interaction with DST and for the recruitment of DST to hemidesmosome	SEQ_UP	1	
REGION:Necessary for interaction with EHD1	SEQ_UP	1	
REGION:Necessary for interaction with EHD2	SEQ_UP	1	
REGION:Necessary for interaction with EIF4E	SEQ_UP	2	
REGION:Necessary for interaction with ELL	SEQ_UP	1	
REGION:Necessary for interaction with FGF13	SEQ_UP	1	
REGION:Necessary for interaction with FLNC	SEQ_UP	1	
REGION:Necessary for interaction with GRB2	SEQ_UP	1	
REGION:Necessary for interaction with H2AX	SEQ_UP	1	
REGION:Necessary for interaction with HDAC3 and transcriptional repression	SEQ_UP	1	
REGION:Necessary for interaction with HNRNPK	SEQ_UP	2	
REGION:Necessary for interaction with HRMT1L1	SEQ_UP	1	
REGION:Necessary for interaction with HSF1	SEQ_UP	1	
REGION:Necessary for interaction with IGF2BP1 and binding to TAU mRNA	SEQ_UP	1	
REGION:Necessary for interaction with ILF3	SEQ_UP	1	
REGION:Necessary for interaction with KIF5A	SEQ_UP	1	
REGION:Necessary for interaction with KNL1	SEQ_UP	2	
REGION:Necessary for interaction with KPNB1 and m3G-cap U1 and U5 snRNP import receptor activity	SEQ_UP	1	
REGION:Necessary for interaction with MAD1L1	SEQ_UP	1	
REGION:Necessary for interaction with MAD2L1	SEQ_UP	1	
REGION:Necessary for interaction with MARK2 and apicobasal microtubule bundle formation in polarized epithelial cells	SEQ_UP	1	
REGION:Necessary for interaction with MDFIC and transcriptional activation or repression	SEQ_UP	1	
REGION:Necessary for interaction with MDM4	SEQ_UP	1	
REGION:Necessary for interaction with NCL	SEQ_UP	1	
REGION:Necessary for interaction with NEK2	SEQ_UP	1	
REGION:Necessary for interaction with NPM1 and for efficient rRNA binding	SEQ_UP	1	
REGION:Necessary for interaction with NR6A1 C-terminus	SEQ_UP	1	
REGION:Necessary for interaction with NR6A1 N-terminus	SEQ_UP	1	
REGION:Necessary for interaction with NUDT21/CPSF5	SEQ_UP	1	
REGION:Necessary for interaction with NXF1	SEQ_UP	1	
REGION:Necessary for interaction with PABPN1	SEQ_UP	1	
REGION:Necessary for interaction with PNN	SEQ_UP	3	
REGION:Necessary for interaction with PNN and exon-skipping	SEQ_UP	1	
REGION:Necessary for interaction with PPP1CA	SEQ_UP	1	
REGION:Necessary for interaction with PPP1CC	SEQ_UP	1	
REGION:Necessary for interaction with PPP2CA and PPP2R1A	SEQ_UP	1	
REGION:Necessary for interaction with RAB11A and function in neurite outgrowth	SEQ_UP	1	
REGION:Necessary for interaction with RAB11A, subcellular location, homo- or heterooligomerization	SEQ_UP	1	
REGION:Necessary for interaction with RAB4A	SEQ_UP	1	
REGION:Necessary for interaction with RAB4A and RAB11A, subcellular location and endosomal recycling	SEQ_UP	1	
REGION:Necessary for interaction with RAB5A	SEQ_UP	1	
REGION:Necessary for interaction with RAB7A and RAB34 and lysosomal distribution and morphology	SEQ_UP	1	
REGION:Necessary for interaction with RABGEF1	SEQ_UP	1	
REGION:Necessary for interaction with RAD51	SEQ_UP	1	
REGION:Necessary for interaction with Ran	SEQ_UP	1	
REGION:Necessary for interaction with Ran and nuclear export complex formation	SEQ_UP	1	
REGION:Necessary for interaction with RANBP3	SEQ_UP	1	
REGION:Necessary for interaction with RASSF1	SEQ_UP	1	
REGION:Necessary for interaction with RB1 and RBL2	SEQ_UP	1	
REGION:Necessary for interaction with RBL2	SEQ_UP	1	
REGION:Necessary for interaction with RCHY1	SEQ_UP	1	
REGION:Necessary for interaction with RELA	SEQ_UP	1	
REGION:Necessary for interaction with RNA polymerase II holoenzyme	SEQ_UP	1	
REGION:Necessary for interaction with RRAGA	SEQ_UP	1	
REGION:Necessary for interaction with RXRA and repressor activity against RXRA	SEQ_UP	1	
REGION:Necessary for interaction with SART3	SEQ_UP	1	
REGION:Necessary for interaction with single-stranded DNA at the 3'-end of the G4-DNA structure	SEQ_UP	1	
REGION:Necessary for interaction with SLC9A3R2 and nuclear accumulation of SLC9A3R2	SEQ_UP	1	
REGION:Necessary for interaction with SRP54, nuclear localization and exon-skipping	SEQ_UP	1	
REGION:Necessary for interaction with SRSF3, SRSF7 and TRA2B/SFRS10	SEQ_UP	1	
REGION:Necessary for interaction with SS18L1/CREST	SEQ_UP	1	
REGION:Necessary for interaction with TANK	SEQ_UP	1	
REGION:Necessary for interaction with TCEA1 and transactivation activity	SEQ_UP	1	
REGION:Necessary for interaction with the cleaved p110 isoform of CDC2L1	SEQ_UP	1	
REGION:Necessary for interaction with the CTD domain of POLR2A	SEQ_UP	1	
REGION:Necessary for interaction with TNPO1	SEQ_UP	1	
REGION:Necessary for interaction with TP53	SEQ_UP	1	
REGION:Necessary for interaction with TP53BP2	SEQ_UP	1	
REGION:Necessary for interaction with TRA2B, nuclear localization and exon-skipping	SEQ_UP	1	
REGION:Necessary for interaction with TRAF6	SEQ_UP	1	
REGION:Necessary for interaction with UPF1	SEQ_UP	1	
REGION:Necessary for interaction with USP2	SEQ_UP	2	
REGION:Necessary for interaction with USP7	SEQ_UP	1	
REGION:Necessary for interaction with USP7 and ATRX	SEQ_UP	1	
REGION:Necessary for interaction with VAPA	SEQ_UP	1	
REGION:Necessary for interaction with XPO1	SEQ_UP	1	
REGION:Necessary for interaction with YBX1, binding to RNA, association together with NPM1 to rRNA, endoribonuclease activity on abasic RNA and localization in the nucleoli	SEQ_UP	1	
REGION:Necessary for interaction with ZC3H12A	SEQ_UP	2	
REGION:Necessary for interaction with ZC3H12D	SEQ_UP	1	
REGION:Necessary for interaction with ZFYVE27	SEQ_UP	1	
REGION:Necessary for interaction with ZNF208 isoform KRAB-O	SEQ_UP	1	
REGION:Necessary for interactions with PAPOLA and PABPN1	SEQ_UP	1	
REGION:Necessary for interactions with UPF2 and UPF3B and UPF2-dependent NMD	SEQ_UP	1	
REGION:Necessary for intracellular retention in Golgi apparatus lumen	SEQ_UP	1	
REGION:Necessary for its cellular translocation to the plasma membrane	SEQ_UP	1	
REGION:Necessary for its endoplasmic reticulum (ER) retention and interaction with HSPA5	SEQ_UP	1	
REGION:Necessary for its G protein-activation ability and normal distribution of melanosomes	SEQ_UP	1	
REGION:Necessary for its localzation to the endoplasmic reticulum and lipid droplets	SEQ_UP	1	
REGION:Necessary for kinetochore localization	SEQ_UP	1	
REGION:Necessary for localization at adherens junction	SEQ_UP	1	
REGION:Necessary for localization at the cell membrane	SEQ_UP	2	
REGION:Necessary for localization in cytoplasmic stress granules	SEQ_UP	1	
REGION:Necessary for localization of ARE-containing mRNAs to processing bodies (PBs)	SEQ_UP	1	
REGION:Necessary for localization to the mitochondria	SEQ_UP	1	
REGION:Necessary for membrane association	SEQ_UP	1	
REGION:Necessary for membrane localization	SEQ_UP	1	
REGION:Necessary for mitochondria recruitment at the lipid droplet surface	SEQ_UP	1	
REGION:Necessary for mRNA 3'-end cleavage and cytoplasmic accumulation	SEQ_UP	1	
REGION:Necessary for mRNA decay activation	SEQ_UP	2	
REGION:Necessary for nuclear and nucleolar caps localizations	SEQ_UP	1	
REGION:Necessary for nuclear and nucleolar localization	SEQ_UP	1	
REGION:Necessary for nuclear export	SEQ_UP	1	
REGION:Necessary for nuclear localization	SEQ_UP	11	
REGION:Necessary for nuclear localization and DNA-binding	SEQ_UP	1	
REGION:Necessary for nuclear localization and for nucleolar accumulation in response to heat shock	SEQ_UP	1	
REGION:Necessary for nuclear localization and retention	SEQ_UP	1	
REGION:Necessary for nuclear paraspeckles localization	SEQ_UP	1	
REGION:Necessary for nuclear speckle localization	SEQ_UP	1	
REGION:Necessary for nucleolar localization	SEQ_UP	1	
REGION:Necessary for nucleolar localization and for targeting PPP1CA to the nucleolus	SEQ_UP	1	
REGION:Necessary for oligomerization	SEQ_UP	2	
REGION:Necessary for PEX19 function on peroxisome biogenesis	SEQ_UP	1	
REGION:Necessary for PINK1-dependent localization to mitochondria	SEQ_UP	1	
REGION:Necessary for plasma membrane localization	SEQ_UP	1	
REGION:Necessary for poly U RNA-binding and snRNA export	SEQ_UP	1	
REGION:Necessary for polyamine uptake stimulation	SEQ_UP	1	
REGION:Necessary for repressor activity	SEQ_UP	1	
REGION:Necessary for RNA-binding	SEQ_UP	3	
REGION:Necessary for RNA-binding, interaction with MAGOH and localization in nucleus speckles	SEQ_UP	1	
REGION:Necessary for RNA-binding, TNNT2 exon 5 and NMDA R1 exon 21 inclusion	SEQ_UP	1	
REGION:Necessary for self-assembly, microtubule bundling activity and apicobasal microtubule organization	SEQ_UP	1	
REGION:Necessary for speckles and matrix localization	SEQ_UP	1	
REGION:Necessary for ssDNA and DNA Holliday junction binding	SEQ_UP	1	
REGION:Necessary for stimulating PAPOLA activity	SEQ_UP	1	
REGION:Necessary for stress granule assembly and correct localization in dcp1 bodies	SEQ_UP	1	
REGION:Necessary for targeting to centrosomes	SEQ_UP	2	
REGION:Necessary for targeting to peroxisomes and interaction with PEX19	SEQ_UP	1	
REGION:Necessary for TATA box-bound TBP complex formation	SEQ_UP	1	
REGION:Necessary for the association with the MRN complex	SEQ_UP	1	
REGION:Necessary for the catalytic activity	SEQ_UP	1	
REGION:Necessary for the correct targeting to endosomes	SEQ_UP	1	
REGION:Necessary for the interaction with NMI	SEQ_UP	1	
REGION:Necessary for the microtubule-organizing center localization	SEQ_UP	1	
REGION:Necessary for the mitochondrial aggregation and genome destruction	SEQ_UP	1	
REGION:Necessary for the nuclear export of the 60S ribosomal subunit	SEQ_UP	1	
REGION:Necessary for the translational pausing of its own mRNA	SEQ_UP	1	
REGION:Necessary for tight junction and adherens junction localization; Requires for interaction with PARD3	SEQ_UP	1	
REGION:Necessary for TNNT2 exon 5 inclusion	SEQ_UP	1	
REGION:Necessary for transactivation activity	SEQ_UP	2	
REGION:Necessary for transcription repression	SEQ_UP	1	
REGION:Necessary for transcriptional repression	SEQ_UP	3	
REGION:Necessary for transcriptional repression and sufficient for interaction with PER2	SEQ_UP	1	
REGION:Necessary for transcriptional transactivation	SEQ_UP	1	
REGION:Necessary for tumor-suppressive function	SEQ_UP	1	
REGION:Necessary to inhibit MRTFA-induced SRF transcriptional activity	SEQ_UP	1	
REGION:Necessary to inhibit protein synthesis	SEQ_UP	1	
REGION:Necessary to interact with ESRRA, to regulate its subcellular localization and to inhibit its transcriptional activity	SEQ_UP	1	
REGION:Necessary to rescue apical junction formation	SEQ_UP	1	
REGION:Neck	SEQ_UP	1	
REGION:Neck or regulatory domain	SEQ_UP	3	
REGION:NEDD8-binding 1	SEQ_UP	1	
REGION:NEDD8-binding 2	SEQ_UP	1	
REGION:Needed for transcriptional repression	SEQ_UP	1	
REGION:Negative regulation of PRKAR2A-binding	SEQ_UP	1	
REGION:Negative regulator of AP-1 activity	SEQ_UP	1	
REGION:Negative regulator of microtubule-binding	SEQ_UP	1	
REGION:Negative regulatory domain	SEQ_UP	2	
REGION:Negative regulatory region (NRR)	SEQ_UP	1	
REGION:Negatively regulates HAT activity	SEQ_UP	1	
REGION:Negatively regulates interaction with ARHGEF16	SEQ_UP	1	
REGION:Negatively regulates targeting to plasma membrane	SEQ_UP	1	
REGION:Negatively regulates the responsiveness of the catalytic activity by cardiolipin and is required for optimal activation by the GTP-bound RhoA	SEQ_UP	1	
REGION:NELF-C/D-binding	SEQ_UP	1	
REGION:NEMO-binding	SEQ_UP	2	
REGION:Nervy homology region 2 (NHR2)	SEQ_UP	2	
REGION:Nervy homology region 2 (NHR2); essential for down-regulation of PFKFB3, PFKFB4 and PDK1 expression	SEQ_UP	1	
REGION:Nervy homology region 3 (NHR3)	SEQ_UP	2	
REGION:Nervy homology region 3 (NHR3); essential for down-regulation of PFKFB3, PFKFB4 and PDK1 expression	SEQ_UP	1	
REGION:Neurite growth inhibition	SEQ_UP	1	
REGION:Neuroprotective peptide	SEQ_UP	1	
REGION:Neurotensin binding	SEQ_UP	1	
REGION:NG domain	SEQ_UP	1	
REGION:NG-domain	SEQ_UP	2	
REGION:NGL discriminant loop I	SEQ_UP	2	
REGION:NGL discriminant loop II	SEQ_UP	2	
REGION:NGL discriminant loop III	SEQ_UP	2	
REGION:Nicotinamide ribonucleotide binding	SEQ_UP	1	
REGION:NifU	SEQ_UP	1	
REGION:Nitrobindin	SEQ_UP	1	
REGION:NLRP3-binding	SEQ_UP	1	
REGION:NLS 1	SEQ_UP	1	
REGION:NLS 2	SEQ_UP	1	
REGION:NLS binding site (major)	SEQ_UP	5	
REGION:NLS binding site (minor)	SEQ_UP	5	
REGION:NMP	SEQ_UP	7	
REGION:NMP 1	SEQ_UP	2	
REGION:NMP 2	SEQ_UP	2	
REGION:NMPbind	SEQ_UP	3	
REGION:No DNA binding activity or transactivation activity, but complete prevention of TRAF-dependent NF-Kappa-B activation; associates with TRAF2 and JUN	SEQ_UP	1	
REGION:Non-collagenous domain 1 association domain	SEQ_UP	1	
REGION:Non-collagenous domain 1 hinge region	SEQ_UP	1	
REGION:Non-specific ssDNA binding	SEQ_UP	1	
REGION:Non-specific-nucleotide binding in RNA target	SEQ_UP	2	
REGION:Nonhelical region	SEQ_UP	7	
REGION:Nonhelical region (C-terminal)	SEQ_UP	3	
REGION:Nonhelical region (N-terminal)	SEQ_UP	2	
REGION:Nonhelical region (NC1)	SEQ_UP	7	
REGION:Nonhelical region (NC16)	SEQ_UP	1	
REGION:Nonhelical region (NC2)	SEQ_UP	6	
REGION:Nonhelical region (NC3)	SEQ_UP	2	
REGION:Nonhelical region (NC4)	SEQ_UP	2	
REGION:Nonhelical region 1 (NC1)	SEQ_UP	5	
REGION:Nonhelical region 10 (NC10)	SEQ_UP	2	
REGION:Nonhelical region 11 (NC11)	SEQ_UP	1	
REGION:Nonhelical region 2 (NC2)	SEQ_UP	5	
REGION:Nonhelical region 3 (NC3)	SEQ_UP	5	
REGION:Nonhelical region 4 (NC4)	SEQ_UP	5	
REGION:Nonhelical region 5 (NC5)	SEQ_UP	3	
REGION:Nonhelical region 6 (NC6)	SEQ_UP	3	
REGION:Nonhelical region 7 (NC7)	SEQ_UP	3	
REGION:Nonhelical region 8 (NC8)	SEQ_UP	3	
REGION:Nonhelical region 9 (NC9)	SEQ_UP	2	
REGION:Not essential for folding and stability of GINS complex, but may regulate accessibility to the central complex pore	SEQ_UP	1	
REGION:Not required for free DNA-nuclease activity but required for activity towards liposome-coated DNA	SEQ_UP	1	
REGION:Not required for full biological activity	SEQ_UP	1	
REGION:NPS region	SEQ_UP	1	
REGION:NTAD	SEQ_UP	3	
REGION:NTD region	SEQ_UP	1	
REGION:NTE motif	SEQ_UP	1	
REGION:Nuclear and nucleolar localization	SEQ_UP	1	
REGION:Nuclear export signal	SEQ_UP	2	
REGION:Nuclear export signal (isoform 2)	SEQ_UP	1	
REGION:Nuclear focus formation	SEQ_UP	1	
REGION:Nuclear localization	SEQ_UP	3	
REGION:Nuclear localization region	SEQ_UP	1	
REGION:Nuclear localization regulation	SEQ_UP	1	
REGION:Nuclear localization signal	SEQ_UP	5	
REGION:Nuclear localization signal (isoform 2)	SEQ_UP	1	
REGION:Nuclear localization signal (NLS)	SEQ_UP	1	
REGION:Nuclear localization signal (NLS); in isoforms 1 and isoform 2	SEQ_UP	1	
REGION:Nuclear matrix binding	SEQ_UP	1	
REGION:Nuclear matrix targeting sequence (NMTS)	SEQ_UP	1	
REGION:Nuclear receptor binding site (NRBS)	SEQ_UP	1	
REGION:Nuclear targeting sequence	SEQ_UP	2	
REGION:Nuclease	SEQ_UP	4	
REGION:Nuclease activity	SEQ_UP	1	
REGION:Nuclease domain	SEQ_UP	2	
REGION:Nucleolar localization	SEQ_UP	1	
REGION:Nucleolar localization signal	SEQ_UP	1	
REGION:Nucleoplasmic	SEQ_UP	1	
REGION:Nucleotide-binding (NBD)	SEQ_UP	1	
REGION:Nucleotide-binding domain (NBD)	SEQ_UP	6	
REGION:O-glycosylated at one site	SEQ_UP	1	
REGION:O-glycosylated at seven sites with GalNAc	SEQ_UP	1	
REGION:O-phospho-L-serine binding	SEQ_UP	1	
REGION:OAS domain 1	SEQ_UP	2	
REGION:OAS domain 2	SEQ_UP	2	
REGION:OAS domain 3	SEQ_UP	1	
REGION:OB-fold	SEQ_UP	1	
REGION:OB-fold domain	SEQ_UP	1	
REGION:OB-fold-like subdomains	SEQ_UP	1	
REGION:Occludin (OCLN)-binding region	SEQ_UP	1	
REGION:Octadecanoate binding	SEQ_UP	1	
REGION:ODD	SEQ_UP	2	
REGION:Oleate binding	SEQ_UP	2	
REGION:Oligomerization	SEQ_UP	5	
REGION:Omega-loop	SEQ_UP	1	
REGION:OMPdecase	SEQ_UP	1	
REGION:OPRTase	SEQ_UP	1	
REGION:OR1, C-terminal part	SEQ_UP	1	
REGION:OR1, N-terminal part	SEQ_UP	1	
REGION:OR2	SEQ_UP	1	
REGION:Ornithine binding	SEQ_UP	1	
REGION:Orotidine 5'-phosphate binding	SEQ_UP	1	
REGION:Outer juxtamembrane helix (OJMH)	SEQ_UP	1	
REGION:P domain	SEQ_UP	1	
REGION:P domain (Extended arm)	SEQ_UP	1	
REGION:P-domain	SEQ_UP	2	
REGION:P-domain; part 1	SEQ_UP	1	
REGION:P-domain; part 2	SEQ_UP	1	
REGION:P-domain; part 3	SEQ_UP	1	
REGION:P-helix	SEQ_UP	1	
REGION:P1 (binding site for GEMIN2)	SEQ_UP	1	
REGION:P2 (binding site for SNRPB)	SEQ_UP	1	
REGION:p300 KIX-binding	SEQ_UP	1	
REGION:p38 MAPK-binding site	SEQ_UP	2	
REGION:PABPC1-binding	SEQ_UP	2	
REGION:PABPC1-interacting motif-1 (PAM1)	SEQ_UP	2	
REGION:PABPC1-interacting motif-2 (PAM2)	SEQ_UP	4	
REGION:PAI subdomain	SEQ_UP	9	
REGION:PAIP1 middle domain (PAIP1M)	SEQ_UP	1	
REGION:Palmitate binding	SEQ_UP	2	
REGION:Palmitate-binding groove	SEQ_UP	1	
REGION:Palmitoylated on several cysteines	SEQ_UP	1	
REGION:Pantothenate kinase	SEQ_UP	1	
REGION:PAPS binding	SEQ_UP	5	
REGION:PAR-binding	SEQ_UP	1	
REGION:Part of a helix bundle domain, formed by helices from N-terminal and C-terminal regions	SEQ_UP	2	
REGION:Part of the peptide-binding site	SEQ_UP	2	
REGION:Partial activation of MRGPRA1	SEQ_UP	1	
REGION:PBC-A	SEQ_UP	4	
REGION:PBC-B	SEQ_UP	4	
REGION:PBR	SEQ_UP	2	
REGION:PCGF Ub-like fold domain (PUFD); required for the interaction with the KDM2B-SKP1 heterodimeric complex	SEQ_UP	1	
REGION:pDED	SEQ_UP	2	
REGION:PDIA3-binding site	SEQ_UP	1	
REGION:PDZ domain-binding	SEQ_UP	1	
REGION:PDZ-binding	SEQ_UP	1	
REGION:PDZ-binding domain	SEQ_UP	1	
REGION:PDZ3-binding	SEQ_UP	1	
REGION:PDZD11-binding	SEQ_UP	1	
REGION:Peptidase M2 1	SEQ_UP	1	
REGION:Peptidase M2 2	SEQ_UP	1	
REGION:Peptidase S68	SEQ_UP	2	
REGION:Peptide inhibitor binding	SEQ_UP	1	
REGION:Peptidyl-alpha-hydroxyglycine alpha-amidating lyase	SEQ_UP	1	
REGION:Peptidylglycine alpha-hydroxylating monooxygenase	SEQ_UP	1	
REGION:PEST	SEQ_UP	3	
REGION:PEST-like	SEQ_UP	2	
REGION:PEST1	SEQ_UP	1	
REGION:PEST2	SEQ_UP	1	
REGION:PEST3	SEQ_UP	1	
REGION:PEX19 binding site and required for peroxisomal targeting	SEQ_UP	1	
REGION:PH-like	SEQ_UP	1	
REGION:PH-like; mediates interaction with TGFB1I1	SEQ_UP	1	
REGION:Phenylalkylamine binding	SEQ_UP	4	
REGION:Phosphatase	SEQ_UP	3	
REGION:Phosphatase sequence motif I	SEQ_UP	8	
REGION:Phosphatase sequence motif II	SEQ_UP	8	
REGION:Phosphatase sequence motif III	SEQ_UP	8	
REGION:Phosphatase-like	SEQ_UP	1	
REGION:Phosphate binding	SEQ_UP	8	
REGION:Phosphate loop (P-loop)	SEQ_UP	1	
REGION:Phosphatidylglycerol phosphate binding	SEQ_UP	1	
REGION:Phosphatidylinositol 3-phosphate binding	SEQ_UP	1	
REGION:Phosphatidylinositol 3,4-bisphosphate binding	SEQ_UP	1	
REGION:Phosphatidylinositol 3,4,5-trisphosphate binding	SEQ_UP	5	
REGION:Phosphatidylinositol 4-phosphate binding	SEQ_UP	4	
REGION:Phosphatidylinositol 4,5-bisphosphate binding	SEQ_UP	2	
REGION:Phosphatidylinositol binding	SEQ_UP	5	
REGION:Phosphatidylinositol bisphosphate binding	SEQ_UP	2	
REGION:Phosphatidylinositol-4,5-bisphosphate binding	SEQ_UP	1	
REGION:phosphatidylinositol-4,5-bisphosphate-binding	SEQ_UP	1	
REGION:Phosphatidylserine binding	SEQ_UP	3	
REGION:Phospho-regulated basic and hydrophobic (PRBH) motif	SEQ_UP	2	
REGION:Phosphocholine binding	SEQ_UP	1	
REGION:Phosphodiesterase	SEQ_UP	3	
REGION:Phosphoinositide-3 kinase binding	SEQ_UP	1	
REGION:Phosphoinositide-binding	SEQ_UP	2	
REGION:Phospholipase A2-like	SEQ_UP	1	
REGION:Phospholipase A2-like 1	SEQ_UP	1	
REGION:Phospholipase A2-like 2	SEQ_UP	1	
REGION:Phospholipase A2-like 3	SEQ_UP	1	
REGION:Phospholipid binding	SEQ_UP	3	
REGION:Phosphopantetheine adenylyltransferase	SEQ_UP	1	
REGION:Photolesion recognition	SEQ_UP	1	
REGION:PHR domain 1	SEQ_UP	1	
REGION:PHR domain 2	SEQ_UP	1	
REGION:PIF-pocket	SEQ_UP	1	
REGION:PIK3R1 binding	SEQ_UP	1	
REGION:PIK3R1 binding site	SEQ_UP	1	
REGION:PIM1-binding	SEQ_UP	1	
REGION:PIN (nNOS-inhibiting protein) binding	SEQ_UP	1	
REGION:PIN1-binding	SEQ_UP	1	
REGION:PINT	SEQ_UP	1	
REGION:PKA-RI and PKA-RII subunit binding domain	SEQ_UP	1	
REGION:PKA-RI-alpha subunit binding domain	SEQ_UP	1	
REGION:PKA-RI-binding	SEQ_UP	1	
REGION:PKA-RII subunit binding	SEQ_UP	1	
REGION:PKA-RII subunit binding domain	SEQ_UP	6	
REGION:PKA-RII-alpha subunit binding domain	SEQ_UP	1	
REGION:Plays an important role in murine norovirus (MNV) binding	SEQ_UP	1	
REGION:Pocket; binds E1A	SEQ_UP	1	
REGION:Pocket; binds T and E1A	SEQ_UP	2	
REGION:Polybasic cluster (PBR)	SEQ_UP	1	
REGION:Polybasic region	SEQ_UP	1	
REGION:Polyphosphoinositide (PIP2)-binding	SEQ_UP	1	
REGION:Polyphosphoinositide binding	SEQ_UP	3	
REGION:Polyphosphoinositide-binding domain	SEQ_UP	2	
REGION:Polyubiquitin-binding	SEQ_UP	1	
REGION:Pore side	SEQ_UP	1	
REGION:Pore-forming	SEQ_UP	5	
REGION:Pore-forming motif	SEQ_UP	2	
REGION:Positively charged region required for RNA-binding	SEQ_UP	2	
REGION:Possesses 3'-5' exonuclease activity	SEQ_UP	1	
REGION:PP2A-binding	SEQ_UP	1	
REGION:PPP2CB binding site	SEQ_UP	1	
REGION:PQA	SEQ_UP	1	
REGION:PRAD	SEQ_UP	1	
REGION:Pre-methyltransferase (preMT)	SEQ_UP	1	
REGION:Pre-siRNA binding	SEQ_UP	1	
REGION:preferentially binds ssDNA	SEQ_UP	1	
REGION:PreLIM	SEQ_UP	1	
REGION:Prevents binding to prenylated RHOA	SEQ_UP	1	
REGION:Prevents interaction with ITGB1 when S-554 is not phosphorylated	SEQ_UP	1	
REGION:Primer grip sequence	SEQ_UP	1	
REGION:PRKAR2A-binding	SEQ_UP	1	
REGION:Pro-ACR binding	SEQ_UP	1	
REGION:Proline--tRNA ligase	SEQ_UP	1	
REGION:Proline-rich domain (PRD)	SEQ_UP	4	
REGION:Proline-rich domain (PRD) which mediates interaction with VAV1	SEQ_UP	1	
REGION:Proline-rich domain (PRD); mediates interaction with the COPII coat subunits SEC23A and SEC23B	SEQ_UP	1	
REGION:Proline-rich domain (PRD); probably mediates interaction with COPII coat subunits	SEQ_UP	1	
REGION:Proline-rich region necessary for constitutive interaction with LYN	SEQ_UP	1	
REGION:Proline-rich region; mediates mutually exclusive interactions with itself and NOXA1	SEQ_UP	1	
REGION:Promotes p53/TP53 degradation	SEQ_UP	1	
REGION:Promotes stable association with the 40S ribosome	SEQ_UP	2	
REGION:ProSAAS(1-180)	SEQ_UP	1	
REGION:ProST region	SEQ_UP	1	
REGION:Protease	SEQ_UP	7	
REGION:Protein interaction domain; mediates interaction with DNA polymerase zeta	SEQ_UP	1	
REGION:Protein kinase-like	SEQ_UP	1	
REGION:Protein tyrosine phosphatase	SEQ_UP	1	
REGION:Proteoglycan-like (PG)	SEQ_UP	1	
REGION:Proximal segment	SEQ_UP	1	
REGION:Pseudokinase domain	SEQ_UP	1	
REGION:PSIP1-binding	SEQ_UP	1	
REGION:PT region; mediates the BCR-dependent translocation to plasma membrane	SEQ_UP	1	
REGION:PTB-like F3 module	SEQ_UP	1	
REGION:Purine nucleotide binding	SEQ_UP	2	
REGION:Putative calmodulin-binding region	SEQ_UP	3	
REGION:Putrescine binding	SEQ_UP	1	
REGION:PXDLS motif	SEQ_UP	1	
REGION:Pyridoxal 5'-phosphate	SEQ_UP	1	
REGION:Pyridoxal 5'-phosphate binding	SEQ_UP	2	
REGION:Pyridoxal phosphate binding	SEQ_UP	7	
REGION:Pyridoxal phosphate binding; shared with dimeric partner	SEQ_UP	1	
REGION:Q domain	SEQ_UP	4	
REGION:Q domain; Interaction with PI4KB, TBC1D22A and TBC1D22B	SEQ_UP	1	
REGION:QFP motif	SEQ_UP	1	
REGION:Qua1 domain; involved in homodimerization	SEQ_UP	1	
REGION:Qua2 domain; involved in RNA binding	SEQ_UP	1	
REGION:Quinolinate binding	SEQ_UP	1	
REGION:R-domain (ssRNA-binding)	SEQ_UP	1	
REGION:RAE1 binding	SEQ_UP	1	
REGION:RAF1-binding	SEQ_UP	1	
REGION:Ran-GTP binding	SEQ_UP	2	
REGION:Ras exchanger motif region; required for transforming activity	SEQ_UP	1	
REGION:RASSF1-binding	SEQ_UP	1	
REGION:RB1 binding	SEQ_UP	1	
REGION:RB1CC1-binding	SEQ_UP	1	
REGION:RBL2 association	SEQ_UP	1	
REGION:RBM7 binding	SEQ_UP	1	
REGION:RCL	SEQ_UP	14	
REGION:Reactive center loop	SEQ_UP	1	
REGION:RecA-like domain 1	SEQ_UP	1	
REGION:RecA-like domain 2	SEQ_UP	2	
REGION:Receptor and heparin binding	SEQ_UP	1	
REGION:Receptor binding	SEQ_UP	1	
REGION:Receptor binding site	SEQ_UP	1	
REGION:Recognition loop	SEQ_UP	1	
REGION:Recognized by alloreactive CD8 cytotoxic T-lymphocytes in association with a class I MHC protein	SEQ_UP	1	
REGION:RED subdomain	SEQ_UP	9	
REGION:Region A; interaction with DDX6/RCK	SEQ_UP	1	
REGION:Region C	SEQ_UP	1	
REGION:Region H	SEQ_UP	1	
REGION:Region II	SEQ_UP	2	
REGION:Region N; interaction with decapping machinery	SEQ_UP	1	
REGION:Regulates association with membranes	SEQ_UP	1	
REGION:Regulates microtubule-binding	SEQ_UP	1	
REGION:Regulates polymerization into filaments	SEQ_UP	1	
REGION:Regulates proteasomal degradation	SEQ_UP	1	
REGION:Regulates protein turnover upon amino acid deprivation	SEQ_UP	1	
REGION:Regulates ubiquitin dissociation	SEQ_UP	1	
REGION:Regulatory	SEQ_UP	1	
REGION:Regulatory domain	SEQ_UP	2	
REGION:Regulatory juxtamembrane domain	SEQ_UP	1	
REGION:Regulatory loop	SEQ_UP	2	
REGION:Regulatory region; modulates activity toward RHOA, RAC1 and CDC42	SEQ_UP	1	
REGION:Regulatory/phosphorylation domain	SEQ_UP	1	
REGION:REP	SEQ_UP	1	
REGION:Repeat-rich region	SEQ_UP	3	
REGION:Repeats, Gly-rich	SEQ_UP	1	
REGION:Represses ARE-mediated transcription	SEQ_UP	1	
REGION:Represses p53/TP53 degradation	SEQ_UP	1	
REGION:Represses transcription	SEQ_UP	1	
REGION:Repression domain 1	SEQ_UP	1	
REGION:Repression domain 1 (RD1)	SEQ_UP	1	
REGION:Repression domain 2	SEQ_UP	1	
REGION:Repression domain 3	SEQ_UP	1	
REGION:Repression domain 4	SEQ_UP	1	
REGION:Repression domain; contains 3 sumoylation motifs and massively decrease transcription activity	SEQ_UP	1	
REGION:Repressive function	SEQ_UP	1	
REGION:Repressor domain	SEQ_UP	6	
REGION:Required and sufficient for interaction with BAG6	SEQ_UP	1	
REGION:Required and sufficient for interaction with KDM1A	SEQ_UP	2	
REGION:Required and sufficient for interaction with POMGNT1	SEQ_UP	1	
REGION:Required and sufficient for location at clathrin-coated pits	SEQ_UP	1	
REGION:Required and sufficient for mitochondrial import	SEQ_UP	1	
REGION:Required and sufficient for nuclear import	SEQ_UP	1	
REGION:Required and sufficient for targeting to lysosomes and lamellar bodies	SEQ_UP	1	
REGION:Required for 11-cis-retinal regeneration	SEQ_UP	1	
REGION:Required for 28S ribosomal RNA processing	SEQ_UP	1	
REGION:Required for acceleration of G1 phase	SEQ_UP	1	
REGION:Required for acetyltransferase activity	SEQ_UP	1	
REGION:Required for activation by RHOA, RHOB, GNA12, GNA13 and G-beta gamma	SEQ_UP	1	
REGION:Required for activation of histone gene transcription and interaction with MIZF	SEQ_UP	1	
REGION:Required for activation of histone H4 transcription and contributes to DNA-binding	SEQ_UP	1	
REGION:Required for activation of KAT8 histone acetyltransferase activity	SEQ_UP	1	
REGION:Required for activation of RUNX1-1	SEQ_UP	1	
REGION:Required for activation of RUNX1-2	SEQ_UP	1	
REGION:Required for activation upon DNA viral infection	SEQ_UP	1	
REGION:Required for anti-apoptotic activity	SEQ_UP	1	
REGION:Required for AP2A2-binding	SEQ_UP	1	
REGION:Required for apoptosis induction	SEQ_UP	1	
REGION:Required for assembly of the IB complex	SEQ_UP	1	
REGION:Required for association with Golgi	SEQ_UP	1	
REGION:Required for association with membranes	SEQ_UP	1	
REGION:Required for association with membranes and function in neurite spine formation	SEQ_UP	1	
REGION:Required for association with the cell membrane	SEQ_UP	1	
REGION:Required for association with the CHRAC1/POLE3 complex	SEQ_UP	1	
REGION:Required for association with the NAA10-NAA15 complex	SEQ_UP	1	
REGION:Required for assuming the closed conformation and for interaction with CDC20	SEQ_UP	1	
REGION:Required for ATPase activity	SEQ_UP	1	
REGION:Required for autoinhibition	SEQ_UP	1	
REGION:Required for basal channel activity	SEQ_UP	1	
REGION:Required for basolateral membrane targeting	SEQ_UP	1	
REGION:Required for basolateral targeting	SEQ_UP	1	
REGION:Required for beta-catenin-binding	SEQ_UP	1	
REGION:Required for binding 2'-O-methylated 3'-end of piRNAs	SEQ_UP	1	
REGION:Required for binding alpha, beta and gamma catenins	SEQ_UP	1	
REGION:Required for binding calmodulin	SEQ_UP	1	
REGION:Required for binding CDKs	SEQ_UP	1	
REGION:Required for binding corepressor NCOR1	SEQ_UP	1	
REGION:Required for binding CTNND1 and PSEN1	SEQ_UP	1	
REGION:Required for binding cyclins	SEQ_UP	1	
REGION:Required for binding D-type cyclins	SEQ_UP	1	
REGION:Required for binding DMD and UTRN	SEQ_UP	1	
REGION:Required for binding PP1CC	SEQ_UP	1	
REGION:Required for binding PPP1CC	SEQ_UP	1	
REGION:Required for binding PPP1CC catalytic center, displacing metal ions and inhibition of PPP1CC catalytic activity	SEQ_UP	1	
REGION:Required for binding the 'RVXF' binding groove of PPP1CC	SEQ_UP	1	
REGION:Required for binding to Lilrb4a	SEQ_UP	1	
REGION:Required for binding to MAP2K5	SEQ_UP	1	
REGION:Required for binding to PARVA and ILK	SEQ_UP	1	
REGION:Required for binding to PtdIns(4,5)P2	SEQ_UP	1	
REGION:Required for binding to sulfatide and phosphoinositides	SEQ_UP	1	
REGION:Required for binding to sulfatide and phosphoinositides and for membrane localization	SEQ_UP	1	
REGION:Required for binding to the neuron-restrictive silencer element	SEQ_UP	1	
REGION:Required for binding to tRNA	SEQ_UP	1	
REGION:Required for binding to WASF1	SEQ_UP	1	
REGION:Required for both calcium stimulation and maintenance of autoinhibition	SEQ_UP	1	
REGION:Required for both high-affinity DNA binding and pericentromeric heterochromatin localization	SEQ_UP	1	
REGION:Required for BRCA1 binding	SEQ_UP	1	
REGION:Required for C4-hydroxylase activity	SEQ_UP	1	
REGION:Required for CARD9 binding	SEQ_UP	1	
REGION:Required for centromere localization	SEQ_UP	1	
REGION:Required for centrosomal attachment, Golgi localization and CALM1 interaction	SEQ_UP	1	
REGION:Required for centrosomal attachment, Golgi targeting and CALM1 interaction	SEQ_UP	1	
REGION:Required for centrosomal localization	SEQ_UP	2	
REGION:Required for centrosome localization	SEQ_UP	3	
REGION:Required for centrosome localization and for its function in the suppression of centrosome disjunction	SEQ_UP	1	
REGION:Required for centrosome location	SEQ_UP	1	
REGION:Required for chemotactic activity	SEQ_UP	1	
REGION:Required for chromatin remodeling, strand pairing activities and coupling of ATPase activity	SEQ_UP	1	
REGION:Required for CIT-binding	SEQ_UP	1	
REGION:Required for complex formation with BFSP1 and BFSP2	SEQ_UP	1	
REGION:Required for correct folding and localization	SEQ_UP	1	
REGION:Required for correct nuclear localization and exclusion from the nucleoli	SEQ_UP	1	
REGION:Required for cortical localization	SEQ_UP	1	
REGION:Required for CTNNB1 accumulation and TCF transcription factor activity	SEQ_UP	1	
REGION:Required for cytoplasmic localization	SEQ_UP	1	
REGION:Required for cytoplasmic retention	SEQ_UP	1	
REGION:Required for cytoplasmic retention of the phosphorylated form	SEQ_UP	1	
REGION:Required for cytoplasmic targeting	SEQ_UP	1	
REGION:Required for degradation in response to high membrane cholesterol levels	SEQ_UP	1	
REGION:Required for dendritic targeting	SEQ_UP	1	
REGION:Required for dendritic transport	SEQ_UP	1	
REGION:Required for dimerization	SEQ_UP	3	
REGION:Required for dimerization and maintaining endoplasmic reticulum morphology	SEQ_UP	1	
REGION:Required for dimerization upon membrane association	SEQ_UP	3	
REGION:Required for DNA-binding	SEQ_UP	5	
REGION:Required for DNA-binding and interaction with NFKBIA	SEQ_UP	1	
REGION:Required for DNA-binding and transcriptional repression	SEQ_UP	1	
REGION:Required for DNA-dependent ATPase activity	SEQ_UP	1	
REGION:Required for DNA-PK heterotrimer	SEQ_UP	1	
REGION:Required for down-regulation of SNAI1	SEQ_UP	2	
REGION:Required for E3 SUMO-ligase activity	SEQ_UP	1	
REGION:Required for E3 UFM1-protein ligase activity	SEQ_UP	1	
REGION:Required for efficient Golgi apparatus - endosome sorting	SEQ_UP	1	
REGION:Required for endoplasmic reticulum localization	SEQ_UP	1	
REGION:Required for endoplasmic reticulum targeting	SEQ_UP	1	
REGION:Required for endoribonuclease activity	SEQ_UP	1	
REGION:Required for endosomal and lysosomal localization	SEQ_UP	1	
REGION:Required for endosomal and lysosomal localization and myristoylation	SEQ_UP	1	
REGION:Required for endothelial cell death	SEQ_UP	1	
REGION:Required for endothelial cell migration	SEQ_UP	1	
REGION:Required for enzyme activity	SEQ_UP	1	
REGION:Required for F-X-F-G repeats-nucleoporins recognition and nuclear import	SEQ_UP	1	
REGION:Required for FBXL14-triggered degradation	SEQ_UP	1	
REGION:Required for fibroblast proliferation	SEQ_UP	1	
REGION:Required for formation of a 5-methylcytosine-binding pocket	SEQ_UP	1	
REGION:Required for formation of endosomal tubules when overexpressed with PIP5K1C	SEQ_UP	1	
REGION:Required for formation of RAD51 foci	SEQ_UP	1	
REGION:Required for function in lipid remodeling	SEQ_UP	1	
REGION:Required for G4-DNA- and G4-RNA-binding	SEQ_UP	1	
REGION:Required for galactolipase activity	SEQ_UP	1	
REGION:Required for glycosyltransferase activity	SEQ_UP	1	
REGION:Required for GRB10-binding	SEQ_UP	1	
REGION:Required for GRIP1 interaction	SEQ_UP	1	
REGION:Required for H3K9me2-binding	SEQ_UP	1	
REGION:Required for helicase activity	SEQ_UP	1	
REGION:Required for heterochromatin localization	SEQ_UP	1	
REGION:Required for heterodimer formation with ARNT	SEQ_UP	2	
REGION:Required for heterodimer formation with EPAS1	SEQ_UP	1	
REGION:Required for heterodimer formation with HIF1A	SEQ_UP	1	
REGION:Required for heterodimerization with RXRA	SEQ_UP	1	
REGION:Required for heterodimerization with the heparanase 8 kDa subunit	SEQ_UP	1	
REGION:Required for hexamers formation and DNA helicase activity	SEQ_UP	1	
REGION:Required for histone binding	SEQ_UP	1	
REGION:Required for Holliday junction resolution activity	SEQ_UP	1	
REGION:Required for homodimer formation	SEQ_UP	1	
REGION:Required for homodimer formation and heterodimer formation with ARL6IP1	SEQ_UP	1	
REGION:Required for homodimerization	SEQ_UP	8	
REGION:Required for homodimerization and for interaction with CRY1 and CHEK1	SEQ_UP	1	
REGION:Required for homodimerization and interaction with MTMR2	SEQ_UP	1	
REGION:Required for homodimerization and interaction with NFYA	SEQ_UP	1	
REGION:Required for homodimerization and kinase activation and localization to the nucleus	SEQ_UP	1	
REGION:Required for homodimerization and nuclear accumulation	SEQ_UP	1	
REGION:Required for homodimerization, interaction with PEX11G, and peroxisomal localization	SEQ_UP	1	
REGION:Required for homooligomerization	SEQ_UP	3	
REGION:Required for homophilic binding	SEQ_UP	1	
REGION:Required for homotrimerization and for interaction with CAVIN2 and CAVIN3	SEQ_UP	1	
REGION:Required for homotrimerization and induction of pyroptosomes	SEQ_UP	1	
REGION:Required for IL4-induced gene expression	SEQ_UP	1	
REGION:Required for induction of apoptosis	SEQ_UP	1	
REGION:Required for induction of mitochondrial fragmentation	SEQ_UP	1	
REGION:Required for inhibition of CAPN3 protease activity	SEQ_UP	1	
REGION:Required for inhibition of CLOCK-ARNTL-mediated transcription	SEQ_UP	1	
REGION:Required for inhibition of CLOCK-ARNTL/BMAL1-mediated transcription	SEQ_UP	1	
REGION:Required for inhibition of ESR1-dependent transcription	SEQ_UP	1	
REGION:Required for inhibition of LPL lipase activity	SEQ_UP	1	
REGION:Required for inhibitor TIMP2 binding	SEQ_UP	1	
REGION:Required for inhibitory activity of TNF-induced NF-kappa-B activation	SEQ_UP	1	
REGION:Required for insertion into the membrane	SEQ_UP	4	
REGION:Required for interaction and inhibitory function toward DDX58	SEQ_UP	1	
REGION:Required for interaction with ABI1	SEQ_UP	1	
REGION:Required for interaction with actin-capping proteins	SEQ_UP	1	
REGION:Required for interaction with ADRB2	SEQ_UP	1	
REGION:Required for interaction with AHCYL1	SEQ_UP	1	
REGION:Required for interaction with and acetylation by EP300	SEQ_UP	1	
REGION:Required for interaction with and ubiquitination by MARCHF2	SEQ_UP	1	
REGION:Required for interaction with ankyrins	SEQ_UP	1	
REGION:Required for interaction with APBA3	SEQ_UP	1	
REGION:Required for interaction with ASCC3	SEQ_UP	1	
REGION:Required for interaction with ATG8 family proteins	SEQ_UP	1	
REGION:Required for interaction with ATL1	SEQ_UP	1	
REGION:Required for interaction with ATP6V1D	SEQ_UP	1	
REGION:Required for interaction with BAG6	SEQ_UP	1	
REGION:Required for interaction with beta- and gamma-catenins	SEQ_UP	1	
REGION:Required for interaction with CAV1	SEQ_UP	1	
REGION:Required for interaction with CAV3	SEQ_UP	2	
REGION:Required for interaction with CBX5	SEQ_UP	1	
REGION:Required for interaction with CBX5 and TBPL1	SEQ_UP	1	
REGION:Required for interaction with CCND1	SEQ_UP	1	
REGION:Required for interaction with CEP290	SEQ_UP	1	
REGION:Required for interaction with CIDEC	SEQ_UP	1	
REGION:Required for interaction with CNOT1, CNOT3 and CNOT7	SEQ_UP	1	
REGION:Required for interaction with coatomer	SEQ_UP	1	
REGION:Required for interaction with COP1	SEQ_UP	1	
REGION:Required for interaction with CPEB3	SEQ_UP	1	
REGION:Required for interaction with CRB1	SEQ_UP	1	
REGION:Required for interaction with CSK	SEQ_UP	1	
REGION:Required for interaction with CTNNB1	SEQ_UP	1	
REGION:Required for interaction with CTNNBL1	SEQ_UP	1	
REGION:Required for interaction with CTNND2	SEQ_UP	1	
REGION:Required for interaction with DAG1	SEQ_UP	1	
REGION:Required for interaction with DAZ1	SEQ_UP	1	
REGION:Required for interaction with DDB1	SEQ_UP	1	
REGION:Required for interaction with DDX6	SEQ_UP	1	
REGION:Required for interaction with DHX15	SEQ_UP	1	
REGION:Required for interaction with DRG1	SEQ_UP	1	
REGION:Required for interaction with DVL2 and SUDS3	SEQ_UP	1	
REGION:Required for interaction with EFTUD2 and SNRNP200	SEQ_UP	1	
REGION:Required for interaction with EZR, MSN and RDX and co-localization to microvilli	SEQ_UP	1	
REGION:Required for interaction with EZR, MSN and RDX and for co-localization to microvilli	SEQ_UP	1	
REGION:Required for interaction with EZR, MSN and RDX and for the co-localization to microvilli	SEQ_UP	1	
REGION:Required for interaction with F-actin	SEQ_UP	1	
REGION:Required for interaction with F-actin-capping protein subunit alpha (CAPZA1 or CAPZA2 or CAPZA3)	SEQ_UP	1	
REGION:Required for interaction with FAM83D	SEQ_UP	1	
REGION:Required for interaction with FASLG and localization to lysosomes	SEQ_UP	1	
REGION:Required for interaction with FAT1	SEQ_UP	1	
REGION:Required for interaction with FBXO42	SEQ_UP	1	
REGION:Required for interaction with FCHSD2	SEQ_UP	1	
REGION:Required for interaction with FOXK1	SEQ_UP	1	
REGION:Required for interaction with FOXO1	SEQ_UP	1	
REGION:Required for interaction with FOXO4 and MEF2C	SEQ_UP	1	
REGION:Required for interaction with FYN	SEQ_UP	2	
REGION:Required for interaction with GDF15	SEQ_UP	1	
REGION:Required for interaction with GDF2	SEQ_UP	1	
REGION:Required for interaction with GDI1	SEQ_UP	1	
REGION:Required for interaction with GET4	SEQ_UP	1	
REGION:Required for interaction with GGA1 and GGA2	SEQ_UP	1	
REGION:Required for interaction with GPR78 and PAK1	SEQ_UP	1	
REGION:Required for interaction with GRB2 and CSK	SEQ_UP	1	
REGION:Required for interaction with GRIP1, GRIP2 and PICK1	SEQ_UP	1	
REGION:Required for interaction with GSK3B	SEQ_UP	1	
REGION:Required for interaction with GULP1	SEQ_UP	1	
REGION:Required for interaction with HDAC1	SEQ_UP	1	
REGION:Required for interaction with HIRA	SEQ_UP	1	
REGION:Required for interaction with histone H3	SEQ_UP	2	
REGION:Required for interaction with HSF2BP	SEQ_UP	1	
REGION:Required for interaction with IK	SEQ_UP	1	
REGION:Required for interaction with IKBKG	SEQ_UP	1	
REGION:Required for interaction with IL4R	SEQ_UP	1	
REGION:Required for interaction with INCENP	SEQ_UP	2	
REGION:Required for interaction with INCENP and BIRC5	SEQ_UP	1	
REGION:Required for interaction with IQSEC1	SEQ_UP	1	
REGION:Required for interaction with ISL1	SEQ_UP	1	
REGION:Required for interaction with itself and with MRTFA	SEQ_UP	1	
REGION:Required for interaction with KAT2B	SEQ_UP	1	
REGION:Required for interaction with KCNK2	SEQ_UP	1	
REGION:Required for interaction with KIAA1324	SEQ_UP	1	
REGION:Required for interaction with KIF22 and function in chromosome congression	SEQ_UP	1	
REGION:Required for interaction with KLC1	SEQ_UP	1	
REGION:Required for interaction with KPNB1 and EEA1	SEQ_UP	1	
REGION:Required for interaction with LAMTOR2	SEQ_UP	1	
REGION:Required for interaction with LDB1	SEQ_UP	1	
REGION:Required for interaction with LHFPL4	SEQ_UP	1	
REGION:Required for interaction with LIN28A and pre-let-7 RNA	SEQ_UP	1	
REGION:Required for interaction with LUC7L2	SEQ_UP	1	
REGION:Required for interaction with MAGOH and RBM8A	SEQ_UP	1	
REGION:Required for interaction with MAPK1	SEQ_UP	1	
REGION:Required for interaction with MAPK8	SEQ_UP	1	
REGION:Required for interaction with MAPKs	SEQ_UP	1	
REGION:Required for interaction with MARCHF2	SEQ_UP	1	
REGION:Required for interaction with MAT2A	SEQ_UP	1	
REGION:Required for interaction with MAVS	SEQ_UP	1	
REGION:Required for interaction with microtubules	SEQ_UP	1	
REGION:Required for interaction with microtubules and microtubule severing	SEQ_UP	1	
REGION:Required for interaction with MRTFA	SEQ_UP	1	
REGION:Required for interaction with MYCBP	SEQ_UP	1	
REGION:Required for interaction with MYO5B	SEQ_UP	1	
REGION:Required for interaction with MYO6	SEQ_UP	1	
REGION:Required for interaction with MYRF	SEQ_UP	1	
REGION:Required for interaction with NCOA1	SEQ_UP	1	
REGION:Required for interaction with NCOR1	SEQ_UP	1	
REGION:Required for interaction with NDFIP1	SEQ_UP	1	
REGION:Required for interaction with NEDD4	SEQ_UP	1	
REGION:Required for interaction with NFATC2	SEQ_UP	1	
REGION:Required for interaction with NFYA	SEQ_UP	2	
REGION:Required for interaction with NLRX1	SEQ_UP	1	
REGION:Required for interaction with NMDA receptors	SEQ_UP	1	
REGION:Required for interaction with NOP53	SEQ_UP	1	
REGION:Required for interaction with NOTCH proteins	SEQ_UP	1	
REGION:Required for interaction with NR2C2	SEQ_UP	1	
REGION:Required for interaction with NRIP1	SEQ_UP	1	
REGION:Required for interaction with NRXN1 (via C-terminal tail)	SEQ_UP	1	
REGION:Required for interaction with NUDT21	SEQ_UP	1	
REGION:Required for interaction with NUMA1 and regulation of apoptosis in response to DNA damage	SEQ_UP	1	
REGION:Required for interaction with NuRD complex and for transcriptional repressor activity	SEQ_UP	1	
REGION:Required for interaction with OGT	SEQ_UP	1	
REGION:Required for interaction with OPTN	SEQ_UP	1	
REGION:Required for interaction with p53/TP53	SEQ_UP	1	
REGION:Required for interaction with P65/RELA	SEQ_UP	1	
REGION:Required for interaction with PABPC1	SEQ_UP	2	
REGION:Required for interaction with PAFAH1B1	SEQ_UP	1	
REGION:Required for interaction with PALS1	SEQ_UP	2	
REGION:Required for interaction with PARVA	SEQ_UP	1	
REGION:Required for interaction with PBX1	SEQ_UP	1	
REGION:Required for interaction with PCM1	SEQ_UP	1	
REGION:Required for interaction with PCNT	SEQ_UP	1	
REGION:Required for interaction with PDCD6	SEQ_UP	1	
REGION:Required for interaction with PIP5K1A	SEQ_UP	3	
REGION:Required for interaction with PIWIL1	SEQ_UP	2	
REGION:Required for interaction with PJA2	SEQ_UP	1	
REGION:Required for interaction with PLG	SEQ_UP	1	
REGION:Required for interaction with POLH and POLH DNA synthesis stimulation	SEQ_UP	1	
REGION:Required for interaction with PPP2CA and PPP2R1A	SEQ_UP	1	
REGION:Required for interaction with PPP2R2A	SEQ_UP	1	
REGION:Required for interaction with PPP2R5C	SEQ_UP	1	
REGION:Required for interaction with PPP3CA	SEQ_UP	1	
REGION:Required for interaction with prenylated RAB3A and VAMP2	SEQ_UP	1	
REGION:Required for interaction with PRKCI	SEQ_UP	1	
REGION:Required for interaction with PRKDC, XRCC6 and XRCC5	SEQ_UP	1	
REGION:Required for interaction with PRKRA and TARBP2	SEQ_UP	1	
REGION:Required for interaction with PRPF19	SEQ_UP	1	
REGION:Required for interaction with PTPN11 and PTPN6 and for control of phosphorylation level	SEQ_UP	1	
REGION:Required for interaction with PTPN13	SEQ_UP	1	
REGION:Required for interaction with PTPRD	SEQ_UP	1	
REGION:Required for interaction with PWWP2A	SEQ_UP	1	
REGION:Required for interaction with RAB2	SEQ_UP	1	
REGION:Required for interaction with RAC1	SEQ_UP	1	
REGION:Required for interaction with RAF1 and for the function	SEQ_UP	1	
REGION:Required for interaction with RAP family members	SEQ_UP	1	
REGION:Required for interaction with RARA	SEQ_UP	1	
REGION:Required for interaction with RARA in the absence of its ligand	SEQ_UP	2	
REGION:Required for interaction with RB1	SEQ_UP	1	
REGION:Required for interaction with RELA	SEQ_UP	1	
REGION:Required for interaction with retromer; involved in interaction with ATG8 family proteins	SEQ_UP	1	
REGION:Required for interaction with RNF126	SEQ_UP	1	
REGION:Required for interaction with RPP20/POP7	SEQ_UP	1	
REGION:Required for interaction with RPTOR and for repression of mRNAs with a 5'TOP motif	SEQ_UP	1	
REGION:Required for interaction with RTN1	SEQ_UP	1	
REGION:Required for interaction with RUNX2	SEQ_UP	1	
REGION:Required for interaction with SEC23A	SEQ_UP	1	
REGION:Required for interaction with SENP3	SEQ_UP	2	
REGION:Required for interaction with SEPT8	SEQ_UP	1	
REGION:Required for interaction with SEPTIN4. Required for migration of cortical neurons during corticogenesis	SEQ_UP	1	
REGION:Required for interaction with SLC50A1	SEQ_UP	1	
REGION:Required for interaction with SMARCA5	SEQ_UP	1	
REGION:Required for interaction with SMARCA5 and formation of the CHRAC ISWI chromatin remodeling complex	SEQ_UP	1	
REGION:Required for interaction with SMCA1	SEQ_UP	1	
REGION:Required for interaction with SMN	SEQ_UP	1	
REGION:Required for interaction with SMN1	SEQ_UP	1	
REGION:Required for interaction with SPRED1 and SPRY2. Required for TESK1-mediated dephosphorylation of SPRY2 and SPRY2 inhibition of ERK phosphorylation	SEQ_UP	1	
REGION:Required for interaction with SRC	SEQ_UP	1	
REGION:Required for interaction with SRP72	SEQ_UP	1	
REGION:Required for interaction with SSNA1 and microtubules	SEQ_UP	1	
REGION:Required for interaction with STIP1	SEQ_UP	1	
REGION:Required for interaction with STK16	SEQ_UP	1	
REGION:Required for interaction with STX17	SEQ_UP	2	
REGION:Required for interaction with SYNCRIP	SEQ_UP	1	
REGION:Required for interaction with TAB2	SEQ_UP	1	
REGION:Required for interaction with TAF12	SEQ_UP	1	
REGION:Required for interaction with TBP and formation of a ternary complex with DNA and TBP	SEQ_UP	1	
REGION:Required for interaction with TES	SEQ_UP	1	
REGION:Required for interaction with TESK1	SEQ_UP	2	
REGION:Required for interaction with TESK1 and ILK	SEQ_UP	1	
REGION:Required for interaction with the CHRAC1-POLE3 heterodimer. Required for interaction with the CHRAC1-POLE3 heterodimer	SEQ_UP	1	
REGION:Required for interaction with the inner surface of the mitochondrial outer membrane	SEQ_UP	1	
REGION:Required for interaction with the sumoylated form of CCAR2	SEQ_UP	1	
REGION:Required for interaction with thrombospondins, THBS1 and THBS2	SEQ_UP	1	
REGION:Required for interaction with TLE6	SEQ_UP	1	
REGION:Required for interaction with TMEM98	SEQ_UP	1	
REGION:Required for interaction with TNFAIP3	SEQ_UP	1	
REGION:Required for interaction with TNKS	SEQ_UP	1	
REGION:Required for interaction with TPGS1, LRRC49, and TTLL1	SEQ_UP	1	
REGION:Required for interaction with TPGS2	SEQ_UP	1	
REGION:Required for interaction with TRAF6	SEQ_UP	1	
REGION:Required for interaction with TRIB1	SEQ_UP	1	
REGION:Required for interaction with TRIM28	SEQ_UP	1	
REGION:Required for interaction with U1 RNA	SEQ_UP	1	
REGION:Required for interaction with U2AF2	SEQ_UP	1	
REGION:Required for interaction with ubiquitin and for autoubiquitination	SEQ_UP	1	
REGION:Required for interaction with UFL1 and mediates interaction with CHEK1	SEQ_UP	1	
REGION:Required for interaction with USP4	SEQ_UP	1	
REGION:Required for interaction with VAMP7	SEQ_UP	1	
REGION:Required for interaction with YWHAB	SEQ_UP	1	
REGION:Required for interaction with YY1, SIN3A AND HDAC1, and transcriptional repression activity	SEQ_UP	1	
REGION:Required for interaction with ZDHHC17	SEQ_UP	1	
REGION:Required for interaction with ZFPM1	SEQ_UP	1	
REGION:Required for interaction with ZNF385A	SEQ_UP	1	
REGION:Required for interaction with ZXDC	SEQ_UP	1	
REGION:Required for internalization	SEQ_UP	1	
REGION:Required for IRS1 activation and IL4-induced cell growth	SEQ_UP	1	
REGION:Required for ITGB6 binding	SEQ_UP	1	
REGION:Required for its centrosomal localization	SEQ_UP	1	
REGION:Required for its localization in the mitotic spindle and interaction with alpha-tubulin	SEQ_UP	1	
REGION:Required for its oligomerization and is important for its focal concentration at DNA damage sites	SEQ_UP	1	
REGION:Required for JAK2 activation	SEQ_UP	1	
REGION:Required for JAK2 binding	SEQ_UP	1	
REGION:Required for laminin recognition	SEQ_UP	1	
REGION:Required for late endosome/lysosome localization	SEQ_UP	1	
REGION:Required for lipid droplet localization	SEQ_UP	2	
REGION:Required for lipid raft association	SEQ_UP	1	
REGION:Required for localization at membrane structures	SEQ_UP	1	
REGION:Required for localization at synapses	SEQ_UP	1	
REGION:Required for localization in mitochondria	SEQ_UP	1	
REGION:Required for localization in sarcoplasmic reticulum	SEQ_UP	1	
REGION:Required for localization in the endoplasmic reticulum	SEQ_UP	3	
REGION:Required for localization in the lipid droplets	SEQ_UP	1	
REGION:Required for localization on the plasma membrane	SEQ_UP	1	
REGION:Required for localization to centrosomes	SEQ_UP	1	
REGION:Required for localization to clathrin-coated pits	SEQ_UP	1	
REGION:Required for localization to endoplasmic reticulum exit sites	SEQ_UP	1	
REGION:Required for localization to kinetochores	SEQ_UP	1	
REGION:Required for localization to microtubules and function in microtubule stabilization	SEQ_UP	1	
REGION:Required for localization to nuclear speckles	SEQ_UP	3	
REGION:Required for localization to punctate cytoplasmic foci	SEQ_UP	1	
REGION:Required for localization to SC35 splicing speckles	SEQ_UP	1	
REGION:Required for localization to the centrosome and induction of aggresome formation	SEQ_UP	1	
REGION:Required for localization to the centrosome and interaction with dynein, dynactin, tubulin gamma, PCM1 and PCNT	SEQ_UP	1	
REGION:Required for localization to the interphase centrosome and to the midbody during cytokinesis	SEQ_UP	1	
REGION:Required for localization to the nucleolus and midbody	SEQ_UP	1	
REGION:Required for location at endosomes	SEQ_UP	1	
REGION:Required for location in lysosomes	SEQ_UP	1	
REGION:Required for LPS-binding	SEQ_UP	1	
REGION:Required for Lys-133 sumoylation	SEQ_UP	1	
REGION:Required for lysosomal localization and for TRAF2 lysosomal degradation	SEQ_UP	1	
REGION:Required for maintaining the overall integrity of the AHR:ARNT heterodimer and its transcriptional activity	SEQ_UP	1	
REGION:Required for MARCHF2-mediated degradation	SEQ_UP	1	
REGION:Required for membrane binding	SEQ_UP	2	
REGION:Required for membrane localization	SEQ_UP	2	
REGION:Required for membrane-association	SEQ_UP	1	
REGION:Required for microtubule association, proximal axon localization and axon formation	SEQ_UP	1	
REGION:Required for microtubule binding and for localization to the centrosomes	SEQ_UP	1	
REGION:Required for microtubule-binding with high affinity	SEQ_UP	1	
REGION:Required for midbody localization	SEQ_UP	1	
REGION:Required for mitochondria translocation	SEQ_UP	1	
REGION:Required for mitochondrial import	SEQ_UP	1	
REGION:Required for mitochondrial localization	SEQ_UP	4	
REGION:Required for mitochondrial location	SEQ_UP	2	
REGION:Required for mitochondrial targeting	SEQ_UP	1	
REGION:Required for modulation of ESR1 transcriptional activity	SEQ_UP	1	
REGION:Required for mRNA decay activity	SEQ_UP	1	
REGION:Required for mRNA splicing activation	SEQ_UP	1	
REGION:Required for mRNA-binding	SEQ_UP	1	
REGION:Required for MYC transcriptional repression	SEQ_UP	1	
REGION:Required for MYLIP-triggered down-regulation of LDLR	SEQ_UP	1	
REGION:Required for NEDD4 interaction	SEQ_UP	1	
REGION:Required for netrin-mediated axon repulsion of neuronal growth cones	SEQ_UP	2	
REGION:Required for NGF signaling	SEQ_UP	1	
REGION:Required for normal axon myelination in the central nervous system	SEQ_UP	1	
REGION:Required for nuclear and nucleolar localization	SEQ_UP	1	
REGION:Required for nuclear body formation and for SUMO1 recruitment	SEQ_UP	1	
REGION:Required for nuclear export	SEQ_UP	4	
REGION:Required for nuclear import	SEQ_UP	2	
REGION:Required for nuclear lamina association	SEQ_UP	1	
REGION:Required for nuclear localization	SEQ_UP	16	
REGION:Required for nuclear localization (NLS)	SEQ_UP	1	
REGION:Required for nuclear localization and apoptosis-inducing activity	SEQ_UP	1	
REGION:Required for nuclear localization and interaction with KPNB1, NOTCH1 and PARP1	SEQ_UP	1	
REGION:Required for nuclear location	SEQ_UP	1	
REGION:Required for nuclear retention	SEQ_UP	1	
REGION:Required for nuclear retention and interaction with LMNA isoform C	SEQ_UP	1	
REGION:Required for nuclear speckle localization	SEQ_UP	1	
REGION:Required for nuclear targeting	SEQ_UP	1	
REGION:Required for nuclear translocation	SEQ_UP	1	
REGION:Required for nuclear translocation in heat-shocked cells	SEQ_UP	1	
REGION:Required for nucleolar and nuclear location	SEQ_UP	1	
REGION:Required for nucleolar localization	SEQ_UP	4	
REGION:Required for nucleolar location	SEQ_UP	1	
REGION:Required for oligomerization	SEQ_UP	1	
REGION:Required for outer membrane localization	SEQ_UP	1	
REGION:Required for P-body targeting and interaction with DCP1A	SEQ_UP	1	
REGION:Required for palmitoylation and association with membranes	SEQ_UP	1	
REGION:Required for peroxisomal location	SEQ_UP	1	
REGION:Required for pH-induced assembly of C-terminal ends into antiparallel tetramers	SEQ_UP	1	
REGION:Required for phosphatidylinositol 3,4,5-triphosphate binding	SEQ_UP	1	
REGION:Required for phosphatidylinositol 4,5-bisphosphate-dependent location at the cell membrane	SEQ_UP	3	
REGION:Required for phosphatidylinositol bisphosphate binding	SEQ_UP	1	
REGION:Required for phospholipid binding and regulation of the substrate preference	SEQ_UP	1	
REGION:Required for phosphorylation by CSNK1E	SEQ_UP	1	
REGION:Required for phosphorylation by CSNK1E and cytoplasmic localization	SEQ_UP	2	
REGION:Required for phosphorylation by CSNK2A1	SEQ_UP	1	
REGION:Required for PIP2-mediated channel inhibition	SEQ_UP	1	
REGION:Required for plasma membrane localization	SEQ_UP	2	
REGION:Required for podosome formation	SEQ_UP	1	
REGION:Required for podosome formation and interaction with AKAP9 and microtubules	SEQ_UP	1	
REGION:Required for polyubiquitination	SEQ_UP	1	
REGION:Required for PRC1-binding	SEQ_UP	1	
REGION:Required for PRKAR2A interaction; contributes to a protective effect against H(2)O(2)-induced apoptosis	SEQ_UP	1	
REGION:Required for proapoptotic activity	SEQ_UP	1	
REGION:Required for protein stabilization induced by IL1B	SEQ_UP	1	
REGION:Required for proteosomal degradation of UBE2N and UBE2D3, TRAF6 deubiquitination, and TAX1BP1 interaction with UBE2N	SEQ_UP	1	
REGION:Required for proximal axon localization, axon formation and migration	SEQ_UP	1	
REGION:Required for RAB5A binding	SEQ_UP	2	
REGION:Required for recruitment to cytoplasmic stress granules	SEQ_UP	1	
REGION:Required for recruitment to preautophagosomal structure in response to mitophagy	SEQ_UP	1	
REGION:Required for regulating specificity for telomeric DNA and for processivity for primer elongation	SEQ_UP	1	
REGION:Required for repression of histone gene transcription	SEQ_UP	1	
REGION:Required for repressor activity	SEQ_UP	3	
REGION:Required for response to bacterial lipopolysaccharide (LPS)	SEQ_UP	1	
REGION:Required for response to orexin-A	SEQ_UP	2	
REGION:Required for RHOG activation and mediates interaction with EPHA2	SEQ_UP	1	
REGION:Required for ribosome binding	SEQ_UP	1	
REGION:Required for RNA binding	SEQ_UP	1	
REGION:Required for RNA-binding	SEQ_UP	1	
REGION:Required for ruffle localization	SEQ_UP	2	
REGION:Required for RUNX1 and RUNX2 transcriptional activation	SEQ_UP	1	
REGION:Required for RYR2 clustering	SEQ_UP	1	
REGION:Required for secretion	SEQ_UP	1	
REGION:Required for self-assembly	SEQ_UP	1	
REGION:Required for self-association	SEQ_UP	2	
REGION:Required for self-association and induction of membrane tubulation	SEQ_UP	1	
REGION:Required for self-association and interaction with PAFAH1B2 and PAFAH1B3	SEQ_UP	1	
REGION:Required for shedding	SEQ_UP	1	
REGION:Required for STAT3 phosphorylation	SEQ_UP	1	
REGION:Required for stimulation of nucleotide exchange by RALA	SEQ_UP	2	
REGION:Required for substrate-binding	SEQ_UP	1	
REGION:Required for suppression of NFATC1-mediated transcription	SEQ_UP	1	
REGION:Required for targeting to lipid droplets	SEQ_UP	1	
REGION:Required for targeting to small nuclear foci	SEQ_UP	1	
REGION:Required for targeting to the cytoplasm	SEQ_UP	1	
REGION:Required for targeting to the endoplasmic reticulum	SEQ_UP	1	
REGION:Required for TBK1 and IKBKE-dependent IFNB1 activation	SEQ_UP	1	
REGION:Required for tetramer assembly	SEQ_UP	1	
REGION:Required for tetramerization	SEQ_UP	1	
REGION:Required for tetramerization, but not for dimerization	SEQ_UP	1	
REGION:Required for the anti-angiogenic activity of tumstatin	SEQ_UP	1	
REGION:Required for the anti-tumor cell activity of tumstatin	SEQ_UP	1	
REGION:Required for the colocalization with PCNA in nuclear foci in presence of oxidative-induced DNA damaging agents	SEQ_UP	1	
REGION:Required for the correct localization of PALS1 and PATJ at cell-cell contacts and the normal formation of tight junctions and adherens junctions	SEQ_UP	1	
REGION:Required for the formation of a ternary complex with DNA and TBP; not required for interaction with TBP in the absence of DNA	SEQ_UP	1	
REGION:Required for the histone acetyltransferase activity of the MSL complex	SEQ_UP	1	
REGION:Required for the homodimerization of the C9orf72-SMCR8 complex	SEQ_UP	2	
REGION:Required for the interaction with GRB2 and sufficient to promote the phosphorylation of AKT and cell proliferation	SEQ_UP	1	
REGION:Required for the interaction with KIF5B and for anterograde transport in axons	SEQ_UP	1	
REGION:Required for the interaction with RXRA	SEQ_UP	1	
REGION:Required for the interaction with the KDM2B-SKP1 heterodimeric complex	SEQ_UP	1	
REGION:Required for the lysosomal targeting	SEQ_UP	1	
REGION:Required for the pre-miR-134 transport	SEQ_UP	1	
REGION:Required for the repression of MAVS-induced interferon signaling	SEQ_UP	1	
REGION:Required for TMED10 and TMED2 cis-Golgi network localization	SEQ_UP	3	
REGION:Required for transactivation activity	SEQ_UP	1	
REGION:Required for transcription activation	SEQ_UP	2	
REGION:Required for transcriptional activation	SEQ_UP	7	
REGION:Required for transcriptional activation activity and synergistic coactivation of transcriptional activity with POU3F2	SEQ_UP	2	
REGION:Required for transcriptional activity	SEQ_UP	1	
REGION:Required for transcriptional inhibition	SEQ_UP	1	
REGION:Required for transcriptional repression	SEQ_UP	3	
REGION:Required for transcriptional repression activity; probably mediates sequence-specific DNA-binding	SEQ_UP	1	
REGION:Required for transferring proheparanase to the Golgi apparatus, secretion and subsequent enzyme activity and for enhancement of PKB/AKT1 phosphorylation	SEQ_UP	1	
REGION:Required for translocation to the plasma membrane in response to insulin	SEQ_UP	1	
REGION:Required for TTF1 binding	SEQ_UP	1	
REGION:Required for ubiquitin ligase activity	SEQ_UP	1	
REGION:Required for ubiquitin ligase activity and for protection against ER stress-induced cell death	SEQ_UP	1	
REGION:Required for ubiquitin ligase activity and for protection against staurosporin-induced cell death	SEQ_UP	1	
REGION:Required for ubiquitin ligase activity and protection against ER stress-induced cell death	SEQ_UP	1	
REGION:Required for ubiquitination	SEQ_UP	1	
REGION:Required for ubiquitination activity	SEQ_UP	1	
REGION:Required for ubiquitination of SPRED2	SEQ_UP	1	
REGION:Required for USP4 activation by providing conformational flexibility between the DUSP and catalytic domains	SEQ_UP	1	
REGION:Required for WASH complex assembly	SEQ_UP	1	
REGION:Required for WNT signaling induction	SEQ_UP	1	
REGION:Required for Wnt-activated receptor activity	SEQ_UP	1	
REGION:Required for Wnt-signaling inhibition and LRP6 degradation	SEQ_UP	1	
REGION:Required in homotrimerization	SEQ_UP	1	
REGION:Required to exclude TET3 from the maternal pronucleus	SEQ_UP	1	
REGION:Required to form a minimal CPC core complex that localizes to the central spindle and midbody and properly executes the role of the CPC during cytokinesis	SEQ_UP	1	
REGION:Required to functionally cooperate with SREBF1 in promoter activation	SEQ_UP	1	
REGION:Required to induce adipocyte differentiation	SEQ_UP	1	
REGION:Required to induce plasma membrane rupture	SEQ_UP	1	
REGION:Required to promote base flipping	SEQ_UP	1	
REGION:Required to promote cell adhesion	SEQ_UP	1	
REGION:Required to promote HAND1 transcriptional activator activity	SEQ_UP	1	
REGION:Required to release iHOPS from membranes	SEQ_UP	1	
REGION:Required to repress E2F1:TFDP1-mediated transcription, to inhibit cell cycle and to induce adipocyte differentiation	SEQ_UP	1	
REGION:Requires for dimerization and lipidd rafts association	SEQ_UP	1	
REGION:Requires for efficient binding to CDC20	SEQ_UP	1	
REGION:Requires for interaction with GABARAP, MAP1LC3B AND GABARAPL1	SEQ_UP	1	
REGION:Requires for interaction with LIMA1	SEQ_UP	1	
REGION:Requires for interaction with MSN and EZR	SEQ_UP	1	
REGION:Resiniferatoxin binding; agonist	SEQ_UP	1	
REGION:RESP18 homology domain	SEQ_UP	1	
REGION:Responsible for down-regulation of CD86 and MHC class II cell surface expression	SEQ_UP	1	
REGION:Responsible for low stability	SEQ_UP	1	
REGION:Responsible for slow ATPase activity	SEQ_UP	1	
REGION:Responsible of the affinity for farnesylated versus geranylgeranylated Ras	SEQ_UP	1	
REGION:Restriction endonuclease homology domain	SEQ_UP	1	
REGION:Reticulon homology domain	SEQ_UP	1	
REGION:Retinoblastoma protein binding	SEQ_UP	4	
REGION:Retinoic acid binding	SEQ_UP	2	
REGION:Reverse transcriptase homology domain	SEQ_UP	1	
REGION:RGG	SEQ_UP	1	
REGION:RGG-box 1	SEQ_UP	1	
REGION:RGG-box 2	SEQ_UP	1	
REGION:Rho-like	SEQ_UP	3	
REGION:RHOA binding	SEQ_UP	2	
REGION:RI-alpha-binding	SEQ_UP	1	
REGION:RII-beta subunit binding domain	SEQ_UP	1	
REGION:RII-binding	SEQ_UP	3	
REGION:RING-finger and WD40-associated ubiquitin-like domain (RAWUL); sufficient for interaction with BCOR and BCORL1	SEQ_UP	1	
REGION:Ring-like domain; necessary for ubiquitination of RIPK3	SEQ_UP	1	
REGION:Ripply homology domain	SEQ_UP	3	
REGION:RK-rich region	SEQ_UP	1	
REGION:RK-rich region; required for cAMP responsiveness	SEQ_UP	1	
REGION:RNA binding	SEQ_UP	5	
REGION:RNA binding forefinger loop	SEQ_UP	1	
REGION:RNA binding thumb loop	SEQ_UP	1	
REGION:RNA binding; important for wobble base 34 recognition	SEQ_UP	1	
REGION:RNA gate	SEQ_UP	1	
REGION:RNA recognition motif (RRM) domain	SEQ_UP	2	
REGION:RNA-binding	SEQ_UP	15	
REGION:RNA-binding (RBD)	SEQ_UP	1	
REGION:RNA-binding Arg/Gly-rich region (RGG-box)	SEQ_UP	1	
REGION:RNA-binding region which is sufficient for binding to lncRNA Evf2	SEQ_UP	1	
REGION:RNA-binding RGG-box	SEQ_UP	5	
REGION:RNA-interacting domain 1	SEQ_UP	1	
REGION:RNA-interacting domain 2	SEQ_UP	1	
REGION:RNA:DNA duplex binding	SEQ_UP	1	
REGION:RNA/DNA-binding	SEQ_UP	1	
REGION:RNAPII-binding	SEQ_UP	1	
REGION:RNase	SEQ_UP	1	
REGION:RNase H homology domain	SEQ_UP	1	
REGION:Rod-like helical tail	SEQ_UP	2	
REGION:ROQ	SEQ_UP	2	
REGION:RP domain	SEQ_UP	2	
REGION:RS	SEQ_UP	2	
REGION:RUNX1-binding	SEQ_UP	1	
REGION:S (spacer)	SEQ_UP	1	
REGION:S-100-like	SEQ_UP	3	
REGION:S-adenosyl-L-homocysteine binding	SEQ_UP	2	
REGION:S-adenosyl-L-methionine	SEQ_UP	2	
REGION:S-adenosyl-L-methionine 2 binding	SEQ_UP	1	
REGION:S-adenosyl-L-methionine binding	SEQ_UP	87	
REGION:S-adenosylmethioninamine binding	SEQ_UP	2	
REGION:S-adenosylmethionine binding	SEQ_UP	1	
REGION:S1-S2 loop of repeat IV	SEQ_UP	1	
REGION:S100A10-binding site	SEQ_UP	1	
REGION:S100B binding	SEQ_UP	1	
REGION:S100B-binding	SEQ_UP	1	
REGION:S2 site	SEQ_UP	1	
REGION:S3b-S4 loop of repeat IV	SEQ_UP	1	
REGION:S4-S5 linker	SEQ_UP	6	
REGION:Saccharopine dehydrogenase	SEQ_UP	1	
REGION:SAD	SEQ_UP	1	
REGION:SAH	SEQ_UP	4	
REGION:SAICAR synthetase domain	SEQ_UP	1	
REGION:SAM-like domain	SEQ_UP	1	
REGION:SAM2-like domain	SEQ_UP	1	
REGION:SAY	SEQ_UP	1	
REGION:SBD	SEQ_UP	3	
REGION:SCF-binding	SEQ_UP	1	
REGION:SEC16A-interacting region (SIR); required for its localization to endoplasmic reticulum exit sites and for its interaction with SEC16A	SEQ_UP	1	
REGION:SEC8 and ARHQ binding	SEQ_UP	1	
REGION:Second lumenal domain	SEQ_UP	2	
REGION:Secondary area of contact	SEQ_UP	1	
REGION:Segment A	SEQ_UP	1	
REGION:Segment B1	SEQ_UP	1	
REGION:Segment B2	SEQ_UP	1	
REGION:Segment C	SEQ_UP	1	
REGION:Segment S1	SEQ_UP	1	
REGION:Segment S10	SEQ_UP	1	
REGION:Segment S6	SEQ_UP	1	
REGION:Segment S7	SEQ_UP	2	
REGION:Segment S8	SEQ_UP	2	
REGION:Segment S9	SEQ_UP	2	
REGION:Selective for apoptosis induction in cancer cells (SAC)	SEQ_UP	1	
REGION:Selectivity filter	SEQ_UP	1	
REGION:Selectivity filter 1	SEQ_UP	2	
REGION:Selectivity filter 2	SEQ_UP	2	
REGION:Self-association	SEQ_UP	11	
REGION:Self-association (with itself or C-terminus)	SEQ_UP	1	
REGION:Self-association (with itself or N-terminus)	SEQ_UP	1	
REGION:Self-association and FN1-binding	SEQ_UP	1	
REGION:Self-association and interaction with Hsp90	SEQ_UP	1	
REGION:Self-association site, tail	SEQ_UP	3	
REGION:Ser/Thr-rich	SEQ_UP	1	
REGION:Serine protease	SEQ_UP	6	
REGION:Seven-bladed beta propeller	SEQ_UP	1	
REGION:Seven-bladed beta propeller repeats	SEQ_UP	1	
REGION:Seven-bladed beta-propeller	SEQ_UP	1	
REGION:SH2-like	SEQ_UP	3	
REGION:SH2-like; required for interaction with growth factor receptors	SEQ_UP	1	
REGION:Shielding domain	SEQ_UP	1	
REGION:Short helix H1-1	SEQ_UP	1	
REGION:Short helix H1-2	SEQ_UP	1	
REGION:Short helix H2-1	SEQ_UP	1	
REGION:Short helix H2-2	SEQ_UP	1	
REGION:Short nonhelical segment	SEQ_UP	1	
REGION:SHROOM3 binding	SEQ_UP	1	
REGION:Sialic acid binding	SEQ_UP	1	
REGION:Signal for sorting from recycling endosomes; interaction with ACAP1	SEQ_UP	1	
REGION:Silencing domain; interaction with CNOT1 and PAN3	SEQ_UP	2	
REGION:Sin3 interaction domain (SID)	SEQ_UP	1	
REGION:siRNA-binding	SEQ_UP	1	
REGION:SKS domain	SEQ_UP	1	
REGION:SLA C-terminal	SEQ_UP	2	
REGION:SM 1	SEQ_UP	1	
REGION:SM 2	SEQ_UP	1	
REGION:SMAD-interaction domain (SID)	SEQ_UP	1	
REGION:SMAD-MH2 binding domain	SEQ_UP	1	
REGION:Small GTPase-like	SEQ_UP	10	
REGION:SNAG domain	SEQ_UP	10	
REGION:SNAPC2-binding	SEQ_UP	1	
REGION:SNAPC3-binding	SEQ_UP	1	
REGION:SNAPC4-binding	SEQ_UP	1	
REGION:SNAPC5-binding	SEQ_UP	1	
REGION:SNARE-like	SEQ_UP	1	
REGION:SNW	SEQ_UP	1	
REGION:SOAR/CAD	SEQ_UP	1	
REGION:SP domain	SEQ_UP	4	
REGION:Spacer	SEQ_UP	16	
REGION:Spacer 1	SEQ_UP	1	
REGION:Spacer 2	SEQ_UP	1	
REGION:Spacer region	SEQ_UP	1	
REGION:Specificity for association with VLDL	SEQ_UP	1	
REGION:Spectrin--actin-binding	SEQ_UP	4	
REGION:Spectrin-fold	SEQ_UP	1	
REGION:Speedy/Ringo box; Required for CDK-binding	SEQ_UP	2	
REGION:Spermidine binding	SEQ_UP	1	
REGION:Sphingosine 1-phosphate binding	SEQ_UP	1	
REGION:Spir-box	SEQ_UP	2	
REGION:SS DNA-binding	SEQ_UP	1	
REGION:Stalk	SEQ_UP	10	
REGION:Staurosporine binding	SEQ_UP	2	
REGION:Stem	SEQ_UP	9	
REGION:Stem region	SEQ_UP	1	
REGION:Steroid-binding	SEQ_UP	1	
REGION:Sterol-binding	SEQ_UP	1	
REGION:Stimulates PAPOLA	SEQ_UP	1	
REGION:Straightjacket domain	SEQ_UP	1	
REGION:Stress-sensor region	SEQ_UP	1	
REGION:Strong poly(A) affinity and self-association	SEQ_UP	1	
REGION:Strong transcription activation domain	SEQ_UP	2	
REGION:Strychnine-binding	SEQ_UP	5	
REGION:STXBP1-binding	SEQ_UP	1	
REGION:Subdomain NA (Cys-rich)	SEQ_UP	1	
REGION:Subdomain NB (Cys-free)	SEQ_UP	1	
REGION:Substrate	SEQ_UP	4	
REGION:Substrate binding	SEQ_UP	345	
REGION:Substrate binding (B site)	SEQ_UP	1	
REGION:Substrate binding; shared with dimeric partner	SEQ_UP	1	
REGION:Substrate binding; shared with homodimeric partner	SEQ_UP	1	
REGION:Substrate binding; shared with neighboring subunit	SEQ_UP	1	
REGION:Substrate binding; shared with subunit alpha	SEQ_UP	2	
REGION:Substrate for kinases	SEQ_UP	1	
REGION:Substrate-binding	SEQ_UP	2	
REGION:Substrate-binding (SBD)	SEQ_UP	1	
REGION:Substrate-binding apical domain	SEQ_UP	1	
REGION:Substrate-binding domain (SBD)	SEQ_UP	5	
REGION:Substrate-binding motif	SEQ_UP	1	
REGION:Subunit association domain (SAD)	SEQ_UP	1	
REGION:Sufficicient and required for interaction with CCDC93	SEQ_UP	1	
REGION:Sufficient and essential for mediating its nuclear import	SEQ_UP	1	
REGION:Sufficient for activation of CTE-mediated expression	SEQ_UP	1	
REGION:Sufficient for antibacterial activity	SEQ_UP	1	
REGION:Sufficient for basal bodies localization	SEQ_UP	1	
REGION:Sufficient for binding to genomic CpG islands	SEQ_UP	1	
REGION:Sufficient for binding to RE2 sequence motifs	SEQ_UP	1	
REGION:Sufficient for catalytic activity	SEQ_UP	1	
REGION:Sufficient for dimerization of proICA512	SEQ_UP	1	
REGION:Sufficient for E3 SUMO-protein ligase activity	SEQ_UP	1	
REGION:Sufficient for enzyme activity	SEQ_UP	1	
REGION:Sufficient for GEF activity towards RAB21	SEQ_UP	1	
REGION:Sufficient for heterochromatin association in interphase and chromatin association in anaphase	SEQ_UP	1	
REGION:Sufficient for heterodimer formation with ARNTL/BMAL1, E-box binding and for the effect of NADPH	SEQ_UP	1	
REGION:Sufficient for homodimerization	SEQ_UP	1	
REGION:Sufficient for homooligomerization	SEQ_UP	1	
REGION:Sufficient for inhibitory activity of TNF-induced NF-kappa-B activity	SEQ_UP	1	
REGION:Sufficient for interaction with ABL1	SEQ_UP	1	
REGION:Sufficient for interaction with ACIN1, PRPF8, SFRS3, SNRPB, SNRPN, SNRNP70 and SNRNP200	SEQ_UP	1	
REGION:Sufficient for interaction with AGO1 and AGO4	SEQ_UP	1	
REGION:Sufficient for interaction with AGO1, AGO3 and AGO4	SEQ_UP	1	
REGION:Sufficient for interaction with AGO2	SEQ_UP	1	
REGION:Sufficient for interaction with AHCYL1	SEQ_UP	1	
REGION:Sufficient for interaction with AICDA	SEQ_UP	1	
REGION:Sufficient for interaction with AKTIP and VPS18	SEQ_UP	1	
REGION:Sufficient for interaction with argonaute family proteins	SEQ_UP	1	
REGION:Sufficient for interaction with calmodulin	SEQ_UP	1	
REGION:Sufficient for interaction with CCDC22	SEQ_UP	1	
REGION:Sufficient for interaction with CCDC93	SEQ_UP	1	
REGION:Sufficient for interaction with CHMP1B	SEQ_UP	1	
REGION:Sufficient for interaction with CLNS1A	SEQ_UP	1	
REGION:Sufficient for interaction with CNTRL	SEQ_UP	1	
REGION:Sufficient for interaction with COMMD1	SEQ_UP	1	
REGION:Sufficient for interaction with CPSF1 and CSTF3	SEQ_UP	1	
REGION:Sufficient for interaction with CPSF4	SEQ_UP	1	
REGION:Sufficient for interaction with CTNNB1	SEQ_UP	1	
REGION:Sufficient for interaction with DAPK3	SEQ_UP	1	
REGION:Sufficient for interaction with DICER1	SEQ_UP	1	
REGION:Sufficient for interaction with DLG4	SEQ_UP	1	
REGION:Sufficient for interaction with DLX1	SEQ_UP	1	
REGION:Sufficient for interaction with EIF3B	SEQ_UP	2	
REGION:Sufficient for interaction with EIF3E	SEQ_UP	1	
REGION:Sufficient for interaction with EIF3J	SEQ_UP	1	
REGION:Sufficient for interaction with EIF4A1 and EIF1	SEQ_UP	1	
REGION:Sufficient for interaction with EP300	SEQ_UP	1	
REGION:Sufficient for interaction with EPAS1	SEQ_UP	1	
REGION:Sufficient for interaction with EPHB1	SEQ_UP	1	
REGION:Sufficient for interaction with ESR1	SEQ_UP	1	
REGION:Sufficient for interaction with EZH2	SEQ_UP	1	
REGION:Sufficient for interaction with FGF2 and FGF2-induced effects	SEQ_UP	1	
REGION:Sufficient for interaction with GRB2	SEQ_UP	1	
REGION:Sufficient for interaction with HAVCR2	SEQ_UP	1	
REGION:Sufficient for interaction with HOOK2	SEQ_UP	1	
REGION:Sufficient for interaction with IIGP1	SEQ_UP	1	
REGION:Sufficient for interaction with KANSL1	SEQ_UP	1	
REGION:Sufficient for interaction with KAT8	SEQ_UP	1	
REGION:Sufficient for interaction with KATNA1:KATNB1	SEQ_UP	1	
REGION:Sufficient for interaction with KATNB1 and for inhibition of katanin-mediated microtubule severing	SEQ_UP	1	
REGION:Sufficient for interaction with KIF2C	SEQ_UP	1	
REGION:Sufficient for interaction with KIF5B	SEQ_UP	2	
REGION:Sufficient for interaction with KPNB1	SEQ_UP	1	
REGION:Sufficient for interaction with MAD2L2	SEQ_UP	2	
REGION:Sufficient for interaction with MAP1B	SEQ_UP	1	
REGION:Sufficient for interaction with MCM7	SEQ_UP	1	
REGION:Sufficient for interaction with microtubules	SEQ_UP	3	
REGION:Sufficient for interaction with MSL1	SEQ_UP	1	
REGION:Sufficient for interaction with NCOA1	SEQ_UP	1	
REGION:Sufficient for interaction with NIPBL	SEQ_UP	1	
REGION:Sufficient for interaction with NLK	SEQ_UP	1	
REGION:Sufficient for interaction with NXF1	SEQ_UP	2	
REGION:Sufficient for interaction with PAPOLA	SEQ_UP	1	
REGION:Sufficient for interaction with PHF12	SEQ_UP	1	
REGION:Sufficient for interaction with PRKRA	SEQ_UP	1	
REGION:Sufficient for interaction with RAB11A and for guanine nucleotide exchange activity	SEQ_UP	1	
REGION:Sufficient for interaction with RENT2	SEQ_UP	1	
REGION:Sufficient for interaction with RNPS1 and SAP18 and formation of th ASAP complex	SEQ_UP	1	
REGION:Sufficient for interaction with ROS1	SEQ_UP	1	
REGION:Sufficient for interaction with RPS6KA2; Prevents association of CDC20 with RPS6KA2	SEQ_UP	1	
REGION:Sufficient for interaction with SALL4	SEQ_UP	1	
REGION:Sufficient for interaction with SH3KBP1 SH3 domain	SEQ_UP	1	
REGION:Sufficient for interaction with SHLD3 and MAD2L2	SEQ_UP	1	
REGION:Sufficient for interaction with SIN3A	SEQ_UP	1	
REGION:Sufficient for interaction with SIRT1	SEQ_UP	1	
REGION:Sufficient for interaction with SLC12A2	SEQ_UP	1	
REGION:Sufficient for interaction with SPTBN1	SEQ_UP	1	
REGION:Sufficient for interaction with STX1A	SEQ_UP	1	
REGION:Sufficient for interaction with STX7; VTI1B AND STX8	SEQ_UP	1	
REGION:Sufficient for interaction with SUN2	SEQ_UP	1	
REGION:Sufficient for interaction with SYNE1 and SYNE2	SEQ_UP	2	
REGION:Sufficient for interaction with the FKBP1A/rapamycin complex	SEQ_UP	1	
REGION:Sufficient for interaction with the PRC2 complex	SEQ_UP	1	
REGION:Sufficient for interaction with TPR	SEQ_UP	1	
REGION:Sufficient for interaction with TRIM27	SEQ_UP	1	
REGION:Sufficient for interaction with UIMC1	SEQ_UP	1	
REGION:Sufficient for interaction with UPF1	SEQ_UP	1	
REGION:Sufficient for interaction with UPF1 C-terminus	SEQ_UP	1	
REGION:Sufficient for interaction with UPF3A and UPF3B	SEQ_UP	1	
REGION:Sufficient for interaction with VPS16, required for interaction with CEP63	SEQ_UP	1	
REGION:Sufficient for interaction with VPS29	SEQ_UP	1	
REGION:Sufficient for interaction with WASHC2C	SEQ_UP	1	
REGION:Sufficient for interaction with WASHC3, WASHC4 and WASHC5; required for interaction with WASHC1	SEQ_UP	1	
REGION:Sufficient for interaction with WASHC5	SEQ_UP	1	
REGION:Sufficient for interaction with XPO4	SEQ_UP	1	
REGION:Sufficient for interaction with ZNF628	SEQ_UP	1	
REGION:Sufficient for localization to endoplasmic reticulum tubular network and for interactions with REEP1, REEP5, ATL1, ATL2, ATL3 and SPAST	SEQ_UP	1	
REGION:Sufficient for localization to Golgi membrane	SEQ_UP	1	
REGION:Sufficient for membrane association	SEQ_UP	1	
REGION:Sufficient for membrane localization	SEQ_UP	1	
REGION:Sufficient for microtubule severing	SEQ_UP	1	
REGION:Sufficient for mitochondrial localization	SEQ_UP	2	
REGION:Sufficient for monouridylation activity	SEQ_UP	2	
REGION:Sufficient for nuclear export	SEQ_UP	1	
REGION:Sufficient for nuclear speckle localization	SEQ_UP	1	
REGION:Sufficient for nuclear targeting	SEQ_UP	1	
REGION:Sufficient for nucleolar localization	SEQ_UP	3	
REGION:Sufficient for oligomerization	SEQ_UP	1	
REGION:Sufficient for paraspeckles localization	SEQ_UP	1	
REGION:Sufficient for perinucleolar caps localization and interaction with NONO	SEQ_UP	1	
REGION:Sufficient for poly U RNA-binding	SEQ_UP	1	
REGION:Sufficient for PSAP complex assembly	SEQ_UP	1	
REGION:Sufficient for RNA-binding	SEQ_UP	1	
REGION:Sufficient for RNA-binding and MSE-dependent splicing activity	SEQ_UP	1	
REGION:Sufficient for RNA-binding, interaction with NXF1-NXT1	SEQ_UP	1	
REGION:Sufficient for RNA-binding, interaction with NXF1-NXT1 heterodimer	SEQ_UP	1	
REGION:Sufficient for self-association and interaction with HD	SEQ_UP	1	
REGION:Sufficient for self-association and interaction with TARBP2	SEQ_UP	1	
REGION:Sufficient for strong transactivation activity	SEQ_UP	1	
REGION:Sufficient for targeting to adherens junction and to inhibit cell proliferation	SEQ_UP	1	
REGION:Sufficient for the delivery of client proteins to the endoplasmic reticulum	SEQ_UP	1	
REGION:Sufficient for transactivation activity	SEQ_UP	2	
REGION:Sufficient for transactivation activity; sufficient for interaction with NOTCH1	SEQ_UP	1	
REGION:Sufficient for translational repression when tethered to a target mRNA	SEQ_UP	1	
REGION:Sufficient for translocalization to p62 bodies/ALIS	SEQ_UP	1	
REGION:Sufficient to bind activated GNAQ	SEQ_UP	1	
REGION:Sufficient to form the EJC	SEQ_UP	1	
REGION:Sufficient to induce apoptosis	SEQ_UP	1	
REGION:Sufficient to inhibit LIPG/EL phospholipase activity	SEQ_UP	1	
REGION:Sufficient to inhibit LPL lipase activity	SEQ_UP	1	
REGION:Sufficient to mediate interaction with PAXBP1	SEQ_UP	1	
REGION:Sufficient to mediate interaction with SGIP1	SEQ_UP	1	
REGION:Sufficient to promote the mitochondrial pathway of apoptosis	SEQ_UP	1	
REGION:Sufficient to suppress UBE2S activity; essential for interaction with UBE2S; competitively inhibits the rapide ubiquitin chain elongation by UBE2D1 which blocks UBE2D1 with APC; indispensable for recruitment and position of FBXO5 to the catalytic site of APC; abrogates the inhibition of ubiquitin chain assembly primarily catalyzed by UBE2S; inhibits the ubiquitination by either UBE2C or UBE2D1	SEQ_UP	1	
REGION:Sulfate adenylyltransferase	SEQ_UP	2	
REGION:SUMO interaction domain (SIM)	SEQ_UP	1	
REGION:Sumo interaction motif (SIM)	SEQ_UP	2	
REGION:SUMO interaction motifs (SIM); required for nuclear localization and kinase activity	SEQ_UP	3	
REGION:SUMO-binding	SEQ_UP	1	
REGION:SUMO1-binding	SEQ_UP	3	
REGION:Sumoylation and localization to discrete nuclear foci	SEQ_UP	1	
REGION:Superoxide dismutase-like	SEQ_UP	1	
REGION:Suppress the PT region-mediated translocation to plasma membrane	SEQ_UP	1	
REGION:Sushi-like	SEQ_UP	1	
REGION:Switch 2 region; required for interaction with REP1/CHM	SEQ_UP	1	
REGION:Switch II region; involved in RAP1GDS1 isoform 3 binding	SEQ_UP	1	
REGION:SYNE2-binding	SEQ_UP	1	
REGION:Syntrophin-binding region	SEQ_UP	2	
REGION:SYT11 binding 1	SEQ_UP	1	
REGION:SYT11 binding 2	SEQ_UP	1	
REGION:T-loop	SEQ_UP	1	
REGION:T-loop/activation segment	SEQ_UP	1	
REGION:TAD1 (Acidic)	SEQ_UP	1	
REGION:TAD2	SEQ_UP	1	
REGION:Tail	SEQ_UP	69	
REGION:Tail (Globular)	SEQ_UP	1	
REGION:Tail, subdomain A	SEQ_UP	1	
REGION:Tail, subdomain B (acidic)	SEQ_UP	1	
REGION:Talin-interaction	SEQ_UP	1	
REGION:Tandem atypical propeller in EMLs	SEQ_UP	2	
REGION:Tandem cysteine domain	SEQ_UP	1	
REGION:Tankyrase binding	SEQ_UP	1	
REGION:Tankyrase-binding	SEQ_UP	1	
REGION:Targeting signals	SEQ_UP	1	
REGION:Targeting to centrosomes	SEQ_UP	1	
REGION:Targeting to endoplasmic reticulum membrane	SEQ_UP	1	
REGION:Targeting to endoplasmic reticulum-associated lipid droplets	SEQ_UP	1	
REGION:Targeting to microtubules	SEQ_UP	1	
REGION:Targeting to peroxisomes	SEQ_UP	2	
REGION:Targeting to the centrosomes	SEQ_UP	1	
REGION:TBP/GTF2A-binding region	SEQ_UP	1	
REGION:TdBR region; mediates interaction with DNTT	SEQ_UP	1	
REGION:Telomerase inhibitory domain (TID)	SEQ_UP	1	
REGION:Telopeptide	SEQ_UP	1	
REGION:Testis-specific N-terminal extension	SEQ_UP	1	
REGION:Tetrahydrobiopterin-binding	SEQ_UP	1	
REGION:Tetrahydrofolate binding	SEQ_UP	1	
REGION:Tetramerization	SEQ_UP	1	
REGION:Tetramerization domain	SEQ_UP	2	
REGION:Thiamine pyrophosphate binding	SEQ_UP	3	
REGION:Thioesterase	SEQ_UP	1	
REGION:Thioredoxin fold	SEQ_UP	4	
REGION:Thioredoxin-like fold	SEQ_UP	1	
REGION:Three-helix bundle	SEQ_UP	1	
REGION:Thrombin-sensitive	SEQ_UP	1	
REGION:TIM barrel	SEQ_UP	1	
REGION:TMD; necessary for mitochondrion outer membrane localization and integration in the TOM complex	SEQ_UP	1	
REGION:TOG 1	SEQ_UP	3	
REGION:TOG 2	SEQ_UP	3	
REGION:TOG 3	SEQ_UP	2	
REGION:TOG 4	SEQ_UP	2	
REGION:TOG 5	SEQ_UP	1	
REGION:TPase	SEQ_UP	1	
REGION:TRAF family member interaction	SEQ_UP	1	
REGION:TRAF-binding	SEQ_UP	3	
REGION:Trans-activation domain A (TAD-A)	SEQ_UP	2	
REGION:Transactivation	SEQ_UP	8	
REGION:Transactivation AF-1; required for ligand-independent transactivation function	SEQ_UP	2	
REGION:Transactivation AF-2	SEQ_UP	1	
REGION:Transactivation AF-2; required for ligand-dependent transactivation function; mediates interaction with CCAR2	SEQ_UP	2	
REGION:Transactivation domain	SEQ_UP	12	
REGION:Transactivation domain (Gln-rich)	SEQ_UP	1	
REGION:Transactivation domain (TAC)	SEQ_UP	3	
REGION:Transactivation domain (TAM)	SEQ_UP	3	
REGION:Transactivation domain 1	SEQ_UP	1	
REGION:Transactivation domain 2	SEQ_UP	1	
REGION:Transactivation domain A (Gln-rich)	SEQ_UP	1	
REGION:Transactivation domain B (Gln-rich)	SEQ_UP	1	
REGION:Transactivation domain C (highly charged)	SEQ_UP	1	
REGION:Transactivation inhibition	SEQ_UP	1	
REGION:Transcription activation	SEQ_UP	10	
REGION:Transcription activation (acidic)	SEQ_UP	1	
REGION:Transcription repression	SEQ_UP	4	
REGION:Transcription repression 1	SEQ_UP	1	
REGION:Transcription repression 2	SEQ_UP	1	
REGION:Transcription repressor	SEQ_UP	2	
REGION:Transcriptional activation	SEQ_UP	4	
REGION:Transcriptional activation (acidic)	SEQ_UP	2	
REGION:Transcriptional activation domain	SEQ_UP	3	
REGION:Transcriptional activation domain 1	SEQ_UP	1	
REGION:Transcriptional activation domain 2	SEQ_UP	1	
REGION:Transcriptional activation domain 3	SEQ_UP	1	
REGION:Transcriptional corepression	SEQ_UP	1	
REGION:Transcriptional repression and interaction with NCOR1 and SIN3A	SEQ_UP	3	
REGION:Transcriptional repression domain (TRD)	SEQ_UP	1	
REGION:Transcriptional repressor domain	SEQ_UP	1	
REGION:Transcriptional transactivator	SEQ_UP	1	
REGION:TRBP-interacting domain; interaction with STIL	SEQ_UP	1	
REGION:TRFH dimerization	SEQ_UP	2	
REGION:Tri-arginine exosite	SEQ_UP	1	
REGION:TRIAD supradomain	SEQ_UP	14	
REGION:Trichohyalin/plectin homology domain	SEQ_UP	1	
REGION:TRIF-NTD	SEQ_UP	1	
REGION:Triggers pyroptosis	SEQ_UP	7	
REGION:Trimerization	SEQ_UP	1	
REGION:Triple-helical	SEQ_UP	1	
REGION:Triple-helical region	SEQ_UP	18	
REGION:Triple-helical region (COL1)	SEQ_UP	3	
REGION:Triple-helical region (COL1) with 2 imperfections	SEQ_UP	1	
REGION:Triple-helical region (COL2)	SEQ_UP	1	
REGION:Triple-helical region (COL2) with 1 imperfection	SEQ_UP	1	
REGION:Triple-helical region (COL3)	SEQ_UP	1	
REGION:Triple-helical region (interrupted)	SEQ_UP	1	
REGION:Triple-helical region 1 (COL1)	SEQ_UP	5	
REGION:Triple-helical region 1 (COL1) with 2 imperfections	SEQ_UP	1	
REGION:Triple-helical region 1 (COL2)	SEQ_UP	1	
REGION:Triple-helical region 10 (COL10)	SEQ_UP	1	
REGION:Triple-helical region 2 (COL1)	SEQ_UP	1	
REGION:Triple-helical region 2 (COL2)	SEQ_UP	5	
REGION:Triple-helical region 2 (COL2) with 2 imperfections	SEQ_UP	1	
REGION:Triple-helical region 3 (COL3)	SEQ_UP	6	
REGION:Triple-helical region 4 (COL4)	SEQ_UP	4	
REGION:Triple-helical region 4 (COL4) with 2 imperfections	SEQ_UP	1	
REGION:Triple-helical region 5 (COL5)	SEQ_UP	3	
REGION:Triple-helical region 5 (COL5) with 3 imperfections	SEQ_UP	1	
REGION:Triple-helical region 6 (COL6)	SEQ_UP	3	
REGION:Triple-helical region 6 (COL6) with 1 imperfection	SEQ_UP	1	
REGION:Triple-helical region 7 (COL7)	SEQ_UP	2	
REGION:Triple-helical region 7 (COL7) with 1 imperfection	SEQ_UP	1	
REGION:Triple-helical region 8 (COL8)	SEQ_UP	1	
REGION:Triple-helical region 8 (COL8) with 1 imperfection	SEQ_UP	1	
REGION:Triple-helical region 9 (COL9)	SEQ_UP	1	
REGION:Triple-helical region 9 (COL9) with 3 imperfections	SEQ_UP	1	
REGION:tRNA-binding	SEQ_UP	1	
REGION:Tropomodulin-like	SEQ_UP	1	
REGION:Tropomyosin-binding	SEQ_UP	1	
REGION:Trxb 1	SEQ_UP	1	
REGION:Trxb 2	SEQ_UP	1	
REGION:TUB	SEQ_UP	1	
REGION:Tubulin-binding domain	SEQ_UP	1	
REGION:Tubulin-binding domain necessary and sufficient for tubulin-binding	SEQ_UP	1	
REGION:Tudor-like	SEQ_UP	1	
REGION:Tudor-like 1	SEQ_UP	1	
REGION:Tudor-like 2	SEQ_UP	1	
REGION:Tudor-like domain 1	SEQ_UP	3	
REGION:Tudor-like domain 2	SEQ_UP	3	
REGION:Tudor-like domain 3	SEQ_UP	3	
REGION:U-box-like	SEQ_UP	1	
REGION:UBA-like	SEQ_UP	3	
REGION:UBC-RWD region (URD)	SEQ_UP	1	
REGION:UBE2D1-binding	SEQ_UP	1	
REGION:Ubiquitin association domain	SEQ_UP	1	
REGION:Ubiquitin binding	SEQ_UP	3	
REGION:Ubiquitin-binding (UBAN)	SEQ_UP	1	
REGION:Ubiquitin-binding domain (UBD)	SEQ_UP	6	
REGION:Ubiquitin-conjugating	SEQ_UP	1	
REGION:Ubiquitin-conjugating enzyme E2 binding	SEQ_UP	1	
REGION:ubiquitin-like	SEQ_UP	1	
REGION:Ubiquitin-like	SEQ_UP	1	
REGION:Ubiquitin-like (UBL) domain	SEQ_UP	1	
REGION:UBX-like	SEQ_UP	1	
REGION:UDP-alpha-D-galactose binding	SEQ_UP	7	
REGION:UDP-alpha-D-glucose binding	SEQ_UP	1	
REGION:UDP-alpha-D-xylose binding	SEQ_UP	1	
REGION:UDP-glucose binding	SEQ_UP	1	
REGION:UDP-N-acetyl-galactosamine binding	SEQ_UP	1	
REGION:UDP-N-acetylglucosamine 2-epimerase	SEQ_UP	1	
REGION:UDP-N-acetylglucosamine binding	SEQ_UP	1	
REGION:UDP-sugar binding	SEQ_UP	1	
REGION:UDP-xylose binding	SEQ_UP	2	
REGION:UEV-like 1	SEQ_UP	1	
REGION:UEV-like 2	SEQ_UP	1	
REGION:UIM-linker	SEQ_UP	1	
REGION:UMP binding	SEQ_UP	1	
REGION:Unstructured hinge	SEQ_UP	3	
REGION:Unstructured, Arg/Lys rich	SEQ_UP	1	
REGION:UPA	SEQ_UP	2	
REGION:UPA domain	SEQ_UP	5	
REGION:Uracil binding	SEQ_UP	1	
REGION:Uracil-nucleotide binding in RNA target	SEQ_UP	2	
REGION:Uridine binding	SEQ_UP	2	
REGION:UTP binding	SEQ_UP	5	
REGION:V (Cys-rich)	SEQ_UP	3	
REGION:V region (type III connecting segment, IIICS)	SEQ_UP	1	
REGION:V segment	SEQ_UP	1	
REGION:Variable number of tandem repeats (VNTR)	SEQ_UP	1	
REGION:Variable-loop	SEQ_UP	7	
REGION:VCA	SEQ_UP	1	
REGION:VCP/p97-interacting motif (VIM)	SEQ_UP	7	
REGION:VCR 1	SEQ_UP	1	
REGION:VCR 2	SEQ_UP	1	
REGION:VEFS-box	SEQ_UP	1	
REGION:VHS-like	SEQ_UP	1	
REGION:Vitamin D3 binding	SEQ_UP	1	
REGION:VTT domain	SEQ_UP	3	
REGION:VTT domain; required for its function in autophagy	SEQ_UP	1	
REGION:VWFA-like	SEQ_UP	1	
REGION:VWFA-like domain	SEQ_UP	1	
REGION:VZV IE62-binding	SEQ_UP	1	
REGION:WD repeat beta-propeller A	SEQ_UP	1	
REGION:WD repeat beta-propeller B; Interaction with CUL4A	SEQ_UP	1	
REGION:WD repeat beta-propeller C	SEQ_UP	1	
REGION:WD repeat-like region	SEQ_UP	1	
REGION:WD40-like repeat 1	SEQ_UP	1	
REGION:WD40-like repeat 2	SEQ_UP	1	
REGION:WD40-like repeat 3	SEQ_UP	1	
REGION:WD40-like repeat 4	SEQ_UP	1	
REGION:WD40-like repeat 5	SEQ_UP	1	
REGION:WD40-like repeat 6	SEQ_UP	1	
REGION:WD40-like repeat 7	SEQ_UP	1	
REGION:WH domain	SEQ_UP	1	
REGION:WHD1	SEQ_UP	1	
REGION:Winged helix-turn-helix (wHTH)	SEQ_UP	1	
REGION:Winged helix-turn-helix (wHTH) 1	SEQ_UP	1	
REGION:Winged helix-turn-helix (wHTH) 2	SEQ_UP	1	
REGION:Winged-Helix (WH)	SEQ_UP	1	
REGION:Winged-helix domain	SEQ_UP	1	
REGION:Winged-helix domain (WHD)	SEQ_UP	2	
REGION:Winged-helix like domain	SEQ_UP	1	
REGION:WIPI-interacting	SEQ_UP	1	
REGION:WIPI2-binding	SEQ_UP	1	
REGION:Wnt-binding	SEQ_UP	1	
REGION:X-domain (extra domain)	SEQ_UP	1	
REGION:XCCR4 binding. Required for localization to the double-strand breaks (DSBs)	SEQ_UP	1	
REGION:XPG-I domain	SEQ_UP	1	
REGION:XPG-N domain	SEQ_UP	1	
REGION:Xylosyltransferase activity	SEQ_UP	2	
REGION:ZAS1	SEQ_UP	1	
REGION:ZAS2	SEQ_UP	1	
REGION:ZCCHC8 binding	SEQ_UP	1	
REGION:ZID domain	SEQ_UP	1	
REGION:Zinc finger loop	SEQ_UP	1	
REGION:Zinc finger-like	SEQ_UP	1	
REGION:Zinc finger-like 1	SEQ_UP	1	
REGION:Zinc finger-like 2	SEQ_UP	1	
REGION:Zinc finger-like 3	SEQ_UP	1	
REGION:Zinc finger-like; important for proper ribosome association	SEQ_UP	1	
REGION:Zinc-binding	SEQ_UP	2	
REGION:Zinc-finger-like region	SEQ_UP	1	
REGION:ZIS1	SEQ_UP	1	
REGION:ZIS5	SEQ_UP	1	
REGION:ZP-C	SEQ_UP	1	
REGION:ZP-N	SEQ_UP	1	
REGION:ZRF1-UBD	SEQ_UP	1	
REGION:ZU5	SEQ_UP	2	
REGION:zUBD/ZHA	SEQ_UP	1	
REGION:Zymogen activation region	SEQ_UP	1	
REPEAT:[DE]-W-[ST] 1	SEQ_UP	1	
REPEAT:[DE]-W-[ST] 2	SEQ_UP	1	
REPEAT:[DE]-W-[ST] 3	SEQ_UP	1	
REPEAT:[DE]-W-[ST] 4	SEQ_UP	1	
REPEAT:[DE]-W-[ST] 5	SEQ_UP	1	
REPEAT:[DE]-X(4)-L-L 1	SEQ_UP	1	
REPEAT:[DE]-X(4)-L-L 2	SEQ_UP	1	
REPEAT:[DE]-X(4)-L-L 3	SEQ_UP	1	
REPEAT:1	SEQ_UP	163	
REPEAT:1-1	SEQ_UP	24	
REPEAT:1-1; approximate	SEQ_UP	3	
REPEAT:1-10	SEQ_UP	3	
REPEAT:1-11	SEQ_UP	2	
REPEAT:1-12	SEQ_UP	2	
REPEAT:1-13	SEQ_UP	2	
REPEAT:1-14	SEQ_UP	2	
REPEAT:1-15	SEQ_UP	1	
REPEAT:1-16	SEQ_UP	1	
REPEAT:1-17	SEQ_UP	1	
REPEAT:1-18	SEQ_UP	1	
REPEAT:1-19	SEQ_UP	1	
REPEAT:1-2	SEQ_UP	24	
REPEAT:1-2; approximate	SEQ_UP	2	
REPEAT:1-20	SEQ_UP	1	
REPEAT:1-21	SEQ_UP	1	
REPEAT:1-22	SEQ_UP	1	
REPEAT:1-23	SEQ_UP	1	
REPEAT:1-24	SEQ_UP	1	
REPEAT:1-25	SEQ_UP	1	
REPEAT:1-26	SEQ_UP	1	
REPEAT:1-3	SEQ_UP	17	
REPEAT:1-3; approximate	SEQ_UP	2	
REPEAT:1-4	SEQ_UP	14	
REPEAT:1-4; approximate	SEQ_UP	2	
REPEAT:1-5	SEQ_UP	5	
REPEAT:1-5; approximate	SEQ_UP	2	
REPEAT:1-5; truncated	SEQ_UP	1	
REPEAT:1-6	SEQ_UP	5	
REPEAT:1-7	SEQ_UP	4	
REPEAT:1-7; approximate	SEQ_UP	1	
REPEAT:1-8	SEQ_UP	4	
REPEAT:1-8; approximate	SEQ_UP	1	
REPEAT:1-9	SEQ_UP	3	
REPEAT:1; approximate	SEQ_UP	4	
REPEAT:1; truncated	SEQ_UP	3	
REPEAT:10	SEQ_UP	50	
REPEAT:10; approximate	SEQ_UP	2	
REPEAT:11	SEQ_UP	44	
REPEAT:11; approximate	SEQ_UP	1	
REPEAT:12	SEQ_UP	39	
REPEAT:12; approximate	SEQ_UP	3	
REPEAT:13	SEQ_UP	38	
REPEAT:13; approximate	SEQ_UP	1	
REPEAT:14	SEQ_UP	35	
REPEAT:14; approximate	SEQ_UP	2	
REPEAT:15	SEQ_UP	30	
REPEAT:15; approximate	SEQ_UP	1	
REPEAT:16	SEQ_UP	22	
REPEAT:16; approximate	SEQ_UP	2	
REPEAT:17	SEQ_UP	23	
REPEAT:18	SEQ_UP	20	
REPEAT:18; approximate	SEQ_UP	1	
REPEAT:19	SEQ_UP	20	
REPEAT:19; approximate	SEQ_UP	1	
REPEAT:2	SEQ_UP	165	
REPEAT:2-1	SEQ_UP	23	
REPEAT:2-1; approximate	SEQ_UP	1	
REPEAT:2-10	SEQ_UP	2	
REPEAT:2-10; approximate	SEQ_UP	1	
REPEAT:2-11	SEQ_UP	2	
REPEAT:2-11; approximate	SEQ_UP	1	
REPEAT:2-12	SEQ_UP	3	
REPEAT:2-13	SEQ_UP	2	
REPEAT:2-14	SEQ_UP	2	
REPEAT:2-15	SEQ_UP	2	
REPEAT:2-16	SEQ_UP	2	
REPEAT:2-17	SEQ_UP	2	
REPEAT:2-18	SEQ_UP	2	
REPEAT:2-19	SEQ_UP	2	
REPEAT:2-2	SEQ_UP	23	
REPEAT:2-2; approximate	SEQ_UP	1	
REPEAT:2-20	SEQ_UP	2	
REPEAT:2-21	SEQ_UP	2	
REPEAT:2-22	SEQ_UP	2	
REPEAT:2-23	SEQ_UP	1	
REPEAT:2-24	SEQ_UP	1	
REPEAT:2-25	SEQ_UP	1	
REPEAT:2-26	SEQ_UP	1	
REPEAT:2-27	SEQ_UP	1	
REPEAT:2-28	SEQ_UP	1	
REPEAT:2-29	SEQ_UP	1	
REPEAT:2-3	SEQ_UP	16	
REPEAT:2-3; approximate	SEQ_UP	1	
REPEAT:2-30	SEQ_UP	1	
REPEAT:2-31	SEQ_UP	1	
REPEAT:2-32	SEQ_UP	1	
REPEAT:2-4	SEQ_UP	9	
REPEAT:2-5	SEQ_UP	5	
REPEAT:2-5; approximate	SEQ_UP	1	
REPEAT:2-6	SEQ_UP	4	
REPEAT:2-6; approximate	SEQ_UP	1	
REPEAT:2-7	SEQ_UP	3	
REPEAT:2-7; approximate	SEQ_UP	2	
REPEAT:2-8	SEQ_UP	4	
REPEAT:2-9	SEQ_UP	2	
REPEAT:2-9; approximate	SEQ_UP	1	
REPEAT:2; approximate	SEQ_UP	4	
REPEAT:20	SEQ_UP	19	
REPEAT:20; approximate	SEQ_UP	2	
REPEAT:21	SEQ_UP	18	
REPEAT:21; approximate	SEQ_UP	1	
REPEAT:22	SEQ_UP	13	
REPEAT:22; approximate	SEQ_UP	1	
REPEAT:23	SEQ_UP	12	
REPEAT:23; approximate	SEQ_UP	1	
REPEAT:24	SEQ_UP	11	
REPEAT:24; approximate	SEQ_UP	2	
REPEAT:25	SEQ_UP	13	
REPEAT:26	SEQ_UP	12	
REPEAT:26; approximate	SEQ_UP	1	
REPEAT:27	SEQ_UP	12	
REPEAT:27; approximate	SEQ_UP	1	
REPEAT:28	SEQ_UP	11	
REPEAT:28; approximate	SEQ_UP	1	
REPEAT:29	SEQ_UP	10	
REPEAT:3	SEQ_UP	134	
REPEAT:3-1	SEQ_UP	5	
REPEAT:3-2	SEQ_UP	4	
REPEAT:3-2; approximate	SEQ_UP	1	
REPEAT:3-3	SEQ_UP	4	
REPEAT:3-4	SEQ_UP	3	
REPEAT:3-5	SEQ_UP	2	
REPEAT:3-6	SEQ_UP	1	
REPEAT:3; approximate	SEQ_UP	9	
REPEAT:3; half-length	SEQ_UP	2	
REPEAT:3; truncated	SEQ_UP	2	
REPEAT:30	SEQ_UP	9	
REPEAT:31	SEQ_UP	9	
REPEAT:32	SEQ_UP	8	
REPEAT:33	SEQ_UP	7	
REPEAT:34	SEQ_UP	7	
REPEAT:35	SEQ_UP	7	
REPEAT:36	SEQ_UP	7	
REPEAT:37	SEQ_UP	6	
REPEAT:38	SEQ_UP	5	
REPEAT:39	SEQ_UP	5	
REPEAT:4	SEQ_UP	112	
REPEAT:4; approximate	SEQ_UP	7	
REPEAT:4; truncated	SEQ_UP	2	
REPEAT:40	SEQ_UP	5	
REPEAT:41	SEQ_UP	5	
REPEAT:42	SEQ_UP	5	
REPEAT:43	SEQ_UP	4	
REPEAT:43; approximate	SEQ_UP	1	
REPEAT:44	SEQ_UP	5	
REPEAT:45	SEQ_UP	5	
REPEAT:46	SEQ_UP	4	
REPEAT:47	SEQ_UP	3	
REPEAT:48	SEQ_UP	3	
REPEAT:49	SEQ_UP	3	
REPEAT:5	SEQ_UP	95	
REPEAT:5; approximate	SEQ_UP	6	
REPEAT:5; truncated	SEQ_UP	2	
REPEAT:50	SEQ_UP	3	
REPEAT:51	SEQ_UP	2	
REPEAT:51; approximate	SEQ_UP	1	
REPEAT:52	SEQ_UP	2	
REPEAT:52; approximate	SEQ_UP	1	
REPEAT:53	SEQ_UP	1	
REPEAT:54	SEQ_UP	1	
REPEAT:55	SEQ_UP	1	
REPEAT:56	SEQ_UP	1	
REPEAT:57	SEQ_UP	1	
REPEAT:58	SEQ_UP	1	
REPEAT:59	SEQ_UP	1	
REPEAT:6	SEQ_UP	75	
REPEAT:6; approximate	SEQ_UP	5	
REPEAT:60	SEQ_UP	1	
REPEAT:61	SEQ_UP	1	
REPEAT:7	SEQ_UP	69	
REPEAT:7; approximate	SEQ_UP	2	
REPEAT:7; truncated	SEQ_UP	1	
REPEAT:8	SEQ_UP	62	
REPEAT:8; approximate	SEQ_UP	1	
REPEAT:9	SEQ_UP	50	
REPEAT:9; approximate	SEQ_UP	1	
REPEAT:9; half-length	SEQ_UP	1	
REPEAT:9; truncated	SEQ_UP	1	
REPEAT:A	SEQ_UP	1	
REPEAT:A; approximate	SEQ_UP	1	
REPEAT:Acidic serine cluster 1	SEQ_UP	1	
REPEAT:Acidic serine cluster 10	SEQ_UP	1	
REPEAT:Acidic serine cluster 11	SEQ_UP	1	
REPEAT:Acidic serine cluster 2	SEQ_UP	1	
REPEAT:Acidic serine cluster 3	SEQ_UP	1	
REPEAT:Acidic serine cluster 4	SEQ_UP	1	
REPEAT:Acidic serine cluster 5	SEQ_UP	1	
REPEAT:Acidic serine cluster 6	SEQ_UP	1	
REPEAT:Acidic serine cluster 7	SEQ_UP	1	
REPEAT:Acidic serine cluster 8	SEQ_UP	1	
REPEAT:Acidic serine cluster 9	SEQ_UP	1	
REPEAT:Alpha-1	SEQ_UP	5	
REPEAT:Alpha-2	SEQ_UP	5	
REPEAT:ANK	SEQ_UP	188	
REPEAT:ANK 0; degenerate	SEQ_UP	1	
REPEAT:ANK 1	SEQ_UP	207	
REPEAT:ANK 10	SEQ_UP	27	
REPEAT:ANK 11	SEQ_UP	19	
REPEAT:ANK 12	SEQ_UP	13	
REPEAT:ANK 13	SEQ_UP	12	
REPEAT:ANK 14	SEQ_UP	12	
REPEAT:ANK 15	SEQ_UP	11	
REPEAT:ANK 16	SEQ_UP	11	
REPEAT:ANK 17	SEQ_UP	10	
REPEAT:ANK 18	SEQ_UP	10	
REPEAT:ANK 19	SEQ_UP	8	
REPEAT:ANK 2	SEQ_UP	207	
REPEAT:ANK 20	SEQ_UP	8	
REPEAT:ANK 21	SEQ_UP	8	
REPEAT:ANK 22	SEQ_UP	7	
REPEAT:ANK 23	SEQ_UP	7	
REPEAT:ANK 24	SEQ_UP	5	
REPEAT:ANK 25	SEQ_UP	4	
REPEAT:ANK 26	SEQ_UP	3	
REPEAT:ANK 27	SEQ_UP	3	
REPEAT:ANK 28	SEQ_UP	2	
REPEAT:ANK 3	SEQ_UP	174	
REPEAT:ANK 4	SEQ_UP	144	
REPEAT:ANK 4; degenerate	SEQ_UP	1	
REPEAT:ANK 5	SEQ_UP	116	
REPEAT:ANK 6	SEQ_UP	88	
REPEAT:ANK 7	SEQ_UP	59	
REPEAT:ANK 8	SEQ_UP	43	
REPEAT:ANK 9	SEQ_UP	38	
REPEAT:Annexin 1	SEQ_UP	12	
REPEAT:Annexin 2	SEQ_UP	12	
REPEAT:Annexin 3	SEQ_UP	12	
REPEAT:Annexin 4	SEQ_UP	12	
REPEAT:Annexin 5	SEQ_UP	1	
REPEAT:Annexin 6	SEQ_UP	1	
REPEAT:Annexin 7	SEQ_UP	1	
REPEAT:Annexin 8	SEQ_UP	1	
REPEAT:Approximate	SEQ_UP	1	
REPEAT:ARM	SEQ_UP	23	
REPEAT:ARM 1	SEQ_UP	36	
REPEAT:ARM 1; truncated	SEQ_UP	5	
REPEAT:ARM 10	SEQ_UP	9	
REPEAT:ARM 10; atypical	SEQ_UP	5	
REPEAT:ARM 11	SEQ_UP	6	
REPEAT:ARM 12	SEQ_UP	6	
REPEAT:ARM 13	SEQ_UP	1	
REPEAT:ARM 14	SEQ_UP	1	
REPEAT:ARM 2	SEQ_UP	41	
REPEAT:ARM 3	SEQ_UP	39	
REPEAT:ARM 4	SEQ_UP	35	
REPEAT:ARM 5	SEQ_UP	30	
REPEAT:ARM 6	SEQ_UP	26	
REPEAT:ARM 7	SEQ_UP	23	
REPEAT:ARM 8	SEQ_UP	21	
REPEAT:ARM 9	SEQ_UP	16	
REPEAT:B-1	SEQ_UP	1	
REPEAT:B-2	SEQ_UP	1	
REPEAT:BIR	SEQ_UP	3	
REPEAT:BIR 1	SEQ_UP	8	
REPEAT:BIR 2	SEQ_UP	8	
REPEAT:BIR 3	SEQ_UP	8	
REPEAT:Blade 1	SEQ_UP	1	
REPEAT:Blade 2	SEQ_UP	1	
REPEAT:Blade 3	SEQ_UP	1	
REPEAT:Blade 4	SEQ_UP	1	
REPEAT:Blade 5	SEQ_UP	1	
REPEAT:Blade 6	SEQ_UP	1	
REPEAT:Blade 7	SEQ_UP	1	
REPEAT:BNR 1	SEQ_UP	10	
REPEAT:BNR 10	SEQ_UP	1	
REPEAT:BNR 11	SEQ_UP	1	
REPEAT:BNR 12	SEQ_UP	1	
REPEAT:BNR 13	SEQ_UP	1	
REPEAT:BNR 14	SEQ_UP	1	
REPEAT:BNR 15	SEQ_UP	1	
REPEAT:BNR 16	SEQ_UP	1	
REPEAT:BNR 2	SEQ_UP	10	
REPEAT:BNR 3	SEQ_UP	9	
REPEAT:BNR 4	SEQ_UP	7	
REPEAT:BNR 5	SEQ_UP	6	
REPEAT:BNR 6	SEQ_UP	4	
REPEAT:BNR 7	SEQ_UP	2	
REPEAT:BNR 8	SEQ_UP	2	
REPEAT:BNR 9	SEQ_UP	2	
REPEAT:BRCA2	SEQ_UP	1	
REPEAT:BRCA2 1	SEQ_UP	1	
REPEAT:BRCA2 2	SEQ_UP	1	
REPEAT:BRCA2 3	SEQ_UP	1	
REPEAT:BRCA2 4	SEQ_UP	1	
REPEAT:BRCA2 5	SEQ_UP	1	
REPEAT:BRCA2 6	SEQ_UP	1	
REPEAT:BRCA2 7	SEQ_UP	1	
REPEAT:Calponin-like	SEQ_UP	3	
REPEAT:Calponin-like 1	SEQ_UP	3	
REPEAT:Calponin-like 2	SEQ_UP	3	
REPEAT:Calponin-like 3	SEQ_UP	3	
REPEAT:Centrin-binding (CBR) 1	SEQ_UP	1	
REPEAT:Centrin-binding (CBR) 2	SEQ_UP	1	
REPEAT:Centrin-binding (CBR) 3	SEQ_UP	1	
REPEAT:CHCR	SEQ_UP	6	
REPEAT:CHCR 1	SEQ_UP	2	
REPEAT:CHCR 2	SEQ_UP	2	
REPEAT:CHCR 3	SEQ_UP	1	
REPEAT:CHCR 4	SEQ_UP	1	
REPEAT:CHCR 5	SEQ_UP	1	
REPEAT:CHCR 6	SEQ_UP	1	
REPEAT:CHCR 7	SEQ_UP	1	
REPEAT:CKB motif 1	SEQ_UP	1	
REPEAT:CKB motif 2	SEQ_UP	1	
REPEAT:CKB motif 3	SEQ_UP	1	
REPEAT:Cortactin 1	SEQ_UP	2	
REPEAT:Cortactin 2	SEQ_UP	2	
REPEAT:Cortactin 3	SEQ_UP	2	
REPEAT:Cortactin 4	SEQ_UP	1	
REPEAT:Cortactin 4; truncated	SEQ_UP	1	
REPEAT:Cortactin 5	SEQ_UP	1	
REPEAT:Cortactin 6	SEQ_UP	1	
REPEAT:Cortactin 7; truncated	SEQ_UP	1	
REPEAT:CSPG	SEQ_UP	5	
REPEAT:CSPG 1	SEQ_UP	5	
REPEAT:CSPG 10	SEQ_UP	5	
REPEAT:CSPG 11	SEQ_UP	5	
REPEAT:CSPG 12	SEQ_UP	5	
REPEAT:CSPG 13	SEQ_UP	1	
REPEAT:CSPG 14	SEQ_UP	1	
REPEAT:CSPG 15	SEQ_UP	1	
REPEAT:CSPG 2	SEQ_UP	5	
REPEAT:CSPG 3	SEQ_UP	5	
REPEAT:CSPG 4	SEQ_UP	5	
REPEAT:CSPG 5	SEQ_UP	5	
REPEAT:CSPG 6	SEQ_UP	5	
REPEAT:CSPG 7	SEQ_UP	5	
REPEAT:CSPG 8	SEQ_UP	5	
REPEAT:CSPG 9	SEQ_UP	5	
REPEAT:CTR1-1; approximate	SEQ_UP	1	
REPEAT:CTR1-2	SEQ_UP	1	
REPEAT:CTR1-3	SEQ_UP	1	
REPEAT:CTR1-4	SEQ_UP	1	
REPEAT:CTR1-5	SEQ_UP	1	
REPEAT:CTR1-6	SEQ_UP	1	
REPEAT:CTR1-7	SEQ_UP	1	
REPEAT:CTR1-8	SEQ_UP	1	
REPEAT:CTR1-9	SEQ_UP	1	
REPEAT:CTR2-1	SEQ_UP	1	
REPEAT:CTR2-10	SEQ_UP	1	
REPEAT:CTR2-2; approximate	SEQ_UP	1	
REPEAT:CTR2-3; approximate	SEQ_UP	1	
REPEAT:CTR2-4; half-length	SEQ_UP	1	
REPEAT:CTR2-5; approximate	SEQ_UP	1	
REPEAT:CTR2-6	SEQ_UP	1	
REPEAT:CTR2-7; approximate	SEQ_UP	1	
REPEAT:CTR2-8	SEQ_UP	1	
REPEAT:CTR2-9	SEQ_UP	1	
REPEAT:CXXCXGXG motif	SEQ_UP	4	
REPEAT:Cys-rich GLG1	SEQ_UP	1	
REPEAT:Cys-rich GLG1 1	SEQ_UP	1	
REPEAT:Cys-rich GLG1 10	SEQ_UP	1	
REPEAT:Cys-rich GLG1 11	SEQ_UP	1	
REPEAT:Cys-rich GLG1 12	SEQ_UP	1	
REPEAT:Cys-rich GLG1 13	SEQ_UP	1	
REPEAT:Cys-rich GLG1 14	SEQ_UP	1	
REPEAT:Cys-rich GLG1 15	SEQ_UP	1	
REPEAT:Cys-rich GLG1 16	SEQ_UP	1	
REPEAT:Cys-rich GLG1 2	SEQ_UP	1	
REPEAT:Cys-rich GLG1 3	SEQ_UP	1	
REPEAT:Cys-rich GLG1 4	SEQ_UP	1	
REPEAT:Cys-rich GLG1 5	SEQ_UP	1	
REPEAT:Cys-rich GLG1 6	SEQ_UP	1	
REPEAT:Cys-rich GLG1 7	SEQ_UP	1	
REPEAT:Cys-rich GLG1 8	SEQ_UP	1	
REPEAT:Cys-rich GLG1 9	SEQ_UP	1	
REPEAT:Desmoglein repeat 1	SEQ_UP	6	
REPEAT:Desmoglein repeat 2	SEQ_UP	6	
REPEAT:Desmoglein repeat 3	SEQ_UP	4	
REPEAT:Desmoglein repeat 4	SEQ_UP	4	
REPEAT:Desmoglein repeat 5	SEQ_UP	3	
REPEAT:Desmoglein repeat 5; truncated	SEQ_UP	1	
REPEAT:Desmoglein repeat 6	SEQ_UP	1	
REPEAT:EAR	SEQ_UP	5	
REPEAT:EAR 1	SEQ_UP	6	
REPEAT:EAR 2	SEQ_UP	6	
REPEAT:EAR 3	SEQ_UP	6	
REPEAT:EAR 4	SEQ_UP	6	
REPEAT:EAR 5	SEQ_UP	6	
REPEAT:EAR 6	SEQ_UP	6	
REPEAT:EAR 7	SEQ_UP	5	
REPEAT:FG 1	SEQ_UP	1	
REPEAT:FG 10	SEQ_UP	1	
REPEAT:FG 11	SEQ_UP	1	
REPEAT:FG 2	SEQ_UP	1	
REPEAT:FG 3	SEQ_UP	1	
REPEAT:FG 4	SEQ_UP	1	
REPEAT:FG 5	SEQ_UP	1	
REPEAT:FG 6	SEQ_UP	1	
REPEAT:FG 7	SEQ_UP	1	
REPEAT:FG 8	SEQ_UP	1	
REPEAT:FG 9	SEQ_UP	1	
REPEAT:FG-GAP	SEQ_UP	20	
REPEAT:FG-GAP 1	SEQ_UP	18	
REPEAT:FG-GAP 1; atypical	SEQ_UP	3	
REPEAT:FG-GAP 2	SEQ_UP	18	
REPEAT:FG-GAP 2; atypical	SEQ_UP	3	
REPEAT:FG-GAP 3	SEQ_UP	18	
REPEAT:FG-GAP 3; atypical	SEQ_UP	2	
REPEAT:FG-GAP 4	SEQ_UP	18	
REPEAT:FG-GAP 4; atypical	SEQ_UP	1	
REPEAT:FG-GAP 5	SEQ_UP	18	
REPEAT:FG-GAP 6	SEQ_UP	18	
REPEAT:FG-GAP 7	SEQ_UP	18	
REPEAT:Filaggrin 1	SEQ_UP	1	
REPEAT:Filaggrin 10	SEQ_UP	1	
REPEAT:Filaggrin 11	SEQ_UP	1	
REPEAT:Filaggrin 12	SEQ_UP	1	
REPEAT:Filaggrin 2	SEQ_UP	1	
REPEAT:Filaggrin 3	SEQ_UP	1	
REPEAT:Filaggrin 4	SEQ_UP	1	
REPEAT:Filaggrin 5	SEQ_UP	1	
REPEAT:Filaggrin 6	SEQ_UP	1	
REPEAT:Filaggrin 7	SEQ_UP	1	
REPEAT:Filaggrin 8	SEQ_UP	1	
REPEAT:Filaggrin 9	SEQ_UP	1	
REPEAT:Filamin	SEQ_UP	11	
REPEAT:Filamin 1	SEQ_UP	3	
REPEAT:Filamin 10	SEQ_UP	3	
REPEAT:Filamin 11	SEQ_UP	3	
REPEAT:Filamin 12	SEQ_UP	3	
REPEAT:Filamin 13	SEQ_UP	3	
REPEAT:Filamin 14	SEQ_UP	3	
REPEAT:Filamin 15	SEQ_UP	3	
REPEAT:Filamin 16	SEQ_UP	3	
REPEAT:Filamin 17	SEQ_UP	3	
REPEAT:Filamin 18	SEQ_UP	3	
REPEAT:Filamin 19	SEQ_UP	3	
REPEAT:Filamin 2	SEQ_UP	3	
REPEAT:Filamin 20	SEQ_UP	2	
REPEAT:Filamin 20; mediates interaction with XIRP1	SEQ_UP	1	
REPEAT:Filamin 21	SEQ_UP	3	
REPEAT:Filamin 22	SEQ_UP	3	
REPEAT:Filamin 23	SEQ_UP	3	
REPEAT:Filamin 24	SEQ_UP	3	
REPEAT:Filamin 3	SEQ_UP	3	
REPEAT:Filamin 4	SEQ_UP	3	
REPEAT:Filamin 5	SEQ_UP	3	
REPEAT:Filamin 6	SEQ_UP	3	
REPEAT:Filamin 7	SEQ_UP	3	
REPEAT:Filamin 8	SEQ_UP	3	
REPEAT:Filamin 9	SEQ_UP	3	
REPEAT:FU	SEQ_UP	2	
REPEAT:FU 1	SEQ_UP	7	
REPEAT:FU 10	SEQ_UP	2	
REPEAT:FU 11	SEQ_UP	2	
REPEAT:FU 12	SEQ_UP	2	
REPEAT:FU 13	SEQ_UP	2	
REPEAT:FU 14	SEQ_UP	2	
REPEAT:FU 15	SEQ_UP	1	
REPEAT:FU 16	SEQ_UP	1	
REPEAT:FU 17	SEQ_UP	1	
REPEAT:FU 18	SEQ_UP	1	
REPEAT:FU 19	SEQ_UP	1	
REPEAT:FU 2	SEQ_UP	7	
REPEAT:FU 20	SEQ_UP	1	
REPEAT:FU 21	SEQ_UP	1	
REPEAT:FU 22	SEQ_UP	1	
REPEAT:FU 3	SEQ_UP	2	
REPEAT:FU 4	SEQ_UP	2	
REPEAT:FU 5	SEQ_UP	2	
REPEAT:FU 6	SEQ_UP	2	
REPEAT:FU 7	SEQ_UP	2	
REPEAT:FU 8	SEQ_UP	2	
REPEAT:FU 9	SEQ_UP	2	
REPEAT:Gelsolin-like	SEQ_UP	3	
REPEAT:Gelsolin-like 1	SEQ_UP	8	
REPEAT:Gelsolin-like 2	SEQ_UP	8	
REPEAT:Gelsolin-like 3	SEQ_UP	8	
REPEAT:Gelsolin-like 4	SEQ_UP	7	
REPEAT:Gelsolin-like 5	SEQ_UP	7	
REPEAT:Gelsolin-like 6	SEQ_UP	5	
REPEAT:GRSGPLPPXP motif 1	SEQ_UP	1	
REPEAT:GRSGPLPPXP motif 2	SEQ_UP	1	
REPEAT:GTF2I-like 1	SEQ_UP	3	
REPEAT:GTF2I-like 2	SEQ_UP	3	
REPEAT:GTF2I-like 3	SEQ_UP	2	
REPEAT:GTF2I-like 4	SEQ_UP	2	
REPEAT:GTF2I-like 5	SEQ_UP	2	
REPEAT:GTF2I-like 6	SEQ_UP	2	
REPEAT:HAT 1	SEQ_UP	10	
REPEAT:HAT 10	SEQ_UP	2	
REPEAT:HAT 11	SEQ_UP	2	
REPEAT:HAT 12	SEQ_UP	2	
REPEAT:HAT 13	SEQ_UP	2	
REPEAT:HAT 14	SEQ_UP	2	
REPEAT:HAT 15	SEQ_UP	1	
REPEAT:HAT 16	SEQ_UP	1	
REPEAT:HAT 2	SEQ_UP	10	
REPEAT:HAT 3	SEQ_UP	10	
REPEAT:HAT 4	SEQ_UP	9	
REPEAT:HAT 5	SEQ_UP	9	
REPEAT:HAT 6	SEQ_UP	7	
REPEAT:HAT 7	SEQ_UP	6	
REPEAT:HAT 8	SEQ_UP	5	
REPEAT:HAT 9	SEQ_UP	5	
REPEAT:HCF repeat 1	SEQ_UP	1	
REPEAT:HCF repeat 2	SEQ_UP	1	
REPEAT:HCF repeat 3	SEQ_UP	1	
REPEAT:HCF repeat 4; degenerate	SEQ_UP	1	
REPEAT:HCF repeat 5	SEQ_UP	1	
REPEAT:HCF repeat 6	SEQ_UP	1	
REPEAT:HCF repeat 7; degenerate	SEQ_UP	1	
REPEAT:HCF repeat 8	SEQ_UP	1	
REPEAT:HEAT	SEQ_UP	20	
REPEAT:HEAT 1	SEQ_UP	58	
REPEAT:HEAT 10	SEQ_UP	21	
REPEAT:HEAT 11	SEQ_UP	19	
REPEAT:HEAT 12	SEQ_UP	18	
REPEAT:HEAT 13	SEQ_UP	17	
REPEAT:HEAT 14	SEQ_UP	16	
REPEAT:HEAT 15	SEQ_UP	14	
REPEAT:HEAT 16	SEQ_UP	11	
REPEAT:HEAT 17	SEQ_UP	10	
REPEAT:HEAT 18	SEQ_UP	10	
REPEAT:HEAT 19	SEQ_UP	10	
REPEAT:HEAT 2	SEQ_UP	58	
REPEAT:HEAT 20	SEQ_UP	9	
REPEAT:HEAT 21	SEQ_UP	6	
REPEAT:HEAT 22	SEQ_UP	6	
REPEAT:HEAT 23	SEQ_UP	6	
REPEAT:HEAT 24	SEQ_UP	6	
REPEAT:HEAT 25	SEQ_UP	5	
REPEAT:HEAT 26	SEQ_UP	4	
REPEAT:HEAT 27	SEQ_UP	3	
REPEAT:HEAT 28	SEQ_UP	2	
REPEAT:HEAT 29	SEQ_UP	2	
REPEAT:HEAT 3	SEQ_UP	49	
REPEAT:HEAT 30	SEQ_UP	2	
REPEAT:HEAT 31	SEQ_UP	2	
REPEAT:HEAT 32	SEQ_UP	2	
REPEAT:HEAT 33	SEQ_UP	1	
REPEAT:HEAT 34	SEQ_UP	1	
REPEAT:HEAT 35	SEQ_UP	1	
REPEAT:HEAT 36	SEQ_UP	1	
REPEAT:HEAT 37	SEQ_UP	1	
REPEAT:HEAT 38	SEQ_UP	1	
REPEAT:HEAT 39	SEQ_UP	1	
REPEAT:HEAT 4	SEQ_UP	45	
REPEAT:HEAT 40	SEQ_UP	1	
REPEAT:HEAT 41	SEQ_UP	1	
REPEAT:HEAT 42	SEQ_UP	1	
REPEAT:HEAT 43	SEQ_UP	1	
REPEAT:HEAT 44	SEQ_UP	1	
REPEAT:HEAT 45	SEQ_UP	1	
REPEAT:HEAT 46	SEQ_UP	1	
REPEAT:HEAT 47	SEQ_UP	1	
REPEAT:HEAT 5	SEQ_UP	37	
REPEAT:HEAT 6	SEQ_UP	33	
REPEAT:HEAT 7	SEQ_UP	28	
REPEAT:HEAT 8	SEQ_UP	25	
REPEAT:HEAT 9	SEQ_UP	23	
REPEAT:HEAT-like PBS-type 1	SEQ_UP	1	
REPEAT:HEAT-like PBS-type 2	SEQ_UP	1	
REPEAT:HEAT-like PBS-type 3	SEQ_UP	1	
REPEAT:HEAT-like PBS-type 4	SEQ_UP	1	
REPEAT:HEAT-like PBS-type 5	SEQ_UP	1	
REPEAT:Hemopexin	SEQ_UP	18	
REPEAT:Hemopexin 1	SEQ_UP	22	
REPEAT:Hemopexin 2	SEQ_UP	22	
REPEAT:Hemopexin 3	SEQ_UP	21	
REPEAT:Hemopexin 4	SEQ_UP	21	
REPEAT:Hemopexin 5	SEQ_UP	1	
REPEAT:Hemopexin 6	SEQ_UP	1	
REPEAT:Hemopexin 7	SEQ_UP	1	
REPEAT:Hemopexin 8	SEQ_UP	1	
REPEAT:HRM 1	SEQ_UP	3	
REPEAT:HRM 2	SEQ_UP	3	
REPEAT:I	SEQ_UP	26	
REPEAT:II	SEQ_UP	26	
REPEAT:III	SEQ_UP	26	
REPEAT:Inhibitory domain 1	SEQ_UP	1	
REPEAT:Inhibitory domain 2	SEQ_UP	1	
REPEAT:Inhibitory domain 3	SEQ_UP	1	
REPEAT:Inhibitory domain 4	SEQ_UP	1	
REPEAT:Involved in LRWD1-binding	SEQ_UP	1	
REPEAT:IV	SEQ_UP	26	
REPEAT:IX	SEQ_UP	1	
REPEAT:K167R 1	SEQ_UP	1	
REPEAT:K167R 10	SEQ_UP	1	
REPEAT:K167R 11	SEQ_UP	1	
REPEAT:K167R 12	SEQ_UP	1	
REPEAT:K167R 13	SEQ_UP	1	
REPEAT:K167R 14	SEQ_UP	1	
REPEAT:K167R 15	SEQ_UP	1	
REPEAT:K167R 16	SEQ_UP	1	
REPEAT:K167R 2	SEQ_UP	1	
REPEAT:K167R 3	SEQ_UP	1	
REPEAT:K167R 4	SEQ_UP	1	
REPEAT:K167R 5	SEQ_UP	1	
REPEAT:K167R 6	SEQ_UP	1	
REPEAT:K167R 7	SEQ_UP	1	
REPEAT:K167R 8	SEQ_UP	1	
REPEAT:K167R 9	SEQ_UP	1	
REPEAT:Kelch 1	SEQ_UP	64	
REPEAT:Kelch 10	SEQ_UP	2	
REPEAT:Kelch 11	SEQ_UP	2	
REPEAT:Kelch 12	SEQ_UP	2	
REPEAT:Kelch 13	SEQ_UP	1	
REPEAT:Kelch 14	SEQ_UP	1	
REPEAT:Kelch 15	SEQ_UP	1	
REPEAT:Kelch 16	SEQ_UP	1	
REPEAT:Kelch 17	SEQ_UP	1	
REPEAT:Kelch 18	SEQ_UP	1	
REPEAT:Kelch 2	SEQ_UP	64	
REPEAT:Kelch 3	SEQ_UP	64	
REPEAT:Kelch 4	SEQ_UP	62	
REPEAT:Kelch 5	SEQ_UP	58	
REPEAT:Kelch 6	SEQ_UP	47	
REPEAT:Kelch 7	SEQ_UP	4	
REPEAT:Kelch 8	SEQ_UP	3	
REPEAT:Kelch 9	SEQ_UP	2	
REPEAT:Knot 1	SEQ_UP	1	
REPEAT:Knot 2	SEQ_UP	1	
REPEAT:Knot 3	SEQ_UP	1	
REPEAT:Knot 4	SEQ_UP	1	
REPEAT:Knot 5	SEQ_UP	1	
REPEAT:LDL-receptor class B	SEQ_UP	12	
REPEAT:LDL-receptor class B 1	SEQ_UP	13	
REPEAT:LDL-receptor class B 10	SEQ_UP	6	
REPEAT:LDL-receptor class B 11	SEQ_UP	6	
REPEAT:LDL-receptor class B 12	SEQ_UP	6	
REPEAT:LDL-receptor class B 13	SEQ_UP	6	
REPEAT:LDL-receptor class B 14	SEQ_UP	6	
REPEAT:LDL-receptor class B 15	SEQ_UP	6	
REPEAT:LDL-receptor class B 16	SEQ_UP	6	
REPEAT:LDL-receptor class B 17	SEQ_UP	6	
REPEAT:LDL-receptor class B 18	SEQ_UP	5	
REPEAT:LDL-receptor class B 19	SEQ_UP	6	
REPEAT:LDL-receptor class B 2	SEQ_UP	13	
REPEAT:LDL-receptor class B 20	SEQ_UP	6	
REPEAT:LDL-receptor class B 21	SEQ_UP	3	
REPEAT:LDL-receptor class B 22	SEQ_UP	3	
REPEAT:LDL-receptor class B 23	SEQ_UP	3	
REPEAT:LDL-receptor class B 24	SEQ_UP	3	
REPEAT:LDL-receptor class B 25	SEQ_UP	3	
REPEAT:LDL-receptor class B 26	SEQ_UP	3	
REPEAT:LDL-receptor class B 27	SEQ_UP	3	
REPEAT:LDL-receptor class B 28	SEQ_UP	3	
REPEAT:LDL-receptor class B 29	SEQ_UP	3	
REPEAT:LDL-receptor class B 3	SEQ_UP	13	
REPEAT:LDL-receptor class B 30	SEQ_UP	3	
REPEAT:LDL-receptor class B 31	SEQ_UP	3	
REPEAT:LDL-receptor class B 32	SEQ_UP	3	
REPEAT:LDL-receptor class B 33	SEQ_UP	3	
REPEAT:LDL-receptor class B 34	SEQ_UP	3	
REPEAT:LDL-receptor class B 35	SEQ_UP	1	
REPEAT:LDL-receptor class B 36	SEQ_UP	1	
REPEAT:LDL-receptor class B 4	SEQ_UP	13	
REPEAT:LDL-receptor class B 5	SEQ_UP	12	
REPEAT:LDL-receptor class B 6	SEQ_UP	9	
REPEAT:LDL-receptor class B 7	SEQ_UP	7	
REPEAT:LDL-receptor class B 8	SEQ_UP	7	
REPEAT:LDL-receptor class B 9	SEQ_UP	6	
REPEAT:LNR 1	SEQ_UP	5	
REPEAT:LNR 2	SEQ_UP	5	
REPEAT:LNR 3	SEQ_UP	4	
REPEAT:LRR	SEQ_UP	3	
REPEAT:LRR 1	SEQ_UP	268	
REPEAT:LRR 1; degenerate	SEQ_UP	7	
REPEAT:LRR 10	SEQ_UP	108	
REPEAT:LRR 11	SEQ_UP	85	
REPEAT:LRR 12	SEQ_UP	71	
REPEAT:LRR 13	SEQ_UP	57	
REPEAT:LRR 14	SEQ_UP	51	
REPEAT:LRR 15	SEQ_UP	49	
REPEAT:LRR 16	SEQ_UP	40	
REPEAT:LRR 17	SEQ_UP	36	
REPEAT:LRR 18	SEQ_UP	29	
REPEAT:LRR 19	SEQ_UP	29	
REPEAT:LRR 2	SEQ_UP	267	
REPEAT:LRR 2; degenerate	SEQ_UP	7	
REPEAT:LRR 20	SEQ_UP	22	
REPEAT:LRR 21	SEQ_UP	16	
REPEAT:LRR 22	SEQ_UP	12	
REPEAT:LRR 23	SEQ_UP	8	
REPEAT:LRR 24	SEQ_UP	7	
REPEAT:LRR 25	SEQ_UP	7	
REPEAT:LRR 26	SEQ_UP	6	
REPEAT:LRR 27	SEQ_UP	3	
REPEAT:LRR 28	SEQ_UP	2	
REPEAT:LRR 29	SEQ_UP	1	
REPEAT:LRR 3	SEQ_UP	256	
REPEAT:LRR 3; degenerate	SEQ_UP	6	
REPEAT:LRR 30	SEQ_UP	1	
REPEAT:LRR 31	SEQ_UP	1	
REPEAT:LRR 32	SEQ_UP	1	
REPEAT:LRR 4	SEQ_UP	241	
REPEAT:LRR 4; degenerate	SEQ_UP	7	
REPEAT:LRR 5	SEQ_UP	225	
REPEAT:LRR 6	SEQ_UP	198	
REPEAT:LRR 7	SEQ_UP	171	
REPEAT:LRR 8	SEQ_UP	148	
REPEAT:LRR 9	SEQ_UP	134	
REPEAT:MAP1B 1	SEQ_UP	1	
REPEAT:MAP1B 10	SEQ_UP	1	
REPEAT:MAP1B 2	SEQ_UP	1	
REPEAT:MAP1B 3	SEQ_UP	1	
REPEAT:MAP1B 4	SEQ_UP	1	
REPEAT:MAP1B 5	SEQ_UP	1	
REPEAT:MAP1B 6	SEQ_UP	1	
REPEAT:MAP1B 7	SEQ_UP	1	
REPEAT:MAP1B 8	SEQ_UP	1	
REPEAT:MAP1B 9	SEQ_UP	1	
REPEAT:MBT	SEQ_UP	8	
REPEAT:MBT 1	SEQ_UP	8	
REPEAT:MBT 2	SEQ_UP	8	
REPEAT:MBT 3	SEQ_UP	7	
REPEAT:MBT 4	SEQ_UP	4	
REPEAT:Mc-1	SEQ_UP	1	
REPEAT:Mc-2	SEQ_UP	1	
REPEAT:Mc-3	SEQ_UP	1	
REPEAT:Mc-4	SEQ_UP	1	
REPEAT:MORN 1	SEQ_UP	14	
REPEAT:MORN 10	SEQ_UP	1	
REPEAT:MORN 2	SEQ_UP	14	
REPEAT:MORN 3	SEQ_UP	13	
REPEAT:MORN 4	SEQ_UP	10	
REPEAT:MORN 5	SEQ_UP	9	
REPEAT:MORN 6	SEQ_UP	9	
REPEAT:MORN 7	SEQ_UP	8	
REPEAT:MORN 8	SEQ_UP	6	
REPEAT:MORN 9	SEQ_UP	1	
REPEAT:MTERF 1	SEQ_UP	1	
REPEAT:MTERF 2	SEQ_UP	1	
REPEAT:MTERF 3	SEQ_UP	1	
REPEAT:MTERF 4	SEQ_UP	1	
REPEAT:MTERF 5	SEQ_UP	1	
REPEAT:MVP 1	SEQ_UP	1	
REPEAT:MVP 2	SEQ_UP	1	
REPEAT:MVP 3	SEQ_UP	1	
REPEAT:MVP 4	SEQ_UP	1	
REPEAT:MVP 5	SEQ_UP	1	
REPEAT:MVP 6	SEQ_UP	1	
REPEAT:MVP 7	SEQ_UP	1	
REPEAT:MVP 8	SEQ_UP	1	
REPEAT:MVP 9	SEQ_UP	1	
REPEAT:Nebulin 1	SEQ_UP	3	
REPEAT:Nebulin 10	SEQ_UP	2	
REPEAT:Nebulin 11	SEQ_UP	2	
REPEAT:Nebulin 12	SEQ_UP	2	
REPEAT:Nebulin 13	SEQ_UP	1	
REPEAT:Nebulin 14	SEQ_UP	1	
REPEAT:Nebulin 15	SEQ_UP	1	
REPEAT:Nebulin 16	SEQ_UP	1	
REPEAT:Nebulin 17	SEQ_UP	1	
REPEAT:Nebulin 18	SEQ_UP	1	
REPEAT:Nebulin 19	SEQ_UP	1	
REPEAT:Nebulin 2	SEQ_UP	3	
REPEAT:Nebulin 20	SEQ_UP	1	
REPEAT:Nebulin 21	SEQ_UP	1	
REPEAT:Nebulin 22	SEQ_UP	1	
REPEAT:Nebulin 23	SEQ_UP	1	
REPEAT:Nebulin 24	SEQ_UP	1	
REPEAT:Nebulin 25	SEQ_UP	1	
REPEAT:Nebulin 26	SEQ_UP	1	
REPEAT:Nebulin 27	SEQ_UP	1	
REPEAT:Nebulin 28	SEQ_UP	1	
REPEAT:Nebulin 29	SEQ_UP	1	
REPEAT:Nebulin 3	SEQ_UP	2	
REPEAT:Nebulin 30	SEQ_UP	1	
REPEAT:Nebulin 31	SEQ_UP	1	
REPEAT:Nebulin 32	SEQ_UP	1	
REPEAT:Nebulin 33	SEQ_UP	1	
REPEAT:Nebulin 34	SEQ_UP	1	
REPEAT:Nebulin 35	SEQ_UP	1	
REPEAT:Nebulin 36	SEQ_UP	1	
REPEAT:Nebulin 37	SEQ_UP	1	
REPEAT:Nebulin 38	SEQ_UP	1	
REPEAT:Nebulin 39	SEQ_UP	1	
REPEAT:Nebulin 4	SEQ_UP	2	
REPEAT:Nebulin 40	SEQ_UP	1	
REPEAT:Nebulin 41	SEQ_UP	1	
REPEAT:Nebulin 5	SEQ_UP	2	
REPEAT:Nebulin 6	SEQ_UP	2	
REPEAT:Nebulin 7	SEQ_UP	2	
REPEAT:Nebulin 8	SEQ_UP	2	
REPEAT:Nebulin 9	SEQ_UP	2	
REPEAT:NHL	SEQ_UP	6	
REPEAT:NHL 1	SEQ_UP	13	
REPEAT:NHL 2	SEQ_UP	13	
REPEAT:NHL 3	SEQ_UP	12	
REPEAT:NHL 4	SEQ_UP	12	
REPEAT:NHL 5	SEQ_UP	11	
REPEAT:NHL 6	SEQ_UP	6	
REPEAT:P-P-P-P-G	SEQ_UP	1	
REPEAT:PbH1 1	SEQ_UP	8	
REPEAT:PbH1 10	SEQ_UP	3	
REPEAT:PbH1 11	SEQ_UP	2	
REPEAT:PbH1 12	SEQ_UP	2	
REPEAT:PbH1 13	SEQ_UP	2	
REPEAT:PbH1 14	SEQ_UP	2	
REPEAT:PbH1 15	SEQ_UP	2	
REPEAT:PbH1 16	SEQ_UP	2	
REPEAT:PbH1 17	SEQ_UP	2	
REPEAT:PbH1 18	SEQ_UP	1	
REPEAT:PbH1 19	SEQ_UP	1	
REPEAT:PbH1 2	SEQ_UP	8	
REPEAT:PbH1 3	SEQ_UP	8	
REPEAT:PbH1 4	SEQ_UP	7	
REPEAT:PbH1 5	SEQ_UP	5	
REPEAT:PbH1 6	SEQ_UP	4	
REPEAT:PbH1 7	SEQ_UP	4	
REPEAT:PbH1 8	SEQ_UP	4	
REPEAT:PbH1 9	SEQ_UP	3	
REPEAT:PC 1	SEQ_UP	3	
REPEAT:PC 10	SEQ_UP	1	
REPEAT:PC 2	SEQ_UP	3	
REPEAT:PC 3	SEQ_UP	3	
REPEAT:PC 4	SEQ_UP	3	
REPEAT:PC 5	SEQ_UP	2	
REPEAT:PC 6	SEQ_UP	2	
REPEAT:PC 7	SEQ_UP	2	
REPEAT:PC 8	SEQ_UP	1	
REPEAT:PC 9	SEQ_UP	1	
REPEAT:PEVK 1	SEQ_UP	1	
REPEAT:PEVK 10	SEQ_UP	1	
REPEAT:PEVK 11	SEQ_UP	1	
REPEAT:PEVK 12	SEQ_UP	1	
REPEAT:PEVK 13	SEQ_UP	1	
REPEAT:PEVK 14	SEQ_UP	1	
REPEAT:PEVK 15	SEQ_UP	1	
REPEAT:PEVK 16	SEQ_UP	1	
REPEAT:PEVK 17	SEQ_UP	1	
REPEAT:PEVK 18	SEQ_UP	1	
REPEAT:PEVK 19	SEQ_UP	1	
REPEAT:PEVK 2	SEQ_UP	1	
REPEAT:PEVK 20	SEQ_UP	1	
REPEAT:PEVK 21	SEQ_UP	1	
REPEAT:PEVK 22	SEQ_UP	1	
REPEAT:PEVK 23	SEQ_UP	1	
REPEAT:PEVK 24	SEQ_UP	1	
REPEAT:PEVK 25	SEQ_UP	1	
REPEAT:PEVK 26	SEQ_UP	1	
REPEAT:PEVK 27	SEQ_UP	1	
REPEAT:PEVK 28	SEQ_UP	1	
REPEAT:PEVK 29	SEQ_UP	1	
REPEAT:PEVK 3	SEQ_UP	1	
REPEAT:PEVK 30	SEQ_UP	1	
REPEAT:PEVK 31	SEQ_UP	1	
REPEAT:PEVK 32	SEQ_UP	1	
REPEAT:PEVK 33	SEQ_UP	1	
REPEAT:PEVK 34	SEQ_UP	1	
REPEAT:PEVK 35	SEQ_UP	1	
REPEAT:PEVK 36	SEQ_UP	1	
REPEAT:PEVK 37	SEQ_UP	1	
REPEAT:PEVK 38	SEQ_UP	1	
REPEAT:PEVK 39	SEQ_UP	1	
REPEAT:PEVK 4	SEQ_UP	1	
REPEAT:PEVK 40	SEQ_UP	1	
REPEAT:PEVK 41	SEQ_UP	1	
REPEAT:PEVK 42	SEQ_UP	1	
REPEAT:PEVK 43	SEQ_UP	1	
REPEAT:PEVK 44	SEQ_UP	1	
REPEAT:PEVK 45	SEQ_UP	1	
REPEAT:PEVK 46	SEQ_UP	1	
REPEAT:PEVK 47	SEQ_UP	1	
REPEAT:PEVK 48	SEQ_UP	1	
REPEAT:PEVK 49	SEQ_UP	1	
REPEAT:PEVK 5	SEQ_UP	1	
REPEAT:PEVK 50	SEQ_UP	1	
REPEAT:PEVK 51	SEQ_UP	1	
REPEAT:PEVK 52	SEQ_UP	1	
REPEAT:PEVK 53	SEQ_UP	1	
REPEAT:PEVK 54	SEQ_UP	1	
REPEAT:PEVK 55	SEQ_UP	1	
REPEAT:PEVK 56	SEQ_UP	1	
REPEAT:PEVK 57	SEQ_UP	1	
REPEAT:PEVK 58	SEQ_UP	1	
REPEAT:PEVK 59	SEQ_UP	1	
REPEAT:PEVK 6	SEQ_UP	1	
REPEAT:PEVK 60	SEQ_UP	1	
REPEAT:PEVK 61	SEQ_UP	1	
REPEAT:PEVK 62	SEQ_UP	1	
REPEAT:PEVK 63	SEQ_UP	1	
REPEAT:PEVK 64	SEQ_UP	1	
REPEAT:PEVK 65	SEQ_UP	1	
REPEAT:PEVK 66	SEQ_UP	1	
REPEAT:PEVK 67	SEQ_UP	1	
REPEAT:PEVK 68	SEQ_UP	1	
REPEAT:PEVK 69	SEQ_UP	1	
REPEAT:PEVK 7	SEQ_UP	1	
REPEAT:PEVK 70	SEQ_UP	1	
REPEAT:PEVK 71	SEQ_UP	1	
REPEAT:PEVK 72	SEQ_UP	1	
REPEAT:PEVK 73	SEQ_UP	1	
REPEAT:PEVK 74	SEQ_UP	1	
REPEAT:PEVK 75	SEQ_UP	1	
REPEAT:PEVK 76	SEQ_UP	1	
REPEAT:PEVK 8	SEQ_UP	1	
REPEAT:PEVK 9	SEQ_UP	1	
REPEAT:PFTA 1	SEQ_UP	2	
REPEAT:PFTA 2	SEQ_UP	2	
REPEAT:PFTA 3	SEQ_UP	2	
REPEAT:PFTA 4	SEQ_UP	2	
REPEAT:PFTA 5	SEQ_UP	2	
REPEAT:PFTA 6	SEQ_UP	1	
REPEAT:PFTB 1	SEQ_UP	4	
REPEAT:PFTB 2	SEQ_UP	4	
REPEAT:PFTB 3	SEQ_UP	4	
REPEAT:PFTB 4	SEQ_UP	4	
REPEAT:PFTB 5	SEQ_UP	2	
REPEAT:PFTB 6	SEQ_UP	1	
REPEAT:Plectin 1	SEQ_UP	7	
REPEAT:Plectin 10	SEQ_UP	4	
REPEAT:Plectin 11	SEQ_UP	3	
REPEAT:Plectin 12	SEQ_UP	3	
REPEAT:Plectin 13	SEQ_UP	3	
REPEAT:Plectin 14	SEQ_UP	3	
REPEAT:Plectin 15	SEQ_UP	3	
REPEAT:Plectin 16	SEQ_UP	3	
REPEAT:Plectin 17	SEQ_UP	3	
REPEAT:Plectin 18	SEQ_UP	2	
REPEAT:Plectin 19	SEQ_UP	2	
REPEAT:Plectin 2	SEQ_UP	7	
REPEAT:Plectin 20	SEQ_UP	2	
REPEAT:Plectin 21	SEQ_UP	2	
REPEAT:Plectin 22	SEQ_UP	2	
REPEAT:Plectin 23	SEQ_UP	2	
REPEAT:Plectin 24	SEQ_UP	2	
REPEAT:Plectin 25	SEQ_UP	2	
REPEAT:Plectin 26	SEQ_UP	2	
REPEAT:Plectin 27	SEQ_UP	2	
REPEAT:Plectin 28	SEQ_UP	2	
REPEAT:Plectin 29	SEQ_UP	2	
REPEAT:Plectin 3	SEQ_UP	6	
REPEAT:Plectin 30	SEQ_UP	2	
REPEAT:Plectin 31	SEQ_UP	2	
REPEAT:Plectin 32	SEQ_UP	2	
REPEAT:Plectin 33	SEQ_UP	2	
REPEAT:Plectin 34	SEQ_UP	1	
REPEAT:Plectin 35	SEQ_UP	1	
REPEAT:Plectin 36	SEQ_UP	1	
REPEAT:Plectin 37	SEQ_UP	1	
REPEAT:Plectin 38	SEQ_UP	1	
REPEAT:Plectin 39	SEQ_UP	1	
REPEAT:Plectin 4	SEQ_UP	6	
REPEAT:Plectin 40	SEQ_UP	1	
REPEAT:Plectin 41	SEQ_UP	1	
REPEAT:Plectin 42	SEQ_UP	1	
REPEAT:Plectin 43	SEQ_UP	1	
REPEAT:Plectin 44	SEQ_UP	1	
REPEAT:Plectin 45	SEQ_UP	1	
REPEAT:Plectin 46	SEQ_UP	1	
REPEAT:Plectin 47	SEQ_UP	1	
REPEAT:Plectin 48	SEQ_UP	1	
REPEAT:Plectin 49	SEQ_UP	1	
REPEAT:Plectin 5	SEQ_UP	6	
REPEAT:Plectin 50	SEQ_UP	1	
REPEAT:Plectin 51	SEQ_UP	1	
REPEAT:Plectin 52	SEQ_UP	1	
REPEAT:Plectin 53	SEQ_UP	1	
REPEAT:Plectin 54	SEQ_UP	1	
REPEAT:Plectin 55	SEQ_UP	1	
REPEAT:Plectin 56	SEQ_UP	1	
REPEAT:Plectin 57	SEQ_UP	1	
REPEAT:Plectin 58	SEQ_UP	1	
REPEAT:Plectin 59	SEQ_UP	1	
REPEAT:Plectin 6	SEQ_UP	5	
REPEAT:Plectin 60	SEQ_UP	1	
REPEAT:Plectin 61	SEQ_UP	1	
REPEAT:Plectin 62	SEQ_UP	1	
REPEAT:Plectin 63	SEQ_UP	1	
REPEAT:Plectin 64	SEQ_UP	1	
REPEAT:Plectin 65	SEQ_UP	1	
REPEAT:Plectin 66	SEQ_UP	1	
REPEAT:Plectin 67	SEQ_UP	1	
REPEAT:Plectin 68	SEQ_UP	1	
REPEAT:Plectin 69	SEQ_UP	1	
REPEAT:Plectin 7	SEQ_UP	5	
REPEAT:Plectin 70	SEQ_UP	1	
REPEAT:Plectin 71	SEQ_UP	1	
REPEAT:Plectin 72	SEQ_UP	1	
REPEAT:Plectin 73	SEQ_UP	1	
REPEAT:Plectin 74	SEQ_UP	1	
REPEAT:Plectin 75	SEQ_UP	1	
REPEAT:Plectin 76	SEQ_UP	1	
REPEAT:Plectin 8	SEQ_UP	4	
REPEAT:Plectin 9	SEQ_UP	4	
REPEAT:PPR	SEQ_UP	9	
REPEAT:PPR 1	SEQ_UP	6	
REPEAT:PPR 10	SEQ_UP	2	
REPEAT:PPR 11	SEQ_UP	1	
REPEAT:PPR 12	SEQ_UP	1	
REPEAT:PPR 13	SEQ_UP	1	
REPEAT:PPR 14	SEQ_UP	1	
REPEAT:PPR 15	SEQ_UP	1	
REPEAT:PPR 16	SEQ_UP	1	
REPEAT:PPR 17	SEQ_UP	1	
REPEAT:PPR 18	SEQ_UP	1	
REPEAT:PPR 19	SEQ_UP	1	
REPEAT:PPR 2	SEQ_UP	6	
REPEAT:PPR 20	SEQ_UP	1	
REPEAT:PPR 3	SEQ_UP	3	
REPEAT:PPR 4	SEQ_UP	3	
REPEAT:PPR 5	SEQ_UP	3	
REPEAT:PPR 6	SEQ_UP	3	
REPEAT:PPR 7	SEQ_UP	3	
REPEAT:PPR 8	SEQ_UP	3	
REPEAT:PPR 9	SEQ_UP	3	
REPEAT:Pumilio	SEQ_UP	3	
REPEAT:Pumilio 1	SEQ_UP	4	
REPEAT:Pumilio 10	SEQ_UP	1	
REPEAT:Pumilio 11	SEQ_UP	1	
REPEAT:Pumilio 2	SEQ_UP	4	
REPEAT:Pumilio 3	SEQ_UP	4	
REPEAT:Pumilio 4	SEQ_UP	4	
REPEAT:Pumilio 5	SEQ_UP	4	
REPEAT:Pumilio 6	SEQ_UP	4	
REPEAT:Pumilio 7	SEQ_UP	3	
REPEAT:Pumilio 8	SEQ_UP	3	
REPEAT:Pumilio 9	SEQ_UP	1	
REPEAT:PXXP 1	SEQ_UP	4	
REPEAT:PXXP 2	SEQ_UP	4	
REPEAT:PXXP 3	SEQ_UP	4	
REPEAT:PXXP 4	SEQ_UP	4	
REPEAT:PXXP 5	SEQ_UP	4	
REPEAT:PXXP 6	SEQ_UP	2	
REPEAT:PXXXP motif	SEQ_UP	1	
REPEAT:PXXXP motif; regulates binding with chromatin and interaction with PCNA	SEQ_UP	1	
REPEAT:RCC1	SEQ_UP	16	
REPEAT:RCC1 1	SEQ_UP	16	
REPEAT:RCC1 1-1	SEQ_UP	1	
REPEAT:RCC1 1-2	SEQ_UP	1	
REPEAT:RCC1 1-3	SEQ_UP	1	
REPEAT:RCC1 1-4	SEQ_UP	1	
REPEAT:RCC1 1-5	SEQ_UP	1	
REPEAT:RCC1 1-6	SEQ_UP	1	
REPEAT:RCC1 1-7	SEQ_UP	1	
REPEAT:RCC1 10	SEQ_UP	1	
REPEAT:RCC1 11	SEQ_UP	1	
REPEAT:RCC1 12	SEQ_UP	1	
REPEAT:RCC1 2	SEQ_UP	16	
REPEAT:RCC1 2-1	SEQ_UP	1	
REPEAT:RCC1 2-2	SEQ_UP	1	
REPEAT:RCC1 2-3	SEQ_UP	1	
REPEAT:RCC1 2-4	SEQ_UP	1	
REPEAT:RCC1 2-5	SEQ_UP	1	
REPEAT:RCC1 2-6	SEQ_UP	1	
REPEAT:RCC1 2-7	SEQ_UP	1	
REPEAT:RCC1 3	SEQ_UP	16	
REPEAT:RCC1 3-1	SEQ_UP	1	
REPEAT:RCC1 3-2	SEQ_UP	1	
REPEAT:RCC1 3-3	SEQ_UP	1	
REPEAT:RCC1 3-4	SEQ_UP	1	
REPEAT:RCC1 3-5	SEQ_UP	1	
REPEAT:RCC1 3-6	SEQ_UP	1	
REPEAT:RCC1 3-7	SEQ_UP	1	
REPEAT:RCC1 4	SEQ_UP	15	
REPEAT:RCC1 5	SEQ_UP	14	
REPEAT:RCC1 6	SEQ_UP	10	
REPEAT:RCC1 7	SEQ_UP	6	
REPEAT:RCC1 8	SEQ_UP	1	
REPEAT:RCC1 9	SEQ_UP	1	
REPEAT:Repeat 1	SEQ_UP	1	
REPEAT:Repeat 2	SEQ_UP	1	
REPEAT:Repeat 3	SEQ_UP	1	
REPEAT:Repeat 4	SEQ_UP	1	
REPEAT:RPEL	SEQ_UP	6	
REPEAT:RPEL 1	SEQ_UP	6	
REPEAT:RPEL 2	SEQ_UP	6	
REPEAT:RPEL 3	SEQ_UP	6	
REPEAT:RPEL 4	SEQ_UP	2	
REPEAT:SEK 1	SEQ_UP	1	
REPEAT:SEK 2	SEQ_UP	1	
REPEAT:SEK 3	SEQ_UP	1	
REPEAT:SEK 4	SEQ_UP	1	
REPEAT:SEK 5	SEQ_UP	1	
REPEAT:SEK 6	SEQ_UP	1	
REPEAT:Sel1-like 1	SEQ_UP	5	
REPEAT:Sel1-like 10	SEQ_UP	2	
REPEAT:Sel1-like 11	SEQ_UP	2	
REPEAT:Sel1-like 2	SEQ_UP	5	
REPEAT:Sel1-like 3	SEQ_UP	5	
REPEAT:Sel1-like 4	SEQ_UP	5	
REPEAT:Sel1-like 5	SEQ_UP	5	
REPEAT:Sel1-like 6	SEQ_UP	4	
REPEAT:Sel1-like 7	SEQ_UP	3	
REPEAT:Sel1-like 8	SEQ_UP	3	
REPEAT:Sel1-like 9	SEQ_UP	2	
REPEAT:Ser/Thr-rich	SEQ_UP	1	
REPEAT:Solcar	SEQ_UP	41	
REPEAT:Solcar 1	SEQ_UP	48	
REPEAT:Solcar 2	SEQ_UP	48	
REPEAT:Solcar 3	SEQ_UP	45	
REPEAT:SP 1	SEQ_UP	1	
REPEAT:SP 2; approximate	SEQ_UP	1	
REPEAT:Spectrin	SEQ_UP	2	
REPEAT:Spectrin 1	SEQ_UP	21	
REPEAT:Spectrin 10	SEQ_UP	9	
REPEAT:Spectrin 11	SEQ_UP	9	
REPEAT:Spectrin 12	SEQ_UP	9	
REPEAT:Spectrin 13	SEQ_UP	9	
REPEAT:Spectrin 14	SEQ_UP	9	
REPEAT:Spectrin 15	SEQ_UP	9	
REPEAT:Spectrin 16	SEQ_UP	9	
REPEAT:Spectrin 17	SEQ_UP	9	
REPEAT:Spectrin 18	SEQ_UP	6	
REPEAT:Spectrin 19	SEQ_UP	6	
REPEAT:Spectrin 2	SEQ_UP	21	
REPEAT:Spectrin 20	SEQ_UP	6	
REPEAT:Spectrin 21	SEQ_UP	4	
REPEAT:Spectrin 22	SEQ_UP	4	
REPEAT:Spectrin 23	SEQ_UP	4	
REPEAT:Spectrin 24	SEQ_UP	4	
REPEAT:Spectrin 25	SEQ_UP	3	
REPEAT:Spectrin 26	SEQ_UP	3	
REPEAT:Spectrin 27	SEQ_UP	3	
REPEAT:Spectrin 28	SEQ_UP	3	
REPEAT:Spectrin 29	SEQ_UP	3	
REPEAT:Spectrin 3	SEQ_UP	18	
REPEAT:Spectrin 30	SEQ_UP	3	
REPEAT:Spectrin 31	SEQ_UP	3	
REPEAT:Spectrin 32	SEQ_UP	3	
REPEAT:Spectrin 33	SEQ_UP	2	
REPEAT:Spectrin 34	SEQ_UP	2	
REPEAT:Spectrin 35	SEQ_UP	2	
REPEAT:Spectrin 36	SEQ_UP	2	
REPEAT:Spectrin 37	SEQ_UP	2	
REPEAT:Spectrin 38	SEQ_UP	2	
REPEAT:Spectrin 39	SEQ_UP	2	
REPEAT:Spectrin 3a	SEQ_UP	1	
REPEAT:Spectrin 3b	SEQ_UP	1	
REPEAT:Spectrin 4	SEQ_UP	17	
REPEAT:Spectrin 40	SEQ_UP	2	
REPEAT:Spectrin 41	SEQ_UP	2	
REPEAT:Spectrin 42	SEQ_UP	2	
REPEAT:Spectrin 43	SEQ_UP	2	
REPEAT:Spectrin 44	SEQ_UP	2	
REPEAT:Spectrin 45	SEQ_UP	2	
REPEAT:Spectrin 46	SEQ_UP	2	
REPEAT:Spectrin 47	SEQ_UP	2	
REPEAT:Spectrin 48	SEQ_UP	2	
REPEAT:Spectrin 49	SEQ_UP	2	
REPEAT:Spectrin 5	SEQ_UP	12	
REPEAT:Spectrin 50	SEQ_UP	2	
REPEAT:Spectrin 51	SEQ_UP	2	
REPEAT:Spectrin 52	SEQ_UP	2	
REPEAT:Spectrin 53	SEQ_UP	2	
REPEAT:Spectrin 54	SEQ_UP	2	
REPEAT:Spectrin 55	SEQ_UP	2	
REPEAT:Spectrin 56	SEQ_UP	2	
REPEAT:Spectrin 57	SEQ_UP	1	
REPEAT:Spectrin 58	SEQ_UP	1	
REPEAT:Spectrin 59	SEQ_UP	1	
REPEAT:Spectrin 6	SEQ_UP	12	
REPEAT:Spectrin 60	SEQ_UP	1	
REPEAT:Spectrin 61	SEQ_UP	1	
REPEAT:Spectrin 62	SEQ_UP	1	
REPEAT:Spectrin 63	SEQ_UP	1	
REPEAT:Spectrin 64	SEQ_UP	1	
REPEAT:Spectrin 65	SEQ_UP	1	
REPEAT:Spectrin 66	SEQ_UP	1	
REPEAT:Spectrin 67	SEQ_UP	1	
REPEAT:Spectrin 68	SEQ_UP	1	
REPEAT:Spectrin 69	SEQ_UP	1	
REPEAT:Spectrin 7	SEQ_UP	10	
REPEAT:Spectrin 70	SEQ_UP	1	
REPEAT:Spectrin 71	SEQ_UP	1	
REPEAT:Spectrin 72	SEQ_UP	1	
REPEAT:Spectrin 73	SEQ_UP	1	
REPEAT:Spectrin 74	SEQ_UP	1	
REPEAT:Spectrin 8	SEQ_UP	10	
REPEAT:Spectrin 9	SEQ_UP	10	
REPEAT:STPGR	SEQ_UP	1	
REPEAT:STPGR 1	SEQ_UP	5	
REPEAT:STPGR 10	SEQ_UP	1	
REPEAT:STPGR 2	SEQ_UP	5	
REPEAT:STPGR 3	SEQ_UP	3	
REPEAT:STPGR 4	SEQ_UP	2	
REPEAT:STPGR 5	SEQ_UP	2	
REPEAT:STPGR 6	SEQ_UP	2	
REPEAT:STPGR 7	SEQ_UP	2	
REPEAT:STPGR 8	SEQ_UP	1	
REPEAT:STPGR 9	SEQ_UP	1	
REPEAT:SURP motif	SEQ_UP	2	
REPEAT:SURP motif 1	SEQ_UP	4	
REPEAT:SURP motif 2	SEQ_UP	4	
REPEAT:Tau/MAP 1	SEQ_UP	3	
REPEAT:Tau/MAP 2	SEQ_UP	3	
REPEAT:Tau/MAP 3	SEQ_UP	3	
REPEAT:Tau/MAP 4	SEQ_UP	2	
REPEAT:TECPR 1	SEQ_UP	1	
REPEAT:TECPR 2	SEQ_UP	1	
REPEAT:TECPR 3	SEQ_UP	1	
REPEAT:TECPR 4	SEQ_UP	1	
REPEAT:TECPR 5	SEQ_UP	1	
REPEAT:TECPR 6	SEQ_UP	1	
REPEAT:TECPR 7	SEQ_UP	1	
REPEAT:TECPR 8	SEQ_UP	1	
REPEAT:TECPR 9	SEQ_UP	1	
REPEAT:TEP1 N-terminal 1	SEQ_UP	1	
REPEAT:TEP1 N-terminal 2	SEQ_UP	1	
REPEAT:TEP1 N-terminal 3	SEQ_UP	1	
REPEAT:TEP1 N-terminal 4	SEQ_UP	1	
REPEAT:THEG 1	SEQ_UP	2	
REPEAT:THEG 2	SEQ_UP	2	
REPEAT:THEG 3	SEQ_UP	2	
REPEAT:THEG 4	SEQ_UP	2	
REPEAT:THEG 5	SEQ_UP	2	
REPEAT:THEG 6	SEQ_UP	2	
REPEAT:THEG 7	SEQ_UP	2	
REPEAT:THEG 8	SEQ_UP	1	
REPEAT:TNFR-Cys	SEQ_UP	19	
REPEAT:TNFR-Cys 1	SEQ_UP	23	
REPEAT:TNFR-Cys 2	SEQ_UP	23	
REPEAT:TNFR-Cys 3	SEQ_UP	19	
REPEAT:TNFR-Cys 3; truncated	SEQ_UP	2	
REPEAT:TNFR-Cys 4	SEQ_UP	10	
REPEAT:TNFR-Cys; atypical	SEQ_UP	1	
REPEAT:TNFR-Cys; truncated	SEQ_UP	1	
REPEAT:TPR	SEQ_UP	86	
REPEAT:TPR 1	SEQ_UP	136	
REPEAT:TPR 10	SEQ_UP	22	
REPEAT:TPR 11	SEQ_UP	15	
REPEAT:TPR 12	SEQ_UP	12	
REPEAT:TPR 13	SEQ_UP	11	
REPEAT:TPR 13; truncated	SEQ_UP	1	
REPEAT:TPR 14	SEQ_UP	8	
REPEAT:TPR 15	SEQ_UP	6	
REPEAT:TPR 16	SEQ_UP	5	
REPEAT:TPR 17	SEQ_UP	3	
REPEAT:TPR 18	SEQ_UP	3	
REPEAT:TPR 19	SEQ_UP	3	
REPEAT:TPR 2	SEQ_UP	136	
REPEAT:TPR 20	SEQ_UP	1	
REPEAT:TPR 21	SEQ_UP	1	
REPEAT:TPR 22	SEQ_UP	1	
REPEAT:TPR 23	SEQ_UP	1	
REPEAT:TPR 24	SEQ_UP	1	
REPEAT:TPR 25	SEQ_UP	1	
REPEAT:TPR 26	SEQ_UP	1	
REPEAT:TPR 27	SEQ_UP	1	
REPEAT:TPR 28	SEQ_UP	1	
REPEAT:TPR 3	SEQ_UP	125	
REPEAT:TPR 4	SEQ_UP	90	
REPEAT:TPR 5	SEQ_UP	69	
REPEAT:TPR 6	SEQ_UP	64	
REPEAT:TPR 7	SEQ_UP	54	
REPEAT:TPR 8	SEQ_UP	46	
REPEAT:TPR 9	SEQ_UP	28	
REPEAT:TSP type-3	SEQ_UP	5	
REPEAT:TSP type-3 1	SEQ_UP	5	
REPEAT:TSP type-3 2	SEQ_UP	5	
REPEAT:TSP type-3 3	SEQ_UP	5	
REPEAT:TSP type-3 4	SEQ_UP	5	
REPEAT:TSP type-3 5	SEQ_UP	5	
REPEAT:TSP type-3 6	SEQ_UP	5	
REPEAT:TSP type-3 7	SEQ_UP	5	
REPEAT:TSP type-3 8	SEQ_UP	5	
REPEAT:Type II	SEQ_UP	1	
REPEAT:Type IIIA	SEQ_UP	1	
REPEAT:Type IIIB	SEQ_UP	1	
REPEAT:ubiquitin-interacting motif (UIM)	SEQ_UP	1	
REPEAT:V	SEQ_UP	1	
REPEAT:VI	SEQ_UP	1	
REPEAT:VII	SEQ_UP	1	
REPEAT:VIII	SEQ_UP	1	
REPEAT:WD	SEQ_UP	181	
REPEAT:WD 1	SEQ_UP	252	
REPEAT:WD 1-1	SEQ_UP	1	
REPEAT:WD 1-2	SEQ_UP	1	
REPEAT:WD 1-3	SEQ_UP	1	
REPEAT:WD 1-4	SEQ_UP	1	
REPEAT:WD 1-5	SEQ_UP	1	
REPEAT:WD 1-6	SEQ_UP	1	
REPEAT:WD 1-7	SEQ_UP	1	
REPEAT:WD 10	SEQ_UP	33	
REPEAT:WD 11	SEQ_UP	32	
REPEAT:WD 12	SEQ_UP	29	
REPEAT:WD 13	SEQ_UP	25	
REPEAT:WD 14	SEQ_UP	14	
REPEAT:WD 15	SEQ_UP	8	
REPEAT:WD 16	SEQ_UP	7	
REPEAT:WD 17	SEQ_UP	6	
REPEAT:WD 18	SEQ_UP	5	
REPEAT:WD 19	SEQ_UP	5	
REPEAT:WD 2	SEQ_UP	252	
REPEAT:WD 2-1	SEQ_UP	1	
REPEAT:WD 2-2	SEQ_UP	1	
REPEAT:WD 2-3	SEQ_UP	1	
REPEAT:WD 2-4	SEQ_UP	1	
REPEAT:WD 2-5	SEQ_UP	1	
REPEAT:WD 2-6	SEQ_UP	1	
REPEAT:WD 2-7	SEQ_UP	1	
REPEAT:WD 2-8	SEQ_UP	1	
REPEAT:WD 20	SEQ_UP	4	
REPEAT:WD 21	SEQ_UP	4	
REPEAT:WD 22	SEQ_UP	2	
REPEAT:WD 23	SEQ_UP	2	
REPEAT:WD 24	SEQ_UP	2	
REPEAT:WD 25	SEQ_UP	2	
REPEAT:WD 26	SEQ_UP	2	
REPEAT:WD 27	SEQ_UP	2	
REPEAT:WD 28	SEQ_UP	2	
REPEAT:WD 29	SEQ_UP	2	
REPEAT:WD 3	SEQ_UP	248	
REPEAT:WD 30	SEQ_UP	1	
REPEAT:WD 4	SEQ_UP	237	
REPEAT:WD 5	SEQ_UP	222	
REPEAT:WD 6	SEQ_UP	184	
REPEAT:WD 7	SEQ_UP	145	
REPEAT:WD 8	SEQ_UP	51	
REPEAT:WD 8; interaction with SEC13	SEQ_UP	2	
REPEAT:WD 9	SEQ_UP	37	
REPEAT:X	SEQ_UP	1	
REPEAT:Xin	SEQ_UP	2	
REPEAT:Xin 1	SEQ_UP	2	
REPEAT:Xin 10	SEQ_UP	2	
REPEAT:Xin 11	SEQ_UP	2	
REPEAT:Xin 12	SEQ_UP	2	
REPEAT:Xin 13	SEQ_UP	2	
REPEAT:Xin 14	SEQ_UP	2	
REPEAT:Xin 15	SEQ_UP	2	
REPEAT:Xin 16	SEQ_UP	2	
REPEAT:Xin 17	SEQ_UP	2	
REPEAT:Xin 18	SEQ_UP	1	
REPEAT:Xin 19	SEQ_UP	1	
REPEAT:Xin 2	SEQ_UP	2	
REPEAT:Xin 20	SEQ_UP	1	
REPEAT:Xin 21	SEQ_UP	1	
REPEAT:Xin 22	SEQ_UP	1	
REPEAT:Xin 23	SEQ_UP	1	
REPEAT:Xin 24	SEQ_UP	1	
REPEAT:Xin 25	SEQ_UP	1	
REPEAT:Xin 26	SEQ_UP	1	
REPEAT:Xin 27	SEQ_UP	1	
REPEAT:Xin 28	SEQ_UP	1	
REPEAT:Xin 3	SEQ_UP	2	
REPEAT:Xin 4	SEQ_UP	2	
REPEAT:Xin 5	SEQ_UP	2	
REPEAT:Xin 6	SEQ_UP	2	
REPEAT:Xin 7	SEQ_UP	2	
REPEAT:Xin 8	SEQ_UP	2	
REPEAT:Xin 9	SEQ_UP	2	
REPEAT:XRSGPXPPXP motif 1	SEQ_UP	1	
REPEAT:XRSGPXPPXP motif 2	SEQ_UP	1	
REPEAT:XRSGPXPPXP motif 3	SEQ_UP	1	
REPEAT:YD 1	SEQ_UP	4	
REPEAT:YD 10	SEQ_UP	4	
REPEAT:YD 11	SEQ_UP	4	
REPEAT:YD 12	SEQ_UP	4	
REPEAT:YD 13	SEQ_UP	4	
REPEAT:YD 14	SEQ_UP	4	
REPEAT:YD 15	SEQ_UP	4	
REPEAT:YD 16	SEQ_UP	4	
REPEAT:YD 17	SEQ_UP	4	
REPEAT:YD 18	SEQ_UP	4	
REPEAT:YD 19	SEQ_UP	4	
REPEAT:YD 2	SEQ_UP	4	
REPEAT:YD 20	SEQ_UP	4	
REPEAT:YD 21	SEQ_UP	4	
REPEAT:YD 22	SEQ_UP	4	
REPEAT:YD 23	SEQ_UP	4	
REPEAT:YD 3	SEQ_UP	4	
REPEAT:YD 4	SEQ_UP	4	
REPEAT:YD 5	SEQ_UP	4	
REPEAT:YD 6	SEQ_UP	4	
REPEAT:YD 7	SEQ_UP	4	
REPEAT:YD 8	SEQ_UP	4	
REPEAT:YD 9	SEQ_UP	4	
REPEAT:Z-repeat 1	SEQ_UP	1	
REPEAT:Z-repeat 2	SEQ_UP	1	
REPEAT:Z-repeat 3	SEQ_UP	1	
REPEAT:Z-repeat 4	SEQ_UP	1	
REPEAT:Z-repeat 5	SEQ_UP	1	
REPEAT:Z-repeat 6	SEQ_UP	1	
SIGNAL:Not cleaved	SEQ_UP	8	
SIGNAL:Or 18	SEQ_UP	1	
SIGNAL:Or 23	SEQ_UP	1	
SITE:(Microbial infection) Cleavage; by C.botulinum neurotoxin type A (BoNT/A, botA)	SEQ_UP	2	
SITE:(Microbial infection) Cleavage; by C.botulinum neurotoxin type B (BoNT/B, botB)	SEQ_UP	1	
SITE:(Microbial infection) Cleavage; by C.botulinum neurotoxin type E (BoNT/E)	SEQ_UP	2	
SITE:(Microbial infection) Cleavage; by C.botulinum neurotoxin type X (BoNT/X)	SEQ_UP	3	
SITE:(Microbial infection) Cleavage; by C.tetani neurotoxin (tetX)	SEQ_UP	1	
SITE:(Microbial infection) Probable cleavage; by anthrax lethal toxin (LT) endopeptidase component	SEQ_UP	1	
SITE:3' overhang DNA-binding	SEQ_UP	1	
SITE:3' overhang DNA-binding; via amide nitrogen	SEQ_UP	1	
SITE:4-hydroxy-2-nonenal adduction	SEQ_UP	1	
SITE:Acetylated histone binding	SEQ_UP	1	
SITE:Activates the enzyme when modified	SEQ_UP	1	
SITE:Activates thiol group during catalysis	SEQ_UP	4	
SITE:Activation by thioester intermediate formation with UBA6	SEQ_UP	1	
SITE:Alternative splice site to produce 'x' isoforms	SEQ_UP	1	
SITE:Alternative splice site to produce 'y' isoforms	SEQ_UP	1	
SITE:Alternative splice site to produce 'z' isoforms	SEQ_UP	1	
SITE:Ancestral active site	SEQ_UP	3	
SITE:Ancestral zinc ligand	SEQ_UP	1	
SITE:Appears to be essential for biological activity	SEQ_UP	1	
SITE:Arginine finger	SEQ_UP	11	
SITE:Arginine-anchor	SEQ_UP	1	
SITE:Aspirin-acetylated lysine	SEQ_UP	1	
SITE:Aspirin-acetylated serine	SEQ_UP	2	
SITE:Autoinhibitory	SEQ_UP	2	
SITE:Binding of alpha-amino group of substrate	SEQ_UP	1	
SITE:Binds calcium which modulates its enzyme activity	SEQ_UP	1	
SITE:Binds Mu-conotoxin KIIIA	SEQ_UP	1	
SITE:Binds Mu-conotoxin KIIIA; via amide nitrogen	SEQ_UP	1	
SITE:Binds Mu-conotoxin KIIIA; via carbonyl oxygen	SEQ_UP	1	
SITE:Binds negatively charged residues of beta-tubulin C-terminal tails	SEQ_UP	1	
SITE:Binds SCN2A	SEQ_UP	1	
SITE:Binds SCN2B; via carbonyl oxygen	SEQ_UP	1	
SITE:Binds to omega-Aga-IVA	SEQ_UP	1	
SITE:Breakpoint for translocation to form MMTRA1A	SEQ_UP	1	
SITE:Breakpoint for translocation to form TRIM24-BRAF oncogene	SEQ_UP	1	
SITE:Calcium ion selectivity and permeability	SEQ_UP	7	
SITE:CDK7 binding	SEQ_UP	1	
SITE:Channel pore-lining	SEQ_UP	1	
SITE:Chemokine binding	SEQ_UP	1	
SITE:Cis/trans isomerization of proline peptide bond; by PIN1; dependent on Thr-110 phosphorylation	SEQ_UP	1	
SITE:Cleavage	SEQ_UP	86	
SITE:Cleavage (activation)	SEQ_UP	1	
SITE:Cleavage (by CASP2, CASP3, and CASP7)	SEQ_UP	1	
SITE:Cleavage (non-hydrolytic); by autocatalysis	SEQ_UP	1	
SITE:Cleavage (non-hydrolytic); by autolysis	SEQ_UP	2	
SITE:Cleavage (when cotranslationally processed)	SEQ_UP	2	
SITE:Cleavage at site S1	SEQ_UP	1	
SITE:Cleavage by BACE2	SEQ_UP	1	
SITE:Cleavage of ectodomain	SEQ_UP	3	
SITE:Cleavage, alpha site; by neurotrypsin	SEQ_UP	1	
SITE:Cleavage, beta site; by neurotrypsin	SEQ_UP	1	
SITE:Cleavage, first; by autolysis	SEQ_UP	1	
SITE:Cleavage, second; by autolysis	SEQ_UP	1	
SITE:Cleavage; alternate	SEQ_UP	1	
SITE:Cleavage; by 20S proteasomal protease	SEQ_UP	1	
SITE:Cleavage; by a caspase	SEQ_UP	1	
SITE:Cleavage; by a caspase during apoptosis	SEQ_UP	1	
SITE:Cleavage; by a caspase-3-like protease	SEQ_UP	1	
SITE:Cleavage; by a metalloproteinase	SEQ_UP	2	
SITE:Cleavage; by activated protein C	SEQ_UP	1	
SITE:Cleavage; by ADAM protease	SEQ_UP	1	
SITE:Cleavage; by ADAM10	SEQ_UP	1	
SITE:Cleavage; by ADAM10 and ADAM17	SEQ_UP	1	
SITE:Cleavage; by ADAM17	SEQ_UP	3	
SITE:Cleavage; by ADAM8	SEQ_UP	1	
SITE:Cleavage; by ADAMTS15	SEQ_UP	1	
SITE:Cleavage; by ADAMTS2 and ADAMTS14	SEQ_UP	1	
SITE:Cleavage; by alpha-secretase	SEQ_UP	1	
SITE:Cleavage; by anthrax lethal factor	SEQ_UP	3	
SITE:Cleavage; by ASTL	SEQ_UP	1	
SITE:Cleavage; by ATG4B	SEQ_UP	5	
SITE:Cleavage; by autocatalytic cleavage	SEQ_UP	1	
SITE:Cleavage; by autolysis	SEQ_UP	40	
SITE:Cleavage; by beta-secretase	SEQ_UP	1	
SITE:Cleavage; by BMP1	SEQ_UP	2	
SITE:Cleavage; by C3 convertase	SEQ_UP	1	
SITE:Cleavage; by calpain	SEQ_UP	4	
SITE:Cleavage; by CAPN1	SEQ_UP	1	
SITE:Cleavage; by CAPN1 and CAPN3	SEQ_UP	1	
SITE:Cleavage; by CAPN2	SEQ_UP	3	
SITE:Cleavage; by carboxypeptidases	SEQ_UP	1	
SITE:Cleavage; by CASP1	SEQ_UP	1	
SITE:Cleavage; by CASP3	SEQ_UP	10	
SITE:Cleavage; by CASP3 and CASP7	SEQ_UP	2	
SITE:Cleavage; by CASP3 in vitro	SEQ_UP	1	
SITE:Cleavage; by CASP3 or granzyme B	SEQ_UP	1	
SITE:Cleavage; by CASP3, CASP6 and CASP7	SEQ_UP	1	
SITE:Cleavage; by CASP6	SEQ_UP	3	
SITE:Cleavage; by CASP8	SEQ_UP	5	
SITE:Cleavage; by caspase	SEQ_UP	3	
SITE:Cleavage; by caspase-3	SEQ_UP	31	
SITE:Cleavage; by caspase-3 and caspase-7	SEQ_UP	3	
SITE:Cleavage; by caspase-3 and/or caspase-7	SEQ_UP	1	
SITE:Cleavage; by caspase-3 or caspase-3-like proteases	SEQ_UP	1	
SITE:Cleavage; by caspase-3 or caspase-7	SEQ_UP	1	
SITE:Cleavage; by caspase-3, caspase-6 and caspase-7	SEQ_UP	2	
SITE:Cleavage; by caspase-3, caspase-6 or caspase-7	SEQ_UP	1	
SITE:Cleavage; by caspase-3, caspase-7 and caspase-8	SEQ_UP	1	
SITE:Cleavage; by caspase-6	SEQ_UP	1	
SITE:Cleavage; by caspase-6 and granzyme B	SEQ_UP	1	
SITE:Cleavage; by caspase-6, caspase-7 and caspase-8	SEQ_UP	1	
SITE:Cleavage; by caspase-8	SEQ_UP	1	
SITE:Cleavage; by caspases	SEQ_UP	4	
SITE:Cleavage; by caspases CASP1, CASP4/CASP11 and CASP8	SEQ_UP	1	
SITE:Cleavage; by chymosin/rennin	SEQ_UP	1	
SITE:Cleavage; by collagenase	SEQ_UP	2	
SITE:Cleavage; by CORIN	SEQ_UP	1	
SITE:Cleavage; by CTSG	SEQ_UP	2	
SITE:Cleavage; by CTSG and ELANE	SEQ_UP	1	
SITE:Cleavage; by CTSL	SEQ_UP	4	
SITE:Cleavage; by DDI2	SEQ_UP	1	
SITE:Cleavage; by ELANE	SEQ_UP	2	
SITE:Cleavage; by endoprotease	SEQ_UP	1	
SITE:Cleavage; by ESPL1	SEQ_UP	1	
SITE:Cleavage; by factor I	SEQ_UP	1	
SITE:Cleavage; by factor Xa	SEQ_UP	1	
SITE:Cleavage; by factor Xa, factor XIIa, factor IXa, or thrombin	SEQ_UP	1	
SITE:Cleavage; by factor XIa	SEQ_UP	1	
SITE:Cleavage; by FAP	SEQ_UP	5	
SITE:Cleavage; by furin	SEQ_UP	13	
SITE:Cleavage; by FURIN	SEQ_UP	5	
SITE:Cleavage; by furin and PCSK5	SEQ_UP	1	
SITE:Cleavage; by furin and PCSK7	SEQ_UP	1	
SITE:Cleavage; by furin like-convertase	SEQ_UP	1	
SITE:Cleavage; by furin-like protease	SEQ_UP	7	
SITE:Cleavage; by gamma-secretase; site 1	SEQ_UP	1	
SITE:Cleavage; by gamma-secretase; site 2	SEQ_UP	1	
SITE:Cleavage; by gamma-secretase; site 3	SEQ_UP	1	
SITE:Cleavage; by gamma-secretase/PS1	SEQ_UP	2	
SITE:Cleavage; by granzyme A	SEQ_UP	1	
SITE:Cleavage; by granzyme B	SEQ_UP	1	
SITE:Cleavage; by hementin; to prevent blood coagulation	SEQ_UP	1	
SITE:Cleavage; by HM13/SPP	SEQ_UP	1	
SITE:Cleavage; by KEL	SEQ_UP	3	
SITE:Cleavage; by MALT1	SEQ_UP	4	
SITE:Cleavage; by MBTPS1	SEQ_UP	6	
SITE:Cleavage; by MBTPS2	SEQ_UP	2	
SITE:Cleavage; by MME	SEQ_UP	1	
SITE:Cleavage; by MMP13	SEQ_UP	1	
SITE:Cleavage; by MMP14	SEQ_UP	2	
SITE:Cleavage; by MMP2, MMP3, MMP7, MMP9, MMP12	SEQ_UP	1	
SITE:Cleavage; by MMP7	SEQ_UP	1	
SITE:Cleavage; by MMP9	SEQ_UP	2	
SITE:Cleavage; by MPP	SEQ_UP	1	
SITE:Cleavage; by mu-calpain	SEQ_UP	1	
SITE:Cleavage; by OMA1	SEQ_UP	1	
SITE:Cleavage; by PCSK1	SEQ_UP	2	
SITE:Cleavage; by PCSK1 and PCSK2	SEQ_UP	1	
SITE:Cleavage; by PCSK1 or PCSK2	SEQ_UP	1	
SITE:Cleavage; by PCSK2	SEQ_UP	1	
SITE:Cleavage; by plasmin	SEQ_UP	1	
SITE:Cleavage; by plasmin; to break down fibrin clots	SEQ_UP	1	
SITE:Cleavage; by procollagen C-endopeptidase	SEQ_UP	1	
SITE:Cleavage; by procollagen N-endopeptidase	SEQ_UP	1	
SITE:Cleavage; by prohormone convertase 2	SEQ_UP	1	
SITE:Cleavage; by prolyl endopeptidase FAP, antiplasmin-cleaving enzyme FAP soluble form	SEQ_UP	1	
SITE:Cleavage; by proprotein convertases	SEQ_UP	1	
SITE:Cleavage; by PS1	SEQ_UP	3	
SITE:Cleavage; by PSEN1	SEQ_UP	1	
SITE:Cleavage; by RHBDL4/RHBDD1	SEQ_UP	2	
SITE:Cleavage; by S1P	SEQ_UP	1	
SITE:Cleavage; by SPPL2A	SEQ_UP	1	
SITE:Cleavage; by SPPL2A or SPPL2B	SEQ_UP	1	
SITE:Cleavage; by ST14/MT-SP1	SEQ_UP	1	
SITE:Cleavage; by ST3; site 1	SEQ_UP	1	
SITE:Cleavage; by ST3; site 2	SEQ_UP	1	
SITE:Cleavage; by subtilisin-like proprotein convertase 4	SEQ_UP	1	
SITE:Cleavage; by TASP1	SEQ_UP	1	
SITE:Cleavage; by TASP1, site 1	SEQ_UP	1	
SITE:Cleavage; by TASP1, site 2	SEQ_UP	1	
SITE:Cleavage; by theta-secretase	SEQ_UP	1	
SITE:Cleavage; by thrombin	SEQ_UP	9	
SITE:Cleavage; by thrombin and CTSG	SEQ_UP	1	
SITE:Cleavage; by thrombin; to produce active factor XIII-A	SEQ_UP	1	
SITE:Cleavage; by thrombin; to release fibrinopeptide A	SEQ_UP	1	
SITE:Cleavage; by thrombin; to release fibrinopeptide B	SEQ_UP	1	
SITE:Cleavage; by thrombin:thrombomodulin	SEQ_UP	1	
SITE:Cleavage; by TIKI1 and TIKI2	SEQ_UP	1	
SITE:Cleavage; by trypsin	SEQ_UP	2	
SITE:Cleavage; for 75 kDa form	SEQ_UP	1	
SITE:Cleavage; for 78 kDa form	SEQ_UP	1	
SITE:Cleavage; to produce processed form	SEQ_UP	1	
SITE:Cleavage; to produce soluble form	SEQ_UP	1	
SITE:Cleaved under oxidative stress	SEQ_UP	1	
SITE:Conserved cysteine within steroid binding domain	SEQ_UP	1	
SITE:Contributes to catalysis	SEQ_UP	3	
SITE:Contributes to high-affinity binding to cocaine	SEQ_UP	1	
SITE:Contributes to redox potential value	SEQ_UP	6	
SITE:Coordinates Mg2+ for interaction with Complement factor B Bb fragment	SEQ_UP	1	
SITE:Covalently modified during suicide inhibition by leukotrienes	SEQ_UP	1	
SITE:Critical for binding to SF3A3	SEQ_UP	1	
SITE:Critical for binding to sialylated and sulfated oligosaccharides	SEQ_UP	1	
SITE:Critical for catalysis	SEQ_UP	5	
SITE:Critical for catalytic activity	SEQ_UP	3	
SITE:Critical for cleavage by neurotrypsin	SEQ_UP	1	
SITE:Critical for IL22-binding	SEQ_UP	1	
SITE:Critical for interaction with target DNA	SEQ_UP	1	
SITE:Critical for protein stability	SEQ_UP	1	
SITE:Critical for recognition and binding of 5'-TTAGGG-3' motifs in telomeric DNA	SEQ_UP	1	
SITE:Critical for specifying symmetric addition of methyl groups	SEQ_UP	1	
SITE:Critical for TLR4-TLR6 dimerization and signaling	SEQ_UP	1	
SITE:Crucial for 5-methylcytosine recognition	SEQ_UP	1	
SITE:Crucial for catalytic activity	SEQ_UP	1	
SITE:Crucial for interaction with calmodulin	SEQ_UP	1	
SITE:Crucial for phosphotyrosine binding	SEQ_UP	1	
SITE:Deprotonates C-terminal active site Cys	SEQ_UP	2	
SITE:Determinant for substrate specificity	SEQ_UP	1	
SITE:Determines ion selectivity	SEQ_UP	1	
SITE:Determines specificity for NEDD8	SEQ_UP	1	
SITE:DNA-binding	SEQ_UP	1	
SITE:Essential for ANKS3 interaction	SEQ_UP	1	
SITE:Essential for auto-cleavage	SEQ_UP	3	
SITE:Essential for autoinhibition maintenance	SEQ_UP	1	
SITE:Essential for autoinhibition maintenance by promoting interaction of the N and C termini	SEQ_UP	1	
SITE:Essential for binding to CKB	SEQ_UP	1	
SITE:Essential for CALM1 interaction	SEQ_UP	1	
SITE:Essential for catalytic activity	SEQ_UP	8	
SITE:Essential for dimerization	SEQ_UP	2	
SITE:Essential for DNA hairpin formation, participates in base-stacking interactions near the cleavage site	SEQ_UP	1	
SITE:Essential for epoxide hydrolase activity, but not for aminopeptidase activity	SEQ_UP	1	
SITE:Essential for function	SEQ_UP	4	
SITE:Essential for GTP hydrolysis	SEQ_UP	1	
SITE:Essential for GTPase activation (GAP) activity	SEQ_UP	1	
SITE:Essential for heterodimerization with RXRA	SEQ_UP	1	
SITE:Essential for histamine binding	SEQ_UP	1	
SITE:Essential for interaction with cadherins	SEQ_UP	1	
SITE:Essential for interaction with CDC6	SEQ_UP	1	
SITE:Essential for interaction with HIF1AN	SEQ_UP	1	
SITE:Essential for interaction with HSPA8	SEQ_UP	1	
SITE:Essential for interaction with INCA1	SEQ_UP	1	
SITE:Essential for interaction with PROZ	SEQ_UP	1	
SITE:Essential for interaction with PTPRD	SEQ_UP	1	
SITE:Essential for interaction with UBE2M	SEQ_UP	1	
SITE:Essential for its interaction with RUNX1 and its ability to inhibit RUNX1 transcriptional activity and suppress TH17 lineage development	SEQ_UP	1	
SITE:Essential for O-xylosylation	SEQ_UP	1	
SITE:Essential for protaglandin-E synthase activity	SEQ_UP	1	
SITE:Essential for proton translocation	SEQ_UP	2	
SITE:Essential for SDCBP-mediated plasma membrane phosphatidylinositol-4,5-bisphosphate recognition	SEQ_UP	1	
SITE:Essential for specifying alpha-elongation versus initiation step of the polyglutamylase activity	SEQ_UP	5	
SITE:Essential for specifying elongation versus initiation step of the polyglycylase activity	SEQ_UP	1	
SITE:Essential for specifying initiation versus elongation step of the polyglutamylase activity	SEQ_UP	3	
SITE:Essential for specifying initiation versus elongation step of the polyglycylase activity	SEQ_UP	2	
SITE:Essential for stabilizing binding to COTL1	SEQ_UP	1	
SITE:Essential for tiotidine binding and implicated in histamine binding	SEQ_UP	1	
SITE:Essential for ubiquitin ligase activity	SEQ_UP	1	
SITE:Facilitates cleavage of polynucleotide substrates	SEQ_UP	1	
SITE:Functional determinant of NMDA receptors	SEQ_UP	4	
SITE:Glutamate flap	SEQ_UP	1	
SITE:Glutamine finger	SEQ_UP	11	
SITE:Heme-binding	SEQ_UP	1	
SITE:Heptad change of phase	SEQ_UP	1	
SITE:Hg(2+)-sensitive residue	SEQ_UP	1	
SITE:Highly important for the agrin receptor complex activity of the 'z' insert	SEQ_UP	1	
SITE:Histone H3A7 binding	SEQ_UP	1	
SITE:Histone H3K36me3 binding	SEQ_UP	1	
SITE:Histone H3K4me0 binding	SEQ_UP	1	
SITE:Histone H3K4me3 and H3R8me2a binding	SEQ_UP	3	
SITE:Histone H3K4me3 binding	SEQ_UP	7	
SITE:Histone H3K9me binding	SEQ_UP	2	
SITE:Histone H3K9me2 binding	SEQ_UP	1	
SITE:Histone H3R2me0 binding	SEQ_UP	1	
SITE:Histone H4 binding; via carbonyl oxygen	SEQ_UP	1	
SITE:Histone H4K20me2 binding	SEQ_UP	1	
SITE:Histone H4K5ac binding	SEQ_UP	1	
SITE:Histone H4K5ac H4K8ac and histone H4K5bu H4K8bu binding	SEQ_UP	1	
SITE:Hydrophobic barrier that decreases the speed of ligand binding and dissociation	SEQ_UP	2	
SITE:Hydrophobic filter residue 1-1	SEQ_UP	1	
SITE:Hydrophobic filter residue 1-2	SEQ_UP	1	
SITE:Hydrophobic filter residue 2-1	SEQ_UP	1	
SITE:Hydrophobic filter residue 2-2	SEQ_UP	1	
SITE:Hydrophobic filter residue 3-1	SEQ_UP	1	
SITE:Hydrophobic filter residue 3-2	SEQ_UP	1	
SITE:Hydrophobic interaction with UBE2I	SEQ_UP	1	
SITE:Implicated in catechol agonist binding	SEQ_UP	2	
SITE:Implicated in catechol agonist binding and receptor activation	SEQ_UP	1	
SITE:Implicated in free radical propagation	SEQ_UP	1	
SITE:Implicated in histamine binding	SEQ_UP	1	
SITE:Implicated in ligand binding	SEQ_UP	4	
SITE:Implicated in sodium coupling	SEQ_UP	2	
SITE:Important for activation by Ca(2+)	SEQ_UP	1	
SITE:Important for activation of transcription	SEQ_UP	1	
SITE:Important for activity	SEQ_UP	4	
SITE:Important for agonist activity on V1aR/AVPR1A	SEQ_UP	1	
SITE:Important for ATP hydrolysis	SEQ_UP	1	
SITE:Important for autoinhibition of adenylyltransferase activity	SEQ_UP	1	
SITE:Important for autoinhibitory function	SEQ_UP	1	
SITE:Important for beta-aspartyl-AMP intermediate formation	SEQ_UP	1	
SITE:Important for binding TNFRSF6B	SEQ_UP	1	
SITE:Important for binding to LRP1	SEQ_UP	1	
SITE:Important for binding with the scorpion mesomartoxin; when the scorpion mesomartoxin-rKv1.2/KCNA2 interaction is modeled, this residue is close to the 'Y-57' residue of the toxin	SEQ_UP	1	
SITE:Important for C5-methylcytosine-recognition	SEQ_UP	1	
SITE:Important for carbohydrate binding	SEQ_UP	1	
SITE:Important for catalysis	SEQ_UP	1	
SITE:Important for catalytic activity	SEQ_UP	37	
SITE:Important for catalytic activity; essential for amidase activity and zinc hydrate coordination	SEQ_UP	1	
SITE:Important for cation transport	SEQ_UP	1	
SITE:Important for channel closure	SEQ_UP	1	
SITE:Important for channel desensitizing	SEQ_UP	1	
SITE:Important for channel gating	SEQ_UP	1	
SITE:Important for channel permeability	SEQ_UP	2	
SITE:Important for cholesterol binding	SEQ_UP	1	
SITE:Important for cleavage by MBTPS2	SEQ_UP	1	
SITE:Important for coenzyme A binding	SEQ_UP	2	
SITE:Important for determining product chain length	SEQ_UP	1	
SITE:Important for dimer formation	SEQ_UP	3	
SITE:Important for dimerization	SEQ_UP	6	
SITE:Important for dinucleotide binding	SEQ_UP	1	
SITE:Important for DNA bending; intercalates between base pairs of target DNA	SEQ_UP	2	
SITE:Important for electron transfer	SEQ_UP	1	
SITE:Important for enzyme activity	SEQ_UP	8	
SITE:Important for FDH activity and activation by fatty acids	SEQ_UP	1	
SITE:Important for G protein-mediated signaling	SEQ_UP	1	
SITE:Important for hydrogen atom transfer	SEQ_UP	1	
SITE:Important for hydroxyacyl-coenzyme A dehydrogenase activity	SEQ_UP	1	
SITE:Important for increased permeability to Na(+) when K(+) levels are subphysiological	SEQ_UP	1	
SITE:Important for induction of apoptosis	SEQ_UP	1	
SITE:Important for inhibition	SEQ_UP	3	
SITE:Important for inhibition by tetrodotoxin	SEQ_UP	1	
SITE:Important for inositol polyphosphate binding	SEQ_UP	1	
SITE:Important for integrin binding	SEQ_UP	1	
SITE:Important for integrin interaction and activation	SEQ_UP	1	
SITE:Important for interaction with acyl carrier protein (ACP)	SEQ_UP	1	
SITE:Important for interaction with adenosine receptors and increasing their affinity for agonists	SEQ_UP	1	
SITE:Important for interaction with ARNTL/BMAL1	SEQ_UP	1	
SITE:Important for interaction with cargo nuclear localization signals	SEQ_UP	1	
SITE:Important for interaction with CLIP1	SEQ_UP	1	
SITE:Important for interaction with CLOCK	SEQ_UP	1	
SITE:Important for interaction with DLAT	SEQ_UP	1	
SITE:Important for interaction with histone H3	SEQ_UP	1	
SITE:Important for interaction with IL6ST and for the stimulation of cell proliferation	SEQ_UP	1	
SITE:Important for interaction with integrin	SEQ_UP	4	
SITE:Important for interaction with PDHX and activity of pyruvate dehydrogenase complex	SEQ_UP	1	
SITE:Important for interaction with phosphotyrosine-binding proteins	SEQ_UP	1	
SITE:Important for interaction with PIK3C2B	SEQ_UP	1	
SITE:Important for interaction with PRELID3A	SEQ_UP	1	
SITE:Important for interaction with RAC1 and RND1	SEQ_UP	1	
SITE:Important for interaction with target DNA	SEQ_UP	1	
SITE:Important for interaction with transmembrane receptors	SEQ_UP	1	
SITE:Important for interaction with TRIAP1	SEQ_UP	1	
SITE:Important for ligand binding	SEQ_UP	1	
SITE:Important for long-chain enoyl-CoA hydratase activity	SEQ_UP	1	
SITE:Important for metal ion-dependent interaction with integrin	SEQ_UP	1	
SITE:Important for monofunctional glycosylase activity	SEQ_UP	1	
SITE:Important for Na(+)-selective paracellular ion transport	SEQ_UP	1	
SITE:Important for normal, slow channel gating	SEQ_UP	1	
SITE:Important for nucleosome binding properties	SEQ_UP	1	
SITE:Important for obstruction of the ion pore in the closed conformation	SEQ_UP	5	
SITE:Important for oligomerization	SEQ_UP	1	
SITE:Important for permeability to glycerol	SEQ_UP	1	
SITE:Important for phospholipase activity	SEQ_UP	1	
SITE:Important for receptor activation	SEQ_UP	2	
SITE:Important for receptor turnover	SEQ_UP	1	
SITE:Important for recycling of cargo proteins with the sequence motif K-D-E-L from the Golgi to the endoplasmic reticulum	SEQ_UP	3	
SITE:Important for responses to orexin	SEQ_UP	2	
SITE:Important for selectivity against geranylgeranyl diphosphate	SEQ_UP	1	
SITE:Important for selectivity toward medium-length fatty acids	SEQ_UP	1	
SITE:Important for serine binding	SEQ_UP	1	
SITE:Important for single-chain activity	SEQ_UP	1	
SITE:Important for species-specific agonist sensitivity	SEQ_UP	1	
SITE:Important for specifying alpha-elongation versus initiation step of the polyglutamylase activity	SEQ_UP	1	
SITE:Important for stabilizing DNA-binding	SEQ_UP	1	
SITE:Important for substrate binding	SEQ_UP	1	
SITE:Important for substrate recognition	SEQ_UP	5	
SITE:Important for substrate specificity	SEQ_UP	9	
SITE:Important for TCPOBOP recognition	SEQ_UP	1	
SITE:Important for the catalytic mechanism; involved in substrate deprotonation	SEQ_UP	1	
SITE:Important for the conversion from active R-state to inactive T-state in the presence of AMP	SEQ_UP	1	
SITE:Important for the formation of tight-junction strand-like structures	SEQ_UP	1	
SITE:Important for the maintenance of the quaternary structure, the catalytic activity and cold stability	SEQ_UP	1	
SITE:Important for the positionning of RRM1 relative to RRM2	SEQ_UP	2	
SITE:Important for the reduction of the redox-active cysteines	SEQ_UP	1	
SITE:Important for the second trafficking step from the Golgi to the endosomal and lysosomal compartments	SEQ_UP	1	
SITE:Important for water channel gating	SEQ_UP	1	
SITE:Important for WDR5-recognition and binding	SEQ_UP	1	
SITE:Important residue for activation by the scorpion wasabi receptor toxin	SEQ_UP	1	
SITE:Increases basicity of active site His	SEQ_UP	1	
SITE:Increases nucleophilicity of active site Cys	SEQ_UP	5	
SITE:Indirect zinc-binding	SEQ_UP	2	
SITE:Inhibitory (P1) (chymotrypsin, elastase)	SEQ_UP	1	
SITE:Inhibitory (P1) (trypsin)	SEQ_UP	1	
SITE:Inserts into a conserved IL7R hydrophobic pocket, important for IL7R-binding	SEQ_UP	1	
SITE:Insulin-binding	SEQ_UP	1	
SITE:Inter-subunit salt bridge with TAPBP	SEQ_UP	2	
SITE:Interaction between pentamers	SEQ_UP	2	
SITE:Interaction with 5' end of substrate DNA	SEQ_UP	1	
SITE:Interaction with APS and STAT5, and activation	SEQ_UP	1	
SITE:Interaction with bacterial lipopeptide	SEQ_UP	1	
SITE:interaction with BFSP1	SEQ_UP	1	
SITE:Interaction with BFSP1	SEQ_UP	1	
SITE:Interaction with coactivator FXXLF and FXXFY motifs	SEQ_UP	1	
SITE:Interaction with coactivator LXXL and FXXFY motifs	SEQ_UP	1	
SITE:Interaction with DLL4	SEQ_UP	1	
SITE:Interaction with DNA	SEQ_UP	15	
SITE:Interaction with DNA substrate	SEQ_UP	3	
SITE:Interaction with dsRNA	SEQ_UP	1	
SITE:Interaction with E-box DNA	SEQ_UP	2	
SITE:Interaction with FBXL7	SEQ_UP	1	
SITE:Interaction with FYB1	SEQ_UP	1	
SITE:Interaction with galactose moiety of substrate glycoprotein	SEQ_UP	3	
SITE:Interaction with glycopeptide substrate	SEQ_UP	1	
SITE:Interaction with GRK1	SEQ_UP	1	
SITE:Interaction with histone H3 that is not methylated at 'Lys-4' (H3K4me0)	SEQ_UP	1	
SITE:Interaction with histone H3K9me3	SEQ_UP	1	
SITE:Interaction with histone H4 N-terminus	SEQ_UP	1	
SITE:Interaction with m3G-cap structure	SEQ_UP	1	
SITE:Interaction with METTL14	SEQ_UP	1	
SITE:Interaction with METTL3	SEQ_UP	1	
SITE:Interaction with MIP	SEQ_UP	1	
SITE:Interaction with myosin V motor complex	SEQ_UP	1	
SITE:Interaction with NCOA2	SEQ_UP	1	
SITE:Interaction with Notch1	SEQ_UP	1	
SITE:Interaction with PHF5A	SEQ_UP	1	
SITE:Interaction with phosphoinositides	SEQ_UP	1	
SITE:Interaction with phosphoserine on interacting protein	SEQ_UP	7	
SITE:Interaction with phosphotyrosine-containing peptide	SEQ_UP	1	
SITE:Interaction with PIAS2	SEQ_UP	1	
SITE:Interaction with PIH1D1	SEQ_UP	1	
SITE:Interaction with PLC-gamma-1	SEQ_UP	1	
SITE:Interaction with PLCG1	SEQ_UP	2	
SITE:Interaction with poly(A)	SEQ_UP	1	
SITE:Interaction with PPP-RNA	SEQ_UP	1	
SITE:Interaction with PTPN6	SEQ_UP	1	
SITE:Interaction with PxVP motif in substrate	SEQ_UP	1	
SITE:Interaction with PxVP motif in substrates of the catalytic subunit	SEQ_UP	2	
SITE:Interaction with RANBP2	SEQ_UP	1	
SITE:Interaction with RNA	SEQ_UP	12	
SITE:Interaction with SF3B1	SEQ_UP	1	
SITE:Interaction with SF3B3	SEQ_UP	2	
SITE:Interaction with SF3B5	SEQ_UP	1	
SITE:Interaction with SH2D1A	SEQ_UP	1	
SITE:Interaction with SHB	SEQ_UP	1	
SITE:Interaction with SHC1	SEQ_UP	3	
SITE:Interaction with STAMBP	SEQ_UP	1	
SITE:Interaction with STX8	SEQ_UP	1	
SITE:Interaction with substrate rRNA	SEQ_UP	1	
SITE:Interaction with substrate tRNA	SEQ_UP	1	
SITE:Interaction with target DNA	SEQ_UP	3	
SITE:Interaction with the 5'-triphosphate group of PPP-RNA	SEQ_UP	1	
SITE:Interaction with the consensus sequence C-X-S-X-[PA]-C in peptide substrates	SEQ_UP	1	
SITE:Interaction with the endogenous ligand GLP-1	SEQ_UP	1	
SITE:Interaction with the K-D-E-L motif on target proteins	SEQ_UP	3	
SITE:Interaction with the N-terminal Pro (Pro/N-degron) of proteins that are targeted for degradation	SEQ_UP	1	
SITE:Interaction with the other subunit in the homodimer	SEQ_UP	1	
SITE:Interaction with TRIB1	SEQ_UP	1	
SITE:Interaction with tRNA	SEQ_UP	1	
SITE:Interaction with TYROBP	SEQ_UP	1	
SITE:Interaction with TYROBP or FcR gamma	SEQ_UP	1	
SITE:Interaction with U4 snRNA	SEQ_UP	2	
SITE:Interaction with U4 snRNA and U4atac snRNA	SEQ_UP	2	
SITE:Interaction with U4 snRNA and with the 7-methylguanosine cap of RNA molecules	SEQ_UP	1	
SITE:Interaction with U4atac snRNA	SEQ_UP	1	
SITE:Interaction with UBA3	SEQ_UP	1	
SITE:Interaction with UBE1C	SEQ_UP	1	
SITE:Interaction with ZMYND11	SEQ_UP	2	
SITE:Interacts with activating enzyme	SEQ_UP	5	
SITE:Interacts with capping protein	SEQ_UP	1	
SITE:Interacts with diacetylated histone H3	SEQ_UP	1	
SITE:Interacts with free ubiquitin	SEQ_UP	1	
SITE:Interacts with GTP/GDP	SEQ_UP	1	
SITE:Interacts with hydroxy-aryl-aldehyde inhibitors	SEQ_UP	1	
SITE:Interacts with lipopolysaccharide	SEQ_UP	1	
SITE:Interacts with target acceptor peptide in protein substrate	SEQ_UP	2	
SITE:Interacts with TELO2	SEQ_UP	1	
SITE:Interacts with the PxVxL motif of TRIM28/TIF1B	SEQ_UP	1	
SITE:Interacts with thioredoxin/glutaredoxin	SEQ_UP	1	
SITE:Intercalates between bases and promotes DNA bending	SEQ_UP	1	
SITE:Intramolecular salt bridge with Arg-57. Essential for the release from the ER	SEQ_UP	1	
SITE:Intramolecular salt bridge with Asp-17. Essential for the release from the ER	SEQ_UP	1	
SITE:Involved in actin-binding	SEQ_UP	1	
SITE:Involved in affinity and selectivity of cations as well as in translocation	SEQ_UP	1	
SITE:Involved in auto-cleavage	SEQ_UP	3	
SITE:Involved in ceramide and phosphatidylcholine binding	SEQ_UP	1	
SITE:Involved in ceramide and phosphatidylcholine binding. Critical for channel structural stability and gating	SEQ_UP	1	
SITE:Involved in cholesterol transfer	SEQ_UP	3	
SITE:Involved in dimerization	SEQ_UP	1	
SITE:Involved in G-protein binding to GAPs	SEQ_UP	1	
SITE:Involved in metalloproteinase-binding	SEQ_UP	4	
SITE:Involved in perlecan binding	SEQ_UP	1	
SITE:Involved in polymerization	SEQ_UP	5	
SITE:Involved in proton transfer during cleavage	SEQ_UP	2	
SITE:Involved in pterin ring binding	SEQ_UP	1	
SITE:Involved in receptor binding	SEQ_UP	1	
SITE:Involved in recognition of organic cations and participates in structural changes that occur during translocation of organic cations	SEQ_UP	1	
SITE:Involved in RNA binding	SEQ_UP	1	
SITE:Involved in sugar-binding/transport and inhibitor binding	SEQ_UP	1	
SITE:Involved in the association of subunits	SEQ_UP	3	
SITE:Involved in the recognition of the lipid substrate on the exoplasmic side	SEQ_UP	1	
SITE:Involved in the release of the transported lipid into the cytosolic leaflet	SEQ_UP	1	
SITE:Involved in the stabilization of negative charge on the oxyanion by the formation of the oxyanion hole	SEQ_UP	1	
SITE:Involved in TNI-TNT interactions	SEQ_UP	1	
SITE:Involved in trimer stabilization	SEQ_UP	1	
SITE:Is directly targeted by the spider protoxin-II	SEQ_UP	1	
SITE:Key residue for a low dissociation (K(off)) from the conotoxin BuIA	SEQ_UP	1	
SITE:Key residue for a rapid dissociation (K(off)) from the conotoxin BuIA	SEQ_UP	1	
SITE:Key residue for activation by the scorpion wasabi receptor toxin	SEQ_UP	1	
SITE:Key residue that facilitates effective access of the conotoxin BuIA to the channel binding site	SEQ_UP	1	
SITE:Key residue that may interfere with effective access of the conotoxin BuIA to the channel binding site	SEQ_UP	1	
SITE:Leu-lock	SEQ_UP	1	
SITE:Linear diubiquitin binding	SEQ_UP	1	
SITE:Lowers pKa of active site Cys	SEQ_UP	1	
SITE:Lowers pKa of active site Tyr	SEQ_UP	17	
SITE:Lowers pKa of C-terminal Cys of first active site	SEQ_UP	2	
SITE:Lowers pKa of C-terminal Cys of second active site	SEQ_UP	3	
SITE:Major binding site for inhibitory zinc or copper	SEQ_UP	1	
SITE:May act as a substrate filter by repelling compounds with a negatively charged alpha-carboxylate	SEQ_UP	1	
SITE:May be important for catalysis	SEQ_UP	2	
SITE:May be involved in allosteric control	SEQ_UP	3	
SITE:May be involved in interaction with TAP	SEQ_UP	1	
SITE:May interact with the LDL receptor	SEQ_UP	1	
SITE:May play an important role for the adaptation of the alcohol substrate into the binding site	SEQ_UP	1	
SITE:May play an important role in binding to the inhibitors DEPC and PDMP	SEQ_UP	1	
SITE:May play an important role in catalytic activity	SEQ_UP	1	
SITE:May play an important role in coenzyme binding	SEQ_UP	1	
SITE:Mediates end-to-end attachment of dimers	SEQ_UP	3	
SITE:Mediates interaction with 53BP1	SEQ_UP	1	
SITE:Mediates interaction with N-terminal MREI motif of beta-tubulin nascent chain	SEQ_UP	1	
SITE:Mediates interaction with PLCG1 and SHB	SEQ_UP	1	
SITE:Mediates preference for acidic residues at subsite P1'	SEQ_UP	1	
SITE:Mediates preference for Asp-containing substrates	SEQ_UP	1	
SITE:Mediates proton transfer from the outer aqueous phase to the interior of the protein; involved in linking H(+) and Cl(-) transport	SEQ_UP	5	
SITE:Mediates proton transfer from the protein to the inner aqueous phase	SEQ_UP	5	
SITE:Mediates recognition of monomethylated and dimethylated peptides	SEQ_UP	1	
SITE:Mediates specificity for sialic acids	SEQ_UP	1	
SITE:mRNA cap binding	SEQ_UP	1	
SITE:Necessary for heterotrimerization	SEQ_UP	1	
SITE:Necessary for preference for fructose 1,6-bisphosphate over fructose 1-phosphate	SEQ_UP	3	
SITE:Necessary for sperm binding	SEQ_UP	1	
SITE:Necessary for synergistic transcriptional activity with SMAD3	SEQ_UP	1	
SITE:Nicotinamide-stacking aromate	SEQ_UP	1	
SITE:Nitration by tetranitromethane destroys a Ca(2+) binding site and inactivates enzyme	SEQ_UP	1	
SITE:Not glycosylated	SEQ_UP	9	
SITE:Not hydroxylated	SEQ_UP	1	
SITE:Not modified	SEQ_UP	1	
SITE:Not required for interaction with OOEP	SEQ_UP	1	
SITE:Part of a hydrophobic barrier that is stochastically dewetted and limits ion permeability	SEQ_UP	1	
SITE:Participates in a stacking interaction with the adenine ring of AMP	SEQ_UP	1	
SITE:Phosphatase-binding	SEQ_UP	1	
SITE:Plays an important role in the conformation switch to the active conformation	SEQ_UP	1	
SITE:Positioned at the entrance of MBT 2 and is required for recognition of monomethylated and dimethylated peptides	SEQ_UP	1	
SITE:Positions substrate for the nucleophilic attack	SEQ_UP	1	
SITE:Potassium ion selectivity and permeability	SEQ_UP	1	
SITE:Pre-siRNA binding	SEQ_UP	1	
SITE:Probable cleavage; by anthrax lethal toxin endopeptidase component	SEQ_UP	1	
SITE:Proline switch	SEQ_UP	1	
SITE:Raises pKa of active site His	SEQ_UP	2	
SITE:Reactive bond	SEQ_UP	52	
SITE:Reactive bond for chymotrypsin	SEQ_UP	1	
SITE:Reactive bond for chymotrypsin, trypsin and elastase	SEQ_UP	1	
SITE:Reactive bond for plasmin	SEQ_UP	1	
SITE:Reactive bond for trypsin	SEQ_UP	1	
SITE:Reactive bond homolog	SEQ_UP	3	
SITE:Reactive site	SEQ_UP	8	
SITE:Required for activity	SEQ_UP	2	
SITE:Required for affinity and specificity for 5-mCpG sequence	SEQ_UP	1	
SITE:Required for anion selectivity	SEQ_UP	1	
SITE:Required for binding 2'-O-methylated 3'-end of piRNAs	SEQ_UP	1	
SITE:Required for binding to 'Lys-15'-acetylated histone 3	SEQ_UP	1	
SITE:Required for binding to BLNK	SEQ_UP	1	
SITE:Required for binding to the NFIL3 promoter	SEQ_UP	1	
SITE:Required for binding TORCs	SEQ_UP	1	
SITE:Required for both pericentromeric heterochromatin localization and complete DNA binding	SEQ_UP	1	
SITE:Required for both pericentromeric heterochromatin localization and DNA binding	SEQ_UP	1	
SITE:Required for CaMK2D-binding	SEQ_UP	1	
SITE:Required for CrkL binding	SEQ_UP	1	
SITE:Required for Cu(2+) reduction	SEQ_UP	2	
SITE:Required for dimerization	SEQ_UP	1	
SITE:Required for DNA-dependent dimerization	SEQ_UP	1	
SITE:Required for endocytosis and down-regulation	SEQ_UP	1	
SITE:Required for enzyme activity	SEQ_UP	1	
SITE:Required for ER export	SEQ_UP	1	
SITE:Required for glycosylase activity	SEQ_UP	1	
SITE:Required for GSK3B interaction; contributes to a protective effect against H(2)O(2)-induced apoptosis	SEQ_UP	1	
SITE:Required for high affinity binding to PTRZ1 by interacting with the chondroitin sulfate chains of PTRZ1	SEQ_UP	1	
SITE:Required for homodimerization	SEQ_UP	1	
SITE:Required for interaction with DNA and JUN and for functional cooperation with JUN	SEQ_UP	1	
SITE:Required for interaction with IL1RAP	SEQ_UP	1	
SITE:Required for interaction with MAP3K7	SEQ_UP	1	
SITE:Required for interaction with NUP50	SEQ_UP	1	
SITE:Required for interaction with TP53BP1	SEQ_UP	1	
SITE:Required for ligand binding	SEQ_UP	1	
SITE:Required for ligand-induced CBL-mediated ubiquitination	SEQ_UP	1	
SITE:Required for neurite tip localization	SEQ_UP	1	
SITE:Required for nucleotide incorporation and primer extension rate	SEQ_UP	1	
SITE:Required for optimal binding of telomeric ssDNA and incorporation of nucleotides at the second position of the template	SEQ_UP	1	
SITE:Required for receptor phosphorylation	SEQ_UP	1	
SITE:Required for RNA-binding activity	SEQ_UP	1	
SITE:Required for sensing abasic sites	SEQ_UP	1	
SITE:Required for specificity	SEQ_UP	1	
SITE:Required for STAT1/STAT3 activation	SEQ_UP	1	
SITE:Required for STAT5/PTPN11/SOCS3 binding	SEQ_UP	1	
SITE:Required for structural stability	SEQ_UP	1	
SITE:Required for the recognition of 25-hydroxycholesterol	SEQ_UP	2	
SITE:Required for the specific determination of the substrate cleavage site	SEQ_UP	1	
SITE:Required for the thiol-dependency of NADase activity	SEQ_UP	1	
SITE:Required for TP53 activation	SEQ_UP	1	
SITE:Required for trimerization	SEQ_UP	1	
SITE:Required for ubiquitin-thioester formation	SEQ_UP	1	
SITE:Required for ubiquitination and degradation	SEQ_UP	2	
SITE:Required to capture Ser that is misactivated by AARS/AlaRS	SEQ_UP	1	
SITE:Required to confer preferential recognition of cytosine over thymine	SEQ_UP	1	
SITE:Required to discriminate between hemimethylated DNA versus symmetrically methylated DNA	SEQ_UP	1	
SITE:Required to orient and stabilize the active site H-224	SEQ_UP	1	
SITE:Required to promote KDM1B demethylase activity toward histone H3K4me1 and H3K4me2	SEQ_UP	1	
SITE:Required to stabilize abasic sites	SEQ_UP	1	
SITE:Responsible for the low discrimination between dNTP and rNTP	SEQ_UP	1	
SITE:Responsible for the stereoselective reduction of 3-ketosteroids into 3alpha-hydroxysteroids and benzil into S-benzoin	SEQ_UP	1	
SITE:Reversibly protonated during proton transport	SEQ_UP	3	
SITE:RNA-binding	SEQ_UP	1	
SITE:Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium	SEQ_UP	14	
SITE:Sensor for electrophilic agents	SEQ_UP	1	
SITE:Stabilizes Arg-84	SEQ_UP	1	
SITE:Stabilizes the active site histidine for nucleophilic attack	SEQ_UP	8	
SITE:Stabilizes the conformation of the regulatory loop	SEQ_UP	1	
SITE:Stabilizes the phosphate intermediate; shared with dimeric partner	SEQ_UP	3	
SITE:Stacks against the aromatic ring of pyridoxal phosphate and stabilizes reaction intermediates	SEQ_UP	1	
SITE:Stutter	SEQ_UP	32	
SITE:Subject to oxidation and hydroselenide loss to dehydroalanine	SEQ_UP	1	
SITE:Substrate binding	SEQ_UP	1	
SITE:Substrate discrimination	SEQ_UP	1	
SITE:Susceptible to oxidation	SEQ_UP	1	
SITE:Transition state stabilizer	SEQ_UP	55	
SITE:Trigger for autolytic processing	SEQ_UP	2	
SITE:Tubulin binding	SEQ_UP	1	
SITE:Ubiquitin-binding	SEQ_UP	2	
SITE:Ubiquitinated; by MARCHF2	SEQ_UP	1	
TOPO_DOM:Cytoplasmic	SEQ_UP	3241	
TOPO_DOM:Exoplasmic loop	SEQ_UP	10	
TOPO_DOM:Extracellular	SEQ_UP	2405	
TOPO_DOM:Intragranular	SEQ_UP	2	
TOPO_DOM:Lumenal	SEQ_UP	619	
TOPO_DOM:Lumenal, melanosome	SEQ_UP	3	
TOPO_DOM:Lumenal, vesicle	SEQ_UP	5	
TOPO_DOM:Mitochondrial intermembrane	SEQ_UP	122	
TOPO_DOM:Mitochondrial matrix	SEQ_UP	79	
TOPO_DOM:Nuclear	SEQ_UP	14	
TOPO_DOM:Perinuclear space	SEQ_UP	19	
TOPO_DOM:Peroxisomal	SEQ_UP	5	
TOPO_DOM:Peroxisomal matrix	SEQ_UP	2	
TOPO_DOM:Vacuolar	SEQ_UP	6	
TOPO_DOM:Vesicular	SEQ_UP	39	
TRANSIT:Mitochondrion	SEQ_UP	531	
TRANSIT:Mitochondrion; not cleaved	SEQ_UP	3	
TRANSIT:Peroxisome	SEQ_UP	4	
TRANSMEM:Beta stranded	SEQ_UP	8	
TRANSMEM:Discontinuously helical	SEQ_UP	2	
TRANSMEM:Discontinuously helical; Name=10	SEQ_UP	2	
TRANSMEM:Discontinuously helical; Name=3	SEQ_UP	2	
TRANSMEM:Discontinuously helical; Name=8	SEQ_UP	1	
TRANSMEM:Helical	SEQ_UP	6780	
TRANSMEM:Helical; Anchor for type IV membrane protein	SEQ_UP	72	
TRANSMEM:Helical; Name=1	SEQ_UP	718	
TRANSMEM:Helical; Name=10	SEQ_UP	68	
TRANSMEM:Helical; Name=11	SEQ_UP	64	
TRANSMEM:Helical; Name=12	SEQ_UP	61	
TRANSMEM:Helical; Name=13	SEQ_UP	9	
TRANSMEM:Helical; Name=14	SEQ_UP	7	
TRANSMEM:Helical; Name=15	SEQ_UP	6	
TRANSMEM:Helical; Name=16	SEQ_UP	4	
TRANSMEM:Helical; Name=17	SEQ_UP	4	
TRANSMEM:Helical; Name=2	SEQ_UP	717	
TRANSMEM:Helical; Name=3	SEQ_UP	698	
TRANSMEM:Helical; Name=4	SEQ_UP	703	
TRANSMEM:Helical; Name=5	SEQ_UP	683	
TRANSMEM:Helical; Name=6	SEQ_UP	678	
TRANSMEM:Helical; Name=7	SEQ_UP	612	
TRANSMEM:Helical; Name=8	SEQ_UP	84	
TRANSMEM:Helical; Name=9	SEQ_UP	77	
TRANSMEM:Helical; Name=C/M3	SEQ_UP	2	
TRANSMEM:Helical; Name=D/M4	SEQ_UP	2	
TRANSMEM:Helical; Name=E/M5	SEQ_UP	2	
TRANSMEM:Helical; Name=F/M5A	SEQ_UP	2	
TRANSMEM:Helical; Name=G/M5B	SEQ_UP	2	
TRANSMEM:Helical; Name=H/M6	SEQ_UP	2	
TRANSMEM:Helical; Name=H1	SEQ_UP	3	
TRANSMEM:Helical; Name=H2	SEQ_UP	3	
TRANSMEM:Helical; Name=H3	SEQ_UP	3	
TRANSMEM:Helical; Name=H4	SEQ_UP	3	
TRANSMEM:Helical; Name=H5	SEQ_UP	3	
TRANSMEM:Helical; Name=H6	SEQ_UP	3	
TRANSMEM:Helical; Name=Helix 1	SEQ_UP	2	
TRANSMEM:Helical; Name=Helix 10	SEQ_UP	1	
TRANSMEM:Helical; Name=Helix 2	SEQ_UP	2	
TRANSMEM:Helical; Name=Helix 3	SEQ_UP	2	
TRANSMEM:Helical; Name=Helix 4	SEQ_UP	2	
TRANSMEM:Helical; Name=Helix 5	SEQ_UP	2	
TRANSMEM:Helical; Name=Helix 6	SEQ_UP	2	
TRANSMEM:Helical; Name=Helix 7	SEQ_UP	1	
TRANSMEM:Helical; Name=Helix 8	SEQ_UP	1	
TRANSMEM:Helical; Name=Helix 9	SEQ_UP	1	
TRANSMEM:Helical; Name=I	SEQ_UP	3	
TRANSMEM:Helical; Name=I/M7	SEQ_UP	2	
TRANSMEM:Helical; Name=II	SEQ_UP	3	
TRANSMEM:Helical; Name=III	SEQ_UP	2	
TRANSMEM:Helical; Name=IV	SEQ_UP	2	
TRANSMEM:Helical; Name=IX	SEQ_UP	1	
TRANSMEM:Helical; Name=J/M8	SEQ_UP	2	
TRANSMEM:Helical; Name=K/M9	SEQ_UP	2	
TRANSMEM:Helical; Name=M/M10	SEQ_UP	2	
TRANSMEM:Helical; Name=M1	SEQ_UP	19	
TRANSMEM:Helical; Name=M10	SEQ_UP	1	
TRANSMEM:Helical; Name=M11	SEQ_UP	1	
TRANSMEM:Helical; Name=M12	SEQ_UP	1	
TRANSMEM:Helical; Name=M2	SEQ_UP	19	
TRANSMEM:Helical; Name=M3	SEQ_UP	4	
TRANSMEM:Helical; Name=M4	SEQ_UP	8	
TRANSMEM:Helical; Name=M5	SEQ_UP	4	
TRANSMEM:Helical; Name=M6	SEQ_UP	4	
TRANSMEM:Helical; Name=M7	SEQ_UP	4	
TRANSMEM:Helical; Name=M8	SEQ_UP	4	
TRANSMEM:Helical; Name=M9	SEQ_UP	1	
TRANSMEM:Helical; Name=S1	SEQ_UP	2	
TRANSMEM:Helical; Name=S1 of repeat I	SEQ_UP	20	
TRANSMEM:Helical; Name=S1 of repeat II	SEQ_UP	20	
TRANSMEM:Helical; Name=S1 of repeat III	SEQ_UP	18	
TRANSMEM:Helical; Name=S1 of repeat IV	SEQ_UP	18	
TRANSMEM:Helical; Name=S2	SEQ_UP	2	
TRANSMEM:Helical; Name=S2 of repeat I	SEQ_UP	20	
TRANSMEM:Helical; Name=S2 of repeat II	SEQ_UP	20	
TRANSMEM:Helical; Name=S2 of repeat III	SEQ_UP	18	
TRANSMEM:Helical; Name=S2 of repeat IV	SEQ_UP	18	
TRANSMEM:Helical; Name=S3	SEQ_UP	2	
TRANSMEM:Helical; Name=S3 of repeat I	SEQ_UP	20	
TRANSMEM:Helical; Name=S3 of repeat II	SEQ_UP	20	
TRANSMEM:Helical; Name=S3 of repeat III	SEQ_UP	18	
TRANSMEM:Helical; Name=S3 of repeat IV	SEQ_UP	18	
TRANSMEM:Helical; Name=S4	SEQ_UP	2	
TRANSMEM:Helical; Name=S4 of repeat I	SEQ_UP	17	
TRANSMEM:Helical; Name=S4 of repeat II	SEQ_UP	17	
TRANSMEM:Helical; Name=S4 of repeat III	SEQ_UP	15	
TRANSMEM:Helical; Name=S4 of repeat IV	SEQ_UP	15	
TRANSMEM:Helical; Name=S5	SEQ_UP	1	
TRANSMEM:Helical; Name=S5 of repeat I	SEQ_UP	20	
TRANSMEM:Helical; Name=S5 of repeat II	SEQ_UP	20	
TRANSMEM:Helical; Name=S5 of repeat III	SEQ_UP	18	
TRANSMEM:Helical; Name=S5 of repeat IV	SEQ_UP	18	
TRANSMEM:Helical; Name=S6	SEQ_UP	2	
TRANSMEM:Helical; Name=S6 of repeat I	SEQ_UP	20	
TRANSMEM:Helical; Name=S6 of repeat II	SEQ_UP	20	
TRANSMEM:Helical; Name=S6 of repeat III	SEQ_UP	18	
TRANSMEM:Helical; Name=S6 of repeat IV	SEQ_UP	18	
TRANSMEM:Helical; Name=Segment S0	SEQ_UP	2	
TRANSMEM:Helical; Name=Segment S1	SEQ_UP	54	
TRANSMEM:Helical; Name=Segment S2	SEQ_UP	54	
TRANSMEM:Helical; Name=Segment S3	SEQ_UP	54	
TRANSMEM:Helical; Name=Segment S4	SEQ_UP	11	
TRANSMEM:Helical; Name=Segment S5	SEQ_UP	52	
TRANSMEM:Helical; Name=Segment S6	SEQ_UP	51	
TRANSMEM:Helical; Name=TM1	SEQ_UP	2	
TRANSMEM:Helical; Name=TM1-1	SEQ_UP	1	
TRANSMEM:Helical; Name=TM1-2	SEQ_UP	1	
TRANSMEM:Helical; Name=TM10	SEQ_UP	2	
TRANSMEM:Helical; Name=TM11	SEQ_UP	2	
TRANSMEM:Helical; Name=TM12	SEQ_UP	1	
TRANSMEM:Helical; Name=TM2	SEQ_UP	2	
TRANSMEM:Helical; Name=TM2-1	SEQ_UP	1	
TRANSMEM:Helical; Name=TM2-2	SEQ_UP	1	
TRANSMEM:Helical; Name=TM3	SEQ_UP	2	
TRANSMEM:Helical; Name=TM3-1	SEQ_UP	1	
TRANSMEM:Helical; Name=TM3-2	SEQ_UP	1	
TRANSMEM:Helical; Name=TM4	SEQ_UP	2	
TRANSMEM:Helical; Name=TM4-1	SEQ_UP	1	
TRANSMEM:Helical; Name=TM4-2	SEQ_UP	1	
TRANSMEM:Helical; Name=TM5	SEQ_UP	2	
TRANSMEM:Helical; Name=TM5-1	SEQ_UP	1	
TRANSMEM:Helical; Name=TM5-2	SEQ_UP	1	
TRANSMEM:Helical; Name=TM6	SEQ_UP	2	
TRANSMEM:Helical; Name=TM6-1	SEQ_UP	1	
TRANSMEM:Helical; Name=TM6-2	SEQ_UP	1	
TRANSMEM:Helical; Name=TM7	SEQ_UP	2	
TRANSMEM:Helical; Name=TM8	SEQ_UP	2	
TRANSMEM:Helical; Name=TM9	SEQ_UP	2	
TRANSMEM:Helical; Name=V	SEQ_UP	2	
TRANSMEM:Helical; Name=VI	SEQ_UP	2	
TRANSMEM:Helical; Name=VII	SEQ_UP	2	
TRANSMEM:Helical; Name=VIII	SEQ_UP	1	
TRANSMEM:Helical; Name=X	SEQ_UP	1	
TRANSMEM:Helical; Name=XI	SEQ_UP	1	
TRANSMEM:Helical; Name=XII	SEQ_UP	1	
TRANSMEM:Helical; Note=After insertion into the membrane	SEQ_UP	4	
TRANSMEM:Helical; Note=Internal signal sequence	SEQ_UP	3	
TRANSMEM:Helical; Signal-anchor	SEQ_UP	5	
TRANSMEM:Helical; Signal-anchor for type II membrane protein	SEQ_UP	388	
TRANSMEM:Helical; Signal-anchor for type III membrane protein	SEQ_UP	36	
TRANSMEM:Helical; Voltage-sensor; Name=S4 of repeat I	SEQ_UP	3	
TRANSMEM:Helical; Voltage-sensor; Name=S4 of repeat II	SEQ_UP	3	
TRANSMEM:Helical; Voltage-sensor; Name=S4 of repeat III	SEQ_UP	3	
TRANSMEM:Helical; Voltage-sensor; Name=S4 of repeat IV	SEQ_UP	3	
TRANSMEM:Helical; Voltage-sensor; Name=Segment S4	SEQ_UP	43	
TRANSMEM:Helical;Name=1	SEQ_UP	2	
TRANSMEM:Helical;Name=2	SEQ_UP	2	
TRANSMEM:Helical;Name=3	SEQ_UP	2	
TRANSMEM:Helical;Name=4	SEQ_UP	2	
TRANSMEM:Helical;Name=5	SEQ_UP	2	
TRANSMEM:Helical;Name=6	SEQ_UP	2	
TRANSMEM:Helical;Name=7	SEQ_UP	2	
TRANSMEM:Signal-anchor for type II membrane protein	SEQ_UP	1	
UNSURE:D or N	SEQ_UP	2	
UNSURE:E or Q	SEQ_UP	1	
ZN_FING:A20-type	SEQ_UP	6	
ZN_FING:A20-type 1	SEQ_UP	1	
ZN_FING:A20-type 2	SEQ_UP	1	
ZN_FING:A20-type 3	SEQ_UP	1	
ZN_FING:A20-type 4	SEQ_UP	1	
ZN_FING:A20-type 5	SEQ_UP	1	
ZN_FING:A20-type 6	SEQ_UP	1	
ZN_FING:A20-type 7	SEQ_UP	1	
ZN_FING:AN1-type	SEQ_UP	4	
ZN_FING:AN1-type 1	SEQ_UP	3	
ZN_FING:AN1-type 2	SEQ_UP	3	
ZN_FING:AN1-type; degenerate	SEQ_UP	1	
ZN_FING:Atypical	SEQ_UP	2	
ZN_FING:B box-type	SEQ_UP	42	
ZN_FING:B box-type 1	SEQ_UP	12	
ZN_FING:B box-type 1; atypical	SEQ_UP	2	
ZN_FING:B box-type 1; degenerate	SEQ_UP	2	
ZN_FING:B box-type 2	SEQ_UP	16	
ZN_FING:B box-type; atypical	SEQ_UP	3	
ZN_FING:B box-type; degenerate	SEQ_UP	2	
ZN_FING:BED-type	SEQ_UP	1	
ZN_FING:BED-type 1	SEQ_UP	2	
ZN_FING:BED-type 2	SEQ_UP	2	
ZN_FING:BED-type 3	SEQ_UP	1	
ZN_FING:BED-type 4	SEQ_UP	1	
ZN_FING:Btk-type	SEQ_UP	8	
ZN_FING:C2H2 AKAP95-type 1	SEQ_UP	3	
ZN_FING:C2H2 AKAP95-type 2	SEQ_UP	3	
ZN_FING:C2H2-type	SEQ_UP	41	
ZN_FING:C2H2-type 1	SEQ_UP	291	
ZN_FING:C2H2-type 1; atypical	SEQ_UP	21	
ZN_FING:C2H2-type 1; degenerate	SEQ_UP	20	
ZN_FING:C2H2-type 10	SEQ_UP	108	
ZN_FING:C2H2-type 10; atypical	SEQ_UP	1	
ZN_FING:C2H2-type 10; degenerate	SEQ_UP	3	
ZN_FING:C2H2-type 11	SEQ_UP	91	
ZN_FING:C2H2-type 11; atypical	SEQ_UP	3	
ZN_FING:C2H2-type 11; degenerate	SEQ_UP	2	
ZN_FING:C2H2-type 12	SEQ_UP	81	
ZN_FING:C2H2-type 12; atypical	SEQ_UP	1	
ZN_FING:C2H2-type 12; degenerate	SEQ_UP	2	
ZN_FING:C2H2-type 13	SEQ_UP	64	
ZN_FING:C2H2-type 13; atypical	SEQ_UP	2	
ZN_FING:C2H2-type 13; degenerate	SEQ_UP	2	
ZN_FING:C2H2-type 14	SEQ_UP	44	
ZN_FING:C2H2-type 14; degenerate	SEQ_UP	1	
ZN_FING:C2H2-type 15	SEQ_UP	34	
ZN_FING:C2H2-type 15; degenerate	SEQ_UP	3	
ZN_FING:C2H2-type 16	SEQ_UP	25	
ZN_FING:C2H2-type 17	SEQ_UP	21	
ZN_FING:C2H2-type 18	SEQ_UP	18	
ZN_FING:C2H2-type 18; degenerate	SEQ_UP	2	
ZN_FING:C2H2-type 19	SEQ_UP	16	
ZN_FING:C2H2-type 19; atypical	SEQ_UP	1	
ZN_FING:C2H2-type 19; degenerate	SEQ_UP	1	
ZN_FING:C2H2-type 2	SEQ_UP	303	
ZN_FING:C2H2-type 2; atypical	SEQ_UP	14	
ZN_FING:C2H2-type 2; degenerate	SEQ_UP	15	
ZN_FING:C2H2-type 20	SEQ_UP	13	
ZN_FING:C2H2-type 20; degenerate	SEQ_UP	1	
ZN_FING:C2H2-type 21	SEQ_UP	9	
ZN_FING:C2H2-type 21; degenerate	SEQ_UP	2	
ZN_FING:C2H2-type 22	SEQ_UP	8	
ZN_FING:C2H2-type 23	SEQ_UP	6	
ZN_FING:C2H2-type 23; degenerate	SEQ_UP	2	
ZN_FING:C2H2-type 24	SEQ_UP	5	
ZN_FING:C2H2-type 25	SEQ_UP	3	
ZN_FING:C2H2-type 25; degenerate	SEQ_UP	2	
ZN_FING:C2H2-type 26	SEQ_UP	5	
ZN_FING:C2H2-type 27	SEQ_UP	4	
ZN_FING:C2H2-type 28	SEQ_UP	2	
ZN_FING:C2H2-type 29	SEQ_UP	2	
ZN_FING:C2H2-type 3	SEQ_UP	295	
ZN_FING:C2H2-type 3; atypical	SEQ_UP	9	
ZN_FING:C2H2-type 3; degenerate	SEQ_UP	9	
ZN_FING:C2H2-type 30	SEQ_UP	2	
ZN_FING:C2H2-type 4	SEQ_UP	244	
ZN_FING:C2H2-type 4; atypical	SEQ_UP	10	
ZN_FING:C2H2-type 4; degenerate	SEQ_UP	9	
ZN_FING:C2H2-type 5	SEQ_UP	215	
ZN_FING:C2H2-type 5; atypical	SEQ_UP	5	
ZN_FING:C2H2-type 5; degenerate	SEQ_UP	9	
ZN_FING:C2H2-type 6	SEQ_UP	178	
ZN_FING:C2H2-type 6; atypical	SEQ_UP	3	
ZN_FING:C2H2-type 6; degenerate	SEQ_UP	5	
ZN_FING:C2H2-type 7	SEQ_UP	154	
ZN_FING:C2H2-type 7; atypical	SEQ_UP	3	
ZN_FING:C2H2-type 7; degenerate	SEQ_UP	7	
ZN_FING:C2H2-type 8	SEQ_UP	139	
ZN_FING:C2H2-type 8; atypical	SEQ_UP	4	
ZN_FING:C2H2-type 8; degenerate	SEQ_UP	3	
ZN_FING:C2H2-type 9	SEQ_UP	122	
ZN_FING:C2H2-type 9; atypical	SEQ_UP	3	
ZN_FING:C2H2-type 9; degenerate	SEQ_UP	7	
ZN_FING:C2H2-type; atypical	SEQ_UP	2	
ZN_FING:C2H2-type; degenerate	SEQ_UP	5	
ZN_FING:C2HC LYAR-type 1	SEQ_UP	1	
ZN_FING:C2HC LYAR-type 2	SEQ_UP	1	
ZN_FING:C2HC MYST-type	SEQ_UP	5	
ZN_FING:C2HC pre-PHD-type	SEQ_UP	18	
ZN_FING:C2HC pre-PHD-type 1	SEQ_UP	1	
ZN_FING:C2HC pre-PHD-type 1; degenerate	SEQ_UP	2	
ZN_FING:C2HC pre-PHD-type 2	SEQ_UP	3	
ZN_FING:C2HC pre-PHD-type; degenerate	SEQ_UP	1	
ZN_FING:C2HC RNF-type	SEQ_UP	4	
ZN_FING:C2HC-type	SEQ_UP	3	
ZN_FING:C3H1-type	SEQ_UP	58	
ZN_FING:C3H1-type 1	SEQ_UP	29	
ZN_FING:C3H1-type 2	SEQ_UP	29	
ZN_FING:C3H1-type 3	SEQ_UP	18	
ZN_FING:C3H1-type 4	SEQ_UP	10	
ZN_FING:C3H1-type 5	SEQ_UP	3	
ZN_FING:C3H1-type; atypical	SEQ_UP	1	
ZN_FING:C3HC-type	SEQ_UP	1	
ZN_FING:C4-type	SEQ_UP	50	
ZN_FING:C4-type 1	SEQ_UP	2	
ZN_FING:C4-type 2	SEQ_UP	2	
ZN_FING:C4-type 3	SEQ_UP	1	
ZN_FING:C4-type 4	SEQ_UP	1	
ZN_FING:C4-type; atypical	SEQ_UP	1	
ZN_FING:C4-type; plays a role in ER morphology	SEQ_UP	1	
ZN_FING:C4H2-type	SEQ_UP	1	
ZN_FING:C5-type	SEQ_UP	4	
ZN_FING:C5HC2	SEQ_UP	3	
ZN_FING:C6-type	SEQ_UP	5	
ZN_FING:CCHC FOG-type 1	SEQ_UP	2	
ZN_FING:CCHC FOG-type 2	SEQ_UP	2	
ZN_FING:CCHC FOG-type 3	SEQ_UP	2	
ZN_FING:CCHC FOG-type 4	SEQ_UP	2	
ZN_FING:CCHC FOG-type 5	SEQ_UP	2	
ZN_FING:CCHC HIVEP-type	SEQ_UP	2	
ZN_FING:CCHC NOA-type	SEQ_UP	3	
ZN_FING:CCHC-type	SEQ_UP	27	
ZN_FING:CCHC-type 1	SEQ_UP	8	
ZN_FING:CCHC-type 2	SEQ_UP	8	
ZN_FING:CCHC-type 3	SEQ_UP	5	
ZN_FING:CCHC-type 4	SEQ_UP	3	
ZN_FING:CCHC-type 5	SEQ_UP	1	
ZN_FING:CCHC-type 6	SEQ_UP	1	
ZN_FING:CCHC-type 7	SEQ_UP	1	
ZN_FING:CCHH-type	SEQ_UP	2	
ZN_FING:CCHHC-type	SEQ_UP	3	
ZN_FING:CCHHC-type 1	SEQ_UP	3	
ZN_FING:CCHHC-type 2	SEQ_UP	3	
ZN_FING:CCHHC-type 3	SEQ_UP	3	
ZN_FING:CCHHC-type 4	SEQ_UP	3	
ZN_FING:CCHHC-type 5	SEQ_UP	3	
ZN_FING:CCHHC-type 6	SEQ_UP	3	
ZN_FING:CCHHC-type 7	SEQ_UP	1	
ZN_FING:CCHHC-type; degenerate	SEQ_UP	1	
ZN_FING:CHHC U11-48K-type	SEQ_UP	2	
ZN_FING:CHHC U11-48K-type 1	SEQ_UP	2	
ZN_FING:CHHC U11-48K-type 2	SEQ_UP	2	
ZN_FING:CHY-type	SEQ_UP	1	
ZN_FING:CR-type	SEQ_UP	4	
ZN_FING:CTCHY-type	SEQ_UP	1	
ZN_FING:CW-type	SEQ_UP	8	
ZN_FING:CXXC-type	SEQ_UP	11	
ZN_FING:CXXC-type 1	SEQ_UP	1	
ZN_FING:CXXC-type 2	SEQ_UP	1	
ZN_FING:CXXC-type 3	SEQ_UP	1	
ZN_FING:CysA-type	SEQ_UP	4	
ZN_FING:DBF4-type	SEQ_UP	1	
ZN_FING:DNL-type	SEQ_UP	1	
ZN_FING:DZANK-type 1	SEQ_UP	1	
ZN_FING:DZANK-type 2	SEQ_UP	1	
ZN_FING:FCS-type	SEQ_UP	5	
ZN_FING:FCS-type 1	SEQ_UP	1	
ZN_FING:FCS-type 2	SEQ_UP	1	
ZN_FING:FLYWCH-type 1	SEQ_UP	1	
ZN_FING:FLYWCH-type 2	SEQ_UP	1	
ZN_FING:FLYWCH-type 3	SEQ_UP	1	
ZN_FING:FLYWCH-type 4	SEQ_UP	1	
ZN_FING:FLYWCH-type 5	SEQ_UP	1	
ZN_FING:FPG-type	SEQ_UP	2	
ZN_FING:FYVE-type	SEQ_UP	38	
ZN_FING:FYVE-type 1	SEQ_UP	1	
ZN_FING:FYVE-type 2	SEQ_UP	1	
ZN_FING:GATA-type	SEQ_UP	6	
ZN_FING:GATA-type 1	SEQ_UP	6	
ZN_FING:GATA-type 2	SEQ_UP	6	
ZN_FING:GATA-type; atypical	SEQ_UP	8	
ZN_FING:GRF-type	SEQ_UP	5	
ZN_FING:GRF-type 1	SEQ_UP	2	
ZN_FING:GRF-type 2	SEQ_UP	2	
ZN_FING:HIT-type	SEQ_UP	6	
ZN_FING:IBR-type	SEQ_UP	14	
ZN_FING:Matrin-type	SEQ_UP	12	
ZN_FING:Matrin-type 1	SEQ_UP	8	
ZN_FING:Matrin-type 2	SEQ_UP	8	
ZN_FING:Matrin-type 3	SEQ_UP	6	
ZN_FING:Matrin-type 4	SEQ_UP	3	
ZN_FING:MYM-type 1	SEQ_UP	4	
ZN_FING:MYM-type 2	SEQ_UP	3	
ZN_FING:MYM-type 2; degenerate	SEQ_UP	1	
ZN_FING:MYM-type 3	SEQ_UP	3	
ZN_FING:MYM-type 4	SEQ_UP	4	
ZN_FING:MYM-type 5	SEQ_UP	4	
ZN_FING:MYM-type 6	SEQ_UP	3	
ZN_FING:MYM-type 7	SEQ_UP	3	
ZN_FING:MYM-type 8	SEQ_UP	3	
ZN_FING:MYM-type 9	SEQ_UP	3	
ZN_FING:MYND-type	SEQ_UP	17	
ZN_FING:MYND-type; atypical	SEQ_UP	2	
ZN_FING:MYND-type; degenerate	SEQ_UP	1	
ZN_FING:Nanos-type	SEQ_UP	3	
ZN_FING:NF-X1-type 1	SEQ_UP	2	
ZN_FING:NF-X1-type 2	SEQ_UP	2	
ZN_FING:NF-X1-type 3	SEQ_UP	2	
ZN_FING:NF-X1-type 4	SEQ_UP	2	
ZN_FING:NF-X1-type 5	SEQ_UP	1	
ZN_FING:NF-X1-type 6	SEQ_UP	1	
ZN_FING:NF-X1-type 7	SEQ_UP	1	
ZN_FING:NF-X1-type 8	SEQ_UP	1	
ZN_FING:NOB1	SEQ_UP	1	
ZN_FING:NR C4-type	SEQ_UP	46	
ZN_FING:PARP-type	SEQ_UP	1	
ZN_FING:PARP-type 1	SEQ_UP	1	
ZN_FING:PARP-type 2	SEQ_UP	1	
ZN_FING:PBZ-type	SEQ_UP	1	
ZN_FING:PBZ-type 1	SEQ_UP	1	
ZN_FING:PBZ-type 2	SEQ_UP	1	
ZN_FING:PHD-type	SEQ_UP	42	
ZN_FING:PHD-type 1	SEQ_UP	36	
ZN_FING:PHD-type 1; degenerate	SEQ_UP	1	
ZN_FING:PHD-type 2	SEQ_UP	33	
ZN_FING:PHD-type 2; atypical	SEQ_UP	1	
ZN_FING:PHD-type 2; degenerate	SEQ_UP	3	
ZN_FING:PHD-type 3	SEQ_UP	11	
ZN_FING:PHD-type 4	SEQ_UP	4	
ZN_FING:PHD-type 4; atypical	SEQ_UP	3	
ZN_FING:PHD-type 5	SEQ_UP	2	
ZN_FING:PHD-type 6	SEQ_UP	2	
ZN_FING:PHD-type 7	SEQ_UP	2	
ZN_FING:PHD-type 8	SEQ_UP	1	
ZN_FING:PHD-type; atypical	SEQ_UP	11	
ZN_FING:PHD-type; degenerate	SEQ_UP	1	
ZN_FING:Phorbol-ester/DAG-type	SEQ_UP	40	
ZN_FING:Phorbol-ester/DAG-type 1	SEQ_UP	21	
ZN_FING:Phorbol-ester/DAG-type 2	SEQ_UP	21	
ZN_FING:Phorbol-ester/DAG-type 3	SEQ_UP	1	
ZN_FING:RAG1-type	SEQ_UP	1	
ZN_FING:RanBP2-type	SEQ_UP	15	
ZN_FING:RanBP2-type 1	SEQ_UP	5	
ZN_FING:RanBP2-type 2	SEQ_UP	5	
ZN_FING:RanBP2-type 3	SEQ_UP	4	
ZN_FING:RanBP2-type 4	SEQ_UP	2	
ZN_FING:RanBP2-type 5	SEQ_UP	2	
ZN_FING:RanBP2-type 6	SEQ_UP	1	
ZN_FING:RING-CH-type	SEQ_UP	10	
ZN_FING:RING-Gid-type	SEQ_UP	3	
ZN_FING:RING-type	SEQ_UP	188	
ZN_FING:RING-type 0; atypical	SEQ_UP	1	
ZN_FING:RING-type 1	SEQ_UP	19	
ZN_FING:RING-type 1; atypical	SEQ_UP	2	
ZN_FING:RING-type 1; degenerate	SEQ_UP	1	
ZN_FING:RING-type 2	SEQ_UP	5	
ZN_FING:RING-type 2; atypical	SEQ_UP	15	
ZN_FING:RING-type 2; degenerate	SEQ_UP	2	
ZN_FING:RING-type 3	SEQ_UP	1	
ZN_FING:RING-type 3; atypical	SEQ_UP	1	
ZN_FING:RING-type 4; degenerate	SEQ_UP	1	
ZN_FING:RING-type; atypical	SEQ_UP	37	
ZN_FING:RING-type; degenerate	SEQ_UP	26	
ZN_FING:RIP-type	SEQ_UP	1	
ZN_FING:RRN7-type	SEQ_UP	1	
ZN_FING:RTR1-type	SEQ_UP	1	
ZN_FING:RZ-type	SEQ_UP	2	
ZN_FING:SGF11-type	SEQ_UP	1	
ZN_FING:SIAH-type	SEQ_UP	3	
ZN_FING:SIAH-type; degenerate	SEQ_UP	1	
ZN_FING:SLX1-type	SEQ_UP	1	
ZN_FING:SP-RING-type	SEQ_UP	7	
ZN_FING:SWIM-type	SEQ_UP	9	
ZN_FING:TAZ-type	SEQ_UP	2	
ZN_FING:TAZ-type 1	SEQ_UP	2	
ZN_FING:TAZ-type 2	SEQ_UP	2	
ZN_FING:TFIIB-type	SEQ_UP	3	
ZN_FING:TFIIS-type	SEQ_UP	6	
ZN_FING:THAP-type	SEQ_UP	7	
ZN_FING:TRAF-type	SEQ_UP	11	
ZN_FING:TRAF-type 1	SEQ_UP	5	
ZN_FING:TRAF-type 2	SEQ_UP	5	
ZN_FING:TRAF-type 3	SEQ_UP	1	
ZN_FING:U1-type 1	SEQ_UP	1	
ZN_FING:U1-type 2	SEQ_UP	1	
ZN_FING:UBP-type	SEQ_UP	10	
ZN_FING:UBP-type; degenerate	SEQ_UP	4	
ZN_FING:UBR-type	SEQ_UP	7	
ZN_FING:UBZ-type	SEQ_UP	1	
ZN_FING:UBZ1-type	SEQ_UP	3	
ZN_FING:UBZ1-type 1	SEQ_UP	1	
ZN_FING:UBZ1-type 2	SEQ_UP	1	
ZN_FING:UBZ2-type	SEQ_UP	1	
ZN_FING:UBZ3-type	SEQ_UP	1	
ZN_FING:UBZ4-type	SEQ_UP	6	
ZN_FING:UBZ4-type 1	SEQ_UP	2	
ZN_FING:UBZ4-type 2	SEQ_UP	2	
ZN_FING:UPF1-type	SEQ_UP	1	
ZN_FING:ZBR-type	SEQ_UP	2	
ZN_FING:ZZ-type	SEQ_UP	14	
ZN_FING:ZZ-type 1	SEQ_UP	1	
ZN_FING:ZZ-type 2	SEQ_UP	1	
ZN_FING:ZZ-type; degenerate	SEQ_UP	2	
